PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Wenzel, SE; Hopkins, R; Saunders, M; Chantry, D; Anderson, L; Aitchison, R; Eberhardt, C; Bell, S; Cole, J; Wolfe, J; Spector, SL; Sher, LD; Kerwin, EM; Burgess, L				Wenzel, Sally E.; Hopkins, Robert; Saunders, Michael; Chantry, David; Anderson, Lisa; Aitchison, Roger; Eberhardt, Christine; Bell, Stacie; Cole, Jeremy; Wolfe, James; Spector, Sheldon L.; Sher, Lawrence D.; Kerwin, Edward M.; Burgess, Larry			Safety and Efficacy Of ARRY-502, a Potent, Selective, Oral CRTh2 Antagonist, In Patients With Mild To Moderate Th2-Driven Asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI)	FEB 28-MAR 04, 2014	San Diego, CA	Amer Acad Allergy Asthma & Immunol					[Wenzel, Sally E.] Univ Pittsburgh, Med Ctr NW, Pittsburgh, PA USA; [Hopkins, Robert; Saunders, Michael; Chantry, David; Anderson, Lisa; Aitchison, Roger; Eberhardt, Christine; Bell, Stacie; Burgess, Larry] Array Biopharma Inc, Boulder, CO USA; [Cole, Jeremy] IPS Res Co, Oklahoma City, OK USA; [Wolfe, James] Allergy & Asthma Associates Santa Clara Cty Res C, San Jose, CA USA; [Spector, Sheldon L.] Calif Allergy & Asthma Med Grp, Los Angeles, CA USA; [Sher, Lawrence D.] Peninsula Res Associates, Rolling Hills Estates, CA USA; [Kerwin, Edward M.] Allergy & Asthma Ctr Southern OR, Medford, OR USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pfizer; Array BioPharma									0	12	12	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2		S		13	AB4	AB4		10.1016/j.jaci.2013.12.037	http://dx.doi.org/10.1016/j.jaci.2013.12.037			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	297FO					2022-12-18	WOS:000330241300014
J	Andiappan, AK; Wang, DY; Anantharaman, R; Suri, BK; Lee, BTK; Rotzschke, O; Liu, JJ; Chew, FT				Andiappan, Anand Kumar; Wang, De Yun; Anantharaman, Ramani; Suri, Bani Kaur; Lee, Bernett Teck Kwong; Rotzschke, Olaf; Liu, Jianjun; Chew, Fook Tim			Replication of genome-wide association study loci for allergic rhinitis and house dust mite sensitization in an Asian population of ethnic Chinese in Singapore	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ASTHMA; IDENTIFICATION; IMPACT		[Andiappan, Anand Kumar; Lee, Bernett Teck Kwong; Rotzschke, Olaf] ASTAR, Singapore Immunol Network SIgN, Singapore, Singapore; [Andiappan, Anand Kumar; Anantharaman, Ramani; Suri, Bani Kaur; Chew, Fook Tim] Natl Univ Singapore, Dept Biol Sci, Singapore, Singapore; [Wang, De Yun] Natl Univ Singapore, Dept Otolaryngol, Singapore, Singapore; [Liu, Jianjun] ASTAR, Genome Inst Singapore, Singapore, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Immunology Network (SIgN); National University of Singapore; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS)	Andiappan, AK (corresponding author), ASTAR, Singapore Immunol Network SIgN, Singapore, Singapore.	dbscft@nus.edu.sg	Chew, Fook Tim/E-7259-2010; Liu, Jianjun/AAK-4989-2020; Roetzschke, Olaf/GXH-0012-2022	Chew, Fook Tim/0000-0003-1337-5146; Liu, Jianjun/0000-0002-3255-3019; Andiappan, Anand Kumar/0000-0002-8442-1544				Andiappan AK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019719; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Brand S, 2012, J ALLERGY CLIN IMMUN, V129, P1602, DOI 10.1016/j.jaci.2011.12.963; Creyghton MP, 2010, P NATL ACAD SCI USA, V107, P21931, DOI 10.1073/pnas.1016071107; Esparza-Gordillo J, 2009, NAT GENET, V41, P596, DOI 10.1038/ng.347; Ferreira MAR, 2011, LANCET, V378, P1006, DOI 10.1016/S0140-6736(11)60874-X; Gao PS, 2010, J ALLERGY CLIN IMMUN, V125, P1403, DOI 10.1016/j.jaci.2010.03.016; Karlic R, 2010, P NATL ACAD SCI USA, V107, P2926, DOI 10.1073/pnas.0909344107; Lee GR, 2006, IMMUNITY, V24, P369, DOI 10.1016/j.immuni.2006.03.007; Ramasamy A, 2011, J ALLERGY CLIN IMMUN, V128, P996, DOI 10.1016/j.jaci.2011.08.030; Zhou XB, 2012, HUM MOL GENET, V21, P1325, DOI 10.1093/hmg/ddr569	12	12	13	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2013	131	5					1431	+		10.1016/j.jaci.2012.11.001	http://dx.doi.org/10.1016/j.jaci.2012.11.001			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	144AU	23228246				2022-12-18	WOS:000318912200027
J	Adler, S; Kolev, M; Varisco, PA; Tham, M; von Gunten, M; Tappeiner, C; Villiger, PM				Adler, Sabine; Kolev, Mirjam; Varisco, Pierre-Alain; Tham, Manuela; von Gunten, Michael; Tappeiner, Christoph; Villiger, Peter M.			Induction of severe systemic lupus erythematosus by TNF blockade and response to anti-IL-6 strategy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							AUTOIMMUNE; INFLIXIMAB; EFFICACY; SAFETY		[Adler, Sabine; Kolev, Mirjam; Varisco, Pierre-Alain; Tham, Manuela; Villiger, Peter M.] Univ Hosp Bern, Dept Rheumatol Clin Immunol & Allergol, CH-3010 Bern, Switzerland; [Adler, Sabine; Kolev, Mirjam; Varisco, Pierre-Alain; Tham, Manuela; Villiger, Peter M.] Univ Bern, Bern, Switzerland; [von Gunten, Michael] Univ Bern, Inst Pathol, Bern, Switzerland; [Tappeiner, Christoph] Univ Bern, Univ Hosp, Dept Ophthalmol, Bern, Switzerland	University of Bern; University Hospital of Bern; University of Bern; University of Bern; University of Bern; University Hospital of Bern	Adler, S (corresponding author), Univ Hosp Bern, Dept Rheumatol Clin Immunol & Allergol, CH-3010 Bern, Switzerland.	peter.villiger@insel.ch	Villiger, Peter/AAV-8132-2021; kolev, mihail/D-1476-2015	kolev, mihail/0000-0002-5226-4759; von Gunten, Michael/0000-0001-6315-016X				Atzeni F, 2007, AUTOIMMUN REV, V6, P529, DOI 10.1016/j.autrev.2007.03.009; Illei GG, 2010, ARTHRITIS RHEUM-US, V62, P542, DOI 10.1002/art.27221; Jones G, 2010, ANN RHEUM DIS, V69, P88, DOI 10.1136/ard.2008.105197; Josselin L, 2008, ANN RHEUM DIS, V67, P1343, DOI 10.1136/ard.2007.083584; Kievit W, 2008, ANN RHEUM DIS, V67, P1229, DOI 10.1136/ard.2007.083675; Ohl K, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/432595; Parks CG, 2002, ARTHRITIS RHEUM-US, V46, P1840, DOI 10.1002/art.10368; STEENLAND K, 1995, AM J IND MED, V28, P603, DOI 10.1002/ajim.4700280505; Villiger PM, 2010, AUTOIMMUN REV, V9, P812, DOI 10.1016/j.autrev.2010.07.009; Williams EL, 2009, RHEUMATOLOGY, V48, P716, DOI 10.1093/rheumatology/kep080	10	12	15	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					1235	1237		10.1016/j.jaci.2012.09.034	http://dx.doi.org/10.1016/j.jaci.2012.09.034			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	23154083				2022-12-18	WOS:000317187200037
J	Bacon, CM; Wilkinson, SJ; Spickett, GP; Barge, D; Lucraft, HH; Jackson, G; Rand, V; Gennery, AR				Bacon, Chris M.; Wilkinson, Sarah J.; Spickett, Gavin P.; Barge, Dawn; Lucraft, Helen H.; Jackson, Graham; Rand, Vikki; Gennery, Andrew R.			Epstein-Barr virus-independent diffuse large B-cell lymphoma in DNA ligase 4 deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							TRANSLOCATIONS; MODEL		[Bacon, Chris M.; Wilkinson, Sarah J.; Jackson, Graham; Rand, Vikki] Newcastle Univ, Northern Inst Canc Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Spickett, Gavin P.; Barge, Dawn; Lucraft, Helen H.] Newcastle Upon Tyne Hosp NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England; [Gennery, Andrew R.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University - UK	Bacon, CM (corresponding author), Newcastle Univ, Northern Inst Canc Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	andrew.gennery@ncl.ac.uk	Jackson, Graham/GMW-7638-2022	Jackson, Graham/0000-0003-0756-969X; Bacon, Chris/0000-0002-8268-2812; Rand, Vikki/0000-0002-2198-8949				Boboila C, 2010, P NATL ACAD SCI USA, V107, P3034, DOI 10.1073/pnas.0915067107; Koelsch K, 2007, J CLIN INVEST, V117, P1558, DOI 10.1172/JCI27628; Nijnik A, 2009, J CLIN INVEST, V119, P1696, DOI 10.1172/JCI32743; O'Driscoll M, 2001, MOL CELL, V8, P1175, DOI 10.1016/S1097-2765(01)00408-7; PLOWMAN PN, 1990, BRIT J RADIOL, V63, P624, DOI 10.1259/0007-1285-63-752-624; Rucci F, 2010, P NATL ACAD SCI USA, V107, P3024, DOI 10.1073/pnas.0914865107; Sharpless NE, 2001, MOL CELL, V8, P1187, DOI 10.1016/S1097-2765(01)00425-7; Slatter MA, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399410001419; Zhu CM, 2002, CELL, V109, P811, DOI 10.1016/S0092-8674(02)00770-5	9	12	15	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					1237	1239		10.1016/j.jaci.2012.10.027	http://dx.doi.org/10.1016/j.jaci.2012.10.027			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	23228243				2022-12-18	WOS:000317187200038
J	Pekkarinen, PT; Vaali, K; Jarva, H; Kekalainen, E; Hetemaki, I; Junnikkala, S; Helminen, M; Vaarala, O; Meri, S; Arstila, TP				Pekkarinen, Pirkka T.; Vaali, Kirsi; Jarva, Hanna; Kekalainen, Eliisa; Hetemaki, Iivo; Junnikkala, Sami; Helminen, Merja; Vaarala, Outi; Meri, Seppo; Arstila, T. Petteri			Impaired intestinal tolerance in the absence of a functional complement system	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mucosal immunity; peripheral tolerance; complement C3; T lymphocytes; humoral immunity	ANTI-SACCHAROMYCES-CEREVISIAE; REGULATORY T-CELLS; DENDRITIC CELLS; TISSUE DISTRIBUTION; COMPONENT C3; ANTIBODIES; CRRY/P65; PROTEIN; DIFFERENTIATION; LYMPHOCYTES	Background: Cells of the innate immune system regulate both adaptive immune responses and the maintenance of tolerance, especially in the gut. However, relatively little is known about the effects of complement on lymphocyte homeostasis. Objective: This study explored complement C3 deficiency in mice and human subjects for its effect on intestinal tolerance. Methods: C3-deficient mice and control C57BL/6 mice were fed ovalbumin (OVA) by means of gavage, and subsequent response to immunization with OVA in Freund's adjuvant was monitored. Serum antibodies against commensal microbes were measured, and the activation status of peripheral blood lymphocytes bearing mucosal homing markers was determined from 2 rare cases of C3-deficient patients. Results: We show in C3-deficient mice and human patients that intestinal tolerance fails in the absence of functional complement. In contrast to wild-type control animals, in which oral tolerance was induced, intragastric administration of OVA did not result in a significantly decreased response to subsequent subcutaneous OVA challenge in C3-deficient mice. In the jejunum of C3-deficient mice the cytokine ratio between IL-10 and IFN-gamma or IL-17 levels was decreased, indicating a shift in favor of proinflammatory cytokines. In 2 C3-deficient children the frequency of gut-homing T cells expressing activation markers was increased, and the patients had increased serum IgG levels against gut commensal microbes. The data also suggest that the impaired oral tolerance was at least partly caused by the absence of signaling through C3-binding complement regulators in T cells. Conclusions: Taken together, our results identify complement as an important and nonredundant regulator of intestinal tolerance. (J Allergy Clin Immunol 2013;131:1167-75.)	[Pekkarinen, Pirkka T.; Vaali, Kirsi; Jarva, Hanna; Kekalainen, Eliisa; Hetemaki, Iivo; Junnikkala, Sami; Meri, Seppo; Arstila, T. Petteri] Univ Helsinki, Haartman Inst, Dept Bacteriol & Immunol, Helsinki, Finland; Univ Helsinki, Fac Vet Med, Dept Vet Basic Sci, Helsinki, Finland; [Vaali, Kirsi; Vaarala, Outi] Natl Inst Hlth & Welf, Dept Vaccinat & Immune Protect, Immune Response Unit, Helsinki, Finland; Univ Bergen, Inst Med, N-5020 Bergen, Norway; [Jarva, Hanna; Meri, Seppo] HUSLAB, Helsinki, Finland; [Jarva, Hanna; Meri, Seppo] Univ Helsinki, Cent Hosp, Helsinki, Finland; [Helminen, Merja] Tampere Univ, Paediat Res Ctr, FIN-33101 Tampere, Finland; [Helminen, Merja] Tampere Univ Hosp, Tampere, Finland	University of Helsinki; University of Helsinki; Finland National Institute for Health & Welfare; University of Bergen; University of Helsinki; Helsinki University Central Hospital; Tampere University; Tampere University; Tampere University Hospital	Pekkarinen, PT (corresponding author), Univ Helsinki, Dept Bacteriol & Immunol, Haartman Inst, PB 21, FIN-00014 Helsinki, Finland.	pirkka.pekkarinen@helsinki.fi	Vaali, Kirsi/AGT-4056-2022; , eliisa.kekalainen@helsinki.fi/G-6140-2010	, eliisa.kekalainen@helsinki.fi/0000-0001-6045-108X; Meri, Seppo/0000-0001-9142-501X; Pekkarinen, Pirkka/0000-0002-8203-3409; Jarva, Hanna/0000-0002-9154-354X	Academy of Finland; Sigrid Juselius Foundation; Finnish Cultural Foundation; Finnish Medical Foundation; Helsinki Biomedical Graduate School; Helsinki University Central Hospital funds (EVO); HUSLAB funds; Helsinki University Hospital Funds; Alexion; Academy for Complement Inhibition; International Congress; Schering-Plough; Bristol-Myers Squibb; Roche	Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Finnish Cultural Foundation(Finnish Cultural FoundationFinnish IT center for science); Finnish Medical Foundation; Helsinki Biomedical Graduate School; Helsinki University Central Hospital funds (EVO); HUSLAB funds; Helsinki University Hospital Funds; Alexion; Academy for Complement Inhibition; International Congress; Schering-Plough(Merck & CompanySchering Plough Corporation); Bristol-Myers Squibb(Bristol-Myers Squibb); Roche(Roche Holding)	Supported by the Academy of Finland, Sigrid Juselius Foundation, Finnish Cultural Foundation, Finnish Medical Foundation, Helsinki Biomedical Graduate School, Helsinki University Central Hospital funds (EVO), and HUSLAB funds.; P. T. Pekkarinen has received research support from the Finnish Cultural Foundation. O. Vaarala is on the Board of the Hero Institute for Infant Nutrition. S. Meri is employed by the University and University Hospital of Helsinki, has received research support from the Sigrid Juselius Foundation and the Helsinki University Hospital Funds, has received lecture fees from Alexion, has received payment for developing educational presentations from the Academy for Complement Inhibition, and has received travel expenses from the International Congress. T. P. Arstila has received lecture fees from Schering-Plough, Bristol-Myers Squibb, and Roche. The rest of the authors declare that they have no relevant conflicts of interest.	Alford SK, 2008, J IMMUNOL, V181, P2544, DOI 10.4049/jimmunol.181.4.2544; Bajtay Z, 2006, IMMUNOL LETT, V104, P46, DOI 10.1016/j.imlet.2005.11.023; Banda NK, 2003, J IMMUNOL, V171, P2109, DOI 10.4049/jimmunol.171.4.2109; Brandtzaeg P, 2009, SCAND J IMMUNOL, V70, P505, DOI 10.1111/j.1365-3083.2009.02319.x; Cardone J, 2010, NAT IMMUNOL, V11, P862, DOI 10.1038/ni.1917; Cong YZ, 2002, J IMMUNOL, V169, P6112, DOI 10.4049/jimmunol.169.11.6112; Cozine CL, 2005, CURR OPIN IMMUNOL, V17, P298, DOI 10.1016/j.coi.2005.04.007; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; Fang YF, 1998, J IMMUNOL, V160, P5273; Fernandez-Centeno E, 2000, J IMMUNOL, V164, P4533, DOI 10.4049/jimmunol.164.9.4533; Frank MM, 2010, J ALLERGY CLIN IMMUN, V125, pS262, DOI 10.1016/j.jaci.2009.10.063; Fukaya T, 2010, BLOOD, V116, P2266, DOI 10.1182/blood-2009-10-250472; Ghannam A, 2008, J IMMUNOL, V181, P5158, DOI 10.4049/jimmunol.181.7.5158; Hadis U, 2011, IMMUNITY, V34, P237, DOI 10.1016/j.immuni.2011.01.016; Israeli E, 2005, GUT, V54, P1232, DOI 10.1136/gut.2004.060228; Jarva H, 2003, MOL IMMUNOL, V40, P95, DOI 10.1016/S0161-5890(03)00108-1; Jimenez-Perianez A, 2005, J LEUKOCYTE BIOL, V78, P1386, DOI 10.1189/jlb.1104642; Kekalainen E, 2007, J IMMUNOL, V178, P1208, DOI 10.4049/jimmunol.178.2.1208; Kemper C, 2003, NATURE, V421, P388, DOI 10.1038/nature01315; LI B, 1993, J IMMUNOL, V151, P4295; Macpherson AJ, 2004, SCIENCE, V303, P1662, DOI 10.1126/science.1091334; Macpherson AJ, 2009, SEMIN IMMUNOPATHOL, V31, P145, DOI 10.1007/s00281-009-0174-3; MAIN J, 1988, BRIT MED J, V297, P1105, DOI 10.1136/bmj.297.6656.1105; Marsh JE, 2001, TRANSPLANTATION, V72, P1310, DOI 10.1097/00007890-200110150-00022; Ojeda G, 2011, ARTHRITIS RHEUM-US, V63, P1562, DOI 10.1002/art.30328; Pabst R, 2008, TRENDS IMMUNOL, V29, P206, DOI 10.1016/j.it.2008.02.006; Pekkarinen PT, 2011, IMMUNOBIOLOGY, V216, P737, DOI 10.1016/j.imbio.2010.10.004; Peng Q, 2006, J IMMUNOL, V176, P3330, DOI 10.4049/jimmunol.176.6.3330; Reis ES, 2006, SCAND J IMMUNOL, V63, P155, DOI 10.1111/j.1365-3083.2006.01729.x; Rivollier A, 2012, J EXP MED, V209, P139, DOI 10.1084/jem.20101387; Russell RK, 2009, J PEDIATR GASTR NUTR, V48, P161, DOI 10.1097/MPG.0b013e318183e112; Sandor N, 2009, MOL IMMUNOL, V47, P438, DOI 10.1016/j.molimm.2009.08.025; Schraufstatter IU, 2002, J IMMUNOL, V169, P2102, DOI 10.4049/jimmunol.169.4.2102; Slack E, 2009, SCIENCE, V325, P617, DOI 10.1126/science.1172747; Suresh M, 2003, J IMMUNOL, V170, P788, DOI 10.4049/jimmunol.170.2.788; Yalcindag A, 2006, J ALLERGY CLIN IMMUN, V117, P1455, DOI 10.1016/j.jaci.2006.01.048	36	12	12	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					1167	1175		10.1016/j.jaci.2012.09.004	http://dx.doi.org/10.1016/j.jaci.2012.09.004			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	23098807				2022-12-18	WOS:000317187200027
J	Hankin, CS; Bronstone, A; Wang, ZH; Small, MB; Buck, P				Hankin, Cheryl S.; Bronstone, Amy; Wang, Zhaohui; Small, Mary Buatti; Buck, Philip			Estimated Prevalence and Economic Burden of Severe, Uncontrolled Asthma in the United States	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI)	FEB 22-26, 2013	San Antonio, TX	Amer Acad Allergy, Asthma & Immunol (AAAAI)					[Hankin, Cheryl S.; Bronstone, Amy; Wang, Zhaohui] BioMedEcon LLC, Moss Beach, CA USA; [Small, Mary Buatti; Buck, Philip] Teva Pharmaceut Inc, Frazer, PA USA										0	12	12	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2		S			AB126	AB126		10.1016/j.jaci.2012.12.1118	http://dx.doi.org/10.1016/j.jaci.2012.12.1118			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	111WC					2022-12-18	WOS:000316550800452
J	Jones, SM; Burks, AW				Jones, Stacie M.; Burks, A. Wesley			The changing CARE for patients with food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Food allergy; advocacy; school programs; immunotherapy; therapeutics; food allergy education; food allergy labeling; food safety; food allergy diagnostics	COWS MILK ALLERGY; ORAL IMMUNOTHERAPY; NATURAL-HISTORY; SUBLINGUAL IMMUNOTHERAPY; DOUBLE-BLIND; PEANUT ALLERGY; IMMUNOLOGICAL CHANGES; GENE POLYMORPHISMS; CHILDREN; IGE	The field of food allergy is continually changing, with advances in clinical care to better understand the mechanisms of disease and in possible new diagnostics and treatment models. The development of several new guidelines that focus on improving the standardization of the diagnosis and management of food allergy has helped to further guide clinicians in providing optimized care for children and adults with food allergy around the world. Much of this work has been made possible through the collaborative efforts of advocacy organizations, industry, and government with clinicians and researchers in the fields of allergy and immunology. We have been able to advance our understanding of disease mechanisms and to help close gaps in knowledge and resolve misconceptions in the treatment of food allergy. This review will focus on the concepts of a holistic approach to food allergy that is working to improve CARE for subjects with food allergy, including new advances in clinical care, advocacy, research, and education. (J Allergy Clin Immunol 2013;131:3-11.)	[Jones, Stacie M.] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; [Jones, Stacie M.] Arkansas Childrens Hosp, Little Rock, AR 72202 USA; [Burks, A. Wesley] Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA	University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital; University of North Carolina; University of North Carolina Chapel Hill	Burks, AW (corresponding author), Univ N Carolina, Dept Pediat, 260 Macnider Bldg,Campus Box 7220, Chapel Hill, NC 27599 USA.	wburks@email.unc.edu						[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Asarnoj A, 2010, ALLERGY, V65, P213, DOI 10.1111/j.1398-9995.2009.02138.x; Asarnoj A, 2012, J ALLERGY CLIN IMMUN, V130, P468, DOI 10.1016/j.jaci.2012.05.019; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Bollinger ME, 2006, ANN ALLERG ASTHMA IM, V96, P415, DOI 10.1016/S1081-1206(10)60908-8; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Brozek JL, 2012, CLIN EXP ALLERGY, V42, P363, DOI 10.1111/j.1365-2222.2011.03948.x; Buchanan R, 2008, J FOOD PROTECT, V71, P1043; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Burks AW, 2012, J ALLERGY CLIN IMMUN, V129, P906, DOI 10.1016/j.jaci.2012.02.001; Carlisle SK, 2010, J SCH NURS, V26, P360, DOI 10.1177/1059840510369482; Chafen JJS, 2010, JAMA-J AM MED ASSOC, V303, P1848, DOI 10.1001/jama.2010.582; Comstock SS, 2008, ANN ALLERG ASTHMA IM, V101, P51, DOI 10.1016/S1081-1206(10)60835-6; Dang TD, 2012, J ALLERGY CLIN IMMUN, V129, P1056, DOI 10.1016/j.jaci.2012.01.056; de Boissieu D, 2006, ALLERGY, V61, P1238, DOI 10.1111/j.1398-9995.2006.01196.x; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Dupont C, 2010, J ALLERGY CLIN IMMUN, V125, P1165, DOI 10.1016/j.jaci.2010.02.029; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; Fernandez-Rivas M, 2009, ALLERGY, V64, P876, DOI 10.1111/j.1398-9995.2008.01921.x; Fiocchi A, 2010, PEDIAT ALLERG IMM-UK, V21, P1, DOI [10.1111/j.1399-3038.2010.01068.x, 10.1097/WOX.0b013e3181defeb9]; Fisher HR, 2011, ARCH DIS CHILD, V96, P259, DOI 10.1136/adc.2009.172460; Fleischer DM, 2013, J ALLERGY CLIN IMMUN, V131, P119, DOI 10.1016/j.jaci.2012.11.011; Ford LS, 2010, J ALLERGY CLIN IMMUN, V126, P384, DOI 10.1016/j.jaci.2010.05.034; Furlong TJ, 2001, J ALLERGY CLIN IMMUN, V108, P867, DOI 10.1067/mai.2001.119157; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Guerlain S, 2010, ANN ALLERG ASTHMA IM, V105, P480, DOI 10.1016/j.anai.2010.09.028; Guerlain S, 2010, ANN ALLERG ASTHMA IM, V104, P172, DOI 10.1016/j.anai.2009.11.023; Hofmann AM, 2009, J ALLERGY CLIN IMMUN, V124, P286, DOI 10.1016/j.jaci.2009.03.045; Hong XM, 2012, SEMIN IMMUNOPATHOL, V34, P655, DOI 10.1007/s00281-012-0323-y; Hong XM, 2011, J ALLERGY CLIN IMMUN, V128, P374, DOI 10.1016/j.jaci.2011.05.007; Hong XM, 2010, J ALLERGY CLIN IMMUN, V126, P1059, DOI 10.1016/j.jaci.2010.08.029; Hong XM, 2009, CURR OPIN PEDIATR, V21, P770, DOI 10.1097/MOP.0b013e32833252dc; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Kim Edwin H, 2011, J Allergy Clin Immunol, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; Kim JS, 2011, J ALLERGY CLIN IMMUN, V128, P125, DOI 10.1016/j.jaci.2011.04.036; Kumar R, 2011, PEDIATRICS, V128, pE821, DOI 10.1542/peds.2011-0691; Lack G, 2008, J ALLERGY CLIN IMMUN, V121, P1331, DOI 10.1016/j.jaci.2008.04.032; Lemon-Mule H, 2008, J ALLERGY CLIN IMMUN, V122, P977, DOI 10.1016/j.jaci.2008.09.007; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Li XM, 2003, J ALLERGY CLIN IMMUN, V112, P159, DOI 10.1067/mai.2003.1622; Li XM, 2003, J IMMUNOL, V170, P3289, DOI 10.4049/jimmunol.170.6.3289; Liu X, 2011, ALLERGY, V66, P1442, DOI 10.1111/j.1398-9995.2011.02681.x; Liu X, 2009, CLIN EXP ALLERGY, V39, P991, DOI 10.1111/j.1365-2222.2009.03228.x; Luccioli S, 2012, CURR OPIN ALLERGY CL, V12, P323, DOI 10.1097/ACI.0b013e3283535aaf; Martos Gustavo, 2011, J Allergy Clin Immunol, V127, P990, DOI 10.1016/j.jaci.2011.01.057; McIntyre CL, 2005, PEDIATRICS, V116, P1134, DOI 10.1542/peds.2004-1475; Mempel M, 2003, J ALLERGY CLIN IMMUN, V111, P1406, DOI 10.1067/mai.2003.1497; Nadeau KC, 2011, J ALLERGY CLIN IMMUN, V127, P1622, DOI 10.1016/j.jaci.2011.04.009; Narisety SD, 2009, J ALLERGY CLIN IMMUN, V124, P610, DOI 10.1016/j.jaci.2009.06.025; National Rural Health Alliance, 2011, DEEP WAT GULF OIL DI, P1; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Nowak-Wegrzyn A, 2008, J ALLERGY CLIN IMMUN, V122, P342, DOI 10.1016/j.jaci.2008.05.043; Nowak-Wegrzyn A, 2011, J ALLERGY CLIN IMMUN, V127, P558, DOI 10.1016/j.jaci.2010.12.1098; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Ott H, 2008, ALLERGY, V63, P1521, DOI 10.1111/j.1398-9995.2008.01748.x; Pieretti MM, 2009, J ALLERGY CLIN IMMUN, V124, P337, DOI 10.1016/j.jaci.2009.05.032; Pongracic JA, 2012, J ALLERGY CLIN IMMUN, V129, P564, DOI 10.1016/j.jaci.2011.09.024; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; Sampson HA, 2011, J ALLERGY CLIN IMMUN, V127, P1309, DOI 10.1016/j.jaci.2011.01.051; Sanz ML, 2011, CURR OPIN ALLERGY CL, V11, P204, DOI 10.1097/ACI.0b013e3283466fe4; Savage JH, 2007, J ALLERGY CLIN IMMUN, V120, P717, DOI 10.1016/j.jaci.2007.07.027; Savage JH, 2010, J ALLERGY CLIN IMMUN, V125, P683, DOI 10.1016/j.jaci.2009.12.994; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]; Sicherer SH, 2012, J PEDIATR-US, V160, P651, DOI 10.1016/j.jpeds.2011.09.056; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P326, DOI 10.1016/j.jaci.2010.11.024; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V126, P1191, DOI 10.1016/j.jaci.2010.08.036; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V104, P186, DOI 10.1016/S0091-6749(99)70133-8; Simons E, 2005, ANN ALLERG ASTHMA IM, V95, P426, DOI 10.1016/S1081-1206(10)61166-0; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Skripak JM, 2007, J ALLERGY CLIN IMMUN, V120, P1172, DOI 10.1016/j.jaci.2007.08.023; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Taylor SL, 2010, FOOD CHEM TOXICOL, V48, P814, DOI 10.1016/j.fct.2009.12.013; Tsai HJ, 2009, CLIN EXP ALLERGY, V39, P101, DOI 10.1111/j.1365-2222.2008.03111.x; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Varshney P, 2009, J ALLERGY CLIN IMMUN, V124, P1351, DOI 10.1016/j.jaci.2009.09.042; Vereda A, 2011, J ALLERGY CLIN IMMUN, V127, P603, DOI 10.1016/j.jaci.2010.09.010; Vickery BP, 2011, J ALLERGY CLIN IMMUN, V127, pAB26, DOI 10.1016/j.jaci.2010.12.114; Vickery BP, 2010, ANN ALLERG ASTHMA IM, V105, P444, DOI 10.1016/j.anai.2010.09.030; Wang JG, 2010, MAGNETIC FRINGE FIELDS AND INTERFERENCE IN HIGH INTENSITY ACCELERATORS, P1; Weiss C, 2008, ANN ALLERG ASTHMA IM, V101, P556, DOI 10.1016/S1081-1206(10)60303-1; Wood R, 2012, J ALLERGY CLIN IMMUN, V129, pAB104; Wood RA, 2003, PEDIATRICS, V111, P1631; Young MC, 2009, J ALLERGY CLIN IMMUN, V124, P175, DOI 10.1016/j.jaci.2009.04.004	84	12	13	0	33	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2013	131	1					3	11		10.1016/j.jaci.2012.11.012	http://dx.doi.org/10.1016/j.jaci.2012.11.012			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	062YR	23265692	Bronze			2022-12-18	WOS:000312961200001
J	Gogishvili, T; Luhder, F; Kirstein, F; Nieuwenhuizen, NE; Goebbels, S; Beer-Hammer, S; Pfeffer, K; Reuter, S; Taube, C; Brombacher, F; Hunig, T				Gogishvili, Tea; Luehder, Fred; Kirstein, Frank; Nieuwenhuizen, Natalie E.; Goebbels, Sandra; Beer-Hammer, Sandra; Pfeffer, Klaus; Reuter, Sebastian; Taube, Christian; Brombacher, Frank; Huenig, Thomas			Interruption of CD28-mediated costimulation during allergen challenge protects mice from allergic airway disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic asthma; costimulation; conditional CD28 knockout mice; ovalbumin; CD28-specific mAb	MURINE MODEL; CD28; HYPERRESPONSIVENESS; EOSINOPHILIA; DIFFERENTIATION; REQUIREMENTS; RECRUITMENT; INHIBITION; PROMOTES; SUBSETS	Background: Allergic asthma is a T(H)2-promoted hyperreactivity with an immediate, IgE, and mast cell-dependent response followed by eosinophil-dominated inflammation and airway obstruction. Objective: Because costimulation by CD28 is essential for T(H)2 but not T(H)1 responses, we investigated the effect of selective interference with this pathway in mice using the models of ovalbumin and house dust mite-induced airway inflammation. Methods: To study the role of CD28 in the effector phase of allergic airway inflammation, we developed an inducibly CD28-deleting mouse strain or alternatively used a CD28 ligand-binding site-specific mouse anti-mouse mAb blocking CD28 engagement. Results: We show that even after systemic sensitization to the allergen, interruption of CD28-mediated costimulation is highly effective in preventing airway inflammation during challenge. In addition to improving airway resistance and histopathologic presentation and reducing inflammatory infiltrates, antibody treatment during allergen challenge resulted in a marked relative increase in regulatory T-cell numbers among the CD4 T-cell subset of the challenged lung. Conclusion: Selective interference with CD28-mediated costimulation during allergen exposure might be an attractive therapeutic concept for allergic asthma. (J Allergy Clin Immunol 2012;130:1394-403.)	[Gogishvili, Tea; Luehder, Fred; Huenig, Thomas] Univ Wurzburg, Inst Virol & Immunbiol, D-97078 Wurzburg, Germany; [Luehder, Fred] Univ Med Ctr Gottingen, Dept Neuroimmunol, Inst Multiple Sclerosis Res, Gottingen, Germany; [Luehder, Fred] Univ Med Ctr Gottingen, Hertie Fdn, Gottingen, Germany; [Goebbels, Sandra] Max Planck Inst Expt Med, D-3400 Gottingen, Germany; [Beer-Hammer, Sandra] Univ Tubingen, Dept Pharmacol & Expt Therapy, Inst Expt & Clin Pharmacol & Toxicol, Eberhard Karls Univ Hosp & Clin, Tubingen, Germany; [Beer-Hammer, Sandra] Univ Tubingen, Interfac Ctr Pharmacogen & Drug Res, Tubingen, Germany; [Pfeffer, Klaus] Univ Dusseldorf, Inst Med Microbiol & Hosp Hyg, Ctr Clin, D-40225 Dusseldorf, Germany; [Reuter, Sebastian] Johannes Gutenberg Univ Mainz, Med Clin 3, Mainz, Germany; [Gogishvili, Tea; Kirstein, Frank; Nieuwenhuizen, Natalie E.; Brombacher, Frank] Univ Cape Town, Int Ctr Genet Engn & Biotechnol, ZA-7925 Cape Town, South Africa; [Gogishvili, Tea; Kirstein, Frank; Nieuwenhuizen, Natalie E.; Brombacher, Frank] Univ Cape Town, IIDMM, Div Immunol, Fac Hlth Sci, ZA-7925 Cape Town, South Africa; [Taube, Christian] Leiden Univ, Med Ctr, Dept Pulmonol, Leiden, Netherlands	University of Wurzburg; University of Gottingen; University of Gottingen; Max Planck Society; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Heinrich Heine University Dusseldorf; Johannes Gutenberg University of Mainz; International Center for Genetic Engineering & Biotechnology (ICGEB); ICGEB Cape Town; University of Cape Town; University of Cape Town; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Hunig, T (corresponding author), Univ Wurzburg, Inst Virol & Immunbiol, Versbacher Str 7, D-97078 Wurzburg, Germany.	huenig@vim.uni-wuerzburg.de	Nieuwenhuizen, Natalie/AAP-2400-2021; Beer-Hammer, Sandra/C-7442-2014; Reuter, Sebastian/L-1804-2013	Pfeffer, Klaus/0000-0002-5652-6330; Beer-Hammer, Sandra/0000-0001-6049-0257; Nieuwenhuizen, Natalie/0000-0001-5749-2462; Reuter, Sebastian/0000-0002-1784-0124	Deutsche Forschungsgemeinschaft [SFB-TR52]; DFG [Ta 275/4-1, Ta 275/5-1, SFB-TR43 TP 11]; National Research Foundation (South Africa); Medical Research Council (South Africa); International Center for Genetic Engineering and Biotechnology; German Research Foundation (DFG); State of Bavaria, Germany; Business Intelligence; Novartis; Almirall; AstraZeneca; GlaxoSmithKline	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); DFG(German Research Foundation (DFG)); National Research Foundation (South Africa)(National Research Foundation - South AfricaSouth African Medical Research Council); Medical Research Council (South Africa); International Center for Genetic Engineering and Biotechnology; German Research Foundation (DFG)(German Research Foundation (DFG)); State of Bavaria, Germany; Business Intelligence; Novartis(Novartis); Almirall(Almirall); AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline)	Supported by Deutsche Forschungsgemeinschaft through SFB-TR52 by DFG Ta 275/4-1 and Ta 275/5-1 (to C. T.) and SFB-TR43 TP 11 (to F. L.) and the National Research Foundation (South Africa), the Medical Research Council (South Africa), and the International Center for Genetic Engineering and Biotechnology.; T. Gogishvili has been supported by one or more grants from the German Research Foundation (DFG). F. Luhder has been supported by one or more grants from the State of Bavaria, Germany. C. Taube has consultancy arrangements with Novartis and Almirall and has received one or more payments for lecturing from or is on the speakers' bureau for Business Intelligence, Novartis, Almirall, AstraZeneca, and GlaxoSmithKline. T. Hunig has been supported by one or more grants from the DFG; has consultancy arrangements with TheraMAB LLC; has received one or more grants from or has one or more grants pending with the DFG; has one or more patents (planned, pending, or issued) with the University of Wurzburg; has received royalties from various companies; has received one or more payments for the development of educational presentations for Publicis Life Brands, Germany; and owns stock/stock options in TheraMAB LLC. The rest of the authors declare that they have no relevant conflicts of interest.	Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Andres PG, 2004, NAT IMMUNOL, V5, P435, DOI 10.1038/ni1044; Beyersdorf N, 2008, BLOOD, V112, P4328, DOI 10.1182/blood-2008-03-146662; Bour-Jordan H, 2011, IMMUNOL REV, V241, P180, DOI 10.1111/j.1600-065X.2011.01011.x; Burr JS, 2001, AM J RESP CELL MOL, V24, P563, DOI 10.1165/ajrcmb.24.5.4375; Dennehy KM, 2006, J IMMUNOL, V176, P5725, DOI 10.4049/jimmunol.176.10.5725; Deppong CM, 2010, EUR J IMMUNOL; DURHAM SR, 1992, J IMMUNOL, V148, P2390; Hahn C, 2003, J ALLERGY CLIN IMMUN, V111, P1361, DOI 10.1067/mai.2003.1527; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Harris N, 1997, EUR J IMMUNOL, V27, P155, DOI 10.1002/eji.1830270123; Honstettre A, 2006, INFECT IMMUN, V74, P1800, DOI 10.1128/IAI.74.3.1800-1808.2006; Jaffar Z, 1999, AM J RESP CELL MOL, V20, P153, DOI 10.1165/ajrcmb.20.1.3255; Ji W, 2008, INT IMMUNOPHARMACOL, V8, P1190, DOI 10.1016/j.intimp.2008.04.008; KeaneMyers A, 1997, J IMMUNOL, V158, P2042; Kimzey SL, 2004, J IMMUNOL, V173, P632, DOI 10.4049/jimmunol.173.1.632; Krinzman SJ, 1996, J CLIN INVEST, V98, P2693, DOI 10.1172/JCI119093; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; Kubo M, 1999, J IMMUNOL, V163, P2432; Lenschow DJ, 1996, IMMUNITY, V5, P285, DOI 10.1016/S1074-7613(00)80323-4; Maddox L, 2002, ANNU REV MED, V53, P477, DOI 10.1146/annurev.med.53.082901.103921; Major T, 2002, VACCINE, V20, P1532, DOI 10.1016/S0264-410X(01)00496-0; Padrid PA, 1998, AM J RESP CELL MOL, V18, P453, DOI 10.1165/ajrcmb.18.4.3055; Poirier N, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000116; Reuter S, 2008, EUR RESPIR J, V31, P773, DOI 10.1183/09031936.00058907; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Robinson DS, 2004, J CLIN INVEST, V114, P1389, DOI 10.1172/JCI200423595; Rodriguez-Palmero M, 1999, EUR J IMMUNOL, V29, P3914; Rulifson IC, 1997, J IMMUNOL, V158, P658; Seibler J, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng012; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; Sharpe AH, 2002, NAT REV IMMUNOL, V2, P116, DOI 10.1038/nri727; Tao X, 1997, J IMMUNOL, V159, P5956; VanOosterhout AJM, 1997, AM J RESP CELL MOL, V17, P386, DOI 10.1165/ajrcmb.17.3.2679; WEBB LMC, 1995, BLOOD, V86, P3479, DOI 10.1182/blood.V86.9.3479.bloodjournal8693479	35	12	12	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2012	130	6					1394	+		10.1016/j.jaci.2012.08.049	http://dx.doi.org/10.1016/j.jaci.2012.08.049			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	044RP	23102920				2022-12-18	WOS:000311641100021
J	Heymann, PW; Kennedy, JL				Heymann, Peter W.; Kennedy, Joshua L.			Rhinovirus-induced asthma exacerbations during childhood: The importance of understanding the atopic status of the host	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Childhood asthma; rhinovirus infections; allergy; innate immunity	VIRAL-INFECTIONS; EARLY-LIFE; CHILDREN; RISK; SENSITIZATION; ALLERGEN; CELLS		[Heymann, Peter W.] Univ Virginia, Sch Med, Dept Pediat, Charlottesville, VA 22908 USA; [Heymann, Peter W.; Kennedy, Joshua L.] Univ Virginia, Sch Med, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Heymann, PW (corresponding author), Univ Virginia, Sch Med, Dept Pediat, POB 800386, Charlottesville, VA 22908 USA.	PWH5A@virginia.edu	Kennedy, Josh/P-1869-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI100799] Funding Source: NIH RePORTER; NIAID NIH HHS [U01 AI 100799, U01 AI100799] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baraldo S, 2012, J ALLERGY CLIN IMMUN, V130, P1307, DOI 10.1016/j.jaci.2012.08.005; Gill MA, 2010, J IMMUNOL, V184, P5999, DOI 10.4049/jimmunol.0901194; Heymann Peter W, 2005, Pediatr Infect Dis J, V24, pS217, DOI 10.1097/01.inf.0000188164.33856.f9; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Jackson DJ, 2012, AM J RESP CRIT CARE, V185, P281, DOI 10.1164/rccm.201104-0660OC; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Miller EK, 2012, AM J RESP CRIT CARE, V185, P508, DOI 10.1164/rccm.201108-1462OC; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Soto-Quiros M, 2012, J ALLERGY CLIN IMMUN, V129, P1499, DOI 10.1016/j.jaci.2012.03.040; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901	12	12	13	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2012	130	6					1315	1316		10.1016/j.jaci.2012.10.024	http://dx.doi.org/10.1016/j.jaci.2012.10.024			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	044RP	23195527	Green Accepted			2022-12-18	WOS:000311641100010
J	Somech, R; Lev, A; Simon, AJ; Hanna, S; Etzioni, A				Somech, Raz; Lev, Atar; Simon, Amos J.; Hanna, Suhair; Etzioni, Amos			T- and B-cell defects in a novel purine nucleoside phosphorylase mutation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Somech, Raz; Lev, Atar; Simon, Amos J.] Edmond & Lily Safra Childrens Hosp, Canc Res Ctr, Tel Hashomer, Israel; [Somech, Raz; Lev, Atar] Edmond & Lily Safra Childrens Hosp, Pediat Dept N B, Tel Hashomer, Israel; [Somech, Raz; Lev, Atar] Edmond & Lily Safra Childrens Hosp, Serv Immunol, Tel Hashomer, Israel; [Somech, Raz; Lev, Atar] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Hanna, Suhair; Etzioni, Amos] Technion Israel Inst Technol, Rappaport Fac Med, Meyers Children Hosp, Haifa, Israel	Tel Aviv University; Sackler Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Somech, R (corresponding author), Edmond & Lily Safra Childrens Hosp, Canc Res Ctr, Tel Hashomer, Israel.	raz.somech@sheba.health.gov.il						Bantia S, 2010, INT IMMUNOPHARMACOL, V10, P784, DOI 10.1016/j.intimp.2010.04.009; Dalal I, 2001, CLIN GENET, V59, P430, DOI 10.1034/j.1399-0004.2001.590608.x; Grunebaum E, 2004, NUCLEOS NUCLEOT NUCL, V23, P1411, DOI 10.1081/NCN-200027647; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Hirschhom R, 2007, PRIMARY IMMUNODEFICI, P169; HIRSCHHORN R, 1986, CLIN IMMUNOL IMMUNOP, V40, P157, DOI 10.1016/0090-1229(86)90081-4; Homminga I, 2011, BLOOD, V118, P2184, DOI 10.1182/blood-2011-02-337840; Jones B., 2003, DESIGN ANAL CROSS OV, V2nd; Juniper E, 1994, HISTAMINE METHACHOLI; Lev A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030494; Markert ML, 2004, J ALLERGY CLIN IMMUN, V113, P734, DOI 10.1016/j.jaci.2004.01.766; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Notarangelo Luigi D, 2009, Hematology Am Soc Hematol Educ Program, P139, DOI 10.1182/asheducation-2009.1.139; Papinazath T, 2011, J ALLERGY CLIN IMMUN, V128, P854, DOI 10.1016/j.jaci.2011.07.039; PEPYS J, 1975, CLIN ASPECTS IMMUNOL; Robak T, 2006, CURR MED CHEM, V13, P3165, DOI 10.2174/092986706778742918; SCHARENBERG JGM, 1986, EUR J IMMUNOL, V16, P381, DOI 10.1002/eji.1830160412; Serana F, 2011, J CLIN IMMUNOL, V31, P540, DOI 10.1007/s10875-011-9526-6; Sottini A, 2010, CLIN IMMUNOL, V136, P217, DOI 10.1016/j.clim.2010.04.005; Subbarao P, 2006, J ALLERGY CLIN IMMUN, V117, P1008, DOI 10.1016/j.jaci.2005.11.048	20	12	14	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					539	542		10.1016/j.jaci.2012.03.038	http://dx.doi.org/10.1016/j.jaci.2012.03.038			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22578971				2022-12-18	WOS:000307002200041
J	Ogawa, H; Fujimura, M; Takeuchi, Y; Makimura, K				Ogawa, Haruhiko; Fujimura, Masaki; Takeuchi, Yasuo; Makimura, Koichi			Possible roles of 2 basidiomycetous fungi in allergic fungal respiratory disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SCHIZOPHYLLUM-COMMUNE; ASTHMA		[Ogawa, Haruhiko] Ishikawa Ken Saiseikai Kanazawa Hosp, Div Pulm Med, Kanazawa, Ishikawa, Japan; [Fujimura, Masaki] Kanazawa Univ, Grad Sch Med Sci, Kanazawa, Ishikawa, Japan; [Takeuchi, Yasuo] Fujita Hlth Univ, Div Resp Med & Clin Allergy, Toyoake, Aichi, Japan; [Makimura, Koichi] Teikyo Univ, Grad Sch Med, Genome Res Ctr, Hachioji, Tokyo, Japan; [Makimura, Koichi] Teikyo Univ, Inst Med Mycol, Dept Mol Biol & Gene Diag, Hachioji, Tokyo, Japan	Kanazawa University; Fujita Health University; Teikyo University; Teikyo University	Ogawa, H (corresponding author), Ishikawa Ken Saiseikai Kanazawa Hosp, Div Pulm Med, Kanazawa, Ishikawa, Japan.	saiseikh@po3.nsknet.or.jp		MAKIMURA, Koichi/0000-0003-1645-3445				Agarwal R, 2011, MED MYCOL, V49, pS150, DOI 10.3109/13693786.2010.504752; Gonzalez GM, 2001, ANTIMICROB AGENTS CH, V45, P633, DOI 10.1128/AAC.45.2.633-635.2001; KAMEI K, 1994, CLIN INFECT DIS, V18, P305, DOI 10.1093/clinids/18.3.305; Knutsen AP, 2012, J ALLERGY CLIN IMMUN, V129, P280, DOI 10.1016/j.jaci.2011.12.970; Ogawa H, 2011, LUNG, V189, P485, DOI 10.1007/s00408-011-9320-5; Ogawa H, 2011, PULM PHARMACOL THER, V24, P559, DOI 10.1016/j.pupt.2011.04.030; Ogawa H, 2009, J ASTHMA, V46, P849, DOI 10.3109/02770900903199946	7	12	12	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					279	280		10.1016/j.jaci.2012.03.051	http://dx.doi.org/10.1016/j.jaci.2012.03.051			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22633326				2022-12-18	WOS:000306644800045
J	Drazen, JM				Drazen, Jeffrey M.			Asthma: The paradox of heterogeneity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Asthma; heterogeneity; inhaled glucocorticosteroid	MONTELUKAST; ASSOCIATION; PREVENTION; TRIAL		[Drazen, Jeffrey M.] Brigham & Womens Hosp, Div Pulm, Dept Med, Boston, MA 02115 USA; [Drazen, Jeffrey M.] Harvard Univ, Dept Med, Cambridge, MA 02138 USA	Harvard University; Brigham & Women's Hospital; Harvard University	Drazen, JM (corresponding author), Brigham & Womens Hosp, Div Pulm, Dept Med, 75 Francis St, Boston, MA 02115 USA.	jdrazen@rics.bwh.harvard.edu	Drazen, Jeffrey M/E-5841-2012	Drazen, Jeffrey/0000-0003-2715-9890				Amlani S, 2011, EXPERT OPIN PHARMACO, V12, P2119, DOI 10.1517/14656566.2011.600689; Barnes PJ, 2012, J ALLERGY CLIN IMMUN, V129, P48, DOI 10.1016/j.jaci.2011.11.006; Busse WW, 2011, J ALLERGY CLIN IMMUN, V128, P740, DOI 10.1016/j.jaci.2011.08.014; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Expert Panel 3, 2012, GUID DIAGN TREATM AS; GINA Science Committee, 2011, GLOB IN ASTHM; Grainge CL, 2011, NEW ENGL J MED, V364, P2006, DOI 10.1056/NEJMoa1014350; Holgate ST, 2011, J ALLERGY CLIN IMMUN, V128, P495, DOI 10.1016/j.jaci.2011.06.052; Jackson DJ, 2011, J ALLERGY CLIN IMMUN, V128, P1165, DOI 10.1016/j.jaci.2011.10.024; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Martinez FD, 2011, J ALLERGY CLIN IMMUN, V128, P939, DOI 10.1016/j.jaci.2011.09.020; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Rackemann FM, 1918, BOSTON MED SURG J, V178, P770, DOI 10.1056/NEJM191806061782302; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Szefler SJ, 2011, J ALLERGY CLIN IMMUN, V128, P485, DOI 10.1016/j.jaci.2011.07.010; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Tschumperlin DJ, 2004, NATURE, V429, P83, DOI 10.1038/nature02543; Weiss ST, 2012, J ALLERGY CLIN IMMUN, V129, P327, DOI 10.1016/j.jaci.2011.12.971	18	12	12	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1200	1201		10.1016/j.jaci.2012.03.026	http://dx.doi.org/10.1016/j.jaci.2012.03.026			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22541360				2022-12-18	WOS:000303418000003
J	Lee, JH; Kim, KW; Gee, HY; Lee, J; Lee, KH; Park, HS; Kim, SH; Kim, SW; Kim, MN; Kim, KE; Kim, KH; Lee, MG; Sohn, MH				Lee, Ji Hyun; Kim, Kyung Won; Gee, Heon Yung; Lee, Jaechun; Lee, Keun-Hwa; Park, Hae-Sim; Kim, Seung-Hyun; Kim, So Won; Kim, Mi Na; Kim, Kyu-Earn; Kim, Kyung Hwan; Lee, Min Goo; Sohn, Myung Hyun			A synonymous variation in protease-activated receptor-2 is associated with atopy in Korean children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Protease-activated receptor-2; SNP; association study; atopy; mRNA stability	UP-REGULATION; INFLAMMATION; EXPRESSION; RESPONSES; RELEASE; ANTIGEN; AIRWAYS; ASTHMA; PAR-2; FAMILIES	Background: Atopic diseases are the most common chronic diseases of childhood, and the genetics of atopy are complex and heterogeneous. Protease-activated receptor-2 (PAR-2) is involved in various inflammatory diseases, but the association of PAR-2 with allergic diseases remains unclear. Objective: To examine the contribution of genetic variation of PAR-2 to atopic phenotypes in the Korean childhood cohort. Methods: We identified PAR-2 variations in a Korean population and conducted association analyses by using 316 unrelated atopic and 210 nonatopic subjects. We analyzed serum IgE and total eosinophil count levels and examined PAR-2 mRNA and protein expression levels. Results: In the case-control association analysis, atopy was significantly associated with a single c.621C>T (p.I207I, rs631465) polymorphism of PAR-2 (P = .001, odds ratio = 1.95). Subjects with the c.621T risk allele had significantly higher serum IgE (P = .004) and total eosinophil count (P = .03) levels. Moreover, the positive association of c.621T was reproduced in the replication study (P = .01, joint P value of the replication < .001). An in silico analysis of RNA secondary structure prediction revealed that the C to T conversion at c.621 greatly increased predicted PAR-2 mRNA stability. This was also confirmed by an in vitro assay for mRNA stability. Furthermore, following an in vivo approach on gene expression in PBMCs showed that the expression levels of PAR-2 mRNA and protein in subjects with the c.621CT or TT genotype were significantly higher than in those with the c.621CC genotype. Conclusions: These results indicate that the synonymous c.621C>T polymorphism in PAR-2 might be associated with the risk of atopy, potentially by altering PAR-2 gene expression. (J Allergy Clin Immunol 2011;128:1326-34.)	[Kim, Kyung Won; Kim, Mi Na; Kim, Kyu-Earn; Sohn, Myung Hyun] Yonsei Univ, Coll Med, Dept Pediat, Seoul 120752, South Korea; [Lee, Ji Hyun; Gee, Heon Yung; Kim, So Won; Kim, Kyung Hwan; Lee, Min Goo] Yonsei Univ, Coll Med, Dept Pharmacol, Res Ctr Membrane Transporters, Seoul 120752, South Korea; [Lee, Ji Hyun] Yonsei Univ, Coll Med, Res Ctr Human Nat Def Syst, Seoul 120752, South Korea; [Kim, Kyung Won; Kim, Mi Na; Kim, Kyu-Earn; Sohn, Myung Hyun] Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Severance Med Res Inst,Inst Allergy, Seoul 120752, South Korea; [Lee, Jaechun; Lee, Keun-Hwa] Jeju Natl Univ, Sch Med, Ctr Environm Hlth, Cheju, South Korea; [Park, Hae-Sim; Kim, Seung-Hyun] Ajou Univ, Sch Med, Dept Allergy & Rheumatol, Suwon 441749, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Jeju National University; Ajou University	Sohn, MH (corresponding author), Yonsei Univ, Coll Med, Dept Pediat, 134 Sinchon Dong, Seoul 120752, South Korea.	mhsohn@yuhs.ac	rchnds, rchnds/D-7595-2016; Gee, Heon Yung/K-7781-2019; Lee, Min Goo/AAS-4636-2020; Park, Hae-Sim/S-7974-2019; Lee, Min Goo/D-5635-2012	Gee, Heon Yung/0000-0002-8741-6177; Lee, Min Goo/0000-0001-7436-012X; Lee, Min Goo/0000-0001-7436-012X; Lee, Jaechun/0000-0003-1220-8282; Park, Hae-Sim/0000-0003-2614-0303; Kim, Kyung Won/0000-0003-4529-6135; Kim, Mi Na/0000-0002-1675-0688; Sohn, Myung Hyun/0000-0002-2478-487X	Yonsei University College of Medicine [6-2010-0017]; Korea Health 21 RD Project [A030001]; Environmental Health Center, Jeju, Korea; Ministry of Health Welfare, Korea; National Research Foundation (NRF) of Korea; Ministry of Education, Science and Technology [2009-0075056, 2011-0001173]	Yonsei University College of Medicine(General Electric); Korea Health 21 RD Project; Environmental Health Center, Jeju, Korea; Ministry of Health Welfare, Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); National Research Foundation (NRF) of Korea(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This study was supported by a faculty research grant of Yonsei University College of Medicine for 2010 (6-2010-0017), grants A030001 from the Korea Health 21 R&D Project, Environmental Health Center, Jeju, Korea, Ministry of Health & Welfare, Korea, and Basic Science Research Program through the National Research Foundation (NRF) of Korea funded by the Ministry of Education, Science and Technology (2009-0075056 and 2011-0001173).	Akers IA, 2000, AM J PHYSIOL-LUNG C, V278, pL193, DOI 10.1152/ajplung.2000.278.1.L193; Antonarakis SE, 1998, HUM MUTAT, V11, P1; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bosco A, 2009, J IMMUNOL, V182, P6011, DOI 10.4049/jimmunol.0804125; Carvalho RFD, 2010, EXP DERMATOL, V19, P117, DOI 10.1111/j.1600-0625.2009.00998.x; Casolaro V, 1996, CURR OPIN IMMUNOL, V8, P796, DOI 10.1016/S0952-7915(96)80007-0; Chow JM, 2000, BRIT J PHARMACOL, V131, P1584, DOI 10.1038/sj.bjp.0703738; Cicala C, 2001, BRIT J PHARMACOL, V132, P1229, DOI 10.1038/sj.bjp.0703934; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; Compton SJ, 2002, BIOCHEM J, V368, P495, DOI 10.1042/BJ20020706; Compton SJ, 2000, J BIOL CHEM, V275, P39207, DOI 10.1074/jbc.M007215200; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; D'Agostino B, 2007, CLIN EXP ALLERGY, V37, P1436, DOI 10.1111/j.1365-2222.2007.02793.x; D'Andrea MR, 1998, J HISTOCHEM CYTOCHEM, V46, P157; Duan JB, 2003, HUM MOL GENET, V12, P205, DOI 10.1093/hmg/ddg055; Ebeling C, 2005, J ALLERGY CLIN IMMUN, V115, P623, DOI 10.1016/j.jaci.2004.11.042; Ebeling C, 2007, J IMMUNOL, V179, P2910, DOI 10.4049/jimmunol.179.5.2910; Hofacker IL, 2003, NUCLEIC ACIDS RES, V31, P3429, DOI 10.1093/nar/gkg599; HOFACKER IL, 2009, CURR PROTOC BIOINFOR, V26; Hollams EM, 2009, J ALLERGY CLIN IMMUN, V124, P463, DOI 10.1016/j.jaci.2009.06.019; Hong JH, 2004, J ALLERGY CLIN IMMUN, V113, P315, DOI 10.1016/j.jaci.2003.11.026; Hunt R, 2009, METHODS MOL BIOL, V578, P23, DOI 10.1007/978-1-60327-411-1_2; Kahn ML, 1998, J BIOL CHEM, V273, P23290, DOI 10.1074/jbc.273.36.23290; Kato T, 2009, ALLERGY, V64, P1366, DOI 10.1111/j.1398-9995.2009.02023.x; Knight DA, 2001, J ALLERGY CLIN IMMUN, V108, P797, DOI 10.1067/mai.2001.119025; Koppelman GH, 2002, J ALLERGY CLIN IMMUN, V109, P498, DOI 10.1067/mai.2002.122235; Lee HM, 2007, ANN OTO RHINOL LARYN, V116, P554, DOI 10.1177/000348940711600712; Ono SJ, 2000, ANNU REV IMMUNOL, V18, P347, DOI 10.1146/annurev.immunol.18.1.347; Peden DB, 2000, ENVIRON HEALTH PERSP, V108, P475, DOI 10.2307/3454539; Qiao LY, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-62; Ramelli G, 2010, IMMUNOLOGY, V129, P20, DOI 10.1111/j.1365-2567.2009.03144.x; Reed CE, 2004, J ALLERGY CLIN IMMUN, V114, P997, DOI 10.1016/j.jaci.2004.07.060; Ronchetti R, 2007, INT ARCH ALLERGY IMM, V142, P79, DOI 10.1159/000096031; Schmidlin F, 2002, J IMMUNOL, V169, P5315, DOI 10.4049/jimmunol.169.9.5315; Schmidlin Fabien, 2001, Current Opinion in Pharmacology, V1, P575, DOI 10.1016/S1471-4892(01)00099-6; Sedgwick JB, 2004, J ALLERGY CLIN IMMUN, V114, P568, DOI 10.1016/j.jaci.2004.05.023; Sengler C, 2001, RESP RES, V3; Shpacovitch V, 2008, J LEUKOCYTE BIOL, V83, P1309, DOI 10.1189/jlb.0108001; Upham JW, 2005, CURR OPIN ALLERGY CL, V5, P167, DOI 10.1097/01.all.0000162310.79555.ed; Venanzi S, 2001, CLIN EXP ALLERGY, V31, P1220, DOI 10.1046/j.1365-2222.2001.01132.x; Vliagoftis A, 2000, J ALLERGY CLIN IMMUN, V106, P537, DOI 10.1067/mai.2000.109058; Vliagoftis H, 2001, J ALLERGY CLIN IMMUN, V107, P679, DOI 10.1067/mai.2001.114245; Webb BT, 2007, HUM GENET, V121, P83, DOI 10.1007/s00439-006-0285-z	45	12	12	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1326	U702		10.1016/j.jaci.2011.06.036	http://dx.doi.org/10.1016/j.jaci.2011.06.036			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	21839502	Bronze			2022-12-18	WOS:000298342700024
J	Turner, PJ; Gray, PEA; Wong, M; Varese, N; Rolland, JM; O'Hehir, R; Campbell, DE				Turner, Paul J.; Gray, Paul E. A.; Wong, Melanie; Varese, Nirupama; Rolland, Jennifer M.; O'Hehir, Robyn; Campbell, Dianne E.			Anaphylaxis to apple and orange seed	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CROSS-REACTIVITY; FOOD ALLERGY; CHILDREN; PEANUT		[Turner, Paul J.; Gray, Paul E. A.; Wong, Melanie; Campbell, Dianne E.] Childrens Hosp Westmead, Dept Allergy & Immunol, Sydney, NSW, Australia; [Turner, Paul J.; Campbell, Dianne E.] Univ Sydney, Sch Med, Discipline Pediat & Child Hlth, Sydney, NSW 2006, Australia; [Varese, Nirupama; Rolland, Jennifer M.; O'Hehir, Robyn] Monash Univ, Dept Immunol, Melbourne, Vic 3004, Australia	University of Sydney; University of Sydney; Monash University	Turner, PJ (corresponding author), Childrens Hosp Westmead, Dept Allergy & Immunol, Sydney, NSW, Australia.	paulyt@doctors.net.uk	Varese, Nirupama P/H-3596-2011; O'Hehir, Robyn E/H-3627-2011	O'Hehir, Robyn E/0000-0002-3489-7595; Gray, Paul/0000-0003-2057-3968; Varese, Nirupama/0000-0001-9074-3710; Turner, Paul/0000-0001-9862-5161; Campbell, Dianne/0000-0002-0907-6963	National Institute for Health Research [CL-2009-18-009] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR))		de Leon MP, 2003, CLIN EXP ALLERGY, V33, P1273, DOI 10.1046/j.1365-2222.2003.01761.x; Glaspole IN, 2007, ANN ALLERG ASTHMA IM, V98, P286, DOI 10.1016/S1081-1206(10)60720-X; Ibanez MD, 2004, J ALLERGY CLIN IMMUN, V113, P175, DOI 10.1016/j.jaci.2003.10.059; Katelaris CH, 2010, CURR OPIN ALLERGY CL, V10, P246, DOI 10.1097/ACI.0b013e32833973fb; SAARINEN UM, 1980, LANCET, V1, P166; Wang ET, 2008, ANN ALLERG ASTHMA IM, V101, P553, DOI 10.1016/S1081-1206(10)60299-2; ZHU SL, 1989, ASIAN PAC J ALLERGY, V7, P5	7	12	12	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1363	1365		10.1016/j.jaci.2011.07.005	http://dx.doi.org/10.1016/j.jaci.2011.07.005			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	21802128				2022-12-18	WOS:000298342700034
J	Kohyama, K; Abe, S; Kodaira, K; Yukawa, T; Hozawa, S; Morioka, J; Inamura, H; Ota, M; Sagara, H; Kurosawa, M				Kohyama, Kenya; Abe, Shyuzo; Kodaira, Kazumi; Yukawa, Tatsuo; Hozawa, Soichiro; Morioka, Junichiro; Inamura, Hiroaki; Ota, Mayumi; Sagara, Hironori; Kurosawa, Motohiro			Polymorphisms of the CYP2C19 gene in Japanese patients with aspirin-exacerbated respiratory disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CYCLOOXYGENASE; INFLAMMATION; ASTHMA		[Kohyama, Kenya; Abe, Shyuzo; Kodaira, Kazumi; Morioka, Junichiro; Inamura, Hiroaki; Ota, Mayumi; Kurosawa, Motohiro] Gunma Hosp Allerg & Resp Dis, Gunma Inst Allergy & Asthma, Gunma, Japan; [Kohyama, Kenya; Ota, Mayumi; Sagara, Hironori] Dokkyo Med Univ, Koshigaya Hosp, Dept Resp Med, Koshigaya, Japan; [Yukawa, Tatsuo] Yukawa Clin Internal Med, Utsunomiya, Tochigi, Japan; [Hozawa, Soichiro] Hiroshima Allergy & Resp Clin, Hiroshima, Japan	Dokkyo Medical University	Kohyama, K (corresponding author), Gunma Hosp Allerg & Resp Dis, Gunma Inst Allergy & Asthma, Ohra Machi, Gunma, Japan.	motohiro@gunma-hosp-allergy.or.jp						Bertrand-Thiebault C, 2008, ANN HUM GENET, V72, P178, DOI 10.1111/j.1469-1809.2007.00417.x; Buhl T, 2011, J ALLERGY CLIN IMMUN, V127, P284, DOI 10.1016/j.jaci.2010.10.044; Giusti B, 2007, PHARMACOGENET GENOM, V17, P1057, DOI 10.1097/FPC.0b013e3282f1b2be; Gray PA, 2002, BRIT J PHARMACOL, V137, P1031, DOI 10.1038/sj.bjp.0704927; Higashi N, 2010, J ALLERGY CLIN IMMUN, V125, P1084, DOI 10.1016/j.jaci.2009.12.977; Kawagishi Y, 2002, J ALLERGY CLIN IMMUN, V109, P936, DOI 10.1067/mai.2002.124466; Kowalski ML, 2003, J ALLERGY CLIN IMMUN, V112, P505, DOI 10.1067/mai.2003.1678; Menzies D, 2008, J ALLERGY CLIN IMMUN, V121, P1184, DOI 10.1016/j.jaci.2008.01.009; Rodrigues AD, 2005, DRUG METAB DISPOS, V33, P1567, DOI 10.1124/dmd.105.006452	9	12	12	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					1117	1120		10.1016/j.jaci.2011.07.013	http://dx.doi.org/10.1016/j.jaci.2011.07.013			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	842FJ	21855977				2022-12-18	WOS:000296578200032
J	Smit, LAM; Bouzigon, E; Bousquet, J; Le Moual, N; Nadif, R; Pin, I; Lathrop, M; Demenais, F; Kauffmann, F; Siroux, V				Smit, Lidwien A. M.; Bouzigon, Emmanuelle; Bousquet, Jean; Le Moual, Nicole; Nadif, Rachel; Pin, Isabelle; Lathrop, Mark; Demenais, Florence; Kauffmann, Francine; Siroux, Valerie		Epidemiological Study Genetics Env	Mold allergen sensitization in adult asthma according to integrin beta 3 polymorphisms and Toll-like receptor 2/+596 genotype	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Alternaria; Aspergillus; allergy; asthma; Cladosporium; epidemiology; epistasis; genetics; innate immunity	RESPIRATORY HEALTH SURVEY; SKIN PRICK TESTS; BRONCHIAL HYPERRESPONSIVENESS; ALTERNARIA-ALTERNATA; IMMUNOGLOBULIN-E; US HOMES; ENVIRONMENT; ATOPY; GENE; ITGB3	Background: Integrin beta 3 (ITGB3) and Toll-like receptor 2 (TLR2) are candidate genes for asthma and sensitization to mold allergens. Integrin beta 3 forms a complex with TLR2, and this biological interaction is required for the response of monocytes to TLR2 agonists such as fungal glucan. Objective: To study whether genetic interaction between single nucleotide polymorphisms (SNPs) in genes encoding the TLR2-ITGB3 complex enhances susceptibility to mold sensitization. Methods: Association analysis was conducted in 1243 adults (524 with asthma) who participated in the follow-up of the Epidemiological Study on the Genetics and Environment of Asthma. Allergic sensitization to mold allergens was determined by skin prick testing. Association of mold sensitization with 14 ITGB3 SNPs was tested under an additive genetic model. Interaction between ITGB3 SNPs and TLR2/+596, which was previously shown to be associated with asthma, was studied. Results: A positive skin prick test to mold was found in 115 subjects with asthma (22.0%) and in 61 subjects without asthma (8.5%). The ITGB3 rs2056131 A allele was associated with mold sensitization in subjects with asthma with an odds ratio (95% CI) of 0.60 (0.43-0.83; P = .001). Ten other ITGB3 SNPs were significantly associated with mold sensitization in TLR2/+596TT subjects with asthma (P = .03-.002), whereas much weaker associations were found in carriers of the TLR2/+596 C allele (P = .60-.04). Interaction between TLR2/+596 and these ITGB3 SNPs was statistically significant (P interaction = .05-.001). Conclusion: TLR2/+596 genotype may influence the association between ITGB3 SNPs and mold sensitization in adults with asthma. (J Allergy Clin Immunol 2011; 128: 185-91.)	[Smit, Lidwien A. M.] Univ Utrecht, Inst Risk Assessment Sci, Div Environm Epidemiol, Utrecht, Netherlands; [Smit, Lidwien A. M.; Bousquet, Jean; Le Moual, Nicole; Nadif, Rachel; Kauffmann, Francine] CESP Ctr Res Epidemiol & Populat Hlth, INSERM, U1018, Resp & Environm Epidemiol Team, Villejuif, France; [Smit, Lidwien A. M.; Le Moual, Nicole; Nadif, Rachel; Kauffmann, Francine] Univ Paris 11, UMRS 1018, Villejuif, France; [Bouzigon, Emmanuelle; Demenais, Florence] INSERM, U946, Paris, France; [Bouzigon, Emmanuelle; Demenais, Florence] Univ Paris Diderot, Inst Univ Hematol, Paris, France; [Bouzigon, Emmanuelle; Demenais, Florence] Fdn Jean Dausset, Ctr Etud Polymorphisme Humain, Paris, France; [Bousquet, Jean] Hop Arnaud Villeneuve, Montpellier, France; [Pin, Isabelle; Siroux, Valerie] INSERM, U823, Grenoble, France; [Pin, Isabelle; Siroux, Valerie] Univ Grenoble 1, F-38041 Grenoble, France; [Pin, Isabelle] Ctr Hosp Univ Grenoble, Grenoble, France; [Lathrop, Mark] Ctr Natl Genotypage, Inst Genom, Commissariat Energie Atom, Evry, France	Utrecht University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Foundation Jean Dausset-CEPH; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite Paris Saclay	Smit, LAM (corresponding author), Univ Utrecht, Inst Risk Assessment Sci, Div Environm Epidemiol, POB 80178, Utrecht, Netherlands.	L.A.Smit@uu.nl	Smit, Lidwien AM/AFC-8689-2022; Bouzigon, Emmanuelle/L-2766-2017; Le Moual, Nicole/GNP-5114-2022; Le Moual, Nicole/R-8976-2016; Nadif, Rachel/R-2876-2016; Demenais, Florence/G-3298-2013; PIN, Isabelle/N-3020-2013; siroux, valerie/N-1865-2013; Bousquet, Jean/O-4221-2019	Smit, Lidwien AM/0000-0003-0292-0946; Bouzigon, Emmanuelle/0000-0001-5756-4286; Le Moual, Nicole/0000-0002-2723-5569; Le Moual, Nicole/0000-0002-2723-5569; Nadif, Rachel/0000-0003-4938-9339; Demenais, Florence/0000-0001-8361-0936; siroux, valerie/0000-0001-7329-7237; 	French Ministry of Higher Education and Research; University Paris Diderot-Paris 7; French Agency for Environmental and Occupational Health Safety [AFSSET-APR-SE-2004]; French National Agency for Research [ANR 05-SEST-020-02/05-9-97, ANR 06-CEBS]; Merck Sharp Dohme; Hospital Program of Clinical Research-Paris; Netherlands Organization for Scientific Research Van Gogh Programme for French-Dutch cooperation; European Academy of Allergology and Clinical Immunology-Global Allergy and Asthma European Network	French Ministry of Higher Education and Research; University Paris Diderot-Paris 7; French Agency for Environmental and Occupational Health Safety; French National Agency for Research(French National Research Agency (ANR)); Merck Sharp Dohme(Merck & Company); Hospital Program of Clinical Research-Paris; Netherlands Organization for Scientific Research Van Gogh Programme for French-Dutch cooperation; European Academy of Allergology and Clinical Immunology-Global Allergy and Asthma European Network	Supported by the French Ministry of Higher Education and Research, University Paris Diderot-Paris 7, grants from the French Agency for Environmental and Occupational Health Safety (grant no. AFSSET-APR-SE-2004), the French National Agency for Research (grant nos. ANR 05-SEST-020-02/05-9-97 and ANR 06-CEBS), Merck Sharp & Dohme, the Hospital Program of Clinical Research-Paris, and The Netherlands Organization for Scientific Research Van Gogh Programme for French-Dutch cooperation. L. A. M. S. was supported by a European Academy of Allergology and Clinical Immunology-Global Allergy and Asthma European Network exchange fellowship award.	BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bojesen SE, 2003, J NATL CANCER I, V95, P1150, DOI 10.1093/jnci/djg005; Bousquet PJ, 2007, ALLERGY, V62, P301, DOI 10.1111/j.1398-9995.2006.01293.x; BRUNEKREEF B, 1989, AM REV RESPIR DIS, V140, P1363, DOI 10.1164/ajrccm/140.5.1363; Carvalho A, 2008, J INFECT DIS, V197, P618, DOI 10.1086/526500; Chen KH, 2011, SHOCK, V35, P35, DOI 10.1097/SHK.0b013e3181eb45b3; Coutinho AM, 2007, HUM GENET, V121, P243, DOI 10.1007/s00439-006-0301-3; Donfack J, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-145; Ege MJ, 2011, J ALLERGY CLIN IMMUN, V127, P138, DOI 10.1016/j.jaci.2010.09.041; Gerold G, 2008, NAT IMMUNOL, V9, P761, DOI 10.1038/ni.1618; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Karihaloo C, 2002, CLIN EXP ALLERGY, V32, P1316, DOI 10.1046/j.1365-2745.2002.01447.x; Kauffmann F, 1997, AM J RESP CRIT CARE, V156, pS123, DOI 10.1164/ajrccm.156.4.12tac9; Kauffmann F, 2002, CLIN EXP ALLERGY, V32, P379, DOI 10.1046/j.1365-2222.2002.01325.x; KAUFFMANN F, 1995, CLIN EXP ALLERGY, V25, P19, DOI 10.1111/j.1365-2222.1995.tb00413.x; Leung TF, 2005, RESP MED, V99, P216, DOI 10.1016/j.rmed.2004.06.004; Ma DQ, 2010, AM J MED GENET B, V153B, P477, DOI 10.1002/ajmg.b.31003; Misiak RT, 2009, J ALLERGY CLIN IMMUN, V123, P1401, DOI 10.1016/j.jaci.2009.03.006; O'Driscoll BR, 2009, CLIN EXP ALLERGY, V39, P1677, DOI 10.1111/j.1365-2222.2009.03339.x; Ober C, 2011, TRENDS GENET, V27, P107, DOI 10.1016/j.tig.2010.12.004; Randriamanantany ZA, 2010, ALLERGY, V65, P368, DOI 10.1111/j.1398-9995.2009.02210.x; Rogers AJ, 2009, AM J RESP CRIT CARE, V179, P1084, DOI 10.1164/rccm.200812-1860OC; Rossouw JE, 2008, ARCH INTERN MED, V168, P2245, DOI 10.1001/archinte.168.20.2245; Salo PM, 2006, J ALLERGY CLIN IMMUN, V118, P892, DOI 10.1016/j.jaci.2006.07.037; Salo PM, 2005, J ALLERGY CLIN IMMUN, V116, P623, DOI 10.1016/j.jaci.2005.05.030; Scaffidi AK, 2001, J CELL SCI, V114, P3507; Simpson A, 2010, CLIN EXP ALLERGY, V40, P209, DOI 10.1111/j.1365-2222.2009.03391.x; Siroux V, 2009, J ALLERGY CLIN IMMUN, V124, P681, DOI 10.1016/j.jaci.2009.06.010; Smit LAM, 2009, AM J RESP CRIT CARE, V179, P363, DOI 10.1164/rccm.200810-1533OC; Thompson EE, 2007, J ALLERGY CLIN IMMUN, V119, P1423, DOI 10.1016/j.jaci.2007.03.029; Undas A, 2001, CIRCULATION, V104, P2666, DOI 10.1161/hc4701.099787; VERHOEFF AP, 1995, AM J EPIDEMIOL, V141, P103, DOI 10.1093/oxfordjournals.aje.a117398; Weiss LA, 2005, AM J RESP CRIT CARE, V172, P67, DOI 10.1164/rccm.200411-1555OC; Weiss LA, 2006, HUM GENET, V120, P93, DOI 10.1007/s00439-006-0196-z; Zock JP, 2002, J ALLERGY CLIN IMMUN, V110, P285, DOI 10.1067/mai.2002.126383; Zureik M, 2002, BMJ-BRIT MED J, V325, P411, DOI 10.1136/bmj.325.7361.411	37	12	14	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2011	128	1					185	U297		10.1016/j.jaci.2011.04.007	http://dx.doi.org/10.1016/j.jaci.2011.04.007			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	785RE	21570717	Green Submitted			2022-12-18	WOS:000292245600024
J	Holt, RJ; Zhang, YM; Binia, A; Dixon, AL; Vandiedonck, C; Cookson, WO; Knight, JC; Moffatt, MF				Holt, Richard J.; Zhang, Youming; Binia, Aristea; Dixon, Anna L.; Vandiedonck, Claire; Cookson, William O.; Knight, Julian C.; Moffatt, Miriam F.			Allele-specific transcription of the asthma-associated PHD finger protein 11 gene (PHF11) modulated by octamer-binding transcription factor 1 (Oct-1)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma genetics; PHF11; IgE; rs1046295; electrophoretic mobility shift assay; Oct-1; gene expression	GENOME-WIDE SEARCH; IMMUNOGLOBULIN-E LEVELS; CHROMOSOME 13Q14; SUSCEPTIBILITY GENE; EXPRESSION ANALYSIS; POSITIONAL CLONING; COMPETITIVE PCR; LINKAGE; LOCI; FAMILIES	Background: Asthma is a common, chronic inflammatory airway disease of major public health importance with multiple genetic determinants. Previously, we found by positional cloning that PHD finger protein 11 (PHF11) on chromosome 13q14 modifies serum immunoglobulin E (IgE) concentrations and asthma susceptibility. No coding variants in PHF11 were identified. Objective: Here we investigate the 3 single nucleotide polymorphisms (SNPs) in this gene most significantly associated with total serum IgE levels-rs3765526, rs9526569, and rs1046295-for a role in transcription factor binding. Methods: We used electrophoretic mobility shift assays to examine the effect of the 3 SNPs on transcription factor binding in 3 cell lines relevant to asthma pathogenesis. Relative preferential expression of alleles was investigated by using the allelotyping method. Results: Electrophoretic mobility shift assays show that rs1046295 modulates allele-specific binding by the octamer-binding transcription factor 1 (Oct-1). Analysis of the relative expression levels of the 2 alleles of this SNP in heterozygous individuals showed a modest, but highly significant (P = 6.5 x 10(-16)), preferential expression of the A allele consistent with a functional role for rs1046295. Conclusion: These results suggest a mechanism by which rs1046295 may act as a regulatory variant modulating transcription at this locus and altering asthma susceptibility. (J Allergy Clin Immunol 2011;127:1054-62.)	[Holt, Richard J.; Vandiedonck, Claire; Knight, Julian C.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; [Zhang, Youming; Binia, Aristea; Cookson, William O.; Moffatt, Miriam F.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England; [Dixon, Anna L.] Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England	University of Oxford; Wellcome Centre for Human Genetics; Imperial College London; University of Bath	Holt, RJ (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.	rholt@well.ox.ac.uk	Cookson, William/HHC-1790-2022; Knight, Julian Charles/W-2399-2019; Knight, Julian/C-7242-2009	Knight, Julian Charles/0000-0002-0377-5536; Knight, Julian/0000-0002-0377-5536; Zhang, Youming/0000-0001-5403-4044; Binia, Aristea/0000-0002-8327-049X; vandiedonck, claire/0000-0002-6669-6923	Wellcome Trust [075491/Z/04]; Medical Research Council [G1000758B, G1000758, G0801056B] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10212] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by the Wellcome Trust (075491/Z/04).	Allen M, 2003, NAT GENET, V35, P258, DOI 10.1038/ng1256; Anderson GG, 2002, EUR J HUM GENET, V10, P266, DOI 10.1038/sj.ejhg.5200801; Anderson HR, 2005, BRIT MED J, V330, P1037, DOI 10.1136/bmj.330.7499.1037; Anderson HR, 2004, BRIT MED J, V328, P1052, DOI 10.1136/bmj.38057.583727.47; Bhattacharyya S, 2000, GENOMICS, V70, P286, DOI 10.1006/geno.2000.6398; Blumenthal MN, 2004, GENES IMMUN, V5, P226, DOI 10.1038/sj.gene.6364063; Bousquet J, 2005, B WORLD HEALTH ORGAN, V83, P548; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bray NJ, 2003, HUM GENET, V113, P149, DOI 10.1007/s00439-003-0956-y; Cheng CK, 2002, ENDOCRINOLOGY, V143, P4693, DOI 10.1210/en.2002-220576; Choudhry S, 2008, HUM GENET, V123, P455, DOI 10.1007/s00439-008-0495-7; Clarke E, 2008, J ALLERGY CLIN IMMUN, V121, P1148, DOI 10.1016/j.jaci.2008.02.028; Cookson W, 2003, TRENDS GENET, V19, P169, DOI 10.1016/S0168-9525(03)00025-8; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Ding CM, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-8; Ding CM, 2003, P NATL ACAD SCI USA, V100, P3059, DOI 10.1073/pnas.0630494100; Dizier MH, 2000, AM J RESP CRIT CARE, V162, P1812, DOI 10.1164/ajrccm.162.5.2002113; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; Fleming DM, 2000, THORAX, V55, P657, DOI 10.1136/thorax.55.8.657; Gao JM, 2010, RESPIRATION, V79, P17, DOI 10.1159/000235545; Gupta R, 2004, CLIN EXP ALLERGY, V34, P520, DOI 10.1111/j.1365-2222.2004.1935.x; Hacking D, 2004, GENES IMMUN, V5, P274, DOI 10.1038/sj.gene.6364067; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Himes BE, 2009, AM J HUM GENET, V84, P581, DOI 10.1016/j.ajhg.2009.04.006; Hizawa N, 1998, J ALLERGY CLIN IMMUN, V102, P436, DOI 10.1016/S0091-6749(98)70132-0; Hui J, 2008, HUM GENET, V123, P297, DOI 10.1007/s00439-008-0477-9; Jang N, 2005, GENES IMMUN, V6, P262, DOI 10.1038/sj.gene.6364169; Kim SH, 2009, CLIN EXP ALLERGY, V39, P203, DOI 10.1111/j.1365-2222.2008.03117.x; Kimura K, 1999, HUM MOL GENET, V8, P1487, DOI 10.1093/hmg/8.8.1487; Knight JC, 2003, NAT GENET, V33, P469, DOI 10.1038/ng1124; Koppelman GH, 2002, J ALLERGY CLIN IMMUN, V109, P498, DOI 10.1067/mai.2002.122235; Laitinen T, 2004, SCIENCE, V304, P300, DOI 10.1126/science.1090010; Lo HS, 2003, GENOME RES, V13, P1855, DOI 10.1101/gr.1006603; Los H, 2001, Twin Res, V4, P81, DOI 10.1375/twin.4.2.81; Marsh DG, 1997, NAT GENET, V15, P389; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Mordvinov VA, 1999, J ALLERGY CLIN IMMUN, V103, P1125, DOI 10.1016/S0091-6749(99)70188-0; Nicolae D, 2005, AM J HUM GENET, V76, P349, DOI 10.1086/427763; Noguchi E, 2005, AM J RESP CRIT CARE, V172, P183, DOI 10.1164/rccm.200409-1223OC; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Ober C, 2008, NEW ENGL J MED, V358, P1682, DOI 10.1056/NEJMoa0708801; Pastinen T, 2004, PHYSIOL GENOMICS, V16, P184, DOI 10.1152/physiolgenomics.00163.2003; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Salerno MS, 2000, J BIOL CHEM, V275, P4525, DOI 10.1074/jbc.275.6.4525; Salerno MS, 2001, CYTOKINE, V15, P4, DOI 10.1006/cyto.2001.0897; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Skrepnek GH, 2004, AM J MANAG CARE, V10, pS129; Thomas MA, 1999, EUR J BIOCHEM, V265, P300, DOI 10.1046/j.1432-1327.1999.00732.x; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Weidinger S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000166; Weiss ST, 2004, HUM MOL GENET, V13, pR83, DOI 10.1093/hmg/ddh080; Wiltshire S, 1998, HUM MOL GENET, V7, P27, DOI 10.1093/hmg/7.1.27; WINGENDER E, 1998, NUCLEIC ACIDS RES, V16, P1879; Xu JF, 2000, AM J HUM GENET, V67, P1163, DOI 10.1086/321190; Yan H, 2002, SCIENCE, V297, P1143, DOI 10.1126/science.1072545; Yokouchi Y, 2000, GENOMICS, V66, P152, DOI 10.1006/geno.2000.6201; Zhang YM, 2003, NAT GENET, V34, P181, DOI 10.1038/ng1166	59	12	13	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4					1054	U322		10.1016/j.jaci.2010.12.015	http://dx.doi.org/10.1016/j.jaci.2010.12.015			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743YL	21320718	Green Accepted, Green Submitted			2022-12-18	WOS:000289055800029
J	Reche, M; Valbuena, T; Fiandor, A; Padial, A; Canete, A; Pascual, C				Reche, M.; Valbuena, T.; Fiandor, A.; Padial, A.; Canete, A.; Pascual, C.			Early Induction Of Oral Tolerance Protocol (OTI) In Children With Cow'S Milk Allergy.	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	American-Academy-of-Allergy-Asthma-and-Immunology Annual Meeting	MAR 18-22, 2011	San Francisco, CA	Amer Acad Allergy Asthma & Immunol					[Reche, M.; Valbuena, T.; Padial, A.; Canete, A.; Pascual, C.] Hosp Infanta Sofia, Madrid, Spain; [Fiandor, A.] Hosp Univ La Paz, Madrid, Spain	Hospital Universitario La Paz			Reche, Marta/ABF-8972-2021; Valbuena, Teresa/ABF-8920-2021						0	12	12	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2		S			AB24	AB24		10.1016/j.jaci.2010.12.108	http://dx.doi.org/10.1016/j.jaci.2010.12.108			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	832YI		Bronze			2022-12-18	WOS:000295846400092
J	Ohmatsu, H; Kadono, T; Sugaya, M; Tomita, M; Kai, H; Miyagaki, T; Saeki, H; Tamaki, K; Steeber, DA; Tedder, TF; Sato, S				Ohmatsu, Hanako; Kadono, Takafumi; Sugaya, Makoto; Tomita, Manabu; Kai, Hiromichi; Miyagaki, Tomomitsu; Saeki, Hidehisa; Tamaki, Kunihiko; Steeber, Douglas A.; Tedder, Thomas F.; Sato, Shinichi			alpha 4 beta 7 Integrin is essential for contact hypersensitivity by regulating migration of T cells to skin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						alpha 4 beta 7 Integrin; contact hypersensitivity responses; VCAM-1	ALPHA(E) (CD103)-DEFICIENT MICE; REGIONAL LYMPH-NODES; VERSUS-HOST-DISEASE; DENDRITIC CELLS; IN-VIVO; ADHESION MOLECULE-1; LANGERHANS CELLS; BETA-7 INTEGRINS; EXTRAVASCULAR TISSUE; VASCULAR ADDRESSIN	Background: beta 7 Integrin, a cell adhesion molecule, is present in the form of alpha 4 beta 7 integrin or alpha E beta 7 integrin. alpha 4 beta 7 Integrin is expressed on most leucocytes and is essential for their migration to gut-associated lymphoid tissues by interacting with its primary ligand, mucosal addressin cell adhesion molecule-1, which is preferentially expressed in gut-associated lymphoid tissues. Although the importance of alpha 4 beta 7 integrin in intestinal inflammation has been established, its role in cutaneous inflammation remains to be elucidated. Objective: We sought to investigate the role of beta 7 integrin in cutaneous inflammation. Methods: We used a murine contact hypersensitivity model and examined the role of beta 7 integrin by using beta 7 integrin-deficient and alpha E integrin-deficient mice. Results: beta 7 Integrin-deficient mice, not aE integrin-deficient mice, are defective in contact hypersensitivity responses. beta 7 Integrin deficiency does not affect irritant contact dermatitis. The distribution, migration, and function of antigen presenting cells from beta 7 integrin-deficient mice are comparable to those from wild-type mice. Moreover, sensitized beta 7 integrin-deficient T cells are able to respond to antigen stimuli in vitro and elicit contact hypersensitivity responses when directly injected into the skin. However, they are defective in reaching the skin under inflammatory conditions, resulting in reduced contact hypersensitivity responses when intravenously injected. Furthermore, intraperitoneal injection of anti-alpha 4 beta 7 integrin neutralizing antibody elicit impaired contact hypersensitivity responses. Conclusion: alpha 4 beta 7 Integrin contributes to contact hypersensitivity responses by regulating T-cell migration to inflammatory skin. (J Allergy Clin Immunol 2010;126:1267-76.)	[Kadono, Takafumi] Univ Tokyo, Dept Dermatol, Fac Med, Bunkyo Ku, Tokyo 1138655, Japan; [Steeber, Douglas A.] Univ Wisconsin, Dept Biol Sci, Milwaukee, WI 53201 USA; [Tedder, Thomas F.] Duke Univ, Med Ctr, Div Immunol, Durham, NC 27710 USA	University of Tokyo; University of Wisconsin System; University of Wisconsin Milwaukee; Duke University	Kadono, T (corresponding author), Univ Tokyo, Dept Dermatol, Fac Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kadono-der@h.u-tokyo.ac.jp	菅谷, 誠/GWC-3786-2022; Miyagaki, Tomomitsu/AFP-0003-2022		Ministry of Education, Culture, Sports and Technology in Japan	Ministry of Education, Culture, Sports and Technology in Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	Supported by grants from the Ministry of Education, Culture, Sports and Technology in Japan.	ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; Andrew DP, 1996, EUR J IMMUNOL, V26, P897, DOI 10.1002/eji.1830260427; Bennett CL, 2005, J CELL BIOL, V169, P569, DOI 10.1083/jcb.200501071; Campbell DJ, 2002, J EXP MED, V195, P135, DOI 10.1084/jem.20011502; Catalina MD, 1996, J EXP MED, V184, P2341, DOI 10.1084/jem.184.6.2341; CHISHOLM PL, 1993, EUR J IMMUNOL, V23, P682, DOI 10.1002/eji.1830230317; D'Amico G, 1998, BLOOD, V92, P207, DOI 10.1182/blood.V92.1.207.413a02_207_214; de Vries IJM, 2003, CANCER RES, V63, P12; deVries IJM, 1997, J ALLERGY CLIN IMMUN, V100, P694, DOI 10.1016/S0091-6749(97)70175-1; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ERLE DJ, 1994, J IMMUNOL, V153, P517; Feagan BG, 2005, NEW ENGL J MED, V352, P2499, DOI 10.1056/NEJMoa042982; Feagan BG, 2008, CLIN GASTROENTEROL H, V6, P1370, DOI 10.1016/j.cgh.2008.06.007; Garg S, 2003, NAT IMMUNOL, V4, P907, DOI 10.1038/ni962; GOEBELER M, 1993, J INVEST DERMATOL, V100, P759, DOI 10.1111/1523-1747.ep12476328; Grabbe S, 1998, IMMUNOL TODAY, V19, P37, DOI 10.1016/S0167-5699(97)01186-9; GURISH MF, 1992, J IMMUNOL, V149, P1964; ISSEKUTZ AC, 1992, IMMUNOLOGY, V76, P655; ISSEKUTZ TB, 1991, J IMMUNOL, V147, P4178; ISSEKUTZ TB, 1993, AM J PATHOL, V143, P1286; Kaplan DH, 2005, IMMUNITY, V23, P611, DOI 10.1016/j.immuni.2005.10.008; Kissenpfennig A, 2005, IMMUNITY, V22, P643, DOI 10.1016/j.immuni.2005.04.004; KRIPKE ML, 1990, J IMMUNOL, V145, P2833; Lefrancois L, 1999, J EXP MED, V189, P1631, DOI 10.1084/jem.189.10.1631; Ludviksson BR, 1999, J IMMUNOL, V162, P4975; MACATONIA SE, 1987, J EXP MED, V166, P1654, DOI 10.1084/jem.166.6.1654; Manie SN, 1996, BLOOD, V87, P1855; McHale JF, 1999, J IMMUNOL, V162, P1648; Mora JR, 2006, TRENDS IMMUNOL, V27, P235, DOI 10.1016/j.it.2006.03.007; NAKACHE M, 1989, NATURE, V337, P179, DOI 10.1038/337179a0; NOJIMA Y, 1995, CELL IMMUNOL, V161, P8, DOI 10.1006/cimm.1995.1002; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PARKER CM, 1992, P NATL ACAD SCI USA, V89, P1924, DOI 10.1073/pnas.89.5.1924; Pauls K, 2001, J INVEST DERMATOL, V117, P569, DOI 10.1046/j.0022-202x.2001.01481.x; PerezVillar JJ, 1996, IMMUNOLOGY, V89, P96, DOI 10.1046/j.1365-2567.1996.d01-706.x; Petrovic A, 2004, BLOOD, V103, P1542, DOI 10.1182/blood-2003-03-0957; PICKER LJ, 1994, EUR J IMMUNOL, V24, P1269, DOI 10.1002/eji.1830240605; Price AA, 1997, J EXP MED, V186, P1725, DOI 10.1084/jem.186.10.1725; Rivera-Nieves J, 2005, J IMMUNOL, V174, P2343, DOI 10.4049/jimmunol.174.4.2343; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; Saeki H, 1999, J IMMUNOL, V162, P2472; Schon MP, 2000, J IMMUNOL, V165, P6583, DOI 10.4049/jimmunol.165.11.6583; Schon MP, 1999, J IMMUNOL, V162, P6641; Schon MP, 2002, J INVEST DERMATOL, V119, P190, DOI 10.1046/j.1523-1747.2002.17973.x; Smithson G, 2001, J EXP MED, V194, P601, DOI 10.1084/jem.194.5.601; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; Sun XY, 2002, TRANSPLANTATION, V74, P1202, DOI 10.1097/00007890-200210270-00029; Szabo MC, 1997, J IMMUNOL, V158, P5584; Szabo SK, 1998, J INVEST DERMATOL, V111, P1072, DOI 10.1046/j.1523-1747.1998.00419.x; TANG AM, 1993, NATURE, V361, P82, DOI 10.1038/361082a0; TOEWS GB, 1980, J IMMUNOL, V124, P445; VONDERHEIDE RH, 1994, J CELL BIOL, V125, P215, DOI 10.1083/jcb.125.1.215; Wagner N, 1996, NATURE, V382, P366, DOI 10.1038/382366a0; Waldman E, 2006, BLOOD, V107, P1703, DOI 10.1182/blood-2005-08-3445; Walsh GM, 1996, IMMUNOLOGY, V89, P112, DOI 10.1046/j.1365-2567.1996.d01-713.x; Werr J, 1998, J EXP MED, V187, P2091, DOI 10.1084/jem.187.12.2091; Werr J, 2000, BLOOD, V95, P1804, DOI 10.1182/blood.V95.5.1804.005k11_1804_1809; Yang Y, 1996, IMMUNOL CELL BIOL, V74, P383, DOI 10.1038/icb.1996.67	59	12	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1267	1276		10.1016/j.jaci.2010.08.048	http://dx.doi.org/10.1016/j.jaci.2010.08.048			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	21047673				2022-12-18	WOS:000284947800027
J	Baye, TM; Martin, LJ; Hershey, GKK				Baye, Tesfaye M.; Martin, Lisa J.; Hershey, Gurjit K. Khurana			Application of genetic/genomic approaches to allergic disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Gene; allergy; database; browser; genome; common variants; rare variants; HapMap; imputation	GENOME-WIDE ASSOCIATION; COPY NUMBER VARIATION; GENE-EXPRESSION DATA; DNA METHYLATION; FILAGGRIN MUTATIONS; ATOPIC ECZEMA; SEVERE ASTHMA; HUMAN BREAST; ORMDL3 GENE; DISEASE	Completion of the human genome project and rapid progress in genetics and bioinformatics have enabled the development of large public databases, which include genetic and genomic data linked to clinical health data. With the massive amount of information available, clinicians and researchers have the unique opportunity to complement and integrate their daily practice with the existing resources to clarify the underlying cause of complex phenotypes, such as allergic diseases. The genome itself is now often used as a starting point for many studies, and multiple innovative approaches have emerged applying genetic/genomic strategies to key questions in the field of allergy and immunology. There have been several successes that have uncovered new insights into the biologic underpinnings of allergic disorders. Herein we will provide an in-depth review of genomic approaches to identifying genes and biologic networks involved in allergic diseases. We will discuss genetic and phenotypic variation, statistical approaches for gene discovery, public databases, functional genomics, clinical implications, and the challenges that remain. (J Allergy Clin Immunol 2010;126:425-36.)	[Baye, Tesfaye M.; Hershey, Gurjit K. Khurana] Cincinnati Childrens Hosp Med Ctr, Div Asthma Res, Cincinnati, OH USA; [Martin, Lisa J.] Univ Cincinnati, Div Epidemiol & Biostat, Cincinnati, OH USA; [Hershey, Gurjit K. Khurana] Univ Cincinnati, Dept Pediat, Div Allergy & Immunol, Cincinnati, OH 45221 USA	Cincinnati Children's Hospital Medical Center; University of Cincinnati; University of Cincinnati; University of Cincinnati	Hershey, GKK (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Asthma Res, Cincinnati, OH USA.	Gurjit.Khurana.Hershey@cchmc.org	Martin, Lisa/E-2425-2016	Martin, Lisa/0000-0001-8702-9946; Khurana Hershey, Gurjit/0000-0001-6663-977X	National Institutes of Health [U19A170235, P30HL10133]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P30HL101333] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070235] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants U19A170235 (G.K.K.H. and L.J.M.) and P30HL10133 (T.M.B.).	Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Badano JL, 2002, NAT REV GENET, V3, P779, DOI 10.1038/nrg910; Baye TM, 2009, PERS MED, V6, P623, DOI 10.2217/PME.09.54; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Biniszkiewicz D, 2002, MOL CELL BIOL, V22, P2124, DOI 10.1128/MCB.22.7.2124-2135.2002; Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913; Bray MS, 2000, J APPL PHYSIOL, V88, P788, DOI 10.1152/jappl.2000.88.2.788; Brazma A, 2003, NUCLEIC ACIDS RES, V31, P68, DOI 10.1093/nar/gkg091; Brooks WH, 2010, J AUTOIMMUN, V34, pJ207, DOI 10.1016/j.jaut.2009.12.006; Brown SJ, 2008, SEMIN CUTAN MED SURG, V27, P128, DOI 10.1016/j.sder.2008.04.001; Browning SR, 2008, HUM GENET, V124, P439, DOI 10.1007/s00439-008-0568-7; Cantero-Recasens G, 2010, HUM MOL GENET, V19, P111, DOI 10.1093/hmg/ddp471; CHAKRABORTY R, 1986, YEARB PHYS ANTHROPOL, V29, P1; Clark JI, 2005, PLANT PHYSIOL, V138, P1268, DOI 10.1104/pp.104.058529; Cohen JC, 2004, SCIENCE, V305, P869, DOI 10.1126/science.1099870; Cookson W, 2009, NAT REV GENET, V10, P184, DOI 10.1038/nrg2537; Cookson WOCM, 2002, CURR OPIN ALLERGY CL, V2, P383, DOI 10.1097/00130832-200210000-00003; Cooper GM, 2008, NAT GENET, V40, P1199, DOI 10.1038/ng.236; Costanzo M, 2010, SCIENCE, V327, P425, DOI 10.1126/science.1180823; Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x; Dickson SP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000294; Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909; Elias PM, 2008, J INVEST DERMATOL, V128, P1067, DOI 10.1038/jid.2008.88; Fanciulli M, 2010, CLIN GENET, V77, P201, DOI 10.1111/j.1399-0004.2009.01342.x; Flory JH, 2009, J ALLERGY CLIN IMMUN, V124, P605, DOI 10.1016/j.jaci.2009.05.047; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Franke L, 2009, METHODS MOL BIOL, V573, P311, DOI 10.1007/978-1-60761-247-6_17; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Galanter J, 2008, AM J RESP CRIT CARE, V177, P1194, DOI 10.1164/rccm.200711-1644OC; Gamazon ER, 2010, BIOINFORMATICS, V26, P259, DOI 10.1093/bioinformatics/btp644; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Haller G, 2009, J ALLERGY CLIN IMMUN, V124, P1204, DOI 10.1016/j.jaci.2009.09.013; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Higgins PS, 2005, CHEST, V128, P3846, DOI 10.1378/chest.128.6.3846; Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106; Hinds DA, 2005, SCIENCE, V307, P1072, DOI 10.1126/science.1105436; Hirota T, 2008, J ALLERGY CLIN IMMUN, V121, P769, DOI 10.1016/j.jaci.2007.09.038; Huang DS, 2006, OMICS, V10, P28, DOI 10.1089/omi.2006.10.28; Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459; Ionita-Laza I, 2008, GENET EPIDEMIOL, V32, P273, DOI 10.1002/gepi.20302; Janson PCJ, 2009, BBA-GEN SUBJECTS, V1790, P906, DOI 10.1016/j.bbagen.2008.12.003; Jones AR, 2007, NAT BIOTECHNOL, V25, P1127, DOI 10.1038/nbt1347; Kulikova T, 2007, NUCLEIC ACIDS RES, V35, pD16, DOI 10.1093/nar/gkl913; Lage K, 2007, NAT BIOTECHNOL, V25, P309, DOI 10.1038/nbt1295; Lal G, 2009, BLOOD, V114, P3727, DOI 10.1182/blood-2009-05-219584; Lara E, 2010, EPIGENETICS OF AGING, P257, DOI 10.1007/978-1-4419-0639-7_14; Leung TF, 2009, ALLERGY, V64, P621, DOI 10.1111/j.1398-9995.2008.01873.x; Levine SJ, 2010, ANN INTERN MED, V152, P232, DOI 10.7326/0003-4819-152-4-201002160-00008; Levy S, 2007, PLOS BIOL, V5, P2113, DOI 10.1371/journal.pbio.0050254; LI E, 1993, COLD SPRING HARB SYM, V58, P297, DOI 10.1101/SQB.1993.058.01.035; Li XL, 2010, AM J RESP CELL MOL, V42, P190, DOI 10.1165/rcmb.2009-0023OC; List K, 2003, J CELL BIOL, V163, P901, DOI 10.1083/jcb.200304161; Locksley RM, 2009, J EXP MED, V206, P1643, DOI 10.1084/jem.20091442; Luca D, 2008, AM J HUM GENET, V82, P453, DOI 10.1016/j.ajhg.2007.11.003; Manica A, 2007, NATURE, V448, P346, DOI 10.1038/nature05951; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; Marchini J, 2007, NAT GENET, V39, P906, DOI 10.1038/ng2088; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; McCarthy MI, 2008, NAT REV GENET, V9, P356, DOI 10.1038/nrg2344; McGrath JA, 2008, AUSTRALAS J DERMATOL, V49, P67, DOI 10.1111/j.1440-0960.2008.00443.x; McGrath JA, 2008, TRENDS MOL MED, V14, P20, DOI 10.1016/j.molmed.2007.10.006; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Morar N, 2007, J INVEST DERMATOL, V127, P1667, DOI 10.1038/sj.jid.5700739; Morton NE, 2008, ADV GENET, V60, P727, DOI 10.1016/S0065-2660(07)00425-7; Myles S, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-45; Nadeau JH, 2009, HUM MOL GENET, V18, pR202, DOI 10.1093/hmg/ddp366; O'Regan GM, 2009, J ALLERGY CLIN IMMUN, V124, pR2, DOI 10.1016/j.jaci.2009.07.013; OLDRIDGE DA, 2010, NUCL ACIDS RES; Oti M, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-208; Out AA, 2009, HUM MUTAT, V30, P1703, DOI 10.1002/humu.21122; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Parra EJ, 1998, AM J HUM GENET, V63, P1839, DOI 10.1086/302148; Perera F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004488; Prabhu S, 2009, GENOME RES, V19, P1254, DOI 10.1101/gr.088559.108; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Pritchard JK, 2000, AM J HUM GENET, V67, P170, DOI 10.1086/302959; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Redden DT, 2006, PLOS GENET, V2, P1254, DOI 10.1371/journal.pgen.0020137; Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329; RENAUDINEAU Y, 2009, CLIN REV ALLERGY IMM; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Salmela E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003519; Schulze TG, 2004, HUM HERED, V58, P131, DOI 10.1159/000083539; Servin B, 2007, PLOS GENET, V3, P1296, DOI 10.1371/journal.pgen.0030114; Shriner D, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn007; Shtir Corina, 2009, BMC Proc, V3 Suppl 7, pS133; Sinclair KD, 2007, P NATL ACAD SCI USA, V104, P19351, DOI 10.1073/pnas.0707258104; Sleiman PMA, 2008, J ALLERGY CLIN IMMUN, V122, P1225, DOI 10.1016/j.jaci.2008.06.041; Spielman RS, 1996, AM J HUM GENET, V59, P983; STOVER PJ, 2010, CURR OPIN LIPIDOL; Tabor HK, 2002, NAT REV GENET, V3, P391, DOI 10.1038/nrg796; Tishkoff SA, 2009, SCIENCE, V324, P1035, DOI 10.1126/science.1172257; Togias A, 2010, J ALLERGY CLIN IMMUN, V125, P540, DOI 10.1016/j.jaci.2010.01.040; Verlaan DJ, 2009, AM J HUM GENET, V85, P377, DOI 10.1016/j.ajhg.2009.08.007; Visscher PM, 2008, EUR J HUM GENET, V16, P387, DOI 10.1038/sj.ejhg.5201990; Wain LV, 2009, LANCET, V374, P340, DOI 10.1016/S0140-6736(09)60249-X; Walston J, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000485; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; Weiss ST, 2009, CURR OPIN GENET DEV, V19, P279, DOI 10.1016/j.gde.2009.05.001; Wells AD, 2009, J IMMUNOL, V182, P7331, DOI 10.4049/jimmunol.0803917; Wheeler DA, 2008, NATURE, V452, P872, DOI 10.1038/nature06884; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Wu H, 2009, ALLERGY, V64, P629, DOI 10.1111/j.1398-9995.2008.01912.x; Yuan HY, 2006, NUCLEIC ACIDS RES, V34, pW635, DOI 10.1093/nar/gkl236; Zhang YQ, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-1	107	12	12	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					425	436		10.1016/j.jaci.2010.05.025	http://dx.doi.org/10.1016/j.jaci.2010.05.025			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20638111	Green Accepted			2022-12-18	WOS:000281512500002
J	Fukuda, K; Nishida, T				Fukuda, Ken; Nishida, Teruo			Reciprocal interaction of the conjunctiva and cornea in ocular allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CELLS; EXPRESSION; EOTAXIN		[Fukuda, Ken; Nishida, Teruo] Yamaguchi Univ, Grad Sch Med, Dept Ophthalmol, Ube, Yamaguchi 755, Japan	Yamaguchi University	Fukuda, K (corresponding author), Yamaguchi Univ, Grad Sch Med, Dept Ophthalmol, Ube, Yamaguchi 755, Japan.	k.fukuda@yamaguchi-u.ac.jp	Fukuda, Ken/A-3076-2011	Fukuda, Ken/0000-0003-4990-6308				Fukuda K, 2003, J ALLERGY CLIN IMMUN, V111, P520, DOI 10.1067/mai.2003.59; Fukushima A, 2003, INVEST OPHTH VIS SCI, V44, P4366, DOI 10.1167/iovs.02-1323; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Kumagai N, 2006, PROG RETIN EYE RES, V25, P165, DOI 10.1016/j.preteyeres.2005.09.002; Kumagai N, 2000, INVEST OPHTH VIS SCI, V41, P1448; Kumagai N., 2005, ALLERGOL INT, V54, P51, DOI [10.2332/allergolint.54.51, DOI 10.2332/ALLERGOLINT.54.51]; Magone MT, 1998, CLIN IMMUNOL IMMUNOP, V87, P75, DOI 10.1006/clin.1997.4507; TROCME SD, 1994, INVEST OPHTH VIS SCI, V35, P3051	9	12	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					493	496		10.1016/j.jaci.2009.10.041	http://dx.doi.org/10.1016/j.jaci.2009.10.041			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	558RU	20159262	Bronze			2022-12-18	WOS:000274764000032
J	Vercelli, D				Vercelli, Donata			Genetics and biology of asthma 2010: La' ci darem la mano ...	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Genetics; asthma; genome-wide association studies	LOCUS-CONTROL REGION; RANGE INTRACHROMOSOMAL INTERACTIONS; TH2 CYTOKINE LOCUS; GENOMEWIDE ASSOCIATION; VARIANTS		[Vercelli, Donata] Univ Arizona, Hlth Sci Ctr, Resp Sci Ctr, Dept Cell Biol, Tucson, AZ 85724 USA; [Vercelli, Donata] Univ Arizona, Arizona Resp Ctr, Arizona Ctr Biol Complex Dis, Arizona Res Labs, Tucson, AZ 85724 USA	University of Arizona; University of Arizona Health Sciences; University of Arizona	Vercelli, D (corresponding author), Univ Arizona, Hlth Sci Ctr, Resp Sci Ctr, Dept Cell Biol, 1501 N Campbell Ave,Suite 2349, Tucson, AZ 85724 USA.	donata@arc.arizona.edu						Bodmer W, 2008, NAT GENET, V40, P695, DOI 10.1038/ng.f.136; Bouzigon E, 2008, NEW ENGL J MED, V359, P1985, DOI 10.1056/NEJMoa0806604; Dermitzakis ET, 2009, SCIENCE, V326, P239, DOI 10.1126/science.1182009; Fields PE, 2004, IMMUNITY, V21, P865, DOI 10.1016/j.immuni.2004.10.015; Flory JH, 2009, J ALLERGY CLIN IMMUN, V124, P605, DOI 10.1016/j.jaci.2009.05.047; Frazer KA, 2009, NAT REV GENET, V10, P241, DOI 10.1038/nrg2554; Galanter J, 2008, AM J RESP CRIT CARE, V177, P1194, DOI 10.1164/rccm.200711-1644OC; Gorlov IP, 2008, AM J HUM GENET, V82, P100, DOI 10.1016/j.ajhg.2007.09.006; Hardy J, 2009, NEW ENGL J MED, V360, P1759, DOI 10.1056/NEJMra0808700; Hirschhorn JN, 2009, NEW ENGL J MED, V360, P1699, DOI 10.1056/NEJMp0808934; Kierkegaard S., 1987, EITHER OR; Lee GR, 2005, NAT IMMUNOL, V6, P42, DOI 10.1038/ni1148; Lee GR, 2003, IMMUNITY, V19, P145, DOI 10.1016/S1074-7613(03)00179-1; Li C, 2008, HUM HERED, V65, P129, DOI 10.1159/000109730; Li XN, 2010, J ALLERGY CLIN IMMUN, V125, P328, DOI 10.1016/j.jaci.2009.11.018; Mathias RA, 2010, J ALLERGY CLIN IMMUN, V125, P336, DOI 10.1016/j.jaci.2009.08.031; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Rogers AJ, 2009, AM J RESP CRIT CARE, V179, P1084, DOI 10.1164/rccm.200812-1860OC; Schork NJ, 2009, CURR OPIN GENET DEV, V19, P212, DOI 10.1016/j.gde.2009.04.010; Spilianakis CG, 2004, NAT IMMUNOL, V5, P1017, DOI 10.1038/ni1115; VERCELLI D, 2010, CURR OPIN A IN PRESS; Wu H, 2010, J ALLERGY CLIN IMMUN, V125, P321, DOI 10.1016/j.jaci.2009.09.007	22	12	18	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					347	348		10.1016/j.jaci.2009.12.976	http://dx.doi.org/10.1016/j.jaci.2009.12.976			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	558RU	20159243				2022-12-18	WOS:000274764000009
J	Gordon, E; Lazarus, SC				Gordon, Erin; Lazarus, Stephen C.			Management of chronic obstructive pulmonary disease: Moving beyond the asthma algorithm	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Chronic obstructive pulmonary disease; asthma; airflow obstruction; inhaled corticosteroids; oral corticosteroids; bronchodilators; long-acting bronchodilators; beta(2)-agonists; anticholinergics; mucolytics; antioxidants; pulmonary rehabilitation; home oxygen; smoking cessation; immunization	LONG-TERM TREATMENT; INHALED ANTICHOLINERGIC BRONCHODILATOR; SUSTAINED-RELEASE BUPROPION; RECEPTOR PARTIAL AGONIST; ONCE-DAILY TIOTROPIUM; AIR-FLOW OBSTRUCTION; LUNG-FUNCTION; SMOKING-CESSATION; DOUBLE-BLIND; FLUTICASONE PROPIONATE	For many years, chronic obstructive pulmonary disease (COPD) was considered a disease of fixed airflow obstruction for which there was no good treatment. Out of desperation and frustration, health care providers extrapolated from asthma to COPD, and standard asthma therapy was adopted without evidence for efficacy. In recent years, we have gained a better understanding of the pathophysiologic differences between asthma and COPD, and prospective controlled trials have provided a rationale for therapy. Smoking cessation is critically important, both as primary prevention and as an effective way to slow the decrease in lung function in patients with established disease. beta(2)-Adrenergic and anticholinergic agonists improve lung function and relieve symptoms in most patients. Tiotropium improves exercise tolerance and quality of life and reduces exacerbations and hospitalizations. The increase in lung function seen with tiotropium is sustained with continued use over at least 3 to 4 years. Inhaled corticosteroids decrease exacerbations and improve quality of life, and their effect seems greatest in patients with lower lung function and in exacerbation-prone patients. There is no evidence that inhaled corticosteroids alone affect mortality, despite the reduction in exacerbations and increased risk of pneumonia. In some patient populations, inhaled fluticasone, salmeterol, or the combination might slow the rate of loss of lung function. Rather than reflexively using effective asthma therapy in the patient with COPD, current and future therapy for COPD is increasingly evidence based and targeted to specific inflammatory pathways that are important in patients with COPD. (J Allergy Clin Immunol 2009;124:873-80.)	[Gordon, Erin; Lazarus, Stephen C.] Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA; [Lazarus, Stephen C.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lazarus, SC (corresponding author), Univ Calif San Francisco, Div Pulm & Crit Care Med, 505 Parnassus Ave,M-1083, San Francisco, CA 94143 USA.	lazma@ucsf.edu		Gordon, Erin/0000-0001-7723-2297				ADAMS NP, 2000, COCHRANE DB SYST REV; Alsaeedi A, 2002, AM J MED, V113, P59, DOI 10.1016/S0002-9343(02)01143-9; Althuis MD, 1999, J ASTHMA, V36, P257, DOI 10.3109/02770909909075409; Altose MD, 2000, NEW ENGL J MED, V343, P1902; [Anonymous], 1980, Ann Intern Med, V93, P391; ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; Anthonisen NR, 2005, ANN INTERN MED, V142, P233, DOI 10.7326/0003-4819-142-4-200502150-00005; Apostol GG, 2002, AM J RESP CRIT CARE, V166, P166, DOI 10.1164/rccm.2007035; Appleton S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD.001387.pub2; Appleton S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001104.pub2; Barnes PJ, 2008, J CLIN INVEST, V118, P3546, DOI 10.1172/JCI36130; Barnes PJ, 2000, CHEST, V117, P63; Barr RG, 2006, THORAX, V61, P854, DOI 10.1136/thx.2006.063271; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Boogaard R, 2008, THORAX, V63, P141, DOI 10.1136/thx.2007.081703; Brightling CE, 2000, LANCET, V356, P1480, DOI 10.1016/S0140-6736(00)02872-5; Brightling CE, 2005, THORAX, V60, P193, DOI 10.1136/thx.2004.032516; Brusasco V, 2003, THORAX, V58, P399, DOI 10.1136/thorax.58.5.399; Bueving HJ, 2004, AM J RESP CRIT CARE, V169, P488, DOI 10.1164/rccm.200309-1251OC; Burge PS, 2000, BMJ-BRIT MED J, V320, P1297, DOI 10.1136/bmj.320.7245.1297; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; Calverley PMA, 2007, AM J RESP CRIT CARE, V176, P154, DOI 10.1164/rccm.200610-1563OC; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; Calverley PMA, 2009, LANCET, V374, P685, DOI 10.1016/S0140-6736(09)61255-1; Casaburi R, 2002, EUR RESPIR J, V19, P217, DOI 10.1183/09031936.02.00269802; Casaburi R, 2009, NEW ENGL J MED, V360, P1329, DOI 10.1056/NEJMct0804632; Castro M, 2001, NEW ENGL J MED, V345, P1529, DOI 10.1056/NEJMoa011961; Cates CJ, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000364.pub3; *CDCP, 2009, MMWR, V57; Celli BR, 2008, AM J RESP CRIT CARE, V178, P332, DOI 10.1164/rccm.200712-1869OC; Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304; Chaudhuri R, 2006, AM J RESP CRIT CARE, V174, P127, DOI 10.1164/rccm.200510-1589OC; Culpitt SV, 1999, AM J RESP CRIT CARE, V160, P1635, DOI 10.1164/ajrccm.160.5.9811058; DECRAMER M, 1992, AM REV RESPIR DIS, V146, P800, DOI 10.1164/ajrccm/146.3.800; DECRAMER M, 1994, AM J RESP CRIT CARE, V150, P11, DOI 10.1164/ajrccm.150.1.8025735; Decramer M, 2005, LANCET, V365, P1552, DOI 10.1016/S0140-6736(05)66456-2; Disse B, 1999, LIFE SCI, V64, P457, DOI 10.1016/S0024-3205(98)00588-8; Dorinsky PM, 1999, CHEST, V115, P966, DOI 10.1378/chest.115.4.966; Dransfield MT, 2009, AM J RESP CRIT CARE, V180, P499, DOI 10.1164/rccm.200903-0488OC; Drummond MB, 2008, JAMA-J AM MED ASSOC, V300, P2407, DOI 10.1001/jama.2008.717; Eisner Mark D, 2005, Environ Health, V4, P7, DOI 10.1186/1476-069X-4-7; Fabbri L, 2004, COPD, V1, P103, DOI 10.1081/ COPD- 120030163; Fabbri Leonardo, 2004, COPD, V1, P105; Fabbri LM, 2009, LANCET, V374, P695, DOI 10.1016/S0140-6736(09)61252-6; FLENLEY DC, 1981, LANCET, V1, P681; Gonzales D, 2006, JAMA-J AM MED ASSOC, V296, P47, DOI 10.1001/jama.296.1.47; Gorecka D, 1997, THORAX, V52, P674, DOI 10.1136/thx.52.8.674; Grandjean EM, 2000, CLIN THER, V22, P209, DOI 10.1016/S0149-2918(00)88479-9; Grootendorst DC, 2007, THORAX, V62, P1081, DOI 10.1136/thx.2006.075937; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; Hattotuwa KL, 2002, AM J RESP CRIT CARE, V165, P1592, DOI 10.1164/rccm.2105025; John M, 2005, RESP MED, V99, P1418, DOI 10.1016/j.rmed.2005.03.034; Jorenby DE, 2006, JAMA-J AM MED ASSOC, V296, P56, DOI 10.1001/jama.296.1.56; Juhn YJ, 2008, J ALLERGY CLIN IMMUN, V122, P719, DOI 10.1016/j.jaci.2008.07.029; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; KANNER RE, 1983, AM J MED, V74, P249, DOI 10.1016/0002-9343(83)90623-X; KERSTJENS HAM, 1992, NEW ENGL J MED, V327, P1413, DOI 10.1056/NEJM199211123272003; Lacasse Y, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003793.pub2; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Lazarus SC, 2007, AM J RESP CRIT CARE, V175, P783, DOI 10.1164/rccm.200511-1746OC; Liu SM, 2007, THORAX, V62, P889, DOI 10.1136/thx.2006.061457; LlewellynJones CG, 1996, AM J RESP CRIT CARE, V153, P616, DOI 10.1164/ajrccm.153.2.8564107; Maltais F, 2005, CHEST, V128, P1168, DOI 10.1378/chest.128.3.1168; MARQUETTE CH, 1992, AM REV RESPIR DIS, V146, P76, DOI 10.1164/ajrccm/146.1.76; Nannini LJ, 2007, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006826, 10.1002/14651858.CD006826.pub2]; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; Niewoehner DE, 2005, ANN INTERN MED, V143, P317, DOI 10.7326/0003-4819-143-5-200509060-00007; O'Donnell DE, 2004, EUR RESPIR J, V23, P832, DOI 10.1183/09031936.04.00116004; Ozol D, 2005, RESP MED, V99, P1494, DOI 10.1016/j.rmed.2005.04.025; Pauwels RA, 2004, LANCET, V364, P613, DOI 10.1016/S0140-6736(04)16855-4; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Pauwels RA, 1999, NEW ENGL J MED, V340, P1948, DOI 10.1056/NEJM199906243402503; Poole PJ, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001287.pub2; Poole PJ, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002733.pub2; Poole PJ, 2001, BMJ-BRIT MED J, V322, P1271, DOI 10.1136/bmj.322.7297.1271; POSTMA DS, 1985, EUR J RESPIR DIS, V67, P360; POSTMA DS, 1986, AM REV RESPIR DIS, V134, P276; Rabe KF, 2005, LANCET, V366, P563, DOI 10.1016/S0140-6736(05)67100-0; Ram FSF, 2005, COCHRANE DB SYST REV, DOI [10.1002/146514858.CD004360.pub2, 10.1002/14651858.CD004360.pub3, 10.1002/14651858.CD003137.pub2]; Renkema TEJ, 1996, CHEST, V109, P1156, DOI 10.1378/chest.109.5.1156; Rice KL, 2000, AM J RESP CRIT CARE, V162, P174, DOI 10.1164/ajrccm.162.1.9909066; Ries AL, 2007, CHEST, V131, p4S, DOI 10.1378/chest.06-2418; Sestini P, 2002, COCHRANE DB SYST REV; Sin DD, 2004, AM J RESP CRIT CARE, V170, P760, DOI 10.1164/rccm.200404-543OC; Siroux V, 2000, EUR RESPIR J, V15, P470, DOI 10.1034/j.1399-3003.2000.15.08.x; Smith Victoria Boswell, 2005, Curr Opin Investig Drugs, V6, P1136; Stey C, 2000, EUR RESPIR J, V16, P253, DOI 10.1034/j.1399-3003.2000.16b12.x; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; Talbot TR, 2005, NEW ENGL J MED, V352, P2082, DOI 10.1056/NEJMoa044113; Tashkin DP, 2008, NEW ENGL J MED, V359, P1543, DOI 10.1056/NEJMoa0805800; THOMPSON AB, 1992, AM REV RESPIR DIS, V146, P389, DOI 10.1164/ajrccm/146.2.389; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; VANSCHAYCK CP, 1991, THORAX, V46, P355, DOI 10.1136/thx.46.5.355; Verhoeven GT, 2002, THORAX, V57, P694, DOI 10.1136/thorax.57.8.694; Vestbo J, 1999, LANCET, V353, P1819, DOI 10.1016/S0140-6736(98)10019-3; Vincken W, 2002, EUR RESPIR J, V19, P209, DOI 10.1183/09031936.02.00238702; Walters JAE, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005374; Westby M, 2004, Cochrane Database Syst Rev, pCD003269; Willart MAM, 2009, CLIN EXP ALLERGY, V39, P12, DOI 10.1111/j.1365-2222.2008.03118.x; Willemse BWM, 2004, EUR RESPIR J, V23, P464, DOI 10.1183/09031936.04.00012704; Yang IA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002991.pub2	105	12	13	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					873	880		10.1016/j.jaci.2009.09.040	http://dx.doi.org/10.1016/j.jaci.2009.09.040			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19895979				2022-12-18	WOS:000272108000001
J	Cicutto, L				Cicutto, Lisa			Supporting successful asthma management in schools: The role of asthma care providers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Asthma; school; children; youth	INNER-CITY SCHOOL; CHILDREN; EDUCATION; BARRIERS		[Cicutto, Lisa] Natl Jewish Hlth, Community Res, Denver, CO USA; [Cicutto, Lisa] Univ Colorado, Denver, CO 80206 USA	National Jewish Health; University of Colorado System; University of Colorado Denver	Cicutto, L (corresponding author), Natl Jewish Hlth, Community Res, Denver, CO USA.	cicuttol@njhealth.org						*AM LUNG ASS, 2007, ASTHM FRIENDL SCH IN; *ASTHM FDN AUSTR, 2009, ASTHM FRIENDL SCH; Bonilla S, 2005, J PEDIATR-US, V147, P802, DOI 10.1016/j.jpeds.2005.06.041; *CDCP, 2008, HLTH TOP ASTHM; Cicutto L, 2005, CHEST, V128, P1928, DOI 10.1378/chest.128.4.1928; Cicutto L, 2006, J SCHOOL HEALTH, V76, P255, DOI 10.1111/j.1746-1561.2006.00107.x; Forbis S, 2006, J SCHOOL HEALTH, V76, P205, DOI 10.1111/j.1746-1561.2006.00097.x; Jones SE, 2004, AM J PUBLIC HEALTH, V94, P1102, DOI 10.2105/AJPH.94.7.1102; Lurie N, 2001, J SCHOOL HEALTH, V71, P9, DOI 10.1111/j.1746-1561.2001.tb06481.x; Merkle SL, 2006, J SCHOOL HEALTH, V76, P202, DOI 10.1111/j.1746-1561.2006.00096.x; *NAT HEART LUNG BL, 2007, GUID DIAGN MAN ASTHM, P340; *NAT HEART LUNG BL, 2008, INF HLTH PROF LUNG D; *ONT MIN HLTH LONG, 2009, CREAT ASTHM FRIENDL; Taras H, 2005, J SCHOOL HEALTH, V75, P296, DOI 10.1111/j.1746-1561.2005.00041.x; WHEELER LS, 2006, J SCH HLTH, V76, P201; Yeatts K, 2000, ANN ALLERG ASTHMA IM, V84, P94	16	12	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2					390	393		10.1016/j.jaci.2009.04.042	http://dx.doi.org/10.1016/j.jaci.2009.04.042			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	482CD	19541361				2022-12-18	WOS:000268860400041
J	Hamasaka, A; Abe, R; Koyama, Y; Yoshioka, N; Fujita, Y; Hoshina, D; Sasaki, M; Hirasawa, T; Onodera, S; Ohshima, S; Leng, L; Bucala, R; Nishihira, J; Shimizu, T; Shimizu, H				Hamasaka, Asuka; Abe, Riichiro; Koyama, Yoshikazu; Yoshioka, Naoya; Fujita, Yasuyuki; Hoshina, Daichi; Sasaki, Mikako; Hirasawa, Tsutomu; Onodera, Shin; Ohshima, Shigeki; Leng, Lin; Bucala, Richard; Nishihira, Jun; Shimizu, Tadamichi; Shimizu, Hiroshi			DNA vaccination against macrophage migration inhibitory factor improves atopic dermatitis in murine models	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; macrophage migration inhibitory factor; DNA vaccination	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; ONGOING ADJUVANT ARTHRITIS; IGE HYPERPRODUCTION; NC/NGA MICE; TNF-ALPHA; INSIGHTS; CYCLOSPORINE; INFLIXIMAB; CYTOKINE; IMMUNITY	Background: Atopic dermatitis (AD) is a common chronic inflammatory skin disease. Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine that has been implicated in the pathogenesis of AD. Recently, we developed a novel DNA vaccine that generates neutralizing endogenous anti-MIF antibodies. Objective: This study explores the preventive and therapeutic effects of this MIF-DNA vaccine in mouse models of AD. Methods: Two different AD model mice (DS-Nh and NC/Nga) received MIF-DNA vaccination to analyze preventive and therapeutic effects, as assessed by clinical skin scores, histologic findings, and serum IgE levels. Results: In murine models of AD, MIF-DNA vaccination prevented the occurrence of the AD skin phenotype. Furthermore, administration of MIF-DNA vaccine to mice that had already developed AD produced a rapid improvement in AD skin manifestation. There were reduced histologic signs of inflammation and lower serum IgE levels in treated mice compared with those seen in control animals. Finally, passive transfer of IgG from MIF-DNA vaccinated mice to AD mice also produced a significant therapeutic effect. These results demonstrate that MIF-DNA vaccination not only prevents the development of AD but also improves the symptoms of pre-existing AD. Conclusion: Taken together, the induction of an anti-MIF autoantibody response using MIF-DNA vaccination appears to be a useful approach in the treatment of AD. (J Allergy Clin Immunol 2009;124:90-9.)	[Hamasaka, Asuka; Abe, Riichiro; Yoshioka, Naoya; Fujita, Yasuyuki; Hoshina, Daichi; Sasaki, Mikako; Shimizu, Hiroshi] Hokkaido Univ, Grad Sch Med, Dept Dermatol, Sapporo, Hokkaido 0608638, Japan; [Onodera, Shin] Hokkaido Univ, Grad Sch Med, Dept Sports Med & Joint Reconstruct Surg, Sapporo, Hokkaido 0608638, Japan; [Ohshima, Shigeki] Hokkaido Univ, Grad Sch Med, Dept Orthoped, Sapporo, Hokkaido 0608638, Japan; [Koyama, Yoshikazu; Nishihira, Jun] Hokkaido Informat Univ, Dept Med Informat, Ebetsu, Hokkaido, Japan; [Hirasawa, Tsutomu] Shionogi & Co Ltd, Discovery Res Labs, Osaka, Japan; [Leng, Lin; Bucala, Richard] Yale Univ, Sch Med, Dept Pathol & Med, New Haven, CT USA; [Shimizu, Tadamichi] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Dermatol, Toyama 930, Japan	Hokkaido University; Hokkaido University; Hokkaido University; Shionogi & Company Limited; Yale University; University of Toyama	Abe, R (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Dermatol, Sapporo, Hokkaido 0608638, Japan.	aberi@med.hokudai.ac.jp; shimizu@med.hokudai.ac.jp	Fujita, Yasuyuki/A-5464-2012; Abe, Riichiro/A-5450-2012; Shimizu, Hiroshi/A-5193-2012	Fujita, Yasuyuki/0000-0001-7934-9261; Shimizu, Tadamichi/0000-0002-3231-0279; Leng, Lin/0000-0002-0605-358X				Abramovits W, 2005, J AM ACAD DERMATOL, V53, pS86, DOI 10.1016/j.jaad.2005.04.034; BerthJones J, 1996, J AM ACAD DERMATOL, V34, P1016, DOI 10.1016/S0190-9622(96)90281-9; BerthJones J, 1997, BRIT J DERMATOL, V136, P76, DOI 10.1046/j.1365-2133.1997.d01-1146.x; Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262; Cassano N, 2006, INT J IMMUNOPATH PH, V19, P237; Jacobi A, 2005, J AM ACAD DERMATOL, V52, P522, DOI 10.1016/j.jaad.2004.11.022; Jung T, 2008, J ALLERGY CLIN IMMUN, V122, P1074, DOI 10.1016/j.jaci.2008.09.042; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Matsuda H, 1997, INT IMMUNOL, V9, P461, DOI 10.1093/intimm/9.3.461; Matsumoto M, 1999, J IMMUNOL, V162, P1056; Morar N, 2006, J ALLERGY CLIN IMMUN, V118, P24, DOI 10.1016/j.jaci.2006.03.037; Onodera S, 2007, ARTHRITIS RHEUM-US, V56, P521, DOI 10.1002/art.22407; Salomon I, 2002, J IMMUNOL, V169, P2685, DOI 10.4049/jimmunol.169.5.2685; Shimizu T, 2005, J DERMATOL SCI, V37, P65, DOI 10.1016/j.jdermsci.2004.08.007; Shimizu T, 1999, J ALLERGY CLIN IMMUN, V104, P659, DOI 10.1016/S0091-6749(99)70339-8; Shimizu T, 1997, BIOCHEM BIOPH RES CO, V240, P173, DOI 10.1006/bbrc.1997.7633; Tohyama S, 2008, GENE THER, V15, P1513, DOI 10.1038/gt.2008.112; Wildbaum G, 1999, GENE THER, V6, P1128, DOI 10.1038/sj.gt.3300915; Wildbaum G, 2002, J IMMUNOL, V168, P5885, DOI 10.4049/jimmunol.168.11.5885; Wildbaum G, 2000, J IMMUNOL, V165, P5860, DOI 10.4049/jimmunol.165.10.5860; Youssef S, 1998, J IMMUNOL, V161, P3870; Youssef S, 2000, J CLIN INVEST, V106, P361, DOI 10.1172/JCI9109	24	12	14	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2009	124	1					90	99		10.1016/j.jaci.2009.04.025	http://dx.doi.org/10.1016/j.jaci.2009.04.025			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	469OR	19482347				2022-12-18	WOS:000267909700011
J	Chen, CH; Lin, YT; Wen, CY; Wang, LC; Lin, KH; Chiu, SH; Yang, YH; Lee, JH; Chiang, BL				Chen, Chien-Han; Lin, Yu-Tsan; Wen, Che-Yen; Wang, Li-Chieh; Lin, Kuo-Hung; Chiu, Shih-Hsuan; Yang, Yao-Hsu; Lee, Jyh-Hong; Chiang, Bor-Luen			Quantitative assessment of allergic shiners in children with allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic shiners; digital photograph; darkness; area; allergic rhinitis	EYE	Background: The knowledge on allergic shiners is extremely limited. A conceivable tool able to quantify allergic shiners has not been established. Objectives: We sought to determine the significance and changeability of allergic shiners through our newly developed computerized method. Methods: We developed a novel computerized method to measure allergic shiners and enrolled a cohort of children with or without allergic rhinitis. Children with allergic rhinitis were prospectively assessed. A standardized digital photograph was taken during each visit, and a modified Pediatric Rhinoconjunctivitis Quality of Life Questionnaire was completed. Subject global assessment for nose symptoms and subject global assessment for eye symptoms (SGAE) were self-recorded daily. Results: We included 126 children with allergic rhinitis and 123 healthy control subjects. One hundred three (82%) participants with allergic rhinitis completed at least 4 prospective assessments. Shiners were darker (P < .001) and larger (P < .001) in children with allergic rhinitis. Darkness and sizes of allergic shiners were paradoxically inversely correlated (P = .02). Darkness of allergic shiners positively correlated with the duration of allergic rhinitis, practical problem scores, and SGAE values (P = .02, P = .004, and P = .002, respectively), but sizes of allergic shiners did not. Shiners were found to be darker in children with scores of eye symptoms of greater than 6, scores of practical problems of greater than 5, and SGAE values of greater than 0 (P = .02, P < .001, and P = .003, respectively), whereas shiners were larger in children with scores of other symptoms of greater than 9 and activity limitations of greater than 4 (P = .02 and P = .002, respectively). Conclusion: Computer-analyzed allergic shiners correlate with the chronicity and severity of allergic rhinitis. (J Allergy Clin Immunol 2009;123:665-71.)	[Chen, Chien-Han; Lin, Yu-Tsan; Wang, Li-Chieh; Yang, Yao-Hsu; Lee, Jyh-Hong; Chiang, Bor-Luen] Natl Taiwan Univ Hosp, Dept Pediat, Taipei 100, Taiwan; [Chen, Chien-Han; Lin, Yu-Tsan; Wang, Li-Chieh; Yang, Yao-Hsu; Lee, Jyh-Hong; Chiang, Bor-Luen] Natl Taiwan Univ, Coll Med, Taipei, Taiwan; [Chen, Chien-Han] Min Sheng Gen Hosp, Dept Pediat, Tao Yuan, Taiwan; [Wen, Che-Yen] Natl Cent Police Univ, Dept Forens Sci, Tao Yuan, Taiwan; [Lin, Kuo-Hung; Chiu, Shih-Hsuan] Natl Taiwan Univ Sci & Technol, Dept Polymer Engn, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University of Science & Technology	Chiang, BL (corresponding author), Natl Taiwan Univ Hosp, Dept Pediat, 7 Chung Shan S Rd, Taipei 100, Taiwan.	gicmbor@ntu.edu.tw	; Yang, Yao-Hsu/A-3450-2019	LIN, YU-TSAN/0000-0002-4192-3165; Yang, Yao-Hsu/0000-0002-8080-0504; Yang, Yao-Hsu/0000-0002-6266-9864; LEE, JYH-HONG/0000-0003-4285-4912; WANG, LI-CHIEH/0000-0002-5773-1627; CHIANG, BOR-LUEN/0000-0002-6705-0286	National Taiwan University Hospital	National Taiwan University Hospital(National Taiwan University)	Supported by a grant from National Taiwan University Hospital.	Alster Tina, 2003, J Cosmet Laser Ther, V5, P39, DOI 10.1080/14764170310000835; Aykroyd RG, 1998, IEEE T PATTERN ANAL, V20, P533, DOI 10.1109/34.682182; Berger William E, 2004, Paediatr Drugs, V6, P233, DOI 10.2165/00148581-200406040-00003; Bielory L, 2006, MED CLIN N AM, V90, P129, DOI 10.1016/j.mcna.2005.08.013; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P1039, DOI 10.1016/0091-6749(90)90048-9; Chuan MT, 1997, DERMATOLOGY, V194, P65, DOI 10.1159/000246061; DALE HB, 1985, QUALITY CONTROL, P18; DUKE WW, 1930, ARCH OTOLARYNGOL, V12, P493; FEIGENBAUM AV, 1983, TOTAL QUALITY CONTRO, P349; Gonzalez Rafael, 2002, DIGITAL IMAGE PROCES, P34; GOREN SB, 1975, POSTGRAD MED, V58, P99, DOI 10.1080/00325481.1975.11714225; Juniper EF, 1998, J ALLERGY CLIN IMMUN, V101, P163, DOI 10.1016/S0091-6749(98)70380-X; KAPUR JN, 1985, COMPUT VISION GRAPH, V29, P273, DOI 10.1016/0734-189X(85)90125-2; KITTLER J, 1986, PATTERN RECOGN, V19, P41, DOI 10.1016/0031-3203(86)90030-0; Lai L, 2005, IMMUNOL ALLERGY CLIN, V25, P283, DOI 10.1016/j.iac.2005.02.003; MARKS MB, 1963, ANN ALLERGY, V21, P26; MARKS MB, 1966, CLIN PEDIATR, V5, P655, DOI 10.1177/000992286600501106; MARKS MB, 1954, PRACTICE ALLERGY, P1023; MARKS MEYER B., 1960, ANN ALLERGY, V18, P1110; MOURA L, 1991, COMPUT PHYS COMMUN, V64, P57, DOI 10.1016/0010-4655(91)90049-Q; PLYBON BF, 1992, INTRO APPL NUMERICAL, P327; Prenner BM, 2006, AM J MED, V119, P230, DOI 10.1016/j.amjmed.2005.06.015; Quillen DM, 2006, AM FAM PHYSICIAN, V73, P1583; Wang MF, 2004, PEDIAT ALLERG IMM-UK, V15, P152, DOI 10.1111/j.1399-3038.2004.00156.x; YE QZ, 1988, PATTERN RECOGN LETT, V7, P201, DOI 10.1016/0167-8655(88)90103-1	25	12	13	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2009	123	3					665	671		10.1016/j.jaci.2008.12.1108	http://dx.doi.org/10.1016/j.jaci.2008.12.1108			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	426TQ	19281911				2022-12-18	WOS:000264731200028
J	Duenas-Laita, A; Ruiz-Munoz, P; Armentia, A; Pinacho, F; Martin-Armentia, B				Duenas-Laita, Antonio; Ruiz-Munoz, Pedro; Armentia, Alicia; Pinacho, Florentino; Martin-Armentia, Blanca			Successful treatment of chronic drug-resistant urticaria with alprazolam	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RECEPTOR		[Duenas-Laita, Antonio; Pinacho, Florentino; Martin-Armentia, Blanca] Hosp Univ Rio Hortega, Serv Farmacol, Unidad Reg Toxicol Clin, Valladolid, Spain; [Armentia, Alicia] Hosp Univ Rio Hortega, Secc Alergia, Valladolid, Spain	Hospital del Rio Hortega; Hospital del Rio Hortega	Duenas-Laita, A (corresponding author), Hosp Univ Rio Hortega, Serv Farmacol, Unidad Reg Toxicol Clin, Valladolid, Spain.	aliciaarmentia@gmail.com	Armentia, Alicia/GLS-3358-2022	Martin-Armentia, Blanca/0000-0003-2110-7395; ARMENTIA, ALICIA/0000-0002-4165-4305				ALVAREZ FJ, 1988, PHARMACOLOGY, V37, P225, DOI 10.1159/000138470; DARIUS H, 1986, INT ARCH ALLER A IMM, V80, P369, DOI 10.1159/000234083; Deacock SJ, 2008, CLIN EXP IMMUNOL, V153, P151, DOI 10.1111/j.1365-2249.2008.03693.x; DeVane CL, 1998, THER DRUG MONIT, V20, P257, DOI 10.1097/00007691-199806000-00004; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; INALOZ HS, 2008, DERMATOLOGY, V35, P276; Kaplan AP, 2004, J ALLERGY CLIN IMMUN, V114, P465, DOI 10.1016/j.jaci.2004.02.049; Morel V, 2008, Rev Med Suisse, V4, P1019; Pereira C, 2007, Eur Ann Allergy Clin Immunol, V39, P237; SELLASDUPRE G, 2006, PHARMACOPSYCHIATRY, V39, P154; Spector SL, 2008, J ALLERGY CLIN IMMUN, V121, P784, DOI 10.1016/j.jaci.2007.12.1174	11	12	12	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					504	505		10.1016/j.jaci.2008.12.005	http://dx.doi.org/10.1016/j.jaci.2008.12.005			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	409GU	19203665				2022-12-18	WOS:000263495000034
J	Emminger, W; Durham, SR; Riis, B; Maloney, J; Nolte, H				Emminger, W.; Durham, S. R.; Riis, B.; Maloney, J.; Nolte, H.			The Efficacy Of Single-grass-allergen-immunotherapy-tablet Treatment In Mono- And Multi-sensitized Allergic Rhinitis Patients: Findings From A Post Hoc Analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	65th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 13-17, 2009	Washington, DC	Amer Acad Allergy, Asthma & Immunol					[Emminger, W.] Allergie Ambulatorium Rennweg, Vienna, Austria; [Durham, S. R.] Natl Heart & Lung Inst, London, England; [Riis, B.] ALK Abello, Horsholm, Denmark; [Maloney, J.; Nolte, H.] Schering Plough Res Inst, Kenilworth, NJ USA	Imperial College London; ALK-Abello AS; Merck & Company; Schering-Plough Research Institute									0	12	12	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2				275	S75	S75		10.1016/j.jaci.2008.12.257	http://dx.doi.org/10.1016/j.jaci.2008.12.257			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	410RR					2022-12-18	WOS:000263596300288
J	Tremblay, K; Daley, D; Chamberland, A; Lemire, M; Montpetit, A; Laviolette, M; Musk, AW; James, AL; Chan-Yeung, M; Becker, A; Kozyrskyj, AL; Sandford, AJ; Hudson, TJ; Parie, PD; Laprise, C				Tremblay, Karine; Daley, Denise; Chamberland, Annie; Lemire, Mathieu; Montpetit, Alexandre; Laviolette, Michel; Musk, Arthur W.; James, Alan L.; Chan-Yeung, Moira; Becker, Allan; Kozyrskyj, Anita L.; Sandford, Andrew J.; Hudson, Thomas J.; Parie, Peter D.; Laprise, Catherine			Genetic variation in immune signaling genes differentially expressed in asthmatic lung tissues	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; microarrays expression profiling; candidate genes; genetic association study; logging single nucleotide polymorphism; 15-lipoxygenase	FAMILY-BASED TESTS; SINGLE-NUCLEOTIDE POLYMORPHISMS; LINKAGE DISEQUILIBRIUM; PRIMARY PREVENTION; POPULATION-SAMPLE; UNDERLYING ASTHMA; BUSSELTON HEALTH; NATURAL-HISTORY; SPASTIC ATAXIA; ASSOCIATION	Background: Eight genes in the immune signaling pathway shown to be differentially expressed in asthmatic lung biopsy specimens in a previous microarray experiment were selected as candidate genes for asthma susceptibility. Objective: We sought to perform an association study with these genes and asthma-related phenotypes in 3 independent Canadian familial asthma collections and I Australian asthma case-control study. Methods: Tagging single nucleotide polymorphisms were selected by using the HapMap public database (r(2) > 0.8; minor allele frequency >0.10) and genotyped with the Illumina platform. Family-based association and trend tests for asthma, atopy, airway hyperresponsiveness, and allergic asthma phenotypes were done in each sample, correcting for multiple testing. Results: Uncorrected associations with polymorphisms within 7 genes were detected with I or more of the phenotypes in I or more of the 4 populations (.001 < P <.05). After correction, the 15-lipoxygenase (15-LO) associations with airway hyperresponsiveness and allergic asthma remained significant in 2 Canadian samples (corrected P =.022 and .049, respectively) and the association of the CD14 antigen with asthma remained significant in 1 Canadian sample (corrected P =.042). In both cases a protective effect of the minor alleles was observed. Conclusion: Expression profiling studies are a useful way to identify candidate genes for asthma because this approach has led to the first report of an association with 15-LO in 2 independent populations. Because 15-LO is involved in anti-inflammatory processes, further functional and clinical investigation of the role of this biologic pathway in asthma is warranted.	[Tremblay, Karine; Chamberland, Annie; Laprise, Catherine] Univ Quebec, Dept Sci Fondamentales, Saguenay, PQ G7H 2B1, Canada; [Tremblay, Karine; Laviolette, Michel] Univ Laval, Hop Laval, Quebec City, PQ, Canada; [Daley, Denise; Sandford, Andrew J.; Parie, Peter D.] Univ British Columbia, James Hogg iCAPTURE Ctr Cardiovasc & Pulm Re, Vancouver, BC V5Z 1M9, Canada; [Lemire, Mathieu; Sandford, Andrew J.] Ontario Inst Canc Res, Toronto, ON, Canada; [Montpetit, Alexandre] McGill Univ, Montreal, PQ, Canada; [Montpetit, Alexandre] Genome Quebec Innovat Centre, Montreal, PQ, Canada; [Musk, Arthur W.] Sir Charles Gairdner Hosp, Dept Resp Med, Nedlands, WA, Australia; [James, Alan L.] Sir Charles Gairdner Hosp, Western Australian Sleep Disorders Res Inst, Nedlands, WA, Australia; [Chan-Yeung, Moira] Univ British Columbia, Occupat & Environm Lung Dis Unit, Vancouver, BC V5Z 1M9, Canada; [Becker, Allan; Kozyrskyj, Anita L.] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; [Kozyrskyj, Anita L.] Univ Manitoba, Fac Pharm, Winnipeg, MB R3T 2N2, Canada; [Kozyrskyj, Anita L.] Univ Manitoba, Dept Community Hlth Sci, Manitoba Ctr Hlth Policy, Fac Med, Winnipeg, MB R3T 2N2, Canada; [Laprise, Catherine] Univ Montreal, Chicoutimi Univ Hosp, Community Genom Med Ctr, Saguenay, PQ, Canada	University of Quebec; University of Quebec Chicoutimi; Laval University; University of British Columbia; Ontario Institute for Cancer Research; University of Toronto; University Toronto Affiliates; McGill University; University of Western Australia; University of Western Australia; University of British Columbia; University of Manitoba; University of Manitoba; University of Manitoba; Universite de Montreal	Laprise, C (corresponding author), Univ Quebec, Dept Sci Fondamentales, 555 Blvd Univ, Saguenay, PQ G7H 2B1, Canada.	catherine_laprise@uqac.ca		Laprise, Catherine/0000-0001-5526-9945; Tremblay, Karine/0000-0002-2774-9738	AllerGen NCE. Inc; Canadian Institutes of Health Research; Respiratory Health Network of the Fonds de la recherche en sante do Quebec; Western Australia Healthway; Fondation de I'Universite Laval; Canadian Institutes of Health Research (CIHR); Institutes of Gender and Health. Genetics, Population and Public Health; CIHR STIHR IMPACT; Association of British Columbia; Fondation de l'Universite du Quebec; CIHR New Investigator; Burroughs Wellcome Fund	AllerGen NCE. Inc; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Respiratory Health Network of the Fonds de la recherche en sante do Quebec; Western Australia Healthway; Fondation de I'Universite Laval; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Institutes of Gender and Health. Genetics, Population and Public Health; CIHR STIHR IMPACT(Canadian Institutes of Health Research (CIHR)); Association of British Columbia; Fondation de l'Universite du Quebec; CIHR New Investigator(Canadian Institutes of Health Research (CIHR)); Burroughs Wellcome Fund(Burroughs Wellcome Fund)	Supported by a grant from AllerGen NCE. Inc (http://www.allergen-nce.ca/). the Canadian Institutes of Health Research, the Respiratory Health Network of the Fonds de la recherche en sante do Quebec. and the Western Australia Healthway. K.T is an AlterGen PhD trainee and is supported by the Fondation de I'Universite Laval studentship. D.D. is supported by grants from the Canadian Institutes of Health Research (CIHR), the Institutes of Gender and Health. Genetics, Population and Public Health, a CIHR STIHR IMPACT fellowship. and the Lung Association of British Columbia. A.C. is supported by the Fondation de l'Universite du Quebec A Chicoutimi studentship. A.L.K. is the recipient of a CIHR New Investigator award. A.S. is the chairholder of the Canada Research Chair (www.chairs.gc.ca) on genetic susceptibility to inflammatory disease. P.D.P. is a Michael Smith Foundation and Jacob Churg Scholar. T.J.H. is recipient of air Investigator Award from the CIHR and a Clinician-scientist Award in Translational Research from the Burroughs Wellcome Fund. C.L. is the chairholder of the Canada Research Chair on genetic determinants in asthma and the director of the Genetics platform of the Respiratory Health Network (RHN) of the Fonds de la recherche en sante du Quebec (FRSQ).	Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Becker A, 2004, J ALLERGY CLIN IMMUN, V113, P650, DOI 10.1016/j.jaci.2004.01.754; Begin P, 2007, AM J RESP CRIT CARE, V175, P1109, DOI 10.1164/rccm.200607-1012OC; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000; Chan-Yeung M, 2005, J ALLERGY CLIN IMMUN, V116, P49, DOI 10.1016/j.jaci.2005.03.029; Chan-Yeung M, 2000, ARCH PEDIAT ADOL MED, V154, P657, DOI 10.1001/archpedi.154.7.657; Chu H. W., 2002, Clinical and Experimental Allergy, V32, P1558, DOI 10.1046/j.1365-2222.2002.01477.x; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Dudbridge F, 2003, GENET EPIDEMIOL, V25, P115, DOI 10.1002/gepi.10252; Engert JC, 2000, NAT GENET, V24, P120, DOI 10.1038/72769; Heyer E, 1997, HUM BIOL, V69, P209; HEYER E, 1995, AM J HUM GENET, V56, P970; HILL MR, 1995, BRIT MED J, V311, P776, DOI 10.1136/bmj.311.7008.776; Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002; Hoffjan S, 2003, RESP RES, V4, DOI 10.1186/1465-9921-4-14; Holloway JW, 2007, CURR OPIN ALLERGY CL, V7, P69, DOI 10.1097/ACI.0b013e328013d51b; Horvath S, 2004, GENET EPIDEMIOL, V26, P61, DOI 10.1002/gepi.10295; James AL, 2005, AM J RESP CRIT CARE, V171, P109, DOI 10.1164/rccm.200402-230OC; Koh MS, 2007, INT J CLIN PRACT, V61, P1371, DOI 10.1111/j.1742-1241.2007.01426.x; Labuda M, 1996, AM J HUM GENET, V59, P633; Laird NM, 2000, GENET EPIDEMIOL, V19, pS36, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI6>3.3.CO;2-D; Laitinen T, 2001, NAT GENET, V28, P87, DOI 10.1038/88319; Lake SL, 2000, AM J HUM GENET, V67, P1515, DOI 10.1086/316895; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Laprise C, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-21; Lemire M, 2004, AM J HUM GENET, V75, P571, DOI 10.1086/424528; LEVY BD, 1993, J CLIN INVEST, V92, P1572, DOI 10.1172/JCI116738; Levy BD, 2002, NAT MED, V8, P1018, DOI 10.1038/nm748; Li J, 2005, HEREDITY, V95, P221, DOI 10.1038/sj.hdy.6800717; Lincoln MR, 2005, NAT GENET, V37, P1108, DOI 10.1038/ng1647; Moffatt MF, 2001, EUR J HUM GENET, V9, P341, DOI 10.1038/sj.ejhg.5200636; Nyholt DR, 2004, AM J HUM GENET, V74, P765, DOI 10.1086/383251; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Palmer LJ, 2001, EUR RESPIR J, V17, P696, DOI 10.1183/09031936.01.17406960; Profita M, 2000, AM J PHYSIOL-CELL PH, V279, pC1249, DOI 10.1152/ajpcell.2000.279.4.C1249; Profita M, 1999, AM J RESP CELL MOL, V20, P61, DOI 10.1165/ajrcmb.20.1.3151; Profita M, 2000, J ALLERGY CLIN IMMUN, V105, P711, DOI 10.1067/mai.2000.105122; Reed CE, 2006, J ALLERGY CLIN IMMUN, V118, P543, DOI 10.1016/j.jaci.2006.06.020; Richter A, 1999, AM J HUM GENET, V64, P768, DOI 10.1086/302274; Sandford A, 1996, AM J RESP CRIT CARE, V153, P1749, DOI 10.1164/ajrccm.153.6.8665031; Schmidt-Weber CB, 2006, CHEM IMMUNOL ALLERGY, V91, P188; Scriver CR, 2001, ANNU REV GENOM HUM G, V2, P69, DOI 10.1146/annurev.genom.2.1.69; Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC; TAKATA S, 1994, J CLIN INVEST, V93, P499, DOI 10.1172/JCI116999; Tremblay K, 2006, GENES IMMUN, V7, P632, DOI 10.1038/sj.gene.6364340; 1987, AM REV RESP DIS, V136, P225	47	12	13	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2008	122	3					529	536		10.1016/j.jaci.2008.05.049	http://dx.doi.org/10.1016/j.jaci.2008.05.049			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	348TW	18774388				2022-12-18	WOS:000259234000013
J	Weinberger, M				Weinberger, Miles			Long-acting beta-agonists and exercise	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						inhaled bronchodilators; exercise-induced dyspnea; asthma; beta(2) receptor downregulation; tolerance; long-acting beta(2)-agonists	INDUCED ASTHMA; SALMETEROL; BETA(2)-AGONISTS; POLYMORPHISMS; ADOLESCENTS; TRIAL		Univ Iowa, Coll Med, Pediat Allergy & Pulm Div, Iowa City, IA 52242 USA	University of Iowa	Weinberger, M (corresponding author), UIHC, Dept Pediat, 200 Hawkins Dr, Iowa City, IA 52242 USA.	miles-weinberger@uiowa.edu	Weinberger, Miles/H-6743-2019					Aaronson DW, 2006, J ALLERGY CLIN IMMUN, V117, P40, DOI 10.1016/j.jaci.2005.08.060; Abu-Hasan M, 2005, ANN ALLERG ASTHMA IM, V94, P366, DOI 10.1016/S1081-1206(10)60989-1; Anderson Sandra D, 2004, Paediatr Drugs, V6, P161, DOI 10.2165/00148581-200406030-00003; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; Kindermann W, 2007, SPORTS MED, V37, P95, DOI 10.2165/00007256-200737020-00001; LaForce C, 2008, ALLERGY, V63, P103, DOI 10.1111/j.1398-9995.2007.01555.x; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; Nelson JA, 1998, NEW ENGL J MED, V339, P141, DOI 10.1056/NEJM199807163390301; Shapiro GS, 2002, CLIN THER, V24, P2077, DOI 10.1016/S0149-2918(02)80098-4; Simons FER, 1997, PEDIATRICS, V99, P655, DOI 10.1542/peds.99.5.655; Solis-Cohen S., 1900, J AM MED ASS, V34, P1164, DOI [10.1001/jama.1900.24610190014001c, DOI 10.1001/JAMA.1900.24610190014001C]; Taylor DR, 2007, EXPERT OPIN PHARMACO, V8, P3195, DOI 10.1517/14656566.8.18.3195; Taylor DR, 2007, LANCET, V370, P2075, DOI 10.1016/S0140-6736(07)61876-5; Weinberger M, 2006, NEW ENGL J MED, V355, P852, DOI 10.1056/NEJMc066282; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590	15	12	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					251	253		10.1016/j.jaci.2008.05.030	http://dx.doi.org/10.1016/j.jaci.2008.05.030			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18582922				2022-12-18	WOS:000258426300004
J	Hauswirth, DW; Sundy, JS; Mervin-Blake, S; Fernandez, CA; Patch, KB; Alexander, KM; Allgood, S; McNair, PD; Levesque, MC				Hauswirth, David W.; Sundy, John S.; Mervin-Blake, Sabrena; Fernandez, Carolyn A.; Patch, Kistie B.; Alexander, Katie M.; Allgood, Sallie; McNair, Patrice D.; Levesque, Marc C.			Normative values for exhaled breath condensate pH and its relationship to exhaled nitric oxide in healthy African Americans	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; exhaled breath condensate; nitric oxide; nitrite; African Americans	HUMAN AIRWAY; ASTHMA; ACIDIFICATION; INHALATION; SMOKING; NASAL	Background: Exhaled breath condensate (EBC) pH and exhaled nitric oxide (FeNO) have been proposed as markers of asthma severity. EBC pH values below 6.5 have been associated with asthma exacerbations. Protonation of airway nitrite occurs at low pH and may contribute to FeNO. Objective: To establish normative EBC pH values and to determine the contribution of EBC pH to FeNO in healthy African Americans. Methods: Two hundred seventy healthy African American subjects without asthma between 18 and 40 years old were evaluated. Subjects had simultaneous measurement of EBC pH, EBC nitrite, nitrate, and FeNO. Results: The median EBC pH was 8.14 (interquartile range, 7.83-8.28). Of subjects, 11.9 % had an EBC pH <= 6.5. In subjects with EBC pH values below 6.5, there was an inverse correlation between EBC pH and FeNO (r(2) = 0.158; P =.0245; n = 32). In the entire cohort, there was a direct correlation between EBC pH and EBC nitrite (r(2) = 0.163; P <.0001), but there was no correlation between EBC nitrite and FeNO. In multivariate analyses, EBC pH and nitrite did not contribute significantly to FeNO variation while controlling for other confounders of FeNO. Conclusion: There was an increased prevalence (11.9%) of low EBC pH (less than 6.5) in healthy African American subjects compared with white subjects (<5%). EBC pH and nitrite were directly correlated, but there was no correlation between EBC nitrite and FeNO. FeNO correlated with EBC pH at pH values less than 6.5 in univariate but not multivariate analyses. This suggests that EBC pH and nitrite are not significant determinants of FeNO in healthy subjects.	[Hauswirth, David W.] Ohio State Univ, Med Ctr, Dept Med, Div Pulm Allergy Crit Care & Sleep Med, Columbus, OH 43221 USA; [Sundy, John S.] Duke Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, Durham, NC USA; [Sundy, John S.; Mervin-Blake, Sabrena; Fernandez, Carolyn A.; Patch, Kistie B.; Alexander, Katie M.; Allgood, Sallie; McNair, Patrice D.; Levesque, Marc C.] Duke Univ, Med Ctr, Dept Med, Div Rheumatol & Immunol, Durham, NC USA	University System of Ohio; Ohio State University; Duke University; Duke University	Hauswirth, DW (corresponding author), Ohio State Univ, Med Ctr, Dept Med, Div Pulm Allergy Crit Care & Sleep Med, 2050 Kenny Rd,Suite 2200, Columbus, OH 43221 USA.	david.hauswirth@osumc.edu		Allgood, Sallie/0000-0002-0329-4572	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K23ES011185] Funding Source: NIH RePORTER; NIAID NIH HHS [T32 AI007062, T32 AI07062-27] Funding Source: Medline; NIEHS NIH HHS [ES011185] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Borrill Z, 2005, EUR RESPIR J, V25, P269, DOI 10.1183/09031936.05.00085804; Dweik RA, 2001, P NATL ACAD SCI USA, V98, P2622, DOI 10.1073/pnas.051629498; Effros RM, 2006, AM J RESP CRIT CARE, V173, P386, DOI 10.1164/rccm.200507-1059OC; Effros RM, 2004, AM J PHYSIOL-LUNG C, V287, pL1073, DOI 10.1152/ajplung.00069.2004; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Garey KW, 2004, CHEST, V125, P22, DOI 10.1378/chest.125.1.22; Gaston B, 2006, J ALLERGY CLIN IMMUN, V118, P817, DOI 10.1016/j.jaci.2006.06.040; Gessner C, 2003, RESP MED, V97, P1188, DOI 10.1016/S0954-6111(03)00225-7; Getahun D, 2005, J ASTHMA, V42, P373, DOI 10.1081/JAS-200062995; Gupta RS, 2006, J ALLERGY CLIN IMMUN, V117, P351, DOI 10.1016/j.jaci.2005.11.047; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Harik-Khan RI, 2001, AM J RESP CRIT CARE, V164, P1647, DOI 10.1164/ajrccm.164.9.2106075; Horvath I, 2005, EUR RESPIR J, V26, P523, DOI 10.1183/09031936.05.00029705; Hunt JF, 2000, AM J RESP CRIT CARE, V161, P694, DOI 10.1164/ajrccm.161.3.9911005; Hunt JF, 2002, AM J RESP CRIT CARE, V165, P101, DOI 10.1164/ajrccm.165.1.2104131; Hunt John, 2006, Cough, V2, P3, DOI 10.1186/1745-9974-2-3; Ireson NJ, 2001, CLIN SCI, V100, P327, DOI 10.1042/CS20000259; JACKSON GG, 1958, ARCH INTERN MED, V101, P267, DOI 10.1001/archinte.1958.00260140099015; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V152, P609, DOI 10.1164/ajrccm.152.2.7543345; Kostikas K, 2002, AM J RESP CRIT CARE, V165, P1364, DOI 10.1164/rccm.200111-068OC; Kullmann T, 2007, EUR RESPIR J, V29, P496, DOI 10.1183/09031936.00084006; Leung TF, 2006, PEDIATR PULM, V41, P87, DOI 10.1002/ppul.20296; Levesque MC, 2008, J ALLERGY CLIN IMMUN, V121, P396, DOI 10.1016/j.jaci.2007.09.031; Marteus H, 2005, THORAX, V60, P219, DOI 10.1136/thx.2004.030635; Modin A, 2001, ACTA PHYSIOL SCAND, V171, P9, DOI 10.1046/j.1365-201x.2001.171001009.x; Niimi A, 2004, THORAX, V59, P608, DOI 10.1136/thx.2003.012906; Paget-Brown AO, 2006, CHEST, V129, P426, DOI 10.1378/chest.129.2.426; Quinn K, 2006, AM J PUBLIC HEALTH, V96, P1599, DOI 10.2105/AJPH.2005.071514; Shin HW, 2007, J APPL PHYSIOL, V102, P1028, DOI 10.1152/japplphysiol.01012.2006; Silkoff Philip E, 2006, Proc Am Thorac Soc, V3, P131; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Sundy JS, 2007, EUR RESPIR J, V30, P1074, DOI 10.1183/09031936.00087807; Vaughan J, 2003, EUR RESPIR J, V22, P889, DOI 10.1183/09031936.03.00038803; Yates DH, 2001, AM J RESP CRIT CARE, V164, P1043, DOI 10.1164/ajrccm.164.6.2005043; Zitter JN, 2002, JAMA-J AM MED ASSOC, V288, P483, DOI 10.1001/jama.288.4.483	36	12	12	2	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					101	106		10.1016/j.jaci.2008.03.024	http://dx.doi.org/10.1016/j.jaci.2008.03.024			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	325RD	18472151				2022-12-18	WOS:000257605100017
J	Daines, CL; Wood, RE; Boesch, RP				Daines, Cori L.; Wood, Robert E.; Boesch, R. Paul			Foreign body aspiration: An important etiology of respiratory symptoms in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						foreign body aspiration; flexible bronchoscopy; chronic cough	BODIES; BRONCHOSCOPY; RADIOGRAPHY; DIAGNOSIS		[Daines, Cori L.] Univ Arizona, Div Pediat Pulm Allergy & Immunol, Dept Pediat, Tucson, AZ 85724 USA; [Wood, Robert E.; Boesch, R. Paul] Cincinnati Childrens Hosp Med Ctr, Div Pediat Pulm Med, Cincinnati, OH USA	University of Arizona; Cincinnati Children's Hospital Medical Center	Daines, CL (corresponding author), Univ Arizona, Div Pediat Pulm, Dept Pediat, 1501 N Campbell Ave,POB 245073, Tucson, AZ 85724 USA.	cdaines@arc.arizona.edu						Assefa D, 2007, PEDIATR EMERG CARE, V23, P154, DOI 10.1097/PEC.0b013e3180328cd8; Eren S, 2003, ANN TROP PAEDIATR, V23, P31, DOI 10.1179/000349803125002959; ESCLAMADO RM, 1987, AM J DIS CHILD, V141, P259, DOI 10.1001/archpedi.1987.04460030037019; Fitzpatrick P C, 1998, J La State Med Soc, V150, P138; Lemberg PS, 1996, ANN OTO RHINOL LARYN, V105, P267, DOI 10.1177/000348949610500404; Martinot A, 1997, AM J RESP CRIT CARE, V155, P1676, DOI 10.1164/ajrccm.155.5.9154875; MU LC, 1990, J LARYNGOL OTOL, V104, P778, DOI 10.1017/S0022215100113891; *NATL SAFT COUNC, 2005, REP INJ AM; RIMELL FL, 1995, JAMA-J AM MED ASSOC, V274, P1763, DOI 10.1001/jama.274.22.1763; Tan HKK, 2000, INT J PEDIATR OTORHI, V56, P91, DOI 10.1016/S0165-5876(00)00391-8; Tokar B, 2004, CLIN RADIOL, V59, P609, DOI 10.1016/j.crad.2004.01.006; WOOD RE, 1984, J PEDIATR SURG, V19, P693, DOI 10.1016/S0022-3468(84)80354-1; Zerella JT, 1998, J PEDIATR SURG, V33, P1651, DOI 10.1016/S0022-3468(98)90601-7; 2001, MMWR MORB MORTAL WKL, V51, P945	14	12	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2008	121	5					1297	1298		10.1016/j.jaci.2008.03.014	http://dx.doi.org/10.1016/j.jaci.2008.03.014			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	302IJ	18466789				2022-12-18	WOS:000255961700042
J	Menzies, D; Nair, A; Meldrurn, KT; Hopkinson, P; Lipworth, BJ				Menzies, Daniel; Nair, Arun; Meldrurn, Karen T.; Hopkinson, Pippa; Lipworth, Brian J.			Effect of aspirin on airway inflammation and pulmonary function in patients with persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; aspirin; inflammation; lipoxin; thromboxane; exhaled nitric oxide; histamine challenge	INHALED LYSINE ACETYLSALICYLATE; LIPOXIN; PREVALENCE; CHALLENGE; MEDIATORS; A(4)	Background: Aspirin can cause bronchoconstriction in some asthmatic patients through increased production of proinflammatory mediators, particularly leukotrienes. However, recent in vivo evidence has suggested that aspirin also triggers the production of lipoxins, which act as natural antagonists of prostaglandins and leukotrienes. Aside from patients with known aspirin-sensitive asthma, physicians have avoided the use of aspirin in asthmatic patients in general because it was believed that this agent might precipitate worsening of their condition. Objective: We sought to establish the effect of aspirin on pulmonary inflammation and function in patients with persistent asthma. Methods: After withdrawal of their usual anti-inflammatory medication, patients with mild-to-moderate persistent asthma undertook double-blind, randomized, crossover treatment with 75 mg/d aspirin and placebo for 3 weeks each. Treatment evaluation included histamine challenge, spirometry, impulse oscillometry, total and alveolar exhaled nitric oxide measurement, and serum thromboxane B2 and 15-epilipoxin A4 levels. Results: Fifteen patients completed the trial. Compared with placebo, there were no differences in histamine PC20 values (0.17 doubling-dilution shift; 95% CI, -0.38 to 0.73; P = 1), exhaled nitric oxide levels (0.95-fold change; 95% CI, 0.45-2.00; P = 1), or any other inflammatory, spirometric, or oscillometry measurements. Aspirin led to a significant decrease in thromboxane B2 levels (17.53-fold difference; 95% CI, 5.4656.49; P <.001). Baseline 15-epilipoxin A4 levels were increased at 4.88 ng/mL, and there was no increase with aspirin versus placebo (0.99-fold difference; 95% CI, 0.79-1.24; P = 1). Conclusion: In this preliminary study of 15 patients, low-dose aspirin did not lead to increased 15-epilipoxin A4 synthesis or alter inflammatory markers in patients with mild-to-moderate persistent asthma.	[Menzies, Daniel; Nair, Arun; Meldrurn, Karen T.; Hopkinson, Pippa; Lipworth, Brian J.] Ninewells Hosp & Med Sch, Asthma & Allergy Res Grp, Dept Med, Dundee DD1 9SY, Scotland	University of Dundee	Lipworth, BJ (corresponding author), Ninewells Hosp & Med Sch, Asthma & Allergy Res Grp, Dept Med, Dundee DD1 9SY, Scotland.	brianlipworth@googlemail.com		Smith, Karen/0000-0002-3968-7458				*2 INT STUD INF SU, 1988, J AM COLL CARDIOL  S, V12, pA3; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; [Anonymous], 1988, BRIT MED J, V296, P320; Barr RG, 2007, AM J RESP CRIT CARE, V175, P120, DOI 10.1164/rccm.200603-411OC; BIANCO S, 1995, J ALLERGY CLIN IMMUN, V95, P937, DOI 10.1016/S0091-6749(95)70092-7; Bonnans C, 2002, AM J RESP CRIT CARE, V165, P1531, DOI 10.1164/rccm.200201-053OC; Celik GE, 2007, CLIN EXP ALLERGY, V37, P1494, DOI 10.1111/j.1365-2222.2007.02806.x; Chiang N, 2004, P NATL ACAD SCI USA, V101, P15178, DOI 10.1073/pnas.0405445101; Chiang N, 2005, PROSTAG LEUKOTR ESS, V73, P163, DOI 10.1016/j.plefa.2005.05.003; Chinn S, 2005, THORAX, V60, P395, DOI 10.1136/thx.2004.039230; Cormican LJ, 2005, CLIN EXP ALLERGY, V35, P717, DOI 10.1111/j.1365-2222.2005.02261.x; CRIMI N, 1995, EUR RESPIR J, V8, P905; Jenkins C, 2004, BMJ-BRIT MED J, V328, P434, DOI 10.1136/bmj.328.7437.434; Kasper L, 2003, ALLERGY, V58, P1064, DOI 10.1034/j.1398-9995.2003.00267.x; Kawagishi Y, 2002, J ALLERGY CLIN IMMUN, V109, P936, DOI 10.1067/mai.2002.124466; Levy BD, 2002, NAT MED, V8, P1018, DOI 10.1038/nm748; Levy BD, 2005, AM J RESP CRIT CARE, V172, P824, DOI 10.1164/rccm.200410-1413OC; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Oostveen E, 2003, EUR RESPIR J, V22, P1026, DOI 10.1183/09031936.03.00089403; Serhan CN, 2005, PROSTAG LEUKOTR ESS, V73, P141, DOI 10.1016/j.plefa.2005.05.002; Tiong AY, 2005, AM HEART J, V150, P11, DOI 10.1016/j.ahj.2004.12.019; Tsoukias NM, 1998, J APPL PHYSIOL, V85, P653, DOI 10.1152/jappl.1998.85.2.653; Vachier I, 2005, J ALLERGY CLIN IMMUN, V115, P55, DOI 10.1016/j.jaci.2004.09.038	23	12	13	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2008	121	5					1184	1189		10.1016/j.jaci.2008.01.009	http://dx.doi.org/10.1016/j.jaci.2008.01.009			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	302IJ	18313127				2022-12-18	WOS:000255961700017
J	Negri, J; Early, SB; Steinke, JW; Borish, L				Negri, Julie; Early, S. Brandon; Steinke, John W.; Borish, Larry			Corticosteroids as inhibitors of cysteinyl leukotriene metabolic and signaling pathways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cysteinyl leukotrienes; corticosteroids; IL-4	PLACEBO-CONTROLLED TRIAL; RECEPTOR EXPRESSION; INHALED CORTICOSTEROIDS; FLUTICASONE PROPIONATE; INFLAMMATORY CELLS; INTOLERANT ASTHMA; HUMAN MONOCYTES; C-4 SYNTHASE; MONTELUKAST; ANTAGONIST	Background: Corticosteroids (CCSs) do not influence secretion of cysteinyl leukotrienes (CysLTs) that occurs on cellular activation during allergic reactions nor do they modulate bronchospastic responses to inhalation challenges with leukotrienes (LTs). Objectives: We speculated that CCSs might modulate pathways responsible for CysLT production and diminish the ability of cellular activation to cause their release. Similarly, CCSs could reduce expression of CysLT receptor 1 (CysLTR1) and CysLT receptor 2 (CysLT2R) and modulate their responsiveness. Methods: We investigated influences of fluticasone on expression of mRNA for LTC4 synthase (LTC4S), CysLT1R, and CysLT2R within T lymphocytes, monocytes, and eosinophils by means of quantitative PCR. Effects on receptor protein expression were evaluated by means of flow cytometry. Results: Circulating immune cells (T cells, monocytes, and eosinophils) express low levels of LTC4S mRNA, and this was not influenced by CCSs. However, IL-4 induced transcripts in T lymphocytes, and this was prevented by fluticasone. Paradoxically, CCSs synergized with IL-4 to increase LTC4S expression in monocytes. Although not influencing basal or IL-4-stimulated CysLT1R expression, fluticasone inhibited basal CysLT2R transcript expression on monocytes and IL-4-induced expression in all 3 cell types. Conclusions: In addition to not blocking the acute release of CysLTs on cellular activation, CCSs do not diminish the capacity of cells to synthesize these compounds. CCSs do not diminish CysLT1R expression, consistent with their lack of influence on bronchospasm, which is mediated through this receptor.	[Negri, Julie; Early, S. Brandon; Steinke, John W.; Borish, Larry] Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, Beirne Carter Ctr Immunol Res, Dept Med, Charlottesville, VA 22908 USA	University of Virginia	Borish, L (corresponding author), Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, Beirne Carter Ctr Immunol Res, Dept Med, Box 801355, Charlottesville, VA 22908 USA.	lb4m@virginia.edu						BEL EH, 1989, AM REV RESPIR DIS, V139, P427, DOI 10.1164/ajrccm/139.2.427; Beller TC, 2004, P NATL ACAD SCI USA, V101, P3047, DOI 10.1073/pnas.0400235101; Bjermer L, 2003, BMJ-BRIT MED J, V327, P891, DOI 10.1136/bmj.327.7420.891; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Dahlen SE, 2006, EUR J PHARMACOL, V533, P40, DOI 10.1016/j.ejphar.2005.12.070; Dahlen SE, 2002, AM J RESP CRIT CARE, V165, P9, DOI 10.1164/ajrccm.165.1.2010080; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; DWORSKI R, 1994, AM J RESP CRIT CARE, V149, P953, DOI 10.1164/ajrccm.149.4.8143061; Early SB, 2007, AM J RESP CELL MOL, V36, P715, DOI 10.1165/rcmb.2006-0252OC; Figueroa DJ, 2001, AM J RESP CRIT CARE, V163, P226, DOI 10.1164/ajrccm.163.1.2003101; Figueroa DJ, 2003, CLIN EXP ALLERGY, V33, P1380, DOI 10.1046/j.1365-2222.2003.01786.x; Gyllfors P, 2006, J ALLERGY CLIN IMMUN, V118, P78, DOI 10.1016/j.jaci.2006.03.040; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Hsieh FH, 2001, J EXP MED, V193, P123, DOI 10.1084/jem.193.1.123; Kanaoka Y, 2004, J IMMUNOL, V173, P1503, DOI 10.4049/jimmunol.173.3.1503; Laviolette M, 1999, AM J RESP CRIT CARE, V160, P1862, DOI 10.1164/ajrccm.160.6.9803042; Lofdahl CG, 1999, BMJ-BRIT MED J, V319, P87, DOI 10.1136/bmj.319.7202.87; Lynch KR, 1999, NATURE, V399, P789; MANSO G, 1992, EUR RESPIR J, V5, P712; OSHAUGHNESSY KM, 1993, AM REV RESPIR DIS, V147, P1472, DOI 10.1164/ajrccm/147.6_Pt_1.1472; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Riddick CA, 1997, EUR J BIOCHEM, V246, P112, DOI 10.1111/j.1432-1033.1997.00112.x; SEBALDT RJ, 1990, P NATL ACAD SCI USA, V87, P6974, DOI 10.1073/pnas.87.18.6974; Sousa AR, 2002, NEW ENGL J MED, V347, P1493, DOI 10.1056/NEJMoa013508; Spinozzi F, 2004, CLIN EXP ALLERGY, V34, P1876, DOI 10.1111/j.1365-2222.2004.02119.x; Steinke JW, 2004, AM J RESP CELL MOL, V30, P212, DOI 10.1165/rcmb.2003-0071OC; Thivierge M, 2000, J IMMUNOL, V165, P5221, DOI 10.4049/jimmunol.165.9.5221; Thivierge M, 2001, J IMMUNOL, V167, P2855, DOI 10.4049/jimmunol.167.5.2855; *US DEP HHS, 1997, NAT ASTHM EV PREV PR; Vachier I, 2003, RESP MED, V97, P1225, DOI 10.1016/S0954-6111(03)00253-1; Virchow JC, 2000, AM J RESP CRIT CARE, V162, P578	31	12	13	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2008	121	5					1232	1237		10.1016/j.jaci.2008.02.007	http://dx.doi.org/10.1016/j.jaci.2008.02.007			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	302IJ	18355910				2022-12-18	WOS:000255961700024
J	Brandt, DM; Levin, L; Matsui, E; Phipatanakid, W; Sinith, AM; Bemstein, JA				Brandt, Dominique M.; Levin, Linda; Matsui, Eliabeth; Phipatanakid, Wanda; Sinith, Alisa M.; Bemstein, Jonathan A.			Allergists' attitudes toward environmental control: Insights into its current application in clinical practice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MITE ALLERGEN; ASTHMA; INTERVENTION; EXPOSURE; CHILDREN		[Brandt, Dominique M.; Bemstein, Jonathan A.] Univ Cincinnati, Coll Med, Dept Internal Med, Div Immunol,Allergy Sect, Cincinnati, OH 45221 USA; [Levin, Linda] Univ Cincinnati, Coll Med, Dept Environm Biostat, Cincinnati, OH USA; [Matsui, Eliabeth] Johns Hopkins Univ, Div Pediat Allergy & Immunol, Baltimore, MD USA; [Phipatanakid, Wanda] Harvard Univ, Childrens Hosp, Sch Med, Div Pediat Allergy & Immunol, Boston, MA 02115 USA; [Sinith, Alisa M.] US EPA, Indoor Environm Div, Washington, DC 20460 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Johns Hopkins University; Harvard University; Boston Children's Hospital; Harvard Medical School; United States Environmental Protection Agency	Brandt, DM (corresponding author), Univ Cincinnati, Coll Med, Dept Internal Med, Div Immunol,Allergy Sect, Cincinnati, OH 45221 USA.	Jonathan.Bemstein@uc.edu		Bernstein, Jonathan/0000-0002-3476-1196; Matsui, Elizabeth/0000-0001-8134-5593	NIAID NIH HHS [K23 AI054972-05, K23 AI054972] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI054972] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		de Blay F, 2003, ALLERGY, V58, P27, DOI 10.1034/j.1398-9995.2003.23674.x; Eggleston PA, 1999, J ALLERGY CLIN IMMUN, V103, P203, DOI 10.1016/S0091-6749(99)70491-4; *ENV PROT AG, NAT SURV ENV MAN AST; Kercsmar CM, 2006, ENVIRON HEALTH PERSP, V114, P1574, DOI 10.1289/ehp.8742; Krieger JW, 2005, AM J PUBLIC HEALTH, V95, P652, DOI 10.2105/AJPH.2004.042994; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; *NIH NAT HEART LUN, 2007, 3 NIH NAT HEART LUNG; Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175	9	12	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					1053	1054		10.1016/j.jaci.2007.11.025	http://dx.doi.org/10.1016/j.jaci.2007.11.025			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18234314	Green Accepted			2022-12-18	WOS:000254884000036
J	Matsui, EC; Eggleston, PA; Breysse, P; Diette, GB				Matsui, Elizabeth C.; Eggleston, Peyton A.; Breysse, Patrick; Diette, Gregory B.			Mouse allergen levels vary over time in inner-city homes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EXPOSURE; CHILDREN; ASTHMA; MORBIDITY		Johns Hopkins Univ, Baltimore, MD 21218 USA	Johns Hopkins University	Matsui, EC (corresponding author), Johns Hopkins Univ, Baltimore, MD 21218 USA.	ematsui@jhmi.edu		Matsui, Elizabeth/0000-0001-8134-5593	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL004266, K23HL067850] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI060955, R01AI070630] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES009606] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL04266, HL67850] Funding Source: Medline; NIAID NIH HHS [AI070630, AI060955] Funding Source: Medline; NIEHS NIH HHS [ES009606] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Chew GL, 2003, ENVIRON HEALTH PERSP, V111, P1348, DOI 10.1289/ehp.6124; Cohn RD, 2004, J ALLERGY CLIN IMMUN, V113, P1167, DOI 10.1016/j.jaci.2003.12.592; JONES RB, 1995, AM IND HYG ASSOC J, V56, P398, DOI 10.1202/0002-8894(1995)056<0398:TEORHO>2.0.CO;2; Matsui EC, 2005, J ALLERGY CLIN IMMUN, V115, P358, DOI 10.1016/j.jaci.2004.11.007; Matsui EC, 2004, J ALLERGY CLIN IMMUN, V113, P910, DOI 10.1016/j.jaci.2004.02.034; Matsui EC, 2006, ANN ALLERG ASTHMA IM, V97, P514, DOI 10.1016/S1081-1206(10)60943-X; OHMAN JL, 1994, J ALLERGY CLIN IMMUN, V94, P810, DOI 10.1016/0091-6749(94)90147-3; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1075, DOI 10.1067/mai.2000.110795; Wood RA, 2001, ANN ALLERG ASTHMA IM, V87, P60, DOI 10.1016/S1081-1206(10)62324-1	9	12	12	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2007	120	4					956	959		10.1016/j.jaci.2007.07.053	http://dx.doi.org/10.1016/j.jaci.2007.07.053			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	220LH	17931566	Bronze			2022-12-18	WOS:000250157700036
J	Ueta, M; Nakamura, T; Tanaka, S; Kojima, K; Kinoshita, S				Ueta, Mayumi; Nakamura, Takao; Tanaka, Satoshi; Kojima, Kentaro; Kinoshita, Shigeru			Development of eosinophilic conjunctival inflammation at late-phase reaction in mast cell-deficient mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							AIRWAY INFLAMMATION; DISEASE		Kyoto Prefectural Univ Med, Dept Ophthalmol, Kyoto, Japan; Otemae Hosp, Dept Ophthalmol, Osaka, Japan; Mukogawa Womens Univ, Sch Pharmaceut Sci, Dept Immunobiol, Hyogo, Japan	Kyoto Prefectural University of Medicine; Mukogawa Women's University	Ueta, M (corresponding author), Kyoto Prefectural Univ Med, Dept Ophthalmol, Kyoto, Japan.	mueta@ophth.kpu-m.ac.jp	TANAKA, Satoshi/B-1624-2011; Tanaka, Satoshi/H-6800-2019	TANAKA, Satoshi/0000-0002-3468-7694; Tanaka, Satoshi/0000-0002-3468-7694; Kojima, Kentaro/0000-0003-2347-4789				BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; El-Asrar AMA, 2000, BR J OPHTHALMOL, V84, P1360; Graziano FM, 2001, ALLERGY ASTHMA PROC, V22, P121, DOI 10.2500/108854101778148782; KUNG TT, 1995, AM J RESP CELL MOL, V12, P404, DOI 10.1165/ajrcmb.12.4.7695919; Leonardi A, 2006, CLIN EXP ALLERGY, V36, P777, DOI 10.1111/j.1365-2222.2006.02499.x; Martin Andrea P, 2003, BMC Ophthalmol, V3, P2, DOI 10.1186/1471-2415-3-2; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; Tsai M, 2005, CHEM IMMUNOL ALLERGY, V87, P179, DOI 10.1159/000087644	8	12	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					476	478		10.1016/j.jaci.2007.04.024	http://dx.doi.org/10.1016/j.jaci.2007.04.024			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	198VF	17531294				2022-12-18	WOS:000248654900041
J	Cohon, A; Arruda, LK; Martins, MA; Guilherme, L; Kalil, J				Cohon, Andrea; Arruda, L. Karla; Martins, Milton A.; Guilherme, Luiza; Kalil, Jorge			Evaluation of BCG administration as an adjuvant to specific immunotherapy in asthmatic children with mite allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							BACILLUS-CALMETTE-GUERIN		Sch Med Sao Paulo, Sao Paulo, Brazil; Univ Sao Paulo, Sch Med Ribeirao Preto, Sao Paulo, Brazil	Universidade de Sao Paulo	Cohon, A (corresponding author), Sch Med Sao Paulo, Sao Paulo, Brazil.	karla@fmrp.usp.br	Arruda, L. Karla/D-5845-2013; Martins, Milton A/D-6658-2012; Guglielmi, Luiza G/E-7676-2013; Martins, Milton A/L-7541-2017; KALIL, JORGE/C-8029-2012	Arruda, L. Karla/0000-0002-7505-210X; KALIL, JORGE/0000-0001-8415-4274				ABRAMSON MJ, 2006, ALLERGEN IMMUNOTHERA; Arikan C, 2004, CLIN EXP ALLERGY, V34, P398, DOI 10.1111/j.1365-2222.2004.01869.x; Barlan I, 2006, IMMUNOL ALLERGY CLIN, V26, P365, DOI 10.1016/j.iac.2006.02.002; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x; Taylor DR, 2006, J ALLERGY CLIN IMMUN, V117, P259, DOI 10.1016/j.jaci.2005.11.010; Trivedi L, 2003, J ALLERGY CLIN IMMUN, V111, P777, DOI 10.1067/mai.2003.1338; Trombone APF, 2002, CLIN EXP ALLERGY, V32, P1323, DOI 10.1046/j.1365-2745.2002.01455.x	9	12	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					210	213		10.1016/j.jaci.2007.04.018	http://dx.doi.org/10.1016/j.jaci.2007.04.018			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	190NS	17531299	Bronze			2022-12-18	WOS:000248066400032
J	Gilmour, J; Cousins, DJ; Richards, DF; Sattar, Z; Lee, TH; Lavender, P				Gilmour, Jane; Cousins, David J.; Richards, David F.; Sattar, Zahid; Lee, Tak H.; Lavender, Paul			Regulation of GM-CSF expression by the transcription factor c-Maf	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human; T(H)1/T(H)2 cells; cytokines; transcription factors; gene regulation	COLONY-STIMULATING FACTOR; CELL TYPE-2 TH2; GENE-EXPRESSION; DENDRITIC CELLS; CYTOKINE GENES; DIFFERENTIATION; INTERLEUKIN-4; GENERATION; ENHANCER; ELEMENT	Background: Inflammation is a key feature of asthma and allergic disease. The proinflammatory cytokines IL-4, IL-5, and IL-13 are clustered on chromosome 5q with GM-CSF in close proximity, and each of these cytokines has been implicated in the pathogenesis of inflammatory disease. Although the expression of IL-4, IL-5, and IL-13 is coordinately regulated, the T(H)2-associated transcription factor c-Maf is thought to be involved only in the regulation of IL-4, the cytokine thought to be the main driver of T(H)2 differentiation. Objective: We sought to determine whether c-Maf influenced the expression of proinflammatory cytokines other than IL-4 in the Jurkat human T-cell line. Methods: RT-PCR, ELISA, and promoter-driven CAT assays were used to determine the effect of c-Maf overexpression on cytokine genes. A biotinylated oligo pulldown assay was used to demonstrate recruitment of c-Maf to the GM-CSF promoter. Results: We found that in addition to induction of IL-4, c-Maf could upregulate GM-CSF expression at both mRNA and protein levels, and that c-Maf could strongly activate the promoters of GM-CSF and IL-4 but not IL-5. Recruitment of c-Maf to the -33 to -97 bp region of the GM-CSF promoter was demonstrated. Conclusion: We propose a novel role for c-Maf in the transcriptional regulation of GM-CSF in human T cells. Clinical implications: These data suggest that c-Maf may be a therapeutic target affecting both IL-4 and GM-CSF.	Kings Coll London, MRC, Guys Hosp, London SE1 9RT, England; Kings Coll London, Med Res Council & Asthma UK Ctr Allerg Mech Asthm, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of London; King's College London	Lavender, P (corresponding author), Kings Coll London, MRC, Guys Hosp, 5th Floor Thomas Guy House, London SE1 9RT, England.	paul.lavender@kcl.ac.uk	Lee, Tak/AAA-9526-2020	Lee, Tak/0000-0002-7554-4059; Cousins, David/0000-0003-3821-9596; Lavender, Paul/0000-0001-8710-0263	MRC [G9536930] Funding Source: UKRI; Medical Research Council [G9536930] Funding Source: Medline; Wellcome Trust [068642/Z/02/Z] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Berger TG, 2002, J IMMUNOL METHODS, V268, P131, DOI 10.1016/S0022-1759(02)00189-8; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; BURKE LA, 1991, J ALLERGY CLIN IMMUN, V88, P226, DOI 10.1016/0091-6749(91)90333-J; Cao SJ, 2002, J IMMUNOL, V169, P5715, DOI 10.4049/jimmunol.169.10.5715; Codlin S, 2003, J ALLERGY CLIN IMMUN, V111, P826, DOI 10.1067/mai.2003.1377; Cousins DJ, 2002, J IMMUNOL, V169, P2498, DOI 10.4049/jimmunol.169.5.2498; EBISAWA M, 1994, J IMMUNOL, V152, P4590; Hausding M, 2004, EUR J IMMUNOL, V34, P3401, DOI 10.1002/eji.200425121; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; HENDERSON AJ, 1994, MOL CELL BIOL, V14, P4286, DOI 10.1128/MCB.14.6.4286; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; Ho IC, 1998, J EXP MED, V188, P1859, DOI 10.1084/jem.188.10.1859; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Hwang ES, 2002, P NATL ACAD SCI USA, V99, P13026, DOI 10.1073/pnas.202474499; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Kim JI, 1999, IMMUNITY, V10, P745, DOI 10.1016/S1074-7613(00)80073-4; Lee GR, 2003, IMMUNITY, V19, P145, DOI 10.1016/S1074-7613(03)00179-1; Lee HJ, 2000, J EXP MED, V192, P105, DOI 10.1084/jem.192.1.105; Matsushima-Hibiya Y, 1998, BIOCHEM BIOPH RES CO, V245, P412, DOI 10.1006/bbrc.1998.8447; Ramezani A, 2000, MOL THER, V2, P458, DOI 10.1006/mthe.2000.0190; Richards DF, 2000, EUR J IMMUNOL, V30, P2344, DOI 10.1002/1521-4141(2000)30:8<2344::AID-IMMU2344>3.0.CO;2-7; Sevinsky JR, 2004, MOL CELL BIOL, V24, P4534, DOI 10.1128/MCB.24.10.4534-4545.2004; STAYNOV DZ, 1995, P NATL ACAD SCI USA, V92, P3606, DOI 10.1073/pnas.92.8.3606; Szabo SJ, 2002, SCIENCE, V295, P338, DOI 10.1126/science.1065543; TAKAMOTO M, 1995, IMMUNOL LETT, V45, P43, DOI 10.1016/0165-2478(94)00223-E; Takemoto N, 2000, J IMMUNOL, V165, P6687, DOI 10.4049/jimmunol.165.12.6687; Weigmann B, 2004, J IMMUNOL, V173, P3446, DOI 10.4049/jimmunol.173.5.3446	27	12	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					56	63		10.1016/j.jaci.2007.03.033	http://dx.doi.org/10.1016/j.jaci.2007.03.033			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	190NS	17507085				2022-12-18	WOS:000248066400008
J	Gordon, SB; Kayhty, H; Molyneux, ME; Haikala, R; Nurkka, A; Musaya, J; Zijlstra, EE; Lindell, D; French, N				Gordon, Stephen B.; Kayhty, Helena; Molyneux, Malcohn E.; Haikala, Raili; Nurkka, Anu; Musaya, Janelisa; Zijlstra, Eduard E.; Lindell, Dennis; French, Neil			Pneumococcal conjugate vaccine is immunogenic in lung fluid of HIV-infected and immunocompetent adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							STREPTOCOCCUS-PNEUMONIAE		Univ Liverpool Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; Queen Elizabeth Cent Hosp, Malawi Liverpool Wellcome Programme Res Trop Med, Blantyre, Malawi; Natl Publ Hlth Inst, Vaccine Immunol Lab, Helsinki, Finland; Univ Malawi, Coll Med, Dept Med, Blantyre, Malawi; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA	Liverpool School of Tropical Medicine; University of Malawi; Finland National Institute for Health & Welfare; University of Malawi; University of Michigan System; University of Michigan	Gordon, SB (corresponding author), Univ Liverpool Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.	sbgordon@liverpool.ac.uk	French, Neil/A-2994-2012	Musaya, Janelisa/0000-0003-2928-0133; Gordon, Stephen/0000-0001-6576-1116; French, Neil/0000-0003-4814-8293	Wellcome Trust [061230, 058390, 061231] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Fisman DN, 2006, CLIN INFECT DIS, V42, P1093, DOI 10.1086/501354; Gordon SB, 2003, J INFECT DIS, V188, P666, DOI 10.1086/377480; Gordon SB, 2000, INFECT IMMUN, V68, P2286, DOI 10.1128/IAI.68.4.2286-2293.2000; Herting E, 1999, AM J RESP CRIT CARE, V159, P1862, DOI 10.1164/ajrccm.159.6.9810047; Huang YCT, 2006, CHEST, V129, P1565, DOI 10.1378/chest.129.6.1565; Lee CJ, 2005, CRIT REV MICROBIOL, V31, P137, DOI 10.1080/10408410591005093; Miiro G, 2005, J INFECT DIS, V192, P1801, DOI 10.1086/497144; Musher DM, 1997, CLIN INFECT DIS, V24, P441, DOI 10.1093/clinids/24.3.441; Obaro SK, 2006, LANCET INFECT DIS, V6, P150, DOI 10.1016/S1473-3099(06)70411-X; Whitney CG, 2005, PEDIATR INFECT DIS J, V24, P729, DOI 10.1097/01.inf.0000174138.25465.ec	10	12	13	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					208	210		10.1016/j.jaci.2007.03.050	http://dx.doi.org/10.1016/j.jaci.2007.03.050			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	190NS	17544493	Green Accepted			2022-12-18	WOS:000248066400031
J	Cardinale, F; Tesse, R; Fucilli, C; Loffredo, MS; Iacoviello, G; Chinellato, I; Armenio, L				Cardinale, Fabio; Tesse, Riccardina; Fucilli, Chiara; Loffredo, Maria Sterpeta; Iacoviello, Gaia; Chinellato, Iolanda; Armenio, Lucio			Correlation between exhaled nitric oxide and dietary consumption of fats and antioxidants in children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							OXIDATIVE STRESS; ADULTS		Univ Bari, Dept Pediat S Maggiore, Bari, Italy; INOC, Milan, Italy	Universita degli Studi di Bari Aldo Moro	Cardinale, F (corresponding author), Univ Bari, Dept Pediat S Maggiore, Bari, Italy.	fabiocardinale@tibero.it	CARDINALE, FABIO/AAL-4357-2020	CARDINALE, FABIO/0000-0002-6774-6152				Baraldi E, 2002, EUR RESPIR J, V20, P223, DOI 10.1183/09031936.02.00293102; Chambers DC, 2001, THORAX, V56, P774, DOI 10.1136/thorax.56.10.774; Chang J, 1996, AM J PHYSIOL-LUNG C, V270, pL931, DOI 10.1152/ajplung.1996.270.6.L931; Dunstan JA, 2006, CLIN EXP ALLERGY, V36, P993, DOI 10.1111/j.1365-2222.2006.02539.x; Farchi S, 2003, EUR RESPIR J, V22, P772, DOI 10.1183/09031936.03.00006703; *GLOB STRAT ASTHM, 2005, PUBL NIH; Nadeem A, 2003, J ALLERGY CLIN IMMUN, V111, P72, DOI 10.1067/mai.2003.17; Ronchetti R, 1997, EUR RESPIR J, V10, P1248, DOI 10.1183/09031936.97.10061248; Schafer T, 2003, CLIN EXP ALLERGY, V33, P1360, DOI 10.1046/j.1365-2222.2003.01780.x	9	12	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1268	1270		10.1016/j.jaci.2007.01.028	http://dx.doi.org/10.1016/j.jaci.2007.01.028			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167CB	17321576				2022-12-18	WOS:000246427200032
J	Kwatia, MA; Doyle, CB; Cho, WW; Enhorning, G; Ackerman, SJ				Kwatia, Mark A.; Doyle, Christine B.; Cho, Wonwha; Enhorning, Goran; Ackerman, Steven J.			Combined activities of secretory phospholipases and eosinophil lysophospholipases induce pulmonary surfactant dysfunction by phospholipid hydrolysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil; phospholipases; lysophospholipases; phosphatidylcholine; pulmonary surfactant; capillary surfactometer; asthma	BRONCHOALVEOLAR LAVAGE FLUID; ACUTE LUNG INJURY; LYSO-PHOSPHOLIPIDS; ALLERGEN CHALLENGE; ASTHMATIC-PATIENTS; ANTIGEN CHALLENGE; CATIONIC PROTEIN; A(2); PHOSPHATIDYLGLYCEROL; PHOSPHATIDYLCHOLINE	Background: Surfactant dysfunction is implicated in small airway closure in asthma. Increased activity of secretory phospholipase A(2) (sPLA(2)) in the airways is associated with asthma exacerbations. Phosphatidylcholine, the principal component of pulmonary surfactant that maintains small airway patency, is hydrolyzed by sPLA(2). The lysophosphatidylcholine product is the substrate for eosinophil lysophospholipases. Objective: To determine whether surfactant phospholipid hydrolysis by the combined activities of sPLA(2)s and eosinophil lysophospholipases induces surfactant dysfunction. Methods: The effect of these enzymes on surfactant function was determined by capillary surfactometry. Thin layer chromatography was used to correlate enzyme-induced changes in surfactant phospholipid composition and function. Phosphatidylcholine and its hydrolytic products were measured by using mass spectrometry. Results: Eosinophils express a 25-kd lysophospholipase and group IIA sPLA(2). Phospholipase A(2) alone induced only a small decrease in surfactant function, and 25-kd lysophospholipase alone degraded lysophosphatidylcholine but had no effect on surfactant function. The combined actions of sPLA(2) and lysophospholipase produced dose-dependent and time-dependent losses of surfactant function, concomitant with hydrolysis of phosphatidylcholine and lysophosphatidylcholine. Lysates of AML14.3D10 eosinophils induced surfactant dysfunction, indicating these cells express all the necessary lipolytic activities. In contrast, lysates of blood eosinophils required exogenous phospholipase A(2) to induce maximal surfactant dysfunction. Conclusion: The combined activities of sPLA(2)s and eosinophil lysophospholipases are necessary to degrade surfactant phospholipids sufficiently to induce functional losses in surfactant activity as reported in asthma. Clinical implications: The phospholipases and lysophospholipases expressed by eosinophils or other airway cells may represent novel therapeutic targets for blocking surfactant degradation, dysfunction, and peripheral airway closure in asthma.	Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Dept Chem, Chicago, IL 60680 USA; SUNY Buffalo, Dept Gynecol & Obstet, Sch Med & Biomed Sci, Buffalo, NY 14260 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Ackerman, SJ (corresponding author), Univ Illinois, Dept Biochem & Mol Genet, MC669,900 S Ashland Ave, Chicago, IL 60607 USA.	sackerma@uic.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR013987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025230] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052598] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR13987] Funding Source: Medline; NIAID NIH HHS [AI25230] Funding Source: Medline; NIDDK NIH HHS [T32 DK07739] Funding Source: Medline; NIGMS NIH HHS [GM52598] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackerman SJ, 2003, CHEST, V123, p355S, DOI 10.1378/chest.123.3_suppl.355S; Ackerman SJ, 2002, J BIOL CHEM, V277, P14859, DOI 10.1074/jbc.M200221200; Ackerman SJ, 1994, EOSINOPHILS ALLERGY, P21; Arbibe L, 1998, J CLIN INVEST, V102, P1152, DOI 10.1172/JCI3236; Babu KS, 2003, EUR RESPIR J, V21, P1046, DOI 10.1183/09031936.03.00069202; Baritussio A, 2004, AM J RESP CRIT CARE, V169, P550, DOI 10.1164/rccm.2312019; Baumann MA, 1998, STEM CELLS, V16, P16, DOI 10.1002/stem.160016; Blom M, 1998, BLOOD, V91, P3037; Borchers MT, 2002, J LEUKOCYTE BIOL, V71, P1033; Bowton DL, 1997, AM J RESP CRIT CARE, V155, P421, DOI 10.1164/ajrccm.155.2.9032172; Chilton FH, 1996, J EXP MED, V183, P2235, DOI 10.1084/jem.183.5.2235; Du J, 2000, J BIOL CHEM, V275, P33167, DOI 10.1074/jbc.M003655200; Dunnill M S, 1971, Ciba Found Study Group, V38, P35; Enhorning G, 2001, COMP BIOCHEM PHYS A, V129, P221, DOI 10.1016/S1095-6433(01)00318-X; Erjefalt JS, 1998, J ALLERGY CLIN IMMUN, V102, P286, DOI 10.1016/S0091-6749(98)70098-3; Erjefalt JS, 1999, AM J RESP CRIT CARE, V160, P304, DOI 10.1164/ajrccm.160.1.9809048; Furue S, 1999, AM J RESP CRIT CARE, V160, P1292, DOI 10.1164/ajrccm.160.4.9812042; Gomes I, 2005, J ALLERGY CLIN IMMUN, V116, P796, DOI 10.1016/j.jaci.2005.06.031; HALLMAN M, 1985, PEDIATR RES, V19, P286, DOI 10.1203/00006450-198503000-00006; Heeley EL, 2000, AM J PHYSIOL-LUNG C, V278, pL305, DOI 10.1152/ajplung.2000.278.2.L305; Hite RD, 1998, AM J PHYSIOL-LUNG C, V275, pL740, DOI 10.1152/ajplung.1998.275.4.L740; Hite RD, 2005, AM J PHYSIOL-LUNG C, V288, pL618, DOI 10.1152/ajplung.00274.2004; Hite RD, 2005, AM J PHYSIOL-LUNG C, V288, pL610, DOI 10.1152/ajplung.00273.2004; Hohlfeld JM, 2004, J ALLERGY CLIN IMMUN, V113, P496, DOI 10.1016/j.jaci.2003.12.008; Hohlfeld JM, 2001, RESPIR RES, V3, DOI 10.1186/rr176; Hohlfeld JM, 1999, AM J RESP CRIT CARE, V159, P1803, DOI 10.1164/ajrccm.159.6.9806145; Holm BA, 1996, PEDIATR RES, V39, P805, DOI 10.1203/00006450-199605000-00010; HOLTSBERG FW, 1995, BIOCHEM J, V309, P141, DOI 10.1042/bj3090141; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Jarjour NN, 1999, AM J RESP CRIT CARE, V160, P336, DOI 10.1164/ajrccm.160.1.9806155; KAHN MC, 1995, AM J PHYSIOL-LUNG C, V269, pL567, DOI 10.1152/ajplung.1995.269.5.L567; Kay AB, 2005, TRENDS MOL MED, V11, P148, DOI 10.1016/j.molmed.2005.02.002; Kim CK, 2005, CLIN EXP ALLERGY, V35, P591, DOI 10.1111/j.1365-2222.2005.02224.x; Kurashima K, 1997, AM J RESP CRIT CARE, V155, P1254, DOI 10.1164/ajrccm.155.4.9105063; KURASHIMA K, 1991, Japanese Journal of Allergology, V40, P160; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Lema G, 1997, BBA-LIPID LIPID MET, V1345, P86, DOI 10.1016/S0005-2760(96)00180-4; MACKLEM PT, 1971, PHYSIOL REV, V51, P368, DOI 10.1152/physrev.1971.51.2.368; Masuda S, 2005, BIOCHEM J, V387, P27, DOI 10.1042/BJ20041307; Samee S, 2003, J ALLERGY CLIN IMMUN, V111, P1205, DOI 10.1067/mai.2003.1544; Snitko Y, 1997, BIOCHEM J, V321, P737, DOI 10.1042/bj3210737; TOUCHSTONE J, 1982, ADV THIN LAYER CHROM; Touqui L, 2003, ACTA PHARMACOL SIN, V24, P1292; VANGOLDE LMG, 1988, PHYSIOL REV, V68, P374, DOI 10.1152/physrev.1988.68.2.374; VanSchaik SM, 1997, PEDIATR RES, V42, P169, DOI 10.1203/00006450-199708000-00007; Wagers SS, 2004, J CLIN INVEST, V114, P104, DOI 10.1172/JCI200419569; Wang AJ, 1999, BBA-MOL CELL BIOL L, V1437, P157, DOI 10.1016/S1388-1981(99)00012-8; Wang AJ, 1997, J BIOL CHEM, V272, P22030, DOI 10.1074/jbc.272.35.22030; WELLER PF, 1980, P NATL ACAD SCI-BIOL, V77, P7440, DOI 10.1073/pnas.77.12.7440; WELLER PF, 1980, EOSINOPHIL HLTH DISE, P115; Wright SM, 2000, J APPL PHYSIOL, V89, P1283, DOI 10.1152/jappl.2000.89.4.1283	52	12	12	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					838	847		10.1016/j.jaci.2006.12.614	http://dx.doi.org/10.1016/j.jaci.2006.12.614			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17321580	Bronze			2022-12-18	WOS:000245729500011
J	Buchanan, BB; Frick, OL				Buchanan, Bob B.; Frick, Oscar L.			Thioredoxin and food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							WHEAT; MAIZE		Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; Univ Calif San Francisco, Sch Med, Dept Pediat, San Francisco, CA 94143 USA	University of California System; University of California Berkeley; University of California System; University of California San Francisco	Buchanan, BB (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA.	view@nature.berkeley.edu						Buchanan BB, 1997, P NATL ACAD SCI USA, V94, P5372, DOI 10.1073/pnas.94.10.5372; del Val G, 1999, J ALLERGY CLIN IMMUN, V103, P690, DOI 10.1016/S0091-6749(99)70244-7; Weichel M, 2006, J ALLERGY CLIN IMMUN, V117, P676, DOI 10.1016/j.jaci.2005.11.040; Weichel M, 2006, ALLERGY, V61, P128, DOI 10.1111/j.1398-9995.2006.00999.x	4	12	12	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					513	514		10.1016/j.jaci.2006.08.039	http://dx.doi.org/10.1016/j.jaci.2006.08.039			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17141854				2022-12-18	WOS:000244327900042
J	Ayuso, R; Grishina, G; Ahn, K; Bardina, L; Beyer, K; Sampson, H				Ayuso, R.; Grishina, G.; Ahn, K.; Bardina, L.; Beyer, K.; Sampson, H.			Identification of a MnSOD-like protein as a new major pistachio allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	63rd Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	FEB 23-27, 2007	San Diego, CA	Amer Acad Allergy, Asthma & Immunol					[Ayuso, R.; Grishina, G.; Ahn, K.; Bardina, L.; Beyer, K.; Sampson, H.] Mt Sinai Med Ctr, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai									0	12	13	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1		1		454	S115	S115		10.1016/j.jaci.2006.11.433	http://dx.doi.org/10.1016/j.jaci.2006.11.433			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	238PT					2022-12-18	WOS:000251460400454
J	Ballow, M				Ballow, Mark			Biologic immune modifiers: Trials and tribulations - are we there yet?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						biologic agents; immune response modifiers; mAbs; recombinant proteins; fission proteins; asthma; allergic diseases	NECROSIS-FACTOR-ALPHA; MONOCLONAL-ANTIBODY; RHEUMATOID-ARTHRITIS; ASTHMA; THERAPY; INFLAMMATION; EOSINOPHILS; INHIBITION; EFALIZUMAB; MOLECULES	Biologic agents as therapeutic modalities have emerged as an important new drug treatment. This article focuses on specific groups of immune response modulators of mAbs and recombinant proteins, and their use or their potential use in asthma as an example of an inflammatory allergic process. Although some of these new biologic agents are currently used only in animal models of allergic disease or in other inflammatory or autoimmune diseases, this field is advancing so rapidly that in a few years, these new treatment modalities could be applied to allergic diseases. This article provides a brief rationale for the use of these new biologic agents in asthma. Although optimism is very high for this new class of drugs, caution is needed in extrapolating in vitro data or studies from animal models; adverse events will happen. Nevertheless, as we learn how to modify and alter the inflammatory and immune processes with these new biologic agents, clinicians will enter a new era of treatment options available for their patients with allergic disorders.	SUNY Buffalo, Womens & Childrens Hosp, Sch Med & Biomed Sci, Dept Pediat,Div Allergy & Clin Immunol, Buffalo, NY 14222 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Women & Children's Hospital of Buffalo	Ballow, M (corresponding author), SUNY Buffalo, Womens & Childrens Hosp, Sch Med & Biomed Sci, Dept Pediat,Div Allergy & Clin Immunol, Buffalo, NY 14222 USA.	ballow@buffalo.edu						Ballow M, 2005, J ALLERGY CLIN IMMUN, V116, P738, DOI 10.1016/j.jaci.2005.07.020; Bennett JS, 2001, ANNU REV MED, V52, P161, DOI 10.1146/annurev.med.52.1.161; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Blanchard C, 2005, CLIN EXP ALLERGY, V35, P1096, DOI 10.1111/j.1365-2222.2005.02299.x; Bochner BS, 2004, IMMUNOL ALLERGY CLIN, V24, P615, DOI 10.1016/j.iac.2004.06.003; Bochner BS, 2004, J ALLERGY CLIN IMMUN, V113, P868, DOI 10.1016/j.jaci.2004.02.016; Bongartz T, 2006, JAMA-J AM MED ASSOC, V295, P2275, DOI 10.1001/jama.295.19.2275; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816, DOI 10.1164/ajrccm.160.6.9808146; Boushey HA, 2001, J ALLERGY CLIN IMMUN, V108, pS77, DOI 10.1067/mai.2001.116434; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Corren J, 2005, J ALLERGY CLIN IMMUN, V115, P202, DOI 10.1016/j.jaci.2004.09.035; Erin EM, 2006, AM J RESP CRIT CARE, V174, P753, DOI 10.1164/rccm.200601-072OC; Feldmann M, 2002, NAT REV IMMUNOL, V2, P364, DOI 10.1038/nri802; Fernandez C, 2005, P AM THORAC SOC, V2, pA359; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Garrett JK, 2004, J ALLERGY CLIN IMMUN, V113, P115, DOI 10.1016/j.jaci.2003.10.049; Gauvreau GM, 2003, J ALLERGY CLIN IMMUN, V112, P331, DOI 10.1067/mai.2003.1689; Genovese MC, 2005, NEW ENGL J MED, V353, P1114, DOI 10.1056/NEJMoa050524; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Kon OM, 1998, LANCET, V352, P1109, DOI 10.1016/S0140-6736(97)12261-9; Kong JSW, 2006, AUTOIMMUN REV, V5, P471, DOI 10.1016/j.autrev.2006.02.014; Kremer JM, 2003, NEW ENGL J MED, V349, P1907, DOI 10.1056/NEJMoa035075; Lebwohl M, 2003, NEW ENGL J MED, V349, P2004, DOI 10.1056/NEJMoa030002; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee SJ, 2005, J ALLERGY CLIN IMMUN, V116, P900, DOI 10.1016/j.jaci.2005.03.028; Liossis SNC, 2005, J ALLERGY CLIN IMMUN, V116, P721, DOI 10.1016/j.jaci.2005.06.035; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696; Moreland L, 2006, NAT REV DRUG DISCOV, V5, P185, DOI 10.1038/nrd1989; Nelson HS, 2005, J ALLERGY CLIN IMMUN, V115, P676, DOI 10.1016/j.jaci.2005.01.037; Nowak D, 2006, RESP MED, V100, P1907, DOI 10.1016/j.rmed.2005.10.004; O'Byrne PM, 2006, CHEST, V130, P244, DOI 10.1378/chest.130.1.244; Polte T, 2006, J CLIN INVEST, V116, P1025, DOI 10.1172/JCI23792; Poole JA, 2005, J ALLERGY CLIN IMMUN, V116, P780, DOI 10.1016/j.jaci.2005.07.007; Prete M, 2005, CLIN EXP MED, V5, P141, DOI 10.1007/s10238-005-0080-5; Reiser H, 1996, NEW ENGL J MED, V335, P1369, DOI 10.1056/NEJM199610313351807; Schulman ES, 2001, AM J RESP CRIT CARE, V164, pS6, DOI 10.1164/ajrccm.164.supplement_1.2103025; SORNASSE TR, 2005, J ALLERGY CLIN IMMUN, V115, P73; Suntharalingam G, 2006, NEW ENGL J MED, V355, P1018, DOI 10.1056/NEJMoa063842; Thomas PS, 2001, IMMUNOL CELL BIOL, V79, P132, DOI 10.1046/j.1440-1711.2001.00980.x; Thomas PS, 2002, THORAX, V57, P774, DOI 10.1136/thorax.57.9.774; von Andrian UH, 2003, NEW ENGL J MED, V348, P68, DOI 10.1056/NEJMe020157; Wallis RS, 2005, CLIN INFECT DIS, V41, pS194, DOI 10.1086/429996; Weaver AL, 2004, RHEUMATOLOGY, V43, P17, DOI 10.1093/rheumatology/keh203; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yang GY, 2005, J PHARMACOL EXP THER, V313, P8, DOI 10.1124/jpet.104.076133	50	12	14	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2006	118	6					1209	1215		10.1016/j.jaci.2006.09.024	http://dx.doi.org/10.1016/j.jaci.2006.09.024			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	117NP	17157649	Bronze			2022-12-18	WOS:000242880300002
J	Mahakittikun, V; Boitano, JJ; Tovey, E; Bunnag, C; Ninsanit, P; Matsumoto, T; Andre, C				Mahakittikun, Vanna; Boitano, John Joseph; Tovey, Euan; Bunnag, Chaweewan; Ninsanit, Prapakorn; Matsumoto, Tomoaki; Andre, Claude			Mite penetration of different types of material claimed as mite proof by the Siriraj chamber method	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mite-proof covers; antimite covers; encasement of beddings	HOUSE-DUST MITES; ALLERGIC RHINITIS; ASTHMA; ENCASEMENT; COVERS; ENCASINGS; CHILDREN; CAT	Background: There are different materials and principles used in the construction of bed encasings. Although these covers claim to have antimite properties, they might not be mite proof. Objective: This study evaluated the effectiveness of mite penetration of these covers by using the Siriraj chamber method. Methods: Thirty-two covers collected from 9 different countries were categorized according to the materials used to manufacture them. They were (1) tightly woven, (2) film or membrane coated and loosely woven, (3) acaricidal coated and loosely woven, (4) nonwoven, (5) film coated and nonwoven, (6) acaricidal coated and nonwoven, and (7) plastic. Adult mites, Dermatophagoides pteronyssinus, were placed on either the outer or inner surfaces of each of the test fabrics for 3 replications, resulting in a total of 6 samples per fabric. All samples were observed for penetration every day for 1 week under a stereomicroscope. If a single mite penetrated any fabric, it was scored as a penetration. Results: Mites penetrated (1) into all samples of film-coated woven and nonwoven covers, an acaricide-coated nonwoven cover, and nonwoven types; (2) from both sides and colonized within the matrix of some samples; and (3) completely in other cases. All of the woven covers and the plastic cover prevented mite penetration. Photomicrographs documented all penetrations. Conclusions: Tightly woven covers and plastic prevent mite penetration, whereas nonwoven, loosely woven, acaricide-coated, and laminated materials do not. The Siriraj chamber method adequately evaluates the effectiveness of antimite barriers.	Mahidol Univ, Siriraj Hosp, Dept Parasitol, Fac Med, Bangkok 10700, Thailand; Mahidol Univ, Siriraj Hosp, Dept OtoLaryngol, Fac Med, Bangkok 10700, Thailand; Univ Sydney, Woolcock Inst Med Res, Sydney, NSW 2006, Australia; Kumamoto Univ, Dept Child Dev, Grad Sch Med Sci, Sch Med, Kumamoto, Japan; Stallergenes, Sci & Med Dept, Antony, France	Mahidol University; Mahidol University; University of Sydney; Woolcock Institute of Medical Research; Kumamoto University; Stallergenes Greer	Mahakittikun, V (corresponding author), Mahidol Univ, Siriraj Hosp, Dept Parasitol, Fac Med, Bangkok 10700, Thailand.	sivmh@mahidol.ac.th	Tovey, Euan R/G-8604-2017	Tovey, Euan R/0000-0002-1802-7266				Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; Dharmage S, 2006, INT ARCH ALLERGY IMM, V139, P132, DOI 10.1159/000090388; Halken S, 2003, J ALLERGY CLIN IMMUN, V111, P169, DOI 10.1067/mai.2003.5; Joseph KE, 2003, ANN ALLERG ASTHMA IM, V90, P550, DOI 10.1016/S1081-1206(10)61849-2; Kniest F. M., 1997, Journal of Allergy and Clinical Immunology, V99, pS162; Kniest FM, 1998, J ALLERGY CLIN IMMUN, V101, pS80; Mahakittikun V, 2003, J ALLERGY CLIN IMMUN, V112, P1239, DOI 10.1016/j.jaci.2003.08.045; Mahakittikun V, 2003, ALLERGY, V58, P981, DOI 10.1034/j.1398-9995.2003.00095.x; MAHAKITTIKUN V, 2003, J TROP MED PARASITOL, V26, P93; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V106, P787, DOI 10.1067/mai.2000.110548; Terreehorst I, 2003, NEW ENGL J MED, V349, P237, DOI 10.1056/NEJMoa023171; Tonnel AB, 2004, ALLERGY, V59, P491, DOI 10.1111/j.1398-9995.2004.00456.x; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; Tovey ER, 2001, J ALLERGY CLIN IMMUN, V108, P369, DOI 10.1067/mai.2001.117799; Vaughan JW, 1999, J ALLERGY CLIN IMMUN, V103, P227, DOI 10.1016/S0091-6749(99)70495-1; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175	16	12	13	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2006	118	5					1164	1168		10.1016/j.jaci.2006.07.025	http://dx.doi.org/10.1016/j.jaci.2006.07.025			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137GY	17088144				2022-12-18	WOS:000244282300024
J	Treudler, R; Simon, JC				Treudler, Regina; Simon, Jan Christoph			Symmetric, drug-related, intertriginous, and flexural exanthema in a patient with polyvalent intolerance to corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALLERGIC CONTACT-DERMATITIS; BABOON-SYNDROME		Univ Klinikum Leipzig AOR, Klin Dermatol Venerol & Allergol, Leipzig, Germany; Global Allergy & Asthma European Network, GA2 LEN, Brussels, Belgium	Leipzig University	Treudler, R (corresponding author), Univ Klinikum Leipzig AOR, Klin Dermatol Venerol & Allergol, Leipzig, Germany.	treudler@medizin.unieipzig.de						ANDERSEN KE, 1984, CONTACT DERMATITIS, V10, P97, DOI 10.1111/j.1600-0536.1984.tb00343.x; Armingaud P, 2005, ANN DERMATOL VENER, V132, P675, DOI 10.1016/S0151-9638(05)79415-1; Garcia-Bravo B, 2000, CONTACT DERMATITIS, V43, P359; Hausermann P, 2004, CONTACT DERMATITIS, V51, P297, DOI 10.1111/j.0105-1873.2004.00445.x; Jacob SE, 2006, J AM ACAD DERMATOL, V54, P723, DOI 10.1016/j.jaad.2005.12.028; Just N, 2005, REV MED INTERNE, V26, P331, DOI 10.1016/j.revmed.2004.12.003; Padial A, 2005, ALLERGY, V60, P665, DOI 10.1111/j.1398-9995.2005.00749.x; Weiss JM, 2001, HAUTARZT, V52, P1104, DOI 10.1007/s001050170022; Wolf Ronni, 2003, Dermatol Online J, V9, P2	9	12	12	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2006	118	4					965	967		10.1016/j.jaci.2006.07.023	http://dx.doi.org/10.1016/j.jaci.2006.07.023			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	097GD	17030256	Bronze			2022-12-18	WOS:000241434200032
J	Vu, AT; Lockey, RF				Vu, Alexander Trien; Lockey, Richard Funk			Benzocaine anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							LOCAL-ANESTHETIC AGENTS; ALLERGIC REACTION; AMIDE GROUP		Univ S Florida, Coll Med, Div Clin Immunol & Allergy, Tampa, FL 33620 USA; James A Haley Vet Hosp, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital	Vu, AT (corresponding author), Univ S Florida, Coll Med, Div Clin Immunol & Allergy, 4202 E Fowler Ave, Tampa, FL 33620 USA.							AUTERHOFF H, 1980, LEHRBUCH PHARM CHEM; BLACK RJ, 1990, CONTACT DERMATITIS, V23, P117, DOI 10.1111/j.1600-0536.1990.tb03237.x; CuestaHerranz J, 1997, J ALLERGY CLIN IMMUN, V99, P427, DOI 10.1016/S0091-6749(97)70064-2; Fisher A A, 1977, Contact Dermatitis, V3, P170, DOI 10.1111/j.1600-0536.1977.tb03637.x; Gall H, 1996, J ALLERGY CLIN IMMUN, V97, P933, DOI 10.1016/S0091-6749(96)80067-4; HOLTI G, 1965, Dent Pract Dent Rec, V15, P294; KENNEDY KS, 1986, ARCH OTOLARYNGOL, V112, P671; Sidhu S K, 1999, Am J Contact Dermat, V10, P57, DOI 10.1016/S1046-199X(99)90000-3; *THOMS HEALTHC, 2005, BENZ PGHYS DES REF; Warrington RJ, 1997, J ALLERGY CLIN IMMUN, V100, P855	10	12	12	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					534	535		10.1016/j.jaci.2006.04.035	http://dx.doi.org/10.1016/j.jaci.2006.04.035			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	075IH	16890789				2022-12-18	WOS:000239877700040
J	Lee, JY; Lee, SH; Lee, HM; Lee, SH; Jung, HH; Lee, SW; Kang, SM				Lee, Jae Yong; Lee, Sang Hag; Lee, Heung Man; Lee, Seung Hoon; Jung, Hak Hyun; Lee, Se Woo; Kang, Sun Mook			Analysis of gene expression profiles of normal human nasal mucosa and nasal polyp tissues by SAGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nasal mucosa; nasal polyp; SAGE	SERIAL ANALYSIS; BETA-MICROSEMINOPROTEIN; MESSENGER-RNA; SECRETION; RHINITIS; MOUSE; RAT	Background: A systemic determination of gene expression profiles in nasal polyp compared with normal nasal mucosa would contribute considerably to the investigation of the disease marker in various rhinopathy and general knowledge on the formation of human nasal polyp. Objective: The aim of this study was to identify the transcriptome of the normal human nasal mucosa and nasal polyp by the serial analysis of gene expression. Methods: mRNA was extracted from normal inferior turbinate mucosa and nasal polyp. Short sequences (tags), each one usually corresponding to a distinct transcript, was isolated and concatemerized into long DNA molecules, which were cloned and sequenced. Results: We detected 65,305 tags for normal nasal mucosa and 55,829 tags for nasal polyp, representing 20,629 and 17,636 potential transcripts species, respectively. Of the unique tags encountered more than once, 92% (normal nasal mucosa) and 90% (nasal polyp) matched known genes or expressed sequence tags, whereas the remainder did not match any GenBank sequences. Therefore, 504 and 539 novel transcripts were identified in normal nasal mucosa and nasal polyp, respectively. Although the expression levels of most transcripts in both libraries were similar, 114 transcripts were differentially expressed at a statistically significant level (P < .05)-that is, 65 and 49 transcripts among them were expressed at a higher level in normal nasal mucosa and nasal polyp, respectively. Conclusion: This information should be very useful for basic knowledge as well as for future studies on pathophysiological conditions of human nasal mucosa, providing some clues to evaluate the altered factors in a variety of rhinopathies. Clinical implications: The results of this study might contribute to general knowledge on the formation of human nasal polyp.	Korea Univ, Coll Med, Dept Otorhinolaryngol Head & Neck Surg, Seoul 136705, South Korea; Soonchunhyang Univ, Bucheon Hosp, Geonggyi Do, South Korea	Korea University; Korea University Medicine (KU Medicine); Soonchunhyang University	Lee, SH (corresponding author), Korea Univ, Coll Med, Dept Otorhinolaryngol Head & Neck Surg, 126-1,5 Ka,Anam Dong, Seoul 136705, South Korea.	sanghag@kumc.or.kr						Augusto A G, 2001, Ear Nose Throat J, V80, P325; Benson M, 2004, J ALLERGY CLIN IMMUN, V113, P1137, DOI 10.1016/j.jaci.2004.02.028; Bernstein JM, 1997, J ALLERGY CLIN IMMUN, V99, P165, DOI 10.1016/S0091-6749(97)70091-5; Bingle CD, 2002, HUM MOL GENET, V11, P937, DOI 10.1093/hmg/11.8.937; CALHOVEN F, 2002, TRENDS MOL MED, V8, P577; Cheng G, 2002, INVEST OPHTH VIS SCI, V43, P1048; Cole AM, 1999, INFECT IMMUN, V67, P3267, DOI 10.1128/IAI.67.7.3267-3275.1999; Delbrouck C, 2003, ARCH OTOLARYNGOL, V129, P665, DOI 10.1001/archotol.129.6.665; Fattori B., 1998, Rhinology (Utrecht), V36, P101; Fernlund P, 1996, ARCH BIOCHEM BIOPHYS, V334, P73, DOI 10.1006/abbi.1996.0431; Goldstein AL, 2004, EXPERT OPIN BIOL TH, V4, P559, DOI 10.1517/eobt.4.4.559.29474; JENEY EVM, 1990, J ALLERGY CLIN IMMUN, V86, P10, DOI 10.1016/S0091-6749(05)80117-4; JENSEN JL, 1994, J DENT RES, V73, P1811, DOI 10.1177/00220345940730120401; Kalfa VC, 2004, ANN ALLERG ASTHMA IM, V93, P288, DOI 10.1016/S1081-1206(10)61503-7; Kennedy DW, 2001, DIS SINUSES DIAGNOSI; Lee SH, 2004, ACTA OTO-LARYNGOL, V124, P179, DOI 10.1080/00016480310016073; Lee SH, 2002, ACTA OTO-LARYNGOL, V122, P866, DOI 10.1080/003655402/000028045; Liu Z, 2004, J ALLERGY CLIN IMMUN, V114, P783, DOI 10.1016/j.jaci.2004.04.052; Marenholz I, 2004, BIOCHEM BIOPH RES CO, V322, P1111, DOI 10.1016/j.bbrc.2004.07.096; Molet SM, 2003, LARYNGOSCOPE, V113, P1803, DOI 10.1097/00005537-200310000-00027; Moore EJ, 2001, AM J RHINOL, V15, P355, DOI 10.1177/194589240101500601; RITTER FN, 1992, ATLAS PARANASAL SINU; RUISSEN FV, 2005, BMC GENOMICS, V6, P91; Settipane GA, 1991, RHINITIS; SETTIPANE GA, 1997, NASAL POLYPS EPIEMIO; Szefler SJ, 2005, AM J RESP CRIT CARE, V171, P672, DOI 10.1164/rccm.2501001; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Weiber H, 1997, HISTOCHEM J, V29, P839, DOI 10.1023/A:1026437706895; Yao JJ, 2004, MAMM GENOME, V15, P433, DOI 10.1007/s00335-004-2347-7	29	12	14	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					134	142		10.1016/j.jaci.2006.02.048	http://dx.doi.org/10.1016/j.jaci.2006.02.048			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	065UH	16815149				2022-12-18	WOS:000239184800017
J	Kumar, R; Wang, BY; Wang, XB; Chen, CZ; Yang, JH; Fu, LL; Xu, XP				Kumar, Rajesh; Wang, Binyan; Wang, Xiaobin; Chen, Changzhong; Yang, Jianhua; Fu, Lingling; Xu, Xiping			Bronchodilator responses in Chinese children from asthma index families and the general population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bronchodilator response; airway responsiveness; epidemiologic study; risk factors; Chinese	BRONCHIAL HYPERRESPONSIVENESS; PULMONARY-FUNCTION; AIRWAY HYPERRESPONSIVENESS; CHILDHOOD ASTHMA; LUNG-FUNCTION; AGE; RESPONSIVENESS; ALBUTEROL; POLYMORPHISMS; ASSOCIATION	Background: Although airway hyperresponsiveness to bronchoconstrictors has been extensively investigated, epidemiologic studies on airway hyperresponsiveness to bronchodilators are limited. Objective: Our goal was to characterize the distribution and determinants of bronchodilator response (BDR) and bronchodilator hyperresponsiveness (BDHR) in rural Chinese children age 8 to 15 years. Methods: Our study included children with and without asthma from asthma index families (1131 boys, 1143 girls) and subjects without asthma from general population controls (457 boys, 377 girls). BDR was calculated as [(post bronchodilator FEV1 - baseline FEV1)/baseline FEV1] X 100. BDHR was defined as BDR greater than 12%. We investigated the distributions and major determinants of BDR and BDHR using scatterplots and multiple linear and logistic regression models. Results: There was a gradient in BDR by asthma status and family history. The mean (+/- SD) BDR was 7%+/- 9% in subjects with asthma, 4%+/- 5% in subjects without asthma from index families, and 3%+/- 5% in controls. This trend was also seen for BHDR. BDR generally decreased with age. There was a notable sex difference in BDR around puberty in subjects with asthma. Sex difference was also seen in the relationship of BDR with body mass index. Additional variables correlated with BDR included height and prebronchodilator FEV1. Atopy was not correlated with BDR. In models accounting, for these variables, chronic respiratory symptoms were associated with BDR and BDHR. Conclusion: In these Chinese children, multiple factors affected BDR, including age, sex, height, body mass index, asthma status, and family history of asthma. Clinical implications: Because BDR can be affected by multiple factors, interpretation of clinical or research findings on BDR needs to take these factors into consideration.	Childrens Mem Hosp, Div Allergy, Chicago, IL 60614 USA; Childrens Mem Hosp, Mary Ann & J Milburn Smith Child Hlth Res Program, Chicago, IL 60614 USA; Childrens Mem Res Ctr, Chicago, IL USA; Anhui Med Univ, Inst Biomed, Hefei, Peoples R China; Harvard Univ, Sch Publ Hlth, Program Populat Genet, Boston, MA 02115 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Ann & Robert H. Lurie Children's Hospital of Chicago; Anhui Medical University; Harvard University; Harvard T.H. Chan School of Public Health	Xu, XP (corresponding author), Univ Illinois, Sch Publ Hlth, Ctr Populat Genet, 1603 W Taylor St, Chicago, IL 60612 USA.			Kumar, Rajesh/0000-0002-1962-7108	NHLBI NIH HHS [1R01HL066385, K23 HL093023] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL093023, R01HL066385] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGUADO LI, 1984, ENDOCRINOLOGY, V114, P1845, DOI 10.1210/endo-114-5-1845; AGUADO LI, 1982, ENDOCRINOLOGY, V110, P1124, DOI 10.1210/endo-110-4-1124; Barr RG, 2002, ARCH INTERN MED, V162, P1761, DOI 10.1001/archinte.162.15.1761; BECKLAKE M, 1991, AM REV RESPIR DIS, V144, P1202; Burchard EG, 2004, AM J RESP CRIT CARE, V169, P386, DOI 10.1164/rccm.200309-1293OC; Castro-Rodriguez LA, 2001, AM J RESP CRIT CARE, V163, P1344, DOI 10.1164/ajrccm.163.6.2006140; Chan-Yeung M, 2000, INT J TUBERC LUNG D, V4, P633; Choudhry S, 2005, AM J RESP CRIT CARE, V171, P563, DOI 10.1164/rccm.200409-1286OC; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; CONNOLLY MJ, 1995, CHEST, V108, P401, DOI 10.1378/chest.108.2.401; CRAPO RO, 1994, NEW ENGL J MED, V331, P25, DOI 10.1056/NEJM199407073310107; D'Amato M, 1998, AM J RESP CRIT CARE, V158, P1968, DOI 10.1164/ajrccm.158.6.9804126; Deerojanawong Jitladda, 1994, Journal of the Medical Association of Thailand, V77, P351; Emala CW, 2002, CHEST, V121, P722, DOI 10.1378/chest.121.3.722; Gray L, 2000, CLIN EXP ALLERGY, V30, P393; HAROLD FM, 1995, MICROBIOL-UK, V141, P2765, DOI 10.1099/13500872-141-11-2765; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Joos GF, 2003, CURR OPIN PHARMACOL, V3, P233, DOI 10.1016/S1471-4892(03)00046-8; Joos L, 2003, THORAX, V58, P703, DOI 10.1136/thorax.58.8.703; KELLY HW, 1992, ANN PHARMACOTHER, V26, P81, DOI 10.1177/106002809202600115; KERSTJENS HAM, 1993, THORAX, V48, P722, DOI 10.1136/thx.48.7.722; Kim SH, 2002, J ALLERGY CLIN IMMUN, V109, P630, DOI 10.1067/mai.2002.122842; Kizkin O, 2003, J ASTHMA, V40, P317, DOI 10.1081/JAS-120018631; KRADJAN WA, 1992, CHEST, V101, P1545, DOI 10.1378/chest.101.6.1545; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Lima JJ, 2000, PULM PHARMACOL THER, V13, P127, DOI 10.1006/pupt.2000.0239; Litonjua AA, 2004, CHEST, V126, P66, DOI 10.1378/chest.126.1.66; MCKAY RT, 1991, OCCUP MED, V6, P43; NELSON HS, 1995, NEW ENGL J MED, V333, P499, DOI 10.1056/NEJM199508243330807; NIU T, 2002, AM J RESP CRIT CARE, V166, P774; Niu TH, 2000, AM J RESP CRIT CARE, V162, P1833, DOI 10.1164/ajrccm.162.5.9908127; Oswald H, 1997, PEDIATR PULM, V23, P14, DOI 10.1002/(SICI)1099-0496(199701)23:1<14::AID-PPUL2>3.0.CO;2-P; Ouksel H, 2003, RESPIRATION, V70, P54, DOI 10.1159/000068419; Palmer LJ, 2000, AM J RESP CRIT CARE, V161, P1836, DOI 10.1164/ajrccm.161.6.9805104; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2002.120951; Rasmussen F, 2002, AM J RESP CRIT CARE, V165, P1480, DOI 10.1164/rccm.2108009; RIJCKEN B, 1987, B EUR PHYSIOPATH RES, V23, P391; Rodrigo G, 1997, CHEST, V112, P19, DOI 10.1378/chest.112.1.19; Rodriguez RN, 1998, PROCEEDINGS OF THE TWENTY-THIRD ANNUAL SAS USERS GROUP INTERNATIONAL CONFERENCE, P1262; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Shore SA, 2003, AM J RESP CRIT CARE, V168, P910, DOI 10.1164/rccm.2307006; Tan KS, 1997, THORAX, V52, P608, DOI 10.1136/thx.52.7.608; Tan KS, 1998, CHEST, V113, P278, DOI 10.1378/chest.113.2.278; TURNER DJ, 1993, PEDIATR PULM, V15, P98, DOI 10.1002/ppul.1950150206; ULLAH MI, 1981, THORAX, V36, P523, DOI 10.1136/thx.36.7.523; van den Toorn LM, 2000, AM J RESP CRIT CARE, V162, P953, DOI 10.1164/ajrccm.162.3.9909033; WANG XB, 1993, AM REV RESPIR DIS, V148, P1502, DOI 10.1164/ajrccm/148.6_Pt_1.1502; WEIR DC, 1991, THORAX, V46, P43, DOI 10.1136/thx.46.1.43; Weise M, 2002, J CLIN ENDOCR METAB, V87, P5038, DOI 10.1210/jc.2002-020590; Xu, 1996, Int J Occup Environ Health, V2, P172; Xu XP, 1999, AM J RESP CRIT CARE, V160, P1928, DOI 10.1164/ajrccm.160.6.9902013	52	12	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1257	1263		10.1016/j.jaci.2006.02.049	http://dx.doi.org/10.1016/j.jaci.2006.02.049			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16750984				2022-12-18	WOS:000238332300009
J	Orange, JS				Orange, JS			Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology (vol 117, pg S525, 2006)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Correction																		Orange JS, 2006, J ALLERGY CLIN IMMUN, V117, pS525, DOI 10.1016/j.jaci.2006.01.015	1	12	12	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1483	1483						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX					2022-12-18	WOS:000238332300043
J	Fuller, CL; Brittingham, KC; Hepburn, MJ; Martin, JW; Petitt, PL; Pittman, PR; Bavari, S				Fuller, CL; Brittingham, KC; Hepburn, MJ; Martin, JW; Petitt, PL; Pittman, PR; Bavari, S			Dominance of human innate immune responses in primary Francisella tularensis live vaccine strain vaccination	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							TULAREMIA VACCINE		USA, Med Res Inst Infect Dis, Bacteriol Div, Ft Detrick, MD 21702 USA		Fuller, CL (corresponding author), USA, Med Res Inst Infect Dis, Bacteriol Div, 425 Porter St, Ft Detrick, MD 21702 USA.		Bavari, Sina/L-3642-2019; Pittman, Phillip/S-3203-2019; Pittman, Phillip/ADI-6097-2022	Bavari, Sina/0000-0001-8424-5635; Pittman, Phillip/0000-0003-1787-759X; Fuller, Claudette/0000-0003-4741-4609				Burnett JC, 2005, NAT REV DRUG DISCOV, V4, P281, DOI 10.1038/nrd1694; Dennis DT, 2001, JAMA-J AM MED ASSOC, V285, P2763, DOI 10.1001/jama.285.21.2763; DRABICK JJ, 1994, AM J MED SCI, V308, P83, DOI 10.1097/00000441-199408000-00003; Elkins KL, 2003, MICROBES INFECT, V5, P135, DOI 10.1016/S1286-4579(02)00084-9; HERZBERG VL, 1987, J IMMUNOL, V139, P998; Isherwood KE, 2005, ADV DRUG DELIVER REV, V57, P1403, DOI 10.1016/j.addr.2005.01.030; Oyston PCF, 2005, ANTON LEEUW INT J G, V87, P277, DOI 10.1007/s10482-004-6251-7; TARNVIK A, 1989, REV INFECT DIS, V11, P440; TARNVIK A, 1975, INFECT IMMUN, V12, P951; Titball RW, 2003, EXPERT OPIN BIOL TH, V3, P645, DOI 10.1517/14712598.3.4.645	10	12	12	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1186	1188		10.1016/j.jaci.2006.01.044	http://dx.doi.org/10.1016/j.jaci.2006.01.044			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	041EM	16675351				2022-12-18	WOS:000237436300035
J	Nelson, HS				Nelson, HS			Advances in upper airway diseases and allergen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sinusitis; rhinosinusitis; rhinitis; skin testing; allergen immunotherapy; sublingual immunotherapy; food immunotherapy	FUROATE NASAL SPRAY; CHRONIC RHINOSINUSITIS; FLUTICASONE PROPIONATE; DOUBLE-BLIND; SUBLINGUAL IMMUNOTHERAPY; GRASS-POLLEN; RHINITIS; INTRANASAL; POLYPOSIS; PLACEBO	The purpose of this review is to highlight important articles on tipper airway disease and immunotherapy that appeared in the Journal of Allergy and Clinical Immunology and elsewhere during 2005. In recent studies of tissue from patients with chronic hypertrophic eositiophilic sinusitis, increased leukotriene C-4 synthase and 5-lipoxygenase activity and increased levels of cysteinyl leukotriene production were demonstrated that correlated with disease severity but not with whether the patient was aspirin sensitive. However, the cysteinyl leukotriene 1 receptor was increased in leukocytes; in the sinus tissue only in those patients with aspirin sensitivity. Major basic protein, released by eosinophils into the mucus in the paranasal sinus lumen, was found to reach concentrations capable of damaging the sinus epithelium, predisposing to bacterial infections. Testing the hypothesis that chronic hypertrophic eosinophilic sinusitis represents a reaction to common fungi, a double-blind trial of intranasal instillation of amphotericin B was conducted. There were marginal but significant differences in favor of amphotericin B treatment for sinus mucosal thickening on the basis of computed tomography and the evidence of eosinophilic inflammation in the sinus mucus. The effectiveness of topical nasal corticosteroids for treatment of nasal polyps was confirmed in 2 large studies. Improvement in sleep quality and daytime drowsiness in patients with allergic rhinitis treated with nasal corticosteroids was reported to correlate with reduction in nasal obstruction. The statistical analysis behind studies that reported a decrease in asthma exacerbations with nasal corticosteroids or oral antihistamines has been questioned. It appears that the results of at least one of these studies are indeed too good to be true. Although caution is still indicated in administering immunotherapy to patients receiving beta-adrenergic blocking agents, the prohibition might not be absolute. A study in patients with Hymenoptera sensitivity given venom immunotherapy revealed no increase in serious adverse reactions to venom injections and no greater incidence of reactions to insect stings in those taking beta-blocking agents. Sublingual immunotherapy for 8 to 12 weeks in patients with hazelnut sensitivity significantly increased their tolerance to hazelnut in double-blind, placebo-controlled challenges while inducing increased IgG(4) and IL-10 levels, indicating induction of regulatory T cells. There were a number of articles in the Journal of Allergy and Clinical Immunology in 2005 that addressed the entity of chronic hypertrophic eosinophilic sinusitis. In addition, an update of the "Practice parameters on sinusitis" was published. The major focus in allergen immunotherapy continues to be sublingual administration.	Natl Jewish Med & Res Ctr, Denver, CO 80206 USA	National Jewish Health	Nelson, HS (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.	nelsonh@njc.org						Asero R, 2005, J ALLERGY CLIN IMMUN, V116, P1036, DOI 10.1016/j.jaci.2005.08.019; Aukema AAC, 2005, J ALLERGY CLIN IMMUN, V115, P1017, DOI 10.1016/j.jaci.2004.12.1144; Borish L, 2005, J ALLERGY CLIN IMMUN, V116, P1269, DOI 10.1016/j.jaci.2005.08.038; Bui CM, 2005, J ALLERGY CLIN IMMUN, V116, P1042, DOI 10.1016/j.jaci.2005.07.031; Bush RK, 2005, J ALLERGY CLIN IMMUN, V115, P123, DOI 10.1016/j.jaci.2004.10.025; Carr WW, 2005, J ALLERGY CLIN IMMUN, V116, P341, DOI 10.1016/j.jaci.2005.03.035; Coker HA, 2005, J ALLERGY CLIN IMMUN, V116, P445, DOI 10.1016/j.jaci.2005.04.032; Corrigan C, 2005, J ALLERGY CLIN IMMUN, V115, P316, DOI 10.1016/j.jaci.2004.10.051; Craig TJ, 2005, J ALLERGY CLIN IMMUN, V116, P1264, DOI 10.1016/j.jaci.2005.10.009; Dahl R, 2005, ALLERGY, V60, P875, DOI 10.1111/j.1398-9995.2005.00819.x; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; Hamilos DL, 2005, J ALLERGY CLIN IMMUN, V116, P1267, DOI 10.1016/j.jaci.2005.09.011; Hufnagl K, 2005, J ALLERGY CLIN IMMUN, V116, P370, DOI 10.1016/j.jaci.2005.04.002; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Koreck AI, 2005, J ALLERGY CLIN IMMUN, V115, P541, DOI 10.1016/j.jaci.2004.11.005; Kussebi F, 2005, J ALLERGY CLIN IMMUN, V115, P323, DOI 10.1016/j.jaci.2004.11.041; Linhart B, 2005, J ALLERGY CLIN IMMUN, V115, P1010, DOI 10.1016/j.jaci.2004.12.1142; Marogna M, 2005, J ALLERGY CLIN IMMUN, V115, P1184, DOI 10.1016/j.jaci.2005.02.031; Meltzer EO, 2005, J ALLERGY CLIN IMMUN, V116, P1289, DOI 10.1016/j.jaci.2005.08.044; Meltzer EO, 2005, J ALLERGY CLIN IMMUN, V115, P791, DOI 10.1016/j.jaci.2005.01.040; Miyake Y, 2005, J ALLERGY CLIN IMMUN, V115, P1176, DOI 10.1016/j.jaci.2005.02.016; Muller UR, 2005, J ALLERGY CLIN IMMUN, V115, P606, DOI [10.1016/j.jaci.2004.11.012, 10.1016/j.jsci.2004.11.012]; Nathan RA, 2005, CHEST, V128, P1910, DOI 10.1378/chest.128.4.1910; Nelson HS, 2004, J ALLERGY CLIN IMMUN, V113, P635, DOI 10.1016/j.jaci.2004.01.741; Nelson HS, 2005, J ALLERGY CLIN IMMUN, V115, P676, DOI 10.1016/j.jaci.2005.01.037; Ono SJ, 2005, J ALLERGY CLIN IMMUN, V115, P118, DOI 10.1016/j.jaci.2004.10.042; Pajno GB, 2005, J ALLERGY CLIN IMMUN, V116, P1380, DOI 10.1016/j.jaci.2005.07.034; Perez-Novo CA, 2005, J ALLERGY CLIN IMMUN, V115, P1189, DOI 10.1016/j.jaci.2005.02.029; Ponikau JU, 2005, J ALLERGY CLIN IMMUN, V116, P362, DOI 10.1016/j.jaci.2005.03.049; Ponikau JU, 2005, J ALLERGY CLIN IMMUN, V115, P125, DOI 10.1016/j.jaci.2004.09.037; Reisinger J, 2005, J ALLERGY CLIN IMMUN, V116, P347, DOI 10.1016/j.jaci.2005.04.003; Simons FER, 2005, J ALLERGY CLIN IMMUN, V116, P355, DOI 10.1016/j.jaci.2005.04.010; SLAVIN RG, 2005, J ALLERGY CLIN IMMUN, V116, pS15; Small CB, 2005, J ALLERGY CLIN IMMUN, V116, P1275, DOI 10.1016/j.jaci.2005.07.027; Suissa S, 2005, J ALLERGY CLIN IMMUN, V115, P714, DOI 10.1016/j.jaci.2004.12.1118; Tabar AI, 2005, J ALLERGY CLIN IMMUN, V116, P109, DOI 10.1016/j.jaci.2005.05.005; Zhang J, 2005, J ALLERGY CLIN IMMUN, V115, P548, DOI 10.1016/j.jaci.2004.11.034	37	12	12	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1047	1053		10.1016/j.jaci.2005.12.1306	http://dx.doi.org/10.1016/j.jaci.2005.12.1306			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	041EM	16675331				2022-12-18	WOS:000237436300011
J	Corry, DB; Kheradmand, F				Corry, DB; Kheradmand, F			Control of allergic airway inflammation through immunomodulation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; IgE; type I hypersensitivity; immunodulation; T(H)2 cell; eosinophil; mast cell; interleukin; airway hyperreactivity; immunostimulatory sequence	KILLED MYCOBACTERIUM-VACCAE; SUPLATAST TOSILATE; ANTIBODY OMALIZUMAB; MONOCLONAL-ANTIBODY; ASTHMA; HYPERRESPONSIVENESS; INTERLEUKIN-12; EOSINOPHILS; RESPONSES; RECEPTOR	Among the asthma clinical trials published over the last several years, a unique subset has focused on novel means for inhibiting the airway inflammation that is believed to cause airway obstruction in many patients. Such interventions, broadly considered here as immune-modifying or immunomodulatory therapies, include several new drugs (omalizumab, suplatast tosilate, anti-cytokine antibodies, soluble receptors, and recombinant cytokines) and bacterial extracts. In this chapter we review the major findings with these clinical trials and indicate which have changed the management of asthma, which have not, and those that deserve further study.	Baylor Coll Med, Med Pulm Sect, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Corry, DB (corresponding author), Baylor Coll Med, Med Pulm Sect, Dept Med, 1 Baylor Plaza,Suite 520B, Houston, TX 77030 USA.	dcorry@bcm.tmc.edu						Borish LC, 2001, J ALLERGY CLIN IMMUN, V107, P963, DOI 10.1067/mai.2001.115624; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816, DOI 10.1164/ajrccm.160.6.9808146; Boushey HA, 2000, LANCET, V356, P2114, DOI 10.1016/S0140-6736(00)03486-3; Broide D, 1998, J IMMUNOL, V161, P7054; Bryan SA, 2000, LANCET, V356, P2149, DOI 10.1016/S0140-6736(00)03497-8; Buhl R, 2002, EUR RESPIR J, V20, P1088, DOI 10.1183/09031936.02.00016502; Buhl R, 2002, EUR RESPIR J, V20, P73, DOI 10.1183/09031936.02.00278102; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Choi IS, 2002, ANN ALLERG ASTHMA IM, V88, P584, DOI 10.1016/S1081-1206(10)61890-X; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Hopfenspirger MT, 2002, J IMMUNOL, V168, P2516, DOI 10.4049/jimmunol.168.5.2516; Horiguchi T, 2001, J ASTHMA, V38, P331, DOI 10.1081/JAS-100000041; Kips JC, 2003, AM J RESP CRIT CARE, V167, P1655, DOI 10.1164/rccm.200206-525OC; Kline JN, 1998, J IMMUNOL, V160, P2555; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Milgrom H, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e36; Omenaas E, 2000, THORAX, V55, P454, DOI 10.1136/thorax.55.6.454; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Shirtcliffe PM, 2001, AM J RESP CRIT CARE, V163, P1410, DOI 10.1164/ajrccm.163.6.2003050; Tamaoki J, 2000, LANCET, V356, P273, DOI 10.1016/S0140-6736(00)02501-0; Tsai Jaw-Ji, 2002, Journal of Microbiology Immunology and Infection, V35, P99; Yoshida M, 2002, J ASTHMA, V39, P545, DOI 10.1081/JAS-120004925; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	28	12	14	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2		1			S461	S464		10.1016/j.jaci.2005.09.001	http://dx.doi.org/10.1016/j.jaci.2005.09.001			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	019VS	16455347	Bronze			2022-12-18	WOS:000235865400008
J	Skoner, D; Maspero, J; Kundu, S; Lloyd, M; Banerji, D				Skoner, D; Maspero, J; Kundu, S; Lloyd, M; Banerji, D			Ciclesonide, administered once daily, has no effect on growth velocity in prepubertal children with mild, persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	62nd Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 03-07, 2006	Miami Beach, FL	Amer Acad Allergy, Asthma & Immunol					Allegheny Gen Hosp, Pittsburgh, PA 15212 USA; Fdn Cidea, Sanatorio San Jose, Buenos Aires, DF, Argentina	Allegheny General Hospital									0	12	13	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2		S		44	S11	S11		10.1016/j.jaci.2005.12.047	http://dx.doi.org/10.1016/j.jaci.2005.12.047			1	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	019VR					2022-12-18	WOS:000235865300045
J	Schildgen, O; Wilkesmann, A; Simon, A				Schildgen, O; Wilkesmann, A; Simon, A			Wheezing in patients with human metapneurnovirus infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Univ Hosp Bonn, Inst Med Microbiol & Immunol, Bonn, Germany; Univ Hosp, Med Ctr, Childrens Clin, D-53113 Bonn, Germany	University of Bonn; University of Bonn	Schildgen, O (corresponding author), Univ Hosp Bonn, Inst Med Microbiol & Immunol, Bonn, Germany.		Schildgen, Oliver/D-5327-2014	Schildgen, Oliver/0000-0003-4297-9627				Schildgen O, 2004, J CLIN VIROL, V31, P283, DOI 10.1016/j.jcv.2004.06.007; Schildgen O, 2005, EMERG INFECT DIS, V11, P467, DOI 10.3201/eid1103.040676; Williams JV, 2005, J ALLERGY CLIN IMMUN, V115, P1311, DOI 10.1016/j.jaci.2005.02.001	3	12	12	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					223	223		10.1016/j.jaci.2005.09.044	http://dx.doi.org/10.1016/j.jaci.2005.09.044			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16387621				2022-12-18	WOS:000235687100046
J	Ricci, A; Avanzini, MA; Scaramuzza, C; Castellazzi, AM; Marconi, M; Marseglia, GL				Ricci, A; Avanzini, MA; Scaramuzza, C; Castellazzi, AM; Marconi, M; Marseglia, GL			Toll-like receptor 2-positive and Toll-like receptor 4-positive cells in adenoids of children exposed to passive smoking	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							LIPOPOLYSACCHARIDE; SMOKERS; MUCOSA; AIRWAY		Policlin San Matteo, Ist Ric Carattere Sci, Res Labs, I-27100 Pavia, Italy; Univ Pavia, Dept Pediat, I-27100 Pavia, Italy	IRCCS Fondazione San Matteo; University of Pavia	Ricci, A (corresponding author), Policlin San Matteo, Ist Ric Carattere Sci, Res Labs, P Golgi 19, I-27100 Pavia, Italy.		MARSEGLIA, GIAN LUIGI/AAL-2254-2020; Avanzini, Maria Antonietta/K-7839-2016	MARSEGLIA, GIAN LUIGI/0000-0003-3662-0159; Avanzini, Maria Antonietta/0000-0002-6056-9018				ABBUD RA, 1995, J INFECT DIS, V172, P859, DOI 10.1093/infdis/172.3.859; Brandtzaeg P, 1996, ACTA OTO-LARYNGOL, V116, P149, DOI 10.3109/00016489609137812; Claeys S, 2003, ALLERGY, V58, P748, DOI 10.1034/j.1398-9995.2003.00180.x; Cook DG, 1999, THORAX, V54, P357, DOI 10.1136/thx.54.4.357; DiFranza JR, 1996, PEDIATRICS, V97, P560; Hagiwara E, 2001, CYTOKINE, V14, P121, DOI 10.1006/cyto.2001.0860; Komai-Koma M, 2004, P NATL ACAD SCI USA, V101, P3029, DOI 10.1073/pnas.0400171101; Li JS, 1999, PEDIATR PULM, V27, P5, DOI 10.1002/(SICI)1099-0496(199901)27:1<5::AID-PPUL3>3.0.CO;2-5; Matsuguchi T, 2000, BLOOD, V95, P1378, DOI 10.1182/blood.V95.4.1378.004k08_1378_1385; Tulic MK, 2004, LANCET, V363, P1689, DOI 10.1016/S0140-6736(04)16253-3; Zeidel A, 2002, ACTA ANAESTH SCAND, V46, P959, DOI 10.1034/j.1399-6576.2002.460806.x	11	12	13	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2005	115	3					631	632		10.1016/j.jaci.2004.11.044	http://dx.doi.org/10.1016/j.jaci.2004.11.044			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	907AN	15753915	Bronze			2022-12-18	WOS:000227687000030
J	File, TM				File, TM			Telithromycin new product overview	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Telithromycin; ketolide; community-acquired pneumonia; acute exacerbations of chronic bronchitis; acute bacterial sinusitis; antibiotic resistance	COMMUNITY-ACQUIRED PNEUMONIA; RESPIRATORY-TRACT INFECTIONS; OBSTRUCTIVE PULMONARY-DISEASE; KETOLIDES HMR 3004; IN-VITRO ACTIVITY; STREPTOCOCCUS-PNEUMONIAE; ACUTE EXACERBATIONS; MACROLIDE RESISTANCE; ANTIMICROBIAL THERAPY; CEFUROXIME AXETIL	Community-acquired respiratory tract infections (CARTIs), including community-acquired pneumonia, acute exacerbations of chronic bronchitis, and acute bacterial sinusitis, contribute substantially to health care costs in the United States. Although many prescriptions for antibiotics are written each year for the treatment of CARTIs, most are prescribed on an empiric basis. Concerns about the increasing prevalence of antimicrobial resistance and the changing pattern of pathogens isolated from subjects with CARTIs have raised questions about the empiric treatment paradigm. When choosing appropriate antimicrobial therapy for CARTIs, physicians must consider not only the spectrum of activity of antibiotics but also the potential risk of resistance. Telithromycin is the first member of the ketolide class, a new family of antimicrobials structurally related to the macrolides, to be approved by the US Food and Drug Administration for the treatment of CARTIs. The spectrum of activity of telithromycin includes common typical and atypical causative pathogens associated with community-acquired respiratory tract infections, including anti biotic-resistant strains of Streptococcus pneumoniae. Clinical trials have shown that telithromycin is as effective as traditionally used antimicrobial agents in the treatment of mild-to-moderate community-acquired pneumonia, acute exacerbations of chronic bronchitis, and acute bacterial sinusitis.	Northeastern Ohio Univ Coll Med & Pharm, Coll Med, Dept Internal Med, Rootstown, OH 44272 USA; Summa Hlth Syst, Dis Serv, Akron, OH USA	Northeast Ohio Medical University (NEOMED); Summa Health System	File, TM (corresponding author), 75 Arch St,Suite 105, Akron, OH 44304 USA.	filet@summa-health.org						Ackermann G, 2003, J ANTIMICROB CHEMOTH, V51, P497, DOI 10.1093/jac/dkg123; Adams S G, 2000, Semin Respir Infect, V15, P234; ALLEGRA L, 1991, ITAL J CHEST DIS, V45, P138; ANTHONISEN NR, 1987, ANN INTERN MED, V106, P196, DOI 10.7326/0003-4819-106-2-196; Aubier M, 2002, RESP MED, V96, P862, DOI 10.1053/rmed.2002.1382; Ball P, 1998, CHEST, V113, p199S, DOI 10.1378/chest.113.3_Supplement.199S; Balter Meyer S, 2003, Can Respir J, V10 Suppl B, p3B; Berisio R, 2003, J BACTERIOL, V185, P4276, DOI 10.1128/JB.185.14.4276-4279.2003; Bhargava V, 2002, SCAND J INFECT DIS, V34, P823, DOI 10.1080/0036554021000026958; Bishai WR, 2002, OTOLARYNG HEAD NECK, V127, pS3, DOI 10.1067/mhn.2002.130030; Bonnefoy A, 1997, J ANTIMICROB CHEMOTH, V40, P85, DOI 10.1093/jac/40.1.85; Bryskier A, 2000, CLIN MICROBIOL INFEC, V6, P661, DOI 10.1046/j.1469-0691.2000.00185.x; Buchanan PP, 2003, AM J RHINOL, V17, P369, DOI 10.1177/194589240301700610; Cantalloube C, 2003, INT J ANTIMICROB AG, V22, P112, DOI 10.1016/S0924-8579(03)00128-6; Carbon C, 2003, CLIN MICROBIOL INFEC, V9, P691, DOI 10.1046/j.1469-0691.2003.00678.x; Champney WS, 2002, CURR MICROBIOL, V45, P328, DOI 10.1007/s00284-002-3710-0; Chen DK, 1999, NEW ENGL J MED, V341, P233, DOI 10.1056/NEJM199907223410403; Clark JP, 2003, MAYO CLIN PROC, V78, P1113, DOI 10.4065/78.9.1113; Davidson R, 2002, NEW ENGL J MED, V346, P747, DOI 10.1056/NEJMoa012122; Davies TA, 2000, ANTIMICROB AGENTS CH, V44, P414, DOI 10.1128/AAC.44.2.414-417.2000; Descheemaeker P, 2000, J ANTIMICROB CHEMOTH, V45, P167, DOI 10.1093/jac/45.2.167; DOEM GV, 2004, J INFECTION, V48, P56; Doern GV, 2001, ANTIMICROB AGENTS CH, V45, P1721, DOI 10.1128/AAC.45.6.1721-1729.2001; Douthwaite S, 2001, CLIN MICROBIOL INFEC, V7, P11, DOI 10.1046/j.1469-0691.2001.0070s3011.x; Douthwaite S, 2001, J ANTIMICROB CHEMOTH, V48, P1; Douthwaite S, 2000, MOL MICROBIOL, V36, P183, DOI 10.1046/j.1365-2958.2000.01841.x; Dunbar LM, 2004, CLIN THER, V26, P48, DOI 10.1016/S0149-2918(04)90005-7; Edelstein PH, 1999, ANTIMICROB AGENTS CH, V43, P90, DOI 10.1128/AAC.43.1.90; Farrell DJ, 2004, ANTIMICROB AGENTS CH, V48, P1882, DOI 10.1128/AAC.48.5.1882-1884.2004; Ferguson BJ, 2004, OTOLARYNG HEAD NECK, V131, P207, DOI 10.1016/j.otohns.2004.05.010; File TM, 2004, CHEST, V125, P1888, DOI 10.1378/chest.125.5.1888; File TM, 2002, CLIN INFECT DIS, V34, pS17, DOI 10.1086/324526; FILE TM, 2003, COMMUNITY ACQUIRED R; Fogarty C, 2000, CLIN INFECT DIS, V31, P613, DOI 10.1086/313976; FOGARTY C, 5 DAY TELITHROMYCIN; Fogarty CM, 2003, J ANTIMICROB CHEMOTH, V51, P947, DOI 10.1093/jac/dkg153; Gustafsson I, 2000, ANTIMICROB AGENTS CH, V44, P1846, DOI 10.1128/AAC.44.7.1846-1849.2000; GWALTNEY JM, 1992, J ALLERGY CLIN IMMUN, V90, P457, DOI 10.1016/0091-6749(92)90169-3; Hagberg L, 2002, INFECTION, V30, P378, DOI 10.1007/s15010-002-2096-z; Hansen LH, 1999, MOL MICROBIOL, V31, P623, DOI 10.1046/j.1365-2958.1999.01202.x; Heffelfinger JD, 2000, ARCH INTERN MED, V160, P1399, DOI 10.1001/archinte.160.10.1399; Ho PL, 2001, J ANTIMICROB CHEMOTH, V48, P659, DOI 10.1093/jac/48.5.659; Hoppe JE, 1998, ANTIMICROB AGENTS CH, V42, P965, DOI 10.1128/AAC.42.4.965; Kays MB, 2002, PHARMACOTHERAPY, V22, P395, DOI 10.1592/phco.22.5.395.33185; Kelley MA, 2000, CLIN INFECT DIS, V31, P1008, DOI 10.1086/318157; Khair OA, 2001, J ANTIMICROB CHEMOTH, V47, P837, DOI 10.1093/jac/47.6.837; KLOSSEK JM, 2002, 22 REUN INT CHIM ANT; Kroll Thilo, 2003, Manag Care Q, V11, P11; LECLERCQ R, 1991, ANTIMICROB AGENTS CH, V35, P1267, DOI 10.1128/AAC.35.7.1267; Lieberman D, 2001, DIAGN MICR INFEC DIS, V40, P95, DOI 10.1016/S0732-8893(01)00255-3; Lonks JR, 2002, CLIN INFECT DIS, V35, P556, DOI 10.1086/341978; Low DE, 2004, J INFECTION, V49, P115, DOI 10.1016/j.jinf.2004.03.009; LUCAS JW, 2004, VITAL HLTH STAT, V10, P1; Luterman Maynard, 2003, Ear Nose Throat J, V82, P576; MACFARLANE JT, 1993, LANCET, V341, P511, DOI 10.1016/0140-6736(93)90275-L; MAGLIO D, 2004, INFECT DIS, V7, P33; Mandell LA, 2003, CLIN INFECT DIS, V37, P1405, DOI 10.1086/380488; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; McGee L, 2002, J ANTIMICROB CHEMOTH, V49, P173, DOI 10.1093/jac/49.1.173; MONSO E, 1995, AM J RESP CRIT CARE, V152, P1316, DOI 10.1164/ajrccm.152.4.7551388; MONTAY G, 2003, 43 INT C ANT AG CHEM; Morosini MI, 2001, ANTIMICROB AGENTS CH, V45, P2427, DOI 10.1128/AAC.45.9.2427-2431.2001; Musher DM, 2002, NEW ENGL J MED, V346, P630, DOI 10.1056/NEJM200202213460820; Namour F, 2001, ANTIMICROB AGENTS CH, V45, P170, DOI 10.1128/AAC.45.1.170-175.2001; NICOLAU DP, 2003, 41 M INF DIS SOC AM; Niederman MS, 1999, CLIN THER, V21, P576, DOI 10.1016/S0149-2918(00)88310-1; Niederman MS, 2001, AM J RESP CRIT CARE, V163, P1730, DOI 10.1164/ajrccm.163.7.at1010; Nieman RB, 2003, CLIN INFECT DIS, V37, P1579, DOI 10.1086/379617; Perret C, 2002, CHEMOTHERAPY, V48, P217, DOI 10.1159/000066766; Pullman J, 2003, INT J CLIN PRACT, V57, P377; Ray NF, 1999, J ALLERGY CLIN IMMUN, V103, P408, DOI 10.1016/S0091-6749(99)70464-1; Rodvold KA, 1997, ANTIMICROB AGENTS CH, V41, P1399, DOI 10.1128/AAC.41.6.1399; Roos K, 2002, CHEMOTHERAPY, V48, P100, DOI 10.1159/000057670; SAINT S, 1995, JAMA-J AM MED ASSOC, V273, P957, DOI 10.1001/jama.273.12.957; Schmitz FJ, 2002, J ANTIMICROB CHEMOTH, V50, P145, DOI 10.1093/jac/dkf085; Sethi S, 2002, NEW ENGL J MED, V347, P465, DOI 10.1056/NEJMoa012561; Shi J, 2004, J CLIN PHARMACOL, V44, P234, DOI 10.1177/0091270003262952; SHI J, 2002, AM SOC HLTH SYST PHA; SHI J, 2002, 42 INT C ANT AG CHEM; Snow V, 2001, CHEST, V119, P1185, DOI 10.1378/chest.119.4.1185; Stanton MW, 2002, IMPROVING TREATMENT; Sutcliffe J, 1996, ANTIMICROB AGENTS CH, V40, P1817, DOI 10.1128/AAC.40.8.1817; TELLIER G, 2002, 42 INT C ANT AG CHEM; Zervos MJ, 2003, J INT MED RES, V31, P157, DOI 10.1177/147323000303100301; Zhanel GG, 2002, DRUGS, V62, P1771, DOI 10.2165/00003495-200262120-00006; Zhanel GG, 2001, DRUGS, V61, P443, DOI 10.2165/00003495-200161040-00003; Zuckerman JM, 2004, INFECT DIS CLIN N AM, V18, P621, DOI 10.1016/j.idc.2004.04.010; 2004, SINUS ALLERGY HLTH P; 2004, TELITHROMYCIN KETEK, V46, P66	89	12	13	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					S362	S373		10.1016/j.jaci.2004.11.029	http://dx.doi.org/10.1016/j.jaci.2004.11.029			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	897YU	15696068	Bronze			2022-12-18	WOS:000227043600049
J	Woolard, MD; Hardy, RD; Simecka, JW				Woolard, MD; Hardy, RD; Simecka, JW			IL-4-independent pathways exacerbate methacholine-induced airway hyperreactivity during mycoplasma respiratory disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-4; mycoplasma; airway hyperresponsiveness	MURINE MODEL; PNEUMONIAE INFECTION; ASTHMA; INFLAMMATION; PULMONIS; LESIONS; RATS; IL-4	Background: Mycoplasma respiratory infections are associated with wheezing and exacerbation of airway hyperresponsiveness (AHR) in asthmatic patients. IL-4 is a key cytokine in the development of AHR and airway reconstruction in asthmatic patients and might be an important component in exacerbation of AHR during pulmonary mycoplasma infection. Objective: This study evaluates the effect of IL-4 on the severity of methacholine-induced AHR associated with mycoplasma pulmonary mycoplasma infection. Methods: BALB/c and IL-4 knockout (KO) mice were infected with Mycoplasma pulmonis, and their enhanced pause scores were monitored before and after methacholine inhalation with whole-body plethysmography. Results: IL-4 KO mice showed no difference in histopathology of the lungs before or after Mycoplasma pulmonis infection when compared with BALB/c mice. There was an increase in airway obstruction from days 7 to 21 after infection in both strains of mice, but there was no strain difference in airway resistance-associated mycoplasma disease. However, IL-4 KO mice had significantly higher methacholine-induced AHR after M pulmonis infection when compared with BALB/c mice. There was no difference in AHR between uninfected IL-4 KO and control mice. Conclusion: In contrast to our hypothesis, IL-4-independent pathways exacerbate methacholine-induced AHR and promote airway obstruction during the pathogenesis of mycoplasma respiratory disease.	Univ N Texas, Ctr Hlth Sci, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA; SW Med Sch, Dept Internal Med Pediat Infect Dis, Dallas, TX USA	University of North Texas System; University of North Texas Health Science Center; University of Texas System; University of Texas Southwestern Medical Center Dallas	Simecka, JW (corresponding author), Univ N Texas, Ctr Hlth Sci, Dept Mol Biol & Immunol, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA.	jsimecka@hsc.unt.edu	Woolard, Matthew/AAE-1536-2020	Woolard, Matthew/0000-0002-8497-5838	NIAID NIH HHS [AI 42075, K08 AI52262] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI052262, R01AI042075] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CASSELL GH, 1973, ANN NY ACAD SCI, V225, P395, DOI 10.1111/j.1749-6632.1973.tb45665.x; Chu HW, 2003, CHEST, V123, p390S, DOI 10.1378/chest.123.3_suppl.390S; DAVIDSON MK, 1988, INFECT IMMUN, V56, P2163, DOI 10.1128/IAI.56.8.2163-2168.1988; Freymuth F, 1999, J CLIN VIROL, V13, P131, DOI 10.1016/S1386-6532(99)00030-X; Hardy RD, 2002, INFECT IMMUN, V70, P649, DOI 10.1128/IAI.70.2.649-654.2002; Hardy RD, 2001, INFECT IMMUN, V69, P3869, DOI 10.1128/IAI.69.6.3869-3876.2001; Jones HP, 2002, J IMMUNOL, V168, P3493, DOI 10.4049/jimmunol.168.7.3493; Komai M, 2003, BRIT J PHARMACOL, V138, P912, DOI 10.1038/sj.bjp.0705105; Kraft M, 1998, AM J RESP CRIT CARE, V158, P998, DOI 10.1164/ajrccm.158.3.9711092; Martin RJ, 2001, AM J RESP CELL MOL, V24, P577, DOI 10.1165/ajrcmb.24.5.4315; NobenTrauth N, 1996, TRANSGENIC RES, V5, P487, DOI 10.1007/BF01980214; OVERCASH RG, 1976, AM J PATHOL, V82, P171; PINSON DM, 1986, VET PATHOL, V23, P550, DOI 10.1177/030098588602300502; Woolard MD, 2004, J IMMUNOL, V172, P6875, DOI 10.4049/jimmunol.172.11.6875; Yssel H, 2000, INT ARCH ALLERGY IMM, V121, P10, DOI 10.1159/000024292	15	12	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					645	649		10.1016/j.jaci.2004.06.019	http://dx.doi.org/10.1016/j.jaci.2004.06.019			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	853AX	15356571				2022-12-18	WOS:000223799600027
J	Holland, SM; Shea, YR; Kwon-Chung, J				Holland, SM; Shea, YR; Kwon-Chung, J			Regarding "Trichosporon pullulans infection in 2 patients with chronic granulomatous disease"	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									NIAID, NIH, Bethesda, MD 20892 USA; NIH, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA	Holland, SM (corresponding author), NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.			Shearer, William/0000-0002-2483-2130	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000646] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DEHOOG GS, 2000, ATLAS CLIN FUNGI, P1030; Gueho E., 1998, P854, DOI 10.1016/B978-044481312-1/50115-5; Moylett EH, 2003, J ALLERGY CLIN IMMUN, V111, P1370, DOI 10.1067/mai.2003.1522	3	12	12	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2004	114	1					205	206		10.1016/j.jaci.2004.01.781	http://dx.doi.org/10.1016/j.jaci.2004.01.781			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	836DA	15282941				2022-12-18	WOS:000222534300034
J	Howell, MD; Tomazic, VJ; Leakakos, T; Truscott, W; Meade, BJ				Howell, MD; Tomazic, VJ; Leakakos, T; Truscott, W; Meade, BJ			Immunomodulatory effect of endotoxin on the development of latex allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex; endotoxin; mouse model; IgE; airway hyperreactivity	HEALTH-CARE WORKERS; BRONCHIAL HYPERRESPONSIVENESS; LIPOPOLYSACCHARIDE EXPOSURE; AIRWAY HYPERRESPONSIVENESS; LUNG EOSINOPHILIA; INTERFERON-GAMMA; IGE; INFLAMMATION; RESPONSES; MICE	Background: Although numerous studies have been conducted delineating the clinical manifestations of latex allergy and characterizing the protein allergens, little is known regarding the natural history of the disease. Objective: These studies were undertaken to investigate the immunomodulatory role of inhaled endotoxin on the development of latex-specific IgE-mediated responses to natural rubber latex (NRL) proteins by using a mouse model. Methods: Female BALB/c mice were exposed to 25 mug of NRL proteins with or without increasing concentrations of endotoxin (50-25,000 EU) through the respiratory tract. Serum antibody levels were evaluated biweekly during the study. After sensitization, mice were challenged with methacholine or NRL proteins, and airway hyperreactivity (AHR) was evaluated with whole-body plethysmography. After NRL challenge, lungs were excised for histopathology, and lung-associated lymph nodes were removed for cytokine mRNA evaluation. Results: When compared with mice exposed to latex alone, mice exposed to latex and endotoxin demonstrated up to 50% lower levels of latex-specific IgE and decreased latex-specific AHR and mucin production. Conversely, these same animals demonstrated increased levels of latex-specific serum IgG2a and IgA antibodies and an increase in IFN-gamma and IL-12 mRNA levels in the draining lymph node cells. Concurrent exposure to LPS with nonammoniated latex resulted in increased alveolitis and nonspecific AHR on respiratory challenge with methacholine. Conclusion: Coexposure with LPS and allergen decreased latex-specific IgE but augmented nonspecific AHR. These studies demonstrate that endotoxin associated with NRL gloves can modulate the development of allergic responses to NRL proteins.	NIOSH, Agr & Immunotoxicol Grp, Morgantown, WV 26505 USA; US FDA, Ctr Devices & Radiol Hlth, Rockville, MD 20857 USA; FeRX Inc, Preclin Dev, San Diego, CA USA; Kimberly Clark Inc, Sci Affairs & Clin Educ, Roswell, GA USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); US Food & Drug Administration (FDA); Kimberly-Clark	Meade, BJ (corresponding author), MS 4020,1095 Willowdale Rd, Morgantown, WV 26505 USA.				NIEHS NIH HHS [Y1 ES 000102] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALENIUS H, 1994, J ALLERGY CLIN IMMUN, V93, P859, DOI 10.1016/0091-6749(94)90378-6; BERTON MT, 1989, P NATL ACAD SCI USA, V86, P2829, DOI 10.1073/pnas.86.8.2829; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Drazen JM, 1999, ANNU REV PHYSIOL, V61, P593, DOI 10.1146/annurev.physiol.61.1.593; FRIEDMAN H, 1987, J BIOL RESP MODIF, V6, P664; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gerhold K, 2002, J ALLERGY CLIN IMMUN, V110, P110, DOI 10.1067/mai.2002.125831; Ginanni R, 1991, Eur Respir J, V4, P251; Giulietti A, 2001, METHODS, V25, P386, DOI 10.1006/meth.2001.1261; Howell MD, 2002, INT ARCH ALLERGY IMM, V128, P204, DOI 10.1159/000064253; Huang TJ, 2001, J IMMUNOL, V166, P207, DOI 10.4049/jimmunol.166.1.207; Huang TJ, 1999, IMMUNOLOGY, V98, P280; Kagy L, 1998, PEDIATR ANN, V27, P727, DOI 10.3928/0090-4481-19981101-08; Kelso JM, 1998, PEDIATR ANN, V27, P736, DOI 10.3928/0090-4481-19981101-09; KUJALA VM, 1995, AM J IND MED, V28, P89, DOI 10.1002/ajim.4700280108; KURUP VP, 1994, INT ARCH ALLERGY IMM, V103, P370, DOI 10.1159/000236656; LANTZ RC, 1985, EXP MOL PATHOL, V43, P305, DOI 10.1016/0014-4800(85)90068-1; Lefort J, 2001, AM J RESP CELL MOL, V24, P345, DOI 10.1165/ajrcmb.24.3.4289; Liss GM, 1999, AM J IND MED, V35, P196, DOI 10.1002/(SICI)1097-0274(199902)35:2<196::AID-AJIM12>3.0.CO;2-Y; Manetz TS, 1999, TOXICOL SCI, V48, P206, DOI 10.1093/toxsci/48.2.206; Metzger DW, 1996, ANN NY ACAD SCI, V795, P100, DOI 10.1111/j.1749-6632.1996.tb52659.x; MORRIS SC, 1994, J IMMUNOL, V152, P1047; *NAT RES COUNC, 1996, GUID CAR US LAB AN, P125; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Phillips VL, 1999, AM J PUBLIC HEALTH, V89, P1024, DOI 10.2105/AJPH.89.7.1024; Rao GVS, 2003, J TOXICOL ENV HEAL A, V66, P1441, DOI 10.1080/15287390306417; Salkowski CA, 1997, INFECT IMMUN, V65, P3239, DOI 10.1128/IAI.65.8.3239-3247.1997; Schwarze J, 1998, J ALLERGY CLIN IMMUN, V102, P86, DOI 10.1016/S0091-6749(98)70058-2; Schwarze J, 1998, AM J RESP CRIT CARE, V158, P519, DOI 10.1164/ajrccm.158.2.9801014; Slater JE, 1998, J ALLERGY CLIN IMMUN, V102, P977, DOI 10.1016/S0091-6749(98)70336-7; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844; Tang CB, 2001, J IMMUNOL, V166, P1471, DOI 10.4049/jimmunol.166.3.1471; Tobias PS, 1999, CLIN INFECT DIS, V28, P476, DOI 10.1086/515163; TOMAZIC VJ, 1992, CLIN IMMUNOL IMMUNOP, V64, P89, DOI 10.1016/0090-1229(92)90185-Q; Tomei F, 2000, PANMINERVA MED, V42, P217; Toward TJ, 2001, J PHARMACOL EXP THER, V298, P298; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Tulic MK, 2002, INT ARCH ALLERGY IMM, V129, P119, DOI 10.1159/000065881; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Vernooy JHJ, 2002, AM J RESP CELL MOL, V26, P152, DOI 10.1165/ajrcmb.26.1.4652; Williams PB, 1997, ANN ALLERG ASTHMA IM, V79, P303, DOI 10.1016/S1081-1206(10)63019-0; Woolhiser MR, 2000, TOXICOL SCI, V55, P343, DOI 10.1093/toxsci/55.2.343; Yanagihara K, 2001, AM J RESP CELL MOL, V24, P66, DOI 10.1165/ajrcmb.24.1.4122; Zak HN, 2000, ARCH ENVIRON HEALTH, V55, P336, DOI 10.1080/00039890009604026	46	12	12	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2004	113	5					916	924		10.1016/j.jaci.2004.02.017	http://dx.doi.org/10.1016/j.jaci.2004.02.017			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	818UC	15131575				2022-12-18	WOS:000221269000015
J	Lee, J; Cho, YS; Park, SY; Lee, CK; Yoo, B; Moon, HB; Park, HS				Lee, J; Cho, YS; Park, SY; Lee, CK; Yoo, B; Moon, HB; Park, HS			Eggplant anaphylaxis in a patient with latex allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CROSS-REACTIVITY; CHILDREN; POTATO; PATATIN; ADULTS; IGE		Univ Ulsan, Coll Med, Asan Med Ctr, Div Allergy & Rheumatol, Seoul, South Korea; Ajou Univ, Sch Med, Suwon 441749, South Korea	University of Ulsan; Asan Medical Center; Ajou University	Lee, J (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr, Div Allergy & Rheumatol, 388-1 Poongnap 2 Dong, Seoul, South Korea.		Park, Hae-Sim/S-7974-2019	Cho, You Sook/0000-0001-8767-2667; Park, Hae-Sim/0000-0003-2614-0303				BLANCO C, 1994, ANN ALLERGY, V73, P309; Gil M, 2002, ALLERGY, V57, P652, DOI 10.1034/j.1398-9995.2002.23749.x; Kim SS, 2001, J ALLERGY CLIN IMMUN, V107, P1095, DOI 10.1067/mai.2001.114341; Reche M, 2001, ALLERGY, V56, P1197, DOI 10.1034/j.1398-9995.2001.00279.x; Sastre J, 1996, ALLERGY, V51, P117, DOI 10.1111/j.1398-9995.1996.tb04568.x; Seppala U, 1999, J ALLERGY CLIN IMMUN, V103, P165, DOI 10.1016/S0091-6749(99)70541-5; Seppala U, 2000, ALLERGY, V55, P266, DOI 10.1034/j.1398-9995.2000.00392.x; Tucke J, 1999, PEDIATR ALLERGY IMMU, V10, P160, DOI 10.1034/j.1399-3038.1999.00013.x	8	12	13	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2004	113	5					995	996		10.1016/j.jaci.2004.01.565	http://dx.doi.org/10.1016/j.jaci.2004.01.565			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	818UC	15148961	Bronze			2022-12-18	WOS:000221269000026
J	Adjers, K; Pessi, T; Karjalainen, J; Hutala, H; Hurme, M				Adjers, K; Pessi, T; Karjalainen, J; Hutala, H; Hurme, M			Epistatic effect of IL1A and IL4RA genes on the risk of atopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL1A; IL4RA; atopy; skin prick test; epistatic effect	POLYMORPHISM; ASTHMA; INTERLEUKIN-1; ASSOCIATION; DISEASE	Background: Several studies have demonstrated a linkage or association of the atopic phenotype with T-cell cytokine genes involved in the regulation of the T(H)1/T(H)2 balance (eg, IL4, IL13, and their common receptor, IL4RA). We have recently shown that polymorphism of the pro-inflammatory cytokine IL1A gene is strongly associated with atopy. Objective: We now examined whether the polymorphisms of IL1A (G/T at +4845) and IL4RA (T/C at +22446) would show an epistatic effect on the risk of atopy. Methods: Skin prick tests and gene polymorphism analyses were performed in a population-based sample of asthmatic and nonasthmatic subjects. Results: Our results showed that in the nonasthmatic group the previously described elevated risk of atopy in noncarriers of allele T of IL1A (ie, having the genotype GG) was restricted to individuals who were also noncarriers of allele C of IL4PA (genotype TT). This finding applies to the general population of Finland, where 3.3% of adults are asthmatic. Conclusion: These data suggest that the ILIA and IL4RA genes show an epistatic effect on the risk of atopy.	Univ Tampere, Sch Med, Dept Microbiol & Immunol, Tampere 33014, Finland; Tampere Univ Hosp, Dept Resp Med, Tampere, Finland; Univ Tampere, Sch Publ Hlth, FIN-33101 Tampere, Finland; Univ Tampere, Lab Ctr, FIN-33101 Tampere, Finland	Tampere University; Tampere University; Tampere University Hospital; Tampere University; Tampere University	Adjers, K (corresponding author), Univ Tampere, Sch Med, Dept Microbiol & Immunol, Tampere 33014, Finland.			Hurme, Mikko/0000-0002-8614-1044				Bidwell J, 1999, GENES IMMUN, V1, P3, DOI 10.1038/sj.gene.6363645; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Cookson W, 1999, NATURE, V402, pB5, DOI 10.1038/35037002; Cox A, 1998, AM J HUM GENET, V62, P1180, DOI 10.1086/301817; Deichmann K, 1997, BIOCHEM BIOPH RES CO, V231, P696, DOI 10.1006/bbrc.1997.6115; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Hackstein H, 2001, IMMUNOGENETICS, V53, P264, DOI 10.1007/s002510100324; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Howard TD, 2002, AM J HUM GENET, V70, P230, DOI 10.1086/338242; Karjalainen J, 2002, J ALLERGY CLIN IMMUN, V110, P429, DOI 10.1067/mai.2002.126784; Kermani F, 2000, TOXICOL APPL PHARM, V169, P231, DOI 10.1006/taap.2000.9085; Kruse S, 1999, IMMUNOLOGY, V96, P365; La EH, 2001, J IMMUNOL, V166, P6149, DOI 10.4049/jimmunol.166.10.6149; Lozano F, 2001, TISSUE ANTIGENS, V57, P216, DOI 10.1034/j.1399-0039.2001.057003216.x; Mitsuyasu H, 1998, NAT GENET, V19, P119, DOI 10.1038/472; *NAT AG MED KEL, 1998, NAT SICKN INS REIMB; Ober C, 2000, AM J HUM GENET, V66, P517, DOI 10.1086/302781; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; Perussia B, 2003, TRENDS IMMUNOL, V24, P235, DOI 10.1016/S1471-4906(03)00080-2; Pessi T, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.5.e66; Rosenwasser LJ, 1996, TOXICOL LETT, V86, P73, DOI 10.1016/0378-4274(96)03675-2; VANDERVELDEN PA, 1993, HUM MOL GENET, V2, P1753; von Stebut E, 2003, J EXP MED, V198, P191, DOI 10.1084/jem.20030159	23	12	19	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2004	113	3					445	447		10.1016/j.jaci.2003.12.582	http://dx.doi.org/10.1016/j.jaci.2003.12.582			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	802DM	15007345				2022-12-18	WOS:000220144200015
J	Klostermann, B; Bellinghausen, I; Bottcher, I; Petersen, A; Becker, WM; Knop, J; Saloga, J				Klostermann, B; Bellinghausen, I; Bottcher, I; Petersen, A; Becker, WM; Knop, J; Saloga, J			Modification of the human allergic immune response by allergen-DNA-transfected dendritic cells in vitro	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adenoviral transfection; allergy; dendritic cells; T(H)1/T(H)2	RECOMBINANT ADENOVIRUS; CELLULAR-IMMUNITY; VECTOR; IMMUNOTHERAPY; IMMUNIZATION; VACCINATION; EFFICIENT; MELANOMA; PROTEIN; MODEL	Background: Atopic-allergic diseases are characterized by T(H)2-dominated immune responses, resulting in IgE production. DNA-based immunotherapies have been shown to shift the immune response toward a T(H)1-type response in animal models. Objective: The aim of the study was to analyze whether dendritic cells (DCs) transfected with allergen-DNA conjugates are able to stimulate human autologous CD4(+) T cells, CD8(+) T cells, or both from atopic individuals to produce T(H)1 cytokines instead of T(H)2 cytokines. Methods: For this purpose, human mature DCs from atopic donors were transfected with an adenovirus encoding the allergen PhI p 1. Autologous CD4(+) and CD8(+) T cells were stimulated with these transfected DCs, and proliferation and cytokine production were measured. Results: By using an adenoviral vector, a transfection rate of 92% could be achieved. The proliferative response of CD4(+) T cells stimulated with autologous transfected DCs was concentration dependent and almost as high as that of T cells stimulated with mature allergen-pulsed DCs. The proliferation of CD8(+) T cells stimulated with transfected DCs, however, was higher than that of cells stimulated with allergen-pulsed DCs. The cytokine pattern showed a shift toward a T(H)1 immune response compared with T cells stimulated with allergen-pulsed DCs. Conclusions: Human DCs can be transfected with allergen-DNA conjugates very efficiently by using an adenoviral vector yielding DCs with high T-cell stimulatory capacities, directing the atopic-allergic immune response from T(H)2 dominance toward T(H)1 dominance.	Univ Mainz, Dept Dermatol, D-6500 Mainz, Germany; Res Ctr Borstel, Borstel, Germany	Johannes Gutenberg University of Mainz; Forschungszentrum Borstel	Klostermann, B (corresponding author), Univ Hautklin, Lagenbeckstr 1, D-55131 Mainz, Germany.							Arthur JF, 1997, CANCER GENE THER, V4, P17; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Bellinghausen I, 2000, J ALLERGY CLIN IMMUN, V105, P988, DOI 10.1067/mai.2000.105526; Graham F L, 1992, Biotechnology, V20, P363; Hochreiter R, 2001, INT ARCH ALLERGY IMM, V124, P406, DOI 10.1159/000053772; Horner AA, 2001, IMMUNOL REV, V179, P102, DOI 10.1034/j.1600-065X.2001.790111.x; Horner AA, 2000, J ALLERGY CLIN IMMUN, V106, P349, DOI 10.1067/mai.2000.107933; Juillard V, 1995, EUR J IMMUNOL, V25, P3467, DOI 10.1002/eji.1830251239; Lambrecht BN, 2001, CLIN EXP ALLERGY, V31, P206, DOI 10.1046/j.1365-2222.2001.01061.x; Malling HJ, 1998, ALLERGY, V53, P461; Mincheff M, 2001, CRIT REV ONCOL HEMAT, V39, P125, DOI 10.1016/S1040-8428(01)00111-1; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; PETERSEN A, 1995, J ALLERGY CLIN IMMUN, V95, P987, DOI 10.1016/S0091-6749(95)70099-4; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; Song W, 1997, J EXP MED, V186, P1247, DOI 10.1084/jem.186.8.1247; Spiegelberg HL, 2002, CURR OPIN MOL THER, V4, P64; Steitz J, 2001, GENE THER, V8, P1255, DOI 10.1038/sj.gt.3301521; Suck R, 1999, J IMMUNOL METHODS, V229, P73, DOI 10.1016/S0022-1759(99)00101-5; Sudowe S, 2002, GENE THER, V9, P147, DOI 10.1038/sj.gt.3301625; Zhong L, 1999, EUR J IMMUNOL, V29, P964, DOI 10.1002/(SICI)1521-4141(199903)29:03<964::AID-IMMU964>3.0.CO;2-P	21	12	14	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					327	333		10.1016/j.jaci.2003.10.067	http://dx.doi.org/10.1016/j.jaci.2003.10.067			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	773EX	14767450				2022-12-18	WOS:000188885700023
J	Maa, SH; Wang, CH; Liu, CY; Lin, HC; Huang, KH; Kuo, HP				Maa, SH; Wang, CH; Liu, CY; Lin, HC; Huang, KH; Kuo, HP			Endogenous nitric oxide downregulates the Bcl-2 expression of eosinophils through mitogen-activated protein kinase in bronchial asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; apoptosis; nitric oxide; Bcl-2 protein; mitogen-activated protein kinase	COLONY-STIMULATING FACTOR; CELL-DEATH; UP-REGULATION; KAPPA-B; APOPTOSIS; SYNTHASE; INDUCTION; SURVIVAL; INFLAMMATION; MACROPHAGES	Background: Eosinophil apoptosis might play a crucial role in the maintenance of persistent airway inflammation in asthma. Nitric oxide (NO) synthase activity is upregulated in eosinophils of asthmatic patients. Mitogen-activated protein kinase (MAPK) is implicated in regulating eosinophil apoptosis by modulating Bcl-2 expression. NO-induced cell apoptosis is associated with an inhibition of Bcl-2 expression. Objective: We sought to study whether NO might induce eosinophil apoptosis through extracellular signal-regulated protein kinase (ERK) or p38 MAPK pathways and Bcl-2 expression. Methods: Eosinophils were freshly isolated from peripheral blood of 16 asthmatic patients and 12 healthy subjects and then cultured with or without the NO synthase inhibitor N-nitro-L-arginine methyl ester (L-NAME) at 1 and 10 mmol/L for 16 hours. The expression of Bcl-2 and induced NO synthase on eosinophils was analyzed by means of flow cytometry. Apoptosis was assessed by means of propidium iodide and DNA ladder. The activity of ERK and p38 MAPK was determined by means of Western blotting. Results: The induced NO synthase immunoreactivities and the spontaneous release of nitrite from the eosinophils of asthmatic patients were higher compared with those of healthy subjects. Eosinophils of asthmatic patients were found to express more highly constitutive Bcl-2 than those of healthy subjects. After incubation for 16 hours, the expression of Bcl-2 on eosinophils from patients with asthma was significantly enhanced by L-NAME. The percentage of apoptosis was decreased by the addition of 1 mmol/L L-NAME in patients with asthma. The activity of p38 MAPK and ERK in eosinophils from patients with asthma was enhanced in the presence of L-NAME. An inhibition of MAPK reduced the Bcl-2 expression and increased eosinophil apoptosis in patients with asthma. Conclusion: We concluded that inhibition of endogenous NO might increase the expression of Bcl-2 in eosinophils from patients with asthma through the signaling pathway of ERK or p38 MAPK, which in turn decrease the apoptosis.	Chang Gung Mem Hosp, Dept Thorac Med 2, Taipei 10591, Taiwan; Chang Gung Univ, Sch Nursing, Taipei, Taiwan	Chang Gung Memorial Hospital; Chang Gung University	Kuo, HP (corresponding author), Chang Gung Mem Hosp, Dept Thorac Med 2, 199 Tung Hwa N Rd, Taipei 10591, Taiwan.		Wang, Chun-Hua/V-9861-2019; Wang, Chun-Hua/C-1488-2016	Wang, Chun-Hua/0000-0002-3514-9353; 				Adachi T, 2000, J IMMUNOL, V165, P2198, DOI 10.4049/jimmunol.165.4.2198; Albina JE, 1996, J IMMUNOL, V157, P279; BARNES PJ, 1995, IMMUNOL TODAY, V51, pA80; Battinelli E, 2000, BLOOD, V95, P3451, DOI 10.1182/blood.V95.11.3451.011k34_3451_3459; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.3.CO;2-S; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CANMAN CE, 1995, SEMIN CANCER BIOL, V6, P17, DOI 10.1006/scbi.1995.0003; Chou C L, 1999, Changgeng Yi Xue Za Zhi, V22, P416; Chung IY, 2000, CELL IMMUNOL, V203, P95, DOI 10.1006/cimm.2000.1678; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; Cruz MT, 2001, IMMUNOL CELL BIOL, V79, P590, DOI 10.1046/j.1440-1711.2001.01041.x; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; delPozo V, 1997, J IMMUNOL, V158, P859; Dewson G, 1999, AM J RESP CELL MOL, V20, P720, DOI 10.1165/ajrcmb.20.4.3453; Dibbert B, 1998, BLOOD, V92, P778, DOI 10.1182/blood.V92.3.778.415k38_778_783; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Iijima H, 2001, AM J RESP CRIT CARE, V163, P1233, DOI 10.1164/ajrccm.163.5.2003145; Ing DJ, 1999, CIRC RES, V84, P21; Ingram AJ, 2000, AM J PHYSIOL-RENAL, V279, pF243, DOI 10.1152/ajprenal.2000.279.2.F243; Jang AS, 2000, THORAX, V55, P370, DOI 10.1136/thorax.55.5.370; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; Kankaanranta H, 2000, J ALLERGY CLIN IMMUN, V106, P77; Kharitonov SA, 1997, J ALLERGY CLIN IMMUN, V99, P58; KUO HP, 1994, EUR RESPIR J, V7, P1452, DOI 10.1183/09031936.94.07081452; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; MESSMER UK, 1994, FEBS LETT, V355, P23; Messmer UK, 1996, J BIOL CHEM, V271, P20192, DOI 10.1074/jbc.271.33.20192; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; *NAT HEART LUNG BL, 1998, GLOB IN ASTHM PRACT; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ochiai K, 1997, CLIN EXP IMMUNOL, V107, P198, DOI 10.1046/j.1365-2249.1997.d01-884.x; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Tsi CJ, 2002, MOL PHARMACOL, V62, P90, DOI 10.1124/mol.62.1.90; Underwood DC, 2000, J PHARMACOL EXP THER, V293, P281; Villunger A, 2000, J EXP MED, V192, P647, DOI 10.1084/jem.192.5.647; Wang CH, 1998, EUR RESPIR J, V11, P809, DOI 10.1183/09031936.98.11040809; Wang CH, 1999, J ALLERGY CLIN IMMUN, V104, P803, DOI 10.1016/S0091-6749(99)70291-5; Wyllie A H, 1980, Int Rev Cytol, V68, P251	46	12	20	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2003	112	4					761	767		10.1016/S0091-6749(03)02009-8	http://dx.doi.org/10.1016/S0091-6749(03)02009-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730LA	14564359				2022-12-18	WOS:000185831200017
J	Meliton, AY; Munoz, NM; Liu, J; Lambertino, AT; Boetticher, E; Myo, S; Myou, S; Zhu, XD; Johnson, M; Leff, AR				Meliton, AY; Munoz, NM; Liu, J; Lambertino, AT; Boetticher, E; Myo, S; Myou, S; Zhu, XD; Johnson, M; Leff, AR			Blockade of LTC4 synthesis caused by additive inhibition of gIV-PLA(2) phosphorylation: Effect of salmeterol and PDE4 inhibition in human eosinophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PDE4; beta(2)-agonist; eosinophils; gIV-PLA(2); cAMP; LTC4; arachidonic acid	PHOSPHODIESTERASE INHIBITORS; RESPIRATORY BURST; SECRETION; THEOPHYLLINE; SUPPRESSION; ACTIVATION; EXPRESSION; PROTEIN; ASTHMA; CELLS	Background: Prior investigations have demonstrated that beta2-adrenoceptor stimulation is ineffective in inhibiting synthesis of eicosanoids in human eosinophils. This effect has been postulated to relate to density or structural differences in the beta2-adrenoceptor or its coupled G-protein. However, recent reports indicate that cAMP-specific PDE4 activity in eosinophils is 10-fold that of other inflammatory cells. We postulated that selective blockade of PDE4 in eosinophils would unmask the inhibitory effect of beta2-adrenoceptor stimulation and that this inhibition would result from decreased phosphorylation of cytosolic group IV-PLA(2) (gIV-PLA(2)). Objective: To determine (a) whether PDE4 inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C-4 (LTC4) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus beta2-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC4 synthesis is regulated by cAMP. Methods: Human eosinophils were pretreated with buffer, salmeterol or rolipram (singly or combination) before FMLP/B activation. Release of AA and LTC4, intracellular cAMP concentration, and phospborylation and activation of gIV-PLA(2) were determined. Results: Rolipram unmasked the inhibitory effect of beta2-adrenoceptor stimulation with salmeterol and significantly attenuated the stimulated release of AA and subsequent LTC4. Inhibition corresponded to increased cAMP production caused by rolipram alone or rolipram plus salmeterol and blocked proportionately the phosphorylation and activation of gIV-PLA(2) in FMLP/B-activated eosinophils. Conclusions: Inhibition of PDE4 by rolipram unmasks beta2-adrenergic blockade of LTC4 synthesis caused by FMLP/B.	Univ Chicago, Dept Med, Pulm & Crit Care Med Sect, Chicago, IL 60637 USA; Univ Chicago, Dept Neurobiol, Chicago, IL 60637 USA; Univ Chicago, Dept Pharmacol & Physiol, Chicago, IL 60637 USA; Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; Univ Chicago, Dept Anesthesia, Chicago, IL 60637 USA; Univ Chicago, Dept Crit Care, Chicago, IL 60637 USA; Univ Chicago, Comm Clin Pharmacol, Chicago, IL 60637 USA; Univ Chicago, Comm Pharmacogenet, Chicago, IL 60637 USA; Univ Chicago, Comm Cell Physiol, Chicago, IL 60637 USA; Univ Chicago, Div Biol Sci, Chicago, IL 60637 USA; GlaxoSmithKline, Uxbridge, Middx, England	University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; GlaxoSmithKline	Leff, AR (corresponding author), Univ Chicago, Dept Med, Pulm & Crit Care Med Sect, MC6076,5841 S Maryland Ave, Chicago, IL 60637 USA.			zhu, xiangdong/0000-0002-5627-8082	NHLBI NIH HHS [HL-43638] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aoki M, 2001, J PHARMACOL EXP THER, V297, P165; Berends C, 1997, EUR RESPIR J, V10, P1000, DOI 10.1183/09031936.97.10051000; BROWN JK, 1982, AM REV RESPIR DIS, V126, P842; Cooper N, 1999, BRIT J PHARMACOL, V126, P1863, DOI 10.1038/sj.bjp.0702520; Crocker IC, 1996, IMMUNOPHARMACOLOGY, V31, P223, DOI 10.1016/0162-3109(95)00053-4; DENT G, 1994, J PHARMACOL EXP THER, V271, P1167; DENT G, 1994, AM J RESP CELL MOL, V10, P565, DOI 10.1165/ajrcmb.10.5.8179921; Essayan DM, 2001, J ALLERGY CLIN IMMUN, V108, P671, DOI 10.1067/mai.2001.119555; Ezeamuzie CI, 2001, EUR J PHARMACOL, V417, P11, DOI 10.1016/S0014-2999(01)00821-4; FONTEH AN, 1993, J IMMUNOL, V151, P339; Gantner F, 1997, J ALLERGY CLIN IMMUN, V100, P527, DOI 10.1016/S0091-6749(97)70146-5; Giembycz MA, 2000, DRUGS, V59, P193, DOI 10.2165/00003495-200059020-00004; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; Kim DH, 1998, BLOOD, V92, P2484, DOI 10.1182/blood.V92.7.2484.2484_2484_2494; Kim K, 1998, BIOCHEM PHARMACOL, V55, P975, DOI 10.1016/S0006-2952(97)00613-8; Leff AR, 1997, PULM PHARMACOL THER, V10, P97, DOI 10.1006/pupt.1997.0082; McGraw DW, 1997, J BIOL CHEM, V272, P7338, DOI 10.1074/jbc.272.11.7338; MUNOZ NM, 1995, J PHARMACOL EXP THER, V273, P850; Munoz NM, 2000, AM J PHYSIOL-LUNG C, V278, pL1172, DOI 10.1152/ajplung.2000.278.6.L1172; Myou S, 2001, NAT IMMUNOL, V2, P145, DOI 10.1038/84244; Ndukwu IM, 1999, AM J RESP CRIT CARE, V160, P1516, DOI 10.1164/ajrccm.160.5.9812126; Roumestan C, 2002, J ALLERGY CLIN IMMUN, V109, pS240, DOI 10.1016/S0091-6749(02)81866-8; SEMINARIO MC, 1994, CURR OPIN IMMUNOL, V6, P860, DOI 10.1016/0952-7915(94)90005-1; Tenor H, 1996, BRIT J PHARMACOL, V118, P1727, DOI 10.1111/j.1476-5381.1996.tb15598.x; TENOR H, 1995, CLIN EXP ALLERGY, V25, P625, DOI 10.1111/j.1365-2222.1995.tb01110.x; Zhu XD, 2001, J IMMUNOL, V167, P461, DOI 10.4049/jimmunol.167.1.461	27	12	12	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					404	410		10.1067/mai.2003.1637	http://dx.doi.org/10.1067/mai.2003.1637			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	709WY	12897749				2022-12-18	WOS:000184650600027
J	Masuyama, K; Morishima, Y; Ishii, Y; Nomura, A; Sakamoto, T; Kimura, T; Mochizuki, M; Uchida, Y; Sekizawa, K				Masuyama, K; Morishima, Y; Ishii, Y; Nomura, A; Sakamoto, T; Kimura, T; Mochizuki, M; Uchida, Y; Sekizawa, K			Sputum E-cadherin and asthma severity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ANTIGEN		Univ Tsukuba, Inst Clin Med, Dept Resp Med, Tsukuba, Ibaraki 3058575, Japan	University of Tsukuba	Masuyama, K (corresponding author), Univ Tsukuba, Inst Clin Med, Dept Resp Med, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058575, Japan.			Sakamoto, Tohru/0000-0002-8876-1466				Evans SM, 2002, AM J RESP CELL MOL, V27, P446, DOI 10.1165/rcmb.4776; FAHY JV, 1993, AM REV RESPIR DIS, V147, P1126, DOI 10.1164/ajrccm/147.5.1126; Goto Y, 2000, AM J RESP CELL MOL, V23, P712, DOI 10.1165/ajrcmb.23.6.4031; Louis R, 2000, AM J RESP CRIT CARE, V161, P9, DOI 10.1164/ajrccm.161.1.9802048; MATSUYOSHI N, 1995, BRIT J DERMATOL, V132, P745; *NHLBI WHO, 1995, PUBL NHLBI WHO	6	12	12	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					208	209		10.1067/mai.2003.1526	http://dx.doi.org/10.1067/mai.2003.1526			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847501				2022-12-18	WOS:000184010600032
J	Kessel, JM; Gern, JE; Vrtis, RF; Sedgwick, JB; Busse, WW				Kessel, JM; Gern, JE; Vrtis, RF; Sedgwick, JB; Busse, WW			Ligation of intercellular adhesion molecule 3 inhibits GM-CSF production by human eosinophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ICAM-3; eosinophils; adhesion molecules; cytokines; GM-CSF	COLONY-STIMULATING FACTOR; PERIPHERAL-BLOOD EOSINOPHILS; FACTOR MESSENGER-RNA; FUNCTION-ASSOCIATED ANTIGEN-1; CD50 MONOCLONAL-ANTIBODIES; ENDOTHELIAL-CELLS; ICAM-1 EXPRESSION; HUMAN NEUTROPHILS; DOWN-REGULATION; ACTIVATION	Background: Intercellular adhesion molecule 3 (ICAM-3) has recently been identified on the surface of eosinophils. Objective: The purpose of this study was to characterize ICAM-3 expression on eosinophils in response to cytokines and to determine whether ligand binding of ICAM-3 modulates inflammatory responses of eosinophils, as it does in other leukocytes. Methods: To determine effects of ICAM-3 on eosinophil function, we isolated human eosinophils and used a monoclonal antibody directed against the epitope of ICAM-3 that binds to leukocyte-function antigen-1 to mimic binding of ICAM-3 and this natural ligand. We measured granulocyte-macrophage colony stimulating factor (GM-CSF) production by unstimulated eosinaphils; and eosinaphils stimulated with ionomycin (1 mumol/L), both in the presence and absence of this anti-ICAM-3 antibody. Results: We found that 99% of eosinophils expressed ICAM-3, regardless of whether allergic symptoms were present or absent. Expression of ICAM-3 was not enhanced by proinflammatory cytokines. Expression of ICAM-3 was reduced in apoptotic cells and in cells incubated with the combination of GMCSF and tumor necrosis factor-alpha (n = 3). Antibody binding of ICAM-3, which mimics leukocyte-function antigen-1 binding, had no effect on baseline GM-CSF production but reduced by 80% the production of GM-CSF stimulated by ionomycin (control 1969 pg/mL +/- 1259 SD versus anti-ICAM-3 396 pg/mL +/- 207 SD, n = 8) and reduced GM-CSF mRNA content. Conclusions. ICAM-3 is highly expressed on the surface of human eosinophils, and downregulation of GM-CSF production by anti-ICAM-3 mAb suggests that ICAM-3 ligation may inhibit eosinophil inflammatory responses and survival.	Univ Wisconsin, Sch Med, Dept Pediat, Madison, WI USA; Univ Wisconsin, Sch Med, Dept Med, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Kessel, JM (corresponding author), Univ Wisconsin Hosp, H4-469 CSC,600 Highland Ave, Madison, WI 53792 USA.							ALAM R, 1994, J EXP MED, V179, P1041, DOI 10.1084/jem.179.3.1041; BOSSY D, 1995, EUR J IMMUNOL, V25, P459, DOI 10.1002/eji.1830250223; CAMPANERO MR, 1991, EUR J IMMUNOL, V21, P3045, DOI 10.1002/eji.1830211222; Champagne B, 1998, J IMMUNOL, V161, P6398; CID MC, 1994, EUR J IMMUNOL, V24, P1377, DOI 10.1002/eji.1830240621; CZECH W, 1993, J INVEST DERMATOL, V100, P417, DOI 10.1111/1523-1747.ep12472082; del Pozo MA, 1998, CELL ADHES COMMUN, V6, P125, DOI 10.3109/15419069809004468; DELPOZO MA, 1994, EUR J IMMUNOL, V24, P2586, DOI 10.1002/eji.1830241104; Douglas IS, 2000, J IMMUNOL, V164, P3385, DOI 10.4049/jimmunol.164.6.3385; Esnault S, 2001, J INTERF CYTOK RES, V21, P117, DOI 10.1089/107999001750069980; Esnault S, 1999, J IMMUNOL, V163, P5228; Esnault S, 2001, J IMMUNOL, V166, P4658, DOI 10.4049/jimmunol.166.7.4658; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; Feldhaus MJ, 1998, J IMMUNOL, V161, P6280; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; GEORAS SN, 1992, AM J RESP CELL MOL, V7, P261, DOI 10.1165/ajrcmb/7.3.261; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; HANSEL TT, 1992, J IMMUNOL, V149, P2130; Hart SP, 2000, CELL DEATH DIFFER, V7, P493, DOI 10.1038/sj.cdd.4400680; Hayflick JS, 1997, J BIOL CHEM, V272, P22207, DOI 10.1074/jbc.272.35.22207; Hayflick JS, 1998, IMMUNOL RES, V17, P313, DOI 10.1007/BF02786454; HOLNESS CL, 1995, J BIOL CHEM, V270, P877, DOI 10.1074/jbc.270.2.877; Hoontrakoon R, 2002, AM J RESP CELL MOL, V26, P404, DOI 10.1165/ajrcmb.26.4.4517; Horie S, 1997, IMMUNOLOGY, V90, P301, DOI 10.1046/j.1365-2567.1997.00146.x; Hubbard AK, 2000, FREE RADICAL BIO MED, V28, P1379, DOI 10.1016/S0891-5849(00)00223-9; Juan M, 1999, ALLERGY, V54, P1293, DOI 10.1034/j.1398-9995.1999.00251.x; Kessel JM, 1998, J IMMUNOL, V160, P5579; KITA H, 1991, J EXP MED, V174, P745, DOI 10.1084/jem.174.3.745; Littler AJ, 1997, BRIT J RHEUMATOL, V36, P164; Lopez-Briones S, 1998, CELL ADHES COMMUN, V6, P465, DOI 10.3109/15419069809010795; Mandeville J T, 1996, Curr Opin Hematol, V3, P63; MENGELERS HJ, 1994, AM J RESP CRIT CARE, V149, P345, DOI 10.1164/ajrccm.149.2.8306028; Moffatt OD, 1999, J IMMUNOL, V162, P6800; Nagata M, 1998, AM J RESP CELL MOL, V19, P158, DOI 10.1165/ajrcmb.19.1.3001; PINOOTIN MR, 1995, J IMMUNOL, V154, P3015; Ruth JH, 1999, AM J RESP CELL MOL, V21, P621, DOI 10.1165/ajrcmb.21.5.3694; Schleimer RP, 1998, CLIN EXP ALLERGY, V28, P15; SKUBITZ KM, 1995, J IMMUNOL, V154, P2888; Skubitz KM, 1997, J IMMUNOL, V159, P820; Stucki A, 2000, BRIT J HAEMATOL, V108, P157, DOI 10.1046/j.1365-2141.2000.01811.x; TAKANASKI S, 1994, J EXP MED, V180, P711, DOI 10.1084/jem.180.2.711; Takashi S, 2001, J APPL PHYSIOL, V91, P613, DOI 10.1152/jappl.2001.91.2.613; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; VAZEUX R, 1992, NATURE, V360, P485, DOI 10.1038/360485a0; Walsh GM, 1998, J IMMUNOL METHODS, V217, P153, DOI 10.1016/S0022-1759(98)00103-3; Woska JR, 1998, J BIOL CHEM, V273, P4725, DOI 10.1074/jbc.273.8.4725; Yamamoto H, 1998, J IMMUNOL, V161, P971; Yousefi S, 1997, INT ARCH ALLERGY IMM, V112, P9, DOI 10.1159/000237424	48	12	13	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					1024	1031		10.1067/mai.2003.1393	http://dx.doi.org/10.1067/mai.2003.1393			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743567				2022-12-18	WOS:000182904500017
J	Kelso, JM; Bardina, L; Beyer, K				Kelso, JM; Bardina, L; Beyer, K			Allergy to canned tuna	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FISH HYPERSENSITIVITY; IDENTIFICATION		USN, Med Ctr, Allergy Clin, San Diego, CA 92134 USA; Mt Sinai Med Ctr, Jaffe Food Allergy Inst, New York, NY 10029 USA	United States Department of Defense; United States Navy; Icahn School of Medicine at Mount Sinai	Kelso, JM (corresponding author), USN, Med Ctr, Allergy Clin, San Diego, CA 92134 USA.							BERNHISELBROADBENT J, 1992, J ALLERGY CLIN IMMUN, V89, P730, DOI 10.1016/0091-6749(92)90381-B; BERNHISELBROADBENT J, 1992, J ALLERGY CLIN IMMUN, V90, P622, DOI 10.1016/0091-6749(92)90135-O; Beyer K, 2002, J ALLERGY CLIN IMMUN, V110, P154, DOI 10.1067/mai.2002.125487; SERO R, 1998, ALLERGY, V53, P816; Yamada S, 1999, ANN ALLERG ASTHMA IM, V82, P395, DOI 10.1016/S1081-1206(10)63290-5	5	12	13	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					901	901		10.1067/mai.2003.1375	http://dx.doi.org/10.1067/mai.2003.1375			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	667WW	12704377				2022-12-18	WOS:000182258500037
J	Siltanen, M; Kajosaari, M; Savilahti, EM; Pohjavuori, M; Savilahti, E				Siltanen, M; Kajosaari, M; Savilahti, EM; Pohjavuori, M; Savilahti, E			IgG and IgA antibody levels to cow's milk are low at age 10 years in children born preterm	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food antigen; food antibodies; prematurity; atopy; allergy	PREMATURE-INFANTS; RESPONSES; FETAL; IMMUNIZATIONS; LACTOGLOBULIN; ABSORPTION; CHILDHOOD; SYMPTOMS; PROTEINS; DISEASE	Background: Both innate and specific defenses of the preterm infant are even less developed than those of term infants, and the immune systems of preterm infants might be skewed differently at birth. Their immune responses to food antigens started early in life might therefore differ from those of term infants. Objective: We sought to compare antibody levels to cow's milk, ovalbumin, and gliadin at age 10 years in children who had been born either preterm or at term. Methods: IgG and IgA isotype antibodies to whole cow's milk, beta-lactoglobulin, alpha-casein, and ovalbumin, as well as IgG antibody levels to gliadin and to tetanus and diphtheria toxoids, were measured for a group of 62 children born preterm and 61 control subjects born at term. These children were studied at the same time for atopy. Results: Children born preterm had markedly lower levels of antibodies to cow's milk and to its protein fractions (P < .0001 for IgA and IgG antibodies to cow's milk and alpha-casein and IgG beta-lactoglobulin. antibodies). IgG gliadin antibodies were also significantly lower in the preterm group (P = .03), although the difference was not significant for IgG ovalbumin antibodies. In the preterm group both those born before gestational week 30 and those given cow's milk-based formula early (before day 50) had the lowest levels of cow's milk antibodies. In the preterm group atopy was associated with low levels of IgG cow's milk antibodies but with high levels of IgG ovalbumin antibodies. Conclusions: Early introduction of food antigens into the immature gastrointestinal tract of preterm infants might result in tolerance. The presence of less atopy in these children might also be a result of tolerance development.	Univ Helsinki, Hosp Children & Adolescents, FIN-00029 Helsinki, Finland	University of Helsinki	Savilahti, E (corresponding author), Univ Helsinki, Hosp Children & Adolescents, POB 281, FIN-00029 Helsinki, Finland.							AXELSSON I, 1989, ACTA PAEDIATR SCAND, V78, P532, DOI 10.1111/j.1651-2227.1989.tb17932.x; BARNES RM, 1995, CLIN EXP ALLERGY, V1, P7; BERNBAUM J, 1984, CLIN PERINATOL, V11, P73, DOI 10.1016/S0095-5108(18)30937-0; BERNBAUM JC, 1985, J PEDIATR-US, V107, P184, DOI 10.1016/S0022-3476(85)80122-0; CONWAY S, 1993, J INFECTION, V27, P143, DOI 10.1016/0163-4453(93)94674-Z; Eysink PED, 1999, CLIN EXP ALLERGY, V29, P604, DOI 10.1046/j.1365-2222.1999.00554.x; Garside P, 2001, SEMIN IMMUNOL, V13, P177, DOI 10.1006/smim.2001.0310; HASUNEN K, 1996, SOSIAALI JA TERVEYSM, V2, P1; HATTEVIG G, 1984, CLIN ALLERGY, V14, P551, DOI 10.1111/j.1365-2222.1984.tb02243.x; Jenmalm MC, 1998, J ALLERGY CLIN IMMUN, V102, P671, DOI 10.1016/S0091-6749(98)70286-6; Jones AC, 1996, PEDIATR ALLERGY IMMU, V7, P109, DOI 10.1111/j.1399-3038.1996.tb00117.x; Jones CA, 2000, ALLERGY, V55, P2, DOI 10.1034/j.1398-9995.2000.00109.x; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Kolho KL, 1997, J PEDIATR GASTR NUTR, V24, P563, DOI 10.1097/00005176-199705000-00014; KUITUNEN OOM, 1994, PEDIATR RES, V35, P344, DOI 10.1203/00006450-199403000-00014; Prescott SL, 1998, J IMMUNOL, V160, P4730; SAUKKONEN T, 1994, DIABETES CARE, V17, P970, DOI 10.2337/diacare.17.9.970; Savilahti E, 1992, J PEDIATR, V121, pS12; Siltanen M, 2001, J ALLERGY CLIN IMMUN, V107, P229, DOI 10.1067/mai.2001.112128; TAINIO VM, 1988, ACTA PAEDIATR SCAND, V77, P807, DOI 10.1111/j.1651-2227.1988.tb10760.x; UDALL JN, 1990, J PEDIATR, V117, P33; Vaarala O, 1999, DIABETES NUTR METAB, V12, P75; Vaarala O, 1995, J ALLERGY CLIN IMMUN, V96, P917, DOI 10.1016/S0091-6749(95)70229-6; Williams TJ, 2000, J ALLERGY CLIN IMMUN, V105, P951, DOI 10.1067/mai.2000.106211	24	12	12	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2002	110	4					658	663		10.1067/mai.2002.128077	http://dx.doi.org/10.1067/mai.2002.128077			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	602JJ	12373277				2022-12-18	WOS:000178501900019
J	De Swert, LFA; Cadot, P; Ceuppens, JL				De Swert, LFA; Cadot, P; Ceuppens, JL			Allergy to cooked white potatoes in infants and young children: A cause of severe, chronic allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cooked potato; allergy; children; atopic dermatitis	FOOD ALLERGY; BIRCH POLLEN; IGE; IDENTIFICATION; DIAGNOSIS; VEGETABLES; FRUITS; APPLE	Background: Cases of allergy to cooked potato in children have been reported, some with immediate and others with late reactions. The clinical effects of chronic allergic reactions to potato and the effectiveness of diet on such reactions have not been described previously. Objective: We sought to evaluate the importance of cooked potato as an allergenic food in individual cases of atopy in children. Methods: Eight atopic children were selected on the basis of suspicion of allergy to cooked potatoes: all had potato-specific IgE, 2 of 8 had experienced immediate allergic reactions, and 6 of 8 had eczema that improved with a potato-elimination diet (decrease in severity scoring of atopic dermatis [SCORAD] index of >50%). The patients were evaluated by using skin prick tests with homemade cooked and noncooked potato extracts and with a commercial extract and by using IgE immunoblots from SDS-PAGE patterns of potato extract. Seven patients were challenged with cooked potato. The control group consisted of 9 age-matched atopic children, 8 of them with eczema. Results: The mean SCORAD index decreased from 43.3 before to 11.5 after elimination of potato from the diet. Potato CAP values ranged from 3.71 to greater than 100 kUa/L. Potato challenge results were positive in 7 of 7 patients. Skin prick test responses were positive for cooked potato extracts in 7 of 7 patients, for noncooked extracts in 7 of 7 patients, and for the commercial extract in 8 of 8 patients compared with in 0 of 9, 1 of 9, and I of 9 subjects in the control group, respectively. During immunoblotting, 8 of 8 patient sera recognized one or more protein bands compared with 0 of 9 control subject sera. Conclusion: Allergy to cooked potatoes is a cause of severe allergic disease, with immediate reactions and eczema in some atopic infants and young children.	Univ Hosp Gasthuisberg, Dept Pediat, B-3000 Louvain, Belgium; Univ Hosp Gasthuisberg, Expt Immunol Lab, B-3000 Louvain, Belgium; Univ Hosp Gasthuisberg, Div Clin Immunol & Allergy, B-3000 Louvain, Belgium	KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven	De Swert, LFA (corresponding author), Univ Hosp Gasthuisberg, Dept Pediat, Herestr 49, B-3000 Louvain, Belgium.			Ceuppens, Jan/0000-0003-4502-2679				Beausoleil JL, 2001, ANN ALLERG ASTHMA IM, V86, P68, DOI 10.1016/S1081-1206(10)62359-9; BIRCHER AJ, 1994, CLIN EXP ALLERGY, V24, P367, DOI 10.1111/j.1365-2222.1994.tb00248.x; Bock SA, 2000, J PEDIATR GASTR NUTR, V30, pS20, DOI 10.1097/00005176-200001001-00004; CALKHOVEN PG, 1987, ALLERGY, V42, P382, DOI 10.1111/j.1398-9995.1987.tb02225.x; CASTELLS MC, 1986, J ALLERGY CLIN IMMUN, V78, P1110, DOI 10.1016/0091-6749(86)90258-7; Delgado J, 1996, CONTACT DERMATITIS, V35, P179, DOI 10.1111/j.1600-0536.1996.tb02342.x; DESWERT LFA, 2000, 17 INT C ALL CLIN IM; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; Eigenmann PA, 2000, PEDIATR ALLERGY IMMU, V11, P95, DOI 10.1034/j.1399-3038.2000.00071.x; Juhlin-Dannfelt C., 1948, ACTA MED SCAND, V26, P563; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGNARIN M, 1995, J ALLERGY CLIN IMMUN, V96, P200, DOI 10.1016/S0091-6749(95)70009-9; Majamaa H, 2001, PEDIAT ALLERG IMM-UK, V12, P283, DOI 10.1034/j.1399-3038.2001.00096.x; Muraro MA, 2001, PEDIAT ALLERG IMM-UK, V12, P31, DOI 10.1034/j.1399-3038.2001.121407.x; Niggemann B, 1994, Pediatr Allergy Immunol, V5, P11, DOI 10.1111/j.1399-3038.1994.tb00212.x; NIINIMAKI A, 1987, CONTACT DERMATITIS, V16, P11, DOI 10.1111/j.1600-0536.1987.tb02609.x; Pascual CY, 2000, EUR J CLIN NUTR, V54, pS75, DOI 10.1038/sj.ejcn.1600990; PEARSON RSB, 1966, ACTA ALLERGOL, V21, P507, DOI 10.1111/j.1398-9995.1966.tb03170.x; QUIRCE S, 1989, ALLERGY, V44, P532, DOI 10.1111/j.1398-9995.1989.tb04197.x; RUDESCHKO O, 1995, ALLERGY, V50, P262, DOI 10.1111/j.1398-9995.1995.tb01144.x; SAMPSON HA, 1988, J ALLERGY CLIN IMMUN, V81, P635, DOI 10.1016/0091-6749(88)91033-0; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Seppala U, 1999, J ALLERGY CLIN IMMUN, V103, P165, DOI 10.1016/S0091-6749(99)70541-5; Seppala U, 2001, ALLERGY, V56, P619, DOI 10.1034/j.1398-9995.2001.00058.x; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; WAHL R, 1990, INT ARCH ALLER A IMM, V92, P168, DOI 10.1159/000235209	28	12	13	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					524	529		10.1067/mai.2002.127435	http://dx.doi.org/10.1067/mai.2002.127435			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	592KM	12209106				2022-12-18	WOS:000177936900029
J	Asmus, MJ; Hendeles, L; Weinberger, M; Ahrens, RC; Bisgaard, H; Lotvall, J; O'Byrne, PM; Cockcroft, DW				Asmus, MJ; Hendeles, L; Weinberger, M; Ahrens, RC; Bisgaard, H; Lotvall, J; O'Byrne, PM; Cockcroft, DW			Levalbuterol has not been established to have therapeutic advantage over racemic albuterol	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SALBUTAMOL; PLACEBO		Univ Florida, Gainesville, FL 32611 USA; Univ Iowa, Iowa City, IA USA; Copenhagen Univ Hosp, Copenhagen, Denmark; Univ Gothenburg, Gothenburg, Sweden; McMaster Univ, Hamilton, ON, Canada; Univ Saskatchewan, Saskatoon, SK, Canada	State University System of Florida; University of Florida; University of Iowa; University of Copenhagen; University of Gothenburg; McMaster University; University of Saskatchewan	Asmus, MJ (corresponding author), Univ Florida, Gainesville, FL 32611 USA.		Asmus, Michael J/U-8654-2019; Kronow, Joern/B-1054-2011; Asmus, Michael/N-4016-2018; Weinberger, Miles/H-6743-2019; Bisgaard, Hans/N-4761-2016	Asmus, Michael J/0000-0002-5939-7802; Asmus, Michael/0000-0002-5939-7802; Bisgaard, Hans/0000-0003-4131-7592; Lotvall, Jan/0000-0001-9195-9249; O'Byrne, Paul/0000-0003-0979-281X				Cockcroft DW, 1997, THORAX, V52, P845, DOI 10.1136/thx.52.10.845; Cockcroft DW, 1999, J ALLERGY CLIN IMMUN, V103, P1049, DOI 10.1016/S0091-6749(99)70178-8; Lipworth BJ, 1997, THORAX, V52, P849, DOI 10.1136/thx.52.10.849; Lotvall J, 2001, J ALLERGY CLIN IMMUN, V108, P726; Milgrom H, 2001, J ALLERGY CLIN IMMUN, V108, P938, DOI 10.1067/mai.2001.120134; Ramsay CM, 1999, EUR J CLIN PHARMACOL, V55, P353, DOI 10.1007/s002280050640	6	12	12	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2					325	325	UNSP 1/8/126375	10.1067/mai.2002.126375	http://dx.doi.org/10.1067/mai.2002.126375			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	585DY	12170277				2022-12-18	WOS:000177509800021
J	Bhatia, S; Mukhopadhyay, S; Jarman, E; Hall, G; George, A; Basu, SK; Rath, S; Lamb, JR; Bal, V				Bhatia, S; Mukhopadhyay, S; Jarman, E; Hall, G; George, A; Basu, SK; Rath, S; Lamb, JR; Bal, V			Scavenger receptor-specific allergen delivery elicits IFN-gamma-dominated immunity and directs established T(H)2-dominated responses to a nonallergic phenotype	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; T(H)1/T(H)2; immunotherapy; scavenger receptor; immunomodulator; eosinophils; skin hypersensitivity	CYTOKINE GENE-EXPRESSION; DUST MITE ALLERGEN; T-CELL RESPONSES; PEPTIDE LIGAND; IN-VITRO; P-II; MODULATION; EPITOPES; DIFFERENTIATION; INDUCTION	Background: Immunotherapeutic approaches to allergy consist of reliably changing allergen-specific T(H)2 immunity associated with secretion of IL-4, IL-5, and IL-13, along with IgE antibodies in atopic individuals to T(H)1 immunity. Our earlier data show that targeting of protein antigens to antigen-pre+ senting cells (APCs), such as macrophages, by means of scavenger receptors (SRs) results in a pronounced T(H)1 immunity. Here we demonstrate a novel experimental approach Fur the conversion of T(H)2 immunity to T(H)1 immunity by using SR delivery of allergens. Objectives: We sought to show that targeting of allergens by means of SRs to APCs triggers TO immunity and that an established T(H)2 immunity to the Der p 1-immunodominant peptide 111-139 (p1, 111-139) can be modulated to a nonallergic T(H)1 phenotype. Methods: Analysis of the T cell-derived cytokines IL-4, IL-5, IL-13, and IFN-gamma in response to p1, 111-139 in C57BL/6 mice 7 to 42 days after immunization, measurement of specific antibody responses, eosinophilic infiltrate, and skin hypersensitivity in response to allergen challenge constitute the parameters of in vivo immunity. Results: We show that p1, 111-139, when delivered to APCs by means of SR, elicits a T(H)1-dominant immunity. If it is delivered to APCs either after chemical coupling to SR ligands or by means of mere coadsorption on alum in the presence of an SR ligand, the established T(H)2 immunity can be modified to T(H)1 immunity. Conclusions: SR-mediated delivery of allergens has immunotherapeutic potential that may be usable in atopic individuals.	Natl Inst Immunol, New Delhi 110067, India; Univ Edinburgh, MRC, Ctr Inflammat Res, Immunobiol Grp, Edinburgh, Midlothian, Scotland; Univ Edinburgh, MRC, Ctr Inflammat Res, Resp Med Unit, Edinburgh, Midlothian, Scotland	Department of Biotechnology (DBT) India; National Institute of Immunology (NII); University of Edinburgh; University of Edinburgh	Bal, V (corresponding author), Natl Inst Immunol, Aruna Asaf Ali Rd, New Delhi 110067, India.			Mukhopadhyay, Sangita/0000-0002-5511-3315				ABRAHAM R, 1995, J IMMUNOL, V154, P1; Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P124, DOI 10.1159/000235102; Das AM, 1999, CLIN EXP IMMUNOL, V117, P223, DOI 10.1046/j.1365-2249.1999.00978.x; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; FIRESTEIN GS, 1989, J IMMUNOL, V143, P518; Fitzpatrick DR, 1998, J EXP MED, V188, P103, DOI 10.1084/jem.188.1.103; Harris SJ, 1997, INT IMMUNOL, V9, P273, DOI 10.1093/intimm/9.2.273; HIGGINS JA, 1994, J ALLERGY CLIN IMMUN, V93, P891, DOI 10.1016/0091-6749(94)90383-2; Hoyne G, 1996, CLIN IMMUNOL IMMUNOP, V80, pS23, DOI 10.1006/clin.1996.0138; HOYNE GF, 1993, IMMUNOLOGY, V78, P65; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; Jahn-Schmid B, 1997, INT IMMUNOL, V9, P1867, DOI 10.1093/intimm/9.12.1867; Jarman ER, 2000, J ALLERGY CLIN IMMUN, V105, P967, DOI 10.1067/mai.2000.105320; Linton MF, 2001, CURR OPIN LIPIDOL, V12, P489, DOI 10.1097/00041433-200110000-00003; LU P, 1994, J EXP MED, V180, P69; MAJUMDAR S, 1991, ANTIMICROB AGENTS CH, V35, P135, DOI 10.1128/AAC.35.1.135; MANETTI R, 1994, J EXP MED, V179, P1273, DOI 10.1084/jem.179.4.1273; Miyamasu M, 1999, INT IMMUNOL, V11, P1001, DOI 10.1093/intimm/11.6.1001; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Murphy KM, 2000, ANNU REV IMMUNOL, V18, P451, DOI 10.1146/annurev.immunol.18.1.451; NICHOLSON LB, 1995, IMMUNITY, V3, P397, DOI 10.1016/1074-7613(95)90169-8; PEREZ VL, 1995, INT IMMUNOL, V7, P869, DOI 10.1093/intimm/7.5.869; PFEIFFER C, 1995, J EXP MED, V181, P1569, DOI 10.1084/jem.181.4.1569; Rolland J, 1998, CURR OPIN IMMUNOL, V10, P640, DOI 10.1016/S0952-7915(98)80082-4; Singh N, 1998, J IMMUNOL, V160, P4869; Srividya S, 2000, BIOCHEM BIOPH RES CO, V268, P772, DOI 10.1006/bbrc.2000.2216; STREET NE, 1990, J IMMUNOL, V144, P1629; Tao X, 1997, J IMMUNOL, V158, P4237; Teixeira MM, 1998, J IMMUNOL, V161, P2516; WINDHAGEN A, 1995, IMMUNITY, V2, P373, DOI 10.1016/1074-7613(95)90145-0; Wurtzen PA, 1999, J ALLERGY CLIN IMMUN, V104, P115, DOI 10.1016/S0091-6749(99)70122-3; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	33	12	13	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2002	109	2					321	328		10.1067/mai.2002.121143	http://dx.doi.org/10.1067/mai.2002.121143			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	528EZ	11842304				2022-12-18	WOS:000174232600019
J	Bakakos, P; Smith, JL; Warner, JO; Vance, G; Moss, CT; Hodges, E; Lanham, S; Howell, WM				Bakakos, P; Smith, JL; Warner, JO; Vance, G; Moss, CT; Hodges, E; Lanham, S; Howell, WM			Modification of T-cell receptor V beta repertoire in response to allergen stimulation in peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ARA H-II; PERIPHERAL-BLOOD; ATOPIC-DERMATITIS; HLA GENES; FOOD; IDENTIFICATION; EXTRACTS; CHILDREN; HUMANS; USAGE	Background: Peanut is one of the most common foods causing allergic reactions and is the most common cause of fatal and near-fatal food-related anaphylaxis, Little is known of the immunologic mechanisms that underlie peanut allergy. Objectives: In this study we examined clonality of the T-cell response (TCR) to peanut in MHC class II identical, peanut allergy-discordant sibling pairs. Methods: Four sibling pairs were investigated. The TCR repertoire was analyzed before and after in vitro stimulation of PBMCs with crude peanut or PHA, as control for general/nonspecific reactivity. Eighteen TCR-V beta families were examined by flow cytometry, Where significant differences in incidence of particular TCR-V beta families were observed, PCR family-specific cDNA amplification and gene scanning were performed. Results: After stimulation with peanut, no selective expansion of any TCR-V beta subpopulation was observed with now cytometry, in either the peanut-allergic or nonallergic siblings, with the exception of 1 peanut-allergic subject who demonstrated a significant increase of TCR-V beta 11(+) cells (0.34-5.9% of the total CD3(+) cells). However, gene scanning revealed predominant single-size PCR products for TCRBV11 in all peanut-allergic subjects after peanut stimulation. TCRSV11 polyclonality was observed in allergic and nonallergic subjects before peanut stimulation and in nonallergic subjects after peanut stimulation. In comparison, all subjects, before and after stimulation with peanut, showed polyclonality for TCRBV2. Conclusions: Our results argue for clonal or oligoclonal TCRs to crude peanut and indicate that changes in the TCRSV11 subpopulation are restricted to peanut-allergic subjects after stimulation with crude peanut allergen.	Univ Southampton, Sch Med, Resp Cell & Mol Biol Res Div, Southampton SO9 5NH, Hants, England; Southampton Gen Hosp, Mol Immunol Grp, Southampton SO16 6YD, Hants, England; Univ Southampton, Sch Med, Resp Cell & Mol Biol Res Div, Southampton, Hants, England	University of Southampton; University of Southampton; University of Southampton	Warner, JO (corresponding author), Southampton Gen Hosp, Mol Immunol Grp, Mailpoint 810,Level G,Ctr Block, Southampton SO16 6YD, Hants, England.		Warner, John/AAF-9587-2020					AKOLKAR PN, 1993, J IMMUNOL, V150, P2761; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BOCK SA, 1977, CLIN ALLERGY, V7, P375, DOI 10.1111/j.1365-2222.1977.tb01466.x; BURKS AW, 1994, INT ARCH ALLERGY IMM, V105, P143; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; deJong EC, 1996, J ALLERGY CLIN IMMUN, V98, P73, DOI 10.1016/S0091-6749(96)70228-2; DORION BJ, 1994, J ALLERGY CLIN IMMUN, V93, P93, DOI 10.1016/0091-6749(94)90237-2; DORION BJ, 1995, PEDIATR ALLERGY IMMU, V6, P95, DOI 10.1111/j.1399-3038.1995.tb00266.x; GULWANIAKOLKAR B, 1995, J IMMUNOL, V154, P3843; HIGGINS JA, 1995, IMMUNOLOGY, V84, P91; Hodges E, 1998, CLIN EXP IMMUNOL, V112, P363; Hourihane JO, 1998, CLIN EXP ALLERGY, V28, P163, DOI 10.1046/j.1365-2222.1998.00213.x; Howell WM, 1998, CLIN EXP ALLERGY, V28, P156, DOI 10.1046/j.1365-2222.1998.00224.x; KEATING MU, 1990, J ALLERGY CLIN IMMUN, V86, P41, DOI 10.1016/S0091-6749(05)80121-6; LOVERIDGE JA, 1991, IMMUNOLOGY, V74, P246; MARSH DG, 1992, 11TH P INT HIST WORK, V1, P765; POSNETT DN, 1994, J EXP MED, V179, P609, DOI 10.1084/jem.179.2.609; REED EF, 1994, HUM IMMUNOL, V40, P111, DOI 10.1016/0198-8859(94)90055-8; SAMPSON HA, 1992, J ALLERGY CLIN IMMUN, V90, P151, DOI 10.1016/0091-6749(92)90065-A; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Wahlstrom J, 1998, CLIN EXP IMMUNOL, V112, P1; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	23	12	12	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2001	107	6					1089	1094		10.1067/mai.2001.114651	http://dx.doi.org/10.1067/mai.2001.114651			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	445JR	11398090				2022-12-18	WOS:000169454800024
J	Mitsunobu, F; Mifune, T; Hosaki, Y; Ashida, K; Tsugeno, H; Okamoto, M; Takata, S; Tanizaki, Y				Mitsunobu, F; Mifune, T; Hosaki, Y; Ashida, K; Tsugeno, H; Okamoto, M; Takata, S; Tanizaki, Y			Enhanced production of leukotrienes by peripheral leukocytes and specific IgE antibodies in patients with chronic obstructive pulmonary disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						COPD; IgE-mediated allergy; LTB4; LTC4; bronchial hyperresponsiveness	CHRONIC-BRONCHITIS; AIRWAY INFLAMMATION; INDUCED SPUTUM; HUMAN EOSINOPHILS; T-LYMPHOCYTES; SERUM IGE; ASTHMA; RELEASE; EXACERBATIONS; SMOKERS	Background: How leukotrienes (LTs) and IgE-mediated allergy reflect clinical features in patients with chronic obstructive pulmonary disease (COPD) remains unclear. Objective: Our goal was to determine whether LTB4 and LTC4 would correlate with airway obstruction and whether IgE-mediated allergy would influence the generation of LTs and bronchial hyperresponsiveness in patients with COPD. Methods: We measured the pulmonary function, methacholine bronchial hyperresponsiveness, and generation of LTB4 and LTC4 from peripheral leukocytes stimulated with calcium ionophore A23187 in relation to the presence of specific IgE antibodies against inhalant allergens. Results: The leukocytes of patients with COPD generated significantly more LTB4 (with allergy, P < .001; without allergy, P < .001) and LTC4 (with allergy, P < .001; without allergy, P < .01) than the leukocytes of the control subjects. LTC4 production was significantly higher in the allergic COPD subjects than in the nonallergic COPD patients (P < .01), but the amount of LTB4 generated was not significantly different. FEV1 significantly correlated with the level of both LTB4 (with allergy, r = -0.556, P = .0375; without allergy; r = -0.731, P = .0046) and LTC4 (with allergy, r = -0.764, P = .0043; without allergy, r = -0.526, P = .0414) generation in COPD. The log(10) of the minimum dose of methacholine was significantly higher in COPD patients without allergy than in those with allergy (P < .05). Conclusion: Enhanced LT generation from peripheral leukocytes is observed in patients with COPD, and the presence of specific IgE antibodies against inhalant allergens enhances LTC4 generation, bronchial hyperresponsiveness, and the relationship between LTC4 generation and airway obstruction.	Okayama Univ, Sch Med, Dept Med, Misasa Med Branch, Misasa, Tottori 6820192, Japan	Okayama University	Mitsunobu, F (corresponding author), Okayama Univ, Sch Med, Dept Med, Misasa Med Branch, 827 Yamada, Misasa, Tottori 6820192, Japan.		MITSUNOBU, Fumihiro/B-1983-2011					BARNES NC, 1984, THORAX, V39, P500, DOI 10.1136/thx.39.7.500; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; Coyle AJ, 1996, J EXP MED, V183, P1303, DOI 10.1084/jem.183.4.1303; Crooks SW, 2000, EUR RESPIR J, V15, P274, DOI 10.1034/j.1399-3003.2000.15b09.x; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DRAZEN JM, 1980, P NATL ACAD SCI USA, V77, P4345; Eder C, 2000, VET IMMUNOL IMMUNOP, V73, P241, DOI 10.1016/S0165-2427(00)00154-9; FAHY JV, 1993, AM REV RESPIR DIS, V147, P1126, DOI 10.1164/ajrccm/147.5.1126; Fujimura M, 1998, EUR RESPIR J, V11, P306, DOI 10.1183/09031936.98.11020306; Grashoff WFH, 1997, AM J PATHOL, V151, P1785; Hill AT, 1999, AM J RESP CRIT CARE, V160, P893, DOI 10.1164/ajrccm.160.3.9901091; *JAP SOC CHEST DIS, 1993, JPN J THORAC DIS, P31; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530, DOI 10.1164/ajrccm.153.2.8564092; KIRBY JG, 1987, AM REV RESPIR DIS, V136, P379, DOI 10.1164/ajrccm/136.2.379; Kjaergard LL, 1996, APMIS, V104, P61, DOI 10.1111/j.1699-0463.1996.tb00687.x; LACOSTE JY, 1993, J ALLERGY CLIN IMMUN, V92, P537, DOI 10.1016/0091-6749(93)90078-T; LAM S, 1988, J ALLERGY CLIN IMMUN, V81, P711, DOI 10.1016/0091-6749(88)91043-3; LINDEN M, 1993, AM REV RESPIR DIS, V148, P1226, DOI 10.1164/ajrccm/148.5.1226; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; OShaughnessy TC, 1997, AM J RESP CRIT CARE, V155, P852, DOI 10.1164/ajrccm.155.3.9117016; OWEN WF, 1987, J IMMUNOL, V138, P532; Peters-Golden M, 1998, CLIN EXP ALLERGY, V28, P1059; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; REED CE, 1994, ANN ALLERGY, V72, P376; Renkema TEJ, 1998, CLIN EXP ALLERGY, V28, P1210; Ronchi MC, 1996, THORAX, V51, P1000, DOI 10.1136/thx.51.10.1000; Saetta M, 1998, AM J RESP CRIT CARE, V157, P822, DOI 10.1164/ajrccm.157.3.9709027; SAETTA M, 1994, AM J RESP CRIT CARE, V150, P1646, DOI 10.1164/ajrccm.150.6.7952628; Saetta M, 1997, AM J RESP CRIT CARE, V156, P1633, DOI 10.1164/ajrccm.156.5.9701081; SCHAUER U, 1989, INT ARCH ALLER A IMM, V90, P201, DOI 10.1159/000235025; Schmidt D, 2000, CLIN EXP ALLERGY, V30, P233; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274; SEGGEV JS, 1991, CHEST, V99, P289, DOI 10.1378/chest.99.2.289; SHAW RJ, 1984, CLIN EXP IMMUNOL, V56, P716; Shindo K, 1997, PROSTAG LEUKOTR ESS, V56, P213, DOI 10.1016/S0952-3278(97)90537-8; TAKISHIMA T, 1981, CHEST, V80, P600, DOI 10.1378/chest.80.5.600; TANIZAKI Y, 1993, INT ARCH ALLERGY IMM, V101, P196, DOI 10.1159/000236519; THOMPSON AB, 1989, AM REV RESPIR DIS, V140, P1527, DOI 10.1164/ajrccm/140.6.1527; Underwood DC, 1996, AM J RESP CRIT CARE, V154, P850, DOI 10.1164/ajrccm.154.4.8887574; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626	40	12	12	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3					492	498		10.1067/mai.2001.112694	http://dx.doi.org/10.1067/mai.2001.112694			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	416RE	11240950				2022-12-18	WOS:000167793300011
J	Schweiger, A; Stern, D; Lohman, IC; Baldini, M; Martinez, FD; Halonen, M				Schweiger, A; Stern, D; Lohman, IC; Baldini, M; Martinez, FD; Halonen, M			Differences in proliferation of the hematopoietic cell line TF-1 and cytokine production by peripheral blood leukocytes induced by 2 naturally occurring forms of human IL-3	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-3; polymorphism; priming; leukotrienes; TNF-alpha; IgE; proliferation; IL-3 receptor	COLONY-STIMULATING FACTOR; RECOMBINANT HUMAN INTERLEUKIN-3; TUMOR-NECROSIS-FACTOR; GRANULOCYTE; MACROPHAGES; BASOPHIL; RELEASE; GENE; CHROMOSOME-5; MONOCYTES	Background: A naturally occurring polymorphism in the coding region of the human IL3 gene leads to a change in amino acid residue 8 from proline to serine. Objective: We sought to determine whether the 2 different forms of IL-3 varied in function. These different forms are available as recombinant proteins (recombinant human IL-3/proline 8 [rhIL-3/P8] and recombinant human IL-3/serine 8 [rhIL-3/S8]). Methods: The erythroleukemic cell line TF-1 was incubated with varying concentrations of rhIL-3/P8 or rhIL-3/S8 to determine the capacity of each type of IL-3 to induce proliferation. Human leukocytes were primed with rhIL-3/P8 or rhIL-3/S8 for up to 24 hours and then stimulated with anti-IgE and assessed for leukotrienes (LTs), IL-4, and TNF-alpha. Results: Proliferation of TF-1 cells was induced by both forms of IL-3 at 48 and 72 hours but to a greater degree by rhIL-3/P8, In contrast, the mean fold increase over control values of LT and IL-4 production was higher after priming the cells with rhIL-3/S8 versus rhIL-3/P8. Additionally, TNF-alpha production was greater (and reached significance only) for rhIL-3/S8. This activity was independent of IgE and thus directly stimulated by IL-3. Studies with basophil-enriched and basophil-depleted cell preparations revealed that LT production was evident only from the former and TNF-alpha only from the latter. Conclusion: We conclude that the 2 naturally occurring forms of human IL-3 have similar spectra of activities on cells with IL-3 receptors, but the 2 forms have reversed relative efficacies for promoting proliferation (rhIL-3/P8 > rhIL-3/S8) compared with priming or inducing mediator secretion (rhIL-3/S8 > rhIL-3/P8).	Univ Arizona, Resp Sci Ctr, Tucson, AZ 85724 USA; Univ Arizona, Dept Pediat, Tucson, AZ 85724 USA; Univ Arizona, Dept Pharmacol, Tucson, AZ 85724 USA	University of Arizona; University of Arizona; University of Arizona	Halonen, M (corresponding author), Univ Arizona, Resp Sci Ctr, 1501 N Campbell,Room 2342, Tucson, AZ 85724 USA.			Halonen, Marilyn/0000-0001-9606-935X	NHLBI NIH HHS [HL 311340, HL 310500, HL 334130] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CANNISTRA SA, 1988, BLOOD, V71, P672; CHEN BDM, 1986, J IMMUNOL, V137, P563; COHEN L, 1991, IMMUNOL LETT, V28, P121, DOI 10.1016/0165-2478(91)90109-N; DIMRI R, 1994, LYMPHOKINE CYTOK RES, V13, P239; ELLIOTT MJ, 1989, BLOOD, V74, P2349; Feng YQ, 1997, PROTEIN SCI, V6, P1777, DOI 10.1002/pro.5560060821; Jeong MC, 1998, MOL CELL PROBE, V12, P49, DOI 10.1006/mcpr.1997.0148; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; Klein BK, 1997, J BIOL CHEM, V272, P22630, DOI 10.1074/jbc.272.36.22630; LEARY AG, 1988, BLOOD, V71, P1759; LEBEAU MM, 1987, P NATL ACAD SCI USA, V84, P5913; LOPEZ AF, 1988, BLOOD, V72, P1797; MACGLASHAN DW, 1986, J IMMUNOL, V136, P2231; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; OHNO I, 1990, AM J RESP CELL MOL, V3, P285, DOI 10.1165/ajrcmb/3.4.285; Palmeri S, 1999, HAEMATOLOGICA, V84, P1016; ROSENWASSER LJ, 1995, CLIN EXP ALLERGY, V25, P74, DOI 10.1111/j.1365-2222.1995.tb00428.x; SCHLEIMER RP, 1989, J IMMUNOL, V143, P1310; SCHLEIMER RP, 1990, AM REV RESPIR DIS S, V141, P59; SCHROEDER JT, 1995, ALLERGY, V50, P463, DOI 10.1111/j.1398-9995.1995.tb01180.x; STEFFEN M, 1989, IMMUNOLOGY, V66, P445; THOMAS JW, 1995, P NATL ACAD SCI USA, V92, P3779, DOI 10.1073/pnas.92.9.3779; WALTER MR, 1992, J MOL BIOL, V224, P1075, DOI 10.1016/0022-2836(92)90470-5; WARNER JA, 1989, J LEUKOCYTE BIOL, V45, P558, DOI 10.1002/jlb.45.6.558; Yang Y. C., 1988, LYMPHOKINES, V15, P375; [No title captured]	26	12	12	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3					505	510		10.1067/mai.2001.113239	http://dx.doi.org/10.1067/mai.2001.113239			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	416RE	11240952	Bronze			2022-12-18	WOS:000167793300013
J	Malmstrom, K; Hampel, FC; Philip, G; Malice, MP; Reiss, TF				Malmstrom, K; Hampel, FC; Philip, G; Malice, MP; Reiss, TF		Montelukast Spring Rhinitis Invest	Montelukast in the treatment of spring allergic rhinitis in a large, double-blind, randomized, placebo-controlled study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									Merck & Co Inc, Rahway, NJ 07065 USA; Cent Texas Hlth Res, New Braunfels, TX USA	Merck & Company									0	12	12	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2		S		519	S157	S157						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	405RE					2022-12-18	WOS:000167172300517
J	Uter, W; Geier, J; Fuchs, T				Uter, W; Geier, J; Fuchs, T		IVDK study grp	Contact allergy to polidocanol, 1992 to 1999	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DERMATITIS		Univ Gottingen, IVDK, Dept Dermatol, Allergy Unit, Gottingen, Germany	University of Gottingen	Uter, W (corresponding author), Univ Gottingen, IVDK, Dept Dermatol, Allergy Unit, Gottingen, Germany.			Uter, Wolfgang/0000-0002-4498-3710				ALE SI, 1995, DERMATOS BER UMWELT, V43, P119; FROSCH PJ, 1989, HAUTARZT, V40, P146; Uter W, 1998, EUR J DERMATOL, V8, P36	3	12	12	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2000	106	6					1203	1204						2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	384ER	11112911				2022-12-18	WOS:000165930300030
J	Leigh, R; Belda, J; Kelly, MM; Cox, G; Squillace, DL; Gleich, GJ; Hargreave, FE				Leigh, R; Belda, J; Kelly, MM; Cox, G; Squillace, DL; Gleich, GJ; Hargreave, FE			Eosinophil cationic protein relates to sputum neutrophil counts in healthy subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sputum; neutrophils			McMaster Univ, St Josephs Hosp, Dept Med, Asthma Res Grp, Hamilton, ON, Canada; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, NY USA; Mayo Clin & Mayo Fdn, Dept Med, Rochester, NY USA	McGill University; McMaster University; Mayo Clinic; Mayo Clinic	Leigh, R (corresponding author), McMaster Univ, St Josephs Hosp, Dept Med, Asthma Res Grp, Hamilton, ON, Canada.		Kelly, Margaret M/G-4128-2012	Kelly, Margaret M/0000-0002-1629-3210	NIAID NIH HHS [AI 34577, AI 09728] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI034577, R01AI009728, R37AI009728, U01AI034577] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Belda J, 2000, AM J RESP CRIT CARE, V161, P475, DOI 10.1164/ajrccm.161.2.9903097; Pizzichini E, 1998, AM J RESP CRIT CARE, V158, P1511, DOI 10.1164/ajrccm.158.5.9804028; PIZZICHINI E, 1996, AM J RESP CRIT CARE, V154, P808; Squillace DL, 2000, J ALLERGY CLIN IMMUN, V105, pS257, DOI 10.1016/S0091-6749(00)91193-X; Sur S, 1998, J LEUKOCYTE BIOL, V63, P715, DOI 10.1002/jlb.63.6.715	5	12	12	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3					593	594						2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	356YN	10984384				2022-12-18	WOS:000089471900027
J	Katsunuma, T; Fujita, K; Mak, JCW; Barnes, PJ; Ueno, K; Iikura, Y				Katsunuma, T; Fujita, K; Mak, JCW; Barnes, PJ; Ueno, K; Iikura, Y			beta-Adrenergic agonists and bronchial hyperreactivity: Role of beta(2)-adrenergic and tachykinin neurokinin-2 receptors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Meeting on New Trends in Immunopharmacology 1998	JUL   25, 1998	TOKYO, JAPAN			asthma; B-2-adrenergic receptor; neurokinin-2 receptor	GUINEA-PIGS; INDUCED BRONCHOCONSTRICTION; SMOOTH-MUSCLE; ASTHMA; RESPONSIVENESS; INHIBITION; EXPRESSION; SALBUTAMOL; FENOTEROL	Background: beta(2)-Adrenergic agonists are the most widely used bronchodilators for the treatment of asthma, On the other hand, there is concern that excessive use of beta(2)-agonists may contribute to the exacerbation of asthma. However, the mechanism of such adverse effects of beta(2)-agonists is not completely clear. Objective: The aim of this study was to assess the direct influence of beta(2)-agonists on airways by analyzing the effect of a beta(2)-agonist, fenoterol, on airway sensitivity in an animal model and on tachykinin neurokinin-2 receptor expression in bovine tracheal smooth muscle. Methods: We performed an acetylcholine challenge test on ovalbumin sensitized guinea pigs that were exposed to daily inhalation of ovalbumin and fenoterol. We also investigated the effects of fenoterol on neurokinin-2 receptor messenger RNA and density with Northern blot analysis and receptor binding assay. Result: The increase of airway responsiveness and the decrease of beta(2)-adrenergic receptors mere found in guinea pigs that mere treated with fenoterol. There were time- and dose-dependent increases of neurokinin-2 receptor mRNA and of density in tracheal smooth muscle that was treated with fenoterol. Conclusion: This increased airway responsiveness, increased neurokinin-2 receptor expression, and decreased beta(2)-adrenergic receptor density may be relevant to asthma exacerbation.	Showa Univ, Sch Med, Dept Pediat, Shinagawa Ku, Tokyo 1428666, Japan; Natl Childrens Hosp, Dept Allergy, Tokyo 154, Japan; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Thorac Med, London, England	Showa University; National Center for Child Health & Development - Japan; Imperial College London	Iikura, Y (corresponding author), Showa Univ, Sch Med, Dept Pediat, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428666, Japan.			Katsunuma, Toshio/0000-0003-2646-3006; Barnes, Peter/0000-0002-5122-4018; Mak, Judith/0000-0002-8234-1313				BERTRAND C, 1993, AM J PHYSIOL, V265, pL507, DOI 10.1152/ajplung.1993.265.5.L507; CHEUNG D, 1992, AM REV RESPIR DIS, V145, P1275, DOI 10.1164/ajrccm/145.6.1275; CHIBA Y, 1995, J APPL PHYSIOL, V78, P394, DOI 10.1152/jappl.1995.78.2.394; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHUNG KF, 1993, J ROY SOC MED, V86, P96; CRIMI N, 1994, CLIN EXP ALLERGY, V24, P115, DOI 10.1111/j.1365-2222.1994.tb00206.x; Kandus J, 1992, Vnitr Lek, V38, P808; Katsunuma T, 1999, AM J RESP CELL MOL, V21, P409, DOI 10.1165/ajrcmb.21.3.3662; Katsunuma T, 1998, EUR J PHARMACOL, V344, P99, DOI 10.1016/S0014-2999(97)01562-8; KIELY DG, 1995, THORAX, V50, P1062, DOI 10.1136/thx.50.10.1062; Kraneveld AD, 1997, AM J RESP CRIT CARE, V156, P367, DOI 10.1164/ajrccm.156.2.9608101; LEOPOLD W, 1990, KINDERARZTL PRAX, V58, P503; LEWIS LD, 1990, AUST NZ J MED, V20, P204, DOI 10.1111/j.1445-5994.1990.tb01019.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NALINE E, 1994, EUR RESPIR J, V7, P914; PACK RJ, 1994, INT J EXP PATHOL, V75, P357; SOLWAY J, 1993, J CLIN INVEST, V92, P315, DOI 10.1172/JCI116569; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; SUISSA S, 1994, AM J RESP CRIT CARE, V149, P604, DOI 10.1164/ajrccm.149.3.8118625; VATHENEN AS, 1988, LANCET, V1, P554	21	12	12	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	2	S			S104	S108		10.1067/mai.2000.106636	http://dx.doi.org/10.1067/mai.2000.106636			5	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	339NF	10887342				2022-12-18	WOS:000088482600015
J	Kaneko, M; Schimming, A; Gleich, GJ; Kita, H				Kaneko, M; Schimming, A; Gleich, GJ; Kita, H			Ligation of IgE receptors causes an anaphylactic response and neutrophil infiltration but does not induce eosinophilic inflammation in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hypersensitivity; inflammation; mast cells; IgE; allergen	LATE-PHASE REACTION; FC-EPSILON-RI; MAST-CELL; AIRWAY HYPERRESPONSIVENESS; IMMUNOGLOBULIN (IG)-E; ASTHMATIC REACTIONS; LYMPHOCYTES-T; LUNG DAMAGE; MOUSE; HYPERREACTIVITY	Background: Eosinophils are selectively recruited into the tissues during chronic allergic inflammation. IgE is considered an initiator of the allergic reaction; however, the roles of IgE in allergic inflammation are not fully understood. Objective: We tested the hypothesis that antigen interaction with specific IgE antibody provokes eosinophilic inflammation. Methods: BALB/c mice mere actively sensitized dth ragweed extract and passively sensitized with anti-dinitrophenyl (anti-DNP) mouse IgE and challenged intraperitoneally by injecting either ragweed extract or DNP-ovalbumin (OVA). Immediate anaphylactic responses mere examined by monitoring vascular permeability and by measuring histamine content in peritoneal lavage fluids. Late-phase allergic responses were examined by total cell counts and cell differentials. Results: Mice sensitized and challenged with ragweed showed immediate anaphylactic responses followed by temporal increases in neutrophils at 3 to 12 hours and sustained increases in eosinophils in their peritoneal cavities after 24 hours. Double-sensitized mice (ie, sensitized actively for ragweed and passively for DNP-OVA) challenged with ragweed showed immediate anaphylactic responses and peritoneal eosinophilia at 48 hours. Double-sensitized mice challenged with DNP-OVA showed comparable immediate anaphylactic responses but no peritoneal eosinophilia. Furthermore, at 8 hours, ragweed-challenged animals recruited both eosinophils and neutrophils, but DNP-OVA-challenged animals recruited only neutrophils. Finally, after active sensitization and challenge with ragweed, mast cell-deficient mice (WBB6F1-W/W-v) lacked the immediate response but showed comparable eosinophil accumulation as their litter mate controls (WBB6F1-+/+). Conclusion: Interaction of antigen dth IgE antibody is insufficient to provoke eosinophilic inflammation in mice.	Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Grad Sch, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Grad Sch, Dept Internal Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Kita, H (corresponding author), Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Internal Med, 200 1st St SW, Rochester, MN 55905 USA.				NIAID NIH HHS [AI 34486, AI 34577] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034486, R56AI034486, R01AI034486, U19AI034577, U01AI034577] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500, DOI 10.1164/ajrccm/146.2.500; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; BUTCHER BT, 1986, J ALLERGY CLIN IMMUN, V78, P547, DOI 10.1016/0091-6749(86)90068-0; BUTTERFIELD JH, 1994, SAMTERS IMMUNOLOGIC, V1, P501; Coyle AJ, 1996, J EXP MED, V183, P1303, DOI 10.1084/jem.183.4.1303; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DURHAM SR, 1984, NEW ENGL J MED, V311, P1398, DOI 10.1056/NEJM198411293112202; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; Good A., 1980, SELECTED METHODS CEL, P343; Hogan SP, 1997, J CLIN INVEST, V99, P1329, DOI 10.1172/JCI119292; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KANEKO M, 1991, INT ARCH ALLER A IMM, V96, P41, DOI 10.1159/000235532; KITAMURA Y, 1978, BLOOD, V52, P447; LEIFERMAN KM, 1990, LAB INVEST, V62, P579; Maurer D, 1996, J IMMUNOL, V157, P607; MAUSER PJ, 1995, AM J RESP CRIT CARE, V152, P467, DOI 10.1164/ajrccm.152.2.7633694; Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344; NAKAJIMA H, 1992, AM REV RESPIR DIS, V146, P374, DOI 10.1164/ajrccm/146.2.374; Oshiba A, 1996, J CLIN INVEST, V97, P1398, DOI 10.1172/JCI118560; OTT NL, 1994, J ALLERGY CLIN IMMUN, V94, P120, DOI 10.1016/0091-6749(94)90078-7; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; VANOOSTERHOUT AJM, 1993, AM REV RESPIR DIS, V147, P548, DOI 10.1164/ajrccm/147.3.548; WATANABE K, 1984, J PHARMACOL METHOD, V11, P167; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; WERSHIL BK, 1992, J EXP MED, V175, P245, DOI 10.1084/jem.175.1.245; WERSHIL BK, 1995, J IMMUNOL, V154, P1391; ZETTERSTROM O, 1978, CLIN ALLERGY, V8, P77, DOI 10.1111/j.1365-2222.1978.tb00452.x	34	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	1				1202	1210		10.1067/mai.2000.106731	http://dx.doi.org/10.1067/mai.2000.106731			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	327EX	10856156				2022-12-18	WOS:000087781800023
J	Jarman, ER; Perschke, K; Montermann, E; Herz, U; Renz, H; Knop, J; Reske-Kunz, AB				Jarman, ER; Perschke, K; Montermann, E; Herz, U; Renz, H; Knop, J; Reske-Kunz, AB			Deficient cytokine response of human allergen-specific T lymphocytes from humanized SCID mice and reconstitution by professional antigen-presenting cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; anergy; hu-PBL-SCID; IgE	SEVERE COMBINED IMMUNODEFICIENCY; BLOOD MONONUCLEAR-CELLS; HUMAN IMMUNE-SYSTEM; MOUSE; IGE; TOLERANCE; CHIMERAS; IL-2	Background: Hu-PBL-SCID mice generated by the transfer of PBMCs from atopic individuals may provide a physiologic in vivo model for investigating human responses to allergens and potential approaches toward immunotherapy. Objective: This study was undertaken to investigate the functional activity and cytokine profile of human allergen-reactive T lymphocytes isolated from hu-PBL-SCID mice. Methods: PBMCs from allergic individuals vc ere coinjected with allergen into SCID mice. Human lymphocyte migration and phenotype were established by reverse transcription-PCR and immunohistochemistry; IgE levels in sera were determined, and the frequency of allergen-reactive cytokine-producing T lymphocytes was established. Results: After immunization with allergen, specific IgE levels in hu-PBL-SCID sera were comparable with levels in donor sera. Although the majority of lymphocytes remained in the peritoneum, significant numbers of T lymphocytes were located in the spleen, where human IL-4, IL-5, and IFN-gamma messenger RNA expression was detected after stimulation with PHA and phorbol myristate acetate, Failure to induce cytokine production by human T lymphocytes isolated from the peritoneum and spleen of hu-PBL-SCID mice by allergen was reversed by stimulating with allergen in the presence of exogenously added IL-2 and antigen-presenting cells (APC), particularly CD14(+) monocytes. Under these conditions, allergen-reactive T cells expressed a T(H)2-like phenotype. Conclusions: These data suggest that, after initial activation and induction of antibody production, human T lymphocytes enter a state of unresponsiveness, arising from a loss of human professional APC, in hu-PBL-SCID mice. The use of hu-PBL-SCID mouse models in studies on therapeutic approaches for allergy may benefit from the additional transfer of human professional APC.	Univ Mainz, Dept Dermatol, Clin Res Unit, D-6500 Mainz, Germany; Charite, Inst Lab Med & Pathobiochem, Berlin, Germany	Johannes Gutenberg University of Mainz; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Reske-Kunz, AB (corresponding author), DMG, Dept Dermatol, Clin Res Unit, Obere Zahlbacher Str 63, D-55131 Mainz, Germany.							Akdis CA, 1996, J CLIN INVEST, V98, P1676, DOI 10.1172/JCI118963; ARMSTRONG N, 1992, CLIN EXP IMMUNOL, V90, P476; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; DEL PG, 1988, J IMMUNOL, V140, P4193; ESSERY G, 1988, IMMUNOLOGY, V64, P413; Faith A, 1997, J IMMUNOL, V159, P53; FASLER S, 1995, J IMMUNOL, V155, P4199; GAGNON R, 1995, J ALLERGY CLIN IMMUN, V95, P1268, DOI 10.1016/S0091-6749(95)70085-4; Herr W, 1997, J IMMUNOL METHODS, V203, P141, DOI 10.1016/S0022-1759(97)00019-7; Herz U, 1998, J INVEST DERMATOL, V110, P224, DOI 10.1046/j.1523-1747.1998.00119.x; KAPSENBERG ML, 1991, IMMUNOL TODAY, V12, P392, DOI 10.1016/0167-5699(91)90137-I; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; MURPHY WJ, 1992, EUR J IMMUNOL, V22, P1421, DOI 10.1002/eji.1830220614; PESTEL J, 1994, J IMMUNOL, V153, P3804; RENZ H, 1992, J INVEST DERMATOL, V99, P403, DOI 10.1111/1523-1747.ep12616114; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROSS R, 1995, PCR METH APPL, V4, P371; SPIEGELBERG HL, 1994, J CLIN INVEST, V93, P711, DOI 10.1172/JCI117024; TARYLEHMANN M, 1995, IMMUNOL TODAY, V16, P529, DOI 10.1016/0167-5699(95)80046-8; TARYLEHMANN M, 1994, J EXP MED, V180, P1817, DOI 10.1084/jem.180.5.1817	22	12	12	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2000	105	5					967	974		10.1067/mai.2000.105320	http://dx.doi.org/10.1067/mai.2000.105320			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	316TW	10808178				2022-12-18	WOS:000087185000016
J	Codina, R; Ardusso, L; Lockey, RF; Crisci, C; Bertoya, N				Codina, R; Ardusso, L; Lockey, RF; Crisci, C; Bertoya, N			Sensitization to soybean hull allergens in subjects exposed to different levels of soybean dust inhalation in Argentina	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							SOY BEAN WORKERS; EPIDEMIC ASTHMA	Background: Soybean hulls (SHs) have been identified as the source of aeroallergens responsible for soybean asthma outbreaks. However, the prevalence of sensitization to SH allergens in subjects from Argentina, a country where soy beans are produced, is unknown. Objective: The purpose of this study was to determine the prevalence of sensitization to SH by in vivo and in vitro tests in subjects with asthma or allergic rhinitis and in control subjects from Argentina who have been exposed to different levels of soybean dust inhalation (SDI), Methods: Exposure to SDI is defined as follows: (1) direct = occupational, (2) indirect = proximity to soybean fields or grain elevators, and (3) urban = urbanized areas without a known source of SDI, Two groups were studied. Group 1 consisted of 365 subjects with asthma or allergic rhinitis and group 2 (control group) of 50 healthy individuals. Subjects from both groups were classified according to their exposure to SDI, All subjects completed standard questionnaires. Prick skin tests (STs) with an SH extract and with common allergens were performed on all subjects. Specific IgE and IgG4 to SH were measured in sera of 51 of 56 subjects from group 1 who had a positive ST to SH and in all sera from group 2. Results: Fifty-six (15.3%) subjects from group 1 and no subjects from group 2 had a positive ST to SH (wheal SH/wheal histamine greater than or equal to 0.5). In group 1, positive STs to SH were 38.7%, 20.3%, and 8.2% in subjects with direct, indirect, and urban exposures, respectively (P < .001). Monosensitization to SH is absent in all subjects from group 1, The percent of subjects with positive STs to mites, pollen, and molds was highest in those with a positive ST to SH versus those with a negative ST to SH (P < .01), Asthmatic patients with a positive ST to SH, compared with those exclusively sensitized to mites, had a higher frequency of daily or weekly symptoms (59.4% vs 25.7%, respectively, P < .001) and a higher percent of glucocorticoid dependence (52.8% vs 34%, respectively, P < .01). Percent positive IgE in group 1 and group 2 were 39.2% and 10% (P < .001) and percents positive IgG 1 are 27.4 % and 12%, respectively (not significant). In subjects from group 1 and group 2 with direct exposure percents positive IgE are 58.3% and 13.3% (P < .001) and percents positive IgG4 were 75% and 20%, respectively (P < .02). IgG4 in group I was significantly higher in subjects with direct exposure compared with subjects with indirect or urban exposure. Conclusion: This study demonstrated that there was (1) a high prevalence of sensitivity to SII in subjects with asthma or allergic rhinitis from Argentina and (2) an association between sensitivity to SII and severity of asthma and level of exposure to SDI.	Univ S Florida, Dept Med, Div Allergy & Immunol, Tampa, FL 33612 USA; James A Haley Vet Adm Hosp, Tampa, FL USA; Univ Nacl Rosario, Dept Pathol, Div Pulmonol Allergy & Immunol, RA-2000 Rosario, Argentina	State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; National University of Rosario	Codina, R (corresponding author), Univ S Florida, Dept Med, Div Allergy & Immunol, 13000 Bruce B Downs Blvd,VAR 111D, Tampa, FL 33612 USA.							BUSH RK, 1977, CLIN ALLERGY, V7, P369, DOI 10.1111/j.1365-2222.1977.tb01465.x; Codina R, 1998, J ALLERGY CLIN IMMUN, V102, P318, DOI 10.1016/S0091-6749(98)70102-2; Codina R, 1998, INT ARCH ALLERGY IMM, V117, P120, DOI 10.1159/000023998; Codina RM, 1997, CHEST, V111, P75, DOI 10.1378/chest.111.1.75; DUKE W. W., 1934, JOUR ALLERGY, V5, P300, DOI 10.1016/S0021-8707(34)90228-8; FARRANT JP, 1978, AM IND HYG ASSOC J, V39, P177; Garcia-Ortega P, 1998, MED CLIN-BARCELONA, V110, P731; GOLBITZ P, 1999, SOYA OILSEED BLUEBOO, P329; GONZALEZ R, 1991, INT ARCH ALLER A IMM, V95, P53, DOI 10.1159/000235454; JAEN C, 1999, P 18 ANN M EAAACI 19; MORELL F, 1995, J ALLERGY CLIN IMMUN, V96, P320, DOI 10.1016/S0091-6749(95)70050-1; OLSEN AM, 1934, P STAFF M MAYO CLIN, V11, P465; PETERS GA, 1965, ANN ALLERGY, V23, P270; Snapper Clifford M., 1993, P837; Soriano JB, 1997, AM J RESP CRIT CARE, V156, P1394, DOI 10.1164/ajrccm.156.5.9701064; SUNYER J, 1989, LANCET, V1, P179; SUNYER J, 1992, AM REV RESPIR DIS, V145, P1096; WHITE MC, 1997, AM J EPIDEMIOL, V145, P1; WIGHTMAN HENRY B., 1938, JOUR ALLERGY, V9, P601, DOI 10.1016/S0021-8707(38)90308-9; ZUSKIN E, 1988, AM J IND MED, V14, P157, DOI 10.1002/ajim.4700140206; ZUSKIN E, 1991, INT ARCH OCC ENV HEA, V63, P15, DOI 10.1007/BF00406192	21	12	12	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2000	105	3					570	576		10.1067/mai.2000.103824	http://dx.doi.org/10.1067/mai.2000.103824			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	347UC	10719309				2022-12-18	WOS:000088946700025
J	Slater, JE; Pastor, RW				Slater, JE; Pastor, RW			The determination of equivalent doses of standardized allergen vaccines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; allergen extract; immunotherapy; standardization; allergy	RAGWEED IMMUNOTHERAPY; HAY-FEVER; EXTRACTS; POTENCY; INJECTION; EFFICACY	Background: Standardized allergen vaccines are tested for potency by manufacturers by using assays proposed in their license applications and approved by the Center for Biologics Evaluation and Research, which reviews and verifies the test results before lot release, The current lot-release limits for mite and grass pollen allergen vaccines impose statistical equivalence to the national reference extract; thus the limits are primarily based on assay variability, Objective: We sought to establish a clinical basis for lot-release limits for the relative potency of allergen vaccines and to evaluate alternative specifications. Methods: We performed literature selection and review, linear and logistic regression analyses of selected studies, and analysis of lots submitted to the Food and Drug Administration for approval since 1995, Results: Therapeutic equivalence is achieved over a 10-fold range of allergen concentration. Safety equivalence is more difficult to assign, but on the basis of injection data, a 4-fold increase in allergen concentration is associated with a 5% to 10% increase in adverse reaction rates. The SD in log relative potency for the submitted allergenic products was determined to be 0.090 for grasses and 0.061 for mites, compared with 0.079 for competition ELISA, Conclusions: Current lot-release limits are well within literature-based estimates of therapeutic, diagnostic, and safety equivalence ranges for the clinical use of allergen vaccines. In addition, the aggregate consistency of the submitted products is comparable with the precision of the assay that is used to assess the products. These results support expanded release limits for verification of relative potency, provided the submitted lots of material remain at their present level of consistency.	US FDA, CBER, DBPAP,Div Allergen Prod & Parasitol, Lab Immunobiochem, Rockville, MD 20852 USA; US FDA, CBER, Div Allergen Prod & Parasitol, Biophys Lab, Rockville, MD 20852 USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Slater, JE (corresponding author), US FDA, CBER, DBPAP,Div Allergen Prod & Parasitol, Lab Immunobiochem, 1401 Rockville Pike,HFM-422, Rockville, MD 20852 USA.							BAER H, 1974, J ALLERGY CLIN IMMUN, V54, P157, DOI 10.1016/0091-6749(74)90052-9; BAER H, 1970, J ALLERGY, V45, P347, DOI 10.1016/0021-8707(70)90043-2; Bernstein IL, 1995, ANN ALLERG ASTHMA IM, V75, P543; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; CRETICOS PS, 1984, J ALLERGY CLIN IMMUN, V73, P94, DOI 10.1016/0091-6749(84)90490-1; CRETICOS PS, 1989, J ALLERGY CLIN IMMUN, V84, P197, DOI 10.1016/0091-6749(89)90325-4; DEGROOT MH, 1975, PROBALITY STAT; FRANKLIN R, 1975, J ALLERGY CLIN IMMUN, V55, P285, DOI 10.1016/0091-6749(75)90001-9; FURIN MJ, 1991, J ALLERGY CLIN IMMUN, V88, P27, DOI 10.1016/0091-6749(91)90297-2; GLEICH GJ, 1976, J ALLERGY CLIN IMMUN, V58, P31, DOI 10.1016/0091-6749(76)90104-4; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; HAUGAARD L, 1993, J ALLERGY CLIN IMMUN, V91, P709, DOI 10.1016/0091-6749(93)90190-Q; HEDLIN G, 1989, J ALLERGY CLIN IMMUN, V84, P390, DOI 10.1016/0091-6749(89)90426-0; JUNG CM, 1995, J ALLERGY CLIN IMMUN, V95, P77, DOI 10.1016/S0091-6749(95)70155-9; LIN Y, 1997, P EHRLICH I BUNDESAM, V91, P127; TURKELTAUB PC, 1990, ALLERGY, V45, P528, DOI 10.1111/j.1398-9995.1990.tb00529.x; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; TURKELTAUB PC, 1989, ALLERGOL IMMUNOPATH, V17, P53; TURKELTAUB PC, 1997, P EHRLICH I BUNDESAM, V91, P145; VANMETRE TE, 1982, J ALLERGY CLIN IMMUN, V69, P181, DOI 10.1016/0091-6749(82)90098-7; Weber RW, 1997, JAMA-J AM MED ASSOC, V278, P1881, DOI 10.1001/jama.278.22.1881; Woolson RF, 1987, STAT METHODS ANAL BI	24	12	12	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2000	105	3					468	474		10.1067/mai.2000.104551	http://dx.doi.org/10.1067/mai.2000.104551			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	347UC	10719295				2022-12-18	WOS:000088946700011
J	Irvin, CG				Irvin, CG			Interaction between the growing lung and asthma: Role of early intervention	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; childhood; glucocorticoid steroids; lung function; lung growth and development; gender	NATURAL-HISTORY; CHILDREN; GROWTH; CHILDHOOD; SEX	Asthma is a syndrome where an imbalance exists between the forces that maintain airway patency and the forces that act to narrow, or close, airways. The child with asthma is a particular problem because of the rapid growth of the lung during growth that leaves it vulnerable. There is some evidence that asthma leads to impaired lung function in children because those children with untreated asthma show a loss of lung growth velocity, For unclear reasons, asthma Is more frequent in boys, What drugs to use to treat childhood asthma is uncertain. Data show that glucocorticoids prevent the structure of the lung from fully developing. In children, the rationale for early intervention seems clear, but the exact means and criteria for initiation of the intervention are uncertain. Finally, childhood asthma raises fundamental issues and questions that are unique to the child with asthma and presents unique and many unresolved treatment dilemmas.	Univ Vermont, Vermont Lung Ctr, Burlington, VT USA	University of Vermont	Irvin, CG (corresponding author), Fletcher Allen Hlth Care, Dept Med, Room 282 Shepardson, Burlington, VT 05405 USA.							ABERG N, 1990, ACTA PAEDIATR SCAND, V79, P206, DOI 10.1111/j.1651-2227.1990.tb11440.x; ADAMSON IYR, 1986, LAB INVEST, V55, P145; AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; BRYAN AC, 1986, HDB PHYSL 3, V0003, P00179; CLIFFORD RD, 1989, ARCH DIS CHILD, V64, P1118, DOI 10.1136/adc.64.8.1118; EGGLESTON PA, 1995, ASTHMA RHINITIS, P1380; ELLIS EF, 1993, ALLERGY PRINCIPLES P, P1225; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; Gergen PT, 1995, ASTHMA RHINITIS, P15; HENDELES L, 1992, J PEDIATR-US, V120, P177, DOI 10.1016/S0022-3476(05)80423-8; IRVIN CG, 1996, RESP CARE, V41, P507; KAMINSKY DA, 1995, AM J RESP CRIT CARE, V152, P1784, DOI 10.1164/ajrccm.152.6.8520737; Kaminsky DA, 1997, AM J RESP CRIT CARE, V155, P1260, DOI 10.1164/ajrccm.155.4.9105064; KOTAS RV, 1974, PEDIATRICS, V53, P358; KOTAS RV, 1980, AM REV RESPIR DIS, V121, P377; LARSEN GL, 1992, NEW ENGL J MED, V326, P1540; LARSEN GL, 1996, SEVERE ASTHMA PATHOG, P77; MARTIN AJ, 1980, AM REV RESPIR DIS, V122, P609; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Milgrom H, 1996, J ALLERGY CLIN IMMUN, V98, P1051, DOI 10.1016/S0091-6749(96)80190-4; MURRAY AB, 1983, PEDIATRICS, V71, P418; *NIH, 1992, NAT I HEAT LUNB BLOO; NINAN TK, 1992, ARCH DIS CHILD, V67, P703, DOI 10.1136/adc.67.6.703; PEDERSEN S, 1992, ASTHMA BASIC MECH CL, P701; REID LM, 1984, BRIT J DIS CHEST, V78, P113, DOI 10.1016/0007-0971(84)90111-6; SPORIK R, 1991, ARCH DIS CHILD, V66, P1050, DOI 10.1136/adc.66.9.1050; STEMPEL DA, 1996, SEVERE ASTHMA PATHOG, P371; SWEEZEY N, 1995, PEDIATR RES, V38, P506, DOI 10.1203/00006450-199510000-00006; THURLBECK WM, 1982, THORAX, V37, P564, DOI 10.1136/thx.37.8.564; TORDAY JS, 1987, EXP LUNG RES, V12, P1, DOI 10.3109/01902148709068811; TSCHANZ SA, 1995, BIOL NEONATE, V68, P229; VAN AP, 1990, J ALLERGY CLIN IMMUN, V85, P790; WILSON NM, 1995, EUR RESPIR J, V8, P369; WITTENBORG MH, 1967, RADIOLOGY, V88, P653, DOI 10.1148/88.4.653	34	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	2	S			S540	S546		10.1016/S0091-6749(00)90058-7	http://dx.doi.org/10.1016/S0091-6749(00)90058-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286JG	10669539				2022-12-18	WOS:000085439600016
J	Canitez, Y; Sapan, N				Canitez, Y; Sapan, N			The prevalences of asthma, allergic rhinitis, and eczema in Bursa,Turkey: An ISAAC study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									Uludag Univ, Fac Med, Div Pediat Allergy, Bursa, Turkey	Uludag University									0	12	13	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	2	S		933	S318	S318		10.1016/S0091-6749(00)91361-7	http://dx.doi.org/10.1016/S0091-6749(00)91361-7			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	287WR					2022-12-18	WOS:000085530100929
J	Brindley, A				Brindley, A			The chlorofluorocarbon to hydrofluoroalkane transition: The effect on pressurized metered dose inhaler suspension stability	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						metered dose inhaler; formulation; suspension; stability hydrofluoroalkane		The phase out of chlorofluorocarbon (CFC) propellants has necessitated the reformulation of pressurized metered dose inhalers (pMDIs) with hydrofluoroalkane (HFA) propellants. One of the main challenges has been that conventional surfactants used for CFC-based pMDIs were not soluble in HFAs, Since one of the main aims of a pMDI is to deliver a reproducible dose of medication to the patient, it is vital that, for suspension-type pMDI formulations, the suspension is stabilized sufficiently for a reproducible dose to be delivered. A new technique has been developed that measures suspension stability more objectively than before. This technique, optical suspension characterization, was used to compare the performance of different formulations of respiratory drugs in HFAs. The optical suspension characterization data were correlated with conventional analytic techniques for the determination of the stability of the suspension formulation.	AstraZeneca R&D Charnwood, Loughborough LE11 5RH, Leics, England	AstraZeneca	Brindley, A (corresponding author), AstraZeneca R&D Charnwood, Bakewell Rd, Loughborough LE11 5RH, Leics, England.							Hallworth G. W., 1987, DRUG DELIVERY RESP T, P87; JINKS PA, 1995, P DRUG DELIVERY LUNG, V6, P10; Purewal TS, 1998, METERED DOSE INHALER TECHNOLOGY, P9; SMITH IJ, 1995, J AEROSOL MED, V8, pS19; United Nations, 1989, MONTR PROT SUBST DEP	5	12	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					S221	S226		10.1016/S0091-6749(99)70034-5	http://dx.doi.org/10.1016/S0091-6749(99)70034-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10588978				2022-12-18	WOS:000084289200034
J	Asero, R				Asero, R			Chronic generalized pruritus caused by nitrate intolerance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							URTICARIA		Osped Caduti Bollatesi, I-20021 Bollate, MI, Italy		Asero, R (corresponding author), Osped Caduti Bollatesi, Via Piave 20, I-20021 Bollate, MI, Italy.							FITZPATRICK TB, 1980, PRINCIPLES INTERNAL, P247; GREAVES MW, 1995, NEW ENGL J MED, V332, P1767, DOI 10.1056/NEJM199506293322608; JUHLIN L, 1981, BRIT J DERMATOL, V104, P369, DOI 10.1111/j.1365-2133.1981.tb15306.x; KAPLAN AP, 1993, ALLERGY PRINCIPLES P, P1553; MONERETVAUTRIN DA, 1980, ANN NUTR ALIMENT, V34, P1125; Simon RA, 1993, ALLERGY PRINCIPLES P, P1687; ZANUSSI C, 1983, ANN ALLERGY, V51, P307	7	12	12	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1999	104	5					1110	1111		10.1016/S0091-6749(99)70098-9	http://dx.doi.org/10.1016/S0091-6749(99)70098-9			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	257JH	10550762	Bronze			2022-12-18	WOS:000083778400041
J	Strunk, RC; Nicklas, RA; Milgrom, H; Ikle, D				Strunk, RC; Nicklas, RA; Milgrom, H; Ikle, D			Fatal and near-fatal asthma questionnaire: Prelude to a national registry	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma mortality; fatal asthma; near-fatal asthma; questionnaire; rapidity of asthma progression; severe asthma; risk factors; asthma medications	VOCAL CORD DYSFUNCTION; NEW-ZEALAND; AFRICAN-AMERICANS; DISTINCT ENTITY; SUDDEN-DEATH; MORTALITY; TRENDS; MORBIDITY; EXPERIENCE; MEDICATION	Background: Asthma mortality rates continue to be unacceptably high in the United States. As a follow-up to the initiatives proposed by the Asthma Mortality Task Force in 1987, the Committee on Asthma Mortality of the American Academy of Allergy, Asthma, and Immunology developed a questionnaire on fatal and near-fatal asthma, Objective: This study assessed completeness of answers from participating physicians and described characteristics of patients with fatal and near-fatal asthma, Methods: There were 111 survey items intended to characterize patients with fatal or near-fatal exacerbations of asthma, The questionnaire was sent to the members of the American Academy of Allergy, Asthma, and Immunology (approximately 3900), and a total of 143 usable questionnaires were received. Results: Responding physicians had information on most items in the questionnaire; the mean number of responses was 120 of 143 possible, with a median of 128 and a range of 40 to 143, Patient demographics, description of the event, identification of overall risk for the event, use of medications, acid characteristics of asthma management had the most complete responses (median response rates were 126-143), Presence of factors contributing to the event had fewer responses (range, 44-125), The physicians frequently had information on some psychologic characteristics (eg, 108 responses for depression and/or hopelessness and 127 responses for social support) but less information on several others (eg, 62 responses for family dysfunction). Statistical analysis of the completed surveys indicated that only 2 characteristics distinguished fatal from near-fatal asthma: progression in minutes (adjusted odds ratio, 4.89; 95% confidence interval, 2.05-12.90) and absence of a past history of intubation (adjusted odds ratio, 3.55; 95% confidence interval, 1.55-8.97), Conclusions: There is a need to gather further data on patients with fatal and near-fatal events to design appropriate prospective studies on asthma morbidity and mortality rates. Physicians can contribute important information about these patients. Gathering such data would be enhanced by establishing a national registry on fatal and near-fatal asthma.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; George Washington Med Ctr, Dept Med, Washington, DC USA; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Natl Jewish Med & Res Ctr, Dept Med, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA	Washington University (WUSTL); George Washington University; Uniformed Services University of the Health Sciences - USA; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Strunk, RC (corresponding author), St Louis Childrens Hosp, 1 Childrens Pl, St Louis, MO 63110 USA.		Ikle, David/AAK-7541-2020	Ikle, David/0000-0003-0091-5246				ARRIGHI HM, 1994, J ALLERGY CLIN IMMUN, V93, P247; BAUMAN A, 1992, AUST NZ J MED, V22, P36, DOI 10.1111/j.1445-5994.1992.tb01706.x; Beasley CRW, 1998, LUNG BIOL HEALTH DIS, V115, P13; BIRKHEAD G, 1989, J ALLERGY CLIN IMMUN, V84, P484, DOI 10.1016/0091-6749(89)90361-8; BRAMAN SS, 1990, JAMA-J AM MED ASSOC, V264, P366, DOI 10.1001/jama.264.3.366; BURGESS C, 1994, EUR RESPIR J, V7, P498, DOI 10.1183/09031936.94.07030498; CAMPBELL DA, 1994, EUR RESPIR J, V7, P490, DOI 10.1183/09031936.94.07030490; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; *CDCP, 1992, MMWR-MORBID MORTAL W, V41, P733; COOREMAN J, 1994, TUBERCLE LUNG DIS, V75, P182, DOI 10.1016/0962-8479(94)90005-1; COUTTS JAP, 1992, ARCH DIS CHILD, V67, P332, DOI 10.1136/adc.67.3.332; DEPALO VA, 1994, CHEST, V106, P447, DOI 10.1378/chest.106.2.447; ERLICH RI, 1994, RESP MED, V88, P195; ERNST P, 1992, JAMA-J AM MED ASSOC, V268, P3462, DOI 10.1001/jama.268.24.3462; GARRETT J, 1995, THORAX, V50, P303, DOI 10.1136/thx.50.3.303; Huss H, 1996, N J Med, V93, P164; ISHAIHARA K, 1995, INTERNAL MED, V34, P77; Ishihara K, 1996, Nihon Rinsho, V54, P2976; JONES A, 1997, THORAX, V52, P205; KEATING G, 1984, BRIT MED J, V289, P348, DOI 10.1136/bmj.289.6441.348; KOLBE J, 1994, CHEST, V106, pS211, DOI 10.1378/chest.106.4_Supplement.211S; KRAVIS LP, 1985, AM J DIS CHILD, V139, P558, DOI 10.1001/archpedi.1985.02140080028026; LANG DM, 1994, NEW ENGL J MED, V331, P1542, DOI 10.1056/NEJM199412083312302; LITTLEJOHNS P, 1994, POSTGRAD MED J, V70, P92, DOI 10.1136/pgmj.70.820.92; Livne M, 1996, ANN ALLERG ASTHMA IM, V76, P261, DOI 10.1016/S1081-1206(10)63438-2; MALVEAUX FJ, 1993, J ASTHMA, V30, P431, DOI 10.3109/02770909309056751; MANN MC, 1992, CHEST, V102, P1342, DOI 10.1378/chest.102.5.1342; MATUSE H, 1995, ANN ALLERG ASTHMA IM, V75, P267; Milgrom H, 1996, J ALLERGY CLIN IMMUN, V98, P1051, DOI 10.1016/S0091-6749(96)80190-4; MILLER BD, 1989, AM J DIS CHILD, V143, P1294, DOI 10.1001/archpedi.1989.02150230052022; Nakazawa T, 1996, Nihon Kyobu Shikkan Gakkai Zasshi, V34, P157; *NAT HEART LUNG BL, PUBL NAT HEART LUNG; NEWMAN KB, 1994, SEM RESP CRIT CARE M, V15, P161, DOI 10.1055/s-2007-1006358; NEWMAN KB, 1995, AM J RESP CRIT CARE, V152, P1382, DOI 10.1164/ajrccm.152.4.7551399; PEARCE N, 1995, LANCET, V345, P41, DOI 10.1016/S0140-6736(95)91159-6; RAND CS, 1992, AM REV RESPIR DIS, V146, P1559, DOI 10.1164/ajrccm/146.6.1559; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; RICHARDS GN, 1993, THORAX, V48, P1105, DOI 10.1136/thx.48.11.1105; ROBERTSON CF, 1992, PEDIATR PULM, V13, P95, DOI 10.1002/ppul.1950130207; ROBIN ED, 1989, CHEST, V96, P790, DOI 10.1378/chest.96.4.790; RUBINSTEIN S, 1984, ANN ALLERGY, V53, P311; SCHENKER MB, 1993, AM REV RESPIR DIS, V147, P1454, DOI 10.1164/ajrccm/147.6_Pt_1.1454; SHEFFER A, 1987, J ALLERGY CLIN IMMUN, V80, P1; SLY RM, 1994, ANN ALLERGY, V73, P259; SPECTOR SL, 1986, J ALLERGY CLIN IMMUN, V77, P65, DOI 10.1016/0091-6749(86)90325-8; STRUNK R, 1998, BIOL HLTH DIS, P31; STRUNK RC, 1985, JAMA-J AM MED ASSOC, V254, P1193; SUR S, 1993, AM REV RESPIR DIS, V148, P713, DOI 10.1164/ajrccm/148.3.713; TARGONSKI PV, 1994, AM J PUBLIC HEALTH, V84, P1830, DOI 10.2105/AJPH.84.11.1830; WASSERFALLEN JB, 1990, AM REV RESPIR DIS, V142, P108, DOI 10.1164/ajrccm/142.1.108; Wood RP, 1996, J ALLERGY CLIN IMMUN, V98, P481, DOI 10.1016/S0091-6749(96)70079-9	51	12	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	1				763	768		10.1016/S0091-6749(99)70285-X	http://dx.doi.org/10.1016/S0091-6749(99)70285-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	248NG	10518819				2022-12-18	WOS:000083281200006
J	Szefler, SJ				Szefler, SJ			Clinical need for a nebulized corticosteroid	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	54th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 13-18, 1998	WASHINGTON, D.C.	Amer Acad Allergy Asthma & Immunol		asthma; pediatric; infant; inhaled corticosteroids; nebulizer therapy; budesonide inhalation suspension	EOSINOPHIL CATIONIC PROTEIN; AIR-FLOW OBSTRUCTION; CHILDHOOD ASTHMA; INHALED CORTICOSTEROIDS; PULMONARY-FUNCTION; ANTIINFLAMMATORY TREATMENT; WHEEZING INFANTS; YOUNG-CHILDREN; PARALLEL-GROUP; BUDESONIDE	Asthma is a leading cause of morbidity in children, leading to frequent emergency room visits and hospitalizations. In recent gears, a steady increase in the number of cases of pediatric asthma has been observed. Mortality rates among children also have increased. The diagnosis of asthma in infants and young children relies on symptoms, and most children become symptomatic before the age of 2 years. The prognosis of an individual child is difficult to predict because of a lack of clear markers; however, respiratory symptoms that begin at, or persist through, the ages of 3 to I years are significantly associated dth future asthma, The inflammatory nature of asthma has prompted recommendations for the routine use of inhaled corticosteroids for all patients with persistent asthma. Studies have indicated that early initiation of corticosteroid therapy can reduce airway inflammation and may prevent more serious asthma or irreversible obstruction in later years. Although treatment guidelines recommend the use of inhaled corticosteroids in infants and children younger than 5 years of age, metered-dose and dry-powder inhalers may be difficult for this population to use because of a lack of coordination or understanding. In addition, there are no commercially available inhaled corticosteroids for use in children younger than 4 Bears of age in the United States.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Clin Pharmacol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Szefler, SJ (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Clin Pharmacol, Room J209,1400 Jackson St, Denver, CO 80206 USA.							ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; AGERTOFT L, 1994, ARCH DIS CHILD, V71, P217, DOI 10.1136/adc.71.3.217; Blais L, 1998, AM J RESP CRIT CARE, V158, P126, DOI 10.1164/ajrccm.158.1.9707107; BROWN PJ, 1984, THORAX, V39, P131, DOI 10.1136/thx.39.2.131; Bush A, 1996, BRIT J HOSP MED, V55, P110; Calpin C, 1997, J ALLERGY CLIN IMMUN, V100, P452, DOI 10.1016/S0091-6749(97)70134-9; CARLSEN KCL, 1995, EUR RESPIR J, V8, P1148, DOI 10.1183/09031936.95.08071148; CARMAN PG, 1990, MED J AUSTRALIA, V152, P23, DOI 10.5694/j.1326-5377.1990.tb124423.x; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P1022; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P350; Clark TJH, 1998, J ALLERGY CLIN IMMUN, V102, pS2; DELACOURT C, 1994, ALLERGY, V49, P843, DOI 10.1111/j.1398-9995.1994.tb00785.x; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; Dodge R, 1996, J ALLERGY CLIN IMMUN, V98, P48, DOI 10.1016/S0091-6749(96)70225-7; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; EDMUNDS AT, 1994, BR J CLIN RES, V5, P11; FERGUSON AC, 1992, J ALLERGY CLIN IMMUN, V90, P609, DOI 10.1016/0091-6749(92)90133-M; Foucard T, 1996, ALLERGY, V51, P367, DOI 10.1111/j.1398-9995.1996.tb04631.x; Godfrey S, 1996, THORAX, V51, pS60, DOI 10.1136/thx.51.Suppl_2.S60; Haahtela T, 1997, CLIN EXP ALLERGY, V27, P351; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; *IMS HLTH GLOB SER, MID INT PRESCR DAB Y; JACKSON RT, 1983, NZ MED J, V96, P727; Kemper K J, 1996, Pediatr Rev, V17, P111, DOI 10.1542/pir.17-4-111; Koller DY, 1997, J ALLERGY CLIN IMMUN, V99, P752, DOI 10.1016/S0091-6749(97)80007-3; Kristjansson S, 1996, J ALLERGY CLIN IMMUN, V97, P1179, DOI 10.1016/S0091-6749(96)70182-3; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; Lemanske RF, 1997, JAMA-J AM MED ASSOC, V278, P1855, DOI 10.1001/jama.278.22.1855; Mannino D M, 1998, MMWR CDC Surveill Summ, V47, P1; MARTINATI LC, 1995, ALLERGY, V50, P701, DOI 10.1111/j.1398-9995.1995.tb01210.x; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MELTZER EO, 1992, J ALLERGY CLIN IMMUN, V90, P2, DOI 10.1016/S0091-6749(06)80005-9; MUELLER GA, 1992, PEDIATR CLIN N AM, V39, P1243; *NAT ASTHM ED PREV, 1997, NIH NAT HEART LUNG B; Overbeek SE, 1996, CHEST, V110, P35, DOI 10.1378/chest.110.1.35; PRICE JF, 1995, RESP MED, V89, P363, DOI 10.1016/0954-6111(95)90009-8; Reijonen TM, 1998, PEDIATR PULM, V26, P113, DOI 10.1002/(SICI)1099-0496(199808)26:2<113::AID-PPUL7>3.0.CO;2-N; SAMET JM, 1983, AM REV RESPIR DIS, V127, P508, DOI 10.1164/arrd.1983.127.4.508; Scher H, 1996, CLIN EXP ALLERGY, V26, P1131, DOI 10.1046/j.1365-2222.1996.d01-266.x; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; Simons FER, 1997, NEW ENGL J MED, V337, P1659, DOI 10.1056/NEJM199712043372304; SLY PD, 1990, J ASTHMA, V27, P137, DOI 10.3109/02770909009073314; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STORR J, 1988, ARCH DIS CHILD, V63, P774, DOI 10.1136/adc.63.7.774; Szefler SJ, 1998, J ALLERGY CLIN IMMUN, V102, pS23, DOI 10.1016/S0091-6749(98)70003-X; Szefler SJ, 1998, J ALLERGY CLIN IMMUN, V102, P170, DOI 10.1016/S0091-6749(98)70081-8; Taussig LM, 1997, PEDIATR PULM, P90; Thorsson L, 1998, EUR RESPIR J, V12, P1340, DOI 10.1183/09031936.98.12061340; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; Verberne AAPH, 1997, AM J RESP CRIT CARE, V156, P688, DOI 10.1164/ajrccm.156.3.9611067; Wainwright C, 1997, MED J AUSTRALIA, V167, P218, DOI 10.5694/j.1326-5377.1997.tb138856.x; Warner JO, 1998, PEDIATR PULM, V25, P1; Wennergren G, 1996, J ALLERGY CLIN IMMUN, V97, P742, DOI 10.1016/S0091-6749(96)80150-3; WRIGHT AL, 1989, AM J EPIDEMIOL, V129, P1232, DOI 10.1093/oxfordjournals.aje.a115243; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888; 1996, IMS HLTH NATL DIS TH	58	12	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	2	S			S162	S168		10.1016/S0091-6749(99)70057-6	http://dx.doi.org/10.1016/S0091-6749(99)70057-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	249RH	10518842				2022-12-18	WOS:000083345700002
J	James, JM				James, JM			Airline snack foods: Tension in the peanut gallery	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							ALLERGY		Colorado Allergy & Asthma Ctr, Ft Collins, CO 80525 USA		James, JM (corresponding author), Colorado Allergy & Asthma Ctr, 1136 E Stuart St,Suite 3200, Ft Collins, CO 80525 USA.							AAAI Board Directors, 1998, J ALLERGY CLIN IMMUN, V102, P173; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; CARLSTON JA, 1988, ANN ALLERGY, V61, P80; Jones R. T., 1996, Journal of Allergy and Clinical Immunology, V97, P423, DOI 10.1016/S0091-6749(96)81179-1; MCCARTNEY S, 1998, WALL STREET J A  SEP, P1; Sampson HA, 1997, JAMA-J AM MED ASSOC, V278, P1888, DOI 10.1001/jama.278.22.1888; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V104, P186, DOI 10.1016/S0091-6749(99)70133-8; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	10	12	12	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					25	27		10.1016/S0091-6749(99)70109-0	http://dx.doi.org/10.1016/S0091-6749(99)70109-0			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400835				2022-12-18	WOS:000081738900004
J	Antall, PM; Meyerson, H; Kaplan, D; Venglarcik, J; Hostoffer, RW				Antall, PM; Meyerson, H; Kaplan, D; Venglarcik, J; Hostoffer, RW			Selective antipolysaccharide antibody deficiency associated with peripheral blood CD5+ B-cell predominance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						selective antipolysaccharide antibody deficiency; CD5+ B cells	BONE-MARROW TRANSPLANTATION; RECURRENT INFECTIONS; CHILDREN; LYMPHOCYTES; RESPONSES; ONTOGENY	Background: Primary humoral deficiencies vary from complete absence of B cells and/or serum immunoglobulin to lacunar deficits involving specific antibody responses to polysaccharides, Objectives: We compared the B-cell CD5 expression in patients with selective antipolysaccharide antibody deficiencies (SPADs), common variable immunodeficiency (CVID), and IgG subclass deficiency and in normal control subjects, Methods: Five patient populations were evaluated: (1) patients with severe SPAD (no protective serologic postvaccine response to any of 12 polysaccharide antigens tested); (2) patients with intermediate SPAD (diminished response to polysaccharide antigens and adequate! response to 1 to 3 of 12 serotypes tested); (3) patients with IgG subclass deficiency; (4) patients with CVID; and (5) age-matched control subjects. Blood was collected from all patients and evaluated by using flow cytometry. Results were compared by using the Student t test. Results: Patients with severe SPAD deficiencies had a marked predominance of CD5+ B cells in the peripheral blood (93% to 97% of total B cells, n = 2), The intermediate SPAD group had a mean CD5+ B-cell percentage that was significantly higher than that of the ape-matched control group (87.4%, n = 7, vs 52.5%, n = 20; P =.007), Patients with CVID and IgG subclass deficiency had mean CD5+ B-cell percentages that were similar to those of the age-matched control subjects. Conclusions: Our studies demonstrate that patients with SPAD had a markedly increased percentage of CD5+ B cells in the peripheral blood as compared with age-matched control subjects and patients with other humoral deficiencies. This observation suggests that an association may be present between CD5+ B-cell predominance and SPAD.	Rainbow Babies & Childrens Hosp, NE Ohio Ctr Immune Disorders, Dept Pediat, Pediat Immunol Div, Cleveland, OH 44142 USA; Univ Hosp Cleveland, Dept Pathol, Cleveland, OH 44106 USA; Tod Childrens Hosp, NE Ohio Ctr Immune Disorders, Dept Pediat, Youngstown, OH USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; University Hospitals of Cleveland	Hostoffer, RW (corresponding author), Rainbow Babies & Childrens Hosp, NE Ohio Ctr Immune Disorders, Dept Pediat, Pediat Immunol Div, 11100 Euclid Ave, Cleveland, OH 44142 USA.			Hostoffer, Robert/0000-0001-8296-3588				AMBROSINO DM, 1987, NEW ENGL J MED, V316, P790, DOI 10.1056/NEJM198703263161306; BARRETT DJ, 1992, CELL IMMUNOL, V143, P66, DOI 10.1016/0008-8749(92)90006-B; BHAT NM, 1992, INT IMMUNOL, V4, P243, DOI 10.1093/intimm/4.2.243; CASALI P, 1987, SCIENCE, V236, P77, DOI 10.1126/science.3105056; CASALI P, 1989, IMMUNOL TODAY, V10, P362; EPSTEIN MM, 1995, ANN ALLERG ASTHMA IM, V75, P125; GERMAINLEE EL, 1990, J PEDIATR-US, V117, P96, DOI 10.1016/S0022-3476(05)82454-0; GIGLIOTTI F, 1988, PEDIATR INFECT DIS J, V7, P417, DOI 10.1097/00006454-198806000-00010; HERZENBERG LA, 1989, CELL, V59, P953, DOI 10.1016/0092-8674(89)90748-4; Hidalgo H, 1996, ANN ALLERG ASTHMA IM, V76, P341, DOI 10.1016/S1081-1206(10)60035-X; KANTOR AB, 1991, IMMUNOL TODAY, V12, P389, DOI 10.1016/0167-5699(91)90136-H; KAWIAK J, 1995, FOLIA HISTOCHEM CYTO, V33, P33; OXELIUS VA, 1979, ACTA PAEDIATR SCAND, V68, P23, DOI 10.1111/j.1651-2227.1979.tb04424.x; Parra C, 1996, BLOOD, V88, P1733; Pospisil R, 1998, IMMUNOL TODAY, V19, P106, DOI 10.1016/S0167-5699(97)01215-2; Rijkers G T, 1993, Immunodeficiency, V5, P1; ROTHBACH C, 1979, J PEDIATR-US, V94, P250, DOI 10.1016/S0022-3476(79)80836-7; SMALL TN, 1990, BLOOD, V76, P1647; SNELLER MC, 1993, ANN INTERN MED, V118, P720, DOI 10.7326/0003-4819-118-9-199305010-00011	19	12	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1999	103	4					637	641		10.1016/S0091-6749(99)70236-8	http://dx.doi.org/10.1016/S0091-6749(99)70236-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	186HY	10200013	Bronze			2022-12-18	WOS:000079723900017
J	Rosenwasser, LJ				Rosenwasser, LJ			Leukotriene modifiers: New drugs, old and new reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material																		ADKINSON NF, 1998, ALLERGY PRINCIPLES P, P1212; Finkel TH, 1999, J ALLERGY CLIN IMMUN, V103, P533, DOI 10.1016/S0091-6749(99)70482-3; Kinoshita M, 1999, J ALLERGY CLIN IMMUN, V103, P534, DOI 10.1016/S0091-6749(99)70483-5; ROSENWASSER LJ, 1996, CECIL TXB MED, P1490; Wechsler ME, 1998, JAMA-J AM MED ASSOC, V279, P455, DOI 10.1001/jama.279.6.455	5	12	14	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1999	103	3	1				374	375		10.1016/S0091-6749(99)70459-8	http://dx.doi.org/10.1016/S0091-6749(99)70459-8			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	176WU	10069868	Bronze			2022-12-18	WOS:000079175700003
J	Shi, HZ; Chen, YQ; Qin, SM				Shi, HZ; Chen, YQ; Qin, SM			Inhaled IL-5 increases concentrations of soluble intracellular adhesion molecule-1 in sputum from atopic asthmatic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-5; intracellular adhesion molecule-1; pathogenesis; asthma	BROWN-NORWAY RATS; BRONCHIAL BIOPSIES; CIRCULATING ICAM-1; VCAM-1 EXPRESSION; INTERFERON-GAMMA; INTERLEUKIN-5; INFLAMMATION; INFILTRATION; CELLS; EOSINOPHILS	Background: Both IL-5 and intracellular adhesion molecule-1 (ICAM-1) have been shown to play important roles in the production of allergic inflammation, including atopic asthma, Objective: The aim of this study was to investigate the effects of recombinant human IL-5 on changes of soluble (s) ICAM-1 concentrations in induced sputum from allergic asthmatic subjects, Methods: In a randomized, double-blind, placebo-controlled study design, 8 nonsmoking patients with allergic asthma and 6 nonallergic normal subjects were administered recombinant human IL-5 by nebulization, and the concentrations of sICAM-1 in induced sputum from each subject were determined before and at 2, 24, 48, and 72 hours after inhalation, Results: sICAM-1 levels in sputum within the control group did not appear to change from baseline at any time throughout the study In allergic asthmatic subjects vehicle challenge was not able to cause any changes in sputum sICAM-1 concentrations. However, there were increases in sputum sICAM-1 concentrations after IL-5 inhalation, which increased with time to significantly greater levers than those at baseline, reaching a maximum at 48 hours and lasting no less than 72 hours, The concentrations of sICAM-1 in sputum after IL-5 challenge exceeded levels that could be accounted for by passive transudation from the circulation on the basis of the magnitude of increases in sputum albumin concentration, Conclusion: Our results indicated that IL-5 inhalation was capable of inducing an elevation of sputum sICAM-1 concentration by stimulating its local release in allergic asthmatic, but not in nonallergic normal, subjects.	Guangxi Univ Tradit Chinese Med, Affiliated Hosp 1, Dept Internal Med, Div Pulm, Nanning 530021, Peoples R China	Guangxi University of Chinese Medicine	Shi, HZ (corresponding author), Guangxi Univ Tradit Chinese Med, Affiliated Hosp 1, Dept Internal Med, Div Pulm, Nanning 530021, Peoples R China.							[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BLOEMEN PGM, 1993, AM J RESP CELL MOL, V9, P586, DOI 10.1165/ajrcmb/9.6.586; BOUSQUET J, 1995, CLIN EXP ALLERGY, V25, P39, DOI 10.1111/j.1365-2222.1995.tb00419.x; CHANDLER DP, 1992, ASPEN INST CONF REP, V7, P13; CHIHARA J, 1994, LANCET, V343, P1108, DOI 10.1016/S0140-6736(94)90224-0; CZECH W, 1993, J INVEST DERMATOL, V100, P417, DOI 10.1111/1523-1747.ep12472082; DELNESTE Y, 1995, CLIN EXP IMMUNOL, V101, P164; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DUSTIN ML, 1986, J IMMUNOL, V137, P245; GOSSET P, 1995, INT ARCH ALLERGY IMM, V106, P69, DOI 10.1159/000236892; Haczku A, 1996, IMMUNOLOGY, V88, P247, DOI 10.1111/j.1365-2567.1996.tb00011.x; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; KRISHNASWAMY G, 1993, AM J RESP CELL MOL, V9, P279, DOI 10.1165/ajrcmb/9.3.279; Louis R, 1997, AM J RESP CRIT CARE, V155, P466, DOI 10.1164/ajrccm.155.2.9032180; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MONTEFORT S, 1994, J CLIN INVEST, V93, P1411, DOI 10.1172/JCI117118; PANETTIERI RA, 1995, J IMMUNOL, V154, P2358; ROTHLEIN R, 1991, J IMMUNOL, V147, P3788; Saetta M, 1996, CLIN EXP ALLERGY, V26, P766, DOI 10.1111/j.1365-2222.1996.tb00606.x; SETH R, 1991, LANCET, V338, P83, DOI 10.1016/0140-6736(91)90077-3; Shi HZ, 1997, AM J RESP CELL MOL, V16, P220, DOI 10.1165/ajrcmb.16.3.9070605; Shi HZ, 1998, AM J RESP CRIT CARE, V157, P204, DOI 10.1164/ajrccm.157.1.9703027; Shi HZ, 1998, CHINESE MED J-PEKING, V111, P127; SHI HZ, 1996, CHIN J TUBERC RESP D, V19, P363; Shiota Y, 1996, CHEST, V109, P94, DOI 10.1378/chest.109.1.94; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SUN J, 1994, INT ARCH ALLERGY IMM, V104, P291, DOI 10.1159/000236679; TERADA N, 1995, INT ARCH ALLERGY IMM, V106, P139, DOI 10.1159/000236834; vandeStolpe A, 1996, J MOL MED, V74, P13, DOI 10.1007/BF00202069; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851	30	12	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1999	103	3	1				463	467		10.1016/S0091-6749(99)70472-0	http://dx.doi.org/10.1016/S0091-6749(99)70472-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	176WU	10069881				2022-12-18	WOS:000079175700016
J	Burton, MD; Blaher, B; Suphioglu, C; O'Hehir, RE; Carbone, FR; Rolland, JM				Burton, MD; Blaher, B; Suphioglu, C; O'Hehir, RE; Carbone, FR; Rolland, JM			T-cell receptor contact and MHC binding residues of a major rye grass pollen allergen T-cell epitope	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Lol p 5; T-cell epitopes; peptide analogues; rye grass; pollen allergen; MHC class II	HOUSE-DUST MITE; LYMPHOKINE PRODUCTION; CRYSTAL-STRUCTURE; IL-4 PRODUCTION; IFN-GAMMA; PEPTIDE; IMMUNOTHERAPY; LIGANDS; RESPONSES; CLONES	Background: T cells are pivotal in the elicitation of allergic diseases. Analogues of T-cell epitope peptides with a modification at a T-cell receptor (TCR) contact site can alter selected T-cell effector functions. Thus the ability to modulate allergen-specific T-cell responses towards T-H1-like by stimulation with peptide analogues may downregulate allergic inflammation. Objectives: The purpose of this study was to characterize the minimal epitope recognized by cloned T cells of a dominant Lol p 5 epitope, p105-116, and identify the critical residues involved in TCR and MHC contact. Methods: Using peptides with progressive truncation of N- and C-terminal residues in T-cell proliferation assays, we identified the core epitope recognized by cloned CD4(+) T cells. An additional series of peptides with single amino acid substitutions were used in T-cell proliferation and live-cell MHC binding assays. Taken together, these results allowed identification of MHC binding and TCR contact residues of p105-116. Results: The core epitope of p105-116 was identified as residues 107-114. Within this core epitope, 3 residues were found to be important for MHC binding, positions 107, 110, and 112, whereas those at positions 108, 109, 110, 111, and 113 were putative TCR contact residues. Conclusions: The identification of the TCR and MHC contact residues of a dominant Lol p 5 T-cell epitope and analogues of this peptide capable of modulating T-cell responses will allow the evaluation of these peptides' potential as immunotherapeutic agents for rye grass pollen allergic disease.	Monash Univ, Sch Med, Dept Pathol & Immunol, Prahran, Vic 3181, Australia; Alfred Hosp, Dept Allergy & Clin Immunol, Prahran, Vic, Australia	Monash University; Florey Institute of Neuroscience & Mental Health	Rolland, JM (corresponding author), Monash Univ, Sch Med, Dept Pathol & Immunol, Commercial Rd, Prahran, Vic 3181, Australia.		Carbone, Francis/ABF-2141-2020; Rolland, Jennifer/E-7543-2011; O'Hehir, Robyn E/H-3627-2011	O'Hehir, Robyn E/0000-0002-3489-7595				Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513; Blaher B, 1996, J ALLERGY CLIN IMMUN, V98, P124, DOI 10.1016/S0091-6749(96)70234-8; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BUSCH R, 1990, INT IMMUNOL, V2, P443, DOI 10.1093/intimm/2.5.443; Dessen A, 1997, IMMUNITY, V7, P473, DOI 10.1016/S1074-7613(00)80369-6; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; EVAVOLD BD, 1993, J IMMUNOL, V150, P3131; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; EVAVOLD BD, 1993, IMMUNOL TODAY, V14, P602, DOI 10.1016/0167-5699(93)90200-5; Fasler S, 1998, J ALLERGY CLIN IMMUN, V101, P521, DOI 10.1016/S0091-6749(98)70406-3; HILL CM, 1991, J IMMUNOL, V147, P189; JAMESON SC, 1995, IMMUNITY, V2, P1, DOI 10.1016/1074-7613(95)90074-8; JUTEL M, 1995, J IMMUNOL, V154, P4187; KAPSENBERG ML, 1991, IMMUNOL TODAY, V12, P392, DOI 10.1016/0167-5699(91)90137-I; KREIGER JI, 1991, J IMMUNOL, V146, P2331; Matsuoka T, 1996, J IMMUNOL, V157, P4837; MCHUGH SM, 1995, CLIN EXP ALLERGY, V25, P828, DOI 10.1111/j.1365-2222.1995.tb00025.x; OHEHIR RE, 1991, J ALLERGY CLIN IMMUN, V87, P1120, DOI 10.1016/0091-6749(91)92158-W; OHEHIR RE, 1991, ANNU REV IMMUNOL, V9, P67, DOI 10.1146/annurev.iy.09.040191.000435; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; Romagnani S, 1997, IMMUNOL TODAY, V18, P263, DOI 10.1016/S0167-5699(97)80019-9; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; SINGH MB, 1991, P NATL ACAD SCI USA, V88, P1384, DOI 10.1073/pnas.88.4.1384; SINIGAGLIA F, 1995, J EXP MED, V181, P449, DOI 10.1084/jem.181.2.449; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; Suphioglu C, 1998, MOL IMMUNOL, V35, P293, DOI 10.1016/S0161-5890(98)00050-9; SUPHIOGLU C, 1992, LANCET, V339, P569, DOI 10.1016/0140-6736(92)90864-Y; Tsitoura DC, 1996, J IMMUNOL, V157, P2160; WINDHAGEN A, 1995, IMMUNITY, V2, P373, DOI 10.1016/1074-7613(95)90145-0; YAN L, 1996, INT IMMUNOL, V8, P897; YING S, 1995, AM J RESP CELL MOL, V12, P477, DOI 10.1165/ajrcmb.12.5.7742012	34	12	15	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1999	103	2	1				255	261		10.1016/S0091-6749(99)70499-9	http://dx.doi.org/10.1016/S0091-6749(99)70499-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167JW	9949316				2022-12-18	WOS:000078630100012
J	Dombrowski, M; Thom, E; McNellis, D				Dombrowski, M; Thom, E; McNellis, D			Maternal-Fetal Medicine Units (MFMU) studies of inhaled corticosteroids during pregnancy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article								Few prospective clinical trials exist to address the use of asthma medications during pregnancy in relation to neonatal outcomes. There is a need to identify favorable pregnancy outcomes in relation to the successful treatment of pregnant women with asthma. To this end, 3 studies have been initiated: (1) a retrospective analysis of inhaled steroid use in a maternal-fetal medicine research center, (2) a large observational cohort study assessing the effects of different types of asthma treatments on perinatal outcomes, and (3) a randomized clinical trial comparing theophylline and inhaled beclomethasone in the treatment of pregnant women with moderately severe asthma. Preliminary information on all 3 studies is described.	Wayne State Univ, Hutzel Hosp, Dept Obstet & Gynecol, Detroit, MI 48201 USA; George Washington Univ, Rockville, MD USA; NICHHD, NIH, Rockville, MD USA	Wayne State University; George Washington University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Dombrowski, M (corresponding author), Wayne State Univ, Hutzel Hosp, Dept Obstet & Gynecol, 4707 St Antoine, Detroit, MI 48201 USA.							Dombrowski M P, 1996, J Matern Fetal Med, V5, P310; MABIE WC, 1992, J MATERNAL FETAL MED, V167, P963	2	12	12	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1999	103	2	2	S			S356	S359		10.1016/S0091-6749(99)70263-0	http://dx.doi.org/10.1016/S0091-6749(99)70263-0			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	171KA	9949338				2022-12-18	WOS:000078861500007
J	Luskin, AT				Luskin, AT			An overview of the recommendations of the Working Group on Asthma and Pregnancy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							BRONCHIAL-ASTHMA; WOMEN; GROWTH	Asthma is the most common potentially serious medical disease complicating pregnancy, and uncontrolled asthma during pregnancy may produce both maternal and fetal complications, The Working Group on Asthma and Pregnancy was established by the National Asthma Education and Prevention Program (NAEPP) to address the issues surrounding asthma management during pregnancy, working within the background of the NAEPP's published asthma guidelines, The Working Group's report, published in 1993, presents recommendations and information for diagnosing and managing asthma during pregnancy, Some key points are: (1) asthma should be treated as aggressively in pregnant women as in nonpregnant women; (2) asthma care and obstetric care should be carefully integrated and should include monitoring of fetal growth and development, maternal symptoms, and maternal lung function; (3) as for nonpregnant women with asthma, medications used to treat asthma during pregnancy should include a short-acting symptom reliever medication (usually an inhaled short-acting beta(2)-agonist) and long-term daily medication to address the underlying inflammation for all patients with more than mild, intermittent disease.	Dean Med Ctr, Dept Allergy, Sun Prairie, WI 53590 USA		Luskin, AT (corresponding author), Dean Med Ctr, Dept Allergy, 10 Tower Dr, Sun Prairie, WI 53590 USA.							BAHNA SL, 1972, ACTA ALLERGOL, V27, P397, DOI 10.1111/j.1398-9995.1972.tb01439.x; BRIGGS GG, 1990, DRUGS PREGNANCY LACT, P237; FITZSIMONS R, 1986, J ALLERGY CLIN IMMUN, V78, P349, DOI 10.1016/S0091-6749(86)80088-4; GORDON M, 1970, AM J OBSTET GYNECOL, V106, P421, DOI 10.1016/0002-9378(70)90371-6; GREENBERGER P, 1978, ANN INTERN MED, V89, P234, DOI 10.7326/0003-4819-89-2-234; GREENBERGER PA, 1983, ANN INTERN MED, V98, P478, DOI 10.7326/0003-4819-98-4-478; *NAT ASTHM ED PROG, 1993, NIH PUBL; National Asthma Education and Prevention Program, 1991, NIH PUBL, V91- 3642; REINISCH JM, 1978, SCIENCE, V202, P436, DOI 10.1126/science.705336; SCHAEFER G, 1961, AM J OBSTET GYNECOL, V82, P182, DOI 10.1016/S0002-9378(16)36114-2; SCHATZ M, 1990, CHEST, V98, P389, DOI 10.1378/chest.98.2.389; SCHATZ M, 1988, Journal of Allergy and Clinical Immunology, V81, P509, DOI 10.1016/0091-6749(88)90187-X; Wilson J, 1982, ACTA THERAP, V8, P45	13	12	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1999	103	2	2	S			S350	S353		10.1016/S0091-6749(99)70261-7	http://dx.doi.org/10.1016/S0091-6749(99)70261-7			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	171KA	9949336				2022-12-18	WOS:000078861500005
J	Simons, FER; Roberts, JR; Gu, XC; Kapur, S; Simons, KJ				Simons, FER; Roberts, JR; Gu, XC; Kapur, S; Simons, KJ			The clinical pharmacology of brompheniramine in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						H-1-receptor antagonists; antihistamines; allergic rhinitis; pharmacokinetics; children; wheat and flare	ANTIHISTAMINE-DECONGESTANT COMBINATION; ALLERGIC RHINITIS; COMMON COLD; PHARMACOKINETICS; PHARMACODYNAMICS; CHLORPHENIRAMINE; TERFENADINE; CETIRIZINE; EFFICACY; PLACEBO	Background: Brompheniramine has been widely used in the treatment of allergic rhinitis and other disorders during the past 3 decades. There are no published studies of its clinical pharmacology in children. Objectives: This study was performed to test the hypothesis that brompheniramine would have a prompt onset of action and a 24-hour duration of action in children. Methods: Before brompheniramine 4 mg was ingested, and at intervals from 0.5 to 30 hours thereafter, blood samples were obtained for quantitation of plasma brompheniramine concentrations by means of HPLC. Concurrently, epicutaneous tests with histamine phosphate were performed; wheals and flares were traced at 10 minutes, and the areas were measured by using a computerized digitizing system. Results: In 14 children, mean age 9.5 +/- 0.4 years (SEM), the peak brompheniramine concentration was 7.7 +/- 0.7 ng/mL, and the time at which peak concentrations occurred was 3.2 +/- 0.3 hours, The terminal elimination half-life was 12.4 +/- 1.1 hours, and the oral clearance was 20.2 +/- 2.1 ml/min/kg. Compared with predose areas, the wheals and flares produced by histamine phosphate 1 mg/mL were significantly decreased from 0.5 to 30 hours and from 1 to 30 hours, respectively (P < .05), with mean maximum inhibition at 12 (52% +/- 9%) and 6 hours (72% +/- 10%), respectively. Conclusions: In children a single dose of brompheniramine produces prompt, long-lasting peripheral H-1-blockade. Revised dosage regimens may be needed in this population.	Univ Manitoba, Fac Pharm, Winnipeg, MB R3T 2N2, Canada; Univ Manitoba, Fac Med, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada	University of Manitoba; University of Manitoba	Simons, FER (corresponding author), Childrens Hosp Winnipeg, 820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.							ALBERT KS, 1975, J PHARMACOKINET BIOP, V3, P159, DOI 10.1007/BF01067905; Clemens CJ, 1997, J PEDIATR-US, V130, P463, DOI 10.1016/S0022-3476(97)70211-7; GIBALDI M, 1982, PHARMACOKINETICS, P1; GILLIS MC, 1996, COMPENDIUM NONPRESCR, P62; Gwaltney JM, 1997, CLIN INFECT DIS, V25, P1188, DOI 10.1086/516105; HOLFORD NHG, 1981, CLIN PHARMACOKINET, V6, P429, DOI 10.2165/00003088-198106060-00002; HUTTON N, 1991, J PEDIATR-US, V118, P125, DOI 10.1016/S0022-3476(05)81865-7; KJELLMAN NIM, 1975, ACTA ALLERGOL, V30, P48; Klein GL, 1996, ANN ALLERG ASTHMA IM, V77, P365, DOI 10.1016/S1081-1206(10)63334-0; McGOVERN JOHN P., 1959, ANN ALLERGY, V17, P915; NETER J, 1990, APPL LINEAR STAT MOD, P517; RANDALL JE, 1979, PEDIATRICS, V63, P483; SIMONS FER, 1982, J ALLERGY CLIN IMMUN, V69, P376, DOI 10.1016/0091-6749(82)90149-X; SIMONS FER, 1982, J ALLERGY CLIN IMMUN, V70, P458, DOI 10.1016/0091-6749(82)90009-4; SIMONS FER, 1990, J ALLERGY CLIN IMMUN, V86, P540; Simons FER, 1996, J ALLERGY CLIN IMMUN, V98, P1062, DOI 10.1016/S0091-6749(96)80192-8; SIMONS FER, 1993, J PEDIATR-US, V122, P641; SIMONS FER, 1984, J PEDIATR-US, V104, P123; SIMONS KJ, 1990, J CLIN PHARMACOL, V30, P665, DOI 10.1002/j.1552-4604.1990.tb01871.x; WATSON WTA, 1989, J ALLERGY CLIN IMMUN, V84, P457, DOI 10.1016/0091-6749(89)90358-8	20	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1999	103	2	1				223	226		10.1016/S0091-6749(99)70494-X	http://dx.doi.org/10.1016/S0091-6749(99)70494-X			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167JW	9949311				2022-12-18	WOS:000078630100007
J	Fujieda, S; Sieling, PA; Modlin, RL; Saxon, A				Fujieda, S; Sieling, PA; Modlin, RL; Saxon, A			CD1-restricted T-cells influence IgG subclass and IgE production	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD1; CD1b; Ige subclass; IgE; isotype switching; IFN-gamma; IL-4	HUMAN B-CELLS; HUMAN LYMPHOCYTES-B; IFN-GAMMA; INTERFERON-GAMMA; MONOCLONAL-ANTIBODY; LEPROSY; ANTIGEN; IL-4; IMMUNOGLOBULIN; CD1	Background: Human CD1 has recently emerged as a third family of antigen-presenting molecules that is distinct from either major histocompatibility complex class I or class II. Objective: We investigated whether the CD1b-restricted T-cell interaction with antigen alters human IgG subclass and IgE isotype production. Methods: CD1b-restricted antigen-specific T cells derived from the skin lesion of a patient with leprosy were stimulated with their cognate antigen, lipoarabinomman (LAM) of Mycobacterium leprae, in the presence of CD1(+) antigen-presenting cells and tested for their ability to alter IgG subclass and IgE production from IgD(+) B cells. Results: CD1-restricted T cells cultured with CD1(+) antigen-presenting cells in the absence of LAM induced IgG1, IgG3, IgG4, and IgE, whereas CD1b-restricted T cells cultured in the presence of LAM induced IgG1 and IgG3 and inhibited production of IgG4 and IgE. Production of IgG4 and IgE was rescued in the CD1-restricted system by the addition of anti-interferon-gamma. IgG1 production was not induced under any circumstances. Conclusion: In this study we demonstrated that a specific CD1b-restricted T-cell line can behave similarly to classically-restricted T-h1-type T cells. CD1b-restricted T-cells of this type may regulate immune responses to microbial pathogens by simultaneously enhancing cell-mediated immunity and downregulating IgG4 and IgE responses.	Fukui Med Univ, Dept Otorhinolaryngol, Fukui 91011, Japan; Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr Inst, Los Angeles, CA USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA USA; Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Los Angeles, CA USA; Univ Calif Los Angeles, Sch Med, Div Dermatol, Los Angeles, CA USA; Univ Calif Los Angeles, Sch Med, Dept Med, Div Clin Immunol Allergy,Hart & Louise Lyon Lab, Los Angeles, CA USA	University of Fukui; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Fujieda, S (corresponding author), Fukui Med Univ, Dept Otorhinolaryngol, Fukui 91011, Japan.		Modlin, Robert L/M-7941-2014	Modlin, Robert L/0000-0003-4720-031X	NATIONAL CANCER INSTITUTE [P01CA012800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034567, U19AI034567, R01AI015251, R21AI015251] Funding Source: NIH RePORTER; NCI NIH HHS [CA-12800] Funding Source: Medline; NIAID NIH HHS [AI-34567, AI-15251] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECKMAN EM, 1995, IMMUNOL TODAY, V16, P349, DOI 10.1016/0167-5699(95)80154-5; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; BLUMBERG RS, 1995, IMMUNOL REV, V147, P5, DOI 10.1111/j.1600-065X.1995.tb00085.x; BRIERE F, 1994, J EXP MED, V179, P757, DOI 10.1084/jem.179.2.757; BRUNNER T, 1993, J EXP MED, V177, P605, DOI 10.1084/jem.177.3.605; CASTANO AR, 1995, SCIENCE, V269, P223, DOI 10.1126/science.7542403; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6234; COFFMAN RL, 1986, J IMMUNOL, V136, P949; DHANDAYUTHAPANI S, 1992, CLIN EXP IMMUNOL, V88, P253, DOI 10.1111/j.1365-2249.1992.tb03069.x; Fujieda S, 1996, J IMMUNOL, V157, P3450; Fujieda S, 1996, J CLIN INVEST, V98, P1527, DOI 10.1172/JCI118944; FUJIEDA S, 1995, ARCH OTOLARYNGOL, V121, P1009; Fujieda S, 1996, MOL IMMUNOL, V33, P1335, DOI 10.1016/S0161-5890(96)00092-2; FUJIEDA S, 1995, J IMMUNOL, V155, P2318; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; HAMMARSTROM L, 1986, MONOGR ALLERGY, V19, P122; HUNTER SW, 1990, J BIOL CHEM, V265, P14065; HUSSAIN R, 1995, INFECT IMMUN, V63, P410, DOI 10.1128/IAI.63.2.410-415.1995; HUSSAIN R, 1994, IMMUNOLOGY, V83, P495; HUSSAIN R, 1995, IMMUNOLOGY, V84, P290; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; KAWANO Y, 1994, J IMMUNOL, V153, P4948; KITANI A, 1993, J IMMUNOL, V151, P3478; Kullberg MC, 1996, J IMMUNOL, V156, P1482; MACY E, 1988, FASEB J, V2, P3003, DOI 10.1096/fasebj.2.14.3263291; MAYUMI M, 1983, J IMMUNOL, V130, P671; PENE J, 1988, J IMMUNOL, V141, P1218; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; PORCELLI SA, 1995, J IMMUNOL, V155, P3709; ROUSSET F, 1991, J EXP MED, V173, P705, DOI 10.1084/jem.173.3.705; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; SAXON A, 1976, J IMMUNOL METHODS, V12, P285, DOI 10.1016/0022-1759(76)90050-8; SHEELA R, 1995, LEPROSY REV, V66, P10; SIELING PA, 1994, IMMUNOBIOLOGY, V191, P378, DOI 10.1016/S0171-2985(11)80443-2; SIELING PA, 1993, J IMMUNOL, V150, P5501; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; ULRICH M, 1995, CLIN EXP IMMUNOL, V100, P54; XU LX, 1994, INT IMMUNOL, V6, P515, DOI 10.1093/intimm/6.4.515; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582; Yamashita M, 1996, J IMMUNOL, V157, P714; ZHANG K, 1991, J IMMUNOL, V146, P1836	45	12	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1998	101	4	1				545	551		10.1016/S0091-6749(98)70362-8	http://dx.doi.org/10.1016/S0091-6749(98)70362-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZH469	9564809				2022-12-18	WOS:000073113500018
J	Wang, WQ; Ip, MSM; Tsang, KWT; Lam, KSL				Wang, WQ; Ip, MSM; Tsang, KWT; Lam, KSL			Antiresorptive therapy in asthmatic patients receiving high-dose inhaled steroids: A prospective study for 18 months	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; corticosteroid; bone mineral density; bone loss; etidronate	BONE-MINERAL DENSITY; INTERMITTENT CYCLICAL ETIDRONATE; DECREASES SERUM OSTEOCALCIN; POSTMENOPAUSAL OSTEOPOROSIS; TURNOVER; CORTICOSTEROIDS; BECLOMETHASONE; BUDESONIDE; WOMEN; MASS	Background: Inhaled steroid therapy is an effective and well tolerated mode of therapy for asthma. Although systemic side-effects of inhaled steroids are much less common than those found with systemic steroids, the drugs may be absorbed through mucosal surfaces. Inhaled steroids have been reported to disturb normal bone metabolism, and they are associated with a decrease in bone mineral density. Objective: We conducted this study to investigate bone density in asthmatic subjects receiving long-term high-dose inhaled steroids and the effects of supplementation with oral calcium with or without etidronate. Methods: We evaluated thirty-eight Chinese subjects (24 men and 14 premenopausal women; 28 patients and 10 healthy control subjects) in this prospective study. Patients were randomized into three arms: those receiving no supplement, those receiving 1000 mg/day calcium supplement, and those receiving 400 mg/day cyclical sodium etidronate with 1000 mg/day calcium, respectively, The patients and control subjects were matched for age, sex, and dose of inhaled steroids. Bone density at lumbar spine and hip region was measured by dual energy x-ray absorptiometry with a densitometer at baseline and at 6, 12, and 18 months for the asthmatic groups and at baseline and at 12 and 18 months For the control group. Serum calcium, phosphate, alkaline phosphatase, osteocalcin, parathyroid hormone, 25-hydroxyvitamin D, and urinary hydroxyproline/creatine were measured simultaneous to bone density assessments. Results: There were 10 control subjects, 10 asthmatic subjects receiving no supplement, eight asthmatic subjects receiving calcium supplement, and 10 asthmatic subjects receiving calcium and etidronate therapy, respectively. The mean (+/- SEM) dosages of beclomethasone or budesonide for the three groups of asthmatic subjects were 2.2 +/- 0.3, 2.0 +/- 0.2, and 2.0 +/- 0.2 mg/day, respectively. Mean dietary calcium intake of the study subjects was 766 +/- 39 mg/day, At baseline, bone mineral density of the spine in the group receiving no supplement was significantly lower than that found in the control group (p < 0.05), At 18 months, patients receiving no supplement had significantly greater bone loss at the lumbar spine than patients receiving etidronate plus calcium lactate-gluconate (CaLG) or CaLG alone (p < 0.05), The increase in bone mineral density versus baseline observed in patients receiving CaLG with or without etidronate (p < 0.05) probably did not result from increased bone formation because serum osteocalcin levels showed a significant reduction in all three groups of patients (p < 0.05), An increase in mean serum calcium (p < 0.05) was seen in patients receiving CaLG with or without etidronate. Conclusion: Our results suggest that long-term administration of high-dose inhaled steroid (21.5 mg/day) induces bone loss that is preventable with calcium supplementation with or without cyclical etidronate. Long-term studies involving more patients should follow to confirm these preliminary findings.	Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong	University of Hong Kong	Lam, KSL (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong.		Lam, Karen Siu Ling/C-4315-2009; Ip, Mary Sau Man/C-4284-2009	Ip, Mary Sau Man/0000-0002-8692-6933				ALI NJ, 1991, THORAX, V46, P160, DOI 10.1136/thx.46.3.160; BARNES PJ, 1993, AM REV RESPIR DIS, V148, pS1, DOI 10.1164/ajrccm/148.4_Pt_2.S1; CUMMING RG, 1990, CALCIFIED TISSUE INT, V47, P194; DULL TA, 1963, NEW ENGL J MED, V268, P132, DOI 10.1056/NEJM196301172680305; ERNST P, 1992, JAMA-J AM MED ASSOC, V268, P3462, DOI 10.1001/jama.268.24.3462; HANANIA NA, 1995, J ALLERGY CLIN IMMUN, V96, P571, DOI 10.1016/S0091-6749(95)70254-7; HARRIS ST, 1993, AM J MED, V95, P557, DOI 10.1016/0002-9343(93)90350-X; HEANEY RP, 1986, BONE MINERAL RES ANN, V4, P255; HOLBROOK TL, 1993, BONE MINER, V20, P141, DOI 10.1016/S0169-6009(08)80023-2; IP M, 1994, CHEST, V105, P1722, DOI 10.1378/chest.105.6.1722; KANDERS B, 1988, J BONE MINER RES, V3, P145; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003-4819-112-5-352; MORRISON D, 1992, THORAX, V47, P418, DOI 10.1136/thx.47.6.418; MULDER H, 1994, BRIT J RHEUMATOL, V33, P348; POUW EM, 1991, BRIT MED J, V302, P627, DOI 10.1136/bmj.302.6777.627; PRAHL P, 1991, CLIN EXP ALLERGY, V21, P145, DOI 10.1111/j.1365-2222.1991.tb00817.x; PRUMMEL MF, 1991, J CLIN ENDOCR METAB, V72, P382, DOI 10.1210/jcem-72-2-382; PUN K K, 1990, Journal of Applied Nutrition, V42, P12; PUOLIJOKI H, 1992, BONE, V13, P285, DOI 10.1016/8756-3282(92)90072-5; REID IR, 1986, AM J CLIN NUTR, V44, P287, DOI 10.1093/ajcn/44.2.287; SCHWARTZ E, 1965, J CLIN INVEST, V44, P1547, DOI 10.1172/JCI105261; SORVA R, 1992, J ALLERGY CLIN IMMUN, V90, P808, DOI 10.1016/0091-6749(92)90106-C; STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803; TOOGOOD JH, 1991, J ALLERGY CLIN IMMUN, V88, P572, DOI 10.1016/0091-6749(91)90150-M	25	12	12	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1998	101	4	1				445	450		10.1016/S0091-6749(98)70351-3	http://dx.doi.org/10.1016/S0091-6749(98)70351-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZH469	9564795	Bronze			2022-12-18	WOS:000073113500003
J	Blumenthal, MN; Casale, TB; Fink, JN; Uryniak, T; Casty, FE; Fineman, SM; Floreani, AA; Gadde, J; Grady, J; Grossman, J; Howland, WG; Klimas, JT; Pierantoni, W; Prenner, B; Raphael, G; Rowe, MS; Ruff, DA; Steinberg, P; Stricker, WE; Weerasinghe, M; Westley, CR; Winder, J; Zeitz, HJ; Harper, A; Birdsall, D; Farrar, JR				Blumenthal, MN; Casale, TB; Fink, JN; Uryniak, T; Casty, FE; Fineman, SM; Floreani, AA; Gadde, J; Grady, J; Grossman, J; Howland, WG; Klimas, JT; Pierantoni, W; Prenner, B; Raphael, G; Rowe, MS; Ruff, DA; Steinberg, P; Stricker, WE; Weerasinghe, M; Westley, CR; Winder, J; Zeitz, HJ; Harper, A; Birdsall, D; Farrar, JR			Evaluation of a non-chlorofluorocarbon formulation of cromolyn sodium (Intal) metered-dose inhaler versus the chlorofluorocarbon formulation in the treatment of adult patients with asthma: A controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chlorofluorocarbon; cromolyn sodium; hydrofluoroalkane; metered-dose inhaler; Montreal Protocol; ozone	BECLOMETHASONE DIPROPIONATE; NEDOCROMIL SODIUM; CROMOGLYCATE; HISTAMINE	Background: Cromolyn sodium is a nonsteroidal inhaled antiinflammatory agent for the treatment of asthma, As with other pressurized aerosol medications, the metered-dose inhaler (MDI) formulation currently contains chlorofluorocarbon (CFC) propellants, Because of their harmful effects on the environment CFCs are now generally banned from production and use, Alternative propellants under production for MDIs include derivatives of hydrofluoroalkane (HFA). This study uses HFA-227 in an MDI formulation of cromolyn sodium. Objectives: The objectives of the study were (1) to examine the efficacy and safety of an HFA formulation of cromolyn sodium (Intal) MDI and (2) to compare the HFA formulation with the CFC formulation. Methods: A multicenter, randomized, double-blind, placebo-controlled, parallel study with two active groups (HFA-cromolyn sodium [n = 113] and CFC-cromolyn sodium [n = 107]) and a placebo-treated group (n = 105). Results: Patients treated with either formulation of cromolyn sodium MDI showed a statistically significant (p < 0.05) improvement of 12% to 18% compared with placebo in symptom summary score, daytime asthma symptoms, and albuterol use. No statistically significant differences were observed in pulmonary function. Patient and physician opinions of overall effectiveness favored HFA-cromolyn sodium over placebo (p = 0.01), with no other significant between-treatment differences. No statistically significant differences existed among groups in the incidence of treatment-related adverse events. Conclusion: The HFA formulation of cromolyn sodium MDI is a well-tolerated and active alternative treatment for asthma patients aged 12 years and more.	Univ Minnesota Hosp & Clin, Minneapolis, MN 55455 USA; Nebraska Med Res Inst, Papillion, NE USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA; Rhone Poulenc Rorer, Collegeville, PA USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota Hospital; Medical College of Wisconsin	Blumenthal, MN (corresponding author), Univ Minnesota Hosp & Clin, Box 434 Mall,420 Delaware St SE, Minneapolis, MN 55455 USA.		Casale, Thomas B/K-4334-2013	Casale, Thomas B/0000-0002-3149-7377				COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; FURUKAWA CT, 1984, PEDIATRICS, V74, P453; HOAG JE, 1991, ANN ALLERGY, V66, P53; *NAT HEART LUNG BL, 1995, NIH PUBL; *NAT HEART LUNG BL, 1992, US DEPT HHS PUBL; National Heart Lung and Blood Institute National Asthma Education Program, 1991, J ALLERGY CLIN IMMUN, V88, P425, DOI DOI 10.1016/0091-6749(91)92135-N; NEWMAN SP, 1990, EUR RESPIR J, V3, P495; NOAKES TJ, 1995, J AEROSOL MED, V8, pS3, DOI 10.1089/jam.1995.8.Suppl_1.S-3; PEARCE FL, 1989, DRUGS, V37, P37, DOI 10.2165/00003495-198900371-00009; PELIKAN Z, 1988, ANN ALLERGY, V60, P211; PETTY TL, 1989, AM REV RESPIR DIS, V139, P694, DOI 10.1164/ajrccm/139.3.694; ReizianFouley A, 1997, ECOTOX ENVIRON SAFE, V36, P197, DOI 10.1006/eesa.1996.1467; ROSS RN, 1988, CLIN THER, V10, P188; Schwartz HJ, 1996, CHEST, V109, P945, DOI 10.1378/chest.109.4.945; SHAPIRO GG, 1991, J ALLERGY CLIN IMMUN, V88, P742, DOI 10.1016/0091-6749(91)90181-M; SMITH IJ, 1995, J AEROSOL MED, V8, pS19; 1994, SCRIP, P26	17	12	12	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	1				7	13		10.1016/S0091-6749(98)70186-1	http://dx.doi.org/10.1016/S0091-6749(98)70186-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YR872	9449494				2022-12-18	WOS:000071539800002
J	Kaila, M; Isolauri, E				Kaila, M; Isolauri, E			Diagnosis of cow's milk allergy: Open or blinded?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ATOPIC-DERMATITIS; INFANTS		TAMPERE UNIV HOSP,DEPT PEDIAT,TAMPERE,FINLAND; UNIV TURKU,DEPT PEDIAT,TURKU,FINLAND	Tampere University; Tampere University Hospital; University of Turku								ISOLAURI E, 1995, J PEDIATR-US, V127, P550, DOI 10.1016/S0022-3476(95)70111-7; Isolauri E, 1996, J ALLERGY CLIN IMMUN, V97, P9, DOI 10.1016/S0091-6749(96)70277-4; MABIN DC, 1995, ARCH DIS CHILD, V73, P208, DOI 10.1136/adc.73.3.208; ZEIGER RS, 1985, J ALLERGY CLIN IMMUN, V75, P633, DOI 10.1016/0091-6749(85)90086-7	4	12	13	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1997	100	5					714	715		10.1016/S0091-6749(97)70180-5	http://dx.doi.org/10.1016/S0091-6749(97)70180-5			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YG202	9389306				2022-12-18	WOS:A1997YG20200023
J	Canning, BJ				Canning, BJ			Potential role of tachykinins in inflammatory diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							MESSENGER-RNA; CAPSAICIN; NEURONS; NEUROPEPTIDES; CAPSAZEPINE				Canning, BJ (corresponding author), JOHNS HOPKINS ASTHMA & ALLERGY CTR,5501 HOPKINS BAYVIEW CIRCLE,BALTIMORE,MD 21224, USA.		Canning, Brendan/AAM-9404-2021; Canning, Brendan/ABE-5261-2020	Canning, Brendan/0000-0003-4197-5560; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009137] Funding Source: NIH RePORTER; NHLBI NIH HHS [F32 HL009137] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALUK P, 1995, AM J PHYSIOL-LUNG C, V268, pL263, DOI 10.1152/ajplung.1995.268.2.L263; BARNES PJ, 1991, AM REV RESPIR DIS, V144, P1391, DOI 10.1164/ajrccm/144.6.1391; Bertrand C, 1996, TRENDS PHARMACOL SCI, V17, P255, DOI 10.1016/S0165-6147(96)10027-4; BRAUNSTEIN G, 1991, AM REV RESPIR DIS, V144, P630, DOI 10.1164/ajrccm/144.3_Pt_1.630; Bruce AN, 1913, Q J EXP PHYSIOL, V6, P339, DOI 10.1113/expphysiol.1913.sp000144; CANNING BJ, 1994, J PHYSIOL-LONDON, V480, P613, DOI 10.1113/jphysiol.1994.sp020388; DE KONINCK Y, 1992, P NATL ACAD SCI USA, V89, P5073, DOI 10.1073/pnas.89.11.5073; DICKENSON AH, 1991, BRIT J PHARMACOL, V104, P1045, DOI 10.1111/j.1476-5381.1991.tb12547.x; Fischer A, 1996, J CLIN INVEST, V98, P2284, DOI 10.1172/JCI119039; Giardina GAM, 1996, J MED CHEM, V39, P2281, DOI 10.1021/jm9602423; GITTER BD, 1995, J PHARMACOL EXP THER, V275, P737; JANSCO N, 1967, BRIT J PHARMACOL, V31, P138; Kudlacz EM, 1996, J PHARMACOL EXP THER, V277, P840; Lewis T, 1937, Br Med J, V1, P431; Lewis T, 1937, Br Med J, V1, P491; LOTTI T, 1995, J AM ACAD DERMATOL, V33, P482, DOI 10.1016/0190-9622(95)91395-5; Lowe JA, 1996, MED RES REV, V16, P527, DOI 10.1002/(SICI)1098-1128(199611)16:6<527::AID-MED2>3.0.CO;2-4; LUNDBERG JM, 1983, NATURE, V302, P251, DOI 10.1038/302251a0; MAGGI CA, 1988, GEN PHARMACOL-VASC S, V19, P1, DOI 10.1016/0306-3623(88)90002-X; MCCARSON KE, 1994, J NEUROSCI, V14, P712; McLean S, 1996, J PHARMACOL EXP THER, V277, P900; NOGUCHI K, 1992, J NEUROSCI, V12, P2563; OTSUKA M, 1993, PHYSIOL REV, V73, P229, DOI 10.1152/physrev.1993.73.2.229; Philip G, 1996, AM J RESP CRIT CARE, V153, P1222, DOI 10.1164/ajrccm.153.4.8616545; Riccio MM, 1996, J PHYSIOL-LONDON, V491, P499, DOI 10.1113/jphysiol.1996.sp021234; SANTICIOLI P, 1993, BRIT J PHARMACOL, V110, P609, DOI 10.1111/j.1476-5381.1993.tb13854.x; UNDEM BJ, 1997, IN PRESS ASTHMA RHIN; URBAN L, 1994, TRENDS NEUROSCI, V17, P432, DOI 10.1016/0166-2236(94)90018-3; 1991, BRIT MED J, V47, P523; 1995, CAN J PHYSL PHARM, V73, P854	30	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1997	99	5					579	582		10.1016/S0091-6749(97)70015-0	http://dx.doi.org/10.1016/S0091-6749(97)70015-0			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WY600	9155820	hybrid			2022-12-18	WOS:A1997WY60000001
J	Quirce, S; Blanco, R; DiezGomez, ML; Cuevas, M; Eiras, P; Losada, E				Quirce, S; Blanco, R; DiezGomez, ML; Cuevas, M; Eiras, P; Losada, E			Carrot-induced asthma: Immunodetection of allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							BIRCH POLLEN		HOSP RAMON Y CAJAL,DEPT IMMUNOL,E-28034 MADRID,SPAIN	Hospital Universitario Ramon y Cajal	Quirce, S (corresponding author), HOSP RAMON Y CAJAL,SERV ALERGIA,DEPT ALLERGY,CTRA COLMENAR KM 9-1,E-28034 MADRID,SPAIN.		s, q/AAD-7171-2020					EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; Gomez M, 1996, ALLERGY, V51, P425, DOI 10.1111/j.1398-9995.1996.tb04642.x; HELBLING A, 1993, ANN ALLERGY, V70, P495; QUIRCE S, 1989, ALLERGY, V44, P532, DOI 10.1111/j.1398-9995.1989.tb04197.x; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1	5	12	12	1	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1997	99	5					718	719		10.1016/S0091-6749(97)70037-X	http://dx.doi.org/10.1016/S0091-6749(97)70037-X			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WY600	9155842				2022-12-18	WOS:A1997WY60000023
J	Arledge, TE; Liddle, R; Stahl, E; Rossing, TH				Arledge, TE; Liddle, R; Stahl, E; Rossing, TH			Salmeterol does not cause tolerance during long-term asthma therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							INHALED SALMETEROL; SALBUTAMOL; ALBUTEROL; SYMPTOMS				Arledge, TE (corresponding author), GLAXO WELLCOME INC,5 MOORE DR,RES TRIANGLE PK,NC 27709, USA.							ARVIDSSON P, 1991, EUR RESPIR J, V4, P1168; BRITTON MG, 1992, EUR RESPIR J, V5, P1062; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; DALONZO GE, 1994, JAMA-J AM MED ASSOC, V271, P1412, DOI 10.1001/jama.271.18.1412; JUNIPER EF, 1981, THORAX, V36, P575, DOI 10.1136/thx.36.8.575; KEMP JP, 1995, AM J RESP CRIT CARE, V151, pA59; LOTVALL J, 1992, ALLERGY, V47, P477, DOI 10.1111/j.1398-9995.1992.tb00668.x; MAKINO S, 1966, J ALLERGY, V38, P127, DOI 10.1016/0021-8707(66)90036-0; MCFADDEN ER, 1995, J ALLERGY CLIN IMMUN, V95, P641, DOI 10.1016/S0091-6749(95)70166-4; MORGAN DJ, 1986, BRIT J CLIN PHARMACO, V22, P587, DOI 10.1111/j.1365-2125.1986.tb02939.x; NATHAN RA, 1995, ANN ALLERG ASTHMA IM, V75, P243; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; RAMAGE L, 1992, THORAX, V47; RESPSHER LH, 1981, ANN ALLERGY, V47, P405; ULLMAN A, 1990, AM REV RESPIR DIS, V142, P571, DOI 10.1164/ajrccm/142.3.571	15	12	12	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	1				1116	1119		10.1016/S0091-6749(96)80200-4	http://dx.doi.org/10.1016/S0091-6749(96)80200-4			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WB378	8977514				2022-12-18	WOS:A1996WB37800018
J	Malo, JL; Cartier, A; Ghezzo, H; ChanYeung, M				Malo, JL; Cartier, A; Ghezzo, H; ChanYeung, M			Compliance with peak expiratory flow readings affects the within- and between-reader reproducibility of interpretation of graphs in subjects investigated for occupational asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VANCOUVER GEN HOSP,DEPT MED,VANCOUVER,BC,CANADA	University of British Columbia	Malo, JL (corresponding author), HOP SACRE COEUR,DEPT CHEST MED,5400 W GOUIN,MONTREAL,PQ H4J 1C5,CANADA.							Burge P. Sherwood, 1993, P171; MALO JL, 1995, J ALLERGY CLIN IMMUN, V96, P601, DOI 10.1016/S0091-6749(95)70258-X; MALO JL, 1993, THORAX, V48, P1211, DOI 10.1136/thx.48.12.1211; MOSCATO G, 1995, J ALLERGY CLIN IMMUN, V96, P295; QUIRCE S, 1995, AM J RESP CRIT CARE, V152, P1100, DOI 10.1164/ajrccm.152.3.7663790	5	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	1				1132	1134		10.1016/S0091-6749(96)80207-7	http://dx.doi.org/10.1016/S0091-6749(96)80207-7			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WB378	8977521				2022-12-18	WOS:A1996WB37800025
J	Mayumi, M; Sumimoto, SI; Kanazashi, SI; Hata, D; Yamaoka, K; Higaki, Y; Ishigami, T; Kim, KM; Heike, T; Katamura, K				Mayumi, M; Sumimoto, SI; Kanazashi, SI; Hata, D; Yamaoka, K; Higaki, Y; Ishigami, T; Kim, KM; Heike, T; Katamura, K			Negative signaling in B cells by surface immunoglobulins	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						B cell; apoptosis; IgM; CD40; adhesion	MEDIATED GROWTH-INHIBITION; PROTEIN-KINASE-C; REACTIVE LYMPHOCYTES-B; ANTIBODIES INDUCE APOPTOSIS; GERMINAL CENTER FORMATION; ANTI-IGD ANTIBODIES; CROSS-LINKING; LYMPHOMA-CELLS; CYCLOSPORINE-A; SELF-TOLERANCE	Cross-linking of surface immunoglobulins generates negative signals that cause B-cell death unless appropriate rescue signals are provided. Surface IgM is the main transducer of the negative signaling, but surface IgD and IgG may also transduce negative signaling when cross-linked intensively. In the surface IgM(+), IgD(+) human malignant B lymphoma cell lines B104 and DND-39, cross-linking of surface IgM by anti-IgM antibodies induced cell death. Anti-IgM antibody-induced B104 cell death was inhibited by stimulation with alpha- and beta-interferons but not stimulation with anti-CD40 antibody or IL-4, whereas anti-IgM antibody-induced DND-39 cell death was inhibited by stimulation with anti-CD40 antibody but not stimulation with alpha- and beta-interferons. Anti-IgM antibody-stimulated B104 cells had morphologic features compatible with necrosis, whereas anti-IgM antibody-stimulated DND-39 cells showed morphologic features of apoptosis. CD11a/CD54-dependent cell adhesion induced by stimulation with anti-CD40 antibody was involved in anti-CD40 antibody-mediated inhibition of anti-IgM antibody-induced DND-39 cells. In normal human mature B cells, cross-linking of surface IgM induced different signaling consequences, including DNA synthesis or cell division (positive signaling) or cell cycle arrest or death (negative signaling). In this system, too, CD40-transduced signal inhibited anti-IgM antibody-induced negative signaling, and CD11a/CD54-dependent cell adhesion played a role in the rescue process. It is suggested that quantitatively different intensities of surface IgM cross-linking induce qualitatively different signaling consequences; relatively weak cross-linking may induce DNA synthesis: moderate cross-linking may induce DNA synthesis with cell cycle arrest at the G(2)/M interphase, and intense cross-linking may induce apoptotic cell death. The reasons for this difference are not yet known. Further elucidation of the molecular mechanisms responsible for surface IgM-mediated negative signaling and its rescue signaling may contribute toward development of therapy for allergic disorders by artificial modulation of specific immunoglobulin production.			Mayumi, M (corresponding author), KYOTO UNIV,FAC MED,DEPT PEDIAT,SAKYO KU,SHOGOIN KAWAHARA CHO,KYOTO 60601,JAPAN.							ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; ADAMS E, 1990, P NATL ACAD SCI USA, V87, P5687, DOI 10.1073/pnas.87.15.5687; ALESMARTINEZ JE, 1991, CELL IMMUNOL, V135, P402, DOI 10.1016/0008-8749(91)90285-J; ALESMARTINEZ JE, 1992, EUR J IMMUNOL, V22, P845, DOI 10.1002/eji.1830220332; ALESMARTINEZ JE, 1988, P NATL ACAD SCI USA, V85, P6919, DOI 10.1073/pnas.85.18.6919; BAIXERAS E, 1993, IMMUNOL REV, V132, P5, DOI 10.1111/j.1600-065X.1993.tb00836.x; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BECKWITH M, 1991, J IMMUNOL, V147, P2411; BISHOP GA, 1993, J IMMUNOL, V150, P2565; BOYD AW, 1981, J IMMUNOL, V126, P2466; BRINK R, 1992, J EXP MED, V176, P991, DOI 10.1084/jem.176.4.991; CALLARD RE, 1995, INT IMMUNOL, V7, P1809, DOI 10.1093/intimm/7.11.1809; CAMBIER JC, 1993, IMMUNOL REV, V132, P85, DOI 10.1111/j.1600-065X.1993.tb00838.x; CHOI MSK, 1994, IMMUNITY, V1, P179, DOI 10.1016/1074-7613(94)90096-5; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; COHEN JJ, 1984, J IMMUNOL, V132, P38; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; DANCESCU M, 1992, J EXP MED, V176, P1319, DOI 10.1084/jem.176.5.1319; ERAY M, 1994, INT IMMUNOL, V6, P1817, DOI 10.1093/intimm/6.12.1817; ERIS JM, 1994, P NATL ACAD SCI USA, V91, P4392, DOI 10.1073/pnas.91.10.4392; FINKELMAN FD, 1995, J EXP MED, V181, P515, DOI 10.1084/jem.181.2.515; FOY TM, 1994, J EXP MED, V180, P157, DOI 10.1084/jem.180.1.157; FULCHER DA, 1994, J EXP MED, V179, P125, DOI 10.1084/jem.179.1.125; FUNAKOSHI S, 1994, BLOOD, V83, P2787, DOI 10.1182/blood.V83.10.2787.2787; GOODNOW CC, 1991, NATURE, V352, P532, DOI 10.1038/352532a0; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GOTTSCHALK AR, 1993, EUR J IMMUNOL, V23, P2011, DOI 10.1002/eji.1830230843; HARTLEY SB, 1993, CELL, V72, P325, DOI 10.1016/0092-8674(93)90111-3; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; HASBOLD J, 1994, EUR J IMMUNOL, V24, P152, DOI 10.1002/eji.1830240123; HATA D, 1992, INT IMMUNOL, V4, P797, DOI 10.1093/intimm/4.7.797; HATA D, 1993, IMMUNOL LETT, V40, P65; HEATH AW, 1993, CELL IMMUNOL, V152, P468, DOI 10.1006/cimm.1993.1305; HIGAKI Y, 1994, IMMUNOL CELL BIOL, V72, P205, DOI 10.1038/icb.1994.31; HOLDER MJ, 1993, EUR J IMMUNOL, V23, P2368, DOI 10.1002/eji.1830230948; HOLLENBAUGH D, 1994, IMMUNOL REV, V138, P23, DOI 10.1111/j.1600-065X.1994.tb00845.x; ILLERA VA, 1993, J IMMUNOL, V151, P2965; ISHIGAMI T, 1992, J IMMUNOL, V148, P360; JAKWAY JP, 1986, J IMMUNOL, V137, P2225; JENKINSON EJ, 1989, EUR J IMMUNOL, V19, P2175, DOI 10.1002/eji.1830191132; KANAZASHI S, 1994, MOL IMMUNOL, V31, P21; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KIM KM, 1994, EMBO J, V13, P3793, DOI 10.1002/j.1460-2075.1994.tb06690.x; KIM KM, 1991, J IMMUNOL, V146, P819; KIM KM, 1992, J IMMUNOL, V148, P29; KIM KM, 1992, J IMMUNOL, V148, P1797; KNOX KA, 1993, INT IMMUNOL, V5, P1085, DOI 10.1093/intimm/5.9.1085; KOOPMAN G, 1994, J IMMUNOL, V152, P3760; LAGRESLE C, 1995, J IMMUNOL, V154, P5746; LEDERMAN S, 1994, J IMMUNOL, V152, P2163; LINDHOUT E, 1995, J EXP MED, V181, P1985, DOI 10.1084/jem.181.6.1985; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; MACDONALD HR, 1990, NATURE, V343, P642, DOI 10.1038/343642a0; MARQUEZ C, 1991, J IMMUNOL, V147, P627; Mayumi M, 1995, J ALLERGY CLIN IMMUN, V96, P1136, DOI 10.1016/S0091-6749(95)70198-2; MAYUMI M, 1994, J ALLERGY CLIN IMMUN, V94, P612, DOI 10.1016/0091-6749(94)90137-6; MCDONNELL TJ, 1990, MOL CELL BIOL, V10, P1901, DOI 10.1128/MCB.10.5.1901; MONGINI PKA, 1989, J IMMUNOL, V143, P1565; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; NEMAZEE D, 1989, P NATL ACAD SCI USA, V86, P8039, DOI 10.1073/pnas.86.20.8039; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NITSCHKE L, 1993, P NATL ACAD SCI USA, V90, P1887, DOI 10.1073/pnas.90.5.1887; NOSSAL GJV, 1983, ANNU REV IMMUNOL, V1, P33, DOI 10.1146/annurev.iy.01.040183.000341; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PARRY SL, 1994, J IMMUNOL, V152, P2821; PARRY SL, 1994, EUR J IMMUNOL, V24, P974, DOI 10.1002/eji.1830240429; PENNELL CA, 1986, EUR J IMMUNOL, V16, P1577, DOI 10.1002/eji.1830161217; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; RAMIREZ R, 1994, J EXP MED, V180, P1147, DOI 10.1084/jem.180.3.1147; ROES J, 1991, INT IMMUNOL, V3, P1367, DOI 10.1093/intimm/3.12.1367; ROES J, 1993, J EXP MED, V177, P45, DOI 10.1084/jem.177.1.45; ROTHSTEIN TL, 1995, NATURE, V374, P163, DOI 10.1038/374163a0; RUSSELL DM, 1991, NATURE, V354, P308, DOI 10.1038/354308a0; SANTOSARGUMEDO L, 1994, CELL IMMUNOL, V156, P272, DOI 10.1006/cimm.1994.1174; SANTOSARGUMEDO L, 1993, J IMMUNOL, V151, P3119; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; SARTHOU P, 1989, EUR J IMMUNOL, V19, P1247, DOI 10.1002/eji.1830190715; SCHEUERMANN RH, 1994, P NATL ACAD SCI USA, V91, P4048, DOI 10.1073/pnas.91.9.4048; SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980; SCOTT DW, 1987, IMMUNOL REV, V99, P153, DOI 10.1111/j.1600-065X.1987.tb01176.x; SCOTT DW, 1987, J IMMUNOL, V139, P3924; SCOTT DW, 1987, J MOL CELL IMMUNOL, V3, P109; SEYFERT VL, 1989, MOL CELL BIOL, V9, P2083, DOI 10.1128/MCB.9.5.2083; SUMIMOTO SI, 1994, J IMMUNOL, V153, P3488; TERASHIMA M, 1994, EMBO J, V13, P3782, DOI 10.1002/j.1460-2075.1994.tb06689.x; TISCH R, 1988, P NATL ACAD SCI USA, V85, P6914, DOI 10.1073/pnas.85.18.6914; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; UDHAYAKUMAR V, 1991, EUR J IMMUNOL, V21, P2605, DOI 10.1002/eji.1830211043; UDHAYAKUMAR V, 1991, J IMMUNOL, V146, P4120; VALENTINE MA, 1992, EUR J IMMUNOL, V22, P3141, DOI 10.1002/eji.1830221217; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; VENKATARAMAN L, 1994, IMMUNITY, V1, P189, DOI 10.1016/1074-7613(94)90097-3; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; YAMAOKA K, 1993, IMMUNOL LETT, V36, P203, DOI 10.1016/0165-2478(93)90053-5; YAO XR, 1993, IMMUNOL REV, V132, P163, DOI 10.1111/j.1600-065X.1993.tb00842.x	101	12	12	1	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	2	S			S238	S247		10.1016/S0091-6749(96)70072-6	http://dx.doi.org/10.1016/S0091-6749(96)70072-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WC447	8977533				2022-12-18	WOS:A1996WC44700010
J	Yamada, N; Wakugawa, M; Kuwata, S; Nakagawa, H; Tamaki, K				Yamada, N; Wakugawa, M; Kuwata, S; Nakagawa, H; Tamaki, K			Changes in eosinophil and leukocyte infiltration and expression of IL-6 and IL-7 messenger RNA in mite allergen patch test reactions in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; eosinophils; mite allergen; patch rest; IL-6; IL-7; reverse-transcription polymerase chain reaction	T-CELLS; INTERLEUKIN-6 PRODUCTION; TRANSGENIC MICE; BLOOD MONOCYTES; KERATINOCYTES; GAMMA; MURINE	Patch testing with dude dust mite extracts after removal of homy layers was performed on normal-appearing skin of II adult patients with atopic dermatitis and high mite-specific IgE antibody scores. Positive skin reactions were observed in 9 subjects. Skin biopsy specimens were obtained from positive reaction sites at 2, 6, 12, 24, and 48 hours after allergen challenge and subjected to histologic studies and ex-traction of messenger RNA (mRNA). Perivascular infiltration of small mononuclear cells began at 2 hours and was followed by eosinophilic infiltration at 6 hours, and the number of eosinophils continued to increase at 24 and 48 hours. In addition to the increased expression of IL-4, IL-5, and tumor necrosis factor-alpha mRNA during the time course detected by reverse-transcription polymerase chain reaction, mRNA of IL-6 and IL-7 was also up-regulated. After the removal of test patches with mite allergen, the number of eosinophils started to decrease in a time-dependent manner. Histopathologic findings at 48 hours after removal showed lymphocyte-dominant infiltration intermingled with occasional eosinophils. These mite allergen patch test reactions may provide a useful model for studying the pathogenesis of atopic eczema, especially with regard to the initiation of eosinophil infiltration and the alternative increase in lymphocytes.	UNIV TOKYO, FAC MED, DEPT DERMATOL, BUNKYO KU, TOKYO 113, JAPAN; UNIV TOKYO, FAC MED, DEPT IMMUNOHEMATOL, TOKYO 113, JAPAN	University of Tokyo; University of Tokyo								AIBA S, 1994, J INVEST DERMATOL, V103, P162, DOI 10.1111/1523-1747.ep12392632; ALDERSON MR, 1991, J EXP MED, V173, P923, DOI 10.1084/jem.173.4.923; ARIIZUMI K, 1995, J IMMUNOL, V154, P6031; BRADDING P, 1993, J IMMUNOL, V151, P3853; CHAZEN GD, 1989, P NATL ACAD SCI USA, V86, P5923, DOI 10.1073/pnas.86.15.5923; GOSSET P, 1992, AM REV RESPIR DIS, V146, P768, DOI 10.1164/ajrccm/146.3.768; GREWE M, 1994, LANCET, V343, P25, DOI 10.1016/S0140-6736(94)90879-6; GREWE M, 1995, J INVEST DERMATOL, V105, P407, DOI 10.1111/1523-1747.ep12321078; HAMID Q, 1992, BLOOD, V80, P1496; HEUFLER C, 1993, J EXP MED, V178, P1109, DOI 10.1084/jem.178.3.1109; MIYAMOTO J, 1975, JPN J EXP MED, V45, P133; RICH BE, 1993, J EXP MED, V177, P305, DOI 10.1084/jem.177.2.305; SAMARIDIS J, 1991, EUR J IMMUNOL, V21, P453, DOI 10.1002/eji.1830210230; STANDIFORD TJ, 1992, J IMMUNOL, V149, P2035; TAKASHIMA A, 1995, J INVEST DERMATOL, V105, pS50, DOI 10.1111/1523-1747.ep12315288; TOSHITANI A, 1993, J INVEST DERMATOL, V100, P299, DOI 10.1111/1523-1747.ep12469875; UEHIRA M, 1993, INT IMMUNOL, V5, P1619, DOI 10.1093/intimm/5.12.1619; VELLENGA E, 1992, J IMMUNOL, V149, P2992; Yamada N, 1995, J ALLERGY CLIN IMMUN, V96, P1069, DOI 10.1016/S0091-6749(95)70192-3	19	12	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	2	S			S201	S206		10.1016/S0091-6749(96)70067-2	http://dx.doi.org/10.1016/S0091-6749(96)70067-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WC447	8977528				2022-12-18	WOS:A1996WC44700005
J	Wenzel, SE				Wenzel, SE			Abnormalities of cell and mediator levels in bronchoalveolar lavage fluid of patients with mild asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; bronchial hyperreactivity; bronchoalveolar lavage; inflammatory cells; lung function; mediators	ENDOBRONCHIAL ALLERGEN CHALLENGE; SYMPTOMATIC ASTHMA; NOCTURNAL ASTHMA; ANTIGEN CHALLENGE; ATOPIC ASTHMATICS; PERIPHERAL-BLOOD; BRONCHIAL-ASTHMA; MAST-CELLS; T-CELLS; AIRWAYS	Increases in numbers and the activation state of inflammatory cells are typical findings even irt patients with mild asthma. Periods of worsening inflammation are characterized by further changes, such as art increased number of eosinophils in patients with nocturnal asthma, an increased number of lymphocytes and basophils after allergen provocation, and art increased number of neutrophils after exposure to toluene diisocyanate. Correlations of bronchoalveolar lavage (BAL) findings with physiologic changes in patients with asthma are helpful but must be analyzed in the context of the difficulties in absolute quantification of cells and mediators in lavage. Correlations have been reported between BAL mast cells, eosinophils, and eosinophilic cationic protein and methacholine PC20 and FEV(1). Correlations of other cell types or mediators with physiologic changes are either controversial (as with lymphocytes and their activation) or nonexistent (as with most mediators that have been measured). Ex vivo mediator production may be a useful measure. The ability to measure peripheral resistance directly at the site of inflammation may become an asset of the endobronchial instillation method Causality can be proved only by selectively adding or removing cer-tain inflammatory mediators through the use of leukotriene synthesis inhibitors, human grade eicosanoids, specific antagonists, agonists, and humanized antibodies. Of these examples, only leukotriene modulation has been evaluated with BAL in studies with human subjects. Whether inflammation and obstruction in patients with asthma result from the lack of certain mediators and/or an excess of others is unknown.			Wenzel, SE (corresponding author), UNIV COLORADO,NATL JEWISH CTR IMMUNOL & RESP MED,CTR HLTH SCI,1400 JACKSON ST,DENVER,CO 80206, USA.							ADELROTH E, 1990, AM REV RESPIR DIS, V142, P91; ALAM R, 1993, AM REV RESPIR DIS, V148, P1066, DOI 10.1164/ajrccm/148.4_Pt_1.1066; BORISH L, 1992, J IMMUNOL, V149, P3078; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; BROIDE DH, 1991, J ALLERGY CLIN IMMUN, V88, P637, DOI 10.1016/0091-6749(91)90158-K; BROIDE DH, 1991, J CLIN INVEST, V88, P1048, DOI 10.1172/JCI115366; CALHOUN WJ, 1993, AM REV RESPIR DIS, V147, pA520; CASALE TB, 1987, J CLIN INVEST, V79, P1197, DOI 10.1172/JCI112937; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DIAZ P, 1984, J ALLERGY CLIN IMMUN, V74, P41, DOI 10.1016/0091-6749(84)90085-X; DIAZ P, 1989, AM REV RESPIR DIS, V139, P1383, DOI 10.1164/ajrccm/139.6.1383; GEORAS SN, 1992, AM J RESP CELL MOL, V7, P261, DOI 10.1165/ajrcmb/7.3.261; GRATZIOU C, 1992, AM REV RESPIR DIS, V145, P1259, DOI 10.1164/ajrccm/145.6.1259; JARJOUR NN, 1992, AM REV RESPIR DIS, V146, P905, DOI 10.1164/ajrccm/146.4.905; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; LAM S, 1988, J ALLERGY CLIN IMMUN, V81, P711, DOI 10.1016/0091-6749(88)91043-3; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; MARINI M, 1992, CHEST, V102, P661, DOI 10.1378/chest.102.3.661; MARTIN RJ, 1991, AM REV RESPIR DIS, V143, P351, DOI 10.1164/ajrccm/143.2.351; MAXWELL DL, 1993, EUR RESPIR J, V6, P1145; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; PARK CS, 1993, J ALLERGY CLIN IMMUN, V91, P623, DOI 10.1016/0091-6749(93)90268-K; PAVORD ID, 1993, AM REV RESPIR DIS, V148, P87, DOI 10.1164/ajrccm/148.1.87; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; TONNEL AB, 1983, LANCET, V2, P1406; WAGNER EM, 1990, AM REV RESPIR DIS, V141, P584, DOI 10.1164/ajrccm/141.3.584; WALKER C, 1991, J IMMUNOL, V146, P1829; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WENZEL SE, 1995, AM J RESP CRIT CARE, V152, P897, DOI 10.1164/ajrccm.152.3.7663802; WENZEL SE, 1990, AM REV RESPIR DIS, V142, P112, DOI 10.1164/ajrccm/142.1.112; WENZEL SE, 1988, AM REV RESPIR DIS, V137, P1002, DOI 10.1164/ajrccm/137.5.1002; WENZEL SE, 1989, AM REV RESPIR DIS, V139, P450, DOI 10.1164/ajrccm/139.2.450; WENZEL SE, 1994, ANN ALLERGY, V72, P261; WILSON JW, 1992, AM REV RESPIR DIS, V145, P958, DOI 10.1164/ajrccm/145.4_Pt_1.958; ZOCCA E, 1990, J APPL PHYSIOL, V68, P1576, DOI 10.1152/jappl.1990.68.4.1576	39	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1996	98	5	2	S			S17	S21		10.1016/S0091-6749(96)80124-2	http://dx.doi.org/10.1016/S0091-6749(96)80124-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VW140	8939172				2022-12-18	WOS:A1996VW14000004
J	Stevens, WJ; VandenAbbeele, J; Bridts, CH				Stevens, WJ; VandenAbbeele, J; Bridts, CH			Anaphylactic reaction after bites by Glossina morsitans (tsetse fly) in a laboratory worker	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											Stevens, WJ (corresponding author), UNIV INSTELLING ANTWERP,UNIV PLEIN 1,B-2610 ANTWERP,BELGIUM.		BRIDTS, Chris HM/M-7933-2016	BRIDTS, Chris HM/0000-0002-3324-7320; Van Den Abbeele, Jan/0000-0002-4533-4480				BRUMMERKORVENKONTIO H, 1994, J ALLERGY CLIN IMMUN, V93, P551, DOI 10.1016/S0091-6749(94)70066-4; Funfstuck V, 1989, Dermatol Monatsschr, V175, P499; OKA K, 1989, Journal of Dermatology (Tokyo), V16, P212; PENCHENIER L, 1981, Cahiers O.R.S.T.O.M. (Office de la Recherche Scientifique et Technique Outre-Mer) Serie Entomologie Medicale et Parasitologie, V19, P55	4	12	14	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1996	98	3					700	701		10.1016/S0091-6749(96)70105-7	http://dx.doi.org/10.1016/S0091-6749(96)70105-7			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VJ428	8828549				2022-12-18	WOS:A1996VJ42800028
J	Karaayvaz, M; Ozanguc, N				Karaayvaz, M; Ozanguc, N			Recall urticaria: A case report	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											Karaayvaz, M (corresponding author), GULHANE MIL MED ACAD,DEPT ALLERG DIS,TR-06018 ETLIK,ANKARA,TURKEY.							BRUYNZEEL DP, 1986, ARCH DERMATOL, V122, P323, DOI 10.1001/archderm.122.3.323; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; FEINBERG S, 1946, ALLERGY PRACTICE, P601; KELSO JM, 1994, J ALLERGY CLIN IMMUN, V93, P949, DOI 10.1016/0091-6749(94)90392-1; NELSON BL, 1986, ANN ALLERGY, V56, P331	5	12	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1996	97	6					1419	1420		10.1016/S0091-6749(96)70215-4	http://dx.doi.org/10.1016/S0091-6749(96)70215-4			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VD607	8648043				2022-12-18	WOS:A1996VD60700035
J	Lai, CKW; Ho, ASS; Chan, CHS; Tang, J; Leung, JCK; Lai, KN				Lai, CKW; Ho, ASS; Chan, CHS; Tang, J; Leung, JCK; Lai, KN			Interleukin-5 messenger RNA expression in peripheral blood CD4(+) cells in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cytokines; IL-5; eosinophils; eosinophil cationic protein; asthma; corticosteroids; T lymphocytes	LYMPHOCYTE-T ACTIVATION; CATIONIC PROTEIN ECP; BRONCHOALVEOLAR LAVAGE; ATOPIC ASTHMA; GLUCOCORTICOID THERAPY; EOSINOPHIL FUNCTION; BRONCHIAL-ASTHMA; SERUM; SALMETEROL; CD4+	Background: IL-5 has been implicated in the pathogenesis of asthma through its regulatory role on eosinophil survival proliferation, and effector function. Objective: The study was designed to investigate the relationships between IL-5 messenger RNA expression in circulating CD4(+) cells and serum concentrations of eosinophil cationic protein (ECP), a marker of eosinophil activation and disease activity in asthma. Methods: IL-5 gene expression was assessed semiquantitatively in ex vivo stimulated CD4(+) cells by reverse transcription-polymerase chain reaction and serum ECP concentration measured from venous blood samples collected fl om patients with acute severe asthma before the commencement of systemic steroid therapy (day 1) and on day 7 and from patients with stable asthma and healthy volunteers. Results: IL-5 gene expression was significantly higher in patients with acute asthma before steroid treatment than in those with stable disease and healthy subjects (p < 0.0001). Similar results were obtained with serum ECP levels: levels in patients with acute asthma were highest (20.30 +/- 5.31 mu g/L), followed by levels in patients with stable asthma (2.76 +/- 0.65 mu g/L) and levels in normal control subjects (1.37 +/- 0.06 mu g/L; p < 0.01 for all comparisons). Significant falls in both IL-5 expression and serum ECP level were seen on day 7 (p < 0.001) and coincided with a significant improvement in peak expiratory flow (p < 0.0001). Significant correlations were observed between IL-5 expression and ECP level (rho = 0.39, p < 0.01), IL-5 expression and peak expiratory flow (rho = -0.55, p < 0.0002), and peak expiratory flow and ECP level (rho = -0.32, p < 0.04). Conclusion: Our data therefore support an important regulatory role of IL-5 on eosinophil function in human asthma in vivo.			Lai, CKW (corresponding author), CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT MED,SHATIN,NT,HONG KONG.							ALEXANDER AG, 1994, THORAX, V49, P1231, DOI 10.1136/thx.49.12.1231; BRENNER CA, 1989, BIOTECHNIQUES, V7, P1096; BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; BROWN PH, 1991, LANCET, V338, P590, DOI 10.1016/0140-6736(91)90605-O; CAMPBELL HD, 1987, P NATL ACAD SCI USA, V84, P6629, DOI 10.1073/pnas.84.19.6629; CASTLE W, 1993, BRIT MED J, V306, P1034, DOI 10.1136/bmj.306.6884.1034; CHAPMAN KR, 1994, LANCET, V343, P1379, DOI 10.1016/S0140-6736(94)92520-8; CORRIGAN CJ, 1993, AM REV RESPIR DIS, V147, P540, DOI 10.1164/ajrccm/147.3.540; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; CORRIGAN CJ, 1988, LANCET, V1, P1129; COUSINS DJ, 1994, AM J RESP CRIT CARE, V150, pS50, DOI 10.1164/ajrccm/150.5_Pt_2.S50; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DOI S, 1994, CLIN EXP ALLERGY, V24, P854, DOI 10.1111/j.1365-2222.1994.tb01808.x; GARDINER PV, 1994, AM J RESP CRIT CARE, V150, P1006, DOI 10.1164/ajrccm.150.4.7921429; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HEINO M, 1994, J ALLERGY CLIN IMMUN, V93, P80, DOI 10.1016/0091-6749(94)90235-6; HOLGATE S, 1993, THORAX, V48, P103, DOI 10.1136/thx.48.2.103; HOLGATE ST, 1993, CLIN EXP ALLERGY S2, V23, P15; KELLY EAB, 1995, AM J RESP CRIT CARE, V151, pA778; LAI CKW, 1993, CHEST, V103, P782, DOI 10.1378/chest.103.3.782; LAI CKW, 1995, J ALLERGY CLIN IMMUN, V95, P276; LEE HJ, 1993, J IMMUNOL, V151, P6135; LEUNG JCK, 1992, CLIN EXP IMMUNOL, V90, P147; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; PETERSON CGB, 1991, CLIN EXP ALLERGY, V21, P561, DOI 10.1111/j.1365-2222.1991.tb00847.x; PICCINNI MP, 1991, P NATL ACAD SCI USA, V88, P8656, DOI 10.1073/pnas.88.19.8656; ROBERTS J A, 1992, American Review of Respiratory Disease, V145, pA418; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROBINSON DS, 1993, CLIN EXP ALLERGY, V23, P1, DOI 10.1111/j.1365-2222.1993.tb02475.x; ROBINSON DS, 1993, J ALLERGY CLIN IMMUN, V92, P397, DOI 10.1016/0091-6749(93)90118-Y; Siebert P., 1991, RT PCR METHODS APPL; SNIJDEWINT FGM, 1993, J IMMUNOL, V150, P5321; VENGE P, 1993, CLIN EXP ALLERGY, V23, P3, DOI 10.1111/j.1365-2222.1993.tb00372.x; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; WALSH GM, 1990, IMMUNOLOGY, V71, P258; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737	39	12	14	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1996	97	6					1320	1328		10.1016/S0091-6749(96)70201-4	http://dx.doi.org/10.1016/S0091-6749(96)70201-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VD607	8648029				2022-12-18	WOS:A1996VD60700021
J	Niimi, A; Amitani, R; Yamada, K; Tanaka, KI; Kuze, F				Niimi, A; Amitani, R; Yamada, K; Tanaka, KI; Kuze, F			Late respiratory response and associated eosinophilic inflammation induced by repeated exposure to toluene diisocyanate in guinea pigs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Toluene diisocyanate; late respiratory response; eosinophilic airway inflammation,; bronchoalveolar lavage; histology; guinea pigs; metyrapone	LATE-PHASE BRONCHOCONSTRICTION; LATE ASTHMATIC REACTIONS; BRONCHOALVEOLAR LAVAGE; LEUKOCYTE INFILTRATION; OCCUPATIONAL ASTHMA; ALLERGEN CHALLENGE; ANIMAL-MODELS; DOGS	Objective: The study was designed to establish an animal model of toluene diisocyanate (TDI)-induced late respiratory response and to investigate airway inflammatory cell dynamics in this model. Methods: Guinea pigs were exposed to 2,4-TDI dissolved in ethyl acetate by nasal application according to three schedules. Schedule 1 consisted of sensitization and multiple challenge (n = 58): 10% TDI was applied once daily for 7 days (sensitization) followed by challenges with 5% TDI once weekly for 4 weeks. Schedule 2 consisted of sensitization only (n = 5). 10% TDI was applied once daily for 7 days. Schedule 3 consisted of single challenge only (n = 12): 5% TDI was applied only once. As controls, ethyl acetate was applied according to the three schedules described above. Each animal was premedicated with metyrapone before each challenge. Bronchoalveolar lavage and histologic examination were performed at various times after the last challenge. Results: Schedule 1 induced immediate and late respiratory responses at a prevalence of 63% and 56%, respectively. Schedules 2 and 3 induced an immediate response in some animals but no late response. Neither immediate nor late response was observed in control animals. All of the subgroups of schedule I that developed late responses (examined at 2, 3, 6, 24 and 168 hours) showed a significant increase of eosinophils in bronchoalveolar lavage fluid and tissue compared with the corresponding control of each (examined at the same time points). Two of the subgroups with late responses (examined at 3 and 6 hours) were compared with their corresponding subgroups, which were given the same treatment, failed to develop late response, and were examined at the same time points; they again proved to have a significant increase of eosinophils in both samples. Subgroups of schedule 1 without late response (30 minutes, 3 and 6 hours), schedule 2 (6 hours), or schedule 3 (2 and 6 hours) did not show significant changes in lavage or tissue cell composition, except for the schedule 1 subgroup examined at 6 hours, which showed a significant increase of eosinophils only in the tissue compared with its control. Conclusions: Sensitization and multiple challenge with TDI induced immediate and/or late respiratory responses at a high prevalence in guinea pigs. Eosinophilic but not neutrophilic inflammation was involved in the late response.	KYOTO IND HLTH ASSOC, KYOTO, JAPAN; OSAKA MED COLL, DEPT INTERNAL MED 1, OSAKA, JAPAN	Osaka Medical College	Niimi, A (corresponding author), KYOTO UNIV, CHEST DIS RES INST, DEPT INFECT & INFLAMMAT, SAKYO KU, 53 KAWAHARA CHO, KYOTO 606, JAPAN.							BERNSTEIN IL, 1982, J ALLERGY CLIN IMMUN, V70, P393, DOI 10.1016/0091-6749(82)90030-6; BUTCHER BT, 1979, J ALLERGY CLIN IMMUN, V64, P146, DOI 10.1016/0091-6749(79)90049-6; COBBOLD RSC, 1974, TRANSDUCERS BIOMEDIC, P114; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DIAZ P, 1989, AM REV RESPIR DIS, V139, P1383, DOI 10.1164/ajrccm/139.6.1383; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36, DOI 10.1164/ajrccm/136.1.36; GORDON T, 1985, AM REV RESPIR DIS, V132, P1106; HUTSON PA, 1988, AM REV RESPIR DIS, V138, P1157, DOI 10.1164/ajrccm/138.5.1157; HUTSON PA, 1988, AM REV RESPIR DIS, V137, P548, DOI 10.1164/ajrccm/137.3.548; IIJIMA H, 1987, AM REV RESPIR DIS, V136, P922, DOI 10.1164/ajrccm/136.4.922; KAROL MH, 1994, EUR RESPIR J, V7, P555, DOI 10.1183/09031936.94.07030555; KAROL MH, 1981, TOXICOL APPL PHARM, V58, P221, DOI 10.1016/0041-008X(81)90426-9; KAROL MH, 1983, TOXICOL APPL PHARM, V68, P229, DOI 10.1016/0041-008X(83)90007-8; MAPP CE, 1988, EUR RESPIR J, V1, P273; MAUDERLY JL, 1977, LAB ANIM SCI, V27, P255; MOIRA CY, 1986, AM REV RESPIR DIS, V133, P686; NAGAI H, 1987, PROSTA LEUKOTR MED, V30, P111, DOI 10.1016/0262-1746(87)90141-7; PAGGIARO PL, 1986, THORAX, V41, P279, DOI 10.1136/thx.41.4.279; PATTERSON R, 1983, J ALLERGY CLIN IMMUN, V71, P604, DOI 10.1016/0091-6749(83)90443-8; PATTERSON R, 1974, ANNU REV MED, V25, P53, DOI 10.1146/annurev.me.25.020174.000413; ROSSI GA, 1991, AM REV RESPIR DIS, V144, P379, DOI 10.1164/ajrccm/144.2.379; SASAKI H, 1987, AM REV RESPIR DIS, V136, P1459, DOI 10.1164/ajrccm/136.6.1459; SUGAWARA Y, 1993, INT ARCH ALLERGY IMM, V101, P95, DOI 10.1159/000236504; Tanaka K, 1983, Bull Chest Dis Res Inst Kyoto Univ, V16, P1; THOMPSON JE, 1987, AM REV RESPIR DIS, V136, P43, DOI 10.1164/ajrccm/136.1.43	25	12	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1996	97	6					1308	1319		10.1016/S0091-6749(96)70200-2	http://dx.doi.org/10.1016/S0091-6749(96)70200-2			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VD607	8648028				2022-12-18	WOS:A1996VD60700020
J	MiraPerceval, JL; Ortiz, JL; Sarrio, F; Miralles, JC; Hernandez, J; NegroAlvarez, JM; LopezSanchez, JD; GarciaSelles, FJ; Pagan, JA				MiraPerceval, JL; Ortiz, JL; Sarrio, F; Miralles, JC; Hernandez, J; NegroAlvarez, JM; LopezSanchez, JD; GarciaSelles, FJ; Pagan, JA			Nizatidine anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							RANITIDINE		UNIV HOSP VIRGEN ARRIXACA,DEPT MED,ALLERGY UNIT,MURCIA,SPAIN	Hospital Clinico Universitario Virgen de la Arrixaca								di Ciommo V, 1993, Clin Ter, V143, P201; Enzan K, 1993, Masui, V42, P1833; GREER IA, 1990, BRIT J CLIN PRACT, V44, P78; LAZARO M, 1993, ALLERGY, V46, P385; POWELL JA, 1993, ANAESTH INTENS CARE, V21, P702, DOI 10.1177/0310057X9302100539	5	12	12	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1996	97	3					855	856		10.1016/S0091-6749(96)80165-5	http://dx.doi.org/10.1016/S0091-6749(96)80165-5			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UA975	8613644	Bronze			2022-12-18	WOS:A1996UA97500018
J	Donovan, GR; Manolios, N; Weiner, JM; Grennan, D; Huang, QR; Dunckley, H; Baldo, BA				Donovan, GR; Manolios, N; Weiner, JM; Grennan, D; Huang, QR; Dunckley, H; Baldo, BA			A family study of allergy: Segregation with HLA but not with T-cell receptor genes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ROYAL N SHORE HOSP, DEPT RHEUMATOL, ST LEONARDS, NSW 2065, AUSTRALIA; ALFRED HOSP, DEPT RESP MED, ASTHMA & ALLERGY UNIT, PRAHRAN, VIC 3181, AUSTRALIA; NEW S WALES RED CROSS BLOOD BANK, SYDNEY, NSW, AUSTRALIA	Royal North Shore Hospital; Florey Institute of Neuroscience & Mental Health; Australian Red Cross Blood Service	Donovan, GR (corresponding author), ROYAL N SHORE HOSP, KOLLING INST MED RES, ST LEONARDS, NSW 2065, AUSTRALIA.			Weiner, John/0000-0001-5895-8973; Manolios, Nicholas/0000-0002-6525-7830				CORNELIS F, 1992, GENOMICS, V13, P820, DOI 10.1016/0888-7543(92)90159-P; LI YX, 1990, J EXP MED, V171, P221, DOI 10.1084/jem.171.1.221; MOFFATT F, 1994, LANCET, V343, P1597, DOI 10.1016/S0140-6736(94)93057-0; OHEHIR RE, 1991, ANNU REV IMMUNOL, V9, P67, DOI 10.1146/annurev.iy.09.040191.000435; OTA M, 1992, TISSUE ANTIGENS, V39, P187, DOI 10.1111/j.1399-0039.1992.tb01935.x	5	12	12	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1996	97	2					712	713		10.1016/S0091-6749(96)70320-2	http://dx.doi.org/10.1016/S0091-6749(96)70320-2			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TW087	8621860	Bronze			2022-12-18	WOS:A1996TW08700020
J	MORELL, F; CODINA, R; RODRIGO, MJ; SUNYER, J; ANTO, JM; REED, CE				MORELL, F; CODINA, R; RODRIGO, MJ; SUNYER, J; ANTO, JM; REED, CE			DIAGNOSIS OF SOYBEAN-INDUCED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; ELISA; SOYBEANS; SKIN TEST	EPIDEMIC ASTHMA; DUST; ALLERGENS	Background: The role of soybean dust as a causal agent of asthma has been clearly established since the Barcelona asthma epidemics in the 1980s. The large number of patients who were first Seen with asthma symptoms during those epidemics provided an excellent opportunity to study the possibilities of different diagnostic tests. Objective: This study was designed to evaluate the usefulness of the skin test and amplified ELISA technique for quantifying specific IgE in the diagnosis of soybean asthma. Patients and results: Ninety epidemic asthmatic patients and 95 nonepidemic asthmatic patients were studied 2 years after the last epidemic. Results of prick tests and ELISAs for specific IgE with hall and dust extracts showed a significant difference between the two groups of patients (p < 0.001). Sensitivity and specificity of glycerinated prick test with hull extract in epidemic asthmatic patients were 57.7% and 95.3%, respectively, and ELISA values were 56.6% and 93.7%, respectively Similar results were obtained with dust extracts. Conclusion: Glycerinated skirt prick tests and ELISAs with soybean hull and dust extracts have proved effective in the diagnosis of soybean asthma, even 2 years after the epidemics. Taking into account the sensitivity (90.5%) and specificity (93.7%) of ELISA test results for epidemic asthmatic patients found when the epidemic occurred data from this study suggest that both tests may be very useful for the diagnosis of soybean dust-induced asthma.	UNIV BARCELONA,GEN HOSP,SERV BIOQUIM,IMMUNOL UNIT,BARCELONA,SPAIN; INST MUNICIPAL INVEST MED,DEPT EPIDEMIOL & SALUT PUBL,E-08003 BARCELONA,SPAIN; MAYO CLIN,ALLERGY RES DEPT,ROCHESTER,MN	University of Barcelona; Mayo Clinic	MORELL, F (corresponding author), UNIV BARCELONA,GEN HOSP,SERV PNEUMOL,PASSEIG VALL HEBRON S-N,E-08035 BARCELONA,SPAIN.		Sunyer, Jordi/G-6909-2014; Anto, J M/H-2676-2014	Sunyer, Jordi/0000-0002-2602-4110; Anto, J M/0000-0002-4736-8529; Morell Brotad, Ferran/0000-0002-7206-4543				ALBERT R, 1973, REV FR ALLERGOL, V13, P399, DOI 10.1016/S0035-2845(73)80061-7; ALVAREZDARDET C, 1989, NEW ENGL J MED, V320, P1127; ANTO JM, 1993, NEW ENGL J MED, V329, P1760, DOI 10.1056/NEJM199312093292402; ANTO JM, 1989, NEW ENGL J MED, V320, P1997; BOURGEOIS M, 1984, REV FR ALLERGOL, V24, P209, DOI 10.1016/S0335-7457(84)80052-0; BUSH RK, 1977, CLIN ALLERGY, V7, P369, DOI 10.1111/j.1365-2222.1977.tb01465.x; FLEISS JL, 1981, STATISTICAL METHODS, P215; GONZALEZ R, 1992, CLIN EXP ALLERGY, V22, P748, DOI 10.1111/j.1365-2222.1992.tb02814.x; HERNANDO L, 1989, LANCET, V1, P502; METZGER WJ, 1981, CLIN ALLERGY, V11, P523, DOI 10.1111/j.1365-2222.1981.tb02170.x; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; PLATTMILLS TE, 1982, CLIN ASPECTS IMMUNOL, P598; RODRIGO MJ, 1990, J ALLERGY CLIN IMMUN, V85, P778, DOI 10.1016/0091-6749(90)90198-D; SUNYER J, 1992, AM REV RESPIR DIS, V145, P1098, DOI 10.1164/ajrccm/145.5.1098; SUNYER J, 1989, LANCET, V1, P179; SWANSON MC, 1991, J ALLERGY CLIN IMMUN, V87, P783, DOI 10.1016/0091-6749(91)90123-6; SWANSON MC, 1991, 4TH INT C ENV LUNG D; VANMETRE TE, 1990, J ALLERGY CLIN IMMUN, V86, P583, DOI 10.1016/S0091-6749(05)80216-7	18	12	12	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1995	96	3					320	324		10.1016/S0091-6749(95)70050-1	http://dx.doi.org/10.1016/S0091-6749(95)70050-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RU660	7560633				2022-12-18	WOS:A1995RU66000003
J	HENRICKS, PAJ; ENGELS, F; VANDERLINDE, HJ; GARSSEN, J; NIJKAMP, FP				HENRICKS, PAJ; ENGELS, F; VANDERLINDE, HJ; GARSSEN, J; NIJKAMP, FP			13-HYDROXY-LINOLEIC ACID INDUCES AIRWAY HYPERRESPONSIVENESS TO HISTAMINE AND METHACHOLINE IN GUINEA-PIGS IN-VIVO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						AIRWAY HYPERRESPONSIVENESS; 13-HODE; LINOLEIC ACID; HISTAMINE; METHACHOLINE	HUMAN POLYMORPHONUCLEAR LEUKOCYTES; LINOLEIC-ACID; 13-HYDROXYOCTADECADIENOIC ACID; ARACHIDONIC-ACID; PROSTAGLANDIN-E2 PRODUCTION; BRONCHIAL HYPERREACTIVITY; BRONCHOALVEOLAR LAVAGE; ENDOTHELIAL-CELLS; ISOLATED TRACHEA; FATTY-ACIDS	The influence of 13-hydroxy-linoleic acid (13-HODE) on the pulmonary resistance and dynamic compliance of guinea pigs in vivo was determined. Intravenously administered histamine and methacholine caused dose-dependent increases in pulmonary resistance and dose-dependent decreases in dynamic compliance in anesthetized, spontaneously breathing guinea pigs. Inhalation of an aerosol containing 13-HODE (10 mu mol/L) enhanced the increases in pulmonary resistance observed after administration of histamine or methacholine when compared with the respective control animals. The effect of 13-HODE on the increase in pulmonary resistance after administration of histamine was dose-dependent. An enhancement in the pulmonary resistance was already measured after treatment of guinea pigs with aerosols of solutions containing 0.1 mu mol/L 13-HODE when compared with that of control animals, In contrast, the changes in dynamic compliance were not affected by 13-HODE. These results indicate that 13-HODE may play an important role in the induction of airway hyperresponsiveness in vivo when it is produced or released in significant amounts in the airways.	NATL INST PUBL HLTH & ENVIRONM PROTECT,DEPT PATHOL,3720 BA BILTHOVEN,NETHERLANDS	Netherlands National Institute for Public Health & the Environment	HENRICKS, PAJ (corresponding author), UNIV UTRECHT,UTRECHT INST PHARMACEUT SCI,DEPT PHARMACOL,POB 80082,3508 TB UTRECHT,NETHERLANDS.		Henricks, Paul/I-8255-2016; garssen, johan/I-7159-2016	Engels, Ferdi/0000-0002-5761-9328				ABBRACCHIO MP, 1986, PHARMACOL RES, V18, P93, DOI 10.1016/0031-6989(86)90138-4; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRAUNSTEIN G, 1988, BRIT J PHARMACOL, V95, P300, DOI 10.1111/j.1476-5381.1988.tb16577.x; BUCHANAN MR, 1985, J BIOL CHEM, V260, P6056; BUCKLEY TL, 1992, EUR J PHARMACOL, V218, P369, DOI 10.1016/0014-2999(92)90195-A; CAMP RDR, 1985, BRIT J PHARMACOL, V85, P837, DOI 10.1111/j.1476-5381.1985.tb11082.x; CLAEYS M, 1985, BIOCHIM BIOPHYS ACTA, V837, P35, DOI 10.1016/0005-2760(85)90083-9; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DEMEYER GRY, 1992, BRIT J PHARMACOL, V107, P597; ENGELS F, 1989, EUR J BIOCHEM, V184, P197, DOI 10.1111/j.1432-1033.1989.tb15007.x; ENGELS F, 1991, PROSTAGLANDINS, V42, P441, DOI 10.1016/0090-6980(91)90035-E; ENGELS F, 1986, FEBS LETT, V209, P249, DOI 10.1016/0014-5793(86)81121-8; ENGELS F, 1992, AM REV RESPIR DIS, V45, pA287; FERGUSON AC, 1992, J ALLERGY CLIN IMMUN, V90, P609, DOI 10.1016/0091-6749(92)90133-M; FOLKERTS G, 1985, EUR J PHARMACOL, V119, P117, DOI 10.1016/0014-2999(85)90329-2; FOLKERTS G, 1989, BRIT J PHARMACOL, V96, P388, DOI 10.1111/j.1476-5381.1989.tb11829.x; FORMAN HJ, 1989, ARCH BIOCHEM BIOPHYS, V274, P443, DOI 10.1016/0003-9861(89)90457-8; GARSSEN GJ, 1971, BIOCHEM J, V122, P327, DOI 10.1042/bj1220327; GLEICH GJ, 1988, J ALLERGY CLIN IMMUN, V81, P776, DOI 10.1016/0091-6749(88)90931-1; Henricks P A, 1990, Agents Actions Suppl, V31, P283; HENRICKS PAJ, 1991, EUR J PHARMACOL, V197, P233, DOI 10.1016/0014-2999(91)90530-4; HENRICKS PAJ, 1991, PROSTAGLANDINS, V41, P21, DOI 10.1016/0090-6980(91)90101-K; KAYE MG, 1990, AM REV RESPIR DIS, V141, P993, DOI 10.1164/ajrccm/141.4_Pt_1.993; LOESBERG C, 1987, AGENTS ACTIONS, V22, P223, DOI 10.1007/BF02009050; NIJKAMP FP, 1993, AM REV RESPIR DIS, V148, P727, DOI 10.1164/ajrccm/148.3.727; OOSTHUIZEN MJ, 1990, INFLAMMATION, V14, P401, DOI 10.1007/BF00914091; OREHEK J, 1973, NATURE-NEW BIOL, V245, P84, DOI 10.1038/newbio245084a0; OREHEK J, 1975, J PHARMACOL EXP THER, V194, P544; REINAUD O, 1989, BIOCHEM BIOPH RES CO, V161, P883, DOI 10.1016/0006-291X(89)92682-X; SETTY BNY, 1987, BIOCHEM BIOPH RES CO, V148, P528, DOI 10.1016/0006-291X(87)90908-9; SETTY BNY, 1987, BIOCHEM BIOPH RES CO, V146, P502, DOI 10.1016/0006-291X(87)90557-2; SOBERMAN RJ, 1985, J BIOL CHEM, V260, P4508; STOLL LL, 1994, AM J PHYSIOL, V266, pC990, DOI 10.1152/ajpcell.1994.266.4.C990; VANDEVELDE MJ, 1994, J LEUKOCYTE BIOL, V56, P200, DOI 10.1002/jlb.56.2.200; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62	35	12	12	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1995	96	1					36	43		10.1016/S0091-6749(95)70030-7	http://dx.doi.org/10.1016/S0091-6749(95)70030-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RK383	7622761				2022-12-18	WOS:A1995RK38300005
J	GODEAU, B; BROCHARD, L; THEODOROU, I; LEBARGY, F; AIACHE, JM; LEMAIRE, F; SCHAEFFER, A				GODEAU, B; BROCHARD, L; THEODOROU, I; LEBARGY, F; AIACHE, JM; LEMAIRE, F; SCHAEFFER, A			A CASE OF ACUTE EOSINOPHILIC PNEUMONIA WITH HYPERSENSITIVITY TO RED SPIDER ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							RESPIRATORY-FAILURE		HOP HENRI MONDOR,SERV REANIMAT MED,F-94010 CRETEIL,FRANCE; HOP SABOURIN,CHRU CLERMONT FERRAND,ALLERGOL RESP LAB,CLERMONT FERRAND,FRANCE	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; CHU Clermont Ferrand	GODEAU, B (corresponding author), HOP HENRI MONDOR,SERV MED INTERNE 1,F-94010 CRETEIL,FRANCE.							ALLEN JN, 1989, NEW ENGL J MED, V321, P569, DOI 10.1056/NEJM198908313210903; BADESCH DB, 1989, AM REV RESPIR DIS, V139, P249, DOI 10.1164/ajrccm/139.1.249; CARBONNELLE M, 1986, REV FR ALLERGOL, V26, P171, DOI 10.1016/S0335-7457(86)80028-4; DAVIS WB, 1986, CHEST, V90, P7, DOI 10.1378/chest.90.1.7; IVANICK MJ, 1986, SOUTHERN MED J, V79, P686, DOI 10.1097/00007611-198606000-00009	5	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1995	95	5	1				1056	1058		10.1016/S0091-6749(95)70110-9	http://dx.doi.org/10.1016/S0091-6749(95)70110-9			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QY917	7751505				2022-12-18	WOS:A1995QY91700021
J	ATKINS, PC; ZWEIMAN, B; LITTMAN, B; PRESTI, C; VONALLMEN, C; MOSKOVITZ, A; ESKRA, JD				ATKINS, PC; ZWEIMAN, B; LITTMAN, B; PRESTI, C; VONALLMEN, C; MOSKOVITZ, A; ESKRA, JD			PRODUCTS OF ARACHIDONIC-ACID METABOLISM AND THE EFFECTS OF CYCLOOXYGENASE INHIBITION ON ONGOING CUTANEOUS ALLERGIC REACTIONS IN HUMAN-BEINGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ARACHIDONIC ACID METABOLISM; CYCLOOXYGENASE INHIBITION; CUTANEOUS ALLERGIC REACTIONS; TENIDAP	LATE-PHASE RESPONSE; SKIN REACTIONS; ANTIGEN CHALLENGE; HISTAMINE; RELEASE; INVIVO; LEUKOTRIENE-B4; INDOMETHACIN; IMMEDIATE; MEDIATOR	Background: There have been conflicting reports about the effects of inhibition of arachidonic acid metabolism on early- and late-phase cutaneous reactions. We re-examined this question with a unique nonsteroidal antiinflammatory drug, tenidap sodium. Tenidap sodium has been demonstrated in in vitro studies to inhibit cyclooxygenase, lipoxygenase, and cytokine production (interleukin-1, interleukin-6, tumor necrosis factor-alpha). Methods: In a double-blind, randomized, crossover study, seven pollen-sensitive subjects ingested tenidap (120 mg, by mouth, daily) and placebo for 9 days with a 3-week washout period between treatments. On the eighth day they underwent allergen skin testing, measurable for up to 12 hours, and on the ninth day they underwent 5-hour skin chamber exposures to allergen and buffer. Chamber fluids were analyzed for cellular content, neutrophil granule protein release, cyclooxygenase and lipoxygenase arachidonic acid metabolites, histamine, and tryptase. Results: Tenidap did significantly inhibit cyclooxygenase metabolites at both antigen and buffer sites but had no effect on histamine, tryptase, lipoxygenase metabolites, or granulocyte infiltration. Neutrophil granule release of lactoferrin was lower at the antigen site during tenidap administration, but there was no reduction of elastase release. Prostaglandin E(2) and leukotriene E(4) increased significantly at antigen sites compared with buffer sites during placebo administration and were the most prominent arachidonic acid metabolites detected. Conclusion: Tenidap, despite inhibiting cyclooxygenase release at antigen sites, had no effect on skin test responses to antigen or on antigen-induced mediator release or granulocyte infiltration. We conclude that cyclooxygenase metabolites are not important in the development of an allergic cutaneous inflammatory response.	PFIZER INC,CENT RES,GROTON,CT	Pfizer	ATKINS, PC (corresponding author), UNIV PENN,SCH MED,DEPT MED,DIV ALLERGY & IMMUNOL,510 JOHNSON PAVIL,PHILADELPHIA,PA 19104, USA.				NIAID NIH HHS [AI-14332] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014332] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATKINS P, 1973, J ALLERGY CLIN IMMUN, V51, P263, DOI 10.1016/0091-6749(73)90128-0; ATKINS P, 1987, ALLERGY INT TXB, P255; ATKINS PC, 1982, J ALLERGY CLIN IMMUN, V69, P39, DOI 10.1016/0091-6749(82)90085-9; ATKINS PC, 1990, J ALLERGY CLIN IMMUN, V86, P360, DOI 10.1016/S0091-6749(05)80099-5; ATKINS PC, 1984, IMMUNOL ALLERGY PRAC, V6, P376; BLACKBURN WD, 1991, ARTHRITIS RHEUM, V34, P204, DOI 10.1002/art.1780340212; CAMP RDR, 1982, CLIN EXP DERMATOL, V7, P435, DOI 10.1111/j.1365-2230.1982.tb02453.x; DORSCH W, 1980, ALLERGY, V35, P503, DOI 10.1111/j.1398-9995.1980.tb01797.x; FARMER JC, 1991, AM REV RESPIR DIS, V144, P593, DOI 10.1164/ajrccm/144.3_Pt_1.593; FREELAND HS, 1989, J ALLERGY CLIN IMMUN, V83, P634, DOI 10.1016/0091-6749(89)90076-6; GRONNEBERG R, 1990, J ALLERGY CLIN IMMUN, V85, P843, DOI 10.1016/0091-6749(90)90066-D; GRONNEBERG R, 1985, ALLERGY, V40, P36, DOI 10.1111/j.1398-9995.1985.tb04152.x; MASSEY WA, 1991, BRIT J DERMATOL, V125, P529, DOI 10.1111/j.1365-2133.1991.tb14789.x; Moilanen E, 1988, Eicosanoids, V1, P35; OKAZAKI T, 1977, J ALLERGY CLIN IMMUN, V60, P360, DOI 10.1016/0091-6749(77)90067-7; RESHEF A, 1989, J ALLERGY CLIN IMMUN, V84, P678, DOI 10.1016/0091-6749(89)90296-0; SCHWARTZ LB, 1987, J ALLERGY CLIN IMMUN, V80, P850, DOI 10.1016/S0091-6749(87)80276-2; SHALIT M, 1989, J ALLERGY CLIN IMMUN, V83, P691, DOI 10.1016/0091-6749(89)90084-5; SIPE JD, 1992, J IMMUNOL, V148, P480; SMITH JA, 1980, J ALLERGY CLIN IMMUN, V65, P118, DOI 10.1016/0091-6749(80)90195-5; TALBOT SF, 1985, J CLIN INVEST, V76, P650, DOI 10.1172/JCI112018; ZIBACH VA, 1992, SEMIN DERMATOL, V11, P114; ZWEIMAN B, 1990, J IMMUNOL, V144, P3953	23	12	12	1	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1995	95	3					742	747		10.1016/S0091-6749(95)70180-X	http://dx.doi.org/10.1016/S0091-6749(95)70180-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QM017	7897158				2022-12-18	WOS:A1995QM01700015
J	OCONNELL, MA; PLUSS, JL; SCHKADE, P; HENRY, AR; GOODMAN, DL				OCONNELL, MA; PLUSS, JL; SCHKADE, P; HENRY, AR; GOODMAN, DL			RHIZOPUS-INDUCED HYPERSENSITIVITY PNEUMONITIS IN A TRACTOR DRIVER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							DISEASE		FITZSIMONS ARMY MED CTR,PULM DIS SERV,AURORA,CO 80045		OCONNELL, MA (corresponding author), FITZSIMONS ARMY MED CTR,HSHG,MDA,ALLERGY IMMUNOL SERV,AURORA,CO 80045, USA.							Alexandersson R, 1988, Arh Hig Rada Toksikol, V39, P405; BELIN KWL, 1980, EUR J RESIR DIS S, V61, P163; BELIN L, 1980, EUR J RESPIR DIS, V61, P169; BRUCE RA, 1971, ANN CLIN RES, V3, P323; Fink JN, 1993, ALLERGY PRINCIPLES P, P1415; HALLIWELL REW, 1979, J AM VET MED ASSOC, V174, P277	6	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1995	95	3					779	780		10.1016/S0091-6749(95)70188-5	http://dx.doi.org/10.1016/S0091-6749(95)70188-5			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QM017	7897166				2022-12-18	WOS:A1995QM01700023
J	COLUMBO, M; HOROWITZ, EW; KAGEYSOBOTKA, A; LICHTENSTEIN, LM				COLUMBO, M; HOROWITZ, EW; KAGEYSOBOTKA, A; LICHTENSTEIN, LM			HISTAMINE-RELEASE FROM HUMAN BASOPHILS INDUCED BY PLATELET-ACTIVATING-FACTOR - THE ROLE OF EXTRACELLULAR CALCIUM, INTERLEUKIN-3, AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BASOPHILS; HISTAMINE; PAF; CALCIUM CYTOKINES	METHIONYL-LEUCYL-PHENYLALANINE; HEMATOPOIETIC GROWTH-FACTORS; MEDIATOR RELEASE; HUMAN EOSINOPHILS; HUMAN-LEUKOCYTES; FACTOR PAF; DE-GRANULATION; MAST-CELLS; NEUTROPHILS; CYTOCHALASIN	Although we have demonstrated that platelet activating factor (PAF) directly induces histamine release from human basophils, other studies have failed to report similar effects. In an attempt to understand the variability of these results, we examined the effect of some factors that could influence the basophils' response to PAF such as, extracellular Ca2+ and cytokines (interleukin-3 and granulocyte-macrophage colony-stimulating factor [GM-CSF]). The secretion of histamine induced by PRF was optimal when the cells were incubated in Ca2+ for 2 to 5 minutes whereas it declined at longer time intervals up to 15 minutes. If cytochalasin B (5 mu g/ml) was coincubated with PAF (1 mu mol/L) to enhance the secretory response, histamine release was maximal at time 0 and decreased in parallel with the rime of the basophils' exposure to Ca2+, like 0.1 mu g/ml anti-IgE-induced histamine secretion but unlike 1 mu g/L formyl-methionyl-leucyl-phenylalanine-induced histamine secretion. We found that there is synergy between interleukin-3 (1 to 3 ng/ml and PAF (1 mu mol/L) for secretion of histamine from human basophils (p < 0.05) and that GM-CSF (10 ng/ml) significantly (p < 0.02) potentiates the secretion of histamine activated by PAF (1 mu mol/L). Our results demonstrate that: (1) the kinetics of the interaction between Ca2+ and the activation pathway that leads to histamine secretion are central events in the release reaction elicited by PAF in human basophils, and (2) interleukin-3 and GM-CSF can potentiate the secretory response of human basophils stimulated by PAF.	JOHNS HOPKINS UNIV,SCH MED,JOHNS HOPKINS ASTHMA & ALLERGY CTR,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD	Johns Hopkins University; Johns Hopkins Medicine					NIAID NIH HHS [AI07290] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADKINSON NF, 1980, MANUAL CLIN IMMUNOLO, P800; BETZ SJ, 1980, J IMMUNOL, V125, P2756; BRUNNER T, 1991, J IMMUNOL, V147, P237; CAMUSSI G, 1981, IMMUNOLOGY, V42, P191; CHILTON FH, 1982, J BIOL CHEM, V257, P5402; CIRILLO R, 1990, CYTOKINES BASIC PRIN, P351; COLUMBO M, 1990, J IMMUNOL, V145, P3855; COLUMBO M, 1990, BIOCHEM PHARMACOL, V39, P285, DOI 10.1016/0006-2952(90)90027-I; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; GILLESPIE E, 1972, J CLIN INVEST, V51, P2941, DOI 10.1172/JCI107118; HAAKFRENDSCHO M, 1988, J CLIN INVEST, V82, P17, DOI 10.1172/JCI113567; HESS AD, 1988, J IMMUNOL, V141, P3263; HIRAI K, 1988, J IMMUNOL, V141, P3958; HIRAI K, 1990, J EXP MED, V172, P1525, DOI 10.1084/jem.172.5.1525; IHLE JN, 1981, J IMMUNOL, V126, P2184; KROEGEL C, 1989, J IMMUNOL, V142, P3518; LEE TC, 1984, J BIOL CHEM, V259, P5526; LICHTENSTEIN LM, 1971, J IMMUNOL, V107, P1122; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; MACDONALD SM, 1989, J IMMUNOL, V142, P3527; MACGLASHAN DW, 1991, LUNG, P591; MARONE G, 1984, J IMMUNOL, V133, P1542; MASSEY WA, 1989, J IMMUNOL, V143, P1875; OKUDA Y, 1988, INT ARCH ALLER A IMM, V85, P341, DOI 10.1159/000234529; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; SCHLEIMER RP, 1981, J IMMUNOL, V126, P570; SCHLEIMER RP, 1991, AM REV RESPIR DIS, V143, P1169, DOI 10.1164/ajrccm/143.5_Pt_1.1169; SCHLEIMER RP, 1989, J IMMUNOL, V143, P1310; SHAW JO, 1981, J IMMUNOL, V127, P1250; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; TAMURA N, 1988, J IMMUNOL, V141, P4291; WALKER BAM, 1991, J IMMUNOL, V146, P3124; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; YASAKA T, 1982, J IMMUNOL, V128, P1939	34	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1995	95	2					565	573		10.1016/S0091-6749(95)70319-5	http://dx.doi.org/10.1016/S0091-6749(95)70319-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QH697	7531728				2022-12-18	WOS:A1995QH69700009
J	DONOHOE, PJ; HEDDLE, RJ; SYKES, PJ; FUSCO, M; FLEGO, LR; ZOLA, H				DONOHOE, PJ; HEDDLE, RJ; SYKES, PJ; FUSCO, M; FLEGO, LR; ZOLA, H			IGE+ CELLS IN THE PERIPHERAL-BLOOD OF ATOPIC, NONATOPIC, AND BEE VENOM-HYPERSENSITIVE INDIVIDUALS EXHIBIT THE PHENOTYPE OF HIGHLY DIFFERENTIATED B-CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IGE CELL PHENOTYPE; ENUMERATION; BEE VENOM HYPERSENSITIVITY; DESENSITIZATION; IMMUNOTHERAPY MECHANISM	HUMAN LYMPHOCYTES-B; MONOCLONAL-ANTIBODIES; INTERFERON-GAMMA; EXPRESSION; RECEPTOR; INTERLEUKIN-4; ANTIGENS; ALPHA; IMMUNOFLUORESCENCE; ENUMERATION	We have analyzed IgE(+) cells in peripheral blood of atopic donors, donors hypersensitive to bee venom, and nonatopic control donors with two- and three-color flow cytometry. Although the percentage of IgE(+) cells varied among these groups, the overall phenotypic patterns were similar. Most IgE(+) cells do not display typical B-cell markers, such as CD19, CD20, and CD21. A significant proportion of these cells stain for CD38, indicating that they are more differentiated. IgE(+) cells express Fc gamma RII and CD45RO, an isoform associated with an advanced level of differentiation The majority of IgE(+) cells do nor coexpress other surface immunoglobulin isotypes. In the case of bee venom-hypersensitive donors, we have been able to identify a small population of IgE(+) cells with a specificity for phospholipase A2 a major immunogenic component of bee venom. The phospholipase A2(+) cells display a phenotype similar to that of the IgE(+) cells.	FLINDERS MED CTR, DEPT CLIN IMMUNOL, BEDFORD PK, SA 5042, AUSTRALIA; FLINDERS MED CTR, DEPT HAEMATOL, BEDFORD PK, SA 5042, AUSTRALIA; FLINDERS UNIV S AUSTRALIA, BEDFORD PK, SA 5042, AUSTRALIA	Flinders Medical Centre; Flinders Medical Centre; Flinders University South Australia				Sykes, Pam/0000-0001-9239-7639				ANDERSON CL, 1989, CLIN IMMUNOL IMMUNOP, V53, pS63, DOI 10.1016/0090-1229(89)90071-8; ANDERSON KC, 1983, J IMMUNOL, V130, P1132; BARR IG, 1984, SCAND J HAEMATOL, V33, P187; BETTELHEIM P, 1994, LEUKOCYTE TYPING, V4, P891; CAPRON M, 1987, J IMMUNOL, V139, P2059; CHEN YW, 1986, J EXP MED, V164, P562, DOI 10.1084/jem.164.2.562; DEFRANCE T, 1987, J IMMUNOL, V139, P1135; DELPRETE G, 1989, J CLIN INVEST, V84, P1830, DOI 10.1172/JCI114368; DORKEN B, 1989, LEUCOCYTE TYPING, V4, P34; FAVALORO EJ, 1987, DIS MARKERS, V5, P215; Goding J., 1986, MONOCLONAL ANTIBODIE, P108; HAMMARSTROM L, 1986, IMMUNOGLOBULINS HLTH, P31; HANCOCK WW, 1983, BLOOD, V62, P1271; HOOK WA, 1983, FED PROC, V42, P713; JENSEN GS, 1991, BLOOD, V78, P711, DOI 10.1182/blood.V78.3.711.bloodjournal783711; KANSAS GS, 1991, J IMMUNOL, V147, P4094; KENNEY JS, 1990, LABORATORY METHODS I, P231; KING CL, 1990, J IMMUNOL METHODS, V132, P37, DOI 10.1016/0022-1759(90)90395-C; KING CL, 1991, J IMMUNOL, V146, P1478; KIPPS TJ, 1989, ADV IMMUNOL, V47, P117, DOI 10.1016/S0065-2776(08)60663-X; KURITANI T, 1982, J EXP MED, V155, P839, DOI 10.1084/jem.155.3.839; LAWSON DAT, 1985, J IMMUNOL, V134, P3007; LEE FK, 1991, J CLIN IMMUNOL, V11, P213, DOI 10.1007/BF00917427; LOOK AT, 1989, LEUCOCYTE TYPING, V4, P784; MACKENZIE T, 1989, J EXP MED, V169, P407, DOI 10.1084/jem.169.2.407; MANTZIORIS BX, 1993, J IMMUNOL, V150, P5175; MILLS FC, 1992, J IMMUNOL, V149, P1075; MULLER K M, 1991, Journal of Dermatological Science, V2, P125, DOI 10.1016/0923-1811(91)90022-P; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; REIMER CB, 1984, HYBRIDOMA, V3, P263, DOI 10.1089/hyb.1984.3.263; RIMMER EF, 1987, CLIN EXP IMMUNOL, V68, P712; SHAH VO, 1989, LEUKOCYTE TYPING, V4, P855; SMITH SH, 1986, IMMUNOLOGY, V58, P63; STEIN LD, 1986, EUR J IMMUNOL, V16, P1167, DOI 10.1002/eji.1830160922; TERHORST C, 1981, CELL, V23, P771, DOI 10.1016/0092-8674(81)90441-4; THYPHRONITIS G, 1989, P NATL ACAD SCI USA, V86, P5580, DOI 10.1073/pnas.86.14.5580; VALENT P, 1994, LEUKOCYTE TYPING, V4, P913; VANDONGEN JJM, 1988, BLOOD, V71, P603; WEINBERG DS, 1984, BLOOD, V63, P1080, DOI 10.1182/blood.V63.5.1080.1080; WEIS JJ, 1984, P NATL ACAD SCI-BIOL, V81, P881, DOI 10.1073/pnas.81.3.881; ZIPF TF, 1983, J IMMUNOL, V131, P3064; ZOLA H, 1990, J IMMUNOL METHODS, V135, P247, DOI 10.1016/0022-1759(90)90278-4; ZOLA H, 1987, DIS MARKERS, V5, P227; ZOLA H, 1989, IMMUNOL CELL BIOL, V67, P233, DOI 10.1038/icb.1989.35; ZOLA H, 1991, DIS MARKERS, V9, P103; ZOLA H, 1990, HUM IMMUNOL, V27, P368, DOI 10.1016/0198-8859(90)90087-6	46	12	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1995	95	2					587	596		10.1016/S0091-6749(95)70321-7	http://dx.doi.org/10.1016/S0091-6749(95)70321-7			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QH697	7531730	Bronze			2022-12-18	WOS:A1995QH69700011
J	CASTILLO, S; SANCHEZBORGES, M; CAPRILES, A; SUAREZCHACON, R; CABALLERO, F; FERNANDEZCALDAS, E				CASTILLO, S; SANCHEZBORGES, M; CAPRILES, A; SUAREZCHACON, R; CABALLERO, F; FERNANDEZCALDAS, E			SYSTEMIC-ANAPHYLAXIS AFTER INGESTION OF MITE-CONTAMINATED FLOUR	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1995	95	1	2				304	304						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QE854					2022-12-18	WOS:A1995QE85400652
J	VADAS, M; LOPEZ, A; GAMBLE, J; KHEWGOODALL, Y; SMITH, W; BERNARD, C; COCKERILL, G; COCKERILL, P; SHANNON, F; SUN, QY; KORPELAINEN, E; VANDENHEUVEL, C; HERCUS, T				VADAS, M; LOPEZ, A; GAMBLE, J; KHEWGOODALL, Y; SMITH, W; BERNARD, C; COCKERILL, G; COCKERILL, P; SHANNON, F; SUN, QY; KORPELAINEN, E; VANDENHEUVEL, C; HERCUS, T			CYTOKINES AND ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							PERIPHERAL-BLOOD EOSINOPHILS; COLONY-STIMULATING FACTOR; INTERLEUKIN-3; TRANSMIGRATION; RELEASE				VADAS, M (corresponding author), INST MED & VET SCI,HANSON CTR CANC RES,POB 14,RUNDLE MALL,ADELAIDE,SA 5000,AUSTRALIA.		Vadas, Mathew/R-1378-2019; van den Heuvel, Cameron J./E-1993-2012	van den Heuvel, Cameron J./0000-0001-7264-4655; Lopez, Angel F/0000-0001-7430-0135; Smith, William/0000-0002-4610-998X; Cockerill, Peter/0000-0002-4410-8174	NCI NIH HHS [CA45822] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045822] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRAUN RK, 1993, EUR J IMMUNOL, V23, P956, DOI 10.1002/eji.1830230429; COCKERILL GW, 1994, ANN REV CYTOL, V154; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; HERCUS TR, 1994, P NATL ACAD SCI USA, V91, P5838, DOI 10.1073/pnas.91.13.5838; KHEWGOODALL Y, UNPUB CHRONIC EXPRES; KITA H, 1991, J EXP MED, V174, P745, DOI 10.1084/jem.174.3.745; KORPELAINEN EI, 1993, P NATL ACAD SCI USA, V90, P11137, DOI 10.1073/pnas.90.23.11137; MOSER R, 1992, J IMMUNOL, V149, P1432; SMITH WB, IN PRESS P NATL ACAD	9	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	2	S			1289	1293		10.1016/0091-6749(94)90344-1	http://dx.doi.org/10.1016/0091-6749(94)90344-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA020	7798570				2022-12-18	WOS:A1994QA02000024
J	NOVEMBRE, E; FRONGIA, G; LOMBARDI, E; VENERUSO, G; VIERUCCI, A				NOVEMBRE, E; FRONGIA, G; LOMBARDI, E; VENERUSO, G; VIERUCCI, A			THE PREVENTIVE EFFECT OF NEDOCROMIL OR FUROSEMIDE ALONE OR IN COMBINATION ON EXERCISE-INDUCED ASTHMA IN CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EXERCISE-INDUCED ASTHMA; FUROSEMIDE; NEDOCROMIL; CHILDREN	INDUCED BRONCHOCONSTRICTION; INHALED FUROSEMIDE; MAST-CELL; BRONCHIAL RESPONSE; CROMOLYN SODIUM; COLD; AIR; HYPERVENTILATION; METHACHOLINE; FRUSEMIDE	Background: Recent evidence suggests that inhaled nedocromil and furosemide are effective in preventing asthma by ultrasonically nebulized distilled water allergen, and exercise. There are, however no studies that compare the effects of these two drugs. The aim of this study was to investigate the effect of inhaled furosemide (30 mg), nedocromil (4 mg), the combination of these two drugs, and placebo aerosol in preventing exercise-induced asthma. Methods: Twenty-four children with exercise-induced asthma, aged 6 to 16 years, performed a treadmill test before and 20 minutes after a single dose of drug(s) in a double-blind trial. Lung function measurements were taken before drug administration, before the exercise test (20 minutes after drug administration), and then 2, 4, 6, 8, 10, 15, 20, and 30 minutes after the exercise test. Results: Both active drugs performed significantly better than placebo. In fact, the exercise challenge resulted in a mean maximum fall in forced expiratory volume in 1 second of 28.46% +/- 13.84% after administration of placebo but of only 15.42% +/- 8.35% after administration of nedocromil (p < 0.001) and of 11.37% +/- 9.14% after administration of furosemide (p < 0.001). When the two drugs were given together there was a statistically significant additive effect because the mean maximum fall in forced expiratory volume in 1 second was 5.75% +/- 3.57% (nedocromil vs nedocromil + furosemide: p < 0.001; furosemide vs nedocromil + furosemide: p < 0.01). Conclusion: This study suggests that nedocromil and furosemide provide a comparable effect in preventing exercise-induced asthma in children. The combined administration of the two drugs significantly increases the protective effects, suggesting a potential therapeutic use.			NOVEMBRE, E (corresponding author), OSPED A MEYER,DEPT PEDIAT,ALLERGY & CLIN IMMUNOL UNIT,V L GIORDANO 13,FLORENCE,ITALY.		Lombardi, Enrico/K-3356-2016	Lombardi, Enrico/0000-0003-4749-9091				ALBAZZAZ MK, 1989, THORAX, V44, P816, DOI 10.1136/thx.44.10.816; ANDERSON SA, 1986, J ALLERGY CLIN IMMUN, V76, P763; BIANCO S, 1988, LANCET, V2, P252; BIANCO S, 1989, NEW ENGL J MED, V321, P1069, DOI 10.1056/NEJM198910193211602; BONER AL, 1989, ANN ALLERGY, V62, P38; BROIDE DH, 1990, AM REV RESPIR DIS, V141, P563, DOI 10.1164/ajrccm/141.3.563; BUNDGAARD A, 1988, ALLERGY, V43, P493, DOI 10.1111/j.1398-9995.1988.tb01625.x; CHURCH MK, 1991, ASTHMA ITS PATHOLOGY, P561; DEAL EC, 1980, J CLIN INVEST, V65, P659, DOI 10.1172/JCI109711; DIXON CMS, 1990, BRIT J CLIN PHARMACO, V30, P371, DOI 10.1111/j.1365-2125.1990.tb03786.x; GONZALEZ JP, 1987, DRUGS, V34, P560, DOI 10.2165/00003495-198734050-00004; GRUBBE RE, 1990, J ALLERGY CLIN IMMUN, V85, P881, DOI 10.1016/0091-6749(90)90072-C; JARJOUR NN, 1992, J ALLERGY CLIN IMMUN, V89, P60, DOI 10.1016/S0091-6749(05)80041-7; KAWABORI I, 1976, J ALLERGY CLIN IMMUN, V58, P447, DOI 10.1016/0091-6749(76)90188-3; KONIG P, 1987, J ALLERGY CLIN IMMUN, V79, P64, DOI 10.1016/S0091-6749(87)80018-0; LEE TH, 1983, LANCET, V1, P520; LLOYD EL, 1988, LANCET, V2, P564; LUNDERGAN CF, 1988, J PHARMACOL EXP THER, V246, P102; MORGAN DJR, 1983, THORAX, V38, P771, DOI 10.1136/thx.38.10.771; MORTON AR, 1992, ANN ALLERGY, V68, P143; MOSCATO G, 1991, AM REV RESPIR DIS, V143, P561, DOI 10.1164/ajrccm/143.3.561; NICHOL GM, 1990, AM REV RESPIR DIS, V142, P576, DOI 10.1164/ajrccm/142.3.576; OCONNOR BJ, 1990, THORAX, V45, P333; ODONNELL WJ, 1992, AM REV RESPIR DIS, V146, P1518, DOI 10.1164/ajrccm/146.6.1518; PAVORD ID, 1991, AM REV RESPIR DIS, V143, P210; ROBERTS JA, 1985, CLIN ALLERGY, V15, P377, DOI 10.1111/j.1365-2222.1985.tb03006.x; SEIDENBERG J, 1992, ARCH DIS CHILD, V67, P214, DOI 10.1136/adc.67.2.214; SHEPPARD D, 1987, AM REV RESPIR DIS, V136, P592; VARGAS FS, 1992, CHEST, V102, P408, DOI 10.1378/chest.102.2.408; VILSVIK J, 1988, ANN ALLERGY, V61, P367; WELSH MJ, 1983, J CLIN INVEST, V71, P1392, DOI 10.1172/JCI110892; ZAPLETAL A, 1969, J APPL PHYSIOL, V26, P308, DOI 10.1152/jappl.1969.26.3.308	32	12	12	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1994	94	2					201	206		10.1016/0091-6749(94)90041-8	http://dx.doi.org/10.1016/0091-6749(94)90041-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PC926	8064072				2022-12-18	WOS:A1994PC92600010
J	TERR, AI				TERR, AI			MULTIPLE CHEMICAL SENSITIVITIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Symposium on Building-Related and Home-Related Complaints and Illnesses: Sick Building Syndrome	DEC 03-05, 1992	LAKE BUENA VISTA, FL				ENVIRONMENTAL ILLNESS; 20TH-CENTURY DISEASE; CLINICAL ECOLOGY; FOOD; ALLERGY; MIGRAINE		STANFORD UNIV,CTR MED,STANFORD,CA 94305	Stanford University								ASHFORD NA, 1991, CHEM EXPOSURES; BELL IR, 1982, CLIN ECOLOGY NEW MED; BENNETT JE, 1990, NEW ENGL J MED, V323, P1766, DOI 10.1056/NEJM199012203232509; BLACK DW, 1990, JAMA-J AM MED ASSOC, V264, P3166, DOI 10.1001/jama.264.24.3166; BRODSKY CM, 1983, PSYCHOSOMATICS, V24, P731, DOI 10.1016/S0033-3182(83)73168-3; CULLEN MR, 1987, OCCUP MED, V2, P655; DICKEY LD, 1976, CLIN ECOLOGY; GOLBERT TM, 1975, J ALLERGY CLIN IMMUN, V56, P170, DOI 10.1016/0091-6749(75)90089-5; JEWETT DL, 1990, NEW ENGL J MED, V323, P429, DOI 10.1056/NEJM199008163230701; LEVIN AS, 1987, STATE ART REV OCCUP, V2, P669; LEVINE SA, 1983, ORTHOMOL PSYCHIAT, V12, P166; MABRAY CR, 1982, OBSTET GYNECOL, V59, P560; MCGOVERN JJ, 1983, ARCH OTOLARYNGOL, V109, P292; MONRO J, 1984, LANCET, V2, P719; MONRO JA, 1983, P NUTR SOC, V42, P241, DOI 10.1079/PNS19830028; Randolph T.G., 1962, HUMAN ECOLOGY SUSCEP; RANDOLPH TG, 1980, ALTERNATIVE APPROACH; RINKEL HJ, 1948, J PEDIATR, V32, P266, DOI 10.1016/S0022-3476(48)80030-2; ROOT DE, 1985, MAY P NAT C HAZ WAST, P150; SIMON GE, 1990, AM J PSYCHIAT, V147, P7; SPARKS PJ, 1990, WESTERN J MED, V153, P28; STEWART DE, 1985, CAN MED ASSOC J, V133, P1001; TERR AI, 1987, J ALLERGY CLIN IMMUN, V79, P423, DOI 10.1016/0091-6749(87)90357-5; TERR AI, 1989, J OCCUP ENVIRON MED, V31, P257, DOI 10.1097/00043764-198903000-00012; TERR AI, 1987, STATE ART REV OCCUP, V2, P683; TERR AI, 1986, ARCH INTERN MED, V146, P145	26	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1994	94	2	2				362	366		10.1053/ai.1994.v94.a56015	http://dx.doi.org/10.1053/ai.1994.v94.a56015			5	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG770	8077590				2022-12-18	WOS:A1994PG77000012
J	CARTIER, A; GHEZZO, H; LARCHEVEQUE, J; TRUDEAU, C; MALO, JL				CARTIER, A; GHEZZO, H; LARCHEVEQUE, J; TRUDEAU, C; MALO, JL			DURATION AND MAGNITUDE OF ACTION OF 50-MU-G AND 100-MU-G OF INHALED SALMETEROL IN PROTECTING AGAINST BRONCHOCONSTRICTION INDUCED BY HYPERVENTILATION OF DRY COLD-AIR IN SUBJECTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									HOP SACRE COEUR, DEPT CHEST MED, 5400 W GOUIN, MONTREAL H4J 1C5, QUEBEC, CANADA	Universite de Montreal								DEROM EY, 1992, J ALLERGY CLIN IMMUN, V89, P811, DOI 10.1016/0091-6749(92)90435-5; JOHNSON M, 1991, AGENT ACTION SUPPL, V34, P79; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; MALO JL, 1992, J ALLERGY CLIN IMMUN, V89, P567, DOI 10.1016/0091-6749(92)90324-U; TESSIER P, 1986, J ALLERGY CLIN IMMUN, V78, P379, DOI 10.1016/0091-6749(86)90021-7; 1962, AM REV RESPIR DIS, V85, P762	6	12	12	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1993	92	3					488	492		10.1016/0091-6749(93)90128-3	http://dx.doi.org/10.1016/0091-6749(93)90128-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LX309	8360399				2022-12-18	WOS:A1993LX30900015
J	WARRINGA, RAJ; MENGELERS, HJJ; MAIKOE, T; BRUIJNZEEL, PLB; KOENDERMAN, L				WARRINGA, RAJ; MENGELERS, HJJ; MAIKOE, T; BRUIJNZEEL, PLB; KOENDERMAN, L			INHIBITION OF CYTOKINE-PRIMED EOSINOPHIL CHEMOTAXIS BY NEDOCROMIL SODIUM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; CHEMOTAXIS; EOSINOPHILS; NEDOCROMIL SODIUM	PLATELET-ACTIVATING-FACTOR; COLONY-STIMULATING FACTOR; RECOMBINANT HUMAN INTERLEUKIN-5; NEUTROPHIL; ASTHMA; CROMOGLYCATE; RESPONSES; SURVIVAL; BLOOD	Background: Eosinophil influx into the lung tissue is considered to be relevant for the pathogenesis of asthma. Various chemotactic factors may be responsible for this influx. Recently it has been demonstrated that the cytokines granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), and interleukin-5 (IL-5) are present in the circulation of individuals with allergic asthma. These cytokines have the capacity to modulate chemotactic responses of eosinophils toward platelet-activating factor, formyl-methionyl-leucyl-phenylalanine, (FMLP) and neutrophil-activating factor (NAF)/IL-8, but not toward complement fragment C5a (C5a). Here the effect of nedocromil sodium on the chemotactic response of eosinophils from allergic asthmatic individuals and from normal donors preincubated with GM-CSF or IL-3 toward FMLP, NAF/IL-8 was evaluated. Results: Nedocromil sodium inhibited the chemotactic response toward FMLP and NAF/IL-8 of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50]approximately 1 to 10 nmol/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol/L). Conclusions: The chemotactic responses toward C5a were inhibited by nedocromil sodium at higher concentrations than were required in the priming studies (IC50 approximately 10 to 100 nmol/L). Nedocromil sodium (0.1 mumol/L) was also effective in inhibiting the chemotactic response toward FMLP (10 nmol/L) of eosinophils isolated from the circulation of patients with allergic asthma 3 hours after allergen challenge. These findings might explain in part the antiinflammatory action of nedocromil sodium.	UNIV HOSP UTRECHT,DEPT PULM DIS,POB 85500,3500 GA UTRECHT,NETHERLANDS; SWISS INST ALLERGY & ASTHMA RES,DAVOS,SWITZERLAND	Utrecht University; Utrecht University Medical Center; Swiss Institute of Allergy & Asthma Research			Koenderman, Leo/AAE-7870-2020	Koenderman, Leo/0000-0002-5636-6453				ALTMAN LC, 1981, J CLIN INVEST, V67, P28, DOI 10.1172/JCI110024; ATKINS PC, 1983, CLIN REV ALLERG, V1, P385; AUTY RM, 1989, ALLERGY ASTHMA NEW T, P171; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRUIJNZEEL PLB, 1990, BRIT J PHARMACOL, V99, P798, DOI 10.1111/j.1476-5381.1990.tb13009.x; BRUIJNZEEL PLB, 1989, BRIT J PHARMACOL, V97, P1251, DOI 10.1111/j.1476-5381.1989.tb12586.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; CORRIGAN CJ, 1988, LANCET, V1, P1129; DEMONCHY JG, 1985, AM REV RESPIR DIS, V426, P373; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; ENGLISH D, 1988, J IMMUNOL, V141, P2400; HANSEL TT, 1989, J IMMUNOL METHODS, V122, P97, DOI 10.1016/0022-1759(89)90339-6; HOLGATE ST, 1986, EUR J RESPIR DIS, V69, P149; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; KOENDERMAN L, 1990, J IMMUNOL, V145, P3883; KOENDERMAN L, 1991, J ALLERGY CLIN IMMUN, V87, P947, DOI 10.1016/0091-6749(91)90416-L; KOENDERMAN L, 1988, J LEUKOCYTE BIOL, V44, P79, DOI 10.1002/jlb.44.2.79; LEONARD EJ, 1990, J IMMUNOL, V144, P1323; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; METZGER WJ, 1985, CHEST, V87, pS16, DOI 10.1378/chest.87.1_Supplement.16S; METZGER WJ, 1985, CLIN REV ALLERG, V3, P145, DOI 10.1007/BF02992980; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; SILBERSTEIN DS, 1987, IMMUNOL TODAY, V8, P380, DOI 10.1016/0167-5699(87)90214-3; THORNE KJ, 1988, EUR J IMMUNOL, V16, P1143; WALKER C, 1991, J IMMUNOL, V146, P1829; WANG JM, 1989, EUR J IMMUNOL, V19, P701, DOI 10.1002/eji.1830190420; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; WARRINGA RAJ, 1991, BLOOD, V77, P2694; WARRINGA RAJ, 1992, BLOOD, V79, P1836; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WEISBART RH, 1986, J IMMUNOL, V137, P3584; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737; ZIGMOND SH, 1988, CELL MOTIL CYTOSKEL, V9, P84	35	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1993	91	3					802	809		10.1016/0091-6749(93)90200-Y	http://dx.doi.org/10.1016/0091-6749(93)90200-Y			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KU203	8384226				2022-12-18	WOS:A1993KU20300013
J	GEORGITIS, JW				GEORGITIS, JW			THE ANTICHOLINERGIC TREATMENT OF ALLERGIC PERENNIAL RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	CONF ON INTRANASAL ANTICHOLINERGIC TREATMENT OF NASAL DISORDERS	MAR   06, 1991	SAN FRANCISCO, CA	BOEHRINGER INGELHEIM PHARM		RHINITIS; ALLERGIC; PERENNIAL; IPRATROPIUM BROMIDE	IPRATROPIUM; BROMIDE	Anticholinergic agents have been used for nonallergic rhinitis expressly to control rhinorrhea. In allergic rhinitis, rhinorrhea can be extremely troublesome and unresponsive to traditional pharmacotherapeutic rhinitis treatments. Anticholinergic agents, through their specific ability to decrease nasal secretory response, should have beneficial effects for allergic rhinitis. In a recent trial ipratropium bromide at concentrations of 0.03% and 0.06% reduced rhinorrhea in allergic subjects without any demonstrable rebound effect. Therefore anticholinergic therapies may be a useful adjunct in controlling the rhinorrhea associated with allergic rhinitis.			GEORGITIS, JW (corresponding author), BOWMAN GRAY SCH MED,DEPT PEDIAT,MED CTR BLVD,WINSTON SALEM,NC 27157, USA.							BOK HE, 1983, EUR J RESPIR DIS, V64, P486; BOUSQUET J, 1990, RESP MED, V84, P11, DOI 10.1016/S0954-6111(08)80002-9; BUSSE W, 1988, J ALLERGY CLIN IMMUN, V82, P890, DOI 10.1016/0091-6749(88)90031-0; DELAFUENTE JC, 1989, CLIN PHARMACY, V8, P474; DEVILLIER P, 1988, EUR RESPIR J, V1, P356; DUSHAY ME, 1989, PHARMACOTHERAPY, V9, P338; FRANKLIN W, 1979, RHINITIS MECHANISMS, P117; KIRKEGAARD J, 1987, J ALLERGY CLIN IMMUN, V79, P585, DOI 10.1016/S0091-6749(87)80153-7; MALMBERG H, 1983, CLIN OTOLARYNGOL, V8, P273, DOI 10.1111/j.1365-2273.1983.tb01441.x; MELTZER EO, IN PRESS J ALLERGY C; MEREDITH SD, 1989, J ALLERGY CLIN IMMUN, V84, P920, DOI 10.1016/0091-6749(89)90390-4; MILFORD CA, 1990, J LARYNGOL OTOL, V104, P123, DOI 10.1017/S0022215100112022; Mygind N, 1989, Rhinol Suppl, V9, P37; ODWYER TP, 1988, J LARYNGOL OTOL, V102, P799, DOI 10.1017/S0022215100106498; SIMONS FER, 1987, J ALLERGY CLIN IMMUN, V80, P239, DOI 10.1016/0091-6749(87)90025-X; VANMEGEN YJB, 1991, J ALLERGY CLIN IMMUN, V87, P521, DOI 10.1016/0091-6749(91)90011-C	16	12	13	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1992	90	6	2	S			1071	1076		10.1016/0091-6749(92)90125-L	http://dx.doi.org/10.1016/0091-6749(92)90125-L			6	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KD635	1460210				2022-12-18	WOS:A1992KD63500008
J	WITEK, TJ; CANESTRARI, DA; MILLER, RD; YANG, JY; RIKER, DK				WITEK, TJ; CANESTRARI, DA; MILLER, RD; YANG, JY; RIKER, DK			THE EFFECTS OF PHENINDAMINE TARTRATE ON SLEEPINESS AND PSYCHOMOTOR PERFORMANCE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PHENINDAMINE; DIPHENHYDRAMINE; TERFENADINE; PSEUDOEPHEDRINE; H1-RECEPTOR ANTAGONISTS; SLEEP; PSYCHOMOTOR PERFORMANCE	ANTIHISTAMINES; ANTAGONISTS; ASTHMA	Phenindamine, an H-1-receptor antagonist that was developed almost 50 years ago, has been associated with both drowsiness and insomnia. Since its central nervous system profile has not been well characterized, we used a series of psychomotor tests to conduct two studies. In the first, 12 subjects received single oral doses of phenindamine (25 mg), diphenhydramine (50 mg), terfenadine (60 mg), or placebo in a four-way crossover study. Psychomotor tests included choice reaction time (CRT), tracking, and hand steadiness (HS). In the second trial, 15 subjects received single oral doses of phenindamine (25 mg), pseudoephedrine (60 mg), phenindamine and pseudoephedrine, diphenhydramine (50 mg), or placebo in a five-way crossover study. Psychomotor tests included CRT, HS, and a task that divided attention between tracking and reaction time. Introspective drowsiness was measured in both trials with use of a visual analog scale (VAS) and the Stanford Sleepiness Scale (SSS). All assessments were made before and 1, 3, and 5 hours after drug administration. In the first trial, diphenhydramine produced significant impairment relative to placebo (p < 0.05) in CRT, tracking, and HS tasks and higher SSS and VAS scores, with peak effect noted at 3 hours. Phenindamine did not significantly differ from placebo or terfenadine. In the second trial, diphenhydramine produced significant impairment relative to placebo (p < 0.05) in CRT, divided attention, HS, and VAS, and SSS, also peaking at 3 hours. Stanford Sleepiness Scale scores after phenindamine were greater than placebo at 3 hours (p < 0.05) but significantly less than diphenhydramine (p < 0.05). Psychomotor test scores after phenindamine and pseudoephedrine, either alone or in combination, were consistently and most often significantly better than diphenhydramine and not significantly different from placebo. Taken together, these data indicate that sleepiness after a single dose of phenindamine is rank ordered between placebo and diphenhydramine. We speculate that the relative lack of impairment reflected by the psychomotor tests from phenindamine may be related to its paradoxic sedative and stimulatory effects.	PROCTER & GAMBLE CO,REGULATORY & CLIN DEV,11370 REED HARTMAN HIGHWAY,CINCINNATI,OH 45241	Procter & Gamble			Riker, Donald/AAR-8380-2020					BAGRATUNI L., 1960, ANN ALLERGY, V18, P859; BERKOWITZ RB, 1992, J ALLERGY CLIN IMMUN, V89, P181; COWAN DW, 1950, JAMA-J AM MED ASSOC, V143, P421, DOI 10.1001/jama.1950.02910400013004; FRANK R, 1948, Ann Allergy, V6, P398; GENGO F, 1989, CLIN PHARMACOL THER, V45, P15, DOI 10.1038/clpt.1989.3; GENGO FM, 1990, J ALLERGY CLIN IMMUN, V86, P1034, DOI 10.1016/S0091-6749(05)80250-7; GREEN E W, 1991, Annals of Allergy, V66, P98; HODDES E, 1972, PSYCHOPHYSIOLOGY, V9, P150; HOLGATE ST, 1989, J ALLERGY CLIN IMMUN, V83, P537, DOI 10.1016/0091-6749(89)90035-3; HUBBARD T F, 1950, Ann Allergy, V8, P350; ISAAC L, 1967, J PHARMACOL EXP THER, V156, P463; LOVELESS M H, 1949, J Am Med Womens Assoc, V4, P105; MCTAVISH D, 1990, DRUGS, V39, P552, DOI 10.2165/00003495-199039040-00006; MELTZER EO, 1991, ANN ALLERGY, V67, P625; MELTZER EO, 1990, J ALLERGY CLIN IMMUN, V86, P613, DOI 10.1016/S0091-6749(05)80225-8; MIDDLETON JW, 1949, DIS CHEST, V16, P879, DOI 10.1378/chest.16.6.879; RAFFERTY P, 1989, J ALLERGY CLIN IMMUN, V84, P144, DOI 10.1016/0091-6749(89)90317-5; RICHARDS DM, 1984, DRUGS, V28, P38, DOI 10.2165/00003495-198428010-00003; ROMBAUT N E I, 1989, Medical Science Research, V17, P831; ROSA RR, 1985, BEHAV RES METH INS C, V17, P6, DOI 10.3758/BF03200891; ROTH T, 1987, J ALLERGY CLIN IMMUN, V80, P94, DOI 10.1016/S0091-6749(87)80197-5; ROTH T, 1992, J ALLERGY CLIN IMMUN, V89, P181; SEIDEL WF, 1990, J ALLERGY CLIN IMMUN, V86, P1029, DOI 10.1016/S0091-6749(05)80249-0; SIMONS FER, 1991, ANN ALLERGY, V66, P5; SIMONS FER, 1990, J ALLERGY CLIN IMMUN, V86, P995; 1987, FED REG         0124, V52, P31913; 1985, FED REG         0115, V50, P2216	27	12	12	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1992	90	6	1				953	961		10.1016/0091-6749(92)90468-H	http://dx.doi.org/10.1016/0091-6749(92)90468-H			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KD190	1360991	Bronze			2022-12-18	WOS:A1992KD19000012
J	UEDA, A; TOCHIGI, T; UEDA, T; AOYAMA, K; MANDA, F				UEDA, A; TOCHIGI, T; UEDA, T; AOYAMA, K; MANDA, F			IMMEDIATE TYPE OF ALLERGY IN STATIS GROWERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IMMEDIATE ALLERGY; STATIS GROWER; OCCUPATIONAL ALLERGY; FLOWER; CASE STUDY; INTRADERMAL TEST; PROVOCATION TEST; RAST IGE; RAST INHIBITION; CROSS-REACTION		Three statis growers complaining of immediate allergic symptoms induced by harvesting statis in a plastic greenhouse were examined to clarify their allergic conditions. Distinct positive reactions in the intradermal test and nasal and eye provocation test to the statis extracts were shown in all three cases. High score of radioallergosorbent test (RAST) IgE and remarkable RAST inhibitory effects to the statis extracts were seen in these cases. The immunologic cross-reactivity between statis and chrysanthemum was absent in the RAST inhibition in the patient labeled case C who had complained of the same allergic symptoms when handling chrysanthemums in the off-season for harvesting statis. Those results indicated that the allergic conditions of the present cases were from an immediate type of allergy mediated by a specific IgE antibody to the statis extract.			UEDA, A (corresponding author), KAGOSHIMA UNIV,FAC MED,DEPT ENVIRONM MED,8-35-1 SAKURAGAOKA,KAGOSHIMA 890,JAPAN.							BLEUMINK E, 1973, ARCH DERMATOL, V108, P220, DOI 10.1001/archderm.108.2.220; CAIRNS R, 1964, T ST JOHNS HOSP DERM, V261, P311; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; Coca AF, 1922, J IMMUNOL, V7, P163; EBIHARA I, 1976, J SCI LABOUR, V52, P407; FREGERT S, 1967, T ST JOHNS HOSP DERM, V55, P17; HJORTH DS, 1968, BRIT J DERMATOL, V80, P696; KOBAYASHI T, 1973, JPN J ALLERGOL, V22, P699; MATSUYAMA R, 1972, JAN J ALLERGOL, V21, P235; NAKAGAWA S, 1975, Japanese Journal of Allergology, V24, P535; NAKAZAWA T, 1971, J JPN INT MED, V60, P43; NOMURA S, 1978, J JPN ASS RURAL MED, V27, P734; SAWADA Y, 1980, JPN J ALLERGOL, V29, P293; TANAKA T, 1987, CONTACT DERMATITIS, V16, P152, DOI 10.1111/j.1600-0536.1987.tb01410.x; TERANISHI H, 1981, JPN J IND HLTH, V23, P166; UEDA A, 1987, Japanese Journal of Industrial Health, V29, P3; Ueda A, 1986, J JPN ASS RURAL MED, V35, P55; URSING B, 1968, ACTA ALLERGOL, V23, P396, DOI 10.1111/j.1398-9995.1968.tb04072.x; YUO T, 1979, JPN J ALLERGOL, V28, P619	19	12	12	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1992	90	5					742	748		10.1016/0091-6749(92)90097-L	http://dx.doi.org/10.1016/0091-6749(92)90097-L			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JZ319	1430700				2022-12-18	WOS:A1992JZ31900003
J	LUSK, RP				LUSK, RP			ENDOSCOPIC APPROACH TO SINUS DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	SYMP ON MECHANISMS, DIAGNOSIS, AND TREATMENT OF SINUSITIS IN CHILDREN AND ADULTS	JAN 24-25, 1992	SCOTTSDALE, AZ	ALLEN & HANBURYS		ETHMOIDECTOMY; ANTROSTOMY; COMPUTERIZED PROPOSED TOMOGRAPHY	RECURRING RHINOSINUSITIS; ENDONASAL SURGERY; ETHMOIDECTOMY; ANTROSTOMY; CHILDREN; NASAL	Surgical modalities such as tonsillectomy and/or adenoidectomy, antral irrigations, and inferior meatal windows have not been effective in treating most cases of chronic sinusitis. Recent advances in technology have allowed a more direct approach to the obstruction and diseased tissue. The ethmoid sinus can now be approached directly and safely. The natural ostium to the maxillary sinus can be enlarged endoscopically with a high degree of patency. Techniques have been developed that limit the amount of scarring, and the procedure can be performed safely. The endoscopic ethmoidectomy and maxillary antrostomy has provided our best surgical modality for the treatment of chronic sinusitis in children to date.			LUSK, RP (corresponding author), WASHINGTON UNIV,ST LOUIS CHILDRENS HOSP,SCH MED,400 S KINGSHIGHWAY,3S-35,ST LOUIS,MO 63110, USA.							EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; GROSS CW, 1989, LARYNGOSCOPE, V99, P272; GROSS CW, 1989, OTOLARYNG CLIN N AM, V22, P733; Hilding AC., 1941, ANN OTOL, V50, P379; Kennedy D W, 1986, Laryngoscope, V96, P1170; Kennedy D W, 1985, AORN J, V42, P936, DOI 10.1016/S0001-2092(07)64430-5; KENNEDY DW, 1985, ARCH OTOLARYNGOL, V111, P576; KENNEDY DW, 1987, LARYNGOSCOPE, V97, P1, DOI 10.1288/00005537-198708002-00001; Kopp W, 1991, FUNCTIONAL ENDOSCOPI; LANG J, 1989, CLIN ANATOMY NOSE NA, P50; LAVELLE RJ, 1971, LARYNGOSCOPE, V81, P90, DOI 10.1288/00005537-197101000-00008; LUSK RP, 1991, ARCH OTOLARYNGOL, V117, P60; LUSK RP, 1990, LARYNGOSCOPE, V100, P654; MCALISTER WH, 1989, AM J ROENTGENOL, V153, P1259, DOI 10.2214/ajr.153.6.1259; Messerklinger W, 1967, Monatsschr Ohrenheilkd Laryngorhinol, V101, P313; Messerklinger W., 1978, ENDOSCOPY NOSE; MIKULICZ J, 1887, LAGENBECKS ARCH KLIN, V34, P626; PROETZ AW, 1931, DISPLACEMENT METHOD, P47; PROETZ AW, 1941, ESSAYS APPLIED PHYSL, P356; RICE D, 1988, ENDOSCOPIC PARANASAL; STAMMBERGER H, 1986, ENDOSCOPY, V18, P213, DOI 10.1055/s-2007-1018382; STAMMBERGER H, 1986, OTOLARYNG HEAD NECK, V94, P147, DOI 10.1177/019459988609400203; STAMMBERGER H, 1985, LARYNG RHINOL OTOL V, V64, P559, DOI 10.1055/s-2007-1008205; STAMMBERGER H, 1986, OTOLARYNG HEAD NECK, V94, P143, DOI 10.1177/019459988609400202; STAMMBERGER H, 1985, ANN OTOL RHINOL LA S, V119, P1; STANKIEWICZ JA, 1989, OTOLARYNG HEAD NECK, V101, P320, DOI 10.1177/019459988910100305; STANKIEWICZ JA, 1989, LARYNGOSCOPE, V99, P686; WIGAND ME, 1990, ENDOSCOPIC SURGERY P; WILKERSON WW, 1949, ARCH OTOLARYNGOL, V49, P463	29	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	2	S			496	505		10.1016/0091-6749(92)90174-Z	http://dx.doi.org/10.1016/0091-6749(92)90174-Z			10	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP521	1527340				2022-12-18	WOS:A1992JP52100015
J	SIM, TC; ALAM, R; FORSYTHE, PA; WELTER, JB; LETTBROWN, MA; GRANT, JA				SIM, TC; ALAM, R; FORSYTHE, PA; WELTER, JB; LETTBROWN, MA; GRANT, JA			MEASUREMENT OF HISTAMINE-RELEASING FACTOR ACTIVITY IN INDIVIDUAL NASAL WASHINGS - RELATIONSHIP WITH ATOPY, BASOPHIL RESPONSE, AND MEMBRANE-BOUND IGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HISTAMINE-RELEASING FACTORS; NASAL WASHINGS; ALLERGIC RHINITIS; BASOPHIL HISTAMINE RELEASE; IGE; CYTOKINE	HUMAN MONONUCLEAR-CELLS; ASTHMATIC-PATIENTS; ALLERGIC RHINITIS; ACTIVITY HRA; MAST-CELLS; RELEASABILITY; HETEROGENEITY; LYMPHOKINE; CHALLENGE; MEDIATOR	We collected individual pools of nasal washings (NWs) from 15 allergic and 15 nonallergic subjects to determine histamine-releasing factor (HRF) activity and to ascertain the relationship of these cytokines with atopic status, basophil releasability, and cell membrane-bound IgE. NWs were concentrated, dialyzed, and assayed with basophils from a single donor. Samples from 12 of 15 allergic subjects and from all the nonallergic subjects revealed greater-than-or-equal-to 15% histamine release (HR), 33.5% +/- 21.3% (mean +/- SD) and 38.6% +/- 19.6%, respectively (p > 0.05). When we assayed the same samples with autologous basophils, the allergic group demonstrated higher HR than the nonallergic group (31.9% +/- 19.7% versus 4.8% +/- 4.3%; p < 0.001). A standard lot of mononuclear cell-derived HRFs was also screened with basophils from both groups. Means for HR from basophils of allergic and nonallergic subjects were 51.9% t 16.7% versus 26.3% +/- 8.2%, respectively (p < 0.001). Pretreatment of basophils with lactic acid led to abrogation of sensitivity to HRF. Acid-stripped cells incubated with sera from patients with asthma regained their capacity to release histamine. We found that HRF activity can be detected in NWs of most donors, and there is no difference among allergic and nonallergic subjects. Our results suggest that the capacity of these cytokines to induce HR depends on several factors: atopic status, basophil releasability, and membrane-bound IgE.			SIM, TC (corresponding author), UNIV TEXAS, MED BRANCH,DEPT INTERNAL MED, DIV ALLERGY & IMMUNOL,ROUTE G-62, CLIN SCI BLDG, GALVESTON, TX 77550 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI027864, R01AI022940] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-22940, AI-27864] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALAM R, 1985, ANN ALLERGY, V55, P825; ALAM R, 1992, J CLIN INVEST, V89, P723, DOI 10.1172/JCI115648; ALAM R, 1990, AM REV RESPIR DIS, V141, P666, DOI 10.1164/ajrccm/141.3.666; ALAM R, 1985, ALLERGY, V40, P124, DOI 10.1111/j.1398-9995.1985.tb02671.x; ALAM R, 1990, J ALLERGY CLIN IMMUN, V86, P73, DOI 10.1016/S0091-6749(05)80125-3; ALAM R, 1987, J ALLERGY CLIN IMMUN, V79, P103, DOI 10.1016/S0091-6749(87)80023-4; BAEZA ML, 1988, J IMMUNOL, V141, P2688; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BUSSE WW, 1986, J ALLERGY CLIN IMMUN, V78, P90, DOI 10.1016/0091-6749(86)90119-3; CASOLARO V, 1990, AM REV RESPIR DIS, V142, P1108, DOI 10.1164/ajrccm/142.5.1108; CLAVEAU J, 1991, Journal of Allergy and Clinical Immunology, V87, P223, DOI 10.1016/0091-6749(91)91618-4; COCCHIARA R, 1987, INT ARCH ALLER A IMM, V84, P321, DOI 10.1159/000234442; CONROY MC, 1977, J IMMUNOL, V118, P1317; DVORAK AM, 1984, CLIN IMMUNOL IMMUNOP, V32, P142, DOI 10.1016/0090-1229(84)90116-8; EZEAMUZIE IC, 1987, INT ARCH ALLER A IMM, V82, P221, DOI 10.1159/000234192; KAPLAN AP, 1985, J IMMUNOL, V135, P2027; KUNA P, 1989, J ALLERGY CLIN IMMUN, V83, P816, DOI 10.1016/0091-6749(89)90020-1; LETTBROWN MA, 1984, CELL IMMUNOL, V87, P445, DOI 10.1016/0008-8749(84)90013-3; LEVY DA, 1966, J IMMUNOL, V97, P203; LICHTENSTEIN LM, 1988, J ALLERGY CLIN IMMUN, V81, P814, DOI 10.1016/0091-6749(88)90936-0; LIU MC, 1986, J IMMUNOL, V136, P2588; MACDONALD SM, 1987, J IMMUNOL, V139, P506; MACDONALD SM, 1987, J ALLERGY CLIN IMMUN, V79, P248; MARONE G, 1986, J ALLERGY CLIN IMMUN, V78, P974, DOI 10.1016/0091-6749(86)90288-5; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; ORCHARD MA, 1986, J IMMUNOL, V136, P2240; PLAUT M, 1986, J ALLERGY CLIN IMMUN, V78, P968, DOI 10.1016/0091-6749(86)90287-3; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; SAMPSON HA, 1989, NEW ENGL J MED, V321, P228, DOI 10.1056/NEJM198907273210405; SCHLEIMER RP, 1985, J ALLERGY CLIN IMMUN, V76, P369, DOI 10.1016/0091-6749(85)90656-6; SCHLEIMER RP, 1986, FASEB J, V45, P1105; SCHULMAN ES, 1985, AM REV RESPIR DIS, V131, P230; SCHULMAN ES, 1988, J IMMUNOL, V140, P2369; SEDGWICK JD, 1981, CLIN EXP IMMUNOL, V45, P409; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; THUESON DO, 1979, J IMMUNOL, V123, P626; WARNER JA, 1986, J IMMUNOL, V136, P2583; WHITE MV, 1987, J IMMUNOL, V139, P1624; WHITE MV, 1988, J IMMUNOL, V141, P3575	40	12	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1992	89	6					1157	1165		10.1016/0091-6749(92)90300-Q	http://dx.doi.org/10.1016/0091-6749(92)90300-Q			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HZ748	1376736				2022-12-18	WOS:A1992HZ74800011
J	GRAFT, DF; REISMAN, RE; VALENTINE, MD; YUNGINGER, JW; GOLDEN, DBK				GRAFT, DF; REISMAN, RE; VALENTINE, MD; YUNGINGER, JW; GOLDEN, DBK			WHEN TO START, WHEN TO STOP, AND WHAT TO MEASURE IN VENOM IMMUNOTHERAPY - ISSUES IN ALLERGY GRAND SEMINAR, AAAL ANNUAL-MEETING 1990	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Discussion									SUNY BUFFALO,ALLERGY RES LAB,BUFFALO,NY 14260; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205; MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Johns Hopkins University; Mayo Clinic	GRAFT, DF (corresponding author), PARK NICOLLET MED CTR,5000 W 39TH ST,MINNEAPOLIS,MN 55416, USA.								0	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1991	88	3	1				409	413		10.1016/0091-6749(91)90105-W	http://dx.doi.org/10.1016/0091-6749(91)90105-W			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GG126					2022-12-18	WOS:A1991GG12600037
J	HAYES, JP; RIDGE, SM; GRIFFITH, S; BARNES, PJ; CHUNG, KF				HAYES, JP; RIDGE, SM; GRIFFITH, S; BARNES, PJ; CHUNG, KF			INHIBITION OF CUTANEOUS AND PLATELET RESPONSES TO PLATELET-ACTIVATING-FACTOR BY ORAL WEB 2086 IN MAN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PAF; PAF ANTAGONIST; WEB 2086; HISTAMINE	PAF-ACETHER ANTAGONIST; WEB-2086; AGGREGATION	WEB 2086, an antagonist of platelet-activating factor (PAF), was assessed against the cutaneous response in vivo and the aggregation of platelets ex vivo induced by PAF in a double-blind, placebo-controlled, crossover study in 12 normal male volunteers. Wheal-and-flare responses to intradermal PAF (200 ng) and histamine (1-mu-g) were measured 1 hour after placebo or control administration. Wheal volumes were significantly reduced by 66% +/- 8.7% (mean +/- SEM), 86% +/- 8.3%, and 90% +/- 6.0% after 10, 40, and 100 mg of WEB 2086 compared to placebo administration (p < 0.005). Flare responses were correspondingly inhibited by 66% +/- 8.3%, 82% +/- 8.7%, and 84% +/- 7.8% at 10, 40, and 100 mg of WEB 2086, respectively. Cutaneous responses to histamine were unaffected. Ex vivo platelet responses to PAF were significantly inhibited at all three doses of WEB 2086. Oral WEB 2086 is a potent and specific inhibitor of cutaneous and platelet responses to PAF in man.	ROYAL BROMPTON & NATL HEART HOSP,NATL HEART & LUNG INST,DEPT THORAC MED,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND; BOEHRINGER INGELHEIM,BRACKNELL,ENGLAND	Imperial College London; Boehringer Ingelheim			Chung, Kian Fan/I-8456-2019; Chung, Kian Fan/B-1872-2012	Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426; Barnes, Peter/0000-0002-5122-4018				ADAMUS WS, 1988, EUR J CLIN PHARMACOL, V35, P237; ADAMUS WS, 1990, CLIN PHARMACOL THER, V47, P456, DOI 10.1038/clpt.1990.57; ARNOUT J, 1988, BRIT J CLIN PHARMACO, V25, P445, DOI 10.1111/j.1365-2125.1988.tb03328.x; BARNES PJ, 1988, J ALLERGY CLIN IMMUN, V81, P919, DOI 10.1016/0091-6749(88)90952-9; CASALSSTENZEL J, 1987, BRIT J PHARMACOL, V90, P139, DOI 10.1111/j.1476-5381.1987.tb16833.x; CASALSSTENZEL J, 1987, J PHARMACOL EXP THER, V241, P974; CHUNG KF, 1987, LANCET, V1, P248; CHUNG KF, 1988, DRUGS, V35, P93, DOI 10.2165/00003495-198835020-00001; EVANS TW, 1988, BRIT J PHARMACOL, V94, P164, DOI 10.1111/j.1476-5381.1988.tb11511.x; HOSFORD D, 1989, PLATELET ACTIVATING, P82; KROEGEL C, 1988, IMMUNOLOGY, V64, P559; LEILOUCHTUBIANA A, 1988, AM REV RESPIR DIS, V137, P948	12	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1991	88	1					83	88		10.1016/0091-6749(91)90304-7	http://dx.doi.org/10.1016/0091-6749(91)90304-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY204	2071787				2022-12-18	WOS:A1991FY20400010
J	ZEISS, CR				ZEISS, CR			REACTIVE CHEMICALS IN INDUSTRIAL ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							TRIMELLITIC ANHYDRIDE; TOLUENE-DIISOCYANATE; OCCUPATIONAL ASTHMA; HISTAMINE-RELEASE; IMMUNOGLOBULIN-E; ANTIBODIES; WORKERS; SERUM; HYPERSENSITIVITY; INHALATION		NORTHWESTERN UNIV, SCH MED, DEPT MED, ALLERGY & IMMUNOL SECT, CHICAGO, IL 60611 USA	Northwestern University	ZEISS, CR (corresponding author), DEPT VET AFFAIRS, LAKESIDE MED CTR, 400 E ONTARIO ST, CHICAGO, IL 60611 USA.							AKIYAMA K, 1984, J IMMUNOL, V133, P3286; BAUR X, 1984, J ALLERGY CLIN IMMUN, V73, P610, DOI 10.1016/0091-6749(84)90520-7; BERNSTEIN DI, 1984, J ALLERGY CLIN IMMUN, V74, P794, DOI 10.1016/0091-6749(84)90181-7; BERNSTEIN IL, 1982, J ALLERGY CLIN IMMUN, V70, P24, DOI 10.1016/0091-6749(82)90197-X; BUTCHER BT, 1976, J ALLERGY CLIN IMMUN, V58, P89, DOI 10.1016/0091-6749(76)90110-X; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; DANKS JM, 1981, CLIN ALLERGY, V11, P161, DOI 10.1111/j.1365-2222.1981.tb01580.x; DYKEWICZ MS, 1988, J LAB CLIN MED, V111, P459; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36, DOI 10.1164/ajrccm/136.1.36; ISHIZAKA T, 1981, J ALLERGY CLIN IMMUN, V67, P90, DOI 10.1016/0091-6749(81)90002-6; KAGEYSOBOTKA A, 1981, J IMMUNOL, V127, P2285; KAROL MH, 1979, TOXICOL APPL PHARM, V51, P73, DOI 10.1016/0041-008X(79)90009-7; KAROL MH, 1978, AM IND HYG ASSOC J, V39, P454, DOI 10.1080/0002889778507789; KERN RICHARD A., 1939, JOUR ALLERGY, V10, P164, DOI 10.1016/S0021-8707(39)90050-X; McGrath K G, 1983, Clin Immunol Rev, V2, P1; MOIRA CY, 1986, AM REV RESPIR DIS, V133, P686; PATTERSON R, 1982, J ALLERGY CLIN IMMUN, V70, P19, DOI 10.1016/0091-6749(82)90196-8; PATTERSON R, 1978, J CLIN INVEST, V62, P971, DOI 10.1172/JCI109226; PATTERSON R, 1981, J CLIN IMMUNOL, V1, P181, DOI 10.1007/BF00922761; PEPYS J, 1984, CLIN IMMUNOL ALLERGY, V4, P131; ROITT I, 1985, IMMUNOLOGY, V19, P1; SALVAGGIO JE, 1986, J ALLERGY CLIN IMMUN, V78, P1053, DOI 10.1016/0091-6749(86)90304-0; ZEISS CR, 1985, CLIN REV ALLERG, V3, P217, DOI 10.1007/BF02992984; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1; ZEISS CR, 1980, INT ARCH ALLER A IMM, V61, P380; ZEISS CR, 1989, IMMUNOL ALLERGY CLIN, V9, P235	26	12	12	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1991	87	4					755	761		10.1016/0091-6749(91)90118-8	http://dx.doi.org/10.1016/0091-6749(91)90118-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FG059	2013668	Bronze			2022-12-18	WOS:A1991FG05900001
J	CASALE, TB; ABBAS, MK				CASALE, TB; ABBAS, MK			EFFECTS OF VARIOUS BARRIERS ON PLATELET-ACTIVATING FACTOR-INDUCED NEUTROPHIL CHEMOTAXIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							VASCULAR ENDOTHELIAL-CELLS; HUMAN EOSINOPHILS; ANTAGONIST; STIMULATION; MONOLAYER; ADHERENCE; WEB-2086; BINDING	Platelet-activating factor (PAF)-induced neutrophil migration across endothelial and epithelial barriers is an important event in inflammation. We compared the effects of PAF on human neutrophil migration through filters alone, and human umbilical vein endothelial and Madin-Darby canine kidney epithelial cells cultured on these filters. We found that the amount of PAF-induced neutrophil migration was barrier dependent. At low PAF concentrations, neutrophil migration through filters exceeded migration measured through either cellular barrier. As PAF concentrations increased to greater-than-or-equal-to 1-mu-mol/L, neutrophil migration through human umbilical vein endothelial cells often equaled or exceeded migration measured through filters alone. In contrast, significant neutrophil migration through Madin-Darby canine kidney cells was not observed until PAF concentrations exceeded 50-mu-mol/L. Thus, the intensity of PAF-induced neutrophil inflammatory processes is, in part, dependent on the barrier through which the neutrophils must migrate.	VET ADM MED CTR,DEPT INTERNAL MED,IOWA CITY,IA 52240; UNIV IOWA,COLL MED,IOWA CITY,IA 52242	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Iowa			Casale, Thomas B/K-4334-2013	Casale, Thomas B/0000-0002-3149-7377	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI019093] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 19093] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baggiolini M, 1988, Prog Biochem Pharmacol, V22, P90; CASALE TB, 1990, AM J PHYSIOL, V258, pC639, DOI 10.1152/ajpcell.1990.258.4.C639; CASALSSTENZEL J, 1987, J PHARMACOL EXP THER, V241, P974; DENT G, 1989, FEBS LETT, V244, P365, DOI 10.1016/0014-5793(89)80564-2; DOUKAS J, 1988, BLOOD, V71, P771; FERRANTE A, 1978, J IMMUNOL METHODS, V24, P389, DOI 10.1016/0022-1759(78)90143-6; GALLIN JI, 1973, J IMMUNOL, V110, P233; GARCIA JGN, 1988, THROMB RES, V51, P83, DOI 10.1016/0049-3848(88)90285-X; GIMBRONE MA, 1984, J CLIN INVEST, V74, P1552, DOI 10.1172/JCI111570; GONZALEZMARISCAL L, 1985, J MEMBRANE BIOL, V86, P113, DOI 10.1007/BF01870778; HARLAN JM, 1985, LAB INVEST, V52, P141; HOPKINS NK, 1984, BIOCHIM BIOPHYS ACTA, V805, P30, DOI 10.1016/0167-4889(84)90033-8; HOSHI H, 1984, P NATL ACAD SCI-BIOL, V81, P6413, DOI 10.1073/pnas.81.20.6413; KURIHARA K, 1989, J ALLERGY CLIN IMMUN, V83, P83, DOI 10.1016/0091-6749(89)90480-6; NIEDERMEYER ME, 1984, AM J PATHOL, V117, P252; PINCKARD RN, 1988, INFLAMMATION BASIC P, P139; SCHLEIMER RP, 1986, J IMMUNOL, V136, P649; SHAW JO, 1981, J IMMUNOL, V127, P1250; SIGAL CE, 1987, J CLIN IMMUNOL, V7, P179, DOI 10.1007/BF00916012; TONNESEN MG, 1989, J CLIN INVEST, V83, P637, DOI 10.1172/JCI113928; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; ZIGMOND SH, 1989, AM J RESP CELL MOL, V1, P451, DOI 10.1165/ajrcmb/1.6.451; ZIMMERMAN GA, 1988, J CLIN INVEST, V81, P531, DOI 10.1172/JCI113351	23	12	12	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1991	87	2					565	574		10.1016/0091-6749(91)90016-H	http://dx.doi.org/10.1016/0091-6749(91)90016-H			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX987	1993814				2022-12-18	WOS:A1991EX98700015
J	SCHELLENBERG, RR; OHTAKA, H; PADDON, HB; BRAMBLE, SE; RANGNO, RE				SCHELLENBERG, RR; OHTAKA, H; PADDON, HB; BRAMBLE, SE; RANGNO, RE			CATECHOLAMINE RESPONSES TO HISTAMINE INFUSION IN MAN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							BLOCKING-AGENTS; HUMAN-HEART; ANAPHYLAXIS; RISK; IMMUNOTHERAPY; BLOCKADE; RELEASE; TISSUE; DRUGS	To evaluate the effects of histamine-induced hypotension on plasma catecholamine levels, eight normal men, aged 20 to 40 years, were infused with incremental doses of histamine starting at 0.2-mu-g/kg/min at a 30 degree tilt position with monitoring of blood pressure (BP) and heart rate. Histamine dosage was increased every 5 minutes by 0.1 to 0.2-mu-g/kg/min until mean BP fell > 15 mm Hg or a dosage of 1.6-mu-g/kg/min was reached. Plasma catecholamine samples were taken between the fourth and fifth minute of each histamine dosage. Identical measurements were made during nitroglycerin-induced hypotension in these subjects. Histamine produced threefold greater increases in heart rate and plasma norepinephrine (NE) levels than did nitroglycerin for comparable decreases in BP. Although NE levels increased twofold to fivefold from baseline with histamine infusion, epinephrine levels increased minimally at the highest doses or not at all. Our data demonstrate that histamine selectively releases NE from adrenergic nerve terminals without significant adrenal catecholamine release. We suggest that neural NE release plays an important role in the cardiac effects of histamine.	ST PAULS HOSP,DIV CLIN PHARMACOL,VANCOUVER V6Z 1Y6,BC,CANADA	St. Paul's Hospital; University of Saskatchewan	SCHELLENBERG, RR (corresponding author), UNIV BRITISH COLUMBIA,ST PAULS HOSP,PULM RES LAB,1081 BURRARD ST,VANCOUVER V6T 1Y6,BC,CANADA.							ASSEM ESK, 1971, BRIT J PHARMACOL, V42, P620, DOI 10.1111/j.1476-5381.1971.tb07146.x; ASSEM ESK, 1969, NATURE, V224, P1028, DOI 10.1038/2241028a0; BUTCHERS PR, 1980, BRIT J PHARMACOL, V71, P663, DOI 10.1111/j.1476-5381.1980.tb10987.x; Dale HH, 1910, J PHYSIOL-LONDON, V41, P318; DUNER H, 1960, ACTA MED SCAND, V168, P307; FOSTER NK, 1986, J APPL PHYSIOL, V61, P2218; GINSBURG R, 1980, LIFE SCI, V26, P2245, DOI 10.1016/0024-3205(80)90209-X; GRAVER LM, 1986, J ALLERGY CLIN IMMUN, V77, P709, DOI 10.1016/0091-6749(86)90415-X; HAMILTON G, 1985, CAN MED ASSOC J, V133, P122; HANNAWAY PJ, 1983, NEW ENGL J MED, V308, P1536; HJEMDAHL P, 1979, LIFE SCI, V25, P131, DOI 10.1016/0024-3205(79)90384-9; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V68, P125, DOI 10.1016/0091-6749(81)90170-6; KALINER M, 1982, J ALLERGY CLIN IMMUN, V69, P283, DOI 10.1016/S0091-6749(82)80005-5; KALINER M, 1981, J ALLERGY CLIN IMMUN, V68, P365, DOI 10.1016/0091-6749(81)90134-2; LICHTENS.LM, 1968, SCIENCE, V161, P902, DOI 10.1126/science.161.3844.902; LICHTENSTEIN LM, 1971, J IMMUNOL, V107, P1131; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; Marone G, 1985, Prog Biochem Pharmacol, V20, P38; MCNEILL JH, 1984, CAN J PHYSIOL PHARM, V62, P720, DOI 10.1139/y84-119; NEWMAN BR, 1981, ANN ALLERGY, V47, P35; STARK BJ, 1986, J ALLERGY CLIN IMMUN, V78, P76, DOI 10.1016/0091-6749(86)90117-X; TOOGOOD JH, 1988, J ALLERGY CLIN IMMUN, V81, P1, DOI 10.1016/0091-6749(88)90212-6; TOOGOOD JH, 1987, CAN MED ASSOC J, V136, P929; VIGORITO C, 1983, J CARDIOVASC PHARM, V5, P531, DOI 10.1097/00005344-198307000-00004; WATKINS J, 1982, BRIT HEART J, V47, P539; WEISS SOMA, 1929, AMER JOUR PHYSIOL, V90, P551; YOUNG C, 1986, J ALLERGY CLIN IMMUN, V77, P225; ZALOGA GP, 1986, ANN INTERN MED, V105, P65, DOI 10.7326/0003-4819-105-1-65	28	12	12	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1991	87	2					499	504		10.1016/0091-6749(91)90008-C	http://dx.doi.org/10.1016/0091-6749(91)90008-C			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX987	1899682				2022-12-18	WOS:A1991EX98700007
J	HILL, DJ; HOSKING, CS				HILL, DJ; HOSKING, CS			SOME LIMITATIONS OF DOUBLE-BLIND, PLACEBO-CONTROLLED FOOD CHALLENGES IN YOUNG-CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MILK ALLERGY; MANIFESTATIONS		ROYAL CHILDRENS HOSP,PATHOL,PARKVILLE,VIC 3052,AUSTRALIA	Royal Children's Hospital Melbourne	HILL, DJ (corresponding author), ROYAL CHILDRENS HOSP,DEPT ALLERGY,PARKVILLE,VIC 3052,AUSTRALIA.							BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; HILL DJ, 1986, J PEDIATR-US, V109, P270, DOI 10.1016/S0022-3476(86)80384-5; HILL DJ, 1988, CLIN ALLERGY, V18, P481, DOI 10.1111/j.1365-2222.1988.tb02898.x	3	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1991	87	1	1				136	136		10.1016/0091-6749(91)90230-L	http://dx.doi.org/10.1016/0091-6749(91)90230-L			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX985	1991919	Bronze			2022-12-18	WOS:A1991EX98500025
J	RUSSELL, DW; FERNANDEZCALDAS, E; SWANSON, MC; SELEZNICK, MJ; TRUDEAU, WL; LOCKEY, RF				RUSSELL, DW; FERNANDEZCALDAS, E; SWANSON, MC; SELEZNICK, MJ; TRUDEAU, WL; LOCKEY, RF			CAFFEINE, A NATURALLY-OCCURRING ACARICIDE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HOUSE-DUST MITES; SENSITIVE ADULT ASTHMA; CONTROLLED TRIAL; ALLERGEN AVOIDANCE; PREVENTIVE MEASURES; TANNIC-ACID; REDUCTION; CHILDREN; BLANKETS; CARPETS	Since caffeine is a plant alkaloid that has been described as a naturally occurring insecticide, its acaricidal effect on Dermatophagoides pteronyssinus (Dp) was investigated. Twelve cultures were established by adding 30 Dp to 200 mg of Tetramin fish food and brewer's yeast (8:2 ratio); six cultures were treated with 20 mg of finely ground caffeine. All 12 cultures were incubated at 75% relative humidity, 25-degrees-C, and observed during 8 weeks. Live mites were then counted under a stereoscope, cultures were extracted, and supernatants were analyzed for Der p I and Der f I allergen content with a two-site monoclonal RIA. Live mite counts in untreated cultures varied from 146 to 274 (215 +/- 47.1), and in caffeine-treated cultures from 0 to 3 (1 +/- 1.2; p less-than-or-equal-to 0.0001). Der p I concentrations in untreated cultures varied from 588 to 9000 ng/gm (3138.3 +/- 2990.8 ng/gm), and in caffeine-treated cultures from 52 to 117 ng/gm (78 +/- 23.8 ng/gm; p less-than-or-equal-to 0.01). Der p I was not detected in the food media or caffeine; Der f I was not detected in any of the cultures. Results demonstrate that caffeine inhibits mite growth and allergen production.	UNIV S FLORIDA,DIV ALLERGY & CLIN IMMUNOL VAR IIID,13000 N BRUCE B DOWNS BLVD,TAMPA,FL 33612; JAMES A HALEY VET AFFAIRS HOSP,TAMPA,FL; MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55905	State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; Mayo Clinic								BISCHOFF E, 1986, ALLERGOLOGIE, V9, P171; BOWLER SD, 1985, ANN ALLERGY, V55, P498; BURR ML, 1980, THORAX, V35, P513, DOI 10.1136/thx.35.7.513; BURR ML, 1980, THORAX, V35, P506, DOI 10.1136/thx.35.7.506; BURR ML, 1976, LANCET, V1, P333; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; COLLOFF MJ, 1986, CLIN ALLERGY, V16, P41, DOI 10.1111/j.1365-2222.1986.tb01952.x; CUSHLEY MJ, 1985, THORAX, V40, P176, DOI 10.1136/thx.40.3.176; DESAINTGEORGESGRIDELET D, 1981, ACTA OECOL-OEC APPL, V2, P117; GREEN WF, 1984, LANCET, V2, P160; GREEN WF, 1989, CLIN EXP ALLERGY, V19, P203, DOI 10.1111/j.1365-2222.1989.tb02365.x; HELLERHAUPT A, 1974, J MED ENTOMOL, V2, P551; KAPLAN RJ, 1978, ARCH DERMATOL, V114, P60, DOI 10.1001/archderm.114.1.60; KORSGAARD J, 1982, AM REV RESPIR DIS, V125, P80; KORSGAARD J, 1983, ALLERGY, V38, P93, DOI 10.1111/j.1398-9995.1983.tb01592.x; MILLER JD, 1989, J ALLERGY CLIN IMMUN, V83, P262; MITCHELL EB, 1985, CLIN ALLERGY, V15, P235, DOI 10.1111/j.1365-2222.1985.tb02280.x; MOSBECH H, 1988, J ALLERGY CLIN IMMUN, V81, P706, DOI 10.1016/0091-6749(88)91042-1; MURRAY AB, 1983, PEDIATRICS, V71, P418; NATHANSON JA, 1984, SCIENCE, V226, P184, DOI 10.1126/science.6207592; PENAUD J, 1975, CLIN ALLERGY, V5, P109; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; PLATTSMILLS TAE, 1982, LANCET, V2, P675; REED CE, 1987, J ALLERGY CLIN IMMUN, V78, P1028; SOLIMAN MY, 1986, AM REV RESPIR DIS, V134, P962, DOI 10.1164/arrd.1986.134.5.962; SWANSON MC, 1989, J ALLERGY CLIN IMMUN, V83, P776, DOI 10.1016/0091-6749(89)90014-6; VANBRONSWIJK JEMH, 1987, EXP APPL ACAROL, V3, P271, DOI 10.1007/BF01193164; VERVLOET D, 1982, J ALLERGY CLIN IMMUN, V69, P290, DOI 10.1016/S0091-6749(82)80006-7; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; WALSHAW MJ, 1986, Q J MED, V58, P199; WALSHAW MJ, 1985, THORAX, V40, P224	31	12	12	0	22	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1991	87	1	1				107	110		10.1016/0091-6749(91)90220-I	http://dx.doi.org/10.1016/0091-6749(91)90220-I			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX985	1991914	Bronze			2022-12-18	WOS:A1991EX98500015
J	PETERSEN, PE; EVANS, RB; JOHNSTONE, MA; HENDERSON, WR				PETERSEN, PE; EVANS, RB; JOHNSTONE, MA; HENDERSON, WR			EVALUATION OF OCULAR HYPERSENSITIVITY TO DIPIVALYL EPINEPHRINE BY COMPONENT EYE-DROP TESTING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WASHINGTON, DEPT MED, SJ-10, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT OPHTHALMOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Johnstone, Murray/ABG-3511-2020	Johnstone, Murray/0000-0003-2136-2433				BECKER B, 1966, AM J OPHTHALMOL, V62, P272, DOI 10.1016/0002-9394(66)91483-8; CHIPPERFIELD EJ, 1975, INFECT IMMUN, V11, P215, DOI 10.1128/IAI.11.2.215-221.1975; COHEN SC, 1952, AM J OPHTHALMOL, V35, P1704; FISHER AA, 1972, ARCH DERMATOL, V106, P169, DOI 10.1001/archderm.106.2.169; KASS MA, 1979, ARCH OPHTHALMOL-CHIC, V97, P1865, DOI 10.1001/archopht.1979.01020020313004; KERR CR, 1982, BRIT J OPHTHALMOL, V66, P109, DOI 10.1136/bjo.66.2.109; KOHN AN, 1979, AM J OPHTHALMOL, V87, P196, DOI 10.1016/0002-9394(79)90142-9; LAMBERTS DW, 1979, SURV OPHTHALMOL, V24, P157, DOI 10.1016/0039-6257(79)90019-5; LIESEGANG TJ, 1985, OPHTHALMOLOGY, V92, P228; MANDELL AI, 1978, OPHTHALMOLOGY, V85, P268; MEHELAS TJ, 1982, AM J OPHTHALMOL, V94, P682, DOI 10.1016/0002-9394(82)90019-8; MILLS KB, 1988, BRIT J OPHTHALMOL, V72, P465, DOI 10.1136/bjo.72.6.465; NAIR PNR, 1983, INFECT IMMUN, V41, P399, DOI 10.1128/IAI.41.1.399-409.1983; OGRA PL, 1973, J IMMUNOL, V110, P1307; OGRA PL, 1968, NEW ENGL J MED, V279, P893, DOI 10.1056/NEJM196810242791701; SCHWARTZ HJ, 1985, ARCH OPHTHALMOL-CHIC, V103, P14; THEODORE FH, 1983, CLIN ALLERGY IMMUNOL, P36; THEODORE J, 1979, AM J OPHTHALMOL, V88, P1013, DOI 10.1016/0002-9394(79)90407-0; WEI C, 1978, INVEST OPHTH VIS SCI, V17, P315	19	12	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1990	85	5					954	958		10.1016/0091-6749(90)90083-G	http://dx.doi.org/10.1016/0091-6749(90)90083-G			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DD959	2332569				2022-12-18	WOS:A1990DD95900021
J	CZARNETZKI, BM; THIELE, T; ROSENBACH, T				CZARNETZKI, BM; THIELE, T; ROSENBACH, T			EVIDENCE FOR LEUKOTRIENES IN ANIMAL VENOMS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CLIN MUNSTER,DEPT DERMATOL,MUNSTER,GERMANY	University of Munster								BURNETT JW, 1983, J AM ACAD DERMATOL, V9, P229, DOI 10.1016/S0190-9622(83)80356-9; BURNETT JW, 1977, TOXICOLOGY, V15, P117; CAMP RDR, 1983, BRIT J PHARMACOL, V80, P497, DOI 10.1111/j.1476-5381.1983.tb10721.x; CZARNETZKI B, 1983, CLIN EXP IMMUNOL, V54, P486; CZARNETZKI BM, 1986, PROSTAGLANDINS, V31, P851, DOI 10.1016/0090-6980(86)90018-3; CZARNETZKI BM, 1989, DERMATOLOGICA, V179, P54, DOI 10.1159/000248450; CZARNETZKI BM, 1975, INFLAMMATION, V1, P201; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; HARTMAN KR, 1981, COMP BIOCHEM PHYS C, V68, P235, DOI 10.1016/0306-4492(81)90022-8; HOBUROVA KL, 1985, ACTA PHYSL PHARM BUL, V11, P500; HOFFMAN DR, 1977, J ALLERGY CLIN IMMUN, V59, P364, DOI 10.1016/0091-6749(77)90019-7; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P599, DOI 10.1016/0091-6749(85)90036-3; JACQUES R, 1954, BRIT J PHARMACOL, V9, P49; JAQUES R, 1954, BRIT J PHARM CHEMOTH, V9, P53, DOI 10.1111/j.1476-5381.1954.tb00816.x; Levine L, 1985, Adv Prostaglandin Thromboxane Leukot Res, V15, P83; Nakajima T., 1986, VENOMS HYMENOPTERA; ROSENBACH T, 1987, CLIN EXP IMMUNOL, V69, P221; SALMON JA, 1982, PROSTAGLANDINS, V24, P225, DOI 10.1016/0090-6980(82)90148-4; SERAFIN WE, 1987, NEW ENGL J MED, V317, P30, DOI 10.1056/NEJM198707023170106; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738	21	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1990	85	2					505	509		10.1016/0091-6749(90)90162-W	http://dx.doi.org/10.1016/0091-6749(90)90162-W			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CP511	1968071	Bronze			2022-12-18	WOS:A1990CP51100013
J	RANGI, SP; SERWONSKA, MH; LENAHAN, GA; PICKETT, WC; BLAKE, VA; SAMPLE, S; GOETZL, EJ				RANGI, SP; SERWONSKA, MH; LENAHAN, GA; PICKETT, WC; BLAKE, VA; SAMPLE, S; GOETZL, EJ			SUPPRESSION BY INGESTED EICOSAPENTAENOIC ACID OF THE INCREASES IN NASAL MUCOSAL BLOOD-FLOW AND EOSINOPHILIA OF RYEGRASS-ALLERGIC REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF SAN FRANCISCO,MED CTR,DEPT MED,533 PARNASSUS,ROOM U426,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,MED CTR,SCH PHARM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,MED CTR,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,MED CTR,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; AMER CYANAMID CO,LEDERLE LABS,PEARL RIVER,NY 10965	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco					NIAID NIH HHS [AI 19784] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI019784] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BONNER RF, 1981, SCATTERING TECHNIQUE, P685; BURRALL BA, 1988, ALLERGY PRINCIPLES P, P164; CODDE JP, 1987, CLIN EXP PHARMACOL P, V14, P197, DOI 10.1111/j.1440-1681.1987.tb00375.x; DRUCE HM, 1984, J APPL PHYSIOL, V57, P1276, DOI 10.1152/jappl.1984.57.4.1276; FISHER M, 1986, INFLAMMATION, V10, P387, DOI 10.1007/BF00915822; GALLOWAY JH, 1985, CLIN SCI, V68, P449, DOI 10.1042/cs0680449; Goetzl E. J., 1986, Health effects of polyunsaturated fatty acids in seafoods, P239; GOLDMAN DW, 1983, BIOCHEM BIOPH RES CO, V117, P282, DOI 10.1016/0006-291X(83)91572-3; HASHIMOTO Y, 1984, THROMB RES, V34, P439, DOI 10.1016/0049-3848(84)90248-2; KELLEY VE, 1985, J IMMUNOL, V134, P1914; KREMER JM, 1985, LANCET, V1, P184; KREMER JM, 1987, ANN INTERN MED, V106, P497, DOI 10.7326/0003-4819-106-4-497; LEE TH, 1984, J BIOL CHEM, V259, P2383; LEITCH AG, 1984, J IMMUNOL, V132, P2559; LESLIE CA, 1985, J EXP MED, V162, P1336, DOI 10.1084/jem.162.4.1336; MAURICE PDL, 1987, BRIT J DERMATOL, V117, P599, DOI 10.1111/j.1365-2133.1987.tb07492.x; MORROW WJW, 1986, IMMUNOLOGY, V59, P439; PARM J, 1988, THORAX, V43, P84, DOI 10.1136/thx.43.2.84; PAYAN DG, 1986, J CLIN IMMUNOL, V6, P402, DOI 10.1007/BF00915380; PRICKETT JD, 1982, IMMUNOLOGY, V46, P819; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1987, ADV PROSTAGLANDIN TH, V17; SIGAL CE, 1987, J CLIN IMMUNOL, V7, P179, DOI 10.1007/BF00916012; STRASSER T, 1985, P NATL ACAD SCI USA, V82, P1540, DOI 10.1073/pnas.82.5.1540; VONSCHACKY C, 1985, J CLIN INVEST, V76, P1626, DOI 10.1172/JCI112147; WATSON J, 1988, INT J IMMUNOPHARMACO, V10, P467, DOI 10.1016/0192-0561(88)90135-X; WEAVER BJ, 1985, NUTR RES, V5, P31, DOI 10.1016/S0271-5317(85)80016-6	27	12	13	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1990	85	2					484	489		10.1016/0091-6749(90)90159-2	http://dx.doi.org/10.1016/0091-6749(90)90159-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CP511	2406326				2022-12-18	WOS:A1990CP51100010
J	PATTERSON, R; WONG, S; DYKEWICZ, MS; HARRIS, KE				PATTERSON, R; WONG, S; DYKEWICZ, MS; HARRIS, KE			MALIGNANT IDIOPATHIC ANAPHYLAXIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											PATTERSON, R (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,303 E CHICAGO AVE,CHICAGO,IL 60611, USA.				NIAID NIH HHS [AI 11403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BACAL E, 1978, CLIN ALLERGY, V8, P295, DOI 10.1111/j.1365-2222.1978.tb03227.x; DYKEWICZ MS, UNPUB EVALUATION KET; LIEBERMAN P, 1979, ARCH INTERN MED, V139, P1032, DOI 10.1001/archinte.139.9.1032; PATTERSON R, 1988, ALLERGY PROC, V9, P611, DOI 10.2500/108854188778965410; SALE SR, 1981, JAMA-J AM MED ASSOC, V246, P2336, DOI 10.1001/jama.246.20.2336; WIGGINS CA, 1988, J ALLERGY CLIN IMMUN, V82, P849, DOI 10.1016/0091-6749(88)90089-9; WIGGINS CA, 1989, J ALLERGY CLIN IMMUN, V84, P311, DOI 10.1016/0091-6749(89)90413-2	7	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1990	85	1	1				86	88		10.1016/0091-6749(90)90226-T	http://dx.doi.org/10.1016/0091-6749(90)90226-T			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM378	2299110	Bronze			2022-12-18	WOS:A1990CM37800014
J	FRANK, MM				FRANK, MM			COMPLEMENT - A BRIEF REVIEW	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											FRANK, MM (corresponding author), NIAID, LCI, BLDG 10, RM 11N228, BETHESDA, MD 20892 USA.							ALSENZ J, 1987, NEW ENGL J MED, V316, P1360, DOI 10.1056/NEJM198705283162202; ANDERSON DC, 1985, J INFECT DIS, V152, P668, DOI 10.1093/infdis/152.4.668; AWDEH ZL, 1980, P NATL ACAD SCI-BIOL, V77, P3576, DOI 10.1073/pnas.77.6.3576; BERGER M, 1983, CLIN IMMUNOL REV, V1, P471; BIESECKER G, 1981, J EXP MED, V154, P1779, DOI 10.1084/jem.154.6.1779; BIESECKER G, 1982, NEW ENGL J MED, V306, P264, DOI 10.1056/NEJM198202043060503; BORSOS T, 1971, PROGR IMMUNOLOGY, P841; BROWN EJ, 1984, FUNDAMENTAL IMMUNOLO, P645; Caldwell JR, 1972, CLIN IMMUNOL IMMUNOP, V1, P39; COOPER NR, 1985, ADV IMMUNOL, V37, P151, DOI 10.1016/S0065-2776(08)60340-5; CORNACOFF JB, 1983, J CLIN INVEST, V71, P236, DOI 10.1172/JCI110764; DAVITZ MA, 1986, J EXP MED, V163, P1150, DOI 10.1084/jem.163.5.1150; DAWKINS RL, 1983, IMMUNOL REV, V70, P5, DOI 10.1111/j.1600-065X.1983.tb00707.x; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; DONALDSON VH, 1969, J CLIN INVEST, V48, P642, DOI 10.1172/JCI106022; FALK RJ, 1983, J CLIN INVEST, V72, P560, DOI 10.1172/JCI111004; FEARON DT, 1983, ANNU REV IMMUNOL, V1, P243, DOI 10.1146/annurev.iy.01.040183.001331; FIELDS T, 1983, J ALLERGY CLIN IMMUN, V72, P54, DOI 10.1016/0091-6749(83)90052-0; FRANK MM, 1976, ANN INTERN MED, V84, P580, DOI 10.7326/0003-4819-84-5-580; FRANK MM, 1972, NEW ENGL J MED, V286, P808, DOI 10.1056/NEJM197204132861503; GADEK JE, 1979, J CLIN INVEST, V64, P280, DOI 10.1172/JCI109449; GEHA RS, 1985, NEW ENGL J MED, V312, P534, DOI 10.1056/NEJM198502283120902; GELFAND JA, 1979, MEDICINE, V58, P321, DOI 10.1097/00005792-197907000-00004; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; GLASS D, 1976, J CLIN INVEST, V58, P853, DOI 10.1172/JCI108538; HARPEL PC, 1982, CLIN RES, V30, pA563; HOWARD PF, 1986, AM J MED, V81, P187, DOI 10.1016/0002-9343(86)90250-0; Hugli T E, 1978, Adv Immunol, V26, P1, DOI 10.1016/S0065-2776(08)60228-X; HUGLI TE, 1984, REGULATION LEUCOCYTE, P109; INAI S, 1985, COMPLEMENT, V2, pA38; JACOB HS, 1980, NEW ENGL J MED, V302, P789; LAWLEY TJ, 1984, NEW ENGL J MED, V311, P1407, DOI 10.1056/NEJM198411293112204; LLOYD W, 1981, MEDICINE, V60, P208, DOI 10.1097/00005792-198105000-00004; MALBRAN A, 1988, J ALLERGY CLIN IMMUN, V81, P1199, DOI 10.1016/0091-6749(88)90891-3; MALLYA RK, 1982, CLIN EXP IMMUNOL, V48, P747; MAROM Z, 1985, J EXP MED, V161, P658; Mayer M M, 1984, Complement, V1, P2; MAYES JT, 1984, J CLIN INVEST, V73, P160, DOI 10.1172/JCI111187; MEDOF ME, 1984, J EXP MED, V160, P1558, DOI 10.1084/jem.160.5.1558; MULLEREBERHARD HJ, 1984, SPRINGER SEMIN IMMUN, V7, P93, DOI 10.1007/BF01893017; NELSON RA, 1953, SCIENCE, V118, P733, DOI 10.1126/science.118.3077.733; NICHOLSONWELLER A, 1983, P NATL ACAD SCI-BIOL, V80, P5066, DOI 10.1073/pnas.80.16.5066; PANGBURN MK, 1983, P NATL ACAD SCI-BIOL, V80, P5430, DOI 10.1073/pnas.80.17.5430; PANGBURN MK, 1984, SPRINGER SEMIN IMMUN, V7, P163, DOI 10.1007/BF01893019; RAPP HJ, 1970, MOL BASIS COMPLEMENT; RATNOFF OD, 1969, J EXP MED, V129, P315, DOI 10.1084/jem.129.2.315; ROSEN FS, 1965, SCIENCE, V148, P957, DOI 10.1126/science.148.3672.957; ROSEN FS, 1971, J CLIN INVEST, V50, P2143, DOI 10.1172/JCI106708; ROSS GD, 1985, J IMMUNOL, V135, P2005; ROSS SC, 1984, MEDICINE, V63, P243, DOI 10.1097/00005792-198409000-00001; Rosse W F, 1969, J Clin Invest, V47, P2430; SANDERS ME, 1985, J IMMUNOL METHODS, V85, P245, DOI 10.1016/0022-1759(85)90135-8; SANDERS ME, 1986, J IMMUNOL, V136, P4456; SCHAPIRA M, 1983, NEW ENGL J MED, V308, P1050, DOI 10.1056/NEJM198305053081802; SCHREIBER AD, 1976, BLOOD, V48, P567; SHIN ML, 1986, J IMMUNOL, V136, P1777; SPAULDING WB, 1960, ANN INTERN MED, V53, P739, DOI 10.7326/0003-4819-53-4-739; UNKELESS JC, 1988, BASIC PRINCIPLES CLI, P309; WEINBERG PF, 1984, AM REV RESPIR DIS, V130, P71; ZALMAN LS, 1986, P NATL ACAD SCI USA, V83, P6975, DOI 10.1073/pnas.83.18.6975; ZUBLER RH, 1976, J IMMUNOL, V116, P232	61	12	17	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1989	84	4	1				411	420		10.1016/0091-6749(89)90350-3	http://dx.doi.org/10.1016/0091-6749(89)90350-3			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW760	2677090				2022-12-18	WOS:A1989AW76000001
J	JAGGI, KS; ARORA, N; NIPHADKAR, PV; GANGAL, SV				JAGGI, KS; ARORA, N; NIPHADKAR, PV; GANGAL, SV			IMMUNOCHEMICAL CHARACTERIZATION OF COCOS-NUCIFERA POLLEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CSIR,CTR BIOCHEM,UNIV CAMPUS,DELHI 110007,INDIA; ST GEORGE HOSP,PULM FUNCT LAB,BOMBAY,INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Genomics & Integrative Biology (IGIB)								AXELSEN NH, 1973, SCAND J IMMUNOL S2, V2, P49; BERNSTEIN IL, 1976, J ALLERGY CLIN IMMUN, V57, P141, DOI 10.1016/0091-6749(76)90033-6; EKRAMODDOULLAH AKM, 1986, MOL IMMUNOL, V23, P111, DOI 10.1016/0161-5890(86)90031-3; GLEICH GJ, 1976, MANUAL CLIN IMMUNOLO; JAGGI KS, 1987, J ALLERGY CLIN IMMUN, V80, P562, DOI 10.1016/0091-6749(87)90008-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAIR PKK, 1986, ATMOSPHERIC POLLEN S; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Voller A., 1980, MANUAL CLIN IMMUNOLO, P359	10	12	13	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1989	84	3					378	385		10.1016/0091-6749(89)90424-7	http://dx.doi.org/10.1016/0091-6749(89)90424-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AR199	2778244				2022-12-18	WOS:A1989AR19900017
J	MENENDEZ, R; LOWE, RS; KERSEY, J				MENENDEZ, R; LOWE, RS; KERSEY, J			BENZALKONIUM CHLORIDE AND BRONCHOCONSTRICTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter											MENENDEZ, R (corresponding author), ALLERGY & ASTHMA CTR EL PASO,EL PASO,TX 79925, USA.							BEASLEY CRW, 1987, BRIT MED J, V294, P1197, DOI 10.1136/bmj.294.6581.1197-a; BEASLEY R, 1988, BRIT J CLIN PHARMACO, V25, P283, DOI 10.1111/j.1365-2125.1988.tb03305.x; CONNOLLY CK, 1982, BRIT MED J, V285, P934, DOI 10.1136/bmj.285.6346.934; FANTA CH, 1985, ACCP, V4, P1; KOEPKE JW, 1983, J ALLERGY CLIN IMMUN, V72, P504, DOI 10.1016/0091-6749(83)90588-2; MANN JS, 1984, BRIT MED J, V289, P469, DOI 10.1136/bmj.289.6443.469; MCFADDEN ER, 1986, AM REV RESPIR DIS, V133, P723; MISZKIEL KA, 1988, BRIT J CLIN PHARMACO, V26, P295, DOI 10.1111/j.1365-2125.1988.tb05280.x; MISZKIEL KA, 1988, BRIT J CLIN PHARMACO, V25, P157, DOI 10.1111/j.1365-2125.1988.tb03286.x; MOLER FW, 1988, J ALLERGY CLIN IMMUN, V81, P1101, DOI 10.1016/0091-6749(88)90876-7; OCALLAGHAN C, 1986, LANCET, V2, P1424, DOI 10.1016/S0140-6736(86)92735-2; PANCORBO S, 1983, CLIN PHARMACY, V2, P45; PRENDIVILLE A, 1987, THORAX, V42, P86, DOI 10.1136/thx.42.2.86; RAFFERTY P, 1988, THORAX, V43, P446, DOI 10.1136/thx.43.6.446; REISMAN RE, 1970, J ALLERGY, V46, P162, DOI 10.1016/0021-8707(70)90095-X; SCHWARTZ HJ, 1984, J ALLERGY CLIN IMMUN, V74, P511, DOI 10.1016/0091-6749(84)90387-7; TRAUTLEIN J, 1976, CHEST, V70, P711, DOI 10.1378/chest.70.6.711; TWAROG FJ, 1982, JAMA-J AM MED ASSOC, V248, P2030, DOI 10.1001/jama.248.16.2030; WILLIAMS SJ, 1981, THORAX, V36, P629, DOI 10.1136/thx.36.8.629	19	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1989	84	2					272	274		10.1016/0091-6749(89)90336-9	http://dx.doi.org/10.1016/0091-6749(89)90336-9			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL836	2760364				2022-12-18	WOS:A1989AL83600021
J	YAMAZAKI, M; MATSUOKA, T; YASUI, K; KOMIYAMA, A; AKABANE, T				YAMAZAKI, M; MATSUOKA, T; YASUI, K; KOMIYAMA, A; AKABANE, T			DOPAMINE-INHIBITION OF SUPEROXIDE ANION PRODUCTION BY POLYMORPHONUCLEAR LEUKOCYTES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SHINSHU UNIV,SCH MED,DEPT PEDIAT,MATSUMOTO,NAGANO 390,JAPAN	Shinshu University								BABIOR BM, 1981, METHODS HEMATOLOGY, V3, P1; BECKER EL, 1986, FASEB J, V45, P2151; BOURNE HR, 1974, SCIENCE, V184, P19, DOI 10.1126/science.184.4132.19; BOXER LA, 1980, J CLIN INVEST, V66, P268, DOI 10.1172/JCI109853; BUSSE WW, 1984, J ALLERGY CLIN IMMUN, V73, P404, DOI 10.1016/0091-6749(84)90416-0; CHRISTIANSEN NO, 1986, BIOCHIM BIOPHYS ACTA, V882, P57, DOI 10.1016/0304-4165(86)90055-3; CRONSTEIN BN, 1983, J EXP MED, V158, P1160, DOI 10.1084/jem.158.4.1160; DAVIS PB, 1983, J CLIN INVEST, V71, P1787, DOI 10.1172/JCI110934; GALANT SP, 1980, J LAB CLIN MED, V96, P15; IGNARRO LJ, 1974, J EXP MED, V139, P1395, DOI 10.1084/jem.139.6.1395; KOMIYAMA A, 1985, BLOOD, V66, P99; KOMIYAMA A, 1986, SCAND J HAEMATOL, V37, P162; KORCHAK HM, 1984, J BIOL CHEM, V259, P4076; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARIDONNEAUPARINI I, 1986, BIOCHEM BIOPH RES CO, V138, P1099, DOI 10.1016/S0006-291X(86)80395-3; MARONE G, 1980, J IMMUNOL, V125, P2277; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; McPhail L C, 1984, Contemp Top Immunobiol, V14, P247; MCPHAIL LC, 1983, J CLIN INVEST, V72, P192, DOI 10.1172/JCI110957; MELMON KL, 1981, AM J MED, V71, P100, DOI 10.1016/0002-9343(81)90264-3; Mittal C K, 1986, Methods Enzymol, V132, P428; RIVKIN I, 1975, J IMMUNOL, V115, P1126; SHAAFI RI, 1983, BIOCHEM BIOPH RES CO, V114, P68; TAUBER AI, 1987, BLOOD, V69, P711; TAUBER AI, 1979, BIOCHEMISTRY-US, V18, P5577; WACKER WEC, 1956, NEW ENGL J MED, V255, P449, DOI 10.1056/NEJM195609062551001; YAMAZAKI M, 1984, AM J DIS CHILD, V138, P192, DOI 10.1001/archpedi.1984.02140400074018; YAMAZAKI M, 1988, AM J HEMATOL, V27, P169, DOI 10.1002/ajh.2830270304; YAMAZAKI M, 1985, SCAND J HAEMATOL, V35, P481; ZURIER RB, 1974, J CLIN INVEST, V53, P297, DOI 10.1172/JCI107550	30	12	14	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1989	83	5					967	972		10.1016/0091-6749(89)90113-9	http://dx.doi.org/10.1016/0091-6749(89)90113-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U7161	2541191				2022-12-18	WOS:A1989U716100019
J	BORTS, MR; SLAVIN, RG; SAMUELS, LD; DRUCE, HM; GENTILCORE, R				BORTS, MR; SLAVIN, RG; SAMUELS, LD; DRUCE, HM; GENTILCORE, R			FURTHER-STUDIES IN ALLERGIC SINUSITIS UTILIZING SINGLE PHOTON-EMISSION COMPUTERIZED-TOMOGRAPHY (SPECT)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1989	83	1					302	302						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T0419					2022-12-18	WOS:A1989T041900542
J	HYLANDER, RD; ORTIZ, AA; FREEMAN, TM; MARTIN, ME				HYLANDER, RD; ORTIZ, AA; FREEMAN, TM; MARTIN, ME			IMPORTED FIRE ANT IMMUNOTHERAPY - EFFECTIVENESS OF WHOLE-BODY EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	12	12	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1989	83	1					232	232						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T0419					2022-12-18	WOS:A1989T041900262
J	MALO, JL; LARCHEVEQUE, J; CARTIER, A				MALO, JL; LARCHEVEQUE, J; CARTIER, A			SIGNIFICANT CHANGES IN NONSPECIFIC BRONCHIAL RESPONSIVENESS AFTER ISOLATED IMMEDIATE BRONCHOSPECIFIC REACTIONS CAUSED BY ISOCYANATES BUT NOT AFTER A LATE REACTION CAUSED BY PLICATIC ACID	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MALO, JL (corresponding author), HOP SACRE COEUR, DEPT CHEST MED, 5400 W GOUIN, MONTREAL H4J 1C5, QUEBEC, CANADA.							CARTIER A, 1986, J ALLERGY CLIN IMMUN, V77, P570, DOI 10.1016/0091-6749(86)90347-7; CARTIER A, 1986, J ALLERGY CLIN IMMUN, V78, P1185, DOI 10.1016/0091-6749(86)90270-8; CARTIER A, 1984, J ALLERGY CLIN IMMUN, V74, P261, DOI 10.1016/0091-6749(84)90256-2; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; COCKCROFT DW, 1979, AM REV RESPIR DIS, V119, P505; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DEHAUT P, 1983, THORAX, V38, P516, DOI 10.1136/thx.38.7.516; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DURHAM SR, 1987, J ALLERGY CLIN IMMUN, V79, P398, DOI 10.1016/0091-6749(87)90161-8; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36, DOI 10.1164/ajrccm/136.1.36; HARGREAVE FE, 1985, J ALLERGY CLIN IMMUN, V76, P272, DOI 10.1016/0091-6749(85)90641-4; JUPITER EF, 1978, THORAX, V33, P705; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; LEMIRE I, 1984, J ALLERGY CLIN IMMUN, V73, P234, DOI 10.1016/S0091-6749(84)80013-5; MALO JL, 1986, J ALLERGY CLIN IMMUN, V78, P1153, DOI 10.1016/0091-6749(86)90265-4; MALO JL, 1983, J ALLERGY CLIN IMMUN, V72, P413, DOI 10.1016/0091-6749(83)90508-0; MANNING PJ, 1987, J APPL PHYSIOL, V63, P1572, DOI 10.1152/jappl.1987.63.4.1572; MAPP CE, 1986, EUR J RESPIR DIS, V69, P276; MAPP CE, 1985, J ALLERGY CLIN IMMUN, V75, P568, DOI 10.1016/0091-6749(85)90031-4; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; RAFFERTY P, 1988, J ALLERGY CLIN IMMUN, V81, P231, DOI 10.1016/0091-6749(88)90485-X; RUFFIN RE, 1981, J ALLERGY CLIN IMMUN, V67, P285, DOI 10.1016/0091-6749(81)90023-3; STEINBERG D R, 1987, American Review of Respiratory Disease, V135, pA312; TSE KS, 1982, CLIN ALLERGY, V12, P249, DOI 10.1111/j.1365-2222.1982.tb02525.x; WOOLCOCK AJ, 1984, AM REV RESPIR DIS, V130, P71	27	12	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1989	83	1					159	165		10.1016/0091-6749(89)90491-0	http://dx.doi.org/10.1016/0091-6749(89)90491-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T0419	2643658				2022-12-18	WOS:A1989T041900022
J	PIEN, LC; ZEISS, CR; LEACH, CL; HATOUM, NS; LEVITZ, D; GARVIN, PJ; PATTERSON, R				PIEN, LC; ZEISS, CR; LEACH, CL; HATOUM, NS; LEVITZ, D; GARVIN, PJ; PATTERSON, R			ANTIBODY-RESPONSE TO TRIMELLITYL HEMOGLOBIN IN TRIMELLITIC ANHYDRIDE-INDUCED LUNG INJURY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VET ADM LAKESIDE MED CTR,333 E HURON,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611; IIT,RES INST,CHICAGO,IL 60616; AMOCO CORP,CHICAGO,IL	Northwestern University; Illinois Institute of Technology					NIAID NIH HHS [AI 11403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHANDLER MJ, 1987, J ALLERGY CLIN IMMUN, V80, P223, DOI 10.1016/0091-6749(87)90133-3; LEACH CL, 1987, TOXICOL APPL PHARM, V87, P67, DOI 10.1016/0041-008X(87)90085-8; LEDBETTER AD, 1987, AM IND HYG ASSOC J, V48, P35; PATTERSON R, 1982, J ALLERGY CLIN IMMUN, V70, P19, DOI 10.1016/0091-6749(82)90196-8; PATTERSON R, 1979, AM REV RESPIR DIS, V120, P1259; PATTERSON R, 1978, J CLIN INVEST, V62, P971, DOI 10.1172/JCI109226; TURNER ES, 1980, CLIN EXP IMMUNOL, V39, P470; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1; ZEISS CR, 1983, ANN INTERN MED, V98, P8, DOI 10.7326/0003-4819-98-1-8; ZEISS CR, 1980, INT ARCH ALLER A IMM, V61, P380; ZEISS CR, 1988, AM REV RESPIR DIS, V137, P191, DOI 10.1164/ajrccm/137.1.191; ZEISS CR, 1987, J ALLERGY CLIN IMMUN, V79, P59, DOI 10.1016/S0091-6749(87)80017-9	12	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1988	82	6					1098	1103						6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R6311	3204253				2022-12-18	WOS:A1988R631100020
J	BUTCHER, BT; REED, MA				BUTCHER, BT; REED, MA			EVALUATION OF COMMERCIAL IMPORTED FIRE ANT EXTRACTS BY CROSSED IMMUNOELECTROPHORESIS AND RADIOALLERGOSORBENT TEST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BUTCHER, BT (corresponding author), TULANE UNIV,MED CTR,DEPT MED,CLIN IMMUNOL SECT,1700 PERDIDO ST,NEW ORLEANS,LA 70112, USA.				PHS HHS [21552] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAHNA S, INJ PRESS J ALLERGY; BLOOM FL, 1978, J ALLERGY CLIN IMMUN, V61, P134, DOI 10.1016/0091-6749(78)90256-7; BUTCHER BT, 1988, INT ARCH ALLER A IMM, V85, P458, DOI 10.1159/000234551; BUTCHER BT, 1988, J ALLERGY CLIN IMMUN, V81, P1096, DOI 10.1016/0091-6749(88)90875-5; BUTCHER BT, 1988, J ALLERGY CLIN IMMUN, V82, P133; CROWLE AJ, 1980, MANUAL CLIN IMMUNOLO, P3; DESHAZO RD, 1984, J ALLERGY CLIN IMMUN, V74, P841, DOI 10.1016/0091-6749(84)90188-X; HANNAN CJ, 1986, J ALLERGY CLIN IMMUN, V78, P331, DOI 10.1016/S0091-6749(86)80085-9; LOFGREN CS, 1975, ANNU REV ENTOMOL, V20, P1, DOI 10.1146/annurev.en.20.010175.000245; RHOADES RB, 1975, J ALLERGY CLIN IMMUN, V56, P84, DOI 10.1016/0091-6749(75)90112-8; RHOADES RB, 1977, J FLA MED ASSOC, V64, P247; RHOADES RB, 1987, IMMUNOL ALLERGY PRAC, V9, P96; STROM GB, 1983, J ALLERGY CLIN IMMUN, V72, P46, DOI 10.1016/0091-6749(83)90051-9; TRIPLETT RF, 1976, SOUTHERN MED J, V69, P258, DOI 10.1097/00007611-197603000-00002; TRIPLETT RF, 1973, SOUTHERN MED J, V66, P477, DOI 10.1097/00007611-197304000-00019; VALENTINE M, 1982, CURRENT PERSPECTIVES, P122; Yaeger W, 1978, J MED ASS GA, V67, P101; 1987, CLIN REV ALLERGY, V5; 1986, CLIN REV ALLERGY, V4; 1983, SIGMA DIAGNOSTICS TO	20	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1988	82	5	1				770	777		10.1016/0091-6749(88)90078-4	http://dx.doi.org/10.1016/0091-6749(88)90078-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R1708	3192862				2022-12-18	WOS:A1988R170800010
J	CRIMI, N; PALERMO, F; OLIVERI, R; PALERMO, B; VANCHERI, C; POLOSA, R; MISTRETTA, A				CRIMI, N; PALERMO, F; OLIVERI, R; PALERMO, B; VANCHERI, C; POLOSA, R; MISTRETTA, A			EFFECT OF VASOACTIVE INTESTINAL PEPTIDE (VIP) ON PROPRANOLOL-INDUCED BRONCHOCONSTRICTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											CRIMI, N (corresponding author), UNIV CATANIA,INST MALATTIE APPARATO RESP & TISIOL,VIA PASSO GRAVINA 187,I-95125 CATANIA,ITALY.		Crimi, Nunzio/AAL-2994-2020; VANCHERI, Carlo/K-9417-2016	Crimi, Nunzio/0000-0002-8591-4535; VANCHERI, Carlo/0000-0002-5120-9926				ANDERSSON RGG, 1986, EUR J PHARMACOL, V123, P181, DOI 10.1016/0014-2999(86)90658-8; BARNES PJ, 1987, J ALLERGY CLIN IMMUN, V79, P285, DOI 10.1016/0091-6749(87)90143-6; BARNES PJ, 1984, AM REV RESPIR DIS, V130, P162; BUNDGAARD A, 1983, EUR J RESPIR DIS, V64, P427; BURNSTOCK G, 1972, PHARMACOL REV, V24, P509; CAMERON AR, 1983, Q J EXP PHYSIOL CMS, V68, P413, DOI 10.1113/expphysiol.1983.sp002735; CAMPBELL G, 1971, Comparative and General Pharmacology, V2, P281, DOI 10.1016/0010-4035(71)90052-8; DAVIS C, 1982, J APPL PHYSIOL, V53, P1080, DOI 10.1152/jappl.1982.53.5.1080; DIAMOND L, 1983, AM REV RESPIR DIS, V128, P827; DIAMOND L, 1976, J APPL PHYSL, V41, P764; LAITINEN A, 1985, EUR J RESPIR DIS, V67, P209; LAITINEN A, 1985, EUR J RESPIR DIS S, V66, P140; LEROUX P, 1984, ENDOCRINOLOGY, V114, P1506, DOI 10.1210/endo-114-5-1506; MATZUSAKI Y, 1980, SCIENCE, V210, P1252; MOJARAD M, 1985, American Review of Respiratory Disease, V131, pA281; MORICE A, 1983, LANCET, V2, P1225; MORICE AH, 1986, ASTHMA CLIN PHARM TH, P91; PALMER JB, 1985, AM REV RESPIR DIS, V131, P282; PALMER JBD, 1986, J APPL PHYSIOL, V61, P1322, DOI 10.1152/jappl.1986.61.4.1322; PALMER JBD, 1986, THORAX, V41, P663, DOI 10.1136/thx.41.9.663; ROBBERECHT P, 1981, BIOCHIM BIOPHYS ACTA, V678, P76, DOI 10.1016/0304-4165(81)90049-0; RODEN K, 1987, AM REV RESPIR DIS S, V91, P135; WALTERS EH, 1984, J APPL PHYSIOL, V57, P129, DOI 10.1152/jappl.1984.57.1.129	23	12	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1988	82	4					617	621		10.1016/0091-6749(88)90973-6	http://dx.doi.org/10.1016/0091-6749(88)90973-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q6399	2971708	Bronze			2022-12-18	WOS:A1988Q639900013
J	MOSCATO, G; RAMPULLA, C; DELLABIANCA, A; ZANOTTI, E; CANDURA, S				MOSCATO, G; RAMPULLA, C; DELLABIANCA, A; ZANOTTI, E; CANDURA, S			EFFECT OF SALBUTAMOL AND INHALED SODIUM CROMOGLYCATE ON THE AIRWAY AND NEUTROPHIL CHEMOTACTIC ACTIVITY IN FOG-INDUCED BRONCHOSPASM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PAVIA,ALLERGOL POSTGRAD SCH,I-27100 PAVIA,ITALY; DEPT RESP PHYSIOPATHOL,MONTESCANO,ITALY	University of Pavia			Candura, Stefano/AAC-2102-2020	Candura, Stefano/0000-0002-1702-4653				ALLEGRA L, 1980, EUR J RESPIR DIS, V61, P41; ANDERSON SD, 1983, THORAX, V38, P284, DOI 10.1136/thx.38.4.284; ASSEM ESK, 1971, IMMUNOLOGY, V21, P729; ATKINS PC, 1979, J ALLERGY CLIN IMMUN, V64, P251, DOI 10.1016/0091-6749(79)90140-4; BASCOM R, 1986, AM REV RESPIR DIS, V134, P248; BIANCO S, 1982, RESPIRATION, V23, P78; BLACK JL, 1985, THORAX, V40, P427, DOI 10.1136/thx.40.6.427; BLACK JL, 1987, J ALLERGY CLIN IMMUN, V80, P39, DOI 10.1016/S0091-6749(87)80188-4; BUTCHERS PR, 1979, BRIT J PHARMACOL, V67, P23; CASALI L, 1980, MED TOR, V2, P289; CHURCH MK, 1983, BRIT J PHARMACOL, V78, P671, DOI 10.1111/j.1476-5381.1983.tb09419.x; CHURCH MK, IN PRESS CLIN ALLERG; FABBRI LM, 1983, J ALLERGY CLIN IMMUN, V71, P468, DOI 10.1016/0091-6749(83)90463-3; GOOSE J, 1969, IMMUNOLOGY, V16, P749; HIGENBOTTAM T, 1983, BRIT MED J, V286, P1012, DOI 10.1136/bmj.286.6370.1012; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; ISHIZAKA T, 1972, J IMMUNOL, V108, P513; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; LITCHTENSTEIN LM, 1968, SCIENCE, V161, P902; MARTIN GL, 1980, J ALLERGY CLIN IMMUN, V66, P204, DOI 10.1016/0091-6749(80)90040-8; MOQBEL R, 1986, AM REV RESPIR DIS, V133, P609; MOSCATO G, 1986, ALLERGY, V41, P581, DOI 10.1111/j.1398-9995.1986.tb00350.x; MOSCATO G, 1986, ANN ALLERGY, V56, P145; NAGY L, 1981, Allergie und Immunologie (Leipzig), V27, P48; PEARCE FL, 1982, J IMMUNOL, V128, P2481; RAMPULLA C, 1986, B EUR PHYSIOPATH RES, V22, pS105; RAMPULLA C, 1984, MED TOR, V6, P267; SCHOEFFEL RE, 1981, BRIT MED J, V283, P1285, DOI 10.1136/bmj.283.6302.1285; SHAW RJ, 1985, ALLERGY, V40, P48, DOI 10.1111/j.1398-9995.1985.tb04154.x; SHEINMAN BD, 1985, PROG RESPIR RES, V19, P56; THOMPSON RA, 1979, TECHNIQUES CLIN IMMU; TURNBULL LW, 1976, IMMUNOLOGY, V31, P797	33	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1988	82	3	1				382	388		10.1016/0091-6749(88)90009-7	http://dx.doi.org/10.1016/0091-6749(88)90009-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q3229	3139728				2022-12-18	WOS:A1988Q322900009
J	VERBURG, KM; BOWSHER, RR; HENRY, DP				VERBURG, KM; BOWSHER, RR; HENRY, DP			QUANTIFICATION OF URINARY HISTAMINE BY A NEW RADIOENZYMATIC ASSAY - DOCUMENTATION OF ASSAY SPECIFICITY AND ESTABLISHMENT OF NORMAL EXCRETION RATES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ELI LILLY & CO,LILLY LABS CLIN RES,INDIANAPOLIS,IN 46285; INDIANA UNIV,SCH MED,DEPT PHARMACOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MED,INDIANAPOLIS,IN 46202	Eli Lilly; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis			Henry, David/AAU-4650-2020	Henry, David/0000-0001-7169-7704				BARTH H, 1980, BIOCHEM PHARMACOL, V29, P1399, DOI 10.1016/0006-2952(80)90436-0; BARTH H, 1978, AGENTS ACTIONS, V8, P359, DOI 10.1007/BF01968615; BEALL GN, 1965, INT ARCH ALLER A IMM, V26, P1; BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; BEAVEN MA, 1982, KLIN WOCHENSCHR, V60, P873, DOI 10.1007/BF01716943; BOWSHER RR, 1983, J BIOL CHEM, V258, P2215; BOWSHER RR, 1984, PHARMACOLOGIST, V26, P222; BROWN DD, 1959, J BIOL CHEM, V234, P2948; BROWN MJ, 1980, ANAL BIOCHEM, V109, P142, DOI 10.1016/0003-2697(80)90022-6; BRUCE C, 1979, ANN CLIN BIOCHEM, V16, P259, DOI 10.1177/000456327901600166; CODE CF, 1956, AM J PHYSL, V30, P219; DENT C, 1979, AGENTS ACTIONS, V9, P34, DOI 10.1007/BF02024097; DENT C, 1982, BIOCH PHARM, V32, P2297; DYER J, 1982, J ALLERGY CLIN IMMUN, V70, P82, DOI 10.1016/0091-6749(82)90233-0; ERSPAMER V, 1964, ARCH BIOCHEM BIOPHYS, V105, P620, DOI 10.1016/0003-9861(64)90059-1; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V66, P295, DOI 10.1016/0091-6749(80)90024-X; GUSTAFSSON A, 1964, ACTA CHEM SCAND, V17, P2069; HEGSTRAND LR, 1985, NEUROCHEM RES, V10, P307, DOI 10.1007/BF00964600; HORAKOVA Z, 1977, CLIN CHIM ACTA, V79, P447, DOI 10.1016/0009-8981(77)90441-7; KAPELLERADLER R, 1957, BIOCHIM BIOPHYS ACTA, V25, P394, DOI 10.1016/0006-3002(57)90484-5; KEYZER JJ, 1983, NEW ENGL J MED, V309, P1603, DOI 10.1056/NEJM198312293092603; KHANDELWAL JK, 1982, AGENTS ACTIONS, V12, P583, DOI 10.1007/BF01965064; KOBAYASHI Y, 1972, ANAL BIOCHEM, V46, P85, DOI 10.1016/0003-2697(72)90397-1; LORENZ W, 1978, MT SINAI J MED, V45, P357; MASLINSKI S, 1977, DIGESTION, V15, P497, DOI 10.1159/000198040; MYERS G, 1981, J ALLERGY CLIN IMMUN, V67, P305, DOI 10.1016/0091-6749(81)90026-9; NAVERT H, 1975, J CHROMATOGR, V106, P218, DOI 10.1016/S0021-9673(01)81069-4; OATES JA, 1962, CLIN CHIM ACTA, V7, P488; ROBERTS LJ, 1985, J CHROMATOGR, V338, P41, DOI 10.1016/0378-4347(85)80068-2; ROBERTS LJ, 1984, ANAL BIOCHEM, V136, P258, DOI 10.1016/0003-2697(84)90333-6; SCHIPPERT B, 1979, PHARMACOLOGY, V19, P86, DOI 10.1159/000137293; SHAFF RE, 1979, ANAL BIOCHEM, V94, P425, DOI 10.1016/0003-2697(79)90385-3; SNYDER SH, 1966, J PHARMACOL EXP THER, V153, P544; TSURUTA Y, 1981, J CHROMATOGR, V224, P105, DOI 10.1016/S0378-4347(00)80142-5; VERBURG KM, 1984, LIFE SCI, V35, P241, DOI 10.1016/0024-3205(84)90107-3; VERBURG KM, 1983, LIFE SCI, V32, P2855, DOI 10.1016/0024-3205(83)90322-3; VERBURG KM, 1984, AGENTS ACTIONS, V14, P633, DOI 10.1007/BF01978899; VERBURG KM, 1985, METHOD ENZYMAT AN, V3, P535; VERBURG KM, 1984, PHARMACOLOGIST, V26, P222; Verburg KM, 1986, NEUROMETHODS, V5, P147, DOI DOI 10.1385/0-89603-079-2:147; WARREN K, 1983, J ALLERGY CLIN IMMUN, V71, P206, DOI 10.1016/0091-6749(83)90101-X; WETTERQUIST H, 1978, HDB EXPT PHARM 2, V18, P131	42	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1988	82	3	1				339	347		10.1016/0091-6749(88)90004-8	http://dx.doi.org/10.1016/0091-6749(88)90004-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q3229	3170983				2022-12-18	WOS:A1988Q322900004
J	BARANIUK, JN; ESCH, RE; BUCKLEY, CE				BARANIUK, JN; ESCH, RE; BUCKLEY, CE			POLLEN GRAIN COLUMN CHROMATOGRAPHY - QUANTITATION AND BIOCHEMICAL-ANALYSIS OF RAGWEED-POLLEN SOLUTES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									DUKE UNIV,DEPT MED,DURHAM,NC 27706; DUKE UNIV,DEPT MED MICROBIOL,DURHAM,NC 27706; GREER LABS,LENOIR,NC	Duke University; Duke University				Baraniuk, James Nicholas/0000-0002-1866-4177				BARANIUK JN, 1986, J ALLERGY CLIN IMMUN, V77, P198; BRIDGER GP, 1971, ANN OTO RHINOL LARYN, V80, P445, DOI 10.1177/000348947108000324; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; FURIC R, 1982, Journal of Allergy and Clinical Immunology, V69, P126; GILLISSEN LJW, 1978, ACTA BOT NEERL, V27, P205, DOI 10.1111/j.1438-8677.1978.tb00281.x; GLADTKE E, 1979, PHARMACOKINETICS, P11; HARRINGTON JB, 1963, AM J BOT, V50, P532, DOI 10.2307/2440028; HENDERSON DC, 1986, INT ARCH ALLER A IMM, V79, P66, DOI 10.1159/000233944; HESLOPHARRISON J, 1975, PROC R SOC SER B-BIO, V190, P275, DOI 10.1098/rspb.1975.0093; HOWLETT BJ, 1973, J CELL SCI, V13, P603; HOWLETT BJ, 1981, COMMENTARIES PLANT S, V2; HUMBLE MW, 1977, J CLIN PATHOL, V30, P275, DOI 10.1136/jcp.30.3.275; HUSSAIN R, 1981, J ALLERGY CLIN IMMUN, V67, P217, DOI 10.1016/0091-6749(81)90064-6; JORDE W, 1974, ACTA ALLERGOL, V29, P165, DOI 10.1111/j.1398-9995.1974.tb01646.x; KAMBOJ RK, 1984, ANN BOT-LONDON, V54, P647, DOI 10.1093/oxfordjournals.aob.a086835; KING TP, 1980, ALLERGY, V35, P187, DOI 10.1111/j.1398-9995.1980.tb01738.x; KLEMAWESCH SJ, J ALLERGY CLIN IMMUN, V59, P619; KNOX RB, 1975, BIOL J LIN SOC S, V1, P177; LEHNINGER AL, 1970, BIOCHEMISTRY-US, P150; LEWIS HL, 1983, AIRBORNE ALLERGENIC, P141; LINSKENS HF, 1974, NATURWISSENSCHAFTEN, V61, P275, DOI 10.1007/BF00595670; LOWENSTEIN H, 1981, J IMMUNOL, V127, P637; LOWENSTEIN H, 1893, J IMMUNOL, V130, P727; LOWENSTEIN H, 1981, J IMMUNOL, V125, P943; MARSH DG, 1981, J ALLERGY CLIN IMMUN, V67, P206, DOI 10.1016/0091-6749(81)90063-4; MURROWBROWN H, 1976, ACTA ALLERGOL, V31, P22; NACLERIO RM, 1986, AM REV RESPIR DIS, V134, P1102, DOI 10.1164/arrd.1986.134.5.1102; SPIES JR, 1969, J ALLERGY, V45, P208; SRIVASTA.SK, 1974, J BIOL CHEM, V249, P2043; Stanley RG., 1974, POLLEN, DOI [10.1007/978-3-642-65905-8, DOI 10.1007/978-3-642-65905-8]; STULL ARTHUR, 1940, JOUR ALLERGY, V11, P439, DOI 10.1016/S0021-8707(40)90456-7; UEHARA K, 1974, J BIOCHEM, V75, P627, DOI 10.1093/oxfordjournals.jbchem.a130431; VOLKHIEM.G, 1968, DIGESTION, V1, P213, DOI 10.1159/000196856; WALKER WA, 1974, GASTROENTEROLOGY, V67, P531; WILLOUGHBY WF, 1984, IMMUNOLOGY LUNG UPPE, P174; 1981, QUANTITATIVE DETERMI	36	12	13	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1988	81	6					1126	1134		10.1016/0091-6749(88)90880-9	http://dx.doi.org/10.1016/0091-6749(88)90880-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P0023	2837503				2022-12-18	WOS:A1988P002300010
J	SHIMODA, T; KRZANOWSKI, J; NELSON, R; MARTIN, DF; POLSON, J; DUNCAN, R; LOCKEY, R				SHIMODA, T; KRZANOWSKI, J; NELSON, R; MARTIN, DF; POLSON, J; DUNCAN, R; LOCKEY, R			INVITRO RED TIDE TOXIN EFFECTS ON HUMAN BRONCHIAL SMOOTH-MUSCLE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NAGASAKI UNIV, SCH MED, DEPT INTERNAL MED 2, NAGASAKI 852, JAPAN; UNIV S FLORIDA, COLL MED, DEPT PHARMACOL & THERAPEUT, TAMPA, FL 33612 USA; UNIV S FLORIDA, COLL NAT SCI, ENVIRONM MANAGEMENT SERV CTR, DEPT CHEM, TAMPA, FL 33612 USA; JAMES A HALEY VET ADM MED CTR, DEPT INTERNAL MED, ALLERGY & IMMUNOL SECT, TAMPA, FL 33612 USA	Nagasaki University; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital	SHIMODA, T (corresponding author), UNIV S FLORIDA, COLL MED, DEPT INTERNAL MED, DIV ALLERGY & IMMUNOL, 12901 N 30TH ST, TAMPA, FL 33612 USA.							ALAM M, 1982, J AM CHEM SOC, V104, P5232, DOI 10.1021/ja00383a043; ASAI S, 1982, J ALLERGY CLIN IMMUN, V69, P418, DOI 10.1016/0091-6749(82)90116-6; ASAI S, 1984, J ALLERGY CLIN IMMUN, V73, P824, DOI 10.1016/0091-6749(84)90454-8; BADEN DG, 1982, TOXICON, V20, P929, DOI 10.1016/0041-0101(82)90081-2; Brydon G A, 1971, Environ Lett, V1, P235; CATTERALL WA, 1980, ANNU REV PHARMACOL, V20, P15, DOI 10.1146/annurev.pa.20.040180.000311; CATTERALL WA, 1984, SCIENCE, V223, P653, DOI 10.1126/science.6320365; CATTERALL WA, 1985, TOXICON, V23, P497, DOI 10.1016/0041-0101(85)90034-0; CUMMINS JM, 1971, T AM FISH SOC, V100, P112, DOI 10.1577/1548-8659(1971)100<112:OOTBMD>2.0.CO;2; ELDRED B, 1972, ENVIRON LETT, V3, P271; FLEMING WW, 1972, J PHARMACOL-PARIS, V181, P339; HEMMERT WH, 1975, 1ST P INT C TOX DIN, P489; MARTIN DF, 1976, J CHEM EDUC, V53, P614, DOI 10.1021/ed053p614; McFARREN E. F., 1965, TOXICON, V3, P111, DOI 10.1016/0041-0101(65)90005-X; Music S I, 1973, JFMA, V60, P27; NARAHASHI T, 1974, PHYSIOL REV, V54, P813, DOI 10.1152/physrev.1974.54.4.813; RISK M, 1982, J NEUROCHEM, V39, P1485, DOI 10.1111/j.1471-4159.1982.tb12596.x; RITCHIE JM, 1977, REV PHYSIOL BIOCH P, V79, P1, DOI 10.1007/BFb0037088; SAKAMOTO Y, 1985, J ALLERGY CLIN IMMUN, V76, P117, DOI 10.1016/0091-6749(85)90814-0; SHIMODA T, 1987, J ALLERGY CLIN IMMUN, V79, P899, DOI 10.1016/0091-6749(87)90239-9; SHINNICKGALLAGHER P, 1980, BRIT J PHARMACOL, V69, P373, DOI 10.1111/j.1476-5381.1980.tb07024.x; SNEDECOR GW, 1959, STATISTICAL METHODS; Steidinger K.A., 1983, Progress phycol. Res., V2, P147; STEIDINGER KA, 1973, MARINE PHARMACOGNOSY, P127; STEPHENS NL, 1970, AIRWAY DYNAMICS PHYS, P199; WESTERFIELD M, 1977, AM J PHYSIOL, V232, pC23, DOI 10.1152/ajpcell.1977.232.1.C23; WU CH, 1985, TOXICON, V23, P481, DOI 10.1016/0041-0101(85)90032-7; [No title captured]	28	12	14	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1988	81	6					1187	1191		10.1016/0091-6749(88)90889-5	http://dx.doi.org/10.1016/0091-6749(88)90889-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P0023	3379231				2022-12-18	WOS:A1988P002300019
J	KAKUTA, Y; KATO, T; SASAKI, H; TAKISHIMA, T				KAKUTA, Y; KATO, T; SASAKI, H; TAKISHIMA, T			EFFECT OF KETOTIFEN ON HUMAN ALVEOLAR MACROPHAGES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TOHOKU UNIV,SCH MED,DEPT INTERNAL MED 1,1-1 SEIRYO MACHI,SENDAI,MIYAGI 980,JAPAN; TOHOKU UNIV,SCH MED,DEPT DERMATOL,SENDAI,MIYAGI 980,JAPAN	Tohoku University; Tohoku University								BARNES PJ, 1986, LANCET, V2, P242; GALLIN EK, 1984, FED PROC, V43, P2385; GOSSET P, 1984, J ALLERGY CLIN IMMUN, V74, P827, DOI 10.1016/0091-6749(84)90186-6; GREENLEE L, 1962, BIOCHEMISTRY-US, V1, P779, DOI 10.1021/bi00911a008; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOIDAL JR, 1978, AM J PATHOL, V91, P469; JOSEPH M, 1980, CLIN EXP IMMUNOL, V40, P416; JOSEPH M, 1985, AGENTS ACTIONS, V16, P27, DOI 10.1007/BF01999635; KAKUTA Y, 1988, J ALLERGY CLIN IMMUN, V81, P460, DOI 10.1016/0091-6749(88)90918-9; KAKUTA Y, 1986, AM REV RESPIR DIS, V133, pA212; KATO T, 1981, KLIN WOCHENSCHR, V59, P203, DOI 10.1007/BF01476577; KATO T, 1986, BIOL ROLE REACTIVE O, P171; MARTIN WJ, 1981, J CLIN INVEST, V68, P1277, DOI 10.1172/JCI110374; MCCANN JD, 1986, J PHYSIOL-LONDON, V372, P113, DOI 10.1113/jphysiol.1986.sp016000; MEECH RW, 1978, ANNU REV BIOPHYS BIO, V7, P1, DOI 10.1146/annurev.bb.07.060178.000245; MOREY J, 1984, LANCET, V2, P1142; NEY UM, 1982, RES CLIN FORUMS, V4, P43; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; PETERSEN OH, 1984, NATURE, V307, P693, DOI 10.1038/307693a0; SCHOPF RE, 1984, J IMMUNOL METHODS, V67, P109, DOI 10.1016/0022-1759(84)90090-5; SOUHRADA M, 1984, SCIENCE, V225, P273; TINKELMAN DG, 1985, J ALLERGY CLIN IMMUN, V76, P487, DOI 10.1016/0091-6749(85)90732-8; TOMIOKA M, 1984, AM REV RESPIR DIS, V129, P1000; WILLIAMS AJ, 1981, THORAX, V36, P866, DOI 10.1136/thx.36.11.866	24	12	12	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1988	81	2					469	474		10.1016/0091-6749(88)90919-0	http://dx.doi.org/10.1016/0091-6749(88)90919-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0993	2448361				2022-12-18	WOS:A1988M099300017
J	BERMAN, B; BUCHMAN, E; DOCKHORN, R; LEESE, P; MANSMANN, H; MIDDLETON, E				BERMAN, B; BUCHMAN, E; DOCKHORN, R; LEESE, P; MANSMANN, H; MIDDLETON, E			CETIRIZINE (C) THERAPY OF PERENNIAL ALLERGIC RHINITIS (PAR)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	12	12	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1988	81	1					177	177		10.1016/0091-6749(88)90273-4	http://dx.doi.org/10.1016/0091-6749(88)90273-4			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0274					2022-12-18	WOS:A1988M027400060
J	BERNSTEIN, IL; BERNSTEIN, DI				BERNSTEIN, IL; BERNSTEIN, DI			THE EFFICACY AND SAFETY OF LORATIDINE IN THE MANAGEMENT OF CHRONIC IDIOPATHIC URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	12	12	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1988	81	1					211	211		10.1016/0091-6749(88)90409-5	http://dx.doi.org/10.1016/0091-6749(88)90409-5			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0274					2022-12-18	WOS:A1988M027400196
J	ONG, R; SULLIVAN, T				ONG, R; SULLIVAN, T			DETECTION AND CHARACTERIZATION OF HUMAN IGE TO CEPHALOSPORIN DETERMINANTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1988	81	1					222	222		10.1016/0091-6749(88)90452-6	http://dx.doi.org/10.1016/0091-6749(88)90452-6			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0274					2022-12-18	WOS:A1988M027400239
J	SZCZEKLIK, A; NIZANKOWSKA, E; SPLAWINSKI, J; DWORSKI, R; GAJEWSKI, P; SPLAWINSKA, B				SZCZEKLIK, A; NIZANKOWSKA, E; SPLAWINSKI, J; DWORSKI, R; GAJEWSKI, P; SPLAWINSKA, B			EFFECTS OF INHIBITION OF THROMBOXANE-A2 SYNTHESIS IN ASPIRIN-INDUCED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SZCZEKLIK, A (corresponding author), COPERNICUS ACAD MED,RZESZOWS DEPT CLIN PHARMACOL,DEPT ALLERGY & CLIN IMMUNOL,SKAWINSKA 8,PL-31066 CRACOW,POLAND.							CAPRON A, 1985, INT ARCH ALLER A IMM, V77, P107, DOI 10.1159/000233762; CHUNG KF, 1986, AM REV RESPIR DIS, V134, P285; DORSCH W, 1983, J ALLERGY CLIN IMMUN, V72, P168, DOI 10.1016/0091-6749(83)90525-0; FLOWER RJ, 1976, BR J PHARM, V56, P299; FUJIMURA M, 1986, THORAX, V41, P955, DOI 10.1136/thx.41.12.955; GOETZL EJ, 1986, J ALLERGY CLIN IMMUN, V77, P693, DOI 10.1016/0091-6749(86)90412-4; GRESELE P, 1984, BIOCHEM PHARMACOL, V33, P2083, DOI 10.1016/0006-2952(84)90577-X; GRYGLEWSKI RJ, IN PRESS BIOCH PHARM; HALL ER, 1984, PROSTA LEUKOTR MED, V13, P279, DOI 10.1016/0262-1746(84)90040-4; HEAVEY DJ, 1984, PROSTAGLANDINS, V28, P755, DOI 10.1016/0090-6980(84)90033-9; HEPTINSTALL S, 1983, BR J CLIN PHARM, V15, P315; MORLEY J, 1985, LANCET, V2, P726; NAGATSUKA K, 1984, KYOTO C PROSTAGLANDI; NIZANKOWSKA E, 1986, EUR J RESPIR DIS, V69, P363; PLESKOW WW, 1984, AM REV RESPIR DIS, V130, P1170; RADOMSKI M, 1985, Acta Physiologica Polonica, V36, P153; SHIKANO M, 1985, ADV PROSTAG THROMB L, V13, P375; SMITH JB, 1987, FASEB J, V46, P139; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V74, P617, DOI 10.1016/0091-6749(84)90115-5; SZCZEKLIK A, 1986, DRUGS, V32, P148, DOI 10.2165/00003495-198600324-00011; SZCZEKLIK A, 1985, THROMB HAEMOSTASIS, V54, P425; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; SZCZEKLIK A, 1978, PHARMACOL RES COMMUN, V10, P545, DOI 10.1016/S0031-6989(78)80053-8; SZCZEKLIK A, IN PRESS CLIN ALLERG; VERMYLEN J, 1981, LANCET, V1, P1073; WEVER AMJ, 1981, EUR J RESPIR DIS, V62, P127	27	12	12	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1987	80	6					839	843		10.1016/S0091-6749(87)80274-9	http://dx.doi.org/10.1016/S0091-6749(87)80274-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	L5020	3693761				2022-12-18	WOS:A1987L502000011
J	SLAUGHTER, RL; GOLDBERG, A; CHOI, L; ADAMS, E; MIDDLETON, E				SLAUGHTER, RL; GOLDBERG, A; CHOI, L; ADAMS, E; MIDDLETON, E			INTRAINDIVIDUAL VARIABILITY IN THEOPHYLLINE PHARMACOKINETICS IN SUBJECTS WITH MILD MODERATE ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY BUFFALO,SCH MED,DIV ALLERGY & CLIN IMMUNOL,BUFFALO,NY 14214; BUFFALO GEN HOSP,DEPT PHARM,BUFFALO,NY 14203; BUFFALO GEN HOSP,DEPT MED,BUFFALO,NY 14203	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Buffalo General Medical Center; Buffalo General Medical Center	SLAUGHTER, RL (corresponding author), SUNY BUFFALO,SCH PHARM,DEPT PHARM,BUFFALO,NY 14260, USA.							ARNOLD JD, 1981, EUR J CLIN PHARMACOL, V20, P443, DOI 10.1007/BF00542097; GINCHANSKY E, 1977, J PEDIATR-US, V91, P655, DOI 10.1016/S0022-3476(77)80527-1; JENNE JW, 1977, AM J HOSP PHARM, V34, P408, DOI 10.1093/ajhp/34.4.408; Jusko WJ, 1986, APPLIED PHARMACOKINE, P9; KUBO M, 1986, J PEDIATR-US, V108, P1011, DOI 10.1016/S0022-3476(86)80951-9; LOREN M, 1977, J PEDIATR-US, V90, P473, DOI 10.1016/S0022-3476(77)80719-1; MILAVETZ G, 1985, DRUG INTELL CLIN PHA, V19, P459; NELSON JW, 1977, CLIN CHEM, V23, P124; POWELL JR, 1978, AM REV RESPIR DIS, V118, P229; UPTON RA, 1982, J PHARMACOKINET BIOP, V10, P123, DOI 10.1007/BF01062330; VOZEH S, 1978, JAMA-J AM MED ASSOC, V240, P1882, DOI 10.1001/jama.240.17.1882; WYATT R, 1978, J PEDIATR-US, V92, P125, DOI 10.1016/S0022-3476(78)80093-6	12	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1987	80	1					33	38		10.1016/S0091-6749(87)80187-2	http://dx.doi.org/10.1016/S0091-6749(87)80187-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J2194	3598028				2022-12-18	WOS:A1987J219400005
J	LINDGREN, BR; BRUNDIN, A; ANDERSSON, RGG				LINDGREN, BR; BRUNDIN, A; ANDERSSON, RGG			INHIBITORY EFFECTS OF CLONIDINE ON THE ALLERGEN-INDUCED WHEAL-AND-FLARE REACTIONS IN PATIENTS WITH EXTRINSIC-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									LINKOPING UNIV HOSP, DEPT LUNG MED, S-58185 LINKOPING, SWEDEN	Linkoping University	LINDGREN, BR (corresponding author), LINKOPING UNIV HOSP, DEPT PHARMACOL, S-58185 LINKOPING, SWEDEN.							ANDERSSON RGG, 1978, ACTA PHARMACOL TOX, V42, P381; ANDERSSON RGG, 1985, TACHYKININ ANTAGONIS, P189; ARNDTS D, 1979, ARZNEIMITTEL-FORSCH, V29-1, P532; BASRAN GS, 1982, BRIT J DERMATOL, V107, P140, DOI 10.1111/j.1365-2133.1982.tb01046.x; BERNSTEIN JE, 1981, J INVEST DERMATOL, V76, P394, DOI 10.1111/1523-1747.ep12520912; BOULET LP, 1984, CLIN ALLERGY, V14, P379, DOI 10.1111/j.1365-2222.1984.tb02219.x; BUSSE WW, 1976, SCIENCE, V194, P737, DOI 10.1126/science.185696; CARPENTER SE, 1981, BRIT J PHARMACOL, V73, P755, DOI 10.1111/j.1476-5381.1981.tb16812.x; CHAPMAN LF, 1977, J INVEST DERMATOL, V69, P88, DOI 10.1111/1523-1747.ep12497896; CLARK RAF, 1977, J IMMUNOL, V118, P137; ERJAVEC F, 1981, N-S ARCH PHARMACOL, V317, P67, DOI 10.1007/BF00506259; HOLSAPPLE MP, 1984, J PHARMACOL EXP THER, V229, P399; HUI TP, 1986, HYPERTENSION, V8, P272, DOI 10.1161/01.HYP.8.4.272; JANCSO G, 1977, NATURE, V270, P741, DOI 10.1038/270741a0; KALINER M, 1985, ASTHMA BRONCHIAL HYP, P17; KIERNAN JA, 1977, J EXP PHYSL, V57, P311; LEMBECK F, 1982, CIBA F SYMP, V91, P35; LEMBECK F, 1979, N-S ARCH PHARMACOL, V310, P175, DOI 10.1007/BF00500282; LEMBECK F, 1982, ADV PHARMACOL THER, V1, P115; LETTBROWN MA, 1977, J IMMUNOL, V118, P815; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1973, NATURE, V244, P287, DOI 10.1038/244287a0; LINDGREN BR, 1986, AM REV RESPIR DIS, V134, P266; LINDGREN BR, IN PRESS ARZNEIMITTE; LINDGREN BR, IN PRESS EUR J PHARM; LUNDBERG JM, 1985, TACHYKININ ANTAGONIS, P159; ROCKLIN RE, 1976, J CLIN INVEST, V57, P1051, DOI 10.1172/JCI108347; SARIA A, 1985, TACHYKININ ANTAGONIS, P149; SHAIKH W, 1977, J ALLERGY CLIN IMMUN, V60, P242, DOI 10.1016/0091-6749(77)90138-5; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; SULLIVAN PA, 1986, HYPERTENSION, V8, P611, DOI 10.1161/01.HYP.8.7.611; UMEMOTO L, 1976, J ALLERGY CLIN IMMUN, V58, P60, DOI 10.1016/0091-6749(76)90107-X; WIDDICOMBE JG, 1985, ASTHMA BRONCHIAL HYP, P8	33	12	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1987	79	6					941	946		10.1016/0091-6749(87)90244-2	http://dx.doi.org/10.1016/0091-6749(87)90244-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	H9044	3584748				2022-12-18	WOS:A1987H904400016
J	HEPNER, M; OWNBY, D; MACKECHNIE, H; ROWE, M; ANDERSON, J				HEPNER, M; OWNBY, D; MACKECHNIE, H; ROWE, M; ANDERSON, J			THE SAFETY OF IMMUNOTHERAPY - A PROSPECTIVE-STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1987	79	1					133	133						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F8810					2022-12-18	WOS:A1987F881000057
J	HIRSHMAN, CA; LEU, DB; AUSTIN, DR; CHAN, SC; VEITH, L; HANIFIN, JM				HIRSHMAN, CA; LEU, DB; AUSTIN, DR; CHAN, SC; VEITH, L; HANIFIN, JM			ELEVATED MONONUCLEAR LEUKOCYTE PHOSPHODIESTERASE IN ALLERGIC DOGS WITH AND WITHOUT AIRWAY HYPERRESPONSIVENESS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									OREGON HLTH SCI UNIV,DEPT ANESTHESIOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT DERMATOL,PORTLAND,OR 97201; ANIM DERMATOL CLIN,PORTLAND,OR	Oregon Health & Science University; Oregon Health & Science University					NHLBI NIH HHS [HL 25831] Funding Source: Medline; NIAID NIH HHS [AI 18615] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018615] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOWLES CA, 1975, J IMMUNOL, V114, P399; BUSSE WW, 1979, J INVEST DERMATOL, V73, P184, DOI 10.1111/1523-1747.ep12581674; BUTLER JM, 1983, J AM ACAD DERMATOL, V8, P33, DOI 10.1016/S0190-9622(83)70004-6; BUTLER JM, 1983, J ALLERGY CLIN IMMUN, V71, P490, DOI 10.1016/0091-6749(83)90467-0; CHAN SC, 1982, J CYCLIC NUCL PROT, V8, P211; CHAN SC, 1985, J ALLERGY CLIN IMMUN, V76, P148, DOI 10.1016/0091-6749(85)90693-1; GLANTZ BA, 1981, PRIMER BIOSTATISTICS, P63; GREWE SR, 1982, J ALLERGY CLIN IMMUN, V70, P452, DOI 10.1016/0091-6749(82)90008-2; HALLIWELL RE, 1973, J IMMUNOL, V110, P422; HANIFIN JM, 1977, ARCH DERMATOL, V113, P663, DOI 10.1001/archderm.113.5.663; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HIRSHMAN CA, 1985, J APPL PHYSIOL, V58, P485, DOI 10.1152/jappl.1985.58.2.485; HIRSHMAN CA, 1984, J APPL PHYSIOL, V56, P1272, DOI 10.1152/jappl.1984.56.5.1272; KALINER M, 1982, ANN INTERN MED, V96, P349, DOI 10.7326/0003-4819-96-3-349; NEIJENS HJ, 1984, AM REV RESPIR DIS, V130, P744; NICHOLAS A, 1983, J EXP MED, V158, P393; PARKER C W, 1973, P185; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; PARKER CW, 1977, J INVEST DERMATOL, V68, P302, DOI 10.1111/1523-1747.ep12494569; REED CE, 1976, J INVEST DERMATOL, V67, P333, DOI 10.1111/1523-1747.ep12514494; RUBINFELD AR, 1977, AM REV RESPIR DIS, V115, P381; SAFKO MJ, 1981, J ALLERGY CLIN IMMUN, V68, P218, DOI 10.1016/0091-6749(81)90187-1; SHELHAMER JH, 1983, J ALLERGY CLIN IMMUN, V71, P57, DOI 10.1016/0091-6749(83)90547-X; SNAPPER JR, 1978, J APPL PHYSIOL, V44, P738, DOI 10.1152/jappl.1978.44.5.738; SPECTOR SL, 1976, CLIN ALLERGY, V6, P83, DOI 10.1111/j.1365-2222.1976.tb01416.x; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TASHKIN DP, 1982, AM REV RESPIR DIS, V125, P185; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; VONNEERGAARD K, 1927, Z KLIN MED, V105, P51; WILLEMSE A, 1984, INVESTIGATIONS CANIN	30	12	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1987	79	1					46	53		10.1016/S0091-6749(87)80015-5	http://dx.doi.org/10.1016/S0091-6749(87)80015-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F8810	3027152	Bronze			2022-12-18	WOS:A1987F881000011
J	BARNETT, EV				BARNETT, EV			CIRCULATING IMMUNE-COMPLEXES - THEIR BIOLOGIC AND CLINICAL-SIGNIFICANCE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BARNETT, EV (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,CTR REHABIL,ROOM 32-47,1000 VET AVE,LOS ANGELES,CA 90024, USA.							ABRASS CK, 1980, CLIN EXP IMMUNOL, V40, P292; AGUADO MT, 1981, ARTHRITIS RHEUM-US, V24, P1225, DOI 10.1002/art.1780241001; AHLSTEDT S, 1981, INT ARCH ALLER A IMM, V64, P195, DOI 10.1159/000232692; AMOROSO P, 1980, CLIN EXP IMMUNOL, V42, P95; ANDERSON CL, 1980, J CLIN INVEST, V66, P353, DOI 10.1172/JCI109863; ARAKI K, 1982, CLIN EXP IMMUNOL, V47, P520; BARNETT EV, 1979, ANN INTERN MED, V91, P430, DOI 10.7326/0003-4819-91-3-430; BOYD RE, 1983, ARTHRITIS RHEUM, V26, P637, DOI 10.1002/art.1780260510; BROOKES GB, 1986, ARCH OTOLARYNGOL, V112, P536; BROWN DL, 1981, CLIN EXP IMMUNOL, V43, P231; CAIRNS SA, 1980, CLIN EXP IMMUNOL, V40, P273; CARPENTIER NA, 1983, IMMUNOBIOLOGY TRANSP, P375; CARR RI, 1980, CLIN EXP IMMUNOL, V39, P562; CHIA D, 1979, CLIN EXP IMMUNOL, V37, P399; CLANCY R, 1980, CLIN EXP IMMUNOL, V39, P170; CONTRERAS CE, 1982, CLIN EXP IMMUNOL, V48, P693; COOPER KM, 1983, J IMMUNOL METHODS, V60, P289, DOI 10.1016/0022-1759(83)90287-9; DAVIES M, 1985, CLIN EXP IMMUNOL, V61, P406; DELESPESSE G, 1980, CLIN EXP IMMUNOL, V40, P96; EMLEN W, 1980, CLIN EXP IMMUNOL, V40, P264; FALUS A, 1983, ARTHRITIS RHEUM, V26, P721, DOI 10.1002/art.1780260604; FEKETE B, 1983, ONCOLOGY, V40, P106, DOI 10.1159/000225705; FINBLOOM DS, 1981, J CLIN INVEST, V68, P214, DOI 10.1172/JCI110238; FRANKLIN EC, 1980, J ALLERGY CLIN IMMUN, V66, P269, DOI 10.1016/0091-6749(80)90020-2; FRIEDMAN J, 1984, J CLIN INVEST, V74, P1027, DOI 10.1172/JCI111470; FURUSE A, 1983, EUR J PEDIATR, V141, P50, DOI 10.1007/BF00445669; FURUSE A, 1983, INT J PED NEPHROL, V4, P123; FUST G, 1981, J IMMUNOL METHODS, V46, P149; GILEAD Z, 1981, J IMMUNOL METHODS, V42, P67, DOI 10.1016/0022-1759(81)90226-X; GOWER RG, 1978, J ALLERGY CLIN IMMUN, V62, P222, DOI 10.1016/0091-6749(78)90211-7; HALL RP, 1980, CLIN EXP IMMUNOL, V40, P431; HENDERSON JM, 1981, J RHEUMATOL, V8, P486; HOOPER DC, 1983, ARCH INTERN MED, V143, P2081, DOI 10.1001/archinte.143.11.2081; HUBBARD RA, 1981, CLIN EXP IMMUNOL, V43, P46; JANSEN HM, 1984, CLIN EXP IMMUNOL, V56, P311; JOHNY KV, 1981, J IMMUNOL METHODS, V40, P61, DOI 10.1016/0022-1759(81)90080-6; JONES VE, 1982, CLIN EXP IMMUNOL, V49, P31; KAMMER GM, 1980, CLIN IMMUNOL IMMUNOP, V15, P658, DOI 10.1016/0090-1229(80)90011-2; KAUFFMANN RH, 1980, CLIN EXP IMMUNOL, V41, P459; KAUFFMANN RH, 1981, J IMMUNOL METHODS, V40, P117, DOI 10.1016/0022-1759(81)90058-2; KAUFFMANN RH, 1981, AM J MED, V71, P17, DOI 10.1016/0002-9343(81)90253-9; KILGALLON W, 1983, CLIN EXP IMMUNOL, V53, P308; KIMBERLY RP, 1986, J IMMUNOL, V137, P91; KUNKEL HG, 1983, BIOL IMMUNOLOGIC DIS, P247; KURAMOTO M, 1982, TOHOKU J EXP MED, V138, P7, DOI 10.1620/tjem.138.7; LAMBERT PH, 1981, J CLIN INVEST, V67, P77, DOI 10.1172/JCI110035; LAMBERT PH, 1978, J CLIN LAB IMMUNOL, V1, P1; LAMBERT PH, 1981, PRINCIPLES IMMUNOLOG, P310; LENNEK R, 1981, J IMMUNOL, V127, P602; LEVY M, 1980, J RHEUMATOL, V7, P886; MALASIT P, 1983, IMMUNOLOGY, V48, P779; MATSUO T, 1986, AM J OPHTHALMOL, V101, P368, DOI 10.1016/0002-9394(86)90833-0; MCDOUGAL JS, 1982, ARTHRITIS RHEUM, V25, P1156, DOI 10.1002/art.1780251003; MCPHADEN A, 1981, IMMUNOLOGY, V44, P193; MEDOF ME, 1981, CLIN EXP IMMUNOL, V44, P416; MOSS RB, 1982, CLIN EXP IMMUNOL, V47, P301; OOI BS, 1980, CLIN IMMUNOL IMMUNOP, V16, P447, DOI 10.1016/0090-1229(80)90186-5; PANAYI GS, 1980, ANN RHEUM DIS, V39, P445, DOI 10.1136/ard.39.5.445; PAPAIOANNOU CC, 1980, ARTHRITIS RHEUM, V23, P1021, DOI 10.1002/art.1780230909; PLOTZ PH, 1982, ARTHRITIS RHEUM, V25, P1151, DOI 10.1002/art.1780251002; POCIDALO MA, 1982, CLIN EXP IMMUNOL, V47, P513; POPE RM, 1983, AM J MED, V74, P973, DOI 10.1016/0002-9343(83)90794-5; RAYNER AA, 1982, JNCI-J NATL CANCER I, V69, P23; SAKURAI T, 1982, CLIN EXP IMMUNOL, V48, P37; SALINAS FA, 1985, CONT TOPICS IMMUNOBI, V15; SANO H, 1982, J IMMUNOL, V128, P1341; SAXON A, 1984, J CLIN INVEST, V73, P342, DOI 10.1172/JCI111218; SCHRIEBER L, 1982, CLIN EXP IMMUNOL, V47, P535; SEHGAL S, 1980, CLIN EXP IMMUNOL, V40, P453; SINGH VK, 1986, ANN RHEUM DIS, V45, P115, DOI 10.1136/ard.45.2.115; SMITH MD, 1980, CLIN EXP IMMUNOL, V39, P141; STARKEBAUM G, 1982, J IMMUNOL, V128, P141; STEELE G, 1983, AM J SURG, V145, P549, DOI 10.1016/0002-9610(83)90056-9; STEIN MR, 1978, J ALLERGY CLIN IMMUN, V62, P211, DOI 10.1016/0091-6749(78)90209-9; STEWARD MW, 1982, CLIN EXP IMMUNOL, V48, P17; THEOFILOPOULOS AN, 1977, J IMMUNOL, V119, P657; THEOFILOPOULOS AN, 1983, BIOL IMMUNOLOGIC DIS, P309; TIKU ML, 1979, CLIN EXP IMMUNOL, V36, P54; TUNG KSK, 1981, CLIN EXP IMMUNOL, V43, P615; UWATOKO S, 1984, J IMMUNOL METHODS, V73, P67, DOI 10.1016/0022-1759(84)90032-2; UWATOKO S, 1984, CLIN IMMUNOL IMMUNOP, V30, P104, DOI 10.1016/0090-1229(84)90011-4; VANDIJK H, 1984, CLIN EXP IMMUNOL, V57, P495; WAIGT A, 1983, ACTA NEUROL SCAND, V68, P378; WALLER SJ, 1981, ARTHRITIS RHEUM, V24, P651, DOI 10.1002/art.1780240504; WILSON CB, 1983, BIOL IMMUNOLOGIC DIS, P209; YOSHINOYA S, 1980, J CLIN INVEST, V65, P136, DOI 10.1172/JCI109643	86	12	12	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1986	78	6					1089	1098		10.1016/0091-6749(86)90252-6	http://dx.doi.org/10.1016/0091-6749(86)90252-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F3026	3491101	Bronze			2022-12-18	WOS:A1986F302600001
J	GEHA, RS; LEUNG, DYM				GEHA, RS; LEUNG, DYM			CELLULAR ABNORMALITIES IN PATIENTS WITH ELEVATED SERUM IGE LEVELS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Harvard Medical School	GEHA, RS (corresponding author), CHILDRENS HOSP MED CTR,DIV ALLERGY,300 LONGWOOD AVE,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI021163, R01AI020373] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM-31925-01] Funding Source: Medline; NIAID NIH HHS [AI-21163, AI-20373-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERGER M, 1980, J IMMUNOL, V125, P2437; BROSTOFF J, 1979, LANCET, V1, P1268; BUCKLEY RH, 1975, J CLIN INVEST, V55, P157, DOI 10.1172/JCI107906; BUCKLEY RH, 1972, PEDIATRICS, V49, P59; BUTLER M, 1982, CLIN EXP IMMUNOL, V50, P92; BYROM NA, 1979, BRIT J DERMATOL, V100, P491, DOI 10.1111/j.1365-2133.1979.tb05574.x; Cohen S., 1979, BIOL LYMPHOKINES; CURRIE JM, 1971, CUTIS, V8, P244; DEBRUIN HG, 1981, J IMMUNOL, V127, P244; DELESPESSE G, 1982, J ALLERGY CLIN IMMUN, V69, pA135; ELLIOTT ST, 1979, ARCH DERMATOL, V115, P36, DOI 10.1001/archderm.115.1.36; FISER PM, 1979, J IMMUNOL, V123, P1788; FULTON R, 1981, ANN DERMATOL VENER, V108, P243; GALLIN JI, 1980, ANN INTERN MED, V92, P520, DOI 10.7326/0003-4819-92-4-520; GEHA RS, 1980, J ALLERGY CLIN IMMUN, V66, P78, DOI 10.1016/0091-6749(80)90142-6; GEHA RS, 1984, CLIN RES, V32, pA504; GEHA RS, 1981, J CLIN INVEST, V68, P783, DOI 10.1172/JCI110315; GOODWIN JS, 1980, CLIN IMMUNOL IMMUNOP, V15, P106, DOI 10.1016/0090-1229(80)90024-0; HASSNER A, 1984, J IMMUNOL, V132, P2844; HEMADY Z, 1983, J ALLERGY CLIN IMM S, V71, pA143; HILL HR, 1974, LANCET, V1, P183; HIRASHIMA M, 1981, J IMMUNOL, V126, P838; INGANAS M, 1981, INT ARCH ALLER A IMM, V65, P51, DOI 10.1159/000232737; ISHIZAKA K, 1983, MONOGR ALLERGY, V18, P52; JONES HE, 1973, ARCH DERMATOL, V107, P217, DOI 10.1001/archderm.107.2.217; KANG K, 1983, J AM ACAD DERMATOL, V8, P372, DOI 10.1016/S0190-9622(83)70042-3; KANG K, 1983, SEMIN DERMATOL, V2, P59; KIKKAWA Y, 1973, PEDIATRICS, V51, P690; KOPOSI M, 1895, PATHOLOGY TREATMENT; LALLEMAND D, 1979, ANN RADIOL, V22, P108; LANZAVECCHIA A, 1983, EUR J IMMUNOL, V13, P820, DOI 10.1002/eji.1830131008; LEUNG DYM, 1984, CLIN IMMUNOL IMMUNOP, V32, P339, DOI 10.1016/0090-1229(84)90277-0; LEUNG DYM, 1981, SPRINGER SEMIN IMMUN, V4, P275, DOI 10.1007/BF01892182; LEUNG DYM, 1983, J ALLERGY CLIN IMMUN, V71, P47, DOI 10.1016/0091-6749(83)90546-8; LEUNG DYM, 1982, J IMMUNOL, V128, P1736; LEUNG DYM, 1984, CLIN RES, V32, pA538; LEUNG DYM, 1983, J CLIN INVEST, V72, P1482, DOI 10.1172/JCI111104; LEUNG DYM, 1983, J IMMUNOL, V130, P1678; LEUNG DYM, 1981, J ALLERGY CLIN IMMUN, V67, P450, DOI 10.1016/0091-6749(81)90098-1; LEUNG DYM, 1984, J ALLERGY CLIN IMMUN, V73, pA176; LEYDEN JJ, 1979, ARCH DERMATOL, V115, P311, DOI 10.1001/archderm.115.3.311; LOBITZ WC, 1972, BRIT J DERMATOL, V86, P317, DOI 10.1111/j.1365-2133.1972.tb05045.x; MIHM MC, 1976, J INVEST DERMATOL, V67, P305, DOI 10.1111/1523-1747.ep12514346; MITSUYA H, 1983, CLIN IMMUNOL IMMUNOP, V26, P171, DOI 10.1016/0090-1229(83)90135-6; PALACIOS J, 1966, J INVEST DERMATOL, V47, P484, DOI 10.1038/jid.1966.172; PAYAN DG, 1984, P NATL ACAD SCI-BIOL, V81, P3501, DOI 10.1073/pnas.81.11.3501; QUINTI I, 1984, CLIN RES, V32, pA146; RAJKA G, 1967, ACTA DERM-VENEREOL, V47, P158; RANKIN JA, 1982, NATURE, V297, P329, DOI 10.1038/297329a0; ROMAGNANI S, 1983, CLIN EXP IMMUNOL, V52, P85; Rostenberg A, 1937, ARCH DERMATOL SYPH, V35, P433, DOI 10.1001/archderm.1937.01470210059006; ROUZER CA, 1982, P NATL ACAD SCI-BIOL, V79, P5656, DOI 10.1073/pnas.79.18.5656; SARYAN F, 1983, J CLIN INVEST, V71, P556; SARYAN JA, 1983, J IMMUNOL, V130, P242; SAXON A, 1980, J CLIN INVEST, V65, P1457, DOI 10.1172/JCI109810; SCHUSTER DL, 1979, J ALLERGY CLIN IMMUN, V64, P139, DOI 10.1016/0091-6749(79)90048-4; SCHUSTER DL, 1980, J IMMUNOL, V124, P1662; SETSUKO I, 1983, CLIN EXP IMMUNOL, V51, P407; SNYDER DS, 1982, NATURE, V299, P163, DOI 10.1038/299163a0; SOLOMON LM, 1966, CAN MED ASSOC J, V95, P978; STEVENS WJ, 1984, J ALLERGY CLIN IMMUN, V73, P276, DOI 10.1016/S0091-6749(84)80020-2; UMETSU DT, 1985, J EXP MED, V162, P202, DOI 10.1084/jem.162.1.202; UMETSU DT, 1985, J CLIN INVEST, V76, P254, DOI 10.1172/JCI111955; WALDMANN TA, 1972, J IMMUNOL, V109, P304; WILLEMZE R, 1983, J INVEST DERMATOL, V80, P60, DOI 10.1111/1523-1747.ep12531102; YOUNG MC, 1984, EUR J IMMUNOL, V14, P871, DOI 10.1002/eji.1830141003; YOUNG MC, 1984, CLIN RES, V32, pA147	67	12	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1986	78	5	2	S			995	999		10.1016/0091-6749(86)90291-5	http://dx.doi.org/10.1016/0091-6749(86)90291-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E9719	3537090				2022-12-18	WOS:A1986E971900012
J	MATTHAY, RA; MAHLER, DA				MATTHAY, RA; MAHLER, DA			THEOPHYLLINE IMPROVES GLOBAL CARDIAC-FUNCTION AND REDUCES DYSPNEA IN CHRONIC OBSTRUCTIVE LUNG-DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									YALE UNIV, SCH MED, DEPT INTERNAL MED, PULM SECT, NEW HAVEN, CT 06510 USA; DARTMOUTH COLL, HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT MED, PULM SECT, HANOVER, NH 03756 USA	Yale University; Dartmouth College								ALEXANDER MR, 1980, JAMA-J AM MED ASSOC, V244, P2286, DOI 10.1001/jama.244.20.2286; BISHOP JM, 1973, MED CLIN N AM, V57, P771, DOI 10.1016/S0025-7125(16)32274-X; BRENT BN, 1982, AM J CARDIOL, V50, P255, DOI 10.1016/0002-9149(82)90174-6; BRUTSAERT D L, 1973, Progress in Cardiovascular Diseases, V16, P337; CAMPBELL EJ, 1963, BRIT MED BULL, V19, P36, DOI 10.1093/oxfordjournals.bmb.a070002; CAMPBELL EJM, 1966, BREATHLESSNESS, P55; EATON ML, 1980, ANN INTERN MED, V92, P758, DOI 10.7326/0003-4819-92-6-758; JENNE JW, 1972, CLIN PHARMACOL THER, V13, P349; LEITCH A G, 1980, American Review of Respiratory Disease, V121, P158; LERTZMAN MM, 1976, AM REV RESPIR DIS, V114, P1145; MAHLER DA, 1985, AM REV RESPIR DIS, V131, P22; MARCUS ML, 1972, AM J PHYSIOL, V222, P1361, DOI 10.1152/ajplegacy.1972.222.6.1361; MASELLI R, 1970, J PEDIATR, V76, P777, DOI 10.1016/S0022-3476(70)80305-5; MATTHAY RA, 1982, AM HEART J, V104, P1022, DOI 10.1016/0002-8703(82)90435-5; MATTHAY RA, 1978, AM J MED, V65, P903, DOI 10.1016/0002-9343(78)90741-6; MATTHAY RA, 1985, CHEST, V88, pS112; MATTHAY RA, 1983, N ENGL SOC ALLERGY P, V4, P274; MATTHAY RA, 1984, SUSTAINED RELEASE TH, P26; MITENKO PA, 1973, NEW ENGL J MED, V289, P600, DOI 10.1056/NEJM197309202891202; MURCIANO D, 1984, NEW ENGL J MED, V311, P349, DOI 10.1056/NEJM198408093110601; MURPHY GW, 1968, CIRCULATION, V37, P361, DOI 10.1161/01.CIR.37.3.361; NAYLER WG, 1966, AM J PHYSIOL, V211, P950, DOI 10.1152/ajplegacy.1966.211.4.950; PARKER JO, 1967, CIRCULATION, V35, P365, DOI 10.1161/01.CIR.35.2.365; PARKER JO, 1966, CIRCULATION, V33, P17, DOI 10.1161/01.CIR.33.1.17; RENZETTI AD, 1966, AM J MED, V41, P115, DOI 10.1016/0002-9343(66)90009-X; RICCI DR, 1979, AM J CARDIOL, V44, P447, DOI 10.1016/0002-9149(79)90395-3; SKELTON CL, 1970, CIRC RES, V26, P35, DOI 10.1161/01.RES.26.1.35; STEIN PD, 1971, CIRCULATION, V43, P227, DOI 10.1161/01.CIR.43.2.227; THOMAS AJ, 1972, BRIT HEART J, V34, P653; WEINBERG.MM, 1974, J PEDIATR-US, V84, P421; WEINBERGER MW, 1976, JAMA-J AM MED ASSOC, V235, P2110, DOI 10.1001/jama.235.19.2110; WINTER RJD, 1984, BRIT J DIS CHEST, V78, P358; WOLFE JD, 1978, NEW ENGL J MED, V298, P363, DOI 10.1056/NEJM197802162980703	33	12	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1986	78	4	2				793	799		10.1016/0091-6749(86)90063-1	http://dx.doi.org/10.1016/0091-6749(86)90063-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E5684	3534060				2022-12-18	WOS:A1986E568400021
J	BUSSE, WW; WILSON, AF				BUSSE, WW; WILSON, AF			WORKSHOP 5 - ASSESSMENT OF EFFICACY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF IRVINE,COLL MED,IRVINE,CA 92717	University of California System; University of California Irvine	BUSSE, WW (corresponding author), UNIV WISCONSIN,SCH MED,MADISON,WI 53706, USA.							BARNES PJ, 1981, J APPL PHYSIOL, V50, P1193, DOI 10.1152/jappl.1981.50.6.1193; FAIRSHTER RD, 1985, PULMONARY FUNCTION T, P45; GOLDSTEIN A, 1974, PRINCIPLES DRUG ACTI, P47; HUME K. M., 1957, THORAX, V12, P276, DOI 10.1136/thx.12.3.276; LORBER DB, 1978, AM REV RESPIR DIS, V118, P855; WILSON AF, 1985, PULMONARY FUNCTION T, P243	6	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1986	78	3	2				525	528		10.1016/0091-6749(86)90099-0	http://dx.doi.org/10.1016/0091-6749(86)90099-0			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E1151					2022-12-18	WOS:A1986E115100007
J	MARQUARDT, DL; GRUBER, HE; WASSERMAN, SI				MARQUARDT, DL; GRUBER, HE; WASSERMAN, SI			AMINOPHYLLINE EXPOSURE ALTERS MOUSE BONE-MARROW DERIVED MAST-CELL ADENOSINE RESPONSIVENESS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MARQUARDT, DL (corresponding author), UNIV CALIF SAN DIEGO,MED CTR,SCH MED,DEPT MED,H-811G,225 DICKINSON ST,SAN DIEGO,CA 92103, USA.				NIADDK NIH HHS [AM-13622] Funding Source: Medline; NIAID NIH HHS [AI-17268] Funding Source: Medline; NIGMS NIH HHS [GM-17702] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM013622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM017702] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALM P E, 1982, Life Sciences, V30, P213, DOI 10.1016/0024-3205(82)90501-X; AUBIER M, 1981, NEW ENGL J MED, V305, P249, DOI 10.1056/NEJM198107303050503; CHURCH MK, 1985, BRIT J PHARMACOL, V85, P3, DOI 10.1111/j.1476-5381.1985.tb08823.x; CUSHLEY MJ, 1983, BRIT J CLIN PHARMACO, V15, P161, DOI 10.1111/j.1365-2125.1983.tb01481.x; GOETZL EJ, 1983, J EXP MED, V158, P731, DOI 10.1084/jem.158.3.731; HENDELES L, 1983, PHARMACOTHERAPY, V3, P2; HIGBEE MD, 1982, J ALLERGY CLIN IMMUN, V70, P377, DOI 10.1016/0091-6749(82)90028-8; HOLGATE ST, 1984, ASTHMA PHYSL IMMUNOP, P391; MACGLASHAN DW, 1982, J CLIN INVEST, V70, P747, DOI 10.1172/JCI110670; MARQUARDT DL, 1982, J IMMUNOL, V129, P2122; MARQUARDT DL, 1978, J IMMUNOL, V120, P871; MARQUARDT DL, 1985, AGENTS ACTIONS, V16, P453, DOI 10.1007/BF01983646; MARQUARDT DL, 1984, J IMMUNOL, V133, P932; MARQUARDT DL, 1984, P NATL ACAD SCI-BIOL, V81, P6192, DOI 10.1073/pnas.81.19.6192; MENCIAHUERTA JM, 1983, J IMMUNOL, V130, P1885; MURRAY TF, 1982, EUR J PHARMACOL, V82, P113, DOI 10.1016/0014-2999(82)90563-5; RALL TW, 1980, PHARMACOL BASIS THER, P582; RAZIN E, 1984, J IMMUNOL, V133, P938; RAZIN E, 1981, P NATL ACAD SCI-BIOL, V78, P2559, DOI 10.1073/pnas.78.4.2559; RAZIN E, 1984, J IMMUNOL, V133, P3282; RAZIN E, 1982, P NATL ACAD SCI-BIOL, V79, P4665, DOI 10.1073/pnas.79.15.4665; SCHWARTZ LB, 1979, J IMMUNOL, V123, P1445; SRENDI B, 1983, J IMMUNOL, V131, P915	23	12	16	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1986	78	3	1				462	469		10.1016/0091-6749(86)90034-5	http://dx.doi.org/10.1016/0091-6749(86)90034-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E1148	3020110				2022-12-18	WOS:A1986E114800015
J	OLSON, GB; KANAAN, MN; KELLEY, LM; JONES, JF				OLSON, GB; KANAAN, MN; KELLEY, LM; JONES, JF			SPECIFIC ALLERGEN-INDUCED EPSTEIN-BARR NUCLEAR ANTIGEN POSITIVE B-CELLS FROM PATIENTS WITH CHRONIC-ACTIVE EPSTEIN-BARR VIRUS-INFECTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO	National Jewish Health	OLSON, GB (corresponding author), UNIV ARIZONA,DEPT MICROBIOL & IMMUNOL,TUCSON,AZ 85721, USA.							DUBOIS RE, 1984, SOUTHERN MED J, V77, P1376, DOI 10.1097/00007611-198411000-00007; JONES JF, 1985, ANN INTERN MED, V102, P1, DOI 10.7326/0003-4819-102-1; OLSON GB, 1986, J ALLERGY CLIN IMMUN, V78, P308, DOI 10.1016/S0091-6749(86)80081-1; RANDOLPH TG, 1945, AM J MED SCI, V209, P306; STRAUS SE, 1985, ANN INTERN MED, V102, P7, DOI 10.7326/0003-4819-102-1-7; TOBI M, 1982, LANCET, V1, P62	6	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1986	78	2					315	320		10.1016/S0091-6749(86)80082-3	http://dx.doi.org/10.1016/S0091-6749(86)80082-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D7261	3016067				2022-12-18	WOS:A1986D726100012
J	KRAUSE, RM				KRAUSE, RM			ACUTE RHEUMATIC-FEVER - AN ELUSIVE ENIGMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KRAUSE, RM (corresponding author), EMORY UNIV,WOODRUFF MED CTR,SCH MED,ADM BLDG,1440 CLIFTON RD NE,ATLANTA,GA 30322, USA.							ANDERSON HC, 1948, J CLIN INVEST, V27, P425, DOI 10.1172/JCI101986; ASHERSON GL, 1968, PROG ALLERGY, V12, P192, DOI 10.1159/000287266; BEACHEY EH, 1983, REV INFECT DIS, V5, pS670; BEACHEY EH, 1976, J EXP MED, V143, P759, DOI 10.1084/jem.143.4.759; BLAND E F, 1959, Trans Am Clin Climatol Assoc, V71, P136; CHRISTENSEN P, 1977, INT ARCH ALLER A IMM, V53, P132, DOI 10.1159/000231743; COLIGAN JE, 1975, J IMMUNOL, V144, P1654; DUBOS R, 1961, MIRAGE HLTH, P85; EMMRICH F, 1985, J EXP MED, V161, P547, DOI 10.1084/jem.161.3.547; EMMRICH F, 1983, EUR J IMMUNOL, V13, P273, DOI 10.1002/eji.1830130402; FALK JA, 1973, TISSUE ANTIGENS, V3, P173; FREIMER EH, 1968, CURRENT RES GROUP A, P145; GOLDSTEIN I, 1968, NATURE, V219, P866, DOI 10.1038/219866a0; GORDIS L, 1969, J CHRON DIS, V21, P645, DOI 10.1016/0021-9681(69)90036-8; GORDIS L, 1969, J CHRON DIS, V21, P655, DOI 10.1016/0021-9681(69)90037-X; HUSBY G, 1976, J EXP MED, V144, P1094, DOI 10.1084/jem.144.4.1094; KRAUSE RM, 1979, CIRCULATION, V60, P972, DOI 10.1161/01.CIR.60.5.972; KRAUSE RM, 1978, IMMUNOLOGICAL DISEAS, P592; LANCEFIELD RC, 1962, J IMMUNOL, V89, P307; MCCARTY M, 1969, HARVEY LECT, V65, P73; MCCARTY M, 1972, STREPTOCOCCI STREPTO, P521; PATARROYO ME, 1979, NATURE, V278, P173, DOI 10.1038/278173a0; PHILLIPS GN, 1981, P NATL ACAD SCI-BIOL, V78, P4689, DOI 10.1073/pnas.78.8.4689; RAMMELKAMP C H Jr, 1955, Harvey Lect, V51, P113; SHULMAN ST, 1974, J CLIN INVEST, V54, P990, DOI 10.1172/JCI107840; STOLLERMAN GH, 1964, STREPTOCOCCUS RHEUMA, P311; ZABRISKIE JB, 1985, ARTHRITIS RHEUM, V28, P1047, DOI 10.1002/art.1780280912; ZABRISKIE JB, 1970, CLIN EXP IMMUNOL, V7, P147; ZABRISKIE JB, 1971, PROGR IMMUNOLOGY, P214	29	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1986	77	2					282	290		10.1016/S0091-6749(86)80105-1	http://dx.doi.org/10.1016/S0091-6749(86)80105-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A0899	3511128				2022-12-18	WOS:A1986A089900003
J	DAY, JH				DAY, JH			A COMPARISON OF VENOM CONCENTRATIONS OF 0.1 UG/ML AND 1.0 UG/ML AS INDICATOR OF SENSITIVITY TO HONEY-BEE STINGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									QUEENS UNIV,KINGSTON K7L 3N6,ONTARIO,CANADA	Queens University - Canada									0	12	12	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1986	77	1	2	S			142	142						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZD38					2022-12-18	WOS:A1986AZD3800084
J	CARPENTER, GB; WIN, GH; FURUMIZO, RT; MASSEY, DG; ORTIZ, AA				CARPENTER, GB; WIN, GH; FURUMIZO, RT; MASSEY, DG; ORTIZ, AA			AIR-CONDITIONING AND HOUSE DUST MITE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	12	12	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	1					121	121		10.1016/0091-6749(85)90201-5	http://dx.doi.org/10.1016/0091-6749(85)90201-5			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ACF22					2022-12-18	WOS:A1985ACF2200066
J	GRAMMER, LC; SHAUGHNESSY, MA; SHAUGHNESSY, JJ; SILVESTRI, L; PATTERSON, R				GRAMMER, LC; SHAUGHNESSY, MA; SHAUGHNESSY, JJ; SILVESTRI, L; PATTERSON, R			ALLERGENICITY, IMMUNOGENICITY, AND SAFETY OF IMMUNOTHERAPY WITH VARIOUS MOLECULAR-WEIGHT RANGES OF POLYMERIZED RAGWEED	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									KEY PHARMACEUT CO,MIAMI,FL; NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611; HOPE COLL,HOLLAND,MI 49423	Northwestern University; Hope College				Grammer, Leslie/0000-0001-6860-2014	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BACAL E, 1978, J ALLERGY CLIN IMMUN, V62, P289, DOI 10.1016/0091-6749(78)90160-4; BRANDRUP J, 1966, POLYM HDB, P77; GRAMMER LC, 1983, J ALLERGY CLIN IMMUN, V72, P160, DOI 10.1016/0091-6749(83)90524-9; GRAMMER LC, 1984, J ALLERGY CLIN IMMUN, V73, P484, DOI 10.1016/0091-6749(84)90359-2; GRAMMER LC, 1982, J ALLERGY CLIN IMMUN, V69, P494, DOI 10.1016/0091-6749(82)90173-7; HENDRIX S, 1980, J ALLERGY CLIN IMMUN, V65, P57, DOI 10.1016/0091-6749(80)90177-3; HENDRIX SG, 1980, J ALLERGY CLIN IMMUN, V66, P486, DOI 10.1016/0091-6749(80)90010-X; LEVY DA, 1980, REGULATORY CONTROL S, P178; LIDD D, 1962, J ALLERGY, V33, P45, DOI 10.1016/0021-8707(62)90062-X; PATTERSON R, 1978, J ALLERGY CLIN IMMUN, V61, P28, DOI 10.1016/0091-6749(78)90470-0; PATTERSON R, 1979, J ALLERGY CLIN IMMUN, V63, P47, DOI 10.1016/0091-6749(79)90161-1; PATTERSON R, 1981, J ALLERGY CLIN IMMUN, V68, P89; ZEISS CR, 1977, CLIN EXP IMMUNOL, V28, P250; ZEISS CR, 1978, J ALLERGY CLIN IMMUN, V61, P216	14	12	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					195	200		10.1016/0091-6749(85)90701-8	http://dx.doi.org/10.1016/0091-6749(85)90701-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE88	4019951				2022-12-18	WOS:A1985APE8800013
J	SAGONA, MA; BRUSZER, GV; NELSON, JC; MASCOLI, C; SERKES, K				SAGONA, MA; BRUSZER, GV; NELSON, JC; MASCOLI, C; SERKES, K			REACTIVITY OF IGE AND IGG SERUM LEVELS TO CHYMOPAPAIN AFTER CHEMONUCLEOLYSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SAGONA, MA (corresponding author), TRAVENOL LABS INC,OMNIS SURG INC,6301 LINCOLN AVE,MORTON GROVE,IL 60053, USA.							BERNSTEIN IL, 1983, JAMA-J AM MED ASSOC, V250, P1167, DOI 10.1001/jama.250.9.1167; DEBANNE MT, 1974, J ALLERGY CLIN IMMUN, V53, P205, DOI 10.1016/0091-6749(74)90082-7; FLINDT MLH, 1978, LANCET, V1, P430; FRANZ T, 1971, J ALLERGY, V47, P170, DOI 10.1016/S0091-6749(71)80295-6; MANSFIELD LE, 1983, J ALLERGY CLIN IMMUN, V71, P371, DOI 10.1016/0091-6749(83)90064-7; Massie W K, 1969, Clin Orthop Relat Res, V67, P2; MCCULLOCH JA, 1981, CAN MED ASSOC J, V124, P879; MCCULLOCH JA, 1981, SPINE, V6, P606, DOI 10.1097/00007632-198111000-00012; MIDDLETON E, 1983, ALLERGY PRINCIPLES P, V1, pCH16; NOVEY HS, 1979, J ALLERGY CLIN IMMUN, V63, P98, DOI 10.1016/0091-6749(79)90198-2; NOVEY HS, 1980, CLIN ALLERGY, V10, P721, DOI 10.1111/j.1365-2222.1980.tb02157.x; RAJAGOPALAN R, 1974, ANESTH ANALG, V53, P191; TARLO SM, 1978, CLIN ALLERGY, V8, P207, DOI 10.1111/j.1365-2222.1978.tb03216.x; Watts C, 1977, Neurosurgery, V1, P2	14	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	6					659	662		10.1016/0091-6749(85)90090-9	http://dx.doi.org/10.1016/0091-6749(85)90090-9			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ALA84	3891823	Bronze			2022-12-18	WOS:A1985ALA8400005
J	SHENASSA, MM; PERELMUTTER, L; GERRARD, JW				SHENASSA, MM; PERELMUTTER, L; GERRARD, JW			DESENSITIZATION TO PEANUT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	12	12	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	1					177	177		10.1016/0091-6749(85)90426-9	http://dx.doi.org/10.1016/0091-6749(85)90426-9			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ACF22		Bronze			2022-12-18	WOS:A1985ACF2200291
J	TING, S; MANSFIELD, LE				TING, S; MANSFIELD, LE			LOCALIZED COLD-REFLEX URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									WILLIAM BEAUMONT ARMY MED CTR,ALLERGY IMMUNOL SERV,EL PASO,TX 79920	William Beaumont Army Medical Center								CZARNETZKI BM, 1981, BRIT J DERMATOL, V104, P83, DOI 10.1111/j.1365-2133.1981.tb01716.x; DYER J, 1982, J ALLERGY CLIN IMMUN, V70, P82, DOI 10.1016/0091-6749(82)90233-0; KAPLAN AP, 1984, J ALLERGY CLIN IMMUN, V73, P453, DOI 10.1016/0091-6749(84)90354-3; TING S, 1984, PEDIATRICS, V73, P105; TING S, 1984, Journal of Allergy and Clinical Immunology, V73, P182	5	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	3					421	421		10.1016/0091-6749(85)90081-8	http://dx.doi.org/10.1016/0091-6749(85)90081-8			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AEB46	3973316	Bronze			2022-12-18	WOS:A1985AEB4600015
J	SHEFFER, AL; PENNOYER, DS				SHEFFER, AL; PENNOYER, DS			MANAGEMENT OF ADVERSE DRUG-REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School								ARNDT KA, 1976, JAMA-J AM MED ASSOC, V235, P918, DOI 10.1001/jama.235.9.918; BORDA IT, 1968, J AMER MED ASSOC, V205, P645, DOI 10.1001/jama.205.9.645; BUNNING RD, 1982, JAMA-J AM MED ASSOC, V248, P2864, DOI 10.1001/jama.248.21.2864; DESWARTE RD, 1980, ALLERGIC DISEASES DI, P452; DUNK AA, 1982, BMJ-BRIT MED J, V284, P1605, DOI 10.1136/bmj.284.6329.1605; DUNN MJ, 1980, KIDNEY INT, V18, P609, DOI 10.1038/ki.1980.179; INCAUDO G, 1978, J ALLERGY CLIN IMMUN, V61, P339, DOI 10.1016/0091-6749(78)90057-X; KUOKKANEN K, 1972, ACTA ALLERGOL, V27, P407, DOI 10.1111/j.1398-9995.1972.tb01440.x; LEVENSON DJ, 1982, AM J MED, V72, P354, DOI 10.1016/0002-9343(82)90826-9; MELMON KL, 1971, NEW ENGL J MED, V284, P1361; PARKER CW, 1980, CLIN IMMUNOLOGY, P1219; PATTERSON R, 1982, JAMA-J AM MED ASSOC, V248, P2637, DOI 10.1001/jama.248.20.2637; SCHATZ M, 1981, MED CLIN N AM, V65, P1055, DOI 10.1016/S0025-7125(16)31489-4; SEIDL LG, 1966, B JOHNS HOPKINS HOSP, V119, P299; SETTIPANE GA, 1983, AM J MED, V74, P102, DOI 10.1016/0002-9343(83)90537-5; SHEFFER AL, 1984, EMERGENCY MED, P163; VANARSDEL PP, 1982, J AM ACAD DERMATOL, V6, P833, DOI 10.1016/S0190-9622(82)70073-8; VANARSDEL PP, 1978, ALLERGY PRINCIPLES P, P1133; WEISS RB, 1981, ANN INTERN MED, V94, P66, DOI 10.7326/0003-4819-94-1-66; WEISS RB, 1982, SEMIN ONCOL, V9, P5; 1968, TASK FORCE PRESCRIPT	21	12	12	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	4					580	588		10.1016/0091-6749(84)90110-6	http://dx.doi.org/10.1016/0091-6749(84)90110-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ163	6491104				2022-12-18	WOS:A1984TQ16300007
J	SLAVIN, RG				SLAVIN, RG			SINUSITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SLAVIN, RG (corresponding author), ST LOUIS UNIV, SCH MED, DEPT INTERNAL MED & MICROBIOL, ALLERGY & IMMUNOL SECT, ST LOUIS, MO 63104 USA.							BRIDGER RC, 1980, J CLIN PATHOL, V33, P276, DOI 10.1136/jcp.33.3.276; BULLEN SS, 1932, J ALLERGY, V4, P402; CLEVELAND HH, 1979, ACTA OTO-LARYNGOL, V368, P129; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; FREDERICK J, 1974, NEW ENGL J MED, V290, P135, DOI 10.1056/NEJM197401172900304; Gottlieb MJ, 1925, J AMER MED ASSOC, V85, P105, DOI 10.1001/jama.1925.02670020025013; HOSHAW TC, 1974, ARCH OTOLARYNGOL, V100, P194; MANN W, 1977, ARCH OTO-RHINO-LARYN, V215, P67, DOI 10.1007/BF00463193; RACHELEFSKY GS, 1982, J ALLERGY CLIN IMMUN, V69, P382, DOI 10.1016/0091-6749(82)90150-6; SANTAGNESE PAD, 1979, AM J MED, V66, P121, DOI 10.1016/0002-9343(79)90491-1; SHEFFIELD RW, 1978, POSTGRAD MED, V63, P93, DOI 10.1080/00325481.1978.11714779; SLAVIN RG, 1982, ANN ALLERGY, V49, P76; SLAVIN RG, 1980, J ALLERGY CLIN IMMUN, V66, P250, DOI 10.1016/0091-6749(80)90048-2; SPECTOR SL, 1981, J ALLERGY CLIN IMMUN, V67, P22, DOI 10.1016/0091-6749(81)90040-3; STIEHM ER, 1980, IMMUNOLOGIC DISORDER, P183; WALD ER, 1981, NEW ENGL J MED, V304, P749, DOI 10.1056/NEJM198103263041302; 1971, DIGEST HLTH STATISTI	17	12	12	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	5					712	716		10.1016/0091-6749(84)90312-9	http://dx.doi.org/10.1016/0091-6749(84)90312-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SS046	6715734	Bronze			2022-12-18	WOS:A1984SS04600019
J	TAN, EM; RUBIN, RL				TAN, EM; RUBIN, RL			AUTO-ALLERGIC REACTIONS INDUCED BY PROCAINAMIDE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											TAN, EM (corresponding author), SCRIPPS CLIN & RES FDN, WM KECK FDN AUTOIMMUNE DIS CTR, LA JOLLA, CA 92037 USA.				PHS HHS [A110036] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BATCHELOR JR, 1980, LANCET, V1, P1107; BLOMGREN SE, 1969, NEW ENGL J MED, V281, P64, DOI 10.1056/NEJM196907102810203; LADD AT, 1962, NEW ENGL J MED, V267, P1357, DOI 10.1056/NEJM196212272672608; PERRY HM, 1970, J LAB CLIN MED, V76, P114; PERRY HM, 1955, JAMA-J AM MED ASSOC, V157, P894; PORTANOVA JP, 1982, CLIN IMMUNOL IMMUNOP, V25, P67, DOI 10.1016/0090-1229(82)90166-0; PORTANOVA JP, 1982, NEPHROTOXIC MECHANIS, P373; TAN EM, 1974, FED PROC, V33, P1894; TAN EM, 1982, ADV IMMUNOL, V33, P167, DOI 10.1016/S0065-2776(08)60836-6; WOOSLEY RL, 1978, NEW ENGL J MED, V298, P1157, DOI 10.1056/NEJM197805252982101	10	12	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	4					631	634		10.1016/0091-6749(84)90117-9	http://dx.doi.org/10.1016/0091-6749(84)90117-9			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ163	6386937				2022-12-18	WOS:A1984TQ16300014
J	LEMANSKE, RF; BARR, L; GUTHMAN, DA; KALINER, M				LEMANSKE, RF; BARR, L; GUTHMAN, DA; KALINER, M			THE BIOLOGIC ACTIVITY OF MAST-CELL GRANULES .5. THE EFFECTS OF ANTIHISTAMINE TREATMENT ON RAT CUTANEOUS EARLY-PHASE AND LATE-PHASE ALLERGIC REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BETHESDA,MD 20205; UNIV WISCONSIN,SCH MED,DEPT PEDIAT,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,DEPT MED,MADISON,WI 53706	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison								ATKINS P, 1973, J ALLERGY CLIN IMMUN, V51, P263, DOI 10.1016/0091-6749(73)90128-0; BASTIAN JW, 1961, DIS NERV SYST, V22, P9; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; BRIMBLECOMBE RW, 1975, J INT MED RES, V3, P86, DOI 10.1177/030006057500300205; BRIMBLECOMBE RW, 1976, FED PROC, V35, P1931; BUSSE WW, 1976, SCIENCE, V194, P737, DOI 10.1126/science.185696; CARPENTER GB, 1980, J ALLERGY CLIN IMMUN, V65, P187; CLARK RAF, 1977, J IMMUNOL, V118, P137; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; GRONNEBERG R, 1981, ALLERGY, V36, P201, DOI 10.1111/j.1398-9995.1981.tb01835.x; HARGREAVE FE, 1974, CAN MED ASSOC J, V110, P415; KLINE B. S., 1932, JOUR ALLERGY, V3, P531, DOI 10.1016/S0021-8707(32)90148-8; LEMANSKE RF, 1983, J IMMUNOL, V130, P1881; LEMANSKE RF, 1982, IMMUNOLOGY, V45, P561; LEMANSKE RF, INT J DERMATOL; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALING HM, 1974, J PHARMACOL EXP THER, V191, P300; OERTEL H, 1981, J ALLERGY CLIN IMMUN, V68, P238, DOI 10.1016/0091-6749(81)90190-1; OERTEL HL, 1981, J IMMUNOL, V127, P1398; POOTHULLIL J, 1976, J ALLERGY CLIN IMMUN, V57, P164, DOI 10.1016/0091-6749(76)90035-X; RAPHAEL GD, 1978, EXP CELL RES, V115, P428, DOI 10.1016/0014-4827(78)90300-2; SELIGMANN B, 1981, CLIN RES, V29, pA172; SIRAGANIAN RP, 1976, MANUAL CLIN IMMUNOLO, P603; SMITH JA, 1980, J ALLERGY CLIN IMMUN, V65, P118, DOI 10.1016/0091-6749(80)90195-5; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SULLIVAN TJ, 1975, J IMMUNOL, V114, P1473; TANNENBAUM S, 1980, J IMMUNOL, V125, P325; UMEMOTO L, 1976, J ALLERGY CLIN IMMUN, V58, P60, DOI 10.1016/0091-6749(76)90107-X; VALONE FH, 1980, CLIN IMMUNOL IMMUNOP, V15, P52, DOI 10.1016/0090-1229(80)90020-3; WESCOTT S, INFLAMMATION	32	12	12	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	1					94	99		10.1016/0091-6749(83)90058-1	http://dx.doi.org/10.1016/0091-6749(83)90058-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QZ198	6602161	Bronze			2022-12-18	WOS:A1983QZ19800013
J	RAMSDELL, JW; BERRY, CC; CLAUSEN, JL				RAMSDELL, JW; BERRY, CC; CLAUSEN, JL			THE IMMEDIATE EFFECTS OF CORTISOL ON PULMONARY-FUNCTION IN NORMALS AND ASTHMATICS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF SAN DIEGO, SCH MED, DEPT MED, DIV PULM, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego								ALBERT RK, 1980, ANN INTERN MED, V92, P753, DOI 10.7326/0003-4819-92-6-753; ARNAUD A, 1979, LUNG, V156, P43, DOI 10.1007/BF02713990; BASS H, 1973, CHEST, V63, P171, DOI 10.1378/chest.63.2.171; BRISCOE WA, 1958, J CLIN INVEST, V37, P1279, DOI 10.1172/JCI103715; COHEN J, 1977, STATISTICAL POWER AN, P15; COLLINS JV, 1970, LANCET, V2, P1047; DETROYER A, 1979, J APPL PHYSIOL, V46, P217, DOI 10.1152/jappl.1979.46.2.217; DIXON WJ, 1977, BMDPP 77 BIOMEDICAL, P540; DRAPER N, 1966, APPLIED REGRESSION A, P150; ELLULMICALLEF R, 1975, THORAX, V30, P312, DOI 10.1136/thx.30.3.312; ELLULMICALLEF R, 1975, LANCET, V2, P1269; GAYRARD P, 1975, AM REV RESPIR DIS, V111, P433; GOLDMAN HI, 1959, AM REV TUBERC PULM, V79, P457; KLAUSTERMEYER WB, 1976, ANN ALLERGY, V37, P80; MCFADDEN ER, 1970, J CLIN INVEST, V49, P779, DOI 10.1172/JCI106291; MCFADDEN ER, 1976, AM J MED, V60, P52, DOI 10.1016/0002-9343(76)90533-7; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; OREHEK J, 1975, BMJ-BRIT MED J, V1, P123, DOI 10.1136/bmj.1.5950.123; PELZER AM, 1966, J APPL PHYSIOL, V21, P469, DOI 10.1152/jappl.1966.21.2.469; PIERSON WE, 1974, PEDIATRICS, V54, P282; REES HA, 1962, BMJ-BRIT MED J, P1575, DOI 10.1136/bmj.1.5292.1575; SHENFIELD GM, 1975, THORAX, V30, P430, DOI 10.1136/thx.30.4.430; Tattersfield A E, 1977, Acta Tuberc Pneumol Belg, V68, P75; VANARSDEL PP, 1977, ANN INTERN MED, V87, P68, DOI 10.7326/0003-4819-87-1-68	24	12	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	1					69	74		10.1016/0091-6749(83)90054-4	http://dx.doi.org/10.1016/0091-6749(83)90054-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QZ198	6853932				2022-12-18	WOS:A1983QZ19800009
J	SUZUKI, S; YAMAUCHI, N; MIYAMOTO, T; MURANAKA, M				SUZUKI, S; YAMAUCHI, N; MIYAMOTO, T; MURANAKA, M			GOLD-INDUCED REDUCTION IN REACTIVITY TO HISTAMINE IN ISOLATED GUINEA-PIG TRACHEAL RINGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SUZUKI, S (corresponding author), UNIV TOKYO,FAC MED,DEPT MED & PHYS THERAPY,BUNKYO KU,TOKYO 113,JAPAN.							BROCKLEHURST WE, 1973, HDB EXPT IMMUNOLOGY; GOTTLIEB NL, 1977, B RHEUM DIS, V27, P912; MURANAKA M, 1978, J ALLERGY CLIN IMMUN, V62, P276, DOI 10.1016/0091-6749(78)90158-6; MURANAKA M, 1978, ANN ALLERGY, V40, P132; MURANAKA M, 1981, J ALLERGY CLIN IMMUN, V67, P350, DOI 10.1016/0091-6749(81)90079-8; NORN S, 1971, ACTA PHARM TOXICO S1, V30, P1; ROSENBERG SA, 1979, J RHEUMATOL, V6, P107; SADLER PJ, 1982, J RHEUMATOL, V9, P71; TYRRELL DAJ, 1965, BRIT J EXP PATHOL, V46, P514; VANARSDEL PP, 1981, J ALLERGY CLIN IMMUN, V67, P348, DOI 10.1016/0091-6749(81)90078-6; YAMAUCHI N, 1982, JPN J ALLERGOL, V31, P576	11	12	12	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	5					469	474		10.1016/0091-6749(83)90583-3	http://dx.doi.org/10.1016/0091-6749(83)90583-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RR916	6415145				2022-12-18	WOS:A1983RR91600007
J	BERNSTEIN, IL; SPLANSKY, GL; CHEN, SE; VINEGAR, A				BERNSTEIN, IL; SPLANSKY, GL; CHEN, SE; VINEGAR, A			THE GUINEA-PIG MODEL OF DIISOCYANATE SENSITIZATION .2. PHYSIOLOGIC STUDIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CINCINNATI,MED CTR,DEPT MED,DIV IMMUNOL,CINCINNATI,OH 45267; UNIV CINCINNATI,MED CTR,DEPT ENVIRONM HLTH,CINCINNATI,OH 45267	University of Cincinnati; University of Cincinnati					NIEHS NIH HHS [ES 00159] Funding Source: Medline; NIOSH CDC HHS [OH 733-01] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000159] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIOSH CDC HHS; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMDUR MO, 1958, AM J PHYSIOL, V192, P364, DOI 10.1152/ajplegacy.1958.192.2.364; BUTCHER BT, 1980, J ALLERGY CLIN IMMUN, V66, P213, DOI 10.1016/0091-6749(80)90041-X; BUTCHER BT, 1979, J ALLERGY CLIN IMMUN, V64, P146, DOI 10.1016/0091-6749(79)90049-6; BUTCHER BT, 1976, J ALLERGY CLIN IMMUN, V58, P89, DOI 10.1016/0091-6749(76)90110-X; CHEN SE, 1982, J ALLERGY CLIN IMMUN, V70, P383, DOI 10.1016/0091-6749(82)90029-X; CHESTER EH, 1979, CHEST, V75, P229, DOI 10.1378/chest.75.2_Supplement.229; GALLAGHER JS, 1981, J OCCUP ENVIRON MED, V23, P610, DOI 10.1097/00043764-198109000-00009; KAROL MH, 1979, TOXICOL APPL PHARM, V51, P73, DOI 10.1016/0041-008X(79)90009-7; KAROL MH, 1978, AM IND HYG ASSOC J, V39, P454, DOI 10.1080/0002889778507789; KAROL MH, 1978, AM IND HYG ASSOC J, V39, P546, DOI 10.1080/0002889778507807; OVARY Z, 1976, INT ARCH ALLER A IMM, V51, P416, DOI 10.1159/000231616; PEPYS J, 1972, Clinical Allergy, V2, P225, DOI 10.1111/j.1365-2222.1972.tb01287.x; SCHEEL L D, 1964, Am Ind Hyg Assoc J, V25, P179, DOI 10.1080/00028896409342574; SMITH AB, 1980, J OCCUP ENVIRON MED, V22, P327, DOI 10.1097/00043764-198005000-00005; TSE CST, 1979, AM REV RESPIR DIS, V120, P829; VINEGAR A, 1979, J APPL PHYSIOL, V46, P867, DOI 10.1152/jappl.1979.46.5.867; 1973, DHEW HSM7311022 PUBL	17	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	5					393	398		10.1016/0091-6749(82)90030-6	http://dx.doi.org/10.1016/0091-6749(82)90030-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PQ105	6290555				2022-12-18	WOS:A1982PQ10500012
J	HIRSCH, SR; KALBFLEISCH, JH; COHEN, SH				HIRSCH, SR; KALBFLEISCH, JH; COHEN, SH			COMPARISON OF RINKEL INJECTION THERAPY WITH STANDARD IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MED COLL WISCONSIN,DEPT MED,MILWAUKEE,WI 53233	Medical College of Wisconsin	HIRSCH, SR (corresponding author), VET ADM MED CTR,RES SERV,WOOD,WI 53193, USA.							EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; GOLBERT TM, 1975, J ALLERGY CLIN IMMUN, V56, P170, DOI 10.1016/0091-6749(75)90089-5; HIRSCH SR, 1981, J ALLERGY CLIN IMMUN, V68, P133, DOI 10.1016/0091-6749(81)90172-X; IRONS JS, 1977, J ALLERGY CLIN IMMUN, V59, P190, DOI 10.1016/0091-6749(77)90149-X; JOHNSTONE DE, 1957, AMA J DIS CHILD, V94, P1; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LOWELL FC, 1963, J ALLERGY, V34, P165, DOI 10.1016/0021-8707(63)90069-8; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; LOWELL FC, 1965, J ALLERGY, V36, P314; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; RINKEL H J, 1949, Ann Allergy, V7, P625; RINKEL H J, 1949, Ann Allergy, V7, P631; RINKEL H J, 1949, Ann Allergy, V7, P639; RINKEL HJ, 1962, ARCHIV OTOLARYNGOL, V76, P491; RINKEL HJ, 1963, ARCHIV OTOLARYNGOL, V77, P42; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; SPRECACE GA, 1966, J ALLERGY, V38, P9, DOI 10.1016/0021-8707(66)90068-2; TUCHINDA M, 1973, J ALLERGY CLIN IMMUN, V51, P131, DOI 10.1016/0091-6749(73)90018-3; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V65, P288, DOI 10.1016/0091-6749(80)90158-X; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V66, P500, DOI 10.1016/0091-6749(80)90012-3; YUNGINGER JW, 1973, J CLIN INVEST, V52, P1268, DOI 10.1172/JCI107294	25	12	12	1	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	3					183	190		10.1016/0091-6749(82)90040-9	http://dx.doi.org/10.1016/0091-6749(82)90040-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG384	7108070				2022-12-18	WOS:A1982PG38400005
J	REED, CE				REED, CE			MEASUREMENT OF AIRBORNE ANTIGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											REED, CE (corresponding author), MAYO CLIN & MAYO FDN,200 1ST ST,SW,ROCHESTER,MN 55905, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011483] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-11483] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGARWAL MK, 1981, J ALLERGY CLIN IMMUN, V68, P194, DOI 10.1016/0091-6749(81)90183-4; HAMILTON RG, 1979, J IMMUNOL, V122, P1073; TWIGGS JT, 1982, J ALLERGY CLIN IMMUN; 1978, DHEW78215 NAT I OCC	4	12	12	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	1					38	40		10.1016/0091-6749(82)90199-3	http://dx.doi.org/10.1016/0091-6749(82)90199-3			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NY715	7086001				2022-12-18	WOS:A1982NY71500010
J	SCHLUETER, DP				SCHLUETER, DP			INFILTRATIVE LUNG-DISEASE HYPERSENSITIVITY PNEUMONITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SCHLUETER, DP (corresponding author), MED COLL WISCONSIN,DEPT PULM MED,MILWAUKEE,WI 53226, USA.				NHLBI NIH HHS [HL-15389] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANASZAK EF, 1970, NEW ENGL J MED, V283, P271, DOI 10.1056/NEJM197008062830601; BECHTEL JJ, 1981, AM REV RESPIR DIS, V124, P759; BRAUN SR, 1979, AM REV RESPIR DIS, V119, P185; DICKIE HA, 1958, JAMA-J AM MED ASSOC, V167, P1069, DOI 10.1001/jama.1958.02990260011004; DORVAL G, 1979, J ALLERGY CLIN IMMUN, V63, P204; FINK JN, 1968, ANN INTERN MED, V68, P1204; HAPKE EJ, 1968, THORAX, V23, P451, DOI 10.1136/thx.23.5.451; HUNNINGHAKE GW, 1981, AM REV RESPIR DIS, V123, P407; MOORE VL, 1974, J ALLERGY CLIN IMMUN, V53, P319, DOI 10.1016/0091-6749(74)90115-8; NIDEN AH, 1976, CHEST, V69, P266; PATTERSON R, 1979, AM REV RESPIR DIS, V120, P1113; RILEY DJ, 1973, AM REV RESPIR DIS, V107, P456; ROBERTS RC, 1977, AM REV RESPIR DIS, V116, P1075; SALVAGGIO J, 1972, CHEST, V62, P242, DOI 10.1378/chest.62.3.242; SCHLUETER DP, 1969, ANN INTERN MED, V70, P457, DOI 10.7326/0003-4819-70-3-457; SCHUYLER MR, 1978, ANN INTERN MED, V88, P355, DOI 10.7326/0003-4819-88-3-355; SEAL RME, 1968, THORAX, V23, P469, DOI 10.1136/thx.23.5.469; UNGER GF, 1973, RADIOL CLIN N AM, V11, P339	18	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	1					50	55		10.1016/0091-6749(82)90201-9	http://dx.doi.org/10.1016/0091-6749(82)90201-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NY715	7086002				2022-12-18	WOS:A1982NY71500012
J	CLAYTON, DE; BUSSE, WW				CLAYTON, DE; BUSSE, WW			DEVELOPMENT OF ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS DURING TREATMENT OF SEVERE ASTHMA WITH SYSTEMIC CORTICOSTEROIDS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN,CTR CLIN SCI,DEPT INTERNAL MED,ALLERGY IMMUNOL SECT,MADISON,WI 53792	University of Wisconsin System; University of Wisconsin Madison					NIAID NIH HHS [AI 00343-01] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARBESMAN C E, 1974, Clinical Allergy, V4, P349, DOI 10.1111/j.1365-2222.1974.tb01396.x; BASICH JE, 1980, J ALLERGY CLIN IMMUN, V65, P219; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; GHORY AC, 1980, INT ARCH ALLER A IMM, V62, P285, DOI 10.1159/000232524; HENDERSON AH, 1968, THORAX, V23, P501, DOI 10.1136/thx.23.5.501; HINSON KFW, 1952, THORAX, V7, P317, DOI 10.1136/thx.7.4.317; HOEHNE JH, 1973, CHEST, V63, P177, DOI 10.1378/chest.63.2.177; IMBEAU SA, 1978, J ALLERGY CLIN IMMUN, V62, P91, DOI 10.1016/0091-6749(78)90084-2; IMBEAU SA, 1977, AM J DIS CHILD, V131, P1127, DOI 10.1001/archpedi.1977.02120230073013; IMBEAU SA, 1978, J ALLERGY CLIN IMMUN, V62, P243, DOI 10.1016/0091-6749(78)90214-2; MCCARTHY D S, 1970, Clinical Radiology, V21, P366, DOI 10.1016/S0009-9260(70)80070-8; McCarthy D S, 1971, Clin Allergy, V1, P415, DOI 10.1111/j.1365-2222.1971.tb00793.x; McCarthy DS, 1971, CLIN ALLERGY, V1, P261, DOI DOI 10.1111/J.1365-2222.1971.TB; PATTERSON R, 1973, AM J MED, V54, P16, DOI 10.1016/0002-9343(73)90078-8; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; ROSENBERG M, 1977, J PEDIATR-US, V91, P914, DOI 10.1016/S0022-3476(77)80889-5; ROSENBERG M, 1978, AM J MED, V64, P599, DOI 10.1016/0002-9343(78)90579-X; SAFIRSTEIN BH, 1973, AM REV RESPIR DIS, V108, P450; SLAVIN RG, 1969, AM J MED, V47, P306, DOI 10.1016/0002-9343(69)90156-9	19	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	3					243	246		10.1016/0091-6749(81)90068-3	http://dx.doi.org/10.1016/0091-6749(81)90068-3			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LG778	7462540				2022-12-18	WOS:A1981LG77800013
J	MULLARKEY, MF				MULLARKEY, MF			THE CLASSIFICATION OF NASAL DISEASE - AN OPINION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											MULLARKEY, MF (corresponding author), MASON CLIN,1100 9TH AVE,POB 900,SEATTLE,WA 98111, USA.							ASHER R, 1959, LANCET, V2, P359; MULLARKEY MF, 1980, J ALLERGY CLIN IMMUN, V65, P122, DOI 10.1016/0091-6749(80)90196-7; SCHATZ M, 1980, CONSULTANT       MAY, P61; SETTIPANE GA, 1977, J ALLERGY CLIN IMMUN, V59, P17, DOI 10.1016/0091-6749(77)90171-3; SPECTOR SL, 1980, J ALLERGY CLIN IMMUN, V66, P129, DOI 10.1016/0091-6749(80)90060-3	5	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	4					251	252		10.1016/0091-6749(81)90018-X	http://dx.doi.org/10.1016/0091-6749(81)90018-X			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LL697	7204782	Bronze			2022-12-18	WOS:A1981LL69700001
J	PATERSON, NAM; CRAIG, ID				PATERSON, NAM; CRAIG, ID			INACTIVATION BY ALVEOLAR MACROPHAGES OF SLOW-REACTING SUBSTANCE OF ANAPHYLAXIS RELEASED FROM PIG LUNG-CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WESTERN ONTARIO,LONDON N6A 3K7,ONTARIO,CANADA; VICTORIA HOSP CORP,DEPT PATHOL,LONDON N6A 4S2,ONTARIO,CANADA	Western University (University of Western Ontario); Dalhousie University; Western University (University of Western Ontario)	PATERSON, NAM (corresponding author), VICTORIA HOSP CORP,DEPT MED,LONDON N6A 4S2,ONTARIO,CANADA.							BACH MK, 1978, J IMMUNOL, V120, P998; BARRETTBEE KJ, 1975, PROSTAGLANDINS, V10, P589, DOI 10.1016/S0090-6980(75)80005-0; BERRY PA, 1964, BRIT J PHARM CHEMOTH, V23, P201, DOI 10.1111/j.1476-5381.1964.tb01579.x; BOOT JR, 1977, PROSTAGLANDINS, V13, P927, DOI 10.1016/0090-6980(77)90222-2; BRAY MA, 1978, BRIT J PHARMACOL, V63, P635, DOI 10.1111/j.1476-5381.1978.tb17276.x; BROCKLEHURST WE, 1962, PROG ALLERGY, V6, P539, DOI 10.1159/000313810; DAVIS GS, 1977, AM REV RESPIR DIS, V115, pA210; DESSAINT JP, 1979, CELL IMMUNOL, V46, P24, DOI 10.1016/0008-8749(79)90242-9; DESSAINT JP, 1979, CELL IMMUNOL, V46, P12, DOI 10.1016/0008-8749(79)90241-7; DRAZEN JM, 1974, J CLIN INVEST, V53, P1679, DOI 10.1172/JCI107719; DRAZEN JM, 1975, J APPL PHYSIOL, V38, P834, DOI 10.1152/jappl.1975.38.5.834; ENGINEER DM, 1978, BRIT J PHARMACOL, V64, P211, DOI 10.1111/j.1476-5381.1978.tb17291.x; FAROOQUI AA, 1977, CLIN CHIM ACTA, V74, P93, DOI 10.1016/0009-8981(77)90209-1; GARLAND LG, 1976, INT ARCH ALLER A IMM, V50, P27, DOI 10.1159/000231477; GEMSA D, 1978, J IMMUNOL, V120, P1187; HAND WL, 1977, NATURE, V265, P543, DOI 10.1038/265543a0; HENDERSON WR, 1979, J IMMUNOL, V122, P1322; HERXHEIMER H, 1963, J PHYSIOL-LONDON, V165, pP78; HUMES JL, 1977, NATURE, V269, P149, DOI 10.1038/269149a0; LEWIS RA, 1980, P NATL ACAD SCI-BIOL, V77, P3710, DOI 10.1073/pnas.77.6.3710; LICHTENSTEIN L M, 1972, Prostaglandins, V2, P519, DOI 10.1016/S0090-6980(72)80040-6; LICHTENSTEIN LM, 1975, J IMMUNOL, V114, P1692; LINDAHL U, 1979, BIOCHEM J, V182, P189, DOI 10.1042/bj1820189; LYNCH SM, 1978, J IMMUNOL, V121, P1394; MICHOUD MC, 1979, AM REV RESPIR DIS, V119, P419; NATHAN CF, 1977, J EXP MED, V146, P1648, DOI 10.1084/jem.146.6.1648; Orange R P, 1969, Adv Immunol, V10, P105, DOI 10.1016/S0065-2776(08)60416-2; ORANGE RP, 1976, J IMMUNOL, V117, P2191; ORANGE RP, 1973, J IMMUNOL, V110, P760; ORANGE RP, 1969, FED PROC, V28, P1710; ORANGE RP, 1974, J IMMUNOL, V113, P316; PATERSON NAM, 1976, J IMMUNOL, V117, P1356; PATERSON NAM, 1981, J ALLERGY CLIN IMMUN, V67, P426, DOI 10.1016/0091-6749(81)90095-6; PATTERSON R, 1976, J LAB CLIN MED, V87, P1016; PATTERSON R, 1978, J CLIN INVEST, V62, P519, DOI 10.1172/JCI109155; PAUL BB, 1973, SCIENCE, V181, P849, DOI 10.1126/science.181.4102.849; SIROIS P, 1979, PROSTAGLANDINS, V17, P395, DOI 10.1016/S0090-6980(79)80007-6; TAUBER AI, 1973, J IMMUNOL, V111, P27; WANNER A, 1975, J APPL PHYSIOL, V39, P950, DOI 10.1152/jappl.1975.39.6.950; WASSERMAN SI, 1975, J IMMUNOL, V114, P645; WASSERMAN SI, 1975, J ALLERGY CLIN IMMUN, V55, P72; WEIDEMANN MJ, 1978, FEBS LETT, V89, P136, DOI 10.1016/0014-5793(78)80539-0	42	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	6					435	443		10.1016/0091-6749(81)90096-8	http://dx.doi.org/10.1016/0091-6749(81)90096-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LU068	7346528				2022-12-18	WOS:A1981LU06800004
J	PATTERSON, R				PATTERSON, R			ALLERGEN IMMUNOTHERAPY WITH MODIFIED ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											PATTERSON, R (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BACAL E, 1978, J ALLERGY CLIN IMMUN, V62, P289, DOI 10.1016/0091-6749(78)90160-4; BERNSTEIN IL, 1976, INT ARCH ALLER A IMM, V50, P181; HENDRIX SG, 1980, J ALLERGY CLIN IMMUN, V66, P486, DOI 10.1016/0091-6749(80)90010-X; HENDRIX SG, 1981, J ALLERGY CLIN IMMUN, V67, P124, DOI 10.1016/0091-6749(81)90007-5; KELLY JF, 1980, J ALLERGY CLIN IMMUN, V65, P50, DOI 10.1016/0091-6749(80)90176-1; KING TP, 1962, BIOCHEMISTRY-US, V1, P709, DOI 10.1021/bi00910a027; LIU FT, 1979, P NATL ACAD SCI USA, V76, P1430, DOI 10.1073/pnas.76.3.1430; LOVELESS MH, 1947, AM J MED SCI, V214, P559, DOI 10.1097/00000441-194711000-00015; MARSH DG, 1970, IMMUNOLOGY, V18, P705; METZGER WJ, 1976, NEW ENGL J MED, V295, P1160, DOI 10.1056/NEJM197611182952103; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; PATTERSON R, 1978, J ALLERGY CLIN IMMUN, V61, P28, DOI 10.1016/0091-6749(78)90470-0; PATTERSON R, 1980, J ALLERGY CLIN IMMUN, V66, P495, DOI 10.1016/0091-6749(80)90011-1; PATTERSON R, 1977, J ALLERGY CLIN IMMUN, V59, P314, DOI 10.1016/0091-6749(77)90053-7; PATTERSON R, 1973, J IMMUNOL, V110, P1402; PATTERSON R, 1981, J ALLERGY CLIN IMMUN, V67, P162, DOI 10.1016/0091-6749(81)90013-0; PATTERSON R, 1976, J ALLERGY CLIN IMMUN, V57, P168, DOI 10.1016/0091-6749(76)90036-1; PATTERSON R, 1973, J IMMUNOL, V110, P1413; PATTERSON R, 1977, ALLERGY PRACTICE PRI; PATTERSON ROY, 1959, ANN ALLERGY, V17, P444; SEHON AH, 1979, J ALLERGY CLIN IMMUN, V64, P242, DOI 10.1016/0091-6749(79)90139-8; ZEISS CR, 1979, J ALLERGY CLIN IMMUN, V63, P273, DOI 10.1016/0091-6749(79)90112-X	22	12	14	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	2					85	90		10.1016/0091-6749(81)90163-9	http://dx.doi.org/10.1016/0091-6749(81)90163-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MD162	6788829				2022-12-18	WOS:A1981MD16200001
J	PATTERSON, R; SUSZKO, IM; HENDRIX, SG; ZEISS, CR				PATTERSON, R; SUSZKO, IM; HENDRIX, SG; ZEISS, CR			POLYMERIZED TREE POLLEN ANTIGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note											PATTERSON, R (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BACAL E, 1978, J ALLERGY CLIN IMMUN, V62, P289, DOI 10.1016/0091-6749(78)90160-4; HENDRIX S, 1980, J ALLERGY CLIN IMMUN, V65, P57, DOI 10.1016/0091-6749(80)90177-3; HENDRIX SG, 1980, J ALLERGY CLIN IMMUN, V66, P486, DOI 10.1016/0091-6749(80)90010-X; HERBERT WJ, 1967, HDB EXPT IMMUNOLOGY, P720; KELLY JF, 1980, J ALLERGY CLIN IMMUN, V65, P50, DOI 10.1016/0091-6749(80)90176-1; METZGER WJ, 1976, NEW ENGL J MED, V295, P1160, DOI 10.1056/NEJM197611182952103; PATTERSON R, 1977, J ALLERGY CLIN IMMUN, V59, P314, DOI 10.1016/0091-6749(77)90053-7; PATTERSON R, 1973, J IMMUNOL, V110, P1402; PATTERSON R, 1973, J IMMUNOL, V110, P1413; PATTERSON R, 1972, ALLERGIC DISEASES DI; PATTERSON R, 1977, EXCERPTA MEDICA  414, P492; ZEISS CR, 1979, J ALLERGY CLIN IMMUN, V63, P273, DOI 10.1016/0091-6749(79)90112-X	12	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	2					162	165		10.1016/0091-6749(81)90013-0	http://dx.doi.org/10.1016/0091-6749(81)90013-0			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LB947	7451783				2022-12-18	WOS:A1981LB94700013
J	MATHEWS, KP; BAYNE, NK; BANAS, JM				MATHEWS, KP; BAYNE, NK; BANAS, JM			CONTROLLED-STUDY OF INTRANASAL IMMUNOTHERAPY WITH POLYMERIZED RAGWEED ANTIGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	3					191	191						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JJ620					2022-12-18	WOS:A1980JJ62000091
J	MOORE, BS; HYDE, JS				MOORE, BS; HYDE, JS			BREED-SPECIFIC DOG HYPERSENSITIVITY IN HUMANS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									RUSH MED CTR,ALLERGY & CLIN IMMUNOL SECT,1753 W CONGRESS PKWY,CHICAGO,IL 60612	Rush University								BLANDS J, 1977, ACTA ALLERGOL, V32, P147, DOI 10.1111/j.1398-9995.1977.tb01346.x; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; CRAWFORD LV, 1973, ALLERGY IMMUNOLOGY C, P378; FAGERBERG E, 1970, INT ARCH ALLER A IMM, V39, P301, DOI 10.1159/000230356; Hooker S. B., 1944, ANN ALLERGY, V2, P281; MOORE BS, 1977, ANN ALLERGY, V39, P240; OHMAN JL, 1976, CLIN ALLERGY, V6, P419, DOI 10.1111/j.1365-2222.1976.tb01926.x; PHILLIPS GL, 1961, REMINGTONS PHARMACEU, P1395; SCHERR MS, 1971, ANN ALLERGY, V29, P30; Spain W. C., 1942, JOUR ALLERGY, V13, P563, DOI 10.1016/S0021-8707(42)90069-8; VARGA JM, 1972, INT ARCH ALLER A IMM, V42, P438, DOI 10.1159/000230624; Walker IC, 1917, J MED RES, V35, P497; Yman L, 1975, Dev Biol Stand, V29, P151; YMAN L, 1973, INT ARCH ALLER A IMM, V44, P358, DOI 10.1159/000230944	15	12	14	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	3					198	203		10.1016/0091-6749(80)90039-1	http://dx.doi.org/10.1016/0091-6749(80)90039-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KH358	7410744				2022-12-18	WOS:A1980KH35800005
J	NISSIM, JE; BLEECKER, ER; NORMAN, PS; MENKES, H; PERMUTT, S; ROSENTHAL, RR				NISSIM, JE; BLEECKER, ER; NORMAN, PS; MENKES, H; PERMUTT, S; ROSENTHAL, RR			FAILURE OF AMINOPHYLLINE PRETREATMENT TO PREVENT ANTIGEN-INDUCED BRONCHOSPASM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	12	12	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	3					180	180						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JJ620					2022-12-18	WOS:A1980JJ62000057
J	COHEN, SG				COHEN, SG			AMERICAN-ACADEMY-OF-ALLERGY - HISTORICAL REVIEW	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review											COHEN, SG (corresponding author), NIAID,PROGRAM ALLERGY & IMMUNOL DIS,BETHESDA,MD 20014, USA.								0	12	12	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	5					332	466		10.1016/0091-6749(79)90005-8	http://dx.doi.org/10.1016/0091-6749(79)90005-8			135	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HT520	385673				2022-12-18	WOS:A1979HT52000005
J	FALLIERS, CJ				FALLIERS, CJ			ASSESSMENT OF ORAL ANTI-ASTHMATIC DRUGS BY INHALATION CHALLENGES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											FALLIERS, CJ (corresponding author), ALLERGY & ASTHMA CLIN,155 COOK ST,DENVER,CO 80206, USA.							CARDOSO RRD, 1974, ACTA ALLERGOL, V29, P1, DOI 10.1111/j.1398-9995.1974.tb01989.x; CARDOSO RRD, CLIN ALLERGY; FALLIERS CJ, 1975, PEDIATR CLIN N AM, V22, P141; FALLIERS CJ, 1976, ANN ALLERGY, V36, P99; FISH JE, 1977, AM REV RESPIR DIS, V115, P371; PEPYS J, 1977, AM REV RESPIR DIS, V116, P573, DOI 10.1164/arrd.1977.116.4.573; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PERMUTT S, 1977, ASTHMA PHYSL IMMUNOP, P265; ROSENTHAL RR, 1978, J ALLERGY CLIN IMMUN, V61, P139, DOI 10.1016/0091-6749(78)90275-0	9	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	6					685	688		10.1016/0091-6749(79)90039-3	http://dx.doi.org/10.1016/0091-6749(79)90039-3			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HX843	389992				2022-12-18	WOS:A1979HX84300027
J	FINEMAN, SM; ROSEN, FS; GEHA, RS				FINEMAN, SM; ROSEN, FS; GEHA, RS			TRANSIENT HYPOGAMMAGLOBULINEMIA, ELEVATED IMMUNOGLOBULIN-E LEVELS, AND FOOD ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS HOSP MED CTR,DEPT MED,DIV ALLERGY,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DEPT MED,DIV IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School								AMENT ME, 1973, MEDICINE, V52, P227, DOI 10.1097/00005792-197305000-00004; BACHMAN KD, 1957, PEDIATRICS, V20, P399; BIANCO C, 1970, J EXP MED, V132, P702, DOI 10.1084/jem.132.4.702; BUCKLEY RH, 1978, IMMUNOL REV, V41, P288, DOI 10.1111/j.1600-065X.1978.tb01469.x; Chandra R K, 1970, Indian J Pediatr, V37, P418, DOI 10.1007/BF02822939; CHIORAZZI N, 1976, J IMMUNOL, V117, P1629; EVANS RL, 1977, J EXP MED, V145, P221, DOI 10.1084/jem.145.1.221; EVANS RL, 1978, J IMMUNOL, V120, P1423; FREIER S, 1970, CLIN PEDIATR, V9, P449, DOI 10.1177/000992287000900806; GEHA RS, 1973, J EXP MED, V138, P1230, DOI 10.1084/jem.138.5.1230; GEHA RS, 1974, EUR J IMMUNOL, V4, P193, DOI 10.1002/eji.1830040308; GEHA RS, 1975, J CLIN INVEST, V56, P386, DOI 10.1172/JCI108103; GEHA RS, 1979, AM ACADEMY ALLERGY; GERRARD JW, 1973, ACTA PEDIATR SCAND S, V234, P71; GOLD ER, 1967, J IMMUNOL, V99, P859; ISHIZAKA K, 1976, J IMMUNOL, V117, P40; JANEWAY CA, 1957, ADV PEDIATR, V9, P65; KATZ DH, 1978, J ALLERGY CLIN IMMUN, V62, P44, DOI 10.1016/0091-6749(78)90072-6; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MOSCATELLI P, 1973, HELV PAEDIATR ACTA, V28, P553; PATTERSON R, 1972, ALLERGIC DISEASES DI; RIEGER CHL, 1977, J PEDIATR-US, V91, P601, DOI 10.1016/S0022-3476(77)80510-6; SCHWARTZ A, 1978, J IMMUNOL, V121, P1573; SPEER F, 1975, ANN ALLERGY, V34, P71; TILLER TL, 1978, J PEDIATR-US, V92, P347, DOI 10.1016/S0022-3476(78)80417-X; WALDMANN TA, 1967, NEW ENGL J MED, V276, P761, DOI 10.1056/NEJM196704062761401; WALDMANN TA, 1974, LANCET, V2, P609; WALDMANN TA, 1976, FED PROC, V35, P2067; WYBRAN J, 1973, NEW ENGL J MED, V288, P1072, DOI 10.1056/NEJM197305172882011	30	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	3					216	222		10.1016/0091-6749(79)90098-8	http://dx.doi.org/10.1016/0091-6749(79)90098-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HL221	89129				2022-12-18	WOS:A1979HL22100010
J	GEHA, RS				GEHA, RS			SUPPRESSOR T-CELLS IN HUMAN ALLERGIC DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material									HARVARD UNIV,SCH MED,DEPT PEDIAT & MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	GEHA, RS (corresponding author), CHILDRENS HOSP MED CTR,DIV ALLERGY & IMMUNOL,BOSTON,MA 02115, USA.							BUCKLEY RH, 1978, IMMUNOL REV, V41, P288, DOI 10.1111/j.1600-065X.1978.tb01469.x; FINEMAN L, 1979, CELL IMMUNOL, V45, P120; GEHA RS, UNPUBLISHED; GERSHON RK, 1971, IMMUNOLOGY, V21, P903; ISHIZAKA K, 1976, ADV IMMUNOL, V23, P1, DOI 10.1016/S0065-2776(08)60318-1; KATZ DH, 1978, IMMUNOL REV, V41, P77, DOI 10.1111/j.1600-065X.1978.tb01461.x; REINHERZ E, N ENGL J MED; REINHERZ EL, 1979, J IMMUNOL, V122, P1335; SHOU L, 1976, J EXP MED, V143, P1100, DOI 10.1084/jem.143.5.1100	9	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	6					477	478		10.1016/0091-6749(79)90055-1	http://dx.doi.org/10.1016/0091-6749(79)90055-1			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HX840	159919				2022-12-18	WOS:A1979HX84000001
J	LEE, YS; DICKINSON, DB; SCHLAGER, D; VELU, JG				LEE, YS; DICKINSON, DB; SCHLAGER, D; VELU, JG			ANTIGEN-E CONTENT OF POLLEN FROM INDIVIDUAL PLANTS OF SHORT RAGWEED (AMBROSIA-ARTEMISIIFOLIA)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV ILLINOIS,DEPT HORT,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign								ARBESMAN CE, 1977, INT ARCH ALLER A IMM, V53, P310, DOI 10.1159/000231767; BAER H, 1970, J ALLERGY, V45, P347, DOI 10.1016/0021-8707(70)90043-2; BERNSTEIN IL, 1976, J ALLERGY CLIN IMMUN, V57, P141, DOI 10.1016/0091-6749(76)90033-6; CENTER JG, 1974, J ALLERGY CLIN IMMUN, V54, P305, DOI 10.1016/0091-6749(74)90016-5; FRANKLIN RM, 1976, J ALLERGY CLIN IMMUN, V58, P51, DOI 10.1016/0091-6749(76)90106-8; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; GOLDFARB AR, 1967, J ALLERGY, V40, P237, DOI 10.1016/0021-8707(67)90086-X; JONES K. L., 1936, AMER MIDLAND NAT, V17, P673, DOI 10.2307/2420093; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; KING TP, 1967, BIOCHEMISTRY-US, V6, P1992, DOI 10.1021/bi00859a017; LEIFERMAN KM, 1976, J ALLERGY CLIN IMMUN, V58, P140, DOI 10.1016/0091-6749(76)90149-4; LICHTENSTEIN L, 1973, J ALLERGY CLIN IMMUN, V51, P285, DOI 10.1016/0091-6749(73)90130-9; MARSH DG, 1973, SCIENCE, V179, P691, DOI 10.1126/science.179.4074.691; MARSH DG, 1975, ANTIGENS, V3, P271; MILLER HE, 1968, AM J BOT, V55, P316, DOI 10.2307/2440418; NIE NH, 1975, STATISTICAL PACKAGE; PAYNE WW, 1970, T WISC ACAD SCI, V58, P353; PAYNE WW, 1972, BRITTONIA, V24, P189, DOI 10.2307/2805869; PAYNE WW, 1976, PLANT SYST EVOL, V125, P169, DOI 10.1007/BF00986149; PEDDECORD KM, 1976, J ALLERGY CLIN IMMUN, V57, P56, DOI 10.1016/0091-6749(76)90079-8; YUNGINGER JW, 1972, J ALLERGY CLIN IMMUN, V50, P326, DOI 10.1016/0091-6749(72)90036-X	21	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	5					336	339		10.1016/0091-6749(79)90128-3	http://dx.doi.org/10.1016/0091-6749(79)90128-3			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GU943	429713	Bronze			2022-12-18	WOS:A1979GU94300007
J	REISMAN, RE; WYPYCH, J; LAZELL, M; ARBESMAN, CE				REISMAN, RE; WYPYCH, J; LAZELL, M; ARBESMAN, CE			SENSITIZATION TO NON-VENOM CONTAMINANTS IN A VENOM PREPARATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY BUFFALO,DEPT MED,DIV ALLERGY,BUFFALO,NY 14214; BUFFALO GEN HOSP,ALLERGY RES LAB,BUFFALO,NY 14203	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Buffalo General Medical Center									0	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	4					281	286		10.1016/0091-6749(79)90145-3	http://dx.doi.org/10.1016/0091-6749(79)90145-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HQ469	113443				2022-12-18	WOS:A1979HQ46900009
J	SPECTOR, SL; MORRIS, HG; SELNER, JC				SPECTOR, SL; MORRIS, HG; SELNER, JC			PULMONARY, PROSTAGLANDIN, AND CLINICAL-RESPONSE OF ASTHMATIC-PATIENTS WITH ASPIRIN IDEOSYNCRASY TO A NEW NONSTEROID ANTI-INFLAMMATORY SUBSTANCE COMPARED TO ASPIRIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	3					154	155						2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GN274					2022-12-18	WOS:A1979GN27400067
J	AZINGE, NO; GARRICK, GA				AZINGE, NO; GARRICK, GA			STEVENS-JOHNSON SYNDROME (ERYTHEMA MULTIFORME) FOLLOWING INGESTION OF TRIMETHOPRIM-SULFAMETHOXAZOLE ON 2 SEPARATE OCCASIONS IN SAME PERSON - CASE-REPORT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											AZINGE, NO (corresponding author), SPECIALIST HOSP,DEPT INTERNAL MED,BENIM CITY,NIGERIA.							BEVERIDGE J, 1964, LANCET, V2, P593; BUSHBY SRM, 1971, P EUROP SOC STUDY DR, V13, P164; CARROLL OM, 1966, JAMA, V195, P674; REEVES DS, 1971, J CLIN PATHOL, V24, P430, DOI 10.1136/jcp.24.5.430; 1964, BRIT MED J, V2, P1410; 1968, POSTGRAD MED J     S, V45; 1970, POSTGRAD MED J     S, V45; 1975, J MED PHARM MKT, V3, P30; 1968, BRIT J DERMATOL, V80, P844	9	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	2					125	126		10.1016/0091-6749(78)90090-8	http://dx.doi.org/10.1016/0091-6749(78)90090-8			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FL835	670606				2022-12-18	WOS:A1978FL83500010
J	FISH, JE; KELLY, JF; PETERMAN, VI				FISH, JE; KELLY, JF; PETERMAN, VI			BRONCHO-CONSTRICTOR AEROSOL RESPONSES IN ASYMPTOMATIC ASTHMA - EFFECT OF PRECHALLENGER PULMONARY-FUNCTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	3					140	140		10.1016/0091-6749(78)90277-4	http://dx.doi.org/10.1016/0091-6749(78)90277-4			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ES173					2022-12-18	WOS:A1978ES17300038
J	FRITH, PA; RUFFIN, RE; COCKCROFT, DW; HARGREAVE, FE				FRITH, PA; RUFFIN, RE; COCKCROFT, DW; HARGREAVE, FE			COMPARISON OF PROTECTIVE EFFECT OF SCH 1000 AND FENOTEROL AGAINST BRONCHOCONSTRICTION INDUCED BY HISTAMINE AND METHACHOLINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract														Frith, Peter Anthony/0000-0003-3265-0131					0	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	3					175	175		10.1016/0091-6749(78)90395-0	http://dx.doi.org/10.1016/0091-6749(78)90395-0			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ES173					2022-12-18	WOS:A1978ES17300156
J	NEIDHART, JA; CHRISTAKIS, N; METZ, EN; BALCERZAK, SP; LOBUGLIO, AF				NEIDHART, JA; CHRISTAKIS, N; METZ, EN; BALCERZAK, SP; LOBUGLIO, AF			SKIN-TEST CONVERSION FOLLOWING TRANSFER-FACTOR - DOUBLE-BLINDED STUDY OF NORMAL INDIVIDUALS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											NEIDHART, JA (corresponding author), OHIO STATE UNIV HOSP,DEPT MED,DIV HEMATOL ONCOL,COLUMBUS,OH 43210, USA.							ARALACHAVES MP, 1967, INT ARCH ALLER A IMM, V31, P353, DOI 10.1159/000229881; BARAM P, 1966, J IMMUNOL, V97, P407; BEARMAN JE, 1964, AM REV RESPIR DIS, V90, P913; CAMPBELL DH, 1964, METHOD IMMUNOL, P69; CHASE MW, 1945, P SOC EXP BIOL MED, V59, P134, DOI 10.3181/00379727-59-15006P; LAWRENCE HS, 1956, J EXP MED, V104, P321, DOI 10.1084/jem.104.3.321; LAWRENCE HS, 1955, J CLIN INVEST, V34, P219, DOI 10.1172/JCI103075; LAWRENCE HS, 1949, P SOC EXP BIOL MED, V71, P516, DOI 10.3181/00379727-71-17242; LAWRENCE HS, 1963, T ASSOC AM PHYSICIAN, V76, P84; LAWRENCE HS, 1960, J CLIN INVEST, V39, P185, DOI 10.1172/JCI104018; LAWRENCE HS, 1971, IN VITRO METHODS CEL, P531; LEVIN AS, 1973, ANNU REV MED, V24, P175, DOI 10.1146/annurev.me.24.020173.001135; Neidhart J A, 1974, Semin Oncol, V1, P379; NEIDHART JA, 1973, CELL IMMUNOL, V9, P319, DOI 10.1016/0008-8749(73)90083-X; ODORISIO MS, 1976, CELL IMMUNOL, V23, P191, DOI 10.1016/0008-8749(76)90185-4; RAPAPORT FT, 1960, J IMMUNOL, V84, P368; RAPAPORT FT, 1960, J IMMUNOL, V84, P358; SMITH CE, 1956, 39 PUBL HLTH MON, P173; WALKER AM, 1975, CELL IMMUNOL, V15, P372, DOI 10.1016/0008-8749(75)90015-5; ZUCKERMAN KS, 1974, J CLIN INVEST, V54, P997, DOI 10.1172/JCI107841	20	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	2					115	118		10.1016/0091-6749(78)90234-8	http://dx.doi.org/10.1016/0091-6749(78)90234-8			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EL413	340492				2022-12-18	WOS:A1978EL41300008
J	NELSON, HS; BRANCH, LB				NELSON, HS; BRANCH, LB			INCIDENCE OF IGG SHORT-TERM SENSITIZING ANTIBODIES IN AN ALLERGIC POPULATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									FITZSIMONS ARMY MED CTR, ALLERGY IMMUNOL SERV, DENVER, CO 80240 USA									ASSEM E S K, 1971, Clinical Allergy, V1, P353, DOI 10.1111/j.1365-2222.1971.tb00786.x; ASSEM ESK, 1976, CLIN EXP IMMUNOL, V26, P67; ASSEM ESK, 1972, MECHANISMS DRUG ALLE, P112; AUGUSTIN R, 1967, HDB EXPT IMMUNOLOGY, P42; BLOCH KJ, 1971, BIOCHEMISTRY ACUTE A, P45; BRYANT DH, 1975, J ALLERGY CLIN IMMUN, V56, P417, DOI 10.1016/0091-6749(75)90060-3; BRYANT DH, 1973, BRIT MED J, V4, P589, DOI 10.1136/bmj.4.5892.589; FLICK JA, 1972, BACTERIOL REV, V36, P311, DOI 10.1128/MMBR.36.3.311-360.1972; ISHIZAKA T, 1975, PROG ALLERGY, V19, P60, DOI 10.1159/000313384; ISHIZAKA T, 1969, J IMMUNOL, V102, P884; ISHIZAKA T, 1972, J IMMUNOL, V108, P513; ISHIZAKA T, 1970, J IMMUNOL, V104, P854; IZHIZAKA T, 1972, J IMMUNOL, V108, P1000; LICHTENSTEIN LM, 1970, IMMUNOLOGY, V19, P831; MALLEY A, 1974, INT ARCH ALLER A IMM, V47, P194, DOI 10.1159/000231213; PARISH WE, 1974, 9TH P EUR C ALL CLIN, P153; PARISH WE, 1973, ASTHMA PHYSIOLOGY IM, pCH6; PAUL W, 1969, CLIN EXP IMMUNOL, V5, P311; REID RT, 1970, J IMMUNOL, V104, P935; STANWORTH DR, 1972, LANCET, V2, P491; VANSELOW NA, 1967, MANUAL CLINICAL ALLE	21	12	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	4					266	270		10.1016/0091-6749(77)90142-7	http://dx.doi.org/10.1016/0091-6749(77)90142-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DX458	409752				2022-12-18	WOS:A1977DX45800012
J	ROBINSON, LD; WOOTEN, SK; MILLER, ME				ROBINSON, LD; WOOTEN, SK; MILLER, ME			PARTIAL CHARACTERIZATION OF INVIVO CHEMOTACTIC ACTIVITY - COMPARISON TO HUMAN C5A	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHARLES R DREW POSTGRAD MED SCH,LOS ANGELES,CA 90059; MARTIN LUTHER KING JR GEN HOSP,LOS ANGELES,CA 90059; UNIV CALIF LOS ANGELES,HARBOR GEN HOSP,SCH MED,TORRANCE,CA 90509	Charles R. Drew University of Medicine & Science; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								COLOWICK SP, 1967, METHODS ENZYMOLOGY, V11, P650; DAY RP, 1970, IMMUNOLOGY, V18, P955; FERNANDEZ H, 1975, NOV COMPL WORKSH; GOLDSTEIN IM, 1975, J IMMUNOL, V115, P665; GRANT JA, 1975, J IMMUNOL, V114, P1101; HOOK WA, 1975, J IMMUNOL, V114, P1185; KAY AB, 1973, IMMUNOLOGY, V24, P969; Maurer H. R., 1971, DISC ELECTROPHORESIS, P41; NORMAN ME, 1974, J PEDIATR-US, V85, P20, DOI 10.1016/S0022-3476(74)80278-7; RAMSEY WS, 1974, INFLAMMATORY PROCESS, V2, P323; ROBINSON LD, 1975, J ALLERGY CLIN IMMUN, V56, P317, DOI 10.1016/0091-6749(75)90106-2; SNYDERMAN R, 1969, J IMMUNOL, V103, P413; VALLOTA EH, 1973, J EXP MED, V137, P1109, DOI 10.1084/jem.137.5.1109; WARD PA, 1971, J CLIN INVEST, V50, P606, DOI 10.1172/JCI106531	14	12	12	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	5					353	358		10.1016/0091-6749(77)90017-3	http://dx.doi.org/10.1016/0091-6749(77)90017-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DF215	856901	Bronze			2022-12-18	WOS:A1977DF21500003
J	TOOGOOD, JH; BASKERVILLE, J; ERRINGTON, N; JENNINGS, B; CHUANG, L; LEFCOE, N				TOOGOOD, JH; BASKERVILLE, J; ERRINGTON, N; JENNINGS, B; CHUANG, L; LEFCOE, N			DETERMINANTS OF RESPONSE TO BECLOMETHASONE AEROSOL AT VARIOUS DOSAGE LEVELS - MULTIPLE-REGRESSION ANALYSIS TO IDENTIFY CLINICALLY USEFUL PREDICTORS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WESTERN ONTARIO,DEPT MED,LONDON N6A 3K7,ONTARIO,CANADA; UNIV WESTERN ONTARIO,DEPT MATH,LONDON N6A 3K7,ONTARIO,CANADA; VICTORIA HOSP,LONDON,ONTARIO,CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario); University of Victoria; Western University (University of Western Ontario)								BROOKS SM, 1972, NEW ENGL J MED, V286, P1125, DOI 10.1056/NEJM197205252862103; BURBANK F, 1969, AM J MED, V46, P401, DOI 10.1016/0002-9343(69)90042-4; CHAMPION P, 1975, CAN MED ASSOC J, V113, P213; DRAPER NR, 1966, APPLIED REGRESSION A; FALLIERS CJ, 1976, J ALLERGY CLIN IMMUN, V57, P1, DOI 10.1016/0091-6749(76)90073-7; FRANCIS RS, 1976, THORAX, V31, P309, DOI 10.1136/thx.31.3.309; GRANT IWB, 1975, POSTGRAD MED J, V51, P57; HERXHEIMER H, 1973, LANCET, V1, P374; JOHANNESSEN H, 1975, CURR THER RES CLIN E, V18, P559; KENNEDY MCS, 1975, POSTGRAD MED J, V51, P84; MACKAY JB, 1975, POSTGRAD MED J, V51, P37; MARTIN LE, 1975, POSTGRAD MED J, V51, P11; MELLIS CM, 1977, THORAX, V32, P29, DOI 10.1136/thx.32.1.29; MINTZ S, 1975, POSTGRAD MED J, V51, P76; Morrow-Brown H., 1972, BRIT MED J, V1, P585; Sackett DL, 1976, COMPLIANCE THERAPEUT; STONE M, 1974, J R STAT SOC B, V36, P111, DOI 10.1111/j.2517-6161.1974.tb00994.x; THOMAS P, 1976, ANN R COLL PHYS SURG, V9, P12; TOOGOOD JH, 1973, CHEST, V63, P881, DOI 10.1378/chest.63.6.881; TOOGOOD JH, 1977, J ALLERGY CLIN IMMUN, V59, P298, DOI 10.1016/0091-6749(77)90051-3; VANDENBERG R, 1975, MED J AUSTRALIA, V1, P189, DOI 10.5694/j.1326-5377.1975.tb111324.x; VEREERSTRAETENSCHMERBER J, 1976, CURR THER RES CLIN E, V19, P363; VOGHT F, 1976, J ALLERGY CLIN IMMUN, V58, P316; 1976, BRIT J DIS CHEST, V70, P95; 1975, LANCET, V2, P469; 1969, COMMITTEE STANDARDS	26	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	6					367	376		10.1016/0091-6749(77)90068-9	http://dx.doi.org/10.1016/0091-6749(77)90068-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ED834	925261				2022-12-18	WOS:A1977ED83400006
J	KIECHEL, F; POLLACK, J; COOPER, D; WEINBERGER, M				KIECHEL, F; POLLACK, J; COOPER, D; WEINBERGER, M			COMPARATIVE EFFICACY OF THEOPHYLLINE (T) AND CROMOLYN (C) IN SUPPRESSING EXERCISE-INDUCED BRONCHOSPASM (EIB)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	3					250	250						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BJ240					2022-12-18	WOS:A1976BJ24000148
J	LEHRER, SB; VAUGHAN, JH				LEHRER, SB; VAUGHAN, JH			PROPERTIES OF MOUSE HOMOCYTOTROPIC AND HETEROCYTOTROPIC ANTIBODIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SCRIPPS CLIN & RES FDN,DEPT CLIN RES,DIV ALLERGY & IMMUNOL,LA JOLLA,CA 92037	Scripps Research Institute								BACH MK, 1973, IMMUNOL COMMUN, V2, P85, DOI 10.3109/08820137309022884; BLOCH KJ, 1967, PROG ALLERGY, V10, P84; CLAUSEN CR, 1969, J IMMUNOL, V103, P768; KIND LS, 1974, J IMMUNOL, V112, P1609; KONIG W, 1974, J IMMUNOL, V112, P1652; LEHRER SB, 1975, INT ARCH ALLER A IMM, V49, P796, DOI 10.1159/000231464; LEHRER SB, 1974, J IMMUNOL, V113, P18; LEHRER SB, 1975, J IMMUNOL, V114, P34; LEVINE BB, 1970, INT ARCH ALLER A IMM, V39, P156, DOI 10.1159/000230343; MCCAMISH J, 1967, NATURE, V214, P1228, DOI 10.1038/2141228a0; MOTA I., 1966, LIFE SCI, V5, P1723, DOI 10.1016/0024-3205(66)90108-1; MOTA I, 1969, LIFE SCI PT 1 PHYSI, V8, P813, DOI 10.1016/0024-3205(69)90099-X; MOTA I, 1968, LIFE SCI PT 1 PHYSI, V7, P1289, DOI 10.1016/0024-3205(68)90258-0; NEWBURGER PE, 1974, J IMMUNOL, V113, P824; NUSSENZWEIG RS, 1964, J EXP MED, V120, P315, DOI 10.1084/jem.120.2.315; OKUDAIRA H, 1973, J IMMUNOL, V111, P1420; ONKELINX E, 1969, IMMUNOLOGY, V16, P35; OVARY Z, 1975, INT ARCH ALLER A IMM, V48, P16, DOI 10.1159/000231289; OVARY Z, 1972, J IMMUNOL, V108, P1055; OVARY Z, 1965, FED PROC, V24, P94; PROUVOSTDANON A, 1972, IMMUNOLOGY, V23, P481; SCHWARTZ HA, 1973, J IMMUNOL, V110, P1638; WILLIAMS MR, 1974, IMMUNOLOGY, V27, P271	23	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	5					422	429		10.1016/0091-6749(76)90057-9	http://dx.doi.org/10.1016/0091-6749(76)90057-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BR201	1262614				2022-12-18	WOS:A1976BR20100005
J	MURPHEY, SM; WHITE, C; WATERS, T; FIREMAN, P				MURPHEY, SM; WHITE, C; WATERS, T; FIREMAN, P			REAGIN SYNTHESIS IN INBRED RATS .2. GENETIC-CONTROL OF REAGINIC ANTIBODY-SYNTHESIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS HOSP,PITTSBURGH,PA 15213; UNIV PITTSBURGH,SCH MED,DEPT PEDIAT,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								BENACERR.B, 1972, SCIENCE, V175, P273, DOI 10.1126/science.175.4019.273; BINAGHI RA, 1966, INT ARCH ALLER A IMM, V29, P105, DOI 10.1159/000229692; BINAGHI RA, 1964, J IMMUNOL, V92, P920; DORF ME, 1974, J IMMUNOL, V112, P1329; GILL TJ, 1970, J IMMUNOL, V105, P14; GILL TJ, 1971, J IMMUNOL, V106, P980; GILL TJ, 1974, J IMMUNOGENET, V1, P413; JARRETT E, 1974, NATURE, V251, P613, DOI 10.1038/251613a0; JARRETT EEE, 1974, IMMUNOLOGY, V27, P365; JOHNSON N, 1964, STATISTICS EXPT DESI, V1, P161; LEVINE BB, 1972, SCIENCE, V178, P1201, DOI 10.1126/science.178.4066.1201; LEVINE BB, 1970, INT ARCH ALLER A IMM, V39, P156, DOI 10.1159/000230343; MARSH DG, 1973, SCIENCE, V179, P691, DOI 10.1126/science.179.4074.691; MOTA I, 1964, IMMUNOLOGY, V7, P681; MURPHEY SM, 1974, IMMUNOLOGY, V27, P245; OKUMURA K, 1971, J IMMUNOL, V106, P1019; ORR TSC, 1972, IMMUNOLOGY, V22, P211; STAVITSKY AB, 1954, J IMMUNOL, V72, P360; TADA T, 1971, J IMMUNOL, V106, P1012; VAZ EM, 1971, IMMUNOLOGY, V21, P11; VAZ NM, 1971, J EXP MED, V134, P1335, DOI 10.1084/jem.134.5.1335; YOO TJ, 1974, FED P FED AM SOC EXP, V33, P74	22	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	3					381	386		10.1016/0091-6749(76)90118-4	http://dx.doi.org/10.1016/0091-6749(76)90118-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD454	965617				2022-12-18	WOS:A1976CD45400004
J	REISS, NM; KOSTIC, SR				REISS, NM; KOSTIC, SR			POLLEN SEASON SEVERITY AND METEOROLOGIC PARAMETERS IN CENTRAL NEW-JERSEY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									RUTGERS STATE UNIV COOK COLL, DEPT METEROL & PHYS OCEANOG, NEW BRUNSWICK, NJ 08903 USA	Rutgers State University New Brunswick								DAVIES RR, 1973, CLIN ALLERGY, V3, P477, DOI 10.1111/j.1365-2222.1973.tb01332.x; DURHAM OC, 1932, J ALLERGY, V3, P58; OGDEN EC, 1967, J ALLERGY, V40, P1, DOI 10.1016/0021-8707(67)90053-6; RAYNOR GS, 1970, ANN ALLERGY, V28, P580; Scheppegrell W, 1917, ARCH INTERN MED, V19, P959	5	12	12	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	6					609	614		10.1016/0091-6749(76)90013-0	http://dx.doi.org/10.1016/0091-6749(76)90013-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BV054	932344				2022-12-18	WOS:A1976BV05400013
J	ZUSKIN, E; BOUHUYS, A				ZUSKIN, E; BOUHUYS, A			PROTECTIVE EFFECT OF DISODIUM-CROMOGLYCATE AGAINST AIRWAY CONSTRICTION INDUCED BY HEMP DUST EXTRACT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									YALE UNIV,CTR LUNG RES,NEW HAVEN,CT 06510	Yale University								ALTOUNYAN RE, 1967, ACTA ALLERGOL, V22, P487; BOUHUYS A, 1960, BMJ-BRIT MED J, V1, P324, DOI 10.1136/bmj.1.5169.324; BOUHUYS A, 1973, T NEW YORK ACAD SCI, V35, P537, DOI 10.1111/j.2164-0947.1973.tb01526.x; BOUHUYS A, 1963, CLIN PHARMACOL THER, V4, P311; BOUHUYS A, 1970, J CLIN INVEST, V49, P106, DOI 10.1172/JCI106209; CADE JF, 1971, CLIN SCI, V40, P381, DOI 10.1042/cs0400381; COX J S G, 1971, British Journal of Diseases of the Chest, V65, P189, DOI 10.1016/0007-0971(71)90028-3; EGGLESTON PA, 1972, J ALLERGY CLIN IMMUN, V50, P57, DOI 10.1016/0091-6749(72)90079-6; GRIECO MH, 1972, CHEST, V61, P432, DOI 10.1378/chest.61.5.432; HITCHCOCK M, 1973, ARCH ENVIRON HEALTH, V26, P177, DOI 10.1080/00039896.1973.10666252; KOLOTKIN BM, 1974, J ALLERGY CLIN IMMUN, V53, P288, DOI 10.1016/0091-6749(74)90108-0; MANSELL A, 1974, J APPL PHYSIOL, V37, P297, DOI 10.1152/jappl.1974.37.3.297; PATERSON N A M, 1973, British Journal of Diseases of the Chest, V67, P197, DOI 10.1016/0007-0971(73)90054-5; Pepys J, 1972, Clin Allergy, V2, P391, DOI 10.1111/j.1365-2222.1972.tb01303.x; PEPYS J, 1972, Clinical Allergy, V2, P197, DOI 10.1111/j.1365-2222.1972.tb01283.x; RYO UY, 1971, J ALLERGY, V47, P96; STANESCU DC, 1973, B PHYSIO-PATHOL RESP, V9, P523; TOWNLEY RG, 1973, J ALLERGY CLIN IMMUN, V51, P121, DOI 10.1016/S0091-6749(73)80092-2; VALIC F, 1971, ARCH ENVIRON HEALTH, V23, P359, DOI 10.1080/00039896.1971.10666021; VALIC F, 1973, BRIT J IND MED, V30, P381; VIRGULTO J, 1973, J APPL PHYSIOL, V35, P145, DOI 10.1152/jappl.1973.35.1.145; ZUSKIN E, 1974, PHARMACOLOGIST, V16, P300; ZUSKIN E, 1975, 8 INT C VLISS	23	12	12	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	5					473	479		10.1016/0091-6749(76)90063-4	http://dx.doi.org/10.1016/0091-6749(76)90063-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BR201	816842	Bronze			2022-12-18	WOS:A1976BR20100011
J	HEINER, DC; NEUCERE, NJ				HEINER, DC; NEUCERE, NJ			RAST ANALYSES OF PEANUT ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	12	14	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	2					82	83						2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	V5498					2022-12-18	WOS:A1975V549800034
J	KLAUSTERMEYER, WB; DIBERNARDO, RL; HALE, FC				KLAUSTERMEYER, WB; DIBERNARDO, RL; HALE, FC			INTRAVENOUS ISOPROTERENOL - RATIONALE FOR BRONCHIAL-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WADSWORTH VET ADM HOSP,DEPT MED,LOS ANGELES,CA; WADSWORTH VET ADM HOSP CTR,CHEST ALLERGY SECT,LOS ANGELES,CA 90073; UNIV CALIF,SCH MED,LOS ANGELES,CA	University of California System; University of California Los Angeles								AHLQUIST RP, 1948, AM J PHYSIOL, V153, P586, DOI 10.1152/ajplegacy.1948.153.3.586; BUTTERWORTH KR, 1963, BRIT J PHARM CHEMOTH, V21, P378, DOI 10.1111/j.1476-5381.1963.tb01536.x; COLLINS JM, 1969, BRIT J PHARMACOL, V36, P35, DOI 10.1111/j.1476-5381.1969.tb08301.x; CONWAY WD, 1968, J PHARM SCI-US, V57, P1135, DOI 10.1002/jps.2600570710; CROMPTON GK, 1968, THORAX, V23, P46, DOI 10.1136/thx.23.1.46; DAIRS DJ, 1972, J ALLERGY, V49, P323; DULFANO MJ, 1968, ANN INTERN MED, V68, P955, DOI 10.7326/0003-4819-68-4-955; FORDHAM RMM, 1968, THORAX, V23, P19, DOI 10.1136/thx.23.1.19; HOUSTON JC, 1953, THORAX, V8, P207, DOI 10.1136/thx.8.3.207; INGRAM RH, 1970, AM REV RESPIR DIS, V101, P364; KEIGHLEY JF, 1966, ANN INTERN MED, V65, P985, DOI 10.7326/0003-4819-65-5-985; KNUDSON RJ, 1967, J APPL PHYSIOL, V22, P405; LOWELL FC, 1949, NEW ENGL J MED, V240, P45, DOI 10.1056/NEJM194901132400201; REES HA, 1968, Q J MED, V37, P541; TAI E, 1967, LANCET, V1, P644; VANMETRE TE, 1969, J ALLERGY, V43, P101, DOI 10.1016/0021-8707(69)90130-0; WOOD DW, 1972, J ALLERGY CLIN IMMUN, V50, P75, DOI 10.1016/0091-6749(72)90002-4	17	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	5					325	333		10.1016/0091-6749(75)90004-4	http://dx.doi.org/10.1016/0091-6749(75)90004-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AB754	1120852				2022-12-18	WOS:A1975AB75400004
J	SCHWARTZ, LW; OSBURN, BI; FRICK, OL				SCHWARTZ, LW; OSBURN, BI; FRICK, OL			ONTOGENIC STUDY OF HISTAMINE AND MAST-CELLS IN FETAL RHESUS-MONKEY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF,SCH VET MED,DEPT PATHOL,DAVIS,CA; UNIV CALIF,DEPT PEDIAT,SAN FRANCISCO,CA; UNIV CALIF,PRIMATE RES CTR,DAVIS,CA 95616	University of California System; University of California Davis; University of California System; University of California San Francisco; University of California System; University of California Davis								CAREY T. NELSON, 1934, JOUR ALLERGY, V5, P488, DOI 10.1016/S0021-8707(34)90248-3; COWAN A, 1972, COMPARATIVE, V3, P75, DOI 10.1016/0010-4035(72)90043-2; DIXON JB, 1960, J PATHOL BACTERIOL, V80, P73, DOI 10.1002/path.1700800109; DIXON JB, 1959, J PHYSIOL-LONDON, V147, P144, DOI 10.1113/jphysiol.1959.sp006229; KAHLSON G, 1962, PERSPECT BIOL MED, V5, P179; KAHLSON G, 1960, LANCET, V1, P67; KAHLSON G, 1959, J PHYSIOL, V145, P30; LINDBERG S, 1963, Acta Obstet Gynecol Scand Suppl, V42(Suppl 1), P49; MALLEY A, 1968, J IMMUNOL, V100, P915; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MENG AL, 1973, J IMMUNOL, V110, P1554; RILEY JF, 1953, J PHYSIOL-LONDON, V120, P528, DOI 10.1113/jphysiol.1953.sp004915; ROCHAESILVA M, 1940, NATURE, P591; SCHWARTZ LW, 1974, LAB INVEST, V31, P441; SCHWARTZ LW, 1974, AM J PATHOL, V74, pA24; SCHWARTZ LW, 1974, FED PROC, V33, P604; ZACHARIAE H, 1964, P SOC EXP BIOL MED, V7, P63	17	12	12	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	5					381	386		10.1016/0091-6749(75)90131-1	http://dx.doi.org/10.1016/0091-6749(75)90131-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW330	810507				2022-12-18	WOS:A1975AW33000007
J	KOPETZKY, MT; MASELLI, R; ELLIS, EF				KOPETZKY, MT; MASELLI, R; ELLIS, EF			PULMONARY-FUNCTION STUDIES WITH SIMPLE EQUIPMENT IN 323 NORMAL CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL JEWISH HOSP & RES CTR,3800 E COLFAX AVE,DENVER,CO 80206	National Jewish Health								CHAI H, 1968, J ALLERGY, V41, P23, DOI 10.1016/0021-8707(68)90005-1; CHERNIACK RM, 1962, CAN MED ASSOC J, V87, P80; DEMUTH GR, 1965, AM J DIS CHILD, V109, P443, DOI 10.1001/archpedi.1965.02090020445012; DUGDALE AE, 1968, ARCH DIS CHILD, V43, P229, DOI 10.1136/adc.43.228.229; ENGSTROM I, 1956, ACTA PAEDIATR, V46, P277; HARDEN KA, 1965, AM REV RESPIR DIS, V91, P869; HELLIESEN PJ, 1958, PEDIATRICS, V22, P80; MURRAY AB, 1963, J PEDIATR-US, V62, P186, DOI 10.1016/S0022-3476(63)80390-X; NAIRN JR, 1961, ARCH DIS CHILD, V36, P253, DOI 10.1136/adc.36.187.253; SCHILDER DP, 1963, J CLIN INVEST, V42, P1705, DOI 10.1172/JCI104856; STRANG L B, 1959, Thorax, V14, P305, DOI 10.1136/thx.14.4.305; WENG TR, 1969, AM REV RESPIR DIS, V99, P879; WRIGHT BM, 1959, BRIT MED J, V2, P1041, DOI 10.1136/bmj.2.5159.1041	13	12	13	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	1					1	8		10.1016/0091-6749(74)90093-1	http://dx.doi.org/10.1016/0091-6749(74)90093-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R8075	4808778				2022-12-18	WOS:A1974R807500001
J	MURANAKA, M; IGARASHI, H; KOIZUMI, K; OKUMURA, H; TAKEDA, K; SUZUKI, S				MURANAKA, M; IGARASHI, H; KOIZUMI, K; OKUMURA, H; TAKEDA, K; SUZUKI, S			ELICITATION OF HOMOLOGOUS PASSIVE CUTANEOUS ANAPHYLACTIC REACTIONS BY A BENZYLPENICILLIN PREPARATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TOKYO,FAC MED,DEPT MED & PHYS THERAPY,7-3-1 HONGO,BUNKYO,TOKYO,JAPAN	University of Tokyo								ATSUMI T, 1967, J IMMUNOL, V99, P1286; BATCHELOR FR, 1967, LANCET, V1, P1175; BENACERRAF B, 1963, J EXP MED, V117, P937, DOI 10.1084/jem.117.6.937; BLOCH KJ, 1967, PROG ALLERGY, V10, P84; BUTCHER BT, 1970, PENICILLIN ALLERGY C, P111; DEWECK AL, 1968, INT ARCH ALLER A IMM, V33, P535, DOI 10.1159/000230070; IGARASHI H, 1973, EXCERPTA MED INT 300, P61; IGARASHI H, 1973, 3 P ANN M JAP SOC IM, P34; KOIZUMI K, 1973, JAP J ALLERGY, V22, P627; LEVINE BB, 1969, INT ARCH ALLER A IMM, V35, P445, DOI 10.1159/000230197; LEVINE BB, 1971, J IMMUNOL, V106, P29; LEVINE BB, 1964, IMMUNOLOGY, V7, P527; LEVINE BB, 1970, INT ARCH ALLER A IMM, V39, P156, DOI 10.1159/000230343; LEVINE BB, 1962, J MED PHARMACEUT CH, V5, P1025, DOI 10.1021/jm01240a016; MURANAKA M, 1970, J ALLERGY, V46, P138, DOI 10.1016/0021-8707(70)90092-4; MURANAKA M, 1973, ACTA ALLERGOL, V28, P50, DOI 10.1111/j.1398-9995.1973.tb02565.x; MURANAKA M, 1969, JAPAN J ALLERGOLOGY, V18, P562; MURANAKA M, 1967, JAP J ALLERGY, V16, P36; OVARY Z, 1960, J IMMUNOL, V84, P409; OVARY Z, 1964, IMMUNOLOGICAL METHOD, P259; ROUPE G, 1971, BRIT J DERMATOL, V84, P330, DOI 10.1111/j.1365-2133.1971.tb14228.x; STEWART GT, 1967, LANCET, V1, P1177	22	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	54	6					329	338		10.1016/0091-6749(74)90023-2	http://dx.doi.org/10.1016/0091-6749(74)90023-2			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U9288					2022-12-18	WOS:A1974U928800001
J	ISHIZAKA, T; SOTO, CS; ISHIZAKA, K				ISHIZAKA, T; SOTO, CS; ISHIZAKA, K			BINDING OF IGE MOLECULES ON HUMAN BASOPHILS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	51	2					79	79		10.1016/S0091-6749(73)80005-3	http://dx.doi.org/10.1016/S0091-6749(73)80005-3			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	O7913					2022-12-18	WOS:A1973O791300005
J	REISMAN, RE				REISMAN, RE			STINGING INSECT ALLERGY - TREATMENT FAILURES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material									AMER ACAD ALLERGY,INSECT COMMITTEE,BUFFALO,NY 14200										0	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	52	5					257	258		10.1016/0091-6749(73)90043-2	http://dx.doi.org/10.1016/0091-6749(73)90043-2			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R2087	4746789				2022-12-18	WOS:A1973R208700001
J	SEABURY, J; SALVAGGIO, J; DOMER, J; FINK, J; KAWAI, T				SEABURY, J; SALVAGGIO, J; DOMER, J; FINK, J; KAWAI, T			CHARACTERIZATION OF THERMOPHILIC ACTINOMYCETES ISOLATED FROM RESIDENTIAL HEATING AND HUMIDIFICATION SYSTEMS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MED COLL WISCONSIN, MILWAUKEE, WI 53706 USA	Medical College of Wisconsin								BANASZAK EF, 1970, NEW ENGL J MED, V283, P271, DOI 10.1056/NEJM197008062830601; BARBORIAK JJ, 1972, J ALLERGY CLIN IMMUN, V49, P81, DOI 10.1016/0091-6749(72)90059-0; BECKER B, 1965, APPL MICROBIOL, V13, P236, DOI 10.1128/AEM.13.2.236-243.1965; COULSON RA, 1965, ANAL BIOCHEM, V10, P159, DOI 10.1016/0003-2697(65)90250-2; CROSS T, 1968, J GEN MICROBIOL, V50, P351, DOI 10.1099/00221287-50-3-351; DE VRIES G. A., 1960, ACTA ALLERGOL, V15, P99; FINK JN, 1971, APPL MICROBIOL, V22, P730, DOI 10.1128/AEM.22.4.730-731.1971; FINK JN, 1971, ANN INTERN MED, V74, P80, DOI 10.7326/0003-4819-74-1-80; FLINT DR, 1965, J AM OIL CHEM SOC, V42, P1001, DOI 10.1007/BF02632464; HOARE DS, 1957, BIOCHEM J, V65, P441, DOI 10.1042/bj0650441; KAWAI T, 1972, J ALLERGY CLIN IMMUN, V49, P134; KRAEGER SJ, 1969, J CHROMATOGR, V41, P113, DOI 10.1016/0021-9673(64)80105-9; KRASSILNIKOV NA, 1961, IZV AN SSSR BIOL+, P107; KUSTER E, 1964, INT B BACT NOMENCL T, V14, P109, DOI 10.1099/0096266X-14-3-109; LECHEVALIER HA, 1967, ANNU REV MICROBIOL, V21, P76; LECHEVALIER MP, 1968, J LAB CLIN MED, V71, P934; LEUDEMANN GM, 1971, T NY ACAD SCI, V33, P2; LUEDEMANN GM, 1971, T NEW YORK ACAD SCI, V33, P207, DOI 10.1111/j.2164-0947.1971.tb02586.x; SALVAGGIO J, 1969, AM J MED, V46, P538, DOI 10.1016/0002-9343(69)90073-4; SEABURY J, 1968, P SOC EXP BIOL MED, V129, P351, DOI 10.3181/00379727-129-33319; SHIRLING E. B., 1966, INT J SYST BACTERIOL, V16, P313; SWEELEY CC, 1963, J AM CHEM SOC, V85, P2497, DOI 10.1021/ja00899a032; SWEET LC, 1971, J ALLERGY CLIN IMMUN, V48, P171, DOI 10.1016/0091-6749(71)90013-3; TOURVILLE DR, 1972, J ALLERGY CLIN IMMUN, V49, P245, DOI 10.1016/0091-6749(72)90087-5; WAKSMAN SA, 1967, ACTINOMYCETALES SUMM, P66; WALBAUM S, 1969, ANN I PASTEUR PARIS, V117, P673; WILLIAMS S, 1968, IDENTIFICATION MET B, P112; YAMAGUCHI T, 1965, J BACTERIOL, V89, P444, DOI 10.1128/JB.89.2.444-453.1965	28	12	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	51	3					161	173		10.1016/0091-6749(73)90021-3	http://dx.doi.org/10.1016/0091-6749(73)90021-3			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P0896	4631664				2022-12-18	WOS:A1973P089600004
J	BARBORIAK, JJ; SCRIBNER, G; FINK, JN				BARBORIAK, JJ; SCRIBNER, G; FINK, JN			IMMUNOLOGICAL CROSS-REACTIONS OF THERMOPHILIC ACTINOMYCETES ISOLATED FROM HOME ENVIRONMENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note																		BANASZAK EF, 1970, NEW ENGL J MED, V283, P271, DOI 10.1056/NEJM197008062830601; BARBORIAK JJ, 1965, J LAB CLIN MED, V65, P600; FINK JN, 1968, J LAB CLIN MED, V71, P20; FINK JN, 1968, ANN INTERN MED, V68, P1205, DOI 10.7326/0003-4819-68-6-1205; FINK JN, 1971, ANN INTERN MED, V74, P80, DOI 10.7326/0003-4819-74-1-80; KABAT EA, 1961, EXPERIMENTAL IMMUNOC, P476; PEPYS J, 1963, LANCET, V2, P607; SAKULA A, 1967, BRIT MED J, V3, P708, DOI 10.1136/bmj.3.5567.708; SALVAGGIO JE, 1967, J ALLERGY, V39, P106; SWEET LC, 1971, J ALLERGY CLIN IMMUN, V48, P171, DOI 10.1016/0091-6749(71)90013-3; WEISS NS, 1971, ANN ALLERGY, V29, P154; WEISS WI, 1971, J ALLERGY, V47, P113; WENZEL FJ, 1967, AM REV RESPIR DIS, V95, P652	13	12	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	49	2					81	+		10.1016/0091-6749(72)90059-0	http://dx.doi.org/10.1016/0091-6749(72)90059-0			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	L5997	4621501	Bronze			2022-12-18	WOS:A1972L599700003
J	LOWNEY, ED				LOWNEY, ED			TOLERANCE OF DINITROCHLOROBENZENE, A CONTACT SENSITIZER, IN MAN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		BAER H, 1970, J IMMUNOL, V104, P178; BOWSER RT, 1963, J IMMUNOL, V91, P791; BRANDRISS MW, 1970, J IMMUNOL, V105, P1416; CHASE MW, 1946, P SOC EXP BIOL MED, V61, P257; COE JE, 1963, J EXP MED, V117, P401, DOI 10.1084/jem.117.3.401; FELDMANN RJ, 1970, J INVEST DERMATOL, V54, P399, DOI 10.1111/1523-1747.ep12259184; LOWNEY ED, 1965, J INVEST DERMATOL, V45, P378, DOI 10.1038/jid.1965.146; LOWNEY ED, 1968, J INVEST DERMATOL, V50, P244, DOI 10.1038/jid.1968.35; LOWNEY ED, 1968, J INVEST DERMATOL, V51, P411, DOI 10.1038/jid.1968.149; LOWNEY ED, 1970, J INVEST DERMATOL, V54, P355, DOI 10.1111/1523-1747.ep12259047; LOWNEY ED, 1967, J INVEST DERMATOL, V48, P391, DOI 10.1038/jid.1967.62; LOWNEY EDMUND D., 1965, J IMMUNOL, V95, P397; MACHER E, 1969, J EXP MED, V129, P103, DOI 10.1084/jem.129.1.103; MASON MS, 1954, J INVEST DERM, V22, P457; POMERANZ JR, 1970, J IMMUNOL, V104, P1486; Sulzberger MB, 1929, ARCH DERMATOL SYPH, V20, P669, DOI 10.1001/archderm.1929.01440050079007; WECK ALD, 1966, MONOGR ALLERG, V1, P1	17	12	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	1					28	&		10.1016/0091-6749(71)90052-2	http://dx.doi.org/10.1016/0091-6749(71)90052-2			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J8503	5282886	Bronze			2022-12-18	WOS:A1971J850300005
J	Pivniouk, V; Gimenes, JA; Ezeh, P; Michael, A; Pivniouk, O; Hahn, S; VanLinden, SR; Malone, SP; Abidov, A; Anderson, D; Gozdz, J; DeVries, A; Martinez, FD; Pasquali, C; Vercelli, D				Pivniouk, Vadim; Gimenes-Junior, Joao A., Jr.; Ezeh, Peace; Michael, Ashley; Pivniouk, Oksana; Hahn, Seongmin; VanLinden, Sydney R.; Malone, Sean P.; Abidov, Amir; Anderson, Dayna; Gozdz, Justyna; DeVries, Avery; Martinez, Fernando D.; Pasquali, Christian; Vercelli, Donata			Airway administration of OM-85, a bacterial lysate, blocks experimental asthma by targeting dendritic cells and the epithelium/IL-33/ILC2 axis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Bacterial lysate; microbial interventions; OM-85; asthma; allergic inflammation; airway compartment; intranasal route; innate immunity; adaptive immunity	RESPIRATORY-TRACT; INNATE IMMUNITY; T-CELLS; ALTERNARIA; MICROBIOTA; INFLAMMATION; INFECTIONS; PREVENTION; PREGNANCY; EXPOSURE	Background: Microbial interventions against allergic asthma have robust epidemiologic underpinnings and the potential to recalibrate disease-inducing immune responses. Oral administration of OM-85, a standardized lysate of human airways bacteria, is widely used empirically to prevent respiratory infections and a clinical trial is testing its ability to prevent asthma in high-risk children. We previously showed that intranasal administration of microbial products from farm environments abrogates experimental allergic asthma. Objectives: We sought to investigate whether direct administration of OM-85 to the airway compartment protects against experimental allergic asthma; and to identify protective cellular and molecular mechanisms activated through this natural route. Methods: Different strains of mice sensitized and challenged with ovalbumin or Alternaria received OM-85 intranasally, and cardinal cellular and molecular asthma phenotypes were measured. Airway transfer experiments assessed whether OM-85-treated dendritic cells protect allergen-sensitized, OM-85-naive mice against asthma. Results: Airway OM-85 administration suppressed allergic asthma in all models acting on multiple innate and adaptive immune targets: the airway epithelium/IL-33/ILC2 axis, lung allergen-induced type 2 responses, and dendritic cells whose Myd88/Trif-dependent tolerogenic reprogramming was sufficient to transfer OM-85-induced asthma protection. Conclusions: We provide the first demonstration that administering a standardized bacterial lysate to the airway compartment protects from experimental allergic asthma by engaging multiple immune pathways. Because protection required a cumulative dose 27-to 46-fold lower than the one reportedly active through the oral route, the efficacy of intranasal OM-85 administration may reflect its direct access to the airway mucosal networks controlling the initiation and development of allergic asthma.	[Pivniouk, Vadim; Vercelli, Donata] Univ Arizona, Dept Cellular & Mol Med, Tucson, AZ USA; [Pivniouk, Vadim; Gimenes-Junior, Joao A., Jr.; Ezeh, Peace; Michael, Ashley; Pivniouk, Oksana; Hahn, Seongmin; VanLinden, Sydney R.; Malone, Sean P.; Anderson, Dayna; Gozdz, Justyna; DeVries, Avery; Martinez, Fernando D.; Vercelli, Donata] Univ Arizona, Asthma & Airway Dis Res Ctr, Tucson, AZ USA; [Pivniouk, Vadim; DeVries, Avery; Martinez, Fernando D.; Vercelli, Donata] Univ Arizona, BIOS Inst, Tucson, AZ USA; [Abidov, Amir] Univ Arizona, Med Student Res Program, Coll Med, Tucson, AZ USA; [Vercelli, Donata] Univ Arizona, Arizona Ctr Biol Complex Dis, Tucson, AZ USA; [Pasquali, Christian] OM Pharma SA, Geneva, Switzerland	University of Arizona; University of Arizona; University of Arizona; University of Arizona; University of Arizona	Pivniouk, V (corresponding author), BIO5 Inst, Room 323,1657 E Helen St, Tucson, AZ 85721 USA.	vadimp@arizona.edu			OM Pharma SA; BIO5 Institute; National Institutes of Health [P01AI148104, R21AI144722];  [T32 ES007091];  [T32 HL007249]	OM Pharma SA; BIO5 Institute; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; 	This work was funded in part by a research grant provided by OM Pharma SA to The University of Arizona. Support was also provided by postdoctoral fellowships from T32 ES007091 and The BIO5 Institute (to A.D.V.) , a predoctoral T32 HL007249 fellowship (to S.R.V.L.) , and the National Institutes of Health (P01AI148104 and R21AI144722 to D.V.) .	Akdis CA, 2021, NAT REV IMMUNOL, V21, P739, DOI 10.1038/s41577-021-00538-7; [Anonymous], 2008, WIPO patent application, Patent No. [WO2008/109669, 2008109669]; Arrieta MC, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab2271; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Bronchial asthma, 2015, BRONCH ASTHM FACT SH; Cavagnero KJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.618807; Cayrol C, 2014, CURR OPIN IMMUNOL, V31, P31, DOI 10.1016/j.coi.2014.09.004; Christianson CA, 2015, J ALLERGY CLIN IMMUN, V136, P59, DOI 10.1016/j.jaci.2014.11.037; Denis O, 2013, EUR J IMMUNOL, V43, P907, DOI 10.1002/eji.201242630; Depner M, 2020, NAT MED, V26, P1766, DOI 10.1038/s41591-020-1095-x; Doherty TA, 2012, AM J PHYSIOL-LUNG C, V303, pL577, DOI 10.1152/ajplung.00174.2012; Esposito S, 2018, CURR OPIN ALLERGY CL, V18, P198, DOI 10.1097/ACI.0000000000000433; Feehley T, 2019, NAT MED, V25, P448, DOI 10.1038/s41591-018-0324-z; Fujimura KE, 2016, NAT MED, V22, P1187, DOI 10.1038/nm.4176; Georas SN, 2014, J ALLERGY CLIN IMMUN, V134, P509, DOI 10.1016/j.jaci.2014.05.049; Gozdz J, 2016, NEW ENGL J MED, V375, P1898, DOI 10.1056/NEJMc1611699; Guilliams M, 2013, MUCOSAL IMMUNOL, V6, P464, DOI 10.1038/mi.2013.14; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; Holt PG, 2020, J ALLERGY CLIN IMMUN, V146, P270, DOI 10.1016/j.jaci.2020.04.008; Hrusch CL, 2019, J ALLERGY CLIN IMMUN, V144, P1391, DOI 10.1016/j.jaci.2019.07.034; Huang YF, 2016, INT IMMUNOL, V28, P23, DOI 10.1093/intimm/dxv044; Idoyaga J, 2013, J CLIN INVEST, V123, P844, DOI 10.1172/JCI65260; Khare A, 2013, J IMMUNOL, V191, P25, DOI 10.4049/jimmunol.1300193; Kobayashi T, 2009, J IMMUNOL, V182, P2502, DOI 10.4049/jimmunol.0802773; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Levan SR, 2019, NAT MICROBIOL, V4, P1851, DOI 10.1038/s41564-019-0498-2; Lynch SV, 2021, AM J RESP CRIT CARE, V203, P802, DOI 10.1164/rccm.202010-3779PP; Lynch SV, 2019, NAT REV GASTRO HEPAT, V16, P656, DOI 10.1038/s41575-019-0204-0; Martinez FD, 2019, IMMUNOL ALLERGY CLIN, V39, P141, DOI 10.1016/j.iac.2018.12.001; Martinez FD, 2013, LANCET, V382, P1360, DOI 10.1016/S0140-6736(13)61536-6; Mincham KT, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.601494; Mincham KT, 2018, J CLIN INVEST, V128, P4856, DOI 10.1172/JCI122631; Navarro S, 2011, MUCOSAL IMMUNOL, V4, P53, DOI 10.1038/mi.2010.51; Pivniouk V, 2020, CLIN EXP ALLERGY, V50, P282, DOI 10.1111/cea.13508; Plantinga M, 2013, IMMUNITY, V38, P322, DOI 10.1016/j.immuni.2012.10.016; Razi CH, 2010, J ALLERGY CLIN IMMUN, V126, P763, DOI 10.1016/j.jaci.2010.07.038; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Salo PM, 2005, J ALLERGY CLIN IMMUN, V116, P623, DOI 10.1016/j.jaci.2005.05.030; Schaad UB, 2002, CHEST, V122, P2042, DOI 10.1378/chest.122.6.2042; Sly PD, 2019, J ALLERGY CLIN IMMUN, V144, P870, DOI 10.1016/j.jaci.2019.05.032; Snelgrove RJ, 2014, J ALLERGY CLIN IMMUN, V134, P583, DOI 10.1016/j.jaci.2014.02.002; Starkey MR, 2019, MUCOSAL IMMUNOL, V12, P299, DOI 10.1038/s41385-018-0130-4; Stein MM, 2016, NEW ENGL J MED, V375, P411, DOI 10.1056/NEJMoa1508749; Stokholm J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02573-2; Strickland DH, 2011, MUCOSAL IMMUNOL, V4, P43, DOI 10.1038/mi.2010.43; Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444; Valladao AC, 2016, J IMMUNOL, V197, P4541, DOI 10.4049/jimmunol.1600007; von Mutius E, 2020, LANCET, V396, P854, DOI 10.1016/S0140-6736(20)31861-4; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yin J, 2018, INT IMMUNOPHARMACOL, V54, P198, DOI 10.1016/j.intimp.2017.10.032	50	11	11	9	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2022	149	3					943	956		10.1016/j.jaci.2021.09.013	http://dx.doi.org/10.1016/j.jaci.2021.09.013			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZO7WJ	34560105				2022-12-18	WOS:000765938100024
J	Akdis, CA				Akdis, Cezmi A.			The epithelial barrier hypothesis proposes a comprehensive understanding of the origins of allergic and other chronic noncommunicable diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Epithelial cells; tight junctions; barrier; allergy; asthma; chronic noncommunicable diseases; microbiome; biodiversity	ANIONIC SURFACTANTS; INTEGRITY		[Akdis, Cezmi A.] Swiss Inst Allergy & Asthma Res SIAF, Obere Str 22, CH-7270 Davos, Switzerland	Swiss Institute of Allergy & Asthma Research	Akdis, CA (corresponding author), Swiss Inst Allergy & Asthma Res SIAF, Obere Str 22, CH-7270 Davos, Switzerland.	akdisac@siaf.uzh.ch						Akdis CA, 2021, NAT REV IMMUNOL, V21, P739, DOI 10.1038/s41577-021-00538-7; Akdis CA, 2020, ALLERGY, V75, P1582, DOI 10.1111/all.14318; Cortese A, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01977-0; GULLIKSON GW, 1977, GASTROENTEROLOGY, V73, P501; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Sugita K, 2019, ALLERGY, V74, P2534, DOI 10.1111/all.13935; Tajik N, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15831-7; Wang M, 2019, J ALLERGY CLIN IMMUN, V143, P1892, DOI 10.1016/j.jaci.2018.11.016; Wawrzyniak P, 2017, J ALLERGY CLIN IMMUN, V139, P93, DOI 10.1016/j.jaci.2016.03.050; Xian M, 2016, J ALLERGY CLIN IMMUN, V138, P890, DOI 10.1016/j.jaci.2016.07.003	10	11	11	3	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2022	149	1					41	44		10.1016/j.jaci.2021.11.010	http://dx.doi.org/10.1016/j.jaci.2021.11.010			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YJ5AM	34822880	Bronze			2022-12-18	WOS:000744544500006
J	Haahtela, T; Valovirta, E; Saarinen, K; Jantunen, J; Lindstrom, I; Kauppi, P; Laatikainen, T; Pelkonen, A; Salava, A; Tommila, E; Bousquet, J; Vasankari, T; Makela, AJ				Haahtela, Tari; Valovirta, Erkka; Saarinen, Kimmo; Jantunen, Juha; Lindstrom, Irmeli; Kauppi, Paula; Laatikainen, Tiina; Pelkonen, Anna; Salava, Alexander; Tommila, Erja; Bousquet, Jean; Vasankari, Tuula; Makela, Andmika J.		Allergy Program Grp	The Finnish Allergy Program 2008-2018: Society-wide proactive program for change of management to mitigate allergy burden	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Allergen avoidance; allergy prevention; allergy program; asthma program; tolerance	SWEDISH CHILDREN; ASTHMA; PREVENTION; PREVALENCE; HOSPITALIZATIONS; STRATEGIES; MICROBIOTA; HELSINKI; INCREASE; EXPOSURE	A 10-year national program to improve prevention and management of allergic diseases and asthma was implemented in Finland (population 5.5. million) in 2008-2018. The main aim was to reduce the long-term burden of these conditions. The strategy was changed from traditional avoidance to tolerance and resilience of the population. Health was endorsed instead of medicalization of mild symptoms. Disease severity was reevaluated, and disabling clinical manifestations were given high priority. For health care, 5 quantitative goals and 1 qualitative goal were set. For each of the goals, specific tasks, tools, and outcome evaluation were stipulated. During the program, 376 educational sessions gathered 24,000 health care participants. An information campaign targeted the lay public, and social media was used to contact people. In the 10 years of the program, the prevalence of allergic diseases and asthma leveled off. Asthma caused fewer symptoms and less disability, and 50% fewer hospital days. Food allergy diets in day care and schools decreased by half. Occupational allergies were reduced by 45%. In 2018, the direct and indirect costs of allergic diseases and asthma ranged from (sic)1.5 billion to (sic)1.8 billion, with the 2018 figures being 30% less than in the respective figures in 2007. The Finnish proactive and real-world intervention markedly reduced the public health burden of allergic disorders. The allergy paradigm was revisited to improve management with systematic education.	[Haahtela, Tari; Kauppi, Paula; Pelkonen, Anna; Salava, Alexander] Univ Helsinki, Helsinki Univ Hosp, Skin & Allergy Hosp, FIN-00029 Helsinki, Finland; [Valovirta, Erkka] Univ Turku, Dept Lung Dis & Clin Allergol, Turku, Finland; [Valovirta, Erkka] Allergy Clin, Suomen Terveystalo Oy, Turku, Finland; [Saarinen, Kimmo; Jantunen, Juha] Allergy Skin & Asthma Federat, Helsinki, Finland; [Lindstrom, Irmeli] Finnish Inst Occupat Hlth, Helsinki, Finland; [Laatikainen, Tiina] Finnish Inst Hlth & Welf, Helsinki, Finland; [Tommila, Erja; Vasankari, Tuula] Finnish Lung Hlth Associat, Helsinki, Finland; [Bousquet, Jean] Univmed Berlin, Berlin Inst Hlth, Dept Dermatol & Allergy, Comprehens Allergy Ctr,Humboldt Univ Berlin, Berlin, Germany; [Bousquet, Jean] Univ Hosp, Montpellier, France; [Bousquet, Jean] MACVIA France, Montpellier, France	University of Helsinki; Helsinki University Central Hospital; University of Turku; Finnish Institute of Occupational Health; Berlin Institute of Health; Humboldt University of Berlin; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier	Haahtela, T (corresponding author), Univ Helsinki, Helsinki Univ Hosp, Skin & Allergy Hosp, FIN-00029 Helsinki, Finland.	tari.haahtela@haahtela.fi	Csonka, Peter/AAB-3172-2022; Salava, Alexander/AFT-6261-2022; Csonka, Peter/AAC-6190-2022; Laatikainen, Tiina/ABD-6622-2021	Csonka, Peter/0000-0003-0819-7875; Laatikainen, Tiina/0000-0002-6614-4782; Bousquet, Jean/0000-0002-4061-4766	Vaino and Laina Kivi Foundation	Vaino and Laina Kivi Foundation	From 2008 to 2016, the Ministry of Welfare and Health allocated from V60,000 to V65,000 annually for educational and coordinating work, which was organized by the Finnish Lung Health Association, an expert nongovernmental organization. The Finnish Lung Health Association also raised private funds in the amount ofV50,000 toV100,000 per year to carry out its various learning activities. From 2011 to 2014, 2 nongovernmental patient organizations received an annual payment of V200,000 for patient education and public communication from the Funding Centre for Social Welfare and Health Organizations. The V_ain_o and Laina Kivi Foundation supported the program.	Asher I, 2017, ALLERGOL IMMUNOPATH, V45, P105, DOI 10.1016/j.aller.2016.10.013; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Bousquet J, 2008, ALLERGY, V63, P631, DOI 10.1111/j.1398-9995.2008.01730.x; Bousquet J, 2019, J ALLERGY CLIN IMMUN, V143, P864, DOI 10.1016/j.jaci.2018.08.049; Brozek JL, 2017, J ALLERGY CLIN IMMUN, V140, P950, DOI 10.1016/j.jaci.2017.03.050; Chang YS, 2012, ASIA PAC ALLERGY, V2, P231, DOI 10.5415/apallergy.2012.2.4.231; Dierick BJH, 2020, EXPERT REV PHARM OUT, V20, P437, DOI 10.1080/14737167.2020.1819793; Diwakar L, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-012647; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Erhola M, 2019, LANCET RESP MED, V7, pE16, DOI 10.1016/S2213-2600(19)30122-5; Erkkola M, 2016, ALLERGY, V71, P1453, DOI 10.1111/all.12902; Global Initiative for Asthma (GINA), GLOB STRAT ASTHM MAN; Haahtela T, 2008, ALLERGY, V63, P634, DOI 10.1111/j.1398-9995.2008.01712.x; HAAHTELA T, 1990, BRIT MED J, V301, P266, DOI 10.1136/bmj.301.6746.266; Haahtela T, 2006, THORAX, V61, P663, DOI 10.1136/thx.2005.055699; Haahtela T, 2015, CLIN EXP ALLERGY, V45, P891, DOI 10.1111/cea.12527; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; Haahtela T, 2017, EUR REPIR J, V49, P1; Haahtela T, 2020, FINNISH MED J, V75, P1760; Haahtela Tari, 2020, Porto Biomed J, V5, pe073, DOI 10.1097/j.pbj.0000000000000073; Haahtela T, 2019, CLIN TRANSL ALLERGY, V9, DOI 10.1186/s13601-019-0295-2; Haahtela T, 2019, ALLERGY, V74, P1445, DOI 10.1111/all.13763; Haahtela T, 2017, J ALLERGY CLIN IMMUN, V139, P408, DOI 10.1016/j.jaci.2016.12.001; Halonen JI, 2020, LANCET PLANET HEALTH, V4, pE503, DOI 10.1016/S2542-5196(20)30242-4; Hanski I, 2012, P NATL ACAD SCI USA, V109, P8334, DOI 10.1073/pnas.1205624109; Heinzerling L, 2005, ALLERGY, V60, P1287, DOI 10.1111/j.1398-9995.2005.00895.x; Hicke-Roberts A, 2017, ACTA PAEDIATR, V106, P75, DOI 10.1111/apa.13433; Hisinger-Molkanen H, 2019, RESP MED, V155, P121, DOI 10.1016/j.rmed.2019.07.014; Jantunen J., 2014, FINN MED J, V69, P641; Khaltaev N, 2007, GLOBAL SURVEILLANCE; Kim YY, 2010, ALLERGY ASTHMA IMMUN, V2, P155, DOI 10.4168/aair.2010.2.3.155; Kivisto JE, 2016, ALLERGY, V71, P677, DOI 10.1111/all.12837; Kivisto JE, 2016, J ALLERGY CLIN IMMUN, V138, P630, DOI 10.1016/j.jaci.2016.05.015; Kivisto JE, 2018, THORAX, V73, P185, DOI 10.1136/thoraxjnl-2016-209739; Kotter JP, 1996, LEADING CHANGE; Lampi J, 2020, CLIN TRANSL ALLERGY, V10, DOI 10.1186/s13601-020-0308-1; Lynch SV, 2014, J ALLERGY CLIN IMMUN, V134, P593, DOI 10.1016/j.jaci.2014.04.018; Makinen-Kiljunen S, 2008, WORLD ALLERGY ORGAN, V1, P184, DOI 10.1097/WOX.0b013e3181898224; Martikainen V, SOMAATTINEN ERIKOISS; Mattiuzzi C, 2020, INT FORUM ALLERGY RH, V10, P75, DOI 10.1002/alr.22464; Ministry of Social Affairs and Health Helsinki Finland, 1983, STAT ALL COMM, V28, P1; Pelkonen AS, 2012, PEDIAT ALLERG IMM-UK, V23, P103, DOI 10.1111/j.1399-3038.2012.01298.x; Reijula J, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.02144-2019; Roslund MI, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba2578; Ruokolainen L, 2017, CLIN EXP ALLERGY, V47, P665, DOI 10.1111/cea.12895; Salimaki J, 2018, SUOM LAAKARIL, V73, P367; Saltman RB., 2016, HLTH STAT NORDIC COU, V104, P1; Savolainen J, 2019, PEDIAT ALLERG IMM-UK, V30, P99, DOI 10.1111/pai.12996; Stein MM, 2016, NEW ENGL J MED, V375, P411, DOI 10.1056/NEJMoa1508749; The Finnish Medical Association Duodecim and the Academy of Finland, 1998, CONS M HAN 11 11 199, P1; Virtanen S, 2020, NATURE STEP WELLBEIN, P1; von Hertzen LC, 2009, ALLERGY, V64, P678, DOI 10.1111/j.1398-9995.2009.02024.x; von Mutius E, 2020, LANCET, V396, P854, DOI 10.1016/S0140-6736(20)31861-4; Warner KE, 2013, TOB CONTROL, V22, P3, DOI 10.1136/tobaccocontrol-2013-050989; Whitmee S, 2015, LANCET, V386, P1973, DOI 10.1016/S0140-6736(15)60901-1	55	11	11	4	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2021	148	2					319	+		10.1016/j.jaci.2021.03.037	http://dx.doi.org/10.1016/j.jaci.2021.03.037		AUG 2021	12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TZ7BX	33965232	Green Published, hybrid			2022-12-18	WOS:000684625700006
J	Kaustio, M; Nayebzadeh, N; Hinttala, R; Tapiainen, T; Astrom, P; Mamia, K; Pernaa, N; Lehtonen, J; Glumoff, V; Rahikkala, E; Honkila, M; Olsen, P; Hassinen, A; Polso, M; Al Sukaiti, N; Al Shekaili, J; Al Kindi, M; Al Hashmi, N; Almusa, H; Bulanova, D; Haapaniemi, E; Chen, P; Suo-Palosaari, M; Vieira, P; Tuominen, H; Kokkonen, H; Al Macki, N; Al Habsi, H; Lopponen, T; Rantala, H; Pietiainen, V; Zhang, SY; Renko, M; Hautala, T; Al Farsi, T; Uusimaa, J; Saarela, J				Kaustio, Meri; Nayebzadeh, Naemeh; Hinttala, Reetta; Tapiainen, Terhi; Astrom, Pirjo; Mamia, Katariina; Pernaa, Nora; Lehtonen, Johanna; Glumoff, Virpi; Rahikkala, Elisa; Honkila, Minna; Olsen, Paivi; Hassinen, Antti; Polso, Minttu; Al Sukaiti, Nashat; Al Shekaili, Jalila; Al Kindi, Mahmood; Al Hashmi, Nadia; Almusa, Henrikki; Bulanova, Daria; Haapaniemi, Emma; Chen, Pu; Suo-Palosaari, Maria; Vieira, Paivi; Tuominen, Hannu; Kokkonen, Hannaleena; Al Macki, Nabil; Al Habsi, Huda; Lopponen, Tuija; Rantala, Heikki; Pietiainen, Vilja; Zhang, Shen-Ying; Renko, Marjo; Hautala, Timo; Al Farsi, Tariq; Uusimaa, Johanna; Saarela, Janna			Loss of DIAPH1 causes SCBMS, combined immunodeficiency, and mitochondrial dysfunction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						DIAPH1; SCBMS; microcephaly; mitochondrial dysfunction; T cells; immunodeficiency	T-CELL-ACTIVATION; FORMIN; MDIA1; POLARIZATION; MUTATIONS; MIGRATION; HOMOLOG; PROTEIN; ROCK; RHOA	Background: Homozygous loss of DIAPH1 results in seizures, cortical blindness, and microcephaly syndrome (SCBMS). We studied 5 Finnish and 2 Omani patients with loss of DIAPH1 presenting with SCBMS, mitochondrial dysfunction, and immunodeficiency. Objective: We sought to further characterize phenotypes and disease mechanisms associated with loss of DIAPH1. Methods: Exome sequencing, genotyping and haplotype analysis, B- and T-cell phenotyping, in vitro lymphocyte stimulation assays, analyses of mitochondrial function, immunofluorescence staining for cytoskeletal proteins and mitochondria, and CRISPR-Cas9 DIAPH1 knockout in heathy donor PBMCs were used. Results: Genetic analyses found all Finnish patients homozygous for a rare DIAPH1 splice-variant (NM_005219:c.68411G>A) enriched in the Finnish population, and Omani patients homozygous for a previously described pathogenic DIAPH1 frameshift-variant (NM_005219:c.2769delT;p.F923fs). In addition to microcephaly, epilepsy, and cortical blindness characteristic to SCBMS, the patients presented with infection susceptibility due to defective lymphocyte maturation and 3 patients developed B-cell lymphoma. Patients' immunophenotype was characterized by poor lymphocyte activation and proliferation, defective B-cell maturation, and lack of naive T cells. CRISPR-Cas9 knockout of DIAPH1 in PBMCs from healthy donors replicated the T-cell activation defect. Patient-derived peripheral blood T cells exhibited impaired adhesion and inefficient microtubule-organizing center repositioning to the immunologic synapse. The clinical symptoms and laboratory tests also suggested mitochondrial dysfunction. Experiments with immortalized, patient-derived fibroblasts indicated that DIAPH1 affects the amount of complex IV of the mitochondrial respiratory chain. Conclusions: Our data demonstrate that individuals with SCBMS can have combined immune deficiency and implicate defective cytoskeletal organization and mitochondrial dysfunction in SCBMS pathogenesis.	[Kaustio, Meri; Lehtonen, Johanna; Hassinen, Antti; Polso, Minttu; Almusa, Henrikki; Bulanova, Daria; Chen, Pu; Pietiainen, Vilja; Saarela, Janna] Univ Helsinki, Inst Mol Med Finland FIMM, HiLIFE, Helsinki, Finland; [Nayebzadeh, Naemeh; Hinttala, Reetta; Tapiainen, Terhi; Rahikkala, Elisa; Honkila, Minna; Olsen, Paivi; Vieira, Paivi; Rantala, Heikki; Renko, Marjo; Uusimaa, Johanna] Univ Oulu, PEDEGO Res Unit, Oulu, Finland; [Nayebzadeh, Naemeh; Hinttala, Reetta; Tapiainen, Terhi; Rahikkala, Elisa; Honkila, Minna; Olsen, Paivi; Suo-Palosaari, Maria; Vieira, Paivi; Kokkonen, Hannaleena; Uusimaa, Johanna] Univ Oulu, Med Res Ctr Oulu, Oulu, Finland; [Nayebzadeh, Naemeh; Hinttala, Reetta; Tapiainen, Terhi] Bioctr Oulu, Oulu, Finland; [Tapiainen, Terhi; Honkila, Minna; Olsen, Paivi; Vieira, Paivi; Uusimaa, Johanna] Oulu Univ Hosp, Dept Pediat & Adolescent Med, Oulu, Finland; [Astrom, Pirjo; Pernaa, Nora; Glumoff, Virpi; Hautala, Timo] Univ Oulu, Res Unit Biomed, Oulu, Finland; [Mamia, Katariina; Lehtonen, Johanna; Haapaniemi, Emma; Saarela, Janna] Univ Oslo, Ctr Mol Med Norway NCMM, Oslo, Norway; [Lehtonen, Johanna] Folkhalsan Res Ctr, Helsinki, Finland; [Rahikkala, Elisa] Oulu Univ Hosp, Dept Clin Genet, Oulu, Finland; [Al Sukaiti, Nashat; Al Farsi, Tariq] Royal Hosp, Dept Pediat Allergy & Clin Immunol, Muscat, Oman; [Al Shekaili, Jalila; Al Kindi, Mahmood] Sultan Qaboos Univ Hosp, Dept Microbiol & Immunol, Muscat, Oman; [Al Hashmi, Nadia] Royal Hosp, Dept Clin & Biochem Genet, Muscat, Oman; [Bulanova, Daria] Univ Copenhagen, Biotech Res & Innovat Ctr BRIC, Copenhagen, Denmark; [Haapaniemi, Emma] Oslo Univ Hosp, Dept Pediat Res, Oslo, Norway; [Haapaniemi, Emma] Univ Helsinki, Fac Med, Mol Neurol & Biomed Stem Cell Ctr, Res Programs Unit, Helsinki, Finland; [Suo-Palosaari, Maria] Oulu Univ Hosp, Dept Diagnost Radiol, Oulu, Finland; [Suo-Palosaari, Maria] Univ Oulu, Oulu, Finland; [Suo-Palosaari, Maria] Univ Oulu, Fac Med, Res Unit Med Imaging Phys & Technol, Oulu, Finland; [Tuominen, Hannu] Oulu Univ Hosp, Dept Pathol, Oulu, Finland; [Kokkonen, Hannaleena] Oulu Univ Hosp, Northern Finland Lab Ctr, Dept Clin Genet, Oulu, Finland; [Al Macki, Nabil] Royal Hosp, Dept Pediat Neurol, Muscat, Oman; [Al Habsi, Huda] Royal Hosp, Dept Gen Pediat, Muscat, Oman; [Lopponen, Tuija; Renko, Marjo] Univ Eastern Finland, Dept Pediat, Kuopio, Finland; [Lopponen, Tuija; Renko, Marjo] Kuopio Univ Hosp, Kuopio, Finland; [Zhang, Shen-Ying] Rockefeller Univ, Rockefeller Branch, St Giles Lab Human Genet Infect Dis, 1230 York Ave, New York, NY 10021 USA; [Zhang, Shen-Ying] Paris Descartes Univ, Imagine Inst, Paris, France; [Zhang, Shen-Ying] Necker Hosp Sick Children, Necker Branch, Lab Human Genet Infect Dis, INSERM,UMR 1163, Paris, France; [Hautala, Timo] Oulu Univ Hosp, Dept Internal Med, Oulu, Finland; [Saarela, Janna] Oslo Univ Hosp, Dept Med Genet, Oslo, Norway; [Saarela, Janna] Helsinki Univ Hosp, Dept Clin Genet, Helsinki, Finland	University of Helsinki; University of Oulu; University of Oulu; University of Oulu; University of Oulu; University of Oulu; University of Oslo; Folkhalsan Research Center; University of Oulu; The Royal Hospital, Sultanate of Oman; Sultan Qaboos University; The Royal Hospital, Sultanate of Oman; University of Copenhagen; University of Oslo; University of Helsinki; University of Oulu; University of Oulu; University of Oulu; University of Oulu; University of Oulu; The Royal Hospital, Sultanate of Oman; The Royal Hospital, Sultanate of Oman; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; Rockefeller University; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Oulu; University of Oslo; University of Helsinki; Helsinki University Central Hospital	Saarela, J (corresponding author), Univ Helsinki, POB 20, FI-00014 Helsinki, Finland.	janna.saarela@helsinki.fi	Alshekaili, Jalila/L-5129-2019	Alshekaili, Jalila/0000-0002-2576-4766; Saarela, Janna/0000-0002-0853-6219; Rahikkala, Elisa/0000-0003-2760-7059; Astrom, Pirjo/0000-0001-7150-2508; Hassinen, Antti/0000-0001-9491-2868; Haapaniemi, Emma/0000-0002-6693-8208; Pietiainen, Vilja/0000-0003-3125-2406; Hautala, Timo/0000-0001-7889-1614	Academy of Finland, Finland [317711, 266498, 273790]; Ester and Uuno Kokki Foundation, Finland; Finnish Cultural Foundation, Finland; Foundation for Pediatric Research, Finland; Alma and KA Snellman Foundation, Finland; Special State Grants for Health Research at the Oulu University Hospital, Finland [VTR K56772]	Academy of Finland, Finland(Academy of Finland); Ester and Uuno Kokki Foundation, Finland; Finnish Cultural Foundation, Finland(Finnish Cultural Foundation); Foundation for Pediatric Research, Finland; Alma and KA Snellman Foundation, Finland; Special State Grants for Health Research at the Oulu University Hospital, Finland	This work was supported by the Academy of Finland, Finland (decision nos. RH: 317711, 266498, 273790), Ester and Uuno Kokki Foundation, Finland; the Finnish Cultural Foundation, Finland; The Foundation for Pediatric Research, Finland; the Alma and KA Snellman Foundation, Finland; and Special State Grants for Health Research at the Oulu University Hospital, Finland (grant no. VTR K56772).	Al-Maawali A, 2016, AM J MED GENET A, V170, P435, DOI 10.1002/ajmg.a.37422; Alosaimi MF, 2019, J ALLERGY CLIN IMMUN, V144, P306, DOI 10.1016/j.jaci.2019.02.020; Angajala A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01605; Bin Riaz I, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00777; Campellone KG, 2010, NAT REV MOL CELL BIO, V11, P237, DOI 10.1038/nrm2867; Diaz F, 2010, BBA-MOL BASIS DIS, V1802, P100, DOI 10.1016/j.bbadis.2009.07.013; Eisenmann KM, 2009, ONCOGENE, V28, P3429, DOI 10.1038/onc.2009.207; Eisenmann KM, 2007, J BIOL CHEM, V282, P25152, DOI 10.1074/jbc.M703243200; Ercan-Sencicek AG, 2015, EUR J HUM GENET, V23, P165, DOI 10.1038/ejhg.2014.82; Galbraith KK, 2019, NEUROSCI RES, V138, P59, DOI 10.1016/j.neures.2018.09.008; Gandolfo LC, 2014, GENETICS, V197, P1315, DOI 10.1534/genetics.114.164616; Gomez TS, 2007, IMMUNITY, V26, P177, DOI 10.1016/j.immuni.2007.01.008; Haapaniemi EM, 2015, BLOOD, V125, P639, DOI 10.1182/blood-2014-04-570101; Hautala TJ, 2018, J CLIN IMMUNOL, V38, P4, DOI 10.1007/s10875-017-0463-x; Janssen E, 2019, IMMUNOL REV, V287, P121, DOI 10.1111/imr.12716; Joseph N, 2014, BBA-BIOMEMBRANES, V1838, P557, DOI 10.1016/j.bbamem.2013.07.009; Kapniciz SM, 2018, METABOLISM, V81, P97, DOI 10.1016/j.metabol.2017.11.010; Kaprio J, 2013, TWIN RES HUM GENET, V16, P157, DOI 10.1017/thg.2012.142; Karczewski KJ., 2019, BIORXIV, DOI [DOI 10.1101/531210, 10.1101/531210]; Kloc M, 2014, J LEUKOCYTE BIOL, V95, P417, DOI 10.1189/jlb.0813468; Li DH, 2010, ENDOCRINOLOGY, V151, P4313, DOI 10.1210/en.2010-0044; Li YF, 2006, J BIOENERG BIOMEMBR, V38, P283, DOI 10.1007/s10863-006-9052-z; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; Machaidze G, 2010, J MOL BIOL, V403, P529, DOI 10.1016/j.jmb.2010.09.017; Mehta MM, 2017, NAT REV IMMUNOL, V17, P608, DOI 10.1038/nri.2017.66; Minin AA, 2006, J CELL SCI, V119, P659, DOI 10.1242/jcs.02762; Narumiya S, 2009, CANCER METAST REV, V28, P65, DOI 10.1007/s10555-008-9170-7; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Peng J, 2007, CANCER RES, V67, P7565, DOI 10.1158/0008-5472.CAN-07-1467; Pierron D, 2012, BBA-BIOENERGETICS, V1817, P590, DOI 10.1016/j.bbabio.2011.07.007; Quintana A, 2007, P NATL ACAD SCI USA, V104, P14418, DOI 10.1073/pnas.0703126104; RStudio Team, 2021, RSTUDIO INT DEV ENV; Sakata D, 2007, J EXP MED, V204, P2031, DOI 10.1084/jem.20062647; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Shi YQ, 2009, J IMMUNOL, V182, P3837, DOI 10.4049/jimmunol.0803838; Stone KD, 2009, CLIN IMMUNOL, V131, P41, DOI 10.1016/j.clim.2008.11.003; Stritt S, 2016, BLOOD, V127, P2903, DOI 10.1182/blood-2015-10-675629; Sukumar M, 2016, CELL METAB, V23, P63, DOI 10.1016/j.cmet.2015.11.002; Tangye SG, 2020, J CLIN IMMUNOL, V40, P24, DOI 10.1007/s10875-019-00737-x; Tanizaki H, 2010, BLOOD, V116, P5875, DOI 10.1182/blood-2010-01-264150; Thumkeo D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025465; Ueyama T, 2016, EMBO MOL MED, V8, P1310, DOI 10.15252/emmm.201606609; Vartiainen E, 2002, J EPIDEMIOL COMMUN H, V56, P167, DOI 10.1136/jech.56.3.167; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Weraarpachai W, 2009, NAT GENET, V41, P833, DOI 10.1038/ng.390; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Yao JB, 1999, HUM MOL GENET, V8, P2541, DOI 10.1093/hmg/8.13.2541	48	11	11	2	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2021	148	2					599	611		10.1016/j.jaci.2020.12.656	http://dx.doi.org/10.1016/j.jaci.2020.12.656		AUG 2021	13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UD3IW	33662367	Green Published, hybrid			2022-12-18	WOS:000687104900011
J	Stevens, WW; Staudacher, AG; Hulse, KE; Poposki, JA; Kato, A; Carter, RG; Suh, LA; Norton, JE; Huang, JLH; Peters, AT; Grammer, LC; Conley, DB; Shintani-Smith, S; Tan, BCK; Welch, KC; Kern, RC; Schleimer, RP				Stevens, Whitney W.; Staudacher, Anna G.; Hulse, Kathryn E.; Poposki, Julie A.; Kato, Atsushi; Carter, Roderick G.; Suh, Lydia A.; Norton, James E.; Huang, Julia H.; Peters, Anju T.; Grammer, Leslie C.; Conley, David B.; Shintani-Smith, Stephanie; Tan, Bruce K.; Welch, Kevin C.; Kern, Robert C.; Schleimer, Robert P.			Studies of the role of basophils in aspirin-exacerbated respiratory disease pathogenesis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aspirin-exacerbated respiratory disease; AERD; baso-phil; nasal polyp; CRSwNP; chronic sinusitis	INNATE LYMPHOID-CELLS; HUMAN BLOOD BASOPHILS; CHRONIC RHINOSINUSITIS; NASAL POLYPS; PROSTAGLANDIN D-2; EXPRESSION; ACTIVATION; EOSINOPHIL; DIFFERENTIATION; IDENTIFICATION	Background: Aspirin-exacerbated respiratory disease (AERD) is characterized by the triad of chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, and intolerance to cyclooxygenase-1 enzyme inhibitors. The underlying mechanisms contributing to AERD pathogenesis are not fully understood, but AERD is characterized by an enhanced type 2 inflammatory phenotype. Basophils are potent type 2 effector cells, but their involvement in AERD pathophysiology remains unclear. Objective: We sought to characterize the systemic and local basophil responses in patients with AERD compared with patients with CRSwNP. Methods: Sinonasal tissues including inferior turbinate and/or nasal polyps (NPs) and peripheral blood were collected from controls, patients with AERD, and patients with CRSwNP. Expression of cell surface (CD45, Fc epsilon RI, CD203c), activation (CD63), and intracellular (2D7) markers associated with basophils was characterized using flow cytometry. Clinical data including Lund-Mackay scores and pulmonary function were obtained. Results: The mean number of basophils (CD45+CD203c+Fc epsilon RI+CD117-) detected in AERD NPs (147 +/- 28 cells/mg tissue) was significantly elevated compared with that detected in CRSwNP NPs (69 +/- 20 cells/mg tissue; P = .01). The number of circulating basophils was significantly elevated in patients with AERD (P = .04). Basophils in NPs had significantly higher CD203c and CD63 mean fluorescence intensity compared with blood in both conditions (P < .01). Basophils from AERD NPs had lower expression of the granule content marker 2D7 compared with those from matched blood (P <.01) or NPs of patients with CRSwNP (P = .06), suggesting ongoing degranulation. Basophil 2D7 mean fluorescence intensity significantly correlated with pulmonary function (r = 0.62; P = .02) and inversely correlated with sinonasal inflammation (r = -0.56; P = .004). Conclusions: Increased basophil numbers and extent of ongoing degranulation in NPs of patients with AERD compared with patients with CRSwNP may contribute to the exaggerated disease pathogenesis and severity unique to AERD.	[Stevens, Whitney W.; Staudacher, Anna G.; Hulse, Kathryn E.; Poposki, Julie A.; Kato, Atsushi; Carter, Roderick G.; Suh, Lydia A.; Norton, James E.; Peters, Anju T.; Grammer, Leslie C.; Schleimer, Robert P.] Northwestern Univ, Dept Med, Div Allergy & Immunol, Feinberg Sch Med, Chicago, IL 60611 USA; [Stevens, Whitney W.; Huang, Julia H.; Peters, Anju T.; Conley, David B.; Shintani-Smith, Stephanie; Tan, Bruce K.; Welch, Kevin C.; Kern, Robert C.; Schleimer, Robert P.] Northwestern Univ, Dept Otolaryngol, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Stevens, WW (corresponding author), Div Allergy Immunol, 211 E Ontario St,Ste 1000, Chicago, IL 60611 USA.	hitney-stevens@northwestern.edu			National Institutes of Health [KL2 TR001424, K23 AI141694, R01 AI137174, U19 AI106683, P01 AI145818]; Parker B. Francis Fellowship Foundation; American Partner-ship for Eosinophilic Disorders (APFED) /AAAAI HOPE Pilot Grant Award; Ernest S. Bazley Foundation	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Parker B. Francis Fellowship Foundation; American Partner-ship for Eosinophilic Disorders (APFED) /AAAAI HOPE Pilot Grant Award; Ernest S. Bazley Foundation	This research was supported in part by the National Institutes of Health grants (grant no. KL2 TR001424, K23 AI141694, R01 AI137174, U19 AI106683, and P01 AI145818) , by grants from the Parker B. Francis Fellowship Foundation and the American Partner-ship for Eosinophilic Disorders (APFED) /AAAAI HOPE Pilot Grant Award, and by the Ernest S. Bazley Foundation.	Bachert C, 2001, J ALLERGY CLIN IMMUN, V107, P607, DOI 10.1067/mai.2001.112374; Bochenek G, 2003, J ALLERGY CLIN IMMUN, V111, P743, DOI 10.1067/mai.2003.1387; Brescia G, 2017, ANN ALLERG ASTHMA IM, V119, P223, DOI 10.1016/j.anai.2017.06.008; Brescia G, 2017, INT FORUM ALLERGY RH, V7, P261, DOI 10.1002/alr.21885; Cahill KN, 2019, AM J RESP CRIT CARE, V200, P704, DOI 10.1164/rccm.201809-1755OC; Cahill KN, 2015, J ALLERGY CLIN IMMUN, V135, P245, DOI 10.1016/j.jaci.2014.07.031; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; DENBURG JA, 1987, INT ARCH ALLER A IMM, V82, P321, DOI 10.1159/000234217; Derycke L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097581; Hauswirth AW, 2007, INT J IMMUNOPATH PH, V20, P267, DOI 10.1177/039463200702000207; Hulse KE, 2013, J ALLERGY CLIN IMMUN, V131, P1075, DOI 10.1016/j.jaci.2013.01.043; KEPLEY CL, 1995, J IMMUNOL, V154, P6548; Kepley CL, 2001, AM J RESP CRIT CARE, V164, P1053, DOI 10.1164/ajrccm.164.6.2102025; KOSHINO T, 1993, CLIN EXP ALLERGY, V23, P919, DOI 10.1111/j.1365-2222.1993.tb00276.x; LAMPL KL, 1985, AM REV RESPIR DIS, V132, P1015; MacGlashan D, 2010, CLIN EXP ALLERGY, V40, P1365, DOI 10.1111/j.1365-2222.2010.03572.x; Mahdavinia M, 2014, J ALLERGY CLIN IMMUN, V133, P1759, DOI 10.1016/j.jaci.2013.12.1092; Miljkovic D, 2014, ALLERGY, V69, P1154, DOI 10.1111/all.12440; Ocmant A, 2007, J IMMUNOL METHODS, V320, P40, DOI 10.1016/j.jim.2006.12.002; OHNISHI M, 1989, J ALLERGY CLIN IMMUN, V83, P1091, DOI 10.1016/0091-6749(89)90451-X; Orlandi RR, 2016, INT FORUM ALLERGY RH, V6, pS22, DOI 10.1002/alr.21695; Perez-Novo CA, 2005, J ALLERGY CLIN IMMUN, V115, P1189, DOI 10.1016/j.jaci.2005.02.029; Perez-Novo CA, 2006, AM J RHINOL, V20, P456, DOI 10.2500/ajr.2006.20.2873; Poposki JA, 2017, IMMUN INFLAMM DIS, V5, P233, DOI 10.1002/iid3.161; Rajan JP, 2015, J ALLERGY CLIN IMMUN, V135, P676, DOI 10.1016/j.jaci.2014.08.020; Roca-Ferrer J, 2011, J ALLERGY CLIN IMMUN, V128, P66, DOI 10.1016/j.jaci.2011.01.065; Schleimer RP, 2017, ANNU REV PATHOL-MECH, V12, P331, DOI 10.1146/annurev-pathol-052016-100401; SCHLEIMER RP, 1984, J ALLERGY CLIN IMMUN, V74, P473, DOI 10.1016/0091-6749(84)90381-6; Schroeder JT, 2001, ADV IMMUNOL, V77, P93, DOI 10.1016/S0065-2776(01)77015-0; Stevens WW, 2021, J ALLERGY CLIN IMMUN, V147, P600, DOI 10.1016/j.jaci.2020.04.031; Stevens WW, 2019, J ALLER CL IMM-PRACT, V7, P2812, DOI 10.1016/j.jaip.2019.05.009; Stevens WW, 2017, J ALLER CL IMM-PRACT, V5, P1061, DOI 10.1016/j.jaip.2016.12.027; Stevens WW, 2015, AM J RESP CRIT CARE, V192, P682, DOI 10.1164/rccm.201412-2278OC; Tokunaga T, 2015, ALLERGY, V70, P995, DOI 10.1111/all.12644; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Van Roey GA, 2017, J ALLERGY CLIN IMMUN, V140, P89, DOI 10.1016/j.jaci.2016.11.015; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Van Zele T, 2009, LARYNGOSCOPE, V119, P1753, DOI 10.1002/lary.20484; Wang XD, 2016, J ALLERGY CLIN IMMUN, V138, P1344, DOI 10.1016/j.jaci.2016.05.041	40	11	11	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2021	148	2					439	+		10.1016/j.jaci.2021.02.045	http://dx.doi.org/10.1016/j.jaci.2021.02.045		AUG 2021	16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TZ7BX	33819512	Green Accepted			2022-12-18	WOS:000684625700021
J	Bozzano, F; Della Chiesa, M; Pelosi, A; Antonini, F; Ascierto, ML; Del Zotto, G; Moretta, F; Muccio, L; Luganini, A; Gribaudo, G; Cenderello, G; Dentone, C; Nicolini, L; Moretta, A; Moretta, L; De Maria, A				Bozzano, Federica; Della Chiesa, Mariella; Pelosi, Andrea; Antonini, Francesca; Ascierto, Maria Libera; Del Zotto, Genny; Moretta, Francesca; Muccio, Letizia; Luganini, Anna; Gribaudo, Giorgio; Cenderello, Giovanni; Dentone, Chiara; Nicolini, Laura; Moretta, Alessandro; Moretta, Lorenzo; De Maria, Andrea			HCMV-controlling NKG2C(+) NK cells originate from novel circulating inflammatory precursors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Natural killer cells; common lymphocyte precursors; hematopoietic stem cells; viral infection; Lin(-)CD34(+)DNAM-1(bright); NKG2C; HCMV; HIV; HCV	NATURAL-KILLER-CELLS; HUMAN CYTOMEGALOVIRUS-INFECTION; CYTOLYTIC FUNCTION; VIRAL REPLICATION; HIV-1 INFECTION; EXPRESSION; RECEPTOR; MEMORY; DIFFERENTIATION; TRANSPLANTATION	Background: There is limited knowledge on the origin and development from CD34(+) precursors of the ample spectrum of human natural killer (NK) cells, particularly of specialized NK subsets. Objective: This study sought to characterize the NK-cell progeny of CD34(+)DNAM-1(bright)CXCR4(+) and of other precursors circulating in the peripheral blood of patients with chronic viral infections (eg, HIV, hepatitis C virus, cytomegalovirus reactivation). Methods: Highly purified precursors were obtained by flow cytometric sorting and cultured in standard NK-cell differentiation media (ie, SCF, FLT3, IL-7, IL-15). Phenotypic and functional analyses on progenies were performed by multiparametric cytofluorimetric assays. Transcriptional signatures of NK-cell progenies were studied by microarray analysis. Inhibition of cytomegalovirus replication was studied by PCR. Results: Unlike conventional CD34(+) precursors, Lin-CD34(+)DNAM-1(bright)CXCR4(+) precursors from patients with chronic infection, rapidly differentiate into cytotoxic, IFNy-secreting CD94/NKG2C(+)KIR(+)CD57(+) NK-cell progenies. An additional novel subset of common lymphocyte precursors was identified among Lin-CD34(-)CD56(-)CD16(+) cells and characterized by expression of CXCR4 and lack of perforM and CD94. Line(-)CD34(-)CD56(-)CD16(+)Perf(-)CD94(-)CXCR4(+) precursors are also endowed with generation potential toward memory-like NKG2C(+)NK cells. Maturing NK-cell progenies mediated strong human cytomegalovirus-inhibiting activity. Microarray analysis confirmed a transcriptional signature compatible with NK-cell progenies and with maturing adaptive NK cells. Conclusions: During viral infections, precursors of adaptive NK cells are released and circulate in the peripheral blood.	[Bozzano, Federica; Pelosi, Andrea; Moretta, Lorenzo] Pediat Hosp Bambino Gesu, Rome, Italy; [Della Chiesa, Mariella; Muccio, Letizia; Moretta, Alessandro] Univ Genoa, Dept Expt Med, Genoa, Italy; [Della Chiesa, Mariella; Muccio, Letizia; Moretta, Alessandro] Univ Genoa, Ctr Excellence Biomed Res, Genoa, Italy; [De Maria, Andrea] Univ Genoa, Dept Life Sci, Via Pastore 1, I-16132 Genoa, Italy; [Antonini, Francesca; Del Zotto, Genny] Pediat Hosp, Ist G Gaslini, Genoa, Italy; [Dentone, Chiara; Nicolini, Laura; De Maria, Andrea] Osped Policlin San Martino Ist Ricovero & Cura Ca, Clin Malattie Infett, Genoa, Italy; [Ascierto, Maria Libera] Medimmune, Gaithersburg, MD USA; [Moretta, Francesca] Ist Ricovero & Cura Carattere Sci Sacro Cuore Don, Verona, Italy; [Moretta, Francesca; Luganini, Anna; Gribaudo, Giorgio] Univ Torino, Dept Life Sci & Syst Biol, Turin, Italy; [Cenderello, Giovanni] ASL1, Osped Sanremo, Unita Operat Complessa Malattie Infett, San Remo, Italy	IRCCS Bambino Gesu; University of Genoa; University of Genoa; University of Genoa; University of Genoa; IRCCS Istituto Giannina Gaslini; AstraZeneca; Medimmune; University of Turin	De Maria, A (corresponding author), Univ Genoa, Dept Life Sci, Via Pastore 1, I-16132 Genoa, Italy.; De Maria, A (corresponding author), Univ Genoa, Dept Life Sci, Via Pastore 1, I-16132 Maria, Italy.	de-maria@unige.it	Del Zotto, Genny/J-9694-2019; Antonini, Francesca/AAA-7074-2020	Del Zotto, Genny/0000-0001-7272-7776; Antonini, Francesca/0000-0002-4469-8522; luganini, anna/0000-0003-4256-5774	Molecular Clinical Oncology Extension Program [IG 531000, 9962]; Associazione Italiana per la Ricerca Sul Cancro Investigator Grant [19920, 15283]; Istituto Superiore di Sanita: Programma nazionale di ricerca sull'AIDS, Accordi di Collaborazione Scientifica [45G.11, 40H69]; Ministero della Salute [RF-2010-2316197]; Federazione Italiana Ricerca sul Cancro;  [531000];  [21147]	Molecular Clinical Oncology Extension Program; Associazione Italiana per la Ricerca Sul Cancro Investigator Grant(Fondazione AIRC per la ricerca sul cancro); Istituto Superiore di Sanita: Programma nazionale di ricerca sull'AIDS, Accordi di Collaborazione Scientifica; Ministero della Salute(Ministry of Health, Italy); Federazione Italiana Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); ; 	This work was supported by grants awarded by 531000 Immunity in Cancer Spreading and Metastasis-Project Code: 21147; IG 531000 Molecular Clinical Oncology Extension Program-Project Code: 9962; Associazione Italiana per la Ricerca Sul Cancro Investigator Grant (L.M.) IG 2017-Project Code: 19920; IG 2014-Project Code: 15283; Istituto Superiore di Sanita: Programma nazionale di ricerca sull'AIDS, Accordi di Collaborazione Scientifica 45G.11 (A.D.M.), 40H69 (A.D.M.); Ministero della Salute RF-2010-2316197 (A.D.M.). L.M. is a recipient of a fellowship awarded by Federazione Italiana Ricerca sul Cancro.	Amadei B, 2010, GASTROENTEROLOGY, V138, P1536, DOI 10.1053/j.gastro.2010.01.006; An NF, 2013, STEM CELLS, V31, P1202, DOI 10.1002/stem.1369; BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; Bjorkstrom NK, 2010, TRENDS IMMUNOL, V31, P401, DOI 10.1016/j.it.2010.08.003; Bozzano F, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9109; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Brault L, 2014, LEUKEMIA, V28, P566, DOI 10.1038/leu.2013.201; Cavaletto N, 2015, J VIROL, V89, P11092, DOI 10.1128/JVI.01141-15; Chan A, 2007, J IMMUNOL, V179, P89, DOI 10.4049/jimmunol.179.1.89; Chen LH, 2003, LIFE SCI, V73, P2373, DOI 10.1016/S0024-3205(03)00606-4; Cichocki F, 2018, J EXP MED, V215, P2379, DOI 10.1084/jem.20172168; Colucci F, 2003, NAT REV IMMUNOL, V3, P413, DOI 10.1038/nri1088; Crotta S, 2010, J HEPATOL, V52, P183, DOI 10.1016/j.jhep.2009.11.003; De Maria A, 2003, EUR J IMMUNOL, V33, P2410, DOI 10.1002/eji.200324141; De Maria A, 2011, P NATL ACAD SCI USA, V108, P728, DOI 10.1073/pnas.1012356108; Della Chiesa M, 2012, BLOOD, V119, P399, DOI 10.1182/blood-2011-08-372003; Fogli M, 2004, EUR J IMMUNOL, V34, P2313, DOI 10.1002/eji.200425251; Foley B, 2012, BLOOD, V119, P2665, DOI 10.1182/blood-2011-10-386995; Freud AG, 2006, J EXP MED, V203, P1033, DOI 10.1084/jem.20052507; Freud AG, 2005, IMMUNITY, V22, P295, DOI 10.1016/j.immuni.2005.01.013; Freud AG, 2017, IMMUNITY, V47, P820, DOI 10.1016/j.immuni.2017.10.008; Gazit R, 2006, NAT IMMUNOL, V7, P517, DOI 10.1038/ni1322; Golden-Mason L, 2010, HEPATOLOGY, V52, P1581, DOI 10.1002/hep.23896; Gordon CL, 2017, J EXP MED, V214, P651, DOI 10.1084/jem.20160758; Gribaudo G, 2002, J GEN VIROL, V83, P2983, DOI 10.1099/0022-1317-83-12-2983; Grundler R, 2009, J EXP MED, V206, P1957, DOI 10.1084/jem.20082074; Grzywacz B, 2006, BLOOD, V108, P3824, DOI 10.1182/blood-2006-04-020198; Guma M, 2006, BLOOD, V107, P3624, DOI 10.1182/blood-2005-09-3682; Guma M, 2004, BLOOD, V104, P3664, DOI 10.1182/blood-2004-05-2058; Hendricks DW, 2014, J IMMUNOL, V192, P4492, DOI 10.4049/jimmunol.1303211; Huntington ND, 2007, NAT IMMUNOL, V8, P856, DOI 10.1038/ni1487; Jung H, 2013, CELL METAB, V18, P75, DOI 10.1016/j.cmet.2013.06.002; Khakoo SI, 2004, SCIENCE, V305, P872, DOI 10.1126/science.1097670; Laurenti E, 2013, NAT IMMUNOL, V14, P756, DOI 10.1038/ni.2615; Lee J, 2015, IMMUNITY, V42, P431, DOI 10.1016/j.immuni.2015.02.013; Lee KN, 2005, IMMUNITY, V22, P195, DOI 10.1016/j.immuni.2004.12.012; Mace EM, 2019, IMMUNOL REV, V287, P202, DOI 10.1111/imr.12725; Mansson R, 2010, BLOOD, V115, P2601, DOI 10.1182/blood-2009-08-236398; Marras F, 2017, J VIROL, V91, DOI 10.1128/JVI.00647-17; Matusali G, 2013, FASEB J, V27, P2440, DOI 10.1096/fj.12-223057; Mavilio D, 2005, P NATL ACAD SCI USA, V102, P2886, DOI 10.1073/pnas.0409872102; Milush JM, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-158; Min-Oo G, 2014, J EXP MED, V211, P1289, DOI 10.1084/jem.20132459; Muccio L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01050; Muccio L, 2016, HAEMATOLOGICA, V101, P371, DOI 10.3324/haematol.2015.134155; Muntasell A, 2013, EUR J IMMUNOL, V43, P1133, DOI 10.1002/eji.201243117; Ohs I, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13708; Patsialou A, 2005, NUCLEIC ACIDS RES, V33, P66, DOI 10.1093/nar/gki145; Paust S, 2010, NAT IMMUNOL, V11, P1127, DOI 10.1038/ni.1953; Petitdemange C, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002268; Renoux VM, 2015, IMMUNITY, V43, P394, DOI 10.1016/j.immuni.2015.07.011; Reymond N, 2004, J EXP MED, V199, P1331, DOI 10.1084/jem.20032206; Romagnani C, 2007, J IMMUNOL, V178, P4947, DOI 10.4049/jimmunol.178.8.4947; Sauce D, 2011, BLOOD, V117, P5142, DOI 10.1182/blood-2011-01-331306; Schlums H, 2015, IMMUNITY, V42, P443, DOI 10.1016/j.immuni.2015.02.008; Sherrington PD, 1997, J BIOL CHEM, V272, P21735, DOI 10.1074/jbc.272.35.21735; Sivori S, 2003, EUR J IMMUNOL, V33, P3439, DOI 10.1002/eji.200324533; Sivori S, 2002, P NATL ACAD SCI USA, V99, P4526, DOI 10.1073/pnas.072065999; Sullivan DP, 2013, AM J PATHOL, V182, P1031, DOI 10.1016/j.ajpath.2012.11.037; Sun JC, 2009, NATURE, V457, P557, DOI 10.1038/nature07665; Trilling M, 2013, CYTOMEGALOVIRUSES IN; Tudor KSRS, 2000, IMMUNITY, V12, P335, DOI 10.1016/S1074-7613(00)80186-7; Walzer T, 2007, NAT IMMUNOL, V8, P1337, DOI 10.1038/ni1523; Ward J, 2007, BLOOD, V110, P1207, DOI 10.1182/blood-2006-06-028175; Werner JM, 2013, HEPATOLOGY, V58, P1621, DOI 10.1002/hep.26353	65	11	11	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2021	147	6					2343	2357		10.1016/j.jaci.2020.12.648	http://dx.doi.org/10.1016/j.jaci.2020.12.648		JUN 2021	15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SM7ID	33493558				2022-12-18	WOS:000657773400001
J	Wilson, JM; Keshavarz, B; James, HR; Retterer, MKC; Schuyler, AJ; Knoedler, A; Workman, LJ; Ng'ang'a, L; Chico, ME; Ronmark, E; Heymann, PW; Perzanowski, MS; Platts-Mills, TAE; Cooper, PJ				Wilson, Jeffrey M.; Keshavarz, Behnam; James, Hayley R.; Retterer, Maya K. C.; Schuyler, Alexander J.; Knoedler, Alice; Workman, Lisa J.; Ng'ang'a, Lucy; Chico, Martha E.; Ronmark, Eva; Heymann, Peter W.; Perzanowski, Matthew S.; Platts-Mills, Thomas A. E.; Cooper, Philip J.			alpha-Gal specific-IgE prevalence and levels in Ecuador and Kenya: Relation to diet, parasites, and IgG(4)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; alpha-Gal; mammalian meat allergy; Ascaris; parasite; sensitization	ANTIBODIES; ASTHMA; ASCARIS; ATOPY; SENSITIZATION; INDIVIDUALS; RELEVANCE; SEVERITY; CHILDREN	Background: IgE to alpha-Gal is a cause of mammalian meat allergy and has been linked to tick bites in North America, Australia, and Eurasia. Reports from the developing world indicate that alpha-Gal sensitization is prevalent but has been little investigated. Objective: We sought evidence for the cause(s) of alpha-Gal sensitization and lack of reported meat allergy among children in less developed settings in Ecuador and Kenya. Methods: IgE to alpha-Gal and total IgE were assessed in children from Ecuador (n = 599) and Kenya (n = 254) and compared with children with (n = 42) and without known (n = 63) mammalian meat allergy from the southeastern United States. Information on diet, potential risk factors, and helminth infections was available for children from Ecuador. IgG(4) to alpha-Gal and antibodies to regionally representative parasites were assessed in a subset of children. Results: In Ecuador (32%) and Kenya (54%), alpha-Gal specific IgE was prevalent, but levels were lower than in children with meat allergy from the United States. Sensitization was associated with rural living, antibody markers of Ascaris exposure, and total IgE, but not active infections with Ascaris or Trichuris species. In Ecuador, 87.5% reported consuming beef at least once per week, including 83.9% of those who had alpha-Gal specific IgE. Levels of alpha-Gal specific IgG(4) were not high in Ecuador, but were greater than in children from the United States. Conclusions: These results suggest that in areas of the developing world with endemic parasitism, alpha-Gal sensitization is (1) common, (2) associated with Ascaris exposure, and (3) distinguished by a low percentage of specific/total IgE compared with individuals with meat allergy in the United States.	[Wilson, Jeffrey M.; Keshavarz, Behnam; James, Hayley R.; Retterer, Maya K. C.; Schuyler, Alexander J.; Knoedler, Alice; Workman, Lisa J.; Heymann, Peter W.; Platts-Mills, Thomas A. E.] Univ Virginia, Div Allergy & Clin Immunol, POB 801355, Charlottesville, VA 22908 USA; [Ng'ang'a, Lucy] US Int Univ, Nairobi, Kenya; [Chico, Martha E.; Cooper, Philip J.] Fdn Ecuatoriana Invest Salud, Quininde, Ecuador; [Ronmark, Eva] Umea Univ, OLIN Unit, Dept Publ Hlth & Clin Med, Umea, Sweden; [Perzanowski, Matthew S.] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA; [Cooper, Philip J.] St Georges Univ London, Inst Infect & Immun, Cranmer Terrace, London SW17 0RE, England; [Cooper, Philip J.] Univ Int Ecuador, Escuela Med, Quito, Ecuador	University of Virginia; United States International University Africa; Umea University; Columbia University; St Georges University London	Platts-Mills, TAE (corresponding author), Univ Virginia, Div Allergy & Clin Immunol, POB 801355, Charlottesville, VA 22908 USA.; Cooper, PJ (corresponding author), St Georges Univ London, Inst Infect & Immun, Cranmer Terrace, London SW17 0RE, England.	tap2z@virginia.edu; pcooper@sgul.ac.uk	K, B/Q-7874-2016	K, B/0000-0001-5121-6950	National Institutes of Health [088862/Z/09/Z]; AAAAI Faculty Development Award [R37 AI-20565]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AAAAI Faculty Development Award	This study was supported by theWellcome Trust grant (grant no. 088862/Z/09/Z to P.C.), National Institutes of Health (grant no. R37 AI-20565 to T.P.-M.) and AAAAI Faculty Development Award (J.W.).	Aalberse RC, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0621-x; Apostolovic D, 2018, ALLERGY, V73, P1525, DOI 10.1111/all.13400; Arkestal K, 2011, J ALLERGY CLIN IMMUN, V127, P1024, DOI 10.1016/j.jaci.2011.01.033; AVILA JL, 1989, J IMMUNOL, V142, P2828; Beck HE, 2018, SCI DATA, V5, DOI 10.1038/sdata.2018.214; Commins SP, 2011, J ALLERGY CLIN IMMUN, V127, P1286, DOI 10.1016/j.jaci.2011.02.019; Cooper Philip J, 2006, BMC Pulm Med, V6, P24, DOI 10.1186/1471-2466-6-24; Duffy MS, 2006, GLYCOBIOLOGY, V16, P854, DOI 10.1093/glycob/cwl001; Endara P, 2015, CLIN EXP ALLERGY, V45, P438, DOI 10.1111/cea.12399; Fischer J, 2017, ALLERGY, V72, P1540, DOI 10.1111/all.13156; Galli SJ, 2016, ALLERGOL INT, V65, P3, DOI 10.1016/j.alit.2015.09.002; Hodzic A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020167; Hunninghake GM, 2007, J ALLERGY CLIN IMMUN, V119, P654, DOI 10.1016/j.jaci.2006.12.609; Kennedy JL, 2014, AM J RESP CRIT CARE, V189, P532, DOI 10.1164/rccm.201310-1767OC; Kennedy JL, 2013, PEDIATRICS, V131, pE1545, DOI 10.1542/peds.2012-2585; Kollmann D, 2017, ALLERGY, V72, P266, DOI 10.1111/all.12948; Mabelane T, 2018, PEDIAT ALLERG IMM-UK, V29, P841, DOI 10.1111/pai.12969; McGowan EC, 2019, ANN ALLERG ASTHMA IM, V122, P563, DOI 10.1016/j.anai.2019.03.024; Mendonca LR, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001886; Palm NW, 2012, NATURE, V484, P465, DOI 10.1038/nature11047; Perzanowski MS, 2016, J ALLERGY CLIN IMMUN, V138, P1582, DOI 10.1016/j.jaci.2016.05.017; Perzanowski MS, 2002, J PEDIATR-US, V140, P582, DOI 10.1067/mpd.2002.122937; Platts-Mills TAE, 2020, J ALLERGY CLIN IMMUN, V145, P1061, DOI 10.1016/j.jaci.2020.01.047; Poltl G, 2007, FEBS J, V274, P714, DOI 10.1111/j.1742-4658.2006.05615.x; Rispens T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055566; Schuyler AJ, 2018, J ALLERGY CLIN IMMUN, V142, P139, DOI 10.1016/j.jaci.2018.02.049; Soto-Quiros M, 2012, J ALLERGY CLIN IMMUN, V129, P1499, DOI 10.1016/j.jaci.2012.03.040; Stoltz LP, 2019, J ALLER CL IMM-PRACT, V7, P664, DOI 10.1016/j.jaip.2018.07.014; Wilson JM, 2021, J ALLERGY CLIN IMMUN, V147, P643, DOI 10.1016/j.jaci.2020.05.034; Wilson JM, 2020, ANN ALLERG ASTHMA IM, V124, P135, DOI 10.1016/j.anai.2019.11.024; Wilson JM, 2019, J ALLER CL IMM-PRACT, V7, P2348, DOI 10.1016/j.jaip.2019.03.031; Wilson JM, 2018, J ALLERGY CLIN IMMUN, V141, P419, DOI 10.1016/j.jaci.2017.07.029; Wuhrer M, 2004, GLYCOBIOLOGY, V14, P115, DOI 10.1093/glycob/cwh021; Yilmaz B, 2014, CELL, V159, P1277, DOI 10.1016/j.cell.2014.10.053	34	11	11	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2021	147	4					1393	+		10.1016/j.jaci.2020.12.650	http://dx.doi.org/10.1016/j.jaci.2020.12.650		APR 2021	16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RX3VK	33539899	Bronze, Green Accepted			2022-12-18	WOS:000647154500004
J	Yan, Q; Forno, E; Herrera-Luis, E; Pino-Yanes, M; Yang, G; Oh, S; Acosta-Perez, E; Hu, DL; Eng, C; Huntsman, S; Rodriguez-Santana, JR; Cloutier, MM; Canino, G; Burchard, EG; Chen, W; Celedon, JC				Yan, Qi; Forno, Erick; Herrera-Luis, Esther; Pino-Yanes, Maria; Yang, Ge; Oh, Sam; Acosta-Perez, Edna; Hu, Donglei; Eng, Celeste; Huntsman, Scott; Rodriguez-Santana, Jose R.; Cloutier, Michelle M.; Canino, Glorisa; Burchard, Esteban G.; Chen, Wei; Celedon, Juan C.			A genome-wide association study of asthma hospitalizations in adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HLA-II genes; asthma; hospitalizations; adults	TOTAL IGE; HLA-DQ; EXACERBATIONS; SUSCEPTIBILITY; CHILDREN; RISK; POLYMORPHISMS; DISEASE; LOCI; DM	Background: Little is known about the genetic determinants of severe asthma exacerbations. Objectives: We aimed to identify genetic variants associated with asthma hospitalizations. Methods: We conducted a genome-wide association study of asthma hospitalizations in 34,167 white British adults with asthma, 1,658 of whom had at least 1 asthma-related hospitalization. This analysis was conducted by using logistic regression under an additive genetic model with adjustment for age, sex, body mass index, smoking status, and the first 5 principal components derived from genotypic data. We then analyzed data from 2 cohorts of Latino children and adolescents for replication and conducted quantitative trait locus and functional annotation analyses. Results: At the chromosome 6p21.3 locus, the single-nucleotide polymorphism (SNP) rs56151658 (8 kb from the promoter of HLA-DQB1) was most significantly associated with asthma hospitalizations (for test allele A, odds ratio = 1.36 [95% CI = 1.22-1.52]; P = 3.11 x 10(-8)); 21 additional SNPs in this locus were associated with asthma hospitalizations at a P value less than 1 x 10(-6). In the replication cohorts, multiple SNPs in strong linkage disequilibrium with rs56151658 were associated with severe asthma exacerbations at a P value of .01 or less in the same direction of association as in the discovery cohort. Three HLA genes (HLA-DQA2, HLA-DRB6, and HLA-DOB) were also shown to mediate the estimated effects of the SNPs associated with asthma hospitalizations through effects on gene expression in lung tissue. Conclusions: We identified strong candidate genes for asthma hospitalizations in adults in the region for class II HLA genes through genomic, quantitative trait locus, and summary data-based mendelian randomization analyses.	[Yan, Qi; Forno, Erick; Yang, Ge; Chen, Wei; Celedon, Juan C.] Univ Pittsburgh, UPMC Childrens Hosp Pittsburgh, Div Pediat Pulm Med, Pittsburgh, PA USA; [Herrera-Luis, Esther; Pino-Yanes, Maria] Univ La Laguna, Genom & Hlth Grp, Dept Biochem Microbiol Cell Biol & Genet, San Cristobal la Laguna, Spain; [Pino-Yanes, Maria] Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain; [Oh, Sam; Hu, Donglei; Eng, Celeste; Huntsman, Scott; Burchard, Esteban G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Acosta-Perez, Edna; Canino, Glorisa] Univ Puerto Rico, Behav Sci Res Inst, San Juan, PR 00936 USA; [Rodriguez-Santana, Jose R.] Ctr Neumol Pediat, San Juan, PR USA; [Cloutier, Michelle M.] Univ Connecticut, Dept Pediat, Farmington, CT USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Universidad de la Laguna; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Instituto de Salud Carlos III; University of California System; University of California San Francisco; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; University of Connecticut	Celedon, JC (corresponding author), UPMC Childrens Hosp Pittsburgh, Div Pulm Med, 4401 Penn Ave, Pittsburgh, PA 15224 USA.	juan.celedon@chp.edu	Pino-Yanes, Maria/C-8498-2017; Herrera-Luis, Esther/AAY-2315-2020	Pino-Yanes, Maria/0000-0003-0332-437X; Herrera-Luis, Esther/0000-0003-4150-5454; acosta, edna/0000-0001-7101-3157	US National Institutes of Health (NIH) [HL079966, HL117191, MD011764, HL138098, U54MD007587]; NIH [HL117004, HL134589, ES015794]; Sandler Family Foundation; American Asthma Foundation; RWJF Amos Medical Faculty Development Program; Harry Wm. and Diana V. Hind Distinguished Professorship in Pharmaceutical Sciences II; Spanish Ministry of Economy, Industry, and Competitiveness [SAF2017-83417R]; State Research Agency; European Regional Development Funds from the European Union (MINECO/AEI/FEDER, UE); Ramon y Cajal Program by the Spanish Ministry of Economy, Industry, and Competitiveness [RYC-2015-17205]; Spanish Ministry of Science, Innovation [PRE2018-083837]	US National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sandler Family Foundation; American Asthma Foundation; RWJF Amos Medical Faculty Development Program; Harry Wm. and Diana V. Hind Distinguished Professorship in Pharmaceutical Sciences II; Spanish Ministry of Economy, Industry, and Competitiveness(Spanish Government); State Research Agency; European Regional Development Funds from the European Union (MINECO/AEI/FEDER, UE); Ramon y Cajal Program by the Spanish Ministry of Economy, Industry, and Competitiveness; Spanish Ministry of Science, Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government)	The UK Biobank Resource was accessed under application no. 43252. The current analysis, like that in the Hartford-Puerto Rico and EVA-PR studies, was supported by the following grants from the US National Institutes of Health (NIH): HL079966, HL117191, and MD011764 (to J.C.C.), HL138098 (to Q.Y.) and U54MD007587 (to the University of Puerto Rico). The Genes-Environments and Admixture in Latino Americans study was supported by NIH grants HL117004 and HL134589; enrollment was supported by the Sandler Family Foundation, the American Asthma Foundation, the RWJF Amos Medical Faculty Development Program, Harry Wm. and Diana V. Hind Distinguished Professorship in Pharmaceutical Sciences II, and NIH grant ES015794. M.P.Y. was supported by grants SAF2017-83417R awarded by the Spanish Ministry of Economy, Industry, and Competitiveness; the State Research Agency and the European Regional Development Funds from the European Union (MINECO/AEI/FEDER, UE); and grant RYC-2015-17205 awarded by the Ramon y Cajal Program by the Spanish Ministry of Economy, Industry, and Competitiveness. E.H.L. was funded by a fellowship (PRE2018-083837) from the Spanish Ministry of Science, Innovation, and Universities.	Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Aguiar VRC, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008091; Bisgaard H, 2009, AM J RESP CRIT CARE, V179, P179, DOI 10.1164/rccm.200809-1436OC; Bonnelykke K, 2014, NAT GENET, V46, P51, DOI 10.1038/ng.2830; Brehm JM, 2012, J ALLERGY CLIN IMMUN, V129, P1484, DOI 10.1016/j.jaci.2012.03.035; Busch R, 2012, EXPERT REV MOL MED, V14, DOI 10.1017/erm.2012.9; Bycroft C, 2018, NATURE, V562, P203, DOI 10.1038/s41586-018-0579-z; Centers for Disease Control and Prevention, MOST RECENT NATL AST; Chang CC, 2015, GIGASCIENCE, V4, DOI 10.1186/s13742-015-0047-8; Cunningham J, 2011, ANN ALLERG ASTHMA IM, V106, P381, DOI 10.1016/j.anai.2011.01.030; Dahlin A, 2015, IMMUN INFLAMM DIS, V3, P350, DOI 10.1002/iid3.73; Das S, 2016, NAT GENET, V48, P1284, DOI 10.1038/ng.3656; Demenais F, 2018, NAT GENET, V50, P42, DOI 10.1038/s41588-017-0014-7; Durinck S, 2005, BIOINFORMATICS, V21, P3439, DOI 10.1093/bioinformatics/bti525; Forno E, 2019, LANCET RESP MED, V7, P336, DOI 10.1016/S2213-2600(18)30466-1; Fuhlbrigge A, 2012, J ALLERGY CLIN IMMUN, V129, pS34, DOI 10.1016/j.jaci.2011.12.983; Gao JM, 2003, CHINESE MED J-PEKING, V116, P1078; Hay SI, 2017, LANCET, V389, pE1; Hernandez-Pacheco N, 2019, CLIN EXP ALLERGY, V49, P789, DOI 10.1111/cea.13354; HOWELL WM, 1995, THORAX, V50, P815, DOI 10.1136/thx.50.8.815; Hunninghake GM, 2007, J ALLERGY CLIN IMMUN, V120, P84, DOI 10.1016/j.jaci.2007.04.032; Johansson A, 2019, HUM MOL GENET, V28, P4022, DOI 10.1093/hmg/ddz175; Kremer AN, 2012, BLOOD, V120, P3246, DOI 10.1182/blood-2011-12-399311; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; McCarthy S, 2016, NAT GENET, V48, P1279, DOI 10.1038/ng.3643; McGeachie MJ, 2015, J ALLERGY CLIN IMMUN, V136, P1503, DOI 10.1016/j.jaci.2015.04.039; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Movahedi M, 2008, IRAN J ALLERGY ASTHM, V7, P215, DOI 07.04/ijaai.215220; Ng PC, 2001, GENOME RES, V11, P863, DOI 10.1101/gr.176601; Nishimura KK, 2013, AM J RESP CRIT CARE, V188, P309, DOI 10.1164/rccm.201302-0264OC; Pino-Yanes M, 2015, J ALLERGY CLIN IMMUN, V135, P228, DOI 10.1016/j.jaci.2014.07.053; Pividori M, 2019, LANCET RESP MED, V7, P509, DOI 10.1016/S2213-2600(19)30055-4; Poluektov YO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071228; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Puranik S, 2017, AM J RESP CRIT CARE, V195, P854, DOI 10.1164/rccm.201606-1213PP; Shiina T, 2004, TISSUE ANTIGENS, V64, P631, DOI 10.1111/j.1399-0039.2004.00327.x; Shrine N, 2019, LANCET RESP MED, V7, P20, DOI 10.1016/S2213-2600(18)30389-8; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Wenzel SE, 2007, AM J RESP CRIT CARE, V175, P570, DOI 10.1164/rccm.200607-909OC; Xu MS, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-90; Yan Q, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01505-2016; Zhou ZM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00262; Zhu ZH, 2016, NAT GENET, V48, P481, DOI 10.1038/ng.3538	44	11	11	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2021	147	3					933	940		10.1016/j.jaci.2020.08.020	http://dx.doi.org/10.1016/j.jaci.2020.08.020		MAR 2021	8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RA9TV	32890573	Green Accepted			2022-12-18	WOS:000631762400015
J	Jha, A; Thwaites, RS; Tunstall, T; Kon, OM; Shattock, RJ; Hansel, TT; Openshaw, PJM				Jha, Akhilesh; Thwaites, Ryan S.; Tunstall, Tanushree; Kon, Onn Min; Shattock, Robin J.; Hansel, Trevor T.; Openshaw, Peter J. M.			Increased nasal mucosal interferon and CCL13 response to a TLR7/8 agonist in asthma and allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Innate immunity; airway mucosa; IFN-stimulated genes; allergic asthma; epithelial cells		Background: Acute respiratory viral infections are a major cause of respiratory morbidity and mortality, especially in patients with preexisting lung diseases such as asthma. Toll-like receptors are critical in the early detection of viruses and in activating innate immunity in the respiratory mucosa, but there is no reliable and convenient method by which respiratory mucosal innate immune responses can be measured. Objective: We sought to assess in vivo immune responses to an innate stimulus and compare responsiveness between healthy volunteers and volunteers with allergy. Methods: We administered the Toll-like receptor 7/8 agonist resiquimod (R848; a synthetic analogue of single-stranded RNA) or saline by nasal spray to healthy participants without allergy (n = 12), those with allergic rhinitis (n = 12), or those with allergic rhinitis with asthma (n = 11). Immune mediators in blood and nasal fluid and mucosal gene expression were monitored over time. Results: R848 was well tolerated and significantly induced IFN-alpha 2a, IFN-gamma, proinflammatory cytokines (TNF-alpha, IL-2, IL-12p70), and chemokines (CXCL10, C-C motif chemokine ligand [CCL]2, CCL3, CCL4, and CCL13) in nasal mucosal fluid, without causing systemic immune activation. Participants with allergic rhinitis or allergic rhinitis with asthma had increased IFN-alpha 2a, CCL3, and CCL13 responses relative to healthy participants; those with asthma had increased induction of IFN-stimulated genes DExD/H-box helicase 58, MX dynamin-like GTPase 1, and IFN-induced protein with tetratricopeptide repeats 3. Conclusions: Responses to nasal delivery of R848 enables simple assessment of mucosal innate responsiveness, revealing that patients with allergic disorders have an increased nasal mucosal IFN and chemokine response to the viral RNA analogue R848. This highlights that dysregulated innate immune responses of the nasal mucosa in allergic individuals may be important in determining the outcome of viral exposure.	[Jha, Akhilesh; Thwaites, Ryan S.; Tunstall, Tanushree; Kon, Onn Min; Hansel, Trevor T.; Openshaw, Peter J. M.] Imperial Coll London, Natl Heart & Lung Inst, St Marys Campus,Norfolk Pl, London W2 1PG, England; [Shattock, Robin J.] Imperial Coll London, Dept Infect Dis, London, England; [Jha, Akhilesh] Univ Cambridge, Dept Med, Cambridge, England	Imperial College London; Imperial College London; University of Cambridge	Openshaw, PJM (corresponding author), Imperial Coll London, Natl Heart & Lung Inst, St Marys Campus,Norfolk Pl, London W2 1PG, England.; Hansel, TT (corresponding author), Imperial Coll, Natl Heart & Lung Inst, Imperial Clin Resp Res Unit, St Marys Hosp, London W2 1NY, England.	t.hansel@imperial.ac.uk		Thwaites, Ryan/0000-0003-3052-2793; Tunstall, Tanushree/0000-0002-3220-8346; Jha, Akhilesh/0000-0002-8413-7738	National Institute for Health Research (NIHR) Imperial College Healthcare Trust Biomedical Research Centre [P45058]; National Institute for Health Research Health Protection Research Unit in Respiratory Infections at Imperial College London; Public Health England (PHE)	National Institute for Health Research (NIHR) Imperial College Healthcare Trust Biomedical Research Centre; National Institute for Health Research Health Protection Research Unit in Respiratory Infections at Imperial College London; Public Health England (PHE)	The study was supported by the National Institute for Health Research (NIHR) Imperial College Healthcare Trust Biomedical Research Centre (grant no. P45058) and by the National Institute for Health Research Health Protection Research Unit in Respiratory Infections at Imperial College London in partnership with Public Health England (PHE). The views expressed are those of the author(s) and not necessarily those of the National Health Service, the NIHR, the Department of Health, or the PHE. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2014, THORAX, V69, P1; Cote O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096217; Delaney S, 2016, BMJ OPEN RESPIR RES, V3, DOI 10.1136/bmjresp-2015-000113; Denholm JT, 2010, MED J AUSTRALIA, V192, P84, DOI 10.5694/j.1326-5377.2010.tb03424.x; Dhariwal J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135363; Djukanovic R, 2014, AM J RESP CRIT CARE, V190, P145, DOI 10.1164/rccm.201312-2235OC; Dunning J, 2018, NAT IMMUNOL, V19, P625, DOI 10.1038/s41590-018-0111-5; Edwards MR, 2017, J ALLERGY CLIN IMMUN, V140, P909, DOI 10.1016/j.jaci.2017.07.025; Edwards MR, 2012, NAT REV MICROBIOL, V10, P459, DOI 10.1038/nrmicro2801; El-Gammal A, 2016, AM J RESP CRIT CARE, V194, P169, DOI 10.1164/rccm.201508-1623OC; GBD 2013 Mortality and Causes of Death Collaborators, 2013, GLOBAL REGIONAL NATL; Gill MA, 2010, J IMMUNOL, V184, P5999, DOI 10.4049/jimmunol.0901194; Habibi MS, 2015, AM J RESP CRIT CARE, V191, P1040, DOI 10.1164/rccm.201412-2256OC; Hansel TT, 2017, EBIOMEDICINE, V19, P128, DOI 10.1016/j.ebiom.2017.03.033; Jackson DJ, 2011, J ALLERGY CLIN IMMUN, V128, P1165, DOI 10.1016/j.jaci.2011.10.024; James AL, 2009, EUR RESPIR J, V34, P1040, DOI 10.1183/09031936.00181608; Jarjour NN, 2012, AM J RESP CRIT CARE, V185, P356, DOI 10.1164/rccm.201107-1317PP; Jha A, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.00949-2019; Lamkhioued B, 2000, AM J RESP CRIT CARE, V162, P723, DOI 10.1164/ajrccm.162.2.9901080; Mansson A, 2009, J LEUKOCYTE BIOL, V85, P719, DOI 10.1189/jlb.0808494; Molyneaux PL, 2013, AM J RESP CRIT CARE, V188, P1224, DOI 10.1164/rccm.201302-0341OC; Myles P, 2013, EUR RESPIR J, V41, P824, DOI 10.1183/09031936.00015512; O'Brien KL, 2019, LANCET, V394, P757, DOI 10.1016/S0140-6736(19)30721-4; O'Neill LAJ, 2013, NAT REV IMMUNOL, V13, P453, DOI 10.1038/nri3446; Openshaw PJ, 2018, AM THORACIC SOC, pA4707, DOI [10.1164/ajrccm-conference.2018.197.1_MeetingAbstracts.A4707, DOI 10.1164/AJRCCM-CONFERENCE.2018.197.1_MEETINGABSTRACTS.A4707]; Pockros PJ, 2007, J HEPATOL, V47, P174, DOI 10.1016/j.jhep.2007.02.025; Progatzky F, 2019, J ALLERGY CLIN IMMUN, V144, P342, DOI 10.1016/j.jaci.2019.04.003; Roponen M, 2010, EUR RESPIR J, V35, P64, DOI 10.1183/09031936.00172008; Salter BM, 2017, CHEST, V152, P410, DOI 10.1016/j.chest.2017.01.021; Sandig H, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00185; Shaw DE, 2015, EUR RESPIR J, V46, P1308, DOI 10.1183/13993003.00779-2015; Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835; Simpson JL, 2016, CHEST, V149, P704, DOI 10.1016/j.chest.2015.12.018; Swiecki M, 2015, NAT REV IMMUNOL, V15, P471, DOI 10.1038/nri3865; Sykes A, 2014, THORAX, V69, P240, DOI 10.1136/thoraxjnl-2012-202909; Sykes A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065921; Thwaites RS, 2018, JOVE-J VIS EXP, DOI 10.3791/56413; Thwaites RS, 2017, J INFECT DIS, V215, P1240, DOI 10.1093/infdis/jix150; Tsitoura D, 2015, CLIN PHARMACOL THER, V98, P369, DOI 10.1002/cpt.157; Vasilakos JP, 2013, EXPERT REV VACCINES, V12, P809, DOI 10.1586/14760584.2013.811208; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Xi Y, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01351; Xirakia C, 2010, AM J RESP CRIT CARE, V181, P1207, DOI 10.1164/rccm.200908-1255OC	43	11	12	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2021	147	2					694	+		10.1016/j.jaci.2020.07.012	http://dx.doi.org/10.1016/j.jaci.2020.07.012		FEB 2021	22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QF1NF	32717253	Green Published			2022-12-18	WOS:000616665800031
J	Quiros-Alcala, L; Hansel, NN; McCormack, M; Calafat, AM; Ye, XY; Peng, RD; Matsui, EC				Quiros-Alcala, Lesliam; Hansel, Nadia N.; McCormack, Meredith; Calafat, Antonia M.; Ye, Xiaoyun; Peng, Roger D.; Matsui, Elizabeth C.			Exposure to bisphenols and asthma morbidity among low-income urban children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; asthma morbidity; childhood asthma; African American; BPA; BPS; BPF; inner-city asthma	ENDOCRINE-DISRUPTING CHEMICALS; BODY-MASS INDEX; A EXPOSURE; URINARY CONCENTRATIONS; LUNG-FUNCTION; TEMPORAL VARIABILITY; OXIDATIVE STRESS; UNITED-STATES; IMMUNE-SYSTEM; ASSOCIATION	Background: Bisphenol A (BPA) has been linked with pediatric asthma development and allergic airway inflammation in animal models. Whether exposure to BPA or its structural analogs bisphenol S (BPS) and bisphenol F (BPF) is associated with asthma morbidity remains unknown. Objective: We examined associations between bisphenols and morbidity due to pediatric asthma. Methods: We quantified concentrations of BPA, BPS, and BPF in 660 urine samples from 148 predominantly low-income, African American children (aged 5-17 years) with established asthma. We used biobanked biospecimens and data on symptoms, health care utilization, and pulmonary function and inflammation that were collected every 3 months over the course of a year. We used generalized estimating equations to examine associations between concentrations or detection of urinary bisphenols and morbidity outcomes and assessed heterogeneity of associations by sex. Results: We observed consistent positive associations between BPA exposure and measures of asthma morbidity. For example, we observed increased odds of general symptom days (adjusted odds ratio [aOR] 5 1.40 [95% C 5 1.02-1.92]), maximal symptom days (aOR 5 1.36 [95% CI 5 1.00-1.83]), and emergency department visits (aOR 5 2.12 [95% CI 51.283.51]) per 10-fold increase in BPA concentration. We also observed evidence of sexually dimorphic effects; BPA concentrations were associated with increased odds of symptom days and health care utilization only among boys. Findings regarding BPS and BPF did not consistently point to associations with asthma symptoms or health care utilization. Conclusion: We found evidence to suggest that BPA exposure in a predominantly low-income, minority pediatric cohort is associated with asthma morbidity and that associations may differ by sex. Our findings support additional studies, given the high pediatric asthma burden and widespread exposure to BPA in the United States.	[Quiros-Alcala, Lesliam] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth & Engn, Baltimore, MD USA; [Peng, Roger D.] Johns Hopkins Univ, Dept Biostat, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; [Hansel, Nadia N.; McCormack, Meredith; Matsui, Elizabeth C.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Quiros-Alcala, Lesliam] Univ Maryland, Maryland Inst Appl Environm Hlth, Sch Publ Hlth, College Pk, MD 20742 USA; [Calafat, Antonia M.; Ye, Xiaoyun] US Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA; [Matsui, Elizabeth C.] Univ Texas Austin, Dell Med Sch, Austin, TX 78712 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; University System of Maryland; University of Maryland College Park; Centers for Disease Control & Prevention - USA; University of Texas System; University of Texas Austin	Quiros-Alcala, L (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth & Engn, 615 N Wolfe St, Baltimore, MD 21205 USA.	lquiros@jhu.edu	Calafat, Antonia/GOP-1115-2022; Quiros-Alcala, Lesliam/Q-4928-2016	Calafat, Antonia/0000-0002-9796-7482; Pham, Hewlett/0000-0003-0330-6104; Matsui, Elizabeth/0000-0001-8134-5593; Quiros-Alcala, Lesliam/0000-0002-6600-7227; Koehl, Rachelle/0000-0002-7797-7456	National Heart, Lung, and Blood Institute [K01HL138124]; National Institute of Environmental Health Sciences (NIEHS) [ES018176, R01 ES022607, R01ES023500]; National Institute on Minority Health and Health Disparities [P50MD010431]; US Environmental Protection Agency (EPA) [83615201, 83451001, 83615001]; NIEHS [P50 ES018176, R21 ES025840, mnvbR01ES023447, R01ES026170, R01ES023447]; EPA [83615201]; National Institute of Allergy and Infectious Diseases [K24AI114769]	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Environmental Health Sciences (NIEHS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); US Environmental Protection Agency (EPA)(United States Environmental Protection Agency); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); EPA(United States Environmental Protection Agency); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	L.Q.A. was supported by a National Heart, Lung, and Blood Institute Career Development Award (K01HL138124). N.N.H. was supported by the National Institute of Environmental Health Sciences (NIEHS) (grants ES018176, R01 ES022607, and R01ES023500), the National Institute on Minority Health and Health Disparities (grant P50MD010431), and the US Environmental Protection Agency (EPA) (agreements 83615201, 83451001, and 83615001). M.C.McC. was supported by the NIEHS (grants P50 ES018176 and R21 ES025840,) the National Institute on Minority Health and Health Disparities (grant P50MD010431), and the EPA (agreement 83615201). R.D.P. was supported by the NIEHS (grants P50 ES018176, mnvbR01ES023447, and R01ES026170). E.C.M. was supported by the National Institute of Allergy and Infectious Diseases (grant K24AI114769) and the NIEHS (grants R01ES023447 and R01ES026170). The findings and conclusions in this article are those of the authors and do not necessarily represent the official position or views of the National Institutes of Health, US Centers for Disease Control and Prevention, or EPA. Use of trade names is for identification only and does not imply endorsement by the US Centers for Disease Control and Prevention, the Public Health Service, or the US Department of Health and Human Services.	Ahluwalia SK, 2013, J ALLERGY CLIN IMMUN, V132, P830, DOI 10.1016/j.jaci.2013.05.005; Ahmed SR, 2000, TOXICOLOGY, V150, P191; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; [Anonymous], 2019, 4 REP HUM EXP ENV CH; [Anonymous], BIOM SUMM BISPH; [Anonymous], DEFINING CHILDHOOD O; [Anonymous], BIOM CAL BISPH DIGL; Arasi S, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00028; Bhandari R, 2013, AM J EPIDEMIOL, V177, P1263, DOI 10.1093/aje/kws391; Bloom B, 2013, VITAL HLTH STAT, V10, P2013; Bonds RS, 2013, CURR OPIN ALLERGY CL, V13, P92, DOI 10.1097/ACI.0b013e32835a6dd6; Bonefeld-Jorgensen EC, 2007, ENVIRON HEALTH PERSP, V115, P69, DOI 10.1289/ehp.9368; Buckley JP, 2018, ENVIRON INT, V115, P79, DOI 10.1016/j.envint.2018.03.016; Cabaton N, 2008, TOXICOL IN VITRO, V22, P1697, DOI 10.1016/j.tiv.2008.07.004; Calafat AM, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3494; Card Jeffrey W, 2009, Proc Am Thorac Soc, V6, P588, DOI 10.1513/pats.200904-020RM; Carwile JL, 2009, ENVIRON HEALTH PERSP, V117, P1368, DOI 10.1289/ehp.0900604; Chalubinski M, 2006, ALLERGY, V61, P1326, DOI 10.1111/j.1398-9995.2006.01135.x; Chen Y, 2018, ENVIRON POLLUT, V238, P299, DOI 10.1016/j.envpol.2018.03.031; Cho YS, 2010, ALLERGY ASTHMA IMMUN, V2, P183, DOI 10.4168/aair.2010.2.3.183; Clark E, 2012, SULFOLANE SULFONES; Cooper JE, 2011, CHEMOSPHERE, V85, P943, DOI 10.1016/j.chemosphere.2011.06.060; DeBoer MD, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-018-0612-x; DeWitt Jamie C., 2018, Current Opinion in Toxicology, V10, P31, DOI 10.1016/j.cotox.2017.12.005; Donohue KM, 2013, J ALLERGY CLIN IMMUN, V131, P736, DOI 10.1016/j.jaci.2012.12.1573; Dumont C, 2011, DRUG CHEM TOXICOL, V34, P445, DOI 10.3109/01480545.2011.585651; Fuseini H, 2017, CURR ALLERGY ASTHM R, V17, DOI 10.1007/s11882-017-0686-1; Habib M. Rowshanul, 2009, Mycobiology, V37, P31, DOI 10.4489/MYCO.2009.37.1.031; Hanioka N, 2008, CHEMOSPHERE, V74, P33, DOI 10.1016/j.chemosphere.2008.09.053; Harley KG, 2013, ENVIRON HEALTH PERSP, V121, P514, DOI 10.1289/ehp.1205548; Hiroi H, 1999, ENDOCR J, V46, P773, DOI 10.1507/endocrj.46.773; Hoepner LA, 2013, ENVIRON RES, V122, P38, DOI 10.1016/j.envres.2012.12.003; Ji K, 2013, ENVIRON SCI TECHNOL, V47, P8793, DOI 10.1021/es400329t; Kim KN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111383; Koch HM, 2012, J EXPO SCI ENV EPID, V22, P610, DOI 10.1038/jes.2012.39; Koike E, 2018, INT J IMMUNOPATH PH, V32, DOI 10.1177/2058738418774897; Ku HY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123309; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kuo CH, 2012, KAOHSIUNG J MED SCI, V28, pS37, DOI 10.1016/j.kjms.2012.05.008; Larson NI, 2009, AM J PREV MED, V36, P74, DOI 10.1016/j.amepre.2008.09.025; Larsson K, 2014, ENVIRON INT, V73, P323, DOI 10.1016/j.envint.2014.08.014; Lee MH, 2003, IMMUNOLOGY, V109, P76, DOI 10.1046/j.1365-2567.2003.01631.x; Lehmler HJ, 2018, ACS OMEGA, V3, P6523, DOI 10.1021/acsomega.8b00824; Liao CY, 2014, ARCH ENVIRON CON TOX, V67, P50, DOI 10.1007/s00244-014-0016-8; Liao CY, 2013, J AGR FOOD CHEM, V61, P4655, DOI 10.1021/jf400445n; Liao CY, 2012, ENVIRON SCI TECHNOL, V46, P6515, DOI 10.1021/es300876n; Lin TJ, 2018, ALLERGY ASTHMA IMMUN, V10, P172, DOI 10.4168/aair.2018.10.2.172; Liu BY, 2019, DIABETES METAB J, V43, P59, DOI 10.4093/dmj.2018.0045; Lu KD, 2013, J ALLERGY CLIN IMMUN, V131, P1017, DOI 10.1016/j.jaci.2012.12.1570; Lubin JH, 2004, ENVIRON HEALTH PERSP, V112, P1691, DOI 10.1289/ehp.7199; Mahalingaiah S, 2008, ENVIRON HEALTH PERSP, V116, P173, DOI 10.1289/ehp.10605; Makris KC, 2013, ENVIRON SCI TECHNOL, V47, P3333, DOI 10.1021/es304038k; Matsui EC, 2005, J ALLERGY CLIN IMMUN, V115, P358, DOI 10.1016/j.jaci.2004.11.007; McCormack MC, 2011, ANN ALLERG ASTHMA IM, V106, P308, DOI 10.1016/j.anai.2011.01.015; Michalowicz J, 2015, TOXICOL IN VITRO, V29, P1464, DOI 10.1016/j.tiv.2015.05.012; Miller MD, 2010, ENVIRON HEALTH PERSP, V118, P1155, DOI 10.1289/ehp.0901856; Milligan KL, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0609-6; Mohanan S, 2014, EXP BIOL MED, V239, P1531, DOI 10.1177/1535370214525302; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Nelson JW, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-10; Qiu WH, 2018, CHEMOSPHERE, V194, P1, DOI 10.1016/j.chemosphere.2017.11.125; Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312; Quiros-Alcala L, 2019, J ALLERGY CLIN IMMUN, V143, P948, DOI 10.1016/j.jaci.2018.08.021; Ruiz D, 2018, DIABETES CARE, V41, P193, DOI 10.2337/dc16-2765; Sawai C, 2003, ENVIRON HEALTH PERSP, V111, P1883, DOI 10.1289/ehp.6359; Scioscia G, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.congress-2018.OA3584; Skledar DG, 2015, XENOBIOTICA, V45, P511, DOI 10.3109/00498254.2014.999140; Spanier AJ, 2012, ENVIRON HEALTH PERSP, V120, P916, DOI 10.1289/ehp.1104175; Teitelbaum SL, 2008, ENVIRON RES, V106, P257, DOI 10.1016/j.envres.2007.09.010; Tian XL, 2003, INT ARCH ALLERGY IMM, V132, P240, DOI 10.1159/000074305; Trasande L, 2012, JAMA-J AM MED ASSOC, V308, P1113, DOI 10.1001/2012.jama.11461; U.S. Department of Health and Human Services. National Institues of Health NH Lung and Blood Institute, NIH PUBL, V08 5846; Uemura Y, 2008, HUM IMMUNOL, V69, P149, DOI 10.1016/j.humimm.2008.01.017; Vandenberg LN, 2013, REPROD TOXICOL, V38, P1, DOI 10.1016/j.reprotox.2013.02.002; von Goetz N, 2010, RISK ANAL, V30, P473, DOI 10.1111/j.1539-6924.2009.01345.x; Wang HX, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-79; Wang IJ, 2016, INT J HYG ENVIR HEAL, V219, P311, DOI 10.1016/j.ijheh.2015.12.001; Wang YX, 2019, ENVIRON INT, V123, P301, DOI 10.1016/j.envint.2018.11.071; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; Whyatt RM, 2014, J ALLERGY CLIN IMMUN, V134, P1195, DOI 10.1016/j.jaci.2014.07.027; Xie MY, 2016, REPROD TOXICOL, V65, P224, DOI 10.1016/j.reprotox.2016.08.007; Xin F, 2014, MUTAT RES-GEN TOX EN, V769, P29, DOI 10.1016/j.mrgentox.2014.04.019; Yan HM, 2008, ENVIRON HEALTH PERSP, V116, P514, DOI 10.1289/ehp.10829; Ye XY, 2015, ENVIRON SCI TECHNOL, V49, P11834, DOI 10.1021/acs.est.5b02135; Zhou XL, 2014, J CHROMATOGR B, V944, P152, DOI 10.1016/j.jchromb.2013.11.009	85	11	11	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2021	147	2					577	+		10.1016/j.jaci.2020.05.031	http://dx.doi.org/10.1016/j.jaci.2020.05.031		FEB 2021	17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QF1NF	32736870	Green Accepted			2022-12-18	WOS:000616665800020
J	Trichot, C; Faucheux, L; Karpf, L; Grandclaudon, M; Pattarini, L; Bagot, M; Mahevas, T; Jachiet, M; Saussine, A; Bouaziz, JD; Soumelis, V				Trichot, Coline; Faucheux, Lilith; Karpf, Lea; Grandclaudon, Maximilien; Pattarini, Lucia; Bagot, Martine; Mahevas, Thibault; Jachiet, Marie; Saussine, Anne; Bouaziz, Jean-David; Soumelis, Vassili			T-H cell diversity and response to dupilumab in patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ACTIVATION; ADULTS		[Trichot, Coline; Karpf, Lea; Grandclaudon, Maximilien; Pattarini, Lucia; Soumelis, Vassili] PSL Univ, Inst Curie, INSERM U932, Paris, France; [Trichot, Coline; Faucheux, Lilith; Karpf, Lea; Soumelis, Vassili] Univ Paris, INSERM U976, Human System Immunol & Inflammatory Network Team, Paris, France; [Faucheux, Lilith] Univ Paris, INSERM UMR 1153, ECSTRRA Team, Paris, France; [Bagot, Martine; Mahevas, Thibault; Jachiet, Marie; Saussine, Anne; Bouaziz, Jean-David] Univ Paris, INSERM U976, Skin Immun & Inflammat Team, Paris, France; [Bagot, Martine; Mahevas, Thibault; Jachiet, Marie; Saussine, Anne; Bouaziz, Jean-David] Hop St Louis, APHP, Dept Dermatol, Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Soumelis, V (corresponding author), PSL Univ, Inst Curie, INSERM U932, Paris, France.; Soumelis, V (corresponding author), Univ Paris, INSERM U976, Human System Immunol & Inflammatory Network Team, Paris, France.	vassili.soumelis@aphp.fr		Grandclaudon, Maximilien/0000-0003-2494-6223	INSERM [HTE2016]; Ligue Nationale contre le cancer [EL2016.LNCC/VaS, ANR-10-IDEX-0001-02 PSL, ANR-11-LABX-0043, ANR15-CHIN-0002, ANR-17-CE14-0025-02]; CIC IGR-Curie [1428]; ANRT; ANRS; French Ministry of Research	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Ligue Nationale contre le cancer(Ligue nationale contre le cancer); CIC IGR-Curie; ANRT(French National Research Agency (ANR)); ANRS(ANRSFrench National Research Agency (ANR)); French Ministry of Research(Ministry of Research, FranceEuropean Commission)	Supported by grants INSERM HTE2016, Ligue Nationale contre le cancer EL2016.LNCC/VaS, ANR-10-IDEX-0001-02 PSL*, ANR-11-LABX-0043, ANR15-CHIN-0002, ANR-17-CE14-0025-02, and CIC IGR-Curie 1428. C.T. was supported by ANRT, M.G. received support from ANRS, L.K. and L.F. are supported by a fellowship from the French Ministry of Research.	Antunez C, 2004, CLIN EXP ALLERGY, V34, P559, DOI 10.1111/j.1365-2222.2004.1933.x; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P941, DOI 10.1016/j.jaci.2015.05.049; Esaki H, 2016, J ALLERGY CLIN IMMUN, V138, P1473, DOI 10.1016/j.jaci.2016.04.052; Hamilton JD, 2014, J ALLERGY CLIN IMMUN, V134, P1293, DOI 10.1016/j.jaci.2014.10.013; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; Simpson EL, 2016, NEW ENGL J MED, V375, P2335, DOI 10.1056/NEJMoa1610020; Souwer Y, 2010, CURR OPIN IMMUNOL, V22, P821, DOI 10.1016/j.coi.2010.10.013; Teraki Y, 2013, J ALLERGY CLIN IMMUN, V132, P971, DOI 10.1016/j.jaci.2013.07.029	9	11	11	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2021	147	2					756	+		10.1016/j.jaci.2020.05.037	http://dx.doi.org/10.1016/j.jaci.2020.05.037		FEB 2021	5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QF1NF	32526313	Bronze			2022-12-18	WOS:000616665800043
J	Ketelaar, ME; Portelli, MA; Dijk, FN; Shrine, N; Faiz, A; Vermeulen, CJ; Xu, CJ; Hankinson, J; Bhaker, S; Henry, AP; Billington, CK; Shaw, DE; Johnson, SR; Benest, AV; Pang, V; Bates, DO; Pogson, ZEK; Fogarty, A; McKeever, TM; Singapuri, A; Heaney, LG; Mansur, AH; Chaudhuri, R; Thomson, NC; Holloway, JW; Lockett, GA; Howarth, PH; Niven, R; Simpson, A; Tobin, MD; Hall, IP; Wain, LV; Blakey, JD; Brightling, CE; Obeidat, M; Sin, DD; Nickle, DC; Bosse, Y; Vonk, JM; van den Berge, M; Koppelman, GH; Sayers, I; Nawijn, MC				Ketelaar, Maria E.; Portelli, Michael A.; Dijk, F. Nicole; Shrine, Nick; Faiz, Alen; Vermeulen, Cornelis J.; Xu, Cheng J.; Hankinson, Jenny; Bhaker, Sangita; Henry, Amanda P.; Billington, Charlote K.; Shaw, Dominick E.; Johnson, Simon R.; Benest, Andrew, V; Pang, Vincent; Bates, David O.; Pogson, Z. E. K.; Fogarty, Andrew; McKeever, Tricia M.; Singapuri, Amisha; Heaney, Liam G.; Mansur, Adel H.; Chaudhuri, Rekha; Thomson, Neil C.; Holloway, John W.; Lockett, Gabrielle A.; Howarth, Peter H.; Niven, Robert; Simpson, Angela; Tobin, Martin D.; Hall, Ian P.; Wain, Louise, V; Blakey, John D.; Brightling, Christopher E.; Obeidat, Ma'en; Sin, Don D.; Nickle, David C.; Bosse, Yohan; Vonk, Judith M.; van den Berge, Maarten; Koppelman, Gerard H.; Sayers, Ian; Nawijn, Martijn C.			Phenotypic and functional translation of IL33 genetics in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma phenotypes; IL33 SNPs; eQTL; bronchial epithelium; functional translation		Background: Asthma is a complex disease with multiple phenotypes that may differ in disease pathobiology and treatment response. IL33 single nucleotide polymorphisms (SNPs) have been reproducibly associated with asthma. IL33 levels are elevated in sputum and bronchial biopsies of patients with asthma. The functional consequences of IL33 asthma SNPs remain unknown. Objective: This study sought to determine whether IL33 SNPs associate with asthma-related phenotypes and with IL33 expression in lung or bronchial epithelium. This study investigated the effect of increased IL33 expression on human bronchial epithelial cell (HBEC) function. Methods: Association between IL33 SNPs (Chr9: 5,815,7866,657,983) and asthma phenotypes (Lifelines/DAG [Dutch Asthma GWAS]/GASP [Genetics of Asthma Severity & Phenotypes] cohorts) and between SNPs and expression (lung tissue, bronchial brushes, HBECs) was done using regression modeling. Lentiviral overexpression was used to study IL33 effects on HBECs. Results: We found that 161 SNPs spanning the IL33 region associated with 1 or more asthma phenotypes after correction for multiple testing. We report a main independent signal tagged by rs992969 associating with blood eosinophil levels, asthma, and eosinophilic asthma. A second, independent signal tagged by rs4008366 presented modest association with eosinophilic asthma. Neither signal associated with FEV1, FEV1/forced vital capacity, atopy, and age of asthma onset. The 2 IL33 signals are expression quantitative loci in bronchial brushes and cultured HBECs, but not in lung tissue. IL33 overexpression in vitro resulted in reduced viability and reactive oxygen species-capturing of HBECs, without influencing epithelial cell count, metabolic activity, or barrier function. Conclusions: We identify IL33 as an epithelial susceptibility gene for eosinophilia and asthma, provide mechanistic insight, and implicate targeting of the IL33 pathway specifically in eosinophilic asthma.	[Ketelaar, Maria E.; Dijk, F. Nicole; Faiz, Alen; Vermeulen, Cornelis J.; Xu, Cheng J.; Vonk, Judith M.; van den Berge, Maarten; Koppelman, Gerard H.; Nawijn, Martijn C.] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma & COPD, Groningen, Netherlands; [Ketelaar, Maria E.; Dijk, F. Nicole; Xu, Cheng J.; Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Dept Pediat Pulmonol & Pediat Allergol, Groningen, Netherlands; [Ketelaar, Maria E.; Nawijn, Martijn C.] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Groningen, Netherlands; [Faiz, Alen; Vermeulen, Cornelis J.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulm Dis, Groningen, Netherlands; [Vonk, Judith M.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands; [Ketelaar, Maria E.; Portelli, Michael A.; Bhaker, Sangita; Henry, Amanda P.; Billington, Charlote K.; Shaw, Dominick E.; Johnson, Simon R.; Hall, Ian P.; van den Berge, Maarten; Sayers, Ian] Univ Nottingham, Div Resp Med, Natl Inst Hlth Res, Nottingham Biomed Res Ctr,Nottingham Univ Biodisc, Nottingham, England; [Pogson, Z. E. K.; Fogarty, Andrew; McKeever, Tricia M.] Univ Nottingham, Div Epidemiol & Publ Hlth, Nottingham, England; [Shrine, Nick; Tobin, Martin D.; Wain, Louise, V] Univ Leicester, Glenfield Hosp, Dept Hlth Sci, Leicester, Leics, England; [Shrine, Nick; Tobin, Martin D.; Wain, Louise, V; Brightling, Christopher E.] Univ Leicester, Glenfield Hosp, Natl Inst Hlth Res, Leicester Resp Biomed Res Ctr, Leicester, Leics, England; [Singapuri, Amisha; Brightling, Christopher E.] Univ Leicester, Glenfield Hosp, Inst Lung Hlth, Dept Resp Sci, Leicester, Leics, England; [Xu, Cheng J.] Helmholtz Ctr Infect Res, CiiM, Hannover, Germany; [Xu, Cheng J.] Helmholtz Ctr Infect Res, TWINCORE, Hannover, Germany; [Xu, Cheng J.] Hannover Med Sch, Hannover, Germany; [Hankinson, Jenny; Niven, Robert; Simpson, Angela] Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England; [Benest, Andrew, V; Pang, Vincent; Bates, David O.] Univ Nottingham, Sch Med, Biodiscovery Inst, Div Canc & Stem Cells, Nottingham, England; [Benest, Andrew, V; Pang, Vincent; Bates, David O.] Univ Birmingham, COMPARE, Birmingham, W Midlands, England; [Benest, Andrew, V; Pang, Vincent; Bates, David O.] Univ Nottingham, Nottingham, England; [Pogson, Z. E. K.] Lincoln Cty Hosp, Dept Resp Med, Lincoln, England; [Heaney, Liam G.] Queens Univ Belfast, Ctr Infect & Immun, Belfast, Antrim, North Ireland; [Mansur, Adel H.] Birmingham Heartlands Hosp, Resp Med, Birmingham, W Midlands, England; [Mansur, Adel H.] Univ Birmingham, Birmingham, W Midlands, England; [Chaudhuri, Rekha; Thomson, Neil C.] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland; [Holloway, John W.; Lockett, Gabrielle A.; Howarth, Peter H.] Univ Southampton, Human Dev & Hlth, Fac Med, Southampton, Hants, England; [Holloway, John W.; Lockett, Gabrielle A.; Howarth, Peter H.] Univ Southampton, Clin & Expt Sci, Fac Med, Southampton, Hants, England; [Holloway, John W.; Lockett, Gabrielle A.; Howarth, Peter H.] Univ Southampton, Natl Inst Hlth, Biomed Res Ctr, Southampton, Hants, England; [Blakey, John D.] Sir Charles Gairdner Hosp, Resp Med, Perth, Scotland; [Obeidat, Ma'en; Sin, Don D.] Univ British Columbia, St Pauls Hosp, Ctr Heart Lung Innovat, Vancouver, BC, Canada; [Sin, Don D.] Univ British Columbia, Div Resp Med, Dept Med, Vancouver, BC, Canada; [Nickle, David C.] Merck Res Labs, Dept Genet & Pharmacogen, Boston, MA USA; [Bosse, Yohan] Laval Univ, Inst Univ Cardiol & Pneumol Quebec, Dept Mol Med, Quebec City, PQ, Canada	University of Groningen; University of Groningen; University of Groningen; University of Groningen; University of Groningen; University of Nottingham; University of Nottingham; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; Helmholtz Association; Helmholtz-Center for Infection Research; Helmholtz Association; Helmholtz-Center for Infection Research; Hannover Medical School; University of Manchester; University of Nottingham; University of Birmingham; University of Nottingham; Queens University Belfast; Heart of England NHS Foundation Trust; University of Birmingham; University of Birmingham; University of Glasgow; University of Southampton; University of Southampton; University of Southampton; St. Paul's Hospital; University of British Columbia; University of Saskatchewan; University of British Columbia; Merck & Company; Laval University	Ketelaar, ME (corresponding author), Univ Med Ctr Groningen, Groningen Res Inst Asthma & COPD, Dept Pediat Pulmonol & Pediat Allergol, CA43,POB 30-001, NL-9700 RB Groningen, Netherlands.	m.e.ketelaar@umcg.nl	Holloway, John W/B-5424-2009; Sin, Don/AAC-2219-2021; Faiz, Alen/AAB-7132-2019; Portelli, Michael/U-7671-2019; Xu, Cheng-Jian/G-9144-2018	Holloway, John W/0000-0001-9998-0464; Faiz, Alen/0000-0003-1740-3538; Portelli, Michael/0000-0003-0821-4575; Xu, Cheng-Jian/0000-0003-1586-4672; Johnson, Simon/0000-0002-9837-2763; van den Berge, Maarten/0000-0002-9336-7340; Sayers, Ian/0000-0001-5601-5410; Nawijn, Martijn/0000-0003-3372-6521; brightling, chris/0000-0002-9345-4903; Koppelman, Gerard/0000-0001-8567-3252; Howarth, Peter/0000-0003-0619-7927	Lung Foundation Netherlands grants [AF 95.05, AF 98.48, AF3.2.09.081JU]; University Medical Center Groningen; Dutch TerMeulen Fund; Ubbo Emmius Foundation; GlaxoSmithKline; Dutch Ministry of Health, Welfare and Sport; Dutch Ministry of Economic Affairs; University Groningen; Northern Provinces of the Netherlands - Asthma UK grant [AUK-PG-2013-188]; Asthma UK [AUK-PG-2013-188]; Rosetrees Trust; AirPROM; Medical Research Council [G1100163]; GSK/British Lung Foundation Chair in Respiratory Research; National Institute for Health Research Leicester Respiratory Biomedical Centre; MRC [MC_PC_12010, G1100163] Funding Source: UKRI	Lung Foundation Netherlands grants; University Medical Center Groningen; Dutch TerMeulen Fund; Ubbo Emmius Foundation; GlaxoSmithKline(GlaxoSmithKline); Dutch Ministry of Health, Welfare and Sport; Dutch Ministry of Economic Affairs(Ministry of Economic Affairs, Netherlands); University Groningen; Northern Provinces of the Netherlands - Asthma UK grant; Asthma UK; Rosetrees Trust(Rosetrees Trust); AirPROM; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); GSK/British Lung Foundation Chair in Respiratory Research; National Institute for Health Research Leicester Respiratory Biomedical Centre; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This study was supported by Lung Foundation Netherlands grants AF 95.05 (G.H.K.), AF 98.48 (G.H.K.), and AF3.2.09.081JU (G.H.K., M.C.N.), the University Medical Center Groningen (G.H.K.), Dutch TerMeulen Fund (M.E.K.), the Ubbo Emmius Foundation (G.H.K.), and a grant from GlaxoSmithKline (I.S., I.H., M.C.N., G.H.K.). The Lifelines Biobank initiative has been made possible by subsidy from the Dutch Ministry of Health, Welfare and Sport; the Dutch Ministry of Economic Affairs; the University Medical Center Groningen; University Groningen; and the Northern Provinces of the Netherlands. The generation of the lung tissue dataset was funded by Merck. This study was also funded by an Asthma UK grant AUK-PG-2013-188 (I.S., I.P.H., D.E.S., C.E.B.) and additional funding by Asthma UK grants 10/006 and 11/031 (I.S., D.E.S.). Genotyping in GASP (Genetics of Asthma Severity & Phenotypes) cohort was additionally supported by Rosetrees Trust (I.S.) and AirPROM (C.E.B., M.T., I.S.). This work was supported by the Medical Research Council grant MC_PC_12010, a Strategic Award (I.P.H., M.D.T., L.V.W.), and Medical Research Council project grant G1100163 (S.R.J.). L.V.W. holds the GSK/British Lung Foundation Chair in Respiratory Research. Asthma UK funded the GASP Initiative (grant AUK-PG-2013-188). This work was part funded by the National Institute for Health Research Leicester Respiratory Biomedical Centre. A.S. is supported by theManchester Biomedical Research Centre.	Adzhubei Ivan, 2013, Curr Protoc Hum Genet, VChapter 7, DOI 10.1002/0471142905.hg0720s76; Al Efraij K, 2018, EXPERT REV CLIN PHAR, V11, P669, DOI 10.1080/17512433.2018.1496819; Altman MC, 2019, J CLIN INVEST, V129, P4979, DOI 10.1172/JCI126402; Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110; Astle WJ, 2016, CELL, V167, P1415, DOI 10.1016/j.cell.2016.10.042; Bonnelykke K, 2014, NAT GENET, V46, P51, DOI 10.1038/ng.2830; Braga FAV, 2019, NAT MED, V25, P1153, DOI 10.1038/s41591-019-0468-5; Cayrol C, 2018, IMMUNOL REV, V281, P154, DOI 10.1111/imr.12619; Davis CA, 2018, NUCLEIC ACIDS RES, V46, pD794, DOI 10.1093/nar/gkx1081; Demenais F, 2018, NAT GENET, V50, P42, DOI 10.1038/s41588-017-0014-7; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Emdin CA, 2017, JAMA-J AM MED ASSOC, V318, P1925, DOI 10.1001/jama.2017.17219; Farne HA, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010834.pub3; Ferreira MA, 2017, NAT GENET, V49, P1752, DOI 10.1038/ng.3985; Ferreira MAR, 2014, J ALLERGY CLIN IMMUN, V133, P1564, DOI 10.1016/j.jaci.2013.10.030; Ferreira MAR, 2011, LANCET, V378, P1006, DOI 10.1016/S0140-6736(11)60874-X; Gao J, 2018, ALLERGY ASTHMA CL IM, V14, DOI 10.1186/s13223-018-0248-7; Gasiuniene E, 2019, SCAND J IMMUNOL, V89, DOI 10.1111/sji.12724; Gorbacheva AM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19102911; Grotenboer NS, 2013, J ALLERGY CLIN IMMUN, V131, P856, DOI 10.1016/j.jaci.2012.11.028; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Hamzaoui A, 2013, J ASTHMA, V50, P803, DOI 10.3109/02770903.2013.816317; Heijink IH, 2014, CLIN EXP ALLERGY, V44, P620, DOI 10.1111/cea.12296; Johansson A, 2019, HUM MOL GENET, V28, P4022, DOI 10.1093/hmg/ddz175; Jurak LM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01895; Kaur R, 2019, J ALLERGY CLIN IMMUN, V144, P1, DOI 10.1016/j.jaci.2019.05.031; Kristjansson RP, 2019, NAT GENET, V51, P267, DOI 10.1038/s41588-018-0314-6; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Lambrecht BN, 2012, NAT MED, V18, P684, DOI 10.1038/nm.2737; Li X, 2015, ALLERGY, V70, P1309, DOI 10.1111/all.12683; Marchini J, 2007, NAT GENET, V39, P906, DOI 10.1038/ng2088; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Molofsky AB, 2015, IMMUNITY, V42, P1005, DOI 10.1016/j.immuni.2015.06.006; Nagakumar P, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.01809-2018; Nieuwenhuis MA, 2016, ALLERGY, V71, P1712, DOI 10.1111/all.12990; Pickrell JK, 2016, NAT GENET, V48, P709, DOI 10.1038/ng.3570; Pividori M, 2019, LANCET RESP MED, V7, P509, DOI 10.1016/S2213-2600(19)30055-4; Portelli MA, 2015, AM J RESP CELL MOL, V53, P174, DOI 10.1165/rcmb.2014-0296OC; Poulsen NN, 2018, RESP MED, V140, P50, DOI 10.1016/j.rmed.2018.05.016; Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Saglani S, 2013, J ALLERGY CLIN IMMUN, V132, P676, DOI 10.1016/j.jaci.2013.04.012; Schiller HB, 2019, AM J RESP CELL MOL, V61, P31, DOI 10.1165/rcmb.2018-0416TR; Scholtens S, 2015, INT J EPIDEMIOL, V44, P1172, DOI 10.1093/ije/dyu229; Shrine N, 2019, LANCET RESP MED, V7, P20, DOI 10.1016/S2213-2600(18)30389-8; Slater M, 2016, PHYSIOL REP, V4, DOI 10.14814/phy2.12960; Smith D, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006659; Team RC, 2013, R LANGUAGE ENV STAT; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Uchida M, 2017, ALLERGY, V72, P1521, DOI 10.1111/all.13158; Vicente CT, 2017, CLIN TRANSL IMMUNOL, V6, DOI 10.1038/cti.2017.54; Wang W, 2018, J IMMUNOL, V201, P2221, DOI 10.4049/jimmunol.1800709; Wark PAB, 2018, SEMIN RESP CRIT CARE, V39, P45, DOI 10.1055/s-0037-1617412; Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340; Zeller T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010693	55	11	11	6	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2021	147	1					144	157		10.1016/j.jaci.2020.04.051	http://dx.doi.org/10.1016/j.jaci.2020.04.051		JAN 2021	14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA7UA	32442646	Green Submitted, Green Accepted, Bronze			2022-12-18	WOS:000613645900019
J	Singanayagam, A; Johnston, SL				Singanayagam, Aran; Johnston, Sebastian L.			Long-term impact of inhaled corticosteroid use in asthma and chronic obstructive pulmonary disease (COPD): Review of mechanisms that underlie risks	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Asthma; COPD; inhaled corticosteroid	INFECTIONS		[Singanayagam, Aran; Johnston, Sebastian L.] Imperial Coll, Natl Heart & Lung Inst, Norfolk Pl, London W2 1PG, England	Imperial College London	Johnston, SL (corresponding author), Imperial Coll, Natl Heart & Lung Inst, Norfolk Pl, London W2 1PG, England.	s.johnston@imperial.ac.uk		Singanayagam, Aran/0000-0001-9849-0033	Wellcome Trust Imperial College Institutional Strategic Support Springboard Fellowship; European Research Council Advanced Grant [788575]; MRC [MR/P028225/1] Funding Source: UKRI	Wellcome Trust Imperial College Institutional Strategic Support Springboard Fellowship; European Research Council Advanced Grant(European Research Council (ERC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Disclosure of potential conflict of interest: A. Singanayagam is supported by aWellcome Trust Imperial College Institutional Strategic Support Springboard Fellowship. S. L. Johnston has personally received consultancy fees from Myelo Therapeutics GmbH, Concert Pharmaceuticals, Bayer, Sanofi Pasteur, and Aviragen; he and his institution received consultancy fees from Synairgen, Novartis, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, and Centocor; he is an inventor on patents on the use of inhaled IFNs for treatment of exacerbations of airway diseases (Interferon-beta therapy for anti-virus therapy for respiratory diseases [International Patent Application No. PCT/GB05/50031] and Interferon-lambda therapy for treatment of respiratory disease [UK Patent application No. 6779645.9]); is the Asthma UK Clinical Chair; is an Emeritus National Institute for Health Research Senior Investigator; and has his salary supported in part by European Research Council Advanced Grant 788575.	Calverley PMA, 2011, CHEST, V139, P505, DOI 10.1378/chest.09-2992; Contoli M, 2015, ALLERGY, V70, P910, DOI 10.1111/all.12627; Djukanovic R, 2014, AM J RESP CRIT CARE, V190, P145, DOI 10.1164/rccm.201312-2235OC; Faiz A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057245; KILBOURNE E, 1961, NATURE, V190, P650, DOI 10.1038/190650a0; Klemets P, 2010, THORAX, V65, P698, DOI 10.1136/thx.2009.132670; Krone CL, 2013, INFECT IMMUN, V81, P4615, DOI 10.1128/IAI.00618-13; Ritchie AI, 2015, ANN AM THORAC SOC, V12, pS115, DOI 10.1513/AnnalsATS.201503-151AW; Singanayagam A, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav3879; Singanayagam A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04574-1	10	11	12	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2020	146	6					1292	1294		10.1016/j.jaci.2019.12.907	http://dx.doi.org/10.1016/j.jaci.2019.12.907			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PC3XH	31953103	Bronze			2022-12-18	WOS:000596937900009
J	Kanagaratham, C; El Ansari, YS; Sallis, BF; Hollister, BMA; Lewis, OL; Minnicozzi, SC; Oyoshi, MK; Rosen, R; Nurko, S; Fiebiger, E; Oettgen, HC				Kanagaratham, Cynthia; El Ansari, Yasmeen S.; Sallis, Benjamin F.; Hollister, Brianna-Marie A.; Lewis, Owen L.; Minnicozzi, Samantha C.; Oyoshi, Michiko K.; Rosen, Rachel; Nurko, Samuel; Fiebiger, Edda; Oettgen, Hans C.			Omeprazole inhibits IgE-mediated mast cell activation and allergic inflammation induced by ingested allergen in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; anaphylaxis; mast cell; omeprazole; proton pump inhibitor	EOSINOPHILIC ESOPHAGITIS; PATHOPHYSIOLOGY; ANAPHYLAXIS; EXPRESSION; DIAGNOSIS; RECEPTOR	Background: Patients with eosinophilic esophagitis have increased numbers of mucosal mast cells. Administration of the proton pump inhibitor omeprazole can reduce both esophageal mast cell and eosinophil numbers and attenuate type 2 inflammation in these subjects. Objective: Given that maintenance of an acidic environment within granules is important for mast cell homeostasis, we sought to evaluate the effects of omeprazole on mast cell functions including development, IgE:FceRI-mediated activation, and responses to food allergen. Methods: Mast cell degranulation, cytokine secretion, and early signaling events in the FceRI pathway, including protein kinase phosphorylation and Ca2+ flux, were measured after IgE crosslinking in murine bone marrow-derived mast cells and human cord blood-derived mast cells. The effects of omeprazole on these responses were investigated as was its impact on mast cell-dependent anaphylaxis and food allergy phenotypes in vivo. Results: Murine and human mast cells treated with omeprazole exhibited diminished degranulation and release of cytokines and histamine in response to allergen. In murine mast cells, phosphorylation of protein kinases, ERK and SYK, was decreased. Differentiation of mast cells from bone marrow progenitors was also inhibited. IgE-mediated passive anaphylaxis was blunted in mice treated with omeprazole as was allergen-induced mast cell expansion and mast cell activation in the intestine in a model of food allergy. Conclusions: Our findings suggest that omeprazole targets pathways important for the differentiation and activation of murine mast cells and for the manifestations of food allergy and anaphylaxis.	[Kanagaratham, Cynthia; El Ansari, Yasmeen S.; Sallis, Benjamin F.; Hollister, Brianna-Marie A.; Lewis, Owen L.; Minnicozzi, Samantha C.; Oyoshi, Michiko K.; Rosen, Rachel; Nurko, Samuel; Fiebiger, Edda; Oettgen, Hans C.] Boston Childrens Hosp, Dept Pediat, Boston, MA USA; [Kanagaratham, Cynthia; El Ansari, Yasmeen S.; Minnicozzi, Samantha C.; Oyoshi, Michiko K.; Rosen, Rachel; Nurko, Samuel; Fiebiger, Edda; Oettgen, Hans C.] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA; [El Ansari, Yasmeen S.] Philipps Univ Marburg, Inst Lab Med, Marburg, Germany	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Philipps University Marburg	Oettgen, HC (corresponding author), 1 Blackfan Circle, Boston, MA 02115 USA.	hans.oettgen@childrens.harvard.edu		Rosen, Rachel/0000-0003-3949-3060; Sallis, Benjamin Fidelius/0000-0001-7572-7210; Nurko, Samuel/0000-0003-0936-4807	National Institutes of Health (NIH) [1R01AI119918-05, DK097112-05, 5T32AI007512-33]; Fonds de recherche du Quebec -Sante; Bridge Grant from the Research Council of Boston Children's Hospital; Emerging Investigator Award from Food Allergy Research& Education (FARE); Crohn's and Colitis Foundation; NIH grant of the Harvard Digestive Diseases Center [P30DK034854]; Sean N. Parker Center Seed Grant; Bunning Family Foundation; Nanji Family Fund for Food Allergy Research; Rao Chakravorti Family Fund; Christine Olsen and Robert Small Food Allergy Research Fund	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fonds de recherche du Quebec -Sante(Fonds de la Recherche en Sante du Quebec); Bridge Grant from the Research Council of Boston Children's Hospital; Emerging Investigator Award from Food Allergy Research& Education (FARE); Crohn's and Colitis Foundation; NIH grant of the Harvard Digestive Diseases Center; Sean N. Parker Center Seed Grant; Bunning Family Foundation; Nanji Family Fund for Food Allergy Research; Rao Chakravorti Family Fund; Christine Olsen and Robert Small Food Allergy Research Fund	Research in this report was funded by the National Institutes of Health (NIH) (grant nos. 1R01AI119918-05 to H.C.O., DK097112-05 to R.R., and 5T32AI007512-33 to S.C.M.). C.K. is supported by a postdoctoral fellowship from the Fonds de recherche du Quebec -Sante. E.F. was supported by a Bridge Grant from the Research Council of Boston Children's Hospital, an Emerging Investigator Award from Food Allergy Research& Education (FARE), a Senior Research Award from the Crohn's and Colitis Foundation, and an unrestricted gift from the Mead Johnson Nutrition Company. This work was further supported by an NIH grant of the Harvard Digestive Diseases Center (grant no. P30DK034854, Core C). Additional generous support was provided by a Sean N. Parker Center Seed Grant, the Bunning Family Foundation, the Nanji Family Fund for Food Allergy Research, the Rao Chakravorti Family Fund, and the Christine Olsen and Robert Small Food Allergy Research Fund.	Abe Y, 2017, CLIN J GASTROENTEROL, V10, P87, DOI 10.1007/s12328-017-0725-4; Ahrens R, 2012, AM J PATHOL, V180, P1535, DOI 10.1016/j.ajpath.2011.12.036; Balza E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.218; Blatman KSH, 2011, J ALLERGY CLIN IMMUN, V127, P1307, DOI 10.1016/j.jaci.2010.12.1118; Bohm M, 2008, AM J GASTROENTEROL, V103, P2635, DOI 10.1111/j.1572-0241.2008.02116.x; Brandt EB, 2003, J CLIN INVEST, V112, P1666, DOI 10.1172/JCI19785; Burton OT, 2013, MUCOSAL IMMUNOL, V6, P740, DOI 10.1038/mi.2012.112; Burton OT, 2014, J ALLERGY CLIN IMMUN, V134, P1310, DOI 10.1016/j.jaci.2014.05.042; Cortes JR, 2009, J ALLERGY CLIN IMMUN, V124, P607, DOI 10.1016/j.jaci.2009.06.023; Dohil R, 2012, DIGEST DIS SCI, V57, P1413, DOI 10.1007/s10620-011-1991-5; Furuta GT, 2015, NEW ENGL J MED, V373, P1640, DOI 10.1056/NEJMra1502863; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Gilfillan AM, 2009, IMMUNOL REV, V228, P149, DOI 10.1111/j.1600-065X.2008.00742.x; Handa O, 2006, INFLAMM RES, V55, P476, DOI 10.1007/s00011-006-6056-4; Holowka D, 2016, BIOCHEM SOC T, V44, P505, DOI 10.1042/BST20150273; JOHNSON RG, 1980, FEBS LETT, V120, P75, DOI 10.1016/0014-5793(80)81050-7; Jordakieva G, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10914-6; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lin RY, 2000, J ALLERGY CLIN IMMUN, V106, P65, DOI 10.1067/mai.2000.107600; Lucendo AJ, 2016, CLIN GASTROENTEROL H, V14, P13, DOI 10.1016/j.cgh.2015.07.041; Madden KB, 2002, J IMMUNOL, V169, P4417, DOI 10.4049/jimmunol.169.8.4417; Mathias CB, 2011, J ALLERGY CLIN IMMUN, V127, P795, DOI 10.1016/j.jaci.2010.11.009; MORIYAMA Y, 1993, BIOCHEM BIOPH RES CO, V196, P699, DOI 10.1006/bbrc.1993.2306; Mukai K, 2018, IMMUNOL REV, V282, P121, DOI 10.1111/imr.12634; Niranjan R, 2013, AM J PHYSIOL-GASTR L, V304, pG1087, DOI 10.1152/ajpgi.00070.2013; O'Shea KM, 2018, GASTROENTEROLOGY, V154, P333, DOI 10.1053/j.gastro.2017.06.065; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; Oettgen HC, 2015, CURR OPIN IMMUNOL, V36, P109, DOI 10.1016/j.coi.2015.07.007; Pali-Scholl I, 2011, ALLERGY, V66, P469, DOI 10.1111/j.1398-9995.2010.02511.x; Pejler G, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.206; Pelz BJ, 2016, CLIN EXP ALLERGY, V46, P1431, DOI 10.1111/cea.12776; Platzer B, 2015, MUCOSAL IMMUNOL, V8, P516, DOI 10.1038/mi.2014.85; Renz H, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2017.98; Shin JM, 2013, J NEUROGASTROENTEROL, V19, P25, DOI 10.5056/jnm.2013.19.1.25; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Sicherer SH, 2009, ANNU REV MED, V60, P261, DOI 10.1146/annurev.med.60.042407.205711; Spergel J, 2018, J ALLERGY CLIN IMMUN, V142, P1, DOI 10.1016/j.jaci.2018.05.001; Suzuki R, 2015, CURR TOP MICROBIOL, V388, P63, DOI 10.1007/978-3-319-13725-4_4; Wen T, 2015, J ALLERGY CLIN IMMUN, V135, P187, DOI 10.1016/j.jaci.2014.08.043; Yoshida N, 2000, ALIMENT PHARM THERAP, V14, P74, DOI 10.1046/j.1365-2036.2000.014s1074.x; Zhang X, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0035700, 10.1371/journal.pone.0035991]	41	11	11	7	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2020	146	4					884	+		10.1016/j.jaci.2020.02.032	http://dx.doi.org/10.1016/j.jaci.2020.02.032			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OH2JO	32194041	Green Accepted			2022-12-18	WOS:000582395800019
J	Johansson, MW; McKernan, EM; Fichtinger, PS; Angulo, EL; Bagley, JL; Lee, KE; Evans, MD; Lomeli, LD; Mosher, DE; Cook, SM; Gaumnitz, EA; Mathur, SK				Johansson, Mats W.; McKernan, Elizabeth M.; Fichtinger, Paul S.; Angulo, Evelyn L.; Bagley, Jennifer L.; Lee, Kristine E.; Evans, Michael D.; Lomeli, Luis D.; Mosher, Deane E.; Cook, Shelly M.; Gaumnitz, Eric A.; Mathur, Sameer K.			alpha(IIb)-Integrin (CD41) associated with blood eosinophils is a potential biomarker for disease activity in eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Johansson, Mats W.; Mosher, Deane E.] Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; [McKernan, Elizabeth M.; Fichtinger, Paul S.; Angulo, Evelyn L.; Bagley, Jennifer L.; Lomeli, Luis D.; Mosher, Deane E.; Gaumnitz, Eric A.; Mathur, Sameer K.] Univ Wisconsin, Dept Med, Madison, WI USA; [Lee, Kristine E.; Evans, Michael D.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA; [Cook, Shelly M.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Johansson, MW (corresponding author), Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA.	mwjohansson@wise.edu		Evans, Michael/0000-0001-7449-3993; Johansson, Mats/0000-0001-5699-978X	National Institutes of Health [R21 AI122103, T32 AI007635]; Clinical and Translational Science Award [U11 RR025011]; University of Wisconsin Carbone Cancer Center [P30 CA014520];  [P01 HL088594]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Clinical and Translational Science Award; University of Wisconsin Carbone Cancer Center; 	This study was funded by the National Institutes of Health (grants R21 AI122103 [to S.K.M., E.A.G., and M.W.J.] and T32 AI007635 [to E.L.A.]); Program Project (grant P01 HL088594 [to N.J. Jarjour, D.F.M., and S.K.M.]); Clinical and Translational Science Award (grant U11 RR025011 [to M. K. Drezner]), and University of Wisconsin Carbone Cancer Center (support grant P30 CA014520 [to H. H. Bailey]). The funding source had no involvement in the study design; the data collection, analysis, or interpretation; the writing of the report; or the decision to submit the article for publication.	Collins MH, 2018, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00261; Dellon ES, 2018, GASTROENTEROLOGY, V154, P319, DOI 10.1053/j.gastro.2017.06.067; Hines BT, 2018, ANN ALLERG ASTHMA IM, V121, P218, DOI 10.1016/j.anai.2018.05.005; Johansson MW, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00075; Johansson Mats W, 2013, Front Pharmacol, V4, P33, DOI 10.3389/fphar.2013.00033; Johansson MW, 2011, AM J RESP CELL MOL, V45, P889, DOI 10.1165/rcmb.2010-0402OC; Metcalfe DD, 2016, WORLD ALLERGY ORGAN, V9, DOI 10.1186/s40413-016-0094-3; Nhu QM, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00128; Shah SA, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00129	9	11	11	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2020	145	6					1699	+		10.1016/j.jaci.2020.01.022	http://dx.doi.org/10.1016/j.jaci.2020.01.022			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LW4ZZ	32004525	Green Accepted			2022-12-18	WOS:000539157800028
J	Krause, K; Bonnekoh, H; Ellrich, A; Tsianakas, A; Wagner, N; Fischer, J; Maurer, M				Krause, Karoline; Bonnekoh, Hanna; Ellrich, Andre; Tsianakas, Athanasios; Wagner, Nicola; Fischer, Joerg; Maurer, Marcus			Long-term efficacy of canakinumab in the treatment of Schnitzler syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							SAFETY		[Krause, Karoline; Bonnekoh, Hanna; Ellrich, Andre; Maurer, Marcus] Charite Univ Med Berlin, Dept Dermatol & Allergy, Berlin, Germany; [Krause, Karoline; Bonnekoh, Hanna; Ellrich, Andre; Maurer, Marcus] Free Univ Berlin, Berlin, Germany; [Krause, Karoline; Bonnekoh, Hanna; Ellrich, Andre; Maurer, Marcus] Humboldt Univ, Berlin, Germany; [Krause, Karoline; Bonnekoh, Hanna; Ellrich, Andre; Maurer, Marcus] Berlin Inst Hlth, Berlin, Germany; [Tsianakas, Athanasios] Univ Klinikum Munster, Dept Dermatol, Munster, Germany; [Tsianakas, Athanasios] Fachklin Bad Bentheim, Dept Dermatol, Bentheim, Germany; [Wagner, Nicola] Klinikum Erlangen, Dept Dermatol, Erlangen, Germany; [Fischer, Joerg] Univ Klinikum Tubingen, Dept Dermatol & Allergy, Tubingen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; University of Munster; University of Erlangen Nuremberg; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Krause, K (corresponding author), Charite Univ Med Berlin, Dept Dermatol & Allergy, Berlin, Germany.; Krause, K (corresponding author), Free Univ Berlin, Berlin, Germany.; Krause, K (corresponding author), Humboldt Univ, Berlin, Germany.; Krause, K (corresponding author), Berlin Inst Hlth, Berlin, Germany.	karoline.krause@charite.de	Maurer, Marcus/ABG-2174-2020; Krause, Karoline/G-5218-2018	Maurer, Marcus/0000-0002-4121-481X; Bonnekoh, Hanna/0000-0002-3567-0149; Krause, Karoline/0000-0001-9711-9654	Novartis Pharma GmbH	Novartis Pharma GmbH	Novartis Pharma GmbH supported this investigation.	Caorsi R, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4184; de Koning HD, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0696-0; de Koning HD, 2013, ANN RHEUM DIS, V72, P1634, DOI 10.1136/annrheumdis-2012-202192; Krause K, 2012, ALLERGY, V67, P943, DOI 10.1111/j.1398-9995.2012.02843.x; Krause K, 2017, J ALLERGY CLIN IMMUN, V139, P1311, DOI 10.1016/j.jaci.2016.07.041; Neel A, 2014, AUTOIMMUN REV, V13, P1035, DOI 10.1016/j.autrev.2014.08.031; Pizzirani C, 2009, RHEUMATOLOGY, V48, P1304, DOI 10.1093/rheumatology/kep222; Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914; Simon A, 2013, ALLERGY, V68, P562, DOI 10.1111/all.12129	9	11	12	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2020	145	6					1681	+		10.1016/j.jaci.2019.12.909	http://dx.doi.org/10.1016/j.jaci.2019.12.909			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LW4ZZ	31940469	Bronze			2022-12-18	WOS:000539157800023
J	Larson, D; Patel, P; Salapatek, AM; Couroux, P; Whitehouse, D; Pina, A; Johnson, JL; Sever, ML; Sanda, S; Poyser, J; Allio, T; Scadding, GW; Qin, TL; Shamji, MH; Kwok, WW; James, EA; French, D; Lelic, A; Larche, M; Altman, MC; Togias, A; Durham, SR				Larson, David; Patel, Piyush; Salapatek, Anne Marie; Couroux, Peter; Whitehouse, Don; Pina, Adela; Johnson, Jacqueline L.; Sever, Michelle L.; Sanda, Srinath; Poyser, Julian; Allio, Theresa; Scadding, Guy W.; Qin, Tielin; Shamji, Mohamed H.; Kwok, William W.; James, Eddie A.; French, Deanna; Lelic, Alina; Larche, Mark; Altman, Matthew C.; Togias, Alkis; Durham, Stephen R.			Nasal allergen challenge and environmental exposure chamber challenge: A randomized trial comparing clinical and biological responses to cat allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Nasal allergen challenge; environmental exposure chamber; Fel d1; cat allergy; total nasal symptom score; peak nasal inspiratory flow; cat dander; epithelium	GRASS-POLLEN IMMUNOTHERAPY; INFLAMMATORY MEDIATORS; PROVOCATION; RHINOCONJUNCTIVITIS; RHINITIS; GUIDE	Background: The direct-instillation nasal allergen challenge (NAC) and the environmental exposure chamber (EEC) are 2 methods of conducting controlled allergen provocations. The clinical and biological comparability of these methods has not been thoroughly investigated. Objective: We sought to compare clinical and immunologic responses to cat allergen in NAC versus EEC. Methods: Twenty-four participants were randomized to receive either NAC followed by a 2-day challenge in an EEC or a 2-day challenge in an EEC followed by NAC. Challenges were separated by 28-day washout periods. We measured total nasal symptom scores, peak nasal inspiratory flow, nasal (0-8 hours) and serum cytokines, serum antibodies, peripheral blood antigen-specific T lymphocytes, and gene expression in nasal scrapings. The primary outcome was the total nasal symptom score area under the curve for the first 3 hours after allergen exposure in NAC or after initiation of exposure in EEC. Results: Both challenges increased IL-5 and IL-13 in nasal fluids and serum and resulted in altered nasal cell expression of gene modules related to mucosal biology and transcriptional regulation. Changes in gene modules, more so than cytokine measurements, showed significant associations with total nasal symptom score and peak nasal inspiratory flow. Overall, EEC exposure generated larger responses and more early terminations compared with NAC. Although the 2 challenges did not correlate in symptom magnitude or temporality, striking correlations were observed in cytokine levels. Conclusions: Although clinical outcomes of NAC and EEC were temporally different and nonequivalent in magnitude, immunologic responses were similar. Selection of a particular allergen challenge method should depend on considerations of study objectives and cost.	[Larson, David; Qin, Tielin] Immune Tolerance Network, Bethesda, MD USA; [Patel, Piyush; Salapatek, Anne Marie; Couroux, Peter] Inflamax Res Ltd, DBA Cliantha Res, Mississauga, ON, Canada; [Whitehouse, Don; Sanda, Srinath] Immune Tolerance Network, San Francisco, CA USA; [Pina, Adela; Johnson, Jacqueline L.; Sever, Michelle L.] Rho Fed Syst Div, Durham, NC USA; [Poyser, Julian; Allio, Theresa; Togias, Alkis] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Scadding, Guy W.; Shamji, Mohamed H.; Durham, Stephen R.] MRC & Asthma UK, Ctr Allerg Mech Asthma, London, England; [Shamji, Mohamed H.; Durham, Stephen R.] Imperial Coll London, Natl Heart & Lung Inst, Immunomodulat & Tolerance Grp, Allergy & Clin Immunol,Sect Inflammat Repair & De, London, England; [Kwok, William W.; James, Eddie A.] Benaroya Res Inst, Dept Translat Res, Seattle, WA USA; [French, Deanna; Larche, Mark] McMaster Univ, Hamilton, ON, Canada; [Lelic, Alina] McMaster Univ, Human Immunol Testing Suite, Hamilton, ON, Canada; [Larche, Mark] St Joes Hamilton, Res Inst, Dept Med, Div Clin Immunol & Allergy & Respirol,Firestone I, Hamilton, ON, Canada; [Altman, Matthew C.] Univ Washington, Dept Med, Seattle, WA USA; [Altman, Matthew C.] Benaroya Res Inst, Syst Immunol Div, Seattle, WA USA	Immune Tolerance Network; Immune Tolerance Network; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Imperial College London; Benaroya Research Institute; McMaster University; McMaster University; McMaster University; University of Washington; University of Washington Seattle; Benaroya Research Institute	Larson, D (corresponding author), 7500 Old Georgetown Rd,Ste 800, Bethesda, MD 20814 USA.	dlarson@immunetolerance.org	Qin, Tielin/H-4564-2019; Shamji, Mohamed/AAD-1788-2019; Shamji, Mohamed/AAU-8811-2020; James, Eddie/V-4929-2019	Shamji, Mohamed/0000-0003-3425-3463; James, Eddie/0000-0002-7217-5729; Larche, Mark/0000-0002-1439-7593; Larson, David/0000-0003-4117-785X	National Institute of Allergy and Infectious Diseases of the National Institutes of Health [UM1AI109565, UM2AI117870, HHSN272200800029C]	National Institute of Allergy and Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This research was performed as a project of the Immune Tolerance Network, an international clinical research consortium headquartered at the Benaroya Research Institute. This work was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Numbers UM1AI109565, UM2AI117870, and HHSN272200800029C. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Ahuja SK, 2017, J ALLERGY CLIN IMMUN, V139, P844, DOI 10.1016/j.jaci.2016.08.019; Altman MC, 2019, NAT IMMUNOL, V20, P637, DOI 10.1038/s41590-019-0347-8; Altman MC, 2018, J ALLERGY CLIN IMMUN, V142, P1856, DOI 10.1016/j.jaci.2018.02.019; Doig GS, 2005, J CRIT CARE, V20, P187, DOI 10.1016/j.jcrc.2005.04.005; Ellis AK, 2013, ANN ALLERG ASTHMA IM, V111, P323, DOI 10.1016/j.anai.2013.07.019; He WJ, 2015, J ALLERGY CLIN IMMUN, V136, P658, DOI 10.1016/j.jaci.2015.02.041; ILIOPOULOS O, 1991, J ALLERGY CLIN IMMUN, V87, P855, DOI 10.1016/0091-6749(91)90134-A; Naclerio RM, 1997, J ALLERGY CLIN IMMUN, V100, P505, DOI 10.1016/S0091-6749(97)70143-X; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; Renand A, 2018, J ALLERGY CLIN IMMUN, V141, P1750, DOI 10.1016/j.jaci.2017.09.041; Sarin S, 2006, J ALLERGY CLIN IMMUN, V118, P999, DOI 10.1016/j.jaci.2006.09.013; Scadding GW, 2015, ALLERGY, V70, P689, DOI 10.1111/all.12608; Scadding GW, 2015, CLIN EXP ALLERGY, V45, P613, DOI 10.1111/cea.12434; Scadding GW, 2017, JAMA-J AM MED ASSOC, V317, P615, DOI 10.1001/jama.2016.21040; Scadding GW, 2012, J IMMUNOL METHODS, V384, P25, DOI 10.1016/j.jim.2012.06.013; SCHUIRMANN DJ, 1987, J PHARMACOKINET BIOP, V15, P657, DOI 10.1007/BF01068419; Shamji MH, 2015, ALLERGY, V70, P171, DOI 10.1111/all.12543; Soliman M, 2014, ANN ALLERG ASTHMA IM, V113, P250, DOI 10.1016/j.anai.2014.06.018; Tenn MW, 2019, ANN ALLERG ASTHMA IM, V123, P105, DOI 10.1016/j.anai.2019.04.003; TOGIAS A, 1985, AM J MED, V79, P26, DOI 10.1016/0002-9343(85)90084-1; Wang W, 2018, J IMMUNOL, V201, P2221, DOI 10.4049/jimmunol.1800709; Yeung D, 2016, J IMMUNOL METHODS, V437, P53, DOI 10.1016/j.jim.2016.08.003	22	11	11	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2020	145	6					1585	1597		10.1016/j.jaci.2020.02.024	http://dx.doi.org/10.1016/j.jaci.2020.02.024			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LW4ZZ	32169380	Bronze, Green Accepted			2022-12-18	WOS:000539157800014
J	Sil, P; Suwanpradid, J; Muse, G; Gruzdev, A; Liu, LW; Corcoran, DL; Willson, CJ; Janardhan, K; Grimm, S; Myers, P; Degraff, LM; MacLeod, AS; Martinez, J				Sil, Payel; Suwanpradid, Jutamas; Muse, Ginger; Gruzdev, Artiom; Liu, Liwen; Corcoran, David L.; Willson, Cynthia J.; Janardhan, Kyathanahalli; Grimm, Sara; Myers, Page; Degraff, Laura Miller; MacLeod, Amanda S.; Martinez, Jennifer			Noncanonical autophagy in dermal dendritic cells mediates immunosuppressive effects of UV exposure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Autophagy; LAP; Rubicon; contact hypersensitivity; inflammation; efferocytosis; antigen presentation; dendritic cells	EPIDERMAL LANGERHANS CELLS; GENOME-WIDE ASSOCIATION; REGULATORY T-CELLS; CONTACT HYPERSENSITIVITY; IN-VIVO; IMMUNE SUPPRESSION; CROHN-DISEASE; RUBICON; INFLAMMATION; DEFENSE	Background: Control of the inflammatory response is critical to maintaining homeostasis, and failure to do so contributes to the burden of chronic inflammation associated with several disease states. The mechanisms that underlie immunosuppression, however, remain largely unknown. Although defects in autophagy machinery have been associated with inflammatory pathologic conditions, we now appreciate that autophagic components participate in noncanonical pathways distinct from classical autophagy. We have previously demonstrated that LC3-associated phagocytosis (LAP), a noncanonical autophagic process dependent on Rubicon (rubicon autophagy regulator [RUBCN]), contributes to immunosuppression. Objective: We used Rubcn(-/-) mice to examine the role of the LAP pathway in mediating the UV-induced immunotolerant program in a model of contact hypersensitivity (CHS). Methods: Flow cytometry and transcriptional analysis were used to measure immune cell infiltration and activation in the skin of Rubcn(+/+) and Rubcn(-/-) mice during the CHS response. Results: Here, we demonstrate that LAP is required for UV-induced immunosuppression and that UV exposure induces a broadly anti-inflammatory transcriptional program dependent on Rubicon. Rubcn(-/-) mice are resistant to UV-induced immunosuppression and instead display exaggerated inflammation in a model of CHS. Specifically, RUBCN deficiency in CD301b(+) dermal dendritic cells results in their increased antigen presentation capacity and subsequent hyperactivation of the CD8(+) T-cell response. Conclusions: LAP functions to limit the immune response and is critical in maintaining the balance between homeostasis and inflammation.	[Sil, Payel; Muse, Ginger; Degraff, Laura Miller; Martinez, Jennifer] NIEHS, Immun Inflammat & Dis Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA; [Gruzdev, Artiom] NIEHS, Knockout Mouse Core Lab, Reprod & Dev Biol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA; [Liu, Liwen] NIEHS, Mol Genom Core Lab, Signal Transduct Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA; [Myers, Page] NIEHS, Comparat Med Branch, NIH, POB 12233, Res Triangle Pk, NC 27709 USA; [Suwanpradid, Jutamas; MacLeod, Amanda S.] Duke Univ, Dept Dermatol, Durham, NC USA; [MacLeod, Amanda S.] Duke Univ, Dept Immunol, Durham, NC USA; [MacLeod, Amanda S.] Duke Univ, Dept Mol Genet & Microbiol, Durham, NC USA; [Corcoran, David L.] Duke Univ, Med Ctr, Duke Ctr Genom & Computat Biol, Durham, NC USA; [Willson, Cynthia J.; Janardhan, Kyathanahalli] Integrated Lab Syst Inc, Res Triangle Pk, NC USA; [Grimm, Sara] Div Intramural Res, Res Triangle Pk, NC USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Duke University; Duke University; Duke University; Duke University	Martinez, J (corresponding author), 111 TW Alexander Dr,Rall Bldg,Room D248A, Res Triangle Pk, NC 27709 USA.	jennifer.martinez3@nih.gov	Sil, Payel/R-4612-2017; Martinez, Jennifer/C-3740-2019	Sil, Payel/0000-0002-5956-3663; Martinez, Jennifer/0000-0002-3060-2518; , Cynthia/0000-0003-0942-3723	National Institutes of Health Intramural Research Program [1ZIAES10328601, 1R01AI13920701]; Duke Physician-Scientist Strong Start Award; Duke Dermatology Department Funding	National Institutes of Health Intramural Research Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Duke Physician-Scientist Strong Start Award; Duke Dermatology Department Funding	Supported by National Institutes of Health Intramural Research Program (grants 1ZIAES10328601 [to J.M.] and 1R01AI13920701), Duke Physician-Scientist Strong Start Award, and Duke Dermatology Department Funding (to A.S.M.).	Ackerman AL, 2003, P NATL ACAD SCI USA, V100, P12889, DOI 10.1073/pnas.1735556100; Akiba H, 2002, J IMMUNOL, V168, P3079, DOI 10.4049/jimmunol.168.6.3079; Allan RS, 2006, IMMUNITY, V25, P153, DOI 10.1016/j.immuni.2006.04.017; Arkwright PD, 2013, J ALLER CL IMM-PRACT, V1, P142, DOI 10.1016/j.jaip.2012.09.002; Assoum M, 2013, CEREBELLUM, V12, P835, DOI 10.1007/s12311-013-0489-4; Assoum M, 2010, BRAIN, V133, P2439, DOI 10.1093/brain/awq181; Bennett CL, 2007, TRENDS IMMUNOL, V28, P525, DOI 10.1016/j.it.2007.08.011; Bennett CL, 2007, J IMMUNOL, V179, P6830, DOI 10.4049/jimmunol.179.10.6830; Bobr A, 2010, J IMMUNOL, V185, P4724, DOI 10.4049/jimmunol.1001802; Cadwell K, 2016, NAT REV IMMUNOL, V16, P661, DOI 10.1038/nri.2016.100; Chovatiya R, 2014, MOL CELL, V54, P281, DOI 10.1016/j.molcel.2014.03.030; Cunha LD, 2018, CELL, V175, P429, DOI 10.1016/j.cell.2018.08.061; Florey O, 2011, NAT CELL BIOL, V13, P1335, DOI 10.1038/ncb2363; GILCHREST BA, 1981, J AM ACAD DERMATOL, V5, P411, DOI 10.1016/S0190-9622(81)70103-8; Green DR, 2011, MEANS END APOPTOSIS; Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954; Haniffa M, 2012, IMMUNITY, V37, P60, DOI 10.1016/j.immuni.2012.04.012; Hart PH, 1998, J EXP MED, V187, P2045, DOI 10.1084/jem.187.12.2045; Hart PH, 2018, PHOTOCH PHOTOBIO SCI, V17, P1872, DOI 10.1039/c7pp00312a; Hayashi K, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aan4144; Heckmann BL, 2019, CELL, V178, P536, DOI 10.1016/j.cell.2019.05.056; Henault J, 2012, IMMUNITY, V37, P986, DOI 10.1016/j.immuni.2012.09.014; IKAI K, 1985, J INVEST DERMATOL, V85, P82, DOI 10.1111/1523-1747.ep12275365; Jo EK, 2012, MICROBES INFECT, V14, P119, DOI 10.1016/j.micinf.2011.08.014; Jongbloed SL, 2010, J EXP MED, V207, P1247, DOI 10.1084/jem.20092140; Jung S, 2002, IMMUNITY, V17, P211, DOI 10.1016/S1074-7613(02)00365-5; Kaplan DH, 2017, NAT IMMUNOL, V18, P1068, DOI 10.1038/ni.3815; Kaplan DH, 2010, TRENDS IMMUNOL, V31, P446, DOI 10.1016/j.it.2010.08.006; Kaplan DH, 2005, IMMUNITY, V23, P611, DOI 10.1016/j.immuni.2005.10.008; Kim I, 2014, GENES DIS, V1, P188, DOI 10.1016/j.gendis.2014.08.005; Kolb JP, 2017, TRENDS IMMUNOL, V38, P705, DOI 10.1016/j.it.2017.06.009; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; Kotas ME, 2015, CELL, V160, P816, DOI 10.1016/j.cell.2015.02.010; Kuhn A, 2016, SEMIN IMMUNOPATHOL, V38, P97, DOI 10.1007/s00281-015-0550-0; Kuipers H, 2010, J IMMUNOL, V185, P400, DOI 10.4049/jimmunol.0903912; Kundu M, 2008, BLOOD, V112, P1493, DOI 10.1182/blood-2008-02-137398; Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782; Lin R, 2012, BRIT J PHARMACOL, V165, P2365, DOI 10.1111/j.1476-5381.2011.01725.x; Lindstedt M, 2005, J IMMUNOL, V175, P4839, DOI 10.4049/jimmunol.175.8.4839; Loi M, 2016, AUTOPHAGY, V12, P1681, DOI 10.1080/15548627.2016.1203488; MacLeod AS, 2014, J IMMUNOL, V192, P5695, DOI 10.4049/jimmunol.1303297; Manson JJ, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-6; Martin SF, 2012, EXP DERMATOL, V21, P382, DOI 10.1111/j.1600-0625.2012.01471.x; Martinez J., 2015, CURR TOP MICROBIOL I; Martinez J, 2016, NATURE, V533, P115, DOI 10.1038/nature17950; Martinez J, 2015, NAT CELL BIOL, V17, P893, DOI 10.1038/ncb3192; Martinez J, 2011, P NATL ACAD SCI USA, V108, P17396, DOI 10.1073/pnas.1113421108; Matsunaga K, 2009, NAT CELL BIOL, V11, P385, DOI 10.1038/ncb1846; McGovern N, 2017, NATURE, V546, P662, DOI 10.1038/nature22795; McGovern N, 2014, IMMUNITY, V41, P465, DOI 10.1016/j.immuni.2014.08.006; Minoda Y, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01419; Ng RLX, 2013, J IMMUNOL, V190, P5471, DOI 10.4049/jimmunol.1202786; Ozawa M, 1999, J EXP MED, V189, P711, DOI 10.1084/jem.189.4.711; Patra V, 2018, FRONT MED-LAUSANNE, V5, DOI [10.3389/fmed.2018.00166, 10.3339/fmed.2013.00166]; Pennino D, 2010, J IMMUNOL, V184, P4880, DOI 10.4049/jimmunol.0901767; Poon IKH, 2014, NAT REV IMMUNOL, V14, P166, DOI 10.1038/nri3607; Prasad R, 2013, NEOPLASIA, V15, P795, DOI 10.1593/neo.13424; Price JG, 2015, NAT IMMUNOL, V16, P1060, DOI 10.1038/ni.3270; Rana S, 2008, AM J PATHOL, V172, P993, DOI 10.2353/ajpath.2008.070517; Ring S, 2009, J ALLERGY CLIN IMMUN, V123, P1287, DOI 10.1016/j.jaci.2009.03.022; Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032; Rueter K, 2019, J ALLERGY CLIN IMMUN, V143, P1012, DOI 10.1016/j.jaci.2018.08.037; Sanjuan MA, 2009, IMMUNOL REV, V227, P203, DOI 10.1111/j.1600-065X.2008.00732.x; Schwarz A, 2011, J ALLERGY CLIN IMMUN, V128, P826, DOI 10.1016/j.jaci.2011.06.005; Schwarz T, 1999, ALLERGY, V54, P1252, DOI 10.1034/j.1398-9995.1999.00105.x; Sharma Arishya, 2012, Methods Mol Biol, V920, P613, DOI 10.1007/978-1-61779-998-3_40; Shin H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13346; Sil P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01376; Sil P, 2018, CURR OPIN IMMUNOL, V50, P21, DOI 10.1016/j.coi.2017.10.004; Sun QM, 2011, J BIOL CHEM, V286, P185, DOI 10.1074/jbc.M110.126425; Sun QM, 2010, P NATL ACAD SCI USA, V107, P19338, DOI 10.1073/pnas.1010554107; Suwanpradid J, 2017, J IMMUNOL, V199, P1827, DOI 10.4049/jimmunol.1700739; Thomas SY, 2018, MUCOSAL IMMUNOL, V11, P796, DOI 10.1038/mi.2017.84; Thyssen JP, 2015, J ALLERGY CLIN IMMUN, V136, P1163, DOI 10.1016/j.jaci.2015.06.042; Tomura M, 2014, SCI REP-UK, V4, DOI 10.1038/srep06030; Udey MC, 2012, J CLIN INVEST, V122, P1602, DOI 10.1172/JCI63190; Vocanson M, 2006, J INVEST DERMATOL, V126, P815, DOI 10.1038/sj.jid.5700174; Wang BH, 2000, J IMMUNOL, V165, P6783, DOI 10.4049/jimmunol.165.12.6783; Wang LC, 2009, J IMMUNOL, V183, P5548, DOI 10.4049/jimmunol.0900235; Yamazaki S, 2014, J IMMUNOL, V193, P5488, DOI 10.4049/jimmunol.1400985; Yang CS, 2012, CELL HOST MICROBE, V11, P264, DOI 10.1016/j.chom.2012.01.018; Yu CI, 2013, IMMUNITY, V38, P818, DOI 10.1016/j.immuni.2013.03.004; Yusuf B, 2013, DEV GROWTH DIFFER, V55, P330, DOI 10.1111/dgd.12043; Zahner SP, 2011, J IMMUNOL, V187, P5069, DOI 10.4049/jimmunol.1101880; Zhang XL, 2016, ONCOTARGET, V7, P37498, DOI 10.18632/oncotarget.9546	85	11	11	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2020	145	5					1389	1405		10.1016/j.jaci.2019.11.041	http://dx.doi.org/10.1016/j.jaci.2019.11.041			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LK7TB	31837371	hybrid, Green Accepted			2022-12-18	WOS:000531063400012
J	Ye, LY; Pan, JX; Pasha, MA; Shen, XF; D'Souza, SS; Fung, ITH; Wang, Y; Guo, BN; Tang, DD; Yang, Q				Ye, Longyun; Pan, Jiexue; Pasha, Muhammad Asghar; Shen, Xiaofei; D'Souza, Shanti S.; Fung, Ivan Ting Hin; Wang, Yinna; Guo, Bingnan; Tang, Dale D.; Yang, Qi			Mucosal-associated invariant T cells restrict allergic airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ASTHMA		[Ye, Longyun; Pan, Jiexue; Shen, Xiaofei; D'Souza, Shanti S.; Fung, Ivan Ting Hin; Guo, Bingnan; Yang, Qi] Albany Med Coll, Dept Immunol & Microbial Dis, Albany, NY 12208 USA; [Pasha, Muhammad Asghar; Yang, Qi] Albany Med Coll, Dept Med, Div Allergy & Immunol, Albany, NY 12208 USA; [Wang, Yinna; Tang, Dale D.] Albany Med Coll, Dept Mol & Cellular Physiol, Albany, NY 12208 USA	Albany Medical College; Albany Medical College; Albany Medical College	Yang, Q (corresponding author), Albany Med Coll, Dept Immunol & Microbial Dis, Albany, NY 12208 USA.; Yang, Q (corresponding author), Albany Med Coll, Dept Med, Div Allergy & Immunol, Albany, NY 12208 USA.	yangq@amc.edu	T, Dale/AAE-9643-2020; Shen, Xiaofei/HDL-7300-2022	T, Dale/0000-0002-7339-9249; Shen, Xiaofei/0000-0002-5816-1814; Fung, Ivan Ting Hin/0000-0001-6773-0743; Pan, Jiexue/0000-0001-7125-9608	Korean Health Technology RAMP;D Project, Ministry of Health AMP; Welfare, Republic of Korea [HI16C0992]; Basic Science Research Program through the National Research Foundation, Republic of Korea - Ministry of Education [2018R1D1A1B07050941]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL137813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K22AI116728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG057782] Funding Source: NIH RePORTER	Korean Health Technology RAMP;D Project, Ministry of Health AMP; Welfare, Republic of Korea; Basic Science Research Program through the National Research Foundation, Republic of Korea - Ministry of Education; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was supported by a grant from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (grant no. HI16C0992). This research was also supported by the Basic Science Research Program through the National Research Foundation, Republic of Korea funded by the Ministry of Education (grant no. 2018R1D1A1B07050941).	[Anonymous], 2019, ALLERGY, V74, P78; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Castellano F, 2017, MOLECULES, V22; Chandra S, 2018, J IMMUNOL, V200, P1995, DOI 10.4049/jimmunol.1701525; Doherty TA, 2012, AM J PHYSIOL-LUNG C, V303, pL577, DOI 10.1152/ajplung.00174.2012; Hinks TSC, 2015, J ALLERGY CLIN IMMUN, V136, P323, DOI 10.1016/j.jaci.2015.01.014; Hoving LR, 2018, METHODS MOL BIOL, V1730, P247, DOI 10.1007/978-1-4939-7592-1_17; Kjer-Nielsen L, 2012, NATURE, V491, P717, DOI 10.1038/nature11605; Kouzaki H, 2011, J IMMUNOL, V186, P4375, DOI 10.4049/jimmunol.1003020; Lee MJ, 2018, J ALLERGY CLIN IMMUN, V141, P1310, DOI 10.1016/j.jaci.2017.11.045; Li WZ, 2012, BRIEF BIOINFORM, V13, P656, DOI 10.1093/bib/bbs035; Magoc T, 2011, BIOINFORMATICS, V27, P2957, DOI 10.1093/bioinformatics/btr507; Marais AAS, 2009, APPL EXTRACTIVE DERI; Park NH, 2017, ANAL METHODS-UK, V9, P2351, DOI [10.1039/C7AY00168A, 10.1039/c7ay00168a]; Psachoulia K, 2016, BRAIN, V139, P3121, DOI 10.1093/brain/aww254; Shenoy MK, 2019, MICROBIOME, V7, DOI 10.1186/s40168-019-0651-4; Snelgrove RJ, 2014, J ALLERGY CLIN IMMUN, V134, P583, DOI 10.1016/j.jaci.2014.02.002; Strzepa A, 2017, J ALLERGY CLIN IMMUN, V140, P121, DOI 10.1016/j.jaci.2016.11.052; Treiner E, 2003, NATURE, V422, P164, DOI 10.1038/nature01433; Zhang Z, 2000, J COMPUT BIOL, V7, P203, DOI 10.1089/10665270050081478	20	11	11	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2020	145	5					1469	+		10.1016/j.jaci.2019.12.891	http://dx.doi.org/10.1016/j.jaci.2019.12.891			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LK7TB	31874183	Green Accepted, Bronze			2022-12-18	WOS:000531063400020
J	Eiwegger, T; Anagnostou, K; Arasi, S; Begin, P; Ben-Shoshan, M; Beyer, K; Blumchen, K; Brough, H; Caubet, JC; Chan, ES; Chen, M; Chinthrajah, S; Davis, CM; Roches, AD; Du Toit, G; Elizur, A; Galli, SJ; Haland, G; Hoffmann-Sommergruber, K; Kim, H; Leung, DYM; Long, A; Muraro, A; Nurmatov, UB; Pajno, GB; Sampath, V; Saxena, J; Sindher, S; Upton, J; Worm, M; Nadeau, KC				Eiwegger, Thomas; Anagnostou, Katherine; Arasi, Stefania; Begin, Philippe; Ben-Shoshan, Moshe; Beyer, Kirsten; Blumchen, Katharina; Brough, Helen; Caubet, Jean-Christoph; Chan, Edmond S.; Chen, Meng; Chinthrajah, Sharon; Davis, Carla M.; Roches, Anne Des; Du Toit, George; Elizur, Arnon; Galli, Stephen J.; Haland, Geir; Hoffmann-Sommergruber, Karin; Kim, Harold; Leung, Donald Y. M.; Long, Andrew; Muraro, Antonella; Nurmatov, Ulugbek B.; Pajno, Giovanni B.; Sampath, Vanitha; Saxena, Jamie; Sindher, Sayantani; Upton, Julia; Worm, Margitta; Nadeau, Kari C.			Conflicting verdicts on peanut oral immunotherapy from the Institute for Clinical and Economic Review and US Food and Drug Administration Advisory Committee: Where do we go from here?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Food allergy; peanut allergy; safety; efficacy; treatment; management; Institute for Clinical and Economic Review; US Food and Drug Administration Allergenic Products Advisory Committee; quality of life			[Eiwegger, Thomas; Upton, Julia] Hosp Sick Children, Dept Pediat, Div Immunol & Allergy, Food Allergy & Anaphylaxis Program, Toronto, ON, Canada; [Eiwegger, Thomas] Hosp Sick Children, Translat Med, Res Inst, Toronto, ON, Canada; [Eiwegger, Thomas] Univ Toronto, Dept Immunol, Toronto, ON, Canada; [Anagnostou, Katherine; Davis, Carla M.] Texas Childrens Hosp, Dept Pediat, Sect Immunol Allergy & Retrovirol, Houston, TX USA; [Anagnostou, Katherine; Davis, Carla M.] Baylor Coll Med, Houston, TX USA; [Arasi, Stefania; Davis, Carla M.] Bambino Gesu Childrens Res Hosp IRCCS, Pediat Allergol Unit, Dept Pediat Med, Rome, Italy; [Begin, Philippe; Roches, Anne Des] CHU Ste Justine, Div Immunol & Allergy, Dept Pediat, Montreal, PQ, Canada; [Begin, Philippe] CHU Montreal, Dept Med, Div Immunol & Allergy, Montreal, PQ, Canada; [Begin, Philippe] McGill Univ, Dept Pediat, Div Pediat Allergy & Clin Immunol, Ctr Hlth, Montreal, PQ, Canada; [Beyer, Kirsten] Charite Univ Med Berlin, Dept Pediat Pneumol Immunol & Intens Care, Berlin, Germany; [Blumchen, Katharina] Univ Hosp Frankfurt, Dept Children & Adolescent Med, Div Pneumol Allergol & Cyst Fibrosis, Frankfurt, Germany; [Ben-Shoshan, Moshe; Brough, Helen; Du Toit, George] Kings Coll London, Fac Life Sci & Med, Sch Life Course Sci, Dept Women & Childrens Hlth Pediat Allergy, London, England; [Brough, Helen; Du Toit, George] Kings Coll London, Sch Immunol & Microbial Sci, Peter Gorer Dept Immunobiol, London, England; [Brough, Helen; Du Toit, George] Guys & St Thomas Hosp, Childrens Allergy Serv, Evelina London, London, England; [Caubet, Jean-Christoph] Univ Hosp Geneva, Dept Pediat, Div Pediat Allergy, Geneva, Switzerland; [Chan, Edmond S.] Univ British Columbia, BC Childrens Hosp, Dept Pediat, Div Allergy & Immunol, Vancouver, BC, Canada; [Chen, Meng; Chinthrajah, Sharon; Galli, Stephen J.; Long, Andrew; Sampath, Vanitha; Saxena, Jamie; Sindher, Sayantani; Nadeau, Kari C.] Stanford Univ, Sean N Parker Ctr Allergy & Asthma Res, 269 Campus Dr,CCSR 3215,MC 5366, Stanford, CA 94305 USA; [Chen, Meng; Chinthrajah, Sharon; Long, Andrew; Sampath, Vanitha; Saxena, Jamie; Sindher, Sayantani; Nadeau, Kari C.] Stanford Univ, Div Pulm & Crit Care Med, Stanford, CA 94305 USA; [Galli, Stephen J.] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; [Galli, Stephen J.] Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA; [Nadeau, Kari C.] Stanford Univ, Div Rheumatol Allergy & Immunol, Stanford, CA 94305 USA; [Elizur, Arnon] Tel Aviv Univ, Yitzhak Shamir Med Ctr, Inst Allergy Immunol & Pediat Pulmonol, Tel Aviv, Israel; [Elizur, Arnon] Tel Aviv Univ, Sackler Fac Med, Dept Pediat, Tel Aviv, Israel; [Haland, Geir] Oslo Univ Hosp, Dept Paediat Allergy & Pulmonol, Oslo, Norway; [Hoffmann-Sommergruber, Karin] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Vienna, Austria; [Kim, Harold] Western Univ, Dept Med, Div Clin Immunol & Allergy, London, ON, Canada; [Kim, Harold] McMaster Univ, Dept Med, Div Clin Immunol & Allergy, Hamilton, ON, Canada; [Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Leung, Donald Y. M.] Univ Colorado, Denver Hlth Sci Ctr, Dept Pediat, Aurora, CO USA; [Muraro, Antonella] Padua Univ Hosp, Dept Woman & Child Hlth, Food Allergy Ctr Veneto Reg, Padua, Italy; [Nurmatov, Ulugbek B.] Natl Ctr Populat Hlth & Wellbeing Res, Div Populat Med, Sch Med, Swansea, W Glam, Wales; [Pajno, Giovanni B.] Univ Messina, Dept Pediat, Allergy Unit, Messina, Italy; [Worm, Margitta] Charite Univ Med Berlin, Div Allergy & Immunol, Dept Dermatol Allergy & Venerol, Berlin, Germany	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Baylor College of Medicine; Baylor College of Medicine; IRCCS Bambino Gesu; Universite de Montreal; Universite de Montreal; McGill University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Goethe University Frankfurt; Goethe University Frankfurt Hospital; University of London; King's College London; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of Geneva; BC Childrens Hospital; University of British Columbia; Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; University of Oslo; Medical University of Vienna; Western University (University of Western Ontario); McMaster University; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Padua; Azienda Ospedaliera - Universita di Padova; Swansea University; University of Messina; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Nadeau, KC (corresponding author), Stanford Univ, Sean N Parker Ctr Allergy & Asthma Res, 269 Campus Dr,CCSR 3215,MC 5366, Stanford, CA 94305 USA.	knadeau@stanford.edu	Arasi, Stefania/K-2858-2018; Long, Andrew/AAF-2527-2020; Bégin, Philippe/AAU-9126-2021; Upton, Julia/T-7425-2019	Arasi, Stefania/0000-0002-8135-0568; Upton, Julia/0000-0001-5320-4232; Hoffmann-Sommergruber, Karin/0000-0002-8830-058X; Brough, Helen/0000-0001-7203-0813; Worm, Margitta/0000-0002-3449-1245; Anagnostou, Aikaterini/0000-0001-6240-7437; Elizur, Arnon/0000-0001-8157-8143	Sean N. Parker Center for Allergy and Asthma Research at Stanford University; Naddisy Foundation; Reinhard Foundation; Food Allergy Research Education	Sean N. Parker Center for Allergy and Asthma Research at Stanford University; Naddisy Foundation; Reinhard Foundation; Food Allergy Research Education	Supported by the Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Naddisy Foundation, Reinhard Foundation, and Food Allergy Research & Education.	Anagnostou K, 2014, LANCET, V383, P1297, DOI 10.1016/S0140-6736(13)62301-6; Blumchen K, 2019, J ALLER CL IMM-PRACT, V7, P479, DOI 10.1016/j.jaip.2018.10.048; Carraro S, 2012, INT J IMMUNOPATH PH, V25, P793, DOI 10.1177/039463201202500329; Chu DK, 2019, LANCET, V393, P2222, DOI 10.1016/S0140-6736(19)30420-9; Epstein-Rigbi N, 2019, J ALLER CL IMM-PRACT, V7, P429, DOI 10.1016/j.jaip.2018.06.016; Galvin AD, 2018, ALLERGY, V73, P560, DOI 10.1111/all.13330; Kim EH, 2019, J ALLERGY CLIN IMMUN, V144, P1320, DOI 10.1016/j.jaci.2019.07.030; Lewis MO, 2019, ANN ALLERG ASTHMA IM, V123, P101, DOI 10.1016/j.anai.2019.04.006; Otani IM, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-25; Reier-Nilsen T, 2019, PEDIAT ALLERG IMM-UK, V30, P638, DOI 10.1111/pai.13066	10	11	11	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2020	145	4					1153	1156		10.1016/j.jaci.2019.10.021	http://dx.doi.org/10.1016/j.jaci.2019.10.021			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LA0FR	31678426				2022-12-18	WOS:000523633400011
J	Sadik, CD; Schmidt, E; Zillikens, D; Hashimoto, T				Sadik, Christian D.; Schmidt, Enno; Zillikens, Detlef; Hashimoto, Takashi			Recent progresses and perspectives in autoimmune bullous diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Autoimmune bullous disease; epidermal basement membrane zone; desmosome; pathomechanisms; pemphigoid diseases			[Sadik, Christian D.; Schmidt, Enno; Zillikens, Detlef] Univ Lubeck, Dept Dermatol Allergy & Venereol, Lubeck, Germany; [Sadik, Christian D.; Schmidt, Enno; Zillikens, Detlef] Univ Lubeck, CRIS, Lubeck, Germany; [Schmidt, Enno] Univ Lubeck, LIED, Lubeck, Germany; [Hashimoto, Takashi] Osaka City Univ, Grad Sch Med, Dept Dermatol, Osaka, Japan	University of Lubeck; University of Lubeck; University of Lubeck; Osaka Metropolitan University	Hashimoto, T (corresponding author), Osaka City Univ, Grad Sch Med, Dept Dermatol, Abeno Ku, 1-4-3 Asahimachi, Osaka 5458585, Japan.; Zillikens, D (corresponding author), Univ Lubeck, Dept Dermatol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	Detlef.Zillikens@uksh.de; hashyt@gmail.com	Sadik, Christian David/G-9593-2014	Sadik, Christian David/0000-0001-6701-048X				Amagai M, 2000, J CLIN INVEST, V105, P625, DOI 10.1172/JCI8748; Chakievska L, 2019, J AUTOIMMUN, V96, P104, DOI 10.1016/j.jaut.2018.09.003; Ellebrecht CT, 2016, SCIENCE, V353, P179, DOI 10.1126/science.aaf6756; Ishii N, 2015, BRIT J DERMATOL, V173, P59, DOI 10.1111/bjd.13711; Lotti R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01387; Muramatsu K, 2018, J ALLERGY CLIN IMMUN, V142, P1818, DOI 10.1016/j.jaci.2018.03.014; Sadik CD, 2018, SEMIN IMMUNOL, V37, P21, DOI 10.1016/j.smim.2018.03.002; Schmidt E, 2019, LANCET, V394, P882, DOI 10.1016/S0140-6736(19)31778-7; Schmidt E, 2013, LANCET, V381, P320, DOI 10.1016/S0140-6736(12)61140-4; Waschke J, 2014, MED RES REV, V34, P1127, DOI 10.1002/med.21310	10	11	11	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2020	145	4					1145	1147		10.1016/j.jaci.2020.02.020	http://dx.doi.org/10.1016/j.jaci.2020.02.020			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LA0FR	32272983	Bronze			2022-12-18	WOS:000523633400009
J	Rafiq, M; Hayward, A; Warren-Gash, C; Denaxas, S; Gonzalez-Izquierdo, A; Lyratzopoulos, G; Thomas, S				Rafiq, Meena; Hayward, Andrew; Warren-Gash, Charlotte; Denaxas, Spiros; Gonzalez-Izquierdo, Arturo; Lyratzopoulos, Georgios; Thomas, Sara			Allergic disease, corticosteroid use, and risk of Hodgkin lymphoma: A United Kingdom nationwide case-control study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic disease; Hodgkin lymphoma; corticosteroids; asthma; eczema; allergic rhinitis; risk; atopic dermatitis	HEMATOLOGICAL MALIGNANCIES; MEDICAL HISTORY; CANCER; AUTOIMMUNE; EPIDEMIOLOGY; ADOLESCENTS; TRANSPLANT; DISORDERS; DIAGNOSIS; BLOCKADE	Background: Immunodeficiency syndromes (acquired/congenital/iatrogenic) are known to increase Hodgkin lymphoma (HL) risk, but the effects of allergic immune dysregulation and corticosteroids are poorly understood. Objective: We sought to assess the risk of HL associated with allergic disease (asthma, eczema, and allergic rhinitis) and corticosteroid use. Methods: We conducted a case-control study using the United Kingdom Clinical Practice Research Datalink (CPRD) linked to hospital data. Multivariable logistic regression investigated associations between allergic diseases and HL after adjusting for established risk factors. Potential confounding or effect modification by steroid treatment were examined. Results: One thousand two hundred thirty-six patients with HL were matched to 7416 control subjects. Immunosuppression was associated with 6-fold greater odds of HL (adjusted odds ratio [aOR], 6.18; 95% CI, 3.04-12.57), with minimal change after adjusting for steroids. Any prior allergic disease or eczema alone was associatedwith 1.4-fold increased odds of HL(aOR, 1.41 [95% CI, 1.24-1.60] and 1.41 [95% CI, 1.20-1.65], respectively). These associations decreased but remained significant after adjustment for steroids (aOR, 1.25 [95% CI, 1.09-1.43] and 1.27 [95% CI, 1.08-1.49], respectively). There was no effect modification by steroid use. Previous steroid treatment was associated with 1.4-fold greater HL odds (aOR, 1.38; 95% CI, 1.20-1.59). Conclusions: In addition to established risk factors (immunosuppression and infectious mononucleosis), allergic disease and eczema are risk factors for HL. This association is only partially explained by steroids, which are associated with increased HL risk. These findings add to the growing evidence that immune system malfunction after allergic disease or immunosuppression is central to HL development.	[Rafiq, Meena; Denaxas, Spiros; Gonzalez-Izquierdo, Arturo] UCL, Inst Hlth Informat, London, England; [Hayward, Andrew; Lyratzopoulos, Georgios] UCL, Inst Epidemiol & Hlth Care, London, England; [Warren-Gash, Charlotte; Thomas, Sara] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London, England	University of London; University College London; University of London; University College London; University of London; London School of Hygiene & Tropical Medicine	Rafiq, M (corresponding author), UCL, Inst Hlth Informat, 222 Euston Rd, London NW1 2DA, England.	Meena.rafiq@ucl.ac.uk		Gonzalez-Izquierdo, Arturo/0000-0002-0984-5830; Denaxas, Spiros/0000-0001-9612-7791; Warren-Gash, Charlotte/0000-0003-4524-3180; Lyratzopoulos, Georgios/0000-0002-2873-7421	National Institute for Health Research (NIHR) [IPF-2017-11-011]; NIHR; Cancer Research UK Advanced Clinician Scientist Fellowship [C18081/A18180]; Cancer Research UK [C8640/A23385]; ESRC [ES/L007517/1] Funding Source: UKRI; MRC [1940103] Funding Source: UKRI	National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); NIHR(National Institute for Health Research (NIHR)); Cancer Research UK Advanced Clinician Scientist Fellowship; Cancer Research UK(Cancer Research UK); ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	M.R. and the work presented in this article are funded by a National Institute for Health Research (NIHR) in-practice clinical fellowship (IPF-2017-11-011). This article presents independent research funded by the NIHR. The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health. The joint senior author G.L. is supported by a Cancer Research UK Advanced Clinician Scientist Fellowship (C18081/A18180). G.L. is Associate Director of the multi-institutional CanTest Collaborative, which is funded by Cancer Research UK (grant number C8640/A23385).	Akbari O, 2010, MUCOSAL IMMUNOL, V3, P81, DOI 10.1038/mi.2009.112; Alarcon PA, PEDIAT HODGKIN LYMPH; [Anonymous], 1997, EPSTEIN BARR VIRUS K; Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Arellano FM, 2007, J INVEST DERMATOL, V127, P808, DOI 10.1038/sj.jid.5700622; Arellano FM, 2009, J ALLERGY CLIN IMMUN, V123, P1111, DOI 10.1016/j.jaci.2009.02.028; Askling J, 2005, ANN RHEUM DIS, V64, P1765, DOI 10.1136/ard.2005.036459; Bagg A, 2013, SEMIN DIAGN PATHOL, V30, P102, DOI 10.1053/j.semdp.2012.08.005; Becker N, 2007, LEUKEMIA RES, V31, P1365, DOI 10.1016/j.leukres.2007.02.019; Bernatsky S, 2007, RHEUMATOLOGY, V46, P830, DOI 10.1093/rheumatology/kel444; Biggar RJ, 2006, BLOOD, V108, P3786, DOI 10.1182/blood-2006-05-024109; Bleyer WA, 2002, MED PEDIATR ONCOL, V38, P1, DOI 10.1002/mpo.1257; Boggon R, 2013, PHARMACOEPIDEM DR S, V22, P168, DOI 10.1002/pds.3374; BOURGUET CC, 1993, CANCER, V72, P2148, DOI 10.1002/1097-0142(19931001)72:7<2148::AID-CNCR2820720714>3.0.CO;2-Q; Choi Jung-Hye, 2006, Korean Journal of Internal Medicine, V21, P46; COZEN W, 1992, CANCER EPIDEM BIOMAR, V1, P261; Dikalioti SK, 2012, EUR J CANCER, V48, P1860, DOI 10.1016/j.ejca.2011.12.010; Dolcetti R, 2013, SEMIN CANCER BIOL, V23, P441, DOI 10.1016/j.semcancer.2013.07.005; DOYLE TJ, 1983, CANCER, V51, P245, DOI 10.1002/1097-0142(19830115)51:2<245::AID-CNCR2820510213>3.0.CO;2-W; Greaves M, 2018, NAT REV CANCER, V18, P471, DOI 10.1038/s41568-018-0015-6; Green MR, 2012, CLIN CANCER RES, V18, P1611, DOI 10.1158/1078-0432.CCR-11-1942; GRIDLEY G, 1993, JNCI-J NATL CANCER I, V85, P307, DOI 10.1093/jnci/85.4.307; Henle W., 1979, EPSTEINBARR VIRUS, P61; Herrett E, 2015, INT J EPIDEMIOL, V44, P827, DOI 10.1093/ije/dyv098; Hjalgrim H, 2004, JNCI-J NATL CANCER I, V96, P780, DOI 10.1093/jnci/djh135; Hjalgrim H, 2012, CHARACTERISTICS HODG, V349, P1324; Hjalgrim H, 2012, DAN MED J, V59; Hollander P, 2015, AM J EPIDEMIOL, V182, P624, DOI 10.1093/aje/kwv081; Huang X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039986; Jaffe ES, 2001, WHO CLASSIFICATION T; Kamel OW, 1996, AM J SURG PATHOL, V20, P1279, DOI 10.1097/00000478-199610000-00015; Knol MJ, 2008, AM J EPIDEMIOL, V168, P1073, DOI 10.1093/aje/kwn217; Legendre L, 2015, J AM ACAD DERMATOL, V72, P992, DOI 10.1016/j.jaad.2015.02.1116; Lewis JD, 2005, PHARMACOEPIDEM DR S, V14, P443, DOI 10.1002/pds.1115; Linabery AM, 2014, INT J CANCER, V135, P1454, DOI 10.1002/ijc.28785; MACMAHON B, 1957, CANCER-AM CANCER SOC, V10, P1045, DOI 10.1002/1097-0142(195709/10)10:5<1045::AID-CNCR2820100527>3.0.CO;2-0; MACMAHON B, 1966, CANCER RES, V26, P1189; Mason M, 2013, INFLAMM BOWEL DIS, V19, P1306, DOI 10.1097/MIB.0b013e3182807618; Matsumoto K, 2004, J IMMUNOL, V172, P2530, DOI 10.4049/jimmunol.172.4.2530; Musolino C, 2014, LEUKEMIA RES, V38, P1137, DOI 10.1016/j.leukres.2014.08.004; Nissen F, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017474; Nunez-Enriquez JC, 2013, BRIT J CANCER, V108, P2334, DOI 10.1038/bjc.2013.237; OLDHAFER KJ, 1989, AM J MED, V87, P218; Opelz G, 2004, AM J TRANSPLANT, V4, P222, DOI 10.1046/j.1600-6143.2003.00325.x; Pottegard A, 2017, PHARMACOEPIDEM DR S, V26, P223, DOI 10.1002/pds.4145; Radhakrishnan S, 2004, J IMMUNOL, V173, P1360, DOI 10.4049/jimmunol.173.2.1360; Rosenwald A, 2003, J EXP MED, V198, P851, DOI 10.1084/jem.20031074; Schneeweiss S, 2009, DERMATOLOGY, V219, P7, DOI 10.1159/000209289; Singh AK, 2011, ALLERGY, V66, P155, DOI 10.1111/j.1398-9995.2010.02458.x; Soderberg KC, 2006, EUR J CANCER, V42, P3028, DOI 10.1016/j.ejca.2006.04.021; Soderberg KC, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-51; Swerdlow SH., 2017, WHO CLASSIFICATION T; Tavani A, 2000, EUR J CANCER PREV, V9, P59, DOI 10.1097/00008469-200002000-00008; Urayama KY, 2012, JNCI-J NATL CANCER I, V104, P240, DOI 10.1093/jnci/djr516; Valenta R, 2009, TRENDS IMMUNOL, V30, P109, DOI 10.1016/j.it.2008.12.004; Vineis P, 2000, J EPIDEMIOL COMMUN H, V54, P431, DOI 10.1136/jech.54.6.431; Worldwide variation in prevalence of symptoms of asthma allergic rhinoconjunctivitis and atopic eczema: ISAAC, 1998, LANCET, V351, P1225, DOI DOI 10.1016/S0140-6736(97)07302-9	57	11	10	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2020	145	3					868	876		10.1016/j.jaci.2019.10.033	http://dx.doi.org/10.1016/j.jaci.2019.10.033			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KT1GD	31730878	Green Published, Green Accepted, hybrid			2022-12-18	WOS:000518756700024
J	Rosa, MJ; Hartman, TJ; Adgent, M; Gardner, K; Gebretsadik, T; Moore, PE; Davis, RL; LeWinn, KZ; Bush, NR; Tylavsky, F; Wright, RJ; Carroll, KN				Rosa, Maria Jose; Hartman, Terryl J.; Adgent, Margaret; Gardner, Kourtney; Gebretsadik, Tebeb; Moore, Paul E.; Davis, Robert L.; LeWinn, Kaja Z.; Bush, Nicole R.; Tylavsky, Frances; Wright, Rosalind J.; Carroll, Kecia N.			Prenatal polyunsaturated fatty acids and child asthma: Effect modification by maternal asthma and child sex	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Polyunsaturated fatty acid; childhood asthma; sex-specific effects; prenatal	JAPANESE INFANTS; POOLED ANALYSIS; UMBILICAL-CORD; PREGNANCY; WHEEZE; ECZEMA; RISK; FISH; N-3; CONSUMPTION	Background: Findings on prenatal polyunsaturated fatty acid (PUFA) intake and child wheeze and asthma have been inconsistent. Objective: We sought to examine associations between prenatal PUFA status and child wheeze/asthma and modifying effects of maternal asthma/atopy, child sex, and maternal race. Methods: Analyses included 1019 mother-child dyads with omega-3 (n-3) and omega-3 (n-6) PUFAs measured in second-trimester plasma; n-6/n-3 ratios were calculated. Child wheeze/asthma outcomes ascertained at age 4 to 6 years included ever physician-diagnosed asthma, current wheeze (symptoms past 12 months), current asthma (diagnosis and medication and/or symptoms past 12 months), and current diagnosed asthma. Each PUFA indicator and outcome was analyzed in separate models using modified Poisson regression with interaction terms. Results: In quartile (Q) analyses, higher n-6 PUFAs were associated with increased risk of ever (risk ratio [RR] high vs low [RR Q4 vs Q1], 1.70; 95% CI, 1.07-2.71) and current (RRQ4 vs Q1, 1.70; 95% CI, 1.07-2.71) diagnosed asthma, whereas n-3 PUFAs were associated with lower risk (RR Q4 vs Q1, 0.59; 95% CI, 0.33-1.03) of current diagnosed asthma (P-trend < .05 for all). Higher n-6 PUFAs were associated with a higher risk of all respiratory outcomes among children born to women with asthma (P-interaction < .05 for all outcomes). A significant 3-way interaction between child sex, maternal asthma, and n-6/n-3 PUFA indicated that male children born to women with asthma and a higher ratio had the highest risk across wheeze/asthma outcomes (P-interaction < .05). Conclusions: Associations between prenatal PUFA status and childhood wheeze/asthma were modified by maternal history of asthma and child sex.	[Rosa, Maria Jose; Wright, Rosalind J.] Icahn Sch Med Mt Sinai, Dept Environm Med & Publ Hlth, New York, NY 10029 USA; [Hartman, Terryl J.] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; [Adgent, Margaret; Carroll, Kecia N.] Vanderbilt Univ, Med Ctr, Dept Pediat, Div Gen Pediat, Nashville, TN 37232 USA; [Gardner, Kourtney] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA; [Gebretsadik, Tebeb] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA; [Moore, Paul E.] Vanderbilt Univ, Med Ctr, Dept Pediat, Div Allergy Immunol & Pulm Med, Nashville, TN 37232 USA; [Davis, Robert L.] Univ Tennessee, Hlth Sci Ctr, Ctr Biomed Informat, Memphis, TN 38163 USA; [LeWinn, Kaja Z.; Bush, Nicole R.] Univ Calif San Francisco, Dept Psychiat, Weill Inst Neurosci, San Francisco, CA USA; [Bush, Nicole R.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA; [Tylavsky, Frances] Univ Tennessee, Hlth Sci Ctr Memphis, Dept Prevent Med, Memphis, TN USA; [Wright, Rosalind J.] Icahn Sch Med Mt Sinai, Inst Expos Res, New York, NY 10029 USA; [Wright, Rosalind J.] Icahn Sch Med Mt Sinai, Kravis Childrens Hosp, Dept Pediat, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Emory University; Rollins School Public Health; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Tennessee System; University of Tennessee Health Science Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Tennessee System; University of Tennessee Health Science Center; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Rosa, MJ (corresponding author), One Gustave L Levy Pl,Box 1057, New York, NY 10029 USA.	maria.rosa@mssm.edu	Rosa, Maria José/AAX-6620-2020; Bush, Nicole/AAH-4935-2020	Rosa, Maria José/0000-0002-1509-7664; 	Urban Child Institute; National Institutes of Health [NHLBI HL109977, HL132338, DK020593]; National Institute of Environmental Health Sciences [R00ES027496]	Urban Child Institute; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was funded by the Urban Child Institute (F.T.) and the National Institutes of Health (grant no. NHLBI HL109977 to K.N.C. and grant no. HL132338 to K.N.C. and R.J.W.). M.J.R. was supported by National Institute of Environmental Health Sciences grant number R00ES027496. The Lipid Core was supported by National Institutes of Health grant number DK020593.	Almqvist C, 2008, ALLERGY, V63, P47, DOI 10.1111/j.1398-9995.2007.01524.x; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Barros R, 2011, BRIT J NUTR, V106, P441, DOI 10.1017/S0007114511000328; Best KP, 2018, WORLD ALLERGY ORGAN, V11, DOI 10.1186/s40413-018-0190-7; Best KP, 2016, AM J CLIN NUTR, V103, P128, DOI 10.3945/ajcn.115.111104; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Blasbalg TL, 2011, AM J CLIN NUTR, V93, P950, DOI 10.3945/ajcn.110.006643; Bloom Barbara, 2013, Vital Health Stat 10, P1; Brenna JT, 2018, AM J CLIN NUTR, V108, P211, DOI 10.1093/ajcn/nqy089; Calder PC, 2003, LIPIDS, V38, P343, DOI 10.1007/s11745-003-1068-y; Calder PC, 2003, CLIN EXP ALLERGY, V33, P412, DOI 10.1046/j.1365-2222.2003.01633.x; Calder PC, 2006, BRIT J NUTR, V96, P774, DOI [10.1079/BJN20061917, 10.1079/BJN20061881]; Calder PC, 2012, J NUTR, V142, p592S, DOI 10.3945/jn.111.155259; Calder PC, 2010, P NUTR SOC, V69, P373, DOI 10.1017/S0029665110001552; Chatzi L, 2008, THORAX, V63, P507, DOI 10.1136/thx.2007.081745; Childs CE, 2008, P NUTR SOC, V67, P19, DOI 10.1017/S0029665108005983; Crozier SR, 2009, J NUTR, V139, P1956, DOI 10.3945/jn.109.109579; Crozier SR, 2009, PAEDIATR PERINAT EP, V23, P446, DOI 10.1111/j.1365-3016.2009.01036.x; Decsi T, 2011, AM J CLIN NUTR, V94, p1914S, DOI 10.3945/ajcn.110.000893; Demissie K, 1998, PEDIATRICS, V102, P84, DOI 10.1542/peds.102.1.84; FOLCH J, 1957, J BIOL CHEM, V226, P497; Furuhjelm C, 2011, PEDIAT ALLERG IMM-UK, V22, P505, DOI 10.1111/j.1399-3038.2010.01096.x; Furuhjelm C, 2009, ACTA PAEDIATR, V98, P1461, DOI 10.1111/j.1651-2227.2009.01355.x; Ishak N, 2014, EXP LUNG RES, V40, P30, DOI 10.3109/01902148.2013.858197; Kim JH, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-49; Lee-Sarwar K, 2019, J ALLER CL IMM-PRACT, V7, P529, DOI 10.1016/j.jaip.2018.07.039; Leermakers ETM, 2013, EUR J CLIN NUTR, V67, P353, DOI 10.1038/ejcn.2013.36; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; Liptzin DR, 2015, PEDIATR PULM, V50, P1159, DOI 10.1002/ppul.23178; Liu XQ, 2018, J ALLERGY CLIN IMMUN, V141, P886, DOI 10.1016/j.jaci.2017.05.016; Lumia M, 2011, PEDIAT ALLERG IMM-UK, V22, P827, DOI 10.1111/j.1399-3038.2011.01202.x; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Miyake Y, 2009, THORAX, V64, P815, DOI 10.1136/thx.2009.115931; Miyake Y, 2013, ANN EPIDEMIOL, V23, P674, DOI 10.1016/j.annepidem.2013.08.004; Montes R, 2013, EUR J CLIN NUTR, V67, P658, DOI 10.1038/ejcn.2013.68; MORRISON WR, 1964, J LIPID RES, V5, P600; Newson RB, 2004, J ALLERGY CLIN IMMUN, V114, P531, DOI 10.1016/j.jaci.2004.05.010; Notenboom ML, 2011, CLIN EXP ALLERGY, V41, P407, DOI 10.1111/j.1365-2222.2010.03672.x; Nurmatov U, 2012, ALLERGY, V67, P1041, DOI 10.1111/j.1398-9995.2012.02858.x; Nwaru BI, 2012, BRIT J NUTR, V108, P720, DOI 10.1017/S0007114511005940; Olsen SF, 2008, AM J CLIN NUTR, V88, P167, DOI 10.1093/ajcn/88.1.167; Palmer DJ, 2013, ALLERGY, V68, P1370, DOI 10.1111/all.12233; Palmer DJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e184; Pele F, 2013, ENVIRON HEALTH-GLOB, V12, DOI 10.1186/1476-069X-12-102; Pham MN, 2018, CURR ALLERGY ASTHM R, V18, DOI 10.1007/s11882-018-0811-9; Pike KC, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/474613; Roy A, 2018, PEDIAT ALLERG IMM-UK, V29, P144, DOI 10.1111/pai.12834; Rucci E, 2016, CLIN EXP ALLERGY, V46, P461, DOI 10.1111/cea.12613; Schmitz G, 2008, PROG LIPID RES, V47, P147, DOI 10.1016/j.plipres.2007.12.004; Sontag-Padilla LM, 2015, METHODOLOGICAL OVERV; Standl M, 2014, PEDIAT ALLERG IMM-UK, V25, P344, DOI 10.1111/pai.12212; Stratakis N, 2018, BRIT J NUTR, V119, P202, DOI [10.1017/S0007114517003348, 10.1017/s0007114517003348]; Stratakis N, 2017, INT J EPIDEMIOL, V46, P1465, DOI 10.1093/ije/dyx007; Volgyi E, 2013, NUTRIENTS, V5, P1511, DOI 10.3390/nu5051511; Willet W, 2013, NUTR EPIDEMIOLOGY, V3rd; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	56	11	12	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2020	145	3					800	+		10.1016/j.jaci.2019.10.039	http://dx.doi.org/10.1016/j.jaci.2019.10.039			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KT1GD	31809758	Bronze, Green Accepted			2022-12-18	WOS:000518756700018
J	Simpson, A; Brough, HA; Haider, S; Belgrave, D; Murray, CS; Custovic, A				Simpson, Angela; Brough, Helen A.; Haider, Sadia; Belgrave, Danielle; Murray, Clare S.; Custovic, Adnan			Early-life inhalant allergen exposure, filaggrin genotype, and the development of sensitization from infancy to adolescence	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen exposure; house dust mite; cat; dog; sensitization; birth cohort; filaggrin; childhood; Fel d 1; Der p 1; Can f 1	HOUSE-DUST MITE; CAT ALLERGEN; ATOPIC ECZEMA; DOG ALLERGEN; RISK-FACTOR; HAY-FEVER; F 1; ASTHMA; MUTATIONS; CHILDREN	Background: We hypothesized that filaggrin (FLG) loss-of-function mutations modify the effect of allergen exposure on the development of allergic sensitization. Objective: We sought to determine whether early-life exposure to inhalant allergens increases the risk of specific sensitization and whether FLG mutations modulate these odds. Methods: In a population-based birth cohort we measured mite, cat, and dog allergen levels in dust samples collected from homes within the first year of life. Sensitization was assessed at 6 time points between infancy and age 16 years. Genotyping was performed for 6 FLG mutations. Results: In the longitudinal multivariable model (age 1-16 years), we observed a significant interaction between FLG and Fel d 1 exposure on cat sensitization, with the effect of exposure being significantly greater among children with FLG mutations compared with those without (odds ratio, 1.36; 95% CI, 1.02-1.80; P = .035). The increase in risk of mite sensitization with increasing Der p 1 exposure was consistently greater among children with FLG mutations, but the interaction did not reach statistical significance. Different associations were observed for dogs: there was a significant interaction between FLG and dog ownership, but the risk of sensitization to any allergen was significantly lower among children with FLG mutations who were exposed to a dog in infancy (odds ratio, 0.16; 95% CI, 0.03-0.86; P = .03). Conclusions: FLG loss-of-function mutations modify the relationship between allergen exposure and sensitization, but effects differ at different ages and between different allergens.	[Simpson, Angela; Murray, Clare S.] Univ Manchester, Div Infect Immun & Resp Med, Fac Biol Med & Hlth, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England; [Simpson, Angela; Murray, Clare S.] Univ Hosp South Manchester NHS Fdn Trust, Manchester, Lancs, England; [Brough, Helen A.] Guys & St Thomas NHS Trust, Childrens Allergy Serv, Evelina London, London, England; [Brough, Helen A.] Sch Life Course Sci, Paediat Allergy Grp, Dept Women & Childrens Heath, London, England; [Brough, Helen A.] Kings Coll London, Paediat Allergy Grp, Sch Immunol & Microbial Sci, London, England; [Haider, Sadia; Custovic, Adnan] Imperial Coll London, Sect Paediat, London, England; [Haider, Sadia; Belgrave, Danielle; Custovic, Adnan] Microsoft Res Cambridge, Cambridge, England	University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Imperial College London; Microsoft	Custovic, A (corresponding author), Imperial Coll London, St Marys Campus Med Sch, London W2 1PG, England.	a.custovic@imperial.ac.uk	Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Haider, Sadia/0000-0002-3607-973X; Brough, Helen/0000-0001-7203-0813; Murray, Clare/0000-0002-8961-8055; Simpson, Angela/0000-0003-2733-6666	UK Medical Research Council [MR/K002449/1, MR/LO12693/1]; Asthma UK [301 (1995-1998), 01/012, 2001-2004, 04/014]; BMA James Trust; JP Moulton Charitable Foundation; North West Lung Centre Charity; Medical Research Council [MR/K002449/1, G0601361, MR/L012693/1]; National Institute for Health Research (NIHR) South Manchester Respiratory and Allergy Clinical Research Facility at Manchester University NHS Foundation Trust (Wythenshawe); NIHR Manchester Biomedical Research Centre; Manchester Biomedical Research Centre; MRC [MR/L012693/1, G0601361, MR/K002449/1] Funding Source: UKRI	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Asthma UK; BMA James Trust; JP Moulton Charitable Foundation; North West Lung Centre Charity; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research (NIHR) South Manchester Respiratory and Allergy Clinical Research Facility at Manchester University NHS Foundation Trust (Wythenshawe); NIHR Manchester Biomedical Research Centre(National Institute for Health Research (NIHR)); Manchester Biomedical Research Centre(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by UK Medical Research Council grants MR/K002449/1 and MR/LO12693/1. The Manchester Asthma and Allergy Study was supported by Asthma UK grants 301 (1995-1998), 362 (1998-2001), 01/012 (2001-2004), and 04/014 (2004-2007); the BMA James Trust (2005) and the JP Moulton Charitable Foundation (2004-current); the North West Lung Centre Charity (1997-current); and Medical Research Council grants G0601361 (2007-2012), MR/K002449/1 (2013-2014), and MR/L012693/1 (2014-2018). This report is independent research supported by the National Institute for Health Research (NIHR) South Manchester Respiratory and Allergy Clinical Research Facility at Manchester University NHS Foundation Trust (Wythenshawe) and by the NIHR Manchester Biomedical Research Centre. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health. A.S. is supported by the Manchester Biomedical Research Centre.	Al-Mousawi MSH, 2004, J ALLERGY CLIN IMMUN, V114, P1389, DOI 10.1016/j.jaci.2004.09.005; Almqvist C, 2003, CLIN EXP ALLERGY, V33, P1190, DOI 10.1046/j.1365-2222.2003.01764.x; Bisgaard H, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050131; Blekic M, 2013, ANN ALLERG ASTHMA IM, V110, P347, DOI 10.1016/j.anai.2013.01.021; Brough HA, 2014, J ALLERGY CLIN IMMUN, V134, P867, DOI 10.1016/j.jaci.2014.08.011; Brown SJ, 2008, SEMIN CUTAN MED SURG, V27, P128, DOI 10.1016/j.sder.2008.04.001; Cullinan P, 2004, THORAX, V59, P855, DOI 10.1136/thx.2003.019877; Custovic A, 1998, THORAX, V53, P33, DOI 10.1136/thx.53.1.33; Custovic A, 2003, J ALLERGY CLIN IMMUN, V111, P402, DOI 10.1067/mai.2003.55; Custovic A, 2015, CLIN EXP ALLERGY, V45, P54, DOI 10.1111/cea.12450; Custovic A, 1996, CLIN EXP ALLERGY, V26, P1246, DOI 10.1111/j.1365-2222.1996.tb00521.x; Custovic A, 2002, PEDIAT ALLERG IMM-UK, V13, P32, DOI 10.1034/j.1399-3038.13.s.15.3.x; Custovic A, 1997, AM J RESP CRIT CARE, V155, P94, DOI 10.1164/ajrccm.155.1.9001295; Custovic A, 2001, J ALLERGY CLIN IMMUN, V108, P537, DOI 10.1067/mai.2001.118599; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; Custovic A, 2015, J ALLERGY CLIN IMMUN, V136, P1645, DOI 10.1016/j.jaci.2015.03.041; Custovic A, 2015, THORAX, V70, P799, DOI 10.1136/thoraxjnl-2015-206781; Custovic A, 2011, J ALLERGY CLIN IMMUN, V127, P390, DOI 10.1016/j.jaci.2010.10.050; De Benedetto A, 2008, J INVEST DERMATOL, V128, P1594, DOI 10.1038/sj.jid.5701208; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Howard R, 2018, J ALLERGY CLIN IMMUN, V142, P1322, DOI 10.1016/j.jaci.2017.11.064; Ihuoma H, 2018, J ALLERGY CLIN IMMUN, V141, P820, DOI 10.1016/j.jaci.2017.09.030; Johnson CC, 2004, J ALLERGY CLIN IMMUN, V114, P105, DOI 10.1016/j.jaci.2004.04.007; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Lawlor DA, 2016, INT J EPIDEMIOL, V45, P1866, DOI 10.1093/ije/dyw314; Lazic N, 2013, ALLERGY, V68, P764, DOI 10.1111/all.12134; Lehtimaki J, 2018, P NATL ACAD SCI USA, V115, P4897, DOI 10.1073/pnas.1719785115; Liu X, 2004, J ALLERGY CLIN IMMUN, V113, P489, DOI 10.1016/j.jaci.2003.12.037; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; Miwa M, 2016, ALLERGOL INT, V65, P338, DOI 10.1016/j.alit.2016.01.007; Nemoto-Hasebe I, 2009, J INVEST DERMATOL, V129, P682, DOI 10.1038/jid.2008.280; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Pregibon D., 1980, APPLIED STATISTICS, V29, P15, DOI [DOI 10.2307/2346405, 10.2307/2346405]; Schuttelaar MLA, 2009, ALLERGY, V64, P1758, DOI 10.1111/j.1398-9995.2009.02080.x; Simpson A, 2002, CLIN EXP ALLERGY, V32, P1413, DOI 10.1046/j.1365-2745.2002.01496.x; Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Sitarik AR, 2018, INDOOR AIR, V28, P539, DOI 10.1111/ina.12456; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Szalai K, 2012, EXP DERMATOL, V21, P842, DOI 10.1111/exd.12015; Thomas WR, 2002, INT ARCH ALLERGY IMM, V129, P1, DOI 10.1159/000065179; Torrent M, 2006, J ALLERGY CLIN IMMUN, V118, P742, DOI 10.1016/j.jaci.2006.04.059; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; Woodcock A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/rccm.200401-083OC; Ziyab AH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21459-x	51	11	11	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2020	145	3					993	1001		10.1016/j.jaci.2019.08.041	http://dx.doi.org/10.1016/j.jaci.2019.08.041			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KT1GD	31629803	Green Published, hybrid			2022-12-18	WOS:000518756700035
J	Verheijen, J; Wong, SY; Rowe, JH; Raymond, K; Stoddard, J; Delmonte, OM; Bosticardo, M; Dobbs, K; Niemela, J; Calzoni, E; Pai, SY; Choi, U; Yamazaki, Y; Comeau, AM; Janssen, E; Henderson, L; Hazen, M; Berry, G; Rosenzweig, SD; Aldhekri, HH; He, M; Notarangelo, LD; Morava, E				Verheijen, Jan; Wong, Sunnie Y.; Rowe, Jared H.; Raymond, Kimiyo; Stoddard, Jennifer; Delmonte, Ottavia M.; Bosticardo, Marita; Dobbs, Kerry; Niemela, Julie; Calzoni, Enrica; Pai, Sung-Yun; Choi, Uimook; Yamazaki, Yasuhiro; Comeau, Anne Marie; Janssen, Erin; Henderson, Lauren; Hazen, Melissa; Berry, Gerard; Rosenzweig, Sergio D.; Aldhekri, Hasan Hamdan; He, Miao; Notarangelo, Luigi D.; Morava, Eva			Defining a new immune deficiency syndrome: MAN2B2-CDG	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							PHENOTYPES		[Verheijen, Jan; Morava, Eva] Mayo Clin, Dept Clin Genom, Ctr Individualized Med, Rochester, MN USA; [Wong, Sunnie Y.] Tulane Univ, Med Sch, Hayward Genet Ctr, New Orleans, LA 70118 USA; [Rowe, Jared H.; Janssen, Erin; Henderson, Lauren; Hazen, Melissa] Boston Childrens Hosp, Div Immunol, Boston, MA USA; [Raymond, Kimiyo] Mayo Clin, Biochem Genet Lab, Dept Lab Med & Pathol, Coll Med, Rochester, MN USA; [Stoddard, Jennifer; Niemela, Julie; Rosenzweig, Sergio D.] NIH, Immunol Serv, Dept Lab Med, Bldg 10, Bethesda, MD 20892 USA; [Delmonte, Ottavia M.; Bosticardo, Marita; Dobbs, Kerry; Calzoni, Enrica; Choi, Uimook; Yamazaki, Yasuhiro; Notarangelo, Luigi D.] NIAID, Lab Clin Immunol & Microbiol, Div Intramural Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Pai, Sung-Yun] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA; [Pai, Sung-Yun] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Comeau, Anne Marie] Univ Massachusetts, Med Sch, New England Newborn Screening Program, Worcester, MA 01605 USA; [Comeau, Anne Marie] Univ Massachusetts, Med Sch, Dept Pediat, Worcester, MA 01605 USA; [Berry, Gerard] Boston Childrens Hosp, Div Genet & Genom, Dept Pediat, Boston, MA USA; [Aldhekri, Hasan Hamdan] King Faisal Hosp & Res Ctr, Sect Pediat Allergy & Immunol, Riyadh, Saudi Arabia; [He, Miao] Childrens Hosp Philadelphia, Palmieri Metab Dis Lab, Philadelphia, PA 19104 USA	Mayo Clinic; Tulane University; Harvard University; Boston Children's Hospital; Mayo Clinic; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Boston Children's Hospital; King Faisal Specialist Hospital & Research Center; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	He, M (corresponding author), Childrens Hosp Philadelphia, Palmieri Metab Dis Lab, Philadelphia, PA 19104 USA.	hem@email.chop.edu; luigi.notarangelo2@nih.gov; Morava-Kozicz.Eva@Mayo.edu	Bosticardo, Marita/ABA-2688-2021	Bosticardo, Marita/0000-0002-1771-4523; Verheijen, Jan/0000-0003-0481-9649; Dobbs, Kerry/0000-0002-3432-3137	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health;  [U54 NS115198-01]	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); 	This work was supported in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health (to L.D.N.) and by grant number U54 NS115198-01 (to E.M.).	Ferreira CR, 2018, J INHERIT METAB DIS, V41, P541, DOI 10.1007/s10545-018-0156-5; Kuokkanen E, 2011, HUM MOL GENET, V20, P2651, DOI 10.1093/hmg/ddr167; Park C, 2005, J BIOL CHEM, V280, P37204, DOI 10.1074/jbc.M508930200; Pascoal C, 2019, J INHERIT METAB DIS, DOI 10.1002/jimd.12126; Stensland HMFR, 2015, HUM MUTAT, V36, P581, DOI 10.1002/humu.22787; Suzuki T, 2016, MOL ASPECTS MED, V51, P89, DOI 10.1016/j.mam.2016.05.004; WENGER DA, 1986, NEW ENGL J MED, V315, P1201, DOI 10.1056/NEJM198611063151906; Winchester B, 2005, GLYCOBIOLOGY, V15, p1R, DOI 10.1093/glycob/cwi041; Yarema KJ, 2001, GENOME BIOL, V2	9	11	11	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2020	145	3					1008	1011		10.1016/j.jaci.2019.11.016	http://dx.doi.org/10.1016/j.jaci.2019.11.016			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KT1GD	31775018	Bronze, Green Accepted, Green Submitted			2022-12-18	WOS:000518756700037
J	Cheng, HD; Tirosh, I; de Haan, N; Stockmann, H; Adamczyk, B; McManus, CA; O'Flaherty, R; Greville, G; Saldova, R; Bonilla, FA; Notarangelo, LD; Driessen, GJ; Holm, IA; Rudd, PM; Wuhrer, M; Ackerman, ME; Nigrovic, PA				Cheng, Hao D.; Tirosh, Irit; de Haan, Noortje; Stockmann, Henning; Adamczyk, Barbara; McManus, Ciara A.; O'Flaherty, Roisin; Greville, Gordon; Saldova, Radka; Bonilla, Francisco A.; Notarangelo, Luigi D.; Driessen, Gertjan J.; Holm, Ingrid A.; Rudd, Pauline M.; Wuhrer, Manfred; Ackerman, Margaret E.; Nigrovic, Peter A.			IgG Fc glycosylation as an axis of humoral immunity in childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HIGH-THROUGHPUT; ANTIBODIES		[Cheng, Hao D.; Ackerman, Margaret E.] Dartmouth Coll, Mol & Cellular Biol Program, Hanover, NH 03755 USA; [Ackerman, Margaret E.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Tirosh, Irit; Bonilla, Francisco A.; Nigrovic, Peter A.] Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Holm, Ingrid A.] Boston Childrens Hosp, Div Endocrinol, Boston, MA USA; [de Haan, Noortje; Wuhrer, Manfred] Leiden Univ, Med Ctr, Ctr Prote & Metabol, Leiden, Netherlands; [Stockmann, Henning; Adamczyk, Barbara; McManus, Ciara A.; O'Flaherty, Roisin; Greville, Gordon; Saldova, Radka; Rudd, Pauline M.] Natl Inst Bioproc Res & Training, Glycosci Grp, Dublin, Ireland; [Saldova, Radka] Univ Coll Dublin, Sch Med, Coll Hlth & Agr Sci, Dublin, Ireland; [Notarangelo, Luigi D.] NIAID, Lab Clin Immunol & Microbiol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Driessen, Gertjan J.] Haga Teaching Hosp, Juliana Childrens Hosp, Dept Pediat, The Hague, Netherlands; [Driessen, Gertjan J.] Sophia Childrens Univ Hosp, Erasmus Med Ctr, Dept Pediat, Rotterdam, Netherlands; [Nigrovic, Peter A.] Brigham & Womens Hosp, Div Rheumatol Inflammat & Immun, 75 Francis St, Boston, MA 02115 USA; [Tirosh, Irit] Sheba Med Ctr, Edmond & Lily Safra Childrens Hosp, Rheumatol Unit, Ramat Gan, Israel	Dartmouth College; Dartmouth College; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University College Dublin; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Haga Hospital; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Harvard University; Brigham & Women's Hospital; Chaim Sheba Medical Center	Ackerman, ME (corresponding author), Dartmouth Coll, Mol & Cellular Biol Program, Hanover, NH 03755 USA.; Ackerman, ME (corresponding author), Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA.; Nigrovic, PA (corresponding author), Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA.; Nigrovic, PA (corresponding author), Brigham & Womens Hosp, Div Rheumatol Inflammat & Immun, 75 Francis St, Boston, MA 02115 USA.	Margaret.e.ackerman@dartmouth.edu; pnigrovic@bwh.harvard.edu	Driessen, Gertjan/AAI-9711-2020; Wuhrer, Manfred/ABE-9168-2020; Stockmann, Henning/A-1891-2012	Wuhrer, Manfred/0000-0002-0814-4995; Rudd, Pauline/0000-0003-3880-0532; Fahey (Saldova), Radka/0000-0001-5085-5080; O'Flaherty, Roisin/0000-0003-1941-4775; Stockmann, Henning/0000-0002-2409-5476	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Science Foundation Ireland Starting Investigator Research Grant (SFI SIRG) [13/SIRG/2164]; EU [278535]; NIH [R21AI099435, R01AR065538, R01AR073201, R01AR075906, P30AR070253, P20GM104416, R01AI131975, P01AI120756]; Rheumatology Research Foundation; Cogan Family Foundation; Fundacion Bechara; Arbuckle Family Fund for Arthritis Research	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Science Foundation Ireland Starting Investigator Research Grant (SFI SIRG)(Science Foundation Ireland); EU(European Commission); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rheumatology Research Foundation; Cogan Family Foundation; Fundacion Bechara; Arbuckle Family Fund for Arthritis Research	L.D.N. was supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health. R.S. was supported by funding from the Science Foundation Ireland Starting Investigator Research Grant (SFI SIRG) under grant number 13/SIRG/2164. H.S. and R.O'F. were supported by the funding from EU FP7 Program HighGlycan, grant number 278535. M.E.A. was supported by NIH grants P20GM104416, R01AI131975, and P01AI120756 and an Innovative Research Award from the Rheumatology Research Foundation. P.A.N. was supported by NIH grants R21AI099435, R01AR065538, R01AR073201, R01AR075906, and P30AR070253; an Innovative Research Award from the Rheumatology Research Foundation; the Cogan Family Foundation; the Fundacion Bechara; and the Arbuckle Family Fund for Arthritis Research.	Ackerman ME, 2013, J CLIN INVEST, V123, P2183, DOI 10.1172/JCI65708; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Boesch AW, 2014, MABS-AUSTIN, V6, P915, DOI 10.4161/mabs.28808; Brown EP, 2012, J IMMUNOL METHODS, V386, P117, DOI 10.1016/j.jim.2012.09.007; de Haan N, 2016, J PROTEOME RES, V15, P1853, DOI 10.1021/acs.jproteome.6b00038; Dekkers G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00553; Driessen GJ, 2013, HAEMATOLOGICA, V98, P1617, DOI 10.3324/haematol.2013.085076; Ercan A, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.89703; Ercan A, 2012, ARTHRITIS RHEUM-US, V64, P3025, DOI 10.1002/art.34507; Falck D, 2017, METHODS MOL BIOL, V1503, P31, DOI 10.1007/978-1-4939-6493-2_4; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Jansen BC, 2016, J PROTEOME RES, V15, P2198, DOI 10.1021/acs.jproteome.6b00171; Kaneko Y, 2006, SCIENCE, V313, P670, DOI 10.1126/science.1129594; Kristic J, 2014, J GERONTOL A-BIOL, V69, P779, DOI 10.1093/gerona/glt190; PAREKH R, 1988, J EXP MED, V167, P1731, DOI 10.1084/jem.167.5.1731; Pucic M, 2012, GLYCOBIOLOGY, V22, P975, DOI 10.1093/glycob/cws062; Stockmann H, 2015, ANAL CHEM, V87, P8316, DOI 10.1021/acs.analchem.5b01463; Stockmann H, 2013, ANAL CHEM, V85, P8841, DOI 10.1021/ac402068r	18	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2020	145	2					710	+		10.1016/j.jaci.2019.10.012	http://dx.doi.org/10.1016/j.jaci.2019.10.012			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK6ZG	31669096	Green Accepted, Bronze			2022-12-18	WOS:000512887400034
J	Meisser, SS; Altunbulakli, C; Bandier, J; Opstrup, MS; Castro-Giner, F; Akdis, M; Bonefeld, CM; Johansen, JD; Akdis, CA				Meisser, Sanne S.; Altunbulakli, Can; Bandier, Josefine; Opstrup, Morten S.; Castro-Giner, Francesc; Akdis, Mueeccel; Bonefeld, Charlotte M.; Johansen, Jeanne D.; Akdis, Cezmi A.			Skin barrier damage after exposure to paraphenylenediamine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic contact dermatitis; p-Phenylenediamine; hair dye contact hypersensitivity; tight junctions; stratum corneum; RNA sequencing	P-PHENYLENEDIAMINE; ATOPIC-DERMATITIS; CONTACT-DERMATITIS; N-ACETYLATION; HAIR-DYES; SENSITIZATION; HAIRDRESSERS; ALLERGY; EXPRESSION; MUTATIONS	Background: p-Phenylenediamine (PPD) is a strong contact allergen used in hair dye that is known to cause allergic contact dermatitis (ACD). Both private and occupational exposure to PPD is frequent, but the effect of PPD exposure in nonallergic occupationally exposed subjects is unknown. Objective: We sought to investigate the effects of PPD exposure on the skin of occupationally exposed subjects with and without clinical symptoms. Methods: Skin biopsy specimens were collected from 4 patients with mild and 5 patients with severe PPD-related ACD and 7 hairdressers without contact dermatitis on day 4 after patch testing with 1% PPD in petrolatum. RNA sequencing and transcriptomics analyses were performed and confirmed by using quantitative RT-PCR. Protein expression was analyzed in skin from 4 hairdressers and 1 patient with ACD by using immunofluorescence staining. Reconstructed human epidermis was used to test the effects of PPD in vitro. Results: RNA sequencing demonstrated downregulation of tight junction and stratum corneum proteins in the skin of patients with severe ACD after PPD exposure. Claudin-1 (CLDN-1), CLDN8, CLDN11, CXADR-like membrane protein (CLMP), occludin (OCLN), membrane-associated guanylate kinase inverted 1 (MAGI1), and MAGI2 mRNA expression was downregulated in patients with severe ACD. CLDN1 and CLMP expression were downregulated in nonresponding hairdressers and patients with mild ACD. Filaggrin 1 (FLG1), FLG2, and loricrin (LOR) expression were downregulated in patients with ACD. Confocal microscopic images showed downregulation of CLDN-1, FLG-1, and FLG-2 expression. In contrast, 3-dimensional skin cultures showed upregulation of FLG-1 in response to PPD but downregulation of FLG-2. Conclusion: PPD-exposed skin is associated with extensive transcriptomic changes, including downregulation of tight junction and stratum corneum proteins, even in the absence of clinical symptoms.	[Meisser, Sanne S.; Bandier, Josefine; Opstrup, Morten S.; Johansen, Jeanne D.] Univ Hosp Gentofte, Res Ctr Hairdressers & Beauticians, Hellerup, Denmark; [Meisser, Sanne S.; Bandier, Josefine; Opstrup, Morten S.; Johansen, Jeanne D.] Univ Hosp Gentofte, Natl Allergy Res Ctr, Dept Dermatol & Allergy, Hellerup, Denmark; [Meisser, Sanne S.; Bonefeld, Charlotte M.] Univ Copenhagen, LEO Fdn, Skin Immunol Res Ctr, Dept Immunol & Microbiol,Fac Hlth & Med Sci, Copenhagen, Denmark; [Meisser, Sanne S.; Altunbulakli, Can; Castro-Giner, Francesc; Akdis, Mueeccel; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Meisser, Sanne S.; Altunbulakli, Can; Castro-Giner, Francesc; Akdis, Mueeccel; Akdis, Cezmi A.] CK CARE, Davos, Switzerland	University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Swiss Institute of Allergy & Asthma Research; University of Zurich	Akdis, CA (corresponding author), Swiss Inst Allergy & Asthma Res SIAF, Obere Str 22,Davos Pl, CH-7270 Davos, Switzerland.	akdisac@siaf.uzh.ch	Johansen, Jeanne/AAM-6382-2021; Akdis, Cezmi/AAV-4844-2020	Johansen, Jeanne/0000-0002-3537-8463; Akdis, Cezmi/0000-0001-8020-019X; Altunbulakli, Can/0000-0003-2264-7377; Meisser, Sanne Steengaard/0000-0002-3063-6355	Danish Hairdressers and Beauticians' Union; Danish Hairdresser Association; Danish Working Environment Research Fund; Dr Aage Bangs Foundation; Swiss Institute for Asthma and Allergy Research	Danish Hairdressers and Beauticians' Union; Danish Hairdresser Association; Danish Working Environment Research Fund; Dr Aage Bangs Foundation; Swiss Institute for Asthma and Allergy Research	This study was funded by the Danish Hairdressers and Beauticians' Union, Danish Hairdresser Association, Danish Working Environment Research Fund, Dr Aage Bangs Foundation, and Swiss Institute for Asthma and Allergy Research.	Andersen YMF, 2017, J EUR ACAD DERMATOL, V31, P1038, DOI 10.1111/jdv.14172; Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; Diepgen TL, 2016, J INVEST DERMATOL, V136, P409, DOI 10.1016/j.jid.2015.10.064; Galbiati V, 2014, J INVEST DERMATOL, V134, P2719, DOI 10.1038/jid.2014.203; Gibson A, 2015, CHEM RES TOXICOL, V28, P2069, DOI 10.1021/acs.chemrestox.5b00294; Gruber R, 2015, AM J PATHOL, V185, P2777, DOI 10.1016/j.ajpath.2015.06.021; Heede NG, 2017, CONTACT DERMATITIS, V76, P167, DOI 10.1111/cod.12731; Howell MD, 2009, J ALLERGY CLIN IMMUN, V124, pR7, DOI 10.1016/j.jaci.2009.07.012; Jenkinson C, 2010, J INVEST DERMATOL, V130, P732, DOI 10.1038/jid.2009.271; Johansen JD, 2015, CONTACT DERMATITIS, V73, P195, DOI 10.1111/cod.12432; Kasemsarn P, 2016, CURR PROBL DERMATOL, V49, P135, DOI 10.1159/000441589; Kawakubo Y, 2000, J PHARMACOL EXP THER, V292, P150; KLIGMAN AM, 1966, J INVEST DERMATOL, V47, P375, DOI 10.1038/jid.1966.159; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Lind ML, 2017, CONTACT DERMATITIS, V77, P303, DOI 10.1111/cod.12833; Lind ML, 2005, ANN OCCUP HYG, V49, P473, DOI 10.1093/annhyg/mei030; Malajian D, 2013, J AM ACAD DERMATOL, V69, P232, DOI 10.1016/j.jaad.2013.03.012; Martin SF, 2008, CURR OPIN ALLERGY CL, V8, P289, DOI 10.1097/ACI.0b013e3283088cf9; McFadden JP, 2011, CLIN DERMATOL, V29, P316, DOI 10.1016/j.clindermatol.2010.11.011; Oreskov KW, 2015, CONTACT DERMATITIS, V72, P362, DOI 10.1111/cod.12336; Panfili E, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14040421; Pellerin L, 2013, J ALLERGY CLIN IMMUN, V131, P1094, DOI 10.1016/j.jaci.2012.12.1566; Pot LM, 2016, CONTACT DERMATITIS, V74, P152, DOI 10.1111/cod.12523; Rastogi SC, 2006, CONTACT DERMATITIS, V55, P95, DOI 10.1111/j.0105-1873.2006.00887.x; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Ross-Hansen K, 2013, BRIT J DERMATOL, V168, P762, DOI 10.1111/bjd.12126; Schuttelaar ML, 2018, CONTACT DERMATITIS, V79, P288, DOI 10.1111/cod.13078; Stterstrom B, 2014, CONTACT DERMATITIS, V71, P154, DOI 10.1111/cod.12231; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V135, P1218, DOI 10.1016/j.jaci.2015.03.003; Thyssen JP, 2013, CONTACT DERMATITIS, V68, P273, DOI 10.1111/cod.12021; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Uter W, 2014, CONTACT DERMATITIS, V71, P13, DOI 10.1111/cod.12196; Vogel TA, 2015, CONTACT DERMATITIS, V72, P355, DOI 10.1111/cod.12354; Young MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-2-r14; Zeller A, 2014, MUTAGENESIS, V29, P37, DOI 10.1093/mutage/get053	38	11	12	3	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2020	145	2					619	+		10.1016/j.jaci.2019.11.023	http://dx.doi.org/10.1016/j.jaci.2019.11.023			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK6ZG	31783056	Bronze, Green Accepted			2022-12-18	WOS:000512887400024
J	Aceves, S; Collins, MH; Rothenberg, ME; Furuta, GT; Gonsalves, N; Abonia, JP; Almonte, S; Andrews, R; Arrington, A; Arva, N; Atkins, F; Bailey, D; Berry, A; Besl, B; Bolton, S; Bonis, P; Book, W; Bray, K; Brown, T; Burger, C; Burke, D; Cahoon, J; Capocelli, K; Chehade, M; Collins, M; Davis, C; Dellon, E; DeMarshall, M; DiTommaso, L; Dohil, R; Eby, M; Falk, G; Fleischer, D; Foote, H; Foss, K; Friedlander, J; Fulkerson, P; Furuta, G; Geno, D; Greuter, T; Gupta, S; Hamilton, F; Harris, K; Harris, J; Hirano, I; Hiremath, G; Holland-Thomas, N; Jacinto, L; Kagalwalla, A; Kaseta, T; Katzka, D; Keeley, K; Khosh-Hemmat, E; Khoury, P; King, E; Kliewer, K; Klion, A; Knowles, J; Kocher, K; Kodroff, E; Krischer, J; Kyle, S; Leung, J; Levy, M; Liacouras, C; Mack, D; Martin, L; Martin, E; McCright-Gill, T; Menard-Katcher, P; Menard-Katcher, C; Mendoza, G; Mingler, M; Minnicozzi, M; Muir, A; Mukkada, V; MurrayPetzold, C; Newbury, R; Nhu, Q; Oyibo, O; Paliana, A; Pan, ZX; Pesek, R; Peterson, K; Poppendeck, H; Putnam, P; Rivera, F; Rothenberg, M; Rudman-Spergel, A; Sable, K; Schoepfer, A; Scott, M; Sheridan, R; Sinanovic, S; Spergel, J; Strobel, M; Sun, K; Tasco, A; Tholen, C; Thompson, K; Tomkinson, T; Tran, D; Tylicki, A; Urv, T; Wang, ML; Wechsler, J; Wershil, B; Wheatley, L; Wilkey, L; Yang, GY; Zalewski, A; Zicarelli, A				Aceves, Seema; Collins, Margaret H.; Rothenberg, Marc E.; Furuta, Glenn T.; Gonsalves, Nirmala; Abonia, J. Pablo; Almonte, Samuel; Andrews, Rachel; Arrington, Ashley; Arva, Nicoleta; Atkins, Fred; Bailey, Dominique; Berry, Alexis; Besl, Bridget; Bolton, Scott; Bonis, Peter; Book, Wendy; Bray, Kimberly; Brown, Teresa; Burger, Cassandra; Burke, Deirdre; Cahoon, Jonathon; Capocelli, Kelley; Chehade, Mirna; Collins, Margaret; Davis, Carla; Dellon, Evan; DeMarshall, Maureen; DiTommaso, Lauren; Dohil, Ranjan; Eby, Michael; Falk, Gary; Fleischer, David; Foote, Heather; Foss, Kelci; Friedlander, Joel; Fulkerson, Patricia; Furuta, Glenn; Geno, Debra; Greuter, Thomas; Gupta, Sandeep; Hamilton, Frank; Harris, Kirk; Harris, Jennifer; Hirano, Ikuo; Hiremath, Girish; Holland-Thomas, Nicole; Jacinto, Lea; Kagalwalla, Amir; Kaseta, Timothy; Katzka, David; Keeley, Kaitlin; Khosh-Hemmat, Emad; Khoury, Paneez; King, Eileen; Kliewer, Kara; Klion, Amy; Knowles, Jennifer; Kocher, Kendra; Kodroff, Ellyn; Krischer, Jeffrey; Kyle, Shay; Leung, John; Levy, Meredith; Liacouras, Chris; Mack, Denise; Martin, Lisa; Martin, Ellen; McCright-Gill, Talaya; Menard-Katcher, Paul; Menard-Katcher, Calies; Mendoza, Gabriela; Mingler, Melissa; Minnicozzi, Mike; Muir, Amanda; Mukkada, Vincent; MurrayPetzold, Cristin; Newbury, Robert; Quan Nhu; Oyibo, Oghenekpaobor (Joel); Paliana, Allisa; Pan, Zhaoxing; Pesek, Robbie; Peterson, Kathryn; Poppendeck, Heidi; Putnam, Philip; Rivera, Fabian; Rothenberg, Marc; Rudman-Spergel, Amanda; Sable, Kathleen; Schoepfer, Alain; Scott, Melissa; Sheridan, Rachel; Sinanovic, Selma; Spergel, Jonathan; Strobel, MaryJo; Sun, Kiki; Tasco, Amy; Tholen, Crystal; Thompson, Katherine; Tomkinson, Tiffany; Tran, Daisy; Tylicki, Alexandra; Urv, Tiina; Wang, Mei-Lun; Wechsler, Joshua; Wershil, Barry; Wheatley, Lisa; Wilkey, Leah; Yang, Guang-Yu; Zalewski, Angelika; Zicarelli, Amy		Consortium Eosinophilic Gastrointe	Advancing patient care through the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Eosinophils; gastrointestinal; consortium; allergy; esophagitis; advocacy	QUALITY-OF-LIFE; ELIMINATION DIET; ESOPHAGITIS; ADULTS; FOOD; DIAGNOSIS; CHILDREN; INFLAMMATION; ACCURACY; SYMPTOMS	Recent advances in rare disease research are accelerated by the work of consortia that have been supported by the National Institutes of Health. Development of such consortia rely on multidisciplinary relationships and engagement with patient advocacy groups, as well as the National Institutes of Health and industry and academic partners. In this rostrum we present the development of such a process that focuses on eosinophilic gastrointestinal diseases. Principal investigators, patient advocacy groups, research assistants, and trainees work together to perform natural history studies that promote clinical trial readiness tools, conduct clinical trials, train a new generation of investigators, and perform innovative pilot studies.	[Aceves, Seema] Univ Calif San Diego, Div Allergy Immunol, San Diego, CA 92103 USA; [Aceves, Seema] Rady Childrens Hosp, San Diego, CA USA; [Collins, Margaret H.] Univ Cincinnati, Coll Med, Dept Pediat, Div Pathol,Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA; [Rothenberg, Marc E.] Univ Cincinnati, Coll Med, Dept Pediat, Div Allergy & Immunol,Cincinnati Childrens Hosp, Cincinnati, OH USA; [Furuta, Glenn T.] Univ Colorado, Childrens Hosp Colorado,Gastrointestinal Eosinoph, Sch Med, Digest Hlth Inst, 13121 E 16th Ave, Aurora, CO 80016 USA; [Gonsalves, Nirmala] Northwestern Univ, Feinberg Sch Med, Div Gastroenterol, Chicago, IL 60611 USA	University of California System; University of California San Diego; Rady Childrens Hospital San Diego; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Northwestern University; Feinberg School of Medicine	Furuta, GT (corresponding author), Univ Colorado, Sch Med, Digest Hlth Inst, Childrens Hosp Colorado,Gastrointestinal Eosinoph, 13121 E 16th Ave, Aurora, CO 80016 USA.	Glenn.Furuta@childrenscolorado.org	Urv, Tiina/AAW-9336-2021; Khoury, Paneez/ABH-1951-2020; Martin, Lisa/E-2425-2016	Khoury, Paneez/0000-0003-1800-0079; Martin, Lisa/0000-0001-8702-9946; Urv, Tiina/0000-0002-2040-4972	Consortium for Eosinophilic Gastrointestinal Diseases Researchers (CEGIR) [U54 AI117804]; National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NCATS; American Partnership for Eosinophilic Disorders (APFED); Campaign Urging Research for Eosinophilic Diseases (CURED); Eosinophilic Family Coalition (EFC); LaCache Chair in Gastrointestinal Allergic and Immunologic Diseases Chair of Pediatrics	Consortium for Eosinophilic Gastrointestinal Diseases Researchers (CEGIR); National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCATS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); American Partnership for Eosinophilic Disorders (APFED); Campaign Urging Research for Eosinophilic Diseases (CURED); Eosinophilic Family Coalition (EFC); LaCache Chair in Gastrointestinal Allergic and Immunologic Diseases Chair of Pediatrics	Supported by the Consortium for Eosinophilic Gastrointestinal Diseases Researchers (CEGIR; U54 AI117804). CEGIR is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), and is funded through collaboration between the National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and NCATS. CEGIR is also supported by patient advocacy groups, including the American Partnership for Eosinophilic Disorders (APFED), Campaign Urging Research for Eosinophilic Diseases (CURED), and Eosinophilic Family Coalition (EFC). G.T.F. is also supported by the LaCache Chair in Gastrointestinal Allergic and Immunologic Diseases Chair of Pediatrics.	Aceves SS, 2018, J ALLERGY CLIN IMMUN, V142, P130, DOI 10.1016/j.jaci.2018.05.014; Aceves Seema S, 2016, Gastroenterol Hepatol (N Y), V12, P516; Aceves SS, 2014, CLIN GASTROENTEROL H, V12, P1216, DOI 10.1016/j.cgh.2013.09.007; Aceves SS, 2014, CURR OPIN GASTROEN, V30, P391, DOI 10.1097/MOG.0000000000000088; Aceves SS, 2005, J ALLERGY CLIN IMMUN, V116, P705, DOI 10.1016/j.jaci.2005.05.011; Ackerman SJ, 2019, AM J GASTROENTEROL, V114, P1614, DOI 10.14309/ajg.0000000000000371; ATTWOOD SEA, 1993, DIGEST DIS SCI, V38, P109, DOI 10.1007/BF01296781; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Bedell A, 2016, AM J GASTROENTEROL, V111, P493, DOI 10.1038/ajg.2016.20; Beppu LY, 2014, J ALLERGY CLIN IMMUN, V134, P1100, DOI 10.1016/j.jaci.2014.04.004; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Bochner BS, 2012, J ALLERGY CLIN IMMUN, V130, P587, DOI 10.1016/j.jaci.2012.07.024; Castro M, 2018, NEW ENGL J MED, V378, P2486, DOI 10.1056/NEJMoa1804092; Cheng Katherine, 2017, Transl Sci Rare Dis, V2, P141, DOI 10.3233/TRD-170016; CHOKSI YA, 2019, CLIN GASTROENTEROL H; Collins MH, 2017, DIS ESOPHAGUS, V30, DOI 10.1111/dote.12470; Collins MH, 2019, AM J SURG PATHOL, V43, P1501, DOI 10.1097/PAS.0000000000001361; Collins MH, 2018, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00261; DeBrosse CW, 2006, PEDIATR DEVEL PATHOL, V9, P210, DOI 10.2350/11-05-0130.1; Dellon ES, 2018, GASTROENTEROLOGY, V155, P1022, DOI 10.1053/j.gastro.2018.07.009; Dellon ES, 2010, GASTROINTEST ENDOSC, V71, P706, DOI 10.1016/j.gie.2009.10.047; Eluri S, 2017, J PEDIATR GASTR NUTR, V65, P53, DOI 10.1097/MPG.0000000000001415; Franciosi JP, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-126; Furuta GT, 2007, GASTROENTEROLOGY, V133, P1342, DOI 10.1053/j.gastro.2007.08.017; Gonsalves N, 2014, GASTROENTEROL CLIN N, V43, P375, DOI 10.1016/j.gtc.2014.02.011; Gonsalves N, 2012, GASTROENTEROLOGY, V142, P1451, DOI 10.1053/j.gastro.2012.03.001; Greuter T, 2019, J ALLERGY CLIN IMMUN; Gupta SK, 2019, GASTROENTEROLOGY, V156, P838, DOI 10.1053/j.gastro.2018.10.057; Gupta SK, 1997, GASTROINTEST ENDOSC, V45, P485, DOI 10.1016/S0016-5107(97)70178-0; Hirano I., 2019, GASTROENTEROLOGY; Hirano I, 2013, GUT, V62, P489, DOI 10.1136/gutjnl-2011-301817; Hiremath G, 2018, CLIN RES HEPATOL GAS, V42, P483, DOI 10.1016/j.clinre.2018.03.003; Jensen ET, 2016, J PEDIATR GASTR NUTR, V62, P36, DOI 10.1097/MPG.0000000000000865; Jung KW, 2011, GASTROINTEST ENDOSC, V73, P15, DOI 10.1016/j.gie.2010.09.036; Kagalwalla AF, 2006, CLIN GASTROENTEROL H, V4, P1097, DOI 10.1016/j.cgh.2006.05.026; Kagalwalla AF, 2012, J PEDIATR GASTR NUTR, V55, P711, DOI 10.1097/MPG.0b013e318268da40; Kagalwalla AF, 2011, J PEDIATR GASTR NUTR, V53, P145, DOI 10.1097/MPG.0b013e31821cf503; Kaijser R., 1937, ARCH KLIN CHIR, V138, P36; Katzka David A, 2019, Gastroenterol Hepatol (N Y), V15, P320; Katzka DA, 2015, CLIN GASTROENTEROL H, V13, P77, DOI 10.1016/j.cgh.2014.06.026; Lowichik A, 1996, MODERN PATHOL, V9, P110; Lucendo AJ, 2018, CURR OPIN GASTROEN, V34, P226, DOI 10.1097/MOG.0000000000000442; Mark JA, 2019, J PEDIATR GASTR NUTR, V68, P630, DOI 10.1097/MPG.0000000000002237; Masterson JC, 2019, J CLIN INVEST, V129, P3224, DOI 10.1172/JCI126744; McGowan EC, 2019, ANN ALLERG ASTHMA IM, V122, P563, DOI 10.1016/j.anai.2019.03.024; Menard-Katcher C, 2017, AM J GASTROENTEROL, V112, P1466, DOI 10.1038/ajg.2017.131; Nguyen N, 2019, CLIN GASTROENTEROL H, V17, P2455, DOI 10.1016/j.cgh.2019.01.023; Richter Joel E, 2018, Gastrointest Endosc Clin N Am, V28, P97, DOI 10.1016/j.giec.2017.07.009; Rothenberg ME, 2012, J ALLERGY CLIN IMMUN, V130, P617, DOI 10.1016/j.jaci.2012.06.051; Rothenberg ME, 2010, NAT GENET, V42, P289, DOI 10.1038/ng.547; Ruffner MA, 2019, ALLERGY, V74, P2449, DOI 10.1111/all.13968; Safroneeva E, 2015, ALIMENT PHARM THER, V42, P1000, DOI 10.1111/apt.13370; Safroneeva E, 2016, GASTROENTEROLOGY, V150, P581, DOI 10.1053/j.gastro.2015.11.004; Schoepfer AM, 2013, GASTROENTEROLOGY, V145, P1230, DOI 10.1053/j.gastro.2013.08.015; Shoda T, 2020, J ALLERGY CLIN IMMUN, V145, P255, DOI 10.1016/j.jaci.2019.11.007; Shoda T, 2018, LANCET GASTROENTEROL, V3, P477, DOI 10.1016/S2468-1253(18)30096-7; Simon D, 2018, ALLERGY, V73, P239, DOI 10.1111/all.13244; Sleiman PMA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6593; Spergel JM, 2018, J ALLERGY CLIN IMMUN, V142, P48, DOI 10.1016/j.jaci.2018.05.005; Spergel JM, 2015, BEST PRACT RES CL GA, V29, P771, DOI 10.1016/j.bpg.2015.06.011; Spergel JM, 2012, J ALLERGY CLIN IMMUN, V129, P456, DOI 10.1016/j.jaci.2011.11.044; Spergel JM, 2011, J PEDIATR GASTR NUTR, V52, P300, DOI 10.1097/MPG.0b013e3181eb5a9f; STRAUMANN A, 1994, SCHWEIZ MED WSCHR, V124, P1419; Syverson EP, 2019, J ALLERGY CLIN IMMUN; Tabatabaei N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20668-8; Taft TH, 2011, ALIMENT PHARM THER, V34, P790, DOI 10.1111/j.1365-2036.2011.04791.x; Wang R, 2018, DIGEST DIS SCI, V63, P1756, DOI 10.1007/s10620-018-5045-0; Warners MJ, 2017, ALIMENT PHARM THER, V45, P777, DOI 10.1111/apt.13953; Warners MJ, 2018, AM J GASTROENTEROL, V113, P836, DOI 10.1038/s41395-018-0052-5; Wechsler JB, 2018, CLIN GASTROENTEROL H, V16, P1056, DOI 10.1016/j.cgh.2017.12.019; Weller PF, 2017, NAT REV IMMUNOL, V17, P746, DOI 10.1038/nri.2017.95; Wen T, 2013, GASTROENTEROLOGY, V145, P1289, DOI 10.1053/j.gastro.2013.08.046; Whelan KA, 2019, CLIN GASTROENTEROL H; Whelan KA, 2017, GUT, V66, P1197, DOI 10.1136/gutjnl-2015-310341; Youngblood BA, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126219	75	11	11	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2020	145	1					28	37		10.1016/j.jaci.2019.11.012	http://dx.doi.org/10.1016/j.jaci.2019.11.012			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KA1WZ	31758958	Green Accepted, Bronze			2022-12-18	WOS:000505590800004
J	Brown, LAK; Ruis, C; Clark, I; Roy, S; Brown, JR; Albuquerque, AS; Patel, SY; Miller, J; Karim, MY; Dervisevic, S; Moore, J; Williams, CA; Cudini, J; Moreira, F; Neild, P; Seneviratne, SL; Workman, S; Toumpanakis, C; Atkinson, C; Burns, SO; Breuer, J; Lowe, DM				Brown, Li-An K.; Ruis, Christopher; Clark, Ian; Roy, Sunando; Brown, Julianne R.; Albuquerque, Adriana S.; Patel, Smita Y.; Miller, Joanne; Karim, Mohammed Yousuf; Dervisevic, Samir; Moore, Jennifer; Williams, Charlotte A.; Cudini, Juliana; Moreira, Fernando; Neild, Penny; Seneviratne, Suranjith L.; Workman, Sarita; Toumpanakis, Christos; Atkinson, Claire; Burns, Siobhan O.; Breuer, Judith; Lowe, David M.			A comprehensive characterization of chronic norovirus infection in immunodeficient hosts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Brown, Li-An K.] Royal Free London NHS Fdn Trust, Dept Infect Dis, London, England; [Clark, Ian] Royal Free London NHS Fdn Trust, Dept Histopathol, London, England; [Moreira, Fernando; Seneviratne, Suranjith L.; Workman, Sarita; Burns, Siobhan O.; Lowe, David M.] Royal Free London NHS Fdn Trust, Dept Clin Immunol, London, England; [Toumpanakis, Christos] Royal Free London NHS Fdn Trust, Dept Gastroenterol, London, England; [Brown, Li-An K.] Whittington Hlth NHS Trust, Dept Microbiol, London, England; [Ruis, Christopher; Roy, Sunando; Williams, Charlotte A.; Cudini, Juliana; Breuer, Judith] UCL, Div Infect & Immun, London, England; [Ruis, Christopher] Univ Cambridge, MRC, Mol Biol Lab, Mol Immun Unit,Dept Med, Cambridge, England; [Brown, Julianne R.] Great Ormond St Hosp Children NHS Fdn Trust, Dept Microbiol Virol & Infect Prevent & Control, London, England; [Albuquerque, Adriana S.; Atkinson, Claire; Burns, Siobhan O.; Lowe, David M.] UCL, Inst Immun & Transplantat, Royal Free Campus, London, England; [Patel, Smita Y.] Oxford Univ Hosp NHS Trust, Oxford, England; [Patel, Smita Y.] NIHR Oxford Biomed Res Ctr, Oxford, England; [Miller, Joanne; Karim, Mohammed Yousuf] Royal Surrey Cty NHS Fdn Trust, Egerton Rd, Guildford, Surrey, England; [Karim, Mohammed Yousuf] Sidra Med, Pathol, Doha, Qatar; [Dervisevic, Samir; Moore, Jennifer] Norfolk & Norwich Univ Hosp, Norwich, Norfolk, England; [Neild, Penny] St Georges Univ Hosp NHS Fdn Trust, London, England	University of London; University College London; Royal Free London NHS Foundation Trust; University of London; University College London; Royal Free London NHS Foundation Trust; University of London; University College London; Royal Free London NHS Foundation Trust; University of London; University College London; Royal Free London NHS Foundation Trust; University of London; University College London; MRC Laboratory Molecular Biology; University of Cambridge; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Oxford University Hospitals NHS Foundation Trust; University of Oxford; Sidra Medical & Research Center; Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital	Lowe, DM (corresponding author), Royal Free London NHS Fdn Trust, Dept Clin Immunol, London, England.; Lowe, DM (corresponding author), UCL, Inst Immun & Transplantat, Royal Free Campus, London, England.	d.lowe@ucl.ac.uk	Karim, Mohammed Yousuf/AAI-6771-2020	Karim, Mohammed Yousuf/0000-0003-0912-1629; Brown, Li-An/0000-0002-8261-0288; Albuquerque, Adriana/0000-0003-3391-0396; Breuer, Judith/0000-0001-8246-0534	National Institute for Health Research (NIHR) [NIHR-HCS-D12-03-15]; Wellcome Trust collaborative award [203268/Z/16/Z]; NIHR UCL/UCLH Biomedical Research Centre	National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); Wellcome Trust collaborative award(Wellcome Trust); NIHR UCL/UCLH Biomedical Research Centre	At the time of the study, J.R.B. was funded by a National Institute for Health Research (NIHR) doctoral fellowship (grant no NIHR-HCS-D12-03-15). C.R. and S.R. were funded by a Wellcome Trust collaborative award (grant no. 203268/Z/16/Z; to J.R.B.). J.R.B. and D.M.L. receive funding from the NIHR UCL/UCLH Biomedical Research Centre.	Baldridge MT, 2015, SCIENCE, V347, P266, DOI 10.1126/science.1258025; Brown JR, 2017, J CLIN VIROL, V96, P44, DOI 10.1016/j.jcv.2017.09.009; Brown JR, 2016, J CLIN MICROBIOL, V54, P2530, DOI 10.1128/JCM.01052-16; Brown LAK, 2017, REV MED VIROL, V27, DOI 10.1002/rmv.1926; Bull RA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000831; Depledge DP, 2018, J INFECT DIS, V218, P1592, DOI 10.1093/infdis/jiy358; NEI M, 1979, P NATL ACAD SCI USA, V76, P5269, DOI 10.1073/pnas.76.10.5269; Rolfes MC, 2019, DIAGN MICR INFEC DIS, V93, P69, DOI 10.1016/j.diagmicrobio.2018.08.002; Ruis C, 2018, NEW ENGL J MED, V379, P2173, DOI 10.1056/NEJMc1806941	9	11	11	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2019	144	5					1450	+		10.1016/j.jaci.2019.07.036	http://dx.doi.org/10.1016/j.jaci.2019.07.036			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JK7EU	31415785	Green Published, hybrid			2022-12-18	WOS:000495004700044
J	Hanakawa, S; Kitoh, A; Shibuya, R; Dainichi, T; Nomura, T; Honda, T; Egawa, G; Otsuka, A; Nakajima, S; Fujita, M; Kabashima, K				Hanakawa, Sho; Kitoh, Akihiko; Shibuya, Rintaro; Dainichi, Teruki; Nomura, Takashi; Honda, Tetsuya; Egawa, Gyohei; Otsuka, Atsushi; Nakajima, Saeko; Fujita, Mitsugu; Kabashima, Kenji			Percutaneous sensitization is limited by in situ inhibition of cutaneous dendritic cell migration through skin-resident regulatory T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Regulatory T cells; IL-10; dendritic cells; skin; percutaneous sensitization	LANGERHANS CELLS; B-CELLS; MEMORY; INDUCTION; HAPTEN; ALPHA; CCR7; DIFFERENTIATION; MECHANISMS; MUTATIONS	Background: Percutaneous sensitization is associated with various allergic diseases, including asthma and food allergies. However, the immunologic mechanisms underlying how the skin regulates percutaneous sensitization are still unclear. Objective: We aimed to investigate whether and how CD4(+)Foxp3(+) regulatory T (Treg) cells residing in the skin regulate percutaneous sensitization in the skin. Methods: Selective reduction of numbers of cutaneous Treg cells was achieved by means of intradermal injection of diphtheria toxin into the ear skin of Foxp3(DTR) mice, in which Treg cells specifically express the diphtheria toxin receptor fused with green fluorescent protein. Results: Thirty percent to 40% of cutaneous Treg cells were capable of IL-10 production in both mice and human subjects. Selective reduction of cutaneous Treg cells at the sensitization site promoted migration of antigen-bearing dendritic cells (DCs) to the draining lymph nodes (dLNs). Accordingly, sensitization through the skin with reduced numbers of Treg cells led to enhanced antigen-specific immune responses in the dLNs, including both effector T-cell differentiation and T cell- dependent B-cell responses, such as the development of germinal center B cells expressing IgG(1) and IgE. Furthermore, antigen-bearing cutaneous DC migration was enhanced in mice with IL-10 deficiency restricted to the cutaneous Treg cell compartment, suggesting an important role of cutaneous IL-10(+) Treg cells in limiting percutaneous sensitization. Treg cells with a skin-homing phenotype in skin dLNs expressed high levels of IL-10, suggesting that they contribute to renewal and maintenance of the cutaneous IL-10(+) Treg cell population. Conclusion: Skin-resident Treg cells limit percutaneous sensitization by suppressing antigen-bearing DC migration through in situ IL-10 production.	[Hanakawa, Sho; Kitoh, Akihiko; Shibuya, Rintaro; Dainichi, Teruki; Nomura, Takashi; Honda, Tetsuya; Egawa, Gyohei; Otsuka, Atsushi; Nakajima, Saeko; Kabashima, Kenji] Kyoto Univ, Grad Sch Med, Dept Dermatol, 54 Shogoin Kawahara, Kyoto 6068507, Japan; [Fujita, Mitsugu] Kindai Univ, Fac Med, Dept Microbiol, Osaka, Japan; [Kabashima, Kenji] ASTAR, Singapore Immunol Network SIgN, Singapore, Singapore; [Kabashima, Kenji] ASTAR, Skin Res Inst Singapore SRIS, Singapore, Singapore	Kyoto University; Kindai University (Kinki University); Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Immunology Network (SIgN); Agency for Science Technology & Research (A*STAR)	Kitoh, A; Kabashima, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Dermatol, 54 Shogoin Kawahara, Kyoto 6068507, Japan.	kichu@kuhp.kyoto-u.ac.jp; kaba@kuhp.kyoto-u.ac.jp	Dainichi, Teruki/AAL-5400-2020; Nakajima, Saeko/AAB-1577-2021; Hanakawa, Sho/GSO-1564-2022; Fujita, Mitsugu/A-6690-2009	Dainichi, Teruki/0000-0002-9497-0029; Hanakawa, Sho/0000-0002-0665-9602; Fujita, Mitsugu/0000-0002-0000-9879; Egawa, Gyohei/0000-0002-6101-4719; Otsuka, Atsushi/0000-0001-7365-947X; Nakajima, Saeko/0000-0003-0831-1447	JSPS KAKENHI [15H05790, 15H1155, 15K15417]; AbbVie GK; Lydia O'leary Memorial Pias Dermatological Foundation; AMED [16ek0410011h0003, 16he0902003h0002, JP17ek0410040];  [16J00559]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); AbbVie GK(AbbVie); Lydia O'leary Memorial Pias Dermatological Foundation; AMED; 	Supported by JSPS KAKENHI (grant nos. 15H05790, 15H1155, and 15K15417 to K.K.), Grant-in-Aid for JSPS Research Fellow (grant no. 16J00559 to S.H.), AbbVie GK (to A.K.), the Lydia O'leary Memorial Pias Dermatological Foundation (to A.K.), and AMED (grant nos. 16ek0410011h0003 and 16he0902003h0002 to K.K. and JP17ek0410040 to S.N.).	Ali N, 2017, CELL, V169, P1119, DOI 10.1016/j.cell.2017.05.002; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Baekkevold ES, 2005, J EXP MED, V201, P1045, DOI 10.1084/jem.20041059; Beck Lisa A., 2000, Journal of Allergy and Clinical Immunology, V106, pS258; Chvatchko Y, 2000, J EXP MED, V191, P1755, DOI 10.1084/jem.191.10.1755; Clark RA, 2006, J IMMUNOL, V176, P4431, DOI 10.4049/jimmunol.176.7.4431; Cumberbatch M, 1997, IMMUNOLOGY, V92, P388, DOI 10.1046/j.1365-2567.1997.00360.x; Czarnowicki T, 2017, J ALLERGY CLIN IMMUN, V139, P1723, DOI 10.1016/j.jaci.2017.04.004; Delacher M, 2017, NAT IMMUNOL, V18, P1160, DOI 10.1038/ni.3799; Dudda JC, 2008, J EXP MED, V205, P1559, DOI 10.1084/jem.20072594; Duyverman AMMJ, 2012, NAT PROTOC, V7, P763, DOI 10.1038/nprot.2012.032; ENK AH, 1994, J EXP MED, V179, P1397, DOI 10.1084/jem.179.4.1397; He DG, 2009, J IMMUNOL, V183, P1463, DOI 10.4049/jimmunol.0804108; Huehn J, 2004, J EXP MED, V199, P303, DOI 10.1084/jem.20031562; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; Kaplan DH, 2012, NAT REV IMMUNOL, V12, P114, DOI 10.1038/nri3150; Kim JM, 2007, NAT IMMUNOL, V8, P191, DOI 10.1038/ni1428; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Lal G, 2016, IMMUNOL LETT, V170, P52, DOI 10.1016/j.imlet.2016.01.002; Malhotra N, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aao6923; McHeyzer-Williams Louise J, 2004, Methods Mol Biol, V271, P173; Miyao T, 2012, IMMUNITY, V36, P262, DOI 10.1016/j.immuni.2011.12.012; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; Mori T, 2008, J INVEST DERMATOL, V128, P1719, DOI 10.1038/jid.2008.5; Nishibu A, 2007, J DERMATOL SCI, V45, P23, DOI 10.1016/j.jdermsci.2006.10.003; Nolan KF, 2004, J IMMUNOL, V172, P2201, DOI 10.4049/jimmunol.172.4.2201; Ohl L, 2004, IMMUNITY, V21, P279, DOI 10.1016/j.immuni.2004.06.014; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Rodriguez RS, 2014, J CLIN INVEST, V124, P1027, DOI 10.1172/JCI72932; Rosenblum MD, 2011, NATURE, V480, P538, DOI 10.1038/nature10664; Rubtsov YP, 2008, IMMUNITY, V28, P546, DOI 10.1016/j.immuni.2008.02.017; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Sather BD, 2007, J EXP MED, V204, P1335, DOI 10.1084/jem.20070081; Scharschmidt TC, 2015, IMMUNITY, V43, P1011, DOI 10.1016/j.immuni.2015.10.016; Schneider MA, 2007, J EXP MED, V204, P735, DOI 10.1084/jem.20061405; Sordi V, 2006, TRANSPLANTATION, V82, P826, DOI 10.1097/01.tp.0000235433.03554.4f; Thyssen JP, 2010, CHEM RES TOXICOL, V23, P309, DOI 10.1021/tx9002726; Tietz W, 1998, J IMMUNOL, V161, P963; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Wang B, 1999, J IMMUNOL, V162, P277; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; Xin G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07492-4; Yang ZY, 2012, IMMUNITY, V36, P857, DOI 10.1016/j.immuni.2012.02.009	43	11	11	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2019	144	5					1343	+		10.1016/j.jaci.2019.05.033	http://dx.doi.org/10.1016/j.jaci.2019.05.033			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JK7EU	31194988	Bronze			2022-12-18	WOS:000495004700025
J	Redwood, AJ; Rwandamuriye, F; Chopra, A; Leary, S; Ram, R; McDonnell, W; Konvinse, K; White, K; Pavlos, R; Koelle, DM; Mallal, S; Phillips, EJ				Redwood, Alec James; Rwandamuriye, Francois; Chopra, Abha; Leary, Shay; Ram, Ramesh; McDonnell, Wyatt; Konvinse, Katherine; White, Katie; Pavlos, Rebecca; Koelle, David M.; Mallal, Simon; Phillips, Elizabeth J.			Single-cell transcriptomics reveal polyclonal memory T-cell responses in skin with positive abacavir patch test results	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HYPERSENSITIVITY; HLA-B-ASTERISK-5701		[Redwood, Alec James; Rwandamuriye, Francois; Chopra, Abha; Leary, Shay; Ram, Ramesh; Pavlos, Rebecca; Mallal, Simon; Phillips, Elizabeth J.] Murdoch Univ, Inst Immunol & Infect Dis, Murdoch, WA, Australia; [McDonnell, Wyatt; White, Katie; Mallal, Simon; Phillips, Elizabeth J.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; [Konvinse, Katherine; Mallal, Simon; Phillips, Elizabeth J.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA; [Phillips, Elizabeth J.] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; [Koelle, David M.] Univ Washington, Dept Med, Seattle, WA USA; [Koelle, David M.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA; [Koelle, David M.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; [Koelle, David M.] Benaroya Res Inst, Seattle, WA USA; [Koelle, David M.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA	Murdoch University; Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Benaroya Research Institute; Fred Hutchinson Cancer Center	Phillips, EJ (corresponding author), Murdoch Univ, Inst Immunol & Infect Dis, Murdoch, WA, Australia.; Phillips, EJ (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA.; Phillips, EJ (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA.; Phillips, EJ (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA.	elizabeth.j.phillips@vanderbilt.edu	Mallal, Simon Alexander/HDM-9561-2022; Pavlos, Rebecca/AAY-9072-2020; Koelle, David/Q-6529-2016; Redwood, Alec/A-6138-2008	Mallal, Simon Alexander/0000-0002-7036-1309; Pavlos, Rebecca/0000-0002-8884-9855; Rwandamuriye, Francois Xavier/0000-0002-3456-3931; Koelle, David/0000-0003-1255-9023; Konvinse, Katherine/0000-0003-2451-9256; Leary, Shay/0000-0002-6966-2294; Redwood, Alec/0000-0001-8601-8292; Chopra, Abha/0000-0001-5008-9080	National Institutes of Health [P50 GM115305, K12 HL143956, R21 AI139021, P30 Al110527, F30 AI131780, T32 GM7347]; National Health AMP; Medical Research Council (Australia); Australian Centre for HIV AMP; Hepatitis Research (ACH2); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI139021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM115305] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Health AMP; Medical Research Council (Australia); Australian Centre for HIV AMP; Hepatitis Research (ACH2); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by National Institutes of Health grants P50 GM115305, K12 HL143956, R21 AI139021, P30 Al110527, F30 AI131780, and T32 GM7347; the National Health & Medical Research Council (Australia); and the Australian Centre for HIV & Hepatitis Research (ACH2).	Chessman D, 2008, IMMUNITY, V28, P822, DOI 10.1016/j.immuni.2008.04.020; Illing PT, 2012, NATURE, V486, P554, DOI 10.1038/nature11147; Li J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148351; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Mallal S, 2008, NEW ENGL J MED, V358, P568, DOI 10.1056/NEJMoa0706135; Ostrov DA, 2012, P NATL ACAD SCI USA, V109, P9959, DOI 10.1073/pnas.1207934109; Phillips EJ, 2002, AIDS, V16, P2223, DOI 10.1097/00002030-200211080-00017; Saag M, 2008, CLIN INFECT DIS, V46, P1111, DOI 10.1086/529382; Sinclair LV, 2013, NAT IMMUNOL, V14, P500, DOI 10.1038/ni.2556	9	11	11	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2019	144	5					1413	+		10.1016/j.jaci.2019.09.013	http://dx.doi.org/10.1016/j.jaci.2019.09.013			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JK7EU	31574267	Bronze, Green Accepted			2022-12-18	WOS:000495004700032
J	Gliklich, RE; Castro, M; Leavy, MB; Press, VG; Barochia, A; Carroll, CL; Harris, J; Rittner, SS; Freishtat, R; Panettieri, RA; Mosnaim, GS				Gliklich, Richard E.; Castro, Mario; Leavy, Michelle B.; Press, Valerie G.; Barochia, Amisha; Carroll, Christopher L.; Harris, Julie; Rittner, Sarah S.; Freishtat, Robert; Panettieri, Reynold A., Jr.; Mosnaim, Giselle S.			Harmonized outcome measures for use in asthma patient registries and clinical practice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; patient registry; outcome measure; patient outcome; data standard; common data element; harmonization	HEALTH	Background: Asthma, a common chronic airway disorder, affects an estimated 25 million persons in the United States and 330 million persons worldwide. Although many asthma patient registries exist, the ability to link and compare data across registries is hindered by a lack of harmonization in the outcome measures collected by each registry. Objectives: The purpose of this project was to develop a minimum set of patient- and provider-relevant standardized outcome measures that could be collected in asthma patient registries and clinical practice. Methods: Asthma registries were identified through multiple sources and invited to join the workgroup and submit outcome measures. Additional measures were identified through literature searches and reviews of quality measures and consensus statements. Outcome measures were categorized by using the Agency for Healthcare Research and Quality's supported Outcome Measures Framework. A minimum set of broadly relevant measures was identified. Measure definitions were harmonized through in-person and virtual meetings. Results: Forty-six outcome measures, including those identified from 13 registries, were curated and harmonized into a minimum set of 21 measures in the Outcome Measures Framework categories of survival, clinical response, events of interest, patient-reported outcomes, resource utilization, and experience of care. The harmonized definitions build on existing consensus statements and are appropriate for adult and pediatric patients. Conclusions: The harmonized measures represent a minimum set of outcomes that are relevant in asthma research and clinical practice. Routine and consistent collection of these measures in registries and other systems would support creation of a national research infrastructure to efficiently address new questions and improve patient management and outcomes.	[Gliklich, Richard E.; Leavy, Michelle B.] OM1, Boston, MA USA; [Gliklich, Richard E.] Harvard Med Sch, Boston, MA 02115 USA; [Castro, Mario] Washington Univ, Sch Med, Div Pulm & Crit Care Med, St Louis, MO USA; [Press, Valerie G.] Univ Chicago, Dept Med, Internal Med Pediat, Chicago, IL 60637 USA; [Barochia, Amisha] NHLBI, Lab Asthma & Lung Inflammat, Pulm Branch, Bldg 10, Bethesda, MD 20892 USA; [Carroll, Christopher L.] Connecticut Childrens Med Ctr, Hartford, CT USA; [Harris, Julie] Childrens Hlth Fdn, Portland, OR USA; [Rittner, Sarah S.] Alliance Chicago, Chicago, IL USA; [Freishtat, Robert] Childrens Res Inst, Washington, DC USA; [Panettieri, Reynold A., Jr.] Rutgers State Univ, Rutgers Inst Translat Med & Sci, New Brunswick, NJ USA; [Mosnaim, Giselle S.] NorthShore Univ HealthSyst, Div Pulm Allergy & Crit Care Med, Chicago, IL USA	Harvard University; Harvard Medical School; Washington University (WUSTL); University of Chicago; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Connecticut Children's Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; NorthShore University Health System	Gliklich, RE (corresponding author), 800 Boylston St,Suite 1410, Boston, MA 02199 USA.	rgliklich@oml.com	panettieri, reynold/AAG-9485-2019	Freishtat, Robert/0000-0002-7411-2342; Leavy, Michelle/0000-0003-1927-7248	Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services (HHS) [HHSA290201400004C]; Office of the Secretary Patient-Centered Outcomes Research Trust Fund [16-566R-16]; Intramural Research Program of the National Institutes of Health/National Heart, Lung, and Blood Institute	Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services (HHS); Office of the Secretary Patient-Centered Outcomes Research Trust Fund; Intramural Research Program of the National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported under contract HHSA290201400004C from the Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services (HHS). Statements in the manuscript do not necessarily represent the official views of or imply endorsement by AHRQ or HHS. This work was supported by the Office of the Secretary Patient-Centered Outcomes Research Trust Fund under Interagency Agreement #16-566R-16. This research was supported in part by the Intramural Research Program of the National Institutes of Health/National Heart, Lung, and Blood Institute.	AAAAI Allergy, 2017, QUALITY MEASURE SPEC; Adams Sarah A, 2017, JMIR Res Protoc, V6, pe48, DOI 10.2196/resprot.6674; Afshar M, 2018, J ASTHMA, V55, P1035, DOI 10.1080/02770903.2017.1389952; Akinbami LJ, 2014, J ALLERGY CLIN IMMUN, V134, P547, DOI 10.1016/j.jaci.2014.05.037; Akinbami LJ, 2012, J ALLERGY CLIN IMMUN, V129, pS49, DOI 10.1016/j.jaci.2011.12.984; American Academy of Allergy Asthma & Immunology, AAAAI ALLERGY ASTHMA; Barrett M, 2018, HEALTH AFFAIR, V37, P525, DOI 10.1377/hlthaff.2017.1315; Barrett MA, 2017, ANN ALLERG ASTHMA IM, V119, P415, DOI 10.1016/j.anai.2017.08.002; Beck AF, 2014, PEDIATRICS, V133, P431, DOI 10.1542/peds.2013-2437; Busse WW, 2012, J ALLERGY CLIN IMMUN, V129, pS1, DOI 10.1016/j.jaci.2011.12.985; Centers for Disease Control and Prevention, ASTHMA DATA STATISTI; Centers for Disease Control and Prevention, ASTHMA IN CHILDREN; Centers for Disease Control and Prevention, ASTHMA AS THE UNDERL; Cloutier MM, 2012, J ALLERGY CLIN IMMUN, V129, pS24, DOI 10.1016/j.jaci.2011.12.980; Fajt ML, 2015, J ALLERGY CLIN IMMUN, V135, P299, DOI 10.1016/j.jaci.2014.12.1871; Fuhlbrigge A, 2012, J ALLERGY CLIN IMMUN, V129, pS34, DOI 10.1016/j.jaci.2011.12.983; Gliklich R, 2014, AHRQ PUBLICATION NO; Gliklich RE, 2014, J COMP EFFECT RES, V3, P473, DOI [10.2217/CER.14.38, 10.2217/cer.14.38]; Keet CA, 2017, J ALLERGY CLIN IMMUN, V140, P822, DOI 10.1016/j.jaci.2017.01.036; Kim AS, 2016, ANN ALLERG ASTHMA IM, V116, P14, DOI 10.1016/j.anai.2015.08.001; Krishnan JA, 2012, J ALLERGY CLIN IMMUN, V129, pS124, DOI 10.1016/j.jaci.2011.12.981; Levy BD, 2015, AM J RESP CRIT CARE, V192, P1366, DOI 10.1164/rccm.201505-0963WS; Nurmagambetov T, 2018, ANN AM THORAC SOC, V15, P348, DOI 10.1513/AnnalsATS.201703-259OC; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Rubin BK, 2018, PAEDIATR RESPIR REV, V27, P86, DOI 10.1016/j.prrv.2017.11.002; Schatz M, 2006, CHEST, V130, P43, DOI 10.1378/chest.130.1.43; Szefler SJ, 2012, J ALLERGY CLIN IMMUN, V129, pS9, DOI 10.1016/j.jaci.2011.12.979; Teague WG, 2018, J ALLER CL IMM-PRACT, V6, P545, DOI 10.1016/j.jaip.2017.05.032; Tepper RS, 2012, J ALLERGY CLIN IMMUN, V129, pS65, DOI 10.1016/j.jaci.2011.12.986; Wilson SR, 2012, J ALLERGY CLIN IMMUN, V129, pS88, DOI 10.1016/j.jaci.2011.12.988	30	11	11	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2019	144	3					671	+		10.1016/j.jaci.2019.02.025	http://dx.doi.org/10.1016/j.jaci.2019.02.025			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IW8CV	30857981	Bronze			2022-12-18	WOS:000485222300013
J	Miller, RL; Shtessel, M; Robinson, LB; Banerji, A				Miller, Rachel L.; Shtessel, Maria; Robinson, Lacey B.; Banerji, Aleena			Advances in drug allergy, urticaria, angioedema, and anaphylaxis in 2018	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Drug allergy; urticaria; anaphylaxis; angioedema	QUALITY-OF-LIFE; REPORTED PENICILLIN ALLERGY; HEREDITARY ANGIOEDEMA; ACUTE ATTACKS; EPINEPHRINE; INHIBITOR; PLACEBO; PERSPECTIVE; PREVENTION; OMALIZUMAB	Many notable advances in drug allergy, urticaria, angioedema, and anaphylaxis were reported in 2018. Broad-spectrum antibiotic use and, consequently, antibiotic resistance are widespread, and algorithms to clarify beta-lactam allergy and optimize antibiotic use were described. Meaningful data emerged on the pathogenesis of delayed drug hypersensitivity reactions. Progress not only in defining biomarkers but also in understanding the effect on quality of life and developing better treatments has been made for patients with chronic idiopathic urticaria. Patients with hereditary angioedema (HAE) have gained additional access to highly efficacious therapies, with associated improvements in quality of life, and some progress was made in our understanding of recurrent angioedema in patients with normal laboratory results. Guidelines have defined clear goals to help providers optimize therapies in patients with HAE. The epidemiology and triggers of anaphylaxis and the mechanisms underlying anaphylaxis were elucidated further. In summary, these disorders (and labels) cause substantial burdens for individual persons and even society. Fortunately, publications in 2018 have informed on advancements in diagnosis and management and have provided better understanding of mechanisms that potentially could yield new therapies. This progress should lead to better health outcomes and paths forward in patients with drug allergy, urticaria, HAE, and anaphylaxis.	[Miller, Rachel L.] Columbia Univ, Vagelos Coll Phys & Surg, Div Pulm Allergy & Crit Care Med, Dept Med, New York, NY USA; [Miller, Rachel L.; Shtessel, Maria] Columbia Univ, Dept Pediat, Vagelos Coll Phys & Surg, Div Allergy Immunol & Rheumatol, New York, NY 10027 USA; [Robinson, Lacey B.; Banerji, Aleena] Massachusetts Gen Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA	Columbia University; Columbia University; Harvard University; Massachusetts General Hospital	Miller, RL (corresponding author), Columbia Univ, Irving Med Ctr, PH8-101B,630 W 168th St, New York, NY 10032 USA.	rlm14@cumc.columbia.edu	Banerji, Aleena/ABG-1245-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL116275] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL116275] Funding Source: Medline; NIEHS NIH HHS [R01 ES013163] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Altrichter S, 2019, J ALLERGY CLIN IMMUN, V143, P788, DOI 10.1016/j.jaci.2018.08.050; Aygoren-Pursun E, 2018, NEW ENGL J MED, V379, P352, DOI 10.1056/NEJMoa1716995; Aygoren-Pursun E, 2018, ORPHANET J RARE DIS, V13, DOI 10.1186/s13023-018-0815-5; Bafunno V, 2018, J ALLERGY CLIN IMMUN, V141, P1009, DOI 10.1016/j.jaci.2017.05.020; Bahri R, 2018, J ALLERGY CLIN IMMUN, V142, P485, DOI 10.1016/j.jaci.2018.01.043; Baiardini I, 2018, J ALLER CL IMM-PRACT, V6, P208, DOI 10.1016/j.jaip.2017.06.023; Ball R, 2018, PHARMACOEPIDEM DR S, V27, P1077, DOI 10.1002/pds.4645; Banerji A, 2018, JAMA-J AM MED ASSOC, V320, P2108, DOI 10.1001/jama.2018.16773; Banerji A, 2018, ALLERGY ASTHMA PROC, V39, P212, DOI 10.2500/aap.2018.39.4123; Beutier H, 2018, SCI IMMUNOL, P3; Blumenthal KG, 2018, ALLERGY, V73, P2012, DOI 10.1111/all.13440; Blumenthal KG, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k2400; Blumenthal KG, 2018, J ALLER CL IMM-PRACT, V6, P1019, DOI 10.1016/j.jaip.2017.08.006; Blumenthal KG, 2018, CLIN INFECT DIS, V66, P329, DOI 10.1093/cid/cix794; Bork K, 2018, ALLERGY, V73, P442, DOI 10.1111/all.13270; Busse PJ, 2019, J ALLER CL IMM-PRACT, V7, P1679, DOI 10.1016/j.jaip.2018.11.042; Carter MC, 2018, J ALLERGY CLIN IMMUN, V141, P180, DOI 10.1016/j.jaci.2017.05.036; Cassard L, 2018, J ALLERGY CLIN IMMUN, V142, P1548, DOI 10.1016/j.jaci.2017.11.053; Chen JR, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy106; Choi HW, 2018, SCIENCE, P362; Cicardi M, 2018, J ALLER CL IMM-PRACT, V6, P1132, DOI 10.1016/j.jaip.2018.04.022; Clay CD, 2018, J ALLERGY CLIN IMMUN, V141, P1373, DOI 10.1016/j.jaci.2017.05.027; Craig TJ, 2009, J ALLERGY CLIN IMMUN, V124, P801, DOI 10.1016/j.jaci.2009.07.017; D'Costa S, 2019, J ALLERGY CLIN IMMUN, V143, P1865, DOI 10.1016/j.jaci.2018.08.053; Dewald G, 2018, BIOCHEM BIOPH RES CO, V498, P193, DOI 10.1016/j.bbrc.2017.12.060; Deza G, 2018, J ALLER CL IMM-PRACT, V6, P1108, DOI 10.1016/j.jaip.2018.02.024; Deza G, 2018, J ALLERGY CLIN IMMUN, V141, P2313, DOI 10.1016/j.jaci.2018.02.021; Dhopeshwarkar N, 2019, J ALLER CL IMM-PRACT, V7, P103, DOI 10.1016/j.jaip.2018.06.010; Dressler C, 2018, J ALLERGY CLIN IMMUN, V141, P1726, DOI 10.1016/j.jaci.2018.01.031; Dubus JC, 2019, EUR J PEDIATR, V178, P69, DOI 10.1007/s00431-018-3246-3; Eun SJ, 2019, ALLERGOL INT, V68, P52, DOI 10.1016/j.alit.2018.05.011; Ferrer M, 2018, J ALLER CL IMM-PRACT, V6, P1191, DOI 10.1016/j.jaip.2018.04.003; Giavina-Bianchi P, 2018, CLINICS, V73, DOI 10.6061/clinics/2018/e354; Goss FR, 2018, J AM MED INFORM ASSN, V25, P661, DOI 10.1093/jamia/ocx139; Gour N, 2018, SCI IMMUNOL, P3; Hawro T, 2018, ALLERGY, V73, P251, DOI 10.1111/all.13271; Hogue SL, 2018, J SCHOOL HEALTH, V88, P396, DOI 10.1111/josh.12620; Huang KHG, 2018, CLIN INFECT DIS, V67, P27, DOI 10.1093/cid/ciy037; Iammatteo M, 2019, J ALLER CL IMM-PRACT, V7, P236, DOI 10.1016/j.jaip.2018.05.008; Javaud N, 2019, J ALLER CL IMM-PRACT, V7, P328, DOI 10.1016/j.jaip.2018.05.036; Jeong K, 2018, ALLERGY ASTHMA CL IM, V14, DOI 10.1186/s13223-018-0251-z; Kaplan AP, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00206; Kim JK, 2018, J ALLER CL IMM-PRACT, V6, P582, DOI 10.1016/j.jaip.2017.07.012; Klein EY, 2018, P NATL ACAD SCI USA, V115, pE3463, DOI 10.1073/pnas.1717295115; Kolkhir P, 2018, ALLERGY, V73, P940, DOI 10.1111/all.13352; Kulthanan K, 2018, J ALLER CL IMM-PRACT, V6, P586, DOI 10.1016/j.jaip.2017.07.017; la Tour AT, 2018, J ALLER CL IMM-PRACT, V6, P1321, DOI 10.1016/j.jaip.2017.10.008; Lacour JP, 2018, EUR J DERMATOL, V28, P795, DOI 10.1684/ejd.2018.3446; Laguna JJ, 2018, J ALLER CL IMM-PRACT, V6, P1628, DOI 10.1016/j.jaip.2017.12.001; Lara-Marquez ML, 2018, CLIN EXP ALLERGY, V48, P1429, DOI 10.1111/cea.13219; Lee J, 2018, PEDIATRICS, P141; Levy RJ, 2010, ANN ALLERG ASTHMA IM, V104, P523, DOI 10.1016/j.anai.2010.04.012; Li HH, 2018, ALLERGY ASTHMA PROC, V39, P365, DOI 10.2500/aap.2018.39.4164; Li YP, 2018, J ALLERGY CLIN IMMUN, V142, P1173, DOI 10.1016/j.jaci.2017.10.043; Loules G, 2018, GENE, V667, P76, DOI 10.1016/j.gene.2018.05.029; Lucas M, 2018, J ALLERGY CLIN IMMUN, V7, P975; Lumry WR, 2018, J ALLER CL IMM-PRACT, V6, P1733, DOI 10.1016/j.jaip.2017.12.039; Lumry WR, 2018, J ALLERGY CLIN IMMUN, V141, pAB47, DOI 10.1016/j.jaci.2017.12.154; Lumry WR, 2011, ANN ALLERG ASTHMA IM, V107, P529, DOI 10.1016/j.anai.2011.08.015; Lumry WR, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00022; MacGlashan D, 2019, J ALLERGY CLIN IMMUN, V143, P1100, DOI 10.1016/j.jaci.2018.05.019; Mattingly TJ, 2018, J ALLER CL IMM-PRACT, V6, P1649, DOI 10.1016/j.jaip.2017.12.033; Maurer M, 2018, ALLERGY, V73, P1575, DOI 10.1111/all.13384; Maurer M, 2018, J ALLERGY CLIN IMMUN, V141, P1138, DOI 10.1016/j.jaci.2017.10.018; Maurer M, 2018, J ALLERGY CLIN IMMUN, V141, P638, DOI 10.1016/j.jaci.2017.06.032; McWilliam VL, 2018, J ALLERGY CLIN IMMUN, V141, P982, DOI 10.1016/j.jaci.2017.09.012; Moldovan D., 2018, CASE REP EMERG MED, V2018; Monroy-Arreola A, 2018, CHEM RES TOXICOL, V31, P454, DOI 10.1021/acs.chemrestox.7b00330; Motosue MS, 2018, PEDIAT ALLERG IMM-UK, V29, P538, DOI 10.1111/pai.12908; Niemeyer-van der Kolk T, 2018, J ALLERGY CLIN IMMUN, V142, P1992, DOI 10.1016/j.jaci.2018.07.032; O'Connell RM, 2010, IMMUNITY, V33, P607, DOI 10.1016/j.immuni.2010.09.009; Pharming Group NV, PHARM ANN POS DAT PA; Qiu T, 2019, ALLERGY, V74, P1081, DOI 10.1111/all.13582; Retterer MKC, 2018, J ALLERGY CLIN IMMUN, V141, P1956, DOI 10.1016/j.jaci.2017.08.047; Riedl MA, 2018, ALLERGY, V73, P1871, DOI 10.1111/all.13466; Riedl MA, 2014, ANN ALLERG ASTHMA IM, V112, P163, DOI 10.1016/j.anai.2013.12.004; Robinson M, 2019, J ALLER CL IMM-PRACT, V7, P437, DOI 10.1016/j.jaip.2018.06.025; Salas M, 2018, J ALLER CL IMM-PRACT, V6, P1010, DOI 10.1016/j.jaip.2017.08.009; Sanchez E, 2019, J BIOL CHEM, V294, P3012, DOI 10.1074/jbc.RA118.005532; Sanchez J, 2018, J ALLER CL IMM-PRACT, V6, P177, DOI 10.1016/j.jaip.2017.06.002; Schmetzer O, 2018, J ALLERGY CLIN IMMUN, V142, P876, DOI 10.1016/j.jaci.2017.10.035; Segura-Bedmar I, 2018, J BIOMED INFORM, V87, P50, DOI 10.1016/j.jbi.2018.09.012; Shefler I, 2018, J ALLERGY CLIN IMMUN, V141, P2132, DOI 10.1016/j.jaci.2017.06.045; Song TT, 2018, J ALLER CL IMM-PRACT, V6, P1559, DOI 10.1016/j.jaip.2018.01.019; Song TT, 2018, ANN ALLERG ASTHMA IM, V121, P132, DOI 10.1016/j.anai.2018.03.018; Sousa-Pinto B, 2018, INT ARCH ALLERGY IMM, V176, DOI 10.1159/000488857; Staicu ML, 2018, J ALLER CL IMM-PRACT, V6, P2033, DOI 10.1016/j.jaip.2018.04.038; Sullivan A, 2018, J ALLERGY CLIN IMMUN, V141, P235, DOI 10.1016/j.jaci.2017.01.020; Tharp MD, 2018, JAMA DERMATOL; Trubiano JA, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy306; Warren CM, 2018, ANN ALLERG ASTHMA IM, V121, P479, DOI 10.1016/j.anai.2018.06.010; Wong A, 2019, J ALLER CL IMM-PRACT, V7, P1253, DOI 10.1016/j.jaip.2018.11.023; Xie GG, 2018, J ALLERGY CLIN IMMUN, V141, P788, DOI 10.1016/j.jaci.2017.07.040; Yamani A, 2018, J ALLERGY CLIN IMMUN, V142, P1159, DOI 10.1016/j.jaci.2017.08.046; Yao TC, 2018, WORLD ALLERGY ORGAN, V11, DOI 10.1186/s40413-018-0202-7; Yu JE, 2018, CLIN REV ALLERG IMMU, V54, P366, DOI 10.1007/s12016-015-8503-x; Zanichelli A, 2018, CLIN TRANSL ALLERGY, V8, DOI 10.1186/s13601-018-0229-4; Zanichelli A, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0233-x; Zuberbier T, 2018, ALLERGY, V73, P1393, DOI 10.1111/all.13397; Zuraw BL, 2018, J ALLERGY CLIN IMMUN, V141, P884, DOI 10.1016/j.jaci.2018.01.015	100	11	12	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2019	144	2					381	392		10.1016/j.jaci.2019.06.010	http://dx.doi.org/10.1016/j.jaci.2019.06.010			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IN6LC	31247266	Bronze, Green Accepted			2022-12-18	WOS:000478789300004
J	Stevens, EL; Rosser, F; Forno, E; Peden, D; Celedon, JC				Stevens, Erica L.; Rosser, Franziska; Forno, Erick; Peden, David; Celedon, Juan C.			Can the effects of outdoor air pollution on asthma be mitigated?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Pollution; smoking; stress; obesity; diet	PARENTAL STRESS INCREASES; CHILDHOOD ASTHMA; LUNG-FUNCTION; OZONE EXPOSURE; DIESEL EXHAUST; CHILDREN; ALLERGEN; QUALITY; OBESITY; ASSOCIATION		[Stevens, Erica L.; Rosser, Franziska; Forno, Erick; Celedon, Juan C.] Univ Pittsburgh, Dept Pediat, Div Pulm Med, UPMC Childrens Hosp Pittsburgh, Pittsburgh, PA 15260 USA; [Peden, David] Univ N Carolina, Dept Pediat, Div Allergy Immunol & Rheumatol, Chapel Hill, NC 27515 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of North Carolina; University of North Carolina Chapel Hill	Celedon, JC (corresponding author), UPMC Childrens Hosp Pittsburgh, Div Pediat Pulm Med, 4401 Penn Ave, Pittsburgh, PA 15224 USA.	juan.celedon@chp.edu	Forno, Erick/I-1476-2019	Forno, Erick/0000-0001-6497-9885; Rosser, Franziska/0000-0003-1202-044X; Peden, David/0000-0003-4526-4627	National Institutes of Health (NIH) [HL117191, HL119952, MD011764, ES023349, UL1TR002489]; Environmental Protection Agency (EPA) [CR 83578501]; NIH [T32 HL129949]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL119952] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES023349] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [R01MD011764] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Environmental Protection Agency (EPA)(United States Environmental Protection Agency); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	Supported by grants HL117191, HL119952, MD011764, ES023349, and UL1TR002489 from the National Institutes of Health (NIH), and by grant CR 83578501 from the Environmental Protection Agency (EPA). E.L.S. is supported by grant T32 HL129949 from the NIH.	Alexeeff SE, 2007, CHEST, V132, P1890, DOI 10.1378/chest.07-1126; Barck C, 2005, ENVIRON RES, V97, P58, DOI 10.1016/j.envres.2004.02.009; Bennett WD, 2007, INHAL TOXICOL, V19, P1147, DOI 10.1080/08958370701665475; Berhane K, 2016, JAMA-J AM MED ASSOC, V315, P1491, DOI 10.1001/jama.2016.3444; Bolcas PE, 2019, J ALLERGY CLIN IMMUN, V143, P386, DOI 10.1016/j.jaci.2018.04.042; Bose S, 2019, J ALLERGY CLIN IMMUN; Bose S, 2018, ENVIRON RES, V167, P591, DOI 10.1016/j.envres.2018.08.019; Bose S, 2017, AM J RESP CRIT CARE, V196, P1396, DOI 10.1164/rccm.201702-0421OC; Brandt EB, 2015, J ALLERGY CLIN IMMUN, V136, P295, DOI 10.1016/j.jaci.2014.11.043; Burbank AJ, 2018, J ALLERGY CLIN IMMUN, V141, P1231, DOI 10.1016/j.jaci.2017.06.029; Burbank AJ, 2017, J ALLERGY CLIN IMMUN, V140, P1, DOI 10.1016/j.jaci.2017.05.010; Burte Emilie, 2016, Curr Environ Health Rep, V3, P23, DOI 10.1007/s40572-016-0084-1; Cakmak S, 2012, J ALLERGY CLIN IMMUN, V129, P228, DOI 10.1016/j.jaci.2011.09.025; Carlsten C, 2016, THORAX, V71, P35, DOI 10.1136/thoraxjnl-2015-207399; Clougherty JE, 2007, ENVIRON HEALTH PERSP, V115, P1140, DOI 10.1289/ehp.9863; Doiron D, 2017, ENVIRON HEALTH PERSP, V125, DOI [10.1289/EHP1353, 10.1289/ehp1353]; Dong GH, 2013, INT J OBESITY, V37, P94, DOI 10.1038/ijo.2012.125; Gauderman WJ, 2015, NEW ENGL J MED, V372, P905, DOI 10.1056/NEJMoa1414123; Gref A, 2017, AM J RESP CRIT CARE, V195, P1373, DOI 10.1164/rccm.201605-1026OC; Islam T, 2011, AM J RESP CRIT CARE, V184, P822, DOI 10.1164/rccm.201104-0720OC; Jung KH, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0361-3; Lee A, 2018, J ALLERGY CLIN IMMUN, V141, P1880, DOI 10.1016/j.jaci.2017.07.017; Lichtenfels AJDC, 2018, ENVIRON HEALTH PERSP, V126, DOI [10.1289/EHP2045, 10.1289/ehp2045]; Rabinovitch N, 2011, AM J RESP CRIT CARE, V184, P1350, DOI 10.1164/rccm.201010-1706OC; Rider CF, 2018, ANN AM THORAC SOC, V15, pS130, DOI 10.1513/AnnalsATS.201706-479MG; Romieu I, 2002, AM J RESP CRIT CARE, V166, P703, DOI 10.1164/rccm.2112074; Romieu Isabelle, 2010, Proc Am Thorac Soc, V7, P116, DOI 10.1513/pats.200909-097RM; Romieu I, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-122; Rosser F, 2014, AM J RESP CRIT CARE, V190, P1190, DOI 10.1164/rccm.201408-1568LE; Schikowski T, 2013, ENVIRON HEALTH PERSP, V121, P1034, DOI 10.1289/ehp.1206145; Shankardass K, 2009, P NATL ACAD SCI USA, V106, P12406, DOI 10.1073/pnas.0812910106; Sonnenschein-van der Voort AMM, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-91; Vagaggini B, 2002, AM J RESP CRIT CARE, V166, P1073, DOI 10.1164/rccm.2201013	33	11	11	3	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2019	143	6					2016	+		10.1016/j.jaci.2019.04.011	http://dx.doi.org/10.1016/j.jaci.2019.04.011			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IB2QG	31029773	Bronze, Green Accepted			2022-12-18	WOS:000470113200006
J	Yu, W; Zhou, XY; Dunham, D; Lyu, SC; Manohar, M; Zhang, WM; Zhao, F; Davis, MM; Nadeau, K				Yu, Wong; Zhou, Xiaoying; Dunham, Diane; Lyu, Shu Chen; Manohar, Monali; Zhang, Wenming; Zhao, Fan; Davis, Mark M.; Nadeau, Kari			Allergen-specific CD8(+) T cells in peanut-allergic individuals	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Yu, Wong; Zhou, Xiaoying; Dunham, Diane; Lyu, Shu Chen; Manohar, Monali; Zhang, Wenming; Nadeau, Kari] Stanford Univ, Sch Med, Sean N Parker Ctr Allergy & Asthma Res, Stanford, CA 94305 USA; [Yu, Wong; Zhou, Xiaoying; Dunham, Diane; Lyu, Shu Chen; Manohar, Monali; Zhang, Wenming; Nadeau, Kari] Stanford Univ, Dept Med, Div Pulm & Crit Care Med, Stanford, CA 94305 USA; [Yu, Wong; Nadeau, Kari] Stanford Univ, Dept Pediat, Div Allergy Immunol & Rheumatol, Stanford, CA 94305 USA; [Zhao, Fan; Davis, Mark M.] Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA; [Davis, Mark M.] Stanford Univ, Inst Immun Transplantat & Infect, Stanford, CA 94305 USA; [Davis, Mark M.] Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University	Nadeau, K (corresponding author), Stanford Univ, Sch Med, Sean N Parker Ctr Allergy & Asthma Res, Stanford, CA 94305 USA.; Nadeau, K (corresponding author), Stanford Univ, Dept Med, Div Pulm & Crit Care Med, Stanford, CA 94305 USA.; Nadeau, K (corresponding author), Stanford Univ, Dept Pediat, Div Allergy Immunol & Rheumatol, Stanford, CA 94305 USA.	knadeau@stanford.edu	Zhang, Wenming/AAU-7795-2021; Zhao, Fan/A-3686-2012	Zhao, Fan/0000-0002-6103-5608; Zhang, Wenming/0000-0002-9298-8460; Davis, Mark/0000-0001-6868-657X	National Institutes of Health [U19AI104209, R01AI140134, R01HL118612]; Sean N. Parker Center for Allergy and Asthma Research at Stanford University; FARE (Food Allergy Research and Education); Myra Reinhard Foundation; Hartman Family Foundation; Naddisy Foundation; End Allergies Together; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL118612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI140134, U19AI057229] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sean N. Parker Center for Allergy and Asthma Research at Stanford University; FARE (Food Allergy Research and Education); Myra Reinhard Foundation; Hartman Family Foundation; Naddisy Foundation; End Allergies Together; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank the National Institutes of Health (grant nos. U19AI104209, R01AI140134, R01HL118612), the Sean N. Parker Center for Allergy and Asthma Research at Stanford University, FARE (Food Allergy Research and Education), the Myra Reinhard Foundation, End Allergies Together, the Hartman Family Foundation, the Naddisy Foundation, and Jeff and MacKenzie Bezos for their generous support.	Brodin P, 2015, CELL, V160, P37, DOI 10.1016/j.cell.2014.12.020; Han A, 2013, P NATL ACAD SCI USA, V110, P13073, DOI 10.1073/pnas.1311861110; Hennino A, 2007, J IMMUNOL, V178, P5571, DOI 10.4049/jimmunol.178.9.5571; Lloyd CM, 2010, NAT REV IMMUNOL, V10, P838, DOI 10.1038/nri2870; Olivares-Villagomez D, 2018, TRENDS IMMUNOL, V39, P264, DOI 10.1016/j.it.2017.11.003; Srivastava KD, 2009, J ALLERGY CLIN IMMUN, V123, P443, DOI 10.1016/j.jaci.2008.12.1107; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Yu W, 2016, NAT REV IMMUNOL, V16, P751, DOI 10.1038/nri.2016.111; Yu W, 2015, IMMUNITY, V42, P929, DOI 10.1016/j.immuni.2015.05.001	9	11	12	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2019	143	5					1948	+		10.1016/j.jaci.2019.01.011	http://dx.doi.org/10.1016/j.jaci.2019.01.011			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HW6FP	30682458	Green Accepted, Bronze			2022-12-18	WOS:000466784600036
J	Hammaren, HM; Virtanen, AT; Abraham, BG; Peussa, H; Hubbard, SR; Silvennoinen, O				Hammaren, Henrik M.; Virtanen, Anniina T.; Abraham, Bobin George; Peussa, Heidi; Hubbard, Stevan R.; Silvennoinen, Olli			Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Janus kinase; JAK2 V617F; cytokine signaling; myeloproliferative neoplasm; kinase activation; drug design	JAK2 TYROSINE KINASE; PSEUDOKINASE-DOMAIN; CYTOKINE-RECEPTOR; CONSTITUTIVE ACTIVATION; SIGNAL-TRANSDUCTION; POLYCYTHEMIA-VERA; PROTEIN-KINASE; FERM DOMAIN; GAMMA; ALPHA	Background: Janus kinases (JAKs; JAK1 to JAK3 and tyrosine kinase 2) mediate cytokine signals in the regulation of hematopoiesis and immunity. JAK2 clinical mutations cause myeloproliferative neoplasms and leukemia, and the mutations strongly concentrate in the regulatory pseudokinase domain Janus kinase homology (JH) 2. Current clinical JAK inhibitors target the tyrosine kinase domain and lack mutation and pathway selectivity. Objective: We sought to characterize mechanisms and differences for pathogenic and cytokine-induced JAK2 activation to enable design of novel selective JAK inhibitors. Methods: We performed a systematic analysis of JAK2 activation requirements using structure-guided mutagenesis, cell-signaling assays, microscopy, and biochemical analysis. Results: Distinct structural requirements were identified for activation of different pathogenic mutations. Specifically, the predominant JAK2 mutation, V617F, is the most sensitive to structural perturbations in multiple JH2 elements (C helix [aC], Src homology 2-JH2 linker, and ATP binding site). In contrast, activation of K539L is resistant to most perturbations. Normal cytokine signaling shows distinct differences in activation requirements: JH2 ATP binding site mutations have only a minor effect on signaling, whereasJH2aCmutations reduce homomeric (JAK2-JAK2) erythropoietin signaling and almost completely abrogate heteromeric (JAK2-JAK1) IFN-gamma signaling, potentially by disrupting a dimerization interface on JH2. Conclusions: These results suggest that therapeutic approaches targeting the JH2 ATP binding site and aC could be effective in inhibiting most pathogenic mutations. JH2 ATP site targeting has the potential for reduced side effects by retaining erythropoietin and IFN-gamma functions. Simultaneously, however, we identified the JH2 aC interface as a potential target for pathway-selective JAK inhibitors in patients with diseases with unmutated JAK2, thus providing new insights into the development of novel pharmacologic interventions.	[Hammaren, Henrik M.; Virtanen, Anniina T.; Abraham, Bobin George; Peussa, Heidi; Silvennoinen, Olli] Univ Tampere, Fac Med & Life Sci, Tampere, Finland; [Hubbard, Stevan R.] NYU, Skirball Inst, Kimmel Ctr Biol & Med, Sch Med, New York, NY 10003 USA; [Hubbard, Stevan R.] NYU, Sch Med, Dept Biochem & Mol Pharmacol, New York, NY 10003 USA; [Silvennoinen, Olli] Fimlab Labs, Tampere, Finland; [Silvennoinen, Olli] Univ Helsinki, Inst Biotechnol, Helsinki, Finland; [Hammaren, Henrik M.] European Mol Biol Lab, Struct & Computat Biol Unit, Heidelberg, Germany; [Hammaren, Henrik M.] Genome Biol Unit, Heidelberg, Germany	Tampere University; New York University; New York University; University of Helsinki; European Molecular Biology Laboratory (EMBL)	Silvennoinen, O (corresponding author), Arvo Ylpon Katu 34, Tampere 33014, Finland.	olli.silvennoinen@uta.fi	Abraham, Bobin George/AAX-2600-2020; Hammarén, Henrik/AAB-5120-2022	Hammarén, Henrik/0000-0002-8534-2530; George Abraham, Bobin/0000-0002-1373-4244; Hubbard, Stevan/0000-0002-2707-9383; Virtanen, Anniina/0000-0001-7332-4880	Academy of Finland; Sigrid Juselius Foundation; Jane and Aatos Erkko Foundation; Finnish Cancer Foundation; Prostate Cancer Foundation; Tampere Tuberculosis Foundation; Tampere University Hospital District; National Institutes of Health [R01AI101256]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI101256] Funding Source: NIH RePORTER	Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Jane and Aatos Erkko Foundation; Finnish Cancer Foundation; Prostate Cancer Foundation; Tampere Tuberculosis Foundation; Tampere University Hospital District; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	H.M.M., B.G.A., A.T.V., and O.S. report grants from the Academy of Finland, the Sigrid Juselius Foundation, the Jane and Aatos Erkko Foundation, the Finnish Cancer Foundation, the Prostate Cancer Foundation, Tampere Tuberculosis Foundation, and Tampere University Hospital District competitive research funding. S. R. H reports National Institutes of Health grant R01AI101256.	Bandaranayake RM, 2012, NAT STRUCT MOL BIOL, V19, P754, DOI 10.1038/nsmb.2348; Bastiaens PIH, 1996, EMBO J, V15, P4246, DOI 10.1002/j.1460-2075.1996.tb00799.x; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Bercovich D, 2008, LANCET, V372, P1484, DOI 10.1016/S0140-6736(08)61341-0; Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; Del Bel KL, 2017, J ALLERGY CLIN IMMUN, V139, P2016, DOI 10.1016/j.jaci.2016.12.957; Dusa A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011157; Eletto D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13992; Ferrao R, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00071; Funakoshi-Tago M, 2008, MOL CELL BIOL, V28, P1792, DOI 10.1128/MCB.01447-07; Gnanasambandan K, 2010, BIOCHEMISTRY-US, V49, P9972, DOI 10.1021/bi1014858; Haan C, 2011, CHEM BIOL, V18, P314, DOI 10.1016/j.chembiol.2011.01.012; Haan C, 2009, J IMMUNOL, V182, P2969, DOI 10.4049/jimmunol.0800572; Hammaren HM, 2015, P NATL ACAD SCI USA, V112, P4642, DOI 10.1073/pnas.1423201112; Hammaren HM, 2018, CYTOKINE; Hofmann SR, 2004, MOL CELL BIOL, V24, P5039, DOI 10.1128/MCB.24.11.5039-5049.2004; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Keil E, 2014, BLOOD, V123, P520, DOI 10.1182/blood-2013-03-492157; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Leroy E, 2017, LEUKEMIA, V31, P1023, DOI 10.1038/leu.2017.43; Leroy E, 2016, BIOCHEM J, V473, P1579, DOI 10.1042/BCJ20160085; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Li Z, 2013, J IMMUNOL, V190, P2335, DOI 10.4049/jimmunol.1203118; Losdyck E, 2015, J BIOL CHEM, V290, P29022, DOI 10.1074/jbc.M115.670224; Lu XH, 2008, J BIOL CHEM, V283, P5258, DOI 10.1074/jbc.M707125200; Lupardus PJ, 2014, P NATL ACAD SCI USA, V111, P8025, DOI 10.1073/pnas.1401180111; Mercher T, 2006, BLOOD, V108, P2770, DOI 10.1182/blood-2006-04-014712; Mullighan CG, 2009, P NATL ACAD SCI USA, V106, P9414, DOI 10.1073/pnas.0811761106; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; Saharinen P, 2003, MOL BIOL CELL, V14, P1448, DOI 10.1091/mbc.E02-06-0342; Saharinen P, 2002, J BIOL CHEM, V277, P47954, DOI 10.1074/jbc.M205156200; Sanz A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018522; Schwartz DM, 2017, NAT REV DRUG DISCOV, V16, P843, DOI 10.1038/nrd.2017.201; Schwartz DM, 2016, NAT REV RHEUMATOL, V12, P25, DOI 10.1038/nrrheum.2015.167; Scott LM, 2007, NEW ENGL J MED, V356, P459, DOI 10.1056/NEJMoa065202; Shan YB, 2014, NAT STRUCT MOL BIOL, V21, P579, DOI 10.1038/nsmb.2849; Skoda RC, 2015, EXP HEMATOL, V43, P599, DOI 10.1016/j.exphem.2015.06.007; SLIVA D, 1994, J BIOL CHEM, V269, P26208; Sonbol MB, 2013, THER ADV HEMATOL, V4, P15, DOI 10.1177/2040620712461047; Tokarski JS, 2015, J BIOL CHEM, V290, P11061, DOI 10.1074/jbc.M114.619502; Toms AV, 2013, NAT STRUCT MOL BIOL, V20, P1221, DOI 10.1038/nsmb.2673; Ungureanu D, 2011, NAT STRUCT MOL BIOL, V18, P971, DOI 10.1038/nsmb.2099; Wernig G, 2008, BLOOD, V111, P3751, DOI 10.1182/blood-2007-07-102186; Yamaoka K, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-12-253; Yao H, 2017, LEUKEMIA, V31, P2122, DOI 10.1038/leu.2017.1; Yeh TC, 2000, P NATL ACAD SCI USA, V97, P8991, DOI 10.1073/pnas.160130297	48	11	11	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2019	143	4					1549	+		10.1016/j.jaci.2018.07.022	http://dx.doi.org/10.1016/j.jaci.2018.07.022			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HR7QE	30092288	Green Accepted, Bronze			2022-12-18	WOS:000463348900029
J	Nguyen, AM; Muccino, D; Birring, S; Bacci, ED; Vernon, MK; Mines, D; Smith, JA				Nguyen, Allison M.; Muccino, David; Birring, Surinder; Bacci, Elizabeth D.; Vernon, Margaret K.; Mines, Daniel; Smith, Jaclyn A.			Defining Minimal Clinically Important Differences (MCID) in Chronic Cough: Analyses of Objective Cough Counts from a Phase 2 Randomized Controlled Trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI)	FEB 22-25, 2019	San Francisco, CA	Amer Acad Allergy, Asthma & Immunol					[Nguyen, Allison M.; Muccino, David; Mines, Daniel] Merck Sharp & Dohme Corp, Kenilworth, NJ USA; [Birring, Surinder] Kings Coll London, Leicester, Leics, England; [Bacci, Elizabeth D.] Evidera, Seattle, WA USA; [Vernon, Margaret K.] Evidera, Bethesda, MD USA; [Smith, Jaclyn A.] Univ Manchester, Manchester, Lancs, England	Merck & Company; Evidera; Evidera; University of Manchester			Birring, Surinder/GWU-6967-2022						0	11	11	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2019	143	2		S		516	AB169	AB169		10.1016/j.jaci.2018.12.519	http://dx.doi.org/10.1016/j.jaci.2018.12.519			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	HK2VO		Bronze			2022-12-18	WOS:000457771200512
J	del Rio, PR; Escudero, C; Sanchez-Garcia, S; Ibanez, MD; Vickery, BP				Rodriguez del Rio, Pablo; Escudero, Carmelo; Sanchez-Garcia, Silvia; Dolores Ibanez, Maria; Vickery, Brian P.			Evaluating primary end points in peanut immunotherapy clinical trials	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Peanut allergy; food immunotherapy; desensitization; sustained unresponsiveness; randomized clinical trial; food allergy; oral food challenge	ORAL FOOD CHALLENGE; DOUBLE-BLIND; ALLERGEN IMMUNOTHERAPY; EPICUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; ADVERSE REACTIONS; EUROPEAN ACADEMY; PLACEBO; CHILDREN; THRESHOLD	Food immunotherapy has been the focus of several allergy research initiatives over the last decade. Although many questions remain unanswered, the evidence suggests that this treatment might be available in the near future outside clinical trials. Additionally, pharmaceutical companies, in light of promising early-stage results, have shown interest in developing commercially available products, thus increasing the likelihood that new immunotherapy treatments will be introduced, especially for peanut allergy. Given this optimistic scenario and given the prospect of rigorously developed products for peanut allergy treatment, each allergist will need to understand the specificities of these treatments and their expected efficacy and adverse event profiles. Thus it is imperative that allergists understand the differences in efficacy between the different management options, as well as how the end points are measured in the relevant literature. However, given the significant heterogeneity detected among food immunotherapy trials, this task might not be as straightforward as desired. This article aims to dissect how primary efficacy end points are defined and assessed to facilitate understanding of the design of these trials and the potential effect that this variation might have on the reported outcomes.	[Rodriguez del Rio, Pablo; Escudero, Carmelo; Sanchez-Garcia, Silvia; Dolores Ibanez, Maria] Hosp Infantil Univ Nino Jesus, Allergy Dept, Madrid, Spain; [Rodriguez del Rio, Pablo; Escudero, Carmelo; Sanchez-Garcia, Silvia; Dolores Ibanez, Maria] Hlth Res Inst Princesa, Madrid, Spain; [Rodriguez del Rio, Pablo; Escudero, Carmelo; Sanchez-Garcia, Silvia; Dolores Ibanez, Maria] ARADyAL RD16 0006 0026, Madrid, Spain; [Vickery, Brian P.] Emory Univ, Sch Med, Atlanta, GA USA	Emory University	del Rio, PR (corresponding author), Univ Nino Jesus, Hosp Infantil, Allergy Dept, Ave Menendez,65 CP, Madrid 28009, Spain.	prrio@yahoo.es	del Rio, Pablo Rodriguez/P-6184-2019; Escudero, Carmelo/B-5197-2017	del Rio, Pablo Rodriguez/0000-0002-0783-1988; Escudero, Carmelo/0000-0003-2157-8699				Allen K, 2012, J SCH NURS, V28, P47, DOI 10.1177/1059840511420726; Anagnostou K, 2011, CLIN EXP ALLERGY, V41, P1273, DOI 10.1111/j.1365-2222.2011.03699.x; Anagnostou K, 2014, SOUTHAMPTON UK NIHR; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Ballmer-Weber BK, 2015, ALLERGY, V70, P391, DOI 10.1111/all.12574; Ballmer-Weber BK, 2015, J ALLERGY CLIN IMMUN, V135, P964, DOI 10.1016/j.jaci.2014.10.047; Baumert JL, 2018, J ALLER CL IMM-PRACT, V6, P457, DOI 10.1016/j.jaip.2017.05.006; Begin P, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-1; Bindslev-Jensen C, 2004, ALLERGY, V59, P690, DOI 10.1111/j.1398-9995.2004.00466.x; Bird JA, 2018, J ALLER CL IMM-PRACT, V6, P476, DOI 10.1016/j.jaip.2017.09.016; Bird JA, 2015, J ALLER CL IMM-PRACT, V3, P433, DOI 10.1016/j.jaip.2014.11.020; Bird JA, 2015, J ALLERGY CLIN IMMUN, V3, pe1; Blumchen K, 2014, J ALLERGY CLIN IMMUN, V134, P390, DOI 10.1016/j.jaci.2014.03.035; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; BOCK SA, 1987, PEDIATRICS, V79, P683; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Burks AW, 2015, J ALLERGY CLIN IMMUN, V135, P1240, DOI 10.1016/j.jaci.2014.12.1917; Burks AW, 2015, J ALLERGY CLIN IMMUN, V135, pe1; Clark AT, 2009, ALLERGY, V64, P1218, DOI 10.1111/j.1398-9995.2009.01982.x; Cochrane SA, 2012, ALLERGY, V67, P107, DOI 10.1111/j.1398-9995.2011.02715.x; Deschildre A, 2016, CLIN EXP ALLERGY, V46, P610, DOI 10.1111/cea.12681; Dhami S, 2016, CLIN TRANSL ALLERGY, V6, DOI 10.1186/s13601-016-0113-z; Filep S, 2018, J ALLERGY CLIN IMMUN, V141, P626, DOI 10.1016/j.jaci.2017.05.049; Fleischer DM, 2013, J ALLERGY CLIN IMMUN, V131, P119, DOI 10.1016/j.jaci.2012.11.011; Glaumann S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053465; Grabenhenrich LB, 2017, ALLERGY, V72, P453, DOI 10.1111/all.13049; Greenhawt MJ, 2013, ALLERGY ASTHMA PROC, V34, P197, DOI 10.2500/aap.2013.34.3661; Grimshaw KEC, 2003, CLIN EXP ALLERGY, V33, P1581, DOI 10.1046/j.1365-2222.2003.01795.x; Hofmann AM, 2009, J ALLERGY CLIN IMMUN, V124, P286, DOI 10.1016/j.jaci.2009.03.045; Hourihane JO, 2017, J ALLERGY CLIN IMMUN, V139, P1583, DOI 10.1016/j.jaci.2017.01.030; Jones SM, 2017, J ALLERGY CLIN IMMUN, V139, P1242, DOI 10.1016/j.jaci.2016.08.017; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Jutel M, 2015, J ALLERGY CLIN IMMUN, V136, P556, DOI 10.1016/j.jaci.2015.04.047; Kim EH, 2011, J ALLERGY CLIN IMMUN, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; Kukkonen AK, 2017, ACTA PAEDIATR, V106, P274, DOI 10.1111/apa.13668; MacGinnitie AJ, 2017, J ALLERGY CLIN IMMUN, V139, P873, DOI 10.1016/j.jaci.2016.08.010; Mansfield LE, 2013, ALLERGY ASTHMA PROC, V34, P205, DOI 10.2500/aap.2013.34.3666; Martorell A, 2017, J INVEST ALLERG CLIN, V27, P225, DOI 10.18176/jiaci.0177; METCALFE DD, 1990, J ALLERGY CLIN IMMUN, V86, P421, DOI 10.1016/S0091-6749(05)80252-0; Moher D., 2009, ANN INTERN MED, V6, DOI [10.1371/journal.pmed.100009, DOI 10.18632/aging.103000]; Narisety SD, 2015, J ALLERGY CLIN IMMUN, V135, pe1; Nelson HS, 2017, CURR ALLERGY ASTHM R, V17, DOI 10.1007/s11882-017-0687-0; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Nguyen JM, 2014, J ALLERGY CLIN IMMUN, V133, P91, DOI 10.1016/j.jaci.2013.06.029; Nha UNL, 2012, PEDIAT ALLERG IMM-UK, V23, P134, DOI 10.1111/j.1399-3038.2011.01235.x; Niggemann B, 2010, ALLERGY, V65, P2, DOI 10.1111/j.1398-9995.2009.02170.x; Nozawa A, 2014, PEDIAT ALLERG IMM-UK, V25, P323, DOI 10.1111/pai.12243; Nurmatov U, 2017, ALLERGY, V72, P1133, DOI 10.1111/all.13124; Nwaru BI, 2014, ALLERGY, V69, P992, DOI 10.1111/all.12423; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; Pajno GB, 2018, ALLERGY, V73, P799, DOI 10.1111/all.13319; Patriarca G, 2003, ALIMENT PHARM THER, V17, P459, DOI 10.1046/j.1365-2036.2003.01468.x; Pfaar O, 2014, ALLERGY, V69, P854, DOI 10.1111/all.12383; Pitsios C, 2015, ALLERGY, V70, P897, DOI 10.1111/all.12638; Plaut M, 2009, J ALLERGY CLIN IMMUN, V124, P671, DOI 10.1016/j.jaci.2009.05.027; Remington BC, 2015, ALLERGY, V70, P813, DOI 10.1111/all.12625; Sampson HA, 2017, JAMA-J AM MED ASSOC, V318, P1798, DOI 10.1001/jama.2017.16591; Sampson HA, 2014, J ALLERGY CLIN IMMUN, V134, P1016, DOI 10.1016/j.jaci.2014.05.013; Sampson HA, 2013, J ALLER CL IMM-PRACT, V1, P15, DOI 10.1016/j.jaip.2012.10.009; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Schatz M, 2009, J ALLERGY CLIN IMMUN, V124, P719, DOI 10.1016/j.jaci.2009.06.053; Schneider LC, 2013, J ALLERGY CLIN IMMUN, V132, P1368, DOI 10.1016/j.jaci.2013.09.046; Smith PK, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0081-0; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Tang MLK, 2015, J ALLERGY CLIN IMMUN, V135, P737, DOI 10.1016/j.jaci.2014.11.034; Tao B, 2016, CLIN EXP ALLERGY, V46, P1004, DOI 10.1111/cea.12740; Taylor SL, 2002, J ALLERGY CLIN IMMUN, V109, P24, DOI 10.1067/mai.2002.120564; Thomas Mike, 2009, Prim Care Respir J, V18, P41, DOI 10.4104/pcrj.2009.00010; Thyagarajan A, 2010, J ALLERGY CLIN IMMUN, V126, P31, DOI 10.1016/j.jaci.2010.05.012; Turner PJ, 2017, ALLERGY, V72, P9, DOI 10.1111/all.12997; Turner PJ, 2016, ALLERGY, V71, P1241, DOI 10.1111/all.12924; Turner PJ, 2015, J ALLERGY CLIN IMMUN, V135, P956, DOI 10.1016/j.jaci.2014.10.021; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Vazquez-Ortiz M, 2016, PEDIAT ALLERG IMM-UK, V27, P117, DOI 10.1111/pai.12510; Vickery BP, 2017, J ALLERGY CLIN IMMUN, V139, P173, DOI 10.1016/j.jaci.2016.05.027; Vickery BP, 2014, J ALLERGY CLIN IMMUN, V133, P468, DOI 10.1016/j.jaci.2013.11.007; Vissers YM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023998; Vlieg-Boerstra BJ, 2007, ALLERGY, V62, P905, DOI 10.1111/j.1398-9995.2007.01430.x; Wasserman RL, 2014, J ALLER CL IMM-PRACT, V2, P91, DOI 10.1016/j.jaip.2013.10.001; Wasserman RL, 2011, J ALLERGY CLIN IMMUN, V127, P290, DOI 10.1016/j.jaci.2010.08.052; Wood RA, 2016, J ALLERGY CLIN IMMUN, V137, P973, DOI 10.1016/j.jaci.2016.01.001; Wood RA, 2014, J ALLER CL IMM-PRACT, V2, P97, DOI 10.1016/j.jaip.2013.11.010; Yee CSK, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0602-0	86	11	11	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2019	143	2					494	506		10.1016/j.jaci.2018.09.035	http://dx.doi.org/10.1016/j.jaci.2018.09.035			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HK2DJ	30367908				2022-12-18	WOS:000457718700005
J	Sampson, HA; Berin, MC; Plaut, M; Sicherer, SH; Jones, S; Burks, AW; Lindblad, R; Leung, DYM; Wood, RA				Sampson, Hugh A.; Berin, M. Cecilia; Plaut, Marshall; Sicherer, Scott H.; Jones, Stacie; Burks, A. Wesley; Lindblad, Robert; Leung, Donald Y. M.; Wood, Robert A.			The Consortium for Food Allergy Research (CoFAR): The first generation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Food allergy; peanut allergy; egg allergy; immunotherapy; oral immunotherapy; sublingual immunotherapy; epicutaneous immunotherapy	FC-GAMMA-RIIB; ORAL IMMUNOTHERAPY; PEANUT ALLERGY; EGG ALLERGY; SUSTAINED UNRESPONSIVENESS; NATURAL-HISTORY; MILK ALLERGY; T-CELLS; IGE; CHILDREN	The Consortium for Food Allergy Research (CoFAR) was established by the National Institute of Allergy and Infectious Diseases in 2005 as a collaborative research program bringing together centers focused on the study of food allergy. CoFAR was charged with developing studies to better understand the pathogenesis and natural history of food allergy, as well as potential approaches to the treatment of food allergy. In its first iteration an observational study of infants with milk and egg allergy was established, and studies of oral immunotherapy for egg allergy and sublingual immunotherapy for peanut allergy were initiated, as was a phase 1 study of a recombinant peanut protein vaccine. CoFAR was renewed in 2010 for an additional 5-year period during which the initial observational study was continued, a study of eosinophilic esophagitis was initiated, and new therapeutic trials were established to study epicutaneous immunotherapy for peanut allergy and to compare the safety and efficacy of egg oral immunotherapy to the ingestion of baked egg for the treatment of egg allergy. The results of these efforts will be reviewed in this rostrum, with a brief look to the future of CoFAR.	[Sampson, Hugh A.; Berin, M. Cecilia; Sicherer, Scott H.] Icahn Sch Med Mt Sinai, Jaffe Food Allergy Inst, New York, NY 10029 USA; [Plaut, Marshall] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Jones, Stacie] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; [Jones, Stacie] Arkansas Childrens Hosp, 800 Marshall St, Little Rock, AR 72202 USA; [Burks, A. Wesley] Univ N Carolina, Dept Pediat, Chapel Hill, NC 27515 USA; [Lindblad, Robert] Emmes Corp, Rockville, MD USA; [Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA	Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital; University of North Carolina; University of North Carolina Chapel Hill; Emmes Corporation; National Jewish Health; Johns Hopkins University	Wood, RA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, 600 N Wolfe St, Baltimore, MD 21287 USA.	rwood@jhmi.edu		berin, cecilia/0000-0002-9051-9249	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM2AI130836, U19AI066738] Funding Source: NIH RePORTER; NIAID NIH HHS [U19 AI066738, UM2 AI130836] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baker SS, 2000, PEDIATRICS, V106, P346; Berin MC, 2018, J ALLERGY CLIN IMMUN, V142, P149, DOI 10.1016/j.jaci.2018.01.044; Brough HA, 2015, J ALLERGY CLIN IMMUN, V135, P164, DOI 10.1016/j.jaci.2014.10.007; Bunyavanich S, 2016, J ALLERGY CLIN IMMUN, V138, P1122, DOI 10.1016/j.jaci.2016.03.041; Burks AW, 2015, J ALLERGY CLIN IMMUN, V135, P1240, DOI 10.1016/j.jaci.2014.12.1917; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Burton OT, 2018, J ALLERGY CLIN IMMUN, V141, P189, DOI 10.1016/j.jaci.2017.03.045; Burton OT, 2014, J ALLERGY CLIN IMMUN, V134, P1310, DOI 10.1016/j.jaci.2014.05.042; Carlisle SK, 2010, J SCH NURS, V26, P360, DOI 10.1177/1059840510369482; Caubet JC, 2014, PEDIAT ALLERG IMM-UK, V25, P243, DOI 10.1111/pai.12207; Chehade M, 2018, J ALLER CL IMM-PRACT, V6, P1534, DOI 10.1016/j.jaip.2018.05.038; Chiang D, 2018, J ALLERGY CLIN IMMUN, V141, P2107, DOI 10.1016/j.jaci.2017.11.060; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Fazlollahi M, 2018, ALLERGY, V73, P1515, DOI 10.1111/all.13389; Fleischer DM, 2013, J ALLERGY CLIN IMMUN, V131, P119, DOI 10.1016/j.jaci.2012.11.011; Fleischer DM, 2012, PEDIATRICS, V130, pE25, DOI 10.1542/peds.2011-1762; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Groetch ME, 2010, J NUTR EDUC BEHAV, V42, P259, DOI 10.1016/j.jneb.2009.06.003; Jones SM, 2017, J ALLERGY CLIN IMMUN, V139, P1242, DOI 10.1016/j.jaci.2016.08.017; Jones SM, 2016, J ALLERGY CLIN IMMUN, V137, P1117, DOI 10.1016/j.jaci.2015.12.1316; Kosoy R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163831; Kottyan LC, 2019, GENES IMMUN, V20, P281, DOI 10.1038/s41435-018-0034-z; Kottyan LC, 2014, NAT GENET, V46, P895, DOI 10.1038/ng.3033; Kulis M, 2012, J ALLERGY CLIN IMMUN, V129, P1159, DOI 10.1016/j.jaci.2011.11.045; Sicherer SH, 2016, J ALLERGY CLIN IMMUN, V137, pAB152, DOI 10.1016/j.jaci.2015.12.626; Sicherer SH, 2016, J ALLER CL IMM-PRACT, V4, P239, DOI 10.1016/j.jaip.2015.11.015; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P492, DOI 10.1016/j.jaci.2013.12.1041; Sicherer SH, 2012, J PEDIATR-US, V160, P651, DOI 10.1016/j.jpeds.2011.09.056; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V126, P1191, DOI 10.1016/j.jaci.2010.08.036; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1077, DOI 10.1016/j.jaci.2010.02.038; Suprun M, 2018, ALLERGY, V73, P116, DOI 10.1111/all.13536; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Vargas PA, 2011, PEDIAT ALLERG IMM-UK, V22, P575, DOI 10.1111/j.1399-3038.2011.01152.x; Vickery BP, 2014, J ALLERGY CLIN IMMUN, V133, P468, DOI 10.1016/j.jaci.2013.11.007; Wambre E, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam9171; Watson CT, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02188-7; Wood RA, 2013, ALLERGY, V68, P803, DOI 10.1111/all.12158; Wood RA, 2013, J ALLERGY CLIN IMMUN, V131, P805, DOI 10.1016/j.jaci.2012.10.060; Wright BL, 2016, ALLERGY, V71, P1552, DOI 10.1111/all.12895	39	11	11	2	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2019	143	2					486	493		10.1016/j.jaci.2018.12.989	http://dx.doi.org/10.1016/j.jaci.2018.12.989			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HK2DJ	30586557	Green Accepted, Bronze			2022-12-18	WOS:000457718700004
J	Theoharides, TC; Leeman, SE				Theoharides, Theoharis C.; Leeman, Susan E.			Effect of IL-33 on de novo synthesized mediators from human mast cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SECRETION		[Theoharides, Theoharis C.] Tufts Univ, Sch Med, Dept Immunol, Lab Mol Immunopharmacol & Drug Discovery, Boston, MA 02111 USA; [Theoharides, Theoharis C.] Tufts Univ, Sch Med, Grad Program Pharmacol & Expt Therapeut, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA; [Theoharides, Theoharis C.] Tufts Univ, Sch Med, Dept Internal Med, Boston, MA 02111 USA; [Theoharides, Theoharis C.] Tufts Med Ctr, Boston, MA 02111 USA; [Leeman, Susan E.] Boston Univ, Sch Med, Dept Pharmacol, Boston, MA 02118 USA	Tufts University; Tufts University; Tufts University; Tufts Medical Center; Boston University	Theoharides, TC (corresponding author), Tufts Univ, Sch Med, Dept Immunol, Lab Mol Immunopharmacol & Drug Discovery, Boston, MA 02111 USA.; Theoharides, TC (corresponding author), Tufts Univ, Sch Med, Grad Program Pharmacol & Expt Therapeut, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA.; Theoharides, TC (corresponding author), Tufts Univ, Sch Med, Dept Internal Med, Boston, MA 02111 USA.; Theoharides, TC (corresponding author), Tufts Med Ctr, Boston, MA 02111 USA.	theoharis.theoharides@tufts.edu						Brockow K, 2005, CLIN IMMUNOL, V115, P216, DOI 10.1016/j.clim.2005.01.011; Kandere-Grzybowska K, 2003, J IMMUNOL, V171, P4830, DOI 10.4049/jimmunol.171.9.4830; Olivera A, 2018, J ALLERGY CLIN IMMUN, V142, P381, DOI 10.1016/j.jaci.2018.01.034; Petra AI, 2018, ALLERGY ASTHMA PROC, V39, P153, DOI 10.2500/aap.2018.38.4105; Taracanova A, 2018, P NATL ACAD SCI USA, V115, pE9381, DOI 10.1073/pnas.1810133115; Theoharides TC, 2002, INT ARCH ALLERGY IMM, V128, P344, DOI 10.1159/000063858; Theoharides TC, 2010, P NATL ACAD SCI USA, V107, P4448, DOI 10.1073/pnas.1000803107	7	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					451	451		10.1016/j.jaci.2018.09.014	http://dx.doi.org/10.1016/j.jaci.2018.09.014			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	30390921				2022-12-18	WOS:000454918300060
J	Biefer, HRC; Heinbokel, T; Uehara, H; Camacho, V; Minami, K; Nian, YQ; Koduru, S; El Fatimy, R; Ghiran, I; Trachtenberg, AJ; de la Fuente, MA; Azuma, H; Akbari, O; Tullius, SG; Vasudevan, A; Elkhal, A				Biefer, Hector Rodriguez Cetina; Heinbokel, Timm; Uehara, Hirofumi; Camacho, Virginia; Minami, Koichiro; Nian, Yeqi; Koduru, Suresh; El Fatimy, Rachid; Ghiran, Ionita; Trachtenberg, Alexander J.; de la Fuente, Miguel A.; Azuma, Haruhito; Akbari, Omid; Tullius, Stefan G.; Vasudevan, Anju; Elkhal, Abdallah			Mast cells regulate CD4(+) T-cell differentiation in the absence of antigen presentation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Nicotinamide adenine dinucleotide; mast cells; T cells; antigen presentation; MHC; T-cell receptor; CD4(+) T-cell differentiation; dendritic cells; macrophages; Listeria monocytogenes; cytokine	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; DYSTROPHY PROTEIN-KINASE; DENDRITIC CELLS; LYSOPHOSPHATIDIC ACID; CUTTING EDGE; RECEPTOR; ACTIVATION; IMMUNITY; NAD(+); MICE	Background: Given their unique capacity for antigen uptake, processing, and presentation, antigen-presenting cells (APCs) are critical for initiating and regulating innate and adaptive immune responses. We have previously shown the role of nicotinamide adenine dinucleotide (NAD(+)) in T-cell differentiation independently of the cytokine milieu, whereas the precise mechanisms remained unknown. Objective: The objective of this study is to further dissect the mechanism of actions of NAD(+) and determine the effect of APCs on NAD(+)-mediated T-cell activation. Methods: Isolated dendritic cells and bone marrow-derived mast cells (MCs) were used to characterize the mechanisms of action of NAD(+) on CD4(+) T-cell fate in vitro. Furthermore, NAD(+)-mediated CD4(+) T-cell differentiation was investigated in vivo by using wild-type C57BL/6, MC-/-, MHC class II-/-, Wiskott-Aldrich syndrome protein (WASP)(-/-), 5C.C7 recombination-activating gene 2 (Rag2)(-/-), and CD11b-DTR transgenic mice. Finally, we tested the physiologic effect of NAD(+) on the systemic immune response in the context of Listeria monocytogenes infection. Results: Our in vivo and in vitro findings indicate that after NAD(+) administration, MCs exclusively promote CD4(+) T-cell differentiation, both in the absence of antigen and independently of major APCs. Moreover, we found that MCs mediated CD4(+) T-cell differentiation independently of MHC II and T-cell receptor signaling machinery. More importantly, although treatment with NAD(+) resulted in decreased MHC II expression on CD11c(+) cells, MC-mediated CD4(+) T-cell differentiation rendered mice resistant to administration of lethal doses of L monocytogenes. Conclusions: Collectively, our study unravels a novel cellular and molecular pathway that regulates innate and adaptive immunity through MCs exclusively and underscores the therapeutic potential of NAD(+) in the context of primary immunodeficiencies and antimicrobial resistance.	[Biefer, Hector Rodriguez Cetina; Heinbokel, Timm; Minami, Koichiro; Nian, Yeqi; Tullius, Stefan G.; Elkhal, Abdallah] Harvard Med Sch, Brigham & Womens Hosp, Div Transplant Surg, Boston, MA USA; [Biefer, Hector Rodriguez Cetina; Heinbokel, Timm; Minami, Koichiro; Nian, Yeqi; Tullius, Stefan G.; Elkhal, Abdallah] Harvard Med Sch, Brigham & Womens Hosp, Transplantat Surg Res Lab, Boston, MA USA; [El Fatimy, Rachid] Harvard Med Sch, Brigham & Womens Hosp, Initiat RNA Med, Dept Neurol,Ctr Neurol Dis, Boston, MA USA; [Biefer, Hector Rodriguez Cetina] Univ Hosp Zurich, Clin Cardiovasc Surg, Zurich, Switzerland; [Heinbokel, Timm] Charite Univ Med Berlin, Dept Nephrol, Berlin, Germany; [Uehara, Hirofumi; Azuma, Haruhito] Osaka Med Coll, Dept Urol, Takatsuki, Osaka, Japan; [Camacho, Virginia] Harvard Stem Cell Inst, Beth Israel Deaconess Med Ctr, Flow Cytometry Core Facil, Boston, MA USA; [Koduru, Suresh] Harvard Stem Cell Inst, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA USA; [Ghiran, Ionita] Univ Hyderabad, Sch Med Sci, Hyderabad, Telangana, India; [Trachtenberg, Alexander J.] StART Families, Boston, MA USA; [de la Fuente, Miguel A.] Univ Valladolid, Inst Biol & Genet Mol, Valladolid, Spain; [Akbari, Omid] Univ Southern Calif, Keck Sch Med, Dept Mol Microbiol, Los Angeles, CA USA; [Vasudevan, Anju] Harvard Med Sch, McLean Hosp, Div Basic Neurosci, Angiogenesis & Brain Dev Lab, Belmont, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Zurich; University Zurich Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Osaka Medical College; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; University of Hyderabad; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de Valladolid; University of Southern California; Harvard University; McLean Hospital	Elkhal, A (corresponding author), Brigham & Womens Hosp, Dept Surg, Div Transplant Surg, 221 Longwood Ave, Boston, MA 02115 USA.	aelkhal@partners.org	Heinbokel, Timm/AAN-9676-2021; de la Fuente, Miguel A/C-7478-2013	de la Fuente, Miguel A/0000-0003-4619-8756; Heinbokel, Timm/0000-0002-3595-0562; EL FATIMY, Rachid/0000-0002-7652-5562; Rodriguez Cetina Biefer, Hector/0000-0002-5855-8993; VASUDEVAN, ANJU/0000-0001-9814-2389; Camacho, Virginia/0000-0002-6970-0932	National Institutes of Health [R01NS073635, R01MH110438, R01 HL096795, U01 HL126497, R01AG039449]; Swiss Society of Cardiac Surgery; FIS-ISCIII [PI10/02 511]; Fundacion Ramon Areces [CIVP16A1843]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL126497] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH110438] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG039449] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Swiss Society of Cardiac Surgery; FIS-ISCIII(Instituto de Salud Carlos III); Fundacion Ramon Areces; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported by National Institutes of Health grants R01NS073635 and R01MH110438 (to A.V.), R01 HL096795 and U01 HL126497 (to I.G.), and R01AG039449 (to S.G.T.). H.R.C.B. was supported by the Swiss Society of Cardiac Surgery. M.A.d.l.F was supported by FIS-ISCIII (grant PI10/02 511) and Fundacion Ramon Areces (CIVP16A1843).	Abraham SN, 2010, NAT REV IMMUNOL, V10, P440, DOI 10.1038/nri2782; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Anderson RM, 2002, J BIOL CHEM, V277, P18881, DOI 10.1074/jbc.M111773200; Andersson A, 1998, J IMMUNOL, V161, P5600; Atarashi K, 2008, NATURE, V455, P808, DOI 10.1038/nature07240; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bonkowski MS, 2016, NAT REV MOL CELL BIO, V17, P679, DOI 10.1038/nrm.2016.93; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Elkhal A, 2016, SCI REP-UK, V6, DOI 10.1038/srep22325; Exley M, 1991, Semin Immunol, V3, P283; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Goetzl EJ, 2000, J IMMUNOL, V164, P4996, DOI 10.4049/jimmunol.164.10.4996; Gomes AP, 2013, CELL, V155, P1624, DOI 10.1016/j.cell.2013.11.037; Gregory GD, 2005, EUR J IMMUNOL, V35, P3478, DOI 10.1002/eji.200535271; Hambleton S, 2011, NEW ENGL J MED, V365, P127, DOI 10.1056/NEJMoa1100066; HASKINS K, 1984, ANNU REV IMMUNOL, V2, P51, DOI 10.1146/annurev.iy.02.040184.000411; Hu JX, 2014, FEBS LETT, V588, P4348, DOI 10.1016/j.febslet.2014.10.012; Iwasaki A, 2015, NAT IMMUNOL, V16, P343, DOI 10.1038/ni.3123; Jung S, 2002, IMMUNITY, V17, P211, DOI 10.1016/S1074-7613(02)00365-5; Kaliman P, 2005, J BIOL CHEM, V280, P8016, DOI 10.1074/jbc.M412845200; Kambayashi T, 2014, NAT REV IMMUNOL, V14, P719, DOI 10.1038/nri3754; Knowlden S, 2014, J IMMUNOL, V192, P851, DOI 10.4049/jimmunol.1302831; Knowlden SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101655; Kotarsky K, 2006, J PHARMACOL EXP THER, V318, P619, DOI 10.1124/jpet.105.098848; Lam LT, 2000, HUM MOL GENET, V9, P2167, DOI 10.1093/hmg/9.14.2167; Lemos MP, 2004, J EXP MED, V199, P725, DOI 10.1084/jem.20030795; Lemos MP, 2003, J IMMUNOL, V171, P5077, DOI 10.4049/jimmunol.171.10.5077; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li HM, 2011, J IMMUNOL, V187, P274, DOI 10.4049/jimmunol.1003603; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Maurer M, 2006, FASEB J, V20, P2460, DOI 10.1096/fj.06-5860com; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Mills KHG, 2011, NAT REV IMMUNOL, V11, P807, DOI 10.1038/nri3095; Mori K, 2007, VIRCHOWS ARCH, V451, P47, DOI 10.1007/s00428-007-0425-4; Nomura F, 2000, J IMMUNOL, V164, P3476, DOI 10.4049/jimmunol.164.7.3476; Oberhuber R, 2015, CIRCULATION, V132, P122, DOI 10.1161/CIRCULATIONAHA.114.014917; Oda SK, 2013, CANCER IMMUNOL RES, V1, P245, DOI 10.1158/2326-6066.CIR-13-0043-T; Park GY, 2013, AM J RESP CRIT CARE, V188, P928, DOI 10.1164/rccm.201306-1014OC; Piconese S, 2011, LAB INVEST, V91, P627, DOI 10.1038/labinvest.2011.3; Poltorak A, 1998, BLOOD CELL MOL DIS, V24, P340, DOI 10.1006/bcmd.1998.0201; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Raposo G, 1997, MOL BIOL CELL, V8, P2631, DOI 10.1091/mbc.8.12.2631; Reese TA, 2007, NATURE, V447, P92, DOI 10.1038/nature05746; Roses RE, 2008, J IMMUNOL, V181, P5120, DOI 10.4049/jimmunol.181.7.5120; Sayed BA, 2008, ANNU REV IMMUNOL, V26, P705, DOI 10.1146/annurev.immunol.26.021607.090320; Sayed BA, 2011, J IMMUNOL, V186, P3294, DOI 10.4049/jimmunol.1003574; Schenk U, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001270; Snapper SB, 1998, IMMUNITY, V9, P81, DOI 10.1016/S1074-7613(00)80590-7; Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175; Tkaczyk C, 2000, J ALLERGY CLIN IMMUN, V105, P134, DOI 10.1016/S0091-6749(00)90188-X; Tullius SG, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6101; Urb M, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002619; Van Gool F, 2009, NAT MED, V15, P206, DOI 10.1038/nm.1906; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0; ZINKERNA.RM, 1974, NATURE, V251, P547, DOI 10.1038/251547a0; Zinkernagel RM, 1997, IMMUNOL TODAY, V18, P14, DOI 10.1016/S0167-5699(97)80008-4	58	11	11	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2018	142	6					1894	+		10.1016/j.jaci.2018.01.038	http://dx.doi.org/10.1016/j.jaci.2018.01.038			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD2BJ	29470999	Green Accepted, Green Published, hybrid			2022-12-18	WOS:000452315800023
J	Pulvirenti, F; Camilli, R; Giufre, M; Milito, C; de Araujo, FP; Mancini, F; Cardines, R; Ciervo, A; Pantosti, A; Cerquetti, M; Quinti, I				Pulvirenti, Federica; Camilli, Romina; Giufre, Maria; Milito, Cinzia; de Araujo, Fernanda Pimentel; Mancini, Fabiola; Cardines, Rita; Ciervo, Alessandra; Pantosti, Annalisa; Cerquetti, Marina; Quinti, Isabella			Risk factors for Haemophilus influenzae and pneumococcal respiratory tract colonization in CVID	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							IMMUNE-DEFICIENCY		[Pulvirenti, Federica; Milito, Cinzia; Quinti, Isabella] Sapienza Univ Rome, Dept Mol Med, Rome, Italy; [Camilli, Romina; Giufre, Maria; de Araujo, Fernanda Pimentel; Mancini, Fabiola; Cardines, Rita; Ciervo, Alessandra; Pantosti, Annalisa; Cerquetti, Marina] Ist Super Sanita, Dept Infect Dis, Rome, Italy	Sapienza University Rome; Istituto Superiore di Sanita (ISS)	Quinti, I (corresponding author), Sapienza Univ Rome, Dept Mol Med, Rome, Italy.	isabella.quinti@uniroma1.it	CIERVO, ALESSANDRA/C-8812-2016; CAMILLI, ROMINA/C-8811-2016; de Araujo, Fernanda Pimentel/AAB-2121-2019; Ciervo, Alessandra/AAA-8765-2021; Giufre, Maria/B-8725-2016; MANCINI, FABIOLA/C-8818-2016; Milito, Cinzia/AAP-7075-2020	CAMILLI, ROMINA/0000-0003-1309-5670; Ciervo, Alessandra/0000-0002-0664-9375; Giufre, Maria/0000-0002-6692-0120; MANCINI, FABIOLA/0000-0003-1377-178X; Quinti, Isabella/0000-0002-3328-7584; Pulvirenti, Federica/0000-0002-3466-9496; Pimentel de Araujo, Fernanda/0000-0002-9446-5807	Progetto Ateneo Sapienza	Progetto Ateneo Sapienza	This study was supported by Progetto Ateneo Sapienza, 2015.	BARRA A, 1993, VACCINE, V11, P1003, DOI 10.1016/0264-410X(93)90124-G; Bonilla FA, 2016, J ALLER CL IMM-PRACT, V4, P38, DOI 10.1016/j.jaip.2015.07.025; Cameron EJ, 2012, CLIN EXP ALLERGY, V42, P1302, DOI 10.1111/j.1365-2222.2012.03979.x; Choi J, 2015, VACCINE, V33, P1941, DOI 10.1016/j.vaccine.2015.02.060; Flasche S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001017; Kuruvilla M, 2013, J ALLER CL IMM-PRACT, V1, P573, DOI 10.1016/j.jaip.2013.09.013; Micol R, 2012, J ALLERGY CLIN IMMUN, V129, P770, DOI 10.1016/j.jaci.2011.09.047; Quinti I, 2016, J ALLER CL IMM-PRACT, V4, P1169, DOI 10.1016/j.jaip.2016.07.012; Quinti I, 2011, J CLIN IMMUNOL, V31, P315, DOI 10.1007/s10875-011-9511-0	9	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2018	142	6					1999	+		10.1016/j.jaci.2018.08.014	http://dx.doi.org/10.1016/j.jaci.2018.08.014			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD2BJ	30170126	hybrid			2022-12-18	WOS:000452315800041
J	Shim, SS; Schiebler, ML; Evans, MD; Jarjour, N; Sorkness, RL; Denlinger, LC; Rodriguez, A; Wenzel, S; Hoffman, EA; Lin, CL; Gierada, DS; Castro, M; Fain, SB				Shim, Sung Shine; Schiebler, Mark L.; Evans, Michael D.; Jarjour, Nizar; Sorkness, Ron L.; Denlinger, Loren C.; Rodriguez, Alfonso; Wenzel, Sally; Hoffman, Eric A.; Lin, Ching-Long; Gierada, David S.; Castro, Mario; Fain, Sean B.		Natl Heart Lung Blood Inst Severe	Lumen area change (Delta Lumen) between inspiratory and expiratory multidetector computed tomography as a measure of severe outcomes in asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Quantitative computed tomography; asthma; airway remodeling; severe asthma; air trapping	AIRWAY WALL THICKNESS; NEAR-FATAL ASTHMA; LUNG-FUNCTION; SMOOTH-MUSCLE; CT; OBSTRUCTION	Background: Quantitative computed tomographic (QCT) biomarkers of airway morphology hold potential for understanding and monitoring regional airway remodeling in asthmatic patients. Objective: We sought to determine whether the change in airway lumen area between total lung capacity (TLC) and functional residual capacity (FRC) lung volumes measured from CT imaging data was correlated with severe outcomes in asthmatic patients. Methods: We studied 152 asthmatic patients (90 female and 62 male patients) and 33 healthy subjects (12 female and 21 male subjects) using QCT. Postprocessing of airways at generations 1 to 5 (1 5 trachea) was performed for wall area percentage, wall thickness percentage (WT%), lumen area at baseline total lung capacity (LA(TLC)), lumen area at baseline functional residual capacity (LA(FRC)), and low attenuation area at FRC. A new metric (reflecting remodeling, distal air trapping, or both), Delta Lumen, was determined as follows: Percentage difference in lumen area (LA(TLC) - LA(FRC))/LA(TLC) x 100. Results: Postprocessing of 4501 airway segments was performed (3681 segments in the 152 patients with asthma and 820 segments in the 33 healthy subjects; range, 17-28 segments per subject). Delta Lumen values were negatively correlated with WT% and low attenuation area (P < .01) in asthmatic patients. Delta Lumen values were significantly lower for airway generations 3 to 5 (segmental airways) in subjects undergoing hospitalization because of exacerbation and in patients with refractory asthma requiring treatment with systemic corticosteroids. WT% and low attenuation area were positively and Delta Lumen values were negatively associated with systemic corticosteroid treatment (P < .05), suggesting that a reduced Delta Lumen value is a potential outcome biomarker in patients with severe asthma. Conclusion: Reduced Delta Lumen value in the central airways measured by using QCT is a promising exploratory biomarker of unstable refractory asthma that warrants further study.	[Shim, Sung Shine] Ewha Womans Univ, Sch Med, Mokdong Hosp, Dept Radiol, Seoul, South Korea; [Schiebler, Mark L.; Fain, Sean B.] Univ Wisconsin, Dept Radiol, Madison, WI 53706 USA; [Evans, Michael D.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA; [Jarjour, Nizar; Denlinger, Loren C.] Univ Wisconsin, Dept Med, Madison, WI USA; [Sorkness, Ron L.] Univ Wisconsin, Sch Pharm, 425 N Charter St, Madison, WI 53706 USA; [Rodriguez, Alfonso; Fain, Sean B.] Univ Wisconsin, Dept Med Phys, 1530 Med Sci Ctr, Madison, WI 53706 USA; [Wenzel, Sally] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA; [Hoffman, Eric A.; Lin, Ching-Long] Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA; [Hoffman, Eric A.; Lin, Ching-Long] Univ Iowa, Dept Biomed Engn, Iowa City, IA 52242 USA; [Hoffman, Eric A.; Lin, Ching-Long] Univ Iowa, Dept Mech & Ind Engn, Iowa City, IA USA; [Hoffman, Eric A.; Lin, Ching-Long] Univ Iowa, Dept Med, Iowa City, IA 52242 USA; [Castro, Mario] Washington Univ, Dept Med, St Louis, MO USA; [Gierada, David S.; Castro, Mario] Washington Univ, Dept Radiol, St Louis, MO USA	Ewha Womans University; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Iowa; University of Iowa; University of Iowa; University of Iowa; Washington University (WUSTL); Washington University (WUSTL)	Fain, SB (corresponding author), 1111 Highland Ave,Rm 1005, Madison, WI 53705 USA.	sfain@wisc.edu	Schiebler, Mark/V-5201-2019; Fain, Sean/K-4260-2016	Hoffman, Eric/0000-0001-8456-9437; Wenzel, Sally/0000-0002-4242-0164; Evans, Michael/0000-0001-7449-3993; Fain, Sean/0000-0001-5461-0646	National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) [R01 HL069116, U10 HL109168]; NIH [U01 HL114494, UL1TR000427]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000427, UL1TR002373] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080412, UG1HL139118, R01HL126771, U10HL109168, R01HL064066, U01HL114494] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK054759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES005605] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [S10OD016394] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) grants R01 HL069116 and U10 HL109168 and NIH grants U01 HL114494 and UL1TR000427.	Awadh N, 1998, THORAX, V53, P248, DOI 10.1136/thx.53.4.248; Aysola RS, 2008, CHEST, V134, P1183, DOI 10.1378/chest.07-2779; Brackel HJL, 2000, AM J RESP CRIT CARE, V162, P896, DOI 10.1164/ajrccm.162.3.9905034; Brown RH, 2001, AM J RESP CRIT CARE, V163, P994, DOI 10.1164/ajrccm.163.4.2007119; Bumbacea D, 2004, EUR RESPIR J, V24, P122, DOI 10.1183/09031936.04.00077803; BURNS CB, 1985, J APPL PHYSIOL, V59, P1590, DOI 10.1152/jappl.1985.59.5.1590; Busacker A, 2009, CHEST, V135, P48, DOI 10.1378/chest.08-0049; Castro M, 2011, J ALLERGY CLIN IMMUN, V128, P467, DOI 10.1016/j.jaci.2011.04.051; Chae EJ, 2011, ALLERGY ASTHMA IMMUN, V3, P111, DOI 10.4168/aair.2011.3.2.111; Choi S, 2015, J APPL PHYSIOL, V118, P1286, DOI 10.1152/japplphysiol.01094.2014; Choi S, 2013, J APPL PHYSIOL, V115, P730, DOI 10.1152/japplphysiol.00113.2013; DeBoer EM, 2017, J ALLERGY CLIN IMMUN, V139, P21, DOI 10.1016/j.jaci.2016.11.004; Gono H, 2003, EUR RESPIR J, V22, P965, DOI 10.1183/09031936.03.00085302; Gupta S, 2010, THORAX, V65, P775, DOI 10.1136/thx.2010.136374; Hardy CL, 2013, THORAX, V68, P9, DOI 10.1136/thoraxjnl-2011-201128; James AL, 2007, EUR RESPIR J, V30, P134, DOI 10.1183/09031936.00146905; Jarjour NN, 2012, AM J RESP CRIT CARE, V185, P356, DOI 10.1164/rccm.201107-1317PP; Kasahara K, 2002, THORAX, V57, P242, DOI 10.1136/thorax.57.3.242; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771, DOI 10.1152/jappl.1993.74.6.2771; Lee YM, 2004, CHEST, V126, P1840, DOI 10.1378/chest.126.6.1840; Little SA, 2002, THORAX, V57, P247, DOI 10.1136/thorax.57.3.247; Murgu SD, 2006, RESPIROLOGY, V11, P388, DOI 10.1111/j.1440-1843.2006.00862.x; Niimi A, 2000, AM J RESP CRIT CARE, V162, P1518, DOI 10.1164/ajrccm.162.4.9909044; Okazawa M, 2000, J APPL PHYSIOL, V89, P2373, DOI 10.1152/jappl.2000.89.6.2373; Okazawa M, 1996, AM J RESP CRIT CARE, V154, P1557, DOI 10.1164/ajrccm.154.5.8912780; Paganin F, 1996, AM J RESP CRIT CARE, V153, P110, DOI 10.1164/ajrccm.153.1.8542102; Papandrinopoulou D, 2012, PULM MED, V2012, DOI 10.1155/2012/542769; Rodriguez A, 2017, MED PHYS, V44, P2267, DOI 10.1002/mp.12255; Rodriguez V, 2014, MED PHYS, V41, P327, DOI 10.1118/1.4898098; Saetta M, 2001, EUR RESPIR J, V18, p18S, DOI 10.1183/09031936.01.00229501; San Jose Estepar Raul, 2008, Proc Am Thorac Soc, V5, P905, DOI 10.1513/pats.200809-104QC; Shifren Adrian, 2012, J Allergy (Cairo), V2012, P316049, DOI 10.1155/2012/316049; Sieren JP, 2014, MED PHYS, V41, DOI 10.1118/1.4893498; Sorkness RL, 2008, J APPL PHYSIOL, V104, P394, DOI 10.1152/japplphysiol.00329.2007; WANG YT, 1990, J APPL PHYSIOL, V68, P363, DOI 10.1152/jappl.1990.68.1.363; Williamson JP, 2011, AM J RESP CRIT CARE, V183, P612, DOI 10.1164/rccm.201002-0178OC; Woodruff PG, 2004, AM J RESP CRIT CARE, V169, P1001, DOI 10.1164/rccm.200311-1529OC; Yamashiro T, 2011, ACAD RADIOL, V18, P299, DOI 10.1016/j.acra.2010.11.005	38	11	11	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2018	142	6					1773	+		10.1016/j.jaci.2017.12.1004	http://dx.doi.org/10.1016/j.jaci.2017.12.1004			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD2BJ	29438772	Bronze, Green Accepted			2022-12-18	WOS:000452315800013
J	Huang, Y; Chen, ZY; Jang, JH; Baig, MS; Bertolet, G; Schroeder, C; Huang, SJ; Hu, Q; Zhao, Y; Lewis, DE; Qin, LD; Zhu, MX; Liu, DF				Huang, Yu; Chen, Zhiying; Jang, Joon Hee; Baig, Mirza S.; Bertolet, Grant; Schroeder, Casey; Huang, Shengjian; Hu, Qian; Zhao, Yong; Lewis, Dorothy E.; Qin, Lidong; Zhu, Michael Xi; Liu, Dongfang			PD-1 blocks lytic granule polarization with concomitant impairment of integrin outside-in signaling in the natural killer cell immunological synapse	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Natural killer cell; programmed cell death protein 1; lytic granule; leukocyte function-associated antigen 1; immunological synapse	PROGRAMMED DEATH 1; INHIBITORY RECEPTORS; IMMUNE SYNAPSES; NK CELLS; T-CELLS; CYTOTOXICITY; PATHWAY; EXPRESSION; TOLERANCE; RESPONSES	Background: The inhibitory receptor programmed cell death protein 1 (PD-1) is upregulated on a variety of immune cells, including natural killer (NK) cells, during chronic viral infection and tumorigenesis. Blockade of PD-1 or its ligands produces durable clinical responses with tolerable side effects in patients with a broad spectrum of cancers. However, the underlying molecular mechanisms of how PD-1 regulates NK cell function remain poorly characterized. Objective: We sought to determine the effect of PD-1 signaling on NK cells. Methods: PD-1 was overexpressed in CD16-KHYG-1 (a human NK cell line with both antibody-dependent cellular cytotoxicity through CD16 and natural cytotoxicity through NKG2D) cells and stimulated by exposing the cells to NK-sensitive target cells expressing programmed death ligand 1 (PD-L1). Results: PD-1 engagement by PD-L1 specifically blocked NK cell-mediated cytotox`icity without interfering with the conjugation between NK cells and target cells. Further examination showed that PD-1 signaling blocked lytic granule polarization in NK cells, which was accompanied by failure of integrin-linked kinase, a key molecule in the integrin outside-in signaling pathway, to accumulate in the immunological synapse after NK-target cell conjugation. Conclusion: Our results suggest that NK cell cytotoxicity is inhibited by PD-1 engagement, which blocks lytic granule polarization to the NK cell immunological synapse with concomitant impairment of integrin outside-in signaling. This study provides novel mechanistic insights into how PD-1 inhibition disrupts NK cell function.	[Huang, Yu; Zhu, Michael Xi] Univ Texas Hlth Sci Ctr Houston, Grad Program Cell & Regulatory Biol, McGovern Med Sch, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; [Huang, Yu; Chen, Zhiying; Jang, Joon Hee; Bertolet, Grant; Schroeder, Casey; Hu, Qian; Liu, Dongfang] Houston Methodist Res Inst, Ctr Inflammat & Epigenet, 6670 Bertner Ave, Houston, TX 77030 USA; [Jang, Joon Hee; Qin, Lidong] Houston Methodist Res Inst, Dept Nanomed, Houston, TX USA; [Chen, Zhiying] Cent S Univ, Xiangya Sch Med, Xiangya Hosp, Changsha, Hunan, Peoples R China; [Baig, Mirza S.] IIT, Ctr Biosci & Biomed Engn BSBE, Indore, Madhya Pradesh, India; [Bertolet, Grant] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Huang, Shengjian] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA; [Hu, Qian; Zhao, Yong] Sun Yat Sen Univ, Key Lab Gene Engn, Cooperat Innovat Ctr High Performance Comp, Minist Educ,Sch Life Sci, Guangzhou, Guangdong, Peoples R China; [Lewis, Dorothy E.] Univ Texas Hlth Sci Ctr Houston, Dept Internal Med, Houston, TX 77030 USA; [Liu, Dongfang] Cornell Univ, Weill Cornell Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	University of Texas System; University of Texas Health Science Center Houston; The Methodist Hospital System; The Methodist Hospital - Houston; The Methodist Hospital System; The Methodist Hospital - Houston; Central South University; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Indore; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; Sun Yat Sen University; University of Texas System; University of Texas Health Science Center Houston; Cornell University	Zhu, MX (corresponding author), Univ Texas Hlth Sci Ctr Houston, Grad Program Cell & Regulatory Biol, McGovern Med Sch, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA.; Liu, DF (corresponding author), Houston Methodist Res Inst, Ctr Inflammat & Epigenet, 6670 Bertner Ave, Houston, TX 77030 USA.	Michael.X.Zhu@uth.tmc.edu; dliu2@houstonmethodist.org	Baig, Mirza S./S-8447-2019; HUANG, YU/U-2835-2019	Liu, Dongfang/0000-0002-7295-8088; HUANG, YU/0000-0002-6982-8485	Houston Methodist Career Cornerstone Award; Lymphoma SPORE Developmental Research Program [P50 CA126752]; Houston Methodist Research Institute for Academic Medicine NIH Competitiveness Initiative Award; Baylor-UT Houston Center for AIDS Research Core Support grant from the National Institute of Allergy and Infectious Diseases [AI036211];  [HL125018];  [AI124769];  [AI129594];  [AI130197];  [R01 NS102452]; NATIONAL CANCER INSTITUTE [P50CA126752] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL125018] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI124769, R21AI129594, R56AI130197, R01AI130197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS102452] Funding Source: NIH RePORTER	Houston Methodist Career Cornerstone Award; Lymphoma SPORE Developmental Research Program; Houston Methodist Research Institute for Academic Medicine NIH Competitiveness Initiative Award; Baylor-UT Houston Center for AIDS Research Core Support grant from the National Institute of Allergy and Infectious Diseases; ; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Supported in part by grants HL125018, AI124769, AI129594, and AI130197 (to D.L.); R01 NS102452 (to M.X.Z.); the Houston Methodist Career Cornerstone Award; the Lymphoma SPORE Developmental Research Program (P50 CA126752); Houston Methodist Research Institute for Academic Medicine NIH Competitiveness Initiative Award; and Baylor-UT Houston Center for AIDS Research Core Support grant number AI036211 from the National Institute of Allergy and Infectious Diseases.	Abeyweera TP, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00410; Alpert MD, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002890; Alpert MD, 2012, J VIROL, V86, P12039, DOI 10.1128/JVI.01650-12; Alvarez IB, 2010, J INFECT DIS, V202, P524, DOI 10.1086/654932; Anikeeva N, 2005, P NATL ACAD SCI USA, V102, P6437, DOI 10.1073/pnas.0502467102; Azoulay-Alfaguter I, 2015, J ALLERGY CLIN IMMUN, V135, P564, DOI 10.1016/j.jaci.2014.07.055; Barber DF, 2004, J IMMUNOL, V173, P3653, DOI 10.4049/jimmunol.173.6.3653; Beldi-Ferchiou A, 2016, ONCOTARGET, V7, P72961, DOI 10.18632/oncotarget.12150; Benson DM, 2010, BLOOD, V116, P2286, DOI 10.1182/blood-2010-02-271874; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Bryceson YT, 2008, CURR OPIN IMMUNOL, V20, P344, DOI 10.1016/j.coi.2008.03.005; Bryceson YT, 2005, J EXP MED, V202, P1001, DOI 10.1084/jem.20051143; Das A, 2010, J IMMUNOL, V185, P4698, DOI 10.4049/jimmunol.1001220; Dieckmann NMG, 2016, J CELL SCI, V129, P2881, DOI 10.1242/jcs.186205; Dustin ML, 2012, ANNU REV BIOPHYS, V41, P543, DOI 10.1146/annurev-biophys-042910-155238; Eissmann P, 2010, CURR TOP MICROBIOL, V340, P63, DOI 10.1007/978-3-642-03858-7_4; Fife BT, 2009, NAT IMMUNOL, V10, P1185, DOI 10.1038/ni.1790; Francisco LM, 2009, J EXP MED, V206, P3015, DOI 10.1084/jem.20090847; Fuller MJ, 2013, P NATL ACAD SCI USA, V110, P15001, DOI 10.1073/pnas.1312772110; Grier JT, 2012, J CLIN INVEST, V122, P3769, DOI 10.1172/JCI64837; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; Jang JH, 2015, J IMMUNOL, V195, P1320, DOI 10.4049/jimmunol.1403143; Kamphorst AO, 2013, CURR OPIN IMMUNOL, V25, P381, DOI 10.1016/j.coi.2013.03.003; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Kinashi T, 2011, METHODS MOL BIOL, V757, P261, DOI 10.1007/978-1-61779-166-6_17; Kuchroo VK, 2014, CURR OPIN HIV AIDS, V9, P439, DOI 10.1097/COH.0000000000000088; Liu DF, 2012, IMMUNITY, V36, P600, DOI 10.1016/j.immuni.2012.03.007; Liu DF, 2009, IMMUNITY, V31, P99, DOI 10.1016/j.immuni.2009.05.009; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; Long EO, 2013, ANNU REV IMMUNOL, V31, P227, DOI 10.1146/annurev-immunol-020711-075005; Ma WJ, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0277-y; Mace EM, 2014, IMMUNOL CELL BIOL, V92, P245, DOI 10.1038/icb.2013.96; March ME, 2011, J IMMUNOL, V186, P2998, DOI 10.4049/jimmunol.1002438; Norris S, 2012, VIRAL IMMUNOL, V25, P329, DOI 10.1089/vim.2011.0096; Orange JS, 2008, NAT REV IMMUNOL, V8, P713, DOI 10.1038/nri2381; Patsoukis N, 2012, CELL CYCLE, V11, P4305, DOI 10.4161/cc.22135; Pedoeem A, 2014, CLIN IMMUNOL, V153, P145, DOI 10.1016/j.clim.2014.04.010; Pentcheva-Hoang T, 2007, P NATL ACAD SCI USA, V104, P17765, DOI 10.1073/pnas.0708767104; Pesce S, 2017, J ALLERGY CLIN IMMUN, V139, P335, DOI 10.1016/j.jaci.2016.04.025; Riley JL, 2009, IMMUNOL REV, V229, P114, DOI 10.1111/j.1600-065X.2009.00767.x; Santarpia M, 2015, CANCER BIOL MED, V12, P74, DOI 10.7497/j.issn.2095-3941.2015.0022; Saunders PA, 2005, EUR J IMMUNOL, V35, P3561, DOI 10.1002/eji.200526347; Schleinitz N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003278; Song H, 2006, CELL IMMUNOL, V239, P22, DOI 10.1016/j.cellimm.2006.03.002; Springer TA, 2012, CURR OPIN CELL BIOL, V24, P107, DOI 10.1016/j.ceb.2011.10.004; Urdahl KB, 2011, MUCOSAL IMMUNOL, V4, P288, DOI 10.1038/mi.2011.10; Wei F, 2013, P NATL ACAD SCI USA, V110, pE2480, DOI 10.1073/pnas.1305394110; Wiesmayr S, 2012, EUR J IMMUNOL, V42, P541, DOI 10.1002/eji.201141832; Yokosuka T, 2012, J EXP MED, V209, P1201, DOI 10.1084/jem.20112741; Zhang MG, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005629; Zhang YH, 2015, AM J REPROD IMMUNOL, V74, P201, DOI 10.1111/aji.12365; Zinselmeyer BH, 2013, J EXP MED, V210, P757, DOI 10.1084/jem.20121416; Zou WP, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7118	53	11	12	3	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2018	142	4					1311	+		10.1016/j.jaci.2018.02.050	http://dx.doi.org/10.1016/j.jaci.2018.02.050			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GV7RG	29679656	Bronze, Green Accepted			2022-12-18	WOS:000446327300028
J	Nakao, A				Nakao, Atsuhito			Clockwork allergy: How the circadian clock underpins allergic reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Circadian clock; period2; allergy; mast cell; chronotherapy	MAST-CELL CLOCK; ATOPIC-DERMATITIS; EATING PATTERNS; MOLECULAR CLOCK; SLEEP; ASTHMA; GLUCOCORTICOIDS; MELATONIN; SYMPTOMS; IMMUNITY	Allergic disease is characterized by marked day-night changes in the clinical symptoms and laboratory parameters of allergy. Recent reports suggest that the circadian clock, which drives a biological rhythm with a periodicity of approximately 24 hours in behavior and physiology, underpins a time of day-dependent variation in allergic reactions. New studies also suggest that disruption of clock activity not only influences temporal variation but can also enhance the severity of allergic reactions and even increase susceptibility to allergic disease. These findings suggest that the circadian clock is a potent regulator of allergic reactions that plays more than a simple circadian timekeeping role in allergy. A better understanding of these processes will provide new insight into previously unknown aspects of the biology of allergies and can lead to the application of clock modifiers to treat allergic disease. Finally, this area of research provides a novel opportunity to consider how modern lifestyles in the developed world are changing the clinical manifestations of allergy as our society quickly transforms into a circadian rhythm-disrupted society in which sleeping, working, and eating habits are out of sync with endogenous circadian rhythmicity. Such findings might reveal lifestyle interventions that enable us to better control allergic disease.	[Nakao, Atsuhito] Univ Yamanashi, Fac Med, Dept Immunol, Tokyo, Japan; [Nakao, Atsuhito] Juntendo Univ, Sch Med, Atopy Res Ctr, Tokyo, Japan	University of Yamanashi; Juntendo University	Nakao, A (corresponding author), Univ Yamanashi, Fac Med, Dept Immunol, 1110 Shimokato, Chuo, Yamanashi 4093898, Japan.	anakao@yamanashi.ac.jp			JSPS KAKEN grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan [18H02848]	JSPS KAKEN grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan	Supported in part by a JSPS KAKEN grant (no. 18H02848) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Albrecht U, 2012, NEURON, V74, P246, DOI 10.1016/j.neuron.2012.04.006; Ando N, 2015, ALLERGY, V70, P319, DOI 10.1111/all.12552; Archer SN, 2015, J SLEEP RES, V24, P476, DOI 10.1111/jsr.12307; Arjona A, 2012, TRENDS IMMUNOL, V33, P607, DOI 10.1016/j.it.2012.08.007; Askari VR, 2016, ALLERGOL IMMUNOPATH, V44, P359, DOI 10.1016/j.aller.2015.10.002; Blum ID, 2018, TRENDS GENET, V34, P379, DOI 10.1016/j.tig.2018.01.001; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Bunger MK, 2000, CELL, V103, P1009, DOI 10.1016/S0092-8674(00)00205-1; Burioka N, 2007, J PHARMACOL SCI, V103, P144, DOI 10.1254/jphs.FMJ06003X4; Cedernaes J, 2015, J CLIN ENDOCR METAB, V100, pE1255, DOI [10.1210/JC.2015-2284, 10.1210/jc.2015-2284]; Cermakian N, 2013, CHRONOBIOL INT, V30, P870, DOI 10.3109/07420528.2013.782315; Chang YS, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040462; Chang YS, 2016, JAMA PEDIATR, V170, P35, DOI 10.1001/jamapediatrics.2015.3092; Chang YS, 2014, PEDIATRICS, V134, pE397, DOI 10.1542/peds.2014-0376; Chen Z, 2018, ANNU REV PHARMACOL, V58, P231, DOI 10.1146/annurev-pharmtox-010617-052645; Cuesta M, 2015, FASEB J, V29, P1360, DOI 10.1096/fj.14-265686; Curie T, 2015, SLEEP, V38, P1381, DOI 10.5665/sleep.4974; Curtis AM, 2014, IMMUNITY, V40, P178, DOI 10.1016/j.immuni.2014.02.002; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; Dibner C, 2010, ANNU REV PHYSIOL, V72, P517, DOI 10.1146/annurev-physiol-021909-135821; Druzd D, 2017, IMMUNITY, V46, P120, DOI 10.1016/j.immuni.2016.12.011; Durrington HJ, 2014, THORAX, V69, P90, DOI 10.1136/thoraxjnl-2013-203482; Ehlers A, 2018, MUCOSAL IMMUNOL, V11, P97, DOI 10.1038/mi.2017.24; Fishbein AB, 2015, J ALLERGY CLIN IMMUN, V136, P1170, DOI 10.1016/j.jaci.2015.08.028; Gaber T, 2017, NAT REV RHEUMATOL, V13, P267, DOI 10.1038/nrrheum.2017.37; Gibbs J, 2014, NAT MED, V20, P919, DOI 10.1038/nm.3599; Gibbs JE, 2012, P NATL ACAD SCI USA, V109, P582, DOI 10.1073/pnas.1106750109; Gill S, 2015, CELL METAB, V22, P789, DOI 10.1016/j.cmet.2015.09.005; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Haspel JA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5753; Hayasaka N, 2007, ENDOCRINOLOGY, V148, P3316, DOI 10.1210/en.2007-0010; Honma A, 2015, ENDOCRINOLOGY, V156, P4302, DOI 10.1210/en.2015-1490; Johnston JD, 2015, J ENDOCRINOL, V226, pT187, DOI 10.1530/JOE-15-0119; Kawauchi T, 2017, ALLERGOL INT, V66, P472, DOI 10.1016/j.alit.2017.02.004; Keller M, 2009, P NATL ACAD SCI USA, V106, P21407, DOI 10.1073/pnas.0906361106; Kim TH, 2009, J PINEAL RES, V47, P324, DOI 10.1111/j.1600-079X.2009.00718.x; Kim YS, 2015, EUR J NEUROSCI, V42, P2467, DOI 10.1111/ejn.13030; Lamia KA, 2011, NATURE, V480, P552, DOI 10.1038/nature10700; Laposky A, 2005, SLEEP, V28, P395, DOI 10.1093/sleep/28.4.395; Leaker BR, 2017, MUCOSAL IMMUNOL, V10, P408, DOI 10.1038/mi.2016.74; Lind C, 2018, J ALLERGY CLIN IMMUN, V141, P1906, DOI 10.1016/j.jaci.2017.10.048; Man K, 2016, SCIENCE, V354, P999, DOI 10.1126/science.aah4966; Matsunaga N, 2014, J INVEST DERMATOL, V134, P1636, DOI 10.1038/jid.2014.13; Meng QJ, 2010, P NATL ACAD SCI USA, V107, P15240, DOI 10.1073/pnas.1005101107; Mohawk JA, 2012, ANNU REV NEUROSCI, V35, P445, DOI 10.1146/annurev-neuro-060909-153128; Mongrain V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026622; Nakamura Y, 2017, SCI REP-UK, V7, DOI 10.1038/srep39934; Nakamura Y, 2016, J ALLERGY CLIN IMMUN, V137, P1226, DOI 10.1016/j.jaci.2015.08.052; Nakamura Y, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/474217; Nakamura Y, 2014, J ALLERGY CLIN IMMUN, V133, P568, DOI 10.1016/j.jaci.2013.07.040; Nakamura Y, 2011, J ALLERGY CLIN IMMUN, V127, P1038, DOI 10.1016/j.jaci.2011.02.006; Nakao A, 2015, ALLERGY, V70, P467, DOI 10.1111/all.12596; Nussbaum JC, 2013, NATURE, V502, P245, DOI 10.1038/nature12526; Oh-oka K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098016; Ohmori K, 2014, J VET MED SCI, V76, P1501, DOI 10.1292/jvms.14-0173; Paganelli Roberto, 2018, Clin Mol Allergy, V16, P1, DOI 10.1186/s12948-018-0080-0; Paschos GK, 2017, TRENDS GENET, V33, P760, DOI 10.1016/j.tig.2017.07.010; Pavlov VA, 2017, NAT NEUROSCI, V20, P156, DOI 10.1038/nn.4477; Pezuk P, 2012, ENDOCRINOLOGY, V153, P4775, DOI 10.1210/en.2012-1486; Pongratz G, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075-014-0504-2; Scheiermann C, 2018, NAT REV IMMUNOL, V18, P423, DOI 10.1038/s41577-018-0008-4; SELYE H, 1951, AM J MED, V10, P549, DOI 10.1016/0002-9343(51)90327-0; Smolensky MH, 2007, ADV DRUG DELIVER REV, V59, P852, DOI 10.1016/j.addr.2007.08.016; So AYL, 2009, P NATL ACAD SCI USA, V106, P17582, DOI 10.1073/pnas.0909733106; Son GH, 2018, J ENDOCR SOC, V2, P444, DOI 10.1210/js.2018-00021; Stokkan KA, 2001, SCIENCE, V291, P490, DOI 10.1126/science.291.5503.490; Storms WW, 2004, J ALLERGY CLIN IMMUN, V114, pS146, DOI 10.1016/j.jaci.2004.08.045; Sulli G, 2018, NATURE, V553, P351, DOI 10.1038/nature25170; Sundar IK, 2015, AM J PHYSIOL-LUNG C, V309, pL1056, DOI 10.1152/ajplung.00152.2015; Suzuki K, 2016, J EXP MED, V213, P2567, DOI 10.1084/jem.20160723; Tahara Y, 2017, NPJ AGING MECH DIS, V3, DOI 10.1038/npjamd.2016.30; Tahara Y, 2017, J PHYSIOL SCI, V67, P1, DOI 10.1007/s12576-016-0450-7; Takahashi JS, 2017, NAT REV GENET, V18, P164, DOI 10.1038/nrg.2016.150; Tanabe K, 2015, SCI REP-UK, V5, DOI 10.1038/srep14424; Toh KL, 2001, SCIENCE, V291, P1040, DOI 10.1126/science.1057499; Turek FW, 2016, SCIENCE, V354, P992, DOI 10.1126/science.aal2613; Undem BJ, 2014, J ALLERGY CLIN IMMUN, V133, P1521, DOI 10.1016/j.jaci.2013.11.027; Wang GZ, 2015, CELL REP, V13, P1868, DOI 10.1016/j.celrep.2015.10.043; Weidemann BJ, 2018, GENE DEV, V32, P321, DOI 10.1101/gad.314187.118; West AC, 2015, BIOESSAYS, V37, P777, DOI 10.1002/bies.201400173; Yang G, 2017, J ALLERGY CLIN IMMUN, V138; Zarrinpar A, 2016, TRENDS ENDOCRIN MET, V27, P69, DOI 10.1016/j.tem.2015.11.007; Zaslona Z, 2017, AM J PHYSIOL-LUNG C, V312, pL855, DOI 10.1152/ajplung.00072.2017	83	11	12	1	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2018	142	4					1021	1031		10.1016/j.jaci.2018.08.007	http://dx.doi.org/10.1016/j.jaci.2018.08.007			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GV7RG	30293559	Bronze			2022-12-18	WOS:000446327300001
J	Capo, V; Castiello, MC; Fontana, E; Penna, S; Bosticardo, M; Draghici, E; Poliani, LP; Sergi, LS; Rigoni, R; Cassani, B; Zanussi, M; Carrera, P; Uva, P; Dobbs, K; Sacchetti, N; Notarangelo, LD; van Til, NP; Wagemaker, G; Villa, A				Capo, Valentina; Castiello, Maria Carmina; Fontana, Elena; Penna, Sara; Bosticardo, Marita; Draghici, Elena; Poliani, Luigi P.; Sergi, Lucia Sergi; Rigoni, Rosita; Cassani, Barbara; Zanussi, Monica; Carrera, Paola; Uva, Paolo; Dobbs, Kerry; Sacchetti, Nicole; Notarangelo, Luigi D.; van Til, Niek P.; Wagemaker, Gerard; Villa, Anna			Efficacy of lentivirus-mediated gene therapy in an Omenn syndrome recombination-activating gene 2 mouse model is not hindered by inflammation and immune dysregulation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Gene therapy; Omenn syndrome; auto immunity; lentiviral vector; Rag genes	SEVERE COMBINED IMMUNODEFICIENCY; STEM-CELL TRANSPLANTATION; COMMON VARIABLE IMMUNODEFICIENCY; IMMUNOGLOBULIN-SECRETING CELLS; RAG1 DEFICIENCY; BONE-MARROW; B-CELLS; AUTOIMMUNE; MUTATIONS; TOLERANCE	Background: Omenn syndrome (OS) is a rare severe combined immunodeficiency associated with autoimmunity and caused by defects in lymphoid-specific V(D)J recombination. Most patients carry hypomorphic mutations in recombination-activating gene (RAG) 1 or 2. Hematopoietic stem cell transplantation is the standard treatment; however, gene therapy (GT) might represent a valid alternative, especially for patients lacking a matched donor. Objective: We sought to determine the efficacy of lentiviral vector (LV) mediated GT in the murine model of OS (Rag2(R229Q/R229Q)), in correcting immunodeficiency and autoimmunity. Methods: Lineage-negative cells from mice with OS were transduced with an LV encoding the human RAG2 gene and injected into irradiated recipients with OS. Control mice underwent transplantation with wild-type or OS-untransduced lineage-negative cells. Immunophenotyping, T-dependent and T-independent antigen challenge, immune spectratyping, autoantibody detection, and detailed tissue immunohistochemical analyses were performed. Results: LV-mediated GT allowed immunologic reconstitution, although it was suboptimal compared with that seen in wild-type bone marrow (BM) transplanted OS mice in peripheral blood and hematopoietic organs, such as the BM, thymus, and spleen. We observed in vivo variability in the efficacy of GT correlating with the levels of transduction achieved. Immunoglobulin levels and T-cell repertoire normalized, and gene-corrected mice responded properly to challenges in vivo. Autoimmune manifestations, such as skin infiltration and autoantibodies, dramatically improved in GT mice with a vector copy number/ genome higher than 1 in the BM and 2 in the thymus. Conclusions: Our data show that LV-mediated GT for patients with OS significantly ameliorates the immunodeficiency, even in an inflammatory environment.	[Capo, Valentina; Castiello, Maria Carmina; Penna, Sara; Bosticardo, Marita; Draghici, Elena; Sergi, Lucia Sergi; Sacchetti, Nicole; Villa, Anna] Ist Sci San Raffaele, Div Regenerat Med Stem Cells & Gene Therapy, San Raffaele Telethon Inst Gene Therapy SR TIGET, Via Olgettina 60, I-20132 Milan, Italy; [Zanussi, Monica; Carrera, Paola] Ist Sci San Raffaele, Genom Diag Human Pathol, Milan, Italy; [Fontana, Elena; Rigoni, Rosita; Cassani, Barbara] Humanitas Clin & Res Ctr, Milan, Italy; [Poliani, Luigi P.] Univ Hosp Spedali Civili, Inst Mol Med A Nocivelli, Brescia, Italy; [Fontana, Elena; Rigoni, Rosita; Cassani, Barbara; Villa, Anna] CNR, Milan Unit, Ist Ric Genet & Biomed, Milan, Italy; [Uva, Paolo] CRS4, Sci & Technol Pk Polaris, Pula, Croatia; [Dobbs, Kerry; Notarangelo, Luigi D.] NIAID, Lab Host Def, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Sacchetti, Nicole] Univ Vita Salute San Raffaele, Milan, Italy; [van Til, Niek P.; Wagemaker, Gerard] Erasmus Univ, Dept Hematol, Med Ctr, Rotterdam, Netherlands; [van Til, Niek P.] Univ Med Ctr Utrecht, Lab Translat Immunol, Utrecht, Netherlands; [Wagemaker, Gerard] Hacettepe Univ, Stem Cell Res & Dev Ctr, Ankara, Turkey; [Wagemaker, Gerard] Raisa Gorbacheva Mem Res Inst Pediat Oncol & Hema, St Petersburg, Russia	Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Hospital Spedali Civili Brescia; Consiglio Nazionale delle Ricerche (CNR); Istituto di Ricerca Genetica e Biomedica (IRGB-CNR); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Vita-Salute San Raffaele University; Erasmus University Rotterdam; Erasmus MC; Utrecht University; Utrecht University Medical Center; Hacettepe University	Villa, A (corresponding author), Ist Sci San Raffaele, Div Regenerat Med Stem Cells & Gene Therapy, San Raffaele Telethon Inst Gene Therapy SR TIGET, Via Olgettina 60, I-20132 Milan, Italy.	villa.anna@hsr.it	Castiello, Maria Carmina/K-9767-2016; Bosticardo, Marita/ABA-2688-2021; Capo, Valentina/ABG-3418-2020; Uva, Paolo/A-2877-2011; Fontana, Elena/K-3845-2016; Rigoni, Rosita/J-3151-2018	Castiello, Maria Carmina/0000-0003-2581-9648; Bosticardo, Marita/0000-0002-1771-4523; Capo, Valentina/0000-0002-1851-1429; Uva, Paolo/0000-0002-9524-8492; Fontana, Elena/0000-0001-8853-3335; Rigoni, Rosita/0000-0002-2419-7907; Dobbs, Kerry/0000-0002-3432-3137; Carrera, Paola/0000-0001-7376-2119; lucia, Sergi Sergi/0000-0002-8631-7433; van Til, Niek/0000-0002-9515-4103	Italian Telethon foundation (Telethon CoreTGTE2 Grant); European Commission [QLK3-CT-2001-00427-INHERINET, LSHB-CT-2004-005242-CONSERT, 261387 CELL-PID, 666908-SCIDNET]; Netherlands Health Research and Development Organization ZonMw, Translational Gene Therapy Program [43100016]; Italian Ministry of Health [GR-2011-02349759]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001222] Funding Source: NIH RePORTER	Italian Telethon foundation (Telethon CoreTGTE2 Grant)(Fondazione Telethon); European Commission(European CommissionEuropean Commission Joint Research Centre); Netherlands Health Research and Development Organization ZonMw, Translational Gene Therapy Program; Italian Ministry of Health(Ministry of Health, Italy); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Italian Telethon foundation (Telethon CoreTGTE2 Grant to A.V.); by the European Commission's 5th, 6th, and 7th and Horizon 2020 Framework Programs (contracts QLK3-CT-2001-00427-INHERINET, LSHB-CT-2004-005242-CONSERT, grant agreement 261387 CELL-PID to A.V. and grant 666908-SCIDNET to A.V.); and by The Netherlands Health Research and Development Organization ZonMw, Translational Gene Therapy Program (project 43100016 to G.W.) and by Italian Ministry of Health (grant GR-2011-02349759 to B.C.).	Abolhassani H, 2014, J ALLERGY CLIN IMMUN, V134, P1375, DOI 10.1016/j.jaci.2014.04.042; Abramson J, 2016, IMMUNOL REV, V271, P127, DOI 10.1111/imr.12419; Aiuti A, 2009, NEW ENGL J MED, V360, P447, DOI 10.1056/NEJMoa0805817; Booth C, 2016, TRENDS MOL MED, V22, P317, DOI 10.1016/j.molmed.2016.02.002; Bosticardo M, 2011, J ALLERGY CLIN IMMUN, V127, P1376, DOI 10.1016/j.jaci.2011.03.030; Buchbinder D, 2015, J CLIN IMMUNOL, V35, P119, DOI 10.1007/s10875-014-0121-5; Buckley RH, 2013, J CLIN IMMUNOL, V33, P96, DOI 10.1007/s10875-012-9797-6; Buckley RH, 2010, J ALLERGY CLIN IMMUN, V125, P790, DOI 10.1016/j.jaci.2010.02.012; Cancro MP, 2009, NAT REV IMMUNOL, V9, P657, DOI 10.1038/nri2621; Candotti Fabio, 2016, F1000Res, V5, DOI 10.12688/f1000research.7512.1; Candotti F, 2012, BLOOD, V120, P3635, DOI 10.1182/blood-2012-02-400937; Cassani B, 2010, J EXP MED, V207, P1525, DOI 10.1084/jem.20091928; Cavadini P, 2005, J CLIN INVEST, V115, P728, DOI 10.1172/JCI200523087; Cavazzana M, 2016, HUM GENE THER, V27, P108, DOI 10.1089/hum.2015.137; Chiriaco M, 2014, MOL THER, V22, P1472, DOI 10.1038/mt.2014.87; Cifaldi C, 2017, PEDIAT ALLERG IMM-UK, V28, P203, DOI 10.1111/pai.12684; Corneo B, 2001, BLOOD, V97, P2772, DOI 10.1182/blood.V97.9.2772; Cornu TI, 2017, NAT MED, V23, P415, DOI 10.1038/nm.4313; De Ravin SS, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah3480; De Ravin SS, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad8856; Dever DP, 2017, CURR OPIN HEMATOL, V24, P481, DOI 10.1097/MOH.0000000000000385; Fischer A, 2017, J ALLERGY CLIN IMMUN, V140, P1388, DOI 10.1016/j.jaci.2016.12.978; Gennery AR, 2010, J ALLERGY CLIN IMMUN, V126, P602, DOI 10.1016/j.jaci.2010.06.015; Genovese P, 2014, NATURE, V510, P235, DOI 10.1038/nature13420; Haddad E, 2013, J ALLERGY CLIN IMMUN, V131, P994, DOI 10.1016/j.jaci.2013.01.047; Hao ZY, 2001, J EXP MED, V194, P1151, DOI 10.1084/jem.194.8.1151; Heimall J, 2017, BIOL BLOOD MARROW TR, V23, P379, DOI 10.1016/j.bbmt.2016.12.619; Kato T, 2015, J CLIN IMMUNOL, V35, P280, DOI 10.1007/s10875-015-0146-4; Knight S, 2012, J VIROL, V86, P9088, DOI 10.1128/JVI.00485-12; Kohn DB, 2017, J ALLERGY CLIN IMMUN, V139, P726, DOI 10.1016/j.jaci.2017.01.007; Li QZ, 2007, CLIN EXP IMMUNOL, V147, P60, DOI 10.1111/j.1365-2249.2006.03251.x; Maina V, 2013, J LEUKOCYTE BIOL, V94, P1221, DOI 10.1189/jlb.0713365; Marangoni F, 2009, MOL THER, V17, P1073, DOI 10.1038/mt.2009.31; Marrella V, 2007, J CLIN INVEST, V117, P1260, DOI 10.1172/JCI30928; Marrella V, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00259; Marrella V, 2012, BLOOD, V120, P1005, DOI 10.1182/blood-2012-01-406827; Myers LA, 2002, BLOOD, V99, P872, DOI 10.1182/blood.V99.3.872; Neven B, 2009, BLOOD, V113, P4114, DOI 10.1182/blood-2008-09-177923; Notarangelo LD, 2016, NAT REV IMMUNOL, V16, P234, DOI 10.1038/nri.2016.28; OMENN GS, 1965, NEW ENGL J MED, V273, P427, DOI 10.1056/NEJM196508192730806; Pai SY, 2014, NEW ENGL J MED, V371, P434, DOI 10.1056/NEJMoa1401177; Pike-Overzet K, 2011, LEUKEMIA, V25, P1471, DOI 10.1038/leu.2011.106; Poliani PL, 2009, BLOOD, V114, P105, DOI 10.1182/blood-2009-03-211029; Railey MD, 2009, J PEDIATR-US, V155, P834, DOI 10.1016/j.jpeds.2009.07.049; Rigoni R, 2016, J EXP MED, V213, P355, DOI 10.1084/jem.20151116; Schatz DG, 2011, ANNU REV GENET, V45, P167, DOI 10.1146/annurev-genet-110410-132552; Schuetz C, 2014, BLOOD, V123, P281, DOI 10.1182/blood-2013-01-476432; Seidel MG, 2014, BLOOD, V124, P2337, DOI 10.1182/blood-2014-06-583260; Srivastava B, 2005, J EXP MED, V202, P1225, DOI 10.1084/jem.20051038; Takaba H, 2015, CELL, V163, P975, DOI 10.1016/j.cell.2015.10.013; Thrasher AJ, 2017, MOL THER, V25, P1132, DOI 10.1016/j.ymthe.2017.03.018; van Til NP, 2014, J ALLERGY CLIN IMMUN, V133, P1116, DOI 10.1016/j.jaci.2013.10.009; van Til NP, 2012, MOL THER, V20, P1968, DOI 10.1038/mt.2012.110; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8; Walter JE, 2015, J CLIN INVEST, V125, P4135, DOI 10.1172/JCI80477; Walter JE, 2010, J EXP MED, V207, P1541, DOI 10.1084/jem.20091927; Yates F, 2002, BLOOD, V100, P3942, DOI 10.1182/blood-2002-03-0782	57	11	11	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2018	142	3					928	+		10.1016/j.jaci.2017.11.015	http://dx.doi.org/10.1016/j.jaci.2017.11.015			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GS5RJ	29241731	Bronze, Green Accepted			2022-12-18	WOS:000443726500025
J	Nadeau, P; Henehan, M; De Benedetto, A				Nadeau, Peter; Henehan, Mason; De Benedetto, Anna			Activation of protease-activated receptor 2 leads to impairment of keratinocyte tight junction integrity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							SKIN		[Nadeau, Peter; Henehan, Mason; De Benedetto, Anna] Univ Florida, Coll Med, Dept Dermatol, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	De Benedetto, A (corresponding author), Univ Florida, Coll Med, Dept Dermatol, Gainesville, FL 32611 USA.	adebenedetto@ufl.edu			Medical Student Research Program project, College of Medicine, University of Florida; MBI, Office of Research, College of Medicine; NIH Shared Instrumentation Grant [1S10OD020026]	Medical Student Research Program project, College of Medicine, University of Florida; MBI, Office of Research, College of Medicine; NIH Shared Instrumentation Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	M.H. is supported by the Medical Student Research Program project, College of Medicine, University of Florida; Nikon A1RMPsi-STORM4.0 multiphoton/super resolution imaging system is supported by the MBI, Office of Research, College of Medicine, and an NIH Shared Instrumentation Grant (1S10OD020026) at the University of Florida.	De Benedetto A, 2012, J INVEST DERMATOL, V132, P949, DOI 10.1038/jid.2011.435; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; Guenther F, 2015, J PHARM PHARMACOL, V67, P1623, DOI 10.1111/jphp.12447; Jacob C, 2005, J BIOL CHEM, V280, P31936, DOI 10.1074/jbc.M506338200; Lee SE, 2010, YONSEI MED J, V51, P808, DOI 10.3349/ymj.2010.51.6.808; Roelandt T, 2011, J DERMATOL SCI, V61, P101, DOI 10.1016/j.jdermsci.2010.11.016; Rothmeier AS, 2012, SEMIN IMMUNOPATHOL, V34, P133, DOI 10.1007/s00281-011-0289-1; Steinhoff M, 1999, EXP DERMATOL, V8, P282; Voegeli R, 2009, BRIT J DERMATOL, V161, P70, DOI 10.1111/j.1365-2133.2009.09142.x	9	11	12	2	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2018	142	1					281	284		10.1016/j.jaci.2018.01.007	http://dx.doi.org/10.1016/j.jaci.2018.01.007			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GM1OC	29382595	Bronze			2022-12-18	WOS:000437837500031
J	Ramakrishnan, VR; Frank, DN				Ramakrishnan, Vijay R.; Frank, Daniel N.			Microbiome in patients with upper airway disease: Moving from taxonomic findings to mechanisms and causality	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Rhinitis; chronic rhinosinusitis; sinusitis; atopy; atopic disease; upper airway; inflammation; infection; microbiome; microbial community; dysbiosis			[Ramakrishnan, Vijay R.] Univ Colorado, Sch Med, Dept Otolaryngol, Aurora, CO USA; [Frank, Daniel N.] Univ Colorado, Sch Med, Div Infect Dis, Aurora, CO USA; [Frank, Daniel N.] Univ Colorado, Sch Med, Microbiome Res Consortium, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Ramakrishnan, VR (corresponding author), Univ Colorado, Dept Otolaryngol, 12631 E 17th Ave,B205, Aurora, CO 80045 USA.	Vijay.Ramakrishnan@ucdenver.edu			National Institute on Deafness and Other Communication Disorders/National Institutes of Health [K23DC014747]; Flight Attendant Medical Research Institute [CIA130066, CIA160014]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [K23DC014747] Funding Source: NIH RePORTER	National Institute on Deafness and Other Communication Disorders/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); Flight Attendant Medical Research Institute; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	V.R. Ramakrishnan serves as a consultant for Medtronic and OptiNose, is supported by a grant from the National Institute on Deafness and Other Communication Disorders/National Institutes of Health (K23DC014747). D. N. Frank and V. R. Ramakrishnan are supported by grants from the Flight Attendant Medical Research Institute (CIA130066 and CIA160014).	Bomar L, 2016, MBIO, V7, DOI 10.1128/mBio.01725-15; Frank DN, 2011, TRENDS MICROBIOL, V19, P427, DOI 10.1016/j.tim.2011.06.005; Ta LDH, 2018, J ALLERGY CLIN IMMUN, V142, P86, DOI 10.1016/j.jaci.2018.01.032; Lee JT, 2016, AM J RHINOL ALLERGY, V30, P3, DOI 10.2500/ajra.2016.30.4255; Mahdavinia M, 2018, J ALLERGY CLIN IMMUN, V142, P287, DOI 10.1016/j.jaci.2018.01.033; Nash MJ, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00349; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; Stefka AT, 2014, P NATL ACAD SCI USA, V111, P13145, DOI 10.1073/pnas.1412008111; Yan ML, 2013, CELL HOST MICROBE, V14, P631, DOI 10.1016/j.chom.2013.11.005	9	11	11	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2018	142	1					73	75		10.1016/j.jaci.2018.05.006	http://dx.doi.org/10.1016/j.jaci.2018.05.006			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GM1OC	29803801	Bronze, Green Accepted			2022-12-18	WOS:000437837500011
J	Sng, CCT; O'Byrne, S; Prigozhin, DM; Bauer, MR; Harvey, JC; Ruhle, M; Challis, BG; Lear, S; Roberts, LD; Workman, S; Janowitz, T; Magiera, L; Doffinger, R; Buckland, MS; Jodrell, DJ; Semple, RK; Wilson, TJ; Modis, Y; Thaventhiran, JED				Sng, Christopher C. T.; O'Byrne, Sorcha; Prigozhin, Daniil M.; Bauer, Matthias R.; Harvey, Jennifer C.; Ruhle, Michelle; Challis, Ben G.; Lear, Sara; Roberts, Lee D.; Workman, Sarita; Janowitz, Tobias; Magiera, Lukasz; Doffinger, Rainer; Buckland, Matthew S.; Jodrell, Duncan J.; Semple, Robert K.; Wilson, Timothy J.; Modis, Yorgo; Thaventhiran, James E. D.			A type III complement factor D deficiency: Structural insights for inhibition of the alternative pathway	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ACTIVATION; FAMILY		[Sng, Christopher C. T.; Janowitz, Tobias; Magiera, Lukasz; Jodrell, Duncan J.; Thaventhiran, James E. D.] Canc Res UK Cambridge Inst, Cambridge, England; [O'Byrne, Sorcha; Lear, Sara; Doffinger, Rainer; Thaventhiran, James E. D.] Addenbrookes Hosp, Cambridge Univ Hosp Natl Hlth Serv Trust, Dept Clin Immunol, Cambridge, England; [Prigozhin, Daniil M.; Modis, Yorgo] MRC, Lab Mol Biol, Dept Med, Mol Immun Unit, Cambridge, England; [Bauer, Matthias R.] MRC, Lab Mol Biol, Div Struct Studies, Cambridge, England; [Harvey, Jennifer C.; Workman, Sarita; Buckland, Matthew S.] Royal Free London Natl Hlth Serv Fdn Trust, Dept Immunol, London, England; [Ruhle, Michelle] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia; [Challis, Ben G.; Semple, Robert K.] Univ Cambridge, Addenbrookes Hosp, Wellcome Trust MRC Inst Metab Sci, Cambridge, England; [Roberts, Lee D.] Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge, England; [Semple, Robert K.] Univ Leeds, Leeds Inst Cardiovasc & Metab Med, Leeds Inst Genet Hlth & Therapeut LIGHT Labs, Leeds, W Yorkshire, England; [Wilson, Timothy J.] Univ Edinburgh, Ctr Cardiovasc Sci, Queens Med Res Inst, Edinburgh, Midlothian, Scotland; [Thaventhiran, James E. D.] Miami Univ, Dept Microbiol, Oxford, OH 45056 USA; [Thaventhiran, James E. D.] Univ Leicester, MRC Toxicol Unit, Leicester, Leics, England	Cancer Research UK; CRUK Cambridge Institute; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; MRC Laboratory Molecular Biology; MRC Laboratory Molecular Biology; University of London; University College London; Royal Free London NHS Foundation Trust; Walter & Eliza Hall Institute; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Leeds; University of Edinburgh; University System of Ohio; Miami University; University of Leicester	Thaventhiran, JED (corresponding author), Canc Res UK Cambridge Inst, Cambridge, England.; Thaventhiran, JED (corresponding author), Addenbrookes Hosp, Cambridge Univ Hosp Natl Hlth Serv Trust, Dept Clin Immunol, Cambridge, England.; Thaventhiran, JED (corresponding author), Miami Univ, Dept Microbiol, Oxford, OH 45056 USA.; Thaventhiran, JED (corresponding author), Univ Leicester, MRC Toxicol Unit, Leicester, Leics, England.	jedt2@cam.ac.uk	O'Rahilly, Stephen/ABF-6509-2020; Semple, Robert/AAB-2948-2019; Buckland, Matthew/H-7049-2019	O'Rahilly, Stephen/0000-0003-2199-4449; Buckland, Matthew/0000-0002-5646-4707; Bauer, Matthias/0000-0003-4015-6483; Roberts, Lee/0000-0002-1455-5248; O'Byrne, Sorcha/0000-0002-3116-1646; Wilson, Timothy/0000-0001-8403-9401; Semple, Robert Kenneth/0000-0001-6539-3069; Modis, Yorgo/0000-0002-6084-0429; Prigozhin, Daniil M/0000-0003-2075-0231; Magiera, Lukasz/0000-0002-8234-5066	MRC Clinician Scientist Fellowship [MR/L006197/1]; Cambridge Biomedical Research Centre Inflammation, Infection and Immunotherapeutics Pump-Priming Grant (BRC III PPG); Wellcome Trust Senior Research Fellowship [101908/Z/13/Z]; Wellcome Trust [WT098498, 100574/Z/12/Z]; United Kingdom Medical Research Council [MRC_MC_UU_12012/5]; United Kingdom National Institute for Health Research, Cambridge Biomedical Research Centre; Cancer Research UK [C42738/A24868]; Cancer Research UK [15678, 24868] Funding Source: researchfish; Medical Research Council [MR/L006197/1] Funding Source: researchfish; MRC [MC_UU_12012/5, MR/L006197/1] Funding Source: UKRI	MRC Clinician Scientist Fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cambridge Biomedical Research Centre Inflammation, Infection and Immunotherapeutics Pump-Priming Grant (BRC III PPG); Wellcome Trust Senior Research Fellowship(Wellcome Trust); Wellcome Trust(Wellcome TrustEuropean Commission); United Kingdom Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); United Kingdom National Institute for Health Research, Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	J.E.D.T. is supported by an MRC Clinician Scientist Fellowship (MR/L006197/1). This work was funded by Cambridge Biomedical Research Centre Inflammation, Infection and Immunotherapeutics Pump-Priming Grant (BRC III PPG) funding and a Wellcome Trust Senior Research Fellowship to Y.M. (101908/Z/13/Z). R.K.S. is funded by the Wellcome Trust (grant WT098498 and strategic award 100574/Z/12/Z), the United Kingdom Medical Research Council (MRC_MC_UU_12012/5), and the United Kingdom National Institute for Health Research, Cambridge Biomedical Research Centre. T.J. is funded by Cancer Research UK (Clinician Scientist Fellowship C42738/A24868). B.G.C. is now a full-time employee of AstraZeneca.	Biesma DH, 2001, J CLIN INVEST, V108, P233, DOI 10.1172/JCI200112023; Fitzpatrick AM, 2016, J ALLERGY CLIN IMMUN, V138, P1608, DOI 10.1016/j.jaci.2016.09.028; Forneris F, 2010, SCIENCE, V330, P1816, DOI 10.1126/science.1195821; HIEMSTRA PS, 1989, J CLIN INVEST, V84, P1957, DOI 10.1172/JCI114384; Katschke KJ, 2012, J BIOL CHEM, V287, P12886, DOI 10.1074/jbc.M112.345082; Lo JC, 2014, CELL, V158, P41, DOI 10.1016/j.cell.2014.06.005; Maibaum J, 2016, NAT CHEM BIOL, V12, P1105, DOI [10.1038/NCHEMBIO.2208, 10.1038/nchembio.2208]; NARAYANA SVL, 1994, J MOL BIOL, V235, P695, DOI 10.1006/jmbi.1994.1021; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Sheehan WJ, 2016, NEW ENGL J MED, V375, P619, DOI 10.1056/NEJMoa1515990; Sprong T, 2006, BLOOD, V107, P4865, DOI 10.1182/blood-2005-07-2820; Sullivan JE, 2011, PEDIATRICS, V127, P580, DOI 10.1542/peds.2010-3852; Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443	13	11	11	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2018	142	1					311	314		10.1016/j.jaci.2018.01.048	http://dx.doi.org/10.1016/j.jaci.2018.01.048			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GM1OC	29522842	Green Accepted, Green Published, hybrid			2022-12-18	WOS:000437837500040
J	Matsumoto, K; Mori, R; Miyazaki, C; Ohya, Y; Saito, H				Matsumoto, Kenji; Mori, Rintaro; Miyazaki, Celine; Ohya, Yukihiro; Saito, Hirohisa			Are both early egg introduction and eczema treatment necessary for primary prevention of egg allergy?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; primary prevention; boiled egg; eczema; proactive treatment	INDUCED ENTEROCOLITIS SYNDROME; ATOPIC-DERMATITIS; FOOD ALLERGY; COWS MILK; INFANTS; RISK; SENSITIZATION; EXPOSURE; CELLS; SKIN	The Learning Early About Peanut Allergy (LEAP) study proved that early introduction of peanut significantly prevented the development of peanut allergy. However, in regard to similar attempts to prevent egg allergy through early egg introduction, the Prevention of Egg Allergy in High-risk Infants with Eczema (PETIT) study is the only randomized intervention trial to show a statistically significant effect. Meta-analysis of those studies indicated that neither the total amount nor pretreatment of egg showed any effect on egg allergy at the age of 12 months. However, raw egg powder resulted in a significantly higher prevalence of allergic reactions at initial introduction, whereas use of boiled egg was much safer. The prevalence of atopic dermatitis/ eczema at introduction of egg correlated significantly with the subsequent prevalence of allergic reactions at initial introduction. In addition, the prevalence of egg allergy in the late introduction group correlated significantly with the prevalence of atopic dermatitis at introduction, even when the atopic dermatitis was proactively treated with a topical corticosteroid ointment. It is definitely true that the number of trials and number of participants in each trial are insufficient for drawing firm conclusions, especially regarding the optimal dose, raw versus boiled, when to start, and for whom to intervene. Therefore we propose various studies that should be performed to generate stronger data and conclusions. However, on the basis of the most recent results, we postulate that simultaneous intervention by both early boiled egg introduction and eczema treatment is probably indispensable for primary prevention of egg allergy.	[Matsumoto, Kenji; Saito, Hirohisa] Natl Res Inst Child Hlth & Dev, Dept Allergy & Clin Immunol, Tokyo, Japan; [Mori, Rintaro; Miyazaki, Celine] Natl Res Inst Child Hlth & Dev, Dept Hlth Policy, Tokyo, Japan; [Ohya, Yukihiro] Natl Ctr Child Hlth & Dev, Div Allergy, Tokyo, Japan	National Center for Child Health & Development - Japan; National Center for Child Health & Development - Japan; National Center for Child Health & Development - Japan	Matsumoto, K (corresponding author), Natl Res Inst Child Hlth & Dev, Dept Allergy & Clin Immunol, Setagaya Ku, 2-10-1 Okura, Tokyo 1578535, Japan.	matsumoto-k@ncchd.go.jp	Ohya, Yukihiro/Y-9002-2019	Ohya, Yukihiro/0000-0002-1560-3942; Mori, Rintaro/0000-0001-7656-6156; Saito, Hirohisa/0000-0002-6630-8337	Food Safety Commission of Japan [1506, 1705]; National Center for Child Health and Development [26-9]; Grants-in-Aid for Scientific Research [15H04866] Funding Source: KAKEN	Food Safety Commission of Japan(Food Safety Commission of Japan); National Center for Child Health and Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported in part by grants from the Food Safety Commission of Japan (#1506 and #1705 to K.M., Y.O., and H.S.) and from the National Center for Child Health and Development (#26-9 to K.M.).	Bellach J, 2017, J ALLERGY CLIN IMMUN, V139, P1591, DOI 10.1016/j.jaci.2016.06.045; Dioszeghy V, 2011, J IMMUNOL, V186, P5629, DOI 10.4049/jimmunol.1003134; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Fukuie T, 2016, J DERMATOL, V43, P1283, DOI 10.1111/1346-8138.13408; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Ierodiakonou D, 2016, JAMA-J AM MED ASSOC, V316, P1181, DOI 10.1001/jama.2016.12623; Katz Y, 2011, J ALLERGY CLIN IMMUN, V127, P647, DOI 10.1016/j.jaci.2010.12.1105; Lack G, 2008, J ALLERGY CLIN IMMUN, V121, P1331, DOI 10.1016/j.jaci.2008.04.032; Matsumoto K, 2014, J ALLERGY CLIN IMMUN, V134, P865, DOI 10.1016/j.jaci.2014.08.006; Mehr S, 2017, J ALLERGY CLIN IMMUN, V140, P1323, DOI 10.1016/j.jaci.2017.03.027; Miyazawa T, 2013, ALLERGOL INT, V62, P85, DOI 10.2332/allergolint.11-OA-0417; Mondoulet Lucie, 2012, Clin Transl Allergy, V2, P22, DOI 10.1186/2045-7022-2-22; Natsume O, 2017, LANCET, V389, P276, DOI 10.1016/S0140-6736(16)31418-0; Noti M, 2014, J ALLERGY CLIN IMMUN, V133, P1390, DOI 10.1016/j.jaci.2014.01.021; Palmer DJ, 2017, J ALLERGY CLIN IMMUN, V139, P1600, DOI 10.1016/j.jaci.2016.06.052; Palmer DJ, 2013, J ALLERGY CLIN IMMUN, V132, P387, DOI 10.1016/j.jaci.2013.05.002; Perkin MR, 2016, NEW ENGL J MED, V374, P1733, DOI 10.1056/NEJMoa1514210; Tan JWL, 2017, J ALLERGY CLIN IMMUN, V139, P1621, DOI 10.1016/j.jaci.2016.08.035; Togias A, 2017, J ALLERGY CLIN IMMUN, V139, P29, DOI 10.1016/j.jaci.2016.10.010; Tsakok T, 2016, J ALLERGY CLIN IMMUN, V137, P1071, DOI 10.1016/j.jaci.2015.10.049; Wollenberg A, 2016, J EUR ACAD DERMATOL, V30, P729, DOI 10.1111/jdv.13599; Yoshida K, 2014, J ALLERGY CLIN IMMUN, V134, P856, DOI 10.1016/j.jaci.2014.08.001	22	11	11	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					1997	+		10.1016/j.jaci.2018.02.033	http://dx.doi.org/10.1016/j.jaci.2018.02.033			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	29522845	Bronze			2022-12-18	WOS:000434701600005
J	Ban, L; Langan, SM; Abuabara, K; Thomas, KS; Sultan, AA; Sach, T; McManus, E; Santer, M; Ratib, S				Ban, Lu; Langan, Sinead M.; Abuabara, Katrina; Thomas, Kim S.; Sultan, Alyshah Abdul; Sach, Tracey; McManus, Emma; Santer, Miriam; Ratib, Sonia			Incidence and sociodemographic characteristics of eczema diagnosis in children: A cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							EPIDEMIOLOGY; PREVALENCE		[Ban, Lu; Thomas, Kim S.; Ratib, Sonia] Univ Nottingham, Ctr Evidence Based Dermatol, Nottingham, England; [Ban, Lu; Sultan, Alyshah Abdul] Nottingham Univ Hosp NHS Trust, NIHR Nottingham Biomed Res Ctr BRC, Nottingham, England; [Ban, Lu; Sultan, Alyshah Abdul] Univ Nottingham, Nottingham, England; [Langan, Sinead M.] London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, London, England; [Abuabara, Katrina] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; [Sultan, Alyshah Abdul] Keele Univ, Arthrit Res UK Primary Care Ctr, Res Inst Primary Care & Hlth Sci, Keele, Staffs, England; [Sach, Tracey; McManus, Emma] Univ East Anglia, Hlth Econ Grp, Norwich, Norfolk, England; [Santer, Miriam] Univ Southampton, Primary Care & Populat Sci, Southampton, Hants, England	University of Nottingham; Nottingham University Hospital NHS Trust; University of Nottingham; University of London; London School of Hygiene & Tropical Medicine; University of California System; University of California San Francisco; Keele University; University of East Anglia; University of Southampton	Ban, L (corresponding author), Univ Nottingham, Ctr Evidence Based Dermatol, Nottingham, England.; Ban, L (corresponding author), Nottingham Univ Hosp NHS Trust, NIHR Nottingham Biomed Res Ctr BRC, Nottingham, England.; Ban, L (corresponding author), Univ Nottingham, Nottingham, England.	lu.ban@nottingham.ac.uk		McManus, Emma/0000-0002-3442-8721; Ban, Lu/0000-0001-9388-9141; Sach, Tracey/0000-0002-8098-9220; Langan, Sinead/0000-0002-7022-7441; Gran, Sonia/0000-0002-2443-5100; Santer, Miriam/0000-0001-7264-5260; Thomas, Kim/0000-0001-7785-7465	University of Nottingham; National Institute for Health Research (NIHR) [CDF-2014-07-006]; NIHR Clinician Scientist award [NIHR/CS/010/014]; Wellcome Trust Senior Clinical Fellowship in Science [205039/Z/16/Z]; Medical Research Council [HDR-2004] Funding Source: researchfish; National Institute for Health Research [PDF-2009-02-45, CDF-2014-07-006] Funding Source: researchfish	University of Nottingham; National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); NIHR Clinician Scientist award; Wellcome Trust Senior Clinical Fellowship in Science; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	This work has been internally funded by the University of Nottingham. T.S. holds a Career Development Fellowship (CDF-2014-07-006) supported by the National Institute for Health Research (NIHR). S.M.L. was funded by an NIHR Clinician Scientist award (NIHR/CS/010/014) and is currently funded by a Wellcome Trust Senior Clinical Fellowship in Science (205039/Z/16/Z). The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, National Health Service, or the Department of Health.	Abuabara K, 2017, J INVEST DERMATOL, V137, P1655, DOI 10.1016/j.jid.2017.03.029; Cipriani F, 2014, PEDIAT ALLERG IMM-UK, V25, P630, DOI 10.1111/pai.12309; Clough S, 2011, SOC SCI MED, V72, P486, DOI 10.1016/j.socscimed.2010.11.021; Crooks CJ, 2013, EPIDEMIOLOGY UPPER G; Ellwood P, 2001, EUR RESPIR J, V17, P436, DOI 10.1183/09031936.01.17304360; Flohr C, 2014, ALLERGY, V69, P3, DOI 10.1111/all.12270; GREEN LA, 1992, J FAM PRACTICE, V34, P633; Herrett E, 2015, INT J EPIDEMIOL, V44, P827, DOI 10.1093/ije/dyv098; ISRCTN Registry, BARR ENH ECZ PREV; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Mathur R, 2014, J PUBLIC HEALTH-UK, V36, P684, DOI 10.1093/pubmed/fdt116; Muenchhoff M, 2014, J INFECT DIS, V209, pS120, DOI 10.1093/infdis/jiu232; Noble M, 2006, ENVIRON PLANN A, V38, P169, DOI 10.1068/a37168; Odhiambo JA, 2009, J ALLERGY CLIN IMMUN, V124, P1251, DOI 10.1016/j.jaci.2009.10.009; Taylor-Robinson DC, 2016, BRIT J DERMATOL, V174, P569, DOI 10.1111/bjd.14310; Thyssen JP, 2015, J ALLERGY CLIN IMMUN, V136, P1163, DOI 10.1016/j.jaci.2015.06.042; Zuberbier T, 2006, J ALLERGY CLIN IMMUN, V118, P226, DOI 10.1016/j.jaci.2006.02.031	17	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1927	+		10.1016/j.jaci.2017.12.997	http://dx.doi.org/10.1016/j.jaci.2017.12.997			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	29382597	hybrid, Green Published, Green Accepted			2022-12-18	WOS:000432148200048
J	Sampaio, EP; Ding, L; Rose, SR; Cruz, P; Hsu, AP; Kashyap, A; Rosen, LB; Smelkinson, M; Tavella, TA; Ferre, EMN; Wierman, MK; Zerbe, CS; Lionakis, MS; Holland, SM				Sampaio, Elizabeth P.; Ding, Li; Rose, Stacey R.; Cruz, Phillip; Hsu, Amy P.; Kashyap, Anuj; Rosen, Lindsey B.; Smelkinson, Margery; Tavella, Tatyana A.; Ferre, Elise M. N.; Wierman, Meredith K.; Zerbe, Christa S.; Lionakis, Michail S.; Holland, Steven M.			Novel signal transducer and activator of transcription 1 mutation disrupts small ubiquitin-related modifier conjugation causing gain of function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Signal transducer and activator of transcription 1; gain of function; sumoylation; small ubiquitin-related modifier; IFN-gamma; Rhodococcus species infection	CHRONIC MUCOCUTANEOUS CANDIDIASIS; OF-FUNCTION MUTATIONS; STAT1 MUTATIONS; MOLECULAR-DYNAMICS; SUMO-1 CONJUGATION; I-TASSER; SUMOYLATION; INFECTION; PARACRYSTALS; SOLUBILITY	Background: Sumoylation is a posttranslational reversible modification of cellular proteins through the conjugation of small ubiquitin-related modifier (SUMO) and comprises an important regulator of protein function. Objective: We sought to characterize the molecular mechanism of a novel mutation at the SUMO motif on signal transducer and activator of transcription 1 (STAT1). Methods: STAT1 sequencing and functional characterization were performed in transfection experiments by using immunoblotting and immunoprecipitation in STAT1-deficient cell lines. Transcriptional response and target gene activation were also investigated in PBMCs. Results: We identified a novel STAT1 mutation (c.2114A>T, p.E705V) within the SUMO motif (702 IKTE 705) in a patient with disseminated Rhodococcus species infection, Norwegian scabies, chronic mucocutaneous candidiasis, hypothyroidism, and esophageal squamous cell carcinoma. The mutation is located in the tail segment and is predicted to disrutp STAT1 sumoylation. Immunoprecipitation experiments performed in transfected cells confirmed absent STAT1 sumoylation for E705V, whereas it was present in wild-type (WT) STAT1 cells, as well as the loss-of-function mutants L706S and Y701C. Furthermore, stimulation with IFN-gamma led to enhanced STAT1 phosphorylation, enhanced transcriptional activity, and target gene expression in the E705V-transfected compared with WT-ransfected cells. Computer modeling of WT and mutant STAT1 molecules showed variations in the accessibility of the phosphorylation site Y701, which corresponded to the loss-of-function and gain-of-function variants. Conclusion: This is the first report of a mutation in the STAT1 sumoylation motif associated with clinical disease. These data reinforce sumoylation as a key posttranslational regulatory modification of STAT1 and identify a novel mechanism for gain-of-function STAT1 disease in human subjects.	[Sampaio, Elizabeth P.; Ding, Li; Hsu, Amy P.; Kashyap, Anuj; Rosen, Lindsey B.; Tavella, Tatyana A.; Zerbe, Christa S.; Holland, Steven M.] NIAID, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Rose, Stacey R.; Ferre, Elise M. N.; Lionakis, Michail S.] NIAID, Fungal Pathogenesis Unit, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Cruz, Phillip] NIAID, Computat Biol Sect, BCBB, OCICB,OSMO,OD,NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Smelkinson, Margery] NIAID, Biol Imaging Sect, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Wierman, Meredith K.] St Joseph Phys Network Practices, Infect Dis, Mishawaka, IN USA; [Sampaio, Elizabeth P.] Fiocruz MS, Leprosy Lab, Inst Oswaldo Cruz, Rio De Janeiro, Brazil; [Rose, Stacey R.] Baylor Coll Med, Div Infect Dis, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Fundacao Oswaldo Cruz; Baylor College of Medicine	Sampaio, EP (corresponding author), CRC 11N248 MSC 1960, Bethesda, MD 20892 USA.	sampaioe@niaid.nih.gov	Lionakis, Michail/J-8840-2017	Lionakis, Michail/0000-0003-4994-9500; Smelkinson, Margery/0000-0001-7777-5574	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH); National Cancer Institute, NIH [HHSN]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001175, ZIAAI000647, ZIAAI000646, ZICAI001051] Funding Source: NIH RePORTER	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Cancer Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), and has been funded in part with federal funds from the National Cancer Institute, NIH, under contract no. HHSN	Begitt A, 2011, BLOOD, V118, P1002, DOI 10.1182/blood-2011-04-347930; Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287; Chang TH, 2012, J IMMUNOL, V189, P3548, DOI 10.4049/jimmunol.1201104; Chang TH, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000493; Cheng J, 2007, CELL, V131, P584, DOI 10.1016/j.cell.2007.08.045; Da Silva-Ferrada E, 2012, BIOCHEM RES INT, V2012, DOI 10.1155/2012/875148; Darraj M, 2017, J INFECT PUBLIC HEAL, V10, P224, DOI 10.1016/j.jiph.2016.05.001; Droescher M, 2011, ONCOTARGET, V2, P527; Droescher M, 2011, J BIOL CHEM, V286, P18731, DOI 10.1074/jbc.M111.235978; Dupuis S, 2001, SCIENCE, V293, P300, DOI 10.1126/science.1061154; Eifler K, 2015, FEBS J, V282, P3669, DOI 10.1111/febs.13378; Fu JH, 2011, MOL IMMUNOL, V48, P415, DOI 10.1016/j.molimm.2010.09.003; Gareau JR, 2010, NAT REV MOL CELL BIO, V11, P861, DOI 10.1038/nrm3011; Gronholm J, 2012, BMC BIOCHEM, V13, DOI 10.1186/1471-2091-13-20; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hendriks IA, 2016, NAT REV MOL CELL BIO, V17, P581, DOI 10.1038/nrm.2016.81; Hirata O, 2013, HAEMATOLOGICA, V98, P1641, DOI 10.3324/haematol.2013.083741; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Kubota T, 2008, J BIOL CHEM, V283, P25660, DOI 10.1074/jbc.M804479200; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; Maarifi G, 2015, J IMMUNOL, V195, P2312, DOI 10.4049/jimmunol.1500035; Mi ZQ, 2010, PROTEIN CELL, V1, P275, DOI 10.1007/s13238-010-0030-1; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5; Sampaio EP, 2013, J ALLERGY CLIN IMMUN, V131, P1624, DOI 10.1016/j.jaci.2013.01.052; Sobh A, 2016, J ALLERGY CLIN IMMUN, V138, P297, DOI 10.1016/j.jaci.2015.12.1320; Song L, 2006, BLOOD, V108, P3237, DOI 10.1182/blood-2006-04-020271; Toubiana J, 2016, BLOOD, V127, P3154, DOI 10.1182/blood-2015-11-679902; Ungureanu D, 2005, BLOOD, V106, P224, DOI 10.1182/blood-2004-11-4514; Ungureanu D, 2003, BLOOD, V102, P3311, DOI 10.1182/blood-2002-12-3816; Uzel G, 2013, J ALLERGY CLIN IMMUN, V131, P1611, DOI 10.1016/j.jaci.2012.11.054; van de Veerdonk FL, 2011, NEW ENGL J MED, V365, P54, DOI 10.1056/NEJMoa1100102; Wilkinson KA, 2010, BIOCHEM J, V428, P133, DOI 10.1042/BJ20100158; Yueh A, 2006, J VIROL, V80, P342, DOI 10.1128/JVI.80.1.342-352.2006; Zhang Y, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-40; Zimnik S, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp020	38	11	12	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1844	+		10.1016/j.jaci.2017.07.027	http://dx.doi.org/10.1016/j.jaci.2017.07.027			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	28859974	Green Accepted, Bronze			2022-12-18	WOS:000432148200029
J	Comrie, WA; Faruqi, AJ; Price, S; Zhang, Y; Rao, VK; Su, HC; Lenardo, MJ				Comrie, William A.; Faruqi, Aiman J.; Price, Susan; Zhang, Yu; Rao, V. Koneti; Su, Helen C.; Lenardo, Michael J.			RELA haploinsufficiency in CD4 lymphoproliferative disease with autoimmune cytopenias	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							IKK-EPSILON; KAPPA-B		[Comrie, William A.; Faruqi, Aiman J.; Lenardo, Michael J.] NIAID, Mol Dev Immune Syst Sect, Lab Immunol, NIH, Bethesda, MD 20892 USA; [Comrie, William A.; Faruqi, Aiman J.; Price, Susan; Zhang, Yu; Rao, V. Koneti; Su, Helen C.; Lenardo, Michael J.] NIAID, Clin Genom Program, NIH, Bethesda, MD 20892 USA; [Zhang, Yu; Su, Helen C.] NIAID, Human Immunol Dis Sect, Lab Clin Immunol & Microbiol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Lenardo, MJ (corresponding author), NIAID, Mol Dev Immune Syst Sect, Lab Immunol, NIH, Bethesda, MD 20892 USA.; Lenardo, MJ (corresponding author), NIAID, Clin Genom Program, NIH, Bethesda, MD 20892 USA.	Lenardo@nih.gov	Rao, V. Koneti/AAR-2171-2020; Su, Helen C/H-9541-2015	Rao, V. Koneti/0000-0002-7881-6902; Su, Helen C/0000-0002-5582-9110; Faruqi, Aiman/0000-0002-4421-3767	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health [NCT00246857]; American Diabetes Association [1-16-PDF-025]; PRAT program at the National Institute of General Medical Sciences [1FI2GM119979-01]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000565, ZIAAI000717, ZIAAI000732, ZIAAI001059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [FI2GM119979] Funding Source: NIH RePORTER	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); American Diabetes Association(American Diabetes Association); PRAT program at the National Institute of General Medical Sciences; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This project was supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, ClinicalTrials.gov number (NCT00246857), a fellowship grant from the American Diabetes Association (grant no. 1-16-PDF-025), and an F12 postdoctoral fellowship from the PRAT program at the National Institute of General Medical Sciences (grant no. 1FI2GM119979-01 to W.A.C.).	Badran YR, 2017, J EXP MED, V214, P1937, DOI 10.1084/jem.20160724; Fliegauf M, 2015, AM J HUM GENET, V97, P389, DOI 10.1016/j.ajhg.2015.07.008; Hofer-Warbinek R, 2004, CELL DEATH DIFFER, V11, P1317, DOI 10.1038/sj.cdd.4401502; Liu SH, 2013, J CHEM-NY, V2013, DOI 10.1155/2013/651901; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Ruan QG, 2009, IMMUNITY, V31, P932, DOI 10.1016/j.immuni.2009.10.006; Siggers T, 2012, NAT IMMUNOL, V13, P95, DOI 10.1038/ni.2151; Tenoever BR, 2007, SCIENCE, V315, P1274, DOI 10.1126/science.1136567; Zhang Q, 2017, CELL, V168, P37, DOI 10.1016/j.cell.2016.12.012	9	11	11	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1507	+		10.1016/j.jaci.2017.11.036	http://dx.doi.org/10.1016/j.jaci.2017.11.036			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	29305315	Green Accepted, Bronze			2022-12-18	WOS:000429197800043
J	Oliveria, JP; El-Gammal, AI; Yee, M; Obminski, CD; Scime, TX; Watson, RM; Howie, K; O'Byrne, PM; Sehmi, R; Gauvreau, GM				Oliveria, John-Paul; El-Gammal, Amani I.; Yee, Michelle; Obminski, Caitlin D.; Scime, Tara X.; Watson, Richard M.; Howie, Karen; O'Byrne, Paul M.; Sehmi, Roma; Gauvreau, Gail M.			Changes in regulatory B-cell levels in bone marrow, blood, and sputum of patients with asthma following inhaled allergen challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							MURINE MODEL; REPRODUCIBILITY; TESTS; BETA		[Oliveria, John-Paul; El-Gammal, Amani I.; Yee, Michelle; Obminski, Caitlin D.; Scime, Tara X.; Watson, Richard M.; Howie, Karen; O'Byrne, Paul M.; Sehmi, Roma; Gauvreau, Gail M.] McMaster Univ, Dept Med, Div Respirol, Hamilton, ON, Canada	McMaster University	Gauvreau, GM (corresponding author), McMaster Univ, Dept Med, Div Respirol, Hamilton, ON, Canada.	gauvreau@mcmaster.ca	Oliveria, John-Paul/AAH-8080-2020	Oliveria, John-Paul/0000-0002-7192-7634; Gauvreau, Gail/0000-0002-6187-2385; O'Byrne, Paul/0000-0003-0979-281X	AstraZeneca; GSK; Merck; Boehringer; Amgen; Genentech; GalxoSmithKline; Sanofi Regeneron; AllerGen NCE	AstraZeneca(AstraZeneca); GSK(GlaxoSmithKline); Merck(Merck & Company); Boehringer(Boehringer Ingelheim); Amgen(Amgen); Genentech(Roche HoldingGenentech); GalxoSmithKline; Sanofi Regeneron(Regeneron); AllerGen NCE	P. M. O'Byrne personally received board membership from Joint Oversight Board for LABA safety study and consultancy fees from AstraZeneca, GSK, Merck, and Boehringer; his institution received grants from AstraZeneca, Amgen, and Genentech for other works. R. Sehmi's institution received grants from GalxoSmithKline, AstraZeneca, Genetech, Sanofi Regeneron, and AllerGen NCE for other works. The rest of the authors declare that they have no relevant conflicts of interest.	Amu S, 2010, J ALLERGY CLIN IMMUN, V125, P1114, DOI 10.1016/j.jaci.2010.01.018; Bousquet J, 2007, ALLERGY, V62, P102, DOI 10.1111/j.1398-9995.2006.01305.x; CLARKE CW, 1982, CLIN ALLERGY, V12, P1, DOI 10.1111/j.1365-2222.1982.tb03120.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; HENDRICK DJ, 1975, THORAX, V30, P2, DOI 10.1136/thx.30.1.2; Karnekura R, 2015, CLIN IMMUNOL, V158, P204, DOI 10.1016/j.clim.2015.02.016; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Natarajan P, 2012, MUCOSAL IMMUNOL, V5, P691, DOI 10.1038/mi.2012.42; Noh J, 2012, CELL IMMUNOL, V274, P109, DOI 10.1016/j.cellimm.2012.01.005; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; Oliveria JP, 2017, J ALLERGY CLIN IMMUN, V140, P590, DOI 10.1016/j.jaci.2016.12.981; Oliveria JP, 2017, AM J RESP CRIT CARE, V196, P107, DOI 10.1164/rccm.201611-2274LE; Panousis C, 2016, MABS-AUSTIN, V8, P436, DOI 10.1080/19420862.2015.1119352; PEPYS J, 1975, NEW ENGL J MED, V293, P758; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Singh A, 2008, J IMMUNOL, V180, P7318, DOI 10.4049/jimmunol.180.11.7318; Sohani ZN, 2011, J ASTHMA, V48, P952, DOI 10.3109/02770903.2011.617477; van de Veen W, 2013, J ALLERGY CLIN IMMUN, V131, P1204, DOI 10.1016/j.jaci.2013.01.014; van der Vlugt LEPM, 2014, CLIN EXP ALLERGY, V44, P517, DOI 10.1111/cea.12238	19	11	11	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1495	+		10.1016/j.jaci.2017.11.013	http://dx.doi.org/10.1016/j.jaci.2017.11.013			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	29221714	hybrid			2022-12-18	WOS:000429197800039
J	Peden, DB				Peden, David B.			Effect of pollution on allergy/immunology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Pollution; allergy	CLIMATE-CHANGE; AIR-POLLUTION; ASTHMA; ASSOCIATION; CHILDREN; QUALITY		[Peden, David B.] Univ N Carolina, UNC Sch Med, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Peden, DB (corresponding author), Ctr Environm Med Asthma & Lung Biol, CB 7310, Chapel Hill, NC 27599 USA.	david_peden@med.unc.edu		Peden, David/0000-0003-4526-4627				Anise A, 2016, J ALLERGY CLIN IMMUN, V138, P1503, DOI 10.1016/j.jaci.2016.10.003; Berhane K, 2016, JAMA-J AM MED ASSOC, V315, P1491, DOI 10.1001/jama.2016.3444; Bernstein JA, 2004, J ALLERGY CLIN IMMUN, V114, P1116, DOI 10.1016/j.jaci.2004.08.030; Bryant-Stephens T, 2016, J ALLERGY CLIN IMMUN, V138, P1526, DOI 10.1016/j.jaci.2016.10.006; Gauderman WJ, 2015, NEW ENGL J MED, V372, P905, DOI 10.1056/NEJMoa1414123; Guarnieri M, 2014, LANCET, V383, P1581, DOI 10.1016/S0140-6736(14)60617-6; Landrigan P, 2017, LANCET; Shea KM, 2008, J ALLERGY CLIN IMMUN, V122, P443, DOI 10.1016/j.jaci.2008.06.032; Ziska L, 2011, P NATL ACAD SCI USA, V108, P4248, DOI 10.1073/pnas.1014107108; Ziska LH, 2012, J ALLERGY CLIN IMMUN, V129, P27, DOI 10.1016/j.jaci.2011.10.032	10	11	13	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					878	879		10.1016/j.jaci.2018.01.017	http://dx.doi.org/10.1016/j.jaci.2018.01.017			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	29410333	Bronze			2022-12-18	WOS:000426974800005
J	Versluys, B; Bierings, M; Murk, JL; Wolfs, T; Lindemans, C; van der Ent, K; Boelens, JJ				Versluys, Birgitta; Bierings, Marc; Murk, Jean Luc; Wolfs, Tom; Lindemans, Caroline; van der Ent, Kors; Boelens, Jaap Jan			Infection with a respiratory virus before hematopoietic cell transplantation is associated with alloimmune-mediated lung syndromes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hematopoietic cell transplantation; respiratory virus; bronchoalveolar lavage; alloimmune lung syndromes; graft-versus-host disease; bronchiolitis obliterans syndrome; idiopathic pneumonia syndrome	VERSUS-HOST-DISEASE; IDIOPATHIC PNEUMONIA SYNDROME; ALLOGRAFT DYSFUNCTION; CLINICAL-TRIALS; CHILDREN; MICROBIOME; RHINOVIRUS; RECIPIENTS; MARROW; HEALTH	Background: Alloimmune-mediated lung syndromes (allo-LSs) are life-threatening complications after hematopoietic cell transplantation (HCT). Respiratory virus (RV) has been suggested to play a role in the pathogenesis. Objective: We studied the relation between RV DNA/RNA detection in the upper/lower airways before HCT and the occurrence of allo-LSs. Methods: We retrospectively analyzed all HCT recipients between 2004 and 2014, in whom real-time PCR for RV was performed in nasopharyngeal aspirates (NPAs) and bronchoalveolar lavage (BAL) fluid before HCT. The main outcome of interest was the presence of an allo-LS, which was defined as idiopathic pneumonia syndrome or bronchiolitis obliterans syndrome. Other outcomes were overall survival and treatment-related mortality. We used Cox proportional hazard models, logistic regression models, and Fine-Gray competing risk regression for analyses. Results: One hundred seventy-nine children (median age, 6.8 years) were included. RVs were found in 61% (41% in BAL fluid/NPAs and 20% in NPAs only). Rhinovirus was the most frequently detected RV (42%). Allo-LSs occurred in 13%. RV positivity in BAL fluid was a predictor for allo-LSs (hazard ratio, 3.8; 95% CI, 1.4-10.7; P = .01), whereas RV positivity in NPAs only was not. No other predictors were found. Grade II to IV acute graft-versus-host disease related to steroid treatment shows a trend toward a protective effect (odds ratio, 0.16; 95% CI, 0.0-1.3; P = .08). Allo-LSs significantly increased treatment-related mortality (52% 6 10% in allo-LSs and 20% 6 4% in non-allo-LSs, P = .007). Conclusions: These results show that pre-HCT BAL fluid RV positivity was a predictor for allo-LSs. Screening for RVs before HCT might identify patients at risk for allo-LSs. This could have implications for prevention and treatment and might subsequently influence the outcomes of HCT.	[Versluys, Birgitta; Bierings, Marc; Lindemans, Caroline; Boelens, Jaap Jan] Univ Med Ctr Utrecht, Dept Pediat, Blood & Marrow Transplantat Program, Lundlaan 6, NL-3584 EA Utrecht, Netherlands; [Murk, Jean Luc] Univ Med Ctr Utrecht, Dept Virol & Microbiol, Utrecht, Netherlands; [Wolfs, Tom] Univ Med Ctr Utrecht, Dept Pediat Infect Dis, Utrecht, Netherlands; [van der Ent, Kors] Univ Med Ctr Utrecht, Dept Pediat Pulmonol, Utrecht, Netherlands; [Boelens, Jaap Jan] Univ Med Ctr Utrecht, U DANCE Lab Translat Immunol, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Versluys, B (corresponding author), Univ Med Ctr Utrecht, Dept Pediat, Blood & Marrow Transplantat Program, Lundlaan 6, NL-3584 EA Utrecht, Netherlands.	a.b.versluys@umcutrecht.nl		Van der Ent, Cornelis/0000-0002-2501-4121; Murk, J.L./0000-0003-3661-9035	Chimerix (Brincidofovir)	Chimerix (Brincidofovir)	C. Lindemans has received Medical Consultancy fees from Chimerix (Brincidofovir). The rest of the authors declare that they have no relevant conflicts of interest.	Bredius RGM, 2004, PEDIATR INFECT DIS J, V23, P518, DOI 10.1097/01.inf.0000125161.33843.bb; Brennan TV, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00101; Cadwell K, 2015, IMMUNITY, V42, P805, DOI 10.1016/j.immuni.2015.05.003; Campbell AP, 2015, CLIN INFECT DIS, V61, P192, DOI 10.1093/cid/civ272; Cooke KR, 2005, PEDIATR TRANSPLANT, V9, P25, DOI 10.1111/j.1399-3046.2005.00450.x; Fisher CE, 2016, CLIN INFECT DIS, V62, P313, DOI 10.1093/cid/civ871; Gerna G, 2009, J MED VIROL, V81, P1498, DOI 10.1002/jmv.21548; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; Hirsch HH, 2013, CLIN INFECT DIS, V56, P258, DOI 10.1093/cid/cis844; Holtan SG, 2014, BLOOD, V124, P363, DOI 10.1182/blood-2014-01-514786; Huang YJ, 2013, AM J RESP CRIT CARE, V187, P1382, DOI 10.1164/rccm.201303-0488WS; Hutspardol S, 2015, BIOL BLOOD MARROW TR, V21, P1802, DOI 10.1016/j.bbmt.2015.06.015; Jagasia MH, 2015, BIOL BLOOD MARROW TR, V21, P389, DOI 10.1016/j.bbmt.2014.12.001; Kumar D, 2005, AM J TRANSPLANT, V5, P2031, DOI 10.1111/j.1600-6143.2005.00971.x; Kumar D, 2010, TRANSPLANTATION, V89, P1028, DOI 10.1097/TP.0b013e3181d05a71; Lynch Susan V, 2014, Ann Am Thorac Soc, V11 Suppl 1, pS57, DOI 10.1513/AnnalsATS.201306-158MG; Martin-Gandul C, 2015, AM J TRANSPLANT, V15, P3024, DOI 10.1111/ajt.13486; Panoskaltsis-Mortari A, 2011, AM J RESP CRIT CARE, V183, P1262, DOI 10.1164/rccm.2007-413ST; Reddy P, 2003, BLOOD REV, V17, P187, DOI 10.1016/S0268-960X(03)00009-2; Seo S, 2015, BLOOD, V125, P3789, DOI 10.1182/blood-2014-12-617035; Seo S, 2013, BIOL BLOOD MARROW TR, V19, pS167, DOI 10.1016/j.bbmt.2012.11.139; Shono Y, 2015, INT J HEMATOL, V101, P428, DOI 10.1007/s12185-015-1781-5; Srinivasan A, 2013, PEDIATR BLOOD CANCER, V60, P149, DOI 10.1002/pbc.24314; Tracy M, 2015, CURR OPIN PEDIATR, V27, P348, DOI 10.1097/MOP.0000000000000212; van de Pol AC, 2006, CRIT CARE, V10, DOI 10.1186/cc4895; van Montfrans Joris, 2015, Biol Blood Marrow Transplant, V21, P772, DOI 10.1016/j.bbmt.2015.01.009; Versluys AB, 2010, BIOL BLOOD MARROW TR, V16, P782, DOI 10.1016/j.bbmt.2009.12.534; Versluys AB, 2015, BIOL BLOOD MARROW TR, V21, P1622, DOI 10.1016/j.bbmt.2015.06.002; Vu DL, 2011, AM J TRANSPLANT, V11, P1071, DOI 10.1111/j.1600-6143.2011.03490.x; Yanik GA, 2015, BIOL BLOOD MARROW TR, V21, P67, DOI 10.1016/j.bbmt.2014.09.019; Yanik GA, 2014, BIOL BLOOD MARROW TR, V20, P858, DOI 10.1016/j.bbmt.2014.02.026	31	11	11	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					697	+		10.1016/j.jaci.2017.03.055	http://dx.doi.org/10.1016/j.jaci.2017.03.055			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	28716387	Green Published, Bronze			2022-12-18	WOS:000424410800026
J	Kim, WJ; Koo, JH; Cho, HJ; Lee, JU; Kim, JY; Lee, HG; Lee, S; Kim, JH; Oh, MS; Suh, M; Shin, EC; Ko, JY; Sohn, MH; Choi, JM				Kim, Won-Ju; Koo, Ja-Hyun; Cho, Hyun-Jung; Lee, Jae-Ung; Kim, Ji Yun; Lee, Hong-Gyun; Lee, Sohee; Kim, Jong Hoon; Oh, Mi Seon; Suh, Minah; Shin, Eui-Cheol; Ko, Joo Yeon; Sohn, Myung Hyun; Choi, Je-Min			Protein tyrosine phosphatase conjugated with a novel transdermal delivery peptide, astrotactin 1-derived peptide recombinant protein tyrosine phosphatase (AP-rPTP), alleviates both atopic dermatitis-like and psoriasis-like dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; psoriasis; transdermal delivery peptide; protein tyrosine phosphatase; T-cell protein tyrosine phosphatase; transcutaneous drug; immunomodulatory protein	SKIN PENETRATION ENHANCERS; TACROLIMUS OINTMENT; CYCLOSPORINE-A; NEGATIVE REGULATOR; TOPICAL DELIVERY; DRUG-DELIVERY; NC/NGA MICE; T-CELLS; INFLAMMATION; MECHANISMS	Background: Atopic dermatitis (AD) and psoriasis are the 2 most common chronic inflammatory skin diseases. There is an unmet medical need to overcome limitations for transcutaneous drug development posed by the skin barrier. Objective: We aimed to identify a novel transdermal delivery peptide and to develop a transcutaneously applicable immunomodulatory protein for treating AD and psoriasis. Methods: We identified and generated reporter proteins conjugated to astrotactin 1-derived peptide (AP), a novel transdermal delivery peptide of human origin, and analyzed the intracellular delivery efficiency of these proteins in mouse and human skin cells and tissues using multiphoton confocal microscopy. We also generated a recombinant therapeutic protein, AP-recombinant protein tyrosine phosphatase (rPTP), consisting of the phosphatase domain of the T-cell protein tyrosine phosphatase conjugated to AP. The immunomodulatory function of AP-rPTP was confirmed in splenocytes on cytokine stimulation and T-cell receptor stimulation. Finally, we confirmed the in vivo efficacy of AP-rPTP transdermal delivery in patients with oxazolone-induced contact hypersensitivity, ovalbumin-induced AD-like, and imiquimod-induced psoriasis-like skin inflammation models. Results: AP-conjugated reporter proteins exhibited significant intracellular transduction efficacy in keratinocytes, fibroblasts, and immune cells. In addition, transcutaneous administration of AP-dTomato resulted in significant localization into the dermis and epidermis in both mouse and human skin. AP-rPTP inhibited phosphorylated signal transducer and activator of transcription (STAT) 1, STAT3, and STAT6 in splenocytes and also regulated T-cell activation and proliferation. Transcutaneous administration of AP-rPTP through the paper-patch technique significantly ameliorated skin tissue thickening, inflammation, and cytokine expression in both AD-like and psoriasis-like dermatitis models. Conclusion: We identified a 9-amino-acid novel transdermal delivery peptide, AP, and demonstrated its feasibility for transcutaneous biologic drug development. Moreover, AP-rPTP is a novel immunomodulatory drug candidate for human dermatitis.	[Kim, Won-Ju; Koo, Ja-Hyun; Cho, Hyun-Jung; Lee, Jae-Ung; Kim, Ji Yun; Lee, Hong-Gyun; Choi, Je-Min] Hanyang Univ, Coll Nat Sci, Dept Life Sci, Seoul, South Korea; [Kim, Won-Ju; Koo, Ja-Hyun; Cho, Hyun-Jung; Lee, Jae-Ung; Kim, Ji Yun; Lee, Hong-Gyun; Choi, Je-Min] Hanyang Univ, Res Inst Nat Sci, Seoul, South Korea; [Lee, Sohee; Suh, Minah; Choi, Je-Min] Hanyang Univ, Dept Dermatol, Coll Med, Seoul, South Korea; [Kim, Jong Hoon; Shin, Eui-Cheol] Inst Basic Sci, CNIR, Suwon, South Korea; [Oh, Mi Seon; Sohn, Myung Hyun] Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Lab Immunol & Infect Dis, Daejeon, South Korea; [Suh, Minah] Yonsei Univ, Coll Med, Brain Korea PLUS Project Med Sci 21, Dept Pediat,Severance Hosp,Inst Allergy, Seoul, South Korea; [Suh, Minah] Sungkyunkwan Univ, Dept Biomed Engn, Suwon, South Korea; [Ko, Joo Yeon] SAIHST, Seoul, South Korea	Hanyang University; Hanyang University; Hanyang University; Institute for Basic Science - Korea (IBS); Korea Advanced Institute of Science & Technology (KAIST); Yonsei University; Yonsei University Health System; Sungkyunkwan University (SKKU)	Choi, JM (corresponding author), Hanyang Univ, Dept Life Sci, 222 Wangsimni Ro, Seoul 04763, South Korea.	jeminchoi@hanyang.ac.kr	Kim, Jong Hoon/I-3135-2019; Shin, Eui-Cheol/C-1690-2011	Kim, Jong Hoon/0000-0002-3385-8180; Shin, Eui-Cheol/0000-0002-6308-9503; Choi, Je-Min/0000-0002-9482-710X; Koo, Jahyun/0000-0002-0291-6288; Lee, Hong-Gyun/0000-0001-5960-5504; Kim, Wonju/0000-0002-1800-0485; Sohn, Myung Hyun/0000-0002-2478-487X	Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI14C0234]; Korea Drug Development Fund (KDDF) - Ministry of Science, ICT, and Future Planning [KDDF-201404-04]; Ministry of Trade, Industry, Energy; Ministry of Health Welfare	Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea; Korea Drug Development Fund (KDDF) - Ministry of Science, ICT, and Future Planning; Ministry of Trade, Industry, Energy; Ministry of Health Welfare	Supported by a grants from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), which is funded by the Ministry of Health & Welfare, Republic of Korea (grant no. HI14C0234). It was also supported in part by a grant (KDDF-201404-04 to J.-M.C.) from the Korea Drug Development Fund (KDDF), which is funded by the Ministry of Science, ICT, and Future Planning; the Ministry of Trade, Industry, & Energy; and the Ministry of Health & Welfare.	Amand HL, 2012, BIOCHEM BIOPH RES CO, V418, P469, DOI 10.1016/j.bbrc.2012.01.041; Aoki N, 2002, MOL ENDOCRINOL, V16, P58, DOI 10.1210/me.16.1.58; Barry BW, 2004, NAT BIOTECHNOL, V22, P165, DOI 10.1038/nbt0204-165; Bechara C, 2013, FASEB J, V27, P738, DOI 10.1096/fj.12-216176; Bos JD, 2000, EXP DERMATOL, V9, P165, DOI 10.1034/j.1600-0625.2000.009003165.x; Candan G, 2012, BIOMATERIALS, V33, P6468, DOI 10.1016/j.biomaterials.2012.04.056; Carretero M, 2016, J INVEST DERMATOL, V136, P136, DOI 10.1038/JID.2015.362; Chen M, 2015, J CONTROL RELEASE, V199, P190, DOI 10.1016/j.jconrel.2014.11.015; Chen YP, 2006, NAT BIOTECHNOL, V24, P455, DOI 10.1038/nbt1193; Cork MJ, 2009, J INVEST DERMATOL, V129, P1892, DOI 10.1038/jid.2009.133; Dalgard FJ, 2015, J INVEST DERMATOL, V135, P984, DOI 10.1038/jid.2014.530; DERIE MA, 1991, ACTA DERM-VENEREOL, V71, P452; Guttman-Yassky E, 2013, EXPERT OPIN BIOL TH, V13, P549, DOI 10.1517/14712598.2013.758708; Hamilton JD, 2014, J ALLERGY CLIN IMMUN, V134, P1293, DOI 10.1016/j.jaci.2014.10.013; Hanifin JM, 2001, J AM ACAD DERMATOL, V44, pS28, DOI 10.1067/mjd.2001.109810; Haw S, 2010, ANN DERMATOL, V22, P9, DOI 10.5021/ad.2010.22.1.9; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.0.CO;2-R; Hodge JA, 2016, CLIN EXP RHEUMATOL, V34, P318; Holgate ST, 2008, NAT REV IMMUNOL, V8, P218, DOI 10.1038/nri2262; Jensen KB, 2010, NAT PROTOC, V5, P898, DOI 10.1038/nprot.2010.39; Jha D, 2011, BIOCONJUGATE CHEM, V22, P319, DOI 10.1021/bc100045s; Karande P, 2004, NAT BIOTECHNOL, V22, P192, DOI 10.1038/nbt928; Kim SY, 2011, J INVEST DERMATOL, V131, P1477, DOI 10.1038/jid.2011.49; Kim YC, 2007, J CONTROL RELEASE, V122, P375, DOI 10.1016/j.jconrel.2007.05.031; Kirsner RS, 2010, ACTA DERM-VENEREOL, V90, P58, DOI 10.2340/00015555-0748; Koga C, 2008, J INVEST DERMATOL, V128, P2625, DOI 10.1038/jid.2008.111; Koivusalo M, 2010, J CELL BIOL, V188, P547, DOI 10.1083/jcb.200908086; Koo JH, 2014, MOL BIOL REP, V41, P8117, DOI 10.1007/s11033-014-3711-7; Kopf M, 2010, NAT REV DRUG DISCOV, V9, P703, DOI 10.1038/nrd2805; Koren E, 2012, TRENDS MOL MED, V18, P385, DOI 10.1016/j.molmed.2012.04.012; Kumar S, 2015, J CONTROL RELEASE, V199, P168, DOI 10.1016/j.jconrel.2014.12.006; Lane ME, 2013, INT J PHARMACEUT, V447, P12, DOI 10.1016/j.ijpharm.2013.02.040; Leonardi S, 2009, ANN ALLERG ASTHMA IM, V103, P86, DOI 10.1016/S1081-1206(10)60153-6; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Lim S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155689; Lim S, 2016, IMMUNE NETW, V16, P33, DOI 10.4110/in.2016.16.1.33; Lim S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9244; Lim S, 2012, MOL CELLS, V34, P577, DOI 10.1007/s10059-012-0284-y; Lowes MA, 2014, ANNU REV IMMUNOL, V32, P227, DOI 10.1146/annurev-immunol-032713-120225; Lu XQ, 2007, MOL CELL BIOL, V27, P2166, DOI 10.1128/MCB.01234-06; Machet L, 2002, INT J PHARMACEUT, V243, P1, DOI 10.1016/S0378-5173(02)00299-5; Mitragotri S, 2014, NAT REV DRUG DISCOV, V13, P655, DOI 10.1038/nrd4363; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Nomura T, 2016, J ALLERGY CLIN IMMUN, V138, P1548, DOI 10.1016/j.jaci.2016.10.004; Pasparakis M, 2014, NAT REV IMMUNOL, V14, P289, DOI 10.1038/nri3646; Prausnitz MR, 2008, NAT BIOTECHNOL, V26, P1261, DOI 10.1038/nbt.1504; Prausnitz MR, 2004, NAT REV DRUG DISCOV, V3, P115, DOI 10.1038/nrd1304; Rachakonda TD, 2014, J AM ACAD DERMATOL, V70, P512, DOI 10.1016/j.jaad.2013.11.013; Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359; Sakamoto T, 2004, GENE THER, V11, P317, DOI 10.1038/sj.gt.3302171; Sarrazin S., 2011, COLD SPRING HARB PER, V3; Sidbury R, 2014, J AM ACAD DERMATOL, V71, P327, DOI 10.1016/j.jaad.2014.03.030; Silverberg JI, 2013, J ALLERGY CLIN IMMUN, V132, P1132, DOI 10.1016/j.jaci.2013.08.031; Simoncic PD, 2002, CURR BIOL, V12, P446, DOI 10.1016/S0960-9822(02)00697-8; Spalinger MR, 2015, MUCOSAL IMMUNOL, V8, P918, DOI 10.1038/mi.2014.122; Sullivan SP, 2010, NAT MED, V16, P915, DOI 10.1038/nm.2182; Toke ER, 2014, GENE THER, V21, P566, DOI 10.1038/gt.2014.29; Uchida T, 2011, J PHARMACOL EXP THER, V338, P443, DOI 10.1124/jpet.111.180042; Walter JR, 2015, DRUG DISCOV TODAY, V20, P1293, DOI 10.1016/j.drudis.2015.06.007; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107; Wei ZW, 2015, SCI REP-UK, V5, DOI 10.1038/srep07618; Werfel T, 2016, J ALLERGY CLIN IMMUN, V138, P336, DOI 10.1016/j.jaci.2016.06.010; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; Wiede F, 2011, J CLIN INVEST, V121, P4758, DOI 10.1172/JCI59492; Xu XH, 2002, TRANSPLANTATION, V73, P1835, DOI 10.1097/00007890-200206150-00023; Yu JC, 2015, P NATL ACAD SCI USA, V112, P8260, DOI 10.1073/pnas.1505405112; Zempsky WT, 2004, CLIN THER, V26, P1110, DOI 10.1016/S0149-2918(04)90183-X; Zidovetzki R, 2007, BBA-BIOMEMBRANES, V1768, P1311, DOI 10.1016/j.bbamem.2007.03.026; Zikherman J, 2011, J CLIN INVEST, V121, P4618, DOI 10.1172/JCI60001; Zuris JA, 2015, NAT BIOTECHNOL, V33, P73, DOI 10.1038/nbt.3081	70	11	11	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					137	151		10.1016/j.jaci.2017.04.007	http://dx.doi.org/10.1016/j.jaci.2017.04.007			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28456618				2022-12-18	WOS:000419312200020
J	Albers, FC; Price, RG; Smith, SG; Yancey, SW				Albers, Frank C.; Price, Robert G.; Smith, Steven G.; Yancey, Steven W.			Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Albers, Frank C.; Yancey, Steven W.] GSK, Res Triangle Pk, NC 27709 USA; [Price, Robert G.] GSK, Stockley Pk, Uxbridge, Middx, England; [Smith, Steven G.] GSK, Mississauga, ON, Canada	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Albers, FC (corresponding author), GSK, Res Triangle Pk, NC 27709 USA.	frank.c.albers@gsk.com		Smith, Steven/0000-0001-9928-117X; Price, Robert/0000-0001-6418-6818	GSK [MEA115588, NCT01691521]	GSK(GlaxoSmithKline)	The analysis and parent study was funded by GSK (GSK ID: MEA115588/clinicaltrials. gov ID: NCT01691521).	Asthma G.I.F, 2017, GLOB STRAT ASTHM MAN; Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Reddel HK, 2015, EUR RESPIR J, V46, P622, DOI 10.1183/13993003.00853-2015	6	11	12	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2017	140	5					1464	+		10.1016/j.jaci.2017.06.010	http://dx.doi.org/10.1016/j.jaci.2017.06.010			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FL5RV	28687231	hybrid			2022-12-18	WOS:000414304300035
J	Movassagh, H; Shan, LY; Chakir, J; McConville, JF; Halayko, AJ; Koussih, L; Gounni, AS				Movassagh, Hesam; Shan, Lianyu; Chakir, Jamila; McConville, John F.; Halayko, Andrew J.; Koussih, Latifa; Gounni, Abdelilah S.			Expression of semaphorin 3E is suppressed in severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							AIRWAY INFLAMMATION		[Movassagh, Hesam; Shan, Lianyu; Koussih, Latifa; Gounni, Abdelilah S.] Univ Manitoba, Dept Immunol, Rady Fac Hlth Sci, Max Rady Coll Med, Winnipeg, MB, Canada; [Chakir, Jamila] Univ Laval, Ctr Rech, Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada; [McConville, John F.] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Halayko, Andrew J.] Univ Manitoba, Dept Physiol & Pathophysiol, Rady Fac Hlth Sci, Max Rady Coll Med, Winnipeg, MB, Canada; [Halayko, Andrew J.] Childrens Hosp Res Inst Manitoba, Biol Breathing Theme, Winnipeg, MB, Canada	University of Manitoba; Laval University; University of Chicago; University of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba	Gounni, AS (corresponding author), Univ Manitoba, Dept Immunol, Rady Fac Hlth Sci, Max Rady Coll Med, Winnipeg, MB, Canada.	abdel.gounni@umanitoba.ca	Gounni, Abdelilah Soussi/AAH-3456-2020	Gounni, Abdelilah/0000-0003-1265-6560; Halayko, Andrew/0000-0002-7865-4552; Movassagh, Hesam/0000-0002-0205-1069; Soussi Gounni, Abdelilah/0000-0002-7282-0388	Canadian Institutes of Health Research (MOP) [115115]; National Sciences and Engineering Research Council [RG PIN/386289]; Children Hospital Research Foundation [115115]; Research Manitoba-Children's Hospital Research Institute of Manitoba Studentship	Canadian Institutes of Health Research (MOP)(Canadian Institutes of Health Research (CIHR)); National Sciences and Engineering Research Council(Natural Sciences and Engineering Research Council of Canada (NSERC)); Children Hospital Research Foundation; Research Manitoba-Children's Hospital Research Institute of Manitoba Studentship	This work was supported by the Canadian Institutes of Health Research (MOP grant no. 115115), the National Sciences and Engineering Research Council (grant no. RG PIN/386289), and the Children Hospital Research Foundation (grant no. 115115 to A.S.G.). H.M. was supported by Research Manitoba-Children's Hospital Research Institute of Manitoba Studentship.	[Anonymous], 2000, Am J Respir Crit Care Med, V162, P2341; Bartemes KR, 2012, CLIN IMMUNOL, V143, P222, DOI 10.1016/j.clim.2012.03.001; Chakir J, 2000, METH MOLEC MED, V44, P53, DOI 10.1385/1-59259-072-1:53; Hekking PPW, 2014, J ALLER CL IMM-PRACT, V2, P671, DOI 10.1016/j.jaip.2014.09.007; Kumanogoh A, 2013, NAT REV IMMUNOL, V13, P802, DOI 10.1038/nri3545; Mizutani N, 2015, EUR J PHARMACOL, V764, P149, DOI 10.1016/j.ejphar.2015.07.004; Movassagh H, 2017, J IMMUNOL, V198, P1805, DOI 10.4049/jimmunol.1601514; Movassagh H, 2017, J IMMUNOL, V198, P1023, DOI 10.4049/jimmunol.1601093; Movassagh H, 2014, J ALLERGY CLIN IMMUN, V133, P560, DOI 10.1016/j.jaci.2013.06.011; Nkyimbeng-Takwi EH, 2012, MUCOSAL IMMUNOL, V5, P409, DOI 10.1038/mi.2012.18; Shim EJ, 2013, J KOREAN MED SCI, V28, P1435, DOI 10.3346/jkms.2013.28.10.1435	11	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2017	140	4					1176	+		10.1016/j.jaci.2017.04.031	http://dx.doi.org/10.1016/j.jaci.2017.04.031			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FI7JL	28506853	Bronze			2022-12-18	WOS:000412172900037
J	Mukai, K; Chinthrajah, RS; Nadeau, KC; Tsai, M; Gaudenzio, N; Galli, SJ				Mukai, Kaori; Chinthrajah, R. Sharon; Nadeau, Kari C.; Tsai, Mindy; Gaudenzio, Nicolas; Galli, Stephen J.			A new fluorescent-avidin-based method for quantifying basophil activation in whole blood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FLOW-CYTOMETRY		[Mukai, Kaori; Tsai, Mindy; Gaudenzio, Nicolas; Galli, Stephen J.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Mukai, Kaori; Chinthrajah, R. Sharon; Nadeau, Kari C.; Tsai, Mindy; Gaudenzio, Nicolas; Galli, Stephen J.] Stanford Univ, Sch Med, Sean N Parker Ctr Allergy & Asthma Res, Stanford, CA 94305 USA; [Chinthrajah, R. Sharon; Nadeau, Kari C.] Stanford Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Stanford, CA 94305 USA; [Gaudenzio, Nicolas] Univ Toulouse, INSERM, Unite Differenciat Epitheliale & Autoimmun Rhumat, UMR 1056, Toulouse, France; [Galli, Stephen J.] Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Stanford University	Gaudenzio, N; Galli, SJ (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA.; Gaudenzio, N; Galli, SJ (corresponding author), Stanford Univ, Sch Med, Sean N Parker Ctr Allergy & Asthma Res, Stanford, CA 94305 USA.; Gaudenzio, N (corresponding author), Univ Toulouse, INSERM, Unite Differenciat Epitheliale & Autoimmun Rhumat, UMR 1056, Toulouse, France.; Galli, SJ (corresponding author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA.	nicogaudenzio@gmail.com; sgalli@stanford.edu		Tsai, Mindy/0000-0002-8421-4721; Chinthrajah, Sharon/0000-0003-2467-4256; Gaudenzio, Nicolas/0000-0002-5648-509X	French "Fondation pour la Recherche Medicale FRM'' [SPE20130326582]; Philippe Foundation; National Institutes of Health/National Institute of Allergy and Infectious Disease [5U19AI104209]; Stanford Institute of Immunity, Transplantation and Infection; Department of Pathology, Stanford University; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI104209] Funding Source: NIH RePORTER	French "Fondation pour la Recherche Medicale FRM''(Fondation pour la Recherche Medicale); Philippe Foundation; National Institutes of Health/National Institute of Allergy and Infectious Disease(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Stanford Institute of Immunity, Transplantation and Infection; Department of Pathology, Stanford University(Stanford University); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	N.G. is supported by fellowships from the French "Fondation pour la Recherche Medicale FRM'' (award no. SPE20130326582) and the Philippe Foundation. This work was supported by the National Institutes of Health/National Institute of Allergy and Infectious Disease (grant no. 5U19AI104209), a Seed Grant from the Stanford Institute of Immunity, Transplantation and Infection, and the Department of Pathology, Stanford University.	AZORSA DO, 1991, BLOOD, V78, P280; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; DEBRUIJNEADMIRAAL LG, 1992, BLOOD, V80, P134; Ebo DG, 2008, CYTOM PART B-CLIN CY, V74B, P201, DOI 10.1002/cyto.b.20419; Gaudenzio N, 2016, J CLIN INVEST, V126, P3981, DOI 10.1172/JCI85538; Kleine-Tebbe J, 2006, INT ARCH ALLERGY IMM, V141, P79, DOI 10.1159/000094495; Mukai K, 2017, J ALLERGY CLIN IMMUN, V139, P889, DOI 10.1016/j.jaci.2016.04.060; Stone KD, 2010, J ALLERGY CLIN IMMUN, V125, pS73, DOI 10.1016/j.jaci.2009.11.017; VALENT P, 1990, CRIT REV ONCOL HEMAT, V10, P327, DOI 10.1016/1040-8428(90)90009-H	9	11	11	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2017	140	4					1202	+		10.1016/j.jaci.2017.03.052	http://dx.doi.org/10.1016/j.jaci.2017.03.052			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FI7JL	28606590	Green Accepted, Bronze			2022-12-18	WOS:000412172900046
J	Allenspach, EJ; Finn, LS; Rendi, MH; Eken, A; Singh, AK; Oukka, M; Taylor, SD; Altman, MC; Fligner, CL; Ochs, HD; Rawlings, DJ; Torgerson, TR				Allenspach, Eric J.; Finn, Laura S.; Rendi, Mara H.; Eken, Ahmet; Singh, Akhilesh K.; Oukka, Mohamed; Taylor, Sean D.; Altman, Matthew C.; Fligner, Corinne L.; Ochs, Hans D.; Rawlings, David J.; Torgerson, Troy R.			Absence of functional fetal regulatory T cells in humans causes in utero organ-specific autoimmunity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ENTEROPATHY		[Allenspach, Eric J.; Ochs, Hans D.; Rawlings, David J.; Torgerson, Troy R.] Univ Washington, Dept Pediat, Sch Med, Seattle, WA 98195 USA; [Allenspach, Eric J.; Eken, Ahmet; Singh, Akhilesh K.; Oukka, Mohamed; Taylor, Sean D.; Ochs, Hans D.; Rawlings, David J.; Torgerson, Troy R.] Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, Seattle, WA 98101 USA; [Finn, Laura S.] Seattle Childrens Hosp, Dept Labs, Seattle, WA USA; [Finn, Laura S.; Rendi, Mara H.; Fligner, Corinne L.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA; [Altman, Matthew C.] Benaroya Res Inst, Seattle, WA USA; [Altman, Matthew C.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; [Fligner, Corinne L.] Univ Washington, Sch Med, Dept Lab Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; Seattle Children's Hospital; Seattle Children's Hospital; University of Washington; University of Washington Seattle; Benaroya Research Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Torgerson, TR (corresponding author), Univ Washington, Dept Pediat, Sch Med, Seattle, WA 98195 USA.; Torgerson, TR (corresponding author), Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, Seattle, WA 98101 USA.	troy.torgerson@seattlechildrens.org	Rawlings, David/CAI-4751-2022; Eken, Ahmet/AAR-5863-2021; Eken, Ahmet/AAK-4232-2021	Eken, Ahmet/0000-0002-5816-0686; Allenspach, Eric/0000-0001-7346-5835	University of Washington Rheumatology Training Grant [T32-AR007108-32]; Children's Guild Association Endowed Chair in Pediatric Immunology; Benaroya Family Gift Fund; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI063267, R21AI124735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007108] Funding Source: NIH RePORTER	University of Washington Rheumatology Training Grant; Children's Guild Association Endowed Chair in Pediatric Immunology; Benaroya Family Gift Fund; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Funding support includes the University of Washington Rheumatology Training Grant (grant no. T32-AR007108-32 to E.J.A.). Additional support was provided by the Children's Guild Association Endowed Chair in Pediatric Immunology and the Benaroya Family Gift Fund (D.J.R.).	[Anonymous], 2016, AM J MED GENET A; Blankenberg Daniel, 2010, Curr Protoc Mol Biol, VChapter 19, DOI 10.1002/0471142727.mb1910s89; DeWitt WS, 2015, J VIROL, V89, P4517, DOI 10.1128/JVI.03474-14; Giardine B, 2005, GENOME RES, V15, P1451, DOI 10.1101/gr.4086505; Goecks J, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r86; Kobayashi I, 2001, J MED GENET, V38, P874, DOI 10.1136/jmg.38.12.874; Levy-Labad E, 2001, J PEDIATR-US, V138, P577, DOI 10.1067/mpd.2001.111502; Mold JE, 2008, SCIENCE, V322, P1562, DOI 10.1126/science.1164511; Rechavi E, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa0072; Rivas MN, 2012, J CLIN INVEST, V122, P1933, DOI 10.1172/JCI40591; Rubtsov YP, 2010, SCIENCE, V329, P1667, DOI 10.1126/science.1191996; Smith E, 2016, J PEDIATR GASTR NUTR, V63, pE119, DOI 10.1097/MPG.0000000000000554; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Williams LM, 2007, NAT IMMUNOL, V8, P277, DOI 10.1038/ni1437; Wu XW, 2006, GENE DEV, V20, P571, DOI 10.1101/gad.361406; Xavier-Da-Silva MM, 2015, CLIN IMMUNOL, V156, P131, DOI 10.1016/j.clim.2014.12.007	16	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					616	+		10.1016/j.jaci.2017.02.017	http://dx.doi.org/10.1016/j.jaci.2017.02.017			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28322850	Green Accepted			2022-12-18	WOS:000406855500045
J	Bielor, C; Sopel, N; Maier, A; Blau, A; Sharma, H; Vuorinen, T; Kross, B; Mittler, S; Graser, A; Mousset, S; Melichar, VO; Kiefer, A; Zimmermann, T; Springel, R; Holzinger, C; Trump, S; Taka, S; Papadopoulos, NG; Weiss, ST; Finotto, S				Bielor, Carina; Sopel, Nina; Maier, Anja; Blau, Ashley; Sharma, Himanshu; Vuorinen, Tytti; Kross, Bettina; Mittler, Susanne; Graser, Anna; Mousset, Stephanie; Melichar, Volker O.; Kiefer, Alexander; Zimmermann, Theodor; Springel, Rebekka; Holzinger, Corinna; Trump, Sonja; Taka, Stella; Papadopoulos, Nikolaos G.; Weiss, Scott T.; Finotto, Susetta			Role of TGF-beta in anti-rhinovirus immune responses in asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INFECTIONS		[Bielor, Carina; Sopel, Nina; Maier, Anja; Vuorinen, Tytti; Kross, Bettina; Mittler, Susanne; Graser, Anna; Mousset, Stephanie; Springel, Rebekka; Holzinger, Corinna; Trump, Sonja; Finotto, Susetta] Univ Klinikum Erlangen, Friedrich Alexander Univ FAU Erlangen Nurnberg, Dept Mol Pneumol, Erlangen, Germany; [Blau, Ashley; Sharma, Himanshu; Weiss, Scott T.] Partners HealthCare, Partners Biobank, Personalized Med, Translat Genom Core, Cambridge, MA USA; [Vuorinen, Tytti] Univ Turku, Dept Virol, Turku, Finland; [Melichar, Volker O.; Kiefer, Alexander; Zimmermann, Theodor] Univ Klinikum Erlangen, Friedrich Alexander Univ FAU Erlangen Nurnberg, Dept Allergy & Pneumol, Childrens Hosp, Erlangen, Germany; [Taka, Stella; Papadopoulos, Nikolaos G.] Univ Athens, Allergy & Clin Immunol Unit, Pediat Clin 2, Athens, Greece; [Papadopoulos, Nikolaos G.] Univ Manchester, Div Infect Inflammat & Resp Med, Manchester, Lancs, England	University of Erlangen Nuremberg; Partners Healthcare System; University of Turku; University of Erlangen Nuremberg; National & Kapodistrian University of Athens; University of Manchester	Finotto, S (corresponding author), Univ Klinikum Erlangen, Friedrich Alexander Univ FAU Erlangen Nurnberg, Dept Mol Pneumol, Erlangen, Germany.	susetta.finotto@uk-erlangen.de	Finotto, Susetta/H-2753-2019; N.G., Papadopoulos/L-8670-2013; Finotto, Susetta/AAL-3503-2020	N.G., Papadopoulos/0000-0002-4448-3468; Blau, Ashley/0000-0001-8770-9044	European Grant PreDicta (Post-infectious immune reprogramming and its association with persistence and chronicity of respiratory allergic diseases) in Erlangen; Department of Molecular Pneumology in Erlangen; DFG grant in Erlangen [SFB 643/TP 12]; Graduate Program in Erlangen [SFB 643]; MP-UKER	European Grant PreDicta (Post-infectious immune reprogramming and its association with persistence and chronicity of respiratory allergic diseases) in Erlangen; Department of Molecular Pneumology in Erlangen; DFG grant in Erlangen; Graduate Program in Erlangen; MP-UKER	Supported by the European Grant PreDicta (Post-infectious immune reprogramming and its association with persistence and chronicity of respiratory allergic diseases) in Erlangen and in the other European Centers, by the Department of Molecular Pneumology in Erlangen, and by a DFG grant (SFB 643/TP 12) in Erlangen. C.B. was supported by a fellowship of the SFB 643 Graduate Program in Erlangen. N.S. is supported by MP-UKER and the SFB 643.	Ajamian F, 2015, CLIN EXP ALLERGY, V45, P644, DOI 10.1111/cea.12498; Bedke N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044580; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; Khawar B, 2015, EUR J MED RES, V20, DOI 10.1186/s40001-015-0083-y; Lazarevic V, 2013, NAT REV IMMUNOL, V13, P777, DOI 10.1038/nri3536; Travis MA, 2014, ANNU REV IMMUNOL, V32, P51, DOI 10.1146/annurev-immunol-032713-120257	6	11	11	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					283	+		10.1016/j.jaci.2016.10.049	http://dx.doi.org/10.1016/j.jaci.2016.10.049			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	28139316	Green Published, hybrid			2022-12-18	WOS:000404542000033
J	Miyake, MM; Nocera, A; Levesque, P; Guo, R; Finn, CA; Goldfarb, J; Gray, S; Holbrook, E; Busaba, N; Dolci, JEL; Bleier, BS				Miyake, Marcel M.; Nocera, Angela; Levesque, Patricia; Guo, Rong; Finn, Christine A.; Goldfarb, Jeremy; Gray, Stacey; Holbrook, Eric; Busaba, Nicolas; Dolci, Jose Eduardo L.; Bleier, Benjamin S.			Double-blind placebo-controlled randomized clinical trial of verapamil for chronic rhinosinusitis with nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							P-GLYCOPROTEIN; SECRETION		[Miyake, Marcel M.; Nocera, Angela; Levesque, Patricia; Gray, Stacey; Holbrook, Eric; Busaba, Nicolas; Bleier, Benjamin S.] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Div Rhinol, Boston, MA 02115 USA; [Miyake, Marcel M.; Dolci, Jose Eduardo L.] Santa Casa de Sao Paulo Sch Med Sci, Dept Otolaryngol, Sao Paulo, Brazil; [Guo, Rong] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Div Biostat, Boston, MA USA; [Finn, Christine A.] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Pharm, Boston, MA USA; [Goldfarb, Jeremy] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Anesthesiol, Boston, MA USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary	Bleier, BS (corresponding author), Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Div Rhinol, Boston, MA 02115 USA.	benjamin_bleier@meei.harvard.edu	Bleier, Benjamin S/H-6726-2019; Miyake, Marcel M/AAL-6788-2020	Bleier, Benjamin S/0000-0003-0783-8861; Miyake, Marcel/0000-0002-8485-0496	Medtronic; MEEI Curing Kids Fund; Cook Medical	Medtronic(Medtronic); MEEI Curing Kids Fund; Cook Medical	S. Gray has received travel support from Medtronic. E. Holbrook has consultant arrangements with 480 Biomedical and has provided expert testimony for Margol & Margol PA. B. S. Bleier has received grants from MEEI Curing Kids Fund and Cook Medical; has consultant arrangements with Olympus, Canon, and Storz; has provided expert testimony on ENT-related cases; has a patent for P-gp inhibition for chronic rhinosinusitis and receives royalties from this patent; and has stock/stock options in Interscope. The rest of the authors declare that they have no relevant conflicts of interest.	Bachert C, 2016, JAMA-J AM MED ASSOC, V315, P469, DOI 10.1001/jama.2015.19330; Bleier BS, 2016, INT FORUM ALLERGY RH, V6, P169, DOI 10.1002/alr.21566; Bleier BS, 2015, INT FORUM ALLERGY RH, V5, P10, DOI 10.1002/alr.21436; Bleier BS, 2014, INT FORUM ALLERGY RH, V4, P488, DOI 10.1002/alr.21316; Bleier BS, 2012, INT FORUM ALLERGY RH, V2, P122, DOI 10.1002/alr.21004; Feldman RE, 2013, INT FORUM ALLERGY RH, V3, P684, DOI 10.1002/alr.21176; Hopkins C, 2009, CLIN OTOLARYNGOL, V34, P447, DOI 10.1111/j.1749-4486.2009.01995.x; Mihalcea Mihaela, 2012, J Emerg Trauma Shock, V5, P208, DOI 10.4103/0974-2700.96509; Nocera AL, 2016, AM J RHINOL ALLERGY, V30, P246, DOI 10.2500/ajra.2016.30.4330	9	11	11	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					271	273		10.1016/j.jaci.2016.11.014	http://dx.doi.org/10.1016/j.jaci.2016.11.014			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	28126245	Bronze			2022-12-18	WOS:000404542000029
J	Jurkin, J; Krump, C; Koffel, R; Fieber, C; Schuster, C; Brunner, PM; Borek, I; Eisenwort, G; Lim, C; Mages, J; Lang, R; Bauer, W; Mechtcheriakova, D; Meshcheryakova, A; Elbe-Burger, A; Stingl, G; Strobl, H				Jurkin, Jennifer; Krump, Corinna; Koeffel, Rene; Fieber, Christina; Schuster, Christopher; Brunner, Patrick M.; Borek, Izabela; Eisenwort, Gregor; Lim, Clarice; Mages, Joerg; Lang, Roland; Bauer, Wolfgang; Mechtcheriakova, Diana; Meshcheryakova, Anastasia; Elbe-Burger, Adelheid; Stingl, Georg; Strobl, Herbert			Human skin dendritic cell fate is differentially regulated by the monocyte identity factor Kruppel-like factor 4 during steady state and inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Kruppel-like factor 4; Runt-related transcription factor 3; TGF-beta 1 signaling; Notch; lineage decision; monocyte differentiation	EPIDERMAL LANGERHANS CELLS; COLONY-STIMULATING FACTOR; PERIPHERAL-BLOOD MONOCYTES; T-CELLS; NOTCH LIGAND; CORD BLOOD; TGF-BETA; IN-VITRO; HEMATOPOIETIC PROGENITORS; CLUSTER FORMATION	Background: Langerhans cell (LC) networks play key roles in immunity and tolerance at body surfaces. LCs are established prenatally and can be replenished from blood monocytes. Unlike skin-resident dermal DCs (dDCs)/interstitial-type DCs and inflammatory dendritic epidermal cells appearing in dermatitis/eczema lesions, LCs lack key monocyte-affiliated markers. Inversely, LCs express various epithelial genes critical for their long-term peripheral tissue residency. Objective: Dendritic cells (DCs) are functionally involved in inflammatory diseases; however, the mechanisms remained poorly understood. Methods: In vitro differentiation models of human DCs, gene profiling, gene transduction, and immunohistology were used to identify molecules involved in DC subset specification. Results: Here we identified the monocyte/macrophage lineage identity transcription factor Kruppel-like factor 4 (KLF4) to be inhibited during LC differentiation from human blood monocytes. Conversely, KLF4 is maintained or induced during dermal DC and monocyte-derived dendritic cell/inflammatory dendritic epidermal cell differentiation. We showed that in monocytic cells KLF4 has to be repressed to allow their differentiation into LCs. Moreover, respective KLF4 levels in DC subsets positively correlate with proinflammatory characteristics. We identified epithelial Notch signaling to repress KLF4 in monocytes undergoing LC commitment. Loss of KLF4 in monocytes transcriptionally derepresses Runt-related transcription factor 3 in response to TGF-beta 1, thereby allowing LC differentiation marked by a low cytokine expression profile. Conclusion: Monocyte differentiation into LCs depends on activation of Notch signaling and the concomitant loss of KLF4.	[Krump, Corinna; Borek, Izabela; Lim, Clarice; Strobl, Herbert] Med Univ Graz, Inst Pathophysiol & Immunol, Heinrichstr 31A, A-8010 Graz, Austria; [Jurkin, Jennifer; Koeffel, Rene; Fieber, Christina; Eisenwort, Gregor; Lim, Clarice; Strobl, Herbert] Med Univ Vienna, Inst Immunol, Vienna, Austria; [Schuster, Christopher; Brunner, Patrick M.; Bauer, Wolfgang; Elbe-Burger, Adelheid; Stingl, Georg] Med Univ Vienna, Div Immunol Allergy & Infect Dis, Dept Dermatol, Vienna, Austria; [Mechtcheriakova, Diana; Meshcheryakova, Anastasia] Med Univ Vienna, Dept Pathophysiol, Vienna, Austria; [Mechtcheriakova, Diana; Meshcheryakova, Anastasia] Med Univ Vienna, Dept Allergy Res, Vienna, Austria; [Mages, Joerg; Lang, Roland] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Inst Clin Microbiol Immunol & Hyg, Erlangen, Germany	Medical University of Graz; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; University of Erlangen Nuremberg	Strobl, H (corresponding author), Med Univ Graz, Inst Pathophysiol & Immunol, Heinrichstr 31A, A-8010 Graz, Austria.	herbert.strobl@medunigraz.at	Eisenwort, Gregor/E-7761-2018; Köffel, René/ABI-2028-2020	Eisenwort, Gregor/0000-0003-2735-4645; Köffel, René/0000-0001-9477-4282; Borek, Izabela/0000-0002-2527-6199; Mechtcheriakova, Diana/0000-0002-8737-3592; Bauer, Wolfgang/0000-0002-0155-1176; Lim, Clarice/0000-0001-7297-0055; Lang, Roland/0000-0003-0502-3677; Brunner, Patrick/0000-0002-3488-3345; Strobl, Herbert/0000-0002-8070-4977; Meshcheryakova, Anastasia/0000-0003-4359-9546	Austrian Science Fund (FWF) [P19474-B13, P22441-B13, P23228-B19, P22058, P19245, P25720, SFB-2304];  [W1212];  [W1248-B13];  [W1241]; Austrian Science Fund (FWF) [P 25720] Funding Source: researchfish	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); ; ; ; Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	Supported by research grants of the Austrian Science Fund (FWF; P19474-B13 to A.E.-B., P22441-B13 and P23228-B19 to D.M., and P22058, P19245, P25720, and SFB-2304 to H.S.) and the PhD programs W1212 "Inflammation and Immunity," W1248-B13 "Molecular, Cellular and Clinical Allergology," and W1241 "Molecular Fundamentals of Inflammation."	Alder JK, 2008, J IMMUNOL, V180, P5645, DOI 10.4049/jimmunol.180.8.5645; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Canque B, 2000, BLOOD, V96, P3748, DOI 10.1182/blood.V96.12.3748.h8003748_3748_3756; Caux C, 1997, BLOOD, V90, P1458, DOI 10.1182/blood.V90.4.1458.1458_1458_1470; Chopin M, 2013, J EXP MED, V210, P2967, DOI 10.1084/jem.20130930; Eisenwort G, 2011, J INVEST DERMATOL, V131, P2049, DOI 10.1038/jid.2011.164; Fainaru O, 2004, EMBO J, V23, P969, DOI 10.1038/sj.emboj.7600085; Feinberg MW, 2007, EMBO J, V26, P4138, DOI 10.1038/sj.emboj.7601824; Feinberg MW, 2005, J BIOL CHEM, V280, P38247, DOI 10.1074/jbc.M509378200; Gaiser MR, 2012, P NATL ACAD SCI USA, V109, pE889, DOI 10.1073/pnas.1117674109; Gatti E, 2000, J IMMUNOL, V164, P3600, DOI 10.4049/jimmunol.164.7.3600; Geissmann F, 1998, J EXP MED, V187, P961, DOI 10.1084/jem.187.6.961; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Ginhoux F, 2006, NAT IMMUNOL, V7, P265, DOI 10.1038/ni1307; Gobel F, 2009, BLOOD, V114, P3813, DOI 10.1182/blood-2009-03-210484; Gold D, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-2; Hacker C, 2003, NAT IMMUNOL, V4, P380, DOI 10.1038/ni903; Haddad R, 2004, BLOOD, V104, P3918, DOI 10.1182/blood-2004-05-1845; Heinz LX, 2006, BLOOD, V107, P1445, DOI 10.1182/blood-2005-04-1721; Hirata N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5806; Hoshino N, 2005, J LEUKOCYTE BIOL, V78, P921, DOI 10.1189/jlb.1204746; Hu D, 2011, J BIOL CHEM, V286, P6890, DOI 10.1074/jbc.M110.179952; Hutter C, 2012, BLOOD, V120, P5199, DOI 10.1182/blood-2012-02-410241; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jaksits S, 1999, J IMMUNOL, V163, P4869; Jin S, 2013, ONCOGENE, V32, P4892, DOI 10.1038/onc.2012.517; Jorgl A, 2007, BLOOD, V109, P185, DOI 10.1182/blood-2006-05-022954; Kaplan DH, 2010, TRENDS IMMUNOL, V31, P446, DOI 10.1016/j.it.2010.08.006; Klechevsky E, 2008, IMMUNITY, V29, P497, DOI 10.1016/j.immuni.2008.07.013; Klechevsky E, 2009, HUM IMMUNOL, V70, P281, DOI 10.1016/j.humimm.2009.02.004; LANSDORP PM, 1990, J EXP MED, V172, P363, DOI 10.1084/jem.172.1.363; Larregina AT, 2001, NAT IMMUNOL, V2, P1151, DOI 10.1038/ni731; Manz MG, 2002, P NATL ACAD SCI USA, V99, P11872, DOI 10.1073/pnas.172384399; McGovern N, 2014, IMMUNITY, V41, P465, DOI 10.1016/j.immuni.2014.08.006; Merad M, 2008, NAT REV IMMUNOL, V8, P935, DOI 10.1038/nri2455; Mildner A, 2014, IMMUNITY, V40, P642, DOI 10.1016/j.immuni.2014.04.016; Milne P, 2015, BLOOD, V125, P470, DOI 10.1182/blood-2014-08-593582; Ohishi K, 2001, BLOOD, V98, P1402, DOI 10.1182/blood.V98.5.1402; Pearson R, 2008, INT J BIOCHEM CELL B, V40, P1996, DOI 10.1016/j.biocel.2007.07.018; Pickl WF, 1996, J IMMUNOL, V157, P3850; Platzer B, 2004, BLOOD, V104, P3655, DOI 10.1182/blood-2004-02-0412; Ratzinger G, 2004, J IMMUNOL, V173, P2780, DOI 10.4049/jimmunol.173.4.2780; Riedl E, 2000, BLOOD, V96, P4276; Riedl E, 2000, J IMMUNOL, V165, P1381, DOI 10.4049/jimmunol.165.3.1381; Schuster C, 2009, J EXP MED, V206, P169, DOI 10.1084/jem.20081747; Senechal B, 2007, PLOS MED, V4, P1374, DOI 10.1371/journal.pmed.0040253; Seneschal J, 2012, IMMUNITY, V36, P873, DOI 10.1016/j.immuni.2012.03.018; Sere K, 2012, IMMUNITY, V37, P905, DOI 10.1016/j.immuni.2012.07.019; Spittau B, 2012, CELL TISSUE RES, V347, P65, DOI 10.1007/s00441-011-1186-6; Stary G, 2011, J IMMUNOL, V186, P103, DOI 10.4049/jimmunol.1002485; Stary G, 2010, AM J PATHOL, V177, P2421, DOI 10.2353/ajpath.2010.100277; Strobl H, 1997, BLOOD, V90, P1425, DOI 10.1182/blood.V90.4.1425.1425_1425_1434; Tussiwand R, 2015, IMMUNITY, V42, P916, DOI 10.1016/j.immuni.2015.04.017; Ueno H, 2007, IMMUNOL REV, V219, P118, DOI 10.1111/j.1600-065X.2007.00551.x; Varnum-Finney B, 2000, J CELL SCI, V113, P4313; Wollenberg A, 2002, J INVEST DERMATOL, V118, P327, DOI 10.1046/j.0022-202x.2001.01665.x; Xu YR, 2015, MOL BIOL CELL, V26, P1199, DOI 10.1091/mbc.E14-12-1591; Yasmin N, 2013, J INVEST DERMATOL, V133, P1250, DOI 10.1038/jid.2012.481; Yusuf I, 2008, INT IMMUNOL, V20, P671, DOI 10.1093/intimm/dxn024; Zheng H, 2009, AM J PHYSIOL-GASTR L, V296, pG490, DOI 10.1152/ajpgi.90393.2008; Zimmerli SC, 2007, J INVEST DERMATOL, V127, P2381, DOI 10.1038/sj.jid.5700882	61	11	11	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					1873	+		10.1016/j.jaci.2016.09.018	http://dx.doi.org/10.1016/j.jaci.2016.09.018			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	27742396	Green Accepted, hybrid, Green Published			2022-12-18	WOS:000402724600018
J	Ogburn, RN; Randall, TA; Xu, YR; Roberts, JH; Mebrahtu, B; Karnuta, JM; Rider, SD; Kissling, GE; London, RE; Pomes, A; Arlian, L; Fitzgerald, MC; Mueller, GA				Ogburn, Ryenne N.; Randall, Thomas A.; Xu, Yingrong; Roberts, Julia H.; Mebrahtu, Betelihem; Karnuta, Jaret M.; Rider, S. Dean; Kissling, Grace E.; London, Robert E.; Pomes, Anna; Arlian, Larry; Fitzgerald, Michael C.; Mueller, Geoffrey A.			Are dust mite allergens more abundant and/or more stable than other Dermatophagoides pteronyssinus proteins?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Ogburn, Ryenne N.; Xu, Yingrong; Roberts, Julia H.; Mebrahtu, Betelihem; Karnuta, Jaret M.; Fitzgerald, Michael C.] Duke Univ, Dept Chem, Durham, NC 27706 USA; [Randall, Thomas A.; Kissling, Grace E.; London, Robert E.; Mueller, Geoffrey A.] NIEHS, Intramural Program, POB 12233, Res Triangle Pk, NC 27709 USA; [Rider, S. Dean; Arlian, Larry] Wright State Univ, Fairbornc, OH USA; [Pomes, Anna] Indoor Biotechnol, Charlottesville, VA USA	Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University System of Ohio; Wright State University Dayton; INDOOR Biotechnologies	Mueller, GA (corresponding author), NIEHS, Intramural Program, POB 12233, Res Triangle Pk, NC 27709 USA.	Geoffrey.Mueller@nih.gov	Pomés, Anna/H-7010-2019; London, Robert E/F-7990-2019; Mueller, Geoffrey A/I-2909-2017	Pomés, Anna/0000-0002-8729-1829; London, Robert E/0000-0001-9108-8463; Mueller, Geoffrey A/0000-0001-8361-5323; Randall, Thomas/0000-0002-4605-7606	Intramural Research Program of the National Institute of Environmental Health Sciences [Z01-ES102906-01]; Extramural Research Program of the National Institute of General Medical Sciences [2R01-GM08174]; National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R01AI077653]; National Science Foundation [CHE-1308093]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI077653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES103106, ZIAES102906] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM084174] Funding Source: NIH RePORTER	Intramural Research Program of the National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Extramural Research Program of the National Institute of General Medical Sciences; National Institute of Allergy and Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Science Foundation(National Science Foundation (NSF)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was supported in part by the Intramural Research Program of the National Institute of Environmental Health Sciences (grant no. Z01-ES102906-01 to R.E.L.), the Extramural Research Program of the National Institute of General Medical Sciences (grant no. 2R01-GM08174 to M.C.F.), the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (grant no. R01AI077653 to A.P.), and the National Science Foundation (grant no. CHE-1308093 to M.C.F.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Baldacci S, 2015, RESP MED, V109, P1089, DOI 10.1016/j.rmed.2015.05.017; Batard T, 2016, ALLERGY, V71, P220, DOI 10.1111/all.12796; Bonnelykke K, 2015, CURR OPIN IMMUNOL, V36, P115, DOI 10.1016/j.coi.2015.08.002; Chan TF, 2015, J ALLERGY CLIN IMMUN, V135, P539, DOI 10.1016/j.jaci.2014.09.031; Gilles-Stein S, 2016, ALLERGOLOGIE, V39, P69, DOI 10.5414/ALX01815; Machado Y, 2016, J ALLERGY CLIN IMMUN, V137, P1525, DOI 10.1016/j.jaci.2015.09.026; Morrison D.F., 1976, MULTIVARIATE STAT ME; Platts-Mills TAE, 2015, J ALLERGY CLIN IMMUN, V136, P3, DOI 10.1016/j.jaci.2015.03.048; Thomas WR, 2015, ALLERGOL INT, V64, P304, DOI 10.1016/j.alit.2015.05.004; Vogel C, 2012, NAT REV GENET, V13, P227, DOI 10.1038/nrg3185; Xu YR, 2014, ANAL CHEM, V86, P7041, DOI 10.1021/ac501278j	11	11	11	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					1030	1032		10.1016/j.jaci.2016.08.016	http://dx.doi.org/10.1016/j.jaci.2016.08.016			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27771129	Green Accepted, Bronze			2022-12-18	WOS:000397295800035
J	Londei, M; Kenney, B; Los, G; Marino, MH				Londei, Marco; Kenney, Brian; Los, Gerrit; Marino, Margaret H.			A Phase 1 Study of ANB020, an anti-IL-33 monoclonal Antibody in Healthy Volunteers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI)	MAR 03-16, 2017	Atlanta, GA	Amer Acad Allergy, Asthma & Immunol					[Londei, Marco; Kenney, Brian; Los, Gerrit; Marino, Margaret H.] AnaptysBio, San Diego, CA USA										0	11	14	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2		S		232	AB73	AB73		10.1016/j.jaci.2016.12.286	http://dx.doi.org/10.1016/j.jaci.2016.12.286			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	EV4AF		Bronze			2022-12-18	WOS:000401699800135
J	Qiao, YK; Tam, JKC; Tan, SSL; Tai, YK; Chin, CY; Stewart, AG; Ashman, L; Sekiguchi, K; Langenbach, SY; Stelmack, G; Halayko, AJ; Tran, T				Qiao, Yongkang; Tam, John Kit Chung; Tan, Sheryl S. L.; Tai, Yee Kit; Chin, Chin Yein; Stewart, Alastair G.; Ashman, Leonie; Sekiguchi, Kiyotoshi; Langenbach, Shenna Y.; Stelmack, Gerald; Halayko, Andrew J.; Tran, Thai		Melbourne Epidemiological Study	CD151, a laminin receptor showing increased expression in asthmatic patients, contributes to airway hyperresponsiveness through calcium signaling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway hyperresponsiveness; airway smooth muscle; asthma; contraction; calcium; CD151; G protein-coupled receptor; integrins; laminin; PKC; tetraspanin	SMOOTH-MUSCLE-CELLS; TETRASPANIN CD151; TH2 LYMPHOCYTES; RENAL-DISEASE; PHENOTYPE; MICE; CA2+; PKC; HYPERCONTRACTILE; CARCINOGENESIS	Background: Airway smooth muscle (ASM) contraction underpins airway constriction; however, underlying mechanisms for airway hyperresponsiveness (AHR) remain incompletely defined. CD151, a 4-transmembrane glycoprotein that associates with laminin-binding integrins, is highly expressed in the human lung. The role of CD151 in ASM function and its relationship to asthma have yet to be elucidated. Objective: We sought to ascertain whether CD151 expression is clinically relevant to asthma and whether CD151 expression affects AHR. Methods: Using immunohistochemical analysis, we determined the expression of CD151 in human bronchial biopsy specimens from patients with varying asthma severities and studied the mechanism of action of CD151 in the regulation of ASM contraction and bronchial caliber in vitro, ex vivo, and in vivo. Results: The number of CD151 1 ASM cells is significantly greater in patients with moderate asthma compared with those in healthy nonasthmatic subjects. Fromloss-and gain-of-function studies, we reveal that CD151 is required for and enhances G protein-coupled receptor (GPCR)-induced peak intracellular calcium release, the primary determinant of excitation-contraction coupling. We show that the localization of CD151 can also be perinuclear/cytoplasmic and offer an explanation for a novel functional role for CD151 in supporting protein kinase C (PKC) translocation to the cell membrane in GPCR-mediated ASM contraction at this site. Importantly, CD151(-/-) mice are refractory to airway hyperreactivity in response to allergen challenge. Conclusions: We identify a role for CD151 in human ASM contraction. We implicate CD151 as a determinant of AHR in vivo, likely through regulation of GPCR-induced calcium and PKC signaling. These observations have significant implications in understanding the mechanism for AHR and the efficacy of new and emerging therapeutics.	[Qiao, Yongkang; Tan, Sheryl S. L.; Tai, Yee Kit; Chin, Chin Yein; Tran, Thai] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117548, Singapore; [Tam, John Kit Chung] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Surg, Singapore 117548, Singapore; [Stewart, Alastair G.; Langenbach, Shenna Y.] Univ Melbourne, Dept Pharmacol & Therapeut, Melbourne, Vic 3010, Australia; [Stewart, Alastair G.; Langenbach, Shenna Y.] Univ Melbourne, Lung Hlth Res Ctr, Melbourne, Vic 3010, Australia; [Ashman, Leonie] Univ Newcastle, Sch Biomed Sci, Callaghan, NSW 2308, Australia; [Sekiguchi, Kiyotoshi] Osaka Univ, Inst Prot Res, Suita, Osaka 565, Japan; [Stelmack, Gerald; Halayko, Andrew J.] Univ Manitoba, Dept Physiol & Pathophysiol, Winnipeg, MB, Canada; [Stelmack, Gerald; Halayko, Andrew J.] Manitoba Inst Child Hlth, Biol Breathing Theme, Winnipeg, MB, Canada	National University of Singapore; National University of Singapore; University of Melbourne; University of Melbourne; University of Newcastle; Osaka University; University of Manitoba	Tran, T (corresponding author), Natl Univ Singapore, Dept Physiol, Block MD9,2 Med Dr, Singapore 117597, Singapore.	tran_thai@nuhs.edu.sg	Tai, Yee Kit/HCH-5864-2022; Tai, Yee Kit/AHB-6200-2022; Tai, Yee Kit/AAC-9347-2020; Tran, Thai/D-9087-2012; Tam, John/B-6048-2012	Tai, Yee Kit/0000-0003-0798-3575; stewart, alastair/0000-0002-2271-5942; TRAN, Thai/0000-0002-8662-3676; Halayko, Andrew/0000-0002-7865-4552	Deputy President (Research & Technology) start-up grant; NHMRC project [1045372, 1059665]; Canadian Institutes of Health Research; Canada Research Chairs Program; Singapore Ministry of Health's National Medical Research Council under its IRG scheme [NMRC/1215/2009]	Deputy President (Research & Technology) start-up grant; NHMRC project(National Health and Medical Research Council (NHMRC) of Australia); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canada Research Chairs Program(Canada Research Chairs); Singapore Ministry of Health's National Medical Research Council under its IRG scheme(Ministry of Health-SingaporeNational Medical Research Council, Singapore)	J.K.C.T. is supported by the Deputy President (Research & Technology) start-up grant. A.G.S. is supported by NHMRC project grants #1045372 and #1059665. Part of this work was supported by an operating grant to A.J.H. from the Canadian Institutes of Health Research. A.J.H. is supported by the Canada Research Chairs Program. This research is supported in part by the Singapore Ministry of Health's National Medical Research Council under its IRG scheme (NMRC/1215/2009) and by the Deputy President (Research & Technology) start-up grant (to T.T.).	Abdala-Valencia H, 2015, J IMMUNOL, V195, P1377, DOI 10.4049/jimmunol.1302874; Ammit AJ, 2000, AM J RESP CRIT CARE, V161, P257, DOI 10.1164/ajrccm.161.1.9901005; An SS, 2007, EUR RESPIR J, V29, P834, DOI 10.1183/09031936.00112606; [Anonymous], 2016, NHLBI WHO WORKSH REP; Ashman LK, 2013, ONCOGENE, V32, P4457, DOI 10.1038/onc.2013.73; Ashman LK, 2002, J BIOL REG HOMEOS AG, V16, P223; Baleato RM, 2008, AM J PATHOL, V173, P927, DOI 10.2353/ajpath.2008.071149; Bao Z, 2009, AM J RESP CRIT CARE, V179, P657, DOI 10.1164/rccm.200809-1516OC; BRAMLEY AM, 1994, EUR RESPIR J, V7, P337, DOI 10.1183/09031936.94.07020337; Dixon RE, 2013, J GEN PHYSIOL, V141, P161, DOI 10.1085/jgp.201210953; Fanger CM, 2000, J IMMUNOL, V164, P1153, DOI 10.4049/jimmunol.164.3.1153; Halayko AJ, 1996, AM J PHYSIOL-LUNG C, V270, pL1040, DOI 10.1152/ajplung.1996.270.6.L1040; Hasegawa A, 2003, J VIROL, V77, P2956, DOI 10.1128/JVI.77.5.2956-2963.2003; Hemler ME, 2013, ONCOGENE, V32, P4458, DOI 10.1038/onc.2013.79; Horak E, 2003, BRIT MED J, V326, P422, DOI 10.1136/bmj.326.7386.422; Ijpma G, 2015, AM J RESP CRIT CARE, V191, P884, DOI 10.1164/rccm.201407-1296OC; Keenan CR, 2015, PHARMACOL THERAPEUT, V150, P81, DOI 10.1016/j.pharmthera.2015.01.006; Leguillette R, 2009, AM J RESP CRIT CARE, V179, P194, DOI 10.1164/rccm.200609-1367OC; Ma XF, 2002, AM J PHYSIOL-LUNG C, V283, pL1181, DOI 10.1152/ajplung.00389.2001; Ma XF, 1998, AM J PHYSIOL-CELL PH, V274, pC1206, DOI 10.1152/ajpcell.1998.274.5.C1206; Matusovsky OS, 2016, AM J RESP CELL MOL, V54, P718, DOI 10.1165/rcmb.2015-0180OC; Minner S, 2012, PATHOLOGY, V44, P448, DOI 10.1097/PAT.0b013e32835576ee; OSWALD H, 1994, BRIT MED J, V309, P95, DOI 10.1136/bmj.309.6947.95; Sachs N, 2006, J CELL BIOL, V175, P33, DOI 10.1083/jcb.200603073; Sanderson Michael J, 2008, Proc Am Thorac Soc, V5, P23, DOI 10.1513/pats.200704-050VS; Shigeta M, 2003, J CELL BIOL, V163, P165, DOI 10.1083/jcb.200301075; Sincock PM, 1997, J HISTOCHEM CYTOCHEM, V45, P515, DOI 10.1177/002215549704500404; Sweeney D, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0009-z; Syyong HT, 2011, J APPL PHYSIOL, V111, P642, DOI 10.1152/japplphysiol.00085.2011; Tan SSL, 2014, AM J RESP CELL MOL, V50, P451, DOI 10.1165/rcmb.2013-0273OC; Tran T, 2013, FASEB J, V27, P3991, DOI 10.1096/fj.12-221341; Toldi G, 2012, IMMUNOBIOLOGY, V217, P37, DOI 10.1016/j.imbio.2011.08.007; Tran T, 2003, BRIT J PHARMACOL, V138, P865, DOI 10.1038/sj.bjp.0705106; Tran T, 2007, AM J RESP CELL MOL, V37, P668, DOI 10.1165/rcmb.2007-0165OC; Tran T, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-117; Wang L, 2004, AM J RESP CELL MOL, V31, P54, DOI 10.1165/rcmb.2003-0240OC; Ward JE, 2008, EUR RESPIR J, V32, P362, DOI 10.1183/09031936.00119307; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200	38	11	14	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					82	+		10.1016/j.jaci.2016.03.029	http://dx.doi.org/10.1016/j.jaci.2016.03.029			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27233153	Bronze			2022-12-18	WOS:000393996800010
J	Bandoli, G; von Ehrenstein, O; Ghosh, JK; Ritz, B				Bandoli, Gretchen; von Ehrenstein, Ondine; Ghosh, Jo Kay; Ritz, Beate			Synergistic effects of air pollution and psychosocial stressors on adolescent lung function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RESPIRATORY HEALTH		[Bandoli, Gretchen; Ritz, Beate] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90095 USA; [von Ehrenstein, Ondine] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Community Hlth Sci, Los Angeles, CA USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Bandoli, G (corresponding author), Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90095 USA.	gbandoli@ucla.edu		Bandoli, Gretchen/0000-0003-2167-8921	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R03ES025908] Funding Source: NIH RePORTER; NIEHS NIH HHS [R03 ES025908, P50 ES012383] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Astell-Burt T, 2013, HEALTH PLACE, V23, P171, DOI 10.1016/j.healthplace.2013.07.004; Chen ZH, 2015, J THORAC DIS, V7, P46, DOI 10.3978/j.issn.2072-1439.2014.12.20; Clougherty JE, 2009, ENVIRON HEALTH PERSP, V117, P1351, DOI 10.1289/ehp.0900612; Hansel A, 2010, NEUROSCI BIOBEHAV R, V35, P115, DOI 10.1016/j.neubiorev.2009.12.012; Islam T, 2011, AM J RESP CRIT CARE, V184, P822, DOI 10.1164/rccm.201104-0720OC; Kelly FJ, 2003, OCCUP ENVIRON MED, V60, P612, DOI 10.1136/oem.60.8.612; Peters J, 2004, PREV MED BALTIM; Peterson CE, 2012, LOS ANGELES FAMILY N; Wright RJ, 2011, IMMUNOL ALLERGY CLIN, V31, P19, DOI 10.1016/j.iac.2010.09.011	9	11	11	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2016	138	3					918	+		10.1016/j.jaci.2016.04.012	http://dx.doi.org/10.1016/j.jaci.2016.04.012			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DY9ZM	27262744	Green Accepted, Bronze			2022-12-18	WOS:000385496000036
J	Brigida, I; Scaramuzza, S; Lazarevic, D; Cittaro, D; Ferrua, F; Leonardelli, L; Alessio, M; Forma, O; Lanzani, C; Viarengo, G; Ciceri, F; Jankovic, M; Pesce, F; Aiuti, A; Cicalese, MP				Brigida, Immacolata; Scaramuzza, Samantha; Lazarevic, Dejan; Cittaro, Davide; Ferrua, Francesca; Leonardelli, Lorena; Alessio, Maria; Forma, Ornella; Lanzani, Chiara; Viarengo, Gianluca; Ciceri, Fabio; Jankovic, Momcilo; Pesce, Fernando; Aiuti, Alessandro; Cicalese, Maria Pia			A novel genomic inversion in Wiskott-Aldrich-associated autoinflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CLINICAL-FEATURES; SINGLE-CENTER; AUTOIMMUNITY		[Brigida, Immacolata; Scaramuzza, Samantha; Ferrua, Francesca; Leonardelli, Lorena; Aiuti, Alessandro; Cicalese, Maria Pia] Hosp San Raffaele, San Raffaele Telethon Inst Gene Therapy SR TIGE, Milan, Italy; [Lazarevic, Dejan; Cittaro, Davide] Hosp San Raffaele, Ctr Translat Genom & BioInformat, Milan, Italy; [Ferrua, Francesca; Aiuti, Alessandro; Cicalese, Maria Pia] IRCCS San Raffaele Sci Inst, Pediat Immunohematol & Bone Marrow Transplantat U, Milan, Italy; [Ferrua, Francesca; Ciceri, Fabio; Aiuti, Alessandro] Univ Vita Salute San Raffaele, Milan, Italy; [Alessio, Maria] Univ Naples Federico II, Dept Pediat, Rheumatol Unit, Naples, Italy; [Forma, Ornella] IRCCS San Raffaele Sci Inst, Vulnol Nursing Serv, Milan, Italy; [Lanzani, Chiara] IRCCS San Raffaele Sci Inst, Dept Nephrol, Milan, Italy; [Viarengo, Gianluca] Fdn IRCCS Policlin S Matteo, Immunohaematol & Transfus Serv, Pavia, Italy; [Ciceri, Fabio] IRCCS San Raffaele Sci Inst, Haematol & Bone Marrow Transplantat Unit, Milan, Italy; [Jankovic, Momcilo] Univ Milano Bicocca, Fdn Monza & Brianza Bambino & Sua Mamma, San Gerardo Hosp, Monza, Italy; [Pesce, Fernando] ASO SS Antonio & Biagio & Cesare Arrigo, Alessandria, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; University of Naples Federico II; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; IRCCS Fondazione San Matteo; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; San Gerardo Hospital; University of Milano-Bicocca; Azienda Ospedaliera SS Antonio Biagio Cesare Arrigo	Aiuti, A (corresponding author), Hosp San Raffaele, San Raffaele Telethon Inst Gene Therapy SR TIGE, Milan, Italy.; Aiuti, A (corresponding author), IRCCS San Raffaele Sci Inst, Pediat Immunohematol & Bone Marrow Transplantat U, Milan, Italy.; Aiuti, A (corresponding author), Univ Vita Salute San Raffaele, Milan, Italy.	aiuti.alessandro@hsr.it	Lanzani, Chiara Livia/AAN-2284-2020; Scaramuzza, Samantha/AAN-2204-2020; Cittaro, Davide/K-2405-2018; Ferrua, Francesca/K-4340-2016; Lazarevic, Dejan/AAN-1861-2020; AIUTI, ALESSANDRO/K-3918-2016	Lanzani, Chiara Livia/0000-0002-5332-4012; Scaramuzza, Samantha/0000-0003-2903-3650; Cittaro, Davide/0000-0003-0384-3700; Ferrua, Francesca/0000-0002-5695-4490; AIUTI, ALESSANDRO/0000-0002-5398-1717; Brigida, Immacolata/0000-0002-0338-2230; lazarevic, dejan/0000-0003-4527-290X	Telethon [TGTGSK03] Funding Source: Medline	Telethon(Fondazione Telethon)		Chen JM, 2005, HUM MUTAT, V26, P362, DOI 10.1002/humu.20230; Chen N, 2015, EUR J PEDIATR, V174, P1311, DOI 10.1007/s00431-015-2527-3; Dupuis-Girod S, 2003, PEDIATRICS, V111, pE622, DOI 10.1542/peds.111.5.e622; Geusau A, 2013, JAMA DERMATOL, V149, P209, DOI 10.1001/2013.jamadermatol.717; Imai K, 2004, BLOOD, V103, P456, DOI 10.1182/blood-2003-05-1480; Moratto D, 2011, BLOOD, V118, P1675, DOI 10.1182/blood-2010-11-319376; Scaramuzza S, 2013, MOL THER, V21, P175, DOI 10.1038/mt.2012.23; Starnes TW, 2014, BLOOD, V123, P2703, DOI 10.1182/blood-2013-07-516948	8	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2016	138	2					619	622		10.1016/j.jaci.2016.03.007	http://dx.doi.org/10.1016/j.jaci.2016.03.007			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DS5PY	27113846	hybrid, Green Published			2022-12-18	WOS:000380835800044
J	Katial, RK; Martucci, M; Burnett, T; Faino, A; Finkas, L; Liu, SC; Alam, R				Katial, Rohit K.; Martucci, Michael; Burnett, Trever; Faino, Anna; Finkas, Lindsay; Liu, Sucai; Alam, Rafeul			Nonsteroidal anti-inflammatory-induced inhibition of signal transducer and activator of transcription 6 (STAT-6) phosphorylation in aspirin-exacerbated respiratory disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aspirin-exacerbated respiratory disease; IL-4 signaling inhibition; pSTAT6 inhibition; mechanism of aspirin desensitization	SENSITIVE ASTHMATIC SUBJECTS; DESENSITIZATION-TREATMENT; URINARY LEUKOTRIENE-E4; RHINOSINUSITIS-ASTHMA; BRONCHIAL BIOPSIES; CELLS; PATHOGENESIS; PATHWAY; CANCER	Background: Aspirin desensitization provides long-term clinical benefits. The exact mechanisms of aspirin desensitization are not clearly understood. Objective: We sought to evaluate the effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on T-cell activation of the IL-4 pathway in aspirin-sensitive patients with asthma and control subjects. Methods: A total of 11 aspirin-sensitive patients with asthma, 10 aspirin-tolerant patients with asthma, and 10 controls without asthma were studied. PBMCs were stimulated with an anti-CD3 antibody and IL-4 or IL-12, with and without the presence of NSAIDs. The expression of phosphorylated signal transducers and activators of transcription 6 (pSTAT6), phosphorylated signal transducers and activators of transcription 4, and IL-4 was detected in CD4 T cells by flow cytometry. Results: Stimulation with a combination of anti-CD3 and IL-4 induced pSTAT6 in CD4 T cells from all subjects. The induction of pSTAT6 was significantly higher in aspirin-sensitive patients with asthma than in controls subjects. The increase in pSTAT6 was inhibited in a dose-dependent manner by aspirin and indomethacin and minimally by sodium salicylate. This inhibition was strongest in aspirin-sensitive patients. Two-group comparisons showed significant differences in pSTAT6 inhibition by all concentrations of indomethacin and aspirin: between aspirin-sensitive and aspirin-tolerant groups and between aspirin-sensitive and control groups. No differences were found between aspirin-tolerant and control groups at all 3 concentrations. The inhibition of pSTAT6 was associated with reduced IL-4 expression. Conclusions: NSAIDs inhibited signal transducers and activators of transcription 6 signaling in CD4 T cells. This inhibition was significantly higher in aspirin-sensitive patients than in aspirin-tolerant subjects and was associated with reduced expression of IL-4. These findings have implications for clinical benefits of aspirin desensitization in aspirin-sensitive patients with asthma.	[Katial, Rohit K.; Martucci, Michael; Burnett, Trever; Faino, Anna; Finkas, Lindsay; Liu, Sucai; Alam, Rafeul] Natl Jewish Hlth, Denver, CO USA	National Jewish Health	Katial, RK (corresponding author), 1400 Jackson St, Denver, CO 80206 USA.	katialr@njhealth.org			National Jewish Health; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL126895] Funding Source: NIH RePORTER	National Jewish Health; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	National Jewish Health supported this study.	Antczak A, 2002, AM J RESP CRIT CARE, V166, P301, DOI 10.1164/rccm.2101021; Berges-Gimeno MP, 2003, ANN ALLERG ASTHMA IM, V90, P338, DOI 10.1016/S1081-1206(10)61803-0; Berges-Gimeno MP, 2003, J ALLERGY CLIN IMMUN, V111, P180, DOI 10.1067/mai.2003.7; Cahill KN, 2015, J ALLERGY CLIN IMMUN, V135, P245, DOI 10.1016/j.jaci.2014.07.031; Christianson CA, 2015, J ALLERGY CLIN IMMUN, V136, P59, DOI 10.1016/j.jaci.2014.11.037; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; Cianferoni A, 2001, BLOOD, V97, P1742, DOI 10.1182/blood.V97.6.1742; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Daffern PJ, 1999, J ALLERGY CLIN IMMUN, V104, P559, DOI 10.1016/S0091-6749(99)70324-6; Irvin C, 2014, J ALLERGY CLIN IMMUN, V134, P1175, DOI 10.1016/j.jaci.2014.05.038; JUERGENS UR, 1995, J ALLERGY CLIN IMMUN, V96, P148, DOI 10.1016/S0091-6749(95)70002-1; Katial RK, 2010, J ALLERGY CLIN IMMUN, V126, P738, DOI 10.1016/j.jaci.2010.06.036; Klimek L, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0441-9; Kumar A, 2012, BIOSCIENCE REP, V32, P91, DOI 10.1042/BSR20110027; Machado FS, 2006, NAT MED, V12, P330, DOI 10.1038/nm1355; Nasser SMS, 1996, AM J RESP CRIT CARE, V153, P90, DOI 10.1164/ajrccm.153.1.8542168; NASSER SMS, 1995, AM J RESP CRIT CARE, V151, P1326, DOI 10.1164/ajrccm.151.5.7735581; Perez-G M, 2002, J IMMUNOL, V168, P1428, DOI 10.4049/jimmunol.168.3.1428; PICADO C, 1992, AM REV RESPIR DIS, V145, P65, DOI 10.1164/ajrccm/145.1.65; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; Slattery ML, 2014, BREAST CANCER RES TR, V147, P145, DOI 10.1007/s10549-014-3071-y; Slattery ML, 2013, MOL CARCINOGEN, V52, P155, DOI 10.1002/mc.21841; SMITH CM, 1992, EUR RESPIR J, V5, P693; Steinke JW, 2014, J IMMUNOL, V193, P41, DOI 10.4049/jimmunol.1301753; Steinke JW, 2013, J ALLERGY CLIN IMMUN, V132, P856, DOI 10.1016/j.jaci.2013.05.008; Steinke JW, 2009, J ALLERGY CLIN IMMUN, V124, P724, DOI 10.1016/j.jaci.2009.07.031; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V73, P500, DOI 10.1016/0091-6749(84)90361-0; Stevenson DD, 1996, J ALLERGY CLIN IMMUN, V98, P751, DOI 10.1016/S0091-6749(96)70123-9; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; Widal M, 1922, PRESSE MED, V30, P189	30	11	11	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2016	138	2					579	585		10.1016/j.jaci.2015.11.038	http://dx.doi.org/10.1016/j.jaci.2015.11.038			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DS5PY	26915678				2022-12-18	WOS:000380835800031
J	Liu, AH; Anderson, WC; Dutmer, CM; Searing, DA; Szefler, SJ				Liu, Andrew H.; Anderson, William C., III; Dutmer, Cullen M.; Searing, Daniel A.; Szefler, Stanley J.			Advances in asthma 2015: Across the lifespan	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; exacerbation; chronic obstructive pulmonary disease; pregnancy; allergen sensitization; allergy; genetics; epigenetics; transcriptome; microbiome; disparities; race/ethnicity; rhinovirus; respiratory syncytial virus; fungi/mold; IL-5; IgE; IFN-alpha; eosinophil; T(H)2; ORMDL3; CDHR3; GATA3	OBSTRUCTIVE PULMONARY-DISEASE; CHILDHOOD ASTHMA; DNA METHYLATION; RHINOVIRUS C; RISK; EXACERBATIONS; ASSOCIATIONS; MICROBIOME; PREGNANCY; SUSCEPTIBILITY	In 2015, progress in understanding asthma ranged from insights to asthma inception, exacerbations, and severity to advancements that will improve disease management throughout the lifespan. 2015's insights to asthma inception included how the intestinal microbiome affects asthma expression with the identification of specific gastrointestinal bacterial taxa in early infancy associated with less asthma risk, possibly by promoting regulatory immune development at a critical early age. The relevance of epigenetic mechanisms in regulating asthma-related gene expression was strengthened. Predicting and preventing exacerbations throughout life might help to reduce progressive lung function decrease and disease severity in adulthood. Although allergy has long been linked to asthma exacerbations, a mechanism through which IgE impairs rhinovirus immunity and underlies asthma exacerbations was demonstrated and improved by anti-IgE therapy (omalizumab). Other key molecular pathways underlying asthma exacerbations, such as cadherin-related family member 3 (CDHR3) and orosomucoid like 3 (ORMDL3), were elucidated. New anti-IL-5 therapeutics, mepolizumab and reslizumab, were US Food and Drug Administration approved for the treatment of patients with severe eosinophilic asthma. In a clinical trial the novel therapeutic inhaled GATA3 mRNA-specific DNAzyme attenuated early- and late-phase allergic responses to inhaled allergen. These current findings are significant steps toward addressing unmet needs in asthma prevention, severity modification, disparities, and lifespan outcomes.	[Liu, Andrew H.; Szefler, Stanley J.] Childrens Hosp Colorado, Breathing Inst & Pulm Med Sect, Aurora, CO USA; [Anderson, William C., III; Dutmer, Cullen M.; Searing, Daniel A.] Childrens Hosp Colorado, Allergy & Immunol Sect, Aurora, CO USA; [Anderson, William C., III; Dutmer, Cullen M.; Searing, Daniel A.] Univ Colorado, Sch Med, Aurora, CO USA	Children's Hospital Colorado; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Liu, AH (corresponding author), Childrens Hosp Colorado, 13123 E 16th Ave,Box B395, Aurora, CO 80045 USA.	Andrew.liu@childrenscolorado.org		Szefler, Stanley/0000-0002-6911-3199	Merck; Journal of Allergy and Clinical Immunology; GlaxoSmithKline	Merck(Merck & Company); Journal of Allergy and Clinical Immunology; GlaxoSmithKline(GlaxoSmithKline)	A. H. Liu serves on the board for GlaxoSmithKline and receives payment for lectures from Merck. D. A. Searing receives payment for manuscript preparation from the Journal of Allergy and Clinical Immunology and received travel support from the Inner City Asthma Consortium and the American Academy of Pediatrics. S. J. Szefler serves as a consultant for Roche, AstraZeneca, Aerocrine, Daiichi Sankyo, Boehringer-Ingelheim, Merck, Genentech, Novartis; and has grant support from GlaxoSmithKline. The rest of the authors declare that they have no relevant conflicts of interest.	Acevedo N, 2015, HUM MOL GENET, V24, P875, DOI 10.1093/hmg/ddu479; Anderson WC, 2015, J ALLERGY CLIN IMMUN, V136, P848, DOI 10.1016/j.jaci.2015.07.007; Apter AJ, 2015, J ALLERGY CLIN IMMUN, V135, P46, DOI 10.1016/j.jaci.2014.10.050; Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Arrieta MC, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab2271; Barnes PJ, 2015, J ALLERGY CLIN IMMUN, V136, P531, DOI 10.1016/j.jaci.2015.05.052; Bateman ED, 2015, J ALLERGY CLIN IMMUN, V135, P1457, DOI 10.1016/j.jaci.2014.08.015; Beigelman A, 2015, J ALLERGY CLIN IMMUN, V135; Beigelman A, 2015, J ALLERGY CLIN IMMUN, V136, P1135, DOI 10.1016/j.jaci.2015.07.013; Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291; Bizzintino J, 2011, EUR RESPIR J, V37, P1037, DOI 10.1183/09031936.00092410; Bochkov YA, 2015, P NATL ACAD SCI USA, V112, P5485, DOI 10.1073/pnas.1421178112; Bonnelykke K, 2014, NAT GENET, V46, P51, DOI 10.1038/ng.2830; Bouchaud G, 2015, J ALLERGY CLIN IMMUN, V136, P197, DOI 10.1016/j.jaci.2014.12.1938; Brown SD, 2015, J ALLERGY CLIN IMMUN, V135, P1651, DOI 10.1016/j.jaci.2014.08.054; Calhoun WJ, 2015, J ALLERGY CLIN IMMUN, V136, P1125, DOI 10.1016/j.jaci.2015.05.014; Caliskan M, 2013, NEW ENGL J MED, V368, P1398, DOI 10.1056/NEJMoa1211592; Castanhinha S, 2015, J ALLERGY CLIN IMMUN, V136, P312, DOI 10.1016/j.jaci.2015.01.016; Castro M, 2015, LANCET RESP MED, V3, P355, DOI [10.1016/S2213-2600(15)00042-9, 10.1016/S2213-2600(15)00119-8]; Crameri R, 2014, ALLERGY, V69, P176, DOI 10.1111/all.12325; Darveaux J, 2015, J ALLER CL IMM-PRACT, V3, P152, DOI 10.1016/j.jaip.2014.09.014; Davis MF, 2015, J ALLERGY CLIN IMMUN, V135, P811, DOI 10.1016/j.jaci.2014.10.052; Dunn RM, 2015, AM J RESP CRIT CARE, V192, P551, DOI 10.1164/rccm.201503-0426OC; Eltonsy S, 2015, J ALLERGY CLIN IMMUN, V135, P123, DOI 10.1016/j.jaci.2014.07.051; Fisk WJ, 2007, INDOOR AIR, V17, P284, DOI 10.1111/j.1600-0668.2007.00475.x; Garcia E, 2015, J ALLERGY CLIN IMMUN, V136, P610, DOI 10.1016/j.jaci.2015.01.030; Garne E, 2015, J ALLERGY CLIN IMMUN, V136, P1496, DOI 10.1016/j.jaci.2015.05.043; Gascon M, 2015, J ALLERGY CLIN IMMUN, V135, P370, DOI 10.1016/j.jaci.2014.09.030; Gelb AF, 2015, J ALLERGY CLIN IMMUN, V136, P553, DOI 10.1016/j.jaci.2015.06.013; Ghebre MA, 2015, J ALLERGY CLIN IMMUN, V135, P63, DOI 10.1016/j.jaci.2014.06.035; Harb H, 2015, J ALLERGY CLIN IMMUN, V136, P200, DOI 10.1016/j.jaci.2015.01.027; Hekking PPW, 2015, J ALLERGY CLIN IMMUN, V135, P896, DOI 10.1016/j.jaci.2014.08.042; Hernandez ML, 2015, J ALLERGY CLIN IMMUN, V135, P379, DOI 10.1016/j.jaci.2014.07.039; Holt PG, 2015, J ALLERGY CLIN IMMUN, V136, P15, DOI 10.1016/j.jaci.2015.05.011; Homburg U, 2015, J ALLERGY CLIN IMMUN, V136, P797, DOI 10.1016/j.jaci.2015.02.018; Huang YJ, 2015, J ALLERGY CLIN IMMUN, V136, P874, DOI 10.1016/j.jaci.2015.05.044; Huang YJ, 2015, J ALLERGY CLIN IMMUN, V135, P25, DOI 10.1016/j.jaci.2014.11.011; Jackson DJ, 2015, J ALLERGY CLIN IMMUN, V136; Jartti T, 2015, J ALLERGY CLIN IMMUN, V135, P691, DOI 10.1016/j.jaci.2014.07.001; Jutel M, 2015, J ALLERGY CLIN IMMUN, V136, P556, DOI 10.1016/j.jaci.2015.04.047; Keet CA, 2015, J ALLERGY CLIN IMMUN, V135, P655, DOI 10.1016/j.jaci.2014.11.022; Kim S, 2015, J ALLERGY CLIN IMMUN, V136, P1215, DOI 10.1016/j.jaci.2015.04.043; Krug N, 2015, NEW ENGL J MED, V372, P1987, DOI 10.1056/NEJMoa1411776; Larose MC, 2015, J ALLERGY CLIN IMMUN, V136, P904, DOI 10.1016/j.jaci.2015.02.039; Legrand F, 2015, J ALLER CL IMM-PRACT, V3, P167, DOI 10.1016/j.jaip.2015.01.013; Liu AH, 2015, J ALLERGY CLIN IMMUN, V136, P860, DOI 10.1016/j.jaci.2015.08.012; Lo CY, 2015, J ALLERGY CLIN IMMUN, V135, P1186, DOI 10.1016/j.jaci.2014.10.031; Mendell MJ, 2011, ENVIRON HEALTH PERSP, V119, P748, DOI 10.1289/ehp.1002410; Mika M, 2015, J ALLERGY CLIN IMMUN, V135, P905, DOI 10.1016/j.jaci.2014.12.1909; Namazy J, 2015, J ALLERGY CLIN IMMUN, V135, P407, DOI 10.1016/j.jaci.2014.08.025; Ortega Hector, 2014, Ann Am Thorac Soc, V11, P1011, DOI 10.1513/AnnalsATS.201312-454OC; Ownby DR, 2015, J ALLERGY CLIN IMMUN, V136, P595, DOI 10.1016/j.jaci.2015.02.007; Patel MR, 2015, J ALLERGY CLIN IMMUN, V135, P1444, DOI 10.1016/j.jaci.2014.11.008; Persson H, 2015, J ALLERGY CLIN IMMUN, V136, P638, DOI 10.1016/j.jaci.2015.02.026; Postma DS, 2015, J ALLERGY CLIN IMMUN, V136, P521, DOI 10.1016/j.jaci.2015.06.018; Quansah R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047526; Raedler D, 2015, J ALLERGY CLIN IMMUN, V135, P81, DOI 10.1016/j.jaci.2014.07.046; Reddel HK, 2015, J ALLERGY CLIN IMMUN, V136, P546, DOI 10.1016/j.jaci.2015.06.043; Schedel M, 2015, J ALLERGY CLIN IMMUN, V136, P893, DOI 10.1016/j.jaci.2015.03.014; Sharpe RA, 2015, J ALLERGY CLIN IMMUN, V135, P110, DOI 10.1016/j.jaci.2014.07.002; Simpson A, 2015, J ALLERGY CLIN IMMUN, V136, P1224, DOI 10.1016/j.jaci.2015.03.027; Sordillo JE, 2015, J ALLERGY CLIN IMMUN, V135, P441, DOI 10.1016/j.jaci.2014.07.065; Sullivan PW, 2015, J ALLERGY CLIN IMMUN, V136, P1409, DOI 10.1016/j.jaci.2015.04.046; Szefler SJ, 2015, J ALLERGY CLIN IMMUN, V135, P644, DOI 10.1016/j.jaci.2014.12.1921; Teach SJ, 2015, J ALLERGY CLIN IMMUN, V136, P1476, DOI 10.1016/j.jaci.2015.09.008; Teach SJ, 2015, J ALLERGY CLIN IMMUN, V135, P1465, DOI 10.1016/j.jaci.2014.12.1942; Tovey ER, 2015, J ALLERGY CLIN IMMUN, V135, P663, DOI 10.1016/j.jaci.2014.10.020; Traister RS, 2015, J ALLERGY CLIN IMMUN, V135, P92, DOI 10.1016/j.jaci.2014.06.023; Wang CH, 2015, J ALLERGY CLIN IMMUN, V135, P1154, DOI 10.1016/j.jaci.2014.09.011; West CE, 2015, J ALLERGY CLIN IMMUN, V135, P3, DOI 10.1016/j.jaci.2014.11.012; Yang IV, 2015, J ALLERGY CLIN IMMUN, V136, P69, DOI 10.1016/j.jaci.2015.01.025	71	11	14	1	37	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2016	138	2					397	404		10.1016/j.jaci.2016.06.013	http://dx.doi.org/10.1016/j.jaci.2016.06.013			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DS5PY	27497278	Bronze			2022-12-18	WOS:000380835800008
J	Ryan, D; Fowler, SJ; Niven, RM				Ryan, Dorothy; Fowler, Stephen J.; Niven, Robert M.			Reduction in peripheral blood eosinophil counts after bronchial thermoplasty	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SEVERE ASTHMA; SMOOTH-MUSCLE		[Ryan, Dorothy; Niven, Robert M.] NHS Fdn Trust, Univ Hosp South Manchester, Manchester, Lancs, England; [Ryan, Dorothy; Fowler, Stephen J.; Niven, Robert M.] Univ Manchester, Ctr Resp Med & Allergy, Inst Inflammat & Repair, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England; [Ryan, Dorothy; Fowler, Stephen J.; Niven, Robert M.] NHS Fdn Trust, Univ Hosp South Manchester, Manchester, Lancs, England; [Fowler, Stephen J.] Lancashire Teaching Hosp NHS Fdn Trust, Preston, Lancs, England	Oxford University Hospitals NHS Foundation Trust; Wythenshawe Hospital NHS Foundation Trust; University of Manchester; Oxford University Hospitals NHS Foundation Trust; Wythenshawe Hospital NHS Foundation Trust	Ryan, D (corresponding author), NHS Fdn Trust, Univ Hosp South Manchester, Manchester, Lancs, England.; Ryan, D (corresponding author), Univ Manchester, Ctr Resp Med & Allergy, Inst Inflammat & Repair, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.; Ryan, D (corresponding author), NHS Fdn Trust, Univ Hosp South Manchester, Manchester, Lancs, England.	dorothy.ryan@uhsm.nhs.uk		Fowler, Stephen/0000-0002-4524-1663				Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Bousquet J, 2010, J ALLERGY CLIN IMMUN, V126, P926, DOI 10.1016/j.jaci.2010.07.019; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Calven J, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0645-3; Castro M, 2010, AM J RESP CRIT CARE, V181, P116, DOI 10.1164/rccm.200903-0354OC; Danek CJ, 2004, J APPL PHYSIOL, V97, P1946, DOI 10.1152/japplphysiol.01282.2003; Denner DR, 2015, ANN AM THORAC SOC, V12, P1302, DOI 10.1513/AnnalsATS.201502-082OC; Fowler SJ, 2015, J ALLERGY CLIN IMMUN, V135, P822, DOI 10.1016/j.jaci.2014.09.034; Wilson SJ, 2013, CLIN EXP ALLERGY, V43, P1342, DOI 10.1111/cea.12156	9	11	13	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					308	310		10.1016/j.jaci.2015.11.044	http://dx.doi.org/10.1016/j.jaci.2015.11.044			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	26953157	Bronze			2022-12-18	WOS:000379659100041
J	Sobh, A; Chou, J; Schneider, L; Geha, RS; Massaad, MJ				Sobh, Ali; Chou, Janet; Schneider, Lynda; Geha, Raif S.; Massaad, Michel J.			Chronic mucocutaneous candidiasis associated with an SH2 domain gain-of-function mutation that enhances STAT1 phosphorylation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							AIRWAY SMOOTH-MUSCLE		[Sobh, Ali; Chou, Janet; Schneider, Lynda; Geha, Raif S.; Massaad, Michel J.] Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Sobh, Ali; Chou, Janet; Schneider, Lynda; Geha, Raif S.; Massaad, Michel J.] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA; [Sobh, Ali] Mansoura Univ, Children Hosp, Mansoura Fac Med, Pediat Infect Dis Unit, Mansoura, Egypt	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Egyptian Knowledge Bank (EKB); Mansoura University	Massaad, MJ (corresponding author), Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA.; Massaad, MJ (corresponding author), Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA.	michel.massaad@childrens.harvard.edu	Sobh, Ali/Q-6160-2016	Sobh, Ali/0000-0001-7047-076X				An SS, 2006, AM J RESP CELL MOL, V35, P55, DOI 10.1165/rcmb.2005-0453OC; An SS, 2009, BIOCHEM BIOPH RES CO, V382, P697, DOI 10.1016/j.bbrc.2009.03.118; Boisson-Dupuis S, 2012, CURR OPIN IMMUNOL, V24, P364, DOI 10.1016/j.coi.2012.04.011; Butler JP, 2002, AM J PHYSIOL-CELL PH, V282, pC595, DOI 10.1152/ajpcell.00270.2001; Deshpande DA, 2010, NAT MED, V16, P1299, DOI 10.1038/nm.2237; Engelhardt KR, 2012, J ALLERGY CLIN IMMUN, V129, P294, DOI [10.1016/j.jaci.2011.12.966, 10.1016/j.jaci.2011.12.972]; Fabry B, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.148102; Frans G, 2014, J ALLERGY CLIN IMMUN, V134, P1209, DOI 10.1016/j.jaci.2014.05.044; Hirahara K, 2015, IMMUNITY, V42, P877, DOI 10.1016/j.immuni.2015.04.014; Hori T, 2012, J CLIN IMMUNOL, V32, P1213, DOI 10.1007/s10875-012-9744-6; Krzywinski M, 2014, NAT METHODS, V11, P977, DOI 10.1038/nmeth.3137; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; Mao X, 2005, MOL CELL, V17, P761, DOI 10.1016/j.molcel.2005.02.021; O'Shea JJ, 2015, ANNU REV MED, V66, P311, DOI 10.1146/annurev-med-051113-024537; Takezaki S, 2012, J IMMUNOL, V189, P1521, DOI 10.4049/jimmunol.1200926; van de Veerdonk FL, 2011, NEW ENGL J MED, V365, P54, DOI 10.1056/NEJMoa1100102	16	11	12	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					297	299		10.1016/j.jaci.2015.12.1320	http://dx.doi.org/10.1016/j.jaci.2015.12.1320			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	26948078	Bronze			2022-12-18	WOS:000379659100037
J	Yatagai, Y; Hirota, T; Sakamoto, T; Yamada, H; Masuko, H; Kaneko, Y; Iijima, H; Naito, T; Noguchi, E; Tamari, M; Kubo, M; Takahashi, A; Konno, S; Makita, H; Nishimura, M; Hijikata, M; Keicho, N; Homma, S; Taguchi, Y; Azuma, A; Kudoh, S; Hizawa, N				Yatagai, Yohei; Hirota, Tomomitsu; Sakamoto, Tohru; Yamada, Hideyasu; Masuko, Hironori; Kaneko, Yoshiko; Iijima, Hiroaki; Naito, Takashi; Noguchi, Emiko; Tamari, Mayumi; Kubo, Michiaki; Takahashi, Atsushi; Konno, Satoshi; Makita, Hironi; Nishimura, Masaharu; Hijikata, Minako; Keicho, Naoto; Homma, Sakae; Taguchi, Yoshio; Azuma, Arata; Kudoh, Shoji; Hizawa, Nobuyuki			Variants near the HLA complex group 22 gene (HCG22) confer increased susceptibility to late-onset asthma in Japanese populations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							AIRWAY EPITHELIAL-CELLS; INFLUENZA-VIRUS INFECTION; RESPIRATORY SYNCYTIAL VIRUS; INNATE IMMUNE-RESPONSES; CILIATED CELLS; IN-VITRO; FUNCTIONAL POLYMORPHISM; A VIRUSES; T-CELLS; INDUCTION		[Yatagai, Yohei; Sakamoto, Tohru; Yamada, Hideyasu; Masuko, Hironori; Kaneko, Yoshiko; Hizawa, Nobuyuki] Univ Tsukuba, Fac Med, Dept Pulm Med, Tsukuba, Ibaraki, Japan; [Noguchi, Emiko] Univ Tsukuba, Fac Med, Dept Med Genet, Tsukuba, Ibaraki, Japan; [Hirota, Tomomitsu; Tamari, Mayumi] RIKEN, Inst Phys & Chem Res, Ctr Integrat Med Sci, Lab Resp & Allerg Dis, Yokohama, Kanagawa, Japan; [Kubo, Michiaki] RIKEN, Inst Phys & Chem Res, Ctr Integrat Med Sci, Yokohama, Kanagawa, Japan; [Takahashi, Atsushi] RIKEN, Inst Phys & Chem Res, Ctr Integrat Med Sci, Lab Stat Anal, Yokohama, Kanagawa, Japan; [Iijima, Hiroaki; Naito, Takashi] Tsukuba Med Ctr, Tsukuba, Ibaraki, Japan; [Konno, Satoshi; Makita, Hironi; Nishimura, Masaharu] Hokkaido Univ, Sch Med, Dept Med 1, Sapporo, Hokkaido 060, Japan; [Hijikata, Minako; Keicho, Naoto] JATA, Res Inst TB, Dept Pathophysiol & Host Def, Tokyo, Japan; [Homma, Sakae] Toho Univ, Sch Med, Dept Resp Med, Tokyo, Japan; [Taguchi, Yoshio] Tenri Hosp, Dept Resp Med, Tenri, Nara, Japan; [Azuma, Arata] Nippon Med Sch, Grad Sch Med, Dept Pulm Med & Oncol, Tokyo, Japan; [Kudoh, Shoji] Fukujuji Hosp, Tokyo, Japan	University of Tsukuba; University of Tsukuba; RIKEN; RIKEN; RIKEN; Hokkaido University; Toho University; Tenri Hospital; Nippon Medical School; Fukujuji Hospital	Sakamoto, T (corresponding author), Univ Tsukuba, Fac Med, Dept Pulm Med, Tsukuba, Ibaraki, Japan.	t-saka@md.tsukuba.ac.jp	Tamari, Mayumi/N-5378-2015; Nishimura, Masaharu/A-4062-2012; Keicho, Naoto/GQZ-0301-2022	Nishimura, Masaharu/0000-0002-6456-4361; Azuma, Arata/0000-0003-0506-9966; Sakamoto, Tohru/0000-0002-8876-1466; Keicho, Naoto/0000-0001-8232-9448				Clay CC, 2014, J VIROL, V88, P7412, DOI 10.1128/JVI.00188-14; Deeks S, 2013, NAT MED, V19, P30, DOI 10.1038/nm.3050; Galanter JM, 2014, J ALLERGY CLIN IMMUN, V134, P295, DOI 10.1016/j.jaci.2013.08.055; Hijikata M, 2011, HUM GENET, V129, P117, DOI 10.1007/s00439-010-0906-4; Hizawa N, 2002, AM J RESP CRIT CARE, V166, P686, DOI 10.1164/rccm.200202-090OC; Hoffmann E, 2001, ARCH VIROL, V146, P2275, DOI 10.1007/s007050170002; Isada A, 2010, J HUM GENET, V55, P167, DOI 10.1038/jhg.2010.4; Ivan FX, 2013, GENOMICS, V101, P101, DOI 10.1016/j.ygeno.2012.11.008; Ivan FX, 2012, FUNCT INTEGR GENOMIC, V12, P105, DOI 10.1007/s10142-011-0247-y; Iwai A, 2013, BIOCHEM BIOPH RES CO, V441, P531, DOI 10.1016/j.bbrc.2013.10.100; Kaneko Y, 2013, ALLERGOL INT, V62, P113, DOI 10.2332/allergolint.12-OA-0467; Kolesnikova L, 2013, J GEN VIROL, V94, P971, DOI 10.1099/vir.0.049239-0; Kumar PA, 2011, CELL, V147, P525, DOI 10.1016/j.cell.2011.10.001; Lakdawala SS, 2012, NAT MED, V18, P1468, DOI 10.1038/nm.2953; Lee SMY, 2014, P NATL ACAD SCI USA, V111, P3793, DOI 10.1073/pnas.1324266111; Masaki T, 2011, MOL BIOL CELL, V22, P2144, DOI 10.1091/mbc.E10-11-0875; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Othumpangat S, 2012, AM J PHYSIOL-LUNG C, V302, pL1057, DOI 10.1152/ajplung.00365.2011; Pothlichet J, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003256; Seo SH, 2002, J VIROL, V76, P1071, DOI 10.1128/JVI.76.3.1071-1076.2002; Sun J, 2009, NAT MED, V15, P277, DOI 10.1038/nm.1929; Sutejo R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033732; Tan SSL, 2014, AM J RESP CELL MOL, V50, P451, DOI 10.1165/rcmb.2013-0273OC; Taniguchi N, 2014, ANN ALLERG ASTHMA IM, V113, P31, DOI 10.1016/j.anai.2014.04.012; Taniguchi N, 2013, ANN ALLERG ASTHMA IM, V111, P376, DOI 10.1016/j.anai.2013.08.005; Wang ZF, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7833; Watanabe T, 2013, NATURE, V501, P551, DOI 10.1038/nature12392; Wu D, 2014, BMC MICROBIOL, V14, DOI 10.1186/1471-2180-14-78; Wu WX, 2015, VIROLOGY, V482, P181, DOI 10.1016/j.virol.2015.03.048; Zhang LQ, 2005, J VIROL, V79, P1113, DOI 10.1128/JVI.79.2.1113-1124.2005; Zhang LQ, 2002, J VIROL, V76, P5654, DOI 10.1128/JVI.76.11.5654-5666.2002; Zhao XN, 2012, AM J RHINOL ALLERGY, V26, P345, DOI 10.2500/ajra.2012.26.3794	32	11	12	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					281	283		10.1016/j.jaci.2015.11.023	http://dx.doi.org/10.1016/j.jaci.2015.11.023			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	26830115	Bronze			2022-12-18	WOS:000379659100031
J	Balekian, DS; Banerji, A; Blumenthal, KG; Camargo, CA; Long, AA				Balekian, Diana S.; Banerji, Aleena; Blumenthal, Kimberly G.; Camargo, Carlos A., Jr.; Long, Aidan A.			Allergen immunotherapy: No evidence of infectious risk	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							GERMAN SOCIETY; DIAGNOSTICS; ALLERGOLOGY; GUIDELINE		[Balekian, Diana S.; Banerji, Aleena; Blumenthal, Kimberly G.; Camargo, Carlos A., Jr.; Long, Aidan A.] Massachusetts Gen Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA; [Balekian, Diana S.; Banerji, Aleena; Blumenthal, Kimberly G.; Camargo, Carlos A., Jr.; Long, Aidan A.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Long, AA (corresponding author), Massachusetts Gen Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA.; Long, AA (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.	aalong@partners.org	Camargo, Carlos A./C-2145-2008; Blumenthal, Kimberly/AAG-8290-2019; Banerji, Aleena/ABG-1245-2021	Camargo, Carlos A./0000-0002-5071-7654; Blumenthal, Kimberly/0000-0003-4773-9817; 	NHLBI NIH HHS [T32 HL116275] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL116275] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brochet X, 2008, NUCLEIC ACIDS RES, V36, pW503, DOI 10.1093/nar/gkn316; CAMPBELL MJ, 1992, MOL IMMUNOL, V29, P193, DOI 10.1016/0161-5890(92)90100-C; Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034; Epstein T, 2015, J ALLERGY CLIN IMMUN, V135, pAB215, DOI 10.1016/j.jaci.2014.12.1638; Lay PC, 2007, OTOLARYNG HEAD NECK, V137, P243, DOI 10.1016/j.otohns.2007.02.012; Lefranc MP, 2009, NUCLEIC ACIDS RES, V37, pD1006, DOI 10.1093/nar/gkn838; Letz AG, 2009, J ALLERGY CLIN IMMUN, V123, P1175, DOI 10.1016/j.jaci.2009.01.048; Lindner C, 2012, J EXP MED, V209, P365, DOI 10.1084/jem.20111980; Pallin DJ, 2009, CLIN INFECT DIS, V49, P901, DOI 10.1086/605434; Renz H, 2010, ALLERGO J, V19, P110, DOI 10.1007/BF03362255; Rueff F, 2011, Pneumologie, V65, P484, DOI 10.1055/s-0030-1256476; Soni A, 2008, ALLERGIC RHINITIS TR; Stevenson KB, 2008, AM J INFECT CONTROL, V36, P155, DOI 10.1016/j.ajic.2008.01.004; Weber RW, 2008, PRIMARY CARE, V35, P1, DOI 10.1016/j.pop.2007.09.001; Wheatley LM, 2015, NEW ENGL J MED, V372, P456, DOI 10.1056/NEJMcp1412282	15	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1887	+		10.1016/j.jaci.2016.03.021	http://dx.doi.org/10.1016/j.jaci.2016.03.021			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	27090935	Green Accepted, Bronze			2022-12-18	WOS:000377527200032
J	Timperi, E; Folgori, L; Amodio, D; De Luca, M; Chiurchiu, S; Piconese, S; Di Cesare, S; Pacella, I; Martire, C; Bonatti, G; Perrone, S; Boni, T; Marcovecchio, GE; Reale, A; Parisi, F; Dotta, A; Barnaba, V; Rossi, P				Timperi, Eleonora; Folgori, Laura; Amodio, Donato; De Luca, Maia; Chiurchiu, Sara; Piconese, Silvia; Di Cesare, Silvia; Pacella, Ilenia; Martire, Carmela; Bonatti, Giulia; Perrone, Seila; Boni, Terenzio; Marcovecchio, Genni Enza; Reale, Antonino; Parisi, Francesco; Dotta, Andrea; Barnaba, Vincenzo; Rossi, Paolo			Expansion of activated regulatory T cells inversely correlates with clinical severity in septic neonates	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CD39		[Timperi, Eleonora; Piconese, Silvia; Pacella, Ilenia; Martire, Carmela; Barnaba, Vincenzo] Univ Roma La Sapienza, Policlin Umberto I, Dept Internal Med & Med Specialties, Piazzale Aldo Moro 5, I-00185 Rome, Italy; [Perrone, Seila; Boni, Terenzio] Univ Roma La Sapienza, Policlin Umberto I, Dept Gynecol Obstet Sci & Urol Sci, Piazzale Aldo Moro 5, I-00185 Rome, Italy; [Folgori, Laura; Amodio, Donato; De Luca, Maia; Chiurchiu, Sara; Di Cesare, Silvia; Bonatti, Giulia; Marcovecchio, Genni Enza; Rossi, Paolo] Univ Roma Tor Vergata, Bambino Gesu Childrens Hosp, Univ Dept Pediat, Rome, Italy; [Piconese, Silvia; Barnaba, Vincenzo] Pasteur Inst Cenci Bolognetti Fdn, Rome, Italy; [Reale, Antonino] Bambino Gesu Pediat Hosp, Emergency Dept, Rome, Italy; [Parisi, Francesco] Bambino Gesu Pediat Hosp, Dept Pediat Cardiol & Cardiac Surg, Rome, Italy; [Dotta, Andrea] Bambino Gesu Pediat Hosp, Dept Med & Surg Neonatol, Neonatal Intens Care Unit, Rome, Italy	Sapienza University Rome; University Hospital Sapienza Rome; Sapienza University Rome; University Hospital Sapienza Rome; IRCCS Bambino Gesu; University of Rome Tor Vergata; Fondazione Cenci Bolognetti; IRCCS Bambino Gesu; IRCCS Bambino Gesu; IRCCS Bambino Gesu	Barnaba, V (corresponding author), Univ Roma La Sapienza, Policlin Umberto I, Dept Internal Med & Med Specialties, Piazzale Aldo Moro 5, I-00185 Rome, Italy.; Rossi, P (corresponding author), Univ Roma Tor Vergata, Bambino Gesu Childrens Hosp, Univ Dept Pediat, Rome, Italy.; Barnaba, V (corresponding author), Pasteur Inst Cenci Bolognetti Fdn, Rome, Italy.	vincenzo.barnaba@uniroma1.it; paolo.rossi@opbg.net	De Luca, Maia/AAI-1048-2019; Chiurchiu, Sara/AAA-6347-2020; Rossi, Paolo/K-5746-2016; reale, antonino/AAB-8919-2020; bonatti, giulia/AAD-4989-2022; parisi, francesco/AAB-4978-2020; Folgori, Laura/X-2739-2019; DI CESARE, SILVIA/AAB-5754-2020; Barnaba, Vincenzo/AAB-1945-2019; Timperi, Eleonora/AGU-6201-2022; Amodio, Donato/AAA-9016-2019; Marcovecchio, Genni Enza/AAN-2557-2020	De Luca, Maia/0000-0001-7549-3514; Rossi, Paolo/0000-0003-2620-7918; parisi, francesco/0000-0002-7235-1868; DI CESARE, SILVIA/0000-0002-9912-7997; Amodio, Donato/0000-0003-4550-3018; timperi, eleonora/0000-0002-8357-6587; Folgori, Laura/0000-0002-0680-0450; reale, antonino/0000-0001-8058-7742; Piconese, Silvia/0000-0002-9685-5227; , giulia/0000-0003-2290-7749				Borsellino G, 2007, BLOOD, V110, P1225, DOI 10.1182/blood-2006-12-064527; Friedman DJ, 2009, P NATL ACAD SCI USA, V106, P16788, DOI 10.1073/pnas.0902869106; Goldstein Brahm, 2005, Pediatr Crit Care Med, V6, P2; Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019; Monneret G, 2003, CRIT CARE MED, V31, P2068, DOI 10.1097/01.CCM.0000069345.78884.0F; Piconese S, 2014, HEPATOLOGY, V60, P1494, DOI 10.1002/hep.27188; Schiering C, 2014, NATURE, V513, P564, DOI 10.1038/nature13577; Thornton AM, 2010, J IMMUNOL, V184, P3433, DOI 10.4049/jimmunol.0904028	8	11	12	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1617	+		10.1016/j.jaci.2015.10.048	http://dx.doi.org/10.1016/j.jaci.2015.10.048			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	26792206	Bronze, Green Accepted			2022-12-18	WOS:000376180200047
J	Jensen, ME; Mendelson, MJ; Desplats, E; Zhang, X; Platt, R; Ducharme, FM				Jensen, Megan E.; Mendelson, Morton J.; Desplats, Eve; Zhang, Xun; Platt, Robert; Ducharme, Francine M.			Caregiver's functional status during a young child's asthma exacerbation: A validated instrument	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; caregivers; discrimination; preschool child; quality of life; questionnaire design; randomized controlled trial; reliability; validity	QUALITY-OF-LIFE; EMERGENCY-DEPARTMENT; HEALTH-STATUS; MANAGEMENT; PARENTS; GUIDELINES; DIAGNOSIS; IMPACT	Background: Few instruments exist to measure caregivers' functional status during a young child's asthma exacerbation. Objective: We sought to develop and validate a measure of caregivers' functional status during a preschooler's asthma exacerbation. Methods: The psychometric properties of the 21-item questionnaire Effects of a Young Child's Asthma Flare-up on the Parents (ECAP) were tested in a randomized placebo-controlled trial of pre-emptive high-dose fluticasone in preschoolers with virus-induced asthma. Caregivers completed the ECAP questionnaire on the last day their child exhibited symptoms of an upper respiratory tract infection or asthma exacerbation (episode). The mean of each item, scored on a scale of 1 (best) to 7 (worst), provided the ECAP score. Results: Ninety-three preschoolers (2.5 +/- 1.0 years old; 62.4% male) experienced 878 episodes. Feasibility (80% questionnaire return rate; 90% completion) and internal consistency (Cronbach alpha = 0.97) were high. Of 628 episodes with a completed ECAP questionnaire, 621 (98.9%) had data on exacerbations, and 609 (97.0%) had data on health care use. The ECAP score was significantly higher for children experiencing an asthma exacerbation versus those who were not (mean difference, 0.8; 95% CI, 0.6-1.0) and for episodes resulting versus not resulting in an emergency visit (mean difference, 1.2; 95% CI, 1.0-1.4), systemic corticosteroid use (mean difference, 1.4; 95% CI, 1.1-1.7), or hospitalization (mean difference, 1.9; 95% CI, 1.4-2.5). The ECAP score was significantly lower in children treated with fluticasone versus those treated with placebo (mean difference, -0.7; 95% CI, -1.1 to -0.3). Conclusions: The 21-item ECAP questionnaire, showing high feasibility, internal consistency, discriminative validity, and responsiveness, has the psychometric properties to serve as a validated outcome to measure the burden of preschoolers' asthma exacerbations on their caregivers' functional status.	[Jensen, Megan E.; Ducharme, Francine M.] Univ Montreal, St Justine Univ Hlth Ctr, Clin Res & Knowledge Transfer Unit Childhood Asth, Res Ctr, Montreal, PQ, Canada; [Desplats, Eve] Univ Montreal, St Justine Univ Hlth Ctr, Res Ctr, Unite Rech Clin Appl, Montreal, PQ, Canada; [Mendelson, Morton J.] McGill Univ, Dept Psychol, Montreal, PQ, Canada; [Zhang, Xun] McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ, Canada; [Platt, Robert] McGill Univ, Ctr Hlth, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada; [Platt, Robert] McGill Univ, Ctr Hlth, Dept Pediat, Montreal, PQ, Canada; [Ducharme, Francine M.] Univ Montreal, Dept Pediat, Montreal, PQ H3C 3J7, Canada; [Ducharme, Francine M.] Univ Montreal, Dept Social & Prevent Med, Montreal, PQ, Canada	Universite de Montreal; Universite de Montreal; McGill University; McGill University; McGill University; McGill University; Universite de Montreal; Universite de Montreal	Ducharme, FM (corresponding author), St Justine Univ Hlth Ctr, 3175 Cote St Catherine,Rm 7939, Montreal, PQ H3T 1C5, Canada.	francine.m.ducharme@umontreal.ca	Ducharme, Francine/N-8332-2013; Zhang, Xun/HHM-9059-2022	Ducharme, Francine/0000-0001-5096-0614; Zhang, Xun/0000-0001-5411-2727; Platt, Robert/0000-0002-5981-8443; Desplats, Eve/0000-0002-8781-3615	George Hogg Family Foundation; Bourse de Chercheur National (National Scholarship) of the FRSQ	George Hogg Family Foundation; Bourse de Chercheur National (National Scholarship) of the FRSQ	Supported by the George Hogg Family Foundation. Fonds de la Recherche en Sante du Quebec extended infrastructure support to the Research Centers of the following participating centers: Centre hospitalier universitaire Ste-Justine (CHU Sainte-Justine), McGill University Health Centre (MUHC), Centre hospitalier universitaire de Sherbrooke (CHUS), and Hopital Maisonneuve-Rosemont. F.M.D. and R.P. were awarded the Bourse de Chercheur National (National Scholarship) of the FRSQ.	Asthma G., 2020, GLOB STRAT ASTHM MAN; Benito-Fernandez J, 2004, PEDIATR PULM, V38, P123, DOI 10.1002/ppul.20031; Chow MYK, 2013, QUAL LIFE RES, V22, P2183, DOI 10.1007/s11136-012-0343-z; Ducharme FM, 2015, J ALLERGY CLIN IMMUN; Ducharme FM, 2015, CAN RESPIR J, V22, P135, DOI 10.1155/2015/101572; Ducharme FM, 2009, NEW ENGL J MED, V360, P339, DOI 10.1056/NEJMoa0808907; Farnik M, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-151; Farnik M, 2010, PEDIATR PULM, V45, P1095, DOI 10.1002/ppul.21293; Forns D, 2011, ALLERGOL IMMUNOPATH, V39, P32, DOI 10.1016/j.aller.2010.03.005; Garbutt J, 2009, ANN ALLERG ASTHMA IM, V103, P469, DOI 10.1016/S1081-1206(10)60262-1; GUILLEMIN F, 1993, J CLIN EPIDEMIOL, V46, P1417, DOI 10.1016/0895-4356(93)90142-N; Juniper EF, 1997, J CLIN EPIDEMIOL, V50, P233, DOI 10.1016/S0895-4356(96)00377-0; Juniper EF, 1996, QUAL LIFE RES, V5, P27, DOI 10.1007/BF00435966; KIRSHNER B, 1985, J CHRON DIS, V38, P27, DOI 10.1016/0021-9681(85)90005-0; Lougheed AD, 2006, CHEST, V129, P909, DOI 10.1378/chest.129.4.909; Murphy KR, 2003, PEDIATRICS, V112, pE212, DOI 10.1542/peds.112.3.e212; Reeves MJ, 2006, PEDIATRICS, V117, pS118, DOI 10.1542/peds.2005-2000I; Rosychuk RJ, 2010, PEDIATR PULM, V45, P985, DOI 10.1002/ppul.21281; SCHULZ RM, 1994, J ASTHMA, V31, P209, DOI 10.3109/02770909409044828; Terwee CB, 2007, J CLIN EPIDEMIOL, V60, P34, DOI 10.1016/j.jclinepi.2006.03.012; Varni James W, 2004, Health Qual Life Outcomes, V2, P55, DOI 10.1186/1477-7525-2-55; Wiebe S, 2003, J CLIN EPIDEMIOL, V56, P52, DOI 10.1016/S0895-4356(02)00537-1; Williams AR, 2006, J PEDIATR-US, V149, P257, DOI 10.1016/j.jpeds.2006.04.003	23	11	11	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					782	+		10.1016/j.jaci.2015.08.031	http://dx.doi.org/10.1016/j.jaci.2015.08.031			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26476478				2022-12-18	WOS:000371897500021
J	Li, HG; Li, CX; Zhang, H; Zhang, LY; Cheng, RH; Li, M; Guo, YF; Zhang, Z; Lu, ZY; Zhuang, Y; Yan, M; Gu, Y; Feng, XB; Liang, JY; Yu, X; Wang, HL; Yao, ZR				Li, Huaguo; Li, Chunxiao; Zhang, Hui; Zhang, Lingyun; Cheng, Ruhong; Li, Ming; Guo, Yifeng; Zhang, Zhen; Lu, Zhiyong; Zhuang, Yin; Yan, Ming; Gu, Yan; Feng, Xiaobo; Liang, Jianying; Yu, Xia; Wang, Honglin; Yao, Zhirong			Effects of lidocaine on regulatory T cells in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Li, Huaguo; Li, Chunxiao; Zhang, Hui; Cheng, Ruhong; Li, Ming; Guo, Yifeng; Zhang, Zhen; Lu, Zhiyong; Zhuang, Yin; Yan, Ming; Gu, Yan; Feng, Xiaobo; Liang, Jianying; Yu, Xia; Yao, Zhirong] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Dermatol, Shanghai 200030, Peoples R China; [Zhang, Lingyun; Wang, Honglin] Shanghai Jiao Tong Univ, Sch Med, Inst Med Sci, Shanghai Inst Immunol, Shanghai 200030, Peoples R China	Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Jiao Tong University	Yao, ZR (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Dermatol, Shanghai 200030, Peoples R China.; Wang, HL (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Inst Med Sci, Shanghai Inst Immunol, Shanghai 200030, Peoples R China.	honglin.wang@sjtu.edu.cn; dermatology.yao@sohu.com	WANG, Honglin/AAJ-2708-2020	WANG, Honglin/0000-0001-6302-6927; li, chun-xiao/0000-0002-5821-0225				Brandt C, 2009, ALLERGY, V64, P1588, DOI 10.1111/j.1398-9995.2009.02054.x; Hinz D, 2012, ALLERGY, V67, P380, DOI 10.1111/j.1398-9995.2011.02767.x; Hunt LW, 2004, J ALLERGY CLIN IMMUN, V113, P853, DOI 10.1016/j.jaci.2004.02.039; Jiao QQ, 2013, ARCH DERMATOL RES, V305, P629, DOI 10.1007/s00403-013-1339-4; Pellerin L, 2014, IMMUNOL RES, V58, P358, DOI 10.1007/s12026-014-8512-5; Shi M, 2011, J EUR ACAD DERMATOL, V25, P1206, DOI 10.1111/j.1468-3083.2010.03953.x; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647	7	11	12	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					613	+		10.1016/j.jaci.2015.07.039	http://dx.doi.org/10.1016/j.jaci.2015.07.039			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26371835	hybrid			2022-12-18	WOS:000369235500033
J	Moschese, V; Cavaliere, FM; Graziani, S; Bilotta, C; Milito, C; Chini, L; Quinti, I				Moschese, Viviana; Cavaliere, Filomena Monica; Graziani, Simona; Bilotta, Caterina; Milito, Cinzia; Chini, Loredana; Quinti, Isabella			Decreased IgM, IgA, and IgG response to pneumococcal vaccine in children with transient hypogammaglobulinemia of infancy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PRIMARY IMMUNODEFICIENCIES; DIAGNOSIS		[Moschese, Viviana; Graziani, Simona; Chini, Loredana] Univ Roma Tor Vergata, Policlin Tor Vergata, Pediat Allergol & Immunol Unit, Rome, Italy; [Cavaliere, Filomena Monica; Bilotta, Caterina; Milito, Cinzia; Quinti, Isabella] Univ Roma La Sapienza, Dept Mol Med, Piazzale Aldo Moro 5, I-00185 Rome, Italy	University of Rome Tor Vergata; Policlin Tor Vergata; Sapienza University Rome	Moschese, V (corresponding author), Univ Roma Tor Vergata, Policlin Tor Vergata, Pediat Allergol & Immunol Unit, Rome, Italy.	moschese@med.uniroma2.it	MOSCHESE, VIVIANA/AHE-8931-2022; Milito, Cinzia/AAP-7075-2020	MOSCHESE, VIVIANA/0000-0001-7650-0632; Quinti, Isabella/0000-0002-3328-7584				Bonilla FA, 2005, ANN ALLERG ASTHMA IM, V94, pS1, DOI 10.1016/S1081-1206(10)61142-8; Cavaliere FM, 2013, J CLIN IMMUNOL, V33, P838, DOI 10.1007/s10875-012-9856-z; Conley ME, 1999, CLIN IMMUNOL, V93, P190, DOI 10.1006/clim.1999.4799; Modell V, 2014, IMMUNOL RES, V60, P132, DOI 10.1007/s12026-014-8498-z; Moschese V, 2008, INT J IMMUNOPATH PH, V21, P343, DOI 10.1177/039463200802100211; Moschese V, 2007, J ALLERGY CLIN IMMUN, V120, P474, DOI 10.1016/j.jaci.2007.04.002; Titman P, 2014, J CLIN IMMUNOL, V34, P844, DOI 10.1007/s10875-014-0072-x	7	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					617	+		10.1016/j.jaci.2015.06.014	http://dx.doi.org/10.1016/j.jaci.2015.06.014			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26233927	Bronze, Green Published			2022-12-18	WOS:000369235500034
J	Rabenhorst, A; Leja, S; Schwaab, J; Gehring, M; Forster, A; Arock, M; Reiter, A; Raap, U; Hartmann, K				Rabenhorst, Anja; Leja, Silke; Schwaab, Juliana; Gehring, Manuela; Foerster, Anja; Arock, Michel; Reiter, Andreas; Raap, Ulrike; Hartmann, Karin			Expression of programmed cell death ligand-1 in mastocytosis correlates with disease severity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ANTIBODY; SAFETY		[Rabenhorst, Anja; Leja, Silke; Foerster, Anja; Hartmann, Karin] Univ Cologne, Dept Dermatol, Cologne, Germany; [Schwaab, Juliana; Reiter, Andreas] Med Univ Mannheim, Med Clin 3, Hematol & Oncol, Mannheim, Germany; [Gehring, Manuela; Raap, Ulrike] Hannover Med Sch, Dept Dermatol & Allergy, Hannover, Germany; [Arock, Michel] Ecole Normale Super, Mol Oncol & Pharmacol, LBPA CNRS UMR8113, Cachan, France; [Hartmann, Karin] Med Univ Lubeck, Dept Dermatol, D-23538 Lubeck, Germany	University of Cologne; Ruprecht Karls University Heidelberg; Hannover Medical School; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; University of Lubeck	Rabenhorst, A (corresponding author), Univ Cologne, Dept Dermatol, Cologne, Germany.	karin.hartmann@uksh.de	Hartmann, Karin/N-4865-2015; Rabenhorst, Anja/J-3217-2016	Hartmann, Karin/0000-0002-4595-8226; Illerhaus, Anja/0000-0003-0521-203X				Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Escribano L, 2009, J ALLERGY CLIN IMMUN, V124, P514, DOI 10.1016/j.jaci.2009.05.003; Hartmann K, 2013, J ALLERGY CLIN IMMUN, V132, P232, DOI 10.1016/j.jaci.2012.11.008; Horny HP AC, 2008, WHO CLASSIFICATION T, P54; Kataoka TR, 2013, ALLERGOL INT, V62, P99, DOI 10.2332/allergolint.12-OA-0450; Rabenhorst A, 2013, J ALLERGY CLIN IMMUN, V132, P1234, DOI 10.1016/j.jaci.2013.06.019; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690	9	11	11	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					314	318		10.1016/j.jaci.2015.07.006	http://dx.doi.org/10.1016/j.jaci.2015.07.006			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26299988	Bronze			2022-12-18	WOS:000367724300028
J	Ohtake, J; Kaneumi, S; Tanino, M; Kishikawa, T; Terada, S; Sumida, K; Masuko, K; Ohno, Y; Kita, T; Iwabuchi, S; Shinohara, T; Tanino, Y; Takemura, T; Tanaka, S; Kobayashi, H; Kitamura, H				Ohtake, Junya; Kaneumi, Shun; Tanino, Mishie; Kishikawa, Takuto; Terada, Satoshi; Sumida, Kentaro; Masuko, Kazutaka; Ohno, Yosuke; Kita, Toshiyuki; Iwabuchi, Sadahiro; Shinohara, Toshiya; Tanino, Yoshinori; Takemura, Tamiko; Tanaka, Shinya; Kobayashi, Hiroya; Kitamura, Hidemitsu			Neuropeptide signaling through neurokinin-1 and neurokinin-2 receptors augments antigen presentation by human dendritic cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IMMUNE-RESPONSES; ASTHMA; IL-12		[Ohtake, Junya; Kaneumi, Shun; Kishikawa, Takuto; Terada, Satoshi; Sumida, Kentaro; Masuko, Kazutaka; Ohno, Yosuke; Kita, Toshiyuki; Kitamura, Hidemitsu] Hokkaido Univ, Div Immunoregulat, Sect Dis Control, Inst Genet Med, Sapporo, Hokkaido, Japan; [Tanino, Mishie; Tanaka, Shinya] Hokkaido Univ, Grad Sch Med, Dept Canc Pathol, Sapporo, Hokkaido, Japan; [Iwabuchi, Sadahiro] Univ Iowa, Carver Coll Med, Dept Mol Physiol & Biophys, Iowa City, IA USA; [Shinohara, Toshiya] Teine Keijinkai Hosp, Dept Pathol, Sapporo, Hokkaido, Japan; [Tanino, Yoshinori] Fukushima Med Univ, Dept Pulm Med, Fukushima, Japan; [Takemura, Tamiko] Japanese Red Cross Med Ctr, Dept Pathol, Tokyo, Japan; [Kobayashi, Hiroya] Asahikawa Med Univ, Dept Pathol, Asahikawa, Hokkaido, Japan	Hokkaido University; Hokkaido University; University of Iowa; Teine Keijinkai Hospital; Fukushima Medical University; Japanese Red Cross Medical Center; University of Tokyo; Asahikawa Medical College	Ohtake, J (corresponding author), Hokkaido Univ, Div Immunoregulat, Sect Dis Control, Inst Genet Med, Sapporo, Hokkaido, Japan.	kitamura@igm.hokudai.ac.jp	Tanaka, Shinya/D-3586-2011; Kitamura, Hidemitsu/A-8184-2012; TANINO, YOSHINORI/AAF-8773-2019; Iwabuchi, Sadahiro/AAD-4455-2022					Holgate ST, 2012, NAT MED, V18, P673, DOI 10.1038/nm.2731; Janelsins BM, 2013, BLOOD, V121, P2923, DOI 10.1182/blood-2012-07-446054; Kitamura H, 1999, J EXP MED, V189, P1121, DOI 10.1084/jem.189.7.1121; Kitamura H, 2012, J IMMUNOL, V188, P4200, DOI 10.4049/jimmunol.1102521; Kobayashi M, 2012, EUR J IMMUNOL, V42, P393, DOI 10.1002/eji.201141845; Lacasse Y, 2012, CHEST, V142, P208, DOI 10.1378/chest.11-2479; Nagato T, 2007, J IMMUNOL, V178, P1189, DOI 10.4049/jimmunol.178.2.1189; Ohtake J, 2014, IMMUNOL LETT, V161, P20, DOI 10.1016/j.imlet.2014.04.010; Ramalho R, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-41	9	11	11	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2015	136	6					1690	1694		10.1016/j.jaci.2015.06.050	http://dx.doi.org/10.1016/j.jaci.2015.06.050			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CX9RZ	26371842	Bronze, Green Published			2022-12-18	WOS:000366044300035
J	Beigelman, A; Bacharier, LB; Baty, J; Buller, R; Mason, S; Schechtman, KB; Sajol, G; Isaacson-Schmid, M; Castro, M; Storch, GA				Beigelman, Avraham; Bacharier, Leonard B.; Baty, Jack; Buller, Richard; Mason, Sheila; Schechtman, Kenneth B.; Sajol, Geneline; Isaacson-Schmid, Megan; Castro, Mario; Storch, Gregory A.			Does azithromycin modify viral load during severe respiratory syncytial virus bronchiolitis?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							AIRWAY EPITHELIAL-CELLS; DISEASE SEVERITY; INFECTION; INFANTS; ASTHMA; LIFE		[Beigelman, Avraham; Bacharier, Leonard B.; Buller, Richard; Mason, Sheila; Isaacson-Schmid, Megan; Storch, Gregory A.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Baty, Jack; Schechtman, Kenneth B.] Washington Univ, Sch Med, Div Biostat, St Louis, MO 63110 USA; [Sajol, Geneline; Castro, Mario] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; [Sajol, Geneline; Castro, Mario] St Louis Childrens Hosp, St Louis, MO 63178 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)	Beigelman, A (corresponding author), Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA.	beigelman_a@kids.wustl.edu		Bacharier, Leonard/0000-0003-0432-2704	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000450, UL1TR000448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI097213] Funding Source: NIH RePORTER; NCATS NIH HHS [UL1 TR000448, KL2 TR000450] Funding Source: Medline; NCI NIH HHS [P30 CA091842] Funding Source: Medline; NIAID NIH HHS [R01 AI097213] Funding Source: Medline	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Asada M, 2009, ANTIVIR RES, V83, P191, DOI 10.1016/j.antiviral.2009.05.003; Bacharier LB, 2012, J ALLERGY CLIN IMMUN, V130, P91, DOI 10.1016/j.jaci.2012.02.010; Beigelman A, 2015, J ALLERGY CLIN IMMUN, V135, P1171, DOI 10.1016/j.jaci.2014.10.001; Beigelman A, 2013, CURR OPIN ALLERGY CL, V13, P211, DOI 10.1097/ACI.0b013e32835eb6ef; El Saleeby CM, 2011, J INFECT DIS, V204, P996, DOI 10.1093/infdis/jir494; Escobar GJ, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-97; Falsey AR, 2003, J CLIN MICROBIOL, V41, P4160, DOI 10.1128/JCM.41.9.4160-4165.2003; Gielen V, 2010, EUR RESPIR J, V36, P646, DOI 10.1183/09031936.00095809; Houben ML, 2010, J MED VIROL, V82, P1266, DOI 10.1002/jmv.21771; Schogler A, 2015, EUR RESPIR J, V45, P428, DOI 10.1183/09031936.00102014	10	11	11	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					1129	1131		10.1016/j.jaci.2015.06.011	http://dx.doi.org/10.1016/j.jaci.2015.06.011			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	26215052	Green Accepted			2022-12-18	WOS:000362976300045
J	Kallsen, K; Zehethofer, N; Abdelsadik, A; Lindner, B; Kabesch, M; Heine, H; Roeder, T				Kallsen, Kimberley; Zehethofer, Nicole; Abdelsadik, Ahmed; Lindner, Buko; Kabesch, Michael; Heine, Holger; Roeder, Thomas			ORMDL deregulation increases stress responses and modulates repair pathways in Drosophila airways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ASTHMA		[Kallsen, Kimberley; Abdelsadik, Ahmed; Roeder, Thomas] Univ Kiel, Inst Zool, Dept Mol Physiol, D-24098 Kiel, Germany; [Kallsen, Kimberley; Heine, Holger] Res Ctr Borstel, Div Innate Immun Prior Area Asthma & Allergies, Borstel, Germany; [Zehethofer, Nicole; Lindner, Buko] Res Ctr Borstel, Div Immunochem, Prior Area Infect, Borstel, Germany; [Kabesch, Michael] KUNO Univ Childrens Hosp, Dept Pediat Pneumol & Allergy, Regensburg, Germany; [Kabesch, Michael] German Ctr Lung Res DZL, Biomed Res Endstage & Obstruct Lung Dis Hannover, Hannover, Germany; [Heine, Holger; Roeder, Thomas] German Ctr Lung Res DZL, Airway Res Ctr North, Hannover, Germany	University of Kiel; Forschungszentrum Borstel; Forschungszentrum Borstel	Kallsen, K (corresponding author), Univ Kiel, Inst Zool, Dept Mol Physiol, D-24098 Kiel, Germany.	troeder@zoologie.uni-kiel.de	Roeder, Thomas/B-9016-2011; Abdelsadik, Ahmed/AAP-3439-2021; ABDELSADIK, AHMED/B-8712-2019; Kabesch, Michael/GZM-1583-2022; Kabesch, Michael/AAB-5701-2020; Heine, Holger/H-4552-2012	Roeder, Thomas/0000-0002-3489-3834; Abdelsadik, Ahmed/0000-0002-4782-6681; Heine, Holger/0000-0001-8128-5068				Cantero-Recasens G, 2010, HUM MOL GENET, V19, P111, DOI 10.1093/hmg/ddp471; D'Onofrio BM, 2013, AM J PUBLIC HEALTH, V103, P46, DOI 10.2105/AJPH.2013.301252; Duffy JB, 2002, GENESIS, V34, P1, DOI 10.1002/gene.10150; Holgate ST, 2011, IMMUNOL REV, V242, P205, DOI 10.1111/j.1600-065X.2011.01030.x; Lluis A, 2011, J ALLERGY CLIN IMMUN, V127, P1587, DOI 10.1016/j.jaci.2011.03.015; Miller M, 2012, P NATL ACAD SCI USA, V109, P16648, DOI 10.1073/pnas.1204151109; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Roeder T, 2009, AM J RESP CRIT CARE, V179, P979, DOI 10.1164/rccm.200811-1777PP; Sariaslan A, 2013, INT J EPIDEMIOL, V42, P1057, DOI 10.1093/ije/dyt066; Xiao C, 2011, J ALLERGY CLIN IMMUN, V128, P549, DOI 10.1016/j.jaci.2011.05.038	10	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					1105	1108		10.1016/j.jaci.2015.04.009	http://dx.doi.org/10.1016/j.jaci.2015.04.009			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	25979522	Bronze			2022-12-18	WOS:000362976300034
J	Ilmarinen, P; Moilanen, E; Erjefalt, JS; Kankaanranta, H				Ilmarinen, Pinja; Moilanen, Eeva; Erjefalt, Jonas S.; Kankaanranta, Hannu			The polyamine spermine promotes survival and activation of human eosinophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							APOPTOSIS; DNA		[Ilmarinen, Pinja; Moilanen, Eeva; Kankaanranta, Hannu] Univ Tampere, Sch Med, Immunopharmacol Res Grp, FIN-33101 Tampere, Finland; [Ilmarinen, Pinja; Moilanen, Eeva; Kankaanranta, Hannu] Tampere Univ Hosp, Tampere, Finland; [Ilmarinen, Pinja; Kankaanranta, Hannu] Seinajoki Cent Hosp, Dept Resp Med, Seinajoki, Finland; [Erjefalt, Jonas S.] Lund Univ, Dept Expt Med Sci, Lund, Sweden; [Kankaanranta, Hannu] Univ Tampere, Dept Resp Med, FIN-33101 Tampere, Finland	Tampere University; Tampere University; Tampere University Hospital; Seinajoki Central Hospital; Lund University; Tampere University	Ilmarinen, P (corresponding author), Univ Tampere, Sch Med, Immunopharmacol Res Grp, FIN-33101 Tampere, Finland.	pinja.ilmarinen@uta.fi		Ilmarinen, Pinja/0000-0002-8758-2431; Moilanen, Eeva/0000-0002-8577-0316; Erjefalt, Jonas/0000-0002-6716-3010				Agostinelli E, 2010, AMINO ACIDS, V38, P393, DOI 10.1007/s00726-009-0396-7; Eisenberg T, 2009, NAT CELL BIOL, V11, P1305, DOI 10.1038/ncb1975; Erjefalt JS, 2001, THORAX, V56, P341, DOI 10.1136/thorax.56.5.341; Iacomino G, 2012, BBA-MOL CELL RES, V1823, P1745, DOI 10.1016/j.bbamcr.2012.05.033; Ilmarinen P, 2014, PEPTIDES, V51, P100, DOI 10.1016/j.peptides.2013.10.030; Ilmarinen P, 2014, BASIC CLIN PHARMACOL, V114, P109, DOI 10.1111/bcpt.12163; Ilmarinen-Salo P, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-73; Ilmarinen-Salo P, 2010, PULM PHARMACOL THER, V23, P365, DOI 10.1016/j.pupt.2010.04.001; Kankaanranta H, 2006, MOL PHARMACOL, V69, P1861, DOI 10.1124/mol.105.021170; KUROSAWA M, 1992, ALLERGY, V47, P638, DOI 10.1111/j.1398-9995.1992.tb02388.x; Maarsingh H, 2008, N-S ARCH PHARMACOL, V378, P171, DOI 10.1007/s00210-008-0286-7; North ML, 2013, AM J RESP CELL MOL, V48, P694, DOI 10.1165/rcmb.2012-0323OC; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; Teixeira D, 2002, J NUTR, V132, P3715, DOI 10.1093/jn/132.12.3715; Zhang MH, 2000, CRIT CARE MED, V28, pN60, DOI 10.1097/00003246-200004001-00007	15	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2015	136	2					482	+		10.1016/j.jaci.2014.12.1922	http://dx.doi.org/10.1016/j.jaci.2014.12.1922			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CO2RS	25649081	Bronze			2022-12-18	WOS:000359004900032
J	Vos, BJPR; van der Veer, E; Vader, PCV; Mulder, AB; van der Heide, S; Arends, S; Kluin-Nelemans, JC; de Monchy, JGR; van Doormaal, JJ; Elberink, JNGO				Vos, Byrthe J. P. R.; van der Veer, Eveline; Vader, Pieter C. van Voorst; Mulder, Andre B.; van der Heide, Sicco; Arends, Suzanne; Kluin-Nelemans, Johanna C.; de Monchy, Jan G. R.; van Doormaal, Jasper J.; Elberink, Joanne N. G. Oude			Diminished reliability of tryptase as risk indicator of mastocytosis in older overweight subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Age; body mass index; indolent systemic mastocytosis; mast cell; methylhistamine; methylimidazole acetic acid; tryptase	BLOOD MONONUCLEAR-CELLS; N-TAU-METHYLHISTAMINE; C-KIT MUTATION; SERUM TRYPTASE; SYSTEMIC MASTOCYTOSIS; HISTAMINE METABOLITES; URINE; EXCRETION; POPULATION; MARKERS	Background: Currently, measurement of serum tryptase level is the most commonly used test to estimate the need for bone marrow biopsy in patients suspected to have indolent systemic mastocytosis (ISM). Yet tryptase levels do not solely reflect the mast cell load and can be elevated by overweight, older age, and impaired renal function. The influence of these factors on urinary methylhistamine (MH) and methylimidazole acetic acid (MIMA) is still unknown. Objective: We investigated the impact of age, body mass index (BMI), and kidney function on the diagnostic accuracy of tryptase, MH, and MIMA to select the most optimal test indicating the necessity of a bone marrow biopsy in ISM-suspected patients. Methods: Retrospective data analysis of all adults in whom bone marrow investigations were performed because of high clinical suspicion and/or elevated tryptase, MH, or MIMA. Results: 194 subjects were included. ISM was present in 112 and absent in 82 subjects (non-ISM). Tryptase was elevated by age and body weight in non-ISM subjects and by BMI in ISM subjects; however, these factors did not influence MH or MIMA. In the total study population, the diagnostic accuracy of tryptase, MH, and MIMA were comparable (area under the curve 0.80, 0.80, and 0.83). In subjects > 50 years with a BMI > 25 kg/m(2), the diagnostic accuracy of MIMA was higher compared with that of tryptase (area under the curve 0.93 vs 0.74; P = .011). Conclusion: In ISM-suspected patients > 50 years with a BMI of > 25 kg/m(2), MIMA has a greater value compared with tryptase in estimating the need for bone marrow biopsy.	[Vos, Byrthe J. P. R.; de Monchy, Jan G. R.; van Doormaal, Jasper J.; Elberink, Joanne N. G. Oude] Univ Groningen, Univ Med Ctr Groningen, Dept Allergol, Groningen, Netherlands; [Vos, Byrthe J. P. R.; de Monchy, Jan G. R.; Elberink, Joanne N. G. Oude] Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, Groningen, Netherlands; [van der Veer, Eveline; Mulder, Andre B.; van der Heide, Sicco] Univ Groningen, Univ Med Ctr Groningen, Dept Lab Med, Groningen, Netherlands; [Vader, Pieter C. van Voorst] Univ Groningen, Univ Med Ctr Groningen, Dept Dermatol, Groningen, Netherlands; [Arends, Suzanne] Univ Groningen, Univ Med Ctr Groningen, Dept Rheumatol & Clin Immunol, Groningen, Netherlands; [Kluin-Nelemans, Johanna C.] Univ Groningen, Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen; University of Groningen; University of Groningen; University of Groningen	Elberink, JNGO (corresponding author), Univ Med Ctr Groningen, Dept Allergol, Huispostcode AA23,POB 30-001, NL-9700 RB Groningen, Netherlands.	j.n.g.oude.elberink@umcg.nl	Kluin-Nelemans, Johanna C/F-8658-2018; Arends, Suzanne/M-5436-2015	Kluin-Nelemans, Johanna C/0000-0003-2617-9427; Arends, Suzanne/0000-0002-4422-7640; van der Veer, Eveline/0000-0002-4825-9981	Novartis; ALK-Abello	Novartis(Novartis); ALK-Abello	Disclosure of potential conflict of interest: J. G. R. de Monchy has received compensation from Novartis for board membership and delivering lectures. J. N. G. Oude Elberink's institution has received consultancy fees from ALK-Abello and fees for delivering lectures from ALK-Abello, Merck, and Meda. The rest of the authors declare that they have no relevant conflicts of interest.	Chrostek Lech, 2007, Pol Merkur Lekarski, V23, P225; Donker ML, 2007, HAEMATOLOGICA, V93, P120, DOI 10.3324/haematol.11558; Sirvent AE, 2010, J NEPHROL, V23, P282; Fenger RV, 2012, INT ARCH ALLERGY IMM, V157, P151, DOI 10.1159/000327535; Garcia-Martin E, 2009, PHARMACOGENOMICS, V10, P867, DOI [10.2217/pgs.09.26, 10.2217/PGS.09.26]; Gonzalez-Quintela A, 2010, CLIN CHEM LAB MED, V48, P701, DOI 10.1515/CCLM.2010.124; Granerus G, 1998, BRIT J DERMATOL, V139, P858; GRANERUS G, 1994, AGENTS ACTIONS, V41, pC127, DOI 10.1007/BF02007796; Horny HP, 2007, PATHOBIOLOGY, V74, P121, DOI 10.1159/000101711; KEYZER JJ, 1981, CLIN CHIM ACTA, V113, P165, DOI 10.1016/0009-8981(81)90150-9; KEYZER JJ, 1983, J CHROMATOGR, V275, P261, DOI 10.1016/S0378-4347(00)84373-X; KEYZER JJ, 1982, CLIN CHIM ACTA, V121, P379, DOI 10.1016/0009-8981(82)90247-9; KEYZER JJ, 1984, AGENTS ACTIONS, V15, P189, DOI 10.1007/BF01972348; Lawley W, 2005, MUTAT RES-FUND MOL M, V572, P1, DOI 10.1016/j.mrfmmm.2004.08.015; Liu J, 2009, NAT MED, V15, P940, DOI 10.1038/nm.1994; Maintz L, 2007, AM J CLIN NUTR, V85, P1185, DOI 10.1093/ajcn/85.5.1185; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; OOSTING E, 1988, AGENTS ACTIONS, V23, P307, DOI 10.1007/BF02142572; OOSTING E, 1991, AGENTS ACTIONS, V33, P215, DOI 10.1007/BF01993171; Schliemann S, 2012, ACTA DERM-VENEREOL, V92, P484, DOI 10.2340/00015555-1245; Schwartz LB, 2001, LEUKEMIA RES, V25, P553, DOI 10.1016/S0145-2126(01)00020-0; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8; van Doormaal JJ, 2012, ALLERGY, V67, P683, DOI 10.1111/j.1398-9995.2012.02809.x; van Toorenenbergen AW, 2008, CLIN BIOCHEM, V41, P331, DOI 10.1016/j.clinbiochem.2007.11.003; van Toorenenbergen AW, 2005, CLIN CHIM ACTA, V359, P72, DOI 10.1016/j.cccn.2005.03.041; Worobec AS, 1998, CANCER, V83, P2120, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2120::AID-CNCR10>3.0.CO;2-C; Zimatkin SM, 1999, ALCOHOL ALCOHOLISM, V34, P141, DOI 10.1093/alcalc/34.2.141	28	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2015	135	3					792	798		10.1016/j.jaci.2014.05.047	http://dx.doi.org/10.1016/j.jaci.2014.05.047			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD4PF	25129675	Bronze			2022-12-18	WOS:000351065000027
J	Boguniewicz, M; Leung, DYM				Boguniewicz, Mark; Leung, Donald Y. M.			Targeted therapy for allergic diseases: At the intersection of cutting-edge science and clinical practice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						mAb therapy; biologic therapy; asthma; allergic diseases; atopic dermatitis; food allergy; dupilumab; omalizumab; psoriasis	ORAL IMMUNOTHERAPY; SEVERE ASTHMA; PEANUT; OMALIZUMAB; MEPOLIZUMAB; BIOLOGICS; SAFETY; READY; SKIN		[Boguniewicz, Mark] Natl Jewish Hlth, Dept Pediat, Div Allergy Immunol, Denver, CO 80206 USA; Univ Colorado, Sch Med, Boulder, CO 80309 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder	Boguniewicz, M (corresponding author), Natl Jewish Hlth, 1400 Jackson St,Rm J310, Denver, CO 80206 USA.	boguniewiczm@njhealth.org						[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Bauer RN, 2015, J ALLERGY CLIN IMMUN, V135, P312, DOI 10.1016/j.jaci.2014.12.1908; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Busse W, 2013, J ALLERGY CLIN IMMUN, V132, P485, DOI 10.1016/j.jaci.2013.02.032; Cheng DT, 2013, J ALLERGY CLIN IMMUN, V132, P455, DOI 10.1016/j.jaci.2013.05.011; De Boever EH, 2014, J ALLERGY CLIN IMMUN, V133, P989, DOI 10.1016/j.jaci.2014.01.002; Fajt ML, 2015, J ALLERGY CLIN IMMUN, V135, P299, DOI 10.1016/j.jaci.2014.12.1871; Gevaert P, 2013, J ALLERGY CLIN IMMUN, V131, P110, DOI 10.1016/j.jaci.2012.07.047; Haldar P, 2014, J ALLERGY CLIN IMMUN, V133, P921, DOI 10.1016/j.jaci.2013.11.026; Hamilton JD, 2014, J ALLERGY CLIN IMMUN, V134, P1293, DOI 10.1016/j.jaci.2014.10.013; Kaplan A, 2013, J ALLERGY CLIN IMMUN, V132, P101, DOI 10.1016/j.jaci.2013.05.013; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Laviolette M, 2014, J ALLERGY CLIN IMMUN, V133, P1232; Long A, 2014, J ALLERGY CLIN IMMUN, V134, P560, DOI 10.1016/j.jaci.2014.02.007; Noda S, 2015, J ALLERGY CLIN IMMUN, V135, P324, DOI 10.1016/j.jaci.2014.11.015; Otani IM, 2013, J ALLERGY CLIN IMMUN, V131, P1576, DOI 10.1016/j.jaci.2013.02.042; Roufosse FE, 2013, J ALLERGY CLIN IMMUN, V131, P461, DOI 10.1016/j.jaci.2012.07.055; Sampson HA, 2014, J ALLERGY CLIN IMMUN, V134, P1016, DOI 10.1016/j.jaci.2014.05.013; Sampson HA, 2013, J ALLER CL IMM-PRACT, V1, P15, DOI 10.1016/j.jaip.2012.10.009; Schneider LC, 2013, J ALLERGY CLIN IMMUN, V132, P1368, DOI 10.1016/j.jaci.2013.09.046; Shemer A, 2013, J ALLERGY CLIN IMMUN, V131, P577, DOI 10.1016/j.jaci.2012.11.010; Vickery BP, 2014, J ALLERGY CLIN IMMUN, V133, P468, DOI 10.1016/j.jaci.2013.11.007; Wood RA, 2014, J ALLER CL IMM-PRACT, V2, P97, DOI 10.1016/j.jaip.2013.11.010	23	11	11	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					354	356		10.1016/j.jaci.2014.12.1907	http://dx.doi.org/10.1016/j.jaci.2014.12.1907			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25662304	Bronze			2022-12-18	WOS:000349372300006
J	Fox, AT; Kaymakcalan, H; Perkin, M; du Toit, G; Lack, G				Fox, Adam T.; Kaymakcalan, Hande; Perkin, Michael; du Toit, George; Lack, Gideon			Changes in peanut allergy prevalence in different ethnic groups in 2 time periods	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							UNITED-STATES; FOOD ALLERGY; CHILDREN		[Fox, Adam T.; Perkin, Michael; du Toit, George; Lack, Gideon] Guys & St Thomas NHS Fdn Trust, Asthma UK Ctr Allerg Mech Asthma, Div Asthma Allergy & Lung Biol, London, England; [Kaymakcalan, Hande] Bahcesehir Univ, Fac Arts & Sci, Istanbul, Turkey	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Bahcesehir University	Fox, AT (corresponding author), Kings Coll London, MRC, Muscle & Cell Motil Unit, London WC2B 5RL, England.	adam.fox@gstt.nhs.uk	Fox, Adam/O-3547-2015; Perkin, Michael/AID-7491-2022; Kaymakcalan, Hande/AFP-2191-2022; Kaymakcalan, Hande/AAO-4208-2021	Fox, Adam/0000-0002-3533-9798; Kaymakcalan, Hande/0000-0001-7736-7634; Perkin, Michael/0000-0001-9272-2585; Du Toit, George/0000-0002-0321-2928; Lack, Gideon/0000-0001-7350-4021				Beyer KB, 2001, J ALLERGY CLIN IMMUN, V107, P1077, DOI 10.1067/mai.2001.115480; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Dias RP, 2008, PEDIATR ALLERGY IMMU, V19, P86, DOI 10.1111/j.1399-3038.2007.00582.x; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Kirkpatrick SI, 2012, J ACAD NUTR DIET, V112, P624, DOI 10.1016/j.jand.2011.11.012; Litonjua AA, 2005, J ALLERGY CLIN IMMUN, V115, P751, DOI 10.1016/j.jaci.2004.12.1138; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; LUYT DK, 1995, S AFR MED J, V85, P999; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8	9	11	11	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					580	582		10.1016/j.jaci.2014.09.022	http://dx.doi.org/10.1016/j.jaci.2014.09.022			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25441289				2022-12-18	WOS:000349372300041
J	Fuertes, E; Soderhall, C; Acevedo, N; Becker, A; Brauer, M; Chan-Yeung, M; Dijk, FN; Heinrich, J; de Jongste, J; Koppelman, GH; Postma, DS; Kere, J; Kozyrskyj, AL; Pershagen, G; Sandford, A; Standl, M; Tiesler, CMT; Waldenberger, M; Westman, M; Carlsten, C; Melen, E				Fuertes, Elaine; Soderhall, Cilla; Acevedo, Nathalie; Becker, Allan; Brauer, Michael; Chan-Yeung, Moira; Dijk, F. Nicole; Heinrich, Joachim; de Jongste, Johan; Koppelman, Gerard H.; Postma, Dirkje S.; Kere, Juha; Kozyrskyj, Anita L.; Pershagen, Goran; Sandford, Andrew; Standl, Marie; Tiesler, Carla M. T.; Waldenberger, Melanie; Westman, Marit; Carlsten, Christopher; Melen, Erik			Associations between the 17q21 region and allergic rhinitis in 5 birth cohorts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ASTHMA; VARIANTS; RISK; METAANALYSIS; POPULATION; PREVENTION; DESIGN		[Fuertes, Elaine; Brauer, Michael; Carlsten, Christopher] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada; [Fuertes, Elaine; Heinrich, Joachim; Standl, Marie] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol 1, Neuherberg, Germany; [Soderhall, Cilla; Acevedo, Nathalie; Kere, Juha] Karolinska Inst, Dept Biosci & Nutr, Huddinge, Sweden; [Soderhall, Cilla; Acevedo, Nathalie; Kere, Juha] Karolinska Inst, Ctr Innovat Med, Huddinge, Sweden; [Acevedo, Nathalie] Karolinska Inst, Dept Med Solna, Translat Immunol Unit, Stockholm, Sweden; [Acevedo, Nathalie] St Gorans Univ Hosp, S-11281 Stockholm, Sweden; [Becker, Allan] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; [Brauer, Michael; Chan-Yeung, Moira; Sandford, Andrew; Carlsten, Christopher] Univ British Columbia, Dept Med, Vancouver, BC, Canada; [Dijk, F. Nicole; Koppelman, Gerard H.] Univ Groningen, Dept Pediat Pulmonol & Pediat Allergol, Groningen Res Inst Asthma & COPD, Beatrix Childrens Hosp,Univ Med Ctr Groningen, Groningen, Netherlands; [de Jongste, Johan] Erasmus MC Sophia Childrens Hosp, Dept Pediat Resp Med, Rotterdam, Netherlands; [Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma & COPD, Dept Pulmonol, Groningen, Netherlands; [Kere, Juha] Univ Helsinki, Folkhalsan Inst Genet, Helsinki, Finland; [Kere, Juha] Univ Helsinki, Mol Neurol Res Program, Helsinki, Finland; [Kozyrskyj, Anita L.] Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada; [Pershagen, Goran; Melen, Erik] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [Pershagen, Goran; Melen, Erik] Karolinska Inst, Ctr Allergy Res, S-10401 Stockholm, Sweden; [Tiesler, Carla M. T.] Univ Munich, Div Metab Dis & Nutr Med, Dr von Hauner Childrens Hosp, Munich, Germany; [Waldenberger, Melanie] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Res Unit Mol Epidemiol, Neuherberg, Germany; [Waldenberger, Melanie] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol 2, Neuherberg, Germany; [Westman, Marit] Karolinska Univ Hosp, Karolinska Inst, Dept Clin Sci Intervent & Technol, Div Ear Nose & Throat Dis, Stockholm, Sweden; [Melen, Erik] Karolinska Inst, Sachs Childrens Hosp, Stockholm, Sweden	University of British Columbia; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Saint Goran's Hospital; University of Manitoba; University of British Columbia; University of Groningen; Erasmus University Rotterdam; Erasmus MC; University of Groningen; University of Helsinki; University of Helsinki; University of Alberta; Karolinska Institutet; Karolinska Institutet; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Fuertes, E (corresponding author), Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada.	erik.melen@ki.se	Waldenberger, Melanie/B-5355-2014; Koppelman, Gerard/AAG-9187-2020; Söderhäll, Cilla/E-3940-2012; Kere, Juha/AAX-9117-2021; Kere, Juha/A-9179-2008; Heinrich, Joachim/N-1720-2013; Brauer, Michael/Y-2810-2019	Waldenberger, Melanie/0000-0003-0583-5093; Söderhäll, Cilla/0000-0002-8397-3080; Kere, Juha/0000-0003-1974-0271; Kere, Juha/0000-0003-1974-0271; Heinrich, Joachim/0000-0002-9620-1629; Brauer, Michael/0000-0002-9103-9343; Acevedo, Nathalie/0000-0002-5154-2964; Koppelman, Gerard/0000-0001-8567-3252; Standl, Marie/0000-0002-5345-2049; Fuertes, Elaine/0000-0003-0205-9025; Pershagen, Goran/0000-0002-9701-1130	Canadian Institutes of Health Research Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Andiappan AK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019719; Brunekreef B, 2002, PEDIAT ALLERG IMM-UK, V13, P55, DOI 10.1034/j.1399-3038.13.s.15.1.x; Chan-Yeung M, 2000, ARCH PEDIAT ADOL MED, V154, P657, DOI 10.1001/archpedi.154.7.657; Delaneau O, 2013, NAT METHODS, V10, P5, DOI 10.1038/nmeth.2307; Delaneau O, 2012, NAT METHODS, V9, P179, DOI [10.1038/NMETH.1785, 10.1038/nmeth.1785]; Ferreira MAR, 2014, J ALLERGY CLIN IMMUN, V133, P1564, DOI 10.1016/j.jaci.2013.10.030; Filipiak B, 2007, J PEDIATR-US, V151, P352, DOI 10.1016/j.jpeds.2007.05.018; Ha SG, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3479; Hao K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003029; Heinrich J, 2002, EUR RESPIR J, V20, P617, DOI 10.1183/09031936.02.02322001; Hinds DA, 2013, NAT GENET, V45, P907, DOI 10.1038/ng.2686; Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529; Kozyrskyj AL, 2009, ALLERGY, V64, P1185, DOI 10.1111/j.1398-9995.2009.02033.x; Li Y, 2010, GENET EPIDEMIOL, V34, P816, DOI 10.1002/gepi.20533; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Ramasamy A, 2011, J ALLERGY CLIN IMMUN, V128, P996, DOI 10.1016/j.jaci.2011.08.030; Tomita K, 2013, ALLERGY, V68, P92, DOI 10.1111/all.12066; Verlaan DJ, 2009, AM J HUM GENET, V85, P377, DOI 10.1016/j.ajhg.2009.08.007; Wickman M, 2002, PEDIATR ALLERGY IMMU, V13, P11, DOI 10.1034/j.1399-3038.13.s.15.10.x	20	11	11	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					573	+		10.1016/j.jaci.2014.08.016	http://dx.doi.org/10.1016/j.jaci.2014.08.016			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25262464	Green Published, hybrid			2022-12-18	WOS:000349372300038
J	Gevaert, P; Calus, L; van Bruaene, N; Van Zele, T; Bachert, C				Gevaert, Philippe; Calus, Lien; van Bruaene, Nicholas; Van Zele, Thibaut; Bachert, Claus			Allergic Sensitization, High Local IL-5 and IgE Predict Surgical Outcome 12 Years after Endoscopic Sinus Surgery for Chronic Rhinosinusitis with Nasal Polyposis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI)	FEB 20-24, 2015	Houston, TX	Amer Acad Allergy, Asthma & Immunol					[Gevaert, Philippe; Calus, Lien; van Bruaene, Nicholas; Van Zele, Thibaut] Ghent Univ Hosp, Ghent, Belgium; [Bachert, Claus] Ghent Univ Hosp, Upper Airway Res Lab URL, Ghent, Belgium	Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital			Bachert, Claus/J-8825-2012; Gevaert, Philippe/AAP-1892-2020; Gevaert, Philippe/ABA-4588-2021	Gevaert, Philippe/0000-0002-1629-8468; 					0	11	12	2	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2		S		770	AB238	AB238		10.1016/j.jaci.2014.12.1713	http://dx.doi.org/10.1016/j.jaci.2014.12.1713			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	CR2BN					2022-12-18	WOS:000361129600769
J	Apter, AJ				Apter, Andrea J.			Advances in adult asthma diagnosis and treatment in 2014	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; adults; inhaled corticosteroids; asthma management	VITAMIN-D LEVELS; EXACERBATED RESPIRATORY-DISEASE; GENOME-WIDE ASSOCIATION; ALLERGIC DISEASE; ASPIRIN DESENSITIZATION; AIRWAY INFLAMMATION; GENE-EXPRESSION; NATIONAL HEART; LUNG-FUNCTION; RECEPTOR	In 2014, new biologic therapies are emerging for severe asthma based on identification of relevant phenotypes. The exploration of nutritional supplements to treat asthma has been less successful.	[Apter, Andrea J.] Univ Penn, Perelman Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Apter, AJ (corresponding author), Hosp Univ Penn, 829 Gates Bldg,3600 Spruce St, Philadelphia, PA 19104 USA.	apter@mail.med.upenn.edu			NIEHS NIH HHS [P30 ES013508] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES013508] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agbetile J, 2014, J ALLERGY CLIN IMMUN, V134, P33, DOI 10.1016/j.jaci.2013.09.050; Apter AJ, 2014, J ALLERGY CLIN IMMUN, V133, P49, DOI 10.1016/j.jaci.2013.11.005; Baines KJ, 2014, J ALLERGY CLIN IMMUN, V133, P997, DOI 10.1016/j.jaci.2013.12.1091; Bartemes KR, 2014, J ALLERGY CLIN IMMUN, V134, P671, DOI 10.1016/j.jaci.2014.06.024; Beasley R, 2014, J ALLERGY CLIN IMMUN, V133, P39, DOI 10.1016/j.jaci.2013.10.053; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291; Birrell MA, 2014, J ALLERGY CLIN IMMUN, V133, P679, DOI 10.1016/j.jaci.2013.12.003; Bochenek G, 2014, J ALLERGY CLIN IMMUN, V133, P98, DOI 10.1016/j.jaci.2013.07.004; Busse WW, 2014, J ALLERGY CLIN IMMUN, V134, P260, DOI 10.1016/j.jaci.2014.05.008; Cabana MD, 2014, J ALLERGY CLIN IMMUN, V133, P27, DOI 10.1016/j.jaci.2013.10.026; Castro M, 2014, JAMA-J AM MED ASSOC, V311, P2083, DOI 10.1001/jama.2014.5052; Cheng HM, 2014, J ALLERGY CLIN IMMUN, V133, P1048, DOI 10.1016/j.jaci.2013.10.055; Chinchilli VM, 2014, J ALLERGY CLIN IMMUN, V134, P916, DOI 10.1016/j.jaci.2014.05.027; Daham K, 2014, J ALLERGY CLIN IMMUN, V134, P306, DOI 10.1016/j.jaci.2013.12.002; Dahlen SE, 2014, NEW ENGL J MED, V370, P2144, DOI 10.1056/NEJMe1404737; De Boever EH, 2014, J ALLERGY CLIN IMMUN, V133, P989, DOI 10.1016/j.jaci.2014.01.002; Dizier MH, 2014, J ALLERGY CLIN IMMUN, V134, P576, DOI 10.1016/j.jaci.2013.12.1074; Ferreira MAR, 2014, J ALLERGY CLIN IMMUN, V133, P1564, DOI 10.1016/j.jaci.2013.10.030; Foster JM, 2014, J ALLERGY CLIN IMMUN; Galanter JM, 2014, J ALLERGY CLIN IMMUN, V134, P295, DOI 10.1016/j.jaci.2013.08.055; Gauvreau GM, 2014, NEW ENGL J MED, V370, P2102, DOI 10.1056/NEJMoa1402895; Gelb AF, 2014, J ALLERGY CLIN IMMUN, V133, P263, DOI 10.1016/j.jaci.2013.09.045; Ghebre MA, 2014, J ALLERGY CLIN IMMUN; Gomez-Casado C, 2014, J ALLERGY CLIN IMMUN, V134, P480, DOI 10.1016/j.jaci.2014.03.016; Grabenhenrich LB, 2014, J ALLERGY CLIN IMMUN, V133, P979, DOI 10.1016/j.jaci.2013.11.035; Gupta S, 2014, J ALLERGY CLIN IMMUN, V133, P729, DOI 10.1016/j.jaci.2013.09.039; Haccuria A, 2014, J ALLERGY CLIN IMMUN, V134, P554, DOI 10.1016/j.jaci.2013.12.1070; Haldar P, 2014, J ALLERGY CLIN IMMUN, V133, P921, DOI 10.1016/j.jaci.2013.11.026; Hatchwell L, 2014, J ALLERGY CLIN IMMUN, V133, P1720, DOI 10.1016/j.jaci.2013.11.014; Hosking L, 2014, J ALLERGY CLIN IMMUN, V133, P587, DOI 10.1016/j.jaci.2013.08.024; Ingram JL, 2012, J ALLERGY CLIN IMMUN, V130, P829, DOI 10.1016/j.jaci.2012.06.034; Juhn YJ, 2014, J ALLERGY CLIN IMMUN, V134, P247, DOI 10.1016/j.jaci.2014.04.024; Keet CA, 2014, J ALLERGY CLIN IMMUN, V133, P399, DOI 10.1016/j.jaci.2013.09.042; Khalid S, 2014, J ALLERGY CLIN IMMUN, V134, P56, DOI 10.1016/j.jaci.2014.01.038; Kinoshita T, 2014, J ALLERGY CLIN IMMUN, V133, P696, DOI 10.1016/j.jaci.2013.08.025; Laidlaw TM, 2014, J ALLERGY CLIN IMMUN, V133, P1692, DOI 10.1016/j.jaci.2013.12.1034; Lemiere C, 2014, J ALLERGY CLIN IMMUN, V133, P883, DOI 10.1016/j.jaci.2013.09.005; Leung TF, 2014, J ALLERGY CLIN IMMUN, V133, P42, DOI 10.1016/j.jaci.2013.09.018; Long A, 2014, J ALLERGY CLIN IMMUN, V134, P560, DOI 10.1016/j.jaci.2014.02.007; McGarvey LP, 2014, J ALLERGY CLIN IMMUN, V133, P704, DOI 10.1016/j.jaci.2013.09.016; Moore WC, 2014, J ALLERGY CLIN IMMUN, V133, P1557, DOI 10.1016/j.jaci.2013.10.011; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Morales DR, 2014, J ALLERGY CLIN IMMUN, V134, P40, DOI 10.1016/j.jaci.2013.10.057; Moreno-Macias H, 2014, J ALLERGY CLIN IMMUN, V133, P1237, DOI 10.1016/j.jaci.2014.03.020; Mosbech H, 2014, J ALLERGY CLIN IMMUN, V134, P568, DOI 10.1016/j.jaci.2014.03.019; Muehleisen B, 2013, J ALLERGY CLIN IMMUN, V131, P324, DOI 10.1016/j.jaci.2012.12.1562; Nagasaki T, 2014, J ALLERGY CLIN IMMUN, V133, P1474, DOI 10.1016/j.jaci.2013.12.1084; Nair P, 2014, NEW ENGL J MED, V371, P1249, DOI 10.1056/NEJMe1408614; Nanzer AM, 2014, J ALLERGY CLIN IMMUN, V133, P1755, DOI 10.1016/j.jaci.2014.03.015; Newby C, 2014, J ALLERGY CLIN IMMUN, V134, P287, DOI 10.1016/j.jaci.2014.04.005; Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290; Ortega VE, 2014, LANCET RESP MED, V2, P204, DOI 10.1016/S2213-2600(13)70289-3; Ortega VE, 2014, J ALLERGY CLIN IMMUN, V133, P16, DOI 10.1016/j.jaci.2013.10.040; Park HW, 2014, J ALLERGY CLIN IMMUN, V133, P664, DOI 10.1016/j.jaci.2013.12.1042; Peters MC, 2014, J ALLERGY CLIN IMMUN, V133, P388, DOI 10.1016/j.jaci.2013.07.036; Pugmire J, 2014, J ALLERGY CLIN IMMUN, V134, P962, DOI 10.1016/j.jaci.2014.07.030; Rosenberg SL, 2014, J ALLERGY CLIN IMMUN, V134, P1009, DOI 10.1016/j.jaci.2014.07.005; Savage JH, 2014, J ALLERGY CLIN IMMUN, V133, P1484, DOI 10.1016/j.jaci.2014.01.028; Schatz M, 2014, J ALLERGY CLIN IMMUN, V133, P1549, DOI 10.1016/j.jaci.2013.10.006; Sharma S, 2014, J ALLERGY CLIN IMMUN, V133, P1246, DOI 10.1016/j.jaci.2013.10.039; Sharpe R., 2014, J ALLERGY CLIN IMMUN; Sherbourne CD, 2014, J ALLERGY CLIN IMMUN, V134, P900, DOI 10.1016/j.jaci.2014.03.002; Sheshadri A, 2014, J ALLERGY CLIN IMMUN, V133, P739, DOI 10.1016/j.jaci.2013.12.1036; Slejko JF, 2014, J ALLERGY CLIN IMMUN, V133, P1579, DOI 10.1016/j.jaci.2013.10.028; Snelgrove RJ, 2014, J ALLERGY CLIN IMMUN, V134, P583, DOI 10.1016/j.jaci.2014.02.002; Sterk PJ, 2014, J ALLERGY CLIN IMMUN, V133, P395, DOI 10.1016/j.jaci.2013.10.008; Sutherland ER, 2014, J ALLERGY CLIN IMMUN, V133, P34, DOI 10.1016/j.jaci.2013.10.025; Swierczynska-Krepa M, 2014, J ALLERGY CLIN IMMUN, V134, P883, DOI 10.1016/j.jaci.2014.02.041; Szefler SJ, 2014, J ALLERGY CLIN IMMUN, V133, P654, DOI 10.1016/j.jaci.2014.01.012; Tai A, 2014, J ALLERGY CLIN IMMUN, V133, P1572, DOI 10.1016/j.jaci.2013.12.1033; Tantisira KG, 2011, NEW ENGL J MED, V365, P1173, DOI 10.1056/NEJMoa0911353; Traister RS, 2014, J ALLERGY CLIN IMMUN; Wendell SG, 2014, J ALLERGY CLIN IMMUN, V133, P1255, DOI 10.1016/j.jaci.2013.12.1087; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Westerhof GA, 2014, J ALLERGY CLIN IMMUN, V134, P1051, DOI 10.1016/j.jaci.2014.05.005; Wilson SR, 2012, J ALLERGY CLIN IMMUN, V129, pS88, DOI 10.1016/j.jaci.2011.12.988; Woessner KM, 2014, J ALLERGY CLIN IMMUN, V133, P286, DOI 10.1016/j.jaci.2013.11.016; Wood RA, 2014, J ALLERGY CLIN IMMUN, V133, P846, DOI 10.1016/j.jaci.2013.08.047; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Wu AC, 2014, J ALLERGY CLIN IMMUN, V133, P723, DOI 10.1016/j.jaci.2013.09.037; Wu W, 2014, J ALLERGY CLIN IMMUN, V133, P1280, DOI 10.1016/j.jaci.2013.11.042; Yu S, 2014, J ALLERGY CLIN IMMUN, V133, P943, DOI 10.1016/j.jaci.2014.02.015; Zafari Z, 2014, J ALLERGY CLIN IMMUN, V134, P908, DOI 10.1016/j.jaci.2014.04.009; Zaslona Z, 2014, J ALLERGY CLIN IMMUN, V133, P379, DOI 10.1016/j.jaci.2013.07.037; Zhang Y, 2014, J ALLERGY CLIN IMMUN, V133, P1744, DOI 10.1016/j.jaci.2013.12.004	86	11	13	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					46	53		10.1016/j.jaci.2014.10.050	http://dx.doi.org/10.1016/j.jaci.2014.10.050			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25567042				2022-12-18	WOS:000347298200006
J	Li, J; Goulding, M; Seymour, S; Starke, P				Li, Jie; Goulding, Margie; Seymour, Sally; Starke, Peter			EXCELS study results do not rule out potential cancer risk with omalizumab	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Li, Jie; Goulding, Margie] US FDA, CDER, Div Epidemiol 2, Off Surveillance & Epidemiol, Silver Spring, MD 20993 USA; [Seymour, Sally; Starke, Peter] US FDA, CDER, Div Pulm Allergy & Rheumatol, Off New Drugs, Silver Spring, MD USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Li, J (corresponding author), US FDA, CDER, Div Epidemiol 2, Off Surveillance & Epidemiol, Silver Spring, MD 20993 USA.	jie.j.li@fda.hhs.gov						Long A, 2014, J ALLERGY CLIN IMMUN, V134, P560, DOI 10.1016/j.jaci.2014.02.007	1	11	11	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2015	135	1					289	289		10.1016/j.jaci.2014.09.017	http://dx.doi.org/10.1016/j.jaci.2014.09.017			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AY0PG	25441294				2022-12-18	WOS:000347298200044
J	Kreiner-Moller, E; Bisgaard, H; Bonnelykke, K				Kreiner-Moller, Eskil; Bisgaard, Hans; Bonnelykke, Klaus			Prenatal and postnatal genetic influence on lung function development	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Child; asthma; genetics; respiratory function tests	GENOME-WIDE ASSOCIATION; CHILDHOOD ASTHMA; METAANALYSIS; DISEASE; RISK; LOCI; VARIANTS; IMPUTATION; INFANCY	Background: It is unknown to what extent adult lung function genes affect lung function development from birth to childhood. Objective: Our aim was to study the association of candidate genetic variants with neonatal lung function and lung function development until age 7 years. Methods: Lung function measurement by means of spirometry with the raised-volume thoracoabdominal compression technique and bronchial responsiveness to methacholine challenge were assessed in 411 high-risk newborns from the Copenhagen Prospective Study on Asthma in Childhood 2000 (COPSAC(2000)) cohort. Measures were repeated at age 7 years. Genetic risk scores were calculated based on reported single nucleotide polymorphisms for adult lung function (FEV1/forced expiratory vital capacity [FVC] ratio and FEV1) as the number of risk alleles weighted on known effect size. These genetic risk scores were analyzed against lung function measures as z scores at birth (forced expiratory volume in 0.5 seconds [FEV0.5], forced expiratory flow at 50% of functional vital capacity [FEF50], and provocative dose of methacholine causing a 15% decrease in lung function [PD15]) and at age 7 years (FEV1, FEF50, and provocative dose of methacholine causing a 20% decrease in lung function [PD20]) and with development from birth to age 7 years (FEV0.5/1, FEF50, and PD15/20). Results: The genetic risk scores were not associated with lung function measures at age 1 month, but the FEV1/FVC genetic risk score was associated with reduced FEF50 values at age 7 years (P = .01) and similarly with reduced growth in FEF50 from birth to age 7 years (P = .02). This score was also associated with increased bronchial responsiveness (reduced PD20) at age 7 years (P = .02) and change in responsiveness from birth to age 7 years (P = .05). Conclusion: Lung function genetic variants identified in adults were not associated with neonatal lung function or bronchial responsiveness but with the development of these lung function measures during early childhood, suggesting a window of opportunity for interventions targeting these genetic mechanisms.	[Kreiner-Moller, Eskil] Univ Copenhagen, Fac Hlth Sci, COPSAC, DK-2820 Gentofte, Denmark; Copenhagen Univ Hosp, Danish Pediat Asthma Ctr, Gentofte, Denmark	University of Copenhagen; University of Copenhagen	Kreiner-Moller, E (corresponding author), Univ Copenhagen, Fac Hlth Sci, COPSAC, Gentofte Ledreborg Alle 34, DK-2820 Gentofte, Denmark.	eskil.kreiner@dbac.dk	Bisgaard, Hans/N-4761-2016	Bisgaard, Hans/0000-0003-4131-7592; Kreiner, Eskil/0000-0003-1204-2438; Bonnelykke, Klaus/0000-0003-2003-1018	Copenhagen University; COPSAC; Lundbeck Foundation [R16-2007-1694] Funding Source: researchfish	Copenhagen University; COPSAC; Lundbeck Foundation(Lundbeckfonden)	E.K.-M. was supported for this study by a PhD scholarship from the Copenhagen University. COPSAC is funded by private and public research funds listed on www.copsac.com. The Lundbeck Foundation, the Danish Strategic Research Council, the Pharmacy Foundation of 1991, the Augustinus Foundation, the Danish Medical Research Council, and the Danish Pediatric Asthma Centre provided the core support for COPSAC research center (see Web site for details).	Allen HL, 2010, NATURE, V467, P832, DOI 10.1038/nature09410; Artigas MS, 2011, AM J RESP CRIT CARE, V184, P786, DOI 10.1164/rccm.201102-0192OC; Bisgaard H, 2012, AM J RESP CRIT CARE, V185, P1183, DOI 10.1164/rccm.201110-1922OC; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V128, P646, DOI 10.1016/j.jaci.2011.04.060; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V127, P1155, DOI 10.1016/j.jaci.2011.02.007; Bisgaard H, 2009, J ALLERGY CLIN IMMUN, V123, P651, DOI 10.1016/j.jaci.2008.11.036; Bisgaard H, 2009, AM J RESP CRIT CARE, V179, P179, DOI 10.1164/rccm.200809-1436OC; Bonnelykke K, 2013, NAT GENET, V45, P902, DOI 10.1038/ng.2694; Bradfield JP, 2012, NAT GENET, V44, P526, DOI 10.1038/ng.2247; Castaldi PJ, 2011, AM J RESP CELL MOL, V45, P1147, DOI 10.1165/rcmb.2011-0055OC; Collins SA, 2013, EUR RESPIR J, V41, P756, DOI 10.1183/09031936.00171712; de Bakker PIW, 2008, HUM MOL GENET, V17, pR122, DOI 10.1093/hmg/ddn288; Hancock DB, 2010, NAT GENET, V42, P45, DOI 10.1038/ng.500; Howie B, 2012, NAT GENET, V44, P955, DOI 10.1038/ng.2354; Kerkhof M, 2014, J ALLERGY CLIN IMMUN, V133, P68, DOI 10.1016/j.jaci.2013.06.004; Loland L, 2006, CHEST, V129, P669, DOI 10.1378/chest.129.3.669; Loland L, 2008, CHEST, V133, P115, DOI 10.1378/chest.07-1328; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Paganelli R, 1998, ALLERGY, V53, P763; Paternoster L, 2012, NAT GENET, V44, P187, DOI 10.1038/ng.1017; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2002.120951; R Core Team, 2017, R LANGUAGE ENVIRONME; Repapi E, 2010, NAT GENET, V42, P36, DOI 10.1038/ng.501; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Soler Artigas M, 2011, NAT GENET, V43, P1082, DOI 10.1038/ng.941; Stern DA, 2007, LANCET, V370, P758, DOI 10.1016/S0140-6736(07)61379-8; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; Taal HR, 2012, NAT GENET, V44, P532, DOI 10.1038/ng.2238; von Mutius E, 2002, AM J RESP CRIT CARE, V165, P1467, DOI 10.1164/rccm.2204011	29	11	11	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2014	134	5					1036	+		10.1016/j.jaci.2014.04.003	http://dx.doi.org/10.1016/j.jaci.2014.04.003			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AT4UN	24857373				2022-12-18	WOS:000344938900006
J	Tsai, YG; Lai, JC; Yang, KD; Hung, CH; Yeh, YJ; Lin, CY				Tsai, Yi-Giien; Lai, Jui-Chung; Yang, Kuender D.; Hung, Chih-Hsing; Yeh, Ya-Ju; Lin, Ching-Yuang			Enhanced CD46-induced regulatory T cells suppress allergic inflammation after Dermatophagoides pteronyssinus-specific immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ASTHMA; CD46		[Tsai, Yi-Giien; Yeh, Ya-Ju] Kaohsiung Med Univ, Changhua Christian Hosp, Sch Med, Dept Pediat, Kaohsiung, Taiwan; [Tsai, Yi-Giien] Chung Shan Med Univ, Sch Med, Taichung, Taiwan; [Lai, Jui-Chung] Changhua Christian Hosp, Dept Otorhinolaryngol Head & Neck Surg, Changhua, Taiwan; [Yang, Kuender D.] Show Chwan Mem Hosp, Dept Med Res & Dev, Chang Bing, Taiwan; [Yang, Kuender D.] Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan; [Hung, Chih-Hsing] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Pediat, Kaohsiung, Taiwan; [Lin, Ching-Yuang] China Med Univ, China Med Univ Hosp, Coll Med, Clin Immunol Ctr, Taichung, Taiwan	Changhua Christian Hospital; Kaohsiung Medical University; Chung Shan Medical University; Changhua Christian Hospital; Show Chwan Memorial Hospital; National Yang Ming Chiao Tung University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; China Medical University Taiwan; China Medical University Hospital - Taiwan	Tsai, YG (corresponding author), Kaohsiung Med Univ, Changhua Christian Hosp, Sch Med, Dept Pediat, Kaohsiung, Taiwan.	cylin@mail.cmuh						Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Astier AL, 2006, J CLIN INVEST, V116, P3252, DOI 10.1172/JCI29251; Barchet W, 2006, BLOOD, V107, P1497, DOI 10.1182/blood-2005-07-2951; Bowser C, 2010, ANN ALLERG ASTHMA IM, V104, P42, DOI 10.1016/j.anai.2009.11.021; Laumonnier Y, 2011, CURR ALLERGY ASTHM R, V11, P122, DOI 10.1007/s11882-010-0171-6; Riley-Vargas RC, 2004, TRENDS IMMUNOL, V25, P496, DOI 10.1016/j.it.2004.07.004; Tsai YG, 2012, LAB INVEST, V92, P1260, DOI 10.1038/labinvest.2012.86; Tsai YG, 2010, PEDIAT ALLERG IMM-UK, V21, pE166, DOI 10.1111/j.1399-3038.2009.00870.x; Xu YQ, 2010, J ASTHMA, V47, P367, DOI 10.3109/02770903.2010.481340	9	11	11	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2014	134	5					1206	1209		10.1016/j.jaci.2014.06.005	http://dx.doi.org/10.1016/j.jaci.2014.06.005			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AT4UN	25065720				2022-12-18	WOS:000344938900033
J	Borzutzky, A; Morales, PS; Mezzano, V; Nussbaum, S; Burks, AW				Borzutzky, Arturo; Morales, Pamela S.; Mezzano, Veronica; Nussbaum, Sofia; Burks, A. Wesley			Induction of remission of idiopathic anaphylaxis with rituximab	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHRONIC AUTOIMMUNE URTICARIA; THERAPY		[Borzutzky, Arturo; Morales, Pamela S.; Nussbaum, Sofia] Pontificia Univ Catolica Chile, Sch Med, Div Pediat, Immunol Allergy & Rheumatol Unit, Santiago, Chile; [Borzutzky, Arturo] Pontificia Univ Catolica Chile, Sch Med, Millennium Inst Immunol & Immunotherapy, Santiago, Chile; [Mezzano, Veronica] Pontificia Univ Catolica Chile, Sch Med, Dept Rheumatol & Clin Immunol, Santiago, Chile; [Burks, A. Wesley] Univ N Carolina, Sch Med, Dept Pediat, Chapel Hill, NC USA	Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Borzutzky, A (corresponding author), Pontificia Univ Catolica Chile, Sch Med, Div Pediat, Immunol Allergy & Rheumatol Unit, Alameda 340, Santiago, Chile.	arturobor@med.puc.cl		Burks, Wesley/0000-0003-1873-5702; Borzutzky, Arturo/0000-0002-7904-262X				Alonso MAT, 2002, ANN ALLERG ASTHMA IM, V88, P313, DOI 10.1016/S1081-1206(10)62014-5; Arkwright PD, 2009, J ALLERGY CLIN IMMUN, V123, P510, DOI 10.1016/j.jaci.2008.11.043; Chakravarty SD, 2011, J ALLERGY CLIN IMMUN, V128, P1354, DOI 10.1016/j.jaci.2011.08.023; Ditto AM, 1996, ANN ALLERG ASTHMA IM, V77, P285, DOI 10.1016/S1081-1206(10)63322-4; Gamerman S, 2013, HAEMOPHILIA, V19, pE382, DOI 10.1111/hae.12238; Grammer LC, 2000, ANN ALLERG ASTHMA IM, V85, P368, DOI 10.1016/S1081-1206(10)62547-1; Greenberger PA, 2007, IMMUNOL ALLERGY CLIN, V27, P273, DOI 10.1016/j.iac.2007.03.009; Lieberman P, 2010, J ALLERGY CLIN IMMUN, V126, pe1, DOI 10.1016/j.jaci.2010.06.022; Lieberman P, 2010, J ALLERGY CLIN IMMUN, V126, P477, DOI 10.1016/j.jaci.2010.06.022; Mallipeddi R, 2007, CLIN EXP DERMATOL, V32, P333, DOI 10.1111/j.1365-2230.2007.02365.x; Warrier P, 2009, ANN ALLERG ASTHMA IM, V102, P257, DOI 10.1016/S1081-1206(10)60091-9	11	11	11	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2014	134	4					981	983		10.1016/j.jaci.2014.05.032	http://dx.doi.org/10.1016/j.jaci.2014.05.032			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ9GC	25018095				2022-12-18	WOS:000343155700035
J	Pugmire, J; Vasquez, MM; Zhou, M; Sherrill, DL; Halonen, M; Martinez, FD; Guerra, S				Pugmire, Juliana; Vasquez, Monica M.; Zhou, Muhan; Sherrill, Duane L.; Halonen, Marilyn; Martinez, Fernando D.; Guerra, Stefano			Exposure to parental smoking in childhood is associated with persistence of respiratory symptoms into young adult life	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ASTHMA; PREDICTORS; CHILDREN		[Pugmire, Juliana; Vasquez, Monica M.; Zhou, Muhan; Sherrill, Duane L.; Halonen, Marilyn; Martinez, Fernando D.; Guerra, Stefano] Univ Arizona, Arizona Resp Ctr, Tucson, AZ 85721 USA; [Pugmire, Juliana; Vasquez, Monica M.; Zhou, Muhan; Sherrill, Duane L.] Univ Arizona, Mel & Enid Zuckerman Coll Publ Hlth, Tucson, AZ USA; [Guerra, Stefano] Univ Pompeu Fabra, CIBERESP, Ctr Res Environm Epidemiol CREAL, Barcelona, Spain	University of Arizona; University of Arizona; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Pompeu Fabra University	Pugmire, J (corresponding author), Univ Arizona, Arizona Resp Ctr, Tucson, AZ 85721 USA.	stefano@email.arizona.edu		Halonen, Marilyn/0000-0001-9606-935X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL095021] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL095021, HL095021] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alberg AJ, 2014, AM J EPIDEMIOL, V179, P1418, DOI 10.1093/aje/kwu079; Kerkhof M, 2014, J ALLERGY CLIN IMMUN, V133, P68, DOI 10.1016/j.jaci.2013.06.004; Mannino DM, 2001, CHEST, V120, P718, DOI 10.1378/chest.120.3.718; MARTINEZ FD, 1992, PEDIATRICS, V89, P21; Office on Smoking and Health (US), 2006, HLTH CONS INV EXP TO, P4; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; Strachan DP, 1996, BRIT MED J, V312, P1195; Strachan DP, 1998, THORAX, V53, P204, DOI 10.1136/thx.53.3.204	9	11	11	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2014	134	4					962	965		10.1016/j.jaci.2014.07.030	http://dx.doi.org/10.1016/j.jaci.2014.07.030			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ9GC	25174871	Green Accepted			2022-12-18	WOS:000343155700028
J	Kuo, NW; Tung, KY; Tsai, CH; Chen, YC; Lee, YL				Kuo, Nai-Wei; Tung, Kuan-Yen; Tsai, Ching-Hui; Chen, Yang-Ching; Lee, Yungling Leo			beta 3-Adrenergic receptor gene modifies the association between childhood obesity and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							BODY-MASS INDEX; CHILDREN; AGE; ADOLESCENTS; SYMPTOMS		[Kuo, Nai-Wei; Tung, Kuan-Yen; Tsai, Ching-Hui; Chen, Yang-Ching; Lee, Yungling Leo] Natl Taiwan Univ, Coll Publ Hlth, Inst Epidemiol & Prevent Med, Taipei 10764, Taiwan; [Lee, Yungling Leo] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan	National Taiwan University; Academia Sinica - Taiwan	Kuo, NW (corresponding author), Natl Taiwan Univ, Coll Publ Hlth, Inst Epidemiol & Prevent Med, Taipei 10764, Taiwan.	leolee@ntu.edu.tw	Lee, Yungling/S-7011-2018	Lee, Yungling/0000-0002-2234-9479				Biring MS, 1999, AM J MED SCI, V318, P293, DOI 10.1097/00000441-199911000-00002; Chen W, 2010, PEDIATR NEONATOL, V51, P69, DOI 10.1016/S1875-9572(10)60014-9; Eneli IU, 2008, THORAX, V63, P671, DOI 10.1136/thx.2007.086470; Fujisawa T, 1998, J CLIN ENDOCR METAB, V83, P2441, DOI 10.1210/jc.83.7.2441; Fujisawa T, 1996, DIABETOLOGIA, V39, P349, DOI 10.1007/s001250050452; Gilliland FD, 2003, AM J EPIDEMIOL, V158, P406, DOI 10.1093/aje/kwg175; KRIEF S, 1993, J CLIN INVEST, V91, P344, DOI 10.1172/JCI116191; Mamun AA, 2007, INT J OBESITY, V31, P578, DOI 10.1038/sj.ijo.0803571; Scholtens S, 2009, J ALLERGY CLIN IMMUN, V123, P1312, DOI 10.1016/j.jaci.2009.02.029; Tsai CH, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-11	10	11	11	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					731	+		10.1016/j.jaci.2014.03.018	http://dx.doi.org/10.1016/j.jaci.2014.03.018			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	24786241				2022-12-18	WOS:000341372400030
J	Busse, WW; Gern, JE				Busse, William W.; Gern, James E.			Asthma and infections: Is the risk more profound than previously thought?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Asthma; infections; immune deficiency; antiviral	WHEEZING RHINOVIRUS ILLNESSES; PNEUMOCOCCAL DISEASE; EPITHELIAL-CELLS; IMMUNE-RESPONSES; CHILDREN; DEFICIENT; BACTERIA		[Busse, William W.] Univ Wisconsin, Sch Med & Publ Health, Dept Med, Madison, WI 53706 USA; [Gern, James E.] Univ Wisconsin, Sch Med & Publ Health, Dept Pediat, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Busse, WW (corresponding author), Univ Wisconsin Hosp, Dept Med, K4-910 CSC,MC 9988,600 Highland Ave, Madison, WI 53792 USA.	wwb@medicine.wisc.edu						Bang DW, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003857; Bochkov YA, 2010, MUCOSAL IMMUNOL, V3, P69, DOI 10.1038/mi.2009.109; Durrani SR, 2012, J ALLERGY CLIN IMMUN, V130, P489, DOI 10.1016/j.jaci.2012.05.023; Gill MA, 2010, J IMMUNOL, V184, P5999, DOI 10.4049/jimmunol.0901194; Guilbert TW, 2011, J ALLERGY CLIN IMMUN, V128, P532, DOI 10.1016/j.jaci.2011.06.037; Guilbert TW, 2011, J ALLERGY CLIN IMMUN, V128, pe1; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jakiela B, 2008, AM J RESP CELL MOL, V38, P517, DOI 10.1165/rcmb.2007-0050OC; Juhn YJ, 2008, J ALLERGY CLIN IMMUN, V122, P719, DOI 10.1016/j.jaci.2008.07.029; Juhn YJ, 2014, J ALLERGY CLIN IMMUN, V134, P247, DOI 10.1016/j.jaci.2014.04.024; Kloepfer KM, 2014, J ALLERGY CLIN IMMUN, V133, P1301, DOI 10.1016/j.jaci.2014.02.030; Larsen JM, 2014, J ALLERGY CLIN IMMUN, V133, P1008, DOI 10.1016/j.jaci.2014.01.010; Lopez-Souza N, 2009, J ALLERGY CLIN IMMUN, V123, P1384, DOI 10.1016/j.jaci.2009.03.010; Papadopoulos NG, 2002, CLIN EXP ALLERGY, V32, P537, DOI 10.1046/j.0954-7894.2002.01313.x; Prescott SL, 1998, LANCET, V351, P1489, DOI 10.1016/S0140-6736(05)78871-1; Sykes A, 2014, THORAX, V69, P240, DOI 10.1136/thoraxjnl-2012-202909; Talbot TR, 2005, NEW ENGL J MED, V352, P2082, DOI 10.1056/NEJMoa044113; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901	18	11	11	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2014	134	2					260	261		10.1016/j.jaci.2014.05.008	http://dx.doi.org/10.1016/j.jaci.2014.05.008			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GB	25087225				2022-12-18	WOS:000341370800002
J	Finkelman, FD				Finkelman, Fred D.			Diesel exhaust particle exposure during pregnancy promotes development of asthma and atopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Diesel exhaust particle; asthma; atopy; oxidative stress; NK cells; pregnancy	PRENATAL EXPOSURE; CELLS; ENVIRONMENT; EXPRESSION; DERMATITIS; DISEASE; IL-4; SENSITIZATION; INFLAMMATION; AGE		[Finkelman, Fred D.] Cincinnati Vet Affairs Med Ctr, Dept Med, Cincinnati, OH USA; [Finkelman, Fred D.] Univ Cincinnati, Coll Med, Div Allergy Immunol & Rheumatol, Cincinnati, OH USA; [Finkelman, Fred D.] Cincinnati Childrens Hosp Med Ctr, Div Immunobiol, Cincinnati, OH 45229 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Finkelman, FD (corresponding author), Cincinnati Childrens Hosp Med Ctr, Bldg S,Rm S5-216,3333 Burnet Ave, Cincinnati, OH 45229 USA.	finkelfd@ucmail.uc.edu						Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; ALSHARIF NZ, 1994, TOXICOLOGY, V92, P39, DOI 10.1016/0300-483X(94)90166-X; Bleck B, 2006, J IMMUNOL, V176, P7431, DOI 10.4049/jimmunol.176.12.7431; Bleck B, 2010, J IMMUNOL, V185, P6636, DOI 10.4049/jimmunol.1000719; Brand S, 2011, J ALLERGY CLIN IMMUN, V128, P618, DOI 10.1016/j.jaci.2011.04.035; Brandt EB, 2013, J ALLERGY CLIN IMMUN, V132, P1194, DOI 10.1016/j.jaci.2013.06.048; Cao L, 2010, AM J PHYSIOL-LUNG C, V298, pL670, DOI 10.1152/ajplung.00399.2009; Conrad ML, 2009, J EXP MED, V206, P2869, DOI 10.1084/jem.20090845; Devouassoux G, 2002, J ALLERGY CLIN IMMUN, V109, P847, DOI 10.1067/mai.2002.122843; Diaz-Sanchez D, 2000, J ALLERGY CLIN IMMUN, V106, P1140, DOI 10.1067/mai.2000.111144; Dietert RR, 2008, BIRTH DEFECTS RES B, V83, P547, DOI 10.1002/bdrb.20170; Ege MJ, 2008, J ALLERGY CLIN IMMUN, V122, P407, DOI 10.1016/j.jaci.2008.06.011; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Fedulov AV, 2008, AM J RESP CELL MOL, V38, P57, DOI 10.1165/rcmb.2007-0124OC; Finkelman FD, 2005, J IMMUNOL, V174, P4630, DOI 10.4049/jimmunol.174.8.4630; Hagendorens MM, 2004, PEDIAT ALLERG IMM-UK, V15, P308, DOI 10.1111/j.1399-3038.2004.00169.x; Havstad S, 2011, J ALLERGY CLIN IMMUN, V128, P880, DOI 10.1016/j.jaci.2011.06.039; Hinz D, 2012, ALLERGY, V67, P380, DOI 10.1111/j.1398-9995.2011.02767.x; Holt PG, 1998, ENVIRON HEALTH PERSP, V106, P795, DOI 10.2307/3434191; Kabesch M, 2014, CURR OPIN ALLERGY CL, V14, P62, DOI 10.1097/ACI.0000000000000025; Manners S, 2014, J ALLERGY CLIN IMMUN, V134, P63, DOI 10.1016/j.jaci.2013.10.047; Moore MM, 2004, PEDIATRICS, V113, P468, DOI 10.1542/peds.113.3.468; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Peroni DG, 2010, PEDIAT ALLERG IMM-UK, V21, P977, DOI 10.1111/j.1399-3038.2010.00995.x; Provoost S, 2012, J ALLERGY CLIN IMMUN, V129, P483, DOI 10.1016/j.jaci.2011.07.051; Takano H, 1997, AM J RESP CRIT CARE, V156, P36, DOI 10.1164/ajrccm.156.1.9610054; Veldhoen M, 2008, NATURE, V453, P106, DOI 10.1038/nature06881; Wang Lei, 2008, Birth Defects Research, V84, P54, DOI 10.1002/bdrc.20114; Yanagisawa R, 2006, CLIN EXP ALLERGY, V36, P386, DOI 10.1111/j.1365-2222.2006.02452.x; Yoshida S, 2012, BIOL PHARM BULL, V35, P1238, DOI 10.1248/bpb.b110708	30	11	11	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					73	74		10.1016/j.jaci.2014.04.002	http://dx.doi.org/10.1016/j.jaci.2014.04.002			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	24835501				2022-12-18	WOS:000338930300010
J	Dhanju, R; Min, WX; Ackerley, C; Cimpean, L; Palaniyar, N; Roifman, CM; Grunebaum, E				Dhanju, Rupreet; Min, Weixian; Ackerley, Cameron; Cimpean, Lorand; Palaniyar, Nades; Roifman, Chaim M.; Grunebaum, Eyal			Pulmonary alveolar proteinosis in adenosine deaminase-deficient mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ABNORMALITIES; CONSEQUENCES; INFLAMMATION		[Dhanju, Rupreet; Min, Weixian; Grunebaum, Eyal] Univ Toronto, Hosp Sick Children, Dev & Stem Cell Biol Program, Toronto, ON M5G 1X8, Canada; [Dhanju, Rupreet] Univ Toronto, Fac Med, Inst Med Sci, Toronto, ON M5G 1X8, Canada; [Ackerley, Cameron] Univ Toronto, Hosp Sick Children, Dept Pathobiol & Lab Med, Toronto, ON M5G 1X8, Canada; [Cimpean, Lorand; Roifman, Chaim M.; Grunebaum, Eyal] Univ Toronto, Hosp Sick Children, Div Immunol & Allergy, Toronto, ON M5G 1X8, Canada; [Palaniyar, Nades] Univ Toronto, Hosp Sick Children, Physiol & Expt Med Program, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Dhanju, R (corresponding author), Univ Toronto, Hosp Sick Children, Dev & Stem Cell Biol Program, Toronto, ON M5G 1X8, Canada.	eyal.grunebaum@sickkids.ca		Palaniyar, Nades/0000-0002-2170-8548	Canadian Institutes of Health Research Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Apasov SG, 2001, J CLIN INVEST, V108, P131, DOI 10.1172/JCI200110360; Arpaia E, 2000, J EXP MED, V191, P2197, DOI 10.1084/jem.191.12.2197; Blackburn MR, 2000, J BIOL CHEM, V275, P32114, DOI 10.1074/jbc.M005153200; Blackburn MR, 2000, J EXP MED, V192, P159, DOI 10.1084/jem.192.2.159; Carey B, 2010, CLIN IMMUNOL, V135, P223, DOI 10.1016/j.clim.2010.02.017; Chunn JL, 2005, J IMMUNOL, V175, P1937, DOI 10.4049/jimmunol.175.3.1937; Douda DN, 2009, ORPHANET J RARE DIS, V4, DOI 10.1186/1750-1172-4-29; Flannagan RS, 2010, METHODS MOL BIOL, V591, P121, DOI 10.1007/978-1-60761-404-3_7; Grunebaum E, 2012, J ALLERGY CLIN IMMUN, V129, P1588, DOI 10.1016/j.jaci.2012.02.003; Mansouri A, 2012, NEUROBIOL DIS, V47, P201, DOI 10.1016/j.nbd.2012.04.001; Maygarden SJ, 2001, DIAGN CYTOPATHOL, V24, P389, DOI 10.1002/dc.1086; Mohsenin A, 2007, AM J PHYSIOL-LUNG C, V293, pL753, DOI 10.1152/ajplung.00187.2007; Papinazath T, 2011, J ALLERGY CLIN IMMUN, V128, P854, DOI 10.1016/j.jaci.2011.07.039; Sauer AV, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00265	14	11	12	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1467	+		10.1016/j.jaci.2013.11.029	http://dx.doi.org/10.1016/j.jaci.2013.11.029			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24439080				2022-12-18	WOS:000335450700033
J	Savage, JH; Matsui, EC; McCormack, M; Litonjua, AA; Wood, RA; Keet, CA				Savage, Jessica H.; Matsui, Elizabeth C.; McCormack, Meredith; Litonjua, Augusto A.; Wood, Robert A.; Keet, Corinne A.			The association between asthma and allergic disease and mortality: A 30-year follow-up study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							US POPULATION; UNITED-STATES; LUNG-FUNCTION		[Savage, Jessica H.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; [Savage, Jessica H.; Litonjua, Augusto A.] Harvard Univ, Sch Med, Boston, MA USA; [Matsui, Elizabeth C.; Wood, Robert A.; Keet, Corinne A.] Johns Hopkins Univ, Sch Med, Div Pediat Allergy & Immunol, Baltimore, MD USA; [McCormack, Meredith] Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD USA; [Litonjua, Augusto A.] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA; [Litonjua, Augusto A.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Johns Hopkins University; Johns Hopkins University; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Savage, JH (corresponding author), Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, 75 Francis St, Boston, MA 02115 USA.	jrsavage@partners.org		Koehl, Rachelle/0000-0002-7797-7456; Matsui, Elizabeth/0000-0001-8134-5593; Pham, Hewlett/0000-0003-0330-6104; Keet, Corinne/0000-0002-6585-239X	NCATS NIH HHS [UL1 TR001079, 1KL2 TR001100-01, KL2 TR001100] Funding Source: Medline; NIAID NIH HHS [K23 AI103187, 5T32AI007056-34] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001079, KL2TR001100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI103187, T32AI007056] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Centers for Disease Control and Prevention, NHANES I EP FOLL STU; Diaz-Guzman E, 2011, COPD, V8, P400, DOI 10.3109/15412555.2011.611200; Galobardes B, 2008, THORAX, V63, P423, DOI 10.1136/thx.2007.086744; Gergen PJ, 2000, CLIN EXP ALLERGY, V30, P1717, DOI 10.1046/j.1365-2222.2000.00971.x; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Ingram D D, 1994, Vital Health Stat 2, P1; Knoflach M, 2005, ARCH INTERN MED, V165, P2521, DOI 10.1001/archinte.165.21.2521; Mannino DM, 2003, THORAX, V58, P388, DOI 10.1136/thorax.58.5.388; MCWHORTER WP, 1988, CANCER-AM CANCER SOC, V62, P451, DOI 10.1002/1097-0142(19880715)62:2<451::AID-CNCR2820620234>3.0.CO;2-D; [National Center for Health Statistics Department of Health Education and Welfare], 1973, PLAN OP HLTH NUTR EX; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; Prescott SL, 2013, J ALLERGY CLIN IMMUN, V131, P23, DOI 10.1016/j.jaci.2012.11.019; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Singh K, 2010, J ALLERGY CLIN IMMUN, V126, P778, DOI 10.1016/j.jaci.2010.06.050; US Department of Commerce, 1973, US DEP COM P60, V60; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067	16	11	11	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1484	U441		10.1016/j.jaci.2014.01.028	http://dx.doi.org/10.1016/j.jaci.2014.01.028			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24636085	Green Accepted			2022-12-18	WOS:000335450700039
J	Mulder, B; Schuiling-Veninga, CCM; Bos, JHJ; de Vries, TW; Hak, E				Mulder, Bianca; Schuiling-Veninga, Catharina Carolina Maria; Bos, Jens H. J.; de Vries, Tjalling W.; Hak, Eelko			Acid-suppressive drug use in pregnancy and the toddler's asthma risk: A crossover, case-control study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHILDHOOD ASTHMA; EXPOSURE; CHILDREN		[Mulder, Bianca; Schuiling-Veninga, Catharina Carolina Maria; Bos, Jens H. J.; Hak, Eelko] Univ Groningen, Univ Ctr Pharm, Dept Pharmacoepidemiol & Pharmacoecon, Groningen, Netherlands; [de Vries, Tjalling W.] Med Ctr Leeuwarden, Dept Pediat, Leeuwarden, Netherlands; [Hak, Eelko] Univ Med Ctr Groningen, Dept Epidemiol, NL-9713 AV Groningen, Netherlands	University of Groningen; Medical Center Leeuwarden; University of Groningen	Mulder, B (corresponding author), Univ Groningen, Univ Ctr Pharm, Dept Pharmacoepidemiol & Pharmacoecon, Groningen, Netherlands.	b.mulder@rug.nl						Andersen ABT, 2012, ALIMENT PHARM THER, V35, P1190, DOI 10.1111/j.1365-2036.2012.05073.x; Bianchi M, 2011, EUR J CLIN PHARMACOL, V67, P967, DOI 10.1007/s00228-011-1033-4; Dehlink E, 2009, CLIN EXP ALLERGY, V39, P246, DOI 10.1111/j.1365-2222.2008.03125.x; GREENLAND S, 1986, INT J EPIDEMIOL, V15, P412; Kallen B, 2013, PEDIAT ALLERG IMM-UK, V24, P28, DOI 10.1111/pai.12034; Pali-Scholl I, 2010, CLIN EXP ALLERGY, V40, P1091, DOI 10.1111/j.1365-2222.2010.03468.x; Palosuo K, 2003, J ALLERGY CLIN IMMUN, V111, P1386, DOI 10.1067/mai.2003.1498; Pont LG, 2002, EUR J CLIN PHARMACOL, V57, P819, DOI 10.1007/s00228-001-0395-4; Schirm E, 2004, J CLIN EPIDEMIOL, V57, P737, DOI 10.1016/j.jclinepi.2002.12.001; Scholl I, 2007, FASEB J, V21, P1264, DOI 10.1096/fj.06-7223com	10	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2013	132	6					1438	1440		10.1016/j.jaci.2013.07.012	http://dx.doi.org/10.1016/j.jaci.2013.07.012			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	259PG	23992747	Bronze			2022-12-18	WOS:000327538200027
J	Jackson, J; Titman, P; Butler, S; Bond, K; Rao, A; Veys, P; Chiesa, R; Leiper, A; Riley, L; Gilmour, K; Amrolia, P; Rao, K				Jackson, Jessica; Titman, Penny; Butler, Stephen; Bond, Kathryn; Rao, Anupama; Veys, Paul; Chiesa, Robert; Leiper, Alison; Riley, Lynne; Gilmour, Kimberly; Amrolia, Persis; Rao, Kanchan			Cognitive and psychosocial function post hematopoietic stem cell transplantation in children with hemophagocytic lymphohistiocytosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hemophagocytic lymphohistiocytosis; hematopoietic stem cell transplantation; cognitive; children; psychosocial	DIFFICULTIES QUESTIONNAIRE; FREQUENCY; STRENGTHS	Objectives: This study investigated the cognitive and psychosocial outcomes in childhood survivors of hemophagocytic lymphohistiocytosis after hematopoietic stem cell transplantation. Methods: Twenty-one children were assessed on standardized measures of cognitive and psychosocial functioning and compared with an unaffected sibling control group (n = 14). Parent and teacher reports were obtained to provide additional information. Results: The average full-scale intelligence quotient for the patient cohort was 81 (95% CI, 72-90), which was significantly lower than both the population average of 100 (P = .001) and the average for the unaffected sibling control group (99.2, P = .002). Fifty-six percent of school-aged children were receiving additional support at school, with the majority needing high levels of support. These children also experienced significant psychosocial difficulties. Lower socioeconomic status was associated with poorer cognitive outcomes, but age at transplantation, time to transplantation, type of conditioning, and presence of mixed chimerism were not. Ten (48%) of 21 children had evidence of neurologic involvement at diagnosis, but surprisingly, this was not significantly associated with adverse neurologic outcomes, and some children who did not have any apparent neurologic involvement at diagnosis had severe learning difficulties at follow-up. Conclusions: In summary, childhood survivors of hemophagocytic lymphohistiocytosis are at risk of long-term cognitive and psychosocial difficulties. Prospective and systematic long-term follow-up of these patients is essential for early identification and effective management of these problems.	[Jackson, Jessica; Butler, Stephen] UCL, Res Dept Clin Educ & Hlth Psychol, London, England; [Veys, Paul; Chiesa, Robert; Amrolia, Persis; Rao, Kanchan] Great Ormond St Hosp Children NHS Fdn Trust, Dept Blood & Marrow Transplantat, London WC1N 3JH, England; [Rao, Anupama; Leiper, Alison; Riley, Lynne] Great Ormond St Hosp Children NHS Fdn Trust, Dept Haematol, London WC1N 3JH, England; [Titman, Penny; Bond, Kathryn] Great Ormond St Hosp Children NHS Fdn Trust, Dept Psychosocial Serv, London WC1N 3JH, England; [Gilmour, Kimberly] Great Ormond St Hosp Children NHS Fdn Trust, Dept Immunol, London WC1N 3JH, England	University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Rao, K (corresponding author), Great Ormond St Hosp Children NHS Fdn Trust, Dept Blood & Marrow Transplantat, Great Ormond St, London WC1N 3JH, England.	kanchan.rao@gosh.nhs.uk		Butler, Stephen/0000-0002-2072-5338	Great Ormond Street Hospital Childrens Charity [V1259, V1223] Funding Source: researchfish	Great Ormond Street Hospital Childrens Charity		Cesaro S, 2008, HAEMATOL-HEMATOL J, V93, P1694, DOI 10.3324/haematol.13142; Deiva K, 2012, NEUROLOGY, V78, P1150, DOI 10.1212/WNL.0b013e31824f800a; Emerson E, ESTIMATING CURRENT N; Goodman R, 1999, J CHILD PSYCHOL PSYC, V40, P791, DOI 10.1111/1469-7610.00494; Goodman R, 2000, BRIT J PSYCHIAT, V177, P534, DOI 10.1192/bjp.177.6.534; Haddad E, 1997, BLOOD, V89, P794, DOI 10.1182/blood.V89.3.794; HENTER JI, 1991, ACTA PAEDIATR SCAND, V80, P428, DOI 10.1111/j.1651-2227.1991.tb11878.x; Henter JI, 1998, HEMATOL ONCOL CLIN N, V12, P417, DOI 10.1016/S0889-8588(05)70520-7; Horne A, 2005, BRIT J HAEMATOL, V129, P622, DOI 10.1111/j.1365-2141.2005.05501.x; Horne A, 2008, BRIT J HAEMATOL, V140, P327, DOI 10.1111/j.1365-2141.2007.06922.x; OPCS, STAND OCC CLASS; Ouachee-Chardin M, 2006, PEDIATRICS, V117, pE743, DOI 10.1542/peds.2005-1789; Packman W, 2010, BONE MARROW TRANSPL, V45, P1134, DOI 10.1038/bmt.2010.74; Phipps S, 2008, J CLIN ONCOL, V26, P2027, DOI 10.1200/JCO.2007.13.6135; Rutter M., SOCIAL COMMUNICATION; Sparrow S., 2005, VINELAND ADAPTIVE BE; Tardieu M, 2005, BLOOD, V106, P40, DOI 10.1182/blood-2005-01-0319; Upton Penney, 2005, Health Qual Life Outcomes, V3, P22, DOI 10.1186/1477-7525-3-22; Varni James W, 2005, Expert Rev Pharmacoecon Outcomes Res, V5, P705, DOI 10.1586/14737167.5.6.705; Wechsler D, WECHSLER PRESCHOOL P; Wechsler D., WECHSLER ABBREVIATED	21	11	11	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					889	+		10.1016/j.jaci.2013.05.046	http://dx.doi.org/10.1016/j.jaci.2013.05.046			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	23987797				2022-12-18	WOS:000325096500016
J	Phillips, JE; Peng, RQ; Harris, P; Burns, L; Renteria, L; Lundblad, LKA; Fine, JS; Bauer, CMT; Stevenson, CS				Phillips, Jonathan E.; Peng, Ruoqi; Harris, Paul; Burns, Lisa; Renteria, Lorena; Lundblad, Lennart K. A.; Fine, Jay S.; Bauer, Carla M. T.; Stevenson, Christopher S.			House dust mite models: Will they translate clinically as a superior model of asthma?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PEANUT-SPECIFIC IGE; SKIN PRICK; FILAGGRIN MUTATIONS; FOOD ALLERGY; IMMEDIATE; ANAPHYLAXIS; CHALLENGES; DIAGNOSIS; SEVERITY; CHILDREN		[Phillips, Jonathan E.; Peng, Ruoqi; Harris, Paul; Burns, Lisa; Renteria, Lorena; Fine, Jay S.; Bauer, Carla M. T.; Stevenson, Christopher S.] Hoffmann La Roche Inc, pRED, Inflammat Discovery, Nutley, NJ 07110 USA; [Lundblad, Lennart K. A.] Univ Vermont, Vermont Lung Ctr, Burlington, VT USA	Roche Holding; University of Vermont	Phillips, JE (corresponding author), Hoffmann La Roche Inc, pRED, Inflammat Discovery, 340 Kingsland St, Nutley, NJ 07110 USA.	chris.stevenson@novartis.com	Phillips, Jonathan E/C-3763-2009	Phillips, Jonathan E/0000-0002-9036-649X; Lundblad, Lennart/0000-0002-1749-8242	NCATS NIH HHS [UL1 TR000077] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000077] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))		Birrell MA, 2010, EUR RESPIR J, V36, P1220, DOI 10.1183/09031936.00069110; Brown SJ, 2009, BRIT J DERMATOL, V161, P884, DOI 10.1111/j.1365-2133.2009.09339.x; Carson CG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048678; Chapman JA, 2006, ANN ALLERG ASTHMA IM, V96, pS1, DOI 10.1016/S1081-1206(10)60926-X; Clark AT, 2003, CLIN EXP ALLERGY, V33, P1041, DOI 10.1046/j.1365-2745.2003.01624.x; De Alba J, 2010, EUR RESPIR J, V35, P1377, DOI 10.1183/09031936.00022908; Eigenmann PA, 2000, PEDIATR ALLERGY IMMU, V11, P95, DOI 10.1034/j.1399-3038.2000.00071.x; Eum SY, 1999, BRIT J PHARMACOL, V126, P312, DOI 10.1038/sj.bjp.0702304; Gruber R, 2007, EUR J HUM GENET, V15, P179, DOI 10.1038/sj.ejhg.5201742; Haile S, 1999, EUR RESPIR J, V13, P961, DOI 10.1034/j.1399-3003.1999.13e06.x; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Hill DJ, 2001, CLIN EXP ALLERGY, V31, P1031, DOI 10.1046/j.1365-2222.2001.01113.x; Hubiche T, 2007, ACTA DERM-VENEREOL, V87, P499, DOI 10.2340/00015555-0329; Johannsen H, 2011, CLIN EXP ALLERGY, V41, P994, DOI 10.1111/j.1365-2222.2011.03717.x; Kagan R, 2003, ANN ALLERG ASTHMA IM, V90, P640, DOI 10.1016/S1081-1206(10)61869-8; Mlitz V, 2012, J EUR ACAD DERMATOL, V26, P983, DOI 10.1111/j.1468-3083.2011.04198.x; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Peeters KABM, 2007, CLIN EXP ALLERGY, V37, P108, DOI 10.1111/j.1365-2222.2006.02628.x; Perkins C, 2011, J EXP MED, V208, P853, DOI 10.1084/jem.20100023; Poninska J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016933; Rance F, 2002, J ALLERGY CLIN IMMUN, V109, P1027, DOI 10.1067/mai.2002.124775; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Sampson HA, 2006, ANN EMERG MED, V47, P373, DOI 10.1016/j.annemergmed.2006.01.018; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Seidenari S, 2003, ALLERGY, V58, P495, DOI 10.1034/j.1398-9995.2003.00153.x; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Thyssen JP, 2010, BRIT J DERMATOL, V162, P1278, DOI 10.1111/j.1365-2133.2010.09708.x; van Nieuwaal NHG, 2010, J ALLERGY CLIN IMMUN, V125, P1391, DOI 10.1016/j.jaci.2010.01.057; Wainstein BK, 2007, CLIN EXP ALLERGY, V37, P839, DOI 10.1111/j.1365-2222.2007.02726.x; Wainstein BK, 2007, PEDIAT ALLERG IMM-UK, V18, P231, DOI 10.1111/j.1399-3038.2007.00517.x; Wainstein BK, 2010, PEDIAT ALLERG IMM-UK, V21, P603, DOI 10.1111/j.1399-3038.2010.01063.x; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V122, P560, DOI 10.1016/j.jaci.2008.05.050; Weigand LA, 2009, J PHYSIOL-LONDON, V587, P3355, DOI 10.1113/jphysiol.2009.173054; Wills-Karp M, 2012, J EXP MED, V209, P607, DOI 10.1084/jem.20110079	35	11	11	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2013	132	1					242	244		10.1016/j.jaci.2012.12.1571	http://dx.doi.org/10.1016/j.jaci.2012.12.1571			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	173BF	23403050	Bronze			2022-12-18	WOS:000321052300039
J	Thompson, EE; Myers, RA; Du, GX; Aydelotte, TM; Tisler, CJ; Stern, DA; Evans, MD; Graves, PE; Jackson, DJ; Martinez, FD; Gern, JE; Wright, AL; Lemanske, RF; Ober, C				Thompson, Emma E.; Myers, Rachel A.; Du, Gaixin; Aydelotte, Tessa M.; Tisler, Christopher J.; Stern, Debra A.; Evans, Michael D.; Graves, Penelope E.; Jackson, Daniel J.; Martinez, Fernando D.; Gern, James E.; Wright, Anne L.; Lemanske, Robert F.; Ober, Carole			Maternal microchimerism protects against the development of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; maternal; microchimerism	FETAL CELL MICROCHIMERISM; GENOME-WIDE ASSOCIATION; PERIPHERAL-BLOOD; GENDER-DIFFERENCES; CHILDHOOD ASTHMA; SEX-DIFFERENCES; HEALTHY WOMEN; RISK; POLYMORPHISMS; DIAGNOSIS	Background: Maternal asthma and child's sex are among the most significant and reproducible risk factors for the development of asthma. Although the mechanisms for these effects are unknown, they likely involve nonclassical genetic mechanisms. One such mechanism could involve the transfer and persistence of maternal cells to her offspring, a common occurrence known as maternal microchimerism (MMc). MMc has been associated with many autoimmune diseases but has not been investigated for a role in asthma or allergic disease. Objective: We hypothesized that some of the observed risks for asthma may be due to different rates of transmission or persistence of maternal cells to children of mothers with asthma compared with children of mothers without asthma, or to sons compared with daughters. We further hypothesized that rates of MMc differ between children with and without asthma. Methods: We tested these hypotheses in 317 subjects from 3 independent cohorts by using a real-time quantitative PCR assay to detect a noninherited HLA allele in the child. Results: MMc was detected in 20.5% of the subjects (range 16.8%-27.1% in the 3 cohorts). We observed lower rates of asthma among MMc-positive subjects than among MMc-negative subjects (odds ratio, 0.38; 95% CI, 0.19-0.79; P = .029). Neither maternal asthma nor sex of the child was a significant predictor of MMc in the child (P = .81 and.15, respectively). Conclusions: Our results suggest for the first time that MMc may protect against the development of asthma.	[Thompson, Emma E.; Myers, Rachel A.; Du, Gaixin; Ober, Carole] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; [Aydelotte, Tessa M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA; [Tisler, Christopher J.; Evans, Michael D.; Jackson, Daniel J.; Gern, James E.; Lemanske, Robert F.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI 53706 USA; [Lemanske, Robert F.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA; [Stern, Debra A.; Graves, Penelope E.; Martinez, Fernando D.; Wright, Anne L.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA	University of Chicago; Fred Hutchinson Cancer Center; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Arizona	Thompson, EE (corresponding author), 920 E 58th St,Room 431F, Chicago, IL 60637 USA.	eethomps@uchicago.edu	Du, Gaixin/M-9901-2014	Du, Gaixin/0000-0002-4616-7725; Evans, Michael/0000-0001-7449-3993; Ober, Carole/0000-0003-4626-9809	COAST [P01 HL070831]; Tucson IIS [AI 42268]; Hutterites [R01 HL085197]; K12 HL090003; National Institutes of Health (NIH); NIH; Gilead; GlaxoSmithKline; MedImmune; Abbott; Merck; Biota; Centocor; Boehringer Ingelheim; Theraclone; Pulmatrix; AstraZeneca; Association of American Medical Colleges; University of Vermont; National Heart, Lung, and Blood Institute and Pharmaxis; American Institute of Research; Double Helix Development; Michigan Public Health Institute; Allegheny General Hospital; American Academy of Pediatrics; West Allegheny Health Systems; California Chapter 4 AAP; Colorado Allergy Society; Pennsylvania Allergy and Asthma Association; Harvard Pilgrim Health; California Society of Allergy; NYC Allergy Society; World Allergy Organization; American College of Chest Physicians; APAPARI; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085197, P01HL070831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042268] Funding Source: NIH RePORTER	COAST; Tucson IIS; Hutterites; K12 HL090003; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Gilead(Gilead Sciences); GlaxoSmithKline(GlaxoSmithKline); MedImmune(AstraZenecaMedimmune); Abbott(Abbott Laboratories); Merck(Merck & Company); Biota; Centocor; Boehringer Ingelheim(Boehringer Ingelheim); Theraclone; Pulmatrix; AstraZeneca(AstraZeneca); Association of American Medical Colleges; University of Vermont; National Heart, Lung, and Blood Institute and Pharmaxis; American Institute of Research; Double Helix Development; Michigan Public Health Institute; Allegheny General Hospital(General Electric); American Academy of Pediatrics; West Allegheny Health Systems; California Chapter 4 AAP; Colorado Allergy Society; Pennsylvania Allergy and Asthma Association; Harvard Pilgrim Health; California Society of Allergy; NYC Allergy Society; World Allergy Organization; American College of Chest Physicians(General Electric); APAPARI; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by grant nos. P01 HL070831 (COAST), AI 42268 (Tucson IIS), and R01 HL085197 (Hutterites). E.E.T. was supported by grant no. K12 HL090003.; Disclosure of potential conflict of interest: E. E. Thompson, G. Du, M. D. Evans, and C. Ober have received research support from the National Institutes of Health (NIH). D. A. Stern has received research support from the NIH and is employed by the University of Arizona. D. J. Jackson has received research support from the NIH and Pharmaxis and has received consultancy fees from Gilead and GlaxoSmithKline. F. D. Martinez has received research support from the NIH, consultancy fees from MedImmune, and lecture fees and travel support from Abbott and Merck. J. E. Gern is on the 3V BioSciences board; has received consultancy fees from GlaxoSmithKline, Biota, Centocor, Boehringer Ingelheim, MedImmune, Theraclone, Pulmatrix, and Merck; and has received research support from Merck, AstraZeneca, and GlaxoSmithKline. A. L. Wright has received research support from the NIH; is employed by the University of Arizona; has received lecture fees from the Association of American Medical Colleges and the University of Vermont; is co-owner of and owns stock in Brain for Hire; and is involved in the NIH Study Section. R. F. Lemanske has received research and travel support from the NIH; has received research support from the National Heart, Lung, and Blood Institute and Pharmaxis; has received consultancy fees from Merck, Sepracor, SA Boney and Associates LTD, GlaxoSmithKline, American Institute of Research, Genentech, Double Helix Development, and Boehringer Ingelheim; is employed by the University of Wisconsin School of Medicine and Public Health; has received lecture fees from Michigan Public Health Institute, Allegheny General Hospital, American Academy of Pediatrics, West Allegheny Health Systems, California Chapter 4 AAP, the Colorado Allergy Society, the Pennsylvania Allergy and Asthma Association, Harvard Pilgrim Health, the California Society of Allergy, the NYC Allergy Society, the World Allergy Organization, the American College of Chest Physicians, and APAPARI; and has received royalties from Elsevier and UpToDate. The rest of the authors declare that they have no relevant conflicts of interest.	Almqvist C, 2008, ALLERGY, V63, P47, DOI 10.1111/j.1398-9995.2007.01524.x; Ando T, 2002, J CLIN ENDOCR METAB, V87, P3315, DOI 10.1210/jc.87.7.3315; [Anonymous], 2000, J Pediatr, V137, P470; BUGAWAN TL, 1994, TISSUE ANTIGENS, V44, P137, DOI 10.1111/j.1399-0039.1994.tb02371.x; Cardwell CR, 2003, DIABETES CARE, V26, P2568, DOI 10.2337/diacare.26.9.2568; Chan WFN, 2012, ARTHRITIS RHEUM-US, V64, P380, DOI 10.1002/art.33358; Cirello V, 2010, INT J CANCER, V126, P2874, DOI 10.1002/ijc.24993; Cookson W, 2011, J ALLERGY CLIN IMMUN, V128, P266, DOI 10.1016/j.jaci.2011.06.026; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; Cox LA, 2003, CLIN CHEM, V49, P309, DOI 10.1373/49.2.309; Cusanovich DA, 2012, HUM MOL GENET, V21, P2111, DOI 10.1093/hmg/dds021; Douek IF, 1999, LANCET, V353, P1850, DOI 10.1016/S0140-6736(99)00988-5; Durham AL, 2011, BBA-GEN SUBJECTS, V1810, P1103, DOI 10.1016/j.bbagen.2011.03.006; Evans PC, 1999, BLOOD, V93, P2033, DOI 10.1182/blood.V93.6.2033.406k18_2033_2037; Fugazzola L, 2011, NAT REV ENDOCRINOL, V7, P89, DOI 10.1038/nrendo.2010.216; Gammill HS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024101; Gammill HS, 2010, INT J DEV BIOL, V54, P531, DOI 10.1387/ijdb.082767hg; Gannage M, 2002, EUR J IMMUNOL, V32, P3405, DOI 10.1002/1521-4141(200212)32:12<3405::AID-IMMU3405>3.0.CO;2-B; Haagerup A, 2002, ALLERGY, V57, P680, DOI 10.1034/j.1398-9995.2002.23523.x; Hostetler J, 1974, HUTTERITE SOC; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jacobson DL, 1997, CLIN IMMUNOL IMMUNOP, V84, P223, DOI 10.1006/clin.1997.4412; Kallenbach LR, 2011, CANCER RES, V71, P8, DOI 10.1158/0008-5472.CAN-10-0618; Klintschar M, 2001, J CLIN ENDOCR METAB, V86, P2494, DOI 10.1210/jc.86.6.2494; Lambert NC, 2004, ARTHRITIS RHEUM-US, V50, P906, DOI 10.1002/art.20200; Lemanske RF, 2002, PEDIAT ALLERG IMM-UK, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; Leynaert B, 2012, THORAX, V67, P625, DOI 10.1136/thoraxjnl-2011-201249; Li XN, 2012, J ALLERGY CLIN IMMUN, V130, P861, DOI 10.1016/j.jaci.2012.04.041; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176, DOI 10.1164/ajrccm.158.1.9710014; Loisel DA, 2011, J ALLERGY CLIN IMMUN, V128, P524, DOI 10.1016/j.jaci.2011.06.016; Loubiere LS, 2006, LAB INVEST, V86, P1185, DOI 10.1038/labinvest.3700471; Maloney S, 1999, J CLIN INVEST, V104, P41, DOI 10.1172/JCI6611; Mandhane PJ, 2005, AM J RESP CRIT CARE, V172, P45, DOI 10.1164/rccm.200412-1738OC; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Munthe-Kaas MC, 2004, J ALLERGY CLIN IMMUN, V114, P280, DOI 10.1016/j.jaci.2004.03.050; Nelson JL, 2007, P NATL ACAD SCI USA, V104, P1637, DOI 10.1073/pnas.0606169104; Nelson JL, 1998, LANCET, V351, P559, DOI 10.1016/S0140-6736(97)08357-8; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Ober C, 2003, AM J HUM GENET, V72, P1425, DOI 10.1086/375501; Ober C, 2008, NAT REV GENET, V9, P911, DOI 10.1038/nrg2415; Ober C, 2008, NEW ENGL J MED, V358, P1682, DOI 10.1056/NEJMoa0708801; Ober C, 2011, IMMUNOL REV, V242, P10, DOI 10.1111/j.1600-065X.2011.01029.x; Ober C, 2011, TRENDS GENET, V27, P107, DOI 10.1016/j.tig.2010.12.004; Postma DS, 2007, GENDER MED, V4, pS133, DOI 10.1016/S1550-8579(07)80054-4; Raby BA, 2007, J ALLERGY CLIN IMMUN, V120, P351, DOI 10.1016/j.jaci.2007.05.029; Rak JM, 2009, RHEUMATOLOGY, V48, P363, DOI 10.1093/rheumatology/ken505; Reed AM, 2000, LANCET, V356, P2156, DOI 10.1016/S0140-6736(00)03500-5; Rothers J, 2007, J ALLERGY CLIN IMMUN, V120, P1201, DOI 10.1016/j.jaci.2007.07.036; Steinberg A, 1967, GENETIC STUDIES INBR; Stern DA, 2007, J ALLERGY CLIN IMMUN, V120, P835, DOI 10.1016/j.jaci.2007.05.050; Su Y, 2010, CLIN EXP ALLERGY, V40, P1222, DOI 10.1111/j.1365-2222.2010.03539.x; Suskind David L, 2011, Chimerism, V2, P50, DOI 10.4161/chim.2.2.16556; Townsend EA, 2012, ENDOCR REV, V33, P1, DOI 10.1210/er.2010-0031; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; Wang C, 2012, GENE, V504, P220, DOI 10.1016/j.gene.2012.05.021; Wright AL, 2006, PEDIATR PULM, V41, P318, DOI 10.1002/ppul.20373; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192; Zhernakova A, 2009, NAT REV GENET, V10, P43, DOI 10.1038/nrg2489; Zifa E, 2012, MOL BIOL REP, V39, P4697, DOI 10.1007/s11033-011-1262-8	59	11	12	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2013	132	1					39	U82		10.1016/j.jaci.2012.12.1575	http://dx.doi.org/10.1016/j.jaci.2012.12.1575			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	173BF	23434286	Green Accepted			2022-12-18	WOS:000321052300004
J	Wang, YH; Hogan, SP; Fulkerson, PC; Abonia, JP; Rothenberg, ME				Wang, Yui-Hsi; Hogan, Simon P.; Fulkerson, Patricia C.; Abonia, J. Pablo; Rothenberg, Marc E.			Expanding the paradigm of eosinophilic esophagitis: Mast cells and IL-9	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Eosinophilic esophagitis; immunology; mast cells; IL-9	EXPRESSION PROFILE; GENE-EXPRESSION; CHILDREN		[Wang, Yui-Hsi; Hogan, Simon P.; Fulkerson, Patricia C.; Abonia, J. Pablo; Rothenberg, Marc E.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Allergy & Immunol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Wang, YH (corresponding author), Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Allergy & Immunol, MCL 7028,3333 Burnet Ave, Cincinnati, OH 45229 USA.	yui_hsi.wang@cchmc.org		Abonia, Juan/0000-0003-3788-6485	NIAID NIH HHS [R01 AI090129, R01 AI073553] Funding Source: Medline; NIDDK NIH HHS [R01 DK090119] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI090129, R01AI073553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK090119] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abonia JP, 2012, ANNU REV MED, V63, P421, DOI 10.1146/annurev-med-041610-134138; Abonia JP, 2010, J ALLERGY CLIN IMMUN, V126, P140, DOI 10.1016/j.jaci.2010.04.009; Aceves SS, 2010, J ALLERGY CLIN IMMUN, V126, P1198, DOI 10.1016/j.jaci.2010.08.050; Assa'ad AH, 2011, GASTROENTEROLOGY, V141, P1593, DOI 10.1053/j.gastro.2011.07.044; Bara I, 2010, EUR RESPIR J, V36, P1174, DOI 10.1183/09031936.00019810; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Blanchard C, 2011, J ALLERGY CLIN IMMUN, V127, P208, DOI 10.1016/j.jaci.2010.10.039; Goswami R, 2011, J IMMUNOL, V186, P3283, DOI 10.4049/jimmunol.1003049; Kirsch R, 2007, J PEDIATR GASTR NUTR, V44, P20, DOI 10.1097/MPG.0b013e31802c0d06; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Masterson JC, 2012, GUT; Mishra A, 2003, GASTROENTEROLOGY, V125, P1419, DOI 10.1016/j.gastro.2003.07.007; Mishra A, 2001, J CLIN INVEST, V107, P83, DOI 10.1172/JCI10224; Mishra A, 2002, J IMMUNOL, V168, P2464, DOI 10.4049/jimmunol.168.5.2464; Otani IM, 2013, J ALLERGY CLIN IMMUN, V131, P1576, DOI 10.1016/j.jaci.2013.02.042; Rothenberg ME, 2012, J ALLERGY CLIN IMMUN, V130, P617, DOI 10.1016/j.jaci.2012.06.051; Spergel JM, 2012, J ALLERGY CLIN IMMUN, V129, P456, DOI 10.1016/j.jaci.2011.11.044; Stein ML, 2006, J ALLERGY CLIN IMMUN, V118, P1312, DOI 10.1016/j.jaci.2006.09.007; Straumann A, 2010, GUT, V59, P21, DOI 10.1136/gut.2009.178558; Van Nassauw L, 2007, AUTON NEUROSCI-BASIC, V133, P91, DOI 10.1016/j.autneu.2006.10.003; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Wilhelm C, 2011, NAT IMMUNOL, V12, P1071, DOI 10.1038/ni.2133; Zuo L, 2010, J IMMUNOL, V185, P660, DOI 10.4049/jimmunol.1000471	23	11	11	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2013	131	6					1583	1585		10.1016/j.jaci.2013.04.010	http://dx.doi.org/10.1016/j.jaci.2013.04.010			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	166CT	23726533	Green Accepted			2022-12-18	WOS:000320532800018
J	de Blay, F; Doyen, V; Bloch-Morot, E; Caillot, D; Gayraud, J; de Laval, A; Thillay, A				de Blay, Frederic; Doyen, Virginie; Bloch-Morot, Evelyne; Caillot, Daniel; Gayraud, Jacques; de Laval, Aymar; Thillay, Alain		APSI Grp	French application of the European guidelines for regulation of allergenic extracts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[de Blay, Frederic] SFA, Paris, France; [de Blay, Frederic; Doyen, Virginie] Univ Hosp Strasbourg, Dept Resp Dis, Div Allergy, Strasbourg, France; [de Blay, Frederic; Doyen, Virginie] Univ Strasbourg, Strasbourg, France; [Doyen, Virginie] Univ Libre Brussels, CHU Brugmann, Clin Immunoallergol, Brussels, Belgium; [Bloch-Morot, Evelyne] French Assoc Continual Med Educ Allergists ANAFOR, Aix En Provence, France; [Caillot, Daniel; de Laval, Aymar] French Comm Support Com Soutien Allergol, Clermont Ferrand, France; [Gayraud, Jacques] French Trade Union Allergists SNAF, Tarbes, France; [Thillay, Alain] Trade Union Allergists ANAICE, Tours, France	CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universite Libre de Bruxelles	de Blay, F (corresponding author), SFA, Paris, France.	Frederic.deblay@chru-strasbourg.fr						[Anonymous], 2006, ARB PAUL EHRLICH I B, P43; [Anonymous], OJ, V50, P4101; European Medicine Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP) and Biologics Working Party (BWP), 2007, EMEACHMPBWP304831200; Kaul S, 2011, ALLERGY, V66, P753, DOI 10.1111/j.1398-9995.2011.02552.x; Larsen Jorgen Nedergaard, 2008, V138, P133, DOI 10.1007/978-1-59745-366-0_12; Lorenz AR, 2008, INT ARCH ALLERGY IMM, V147, P263, DOI 10.1159/000146074; Slater JE, 2012, J ALLERGY CLIN IMMUN, V129, P1014, DOI 10.1016/j.jaci.2012.01.066; Slater Jay E, 2008, Clin Allergy Immunol, V21, P273	8	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2013	131	5					1435	+		10.1016/j.jaci.2012.11.003	http://dx.doi.org/10.1016/j.jaci.2012.11.003			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	144AU	23375207				2022-12-18	WOS:000318912200029
J	Gilstrap, DL; Kraft, M				Gilstrap, Daniel L.; Kraft, Monica			Asthma and the host-microbe interaction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							HYGIENE HYPOTHESIS; GUT MICROBIOTA; CLARITHROMYCIN; EXACERBATIONS; AZITHROMYCIN; MYCOPLASMA; RESPONSES; AIRWAY		[Gilstrap, Daniel L.; Kraft, Monica] Duke Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, Durham, NC 27710 USA	Duke University	Gilstrap, DL (corresponding author), Duke Univ, Dept Med, Div Pulm Allergy & Crit Care Med, Box 2629, Durham, NC 27710 USA.	daniel.gilstrap@dm.duke.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI081672] Funding Source: NIH RePORTER; NIAID NIH HHS [P01 AI081672] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 2007, J ALLERGY CLIN IMMUN, V120, pS94, DOI 10.1016/j.jaci.2007.09.029; Asthma Kraft M., 2006, ASTHMA CLIN CHEST ME, P87; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Brusselle GG, 2013, THORAX, V68, P322, DOI 10.1136/thoraxjnl-2012-202698; Bufford JD, 2005, IMMUNOL ALLERGY CLIN, V25, P247, DOI 10.1016/j.iac.2005.03.005; Chawes BL, 2012, J ALLERGY CLIN IMMUN, V130, pe3; Chawes BLK, 2012, J ALLERGY CLIN IMMUN, V130, P354, DOI 10.1016/j.jaci.2012.04.045; Chu HW, 2003, CHEST, V123, p390S, DOI 10.1378/chest.123.3_suppl.390S; Edwards MR, 2012, NAT REV MICROBIOL, V10, P459, DOI 10.1038/nrmicro2801; Frei R, 2012, ALLERGY, V67, P451, DOI 10.1111/j.1398-9995.2011.02783.x; Guilbert Theresa W, 2010, Expert Rev Respir Med, V4, P71, DOI 10.1586/ers.09.60; Han MK, 2012, THORAX, V67, P456, DOI 10.1136/thoraxjnl-2011-201183; Koutsoubari I, 2012, PEDIAT ALLERG IMM-UK, V23, P385, DOI 10.1111/j.1399-3038.2012.01280.x; Maslowski KM, 2011, NAT IMMUNOL, V12, P5, DOI 10.1038/ni0111-5; Maslowski KM, 2009, NATURE, V461, P1282, DOI 10.1038/nature08530; McLoughlin RM, 2011, J ALLERGY CLIN IMMUN, V127, P1097, DOI 10.1016/j.jaci.2011.02.012; Metz G, 2010, IMMUNOL ALLERGY CLIN, V30, P575, DOI 10.1016/j.iac.2010.08.003; Richeldi L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002997.pub3; Simoes EAF, 2007, J PEDIATR-US, V151, P34, DOI 10.1016/j.jpeds.2007.02.032; Simpson JL, 2008, AM J RESP CRIT CARE, V177, P148, DOI 10.1164/rccm.200707-1134OC; Singh M, 2010, PEDIAT ALLERG IMM-UK, V21, pE368, DOI 10.1111/j.1399-3038.2009.00921.x; Stein Renato T, 2009, Paediatr Respir Rev, V10 Suppl 1, P29, DOI 10.1016/S1526-0542(09)70013-2; Strunk RC, 2008, J ALLERGY CLIN IMMUN, V122, P1138, DOI 10.1016/j.jaci.2008.09.028	23	11	12	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2013	131	5					1449	U338		10.1016/j.jaci.2013.03.004	http://dx.doi.org/10.1016/j.jaci.2013.03.004			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	144AU	23622122	Green Accepted			2022-12-18	WOS:000318912200035
J	Brannan, JD; Perry, CP; Anderson, SD				Brannan, John D.; Perry, Clare P.; Anderson, Sandra D.			Mannitol test results in asthmatic adults receiving inhaled corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							THERAPY		[Brannan, John D.; Perry, Clare P.] Westmead Hosp, Dept Resp & Sleep Med, Westmead, NSW 2145, Australia; [Anderson, Sandra D.] Royal Prince Alfred Hosp, Camperdown, NSW 2050, Australia	University of Sydney; University of Sydney	Brannan, JD (corresponding author), Westmead Hosp, Dept Resp & Sleep Med, Westmead, NSW 2145, Australia.	john.brannan@sydney.edu.au		Brannan, John/0000-0001-7243-7998; Anderson, Sandra/0000-0002-6308-8770				Brannan JD, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-144; Brannan JD, 2007, CLIN RESPIR J, V1, P3, DOI 10.1111/j.1752-699X.2007.00004.x; Cockcroft DW, 2012, J ALLERGY CLIN IMMUN, V130, P556, DOI 10.1016/j.jaci.2012.05.050; Cockcroft DW, 2003, CLIN REV ALLERG IMMU, V24, P19, DOI 10.1385/CRIAI:24:1:19; Leuppi JD, 2001, AM J RESP CRIT CARE, V163, P406, DOI 10.1164/ajrccm.163.2.9912091; Lipworth BJ, 2012, CHEST, V141, P607, DOI 10.1378/chest.11-1748; Subbarao P, 2006, J ALLERGY CLIN IMMUN, V117, P1008, DOI 10.1016/j.jaci.2005.11.048; Sumino K, 2012, J ALLERGY CLIN IMMUN, V130, P69, DOI 10.1016/j.jaci.2012.02.025; Weiler John M, 2010, Ann Allergy Asthma Immunol, V105, pS1, DOI 10.1016/j.anai.2010.09.021	9	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					906	907		10.1016/j.jaci.2012.08.028	http://dx.doi.org/10.1016/j.jaci.2012.08.028			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23043849				2022-12-18	WOS:000315587800036
J	Reddy, V; Baman, NS; Whitener, C; Ishmael, FT				Reddy, Vinitha; Baman, Neil S.; Whitener, Cynthia; Ishmael, Faoud T.			Drug Resistant Infections with Methicillin-Resistant Staphylococcus Aureus, Clostridium Difficile, and Vancomycin Resistant Enterococcus Are Associated with a Higher Prevalence of Penicillin Allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI)	FEB 22-26, 2013	San Antonio, TX	Amer Acad Allergy, Asthma & Immunol (AAAAI)					[Reddy, Vinitha; Baman, Neil S.; Whitener, Cynthia] Penn State Hershey Med Ctr, Hershey, PA USA; [Ishmael, Faoud T.] Penn State Univ, Coll Med, Hershey, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health									0	11	11	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2		S			AB170	AB170		10.1016/j.jaci.2012.12.1269	http://dx.doi.org/10.1016/j.jaci.2012.12.1269			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	111WC					2022-12-18	WOS:000316550800601
J	Wu, AC; Gregory, M; Kymes, S; Lambert, D; Edler, J; Stwalley, D; Fuhlbrigge, AL				Wu, Ann Chen; Gregory, Martin; Kymes, Steven; Lambert, Dennis; Edler, Joshua; Stwalley, Dustin; Fuhlbrigge, Anne L.			Modeling asthma exacerbations through lung function in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; pediatric patients; lung function; FEV1% predicted; hospitalizations; emergency department visits; model	TO-MODERATE ASTHMA; COST-EFFECTIVENESS; PULMONARY-FUNCTION; RISK; ADULTS; IMPROVES; HOSPITALIZATION; BARRIERS; GROWTH; VOLUME	Background: Formal economic evaluation using a model-based approach is playing an increasingly important role in health care decision making. Objective: To develop a model by using an objective measure of lung function- prebronchodilator FEV1 as a percent of predicted (FEV1% predicted)-as the primary independent factor to predict the frequency of adverse events related to the exacerbation of asthma on a population level. Methods: We developed a Markov simulation model of childhood asthma by using data from the Childhood Asthma Management Program. The primary outcomes were the result of asthma exacerbations defined as hospitalizations, emergency department (ED) visits, and the need for oral corticosteroid therapy. Predicted monthly frequencies for each acute event were based on negative binomial regression equations estimated from the placebo arm of the Childhood Asthma Management Program with covariates of age, prebronchodilator FEV1% predicted, time in study, prior hospitalizations, and prior nocturnal awakenings. Results: Simulated versus observed mean number of acute events were similar within the placebo and treatment groups. While the trial demonstrated treatment effects of 48% reduction in hospitalizations, 46% reduction in ED visits, and 44% reduction in the need for oral corticosteroid therapy at 48 months, the model simulated similar reductions of 49% in hospitalizations, 41% in ED visits, and 46% in the need for oral corticosteroid therapy. Conclusions: Our findings suggest that longitudinal intervention effects may be modeled through FEV1% predicted to estimate hospitalizations, ED visits, and need for oral corticosteroid therapy in childhood asthma for planning and evaluation purposes. (J Allergy Clin Immunol 2012;130:1065-70.)	[Wu, Ann Chen] Harvard Univ, Dept Populat Med, Sch Med, Boston, MA 02215 USA; [Wu, Ann Chen] Harvard Pilgrim Hlth Care Inst, Ctr Child Hlth Care Studies, Dept Populat Med, Boston, MA USA; [Wu, Ann Chen] Childrens Hosp, Dept Pediat, Boston, MA 02115 USA; [Gregory, Martin; Kymes, Steven; Lambert, Dennis; Edler, Joshua; Stwalley, Dustin] Washington Univ, Sch Med, Ctr Econ Evaluat Med, St Louis, MO 63130 USA; [Fuhlbrigge, Anne L.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Harvard University; Boston Children's Hospital; Washington University (WUSTL); Harvard University; Brigham & Women's Hospital	Wu, AC (corresponding author), Harvard Univ, Dept Populat Med, Sch Med, 133 Brookline Ave,6th Floor, Boston, MA 02215 USA.	ann.wu@childrens.harvard.edu	Wu, Ann/AAY-4293-2020	Wu, Ann/0000-0003-0599-9063	National Heart, Lung, and Blood Institute (The Effectiveness of Pharmacogenetic Testing in Asthma) [K08 HL088046]; National Center for Research Resources at the National Institutes of Health [UL1 RR024992]; National Heart, Lung, and Blood Institute (NHLBI); Harvard Pilgrim Healthcare; Agency for Healthcare Research and Quality; Washington University; Pfizer; Genentech; Treeage; National Institutes of Health; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000448] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024992] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL088046] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute (The Effectiveness of Pharmacogenetic Testing in Asthma); National Center for Research Resources at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Harvard Pilgrim Healthcare; Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Washington University; Pfizer(Pfizer); Genentech(Roche HoldingGenentech); Treeage; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by a grant from the National Heart, Lung, and Blood Institute (The Effectiveness of Pharmacogenetic Testing in Asthma, grant no. K08 HL088046, PI: Wu). The Center for Economic Evaluation in Medicine is supported by the Clinical and Translational Science Award program of the National Center for Research Resources at the National Institutes of Health (grant no. UL1 RR024992).; J. Edler and D. Lambert have been supported by one or more grants from the National Heart, Lung, and Blood Institute (NHLBI). D. Stwalley has been supported by one or more grants from Harvard Pilgrim Healthcare. A. Fuhlbrigge has been supported by one or more grants from the NHLBI; has received support for travel from the NHLBI's Data Coordinating Center; is a Board member for Merck; has consultancy arrangements with Merck, GlaxoSmithKline, ICON Medical Imaging, Sunovion, the Lovelace Respiratory Research Institute, Dmagi, and the NHLBI; and has received one ormore grants from or has one ormore grants pending with Agency for Healthcare Research and Quality. M. Gregory has been supported by one or more grants from Washington University. S. Kymes has been supported by one or more grants from Harvard Pilgrim Healthcare; has consultancy arrangements with Pfizer, Genentech, and Treeage; has received one or more grants from or has one or more grants pending with Pfizer and with Genentech; and has received one or more payments for travel/accommodations/meeting expenses from Pfizer. A. C. Wu has been supported by one or more grants from the National Institutes of Health.	AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Akinbami Lara J, 2011, Natl Health Stat Report, P1; Bacharier LB, 2003, PEDIATRICS, V112, pE85, DOI 10.1542/peds.112.2.e85; Barnett SBL, 2011, J ALLERGY CLIN IMMUN, V127, P145, DOI 10.1016/j.jaci.2010.10.020; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Corren J, 1997, J ALLERGY CLIN IMMUN, V100, P781, DOI 10.1016/S0091-6749(97)70274-4; COULTAS DB, 1988, AM REV RESPIR DIS, V138, P1386, DOI 10.1164/ajrccm/138.6.1386; DZYNGEL B, 1994, J ASTHMA, V31, P291; ENRIGHT PL, 1991, AM REV RESPIR DIS, V143, P1215, DOI 10.1164/ajrccm/143.6.1215; ENRIGHT PL, 1994, AM J RESP CRIT CARE, V149, pS9, DOI 10.1164/ajrccm/149.2_Pt_2.S9; Farber HJ, 1998, J ASTHMA, V35, P95, DOI 10.3109/02770909809055410; Freedberg KA, 1998, JAMA-J AM MED ASSOC, V279, P130, DOI 10.1001/jama.279.2.130; Fuhlbrigge AL, 2006, J ALLERGY CLIN IMMUN, V117, P359, DOI 10.1016/j.jaci.2005.10.036; Fuhlbrigge AL, 2001, J ALLERGY CLIN IMMUN, V107, P61, DOI 10.1067/mai.2001.111590; Fuhlbrigge AL, 2006, PEDIATRICS, V118, pE347, DOI 10.1542/peds.2005-2962; Halpern EF, 2000, MED DECIS MAKING, V20, P314, DOI 10.1177/0272989X0002000308; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; Kuntz KM, 2002, J CLIN EPIDEMIOL, V55, P11, DOI 10.1016/S0895-4356(01)00412-7; Lara M, 2003, J ASTHMA, V40, P289, DOI 10.1081/JAS-120018331; LI D, 1995, AM J RESP CRIT CARE, V151, P647; Lieu TA, 1999, J ASTHMA, V36, P359, DOI 10.3109/02770909909068229; Mandelblatt JS, 1999, CANCER-AM CANCER SOC, V86, P2378, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2378::AID-CNCR28>3.3.CO;2-C; NOONAN M, 1995, AM J RESP CRIT CARE, V152, P1467, DOI 10.1164/ajrccm.152.5.7582278; Okamoto LJ, 1996, ANN ALLERG ASTHMA IM, V76, P455, DOI 10.1016/S1081-1206(10)63463-1; Paltiel AD, 2001, J ALLERGY CLIN IMMUN, V108, P39, DOI 10.1067/mai.2001.116289; Prosser LA, 2000, ANN INTERN MED, V132, P769, DOI 10.7326/0003-4819-132-10-200005160-00002; Sculpher MJ, 2003, RESP MED, V97, P508, DOI 10.1053/rmed.2002.1474; Strunk RC, 2002, J ALLERGY CLIN IMMUN, V110, P395, DOI 10.1067/mai.2002.127433; Tamaoki J, 1997, AM J RESP CRIT CARE, V155, P1235, DOI 10.1164/ajrccm.155.4.9105060; TOSTESON ANA, 1990, ANN INTERN MED, V113, P594, DOI 10.7326/0003-4819-113-8-594; Weinstein MC, 2006, PHARMACOECONOMICS, V24, P1043, DOI 10.2165/00019053-200624110-00002; Wever-Hess J, 2000, PEDIATR PULM, V29, P250, DOI 10.1002/(SICI)1099-0496(200004)29:4<250::AID-PPUL3>3.0.CO;2-4; Wu AC, 2007, J ALLERGY CLIN IMMUN, V120, P1146, DOI 10.1016/j.jaci.2007.07.055; Zahran Hatice S., 2011, Morbidity and Mortality Weekly Report, V60, P547	35	11	11	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2012	130	5					1065	1070		10.1016/j.jaci.2012.08.009	http://dx.doi.org/10.1016/j.jaci.2012.08.009			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	030LE	23021884	Green Accepted			2022-12-18	WOS:000310571400004
J	Hancock, DB; Romieu, I; Chiu, GY; Sienra-Monge, JJ; Li, HL; del Rio-Navarro, BE; London, SJ				Hancock, Dana B.; Romieu, Isabelle; Chiu, Grace Y.; Sienra-Monge, Juan-Jose; Li, Huiling; Estela del Rio-Navarro, Blanca; London, Stephanie J.			STAT6 and LRP1 polymorphisms are associated with food allergen sensitization in Mexican children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SEVERITY		[Hancock, Dana B.; London, Stephanie J.] Natl Inst Environm Hlth Sci, Epidemiol Branch, Div Intramural Res, Res Triangle Pk, NC USA; [Li, Huiling; London, Stephanie J.] Natl Inst Environm Hlth Sci, Lab Resp Biol, Div Intramural Res, Res Triangle Pk, NC USA; [Hancock, Dana B.] Res Triangle Inst Int, Behav Hlth Epidemiol Program, Res Triangle Pk, NC USA; [Romieu, Isabelle] Int Agcy Res Canc, F-69372 Lyon, France; [Chiu, Grace Y.] Westat Corp, Res Triangle Pk, NC USA; [Sienra-Monge, Juan-Jose; Estela del Rio-Navarro, Blanca] Hosp Infantil Mexico Dr Federico Gomez, Mexico City, DF, Mexico	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Research Triangle Institute; World Health Organization; International Agency for Research on Cancer (IARC); Westat; Hospital Infantil de Mexico Federico Gomez	Hancock, DB (corresponding author), Natl Inst Environm Hlth Sci, Epidemiol Branch, Div Intramural Res, Res Triangle Pk, NC USA.	london2@niehs.nih.gov	London, Stephanie/C-3734-2019	London, Stephanie/0000-0003-4911-5290; Hancock, Dana/0000-0003-2240-3604	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES049019, ZIAES049019] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 ES049019, ZIA ES049019-16] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		AAS K, 1980, ALLERGY, V35, P250, DOI 10.1111/j.1398-9995.1980.tb01763.x; Amoli MM, 2002, GENES IMMUN, V3, P220, DOI 10.1038/sj.gene.6363872; Granada M, 2012, J ALLERGY CLIN IMMUN, V129, P840, DOI 10.1016/j.jaci.2011.09.029; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Hancock DB, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000623; Hong XM, 2009, CURR OPIN PEDIATR, V21, P770, DOI 10.1097/MOP.0b013e32833252dc; Li J, 2005, HEREDITY, V95, P221, DOI 10.1038/sj.hdy.6800717; Negoro T, 2006, PEDIATR ALLERGY IMMU, V17, P583, DOI 10.1111/j.1399-3038.2006.00463.x; Nyholt DR, 2004, AM J HUM GENET, V74, P765, DOI 10.1086/383251; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Rothenberg ME, 2010, NAT GENET, V42, P289, DOI 10.1038/ng.547	11	11	11	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1673	1676		10.1016/j.jaci.2012.03.012	http://dx.doi.org/10.1016/j.jaci.2012.03.012			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22534531	Green Accepted			2022-12-18	WOS:000304764600032
J	Liccardi, G; Salzillo, A; Cecchi, L; D'Amato, M; D'Amato, G				Liccardi, Gennaro; Salzillo, Antonello; Cecchi, Lorenzo; D'Amato, Maria; D'Amato, Gennaro			Is cat-keeping the main determinant of new-onset adulthood cat sensitization?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FURRY ANIMALS; ALLERGEN		[Liccardi, Gennaro; Salzillo, Antonello; D'Amato, Gennaro] High Special A Cardarelli Hosp, Div Pneumol & Allergol, Dept Chest Dis, Naples, Italy; [Cecchi, Lorenzo] Azienda Sanit 4, Allergy & Immunol Sect, Prato, Italy; [D'Amato, Maria] High Special V Monaldi Hosp, Div Resp Med, Naples, Italy; [D'Amato, Maria] Univ Naples Federico II, Naples, Italy	Antonio Cardarelli Hospital; University of Naples Federico II	Liccardi, G (corresponding author), High Special A Cardarelli Hosp, Div Pneumol & Allergol, Dept Chest Dis, Naples, Italy.	gennaro.liccardi@tin.it	D'Amato, Maria/H-3074-2012	D'Amato, Maria/0000-0002-5906-5701; Cecchi, Lorenzo/0000-0002-0658-2449				DAmato G, 1997, J ALLERGY CLIN IMMUN, V99, P577, DOI 10.1016/S0091-6749(97)70088-5; Liccardi G, 2005, RESP MED, V99, P535, DOI 10.1016/j.rmed.2004.09.018; Liccardi G, 2011, ALLERGY, V66, P1500, DOI 10.1111/j.1398-9995.2011.02675.x; Liccardi G, 2011, J INVEST ALLERG CLIN, V21, P137; Liccardi G, 2003, INT ARCH ALLERGY IMM, V132, P1, DOI 10.1159/000073259; Liccardi G, 2011, CURR ALLERGY ASTHM R, V11, P421, DOI 10.1007/s11882-011-0214-7; Olivieri M, 2012, J ALLERGY CLIN IMMUN, V129, P420, DOI 10.1016/j.jaci.2011.10.044	7	11	11	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1689	1690		10.1016/j.jaci.2012.02.052	http://dx.doi.org/10.1016/j.jaci.2012.02.052			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22498106				2022-12-18	WOS:000304764600042
J	Stevenson, DD; White, AA; Simon, RA				Stevenson, Donald D.; White, Andrew A.; Simon, Ronald A.			Aspirin as a cause of pancreatitis in patients with aspirin-exacerbated respiratory disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Aspirin; nonsteroidal anti-inflammatory drugs; drug reactions; pancreatitis; aspirin-exacerbated respiratory disease	SEVERITY; THERAPY		[Stevenson, Donald D.; White, Andrew A.; Simon, Ronald A.] Scripps Clin, Div Allergy Asthma & Immunol, San Diego, CA 92130 USA	Scripps Research Institute	Stevenson, DD (corresponding author), Scripps Clin, Div Allergy Asthma & Immunol, 3811 Valley Ctr Dr,4th Floor, San Diego, CA 92130 USA.	stevenson.donald@scrippshealth.org						Antonopoulos S, 2005, J PANCREAS, V6, P264; Badalov N, 2007, CLIN GASTROENTEROL H, V101, P454; Banks PA, 2002, GASTROINTEST ENDOSC, V56, pS226, DOI 10.1067/mge.2002.129022; Daffern PJ, 1999, J ALLERGY CLIN IMMUN, V104, P559, DOI 10.1016/S0091-6749(99)70324-6; Hoyte FCL, 2012, J ALLERGY CLIN IMMUN, V129, P1684, DOI 10.1016/j.jaci.2011.12.003; Lee RU, 2010, ANN ALLERG ASTHMA IM, V105, P130, DOI 10.1016/j.anai.2010.05.020; LEE SP, 1992, NEW ENGL J MED, V326, P589, DOI 10.1056/NEJM199202273260902; Pezzilli R, 2004, DIGEST LIVER DIS, V36, P639, DOI 10.1016/j.dld.2004.05.002; Roger VL, 2011, CIRCULATION, V123, pE18, DOI 10.1161/CIR.0b013e3182009701; Singh Sonal, 2004, JOP, V5, P502; Tenner S, 2010, DIGEST DIS SCI, V55, P2977; Trivedi CD, 2005, J CLIN GASTROENTEROL, V39, P709, DOI 10.1097/01.mcg.0000173929.60115.b4; Williams AN, 2007, J ALLERGY CLIN IMMUN, V120, P273, DOI 10.1016/j.jaci.2007.03.020	13	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1687	1688		10.1016/j.jaci.2012.04.016	http://dx.doi.org/10.1016/j.jaci.2012.04.016			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22554703				2022-12-18	WOS:000304764600039
J	Seppala, U; Francese, S; Turillazzi, S; Moneti, G; Clench, M; Barber, D				Seppala, Ulla; Francese, Simona; Turillazzi, Stefano; Moneti, Gloriano; Clench, Malcolm; Barber, Domingo			In situ imaging of honeybee (Apis mellifera) venom components from aqueous and aluminum hydroxide-adsorbed venom immunotherapy preparations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen; inflammation; imaging; in situ; honeybee; venom; immunotherapy; subcutaneous	ALLERGY; EXPRESSION; CELLS; BEE	Background: Treatment with aqueous and aluminum hydroxide (Al[OH](3))-adsorbed purified honeybee (Apis mellifera) venom (HBV) preparations can reduce the incidence of side effects associated with venom immunotherapy. Objective: The aim of the present study was to assess these purified HBV immunotherapy preparations in situ. Methods: Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) was used to visualize the distribution of HBV components. The preparations were administered on the back legs of naive Wistar rats. The rats were killed, and cryosectioned tissue sections were subjected to hematoxylin and eosin staining and MALDI-MSI analyses. Results: Low-density maps of tissue distribution of HBV peptides, such as secapin, mast cell degranulating peptide, and melittin (Api m 4) were detected in the tissue after administration of HBV immunotherapy preparations. In addition, release of biogenic amines, cytokines, and leukotrienes was observed, and the distribution of HBV allergens, such as Api m 1 and Api m 2, was shown. At the 24-hour time point, the major HBV allergen Api m 1 was still detected at the site of Al(OH)(3)-adsorbed HVB injection, whereas in the case of aqueous HBV preparation, all the allergens, as well as most of the biogenic amines, were cleared at the 24-hour time point. Conclusion: The present study shows that the majority of low-molecular-weight HBV components are rapidly removed from the site of venom immunotherapy administration. Furthermore, Al(OH) 3-adsorbed HBV preparation demonstrated a depot effect, prolonging the availability of bee venom allergens at the site of administration. (J Allergy Clin Immunol 2012;129:1314-20.)	[Seppala, Ulla; Barber, Domingo] ALK Abello, Global Res, Markets & Prod Support, DK-2970 Horsholm, Denmark; [Seppala, Ulla; Barber, Domingo] ALK Abello, Global Res, Markets & Prod Support, Madrid, Spain; [Francese, Simona; Clench, Malcolm] Sheffield Hallam Univ, Sheffield S1 1WB, S Yorkshire, England; [Turillazzi, Stefano; Moneti, Gloriano] Univ Florence, CISM, I-50121 Florence, Italy	ALK-Abello AS; ALK-Abello AS; Sheffield Hallam University; University of Florence	Seppala, U (corresponding author), ALK Abello, Global Res, Markets & Prod Support, Boge Alle 3, DK-2970 Horsholm, Denmark.	USedk@alk-abello.com	Clench, Malcolm/AAA-4100-2020; Barber, Domingo/Y-9516-2019	Barber, Domingo/0000-0002-5488-5700; Clench, Malcolm/0000-0002-0798-831X	ALK-Abello, Horsholm, Denmark; ALK-Abello	ALK-Abello, Horsholm, Denmark; ALK-Abello	Supported by ALK-Abello, Horsholm, Denmark.; Disclosure of potential conflict of interest: S. Francese, G. Moneti, and M. Clench have received research support from ALK-Abello. The rest of the authors declare that they have no relevant conflicts of interest.	Bal SM, 2010, J CONTROL RELEASE, V148, P266, DOI 10.1016/j.jconrel.2010.09.018; Bilo BM, 2005, ALLERGY, V60, P1339, DOI 10.1111/j.1398-9995.2005.00963.x; Bilo MB, 2010, CURR OPIN ALLERGY CL, V10, P330, DOI 10.1097/ACI.0b013e328339f2d1; Blank S, 2010, J IMMUNOL, V184, P5403, DOI 10.4049/jimmunol.0803709; Bonifazi F, 2005, ALLERGY, V60, P1459, DOI 10.1111/j.1398-9995.2005.00960.x; Caprioli RM, 1997, ANAL CHEM, V69, P4751, DOI 10.1021/ac970888i; DREBORG S, 1990, CRIT REV THER DRUG, V6, P315; Du YR, 2011, BIOCHEM BIOPH RES CO, V408, P32, DOI 10.1016/j.bbrc.2011.03.110; Francese S, 2010, MASS SPECTROMETRY MI, P91; Francese S, 2009, J AM SOC MASS SPECTR, V20, P112, DOI 10.1016/j.jasms.2008.09.006; Galli SJ, 2010, EUR J IMMUNOL, V40, P1843, DOI 10.1002/eji.201040559; Grunwald T, 2006, J ALLERGY CLIN IMMUN, V117, P848, DOI 10.1016/j.jaci.2005.12.1331; HIDER RC, 1988, ENDEAVOUR, V12, P60, DOI 10.1016/0160-9327(88)90082-8; Kettner A, 2001, J ALLERGY CLIN IMMUN, V107, P914, DOI 10.1067/mai.2001.113867; King TP, 2000, INT ARCH ALLERGY IMM, V123, P99, DOI 10.1159/000024440; Kupper TS, 2004, NAT REV IMMUNOL, V4, P211, DOI 10.1038/nri1310; Larsen JN, 2008, CLIN ALLERGY IMMUNOL, P283; McDonald TA, 2010, CURR OPIN MOL THER, V12, P461; Muller UR, 2009, ALLERGY, V64, P543, DOI 10.1111/j.1398-9995.2008.01794.x; Prideaux B, 2010, METHODS MOL BIOL, V656, P405, DOI 10.1007/978-1-60761-746-4_23; Rueff F, 2004, ALLERGY, V59, P589, DOI 10.1111/j.1398-9995.2004.00505.x; Schneider JJ, 2005, J MOL MED, V83, P587, DOI 10.1007/s00109-005-0657-1; Strong PN, 2000, METH TOOLS BIOSCI ME, P127	23	11	11	3	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1314	U189		10.1016/j.jaci.2011.10.014	http://dx.doi.org/10.1016/j.jaci.2011.10.014			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22104605				2022-12-18	WOS:000303418000021
J	Frank, MM				Frank, Michael M.			CD21 deficiency, complement, and the development of common variable immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						CD21 deficiency; common variable immunodeficiency	B-CELLS; 2 PARTS; RESPONSES; IMMUNOLOGY; TRANSPORT; RECEPTOR; CD19		Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA	Duke University	Frank, MM (corresponding author), Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA.							Asokan R, 2006, J IMMUNOL, V177, P383, DOI 10.4049/jimmunol.177.1.383; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; Chen ZB, 2000, IMMUNOL REV, V176, P194; Cinamon G, 2008, NAT IMMUNOL, V9, P54, DOI 10.1038/ni1542; Fearon DT, 2000, ANNU REV IMMUNOL, V18, P393, DOI 10.1146/annurev.immunol.18.1.393; Frank M. M., 2001, SAMTERS IMMUNOLOGIC; Gazit Y, 2010, J CLIN IMMUNOL, V30, P308, DOI 10.1007/s10875-009-9354-0; Jozsi M, 2008, TRENDS IMMUNOL, V29, P380, DOI 10.1016/j.it.2008.04.008; Liszewski MK, 1996, ADV IMMUNOL, V61, P201; OCHS HD, 1993, CLIN IMMUNOL IMMUNOP, V67, pS33, DOI 10.1006/clin.1993.1081; Phan TG, 2007, NAT IMMUNOL, V8, P992, DOI 10.1038/ni1494; Thiel J, 2012, J ALLERGY CLIN IMMUN, V129, P801, DOI 10.1016/j.jaci.2011.09.027; van Zelm MC, 2006, NEW ENGL J MED, V354, P1901, DOI 10.1056/NEJMoa051568; van Zelm MC, 2010, J CLIN INVEST, V120, P1265, DOI 10.1172/JCI39748; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; Wu XB, 2000, J IMMUNOL, V165, P3119, DOI 10.4049/jimmunol.165.6.3119	18	11	11	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					811	813		10.1016/j.jaci.2011.12.982	http://dx.doi.org/10.1016/j.jaci.2011.12.982			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22277200				2022-12-18	WOS:000301189300029
J	Johansen, P; Weiss, A; Bunter, A; Waeckerle-Men, Y; Fettelschoss, A; Odermatt, B; Kundig, TM				Johansen, Pal; Weiss, Andreas; Buenter, Antonia; Waeckerle-Men, Ying; Fettelschoss, Antonia; Odermatt, Bernhard; Kuendig, Thomas M.			Clemastine causes immune suppression through inhibition of extracellular signal-regulated kinase-dependent proinflammatory cytokines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Antihistamine; bacterial infections; immune suppression; innate immunity; cytokines; signal transduction; sepsis	NF-KAPPA-B; HISTAMINE SYNTHESIS; INVERSE AGONISM; ACTIVATION; MACROPHAGES; EXPRESSION; CELL; NEUTROPHILS; DEFICIENT; RESPONSES	Background: Antihistamines are considered safe and used worldwide against allergy, pruritus, nausea, and cough and as sleeping aids. Nonetheless, a growing number of reports suggest that antihistamines also have immunoregulatory functions. Objective: We examined the extent and by what potential mechanisms histamine-1-receptor (H1R) antagonists exert immune suppressive effects. Methods: Immune suppression by antihistamines and immunosuppressants was tested in mice infected with Listeria monocytogenes. Potential modes of action were studied in vitro by using murine and human cells. We also tested whether injection of clemastine in healthy volunteers affected the activation of peripheral macrophages and monocytes. Finally, therapeutic application of clemastine-mediated immune suppression was tested in a murine model of sepsis. Results: Clemastine and desloratadine strongly reduced innate responses to Listeria monocytogenes in mice as did dexamethasone. The immune suppression was MyD88 independent and characterized by inhibition of the mitogen-activated protein kinase-extracellular signal-regulated kinase signaling pathway, leading to overall impaired innate immunity with reduced TNF-alpha and IL-6 production. Surprisingly, the observed effects were H1R independent as demonstrated in H1R-deficient mice. Moreover, in a double-blind placebo-controlled clinical trial, 1 intravenous administration of clemastine reduced the TNF-alpha secretion potential of peripheral blood macrophages and monocytes. This inhibition could be exploited to treat sepsis in mice. Conclusions: The safety profile of antihistamines may need to be revisited. However, antihistamine-mediated immune suppression may also be exploited and find applications in the treatment of inflammatory diseases. (J Allergy Clin Immunol 2011;128:1286-94.)	[Johansen, Pal; Weiss, Andreas; Buenter, Antonia; Waeckerle-Men, Ying; Fettelschoss, Antonia; Kuendig, Thomas M.] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland; [Odermatt, Bernhard] Univ Zurich Hosp, Dept Pathol, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital	Johansen, P (corresponding author), Univ Zurich Hosp, Dept Dermatol, Gloriastr 31, CH-8091 Zurich, Switzerland.	pal.johansen@usz.ch	Johansen, Pål/A-1403-2013; Gabriel, Antonia/AAD-2355-2019	Johansen, Pål/0000-0002-5055-6299; Gabriel, Antonia/0000-0002-6189-172X	Swiss National Science Foundation [31003A-122221]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	This study was supported by a grant (#31003A-122221) from the Swiss National Science Foundation.	Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bakker RA, 2001, MOL PHARMACOL, V60, P1133, DOI 10.1124/mol.60.5.1133; Belke K, 1999, INT ARCH ALLERGY IMM, V118, P353, DOI 10.1159/000024133; Bone RC, 1996, JAMA-J AM MED ASSOC, V276, P565, DOI 10.1001/jama.276.7.565; BORISH L, 1989, CELL IMMUNOL, V121, P280, DOI 10.1016/0008-8749(89)90026-9; Chi HB, 2006, P NATL ACAD SCI USA, V103, P2274, DOI 10.1073/pnas.0510965103; Church MK, 1999, CLIN EXP ALLERGY, V29, P39, DOI 10.1046/j.1365-2222.1999.00011.x; Cooper AM, 2007, TRENDS IMMUNOL, V28, P33, DOI 10.1016/j.it.2006.11.002; DALRYMPLE SA, 1995, INFECT IMMUN, V63, P2262, DOI 10.1128/IAI.63.6.2262-2268.1995; Fischer MJE, 1998, BIOCHEM PHARMACOL, V55, P1255, DOI 10.1016/S0006-2952(97)00600-X; Gekara NO, 2009, J INFECT DIS, V199, P124, DOI 10.1086/595562; Johansen P, 2008, CLIN EXP ALLERGY, V38, P512, DOI 10.1111/j.1365-2222.2007.02904.x; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; Kempuraj D, 2003, INT ARCH ALLERGY IMM, V132, P231, DOI 10.1159/000074304; Leurs R, 2002, CLIN EXP ALLERGY, V32, P489, DOI 10.1046/j.0954-7894.2002.01314.x; Mazzoni A, 2003, J IMMUNOL, V170, P2269, DOI 10.4049/jimmunol.170.5.2269; Megyeri K, 2006, MICROBES INFECT, V8, P1035, DOI 10.1016/j.micinf.2005.10.022; MILLIGAN G, 1995, TRENDS PHARMACOL SCI, V16, P10, DOI 10.1016/S0165-6147(00)88963-4; Mocci S, 1997, IMMUNOL REV, V158, P107, DOI 10.1111/j.1600-065X.1997.tb00996.x; Navarini AA, 2009, P NATL ACAD SCI USA, V106, P7107, DOI 10.1073/pnas.0901162106; Nosal' R, 2006, NEUROENDOCRINOL LETT, V27, P148; Pamer EG, 2004, NAT REV IMMUNOL, V4, P812, DOI 10.1038/nri1461; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Simons FER, 2004, NEW ENGL J MED, V351, P2203, DOI 10.1056/NEJMra033121; Stempel DA, 1997, AM J MANAG CARE, V3, pS8; Suzuki M, 1996, BIOCHEM PHARMACOL, V52, P809, DOI 10.1016/0006-2952(96)00342-5; Suzuki M, 1998, INFLAMM RES, V47, pS44; Talreja J, 2004, IMMUNOLOGY, V113, P224, DOI 10.1111/j.1365-2567.2004.01946.x; Triggiani M, 2001, J IMMUNOL, V166, P4083, DOI 10.4049/jimmunol.166.6.4083; Weiss A, 2007, FEBS LETT, V581, P5131, DOI 10.1016/j.febslet.2007.09.062; Yoneda K, 1997, JPN J PHARMACOL, V73, P145, DOI 10.1254/jjp.73.145	32	11	14	2	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1286	1294		10.1016/j.jaci.2011.06.023	http://dx.doi.org/10.1016/j.jaci.2011.06.023			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	21807405				2022-12-18	WOS:000298342700019
J	Marcus, N; Takada, H; Law, J; Cowan, MJ; Gil, J; Regueiro, JR; de Sabando, DPL; Lopez-Granados, E; Dalal, J; Friedrich, W; Manfred, H; Hanson, IC; Grunebaum, E; Shearer, WT; Roifman, CM				Marcus, Nufar; Takada, Hidetoshi; Law, Jason; Cowan, Morton J.; Gil, Juana; Regueiro, Jose R.; Lopez de Sabando, Diego Plaza; Lopez-Granados, Eduardo; Dalal, Jignesh; Friedrich, Wilhelm; Manfred, Hoenig; Hanson, Imelda Celine; Grunebaum, Eyal; Shearer, William T.; Roifman, Chaim M.			Hematopoietic stem cell transplantation for CD3 delta deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD3 delta; severe combined immunodeficiency; bone marrow transplant; stem cell transplant; myeloablative conditioning; engraftment	SEVERE COMBINED IMMUNODEFICIENCY; BONE-MARROW-TRANSPLANTATION; IMMUNE RECONSTITUTION; SINGLE-CENTER; EXPERIENCE; DISEASES; CD3	Background: CD3 delta deficiency is a fatal form of severe combined immunodeficiency that can be cured by hematopoietic stem cell transplantation (HSCT). The presence of a thymus loaded with T-cell progenitors in patients with CD3 delta deficiency may require special considerations in choosing the regimen of conditioning and the type of HSCT. Objectives: To study the outcome of CD3 delta deficiency by using various modalities of stem cell transplantation. Methods: We analyzed data on 13 patients with CD3 delta deficiency who underwent HSCT in 7 centers. HSCT was performed by using different sources of donor stem cells as well as various conditioning regimens. Results: One patient received stem cells from a matched related donor and survived after a second transplant, needing substantial conditioning in order to engraft. Only 2 of 7 other patients who received a mismatched related donor transplant survived; 2 of them had no conditioning, whereas the others received various combinations of conditioning regimens. Engraftment of T cells in the survivors appears incomplete. Three other patients who received stem cells from a matched unrelated donor survived and enjoyed full immune reconstitution. Two patients received unrelated cord blood without conditioning. One of them has had a partial but stable engraftment, whereas the other engrafted well but is only 12 months after HSCT. We also report here for the first time that patients with CD3 delta deficiency can present with typical features of Omenn syndrome. Conclusions: HSCT is a successful treatment for patients with CD3 delta deficiency. The small number of patients in this report prevents definitive statements on the importance of survival factors, but several are suggested: (1) HLA-matched donor transplants are associated with superior reconstitution and survival than are mismatched donor transplants; (2) substantial conditioning appears necessary; and (3) early diagnosis and absence of opportunistic infections may affect outcome. (J Allergy Clin Immunol 2011;128:1050-7.)	[Marcus, Nufar; Grunebaum, Eyal; Roifman, Chaim M.] Hosp Sick Children, Div Immunol & Allergy, Dept Pediat, Canadian Ctr Primary Immunodeficiency, Toronto, ON M5G 1X8, Canada; [Marcus, Nufar; Grunebaum, Eyal; Roifman, Chaim M.] Univ Toronto, Toronto, ON, Canada; [Takada, Hidetoshi] Kyushu Univ, Dept Pediat, Grad Sch Med Sci, Fukuoka 812, Japan; [Law, Jason; Cowan, Morton J.] UCSF Childrens Hosp, Blood & Marrow Transplant Div, San Francisco, CA USA; [Gil, Juana; Regueiro, Jose R.] Univ Complutense, Fac Med, Hosp Gregorio Maranon, E-28040 Madrid, Spain; [Lopez de Sabando, Diego Plaza; Lopez-Granados, Eduardo] Autonoma Univ Sch Med, Hosp La Paz, IdiPAZ, Madrid, Spain; [Dalal, Jignesh] Childrens Mercy Hosp, Dept Hematol Oncol, Kansas City, KS USA; [Friedrich, Wilhelm; Manfred, Hoenig] Univ Childrens Hosp Ulm, Ulm, Germany; [Hanson, Imelda Celine; Shearer, William T.] Baylor Coll Med, Dept Pediat, Sect Allergy & Immunol, Houston, TX 77030 USA; [Hanson, Imelda Celine; Shearer, William T.] Texas Childrens Hosp, Houston, TX 77030 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Kyushu University; University of California System; University of California San Francisco; UCSF Medical Center; Complutense University of Madrid; General University Gregorio Maranon Hospital; Hospital Universitario La Paz; Ulm University; Baylor College of Medicine; Baylor College of Medicine	Roifman, CM (corresponding author), Hosp Sick Children, Div Allergy Immunol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	chaim.roifman@sickkids.ca	Regueiro, José R./B-5499-2014	Regueiro, José R./0000-0001-8442-7762; Shearer, William/0000-0002-2483-2130	Canadian Centre for Primary Immunodeficiency; Jeffrey Modell Foundation; Donald and Audrey Campbell Chair in Immunology; NIH-NIAID [U54-AI082978]; National Institutes of Health National Institute of Allergy and Infectious Diseases; David Center, Texas Children's Hospital; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI082973] Funding Source: NIH RePORTER	Canadian Centre for Primary Immunodeficiency; Jeffrey Modell Foundation; Donald and Audrey Campbell Chair in Immunology; NIH-NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); David Center, Texas Children's Hospital; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the Canadian Centre for Primary Immunodeficiency and the Jeffrey Modell Foundation, the Donald and Audrey Campbell Chair in Immunology, NIH-NIAID U54-AI082978, and The David Center, Texas Children's Hospital.; Disclosure of potential conflict of interest: M.J. Cowan has received research support from the National Institutes of Health National Institute of Allergy and Infectious Diseases. The rest of the authors have declared that they have no conflict of interest.	Antoine C, 2003, LANCET, V361, P553, DOI 10.1016/S0140-6736(03)12513-5; Buckley RH, 2004, ANNU REV IMMUNOL, V22, P625, DOI 10.1146/annurev.immunol.22.012703.104614; Caillat-Zucman S, 2004, BONE MARROW TRANSPL, V33, P1089, DOI 10.1038/sj.bmt.1704510; Dadi HK, 2003, NEW ENGL J MED, V349, P1821, DOI 10.1056/NEJMoa031178; Dalal I, 2000, BONE MARROW TRANSPL, V25, P613, DOI 10.1038/sj.bmt.1702215; de Saint Basile G, 2004, J CLIN INVEST, V114, P1512, DOI 10.1172/JCI200422588; Dvorak CC, 2008, BIOL BLOOD MARROW TR, V14, P1125, DOI 10.1016/j.bbmt.2008.07.008; Gennery AR, 2010, J ALLERGY CLIN IMMUN, V126, P602, DOI 10.1016/j.jaci.2010.06.015; Grunebaum E, 2006, JAMA-J AM MED ASSOC, V295, P508, DOI 10.1001/jama.295.5.508; Haddad E, 1998, BLOOD, V91, P3646; KLEIN C, 1995, BLOOD, V85, P580; Recio MJ, 2007, J IMMUNOL, V178, P2556, DOI 10.4049/jimmunol.178.4.2556; Roifman CM, 2005, IMMUNOL REV, V203, P143, DOI 10.1111/j.0105-2896.2005.00236.x; Siegers GM, 2007, J EXP MED, V204, P2537, DOI 10.1084/jem.20070782; Takada H, 2005, EUR J PEDIATR, V164, P311, DOI 10.1007/s00431-005-1639-6; Tsuji Y, 2006, BONE MARROW TRANSPL, V37, P469, DOI 10.1038/sj.bmt.1705273; van den Beemd R, 2000, CYTOMETRY, V40, P336, DOI 10.1002/1097-0320(20000801)40:4<336::AID-CYTO9>3.0.CO;2-0	17	11	11	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					1050	1057		10.1016/j.jaci.2011.05.031	http://dx.doi.org/10.1016/j.jaci.2011.05.031			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	842FJ	21757226	Green Accepted			2022-12-18	WOS:000296578200019
J	Clark, S; Page, E; Ford, T; Metcalf, R; Pozniak, A; Nelson, M; Henderson, DC; Asboe, D; Gotch, F; Gazzard, BG; Kelleher, P				Clark, Sally; Page, Emma; Ford, Tom; Metcalf, Rebecca; Pozniak, Anton; Nelson, Mark; Henderson, Donald C.; Asboe, David; Gotch, Frances; Gazzard, Brian G.; Kelleher, Peter			Reduced T(H)1/T(H)17 CD4 T-cell numbers are associated with impaired purified protein derivative-specific cytokine responses in patients with HIV-1 infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HIV; Mycobacterium tuberculosis; tuberculosis; CD4; T(H)1/T(H)17 cells; IFN-gamma; IL-2	MYCOBACTERIUM-TUBERCULOSIS; PERIPHERAL-BLOOD; EXPRESSION; DEPLETION	Background: In HIV-1-infected patients impaired IFN-gamma responses to purified protein derivative (PPD) are associated with an increased risk of active tuberculosis. Tuberculosis antigen-specific cells are found in the T(H)1/T(H)17 subset of CD4 T cells, which support HIV-1 replication. Selective loss of T(H)1/T(H)17 cells in patients with HIV-1 infection might contribute to reduced tuberculosis-induced immune responses and an increased susceptibility to active tuberculosis. Objectives: We sought to investigate the association between T(H)1/T(H)17 cells and PPD-specific cytokine responses in HIV-1-infected patients. Methods: A cross-sectional study was performed on healthy control subjects, HIV-1-infected patients receiving successful antiretroviral therapy (ART(+)), and ART-naive HIV-1-infected patients (ART(-)). All patients studied had evidence of BCG vaccination. Four discrete CD4 T-cell subsets were assessed by flow cytometry: T(H)1/T(H)17 cells (CXCR3(+)CCR6(+)CCR4(-)), T(H)1 cells (CXCR3(+)CCR6(-)CCR4(-)), T(H)17 cells (CXCR3(-)CCR6(+)CCR4(+)), and T(H)2 cells (CXCR3(-)CCR6(-)CCR4(+)). IFN-gamma and IL-2 PPD-specific cytokine responses were assessed in PBMCs by using the enzyme-linked immunospot assay. Results: Twenty-nine healthy control subjects, 34 ART(+) patients, and 26 ART(-) patients were recruited. The number and frequency of T(H)1/T(H)17 and T(H)1/T(H)17 CCR5(+) CD4 T cells were significantly reduced in HIV-1-infected patients. IFN-gamma and IL-2PPD responses were significantly lower in ART(-) patients and were partially reconstituted with successful ART. Loss of T(H)1/T(H)17 CCR5(+) cells was associated with reduced IFN-gamma and IL-2 PPD responses. Conclusions: Selective loss of T(H)1/T(H)17 cells may be a risk factor for the development of active tuberculosis in patients with HIV-1 infection and might be a useful biomarker in the development of tuberculosis vaccines. (J Allergy Clin Immunol 2011;128:838-46.)	[Clark, Sally; Page, Emma; Ford, Tom; Metcalf, Rebecca; Henderson, Donald C.; Gotch, Frances; Kelleher, Peter] Univ London Imperial Coll Sci Technol & Med, Immunol Sect, Div Infect Dis, London SW10, England	Imperial College London	Kelleher, P (corresponding author), Univ London Imperial Coll Sci Technol & Med, Immunol Sect, Div Infect Dis, Chelsea & Westminster Hosp Campus,369 Fulham Rd, London SW10, England.	p.kelleher@imperial.ac.uk		Metcalf, Rebecca/0000-0002-6810-8937; Ford, Tom/0000-0002-1131-8335	St Stephen's AIDS Trust [1002285]; Westminster Medical School Research Trust; Chelsea and Westminster Health Charity [247808]; MRC [G0501957] Funding Source: UKRI; Medical Research Council [G0501957] Funding Source: researchfish	St Stephen's AIDS Trust; Westminster Medical School Research Trust; Chelsea and Westminster Health Charity; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by St Stephen's AIDS Trust (charity no. 1002285) and the Westminster Medical School Research Trust and the Chelsea and Westminster Health Charity (charity no. 247808).	Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; Bofill M, 1998, EUR RESPIR J, V11, P548; Diedrich CR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009611; Facco M, 2007, J LEUKOCYTE BIOL, V82, P946, DOI 10.1189/jlb.0307133; Geldmacher C, 2008, J INFECT DIS, V198, P1590, DOI 10.1086/593017; Geldmacher C, 2010, J EXP MED, V207, P2869, DOI 10.1084/jem.20100090; Gosselin A, 2010, J IMMUNOL, V184, P1604, DOI 10.4049/jimmunol.0903058; Harries AD, 2010, LANCET, V375, P1906, DOI 10.1016/S0140-6736(10)60409-6; Jambo KC, 2011, THORAX, V66, P375, DOI 10.1136/thx.2010.153825; JONES BE, 1993, AM REV RESPIR DIS, V148, P1292, DOI 10.1164/ajrccm/148.5.1292; Kalsdorf B, 2009, AM J RESP CRIT CARE, V180, P1262, DOI 10.1164/rccm.200907-1011OC; Kao CY, 2005, J IMMUNOL, V175, P6676, DOI 10.4049/jimmunol.175.10.6676; Kaufmann SHE, 2010, LANCET, V375, P2110, DOI 10.1016/S0140-6736(10)60393-5; Knox KS, 2010, J VIROL, V84, P9010, DOI 10.1128/JVI.01138-10; Lawn SD, 2005, AIDS, V19, P1113, DOI 10.1097/01.aids.0000176211.08581.5a; Rivino L, 2004, J EXP MED, V200, P725, DOI 10.1084/jem.20040774; Scott-Browne JP, 2007, J EXP MED, V204, P2159, DOI 10.1084/jem.20062105; Shacklett Barbara L, 2010, Curr Infect Dis Rep, V12, P19, DOI 10.1007/s11908-009-0072-9; Sonnenberg P, 2005, J INFECT DIS, V191, P150, DOI 10.1086/426827; Sutherland R, 2006, AIDS, V20, P821, DOI 10.1097/01.aids.0000218545.31716.a4; Thomas SY, 2007, J IMMUNOL, V179, P1901, DOI 10.4049/jimmunol.179.3.1901; Trifari S, 2009, NAT IMMUNOL, V10, P864, DOI 10.1038/ni.1770; van de Vosse E, 2009, LANCET INFECT DIS, V9, P688, DOI 10.1016/S1473-3099(09)70255-5; Williams BG, 2003, SCIENCE, V301, P1535, DOI 10.1126/science.1086845; World Health Organization, TB HIV FACTS 2009; ZHANG M, 1994, J CLIN INVEST, V94, P2435, DOI 10.1172/JCI117611	26	11	12	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2011	128	4					838	U547		10.1016/j.jaci.2011.05.025	http://dx.doi.org/10.1016/j.jaci.2011.05.025			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	841UA	21745684	Bronze			2022-12-18	WOS:000296538100022
J	Kette, F; Smith, W				Kette, Frank; Smith, William			Sublingual immunotherapy: Allergen specific or placebo effect?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EFFICACY; SAFETY; TABLET; CHILDREN		[Kette, Frank; Smith, William] Royal Adelaide Hosp, Dept Clin Immunol Allergy, Adelaide, SA 5000, Australia	Royal Adelaide Hospital	Kette, F (corresponding author), Royal Adelaide Hosp, Dept Clin Immunol Allergy, Adelaide, SA 5000, Australia.	fegkette@esc.net.au		Smith, William/0000-0002-4610-998X; Smith, William/0000-0001-9640-1172				Blaiss M, 2011, J ALLERGY CLIN IMMUN, V127, P64, DOI 10.1016/j.jaci.2010.11.034; Bufe A, 2009, J ALLERGY CLIN IMMUN, V123, P167, DOI 10.1016/j.jaci.2008.10.044; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Nelson HS, 2011, J ALLERGY CLIN IMMUN, V127, P72, DOI 10.1016/j.jaci.2010.11.035; Wahn U, 2009, J ALLERGY CLIN IMMUN, V123, P160, DOI 10.1016/j.jaci.2008.10.009	6	11	11	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2011	128	2					430	430		10.1016/j.jaci.2011.04.048	http://dx.doi.org/10.1016/j.jaci.2011.04.048			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	799IQ	21665261				2022-12-18	WOS:000293280800034
J	Soller, L; Fragapane, J; Ben-Shoshan, M; Harrington, DW; Alizadehfar, R; Joseph, L; St Pierre, Y; Godefroy, SB; La Vieille, S; Elliott, SJ; Clarke, AE				Soller, Lianne; Fragapane, Joseph; Ben-Shoshan, Moshe; Harrington, Daniel W.; Alizadehfar, Reza; Joseph, Lawrence; St Pierre, Yvan; Godefroy, Samuel B.; La Vieille, Sebastien; Elliott, Susan J.; Clarke, Ann E.			Possession of epinephrine auto-injectors by Canadians with food allergies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							HYPERSENSITIVITY REACTIONS; IGE ANTIBODY; MAST-CELLS; ANAPHYLAXIS; SKIN		[Soller, Lianne; Fragapane, Joseph; Joseph, Lawrence; St Pierre, Yvan; Clarke, Ann E.] McGill Univ, Ctr Hlth, Div Clin Epidemiol, Montreal, PQ, Canada; [Clarke, Ann E.] McGill Univ, Dept Med, Ctr Hlth, Div Allergy & Clin Immunol, Montreal, PQ, Canada; [Ben-Shoshan, Moshe; Alizadehfar, Reza] McGill Univ, Dept Pediat, Ctr Hlth, Div Pediat Allergy & Clin Immunol, Montreal, PQ H3A 2T5, Canada; [Harrington, Daniel W.] McMaster Univ, Sch Geog & Earth Sci, Hamilton, ON, Canada; [Joseph, Lawrence] McGill Univ, Dept Epidemiol, Montreal, PQ, Canada; [Joseph, Lawrence] McGill Univ, Dept Biostat, Montreal, PQ, Canada; [Godefroy, Samuel B.; La Vieille, Sebastien] Hlth Canada, Food Directorate, Ottawa, ON K1A 0L2, Canada; [Elliott, Susan J.] Univ Waterloo, Fac Appl Hlth Sci, Waterloo, ON N2L 3G1, Canada	McGill University; McGill University; McGill University; McMaster University; McGill University; McGill University; Health Canada; University of Waterloo	Soller, L (corresponding author), McGill Univ, Ctr Hlth, Div Clin Epidemiol, Montreal, PQ, Canada.	liannesoller@gmail.com	La Vieille, Sébastien/AAC-5087-2019; Soller, Lianne/AGR-7219-2022	La Vieille, Sebastien/0000-0001-5368-1266				[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Ben-Shoshan M, 2008, ANN ALLERG ASTHMA IM, V100, P570, DOI 10.1016/S1081-1206(10)60056-7; Ben-Shoshan M, 2010, J ALLERGY CLIN IMMUN, V125, P1327, DOI 10.1016/j.jaci.2010.03.015; Hughes J L, 2003, Ulster Med J, V72, P80; INAGAKI N, 1988, INT ARCH ALLER A IMM, V86, P325, DOI 10.1159/000234592; Kastner M, 2010, ALLERGY, V65, P435, DOI 10.1111/j.1398-9995.2009.02294.x; Kemp AS, 2003, J PAEDIATR CHILD H, V39, P372, DOI 10.1046/j.1440-1754.2003.00157.x; LIU FT, 1980, J IMMUNOL, V124, P2728; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P85, DOI 10.1016/j.jaci.2009.11.031; Talbot Y, 2001, CAN FAM PHYSICIAN, V47, P58; WERSHIL BK, 1987, J IMMUNOL, V139, P2605; WERSHIL BK, 1988, J IMMUNOL, V140, P2356	13	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2011	128	2					426	428		10.1016/j.jaci.2011.05.015	http://dx.doi.org/10.1016/j.jaci.2011.05.015			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	799IQ	21684589				2022-12-18	WOS:000293280800031
J	James, EA; Kwok, WW				James, Eddie A.; Kwok, William W.			Autoreactive CD4(+) T cells in patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						CD4(+) T cell; autoreactive; autoantigen; atopic dermatitis; thioredoxin; Malassezia sympodialis; molecular mimicry	CROSS-REACTIVITY; ALLERGEN		[James, Eddie A.; Kwok, William W.] Benaroya Res Inst Virginia Mason, Seattle, WA 98101 USA; [Kwok, William W.] Univ Washington, Dept Immunol, Seattle, WA 98195 USA	Benaroya Research Institute; Virginia Mason Medical Center; University of Washington; University of Washington Seattle	Kwok, WW (corresponding author), Benaroya Res Inst Virginia Mason, 1201 9th Ave, Seattle, WA 98101 USA.	bkwok@benaroyaresearch.org	James, Eddie/V-4929-2019	James, Eddie/0000-0002-7217-5729	NIAID NIH HHS [HHSN272200700046C] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Balaji H, 2011, J ALLERGY CLIN IMMUN, V128, P92, DOI 10.1016/j.jaci.2011.02.043; Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, P16, DOI 10.1016/j.jaci.2009.11.008; Caubet JC, 2010, IMMUNOL ALLERGY CLIN, V30, P289, DOI 10.1016/j.iac.2010.06.002; Danke NA, 2004, J IMMUNOL, V172, P5967, DOI 10.4049/jimmunol.172.10.5967; Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202; Hober D, 2010, NAT REV ENDOCRINOL, V6, P279, DOI 10.1038/nrendo.2010.27; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V116, P213, DOI 10.1016/j.jaci.2005.04.019; Limacher A, 2007, J IMMUNOL, V178, P389, DOI 10.4049/jimmunol.178.1.389; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Ong PY, 2010, IMMUNOL ALLERGY CLIN, V30, P309, DOI 10.1016/j.iac.2010.05.001; Salvetti M, 2009, CURR OPIN NEUROL, V22, P201, DOI 10.1097/WCO.0b013e32832b4c8d; Schmid-Grendelmeier P, 2005, J ALLERGY CLIN IMMUN, V115, P1068, DOI 10.1016/j.jaci.2005.01.065; Sercarz EE, 2000, J AUTOIMMUN, V14, P275, DOI 10.1006/jaut.2000.0380; Verhagen J, 2006, J ALLERGY CLIN IMMUN, V117, P176, DOI 10.1016/j.jaci.2005.10.040; Zeller S, 2009, J ALLERGY CLIN IMMUN, V124, P278, DOI 10.1016/j.jaci.2009.05.015	15	11	12	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2011	128	1					100	101		10.1016/j.jaci.2011.05.005	http://dx.doi.org/10.1016/j.jaci.2011.05.005			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	785RE	21620451	Green Accepted			2022-12-18	WOS:000292245600012
J	Grunebaum, E; Chung, CTS; Dadi, H; Kim, P; Brigida, I; Ferrua, F; Cicalese, MP; Aiuti, A; Roifman, CM				Grunebaum, Eyal; Chung, Catherine T. -S.; Dadi, Harjit; Kim, Peter; Brigida, Immacolata; Ferrua, Francesca; Cicalese, Maria P.; Aiuti, Alessandro; Roifman, Chaim M.			Purine metabolism, immune reconstitution, and abdominal adipose tumor after gene therapy for adenosine deaminase deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IMMUNODEFICIENCY; LIPOBLASTOMA; LYMPHOMA		[Grunebaum, Eyal; Dadi, Harjit; Roifman, Chaim M.] Hosp Sick Children, Div Clin Immunol & Allergy, Toronto, ON M5G 1X8, Canada; [Chung, Catherine T. -S.] Hosp Sick Children, Div Pathol, Dept Pediat Lab Med, Toronto, ON M5G 1X8, Canada; [Kim, Peter] Hosp Sick Children, Dept Surg, Toronto, ON M5G 1X8, Canada; [Brigida, Immacolata; Ferrua, Francesca; Cicalese, Maria P.; Aiuti, Alessandro] San Raffaele Telethon Inst Gene Therapy HSR TIGET, Milan, Italy; [Aiuti, Alessandro] Univ Roma Tor Vergata, Rome, Italy	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); University of Rome Tor Vergata	Grunebaum, E (corresponding author), Hosp Sick Children, Div Clin Immunol & Allergy, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	Eyal.grunebaum@sickkids.ca	Ferrua, Francesca/K-4340-2016; AIUTI, ALESSANDRO/K-3918-2016	Ferrua, Francesca/0000-0002-5695-4490; AIUTI, ALESSANDRO/0000-0002-5398-1717; Brigida, Immacolata/0000-0002-0338-2230	Telethon [TGT11A01] Funding Source: Medline	Telethon(Fondazione Telethon)		Aiuti A, 2009, NEW ENGL J MED, V360, P447, DOI 10.1056/NEJMoa0805817; Bartuma H, 2008, CANCER GENET CYTOGEN, V183, P60, DOI 10.1016/j.cancergencyto.2008.01.017; Coffin CM, 2009, AM J SURG PATHOL, V33, P1705, DOI 10.1097/PAS.0b013e3181b76462; Gangi-Peterson L, 1999, J CLIN INVEST, V103, P833, DOI 10.1172/JCI4320; Husain M, 2007, J PEDIATR-US, V151, P93, DOI 10.1016/j.jpeds.2007.03.059; KESSERWAN C, 2009, J CLIN ONCOL S, V27, pS15; Roifman CM, 2008, J ALLERGY CLIN IMMUN, V121, P1056, DOI 10.1016/j.jaci.2007.12.1148; Schuetz C, 2010, AUTOIMMUN REV, V9, P477, DOI 10.1016/j.autrev.2010.02.005; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Sproston ARM, 1997, RADIOTHER ONCOL, V42, P53, DOI 10.1016/S0167-8140(96)01865-8	10	11	11	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1417	U160		10.1016/j.jaci.2011.04.014	http://dx.doi.org/10.1016/j.jaci.2011.04.014			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21531016				2022-12-18	WOS:000291048500016
J	Spector, S; Wallace, D; Nicklas, R; Portnoy, J; Blessing-Moore, J; Bernstein, D; Cox, L; Oppenheimer, J; Lang, D; Schuller, D; Randolph, C; Tilles, S; Khan, D; Dykewicz, M				Spector, Sheldon; Wallace, Dana; Nicklas, Richard; Portnoy, Jay; Blessing-Moore, Joann; Bernstein, David; Cox, Linda; Oppenheimer, John; Lang, David; Schuller, Diane; Randolph, Christopher; Tilles, Stephen; Khan, David; Dykewicz, Mark			Comments on Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Spector, Sheldon] Amer Coll Allergy Asthma & Immunol, Arlington Hts, IL USA		Spector, S (corresponding author), Amer Coll Allergy Asthma & Immunol, Arlington Hts, IL USA.	spector@calallergy.com	Cox, Linda/AAP-1697-2021	Cox, Linda/0000-0002-5258-6870				Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; Shekelle PG, 1999, BRIT MED J, V318, P593, DOI 10.1136/bmj.318.7183.593; Wallace DV, 2008, J ALLERGY CLIN IMMUN, V122, pS1, DOI 10.1016/j.jaci.2008.06.003	3	11	13	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1641	1642		10.1016/j.jaci.2011.01.071	http://dx.doi.org/10.1016/j.jaci.2011.01.071			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21496893				2022-12-18	WOS:000291048500057
J	Naumann, A; Soderhall, C; Folster-Holst, R; Baurecht, H; Harde, V; Muller-Wehling, K; Rodriguez, E; Ruether, A; Franke, A; Wagenpfeil, S; Novak, N; Mempel, M; Kalali, BN; Allgaeuer, M; Koch, J; Gerhard, M; Melen, E; Wahlgren, CF; Kull, I; Stahl, C; Pershagen, G; Lauener, R; Riedler, J; Doekes, G; Scheynius, A; Illig, T; von Mutius, E; Schreiber, S; Kere, J; Kabesch, M; Weidinger, S				Naumann, Aline; Soderhall, Cilla; Foelster-Holst, Regina; Baurecht, Hansjoerg; Harde, Viola; Mueller-Wehling, Konstanze; Rodriguez, Elke; Ruether, Andreas; Franke, Andre; Wagenpfeil, Stefan; Novak, Natalija; Mempel, Martin; Kalali, Behnam Naderi; Allgaeuer, Michael; Koch, Jeanette; Gerhard, Markus; Melen, Erik; Wahlgren, Carl-Fredrik; Kull, Inger; Stahl, Caroline; Pershagen, Goran; Lauener, Roger; Riedler, Josef; Doekes, Gert; Scheynius, Annika; Illig, Thomas; von Mutius, Erika; Schreiber, Stefan; Kere, Juha; Kabesch, Michael; Weidinger, Stephan			A comprehensive analysis of the COL29A1 gene does not support a role in eczema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; eczema; genetics; Col29A1	COLLAGEN-VI CHAINS; ATOPIC-DERMATITIS; FILAGGRIN MUTATIONS; ALLERGIC DISEASES; ASSOCIATION; LINKAGE; CHILDREN; METAANALYSIS; VARIANT; DESIGN	Background: Based on a recent positional cloning approach, it was claimed that the collagen 29A1 gene (COL29A1), which encodes an epidermal collagen, represents a major risk gene for eczema underlying a previously reported linkage to chromosome 3q21. However, thus far, not a single replication attempt has been published, and no definitive functional data have been provided. Objectives: We aimed to determine whether COL29A1 polymorphisms contribute to eczema susceptibility and whether COL29A1 expression is altered in eczema. Methods: We investigated the reported association of COL29A1 variants with eczema, subtypes of eczema, and eczema-related traits in 5 independent and large study populations comprehensively phenotyped for allergic diseases: a set of 1687 German patients with eczema and 2387 population control subjects, a collection of 274 German families with eczema-diseases children, a cross-sectional population of German children (n = 3099), the Swedish population-based birth cohort Children Allergy and Milieu in Stockholm, an Epidemiologic Study (BAMSE) (n=2033), and the European cross-sectional Prevention of Allergy-Risk Factors for Sensitization Related to Farming and Anthroposophic Lifestyle (PARSIFAL) study (n = 3113). An additional set of 19 COL29A1 coding single nucleotide polymorphisms was analyzed in BAMSE and PARSIFAL. COL29A1 expression was investigated by using in situ hybridization. Results: We found no evidence for a relationship between COL29A1 polymorphisms and eczema. The equivalence test rejected the hypothesis of association even excluding small effects. In situ hybridization carried out on biopsy specimens from lesional and nonlesional skin of patients with eczema and from healthy control subjects did not show any differences in the cellular distribution pattern of COL29A1 expression at the mRNA level. Conclusions: Our results suggest that COL29A1 is unlikely to contain genetic variants that have a major effect on eczema or atopy susceptibility. (J Allergy Clin Immunol 2011;127:1187-94.)	[Weidinger, Stephan] Tech Univ Munich, Dept Dermatol & Allergy, ZAUM Ctr Allergy & Environm, D-80802 Munich, Germany; [Naumann, Aline; Baurecht, Hansjoerg; Wagenpfeil, Stefan; Stahl, Caroline] Tech Univ Munich, Inst Med Stat & Epidemiol IMSE, D-80802 Munich, Germany; [Naumann, Aline; Baurecht, Hansjoerg; Rodriguez, Elke; Mempel, Martin; Weidinger, Stephan] Tech Univ Munich, Dept Dermatol, D-80802 Munich, Germany; [Baurecht, Hansjoerg; Wagenpfeil, Stefan] Tech Univ Munich, GSISH, D-80802 Munich, Germany; [Kalali, Behnam Naderi; Allgaeuer, Michael; Koch, Jeanette; Gerhard, Markus] Tech Univ Munich, Dept Med 2, D-80802 Munich, Germany; [Soderhall, Cilla; Kere, Juha] Karolinska Inst, Dept Biosci & Nutr, Stockholm, Sweden; [Soderhall, Cilla; Kere, Juha] Karolinska Inst, Clin Res Ctr, Stockholm, Sweden; [Melen, Erik; Kull, Inger] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [Wahlgren, Carl-Fredrik] Karolinska Inst, Dept Med Solna, Dermatol Unit, Stockholm, Sweden; [Kull, Inger] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [Pershagen, Goran] Karolinska Inst, Dept Environm Med, Stockholm, Sweden; [Foelster-Holst, Regina; Harde, Viola; Mueller-Wehling, Konstanze; Weidinger, Stephan] Univ Kiel, Dept Dermatol, D-2300 Kiel, Germany; [Ruether, Andreas; Franke, Andre; Schreiber, Stefan] Univ Hosp Schleswig Holstein, Inst Clin Mol Biol, Kiel, Germany; [Novak, Natalija] Univ Bonn, Dept Dermatol & Allergy, D-5300 Bonn, Germany; [Mempel, Martin] Univ Gottingen, Dept Dermatol Venereol & Allergol, Gottingen, Germany; [Melen, Erik] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Stockholm, Sweden; [Lauener, Roger] Hochgebirgsklin Davos Wolfgang, Davos, Switzerland; [Lauener, Roger] Univ Childrens Hosp, Zurich, Switzerland; [Riedler, Josef] Childrens Hosp, Schwarzach, Austria; [Doekes, Gert] Univ Utrecht, Inst Risk Assessment Sci, Div Environm Epidemiol, NL-3508 TC Utrecht, Netherlands; [Scheynius, Annika] Karolinska Inst, Clin Allergy Res Unit, Dept Med, Stockholm, Sweden; [Scheynius, Annika] St Gorans Univ Hosp, S-11281 Stockholm, Sweden; [Illig, Thomas] Helmholtz Zentrum Munchen, Inst Epidemiol, Neuherberg, Germany; [von Mutius, Erika] Univ Munich, Univ Childrens Hosp, Munich, Germany; [Kere, Juha] Univ Helsinki, Dept Med Genet, Helsinki, Finland; [Kere, Juha] Folkhalsan Inst Genet, Helsinki, Finland; [Kabesch, Michael] Hannover Med Sch, Clin Paediat Pneumol & Neonatol, D-3000 Hannover, Germany; [Weidinger, Stephan] Helmholtz Zentrum Munchen, Munich, Germany	Technical University of Munich; Technical University of Munich; Technical University of Munich; Technical University of Munich; Technical University of Munich; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; University of Kiel; University of Kiel; Schleswig Holstein University Hospital; University of Bonn; University of Gottingen; Karolinska Institutet; Karolinska University Hospital; University Children's Hospital Zurich; Utrecht University; Karolinska Institutet; Saint Goran's Hospital; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; University of Helsinki; Hannover Medical School; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Weidinger, S (corresponding author), Tech Univ Munich, Dept Dermatol & Allergy, ZAUM Ctr Allergy & Environm, Biedersteiner Str 28, D-80802 Munich, Germany.	weidinger@lrz.tum.de	Baurecht, Hansjoerg/C-4035-2013; riedler, josef/AAQ-4666-2020; Kabesch, Michael/GZM-1583-2022; Gerhard, Markus/P-8996-2019; Söderhäll, Cilla/E-3940-2012; Kere, Juha/AAX-9117-2021; Gerhard, Markus/N-3387-2014; Rodríguez, Elke/C-4259-2013; Kabesch, Michael/AAB-5701-2020; Lauener, Roger P/O-8612-2016; Kere, Juha/A-9179-2008; Weidinger, Stephan/C-8461-2011; Franke, Andre/B-2151-2010	Baurecht, Hansjoerg/0000-0002-9265-5594; Gerhard, Markus/0000-0001-9110-3950; Söderhäll, Cilla/0000-0002-8397-3080; Kere, Juha/0000-0003-1974-0271; Gerhard, Markus/0000-0001-9110-3950; Rodríguez, Elke/0000-0003-3692-3950; Lauener, Roger P/0000-0002-8412-606X; Kere, Juha/0000-0003-1974-0271; Weidinger, Stephan/0000-0003-3944-252X; Franke, Andre/0000-0003-1530-5811; Kull, Inger/0000-0001-6096-3771; Allgaeuer, Michael/0000-0003-4518-7887; Pershagen, Goran/0000-0002-9701-1130; von Mutius, Erika/0000-0002-8893-4515	German Research Council (DFG) [WE2678/6-1]; German Ministry of Education and Research (BMBF) as part of the National Genome Research Network [01GS 0429, 01GS 0818]; Christiane Kuhne Center for Allergy Research and Education; Graduate School of Information Science in Health of the Technische Universitat Munchen (TUM-GSISH); COST SKINBAD action; PopGen biobank; Swedish Research Council; Swedish Asthma and Allergy Association; Stockholm County Council; Centre for Allergy Research; Karolinska Institute; DFG [WE 2678/4-1, NO454/-52]; Swedish Society of Medical Research; Kuhne Foundation; European Union; GlaxoSmithKline; ProtectImmun; Novartis; Roxall; Glaxo Wellcome; Sanofi Aventis; Allergopharma; MSD	German Research Council (DFG)(German Research Foundation (DFG)); German Ministry of Education and Research (BMBF) as part of the National Genome Research Network(Federal Ministry of Education & Research (BMBF)); Christiane Kuhne Center for Allergy Research and Education; Graduate School of Information Science in Health of the Technische Universitat Munchen (TUM-GSISH); COST SKINBAD action(European Cooperation in Science and Technology (COST)); PopGen biobank; Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Asthma and Allergy Association; Stockholm County Council(Stockholm County Council); Centre for Allergy Research; Karolinska Institute(Karolinska Institutet); DFG(German Research Foundation (DFG)); Swedish Society of Medical Research; Kuhne Foundation; European Union(European Commission); GlaxoSmithKline(GlaxoSmithKline); ProtectImmun; Novartis(Novartis); Roxall; Glaxo Wellcome; Sanofi Aventis(Sanofi-Aventis); Allergopharma; MSD	Supported by grants of the German Research Council (DFG) (grant WE2678/6-1 and Excellence Cluster "Inflammation at Interfaces'') and the German Ministry of Education and Research (BMBF) as part of the National Genome Research Network (NGFN grants 01GS 0429 and 01GS 0818), the Christiane Kuhne Center for Allergy Research and Education (http://www.ck-care.ch/), the Graduate School of Information Science in Health of the Technische Universitat Munchen (TUM-GSISH), the COST SKINBAD action, the PopGen biobank, the Swedish Research Council, the Swedish Asthma and Allergy Association, Stockholm County Council, the Centre for Allergy Research, and Karolinska Institute. S. W. is supported by a Heisenberg fellowship of the DFG (WE 2678/4-1). N.N. is supported by a Heisenberg-Professorship of the DFG (NO454/-52). C. S. is the recipient of a scholarship from the Swedish Society of Medical Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Disclosure of potential conflict of interest: N. Novak receives research support from the German Research Council. C.-F. Wahlgren receives research support from the Swedish Asthma and Allergy Association. R. Lauener receives research support from the Kuhne Foundation and the European Union. E. von Mutius has consultant arrangements with GlaxoSmithKline, ProtectImmun, and Novartis and receives research support from Airsonett AB. S. Schreiber receives research support from the DFG, the BMBF, and the European Union. M. Kabesch has financial interests in Roxall, Glaxo Wellcome, Novartis, Sanofi Aventis, Allergopharma, and MSD and receives research support from the DFG, the BMBF, and the European Union. S. Weidinger receives research support from the DFG, the BMBF, and the European Union. The rest of the authors have declared that they have no conflict of interest.	Alfven T, 2006, ALLERGY, V61, P414, DOI 10.1111/j.1398-9995.2005.00939.x; Altshuler D, 2008, SCIENCE, V322, P881, DOI 10.1126/science.1156409; Attia J, 2009, JAMA-J AM MED ASSOC, V301, P191, DOI 10.1001/jama.2008.946; Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, P16, DOI 10.1016/j.jaci.2009.11.008; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Baurecht H, 2007, J ALLERGY CLIN IMMUN, V120, P1406, DOI 10.1016/j.jaci.2007.08.067; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Brown SJ, 2009, J INVEST DERMATOL, V129, P543, DOI 10.1038/jid.2008.413; Castro-Giner F, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-128; Chanock SJ, 2007, NATURE, V447, P655, DOI 10.1038/447655a; Cookson WOCM, 2001, NAT GENET, V27, P372, DOI 10.1038/86867; Esparza-Gordillo J, 2009, NAT GENET, V41, P596, DOI 10.1038/ng.347; Fitzgerald J, 2008, J BIOL CHEM, V283, P20170, DOI 10.1074/jbc.M710139200; Gara SK, 2008, J BIOL CHEM, V283, P10658, DOI 10.1074/jbc.M709540200; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Herrington D, 2005, CIRCULATION, V112, P2081, DOI 10.1161/CIRCULATIONAHA.105.570069; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hirschhorn JN, 2005, PEDIATR RES, V57, p74R, DOI 10.1203/01.PDR.0000159574.98964.87; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kabesch M, 2009, THORAX, V64, P370, DOI 10.1136/thx.2008.105197; Krawczak M, 2006, COMMUNITY GENET, V9, P55, DOI 10.1159/000090694; Lee YA, 2000, NAT GENET, V26, P470, DOI 10.1038/82625; Morar N, 2007, J INVEST DERMATOL, V127, P1667, DOI 10.1038/sj.jid.5700739; NELDER JA, 1972, J R STAT SOC SER A-G, V135, P370, DOI 10.2307/2344614; O'Regan GM, 2008, J ALLERGY CLIN IMMUN, V122, P689, DOI 10.1016/j.jaci.2008.08.002; O'Regan GM, 2010, J ALLERGY CLIN IMMUN, V125, P170, DOI 10.1016/j.jaci.2009.10.046; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Patterson M, 2005, PLOS BIOL, V3, P1511, DOI 10.1371/journal.pbio.0030327; Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; R Development Core Team, 2006, R LANG ENV STAT COMP; Ricard-Blum S, 2005, PATHOL BIOL, V53, P430, DOI 10.1016/j.patbio.2004.12.024; Rodriguez E, 2008, PHARMACOGENOMICS, V9, P399, DOI 10.2217/14622416.9.4.399; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Salanti G, 2005, EUR J HUM GENET, V13, P840, DOI 10.1038/sj.ejhg.5201410; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; SCHAID DJ, 1993, AM J HUM GENET, V53, P1114; Soderhall C, 2007, PLOS BIOL, V5, P1952, DOI 10.1371/journal.pbio.0050242; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; Weinberg CR, 1999, AM J HUM GENET, V65, P229, DOI 10.1086/302466; Wellek S, 2004, AM J MED GENET B, V128B, P126, DOI 10.1002/ajmg.b.30012; Wickman M, 2002, PEDIATR ALLERGY IMMU, V13, P11, DOI 10.1034/j.1399-3038.13.s.15.10.x; Wickman M, 2003, PEDIATR ALLERGY IMMU, V14, P441, DOI 10.1046/j.0905-6157.2003.00079.x; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Zucchelli M, 2009, INFLAMM BOWEL DIS, V15, P961, DOI 10.1002/ibd.20749	46	11	12	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1187	U471		10.1016/j.jaci.2010.12.1123	http://dx.doi.org/10.1016/j.jaci.2010.12.1123			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21353297				2022-12-18	WOS:000290018600013
J	Liu, SY; Wang, WZ; Yen, CL; Tsai, MY; Yang, PW; Wang, JY; Ho, CY; Shieh, CC				Liu, Si-Yen; Wang, Wei-Zhi; Yen, Chia-Liang; Tsai, Ming-Yi; Yang, Pei-Wen; Wang, Jiu-Yao; Ho, Chun-Yi; Shieh, Chi-Chang			Leukocyte nicotinamide adenine dinucleotide phosphate-reduced oxidase is required for isocyanate-induced lung inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NADPH oxidase; redox regulation; toluene diisocyanate; leukocyte; lung inflammation	TOLUENE DIISOCYANATE; OXIDATIVE STRESS; OCCUPATIONAL ASTHMA; AIRWAY INFLAMMATION; SULFHYDRYL-GROUPS; KAPPA-B; EXPOSURE; GLUTATHIONE; REDOX; CELLS	Background: Isocyanates are low-molecular-weight compounds noted for inducing occupational and environmental asthma. Isocyanate-induced lung disease, an oxidant stress-dependent pulmonary inflammation, is the leading cause of occupational asthma. Objectives: To address the role of leukocyte-produced oxidants in airway inflammation induced by toluene diisocyanate (TDI), and to elucidate the role of leukocyte nicotinamide adenine dinucleotide phosphate-reduced (NADPH) oxidase in pathogenesis by TDI. Methods: Wild-type mice and NADPH oxidase-deficient mice (neutrophil cytosolic factor 1 mutant, Ncf1(-/-)) were intranasally injected, challenged with inhalatory TDI, and then investigated for lung inflammation. Results: Cell infiltration in lung tissue and leukocytes in bronchoalveolar lavage, airway reactivity to a methacholine challenge, and TDI-induced inflammatory cytokine expression and nuclear factor activation in the lung tissue were all markedly lower in Ncf1(-/-) mice. Wild-type mice treated with blocking antibodies against CD4 and IL-17 showed markedly lower TDI-induced airway hyperresponsiveness. Conclusion: Leukocyte NADPH oxidase is an essential regulator in TDI-induced airway inflammation through redox modification of immune responses. (J Allergy Clin Immunol 2011;127:1014-23.)	[Wang, Jiu-Yao; Shieh, Chi-Chang] Natl Cheng Kung Univ, Dept Pediat, Coll Med, Tainan 70403, Taiwan; [Liu, Si-Yen; Yen, Chia-Liang; Wang, Jiu-Yao; Shieh, Chi-Chang] Natl Cheng Kung Univ, Coll Med, Inst Basic Med, Tainan 70403, Taiwan; [Wang, Wei-Zhi] Natl Cheng Kung Univ, Coll Med, Inst Microbiol & Immunol, Tainan 70403, Taiwan; [Tsai, Ming-Yi; Yang, Pei-Wen; Ho, Chun-Yi; Shieh, Chi-Chang] Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan 70403, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University	Shieh, CC (corresponding author), Natl Cheng Kung Univ, Dept Pediat, Coll Med, 138 Sheng Li Rd, Tainan 70403, Taiwan.	cshieh@mail.ncku.edu.tw		Yen, Chia-Liang/0000-0002-7676-5400	National Science Council, Taiwan; National Science Council; National Health Research Institute, Taiwan	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); National Science Council(Ministry of Science and Technology, Taiwan); National Health Research Institute, Taiwan(National Health Research Institutes - Taiwan)	Supported by grants from the National Science Council, Taiwan. C. C.S. was supported by grants from the National Science Council and National Health Research Institute, Taiwan.	Apel K, 2004, ANNU REV PLANT BIOL, V55, P373, DOI 10.1146/annurev.arplant.55.031903.141701; Babior BM, 2004, CURR OPIN IMMUNOL, V16, P42, DOI 10.1016/j.coi.2003.12.001; Balmes J, 2003, AM J RESP CRIT CARE, V167, P787, DOI 10.1164/rccm.167.5.787; Barrett NA, 2009, IMMUNITY, V31, P425, DOI 10.1016/j.immuni.2009.08.014; BAUR X, 1994, INT ARCH OCC ENV HEA, V66, P141, DOI 10.1007/BF00380772; Bowler RP, 2002, J ALLERGY CLIN IMMUN, V110, P349, DOI 10.1067/mai.2002.126780; Boyce JA, 2009, J ALLERGY CLIN IMMUN, V123, P569, DOI 10.1016/j.jaci.2009.01.041; Brown LAS, 2007, AM J PHYSIOL-LUNG C, V292, pL824, DOI 10.1152/ajplung.00346.2006; Chuang KP, 2004, BLOOD, V104, P4046, DOI 10.1182/blood-2004-05-1822; Dalle-Donne I, 2006, J CELL MOL MED, V10, P389, DOI 10.1111/j.1582-4934.2006.tb00407.x; Donnelly R, 2004, OCCUP MED-OXFORD, V54, P432, DOI 10.1093/occmed/kqg133; Dragos M, 2009, OCCUP ENVIRON MED, V66, P227, DOI 10.1136/oem.2007.038125; Emelyanov A, 2001, CHEST, V120, P1136, DOI 10.1378/chest.120.4.1136; Fitzpatrick AM, 2009, J ALLERGY CLIN IMMUN, V123, P146, DOI 10.1016/j.jaci.2008.10.047; Hagenow K, 2009, J IMMUNOL, V183, P874, DOI 10.4049/jimmunol.0900966; Heyworth PG, 2003, CURR OPIN IMMUNOL, V15, P578, DOI 10.1016/S0952-7915(03)00109-2; Holla LI, 2009, INT ARCH ALLERGY IMM, V148, P73, DOI 10.1159/000151508; Holland SM, 2010, CLIN REV ALLERG IMMU, V38, P3, DOI 10.1007/s12016-009-8136-z; Huang YF, 2009, FREE RADICAL BIO MED, V47, P932, DOI 10.1016/j.freeradbiomed.2009.06.037; Jan RL, 2008, J MICROBIOL IMMUNOL, V41, P337; Janssen-Heininger Yvonne M W, 2009, Proc Am Thorac Soc, V6, P249, DOI 10.1513/pats.200806-054RM; Jose GS, 2008, CLIN SCI, V114, P173, DOI 10.1042/CS20070130; Kaspar JW, 2009, FREE RADICAL BIO MED, V47, P1304, DOI 10.1016/j.freeradbiomed.2009.07.035; Kinnula VL, 2003, AM J RESP CRIT CARE, V167, P1600, DOI 10.1164/rccm.200212-1479SO; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Lantz RC, 2001, TOXICOL SCI, V60, P348, DOI 10.1093/toxsci/60.2.348; Lemiere C, 2002, J ALLERGY CLIN IMMUN, V110, P641, DOI 10.1067/mai.2002.128806; Lin SJ, 2002, BBA-MOL BASIS DIS, V1586, P275, DOI 10.1016/S0925-4439(01)00106-5; Liu SY, 2008, EUR J IMMUNOL, V38, P410, DOI 10.1002/eji.200737556; Loretz B, 2007, BIOCONJUGATE CHEM, V18, P1028, DOI 10.1021/bc0603079; Maestrelli P, 2009, J ALLERGY CLIN IMMUN, V123, P531, DOI 10.1016/j.jaci.2009.01.057; Mapp CE, 2002, J ALLERGY CLIN IMMUN, V109, P867, DOI 10.1067/mai.2002.123234; Matheson JM, 2005, TOXICOL SCI, V84, P88, DOI 10.1093/toxsci/kfi050; Matheson JM, 2002, AM J RESP CELL MOL, V27, P396, DOI 10.1165/rcmb.4614; Minelli C, 2010, INT J EPIDEMIOL, V39, P539, DOI 10.1093/ije/dyp337; Moriarty-Craige SE, 2004, ANNU REV NUTR, V24, P481, DOI 10.1146/annurev.nutr.24.012003.132208; Nials AT, 2008, DIS MODEL MECH, V1, P213, DOI 10.1242/dmm.000323; Olofsson P, 2003, NAT GENET, V33, P25, DOI 10.1038/ng1058; Olsson LM, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2299; Ott MG, 2003, CRIT REV TOXICOL, V33, P1, DOI 10.1080/713611031; Park HS, 2009, RESPIROLOGY, V14, P27, DOI 10.1111/j.1440-1843.2008.01447.x; Paruchuri S, 2009, J EXP MED, V206, P2543, DOI 10.1084/jem.20091240; Pichavant M, 2008, J EXP MED, V205, P385, DOI 10.1084/jem.20071507; Piskorska E, 2009, INT J OCCUP MED ENV, V22, P125, DOI 10.2478/v10001-009-0014-7; Rahman I, 2006, EUR J PHARMACOL, V533, P222, DOI 10.1016/j.ejphar.2005.12.087; Rahman I, 2005, ANTIOXID REDOX SIGN, V7, P42, DOI 10.1089/ars.2005.7.42; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Redlich CA, 2002, INT IMMUNOPHARMACOL, V2, P213, DOI 10.1016/S1567-5769(01)00174-6; Reynaert NL, 2007, J IMMUNOL, V178, P3814, DOI 10.4049/jimmunol.178.6.3814; Reynaert NL, 2006, P NATL ACAD SCI USA, V103, P13086, DOI 10.1073/pnas.0603290103; Riedl MA, 2008, CURR OPIN ALLERGY CL, V8, P49, DOI 10.1097/ACI.0b013e3282f3d913; SAETTA M, 1992, AM REV RESPIR DIS, V145, P160, DOI 10.1164/ajrccm/145.1.160; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; Shimo-Nakanishi Y, 2004, ATHEROSCLEROSIS, V175, P109, DOI 10.1016/j.atherosclerosis.2004.01.043; Sumi Y, 2003, RESPIRATION, V70, P284, DOI 10.1159/000072010; Sumimoto H, 2008, FEBS J, V275, P3249, DOI 10.1111/j.1742-4658.2008.06488.x; Valstar DL, 2004, ARCH TOXICOL, V78, P533, DOI 10.1007/s00204-004-0571-2; Vanoirbeek JAJ, 2004, TOXICOL SCI, V80, P310, DOI 10.1093/toxsci/kfh155; Wikman H, 2002, PHARMACOGENETICS, V12, P227, DOI 10.1097/00008571-200204000-00007; Wisnewski AV, 2001, CURR OPIN ALLERGY CL, V1, P169, DOI 10.1097/01.all.0000011003.36723.d8; Yang ZQ, 2009, AM J RESP CELL MOL, V40, P375, DOI 10.1165/rcmb.2008-0300OC	61	11	13	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4					1014	1023		10.1016/j.jaci.2010.12.008	http://dx.doi.org/10.1016/j.jaci.2010.12.008			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743YL	21272929				2022-12-18	WOS:000289055800024
J	Borish, L; Ayars, AG; Kirkpatrick, CH				Borish, Larry; Ayars, Andrew G.; Kirkpatrick, Charles H.			Common variable immunodeficiency presenting as herpes simplex virus encephalitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MONOCLONAL-ANTIBODY; DEFICIENCY; MICE; DISEASE		[Borish, Larry] Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, Charlottesville, VA USA; [Ayars, Andrew G.; Kirkpatrick, Charles H.] Univ Colorado, Hlth Sci Ctr, Div Clin Immunol & Allergy, Aurora, CO USA	University of Virginia; University of Colorado System; University of Colorado Anschutz Medical Campus	Borish, L (corresponding author), Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, Charlottesville, VA USA.	lb4m@virginia.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI001793, P01AI050989, R01AI047737] Funding Source: NIH RePORTER; NIAID NIH HHS [K24 AI001793-05, P01 AI050989, P01-AI50989., R01 AI047737, R01-AI47737] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beland JL, 1999, J NEUROIMMUNOL, V94, P122, DOI 10.1016/S0165-5728(98)00238-0; Bonilla FA, 2005, ANN ALLERG ASTHMA IM, V94, pS1, DOI 10.1016/S1081-1206(10)61142-8; BUCHMEIER MJ, 1984, VIROLOGY, V132, P261, DOI 10.1016/0042-6822(84)90033-3; Casrouge A, 2006, SCIENCE, V314, P308, DOI 10.1126/science.1128346; Cunningham-Rundles C, 2006, J IMMUNOL, V176, P1978, DOI 10.4049/jimmunol.176.3.1978; DIX RD, 1981, INFECT IMMUN, V34, P192, DOI 10.1128/IAI.34.1.192-199.1981; Malphettes M, 2009, CLIN INFECT DIS, V49, P1329, DOI 10.1086/606059; MINAGAWA H, 1988, ARCH VIROL, V103, P73, DOI 10.1007/BF01319810; Zhang SY, 2007, SCIENCE, V317, P1522, DOI 10.1126/science.1139522	9	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2					541	543		10.1016/j.jaci.2010.11.004	http://dx.doi.org/10.1016/j.jaci.2010.11.004			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	714KH	21167568	Green Accepted, Bronze			2022-12-18	WOS:000286808000037
J	Scheerens, H; Arron, JR; Su, Z; Zheng, Y; Putnam, W; Erickson, RW; Choy, DF; Lee, JH; Harris, JM; Jarjour, NN; Matthews, JG				Scheerens, H.; Arron, J. R.; Su, Z.; Zheng, Y.; Putnam, W.; Erickson, R. W.; Choy, D. F.; Lee, J. H.; Harris, J. M.; Jarjour, N. N.; Matthews, J. G.			Predictive and Pharmacodynamic Biomarkers of Interleukin-13 Blockade: Effect of Lebrikizumab on Late Phase Asthmatic Response to Allergen Challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	American-Academy-of-Allergy-Asthma-and-Immunology Annual Meeting	MAR 18-22, 2011	San Francisco, CA	Amer Acad Allergy Asthma & Immunol					[Scheerens, H.; Arron, J. R.; Su, Z.; Zheng, Y.; Putnam, W.; Erickson, R. W.; Choy, D. F.; Lee, J. H.; Harris, J. M.; Matthews, J. G.] Genentech Inc, San Francisco, CA USA; [Jarjour, N. N.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA	Roche Holding; Genentech; University of Wisconsin System; University of Wisconsin Madison									0	11	12	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2		S			AB164	AB164		10.1016/j.jaci.2010.12.651	http://dx.doi.org/10.1016/j.jaci.2010.12.651			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	832YI					2022-12-18	WOS:000295846400633
J	Slatter, MA; Angus, B; Windebank, K; Taylor, A; Meaney, C; Lester, T; Norbury, G; Hambleton, S; Abinun, M; Flood, TJ; Cant, AJ; Gennery, AR				Slatter, Mary A.; Angus, Brian; Windebank, Kevin; Taylor, Alison; Meaney, Cathy; Lester, Tracey; Norbury, Gail; Hambleton, Sophie; Abinun, Mario; Flood, Terence J.; Cant, Andrew J.; Gennery, Andrew R.			Polymorphous lymphoproliferative disorder with Hodgkin-like features in common gamma-chain-deficient severe combined immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ADENOSINE-DEAMINASE; LYMPHOMA; PATIENT; CELL		[Slatter, Mary A.; Hambleton, Sophie; Abinun, Mario; Flood, Terence J.; Cant, Andrew J.; Gennery, Andrew R.] NHS Fdn Trust, Newcastle Upon Tyne Hosp, Dept Pediat Immunol, Newcastle Upon Tyne, Tyne & Wear, England; [Angus, Brian] NHS Fdn Trust, Newcastle Upon Tyne Hosp, Dept Pathol, Newcastle Upon Tyne, Tyne & Wear, England; [Windebank, Kevin] NHS Fdn Trust, Newcastle Upon Tyne Hosp, Dept Pediat Oncol, Newcastle Upon Tyne, Tyne & Wear, England; [Slatter, Mary A.; Hambleton, Sophie; Abinun, Mario; Cant, Andrew J.; Gennery, Andrew R.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Taylor, Alison; Meaney, Cathy; Lester, Tracey; Norbury, Gail] Great Ormond St Hosp Sick Children, NHS Trust, London, England	Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University - UK; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Slatter, MA (corresponding author), NHS Fdn Trust, Newcastle Upon Tyne Hosp, Dept Pediat Immunol, Newcastle Upon Tyne, Tyne & Wear, England.	a.r.gennery@ncl.ac.uk	Angus, Brian/L-9246-2019	Angus, Brian/0000-0003-3598-7784	Medical Research Council [G0701897] Funding Source: Medline; MRC [G0701897] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		CLARK PA, 1995, HUM GENET, V96, P427; Cunningham-Rundles C, 2005, NAT REV IMMUNOL, V5, P880, DOI 10.1038/nri1713; Gaulard P., 2008, WHO CLASSIFICATION T, P350; Husain M, 2007, J PEDIATR-US, V151, P93, DOI 10.1016/j.jpeds.2007.03.059; Kaufman DA, 2005, PEDIATRICS, V116, pE876, DOI 10.1542/peds.2005-1068; Mustillo P, 2008, PEDIATR BLOOD CANCER, V51, P706, DOI 10.1002/pbc.21651; RATECH H, 1989, AM J PATHOL, V135, P1145; Slatter MA, 2008, J ALLERGY CLIN IMMUN, V121, P361, DOI 10.1016/j.jaci.2007.10.035; Swerdlow SH, 2008, WHO CLASSIFICATION T, P343	9	11	11	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2					533	535		10.1016/j.jaci.2010.09.036	http://dx.doi.org/10.1016/j.jaci.2010.09.036			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	714KH	21094519				2022-12-18	WOS:000286808000034
J	Buhl, T; Meynberg, HC; Kaune, KM; Hunecke, P; Schon, MP; Fuchs, T				Buhl, Timo; Meynberg, Heike C.; Kaune, Kjell M.; Huenecke, Peter; Schoen, Michael P.; Fuchs, Thomas			Long-term follow-up of patients with hypersensitivity to nonsteroidal anti-inflammatory drugs reveals shortcomings in compliance and care	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DIAGNOSIS; ASTHMA		[Buhl, Timo; Meynberg, Heike C.; Kaune, Kjell M.; Huenecke, Peter; Schoen, Michael P.; Fuchs, Thomas] Univ Gottingen, Dept Dermatol Venereol & Allergol, Gottingen, Germany	University of Gottingen	Buhl, T (corresponding author), Univ Gottingen, Dept Dermatol Venereol & Allergol, Gottingen, Germany.	buhl@med.uni-goettingen.de	Buhl, Timo/AFP-7298-2022	Schon, Michael/0000-0002-0698-4130				Aberer W, 2003, ALLERGY, V58, P854, DOI 10.1034/j.1398-9995.2003.00279.x; Cochrane GM, 1999, RESP MED, V93, P763, DOI 10.1016/S0954-6111(99)90260-3; Confino-Cohen R, 1999, CLIN EXP ALLERGY, V29, P1626, DOI 10.1046/j.1365-2222.1999.00656.x; Niggemann B, 2005, ALLERGY, V60, P735, DOI 10.1111/j.1398-9995.2005.00788.x; Nizankowska-Mogilnicka E, 2007, ALLERGY, V62, P1111, DOI 10.1111/j.1398-9995.2007.01409.x; Ring J, 1999, CLIN REV ALLERG IMMU, V17, P387, DOI 10.1007/BF02737644; Rosado A, 2003, ALLERGY, V58, P689, DOI 10.1034/j.1398-9995.2003.00186.x; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P773, DOI 10.1016/j.jaci.2006.07.024; Szczeklik A, 2003, J ALLERGY CLIN IMMUN, V111, P913, DOI 10.1067/mai.2003.1487	9	11	11	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					284	285		10.1016/j.jaci.2010.10.044	http://dx.doi.org/10.1016/j.jaci.2010.10.044			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21211662				2022-12-18	WOS:000285917300047
J	Weinberger, M				Weinberger, Miles			Can we prevent exacerbations of asthma caused by common cold viruses?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Asthma; viral respiratory infections; bacterial products	RESPIRATORY-TRACT INFECTIONS; OM-85 BV; IMMUNOSTIMULANT; MONTELUKAST; CHILDHOOD; ATTACKS		Univ Iowa, Childrens Hosp, Pediat Allergy & Pulm Div, Iowa City, IA 52242 USA	University of Iowa	Weinberger, M (corresponding author), Univ Iowa, Childrens Hosp, Pediat Allergy & Pulm Div, 200 Hawkins Dr, Iowa City, IA 52242 USA.	miles-weinberger@uiowa.edu						Akinbami LJ, 2002, PEDIATRICS, V110, P315, DOI 10.1542/peds.110.2.315; Bisgaard H, 2005, AM J RESP CRIT CARE, V171, P315, DOI 10.1164/rccm.200407-894OC; Dales RE, 1996, EUR RESPIR J, V9, P72, DOI 10.1183/09031936.96.09010072; Douglas RM, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000980.pub3; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Josling P, 2001, ADV THER, V18, P189, DOI 10.1007/BF02850113; Kaur B, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000993.pub3; Lissiman E, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006206.pub2; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; MCKEAN M, 2007, COCHRANE DB SYST REV; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; Razi CH, 2010, J ALLERGY CLIN IMMUN, V126, P763, DOI 10.1016/j.jaci.2010.07.038; Rosenstein N, 1998, PEDIATRICS, V101, P181; Schaad UB, 2010, WORLD J PEDIATR, V6, P5, DOI 10.1007/s12519-010-0001-x; Steurer-Stey C, 2007, EUR J PEDIATR, V166, P365, DOI 10.1007/s00431-006-0248-3; Weinberger M, 2005, AM J RESP CRIT CARE, V172, P783, DOI 10.1164/ajrccm.172.6.953	16	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2010	126	4					770	771		10.1016/j.jaci.2010.08.019	http://dx.doi.org/10.1016/j.jaci.2010.08.019			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	658SP	20920767				2022-12-18	WOS:000282510000013
J	Capitani, N; Amedei, A; Paccani, SR; Matucci, A; Vultaggio, A; Del Prete, G; Baldari, CT; D'Elios, MM				Capitani, Nagaja; Amedei, Amedeo; Paccani, Silvia Rossi; Matucci, Andrea; Vultaggio, Alessandra; Del Prete, Gianfranco; Baldari, Cosima T.; D'Elios, Mario M.			Impaired T(H)2 response in patients with Vav1-deficient common variable immunodeficiency with T-cell defects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							TRANSCRIPTION FACTOR; C-MAF; EXPRESSION; DISEASE; MICE		[Capitani, Nagaja; Paccani, Silvia Rossi; Baldari, Cosima T.] Univ Siena, Dept Evolut Biol, I-53100 Siena, Italy; [Amedei, Amedeo; Del Prete, Gianfranco; D'Elios, Mario M.] Univ Florence, Dept Internal Med, Florence, Italy; [Matucci, Andrea; Vultaggio, Alessandra] AOUC Firenze, Policlin Careggi, SOD Immunoallergol, Florence, Italy; [Matucci, Andrea; Vultaggio, Alessandra; Del Prete, Gianfranco; D'Elios, Mario M.] Univ Careggi, Azienda Osped, Dept Biomed, Florence, Italy	University of Siena; University of Florence; University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Florence; Azienda Ospedaliero Universitaria Careggi	Capitani, N (corresponding author), Univ Siena, Dept Evolut Biol, I-53100 Siena, Italy.	delios@unifi.it	Alessandra, Vultaggio/K-3201-2014; Amedei, Amedeo/G-5378-2011; D'Elios, Mario Milco/Y-9573-2019	Amedei, Amedeo/0000-0002-6797-9343; D'Elios, Mario Milco/0000-0001-9160-0930; Baldari, Cosima/0000-0002-4414-6744	Telethon [GGP06003] Funding Source: Medline	Telethon(Fondazione Telethon)		Bernasconi NL, 2002, SCIENCE, V298, P2199, DOI 10.1126/science.1076071; DElios MM, 1997, J IMMUNOL, V158, P962; Gulbranson-Judge A, 1999, EUR J IMMUNOL, V29, P477, DOI 10.1002/(SICI)1521-4141(199902)29:02&lt;477::AID-IMMU477&gt;3.0.CO;2-V; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Paccani SR, 2005, BLOOD, V106, P626, DOI 10.1182/blood-2004-05-2051; Park MA, 2008, LANCET, V372, P489, DOI 10.1016/S0140-6736(08)61199-X; Poppe D, 2006, J IMMUNOL, V176, P640, DOI 10.4049/jimmunol.176.1.640; Sneller MC, 2001, AM J MED SCI, V321, P42, DOI 10.1097/00000441-200101000-00007; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Tanaka Y, 2005, BLOOD, V106, P1286, DOI 10.1182/blood-2004-10-4074; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	11	11	12	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					671	675		10.1016/j.jaci.2010.05.033	http://dx.doi.org/10.1016/j.jaci.2010.05.033			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20638113				2022-12-18	WOS:000281512500043
J	Tartibi, HM; Majmundar, AR; Khan, DA				Tartibi, Hana M.; Majmundar, Amee R.; Khan, David A.			Successful use of omalizumab for prevention of fire ant anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							WHOLE-BODY EXTRACTS; RUSH IMMUNOTHERAPY; HYPERSENSITIVITY		[Tartibi, Hana M.] Parkland Hlth & Hosp Syst, Dept Internal Med, Dallas, TX USA; [Majmundar, Amee R.] Adv Allergy & Asthma Care SC, Orland Park, IL USA; [Khan, David A.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Allergy & Immunol, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Tartibi, HM (corresponding author), Parkland Hlth & Hosp Syst, Dept Internal Med, Dallas, TX USA.	Dave.Khan@UTSouthwestern.edu						Casale TB, 2006, J ALLERGY CLIN IMMUN, V117, P134, DOI 10.1016/j.jaci.2005.09.036; FREEMAN TM, 1992, J ALLERGY CLIN IMMUN, V90, P210, DOI 10.1016/0091-6749(92)90073-B; Freeman TM, 1997, ANN ALLERG ASTHMA IM, V78, P369, DOI 10.1016/S1081-1206(10)63198-5; HOFFMAN DR, 1991, ANN ALLERGY, V66, P29; Jones JD, 2008, ANN ALLERG ASTHMA IM, V101, P550, DOI 10.1016/S1081-1206(10)60296-7; Kopp MV, 2009, CLIN EXP ALLERGY, V39, P271, DOI 10.1111/j.1365-2222.2008.03121.x; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Moffitt JE, 2004, J ALLERGY CLIN IMMUN, V114, P869, DOI 10.1016/j.jaci.2004.07.046; Tankersley MS, 2002, J ALLERGY CLIN IMMUN, V109, P556, DOI 10.1067/mai.2002.121956	9	11	12	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					664	665		10.1016/j.jaci.2010.06.014	http://dx.doi.org/10.1016/j.jaci.2010.06.014			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20673977				2022-12-18	WOS:000281512500038
J	Abe, R; Kishino, S; Umezawa, K; Ozaki, M; Todo, S; Shimizu, H				Abe, Riichiro; Kishino, Satoshi; Umezawa, Kazuo; Ozaki, Michitaka; Todo, Satoru; Shimizu, Hiroshi			Topical application of dehydroxymethylepoxyquinomicin improves allergic inflammation via NF-kappa B inhibition	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ATOPIC-DERMATITIS; ACTIVATION; CANCER		[Abe, Riichiro; Shimizu, Hiroshi] Hokkaido Univ, Dept Dermatol, Grad Sch Med, Sapporo, Hokkaido, Japan; [Ozaki, Michitaka] Hokkaido Univ, Dept Mol Surg, Grad Sch Med, Sapporo, Hokkaido, Japan; [Todo, Satoru] Hokkaido Univ, Dept Surg 1, Grad Sch Med, Sapporo, Hokkaido, Japan; [Kishino, Satoshi] Meiji Pharmaceut Univ, Dept Medicat Use Anal & Clin Res, Tokyo, Japan; [Umezawa, Kazuo] Keio Univ, Dept Appl Chem, Yokohama, Kanagawa 223, Japan	Hokkaido University; Hokkaido University; Hokkaido University; Meiji Pharmaceutical University; Keio University	Abe, R (corresponding author), Hokkaido Univ, Dept Dermatol, Grad Sch Med, Sapporo, Hokkaido, Japan.	aberi@med.hokudai.ac.jp; shimizu@med.hokudai.ac.jp	Todo, Satoru/G-5659-2012; Ozaki, Michitaka/A-4549-2012					Abramovits W, 2006, CURR OPIN ALLERGY CL, V6, P345, DOI 10.1097/01.all.0000244795.41357.6e; Ariga A, 2002, J BIOL CHEM, V277, P24625, DOI 10.1074/jbc.M112063200; Asakawa M, 2006, J INVEST DERMATOL, V126, P2664, DOI 10.1038/sj.jid.5700468; Kikuchi E, 2003, CANCER RES, V63, P107; Maged M, 2009, J DERMATOL SCI, V54, P76, DOI 10.1016/j.jdermsci.2009.02.002; Matsuda H, 1997, INT IMMUNOL, V9, P461, DOI 10.1093/intimm/9.3.461; Matsumoto G, 2005, CLIN CANCER RES, V11, P1287; Matsumoto N, 2000, BIOORG MED CHEM LETT, V10, P865, DOI 10.1016/S0960-894X(00)00114-1; Morar N, 2006, J ALLERGY CLIN IMMUN, V118, P24, DOI 10.1016/j.jaci.2006.03.037; Nakamura H, 2002, GENE THER, V9, P1221, DOI 10.1038/sj.gt.3301724; Starenki DV, 2004, CLIN CANCER RES, V10, P6821, DOI 10.1158/1078-0432.CCR-04-0463; Tanaka A, 2007, J INVEST DERMATOL, V127, P855, DOI 10.1038/sj.jid.5700603; Ueki S, 2006, TRANSPLANTATION, V82, P1720, DOI 10.1097/01.tp.0000250548.13063.44; Wakamatsu K, 2005, ARTHRITIS RES THER, V7, pR1348, DOI 10.1186/ar1834	14	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2								10.1016/j.jaci.2010.05.020	http://dx.doi.org/10.1016/j.jaci.2010.05.020			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20621346	Bronze			2022-12-18	WOS:000281203800033
J	Incorvaia, C; Mauro, M				Incorvaia, Cristoforo; Mauro, Marina			Do indications to sublingual immunotherapy need to be revised?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SAFETY		[Incorvaia, Cristoforo] ICP Hosp, Milan, Italy; [Mauro, Marina] St Anna Hosp, Como, Italy	University of Ferrara; Arcispedale Sant'Anna	Incorvaia, C (corresponding author), ICP Hosp, Milan, Italy.	cristoforo.incorvaia@fastwebnet.it						Alvarez-Cuesta E, 2006, ALLERGY, V61, P1, DOI 10.1111/j.1398-9995.2006.01219_1.x; Ariano R, 2009, CURR MED RES OPIN, V25, P103, DOI [10.1185/03007990802591673, 10.1185/03007990802591673 ]; Cochard MM, 2009, J ALLERGY CLIN IMMUN, V124, P378, DOI 10.1016/j.jaci.2009.04.040; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; de Groot H, 2009, ALLERGY, V64, P963, DOI 10.1111/j.1398-9995.2009.01998.x	5	11	12	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					277	277		10.1016/j.jaci.2009.10.033	http://dx.doi.org/10.1016/j.jaci.2009.10.033			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	20109757				2022-12-18	WOS:000273660500041
J	Platts-Mills, TAE; Cooper, PJ				Platts-Mills, Thomas A. E.; Cooper, Philip J.			Differences in asthma between rural and urban communities in South Africa and other developing countries	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Developing countries; helminthes; ectoparasites; Ascaris; asthma	GEOHELMINTH PARASITES; CHILDREN; ATOPY; PREVALENCE; INFECTION; EXPOSURE; RISK		[Platts-Mills, Thomas A. E.] Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA USA; [Cooper, Philip J.] Univ San Francisco Quito, Cambaya, Ecuador	University of Virginia	Platts-Mills, TAE (corresponding author), UVA Allergy & Immunol, Box 801355, Charlottesville, VA 22908 USA.	tap2z@virginia.edu		Platts-Mills, Thomas/0000-0002-1263-329X	Wellcome Trust [088862] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Addo-Yobo EOD, 2007, PLOS MED, V4, P355, DOI 10.1371/journal.pmed.0040070; Calvert J, 2010, J ALLERGY CLIN IMMUN, V125, P100, DOI 10.1016/j.jaci.2009.09.010; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Commins SP, 2009, J ALLERGY CLIN IMMUN, V123, P426, DOI 10.1016/j.jaci.2008.10.052; Cooper PJ, 2009, CURR OPIN ALLERGY CL, V9, P29, DOI 10.1097/ACI.0b013e32831f44a6; Cooper PJ, 2006, LANCET, V367, P1598, DOI 10.1016/S0140-6736(06)68697-2; Cooper PJ, 2003, J ALLERGY CLIN IMMUN, V111, P995, DOI 10.1067/mai.2003.1348; Firrincieli V, 2005, PEDIATR PULM, V40, P57, DOI 10.1002/ppul.20214; Gupta RS, 2006, J ALLERGY CLIN IMMUN, V117, P351, DOI 10.1016/j.jaci.2005.11.047; KAZURA JW, 2008, CECIL MED, P2426; KEELEY DJ, 1991, THORAX, V46, P549, DOI 10.1136/thx.46.8.549; Leonardi-Bee J, 2006, AM J RESP CRIT CARE, V174, P514, DOI 10.1164/rccm.200603-331OC; Lynch NR, 1998, J ALLERGY CLIN IMMUN, V101, P217, DOI 10.1016/S0091-6749(98)70386-0; Perzanowski MS, 2002, J PEDIATR-US, V140, P582, DOI 10.1067/mpd.2002.122937; Platts-Mills TAE, 2005, PLOS MED, V2, P122, DOI 10.1371/journal.pmed.0020034; Scrivener S, 2001, LANCET, V358, P1493, DOI 10.1016/S0140-6736(01)06579-5; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; VANNIEKERK CH, 1979, S AFR MED J, V55, P756	18	11	12	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					106	107		10.1016/j.jaci.2009.10.068	http://dx.doi.org/10.1016/j.jaci.2009.10.068			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	20109742				2022-12-18	WOS:000273660500011
J	Tashkin, DP; de Lange, EE				Tashkin, Donald P.; de Lange, Eduard E.			Imaging of the distal airways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Imaging; asthma; distal airways; small airways; computed tomography; high-resolution computed tomography; hyperpolarized magnetic resonance	HE-3 MAGNETIC-RESONANCE; AIR-FLOW OBSTRUCTION; HYPERPOLARIZED HE-3; LUNGS; MRI; ASTHMA; BRONCHOSPASM; EMPHYSEMA; SEVERITY; SPACES	Imaging techniques of the lung continue to advance, with improving ability to image the more distal airways. Two imaging techniques are reviewed: computed tomography and magnetic resonance with hyperpolarized helium-3. (J Allergy Clin Immunol 2009;124:S78-83.)	[Tashkin, Donald P.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA; [de Lange, Eduard E.] Univ Virginia, Hlth Sci Ctr, Dept Radiol, Charlottesville, VA 22908 USA	University of California System; University of California Los Angeles; University of Virginia	Tashkin, DP (corresponding author), Care of Martin RJ, Nacl Jewish Hlth, Dept Immunol Resp Med, 1400 Jackson St, Denver, CO 80206 USA.				Teva Respiratory, LLC; National Institutes of Health/National Heart, Lung, and Blood Institute [RO1 HL66479]; Commonwealth of Virginia Technology Research Fund [IN2002-01]; Siemens Medical Solutions; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066479] Funding Source: NIH RePORTER	Teva Respiratory, LLC(Teva Pharmaceutical Industries); National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Commonwealth of Virginia Technology Research Fund; Siemens Medical Solutions(Siemens AG); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by an unrestricted grant from Teva Respiratory, LLC. The <SUP>3</SUP>He MR imaging studies were funded by the National Institutes of Health/National Heart, Lung, and Blood Institute (grant RO1 HL66479) and by contributions from the Commonwealth of Virginia Technology Research Fund (grant IN2002-01) and Siemens Medical Solutions.	[Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; Broski SE, 2008, J AM OSTEOPATH ASSOC, V108, P211; COSIO M, 1978, NEW ENGL J MED, V298, P1277, DOI 10.1056/NEJM197806082982303; de Lange EE, 2007, J ALLERGY CLIN IMMUN, V119, P1072, DOI 10.1016/j.jaci.2006.12.659; de Lange EE, 2006, CHEST, V130, P1055, DOI 10.1378/chest.130.4.1055; de Lange EE, 2009, RADIOLOGY, V250, P567, DOI 10.1148/radiol.2502080188; de Lange EE, 1999, RADIOLOGY, V210, P851, DOI 10.1148/radiology.210.3.r99fe08851; FAIN SB, P INT SOC MAG RES ME, P335; Fonseca-Guedes CHF, 2003, PEDIATR PULM, V36, P49, DOI 10.1002/ppul.10309; GAARE JD, P RAD SOC N AM 2004, P514; Goldin JG, 1999, J ALLERGY CLIN IMMUN, V104, pS258, DOI 10.1016/S0091-6749(99)70043-6; Goldin JG, 1998, RADIOLOGY, V208, P321, DOI 10.1148/radiology.208.2.9680554; MacFall JR, 1996, RADIOLOGY, V200, P553, DOI 10.1148/radiology.200.2.8685356; Mata JF, 2007, J APPL PHYSIOL, V102, P1273, DOI 10.1152/japplphysiol.00418.2006; McNittGray MF, 1997, J COMPUT ASSIST TOMO, V21, P939, DOI 10.1097/00004728-199711000-00017; MIDDLETON H, 1995, MAGNET RESON MED, V33, P271, DOI 10.1002/mrm.1910330219; Moller HE, 2002, MAGN RESON MED, V47, P1029, DOI 10.1002/mrm.10173; *NIH, 1997, NIH PUBL, P97; Petty TL, 2001, CLIN CHEST MED, V22, P845, DOI 10.1016/S0272-5231(05)70070-8; Raghunathan K, 2006, SOUTH MED J, V99, P288, DOI 10.1097/01.smj.0000202699.93002.e8; Salerno M, 2002, RADIOLOGY, V222, P252, DOI 10.1148/radiol.2221001834; SAMANDARI N, P RAD SOC N AM 2008, P369; Samee S, 2003, J ALLERGY CLIN IMMUN, V111, P1205, DOI 10.1067/mai.2003.1544; van Beek EJR, 2004, J MAGN RESON IMAGING, V20, P540, DOI 10.1002/jmri.20154; WANG C, P RAD SOC N AM 2008, P304; Wang CB, 2008, J MAGN RESON IMAGING, V28, P80, DOI 10.1002/jmri.21408; Zeidler MR, 2006, J ALLERGY CLIN IMMUN, V118, P1075, DOI 10.1016/j.jaci.2006.06.042	27	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2009	124	6		S			S78	S83		10.1016/j.jaci.2009.10.002	http://dx.doi.org/10.1016/j.jaci.2009.10.002			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	536VJ	19962040	Bronze, Green Accepted			2022-12-18	WOS:000273071700003
J	Rank, MA; Li, JT				Rank, Matthew A.; Li, James T.			Clinical pearls for preventing, diagnosing, and treating seasonal and 2009 H1N1 influenza infection in patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Asthma; human influenza; vaccination; antiviral agents; egg hypersensitivity	CHILDREN		[Rank, Matthew A.; Li, James T.] Mayo Clin, Div Allerg Dis, Rochester, MN 55905 USA	Mayo Clinic	Rank, MA (corresponding author), Mayo Clin, Div Allerg Dis, 200 1st St SW, Rochester, MN 55905 USA.	rank.matthew@mayo.edu						Bueving HJ, 2004, AM J RESP CRIT CARE, V169, P488, DOI 10.1164/rccm.200309-1251OC; Castro M, 2001, NEW ENGL J MED, V345, P1529, DOI 10.1056/NEJMoa011961; CATES CJ, 2009, COCHRANE DB SYST REV, V3, P1; Napolitano L. M., 2009, Morbidity and Mortality Weekly Report, V58, P749; Harper SA, 2009, CLIN INFECT DIS, V48, P1003, DOI 10.1086/598513; James JM, 1998, J PEDIATR-US, V133, P624, DOI 10.1016/S0022-3476(98)70101-5; Johnston SL, 2005, PEDIATR INFECT DIS J, V24, P225, DOI 10.1097/01.inf.0000154322.38267.ce	7	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					1123	1126		10.1016/j.jaci.2009.09.028	http://dx.doi.org/10.1016/j.jaci.2009.09.028			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19818998				2022-12-18	WOS:000272108000046
J	Roberts, G				Roberts, Graham			Predicting the long-term outcome of preschool wheeze: Are we there yet?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Asthma; wheeze	CLINICAL-PRACTICE; FOOD ALLERGY; SKIN PRICK; CHILDREN		[Roberts, Graham] Univ Southampton, Sch Med, Southampton SO9 5NH, Hants, England; [Roberts, Graham] St Marys Hosp, David Hide Asthma & Allergy Res Ctr, Newport, Shrops, England	University of Southampton	Roberts, G (corresponding author), Southampton Univ Hosp NHS Trust, Univ Child Hlth MP803, Tremona Rd, Southampton SO16 6YD, Hants, England.	g.c.roberts@southampton.ac.uk		Roberts, Graham/0000-0003-2252-1248				Cane RS, 2000, ARCH DIS CHILD, V82, P327, DOI 10.1136/adc.82.4.327; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Caudri D, 2009, J ALLERGY CLIN IMMUN, V124, P903, DOI 10.1016/j.jaci.2009.06.045; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; Kawamoto K, 2005, BMJ-BRIT MED J, V330, P765, DOI 10.1136/bmj.38398.500764.8F; Kurukulaaratchy RJ, 2003, EUR RESPIR J, V22, P767, DOI 10.1183/09031936.03.00005903; Reilly BM, 2006, ANN INTERN MED, V144, P201, DOI 10.7326/0003-4819-144-3-200602070-00009; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Roberts G, 2000, CLIN EXP ALLERGY, V30, P1495, DOI 10.1046/j.1365-2222.2000.00960.x; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708	10	11	11	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					911	912		10.1016/j.jaci.2009.09.034	http://dx.doi.org/10.1016/j.jaci.2009.09.034			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19895982				2022-12-18	WOS:000272108000005
J	Kessel, A; Toubi, E				Kessel, Aharon; Toubi, Elias			Low-dose cyclosporine is a good option for severe chronic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHRONIC IDIOPATHIC URTICARIA		[Kessel, Aharon; Toubi, Elias] Technion Fac Med, Bnai Zion Med Ctr, Div Clin Immunol & Allergy, Haifa, Israel	Bnai Zion Medical Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Kessel, A (corresponding author), Technion Fac Med, Bnai Zion Med Ctr, Div Clin Immunol & Allergy, Haifa, Israel.	elias.toubi@b-zion.org.il						Grattan CEH, 2000, BRIT J DERMATOL, V143, P365, DOI 10.1046/j.1365-2133.2000.03664.x; Kaplan AP, 2009, J ALLERGY CLIN IMMUN, V123, P713, DOI 10.1016/j.jaci.2008.10.050; Nettis E, 2003, BRIT J DERMATOL, V148, P501, DOI 10.1046/j.1365-2133.2003.05169.x; Ozkan M, 2007, ANN ALLERG ASTHMA IM, V99, P29; Toubi E, 1997, ALLERGY, V52, P312, DOI 10.1111/j.1398-9995.1997.tb00996.x	5	11	11	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2009	123	4					970	970		10.1016/j.jaci.2009.01.065	http://dx.doi.org/10.1016/j.jaci.2009.01.065			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	431JW	19348933				2022-12-18	WOS:000265058600032
J	Walshe, D; Gaspar, HB; Thrasher, AJ; Cale, CM; Gilmour, KC				Walshe, Denise; Gaspar, H. Bobby; Thrasher, Adrian J.; Cale, Catherine M.; Gilmour, Kimberly C.			Signal transducer and activator of transcription 5 tyrosine phosphorylation for the diagnosis and monitoring of patients with severe combined immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INTERLEUKIN-2; CYTOKINES		[Walshe, Denise; Gaspar, H. Bobby; Thrasher, Adrian J.; Cale, Catherine M.; Gilmour, Kimberly C.] UCL, Ctr Immunodeficiency, Inst Child Hlth, London, England	University of London; University College London	Walshe, D (corresponding author), UCL, Ctr Immunodeficiency, Inst Child Hlth, London, England.	gilmok@gosh.nhs.uk		Gilmour, Kimberly/0000-0003-0285-3958; Thrasher, Adrian/0000-0002-6097-6115	Great Ormond Street Hospital Childrens Charity [V1223] Funding Source: researchfish	Great Ormond Street Hospital Childrens Charity		Gaspar HB, 2004, LANCET, V364, P2181, DOI 10.1016/S0140-6736(04)17590-9; GILMOUR KC, 1995, P NATL ACAD SCI USA, V92, P10772, DOI 10.1073/pnas.92.23.10772; Gilmour KC, 2001, BRIT J HAEMATOL, V112, P671, DOI 10.1046/j.1365-2141.2001.02578.x; Grunebaum E, 2006, JAMA-J AM MED ASSOC, V295, P508, DOI 10.1001/jama.295.5.508; Kovanen PE, 2004, IMMUNOL REV, V202, P67, DOI 10.1111/j.0105-2896.2004.00203.x; Lin JX, 2000, ONCOGENE, V19, P2566, DOI 10.1038/sj.onc.1203523	6	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					505	508		10.1016/j.jaci.2008.11.041	http://dx.doi.org/10.1016/j.jaci.2008.11.041			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	409GU	19203666				2022-12-18	WOS:000263495000035
J	Davis, CM; Kancherla, VS; Reddy, A; Chan, WY; Yeh, HW; Noroski, LM; Rosenblatt, H; Shearer, WT; Chinen, J				Davis, Carla M.; Kancherla, Vikas S.; Reddy, Ashwini; Chan, Wenyaw; Yeh, Hung-Wen; Noroski, Lenora M.; Rosenblatt, Howard; Shearer, William T.; Chinen, Javier			Development of specific T-cell responses to Candida and tetanus antigens in partial DiGeorge syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Partial DiGeorge syndrome; 22q11 deletion; velocardiofacial syndrome; T-cell deficiency; tetanus immunity; Candida species immunity	22Q11.2 DELETION SYNDROME; LIVE VIRAL VACCINES; CHILDREN; IMMUNODEFICIENCY; SAFETY; BIRTH	Background: Partial DiGeorge syndrome (pDGS) presents with thymic hypoplasia and a variable decrease in T-cell numbers. Although lymphocyte proliferation to mitogens is generally preserved, it is uncertain whether the development of specific cellular immunity in pDGS is similarly preserved. Objective: We sought to study the development of antigen-specific T-cell responses in patients with pDGS with regard to their initial CD3 T-cell counts. Methods: A retrospective review of 93 patients with pDGS followed at Texas Children's Hospital Allergy and Immunology Clinic from 1991 to 2006 was performed. Serial lymphocyte proliferation to Candida and tetanus antigens was longitudinally analyzed. Antigen-specific lymphoproliferation was compared with initial patient CD3 T-cell counts of less than the 10th percentile (n = 63), the 10th to 50th percentile (n = 20), and greater than the 50th percentile (n = 10) of age-matched normal control values. Tetanus-specific IgG levels and the number of tetanus immunizations were also studied. Results: The median CD3 T-cell counts at baseline in all 3 groups were as follows: 10th percentile, 1188 cells/mm(3) (range, 168-3272 cells/mm(3)); 10th to 50th percentile, 2816 cells/mm(3) (range, 1484-4155 cells/mm(3)); greater than 50th percentile, 4246 cells/mm(3) (range, 2573-6481 cells/mm(3)). Thirty-one (46%) of 68 patients with pDGS who received at least 3 tetanus vaccines had persistent Candida and tetanus-specific cellular immunity, and 24 (35%) did not have immunity to either antigen. Most (22/24) of these patients had CD3 T-cell counts at presentation of less than the 10th percentile of normal values. Protective tetanus-specific IgG titers (>0.10 IU/mL) were detected in all patients tested from the age of 2 to 85 months (n = 72). Conclusion: Some patients with pDGS with low CD3 T-cell counts might not have specific Candida and tetanus cellular immunity. Q Allergy Clin Immunol 2008;122:1194-9.)	[Davis, Carla M.; Kancherla, Vikas S.; Reddy, Ashwini; Noroski, Lenora M.; Rosenblatt, Howard; Shearer, William T.; Chinen, Javier] Baylor Coll Med, Dept Pediat, Allergy & Immunol Sect, Houston, TX 77030 USA; [Chan, Wenyaw] Univ Texas Hlth Sci Ctr Houston, Div Biostat, Sch Publ Hlth, Houston, TX USA; [Rosenblatt, Howard] Dell Childrens Hosp, Allergy & Immunol Serv, Austin, TX USA	Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health	Davis, CM (corresponding author), Baylor Coll Med, Dept Pediat, Allergy & Immunol Sect, 6621 Fannin St,MC FC 330-01, Houston, TX 77030 USA.	cmdavis@texaschildrenshospital.org	Yeh, Hung-Wen/E-8104-2015	Yeh, Hung-Wen/0000-0003-0894-5570; Shearer, William/0000-0002-2483-2130; Yeh, Hung-wen/0000-0002-9904-3275				Azzari C, 2005, VACCINE, V23, P1668, DOI 10.1016/j.vaccine.2004.10.005; BARRETT DJ, 1981, J CLIN LAB IMMUNOL, V6, P1; BASTIAN J, 1989, J PEDIATR-US, V115, P391, DOI 10.1016/S0022-3476(89)80837-6; BONILLA FA, 2002, ANN ALLERGY ASTHM S1, V94, pS1; Botto LD, 2003, PEDIATRICS, V112, P101, DOI 10.1542/peds.112.1.101; Cancrini C, 2005, J CLIN IMMUNOL, V25, P265, DOI 10.1007/s10875-005-4085-3; Chinen J, 2003, J ALLERGY CLIN IMMUN, V111, P573, DOI 10.1067/mai.2003.165; Jawad AF, 2001, J PEDIATR-US, V139, P715, DOI 10.1067/mpd.2001.118534; JUNKER AK, 1995, J PEDIATR-US, V127, P231, DOI 10.1016/S0022-3476(95)70300-4; Markert ML, 2007, BLOOD, V109, P4539, DOI 10.1182/blood-2006-10-048652; Moylett EH, 2004, CLIN IMMUNOL, V112, P106, DOI 10.1016/j.clim.2004.02.008; Perez EE, 2003, PEDIATRICS, V112, pE325, DOI 10.1542/peds.112.4.e325; PICKERING LK, 2006, RED BOOK 2006 REPORT, P73; Pierdominici M, 2003, CLIN EXP IMMUNOL, V132, P323, DOI 10.1046/j.1365-2249.2003.02134.x; Piliero LM, 2004, BLOOD, V103, P1020, DOI 10.1182/blood-2003-08-2824; Sediva A, 2005, MED SCI MONITOR, V11, pCR182; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Sullivan KE, 2004, CURR OPIN ALLERGY CL, V4, P505, DOI 10.1097/00130832-200412000-00006; Sullivan KE, 1999, CLIN DIAGN LAB IMMUN, V6, P906, DOI 10.1128/CDLI.6.6.906-911.1999; Waters V, 2007, ARCH DIS CHILD, V92, P519, DOI 10.1136/adc.2006.097493	20	11	11	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2008	122	6					1194	1199		10.1016/j.jaci.2008.06.039	http://dx.doi.org/10.1016/j.jaci.2008.06.039			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	383ZA	18789819				2022-12-18	WOS:000261711800019
J	Sorkness, RL; Gonzalez-Fernandez, G; Billmeyer, EE; Evans, MD; Gern, JE; Jarjour, NN				Sorkness, Ronald L.; Gonzalez-Fernandez, Guillermo; Billmeyer, Erin E.; Evans, Michael D.; Gern, James E.; Jarjour, Nizar N.			The asthma index: A continuous variable to characterize exacerbations of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Sorkness, Ronald L.] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA; [Sorkness, Ronald L.; Billmeyer, Erin E.; Jarjour, Nizar N.] Univ Wisconsin, Dept Med, Madison, WI 53706 USA; [Sorkness, Ronald L.; Gern, James E.] Univ Wisconsin, Dept Pediat, Madison, WI 53706 USA; [Gonzalez-Fernandez, Guillermo] Univ Wisconsin, Dept Elect Engn, Madison, WI 53706 USA; [Evans, Michael D.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Sorkness, RL (corresponding author), Univ Wisconsin, Sch Pharm, 425 N Charter St, Madison, WI 53706 USA.	rlsorkne@wisc.edu		Evans, Michael/0000-0001-7449-3993	NHLBI NIH HHS [HL-080412] Funding Source: Medline; NIAID NIH HHS [U19 AI070503, AI-050500] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070503, P01AI050500] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bacharier LB, 2007, J ALLERGY CLIN IMMUN, V119, P604, DOI 10.1016/j.jaci.2006.12.607; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; 2007, J ALLERGY CLIN IMM S, V120, pS94	5	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2008	122	4					838	840		10.1016/j.jaci.2008.07.041	http://dx.doi.org/10.1016/j.jaci.2008.07.041			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	359LU	18774167				2022-12-18	WOS:000259989000037
J	Juniper, EF; Schatz, M; Juniper, BA; Zeiger, RS				Juniper, Elizabeth F.; Schatz, Michael; Juniper, Bridget A.; Zeiger, Robert S.			Evaluation of 2 interactive voice-response telephone versions of health-related quality-of-life questionnaires	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							VALIDATION		[Juniper, Elizabeth F.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Schatz, Michael; Zeiger, Robert S.] Kaiser Permanente Med Ctr, Dept Allergy, San Diego, CA USA; [Juniper, Bridget A.] QOL Technol Ltd, Bosham, W Sussex, England	McMaster University; Kaiser Permanente	Juniper, EF (corresponding author), McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada.	juniper@qoltech.co.uk		Zeiger, Robert/0000-0001-5788-5063				Caro JJ, 2001, QUAL LIFE RES, V10, P683, DOI 10.1023/A:1013811109820; Juniper EF, 2007, ALLERGY, V62, P1091, DOI 10.1111/j.1398-9995.2007.01370.x; Juniper EF, 2000, CLIN EXP ALLERGY, V30, P132; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; Pinnock H, 2005, J CLIN EPIDEMIOL, V58, P809, DOI 10.1016/j.jclinepi.2005.01.010	5	11	11	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2008	122	3					654	655		10.1016/j.jaci.2008.05.003	http://dx.doi.org/10.1016/j.jaci.2008.05.003			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	348TW	18554703				2022-12-18	WOS:000259234000034
J	Saltoun, C; Avila, PC				Saltoun, Carol; Avila, Pedro C.			Advances in upper airway diseases and allergen immunotherapy in 2007	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						rhinitis; sinusitis; nasal polyps; conjunctivitis; allergen immunotherapy	SUBLINGUAL IMMUNOTHERAPY; CHRONIC RHINOSINUSITIS; VERNAL KERATOCONJUNCTIVITIS; OCULAR SYMPTOMS; GRASS-POLLEN; NASAL POLYPS; FOOD ALLERGY; BIRCH-POLLEN; DOUBLE-BLIND; RHINITIS	The purpose of this review is to highlight important articles on upper airway diseases and immunotherapy that appeared in 2007. Advances in rhinitis include the realization that allergic rhinitis might he caused by local nasal IgE sensitization to aeroallergens in the absence of systemic evidence of IgE sensitization. After inhalation, allergens might reach systemic circulation. Epidemiologic studies continue to show that allergic rhinitis impairs school performance and is a risk factor for future asthma. New pathways are being identified in chronic sinusitis, as well as in different types of allergic ocular diseases. New treatments for patients with allergic rhinitis include use of beta-1,3-glucan, a mushroom product that can reduce allergic symptoms by inducing T(H)1 response, and olopatadine nasal spray. Studies on immunotherapy in 2007 suggest that sublingual immunotherapy induces similar immunologic alterations as those induced by subcutaneous immunotherapy, although to a lesser degree. Among allergists in the United States, there is a sizable variation in clinical practice, particularly related to concomitant administration of immunotherapy and beta-blockers, to administration of angiotensin-converting enzyme inhibitors, and to patients with HIV or autoimmune diseases. The combination of omalizumab with allergen subcutaneous immunotherapy can enhance clinical efficacy. Recombinant technology can modify allergen structure to prevent binding to IgE (allergenicity) while enhancing immunogenicity (stimulation of T cells), which might improve the safety and efficacy of immunotherapy.	[Avila, Pedro C.] Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, Dept Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Saltoun, C (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, Dept Med, 676 N St Clair St,Room 14-018, Chicago, IL 60611 USA.	pa@northwestern.edu			Northwestern University	Northwestern University	Supported by an Ernest S. Bazley Grant to Northwestern University.	Abelson MB, 2007, CURR EYE RES, V32, P1017, DOI 10.1080/02713680701736558; Akdis M, 2007, J ALLERGY CLIN IMMUN, V119, P780, DOI 10.1016/j.jaci.2007.01.022; Atlas SJ, 2005, LARYNGOSCOPE, V115, P846, DOI 10.1097/01.MLG.0000157693.92975.02; Bielory L, 2008, J ALLERGY CLIN IMMUN, V121, P538, DOI 10.1016/j.jaci.2007.10.013; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Bolhaar STHP, 2004, CLIN EXP ALLERGY, V34, P761, DOI 10.1111/j.1365-2222.2004.1939.x; Bonini S, 2007, CURR OPIN ALLERGY CL, V7, P446, DOI 10.1097/ACI.0b013e3282ef868b; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Bozkurt B, 2007, CLIN EXP OPHTHALMOL, V35, P535, DOI 10.1111/j.1442-9071.2007.01545.x; Burgess JA, 2007, J ALLERGY CLIN IMMUN, V120, P863, DOI 10.1016/j.jaci.2007.07.020; Cannady SB, 2007, J ALLERGY CLIN IMMUN, V120, P1346, DOI 10.1016/j.jaci.2007.07.067; Coifman RE, 2007, J ALLERGY CLIN IMMUN, V119, P1012, DOI 10.1016/j.jaci.2007.01.029; Cox L, 2007, J ALLERGY CLIN IMMUN, V120, pS25, DOI 10.1016/j.jaci.2007.06.019; DeWester J, 2003, ALLERGY ASTHMA PROC, V24, P331; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Ding GQ, 2007, ARCH OTOLARYNGOL, V133, P1097, DOI 10.1001/archotol.133.11.1097; FOKKENS W, 2007, RHINOL S, V20, P1; Gern JE, 2006, J ALLERGY CLIN IMMUN, V117, P72, DOI 10.1016/j.jaci.2005.10.002; Gonzalez-Rioja R, 2007, J ALLERGY CLIN IMMUN, V120, P602, DOI 10.1016/j.jaci.2007.04.039; Hall-Stoodley L, 2006, JAMA-J AM MED ASSOC, V296, P202, DOI 10.1001/jama.296.2.202; Hansen G, 2000, J IMMUNOL, V164, P223, DOI 10.4049/jimmunol.164.1.223; Hens G, 2007, J ALLERGY CLIN IMMUN, V120, P472, DOI 10.1016/j.jaci.2007.03.047; Inada N, 2007, JPN J OPHTHALMOL, V51, P338, DOI 10.1007/s10384-007-0462-1; Janson C, 2007, J ALLERGY CLIN IMMUN, V120, P673, DOI 10.1016/j.jaci.2007.05.003; Joint Task Force on Practice Parameters, 2003, Ann Allergy Asthma Immunol, V90, P1; Juniper EF, 1999, J ALLERGY CLIN IMMUN, V104, P364, DOI 10.1016/S0091-6749(99)70380-5; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; Kaiser HB, 2007, J ALLERGY CLIN IMMUN, V119, P1430, DOI 10.1016/j.jaci.2007.02.022; Kim TH, 2007, ARCH OTOLARYNGOL, V133, P1111, DOI 10.1001/archotol.133.11.1111; Kinaciyan T, 2007, J ALLERGY CLIN IMMUN, V119, P937, DOI 10.1016/j.jaci.2006.11.010; Klunker S, 2007, J ALLERGY CLIN IMMUN, V120, P688, DOI 10.1016/j.jaci.2007.05.034; Kostamo K, 2007, LARYNGOSCOPE, V117, P638, DOI 10.1097/MLG.0b013e318030aca6; Lambiase A, 2007, MOL VIS, V13, P1562; Larche M, 2007, J ALLERGY CLIN IMMUN, V119, P906, DOI 10.1016/j.jaci.2007.02.015; Leonardi A, 2007, CLIN EXP ALLERGY, V37, P872, DOI 10.1111/j.1365-2222.2007.02732.x; Matheson MC, 2007, J ALLERGY CLIN IMMUN, V120, P1051, DOI 10.1016/j.jaci.2007.06.030; Metz-Favre C, 2007, J ALLERGY CLIN IMMUN, V120, P315, DOI 10.1016/j.jaci.2007.03.046; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Nakatani S, 2007, JPN J OPHTHALMOL, V51, P474, DOI 10.1007/s10384-007-0476-8; Nelson HS, 2007, J ALLERGY CLIN IMMUN, V119, P769, DOI 10.1016/j.jaci.2007.01.036; Pajno GB, 2007, J ALLERGY CLIN IMMUN, V119, P796, DOI 10.1016/j.jaci.2007.01.009; Pajno GB, 2007, J ALLERGY CLIN IMMUN, V120, P164, DOI 10.1016/j.jaci.2007.04.008; Passalacqua G, 2007, J ALLERGY CLIN IMMUN, V119, P881, DOI 10.1016/j.jaci.2007.01.045; Patel P, 2007, OTOLARYNG HEAD NECK, V137, P918, DOI 10.1016/j.otohns.2007.08.005; Pflugfelder SC, 2007, CURR OPIN ALLERGY CL, V7, P450, DOI 10.1097/ACI.0b013e3282ef69e3; Piccirillo JF, 1995, AM J RHINOL, V9, P297, DOI 10.2500/105065895781808711; Post J Christopher, 2007, Curr Opin Otolaryngol Head Neck Surg, V15, P347, DOI 10.1097/MOO.0b013e3282b97327; Psaltis AJ, 2007, LARYNGOSCOPE, V117, P2030, DOI 10.1097/MLG.0b013e31812e01ab; Pynnonen MA, 2007, ARCH OTOLARYNGOL, V133, P1115, DOI 10.1001/archotol.133.11.1115; Ramanathan M, 2007, AM J RHINOL, V21, P110, DOI 10.2500/ajr.2007.21.2997; Ramanathan M, 2007, LARYNGOSCOPE, V117, P1839, DOI 10.1097/MLG.0b013e31811edd4f; Roder E, 2007, J ALLERGY CLIN IMMUN, V119, P892, DOI 10.1016/j.jaci.2006.12.651; Rondon C, 2007, J ALLERGY CLIN IMMUN, V119, P899, DOI 10.1016/j.jaci.2007.01.006; Rosenfeld RM, 2007, OTOLARYNG HEAD NECK, V137, P365, DOI 10.1016/j.otohns.2007.07.021; Sayers I, 2004, J ALLERGY CLIN IMMUN, V114, P302, DOI 10.1016/j.jaci.2004.03.057; Shoji J, 2007, JPN J OPHTHALMOL, V51, P332, DOI 10.1007/s10384-007-0461-2; Swamy BN, 2007, OPHTHAL EPIDEMIOL, V14, P311, DOI 10.1080/09286580701299411; Valenta R, 2007, J ALLERGY CLIN IMMUN, V119, P826, DOI 10.1016/j.jaci.2007.01.025; Valero A, 2007, J ALLERGY CLIN IMMUN, V120, P359, DOI 10.1016/j.jaci.2007.04.006; van Oene CM, 2007, ALLERGY, V62, P1359, DOI 10.1111/j.1398-9995.2007.01482.x; Walker S, 2007, J ALLERGY CLIN IMMUN, V120, P381, DOI 10.1016/j.jaci.2007.03.034; Wallner M, 2007, J ALLERGY CLIN IMMUN, V120, P374, DOI 10.1016/j.jaci.2007.05.021; Yamada J, 2007, J ALLERGY CLIN IMMUN, V119, P1119, DOI 10.1016/j.jaci.2007.02.005	63	11	12	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2008	122	3					481	487		10.1016/j.jaci.2008.06.027	http://dx.doi.org/10.1016/j.jaci.2008.06.027			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	348TW	18694591				2022-12-18	WOS:000259234000006
J	Norton, L; Galvin, AD; Hourihane, JO				Norton, Laura; Galvin, Audrey Dunn; Hourihane, Jonathan O'Brien			Allergy rescue medication in schools: Modeling a new approach	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							NUT ALLERGY; CHILDREN		[Norton, Laura; Hourihane, Jonathan O'Brien] Univ Southampton, Southampton SO9 5NH, Hants, England; [Galvin, Audrey Dunn; Hourihane, Jonathan O'Brien] Univ Coll, Cork, Ireland	University of Southampton; University College Cork	Norton, L (corresponding author), Univ Southampton, Southampton SO9 5NH, Hants, England.	J.Hourihane@ucc.ie	DunnGalvin, Audrey/G-1741-2012					Colver A, 2006, BMJ-BRIT MED J, V333, P494, DOI 10.1136/bmj.333.7566.494; Ewan PW, 2005, CLIN EXP ALLERGY, V35, P751, DOI 10.1111/j.1365-2222.2005.02266.x; Hourihane JO, 2007, J ALLERGY CLIN IMMUN, V119, P1197, DOI 10.1016/j.jaci.2006.12.670; Kemp AS, 2003, J PAEDIATR CHILD H, V39, P372, DOI 10.1046/j.1440-1754.2003.00157.x; Nowak-Wegrzyn A, 2001, ARCH PEDIAT ADOL MED, V155, P790, DOI 10.1001/archpedi.155.7.790; Watura JC, 2002, ARCH DIS CHILD, V86, P240, DOI 10.1136/adc.86.4.240	6	11	11	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					209	210		10.1016/j.jaci.2008.04.020	http://dx.doi.org/10.1016/j.jaci.2008.04.020			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	325RD	18538380				2022-12-18	WOS:000257605100033
J	Perzanowski, MS; Rosa, MJ; Divjan, A; Johnson, A; Jacobson, JS; Miller, RL				Perzanowski, Matthew S.; Rosa, Maria Jose; Divjan, Advan; Johnson, Alina; Jacobson, Judith S.; Miller, Rachel L.			Modifications improve an offline exhaled nitiric oxide collection device for use with young children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PRESCHOOL-CHILDREN		[Perzanowski, Matthew S.; Rosa, Maria Jose; Divjan, Advan; Jacobson, Judith S.; Miller, Rachel L.] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10027 USA; [Rosa, Maria Jose; Johnson, Alina; Miller, Rachel L.] Columbia Univ, Coll Phys & Surg, Div Pulm Allergy & Crit Care Med, New York, NY USA	Columbia University; Columbia University	Perzanowski, MS (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10027 USA.	mp2217@columbia.edu	Rosa, Maria José/AAX-6620-2020	Rosa, Maria José/0000-0002-1509-7664; Perzanowski, Matthew/0000-0003-1300-0985; Divjan, Adnan/0000-0002-8895-5965				Bacharier LB, 2008, J ALLERGY CLIN IMMUN, V121, P710, DOI 10.1016/j.jaci.2008.01.018; Moeller A, 2008, J ALLERGY CLIN IMMUN, V121, P705, DOI 10.1016/j.jaci.2007.11.008; 2005, AM J RESP CRIT CARE, V171, P912	3	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					213	213		10.1016/j.jaci.2008.03.030	http://dx.doi.org/10.1016/j.jaci.2008.03.030			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	325RD	18468670				2022-12-18	WOS:000257605100035
J	Apter, AJ				Apter, Andrea J.			Advances in the care of adults with asthma and allergy in 2007	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; adults; atopy; health disparities; therapeutics; adherence; inhaled corticosteroids; omalizumab; pregnancy; menopause	SENSITIZATION; ASSOCIATION; ANAPHYLAXIS; OMALIZUMAB; MORBIDITY; ETHNICITY; ADHERENCE; SEVERITY; HISTORY; HEALTH	In 2007 the National Asthma Education and Prevention Program published the Expert Panel Report 3, updating its 1,997 and 2002 guidelines for the diagnosis and management of asthma with new emphasis on assessment and attainment of control. This review focuses on the journal articles published in 2007 pertaining to risk and impairment in adult asthma and interventions to improve its control.	[Apter, Andrea J.] Univ Penn, Dept Med, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Apter, AJ (corresponding author), Hosp Univ Penn, 829 Gates Bldg,3400 Spruce St, Philadelphia, PA 19104 USA.	apter@mail.med.upenn.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K02HL088469, R01HL073932] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL073932, K02 HL088469] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Apter AJ, 2006, J ALLERGY CLIN IMMUN, V117, P512, DOI 10.1016/j.jaci.2005.12.1353; Apter AJ, 2004, J ALLERGY CLIN IMMUN, V113, P407, DOI 10.1016/j.jaci.2003.12.002; Apter AJ, 2007, J ALLERGY CLIN IMMUN, V120, P729, DOI 10.1016/j.jaci.2007.05.009; Arbes SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1139, DOI 10.1016/j.jaci.2007.07.056; Austen KF, 2007, J ALLERGY CLIN IMMUN, V119, P34, DOI 10.1016/j.jaci.2006.10.008; Baptist AP, 2007, J ALLERGY CLIN IMMUN, V119, P924, DOI 10.1016/j.jaci.2006.11.695; Basheti IA, 2007, J ALLERGY CLIN IMMUN, V119, P1537, DOI 10.1016/j.jaci.2007.02.037; Borrelli B, 2007, J ALLERGY CLIN IMMUN, V120, P1023, DOI 10.1016/j.jaci.2007.08.017; Bourdin A, 2007, J ALLERGY CLIN IMMUN, V119, P1367, DOI 10.1016/j.jaci.2007.01.055; Burgess JA, 2007, J ALLERGY CLIN IMMUN, V120, P863, DOI 10.1016/j.jaci.2007.07.020; Busse WW, 2007, J ALLERGY CLIN IMMUN, V119, pS5, DOI 10.1016/j.jaci.2006.11.034; Camargo CA, 2007, J ALLERGY CLIN IMMUN, V120, P131, DOI 10.1016/j.jaci.2007.03.049; Celedon JC, 2007, J ALLERGY CLIN IMMUN, V120, P144, DOI 10.1016/j.jaci.2007.03.037; Chen H, 2007, J ALLERGY CLIN IMMUN, V120, P396, DOI 10.1016/j.jaci.2007.04.040; Chinchilli VM, 2007, J ALLERGY CLIN IMMUN, V119, P303, DOI 10.1016/j.jaci.2006.11.632; Chipps BE, 2007, J ALLERGY CLIN IMMUN, V119, P1156, DOI 10.1016/j.jaci.2006.12.668; de Lange EE, 2007, J ALLERGY CLIN IMMUN, V119, P1072, DOI 10.1016/j.jaci.2006.12.659; de Marco R, 2007, J ALLERGY CLIN IMMUN, V119, P611, DOI 10.1016/j.jaci.2006.11.696; Dolan CM, 2004, ANN ALLERG ASTHMA IM, V92, P32, DOI 10.1016/S1081-1206(10)61707-3; Dragonieri S, 2007, J ALLERGY CLIN IMMUN, V120, P856, DOI 10.1016/j.jaci.2007.05.043; Enriquez R, 2007, J ALLERGY CLIN IMMUN, V120, P625, DOI 10.1016/j.jaci.2007.05.044; Estelle F, 2007, J ALLERGY CLIN IMMUN, V119, P499, DOI 10.1016/j.jaci.2006.09.017; Gergen PJ, 2007, J ALLERGY CLIN IMMUN, V119, P165, DOI 10.1016/j.jaci.2006.10.032; Jones CA, 2007, J ALLERGY CLIN IMMUN, V119, P1445, DOI 10.1016/j.jaci.2007.02.031; KAFTAN M, 2007, J ALLERGY CLIN IMMUN, V120, P618; Kemeny ME, 2007, J ALLERGY CLIN IMMUN, V119, P1375, DOI 10.1016/j.jaci.2007.03.016; Krishnan JA, 2007, J ALLERGY CLIN IMMUN, V120, P1015, DOI 10.1016/j.jaci.2007.09.027; Kuiper S, 2007, J ALLERGY CLIN IMMUN, V120, P388, DOI 10.1016/j.jaci.2007.03.038; Limb SL, 2007, J ALLERGY CLIN IMMUN, V120, P1378, DOI 10.1016/j.jaci.2007.09.022; Litonjua AA, 2005, J ALLERGY CLIN IMMUN, V115, P751, DOI 10.1016/j.jaci.2004.12.1138; Liu AH, 2007, J ALLERGY CLIN IMMUN, V119, P817, DOI 10.1016/j.jaci.2006.12.662; Menzies D, 2007, J ALLERGY CLIN IMMUN, V119, P328, DOI 10.1016/j.jaci.2006.10.014; Mosnaim GS, 2007, J ALLERGY CLIN IMMUN, V120, P1160, DOI 10.1016/j.jaci.2007.08.040; Naqvi M, 2007, J ALLERGY CLIN IMMUN, V120, P137, DOI 10.1016/j.jaci.2007.02.045; National Institutes of Health, 2007, NIH PUBL, V02-3659; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; Ownby DR, 2007, J ALLERGY CLIN IMMUN, V120, P1018, DOI 10.1016/j.jaci.2007.09.028; Rand C, 2007, J ALLERGY CLIN IMMUN, V119, P916, DOI 10.1016/j.jaci.2006.12.664; REAL FG, 2007, J ALLERGY CLIN  1026; Rowe J, 2007, J ALLERGY CLIN IMMUN, V119, P1164, DOI 10.1016/j.jaci.2007.02.016; Salpeter SR, 2006, ANN INTERN MED, V144, P904, DOI 10.7326/0003-4819-144-12-200606200-00126; Schatz M, 2007, J ALLERGY CLIN IMMUN, V119, P336, DOI 10.1016/j.jaci.2006.08.042; Szefler SJ, 2006, J ALLERGY CLIN IMMUN, V117, P26, DOI 10.1016/j.jaci.2005.11.006; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P470, DOI 10.1016/j.jaci.2004.12.1123; Taback SP, 2007, J ALLERGY CLIN IMMUN, V120, P128, DOI 10.1016/j.jaci.2007.05.020; Tunon-de-Lara JM, 2007, J ALLERGY CLIN IMMUN, V119, P583, DOI 10.1016/j.jaci.2006.11.005; *UD FDA, 2007, OM SUBC US MARK XOL; Williams LK, 2007, J ALLERGY CLIN IMMUN, V119, P168, DOI 10.1016/j.jaci.2006.09.029; Wisnivesky JP, 2007, J ALLERGY CLIN IMMUN, V120, P113, DOI 10.1016/j.jaci.2007.03.044; Wood PR, 2007, J ALLERGY CLIN IMMUN, V120, P1368, DOI 10.1016/j.jaci.2007.09.025; Wu AC, 2007, J ALLERGY CLIN IMMUN, V120, P1146, DOI 10.1016/j.jaci.2007.07.055; Yoo KH, 2007, J ALLERGY CLIN IMMUN, V120, P1468, DOI 10.1016/j.jaci.2007.09.008	53	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					839	844		10.1016/j.jaci.2007.12.1176	http://dx.doi.org/10.1016/j.jaci.2007.12.1176			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18261788				2022-12-18	WOS:000254884000005
J	Markert, ML				Markert, M. Louise			Treatment of infants with complete DiGeorge anomaly	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							TRANSPLANTATION		Duke Univ, Med Ctr, Durham, NC 27706 USA	Duke University	Markert, ML (corresponding author), Duke Univ, Med Ctr, Durham, NC 27706 USA.	marke001@mc.duke.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054843, R01AI047040, R21AI060967] Funding Source: NIH RePORTER; NCRR NIH HHS [M03 RR60] Funding Source: Medline; NIAID NIH HHS [R01 AI 54843, R01 AI 47040, R21 AI 60967] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bowers DC, 1998, LANCET, V352, P1983, DOI 10.1016/S0140-6736(98)00094-4; Land MH, 2007, J ALLERGY CLIN IMMUN, V120, P908, DOI 10.1016/j.jaci.2007.08.048; Markert ML, 2007, BLOOD, V109, P4539, DOI 10.1182/blood-2006-10-048652	3	11	11	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					1063	1063		10.1016/j.jaci.2007.12.1181	http://dx.doi.org/10.1016/j.jaci.2007.12.1181			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18289653				2022-12-18	WOS:000254884000042
J	Holloway, JW; Yang, IA; Holgate, ST				Holloway, John W.; Yang, Ian A.; Holgate, Stephen T.			Interpatient variability in rates of asthma progression: Can genetics provide an answer?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; asthma progression; genetics; genetic testing	LUNG-FUNCTION DECLINE; OBSTRUCTIVE PULMONARY-DISEASE; ENVIRONMENTAL TOBACCO-SMOKE; NECROSIS-FACTOR-ALPHA; S-TRANSFERASE M1; SERUM IGE LEVELS; FAMILIAL AGGREGATION; RISK-FACTORS; BRONCHIAL HYPERRESPONSIVENESS; RECEPTOR POLYMORPHISMS	Asthma is a heterogeneous disorder with a variable natural history. In children 3 patterns of the natural history of asthma have been described: early onset but transient, persistent, and later onset, with only the former leading to persistent asthma later in childhood. In adults a range of different asthma phenotypes differing in their environmental, inflammatory, and prognostic characteristics have also been described. These extend beyond allergic (extrinsic) and nonallergic (intrinsic) asthma to include persistent airflow obstruction and accelerated decrease in lung function over time. Asthma progression can be defined as the change in an individual's phenotype along a continuum ranging from nonasthmatic to asthmatic and subsequent development of severe chronic disease. It is clear that for prevention of asthma progression in patients, there is a need for both better understanding of the pathophysiology of asthma and identification of predictors of progression. Interpatient genetic variability has been shown to affect multiple facets of asthma progression, including increased susceptibility to atopy and subsequent asthma, progression to severe disease, and modification of the response to treatment. Thus genetic testing might provide a means for predicting the likely progression of an individual along the continuum, allowing targeting of preventative treatment. However, the prospect of the use of genetic information in clinical practice raises important social and ethical issues that will need to be addressed before genetic testing can be used to inform the preventative treatment of patients to prevent the development of progression of asthma in individuals.	[Holloway, John W.; Holgate, Stephen T.] Univ Southampton, Div Infect Inflammat & Repair, Sch Med, Southampton SO9 5NH, Hants, England; [Holloway, John W.] Univ Southampton, Div Human Genet, Sch Med, Southampton SO9 5NH, Hants, England; [Yang, Ian A.] Prince Charles Hosp, Dept Thorac Med, Brisbane, Qld 4032, Australia; [Yang, Ian A.] Univ Queensland, Sch Med, Brisbane, Qld, Australia	University of Southampton; University of Southampton; Prince Charles Hospital; University of Queensland	Holloway, JW (corresponding author), Southampton Gen Hosp, Duthie Bldg M808, Southampton SO16 6YD, Hants, England.	J.W.Holloway@soton.ac.uk	Yang, Ian A/B-9609-2008; Holloway, John W/B-5424-2009	Yang, Ian A/0000-0001-8338-1993; Holloway, John W/0000-0001-9998-0464	Medical Research Council [G0800766] Funding Source: Medline; MRC [G0800766] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Allen M, 2003, NAT GENET, V35, P258, DOI 10.1038/ng1256; Bai TR, 2007, EUR RESPIR J, V30, P452, DOI 10.1183/09031936.00165106; Balaci L, 2007, AM J HUM GENET, V80, P1103, DOI 10.1086/518259; Barbato A, 2006, AM J RESP CRIT CARE, V174, P975, DOI 10.1164/rccm.200602-189OC; Barker RD, 1998, OCCUP ENVIRON MED, V55, P684, DOI 10.1136/oem.55.10.684; Barnes PJ, 2006, AM J RESP CRIT CARE, V174, P240, DOI 10.1164/rccm.2604008; Baurecht H, 2007, J ALLERGY CLIN IMMUN, V120, P1406, DOI 10.1016/j.jaci.2007.08.067; BAZARAL M, 1971, J IMMUNOL, V107, P794; Bieli C, 2007, J ALLERGY CLIN IMMUN, V120, P1308, DOI 10.1016/j.jaci.2007.07.034; Bosse Y, 2007, ANNU REV MED, V58, P171, DOI 10.1146/annurev.med.58.071105.111738; Brauer M, 2007, EUR RESPIR J, V29, P879, DOI 10.1183/09031936.00083406; Burke W, 2004, NAT REV GENET, V5, P955, DOI 10.1038/nrg1495; Calsbeek Hiske, 2007, J Genet Couns, V16, P493, DOI 10.1007/s10897-006-9085-9; Chagani T, 1999, AM J RESP CRIT CARE, V160, P278, DOI 10.1164/ajrccm.160.1.9808032; Chanock SJ, 2007, NATURE, V447, P655, DOI 10.1038/447655a; Chinn S, 2006, PAEDIATR RESPIR REV, V7, P223, DOI 10.1016/j.prrv.2006.04.007; Comhair SAA, 2005, AM J PATHOL, V166, P663, DOI 10.1016/S0002-9440(10)62288-2; Contopoulos-Ioannidis DG, 2005, J ALLERGY CLIN IMMUN, V115, P963, DOI 10.1016/j.jaci.2004.12.1119; Descatha A, 2007, ALLERGY, V62, P795, DOI 10.1111/j.1398-9995.2007.01424.x; Devereux G, 2007, PEDIATR PULM, V42, P663, DOI 10.1002/ppul.20640; Devulapalli CS, 2008, THORAX, V63, P8, DOI 10.1136/thx.2006.060616; Dezateux C, 1997, BRIT MED BULL, V53, P40; Dijkstra A, 2006, J ALLERGY CLIN IMMUN, V117, P604, DOI 10.1016/j.jaci.2005.11.023; Dijkstra A, 2006, THORAX, V61, P105, DOI 10.1136/thx.2004.039271; Gao J, 2006, THORAX, V61, P466, DOI 10.1136/thx.2005.051284; GERRARD JW, 1976, ANN ALLERGY, V36, P10; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P457, DOI 10.1164/rccm.2112064; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P710, DOI 10.1164/rccm.2112065; Gosman MME, 2007, THORAX, V62, P242, DOI 10.1136/thx.2006.060988; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Green RH, 2007, CURR OPIN ALLERGY CL, V7, P43, DOI 10.1097/ACI.0b013e3280118a32; Guerra S, 2008, ANNU REV MED, V59, P327, DOI 10.1146/annurev.med.59.060406.213232; Guttmacher AE, 2002, NEW ENGL J MED, V347, P1512, DOI 10.1056/NEJMra012240; Hackett TL, 2007, CURR OPIN ALLERGY CL, V7, P63, DOI 10.1097/ACI.0b013e328013d61b; Haitchi HM, 2005, AM J RESP CRIT CARE, V171, P958, DOI 10.1164/rccm.200409-1251OC; Haland G, 2006, NEW ENGL J MED, V355, P1682, DOI 10.1056/NEJMoa052885; Hall IP, 2007, EUR RESPIR J, V29, P1239, DOI 10.1183/09031936.00088206; Hayashi T, 1995, ANN ALLERG ASTHMA IM, V75, P525; He JQ, 2004, AM J RESP CRIT CARE, V170, P388, DOI 10.1164/rccm.200312-1763OC; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; HENDERSON J, 2007, EUR RESP J; Holgate ST, 2007, EUR RESPIR J, V29, P793, DOI 10.1183/09031936.00087506; Holgate ST, 2007, J ALLERGY CLIN IMMUN, V120, P1233, DOI 10.1016/j.jaci.2007.10.025; Holgate Stephen T, 2004, Proc Am Thorac Soc, V1, P93, DOI 10.1513/pats.2306034; Holloway JW, 2005, J ALLERGY CLIN IMMUN, V115, P960, DOI 10.1016/j.jaci.2005.02.005; Holt PG, 2007, CURR OPIN ALLERGY CL, V7, P547, DOI 10.1097/ACI.0b013e3282f14a17; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V74, P154, DOI 10.1016/0091-6749(84)90279-3; Hoppin AA, 2004, AM J RESP CRIT CARE, V169, P1308, DOI 10.1164/rccm.200309-1228OC; Houlston RS, 1998, EUR J HUM GENET, V6, P80, DOI 10.1038/sj.ejhg.5200156; Howard TD, 2001, AM J RESP CELL MOL, V25, P377, DOI 10.1165/ajrcmb.25.3.4483; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Imboden M, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-2; Islam T, 2007, THORAX, V62, P957, DOI 10.1136/thx.2007.078964; James AL, 2007, EUR RESPIR J, V30, P134, DOI 10.1183/09031936.00146905; Jenkins MA, 1997, GENET EPIDEMIOL, V14, P317, DOI 10.1002/(SICI)1098-2272(1997)14:3<317::AID-GEPI9>3.0.CO;2-1; Jongepier H, 2004, CLIN EXP ALLERGY, V34, P757, DOI 10.1111/j.1365-2222.2004.1938.x; Kabesch M, 2006, J ALLERGY CLIN IMMUN, V117, P269, DOI 10.1016/j.jaci.2005.10.024; Kraft M, 2006, AM J RESP CRIT CARE, V174, P238, DOI 10.1164/rccm.2604007; Kraft M, 2006, AM J RESP CRIT CARE, V174, P243, DOI 10.1164/rccm.2604009; Kurzius-Spencer M, 2004, AM J MED GENET A, V125A, P232, DOI 10.1002/ajmg.a.20481; Laitinen T, 2004, SCIENCE, V304, P300, DOI 10.1126/science.1090010; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Levy S, 2007, PLOS BIOL, V5, P2113, DOI 10.1371/journal.pbio.0050254; Li YF, 2006, AM J RESP CRIT CARE, V173, P970, DOI 10.1164/rccm.200508-1256OC; Liu X, 2000, J ALLERGY CLIN IMMUN, V106, P167, DOI 10.1067/mai.2000.107935; Lowe L, 2002, LANCET, V359, P1904, DOI 10.1016/S0140-6736(02)08781-0; Lucas JS, 2004, AM J RESP CRIT CARE, V170, P534, DOI 10.1164/rccm.200311-1583OC; Malo JL, 1999, AM J RESP CRIT CARE, V159, P1879, DOI 10.1164/ajrccm.159.6.9806159; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; Martinez FD, 2007, EUR RESPIR J, V29, P179, DOI 10.1183/09031936.00087906; Martinez Fernando D, 2007, Proc Am Thorac Soc, V4, P26, DOI 10.1513/pats.200607-144JG; Marx-Stolting L, 2007, PHARMACOGENOMICS J, V7, P293, DOI 10.1038/sj.tpj.6500425; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Nicolae D, 2005, AM J HUM GENET, V76, P349, DOI 10.1086/427763; Orie NGM, 1961, BRONCHITIS INT S; Oryszczyn MP, 2007, J ALLERGY CLIN IMMUN, V119, P57, DOI 10.1016/j.jaci.2006.09.026; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Palmer CNA, 2007, J ALLERGY CLIN IMMUN, V120, P64, DOI 10.1016/j.jaci.2007.04.001; Palmer LJ, 2001, AM J RESP CRIT CARE, V163, P37, DOI 10.1164/ajrccm.163.1.2005013; Palmer LJ, 2000, EUR J HUM GENET, V8, P853, DOI 10.1038/sj.ejhg.5200551; Pearce N, 2000, THORAX, V55, P424, DOI 10.1136/thorax.55.5.424; Pearce N, 1999, THORAX, V54, P268, DOI 10.1136/thx.54.3.268; Pin I, 2002, AM J RESP CRIT CARE, V165, P185, DOI 10.1164/ajrccm.165.2.2012019; POHUNEK P, 2000, EUR RESP J, V11; Postma Dirkje S, 2004, Chest, V126, p96S, DOI 10.1378/chest.126.2_suppl_1.96S; POSTMA DS, 2004, CHEST S, V126, pS59; Puddicombe SM, 2003, AM J RESP CELL MOL, V28, P61, DOI 10.1165/rcmb.4715; Ronchetti R, 2007, INT ARCH ALLERGY IMM, V142, P79, DOI 10.1159/000096031; Ruse CE, 2007, RESP MED, V101, P340, DOI 10.1016/j.rmed.2006.05.017; Saglani S, 2006, EUR RESPIR J, V28, P505, DOI 10.1183/09031936.06.00056405; Salam MT, 2007, THORAX, V62, P1050, DOI 10.1136/thx.2007.080127; SARAFINO EP, 1995, ARCH DIS CHILD, V73, P112, DOI 10.1136/adc.73.2.112; Schaub B, 2006, J ALLERGY CLIN IMMUN, V117, P969, DOI 10.1016/j.jaci.2006.03.003; Schwartz D, 2007, SCIENCE, V316, P695, DOI 10.1126/science.1141331; Shaheen SO, 2002, THORAX, V57, P958, DOI 10.1136/thorax.57.11.958; Simpson A, 2005, AM J RESP CRIT CARE, V172, P55, DOI 10.1164/rccm.200412-1708OC; Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC; Simpson A, 2004, CURR OPIN ALLERGY CL, V4, P45, DOI [10.1097/00130832-200402000-00010, 10.1097/01.all.0000113678.18759.38]; Soderhall C, 2007, PLOS BIOL, V5, P1952, DOI 10.1371/journal.pbio.0050242; Tantisira KG, 2004, HUM MOL GENET, V13, P1353, DOI 10.1093/hmg/ddh149; Teerlink CC, 2007, AM J RESP CRIT CARE, V176, P865, DOI 10.1164/rccm.200703-448OC; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744, DOI 10.1164/ajrccm.164.5.2011026; Thomson NC, 2007, CURR ALLERGY ASTHM R, V7, P303, DOI 10.1007/s11882-007-0045-8; van Diemen CC, 2005, AM J RESP CRIT CARE, V172, P329, DOI 10.1164/rccm.200411-1486OC; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; van Schayck OCP, 2007, J ALLERGY CLIN IMMUN, V119, P1323, DOI 10.1016/j.jaci.2007.02.024; Vladich FD, 2005, J CLIN INVEST, V115, P747, DOI 10.1172/JCI200522818; von Mutius E, 2007, IMMUNOBIOLOGY, V212, P433, DOI 10.1016/j.imbio.2007.03.002; vonMutius E, 1996, AM J RESP CRIT CARE, V153, P1266, DOI 10.1164/ajrccm.153.4.8616552; Wang M, 2003, HUM GENET, V113, P387, DOI 10.1007/s00439-003-1001-x; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wechsler ME, 2006, AM J RESP CRIT CARE, V173, P519, DOI 10.1164/rccm.200509-1519OC; Weiss ST, 2006, PHARMACOGENOMICS J, V6, P311, DOI 10.1038/sj.tpj.6500387; Werner M, 2003, J ALLERGY CLIN IMMUN, V112, P323, DOI 10.1067/mai.2003.1648; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175; Woodcock A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/rccm.200401-083OC; Yang IA, 2005, AM J RESP CRIT CARE, V171, P171, DOI 10.1164/rccm.200402-194OC; Yang IA, 2007, CURR OPIN ALLERGY CL, V7, P75, DOI 10.1097/ACI.0b013e328012ce39; Yao TC, 2003, J ALLERGY CLIN IMMUN, V111, P1285, DOI 10.1067/mai.2003.1506; Yeatts K, 2006, ENVIRON HEALTH PERSP, V114, P634, DOI 10.1289/ehp.8381; Zhang YM, 2003, NAT GENET, V34, P181, DOI 10.1038/ng1166	122	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2008	121	3					573	579		10.1016/j.jaci.2008.01.007	http://dx.doi.org/10.1016/j.jaci.2008.01.007			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	273GR	18328888	Bronze			2022-12-18	WOS:000253918900003
J	Miyahara, S; Miyahara, N; Lucas, JJ; Joetham, A; Matsubara, S; Ohnishi, H; Dakhama, A; Gelfand, EW				Miyahara, Satoko; Miyahara, Nobuaki; Lucas, Joseph J.; Joetham, Anthony; Matsubara, Shikegi; Ohnishi, Hiroshi; Dakhama, Azzeddine; Gelfand, Erwin W.			Contribution of allergen-specific and nonspecific nasal responses to early-phase and late-phase nasal responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; early-phase; late-phase; mouse; mast cell	FC-EPSILON-RI; AIRWAY HYPERRESPONSIVENESS; NEUROGENIC INFLAMMATION; MAST-CELLS; RHINITIS; IGE; CHALLENGE; MICE; PATHOPHYSIOLOGY; PROVOCATION	Background: The relative contributions of the allergen-specific early-phase nasal response and nonspecific nasal response and mast cells to the pathophysiology of allergic rhinitis are not well defined. Objectives: To determine the contributions of specific reactivity, nonspecific reactivity, and mast cells to the development of early-phase and late-phase responses using a mouse model of allergic rhinitis. Methods: Sensitized wild-type and Fc epsilon RI-deficient (FC epsilon RI-/-) mice were exposed to allergen for 3, 5, or 12 days. As indicators of nasal reactivity, respiratory frequency and nasal resistance were monitored. Results: Sensitized mice exposed to 3 days of nasal allergen challenge showed a nonspecific early-phase response. As the number of allergen exposures increased, there was progressive diminution in nonspecific responses with increased allergen-specific early-phase responses and a late-phase response. Sensitized Fc epsilon RI-/- mice did not develop nonspecific nasal responses or late-phase responses, but transfer of in vitro-differentiated wild-type mast cells into Fc epsilon RI-/- mice restored nonspecific early-phase nasal responses but not the late-phase response. Conclusion: These data identify the nonspecific nasal response as a major contributor to the early-phase response, especially during initial allergen exposure, and is dependent on mast cells. Increasing allergen exposure results in increasing allergen-specific responses, converting the nonspecific early-phase response to a late-phase response that is allergen-specific and mast cell-independent.	[Miyahara, Satoko; Miyahara, Nobuaki; Lucas, Joseph J.; Joetham, Anthony; Matsubara, Shikegi; Ohnishi, Hiroshi; Dakhama, Azzeddine; Gelfand, Erwin W.] Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA	National Jewish Health	Gelfand, EW (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, 1400 Jackson St, Denver, CO 80206 USA.	gelfande@njc.org		Ohnishi, Hiroshi/0000-0002-7863-4519	NHLBI NIH HHS [HL-61005, P01 HL036577, HL-36577, P01 HL036577-21A15977] Funding Source: Medline; NIAID NIH HHS [AI-42246] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577, R01HL061005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI042246, R01AI042246] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andoh T, 2004, NEUROREPORT, V15, P2029, DOI 10.1097/00001756-200409150-00007; BORUM P, 1983, EUR J RESPIR DIS, V64, P65; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V87, P737, DOI 10.1016/0091-6749(91)90397-7; Bousquet J, 1996, INT ARCH ALLERGY IMM, V110, P207, DOI 10.1159/000237289; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; GOMEZ E, 1986, J ALLERGY CLIN IMMUN, V78, P637, DOI 10.1016/0091-6749(86)90082-5; Gosepath J, 2005, LARYNGOSCOPE, V115, P512, DOI 10.1097/01.MLG.0000149682.56426.6B; Hjelm F, 2006, SCAND J IMMUNOL, V64, P177, DOI 10.1111/j.1365-3083.2006.01818.x; ISHIZAKA T, 1982, ANN ALLERGY, V48, P313; JACQUES CAJ, 1991, BRIT J PHARMACOL, V104, P859, DOI 10.1111/j.1476-5381.1991.tb12518.x; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; KleinJan A, 1997, J ALLERGY CLIN IMMUN, V99, P515, DOI 10.1016/S0091-6749(97)70079-4; KRAYENBUHL MC, 1988, CLIN ALLERGY, V18, P157, DOI 10.1111/j.1365-2222.1988.tb02855.x; MAJCHEL AM, 1992, J ALLERGY CLIN IMMUN, V90, P85, DOI 10.1016/S0091-6749(06)80014-X; McDonald DM, 1996, ADV EXP MED BIOL, V410, P453; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Miyahara S, 2005, J ALLERGY CLIN IMMUN, V116, P1020, DOI 10.1016/j.jaci.2005.08.020; Miyahara S, 2006, J ALLERGY CLIN IMMUN, V118, P1110, DOI 10.1016/j.jaci.2006.06.014; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NACLERIO RM, 1988, J ALLERGY CLIN IMMUN, V82, P927; Obata K, 2007, BLOOD, V110, P913, DOI 10.1182/blood-2007-01-068718; Riccio MM, 1996, J ALLERGY CLIN IMMUN, V97, P1252, DOI 10.1016/S0091-6749(96)70193-8; Sanico AM, 1997, J ALLERGY CLIN IMMUN, V100, P632, DOI 10.1016/S0091-6749(97)70167-2; Sanico AM, 1999, J APPL PHYSIOL, V86, P1202, DOI 10.1152/jappl.1999.86.4.1202; SHANAHAN F, 1985, J IMMUNOL, V135, P1331; Sheahan P, 2005, CLIN EXP ALLERGY, V35, P45, DOI 10.1111/j.1365-2222.2004.02131.x; SHIMURA S, 1994, AM REV RESPIR DIS, V143, pS25; Skoner DR, 2001, J ALLERGY CLIN IMMUN, V108, pS2, DOI 10.1067/mai.2001.115569; Taube C, 2004, J IMMUNOL, V172, P6398, DOI 10.4049/jimmunol.172.10.6398; TOGIAS A, 1985, AM J MED, V79, P26, DOI 10.1016/0002-9343(85)90084-1; Tomkinson A, 2001, AM J RESP CRIT CARE, V163, P721, DOI 10.1164/ajrccm.163.3.2005010; YANAGISAWA M, 1986, NEUROSCI LETT, V68, P351, DOI 10.1016/0304-3940(86)90515-X	33	11	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2008	121	3					718	724		10.1016/j.jaci.2007.11.002	http://dx.doi.org/10.1016/j.jaci.2007.11.002			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	273GR	18155286	Bronze			2022-12-18	WOS:000253918900028
J	Bielory, L				Bielory, Leonard			Intranasal corticosteroids reduce ocular symptoms of allergic rhinitis as a class effect	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							AQUEOUS NASAL SPRAY		[Bielory, Leonard] Univ Med & Dent New Jersey, Dept Med, Div Rheumatol Allergy & Immunol, Newark, NJ 07103 USA; [Bielory, Leonard] Univ Med & Dent New Jersey, Dept Pediat, Div Rheumatol Allergy & Immunol, Newark, NJ USA; [Bielory, Leonard] Univ Med & Dent New Jersey, Dept Ophthalmol & Visual Sci, Div Rheumatol Allergy & Immunol, Newark, NJ USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Bielory, L (corresponding author), Univ Med & Dent New Jersey, Dept Med, Div Rheumatol Allergy & Immunol, Newark, NJ 07103 USA.	bielory@umdnj.edu						Bernstein DI, 2004, CLIN EXP ALLERGY, V34, P952, DOI 10.1111/j.1365-2222.2004.01952.x; BIELORY L, 2008, IN PRESS ANN ALLERGY; Condemi J, 2000, ANN ALLERG ASTHMA IM, V84, P533, DOI 10.1016/S1081-1206(10)62518-5; Giger R, 2003, EUR ARCH OTO-RHINO-L, V260, P135, DOI 10.1007/s00405-002-0543-1; Kaiser HB, 2007, J ALLERGY CLIN IMMUN, V119, P1430, DOI 10.1016/j.jaci.2007.02.022; Moller C, 2003, CLIN EXP ALLERGY, V33, P816, DOI 10.1046/j.1365-2222.2003.01689.x; Schenkel E, 2007, ALLERGY CLIN IMMUNOL, V19, P50, DOI 10.1027/0838-1925.19.2.50	7	11	11	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					538	539		10.1016/j.jaci.2007.10.013	http://dx.doi.org/10.1016/j.jaci.2007.10.013			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	18158174				2022-12-18	WOS:000253337800050
J	Crimi, E; Saporiti, R; Bartolini, S; Baroffio, M; Pellegrino, R; Brusasco, V				Crimi, Emanuele; Saporiti, Riccardo; Bartolini, Stefano; Baroffio, Michele; Pellegrino, Riccardo; Brusasco, Vito			Airway responsiveness to methacholine and deep inhalations in subjects with rhinitis without asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						methacholine challenge; bronchodilatation; bronchoprotection; spirometry; airway conductance; partial expiratory maneuver	INSPIRATION-INDUCED BRONCHOPROTECTION; SMOOTH-MUSCLE; INDUCED BRONCHOCONSTRICTION; LUNG-INFLATION; HEALTHY; CHALLENGE; TONE	Background: Airway hyperresponsiveness in asthma is believed to be caused in part by the inability of deep inspirations to modulate airway narrowing. Objective: We investigated whether deep inspirations taken before or after methacholine inhalation attenuate bronchoconstriction in subjects with rhinitis. The results were compared with a group of healthy subjects. Methods: Ten subjects with rhinitis without asthma and 10 healthy subjects were studied on 3 different occasions at random. Bronchial challenges were performed with a single dose of methacholine known to decrease the FEV1 by 17% to 40%. Challenges were performed with avoidance of deep inspirations, or with 5 deep inspirations preceding or following the inhalation of methacholine. Lung function measurements were specific airway conductance, forced expiratory flow at 30% to 40% of vital capacity on a maneuver started from end-tidal inspiration (partial flow), and residual volume (partial residual volume). Results: In healthy subjects, deep inspirations taken after methacholine caused less changes in specific airway conductance, partial flow, and partial residual volume (P < .005 for all) than deep inspirations taken before methacholine or avoidance. In subjects with rhinitis, methacholine produced similar functional changes independently of the presence or absence of any deep inspirations. Compared with normal subjects, the attenuating effects of deep inspirations after methacholine on partial flow and partial residual volume were blunted in the subjects with rhinitis.	Univ Genoa, Dipartimento Med Interna, Genoa, Italy; Azienda Osp S Croce & Carle, Ctr Fisiopatol Resp & Studio Dispnea, Cuneo, Italy	University of Genoa	Crimi, E (corresponding author), Padiglione Maragliano Osp San Martino, UO Fisiopatol Resp, Largo R Benzi 10, I-16132 Genoa, Italy.	Emanuele.Crimi@unige.it	Pellegrino, Riccardo/AAA-1667-2022					Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Brown RH, 2003, EUR RESPIR J, V22, P57, DOI 10.1183/09031936.03.00090403; Cockcroft DW, 2006, J ALLERGY CLIN IMMUN, V117, P1244, DOI 10.1016/j.jaci.2006.02.038; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Crimi E, 2002, J APPL PHYSIOL, V93, P1384, DOI 10.1152/japplphysiol.00209.2002; Crimi E, 2002, J APPL PHYSIOL, V92, P2353, DOI 10.1152/japplphysiol.01248.2001; Crimi E, 2001, J APPL PHYSIOL, V91, P1029, DOI 10.1152/jappl.2001.91.3.1029; FISH JE, 1981, J APPL PHYSIOL, V50, P1079, DOI 10.1152/jappl.1981.50.5.1079; FISH JE, 1976, AM REV RESPIR DIS, V113, P579; Fredberg JJ, 1997, AM J RESP CRIT CARE, V156, P1752, DOI 10.1164/ajrccm.156.6.9611016; GUNST SJ, 1983, J APPL PHYSIOL, V55, P759, DOI 10.1152/jappl.1983.55.3.759; Gunst SJ, 2001, J APPL PHYSIOL, V90, P741, DOI 10.1152/jappl.2001.90.2.741; Jensen A, 2001, J APPL PHYSIOL, V91, P506, DOI 10.1152/jappl.2001.91.1.506; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; MITCHELL RW, 1994, AM J PHYSIOL, V267, pL218, DOI 10.1152/ajplung.1994.267.2.L218; PARHAM WM, 1983, AM REV RESPIR DIS, V128, P240; Pellegrino R, 1996, J APPL PHYSIOL, V81, P964, DOI 10.1152/jappl.1996.81.2.964; Pyrgos G, 2003, AM J RESP CRIT CARE, V167, P1660, DOI 10.1164/rccm.2201048; Salerno FG, 2005, J APPL PHYSIOL, V98, P817, DOI 10.1152/japplphysiol.00763.2004; Salome CM, 2003, EUR RESPIR J, V22, P62, DOI 10.1183/09031936.03.00117502; Scichilone N, 2000, AM J RESP CRIT CARE, V162, P910, DOI 10.1164/ajrccm.162.3.9907048; Scichilone N, 2001, AM J RESP CRIT CARE, V163, P413, DOI 10.1164/ajrccm.163.2.2003119; SCOTT GC, 1991, CHEST, V100, P322, DOI 10.1378/chest.100.2.322; Silkoff PE, 2000, AM J RESP CRIT CARE, V161, P1218, DOI 10.1164/ajrccm.161.4.9903111	24	11	11	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					403	407		10.1016/j.jaci.2007.09.009	http://dx.doi.org/10.1016/j.jaci.2007.09.009			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	17980415				2022-12-18	WOS:000253337800019
J	Ebisawa, M; Sugizaki, C				Ebisawa, M.; Sugizaki, C.			Prevalence of pediatric allergic diseases in the first 5 years of life	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	64th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 14-18, 2008	Philadelphia, PA	Amer Acad Allergy, Asthma & Immunol					[Ebisawa, M.; Sugizaki, C.] Sagamiha Natl Hosp, Kanagawa, Japan										0	11	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2		1		912	S237	S237		10.1016/j.jaci.2007.12.936	http://dx.doi.org/10.1016/j.jaci.2007.12.936			1	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266HZ					2022-12-18	WOS:000253426401376
J	Kierstein, S; Krytska, K; Kierstein, G; Hortobagyi, L; Zhu, X; Haczku, A				Kierstein, S.; Krytska, K.; Kierstein, G.; Hortobagyi, L.; Zhu, X.; Haczku, A.			Sugar consumption increases susceptibility to allergic airway inflammation and activates the innate immune system in the lung	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	64th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 14-18, 2008	Philadelphia, PA	Amer Acad Allergy, Asthma & Immunol					[Kierstein, S.; Krytska, K.; Kierstein, G.; Hortobagyi, L.; Zhu, X.; Haczku, A.] Univ Penn, Philadelphia, PA 19104 USA	University of Pennsylvania			HACZKU, ANGELA/A-8486-2013	HACZKU, ANGELA/0000-0002-1301-4941					0	11	11	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2		1		754	S196	S196		10.1016/j.jaci.2007.12.730	http://dx.doi.org/10.1016/j.jaci.2007.12.730			1	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266HZ					2022-12-18	WOS:000253426401218
J	Straumann, A; Conus, S; Kita, H; Kephart, G; Bussmann, C; Beglinger, C; Patel, J; Byrne, M; Simon, HU				Straumann, A.; Conus, S.; Kita, H.; Kephart, G.; Bussmann, C.; Beglinger, C.; Patel, J.; Byrne, M.; Simon, H. U.			Mepolizumab, a humanized monoclonal antibody to IL-5, for severe eosinophilic Esophagitis in adults: A randomized, placebo-controlled double-blind trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	64th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 14-18, 2008	Philadelphia, PA	Amer Acad Allergy, Asthma & Immunol					[Straumann, A.] FMH Gastroenterol, Olten, Switzerland; [Conus, S.; Simon, H. U.] Univ Bern, Dept Pharmacol, CH-3012 Bern, Switzerland; [Kita, H.; Kephart, G.] Mayo Clin, Dept Med, Div Allerg Dis, Rochester, MN USA; [Bussmann, C.] Viollier Lab, Basel, Switzerland; [Beglinger, C.] Univ Basel, Dept Gastroenterol, CH-4003 Basel, Switzerland; [Patel, J.; Byrne, M.] GlaxoSmithKline Inc, Greenford, Middx, England	University of Bern; Mayo Clinic; University of Basel; GlaxoSmithKline			Simon, Hans-Uwe/AAU-7410-2020	Simon, Hans-Uwe/0000-0002-9404-7736					0	11	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2		1		171	S44	S44		10.1016/j.jaci.2007.12.179	http://dx.doi.org/10.1016/j.jaci.2007.12.179			1	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266HZ					2022-12-18	WOS:000253426400172
J	Lavine, E; Somech, R; Zhang, JY; Puel, A; Bossuyt, X; Picard, C; Casanova, JL; Roifman, CM				Lavine, Elana; Somech, Raz; Zhang, Jun Yan; Puel, Anne; Bossuyt, Xavier; Picard, Capucine; Casanova, Jean Laurent; Roifman, Chaim M.			Cellular and humoral aberrations in a kindred with IL-1 receptor-associated kinase 4 deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RECURRENT BACTERIAL-INFECTIONS; LYMPHOCYTE SUBSETS; IRAK-4 DEFICIENCY; HEALTHY-CHILDREN; HYPORESPONSIVENESS; MUTATIONS; PATIENT; AGE		Hosp Sick Children, Div Immunol & Allergy, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON, Canada; Univ Paris, INSERM, U550, Lab Human Genet Infect Dis, F-75252 Paris, France; Univ Paris, Necker Med Sch, F-75252 Paris, France; Katholieke Univ Leuven Hosp, Expt Med Lab, Louvain, Belgium	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Flanders Institute for Biotechnology (VIB); KU Leuven; University Hospital Leuven	Lavine, E (corresponding author), Hosp Sick Children, Div Immunol & Allergy, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Picard, Capucine/H-3914-2017; Casanova, Jean-Laurent/I-3418-2017; Bossuyt, Xavier/B-2085-2019; Puel, Anne/H-7305-2017	Picard, Capucine/0000-0001-8788-5056; Bossuyt, Xavier/0000-0001-6856-8485; Puel, Anne/0000-0003-2603-0323; Casanova, Jean-Laurent/0000-0002-7782-4169				Day N, 2004, J PEDIATR-US, V144, P524, DOI 10.1016/j.jpeds.2003.11.025; Haraguchi S, 1998, P NATL ACAD SCI USA, V95, P13125, DOI 10.1073/pnas.95.22.13125; Ku CL, 2007, J MED GENET, V44, P16, DOI 10.1136/jmg.2006.044446; Kuhns DB, 1997, J IMMUNOL, V158, P3959; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; McNerlan SE, 1999, SCAND J CLIN LAB INV, V59, P89, DOI 10.1080/00365519950185805; Medvedev AE, 2003, J EXP MED, V198, P521, DOI 10.1084/jem.20030701; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; von Bernuth H, 2005, CLIN INFECT DIS, V41, pS436, DOI 10.1086/431994	10	11	14	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2007	120	4					948	950		10.1016/j.jaci.2007.04.038	http://dx.doi.org/10.1016/j.jaci.2007.04.038			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	220LH	17544092	Green Accepted			2022-12-18	WOS:000250157700032
J	Rothenberg, ME				Rothenberg, Marc E.			Eosinophils in the new millennium	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						allergy; eosinophilia; eotaxin; IL-5	ANTI-INTERLEUKIN-5 ANTIBODY; MEPOLIZUMAB THERAPY; ASTHMA; INTERLEUKIN-13; INFLAMMATION; CHEMOKINES; SCH55700; IL-13; LUNG; CCR3		Univ Cincinnati, Childrens Hosp, Med Ctr, Coll Med,Div Allergy & Immunol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Rothenberg, ME (corresponding author), Univ Cincinnati, Childrens Hosp, Med Ctr, Coll Med,Div Allergy & Immunol, 3333 Burnet Ave,ML7028, Cincinnati, OH 45229 USA.	Rothenberg@chmcc.org						Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Foley SC, 2007, J ALLERGY CLIN IMMUN, V119, P1563, DOI 10.1016/j.jaci.2007.03.040; Fulkerson PC, 2006, P NATL ACAD SCI USA, V103, P16418, DOI 10.1073/pnas.0607863103; Fulkerson PC, 2006, AM J PATHOL, V169, P2117, DOI 10.2353/ajpath.2006.060617; Garrett JK, 2004, J ALLERGY CLIN IMMUN, V113, P115, DOI 10.1016/j.jaci.2003.10.049; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Jacobsen EA, 2007, J ALLERGY CLIN IMMUN, V119, P1313, DOI 10.1016/j.jaci.2007.03.043; Kips JC, 2003, AM J RESP CRIT CARE, V167, P1655, DOI 10.1164/rccm.200206-525OC; Klion AD, 2004, BLOOD, V103, P2939, DOI 10.1182/blood-2003-10-3620; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Munitz A, 2007, J ALLERGY CLIN IMMUN, V119, P1382, DOI 10.1016/j.jaci.2007.01.031; Plotz S, 2003, NEW ENGL J MED, V349, P2334, DOI 10.1056/NEJMoa031261; Pope SM, 2005, J IMMUNOL, V175, P5341, DOI 10.4049/jimmunol.175.8.5341; Pope SM, 2005, J BIOL CHEM, V280, P13952, DOI 10.1074/jbc.M406037200; Pope SM, 2001, J ALLERGY CLIN IMMUN, V108, P594, DOI 10.1067/mai.2001.118600; Rosenberg HF, 2007, J ALLERGY CLIN IMMUN, V119, P1303, DOI 10.1016/j.jaci.2007.03.048; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; Rothenberg ME, 2004, J ALLERGY CLIN IMMUN, V113, P11, DOI 10.1016/j.jaci.2003.10.047; Simon D, 2007, J ALLERGY CLIN IMMUN, V119, P1291, DOI 10.1016/j.jaci.2007.02.010; Stein ML, 2006, J ALLERGY CLIN IMMUN, V118, P1312, DOI 10.1016/j.jaci.2006.09.007; Swartz JM, 2006, BLOOD, V108, P2420, DOI 10.1182/blood-2006-04-015933; WONG CK, 2007, AM J RESP CELL 0301; Yu CN, 2002, J EXP MED, V195, P1387, DOI 10.1084/jem.20020656; Zimmermann N, 2003, J ALLERGY CLIN IMMUN, V111, P227, DOI 10.1067/mai.2003.139	25	11	11	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1321	1322		10.1016/j.jaci.2007.03.035	http://dx.doi.org/10.1016/j.jaci.2007.03.035			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17451795				2022-12-18	WOS:000247232800004
J	Apter, AJ				Apter, Andrea J.			Advances in adult asthma 2006: Its risk factors, course, and management	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; adults; health disparities; therapeutics; adherence	EXHALED NITRIC-OXIDE; AIRWAY INFLAMMATION; HEALTH DISPARITIES; OBESITY; ADHERENCE; ALLERGY; HYPERRESPONSIVENESS; RESPONSIVENESS; EPIDEMIOLOGY; PERSISTENCE	This Advances article updates our understanding of risk factors for asthma and its course and management. Studies relevant to clinical practice are discussed, with special attention to their clinical research methods.	Univ Penn, Dept Med, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Apter, AJ (corresponding author), Hosp Univ Penn, 829 Gates Bldg,3600 Spruce St, Philadelphia, PA 19104 USA.	apter@mail.med.upenn.edu						Aaronson DW, 2006, J ALLERGY CLIN IMMUN, V117, P40, DOI 10.1016/j.jaci.2005.08.060; Anderson SD, 2006, J ALLERGY CLIN IMMUN, V117, P767, DOI 10.1016/j.jaci.2005.12.1355; Appleton SL, 2006, J ALLERGY CLIN IMMUN, V118, P1284, DOI 10.1016/j.jaci.2006.08.011; Apter AJ, 2006, J ALLERGY CLIN IMMUN, V117, P512, DOI 10.1016/j.jaci.2005.12.1353; Apter AJ, 2006, J ALLERGY CLIN IMMUN, V117, P345, DOI 10.1016/j.jaci.2005.11.026; Apter AJ, 2004, J ALLERGY CLIN IMMUN, V113, P407, DOI 10.1016/j.jaci.2003.12.002; Arbes SJ, 2006, J ALLERGY CLIN IMMUN, V118, P1169, DOI 10.1016/j.jaci.2006.07.029; Barnes KC, 2006, J ALLERGY CLIN IMMUN, V117, P243, DOI 10.1016/j.jaci.2005.11.030; Barros R, 2006, J ALLERGY CLIN IMMUN, V117, P1501, DOI 10.1016/j.jaci.2006.02.027; Bender BG, 2006, J ALLERGY CLIN IMMUN, V118, P899, DOI 10.1016/j.jaci.2006.07.002; Chinn S, 2006, EUR RESPIR J, V28, P763, DOI 10.1183/09031936.06.00150505; Chinn S, 2002, THORAX, V57, P1028, DOI 10.1136/thorax.57.12.1028; Cockcroft DW, 2006, J ALLERGY CLIN IMMUN, V117, P1244, DOI 10.1016/j.jaci.2006.02.038; Deykin A, 2006, J ALLERGY CLIN IMMUN, V118, P565, DOI 10.1016/j.jaci.2006.06.007; Flaherman V, 2006, ARCH DIS CHILD, V91, P334, DOI 10.1136/adc.2005.080390; Flohr C, 2006, J ALLERGY CLIN IMMUN, V118, P1305, DOI 10.1016/j.jaci.2006.08.035; Ford ES, 2005, J ALLERGY CLIN IMMUN, V115, P897, DOI 10.1016/j.jaci.2004.11.050; Fuhlbrigge AL, 2006, J ALLERGY CLIN IMMUN, V117, P359, DOI 10.1016/j.jaci.2005.10.036; Gold DR, 2006, J ALLERGY CLIN IMMUN, V117, P148, DOI 10.1016/j.jaci.2005.09.021; Gupta RS, 2006, J ALLERGY CLIN IMMUN, V117, P351, DOI 10.1016/j.jaci.2005.11.047; Hallstrand TS, 2005, J ALLERGY CLIN IMMUN, V116, P1235, DOI 10.1016/j.jaci.2005.09.016; Hargreave FE, 2006, J ALLERGY CLIN IMMUN, V117, P1511, DOI 10.1016/j.jaci.2006.03.038; Hennekens C, 1987, EPIDEMIOLOGY MED, P272; Institute of Medicine (US) Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care, 2003, UNEQUAL TREATMENT CO, DOI DOI 10.17226/12875; Jaakkola JJK, 2006, J ALLERGY CLIN IMMUN, V118, P823, DOI 10.1016/j.jaci.2006.06.043; Joseph CLM, 2006, J ALLERGY CLIN IMMUN, V117, P233, DOI 10.1016/j.jaci.2005.11.004; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Marceau C, 2006, J ALLERGY CLIN IMMUN, V118, P574, DOI 10.1016/j.jaci.2006.06.034; Matsuda K, 2006, J ALLERGY CLIN IMMUN, V117, P705, DOI 10.1016/j.jaci.2005.11.007; Murphy S, 2006, J ALLERGY CLIN IMMUN, V117, P34, DOI 10.1016/j.jaci.2005.10.031; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Nelson HS, 2006, J ALLERGY CLIN IMMUN, V117, P3, DOI 10.1016/j.jaci.2005.10.013; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; Pearlman DS, 2006, J ALLERGY CLIN IMMUN, V117, P30, DOI 10.1016/j.jaci.2005.09.030; Radon K, 2006, J ALLERGY CLIN IMMUN, V118, P1279, DOI 10.1016/j.jaci.2006.08.033; Reed CE, 2006, J ALLERGY CLIN IMMUN, V118, P543, DOI 10.1016/j.jaci.2006.06.020; ROTHMAN KJ, 2002, EPIDEMIOLOGY INTRO, P94; Salam MT, 2006, J ALLERGY CLIN IMMUN, V117, P1001, DOI 10.1016/j.jaci.2006.02.004; Schachter LM, 2003, THORAX, V58, P1031, DOI 10.1136/thorax.58.12.1031; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P925, DOI 10.1016/j.jaci.2005.01.064; Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P103, DOI 10.1016/j.jaci.2004.10.007; Shore SA, 2006, J ALLERGY CLIN IMMUN, V118, P389, DOI 10.1016/j.jaci.2006.04.021; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827; Szefler SJ, 2006, J ALLERGY CLIN IMMUN, V117, P26, DOI 10.1016/j.jaci.2005.11.006; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P470, DOI 10.1016/j.jaci.2004.12.1123; Szefler SJ, 2007, J ALLERGY CLIN IMMUN, V119, P558, DOI 10.1016/j.jaci.2006.12.619; Williams LK, 2004, J ALLERGY CLIN IMMUN, V114, P1288, DOI 10.1016/j.jaci.2004.09.028	49	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2007	119	3					563	566		10.1016/j.jaci.2007.01.001	http://dx.doi.org/10.1016/j.jaci.2007.01.001			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	146HL	17270262				2022-12-18	WOS:000244925000005
J	Jerschow, E; Anwar, S; Barzilai, N; Rosenstreich, D				Jerschow, E.; Anwar, S.; Barzilai, N.; Rosenstreich, D.			Macrophages accumulation in visceral and subcutaneous adipose tissue correlates with age	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	63rd Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	FEB 23-27, 2007	San Diego, CA	Amer Acad Allergy, Asthma & Immunol					[Jerschow, E.; Barzilai, N.; Rosenstreich, D.] Albert Einstein Coll Med, Bronx, NY USA; [Anwar, S.] Montefiore Med Ctr, Bronx, NY USA	Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine									0	11	12	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1		1		703	S179	S179		10.1016/j.jaci.2006.12.066	http://dx.doi.org/10.1016/j.jaci.2006.12.066			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	238PT		Bronze			2022-12-18	WOS:000251460401088
J	Kaiser, HB; Naclerio, R; Given, J; Philpot, E; Toler, T; Ellsworth, A				Kaiser, H. B.; Naclerio, R.; Given, J.; Philpot, E.; Toler, T.; Ellsworth, A.			Once-daily fluticasone furoate* nasal spray (FFNS) is effective for the treatment of seasonal allergic rhinitis (SAR) caused by ragweed *LISAN-approved name	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	63rd Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	FEB 23-27, 2007	San Diego, CA	Amer Acad Allergy, Asthma & Immunol					[Kaiser, H. B.] Asthma & Allergy Specialists, Minneapolis, MN USA; [Naclerio, R.] Univ Chicago Hosp, Chicago, IL 60637 USA; [Given, J.] Allergy & Resp Ctr, Canton, OH USA; [Philpot, E.; Toler, T.; Ellsworth, A.] GlaxoSmithKline Inc, Res Triangle Pk, NC USA	University of Chicago; University of Illinois System; GlaxoSmithKline									0	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1		1		910	S232	S232		10.1016/j.jaci.2006.12.278	http://dx.doi.org/10.1016/j.jaci.2006.12.278			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	238PT					2022-12-18	WOS:000251460401294
J	Lavi, RF; Kamchaisatian, W; Sleasman, JW; Martin, DP; Haraguchi, S; Day, NK; Tangsinnuznkong, N				Lavi, Richard F.; Kamchaisatian, Wasu; Sleasman, John W.; Martin, Diana P.; Haraguchi, Soichi; Day, Noorbibi K.; Tangsinnuznkong, Nutthapong			Thymic output markers indicate immune dysfunction in DiGeorge syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IMMUNODEFICIENCY		Univ S Florida, Dept Pediat, St Petersburg, FL 33701 USA	State University System of Florida; University of South Florida	Lavi, RF (corresponding author), Univ S Florida, Dept Pediat, St Petersburg, FL 33701 USA.				NIAID NIH HHS [R01 AI47723-04A1] Funding Source: Medline; PHS HHS [R60 MC 00003-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047723] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARRETT DJ, 1981, J CLIN LAB IMMUNOL, V6, P1; Chinen J, 2005, J ALLERGY CLIN IMMUN, V116, P411, DOI 10.1016/j.jaci.2005.05.010; Chinen J, 2003, J ALLERGY CLIN IMMUN, V111, P573, DOI 10.1067/mai.2003.165; IWATA T, 1981, AM J MED, V71, P385, DOI 10.1016/0002-9343(81)90164-9; Kong FK, 1998, IMMUNITY, V8, P97, DOI 10.1016/S1074-7613(00)80462-8; Kornfeld SJ, 2000, J ALLERGY CLIN IMMUN, V105, P983, DOI 10.1067/mai.2000.105527; Markert ML, 1998, J PEDIATR-US, V132, P15, DOI 10.1016/S0022-3476(98)70478-0; Perez E, 2002, CURR OPIN PEDIATR, V14, P678, DOI 10.1097/00008480-200212000-00005	8	11	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2006	118	5					1184	1186		10.1016/j.jaci.2006.07.052	http://dx.doi.org/10.1016/j.jaci.2006.07.052			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137GY	17088147				2022-12-18	WOS:000244282300027
J	Kespohl, S; Merget, R; Overlack, K; Raulf-Heimsoth, M				Kespohl, Sabine; Merget, Rolf; Overlack, Kvel; Raulf-Heimsoth, Monika			Detection of novel occupational wood allergens in locust wood dust (Robinia pseudoacacia L.)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ASTHMA; IDENTIFICATION		Ruhr Univ Bochum, BGFA, Res Inst Occupat Med Berufsgenossenschaften, D-4630 Bochum, Germany	Ruhr University Bochum	Kespohl, S (corresponding author), Ruhr Univ Bochum, BGFA, Res Inst Occupat Med Berufsgenossenschaften, Univ Str 150, D-4630 Bochum, Germany.			Kespohl, Sabine/0000-0001-7571-1323				Alday E, 2005, J ALLERGY CLIN IMMUN, V115, P634, DOI 10.1016/j.jaci.2004.10.052; Algranti E, 2005, J INVEST ALLERG CLIN, V15, P81; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Ferrer A, 2001, J INVEST ALLERG CLIN, V11, P199; Kespohl S, 2005, ALLERGY, V60, P808, DOI 10.1111/j.1398-9995.2005.00794.x; Quirce S, 2000, J ALLERGY CLIN IMMUN, V106, P400, DOI 10.1067/mai.2000.107601; Sander I, 2005, INT ARCH ALLERGY IMM, V136, P39, DOI 10.1159/000082583; van Ree R, 2002, INT ARCH ALLERGY IMM, V129, P189, DOI 10.1159/000066770; Vieths S, 2002, ANN NY ACAD SCI, V964, P47	9	11	11	1	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					522	524		10.1016/j.jaci.2006.03.042	http://dx.doi.org/10.1016/j.jaci.2006.03.042			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	075IH	16890782				2022-12-18	WOS:000239877700033
J	Covar, RA; Colvin, R; Shapiro, G; Strunk, R				Covar, RA; Colvin, R; Shapiro, G; Strunk, R			Safety of methacholine challenges in a multicenter pediatric asthma study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INHALED HISTAMINE; CHILDHOOD		Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; Johns Hopkins Ctr Clin Trials, Baltimore, MD USA; NW Allergy & Asthma Ctr, Seattle, WA USA; St Louis Childrens Hosp, St Louis, MO 63178 USA	National Jewish Health; Johns Hopkins University; St. Louis Children's Hospital; Washington University (WUSTL)	Covar, RA (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.				NCRR NIH HHS [M01RR00051, M01RR0099718-24, M01RR02719-14, RR00036] Funding Source: Medline; NHLBI NIH HHS [N01-HR-16044, N01-HR-16045, N01-HR-16046, N01-HR-16047, N01-HR-16048, N01-HR-16051, N01-HR-16052, N01-HR-16050, N01-HR-16049] Funding Source: Medline; DIVISION OF LUNG DISEASES [N01HR016049, N01HR016046, N01HR016045, N01HR016044, N01HR016051, N01HR016050, N01HR016048, N01HR016052, N01HR016047] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002719, M01RR000051] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; *CHILDH ASTHM MAN, 1997, CHILDH ASTHM MAN PRO; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; Rasmussen F, 2002, J ALLERGY CLIN IMMUN, V110, P220, DOI 10.1067/mai.2002.125295; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Weiss ST, 2000, AM J RESP CRIT CARE, V162, P50, DOI 10.1164/ajrccm.162.1.9811005	8	11	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					709	711		10.1016/j.jaci.2006.01.010	http://dx.doi.org/10.1016/j.jaci.2006.01.010			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY	16522478				2022-12-18	WOS:000236263100034
J	Apter, AJ				Apter, AJ			The influence of health disparities on individual patient outcomes: What is the link between genes and environment?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						asthma; health disparities; race-ethnicity; genentics	SOCIOECONOMIC-STATUS; RACE		Univ Penn, Div Pulm Allergy Crit Care Med, Dept Med, Philadelphia, PA USA	University of Pennsylvania	Apter, AJ (corresponding author), Hosp Univ Penn, 829 Gates Bldg,3600 Spruce St, Philadelphia, PA 19104 USA.	apter@mail.med.upenn.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL004337] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL K23 04337] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barnes KC, 2006, J ALLERGY CLIN IMMUN, V117, P243, DOI 10.1016/j.jaci.2005.11.030; HAAS JS, 1994, J GEN INTERN MED, V9, P121, DOI 10.1007/BF02600024; *I MED, 2003, UN TREATM CONFR RAC; Johnson RL, 2004, AM J PUBLIC HEALTH, V94, P2084, DOI 10.2105/AJPH.94.12.2084; Joseph CLM, 2006, J ALLERGY CLIN IMMUN, V117, P233, DOI 10.1016/j.jaci.2005.11.004; Leech Kenneth, 1989, QUESTION DISPUTE DEB; Phelan JC, 2004, J HEALTH SOC BEHAV, V45, P265, DOI 10.1177/002214650404500303; Rebbeck TR, 2005, CANCER EPIDEM BIOMAR, V14, P2467, DOI 10.1158/1055-9965.EPI-05-0649; STAPLES B, 2005, NY TIMES        1031, pA18; van Ryn M, 2000, SOC SCI MED, V50, P813, DOI 10.1016/S0277-9536(99)00338-X; van Ryn M, 2002, MED CARE, V40, P140	11	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2					345	350		10.1016/j.jaci.2005.11.026	http://dx.doi.org/10.1016/j.jaci.2005.11.026			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IM	16461135	Bronze			2022-12-18	WOS:000235687300017
J	Busse, W; Gross, G; Korenblat, P; Nayak, N; Tarpay, M; Levitt, D				Busse, W; Gross, G; Korenblat, P; Nayak, N; Tarpay, M; Levitt, D			Phase 2/3 study of the novel vaccine amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate AIC in ragweed-allergic adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	62nd Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 03-07, 2006	Miami Beach, FL	Amer Acad Allergy, Asthma & Immunol					Univ Wisconsin, Sch Med, Madison, WI USA; Pharmaceut Res & Consulting Inc, Dallas, TX USA; LLC, Clin Res Ctr, St Louis, MO USA; Sneeze Wheeze & Itch Associates, Normal, IL USA; Allergy Asthma & Clin Res Ctr, Oklahoma City, OK USA; Dynavax Technol, Berkeley, CA USA	University of Wisconsin System; University of Wisconsin Madison									0	11	11	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2		S		345	S88	S89		10.1016/j.jaci.2005.12.354	http://dx.doi.org/10.1016/j.jaci.2005.12.354			2	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	019VR					2022-12-18	WOS:000235865300345
J	Kendall, M; Mitchell, TJ; Costigan, G; Armitage, M; Lenzo, JC; Thomas, JA; von Garnier, C; Zosky, GR; Turner, DJ; Stumbles, PA; Sly, PD; Holt, PG; Thomas, WR				Kendall, M; Mitchell, TJ; Costigan, G; Armitage, M; Lenzo, JC; Thomas, JA; von Garnier, C; Zosky, GR; Turner, DJ; Stumbles, PA; Sly, PD; Holt, PG; Thomas, WR			Downregulation of IgE antibody and allergic responses in the lung by epidermal biolistic microparticle delivery	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						desensitization; biolistic; Langerhans; IgE; eosinophilic; lung function	DENDRITIC CELLS; LANGERHANS CELLS; IMMUNE-RESPONSES; ORAL TOLERANCE; MURINE MODEL; IMMUNOTHERAPY; ANTIGEN; AIRWAY; IMMUNOGENICITY; IMMUNIZATION	Background: Biolistic injections provide a needle-free delivery of antigen-laden microparticles to the epithelium. The precision of the injection preferentially targets the Langerhans cell network, which, although ideal for vaccination, might not be suitable for the downregulation of immune responses in immunotherapy. Objective: We sought to determine the ability of biolistic injection of antigen into the epithelium of sensitized mice to inhibit IgE antibody and lung inflammatory responses produced by further exposure to antigen. Methods: Mice were sensitized by means of a needle injection of ovalbumin (OVA) in alum and given a series of biolistic injections of OVA or vehicle control, followed by a boost of OVA in alum. Serum IgE and IgG antibodies were measured before and after the boost. The mice were then challenged intranasally, and the infiltration of inflammatory cells was measured by means of bronchoalveolar lavage. Airway reactivity of the challenged mice was measured by examining responses to methacholine with forced oscillatory techniques. Results: Biolistic injection of OVA into the dorsal skin of sensitized mice markedly inhibited IgE and IgG1 antibody responses induced by boosting. IgG2a antibody responses were reduced rather than stimulated. The eosinophilic inflammation in the bronchoalveolar lavage fluid induced by intranasal challenge was also markedly inhibited. Lung hyperreactivity showed an initial increase and then a decrease of responsiveness to methacholine, with elastance returning to the level of unsensitized mice. Biolistic injection into the buccal epithelium was also inhibitory. Conclusions: Biolistic injection of allergen inhibited the boosting of IgE antibody and eosinophilic lung inflammatory responses without inducing TO immunity.	Univ Western Australia, Telethon Inst Child Hlth Res, Perth, WA 6872, Australia; Univ Western Australia, Ctr Child Hlth Res, Perth, WA, Australia; Univ Oxford, PowderJect Ctr Gene & Drug Delivery Res, Oxford, England	Telethon Kids Institute; University of Western Australia; University of Western Australia; University of Oxford	Thomas, WR (corresponding author), Univ Western Australia, Telethon Inst Child Hlth Res, POB 855, Perth, WA 6872, Australia.	mark.kendall@eng.ox.ac.uk	Kendall, Mark/M-4122-2017; Holt, Patrick G/H-1548-2011; Sly, Peter D/F-1486-2010; Zosky, Graeme/B-2048-2014	Holt, Patrick G/0000-0003-1193-0935; Sly, Peter D/0000-0001-6305-2201; Lenzo, Jason/0000-0002-0564-9250; Mitchell, Thomas/0000-0003-0761-9503; Zosky, Graeme/0000-0001-9039-0302; von Garnier, Christophe/0000-0003-3585-9176				Allan RS, 2003, SCIENCE, V301, P1925, DOI 10.1126/science.1087576; Bacci S, 1998, J INVEST DERMATOL, V111, P1134, DOI 10.1046/j.1523-1747.1998.00406.x; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BERGSTRESSER PR, 1980, J INVEST DERMATOL, V74, P77, DOI 10.1111/1523-1747.ep12519909; Burger MS, 2004, J ALLERGY CLIN IMMUN, V114, P1301, DOI 10.1016/j.jaci.2004.08.013; Burkoth TL, 1999, CRIT REV THER DRUG, V16, P331, DOI 10.1615/CritRevTherDrugCarrierSyst.v16.i4.10; Chen Dexiang, 2002, Expert Rev Vaccines, V1, P265, DOI 10.1586/14760584.1.3.265; Chen DX, 2000, NAT MED, V6, P1187, DOI 10.1038/80538; Donahue JG, 1999, ANN ALLERG ASTHMA IM, V82, P339, DOI 10.1016/S1081-1206(10)63282-6; duChatelet IP, 1997, VACCINE, V15, P449, DOI 10.1016/S0264-410X(96)00173-9; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Ennis DP, 2004, CLIN EXP ALLERGY, V34, P1488, DOI 10.1111/j.1365-2222.2004.02042.x; Ford JG, 2001, J IMMUNOL, V167, P1769, DOI 10.4049/jimmunol.167.3.1769; Givens B, 1993, Can Nurse, V89, P37; HANTOS Z, 1992, J APPL PHYSIOL, V72, P168, DOI 10.1152/jappl.1992.72.1.168; JAMICKI AG, 2002, J ALLERGY CLIN IMMUN, V110, P610; Jarnicki AG, 2001, INT IMMUNOL, V13, P1223, DOI 10.1093/intimm/13.10.1223; JOHNSTON SA, 1988, SCIENCE, V240, P1538, DOI 10.1126/science.2836954; Kendall MAF, 2004, EXP FLUIDS, V37, P128, DOI 10.1007/s00348-004-0792-4; Kendall MAF, 2002, SHOCK WAVES, V12, P23, DOI 10.1007/s001930200126; KENDALL MAF, 2000, Patent No. 0002257; LEVINE BB, 1971, INT ARCH ALLER A IMM, V40, P113, DOI 10.1159/000230398; LEVINE BB, 1970, INT ARCH ALLER A IMM, V39, P156, DOI 10.1159/000230343; Li JT, 2003, ANN ALLERG ASTHMA IM, V90, P1, DOI 10.1016/S1081-1206(10)63600-9; Lu SL, 2004, CANCER RES, V64, P4405, DOI 10.1158/0008-5472.CAN-04-1032; Ludwig-Portugall I, 2004, J ALLERGY CLIN IMMUN, V114, P951, DOI 10.1016/j.jaci.2004.06.013; MITCHELL TJ, 2003, BALLISTICS MICRO PAR; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Nettis E, 2002, CLIN EXP ALLERGY, V32, P1745, DOI 10.1046/j.1365-2222.2002.01544.x; Nir Y, 2003, AM J TROP MED HYG, V68, P341, DOI 10.4269/ajtmh.2003.68.341; Norman PS, 1998, J ALLERGY CLIN IMMUN, V102, P1, DOI 10.1016/S0091-6749(98)70046-6; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Panchagnula R, 1997, METHOD FIND EXP CLIN, V19, P335; Passalacqua G, 2004, ANN ALLERG ASTHMA IM, V93, P3, DOI 10.1016/S1081-1206(10)61440-8; Quinlan NJ, 2001, SHOCK WAVES, V10, P395, DOI 10.1007/PL00004052; Randolph DA, 1999, J CLIN INVEST, V104, P1021, DOI 10.1172/JCI7631; Serbina NV, 2003, SCIENCE, V301, P1856, DOI 10.1126/science.1090613; Sly PD, 2003, J APPL PHYSIOL, V94, P1460, DOI 10.1152/japplphysiol.00596.2002; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698; Tobagus IT, 2004, J IMMUNOL, V172, P2274, DOI 10.4049/jimmunol.172.4.2274; van Scott MR, 2000, AM J PHYSIOL-LUNG C, V278, pL667, DOI 10.1152/ajplung.2000.278.4.L667; VANWILSEM EJG, 1994, IMMUNOLOGY, V83, P128; VAZ NM, 1970, SCIENCE, V168, P852, DOI 10.1126/science.168.3933.852; Zhao XY, 2003, J EXP MED, V197, P153, DOI 10.1084/jem.20021109	45	11	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2					275	282		10.1016/j.jaci.2005.09.049	http://dx.doi.org/10.1016/j.jaci.2005.09.049			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IM	16461127				2022-12-18	WOS:000235687300008
J	Srivastava, KD; Zhang, T; Qu, C; Sampson, HA; Li, XM				Srivastava, KD; Zhang, T; Qu, C; Sampson, HA; Li, XM			Silencing peanut allergy: A Chinese herbal formula, Fahf-2, completely blocks peanut-induced anaphylaxis for up to 6 months following therapy in a murine model of peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	62nd Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 03-07, 2006	Miami Beach, FL	Amer Acad Allergy, Asthma & Immunol					Mt Sinai Sch Med, Grad Sch Biol Sci, New York, NY USA	Icahn School of Medicine at Mount Sinai									0	11	12	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2		S		1264	S328	S328		10.1016/j.jaci.2005.12.1292	http://dx.doi.org/10.1016/j.jaci.2005.12.1292			1	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	019VR					2022-12-18	WOS:000235865302342
J	Vaidyanathan, V; Miguel, AG; Taylor, PE; Flagan, RC; Glovsky, MM				Vaidyanathan, V; Miguel, AG; Taylor, PE; Flagan, RC; Glovsky, MM			Effects of electric fields on pollen rupture	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	62nd Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 03-07, 2006	Miami Beach, FL	Amer Acad Allergy, Asthma & Immunol					CALTECH, Pasadena, CA 91125 USA; HMRI, Huntington Asthma & Allergy Ctr, Pasadena, CA USA	California Institute of Technology; Huntington Medical Research Institutes			vaidyanathan, venkatraman/AAD-9939-2020						0	11	11	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2		S		610	S157	S157		10.1016/j.jaci.2005.12.625	http://dx.doi.org/10.1016/j.jaci.2005.12.625			1	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	019VR					2022-12-18	WOS:000235865301107
J	Miller, MM; Miller, MM				Miller, MM; Miller, MM			beta-blockers and anaphylaxis: Are the risks overstated?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IMMUNOTHERAPY		Univ Tennessee, Hlth Sci Ctr, Knoxville, TN 37909 USA	University of Tennessee System; University of Tennessee Health Science Center	Miller, MM (corresponding author), Univ Tennessee, Hlth Sci Ctr, 1114 Weisgarber Rd, Knoxville, TN 37909 USA.							Alam MM, 2005, J ALLERGY CLIN IMMUN, V115, pS40; BICKELL WH, 1984, ANN EMERG MED, V13, P189, DOI 10.1016/S0196-0644(84)80611-3; GREENBERGER PA, 1987, J ALLERGY CLIN IMMUN, V80, P698, DOI 10.1016/0091-6749(87)90290-9; HEPNER MJ, 1990, J ALLERGY CLIN IMMUN, V86, P407, DOI 10.1016/S0091-6749(05)80105-8; HUNT SA, 2005, ACC AHA GUID EV MAN; LIEBERMAN P, 2005, J ALLERGY CLIN IMMUN, V115, pS483, DOI DOI 10.1016/J.JACI.2005.01.010; Muller UR, 2005, J ALLERGY CLIN IMMUN, V115, P606, DOI [10.1016/j.jaci.2004.11.012, 10.1016/j.jsci.2004.11.012]; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936	8	11	11	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2005	116	4					931	933		10.1016/j.jaci.2005.06.019	http://dx.doi.org/10.1016/j.jaci.2005.06.019			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IF	16210077				2022-12-18	WOS:000235686600038
J	Burger, MS; Zuleger, CL; Chu, QL; Gao, XY; Payne, LG; Chen, DX				Burger, MS; Zuleger, CL; Chu, QL; Gao, XY; Payne, LG; Chen, DX			An antigen-independent but not antigen-specific T(H)1 response provides protection in the murine airway inflammation model	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; airway inflammation; T(H)1; CpG; antigen-independent; immunity; eosinophilia; murine model	EPIDERMAL POWDER IMMUNIZATION; ALLERGEN-SPECIFIC TH1; B SURFACE-ANTIGEN; CPG OLIGODEOXYNUCLEOTIDES; IMMUNOSTIMULATORY DNA; IMMUNE-RESPONSES; MOUSE MODEL; LUNG INFLAMMATION; CUTTING EDGE; ASTHMA	Background: Atopic disorders are associated with an imbalanced T-H cell response biased toward a strong T(H)2 type, resulting in excessive production of IgE antibodies, eosinophil recruitment and activation, and mast cell degranulation. Restoring the T(H)1-T(H)2 balance by,increasing the antigen-specific T(H)1 response has been pursued for specific allergy immunotherapy. Synthetic oligodeoxynucleotides containing unmethylated CG dinucleotides (CpG) are strong T(H)1 adjuvants and are being investigated for allergy immunotherapy. Objective: This study was designed to investigate the protective role of antigen-specific T(H)1 responses induced by epidermal powder immunization with ovalbumin (OVA) and CpG in a marine airway inflammation model. Methods: An allergy model was used in which BALB/c mice were sensitized and then challenged with OVA. Mice received prophylactic or therapeutic immunizations with OVA, CpG, or both. After challenge, pulmonary inflammation and cell infiltration were measured on the basis of BAL cell counts and lung histology. Immune response was determined by measuring the levels of lavage cytokines and serum antibodies. Results: Coadministration of OVA and CpG by means of subcutaneous injection or epidermal powder immunization, although inducing a strong T(H)1 response, neither suppressed T(H)2 cytokines nor offered protection against pulmonary eosinophilia and histopathology in a mouse challenge model. However, when CpG was used as a stand-alone treatment of previously sensitized animals, protection against allergic airway inflammation was observed. After challenge with OVA, eosinophilia was suppressed in the lungs of the CpG-treated mice. Conclusion: This finding argues against the approach of boosting an allergen-dependent T(H)1 response and favors induction of an antigen-independent T(H)1 response for allergy immunotherapy.	PowderJect Vaccines Inc, Middleton, WI USA		Chen, DX (corresponding author), 1455 NW Leary Way, Seattle, WA 98107 USA.	dchen@path.org						*AM AC ALL ASTHM I, 2000, ALL REP SCI BAS FIND; Broide D, 1998, J IMMUNOL, V161, P7054; Broide DH, 2001, J CLIN IMMUNOL, V21, P175, DOI 10.1023/A:1011078930363; CEMBRZYNSKANOWAK M, 1993, AM REV RESPIR DIS, V147, P291, DOI 10.1164/ajrccm/147.2.291; Chen D, 2002, AIDS RES HUM RETROV, V18, P715, DOI 10.1089/088922202760072348; Chen Dexiang, 2002, Expert Rev Vaccines, V1, P265, DOI 10.1586/14760584.1.3.265; Chen DX, 2001, J VIROL, V75, P11630, DOI 10.1128/JVI.75.23.11630-11640.2001; Chuang TH, 2002, J LEUKOCYTE BIOL, V71, P538; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; HOMER AA, 1998, CELL IMMUNOL, V190, P77; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Jahn-Schmid B, 1999, J ALLERGY CLIN IMMUN, V104, P1015, DOI 10.1016/S0091-6749(99)70083-7; Kline JN, 1999, J ALLERGY CLIN IMMUN, V104, P1258, DOI 10.1016/S0091-6749(99)70022-9; Kline JN, 1998, J IMMUNOL, V160, P2555; KUNG TT, 1994, INT ARCH ALLERGY IMM, V105, P83, DOI 10.1159/000236807; Li L, 1998, J IMMUNOL, V161, P3128; McCluskie MJ, 1998, J IMMUNOL, V161, P4463; Osorio JE, 2003, IMMUNOL CELL BIOL, V81, P52, DOI 10.1046/j.1440-1711.2003.01134.x; Randolph DA, 1999, J CLIN INVEST, V104, P1021, DOI 10.1172/JCI7631; Randolph DA, 1999, J IMMUNOL, V162, P2375; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Shirota H, 2000, AM J RESP CELL MOL, V22, P176, DOI 10.1165/ajrcmb.22.2.3772; Shirota H, 2000, J IMMUNOL, V164, P5575, DOI 10.4049/jimmunol.164.11.5575; Sur S, 1999, J IMMUNOL, V162, P6284; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; Wagner H, 2002, CURR OPIN MICROBIOL, V5, P62, DOI 10.1016/S1369-5274(02)00287-4	26	11	11	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2004	114	6					1301	1308		10.1016/j.jaci.2004.08.013	http://dx.doi.org/10.1016/j.jaci.2004.08.013			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	877NN	15577827				2022-12-18	WOS:000225577400008
J	Murphy, JR				Murphy, JR			Statistical errors in immunologic research	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Staiistics; P value; power; errors in reporting; variance	GUIDELINES; JOURNALS; MARKERS; ASTHMA	Medical research articles have always been subject to errors in reporting statistical results. Although most of these are minor, they raise questions about the integrity of medical research. Most of the errors come from a misunderstanding about the tools used in statistical analysis. This article discusses some of the most frequent errors and provides examples of how to deal with them correctly.	Natl Jewish Med & Res Ctr, Div Biostat, Denver, CO 80206 USA	National Jewish Health	Murphy, JR (corresponding author), Natl Jewish Med & Res Ctr, Div Biostat, 1400 Jackson St, Denver, CO 80206 USA.	murphyj@njc.org						Adams RJ, 2003, J ALLERGY CLIN IMMUN, V112, P445, DOI 10.1067/mai.2003.1625; Asero R, 2003, J ALLERGY CLIN IMMUN, V112, P427, DOI 10.1067/mai.2003.1611; BAILAR JC, 1976, CLIN PHARMACOL THER, V20, P113; BAILAR JC, 1988, ANN INTERN MED, V108, P266, DOI 10.7326/0003-4819-108-2-266; Clever LH, 1997, ANN INTERN MED, V126, P36, DOI 10.7326/0003-4819-126-1-199701010-00006; Curran-Everett D, 2000, AM J PHYSIOL-REG I, V279, pR1, DOI 10.1152/ajpregu.2000.279.1.R1; Curran-Everett D, 2004, AM J PHYSIOL-CELL PH, V287, pC243, DOI 10.1152/ajpcell.00250.2004; Eggesbo M, 2003, J ALLERGY CLIN IMMUN, V112, P420, DOI 10.1067/mai.2003.1610; GARCIABERTHOU E, 2004, BMC MED RES METHODOL; Olsen CH, 2003, INFECT IMMUN, V71, P6689, DOI 10.1128/IAI.71.12.6689-6692.2003; Sorensen B, 2003, J ALLERGY CLIN IMMUN, V112, P397, DOI 10.1067/mai.2003.1615; Strunk RC, 2003, J ALLERGY CLIN IMMUN, V112, P883, DOI 10.1016/j.jaci.2003.08.014; WHITE SJ, 1979, BRIT J PSYCHIAT, V135, P336, DOI 10.1192/bjp.135.4.336	13	11	11	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2004	114	6					1259	1264		10.1016/j.jaci.2004.09.023	http://dx.doi.org/10.1016/j.jaci.2004.09.023			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	877NN	15577818	Bronze			2022-12-18	WOS:000225577400001
J	Sutherland, ER				Sutherland, ER			Outpatient treatment of chronic obstructive pulmonary disease: Comparisons with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						chronic obstructive pulmonary disease; asthma; therapy	TUMOR-NECROSIS-FACTOR; LONG-TERM TREATMENT; LUNG-FUNCTION; IPRATROPIUM BROMIDE; AIRWAY-OBSTRUCTION; MACROPHAGE METALLOELASTASE; INHALED CORTICOSTEROIDS; FLUTICASONE PROPIONATE; THEOPHYLLINE TREATMENT; ORAL CORTICOSTEROIDS	Chronic obstructive pulmonary disease (COPD) is a progressive syndrome of expiratory airflow limitation caused by chronic inflammation of the airways and lung parenchyma. The airway inflammatory response in COPD is initiated by smoking in the overwhelming majority of cases, and chronic exposure to cigarette smoke initiates a series of events that cause damage to central airways, peripheral airways, and terminal airspaces, leading to physiologic and clinical abnormalities. The contrasting inflammatory phenotypes of asthma and COPD have important implications for clinical and physiologic manifestations of disease, as well as for therapy. The outpatient treatment of COPD differs from the approach used in asthma and can be divided into 3 subgroups: health care maintenance, drug therapy, and nondrug therapy. Smoking cessation, regular spirometry, and immunization are important components of health care maintenance. Drug therapy consists of optimal bronchodilator therapy supplemented, when necessary, with either inhaled corticosteroids or theophylline. Nondrug therapies include pulmonary rehabilitation, supplemental oxygen, and surgery.	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sutherland, ER (corresponding author), 1400 Jackson St,J217, Denver, CO 80206 USA.	sutherlande@njc.org	Sutherland, Everett Rand/B-7666-2008					Aalbers R, 2002, EUR RESPIR J, V19, P936, DOI 10.1183/09031936.02.00240902; Altose MD, 2000, NEW ENGL J MED, V343, P1902; ANDERSON SD, 1991, CHEST, V100, P1254, DOI 10.1378/chest.100.5.1254; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; [Anonymous], 1980, ANN INTERN MED, V93, P391; Anthonisen NR, 2002, AM J RESP CRIT CARE, V166, P675, DOI 10.1164/rccm.2112096; ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; Arcasoy SM, 1999, NEW ENGL J MED, V340, P1081, DOI 10.1056/NEJM199904083401406; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BARNES PJ, 1994, EUR RESPIR J, V7, P579, DOI 10.1183/09031936.94.07030579; Barnes PJ, 2004, LANCET, V363, P731, DOI 10.1016/S0140-6736(04)15650-X; BARNES PJ, 1995, AM J RESP CRIT CARE, V152, pS125, DOI 10.1164/ajrccm/152.6_Pt_2.S125; Barnes PJ, 1998, J ALLERGY CLIN IMMUN, V102, P531, DOI 10.1016/S0091-6749(98)70268-4; Belman MJ, 1996, AM J RESP CRIT CARE, V153, P967, DOI 10.1164/ajrccm.153.3.8630581; BONE R, 1994, CHEST, V105, P1411; Bouros D, 1999, EUR RESPIR J, V14, P627, DOI 10.1034/j.1399-3003.1999.14c24.x; Buffels J, 2004, CHEST, V125, P1394, DOI 10.1378/chest.125.4.1394; Burge PS, 2000, BMJ-BRIT MED J, V320, P1297, DOI 10.1136/bmj.320.7245.1297; Burge PS, 2003, THORAX, V58, P654, DOI 10.1136/thorax.58.8.654; Calverley P, 2003, LANCET, V361, P449, DOI 10.1016/S0140-6736(03)12459-2; Calverley PM, 2003, EUR RESPIR J, V22, P912, DOI 10.1183/09031936.03.00027003; Calverley PMA, 2003, THORAX, V58, P659, DOI 10.1136/thorax.58.8.659; Casaburi R, 2002, EUR RESPIR J, V19, P217, DOI 10.1183/09031936.02.00269802; Cazzola M, 2000, PULM PHARMACOL THER, V13, P301, DOI 10.1006/pupt.2000.0258; Cazzola M, 2004, PULM PHARMACOL THER, V17, P35, DOI 10.1016/j.pupt.2003.09.001; Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; Chaudhuri R, 2003, AM J RESP CRIT CARE, V168, P1308, DOI 10.1164/rccm.200304-503OC; Churg A, 2003, AM J RESP CRIT CARE, V167, P1083, DOI 10.1164/rccm.200212-1396OC; Churg A, 2002, AM J RESP CELL MOL, V27, P368, DOI 10.1165/rcmb.4791; Clini E, 2002, EUR RESPIR J, V20, P529, DOI 10.1183/09031936.02.02162001; Compton CH, 2001, LANCET, V358, P265, DOI 10.1016/S0140-6736(01)05481-2; Cook D, 2001, AM J RESP CRIT CARE, V163, P85, DOI 10.1164/ajrccm.163.1.2004214; Cosio MG, 1999, AM J RESP CRIT CARE, V160, pS21, DOI 10.1164/ajrccm.160.supplement_1.7; Crescioli S, 1996, ANN ALLERG ASTHMA IM, V77, P106, DOI 10.1016/S1081-1206(10)63495-3; Dahl R, 2001, AM J RESP CRIT CARE, V164, P778, DOI 10.1164/ajrccm.164.5.2007006; DEROM EY, 1992, J ALLERGY CLIN IMMUN, V89, P811, DOI 10.1016/0091-6749(92)90435-5; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; Donaldson GC, 2002, THORAX, V57, P847, DOI 10.1136/thorax.57.10.847; Emtner M, 2003, AM J RESP CRIT CARE, V168, P1034, DOI 10.1164/rccm.200212-1525OC; ERIKSSON S, 1965, ACTA MED SCAND, VS177, P5; *EXP PAN REP 2, 1997, PUBL NAT I HLTH NAT; Fabbri LM, 2003, EUR RESPIR J, V22, P1, DOI 10.1183/09031936.03.00063703; FERREIRA IM, 2003, COCHRANE DB SYST REV, P1; FINKELSTEIN R, 1995, AM J RESP CRIT CARE, V152, P1666, DOI 10.1164/ajrccm.152.5.7582312; Fishman A, 2003, NEW ENGL J MED, V348, P2059; Fishman A, 2001, NEW ENGL J MED, V345, P1075; FLENLEY DC, 1981, LANCET, V1, P681; FLETCHER C, 1977, BMJ-BRIT MED J, V1, P1645, DOI 10.1136/bmj.1.6077.1645; GrayDonald K, 1996, AM J RESP CRIT CARE, V153, P961, DOI 10.1164/ajrccm.153.3.8630580; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; Griffiths TL, 2000, LANCET, V355, P362, DOI 10.1016/S0140-6736(99)07042-7; GROSS NJ, 1989, AM REV RESPIR DIS, V139, P1188, DOI 10.1164/ajrccm/139.5.1188; Hanania NA, 2003, CHEST, V124, P834, DOI 10.1378/chest.124.3.834; HIGGINS BG, 1991, EUR RESPIR J, V4, P415; HOGG JC, 1968, NEW ENGL J MED, V278, P1355, DOI 10.1056/NEJM196806202782501; Hogg JC, 2002, THORAX, V57, P830, DOI 10.1136/thorax.57.9.830; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; Israel E, 2001, NEW ENGL J MED, V345, P941, DOI 10.1056/NEJMoa002304; JONES DJM, 1995, AM J RESP CRIT CARE, V152, P538; Kamada AK, 1996, AM J RESP CRIT CARE, V153, P1739, DOI 10.1164/ajrccm.153.6.8665030; Kraft M, 1996, J ALLERGY CLIN IMMUN, V97, P1242, DOI 10.1016/S0091-6749(96)70191-4; Lacasse Y, 1996, LANCET, V348, P1115, DOI 10.1016/S0140-6736(96)04201-8; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; Lemanske RF, 2001, JAMA-J AM MED ASSOC, V285, P2594, DOI 10.1001/jama.285.20.2594; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; Mannino DM, 2003, THORAX, V58, P388, DOI 10.1136/thorax.58.5.388; MCKAY SE, 1993, THORAX, V48, P227, DOI 10.1136/thx.48.3.227; Morgan MDL, 2001, THORAX, V56, P827; Nichol KL, 2003, NEW ENGL J MED, V348, P1322, DOI 10.1056/NEJMoa025028; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; O'Donnell DE, 2004, EUR RESPIR J, V23, P832, DOI 10.1183/09031936.04.00116004; O'Donnell DE, 1999, AM J RESP CRIT CARE, V160, P542, DOI 10.1164/ajrccm.160.2.9901038; O'Donnell Denis E, 2003, Can Respir J, V10 Suppl A, p11A; O'Donoghue FJ, 2002, THORAX, V57, P533, DOI 10.1136/thorax.57.6.533; Page CP, 1998, EUR RESPIR J, V12, P24, DOI 10.1183/09031936.98.12010024; PATESSIO A, 1991, EUR RESPIR J, V4, P296; Pauwels RA, 1999, NEW ENGL J MED, V340, P1948, DOI 10.1056/NEJM199906243402503; Pearson MG, 1997, THORAX, V52, pS1; PerezPadilla R, 1996, AM J RESP CRIT CARE, V154, P701, DOI 10.1164/ajrccm.154.3.8810608; PETRIE GR, 1975, BRIT MED J, V1, P430, DOI 10.1136/bmj.1.5955.430; Ram FSF, 2003, THORAX, V58, P580, DOI 10.1136/thorax.58.7.580; RAMSDALE EH, 1991, AM REV RESPIR DIS, V143, P998, DOI 10.1164/ajrccm/143.5_Pt_1.998; Rennard SI, 2001, AM J RESP CRIT CARE, V163, P1087, DOI 10.1164/ajrccm.163.5.9903053; Rigotti NA, 2002, NEW ENGL J MED, V346, P506, DOI 10.1056/NEJMcp012279; SAETTA M, 1993, AM REV RESPIR DIS, V147, P301, DOI 10.1164/ajrccm/147.2.301; Saetta M, 1998, AM J RESP CRIT CARE, V157, P822, DOI 10.1164/ajrccm.157.3.9709027; SAETTA M, 1994, AM J RESP CRIT CARE, V150, P1646, DOI 10.1164/ajrccm.150.6.7952628; SHAW NJ, 1986, ARCH DIS CHILD, V61, P788, DOI 10.1136/adc.61.8.788; SIMONS FER, 1992, J ALLERGY CLIN IMMUN, V90, P840, DOI 10.1016/0091-6749(92)90110-N; Spencer S, 2001, AM J RESP CRIT CARE, V163, P122, DOI 10.1164/ajrccm.163.1.2005009; Spina D, 1998, CLIN EXP ALLERGY, V28, P24; Stanescu D, 1996, THORAX, V51, P267, DOI 10.1136/thx.51.3.267; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; SULLIVAN P, 1994, LANCET, V343, P1006, DOI 10.1016/S0140-6736(94)90127-9; Sutherland ER, 2004, NEW ENGL J MED, V350, P2689, DOI 10.1056/NEJMra030415; Sutherland ER, 2003, J ALLERGY CLIN IMMUN, V112, P819, DOI 10.1016/S0091-6749(03)02011-6; Tashkin DP, 1996, AM J RESP CRIT CARE, V153, P1802, DOI 10.1164/ajrccm.153.6.8665038; TASHKIN DP, 1992, AM REV RESPIR DIS, V145, P301, DOI 10.1164/ajrccm/145.2_Pt_1.301; TOOGOOD JH, 1980, J ALLERGY CLIN IMMUN, V65, P145, DOI 10.1016/0091-6749(80)90200-6; TWENTYMAN OP, 1990, LANCET, V336, P1338, DOI 10.1016/0140-6736(90)92894-N; van Noord JA, 2000, EUR RESPIR J, V15, P878, DOI 10.1034/j.1399-3003.2000.15e11.x; Verberne AAPH, 1997, AM J RESP CRIT CARE, V156, P688, DOI 10.1164/ajrccm.156.3.9611067; Vestbo J, 1999, LANCET, V353, P1819, DOI 10.1016/S0140-6736(98)10019-3; WAAGE A, 1988, IMMUNOLOGY, V63, P299; Wadbo M, 2002, EUR RESPIR J, V20, P1138, DOI 10.1183/09031936.02.00301702; Walsh LJ, 2001, THORAX, V56, P279, DOI 10.1136/thorax.56.4.279; WILSON JW, 1994, AM J RESP CRIT CARE, V149, P86, DOI 10.1164/ajrccm.149.1.8111605; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590; Zuhlke IE, 2003, EUR RESPIR J, V22, P926, DOI 10.1183/09031936.03.00046203; ZuWallack RL, 2001, CHEST, V119, P1661, DOI 10.1378/chest.119.6.1661	112	11	12	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					715	724		10.1016/j.jaci.2004.07.044	http://dx.doi.org/10.1016/j.jaci.2004.07.044			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480305	Bronze			2022-12-18	WOS:000224439100001
J	Cohen, SG; Zelaya-Quesada, M				Cohen, SG; Zelaya-Quesada, M			Prausnitz and Kustner phenomenon: The P-K reaction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							PASSIVE TRANSFER; ATOPIC REAGIN; HYPERSENSITIVENESS; SKIN; ANTIBODY; SENSITIVITY; ASTHMA; SERUM		NIAID, NIH, Bethesda, MD 20892 USA; NIH, Hist Med Div, Natl Lib Med, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Cohen, SG (corresponding author), NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.							Bell SD, 1931, J IMMUNOL, V20, P447; BIEBERSTIEN H, 1926, Z IMMUN EXP THER, V48, P297; Brunner M, 1928, ARCH INTERN MED, V42, P172, DOI 10.1001/archinte.1928.00130200024002; Brunner M, 1928, J IMMUNOL, V15, P83; Coca AF, 1925, J IMMUNOL, V10, P445; COHEN MB, 1930, J ALLERGY, V1, P529; COOKE RA, 1935, J EXP MED, V69, P723; Cowie DM, 1937, ANN INTERN MED, V11, P949, DOI 10.7326/0003-4819-11-6-949; CRIEP LH, 1937, JAMA-J AM MED ASSOC, V110, P506; DEBESCHE A, 1923, AM J MED SCI, V266, P265; Du Bois RO, 1925, P SOC EXP BIOL MED, V23, P176; DUKE WW, 1926, ALLERGY ASTHMA HAY F, P128; Fineman AH, 1926, J IMMUNOL, V12, P191; Freeman J, 1925, P ROY SOC MED, V18, P29; Gay LN, 1927, B JOHNS HOPKINS HOSP, V40, P270; ISHIZAKA K, 1967, J IMMUNOL, V99, P849; Levine P, 1926, J IMMUNOL, V11, P449; Levine P, 1926, J IMMUNOL, V11, P435; Levine P, 1926, J IMMUNOL, V11, P411; LONDON M, 1940, J ALLERGY, V12, P244; OVARY Z, 1958, PROG ALLERGY, V5, P459, DOI 10.1159/000277653; PATTERSON R, 1962, J IMMUNOL, V88, P262; PRAUSNITZ C, 1921, ZBL BAKT           1, V86, P160; Ramirez MA, 1919, J AMER MED ASSOC, V73, P984, DOI 10.1001/jama.1919.02610390036012; ROWE AH, 1931, FOOD ALLERGY ITS MAN, P364; SAMTER M, 1947, P SOC EXP BIOL MED, V65, P140; Sherman WB, 1940, J EXP MED, V72, P611, DOI 10.1084/jem.72.5.611; STANWORTH DR, 1963, ADV IMMUNOL, V3, P194; Tuft L, 1928, AM J MED SCI, V176, P707, DOI 10.1097/00000441-192811000-00011; Tuft L, 1929, J IMMUNOL, V16, P411; VANDERVEER A, 1927, AM J MED SCI, V164, P101; Walzer A, 1938, ARCH DERMATOL SYPH, V38, P1; Walzer M, 1925, J IMMUNOL, V10, P835; WALZER M, 1931, ASTHMA HAY FEVER THE, P330; Walzer M, 1947, ALLERGY THEORY PRACT, P507; Wright GP, 1941, J PATHOL BACTERIOL, V53, P243, DOI 10.1002/path.1700530208	36	11	11	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					705	710		10.1016/j.jaci.2004.06.039	http://dx.doi.org/10.1016/j.jaci.2004.06.039			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	853AX	15356578	Bronze			2022-12-18	WOS:000223799600041
J	Eberlein-Konig, B; Ring, J				Eberlein-Konig, B; Ring, J			Diagnosis of IgE-mediated hymenoptera venom anaphylaxis in patients with negative skin tests and negative RAST using cellular in vitro tests	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Tech Univ Munich, Natl Res Ctr Environm & Hlth, Div Environm Dermatol & Allergol, Neuherberg, Germany; Tech Univ Munich, Dept Dermatol & Allergy Biederstein, D-8000 Munich, Germany	Technical University of Munich; Technical University of Munich	Eberlein-Konig, B (corresponding author), Tech Univ Munich, Natl Res Ctr Environm & Hlth, Div Environm Dermatol & Allergol, Neuherberg, Germany.		Ring, Johannes/GLN-4341-2022	Ring, Johannes/0000-0001-8236-3152				DEWECK AL, 1993, ALLERGY CLIN IMMUNOL, V5, P9; EBERLEINKONIG B, 2003, IN PRESS J INVESTIG; Golden DBK, 2003, J ALLERGY CLIN IMMUN, V112, P495, DOI [10.1067/mai.2003.1606, 10.1016/S0091-6749(03)01537-9]; Rueff F, 2000, ALLERGO J, V9, P458	4	11	11	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1223	1223		10.1016/j.jaci.2004.01.770	http://dx.doi.org/10.1016/j.jaci.2004.01.770			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	829ZI	15214364				2022-12-18	WOS:000222091000035
J	Park, HS; Kim, KU; Lee, YM; Choi, JH; Lee, JH; Park, SW; Jang, AS; Park, CS				Park, HS; Kim, KU; Lee, YM; Choi, JH; Lee, JH; Park, SW; Jang, AS; Park, CS			Occupational asthma and IgE sensitization to 7-aminocephalosporanic acid	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Ajou Univ, Sch Med, Suwon, South Korea; Soonchunhyang Univ Hosp, Asthma Genome Res Grp, Bucheon, South Korea	Ajou University; Soonchunhyang University; Soonchunhyang University Hospital	Park, HS (corresponding author), Ajou Univ, Sch Med, Suwon, South Korea.		JANG, AN-SOO/A-4686-2011; Park, Hae-Sim/S-7974-2019	Park, Hae-Sim/0000-0003-2614-0303; Lee, Young Mok/0000-0003-4039-0456; Park, Choon-Sik/0000-0003-2977-0255				Fracchia G, 1996, G Ital Med Lav, V18, P3; Sastre J, 1999, EUR RESPIR J, V13, P1189, DOI 10.1034/j.1399-3003.1999.13e40.x; STENTON SC, 1995, EUR RESPIR J, V8, P1421, DOI 10.1183/09031936.95.08081421; Suh YJ, 2003, J ALLERGY CLIN IMMUN, V112, P209, DOI 10.1067/mai.2003.1525	4	11	11	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2004	113	4					785	787		10.1016/j.jaci.2003.12.035	http://dx.doi.org/10.1016/j.jaci.2003.12.035			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	814DY	15112669				2022-12-18	WOS:000220956600031
J	Gorska, MM; Alam, R				Gorska, MM; Alam, R			Signaling molecules as therapeutic targets in allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						signal transduction; therapy; allergy; asthma	T-CELL-ACTIVATION; NF-KAPPA-B; PROTEIN-TYROSINE KINASES; AIRWAY INFLAMMATION; ANTIGEN RECEPTOR; IMMUNE-SYSTEM; EOSINOPHIL DIFFERENTIATION; ANTISENSE OLIGONUCLEOTIDES; CYTOKINE EXPRESSION; NEGATIVE REGULATION	A molecular understanding of physiologic and pathologic processes requires complete knowledge about the signal transduction mechanism of involved cells. Signal transduction research is a rapidly growing field in basic science. Unlike intercellular inflammatory mediators, signaling molecules show less functional redundancy. This allows inhibition of multiple cytokines/mediators by blocking one common signaling molecule. Interference with signaling pathways has shown significant potential for inhibition of fundamental processes as well as clinical phenotype of allergic diseases. The purpose of this review was to provide a theoretical classification of signaling molecules based on their function and to analyze various strategies for developing effective signaling inhibitors for allergic diseases.	Natl Jewish Med & Res Ctr, Div Allergy & Immunol, Denver, CO 80206 USA; Univ Colorado, Ctr Hlth Sci, Denver, CO 80202 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Alam, R (corresponding author), 1400 Jackson St, Denver, CO 80206 USA.							Adachi T, 1999, J IMMUNOL, V163, P939; Adachi T, 2003, J ALLERGY CLIN IMMUN, V111, P113, DOI 10.1067/mai.2003.27; Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Agrawal S, 1997, P NATL ACAD SCI USA, V94, P2620, DOI 10.1073/pnas.94.6.2620; Akimoto T, 1998, J EXP MED, V187, P1537, DOI 10.1084/jem.187.9.1537; Alcock RA, 2002, ONCOGENE, V21, P7883, DOI 10.1038/sj.onc.1205948; Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818; Amin R, 2002, J PHARMACOL EXP THER, V303, P82, DOI 10.1124/jpet.102.036160; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baron BW, 2002, P NATL ACAD SCI USA, V99, P2860, DOI 10.1073/pnas.042702599; Bolland S, 1999, ADV IMMUNOL, V72, P149, DOI 10.1016/S0065-2776(08)60019-X; Bordier BB, 2002, J VIROL, V76, P10465, DOI 10.1128/JVI.76.20.10465-10472.2002; Brassard DL, 2002, EXP CELL RES, V273, P138, DOI 10.1006/excr.2001.5440; Bruhns P, 2000, J BIOL CHEM, V275, P37357, DOI 10.1074/jbc.M003518200; Bukrinsky MI, 2002, TRENDS IMMUNOL, V23, P323, DOI 10.1016/S1471-4906(02)02237-8; Chitnis T, 2001, J CLIN INVEST, V108, P739, DOI 10.1172/JCI200112563; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Donovan CE, 1999, J IMMUNOL, V163, P6827; DOro U, 1997, IMMUNITY, V7, P619, DOI 10.1016/S1074-7613(00)80383-0; Dumont FJ, 2000, CURR MED CHEM, V7, P731, DOI 10.2174/0929867003374723; Egan PJ, 2003, J CLIN INVEST, V111, P915, DOI 10.1172/JCI200316156; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Ettenberg S A, 1999, Mol Cell Biol Res Commun, V2, P111, DOI 10.1006/mcbr.1999.0157; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Finotto S, 2001, J EXP MED, V193, P1247, DOI 10.1084/jem.193.11.1247; Flaswinkel H, 1995, Semin Immunol, V7, P21, DOI 10.1016/1044-5323(95)90004-7; Fowell DJ, 1999, IMMUNITY, V11, P399, DOI 10.1016/S1074-7613(00)80115-6; Goldman FD, 1998, J CLIN INVEST, V102, P421, DOI 10.1172/JCI3205; Greenwood J, 2003, FASEB J, V17, P905, DOI 10.1096/fj.02-1014fje; Grootendorst DC, 2002, CURR OPIN ALLERGY CL, V2, P61, DOI 10.1097/00130832-200202000-00010; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Habisch HJ, 2003, MOL PHARMACOL, V63, P682, DOI 10.1124/mol.63.3.682; Hartenstein B, 2002, EMBO J, V21, P6321, DOI 10.1093/emboj/cdf648; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; Hilliard BA, 2002, J CLIN INVEST, V110, P843, DOI 10.1172/JCI200215254; Isakov N, 2002, ANNU REV IMMUNOL, V20, P761, DOI 10.1146/annurev.immunol.20.100301.064807; Jordan MS, 2003, NAT IMMUNOL, V4, P110, DOI 10.1038/ni0203-110; Kamata T, 2003, J CLIN INVEST, V111, P109, DOI 10.1172/JCI200315719; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Kim JI, 1999, IMMUNITY, V10, P745, DOI 10.1016/S1074-7613(00)80073-4; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Kumano K, 2000, BIOCHEM BIOPH RES CO, V270, P209, DOI 10.1006/bbrc.2000.2403; Latour S, 2001, CURR OPIN IMMUNOL, V13, P299, DOI 10.1016/S0952-7915(00)00219-3; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lewandoski M, 2001, NAT REV GENET, V2, P743, DOI 10.1038/35093537; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; Lobell RB, 2002, MOL CANCER THER, V1, P747; Loewe R, 2002, J IMMUNOL, V168, P4781, DOI 10.4049/jimmunol.168.9.4781; Lu BF, 2001, IMMUNITY, V14, P583, DOI 10.1016/S1074-7613(01)00141-8; MACGLASHAN D, 1994, J ALLERGY CLIN IMMUN, V94, P1146, DOI 10.1016/0091-6749(94)90324-7; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; Morrow MA, 1999, MOL IMMUNOL, V36, P491, DOI 10.1016/S0161-5890(99)00071-1; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nel AE, 2002, J ALLERGY CLIN IMMUN, V109, P901, DOI 10.1067/mai.2002.124965; Nel AE, 2002, J ALLERGY CLIN IMMUN, V109, P758, DOI 10.1067/mai.2002.124259; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Ott VL, 2000, J ALLERGY CLIN IMMUN, V106, P429, DOI 10.1067/mai.2000.109428; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Pendl GG, 1997, INT ARCH ALLERGY IMM, V112, P392, DOI 10.1159/000237486; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Rao N, 2002, J LEUKOCYTE BIOL, V71, P753; Rao NV, 2002, P NATL ACAD SCI USA, V99, P3794, DOI 10.1073/pnas.062055999; Ray A, 1999, J CLIN INVEST, V104, P985, DOI 10.1172/JCI8204; Saijo K, 2003, NAT IMMUNOL, V4, P274, DOI 10.1038/ni893; Samuelsson A, 2001, SCIENCE, V291, P484, DOI 10.1126/science.291.5503.484; SCHARENBERG AM, 1994, J ALLERGY CLIN IMMUN, V94, P1142, DOI 10.1016/0091-6749(94)90323-9; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Seto Y, 2003, J IMMUNOL, V170, P1077, DOI 10.4049/jimmunol.170.2.1077; Silverman ES, 2002, AM J RESP CELL MOL, V27, P697, DOI 10.1165/rcmb.2002-0011OC; Stafford S, 2002, J IMMUNOL, V168, P1978, DOI 10.4049/jimmunol.168.4.1978; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Stenton GR, 2002, J IMMUNOL, V169, P1028, DOI 10.4049/jimmunol.169.2.1028; Sugai M, 2003, NAT IMMUNOL, V4, P25, DOI 10.1038/ni874; Swinney DC, 2002, J BIOL CHEM, V277, P23573, DOI 10.1074/jbc.M200842200; Takeuchi O, 2002, CURR TOP MICROBIOL, V270, P155; Texido G, 2000, MOL CELL BIOL, V20, P1227, DOI 10.1128/MCB.20.4.1227-1233.2000; Ueda E, 1996, J BIOL CHEM, V271, P9790, DOI 10.1074/jbc.271.16.9790; Underwood DC, 2000, J PHARMACOL EXP THER, V293, P281; Vicentini L, 2002, J IMMUNOL, V168, P6446, DOI 10.4049/jimmunol.168.12.6446; WALDER RY, 1988, P NATL ACAD SCI USA, V85, P5011, DOI 10.1073/pnas.85.14.5011; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; Yablonski D, 2001, ADV IMMUNOL, V79, P93, DOI 10.1016/S0065-2776(01)79003-7; Yasukawa H, 2003, J CLIN INVEST, V111, P469, DOI 10.1172/JCI200316491; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1	96	11	12	1	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					241	250		10.1067/mai.2003.1667	http://dx.doi.org/10.1067/mai.2003.1667			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	709WY	12897726				2022-12-18	WOS:000184650600002
J	Solomon, WR				Solomon, WR			How ill the wind? Issues in aeroallergen sampling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						aeroallergen sampling; aerobiology; pollen; allergens	BURKARD SPORE TRAP; HOUSE-DUST MITES; FUNGAL PROPAGULES; ALLERGEN LEVELS; GRASS-POLLEN; ENDOTOXIN; FIELD; AIR; EXPOSURE; ASTHMA	The effective size of bioaerosols is the principal determinant of their behavior during takeoff, transport, and deposition. Collection methods involving impaction, impingement, and filtration allow recovery of increasingly small aerosol units and do so "per unit volume of processed air" with more or less well-defined efficiency. These principles offer direction in choosing sampling devices for specific applications; similarly, a particle's appearance, growth potential, and assayability define the scope of relevant analyses. Where a variety of aerosol types occur, multiple collection and/or analytic approaches might be required. The development of a sampling grid in North America makes possible studies of distribution, transport, and climatic effects in ways never previously possible; however, some directive planning and oversight are essential to realize these goals. Methods sensitive to paucimicronic and submicronic particles should be included increasingly in new and ongoing survey protocols. Similarly, available means now facilitate study of aerosols at specific sites, both indoors and outdoors, with estimates of personal exposure during defined events. Resulting data describing airborne prevalence gain special value in light of competent inspection of implicated venues and consideration of alternative sources, such as incursion of bioaerosols into enclosed spaces.	Univ Michigan, Med Ctr, Dept Internal Med, Div Allergy,Taubaum Ctr 3918, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Solomon, WR (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, Div Allergy,Taubaum Ctr 3918, Ann Arbor, MI 48109 USA.							*AM C GOV IND HYG, 2000, AIR SAMPL INSTR EV A; Barnes C, 2000, ANN ALLERG ASTHMA IM, V84, P47, DOI 10.1016/S1081-1206(10)62740-8; Bellin P, 2001, INDOOR AIR, V11, P65, DOI 10.1034/j.1600-0668.2001.011001065.x; Cooper JF, 1997, PDA J PHARM SCI TECH, V51, P2; Cruz MJ, 2000, INT ARCH ALLERGY IMM, V122, P42, DOI 10.1159/000024357; Dales RE, 1999, MYCOPATHOLOGIA, V147, P21, DOI 10.1023/A:1007096704217; Douwes J, 1999, J ALLERGY CLIN IMMUN, V103, P494, DOI 10.1016/S0091-6749(99)70476-8; Duchaine C, 2001, APPL ENVIRON MICROB, V67, P2775, DOI 10.1128/AEM.67.6.2775-2780.2001; Frei T, 1997, GRANA, V36, P34, DOI 10.1080/00173139709362587; Frenz DA, 2000, ANN ALLERG ASTHMA IM, V85, P392, DOI 10.1016/S1081-1206(10)62553-7; GREGORY PH, 1978, MICROBIOLOGY ATMOSPH; Hamilton RG, 1997, METHODS, V13, P53, DOI 10.1006/meth.1997.0495; Hauck BC, 1997, AM IND HYG ASSOC J, V58, P713, DOI 10.1202/0002-8894(1997)058<0713:FTONAS>2.0.CO;2; Hollander A, 1999, ALLERGY, V54, P142, DOI 10.1034/j.1398-9995.1999.00630.x; Ingold C., 1971, MYCOLOGIA; Kenny LC, 1999, ANN OCCUP HYG, V43, P393, DOI 10.1016/S0003-4878(99)00042-3; MANJRA A, 1994, S AFR MED J, V84, P220; MCDONALD JL, 1975, J ALLERGY CLIN IMMUN, V55, P89; Miller JD, 1997, AM IND HYG ASSOC J, V58, P39, DOI 10.1080/15428119791013062; Milton DK, 1997, AM IND HYG ASSOC J, V58, P861; Newson R, 1997, THORAX, V52, P680, DOI 10.1136/thx.52.8.680; OLDFIELD R., 1994, LIGHT MICROSCOPY ILL; Park JH, 2001, ENVIRON HEALTH PERSP, V109, P859, DOI 10.2307/3454831; RANSOM JH, 1991, J ALLERGY CLIN IMMUN, V87, P886, DOI 10.1016/0091-6749(91)90138-E; Rantio-Lehtimaki A, 1987, Experientia Suppl, V51, P382; RAYNOR GS, 1973, J ALLERGY CLIN IMMUN, V51, P199, DOI 10.1016/0091-6749(73)90139-5; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; Renstrom A, 2002, CLIN EXP ALLERGY, V32, P1769, DOI 10.1046/j.1365-2222.2002.01545.x; Schei MA, 2002, ALLERGY, V57, P538, DOI 10.1034/j.1398-9995.2002.23433.x; SOLOMON WR, 1980, INT J BIOMETEOROL, V24, P107, DOI 10.1007/BF02253798; SOLOMON WR, 2002, PATTERSONS ALLERGIC; SOLOMON WR, 1991, J ALLERGY CLIN IMMUN, V87, P87; Suphioglu C, 1998, INT ARCH ALLERGY IMM, V116, P253, DOI 10.1159/000023953; THORNE PS, 1994, AM IND HYG ASSOC J, V55, P1072, DOI 10.1202/0002-8894(1994)055<1072:BSIFSC>2.0.CO;2; Thorne PS, 1997, AM IND HYG ASSOC J, V58, P792, DOI 10.1202/0002-8894(1997)058<0792:FEOEAS>2.0.CO;2; Wan GH, 1999, ARCH ENVIRON HEALTH, V54, P172, DOI 10.1080/00039899909602256; WATSON H H, 1954, Am Ind Hyg Assoc Q, V15, P21; Young RS, 1998, J PHARM PHARMACOL, V50, P11, DOI 10.1111/j.2042-7158.1998.tb03299.x; [No title captured]	39	11	12	0	10	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					3	8		10.1067/mai.2003.1599	http://dx.doi.org/10.1067/mai.2003.1599			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847470				2022-12-18	WOS:000184010600001
J	Asero, R				Asero, R			Food additives intolerance: A possible cause of perennial rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Osped Caduti Bollatesi, Ambulatorio Allergol, I-20021 Bollate, MI, Italy		Asero, R (corresponding author), Osped Caduti Bollatesi, Ambulatorio Allergol, Via Piave 20, I-20021 Bollate, MI, Italy.							Asero R, 2002, J ALLERGY CLIN IMMUN, V110, P531, DOI 10.1067/mai.2002.126463; Asero R, 2001, J ALLERGY CLIN IMMUN, V107, P197, DOI 10.1067/mai.2001.112132; Bush R.K., 1998, ALLERGY PRINCIPLES P, VII, P1183; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; SAMPSON HA, 1998, ALLERGY PRINCIPLES P, P1162; Simon RA, 1993, ALLERGY PRINCIPLES P, P1687	6	11	11	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2002	110	6					937	938		10.1067/mai.2002.130054	http://dx.doi.org/10.1067/mai.2002.130054			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	624TL	12464964	Bronze			2022-12-18	WOS:000179777400020
J	Bernardini, R; Novembre, E; Lombardi, E; Pucci, N; Marcucci, F; Vierucci, A				Bernardini, R; Novembre, E; Lombardi, E; Pucci, N; Marcucci, F; Vierucci, A			Anaphylaxis to latex after ingestion of a cream-filled doughnut contaminated with latex	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALLERGY		Univ Florence, Dept Pediat, Anna Meyer Childrens Hosp, Pediat Allergy & Pulmonol Ctr, Florence, Italy; Univ Perugia, Dept Pediat, I-06100 Perugia, Italy	University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; University of Perugia	Bernardini, R (corresponding author), Univ Florence, Dept Pediat, Anna Meyer Childrens Hosp, Pediat Allergy & Pulmonol Ctr, Florence, Italy.		Lombardi, Enrico/K-3356-2016	Lombardi, Enrico/0000-0003-4749-9091				Beezhold DH, 2000, ALLERGY ASTHMA PROC, V21, P301, DOI 10.2500/108854100778248214; Bernardini R, 1998, J UROLOGY, V160, P1775, DOI 10.1016/S0022-5347(01)62403-0; Charous BL, 2002, J ALLERGY CLIN IMMUN, V109, P31, DOI 10.1067/mai.2002.120953; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Hamilton RG, 1997, ANN ALLERG ASTHMA IM, V79, P266, DOI 10.1016/S1081-1206(10)63013-X; Ortiz JCG, 1998, ALLERGY, V53, P532, DOI 10.1111/j.1398-9995.1998.tb04092.x; SCHWARTZ HJ, 1995, J ALLERGY CLIN IMMUN, V95, P139, DOI 10.1016/S0091-6749(95)70165-6	7	11	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					534	535		10.1067/mai.2002.127799	http://dx.doi.org/10.1067/mai.2002.127799			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	592KM	12209111				2022-12-18	WOS:000177936900034
J	Bernstein, DI				Bernstein, DI			Management of natural rubber latex allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Meeting on Natural Rubber Latex Sensitivity	FEB 09-10, 2001	SAN FRANCISCO, CA	Malaysian Rubber Res Inst		latex; allergy; management		Issues of impairment, compensation, and disability are appropriately directed at health care workers with latex allergy and occupational asthma or anaphylaxis who may not be able to re-enter a work environment with ambient exposure to latex proteins. The following stepwise approach for managing a high-risk health care worker with natural rubber latex (NRL) allergy is recommended: (1) confirm the diagnosis of NRL allergy by using rational, validated methods; (2) justify cessation of further NRL exposure in the workplace; (3) determine whether there is impairment and disability resulting from NRL allergy; (4) advise employer and risk managers regarding the diagnosis and their responsibility to institute effective environmental interventions; (5) if accommodation efforts are unsuccessful, advise the worker to seek workers' compensation benefits and rehabilitation. Objective evidence of residual impairment caused by NRL-induced anaphylaxis or occupational asthma is often absent. Therefore, the physician must determine disability based on how work restrictions resulting from NRL allergy affect the worker's ability to perform current required tasks and duties. According to the Americans with Disabilities Act, the employer must make reasonable accommodations for an impaired employee. Therefore, an employee with NRL allergy and no objective evidence of impairment would not be considered to be disabled after successful interventions, which totally eliminate continued NRL protein exposure and the risks of work-related asthma and anaphylaxis.	Univ Cincinnati, Coll Med, Div Immunol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Bernstein, DI (corresponding author), Univ Cincinnati, Coll Med, Div Immunol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.							American Medical Association, 1993, GUID EV PERM IMP; Bernstein DI, 1999, ASTHMA WORKPLACE, P145; BERNSTEIN IL, 1999, ASTHMA WORKPLACE, P1; CHANYEUNG M, 1993, AM REV RESPIR DIS, V147, P1056; DEWITTE JD, 1994, EUR RESPIR J, V7, P969; Hamilton RG, 1999, J ALLERGY CLIN IMMUN, V103, P925, DOI 10.1016/S0091-6749(99)70440-9; Hamilton RG, 1996, J ALLERGY CLIN IMMUN, V98, P872, DOI 10.1016/S0091-6749(96)80003-0; Karnani R, 2001, J ALLERGY CLIN IMMUN, V107, pS242; Kujala VM, 1997, AM J IND MED, V32, P197, DOI 10.1002/(SICI)1097-0274(199709)32:3<197::AID-AJIM3>3.0.CO;2-V; Liss GM, 1997, OCCUP ENVIRON MED, V54, P335, DOI 10.1136/oem.54.5.335; MALO JL, 1991, AM REV RESPIR DIS, V143, P528, DOI 10.1164/ajrccm/143.3.528; Perfetti L, 1998, CHEST, V114, P398, DOI 10.1378/chest.114.2.398; Tarlo S M, 1998, Can Respir J, V5, P289; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54, DOI 10.1164/ajrccm.151.1.7812572	14	11	13	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2		S			S111	S116		10.1067/mai.2002.125330	http://dx.doi.org/10.1067/mai.2002.125330			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	586ET	12170251				2022-12-18	WOS:000177572200016
J	Elliott, BA				Elliott, BA			Latex allergy: The perspective from the surgical suite	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Meeting on Natural Rubber Latex Sensitivity	FEB 09-10, 2001	SAN FRANCISCO, CA	Malaysian Rubber Res Inst		latex allergy; surgical gloves; occupational allergy; health care workers	RUBBER GLOVES; SPINA-BIFIDA; INTRAOPERATIVE ANAPHYLAXIS; OCCUPATIONAL ASTHMA; RISK-FACTORS; PREVALENCE; CONTACT; SENSITIZATION; CONTAMINATION; URTICARIA	Latex allergy in the perioperative setting presents unique challenges to the health care system. Specific needs of the latex-sensitive patient are paramount, but consideration must also include the impact on health care workers vis-a-vis latex sensitization, environmental allergen control, and barrier protection against blood-borne pathogens. It has been well documented that the greatest source of latex aeroallergen in the surgical setting is latex gloves (both sterile and nonsterile). Levels of latex aeroallergen correlate strongly with use of high-allergen and powdered gloves, total number of gloves used, and the hours of activity in a given environment. A significant reduction in aeroallergen (>10-fold) can be achieved by switching to low-allergen gloves. Ready availability of and encouragement to use nonlatex alternatives when appropriate can further reduce exposure to latex allergens. Since 1998, the Food and Drug Administration has required all medical devices (or their packaging) that contain natural rubber latex to be so labeled. In addition, industry has responded with a host of latex-free products for use in patient care. This has helped eliminate a great deal of confusion about which products are safe for use with latex-sensitive individuals. However, despite significant efforts to educate the public and the health care industry regarding latex allergies, considerable misinformation persists. Provision of a completely latex-free environment in most surgical suites may be unrealistic, but every effort should be made to minimize the unnecessary exposure of patients and health care workers to latex allergens in this high-risk arena.	Mayo Clin & Mayo Fdn, Dept Anesthesiol, Mayo Med Sch, Rochester, MN 55905 USA	Mayo Clinic	Elliott, BA (corresponding author), Mayo Clin & Mayo Fdn, Dept Anesthesiol, Mayo Med Sch, 200 1St St SW, Rochester, MN 55905 USA.							Bernardini R, 1999, CLIN EXP ALLERGY, V29, P681; Bowyer RVSL, 1999, J CLIN NURS, V8, P139, DOI 10.1046/j.1365-2702.1999.00262.x; CARRILLO T, 1986, CONTACT DERMATITIS, V15, P69, DOI 10.1111/j.1600-0536.1986.tb01279.x; CHAROUS BL, 1994, J ALLERGY CLIN IMMUN, V94, P12, DOI 10.1016/0091-6749(94)90065-5; DeSwert LFA, 1997, CLIN EXP ALLERGY, V27, P1067; GERBER AC, 1989, ANESTHESIOLOGY, V71, P800, DOI 10.1097/00000542-198911000-00031; HAMANN CP, 1993, AM J INFECT CONTROL, V21, P289, DOI 10.1016/0196-6553(93)90385-H; HEESE A, 1991, J AM ACAD DERMATOL, V25, P831, DOI 10.1016/S0190-9622(08)80977-2; Heilman DK, 1996, J ALLERGY CLIN IMMUN, V98, P325, DOI 10.1016/S0091-6749(96)70157-4; HUNT LW, 1995, J OCCUP ENVIRON MED, V37, P1204, DOI 10.1097/00043764-199510000-00011; Hunt LW, 1996, J OCCUP ENVIRON MED, V38, P765, DOI 10.1097/00043764-199608000-00011; Jones RT, 1998, J ALLERGY CLIN IMMUN, V102, P694, DOI 10.1016/S0091-6749(98)70290-8; KARATHANASIS P, 1993, ANN ALLERGY, V71, P526; KORNIEWICZ DM, 1994, AM J INFECT CONTROL, V22, P12, DOI 10.1016/0196-6553(94)90085-X; KWITTKEN PL, 1992, ALLERGY PROC, V13, P123, DOI 10.2500/108854192778878782; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; Laoprasert N, 1998, J ALLERGY CLIN IMMUN, V102, P998, DOI 10.1016/S0091-6749(98)70338-0; LebenbomMansour MH, 1997, ANESTH ANALG, V85, P44, DOI 10.1097/00000539-199707000-00008; Liss GM, 1997, OCCUP ENVIRON MED, V54, P335, DOI 10.1136/oem.54.5.335; MEEROPOL E, 1993, J PEDIATR ORTHOPED, V13, P1, DOI 10.1097/01241398-199301000-00001; National Institute for Occupational Safety and Health, 1997, DHHS PUBL, V31, P21; Newsom S W, 1998, Ann R Coll Surg Engl, V80, P288; OLSEN RJ, 1993, JAMA-J AM MED ASSOC, V270, P350, DOI 10.1001/jama.270.3.350; Ownby DR, 1996, J ALLERGY CLIN IMMUN, V97, P1188, DOI 10.1016/S0091-6749(96)70183-5; Pereira C, 1999, ALLERGY, V54, P291, DOI 10.1034/j.1398-9995.1999.00954.x; Phillips VL, 1999, AM J PUBLIC HEALTH, V89, P1024, DOI 10.2105/AJPH.89.7.1024; Poley GE, 2000, J ALLERGY CLIN IMMUN, V105, P1054, DOI 10.1067/mai.2000.106925; Porri F, 1997, ANESTHESIOLOGY, V86, P599, DOI 10.1097/00000542-199703000-00011; Rego A, 1999, AM J INFECT CONTROL, V27, P405, DOI 10.1016/S0196-6553(99)70006-4; Senst BL, 1997, AM J HEALTH-SYST PH, V54, P1071, DOI 10.1093/ajhp/54.9.1071; SETLOCK MA, 1993, ANESTH ANALG, V76, P650; SLATER JE, 1992, ANN ALLERGY, V68, P203; STEINER DJ, 1995, J AM COLL SURGEONS, V180, P754; Sussman GL, 1998, J ALLERGY CLIN IMMUN, V101, P171, DOI 10.1016/S0091-6749(98)70381-1; SWANSON MC, 1994, J ALLERGY CLIN IMMUN, V94, P445, DOI 10.1016/0091-6749(94)90199-6; TARLO SM, 1994, J ALLERGY CLIN IMMUN, V93, P985, DOI 10.1016/S0091-6749(94)70045-1; Thomsen DJ, 2000, AM J HEALTH-SYST PH, V57, P44, DOI 10.1093/ajhp/57.1.44; TOMAZIC VJ, 1994, J ALLERGY CLIN IMMUN, V93, P751, DOI 10.1016/0091-6749(94)90255-0; TOSI LL, 1993, J PEDIATR ORTHOPED, V13, P709, DOI 10.1097/01241398-199311000-00003; TURJANMAA K, 1990, LANCET, V336, P1588, DOI 10.1016/0140-6736(90)93372-V; Vandenplas O, 1996, THORAX, V51, P452, DOI 10.1136/thx.51.4.452; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P887; VASSALLO SA, 1995, ANESTH ANALG, V80, P1057, DOI 10.1097/00000539-199505000-00039; YASSIN MS, 1994, ANN ALLERGY, V72, P245; Yip E., 1994, J RUBBER RES, V9, P79; Yunginger J W, 1998, Minn Med, V81, P27; Yunginger JW, 1999, ANN ALLERG ASTHMA IM, V83, P630, DOI 10.1016/S1081-1206(10)62885-2; YUNGINGER JW, 1994, J ALLERGY CLIN IMMUN, V93, P836, DOI 10.1016/0091-6749(94)90374-3; YUNGINGER JW, 1994, ALLERGY PRINCIPLES P, P2; YUNGINGER JW, 1994, ALLERGY PRINCIPLES P, P1073	50	11	11	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2		S			S117	S120		10.1067/mai.2002.125594	http://dx.doi.org/10.1067/mai.2002.125594			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	586ET	12170252				2022-12-18	WOS:000177572200017
J	Becker, AB				Becker, AB			Challenges to treatment goals and outcomes in pediatric asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; pediatric; control; outcomes; goals	QUALITY-OF-LIFE; CATIONIC PROTEIN; CHILDREN	To achieve long-term control in pediatric asthma, it is essential to establish treatment goals acceptable to both the patient and care giver and to choose appropriate outcome measures that will show the benefits of the treatment. Differences between the perceptions of patients and care givers of what constitutes a desirable treatment goal, and poor perception of asthma control by both patient and physician, hinder optimal treatment of asthma. The use of objective outcome measures in pediatric asthma generally can provide a good evaluation of asthma severity as well as a basis for setting treatment goals that are acceptable to patients and care givers alike. Objective measurements that assess airway inflammation, which is the fundamental pathophysiology in asthma and the underlying mechanism for chronic airway remodeling, may be the most useful means for gauging pediatric asthma control and evaluating response to treatment. Techniques such as exhaled nitric oxide analysis, bronchoalveolar lavage, and sputum analysis, although used primarily in research, have successfully identified the level of airway inflammation in children. Furthermore, the association of meaningful outcome measures with education about the long-term effects of uncontrolled asthma and the need for anti-inflammatory treatment should help in developing treatment goals and strategies that will be acceptable to both patient and care giver.	Univ Manitoba, Dept Pediat & Child Hlth, Allergy & Clin Immunol Sect, Winnipeg, MB R3T 2N2, Canada	University of Manitoba	Becker, AB (corresponding author), AE101,840 Sherbrook St, Winnipeg, MB R3A 1S1, Canada.							ADAMS P, 1995, US DHHS PUBLICATION; *AM AC ALL ASTHM I, 1999, PED ASTHM PROM BEST; Bisgaard H, 1999, AM J RESP CRIT CARE, V160, P1227, DOI 10.1164/ajrccm.160.4.9903004; Boulet LP, 1999, CAN MED ASSOC J, V161, pS1; CHAI H, 1968, J ALLERGY, V41, P23, DOI 10.1016/0021-8707(68)90005-1; FERGUSON AC, 1995, J ALLERGY CLIN IMMUN, V95, P23, DOI 10.1016/S0091-6749(95)70148-6; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; Lara M, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.6.e68; Mannino D M, 1998, MMWR CDC Surveill Summ, V47, P1; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Rietveld S, 1996, J ASTHMA, V33, P221, DOI 10.3109/02770909609055363; RUBINFELD AR, 1976, LANCET, V1, P882; Santanello NC, 1999, ARCH DIS CHILD, V80, P414, DOI 10.1136/adc.80.5.414; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Stevenson EC, 1997, CLIN EXP ALLERGY, V27, P1027, DOI 10.1111/j.1365-2222.1997.tb01254.x; Twaddell SH, 1996, EUR RESPIR J, V9, P2104, DOI 10.1183/09031936.96.09102104; ZIMMERMAN B, 1993, CLIN EXP ALLERGY, V23, P564, DOI 10.1111/j.1365-2222.1993.tb00895.x	18	11	12	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2002	109	6		S			S533	S538		10.1067/mai.2002.124567	http://dx.doi.org/10.1067/mai.2002.124567			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	568JU	12063509	Bronze			2022-12-18	WOS:000176539300004
J	Poulos, LM; O'Meara, TJ; Hamilton, RG; Tovey, ER				Poulos, LM; O'Meara, TJ; Hamilton, RG; Tovey, ER			Inhaled latex allergen (Hev b 1)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hev b 1; latex; inhaled allergen; occupational exposure; HALOgen assay; nasal air sampler	NATURAL-RUBBER LATEX; HEV B 1; OCCUPATIONAL ASTHMA; MEDICAL-CENTER; SKIN SYMPTOMS; CAT ALLERGEN; AEROALLERGENS; WORKERS; CORNSTARCH; ANTIBODIES	Background: IgE-mediated responses to natural rubber latex allergens have become a major health problem among recognized risk groups. Objective: The purpose of this investigation was to measure the amounts of Hevea brasiliensis latex allergen (Hev b 1) inhaled and deposited on surfaces when latex or vinyl gloves were worn and compare the results, with the conventional measures (breathing zone samplers) of occupational exposure. Methods: He, b I exposure was measured by nasal sampling and breathing zone sampling. Latex allergen exposure was generated by having each subject don a pair of powdered latex examination gloves and continuing his or her normal daily activity for 30 minutes. By means of adhesive tape, surface dust samples were collected from the surfaces of gloves, the subject's hands, and work areas. Sampling was performed with subjects wearing no gloves, subjects wearing powdered vinyl gloves, subjects wearing powdered latex gloves, and nearby colleagues wearing latex gloves. All samples were assayed through use of the HALOgen assay (Inhalix, Sydney, Australia) with a Hev b 1-specific mAb. Particles transporting latex allergen were identified by a surrounding immunostain halo, and these were quantified and reported as total numbers of particles inhaled, airborne, or found on surface areas evaluated. Results: Study subjects inhaled 26 times more allergen when powdered latex gloves were worn than under the "no glove" and powdered vinyl glove conditions. During the same period, Hev b I particle levels measured in the ambient air through use of the breathing zone sampler increased by 24-fold. The median numbers of particles carrying Hev b I allergen per square centimeter on the surface of the hands after the Wearing of latex and vinyl gloves were 1964 and 5, respectively. Latex allergen was physically associated both with cornstarch granules and with larger dust particles having a darker, more irregular appearance. Conclusion: In a laboratory where gloves are worn for protection, the use of latex gloves resulted in a 26-fold increase in inhaled latex allergen over background levels measured while vinyl gloves were worn as controls. Low levels of latex exposure also occurred when vinyl gloves or no gloves were worn; the reasons for this are under investigation.	Univ Sydney, Inst Resp Med, Sydney, NSW 2006, Australia; Johns Hopkins Univ, Baltimore, MD USA	University of Sydney; Johns Hopkins University	Poulos, LM (corresponding author), Univ Sydney, Inst Resp Med, Room 461,Level 4,Blackburn Bldg,D06, Sydney, NSW 2006, Australia.		Tovey, Euan R/G-8604-2017; Poulos, Leanne/B-4051-2009; Poulos, Leanne/N-9527-2019	Tovey, Euan R/0000-0002-1802-7266; 				Alenius H, 1996, INT ARCH ALLERGY IMM, V109, P362, DOI 10.1159/000237264; Allmers H, 1998, J ALLERGY CLIN IMMUN, V102, P841, DOI 10.1016/S0091-6749(98)70026-0; BARTLEY DL, 1998, APPL OCCUP ENV HYG, V13, P274; Baur X, 1998, J ALLERGY CLIN IMMUN, V101, P24, DOI 10.1016/S0091-6749(98)70188-5; BEEZHOLD D, 1992, ARCH SURG-CHICAGO, V127, P1354; Charous BL, 2000, ANN ALLERG ASTHMA IM, V85, P285, DOI 10.1016/S1081-1206(10)62531-8; Chen ZP, 1997, J ALLERGY CLIN IMMUN, V100, P684, DOI 10.1016/S0091-6749(97)70174-X; De Lucca SD, 1999, J ALLERGY CLIN IMMUN, V104, P672, DOI 10.1016/S0091-6749(99)70341-6; De Lucca SD, 2000, J ALLERGY CLIN IMMUN, V106, P874, DOI 10.1067/mai.2000.110804; Graham JAH, 2000, ANN ALLERG ASTHMA IM, V84, P599, DOI 10.1016/S1081-1206(10)62410-6; Hunt LW, 1996, J OCCUP ENVIRON MED, V38, P765, DOI 10.1097/00043764-199608000-00011; Kurup VP, 2000, CLIN EXP ALLERGY, V30, P359; Liss GM, 1997, OCCUP ENVIRON MED, V54, P335, DOI 10.1136/oem.54.5.335; Lundberg M, 1997, ALLERGY, V52, P1222, DOI 10.1111/j.1398-9995.1997.tb02527.x; MARK D, 1986, ANN OCCUP HYG, V30, P89, DOI 10.1093/annhyg/30.1.89; O'Meara TJ, 1998, LANCET, V351, P1488, DOI 10.1016/S0140-6736(05)78870-X; ORFAN NA, 1994, J ALLERGY CLIN IMMUN, V94, P826, DOI 10.1016/0091-6749(94)90149-X; Poulos LM, 1999, CLIN EXP ALLERGY, V29, P1232, DOI 10.1046/j.1365-2222.1999.00613.x; Rask-Andersen A, 2000, ALLERGY, V55, P836, DOI 10.1034/j.1398-9995.2000.00484.x; RENSTROM A, 1999, EUR RESPIR J, V14, pS538; Rihs HP, 2000, CLIN EXP ALLERGY, V30, P1285; RODENSTEIN DO, 1985, AM REV RESPIR DIS, V131, P163; Sussman GL, 1998, J ALLERGY CLIN IMMUN, V101, P171, DOI 10.1016/S0091-6749(98)70381-1; SWANSON MC, 1994, J ALLERGY CLIN IMMUN, V94, P445, DOI 10.1016/0091-6749(94)90199-6; TOMAZIC VJ, 1994, J ALLERGY CLIN IMMUN, V93, P751, DOI 10.1016/0091-6749(94)90255-0; VandenEnde JJ, 1996, CLIN DYSMORPHOL, V5, P1, DOI 10.1097/00019605-199601000-00001; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54, DOI 10.1164/ajrccm.151.1.7812572; VINCENT JH, 1981, ANN OCCUP HYG, V24, P245, DOI 10.1093/annhyg/24.2.245; WRANGSJO K, 1994, CONTACT DERMATITIS, V30, P139, DOI 10.1111/j.1600-0536.1994.tb00694.x; YASSIN MS, 1994, ANN ALLERGY, V72, P245	30	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2002	109	4					701	706		10.1067/mai.2002.122463	http://dx.doi.org/10.1067/mai.2002.122463			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	543YZ	11941322				2022-12-18	WOS:000175132600021
J	Raulf-Heimsoth, M; Stark, R; Sander, I; Maryska, S; Rihs, HP; Bruning, T; Voshaar, T				Raulf-Heimsoth, M; Stark, R; Sander, I; Maryska, S; Rihs, HP; Bruning, T; Voshaar, T			Anaphylactic reaction to apple juice containing acerola: Cross-reactivity to latex due to prohevein	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Ruhr Univ Bochum, BGFA Inst, Res Inst Occupat Med, D-4630 Bochum, Germany; Hosp Bethanien, Moers, Germany	Ruhr University Bochum	Raulf-Heimsoth, M (corresponding author), Ruhr Univ Bochum, BGFA Inst, Res Inst Occupat Med, Univ Str 150, D-4630 Bochum, Germany.		Brüning, Thomas/G-8120-2015; Sander, Ingrid/R-8940-2017	Brüning, Thomas/0000-0001-9560-5464; Sander, Ingrid/0000-0002-5014-4112				Blanco C, 1999, J ALLERGY CLIN IMMUN, V103, P507, DOI 10.1016/S0091-6749(99)70478-1; Chen ZP, 2000, INT ARCH ALLERGY IMM, V123, P291, DOI 10.1159/000053641; Morton Julia F., 1987, FRUITS WARM CLIMATES, P207; Posch A, 1999, CLIN EXP ALLERGY, V29, P667, DOI 10.1046/j.1365-2222.1999.00502.x	4	11	11	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2002	109	4					715	716		10.1067/mai.2002.122464	http://dx.doi.org/10.1067/mai.2002.122464			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	543YZ	11941325				2022-12-18	WOS:000175132600024
J	Magnan, EM; Sanchez, H; Luskin, AT; Bush, RK				Magnan, EM; Sanchez, H; Luskin, AT; Bush, RK			Multicolored Asian ladybeetle (Harmonia axyridis) sensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									Univ Wisconsin, Madison, WI 53706 USA; Vet Adm Hosp, Madison, WI USA; Dean Fdn Hlth Res & Educ, Sun Prairie, WI USA	University of Wisconsin System; University of Wisconsin Madison									0	11	15	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1		S		205	S80	S80		10.1016/S0091-6749(02)81341-0	http://dx.doi.org/10.1016/S0091-6749(02)81341-0			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519UX					2022-12-18	WOS:000173744800204
J	Mitakakis, TZ; Mahmic, A; Tovey, ER				Mitakakis, TZ; Mahmic, A; Tovey, ER			Comparison of vacuuming procedures for reservoir dust mite allergen on carpeted floors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Der p I; exposure; horizontal distribution; reservoir	VARIABILITY	Allergen concentration in dust collected from a single square meter of carpet has been widely used as a proxy for aeroallergen exposure in a room. However, little is known about the horizontal distribution of allergens in carpeting or whether sampling several smaller sites might better approximate the average level. Eight bedrooms and 4 lounge rooms were divided into squares of 0.25 m(2), and the vacuumed dust was assayed for mite allergen (Der p 1). The proximity of each square to windows, doors, and beds was determined. In each room, the total allergen for each of 3 randomly chosen sets of 4 adjacent squares (forming a 1-m(2) area) was compared with that for each of 3 randomly chosen sets of 4 nonadjacent squares. The reliability of measuring allergen concentration from a single 0.25-m(2) area was modest (intraclass correlation coefficient [ICC] = 0.52), indicating wide-ranging allergen concentrations across short distances within each room. The reliability of the measurements based on 4 nonadjacent squares (ICC = 0.782) was higher than that of the measurements based on 4 adjacent squares (ICC = 0.67). Der p 1 concentrations decreased with distance from doors (paired partial correlation coefficient, -0.1217; P = 0.03). We recommend sampling 4 nonadjacent 0.25-m2 areas, that are not equidistant from the door when reservoir concentrations of Der p 1 are being measured.	Royal Prince Alfred Hosp, Inst Resp Med, Sydney, NSW, Australia	University of Sydney	Tovey, ER (corresponding author), Univ Sydney, Inst Resp Med, Allergen Unit, Room 461,Blackburn Bldg D06, Sydney, NSW 2006, Australia.		Tovey, Euan R/G-8604-2017	Tovey, Euan R/0000-0002-1802-7266				Bland JM, 1996, BRIT MED J, V313, P41, DOI 10.1136/bmj.313.7048.41; Hirsch T, 1998, ENVIRON HEALTH PERSP, V106, P659; *INDOOR BIOT, 2002, RAP TEST INSTR, V1; Lewis RD, 1998, AM IND HYG ASSOC J, V59, P606, DOI 10.1080/15428119891010776; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; Marks GB, 1995, CLIN EXP ALLERGY, V25, P1190, DOI 10.1111/j.1365-2222.1995.tb03043.x; PAULI G, 1996, UPDATE LONG LASTING, P43; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; Simpson A, 1998, ALLERGY, V53, P602, DOI 10.1111/j.1398-9995.1998.tb03936.x; Wickens K, 2001, CLIN EXP ALLERGY, V31, P827, DOI 10.1046/j.1365-2222.2001.01108.x	10	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					122	124		10.1067/mai.2002.120523	http://dx.doi.org/10.1067/mai.2002.120523			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519RM	11799377				2022-12-18	WOS:000173739300020
J	Salman, S; Christie, L; Burks, W; Mccabe-Sellers, B				Salman, S; Christie, L; Burks, W; Mccabe-Sellers, B			Dietary intakes of children with food allergies: Comparison of the Food Guide Pyramid and the Recommended Dietary Allowances 10th Ed	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									Univ Arkansas, Little Rock, AR 72204 USA	University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock									0	11	13	1	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1		S		643	S214	S214		10.1016/S0091-6749(02)81780-8	http://dx.doi.org/10.1016/S0091-6749(02)81780-8			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519UX					2022-12-18	WOS:000173744800642
J	Pezzolo, A; Prigione, I; Facchetti, P; Castellano, E; Viale, M; Gimelli, G; Pistoia, V				Pezzolo, A; Prigione, I; Facchetti, P; Castellano, E; Viale, M; Gimelli, G; Pistoia, V			T-cell apoptosis in ICF syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DNA METHYLTRANSFERASE GENE; IMMUNODEFICIENCY SYNDROME; INSTABILITY		Ist Giannina Gaslini, Lab Oncol, I-16148 Genoa, Italy; Ist Giannina Gaslini, Lab Cytogenet, I-16148 Genoa, Italy; Ist Giannina Gaslini, Div Pediat 3, I-16148 Genoa, Italy; Natl Canc Inst, Pharmacol Lab, Genoa, Italy	University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa; IRCCS Istituto Giannina Gaslini	Pezzolo, A (corresponding author), Ist Giannina Gaslini, Lab Oncol, Largo G Gaslini 5, I-16148 Genoa, Italy.		Prigione, Ignazia/K-3011-2016; Viale, Maurizio/AAA-8907-2020; Pezzolo, Annalisa/AAA-7424-2020	Prigione, Ignazia/0000-0002-0877-6255; Viale, Maurizio/0000-0002-0673-5951; 				FRANCESCHINI P, 1995, EUR J PEDIATR, V154, P840, DOI 10.1007/BF01959794; GIMELLI G, 1993, J MED GENET, V30, P429, DOI 10.1136/jmg.30.5.429; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; SMEETS DFCM, 1994, HUM GENET, V94, P240; TIEPOLO L, 1979, HUM GENET, V51, P127, DOI 10.1007/BF00287166; Wijmenga C, 2000, HUM MUTAT, V16, P509, DOI 10.1002/1098-1004(200012)16:6<509::AID-HUMU8>3.3.CO;2-M; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052	7	11	11	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2001	108	2					310	312		10.1067/mai.2001.116863	http://dx.doi.org/10.1067/mai.2001.116863			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	465HY	11496256				2022-12-18	WOS:000170584600028
J	Zaitsu, M; Hamasaki, Y; Aoki, Y; Miyazaki, S				Zaitsu, M; Hamasaki, Y; Aoki, Y; Miyazaki, S			A novel pharmacologic action of glucocorticosteroids on leukotriene C-4 catabolism	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						beclomethasone dipropionate; cysteinyl leukotrienes; fluticasone propionate; gamma-glutamyl transpeptidase; gamma-glutamyl transpeptidase-related enzyme; human bronchial epithelial cells		Leukotriene (LT) C-4, a potent chemical mediator in human bronchial asthma, is metabolized to less active LTE4 via LTD4 in 2 consecutive enzymatic reactions by gamma -glutamyl transpeptidases and dipeptidases. We examined whether this inactivation process of LTC4 was affected by fluticasone propionate, beclomethasone dipropionate, disodium cromoglycate, and salbutamol sulfate in transformed human bronchial epithelial cells. Fluticasone propionate and beclomethasone dipropionate accelerated LTC4 catabolism by inducing activity of a LTC4-degrading enzyme, gamma -glutamyl transpeptidase-related enzyme (gamma -GTPRE), in transformed human bronchial epithelial cells. The activation of gamma -GTPRE might be regulated transcriptionally. This is a novel regulatory mechanism by which glucocorticosteroids exert antiasthma activities.	Saga Med Sch, Dept Pediat, Saga 8498501, Japan; Saga Med Sch, Dept Internal Med, Saga 8498501, Japan	Saga University; Saga University	Zaitsu, M (corresponding author), Saga Med Sch, Dept Pediat, 5-1-1 Nabeshima, Saga 8498501, Japan.							Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; Foe K, 2000, J PHARM SCI-US, V89, P1143, DOI 10.1002/1520-6017(200009)89:9<1143::AID-JPS6>3.0.CO;2-C; HEISTERKAMP N, 1991, P NATL ACAD SCI USA, V88, P6303, DOI 10.1073/pnas.88.14.6303; Lipworth BJ, 1999, LANCET, V353, P57, DOI 10.1016/S0140-6736(98)09019-9; Zaitsu M, 2000, BLOOD, V96, P601	6	11	11	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2001	108	1					122	124						3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	458AN	11447392				2022-12-18	WOS:000170171200017
J	Codina, R; Reichmuth, D; Lockey, RF; Jaen, C				Codina, R; Reichmuth, D; Lockey, RF; Jaen, C			Ferret allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Univ S Florida, Coll Med, Div Clin Immunol & Allergy, James A Haley Vet Hosp, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital	Codina, R (corresponding author), Univ S Florida, Coll Med, Div Clin Immunol & Allergy, James A Haley Vet Hosp, Tampa, FL 33612 USA.							Gomez IJ, 1996, ALLERGY, V51, P364; Gordon S, 1997, J ALLERGY CLIN IMMUN, V99, P716, DOI 10.1016/S0091-6749(97)70036-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Savolainen J, 1997, CLIN EXP ALLERGY, V27, P501; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	5	11	11	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2001	107	5					927	927		10.1067/mai.2001.114704	http://dx.doi.org/10.1067/mai.2001.114704			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	434JX	11344368	Bronze			2022-12-18	WOS:000168812300029
J	Grundy, J; Bateman, BJ; Gant, C; Matthews, SM; Dean, T; Arshad, H				Grundy, J; Bateman, BJ; Gant, C; Matthews, SM; Dean, T; Arshad, H			Peanut allergy in three year old children - A population based study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	11	11	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2		S		758	S231	S231						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	405RE					2022-12-18	WOS:000167172300754
J	Wamboldt, MZ; Bihun, JT; Szefler, S; Hewitt, J				Wamboldt, MZ; Bihun, JT; Szefler, S; Hewitt, J			Perception of induced bronchoconstriction in a community sample of adolescents	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adolescents; epidemiology; methacholine; bronchoconstriction; perception; Borg scale	NEAR-FATAL ASTHMA; INSPIRATORY RESISTIVE LOADS; ADULT-POPULATION; EXERCISE; BREATHLESSNESS; SYMPTOMS; DYSPNEA; ANXIETY	Background: Poor perception of asthma symptoms has been cited as a risk factor for asthma death, yet there is no consensus as to the best way to characterize perception, and little is known about perception in normative samples. Hypoperceivers are of clinical interest because of risks of undertreatment; hyperperceivers are at risk for adverse iatrogenic effects caused by overtreatment. Objective: This study investigates perception of methacholine-induced bronchoconstriction in 175 adolescents. Methods: Breathlessness mas rated after each inhalation by using the Borg scale. Perception groups mere calculated on the basis of change from placebo Borg to high Bog scores (perception score at the highest methacholine dose). Subjects mere called hypoperceivers if their Borg change score was greater than 1 SD below the mean for their FEV1 group, hyperperceivers if their Borg change score was greater than I SD above the mean for their FEV1 group, and accurate perceivers otherwise. Results: For subjects with an FEV1 drop of less than 10%, accurate perceivers had a change in Borg score of 1.4 or less, and hyperperceivers had a change of greater than 1.4. For a drop in FEV1 between 10% and 19%, hypoperceivers had a change in Borg score of less than 0.2, accurate perceivers had a change between 0.2 and 2.1, and hyperperceivers had a change of greater than 2.1. For those with an FEV1 drop of 20% or greater, hypoperceivers had a Borg change of less than 0.2, accurate perceivers had a change between 0.2 and 2.6 and hyperperceivers had a change of greater than 2.6. No differences in age, sex, placebo Borg ratings, baseline pulmonary functions, PC20 values, or psychologic variables mere found among perception groups. Conclusion: This study provides reference Borg values during methacholine challenge for 175 community adolescents.	Natl Jewish Med & Res Ctr, Dept Pediat & Behav Hlth, Denver, CO 80206 USA; Univ Colorado, Inst Behav Genet, Boulder, CO 80309 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA	National Jewish Health; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Wamboldt, MZ (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat & Behav Hlth, Denver, CO 80206 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K08MH001486] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR00051] Funding Source: Medline; NHLBI NIH HHS [R01 HL45157-07] Funding Source: Medline; NIMH NIH HHS [K08MH01486-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Banzett RB, 2000, AM J RESP CRIT CARE, V162, P1178, DOI 10.1164/ajrccm.162.3.9909112; Bijl-Hofland ID, 1999, EUR RESPIR J, V14, P1049, DOI 10.1183/09031936.99.14510499; BORG G, 1990, SCAND J WORK ENV HEA, V16, P55, DOI 10.5271/sjweh.1815; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; BOULET LP, 1991, J ALLERGY CLIN IMMUN, V88, P838, DOI 10.1016/0091-6749(91)90239-K; Boulet LP, 1996, AM J EMERG MED, V14, P623, DOI 10.1016/S0735-6757(96)90075-3; BOULET LP, 1994, CHEST, V105, P1430, DOI 10.1378/chest.105.5.1430; BURDON JGW, 1982, AM REV RESPIR DIS, V126, P825; BURNEY PGJ, 1987, THORAX, V42, P38, DOI 10.1136/thx.42.1.38; Chetta A, 1998, AM J RESP CRIT CARE, V157, P116, DOI 10.1164/ajrccm.157.1.9702093; Childhood Asthma Management Program, 1994, CHILDH ASTHM MAN PRO; Eaves L, 1989, GENES CULTURE PERSON; EYSENCK H, 1968, EYSENCK PERSONALITY, P28; Fritz GK, 1996, J AM ACAD CHILD PSY, V35, P1033, DOI 10.1097/00004583-199608000-00014; Grant S, 1999, CHEST, V116, P1208, DOI 10.1378/chest.116.5.1208; Higgs CMB, 1996, CLIN SCI, V90, P227, DOI 10.1042/cs0900227; HUDGEL DW, 1982, AM REV RESPIR DIS, V126, P121; Isenberg S, 1997, J BEHAV MED, V20, P461, DOI 10.1023/A:1025551532756; KENDRICK AH, 1993, BRIT MED J, V307, P422, DOI 10.1136/bmj.307.6901.422; Kifle Y, 1997, AM J RESP CRIT CARE, V156, P1530, DOI 10.1164/ajrccm.156.5.9703011; KIKUCHI Y, 1994, NEW ENGL J MED, V330, P1329, DOI 10.1056/NEJM199405123301901; KOVAKS M, 1992, CHILDRESN DEPRESSION; LANG DM, 1987, J ALLERGY CLIN IMMUN, V79, P533, DOI 10.1016/0091-6749(87)90372-1; March JS., 2013, MULTIDIMENSIONAL ANX, V2nd; O'Donnell DE, 1998, AM J RESP CRIT CARE, V158, P1557, DOI 10.1164/ajrccm.158.5.9804004; Park SJ, 1996, J PAEDIATR CHILD H, V32, P183, DOI 10.1111/j.1440-1754.1996.tb00919.x; Powers J, 1999, Am J Crit Care, V8, P254; RUBINFELD AR, 1976, LANCET, V1, P882; RUFFIN RE, 1991, CHEST, V99, P77, DOI 10.1378/chest.99.1.77; Spinhoven P, 1997, THORAX, V52, P149, DOI 10.1136/thx.52.2.149; TURCOTTE H, 1990, THORAX, V45, P914, DOI 10.1136/thx.45.12.914; Turner MO, 1998, AM J RESP CRIT CARE, V157, P1804, DOI 10.1164/ajrccm.157.6.9708092; WILSON RC, 1989, CLIN SCI, V76, P277, DOI 10.1042/cs0760277; YOUNG S, IN PRESS NEUROPSYCHI; ZACH M S, 1989, Archives of Disease in Childhood, V64, P1446	35	11	11	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2000	106	6					1102	1107						6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	384ER	11112893				2022-12-18	WOS:000165930300012
J	Peat, JK; Toelle, BG; Mellis, CM				Peat, JK; Toelle, BG; Mellis, CM			Problems and possibilities in understanding the natural history of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						long-term cohort studies; sensitivity; specificity positive predictive value; likelihood ratio; true positive; false positive; airway hyperresponsiveness; atopy	RESPIRATORY SYMPTOMS; CHILDHOOD ASTHMA; BRONCHIAL HYPERREACTIVITY; MEDICAL STATISTICS; ATOPIC DISEASE; LUNG-FUNCTION; ADULT LIFE; CHILDREN; RESPONSIVENESS; SENSITIZATION	In early life, asthma symptoms can occur intermittently or may not be severe enough to limit normal activities, which makes it difficult for the clinician to make reliable predictions and administer therapy with some precision. In the case of pediatric asthma, the identification of children who will experience the development of a clinically important illness that will impair their quality of life can be a complex process. The usual methods for describing this information include the prognostic statistics of sensitivity, specificity, likelihood ratio, and positive predictive value. The sensitivity, specificity and likelihood ratio of various early markers of asthma have been calculated from several cohort studies.	Univ Sydney, Dept Paediat, Sydney, NSW 2145, Australia; Univ Sydney, Dept Child Hlth, Sydney, NSW 2145, Australia; Univ Sydney, Dept Med, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney; University of Sydney	Peat, JK (corresponding author), Univ Sydney, New Childrens Hosp, Dept Pediat & Child Hlth, Clin Epidemiol Unit, Sydney, NSW 2145, Australia.		Toelle, Brett G/B-1531-2008	Toelle, Brett G/0000-0002-7375-0019				ANDERSON HR, 1992, THORAX, V47, P537, DOI 10.1136/thx.47.7.537; Asher MI, 1998, CLIN EXP ALLERGY, V28, P52; Boner AL, 1997, EUR RESPIR REV, V7, P3; BROOKE AM, 1995, AM J RESP CRIT CARE, V152, P1872, DOI 10.1164/ajrccm.152.6.8520749; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; BURROWS B, 1995, AM J RESP CRIT CARE, V152, P1302, DOI 10.1164/ajrccm.152.4.7551386; Carey OJ, 1996, AM J RESP CRIT CARE, V154, P537, DOI 10.1164/ajrccm.154.2.8756835; Carey VJ, 1996, AM J RESP CRIT CARE, V153, P356, DOI 10.1164/ajrccm.153.1.8542143; CHANYEUNG M, 1998, AM J RESP CRIT CARE, V157, pA12; Cook DG, 1997, THORAX, V52, P1081, DOI 10.1136/thx.52.12.1081; Davidoff F, 1999, ANN INTERN MED, V130, P1019, DOI 10.7326/0003-4819-130-12-199906150-00022; DEMISSIE K, 1997, CAN RESPIR J, V4, P91; Forastiere F, 1996, AM J RESP CRIT CARE, V153, P1098, DOI 10.1164/ajrccm.153.3.8630551; FULLERTONSMITH I, 1995, EVIDENCE BASED MED, V1, P7; GODDEN DJ, 1994, AM J RESP CRIT CARE, V149, P106, DOI 10.1164/ajrccm.149.1.8111567; Goodman SN, 1999, ANN INTERN MED, V130, P995, DOI 10.7326/0003-4819-130-12-199906150-00008; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; JENKINS MA, 1994, BRIT MED J, V309, P90, DOI 10.1136/bmj.309.6947.90; JONES A, 1994, THORAX, V49, P757, DOI 10.1136/thx.49.8.757; Kagamimori S, 1996, CLIN EXP ALLERGY, V26, P262; KELLY WJW, 1988, AM REV RESPIR DIS, V138, P26, DOI 10.1164/ajrccm/138.1.26; LAUPACIS A, 1994, JAMA-J AM MED ASSOC, V272, P234, DOI 10.1001/jama.272.3.234; MARTINEZ F, 1995, AM J RESP CRIT CARE, V151, pS2, DOI 10.1164/ajrccm/151.2_Pt_2.S2; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez FD, 1998, EUR RESPIR J, V12, p3S; MARTINEZ FD, 1997, EUR RESPIR REV, V7, P8; Nafstad P, 1999, PEDIATRICS, V103, P753, DOI 10.1542/peds.103.4.753; Nishioka K, 1998, J ALLERGY CLIN IMMUN, V101, P28, DOI 10.1016/S0091-6749(98)70189-7; OSWALD H, 1994, BRIT MED J, V309, P95, DOI 10.1136/bmj.309.6947.95; Peat JK, 1998, J ASTHMA, V35, P235, DOI 10.3109/02770909809068213; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; Peat JK, 1996, ALLERGY, V51, P804, DOI 10.1111/j.1398-9995.1996.tb00026.x; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; PlattsMills TAE, 1997, CIBA F SYMP, V206, P173; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; Sackett DL, 1996, EVIDENCE BASED MED, V1, P37; SEATON A, 1994, THORAX, V49, P171, DOI 10.1136/thx.49.2.171; Sherrill D, 1996, AM J RESP CRIT CARE, V154, pS217, DOI 10.1164/ajrccm/154.6_Pt_2.S217; Sherrill D, 1999, CLIN EXP ALLERGY, V29, P905; SILVERMAN M, 1997, THORAX, V52, P937; SPORIK R, 1991, ARCH DIS CHILD, V66, P1050, DOI 10.1136/adc.66.9.1050; Strachan D, 1996, EUR RESPIR J, V9, pS42; Ulrik CS, 1996, EUR RESPIR J, V9, P1696, DOI 10.1183/09031936.96.09081696; vonMutius E, 1996, THORAX, V51, pS3, DOI 10.1136/thx.51.Suppl_1.S3; vonMutius E, 1997, LANCET, V350, P14; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; WEISS ST, 1998, ASTHMA, P105; WRIGHT AL, 1989, BRIT MED J, V299, P946, DOI 10.1136/bmj.299.6705.946	49	11	11	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3		S			S144	S152		10.1067/mai.2000.109420	http://dx.doi.org/10.1067/mai.2000.109420			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	357XB	10984395	Bronze			2022-12-18	WOS:000089525400006
J	Miura, Y; Ueda, M; Zeng, WH; Wang, HB; Takami, A; Yamazaki, H; Kawamura, Y; Shiobara, S; Nakao, S				Miura, Y; Ueda, M; Zeng, WH; Wang, HB; Takami, A; Yamazaki, H; Kawamura, Y; Shiobara, S; Nakao, S			Induction of autologous graft-versus-host disease with cyclosporin A after peripheral blood stem cell transplantation: Analysis of factors affecting induction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Meeting on New Trends in Immunopharmacology 1998	JUL   25, 1998	TOKYO, JAPAN			autologus graft-versus-host-disease; cyclosporin A; peripheral blood stem cell transplantation	BONE-MARROW TRANSPLANTATION; NON-HODGKINS-LYMPHOMA; PHASE-I TRIAL; TREATED RATS; HEMATOLOGICAL MALIGNANCIES; COMPLETE REMISSION; BREAST-CANCER; CHEMOTHERAPY; LEUKEMIA; IMMUNOBIOLOGY	Background: Induction of autologous graft-versus-host disease after peripheral blood stem cell transplantation has not been studied well. Objective: The purpose of this study was to analyze the factors that affect the development of autologous graft-versus-host disease. Methods: Nineteen patients with non-Hodgkin's lymphoma underwent peripheral blood stem cell transplantation followed by the administration of cyclosporin A for 28 days (group A) or 21 days (group B) and IFN-gamma. Results: Autologous graft-versus-host disease failed to develop in the any of the group A patients, who did not receive total body irradiation for conditioning and underwent the transplantation,vith unmanipulated peripheral blood stem cells, although cytotoxic activity against autologous lymphocytes was detectable in peripheral blood mononuclear cells obtained from all of them after the transplantation. Autologous graft-versus-host disease developed in 2 of 4 patients in group A who received enriched CD34(+) cells and in 7 of 11 patients who underwent conditioning with total body irradiation. Maculopapular erythema that was compatible with graft-versus-host disease developed on days 19 to 27 after the transplantation in these patients and resolved after 3 to 9 days without treatment. Conclusions: Either the depletion of regulatory cells from the graft by enrichment of CD34(+) cells or the abolition of the autoregulation by including total body irradiation in the conditioning regimen may be effective in inducing autologous graft-versus-host disease after peripheral blood stem cell transplantation. Three weeks of cyclosporin A therapy appears to be sufficient to induce autologous graft-versus-host disease in recipients of peripheral blood stem cells.	Kanazawa Univ, Sch Med, Dept Internal Med 3, Kanazawa, Ishikawa 9208641, Japan; Kanazawa Univ, Sch Med, Transfus Sect, Kanazawa, Ishikawa 9208641, Japan; Ishikawa Prefectural Cent Hosp, Div Hematol & Immunol, Ishikawa, Japan	Kanazawa University; Kanazawa University; Ishikawa Prefectural Central Hospital	Nakao, S (corresponding author), Kanazawa Univ, Sch Med, Dept Internal Med 3, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan.		Takami, Akiyoshi/O-5677-2019	Takami, Akiyoshi/0000-0002-1822-9976				ARMITAGE JO, 1994, NEW ENGL J MED, V330, P827, DOI 10.1056/NEJM199403243301206; CARELLA AM, 1991, ANN HEMATOL, V62, P156, DOI 10.1007/BF01703140; FOUCAR K, 1979, BLOOD, V54, P1417; GLAZIER A, 1983, TRANSPLANT P, V15, P3035; GLAZIER A, 1983, J EXP MED, V158, P1, DOI 10.1084/jem.158.1.1; Gruhn B, 1998, BONE MARROW TRANSPL, V21, P901, DOI 10.1038/sj.bmt.1701190; HAIOUN C, 1994, J CLIN ONCOL, V12, P2543, DOI 10.1200/JCO.1994.12.12.2543; Hartmann O, 1997, ANN INTERN MED, V126, P600, DOI 10.7326/0003-4819-126-8-199704150-00002; HESS AD, 1985, J EXP MED, V161, P718, DOI 10.1084/jem.161.4.718; Hess AD, 1997, IMMUNOL REV, V157, P111, DOI 10.1111/j.1600-065X.1997.tb00977.x; HOROWITZ MM, 1990, BLOOD, V75, P555; JONES RJ, 1989, LANCET, V1, P754; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KENNEDY MJ, 1993, J CLIN ONCOL, V11, P478, DOI 10.1200/JCO.1993.11.3.478; KENNEDY MJ, 1994, J CLIN ONCOL, V12, P249, DOI 10.1200/JCO.1994.12.2.249; KERSEY JH, 1987, NEW ENGL J MED, V317, P461, DOI 10.1056/NEJM198708203170801; KusnierzGlaz CR, 1997, BLOOD, V89, P2586, DOI 10.1182/blood.V89.7.2586; Mielcarek M, 1997, BLOOD, V89, P1629, DOI 10.1182/blood.V89.5.1629; NADEMANEE A, 1992, BLOOD, V80, P1130; Pati AR, 1996, BONE MARROW TRANSPL, V17, P1081; PHILIP T, 1995, NEW ENGL J MED, V333, P1540, DOI 10.1056/NEJM199512073332305; RATANATHARATHORN V, 1994, BLOOD, V84, P1050; Schmitz N, 1996, LANCET, V347, P353, DOI 10.1016/S0140-6736(96)90536-X; VERDONCK LF, 1995, NEW ENGL J MED, V332, P1045, DOI 10.1056/NEJM199504203321601; WEAVER CH, 1995, BLOOD, V86, P3961, DOI 10.1182/blood.V86.10.3961.bloodjournal86103961; WEIDEN PL, 1979, NEW ENGL J MED, V300, P1068, DOI 10.1056/NEJM197905103001902; YEAGER AM, 1992, BLOOD, V79, P3031	27	11	11	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	2	S			S51	S57		10.1067/mai.2000.106832	http://dx.doi.org/10.1067/mai.2000.106832			7	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	339NF	10887334				2022-12-18	WOS:000088482600007
J	Sato, E; Nelson, DK; Koyama, S; Hoyt, JC; Robbins, RA				Sato, E; Nelson, DK; Koyama, S; Hoyt, JC; Robbins, RA			Bradykinin stimulates eotaxin production by a human lung fibroblast cell line	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil; chemotaxis; corticosteroids	BRONCHOALVEOLAR LAVAGE FLUID; EOSINOPHIL CHEMOATTRACTANT; ALLERGIC INFLAMMATION; ENDOTHELIAL-CELLS; ATOPIC ASTHMA; T-CELLS; EXPRESSION; RECEPTORS; CHEMOKINES; RELEASE	Background: Bradykinin, a potent inflammatory peptide, is increased in the airways of allergic patients. Accompanying the elevated bradykinin levels are increases in both eosinophils and fibroblasts. Eotaxin, a potent eosinophil-specific chemotactic factor, is released by fibroblasts and increased in the lower respiratory tract of allergic patients. Objective: We sought to test the hypothesis that lung fibroblasts release eotaxin in response to bradykinin. Methods: The potential of bradykinin to induce the release of eotaxin from the human lung fibroblast cell line HFL-1 was tested by cell culture and evaluation of the culture supernatant fluids and RNA for immunoreactive eotaxin and eotaxin messenger RNA. Results: HFL-1 cells released eotaxin constitutively without stimulation, but bradykinin stimulated eotaxin release in a dose- and time-dependent manner and resulted in augmented expression of eotaxin messenger RNA. The release of eotaxin was sensitive to the action of glucocorticoids. Eosinophil chemotactic activity by HFL-1 supernatant fluids was inhibited by anti-human eotaxin-neutralizing antibody. Consistent with these results, inhibitors of bradykinin B2 receptors, but not bradykinin B1 receptors, inhibited bradykinin-induced eotaxin release. Conclusion: These data demonstrate that bradykinin may stimulate lung fibroblasts to release eotaxin and suggest the potential for this mechanism to be important in modulation of lung inflammation.	So Arizona Vet Hlth Care Syst, Res Serv Line, Tucson, AZ 85723 USA; Univ Arizona, Dept Med, Tucson, AZ USA; Shinshu Univ, Sch Med, Dept Internal Med 1, Matsumoto, Nagano 390, Japan	US Department of Veterans Affairs; Veterans Health Administration (VHA); Southern Arizona Veterans Affairs Health Care System; University of Arizona; Shinshu University	Robbins, RA (corresponding author), So Arizona Vet Hlth Care Syst, Res Serv Line, 3601 S 6th Ave, Tucson, AZ 85723 USA.							ABRAHAM WM, 1991, AM REV RESPIR DIS, V143, P787, DOI 10.1164/ajrccm/143.4_Pt_1.787; Azevedo I, 1997, EUR RESPIR J, V10, P1767, DOI 10.1183/09031936.97.10081767; BAENZIGER NL, 1992, EUR J CELL BIOL, V58, P71; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BREUL SD, 1980, J BIOL CHEM, V255, P5250; Brown JR, 1998, CLIN EXP IMMUNOL, V114, P137; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHRISTIANSEN SC, 1987, J CLIN INVEST, V79, P188, DOI 10.1172/JCI112782; Chung KF, 1999, BRIT J PHARMACOL, V127, P1145, DOI 10.1038/sj.bjp.0702660; FARMER SG, 1989, MOL PHARMACOL, V36, P1; FARMER SG, 1992, ANNU REV PHARMACOL, V32, P511; Gonzalo JA, 1996, J CLIN INVEST, V98, P2332, DOI 10.1172/JCI119045; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; HARVATH L, 1980, J IMMUNOL METHODS, V37, P39, DOI 10.1016/0022-1759(80)90179-9; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; KATAYAMA K, 1991, BIOCHEMISTRY-US, V30, P7097, DOI 10.1021/bi00243a009; Koyama S, 1998, AM J PHYSIOL-LUNG C, V275, pL223, DOI 10.1152/ajplung.1998.275.2.L223; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; Lilly CM, 1997, J CLIN INVEST, V99, P1767, DOI 10.1172/JCI119341; Luster AD, 1997, J LEUKOCYTE BIOL, V62, P620, DOI 10.1002/jlb.62.5.620; MARCEAU F, 1995, IMMUNOPHARMACOLOGY, V30, P1, DOI 10.1016/0162-3109(95)00011-H; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683, DOI 10.1165/ajrcmb.17.6.2865; Miyamasu M, 1999, CYTOKINE, V11, P751, DOI 10.1006/cyto.1999.0487; Pan ZK, 1996, J CLIN INVEST, V98, P2042, DOI 10.1172/JCI119009; Polosa R, 1998, EUR RESPIR J, V12, P551, DOI 10.1183/09031936.98.12030551; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; Roisman CL, 1996, AM J RESP CRIT CARE, V153, P381, DOI 10.1164/ajrccm.153.1.8542147; ROTHENBERG ME, 1995, P NATL ACAD SCI USA, V92, P8960, DOI 10.1073/pnas.92.19.8960; SAWUTZ DG, 1992, EUR J PHARM-MOLEC PH, V227, P309, DOI 10.1016/0922-4106(92)90009-K; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SMITH H, 1992, CLIN EXP ALLERGY, V22, P187, DOI 10.1111/j.1365-2222.1992.tb03072.x; SOLER M, 1990, Pulmonary Pharmacology, V3, P9, DOI 10.1016/0952-0600(90)90003-2; Teran LM, 1999, AM J RESP CELL MOL, V20, P777, DOI 10.1165/ajrcmb.20.4.3508; VIRCHOW JC, 1995, AM J RESP CRIT CARE, V151, P960; Wang JH, 1996, AM J RESP CELL MOL, V14, P27, DOI 10.1165/ajrcmb.14.1.8534483; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252	38	11	11	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	1				117	123		10.1067/mai.2000.107400	http://dx.doi.org/10.1067/mai.2000.107400			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337ZH	10887314				2022-12-18	WOS:000088393300016
J	Paul, E; Gall, HM; Muller, I; Moller, R				Paul, E; Gall, HM; Muller, I; Moller, R			Dramatic augmentation of a food allergy by acetylsalicylic acid	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Hautklin & Klinikum Nurnberg Nord, D-90340 Nurnberg, Germany	Klinikum Nurnberg Nord	Paul, E (corresponding author), Hautklin & Klinikum Nurnberg Nord, Prof Ernst Nathan Str 1, D-90340 Nurnberg, Germany.								0	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2000	105	4					844	844		10.1067/mai.2000.105011	http://dx.doi.org/10.1067/mai.2000.105011			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	306PB	10756241				2022-12-18	WOS:000086604100029
J	McFadden, ER				McFadden, ER			Natural history of chronic asthma and its long-term effects on pulmonary function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; natural history; morbidity; mortality; long-term studies on lung function	AIR-FLOW OBSTRUCTION; LUNG-FUNCTION; CHILDHOOD ASTHMA; FOLLOW-UP; ADULTS; HYPERRESPONSIVENESS; COMMUNITY; ILLNESS	Although asthma is a disease that has intrigued physicians since antiquity, its natural history has been incompletely determined. It has long been held that the presence of asthma, per se, does not carry with it any long-term deterioration in lung function, but recently this view has been challenged, and it has become fashionable to define asthma as being only partially reversible, At present, there are limited data to support such a view. All of the available information indicates that the vast majority of patients do not experience the development of a progressive decline in pulmonary mechanics or appear to be at risk for a diminution in life expectancy.	Univ Hosp Cleveland, Div Pulm & Crit Care Med, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA	University Hospitals of Cleveland; Case Western Reserve University	McFadden, ER (corresponding author), Univ Hosp Cleveland, Div Pulm & Crit Care Med, Dept Med, 11100 Euclid Ave, Cleveland, OH 44106 USA.							AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; BOSLEY CM, 1995, EUR RESPIR J, V8, P899; BOULET LP, 1994, CHEST, V105, P1024, DOI 10.1378/chest.105.4.1024; BROWN PJ, 1984, THORAX, V39, P131, DOI 10.1136/thx.39.2.131; *CDC, 1992, JAMA-J AM MED ASSOC, V268, P1995; Centers for Disease Control and Prevention, 2007, AM J RESP CRIT CARE, V55; Fletcher CM, 1976, NATURAL HIST CHRONIC; GERRITSEN J, 1989, AM REV RESPIR DIS, V140, P1325, DOI 10.1164/ajrccm/140.5.1325; *GLOB IN ASTHM NAT, 1995, NIH PUBL; JOSEPHS LK, 1989, AM REV RESPIR DIS, V140, P350, DOI 10.1164/ajrccm/140.2.350; KELLY WJW, 1987, BRIT MED J, V294, P1059, DOI 10.1136/bmj.294.6579.1059; KELLY WJW, 1988, AM REV RESPIR DIS, V138, P26, DOI 10.1164/ajrccm/138.1.26; MARTIN AJ, 1980, AM REV RESPIR DIS, V122, P609; MCFADDEN ER, 1975, J ALLERGY CLIN IMMUN, V56, P18, DOI 10.1016/0091-6749(75)90030-5; MCFADDEN ER, 1995, AM J MED, V99, P651, DOI 10.1016/S0002-9343(99)80253-8; *NAT ASTHM ED PREV, 1997, NIH PUBL; OCONNOR GT, 1989, AM REV RESPIR DIS, V140, P225, DOI 10.1164/ajrccm/140.1.225; Panhuysen CIM, 1997, AM J RESP CRIT CARE, V155, P1267, DOI 10.1164/ajrccm.155.4.9105065; PEAT JK, 1987, CLIN ALLERGY, V17, P288; Ries AL, 1997, AM J RESP CRIT CARE, V155, P1895, DOI 10.1164/ajrccm.155.6.9196092; SAMET JM, 1983, AM REV RESPIR DIS, V127, P508, DOI 10.1164/arrd.1983.127.4.508; SCHACHTER EN, 1984, CHEST, V85, P623, DOI 10.1378/chest.85.5.623; SILVERSTEIN MD, 1994, NEW ENGL J MED, V331, P1537, DOI 10.1056/NEJM199412083312301; SMITH L, 1995, ANN ALLERG ASTHMA IM, V74, P454; Strachan DP, 1996, AM J RESP CRIT CARE, V154, P1629, DOI 10.1164/ajrccm.154.6.8970346; Strauss L, 1997, AM J RESP CRIT CARE, V155, P454, DOI 10.1164/ajrccm.155.2.9032178; ULRIK CS, 1992, THORAX, V47, P14, DOI 10.1136/thx.47.1.14; VANSCHAYCK CP, 1991, BRIT MED J, V303, P1426, DOI 10.1136/bmj.303.6815.1426; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304	29	11	11	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	2	S			S535	S539		10.1016/S0091-6749(00)90057-5	http://dx.doi.org/10.1016/S0091-6749(00)90057-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286JG	10669538				2022-12-18	WOS:000085439600015
J	Rosenwasser, LJ				Rosenwasser, LJ			New immunopharmacologic approaches to asthma: Role of cytokine antagonism	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cytokines; asthma; inflammation	INTERLEUKIN-1 RECEPTOR ANTAGONIST; COLONY-STIMULATING FACTOR; LYMPHOCYTE-T ACTIVATION; BRONCHIAL-ASTHMA; ATOPIC ASTHMA; IGE SYNTHESIS; MAST-CELLS; INFLAMMATION; EOSINOPHILS; DISEASE	This article involves an elucidation of the potential inflammatory mechanisms associated with the treatment of allergic disease and asthma, and the possibility of cytokine antagonism as a potential therapeutic mechanism for the treatment of those diseases. There is a review of the role of cytokines in the allergic process and a description of a number of studies done with the capacity of certain cytokine antagonists to develop potential amelioration of immune dysregulation in asthma and atopic states.	Natl Jewish Med & Res Ctr, Div Clin Immunol & Allergy, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Rosenwasser, LJ (corresponding author), Natl Jewish Med & Res Ctr, Div Clin Immunol & Allergy, 1400 Jackson St, Denver, CO 80206 USA.							AREND WP, 1993, ADV IMMUNOL, V54, P167, DOI 10.1016/S0065-2776(08)60535-0; AURON PE, 1987, J IMMUNOL, V138, P1447; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816, DOI 10.1164/ajrccm.160.6.9808146; BROIDE DH, 1991, J CLIN INVEST, V88, P1048, DOI 10.1172/JCI115366; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHUNG KF, 1986, THORAX, V41, P657, DOI 10.1136/thx.41.9.657; COFFMAN RL, 1986, J IMMUNOL, V136, P949; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; CORRIGAN CJ, 1988, LANCET, V1, P1129; DEL PG, 1988, J IMMUNOL, V140, P4193; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FENTON MJ, 1992, J IMMUNOL, V149, P1283; FERRETTI M, 1994, J CLIN INVEST, V94, P449, DOI 10.1172/JCI117345; GRANOWITZ EV, 1991, J BIOL CHEM, V266, P14147; Hobbs K, 1998, AM J RESP CRIT CARE, V158, P1958, DOI 10.1164/ajrccm.158.6.9804011; HOWELL CJ, 1989, AM REV RESPIR DIS, V140, P1340, DOI 10.1164/ajrccm/140.5.1340; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LEBSACK ME, 1993, ARTHRITIS RHEUM, V36, pS39; MOSER R, 1992, J IMMUNOL, V149, P1432; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; OHISSON K, 1990, NATURE, V348, P550; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6; PAUL WE, 1991, BLOOD, V77, P1859; PAUL WE, 1987, ANNU REV IMMUNOL, V5, P429, DOI 10.1146/annurev.iy.05.040187.002241; RE F, 1994, J EXP MED, V179, P739, DOI 10.1084/jem.179.2.739; REED CE, 1988, CHEST, V94, P175, DOI 10.1378/chest.94.1.175; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROMAGNANI S, 1990, IMMUNOL TODAY, V11, P316, DOI 10.1016/S0167-5699(10)80004-0; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; TAYLOR KJ, 1987, THORAX, V42, P452, DOI 10.1136/thx.42.6.452; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3; TOMIOKA M, 1984, AM REV RESPIR DIS, V129, P1000; URBAN JF, 1991, P NATL ACAD SCI USA, V88, P5513, DOI 10.1073/pnas.88.13.5513; VERCELLI D, 1993, SPRINGER SEMIN IMMUN, V15, P5; WALKER C, 1991, J IMMUNOL, V146, P1829; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WELDMANN B, 1994, NATURE, V370, P434; WIERENGA EA, 1990, J IMMUNOL, V144, P4651	44	11	15	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	2	S			S586	S591		10.1016/S0091-6749(00)90063-0	http://dx.doi.org/10.1016/S0091-6749(00)90063-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286JG	10669544				2022-12-18	WOS:000085439600022
J	Camargo, C				Camargo, C		MARC-4 Investigators	Randomized trial of medium-dose fluticasone vs placebo after an emergency department visit for acute asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School			Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654					0	11	11	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	2	S		777	S262	S262		10.1016/S0091-6749(00)91205-3	http://dx.doi.org/10.1016/S0091-6749(00)91205-3			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	287WR					2022-12-18	WOS:000085530100773
J	Casale, TB; Racine, A; Sallas, W; Taylor, AF; Gupta, N; Rohane, PW				Casale, TB; Racine, A; Sallas, W; Taylor, AF; Gupta, N; Rohane, PW			Relationship between the clinical efficacy of rhuMAb-E25 (E25) and serum free IgE in seasonal allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									Nebraska Med Res Inst, Papillion, NE USA; Novartis Pharmaceut, Basel, Switzerland; Novarits Pharmaceut, E Hanover, NJ USA	Novartis			Casale, Thomas B/K-4334-2013	Casale, Thomas B/0000-0002-3149-7377					0	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	2	S		1052	S357	S357		10.1016/S0091-6749(00)91478-7	http://dx.doi.org/10.1016/S0091-6749(00)91478-7			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	287WR					2022-12-18	WOS:000085530101046
J	Arlian, LG; Morgan, MS; Goelz, JF				Arlian, LG; Morgan, MS; Goelz, JF			Quantitation of dust mites and allergen in small dust samples	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ASTHMA		Wright State Univ, Dept Biol Sci, Dayton, OH 45435 USA; SC Johnson & Son Inc, Racine, WI USA	Wright State University Dayton; SC Johnson & Son	Arlian, LG (corresponding author), Wright State Univ, Dept Biol Sci, Dayton, OH 45435 USA.							ARLIAN LG, 1992, J ALLERGY CLIN IMMUN, V90, P292, DOI 10.1016/S0091-6749(05)80006-5; Frederick JM, 1997, EUR RESPIR J, V10, P361, DOI 10.1183/09031936.97.10020361; Hallam C, 1999, J ALLERGY CLIN IMMUN, V103, pS188; Kemp TJ, 1996, BMJ-BRIT MED J, V313, P916, DOI 10.1136/bmj.313.7062.916	4	11	13	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				707	709		10.1016/S0091-6749(99)70349-0	http://dx.doi.org/10.1016/S0091-6749(99)70349-0			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482853				2022-12-18	WOS:000082870000042
J	Kempf, W; Oman, H; Wuthrich, B				Kempf, W; Oman, H; Wuthrich, B			Allergy to proteases in medical laboratory technicians: A new occupational disease?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									Univ Zurich Hosp, Allergy Unit, Dept Dermatol, CH-8091 Zurich, Switzerland; MIAB, Uppsala, Sweden	University of Zurich; University Zurich Hospital	Wuthrich, B (corresponding author), Univ Zurich Hosp, Allergy Unit, Dept Dermatol, Gloriastrasse 31, CH-8091 Zurich, Switzerland.		Kempf, Werner/A-4875-2008	Kempf, Werner/0000-0002-6552-8629				CARTIER A, 1984, J ALLERGY CLIN IMMUN, V73, P574, DOI 10.1016/0091-6749(84)90513-X; FLINDT MLH, 1969, LANCET, V1, P1177; TARVAINEN K, 1991, CLIN EXP ALLERGY, V21, P609, DOI 10.1111/j.1365-2222.1991.tb00854.x; WURSCH T, 1984, ALLERGOLOGIE, V7, P464; WUTHRICH B, 1969, SCHWEIZ MED WSCHR, V99, P1584	5	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				700	701		10.1016/S0091-6749(99)70345-3	http://dx.doi.org/10.1016/S0091-6749(99)70345-3			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482849				2022-12-18	WOS:000082870000038
J	Costello, J				Costello, J			Prospects for improved therapy in chronic obstructive pulmonary disease by the use of levalbuterol	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic obstructive pulmonary disease; bronchodilator; enantiomers; hyperreactivity	GUINEA-PIGS; BRONCHIAL HYPERRESPONSIVENESS; BETA(2)-ADRENOCEPTOR AGONIST; AIRWAY HYPERREACTIVITY; ASTHMATIC SUBJECTS; MILD ASTHMA; EXPOSURE; ALBUTEROL; IPRATROPIUM; SALBUTAMOL	Like asthma, chronic obstructive pulmonary disease (COPD) is a chronic disease, the most prominent symptom of which is airway obstruction. Airway inflammation may be pathogenomic in both diseases, but only in COPD does inflammation predominate as a determinant of symptoms to make obstruction largely refractory to treatment. Despite a more limited degree of reversibility than in asthma, beta(2)-agonists are used extensively to reduce airway obstruction and to achieve symptomatic improvement, with racemic albuterol being widely favored. In asthma, bronchodilation and bronchoprotection largely account for symptomatic benefit. In COPD, the capacity of racemic albuterol to ameliorate these symptoms is more limited and suppression of edema and of infiltration and activation of leukocytes acquire greater significance, During regular use of racemic albuterol in asthma, bronchoprotection diminishes progressively as hyperresponsiveness becomes increasingly pronounced, a process that is associated with an infiltration and activation of eosinophils. These paradoxic effects of racemic albuterol may be attributed to pharmacologic actions of the distomer, (S)-albuterol, As would be expected, homochiral (R)-albuterol (levalbuterol) is more potent and effective in asthma and may have significant advantages if used in COPD, A substantial (4-8-fold) reduction in the dose of levalbuterol anticipates lesser side effects and diminished risk in patients with cardiovascular disease, Additionally, the increased potency and duration of bronchodilation observed in asthma may extend to COPD, Finally, removal of the proinflammatory actions of (S)-albuterol may eliminate the persisting obstruction and decrease elastance that are associated with enhanced inflammation and may allow levalbuterol to suppress edema and diminish leukocyte activation more effectively.	Guys Kings & St Thomas Sch Med, Sackler Inst Pulm Pharmacol, Dept Resp Med & Allergy, London SE5 9RS, England; Guys Kings & St Thomas Sch Biomed Sci, Div Pharmacol & Therapeut, Sackler Inst Pulm Pharmacol, London, England	University of London; King's College London; University of London; King's College London	Costello, J (corresponding author), Guys Kings & St Thomas Sch Med, Sackler Inst Pulm Pharmacol, Dept Resp Med & Allergy, London SE5 9RS, England.							BARNES PJ, 1995, AM J RESP CRIT CARE, V152, P838, DOI 10.1164/ajrccm.152.3.7663795; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BRAUN SR, 1989, ARCH INTERN MED, V149, P544, DOI 10.1001/archinte.149.3.544; BRITT E J, 1980, Chest, V77, P260; BRITTAIN RT, 1973, BRIT J PHARMACOL, V48, P144, DOI 10.1111/j.1476-5381.1973.tb08232.x; CALVERLEY PMA, 1995, CHRONIC OBSTRUCTIVE, P419; Cockcroft DW, 1996, THORAX, V51, P1051, DOI 10.1136/thx.51.10.1051; COLLINS JM, 1969, BRIT J PHARMACOL, V36, P35, DOI 10.1111/j.1476-5381.1969.tb08301.x; Costello J, 1998, CHEST, V114, P353, DOI 10.1378/chest.114.2.353-a; Crowther SD, 1997, CLIN EXP ALLERGY, V27, P606; CUTZ E, 1978, HISTOPATHOLOGY, V2, P407, DOI 10.1111/j.1365-2559.1978.tb01735.x; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; Gauvreau GM, 1997, AM J RESP CRIT CARE, V156, P1738, DOI 10.1164/ajrccm.156.6.96-08042; Gawchik SM, 1999, J ALLERGY CLIN IMMUN, V103, P615, DOI 10.1016/S0091-6749(99)70233-2; GROSS NJ, 1984, NEW ENGL J MED, V311, P421, DOI 10.1056/NEJM198408163110701; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HARVEY JE, 1982, THORAX, V37, P280, DOI 10.1136/thx.37.4.280; HOGG JC, 1993, J ALLERGY CLIN IMMUN, V92, P1, DOI 10.1016/0091-6749(93)90029-F; HOSHIKO K, 1993, JPN J PHARMACOL, V63, P159, DOI 10.1254/jjp.63.159; HOSHIKO K, 1993, JPN J PHARMACOL, V63, P151, DOI 10.1254/jjp.63.151; HUGHES JA, 1982, THORAX, V37, P667, DOI 10.1136/thx.37.9.667; JENNE JW, 1987, DRUG THERAPY ASTHMA, P213; KOCH P, 1997, AM J RESP CRIT CARE, V173, pA279; KUO PH, 1998, BARC WORLD ASTHM C D, P324; LINDBERG S, 1995, EUR J PHARMACOL, V285, P275, DOI 10.1016/0014-2999(95)00416-I; MANOLITSAS ND, 1995, AM J RESP CRIT CARE, V151, P1925, DOI 10.1164/ajrccm.151.6.7767541; MAZZONI L, 1994, PULM PHARMACOL, V7, P367, DOI 10.1006/pulp.1994.1043; MORLEY J, 1995, AM J RESP CRIT CARE, V151, pA604; Nelson HS, 1998, J ALLERGY CLIN IMMUN, V102, P943, DOI 10.1016/S0091-6749(98)70332-X; NORONHADUTRA AA, 1982, LAB INVEST, V47, P346; SCHELLENBERG RR, 1993, AIRWAY HYPERRESPONSI, P33; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; Small RC, 1997, SYMPATHOMIMETIC ENANTIOMERS IN THE TREATMENT OF ASTHMA, P11; Thomson RJ, 1996, AM J RESP CRIT CARE, V154, P749, DOI 10.1164/ajrccm.154.3.8810615; VANSCHAYCK CP, 1990, J ALLERGY CLIN IMMUN, V86, P793, DOI 10.1016/S0091-6749(05)80185-X; VANSCHAYCK CP, 1991, BRIT MED J, V303, P1426, DOI 10.1136/bmj.303.6815.1426; Volcheck GW, 1998, J ALLERGY CLIN IMMUN, V101, pS35; WANG ZL, 1994, AM J RESP CRIT CARE, V149, P960, DOI 10.1164/ajrccm.149.4.8143062; WANG ZL, 1995, AM J RESP CRIT CARE, V152, P2097, DOI 10.1164/ajrccm.152.6.8520781; WITTENDERBY PA, 1993, EUR J PHARMACOL, V241, P121, DOI 10.1016/0014-2999(93)90942-B; YAN K, 1985, AM REV RESPIR DIS, V132, P25; [No title captured], DOI DOI 10.1136/THX.52.2008.S1]	42	11	12	0	9	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	2	S			S61	S68		10.1016/S0091-6749(99)70275-7	http://dx.doi.org/10.1016/S0091-6749(99)70275-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	233GX	10452790	Bronze			2022-12-18	WOS:000082419400008
J	Rinn, K; Schiffman, K; Otero, HO; Disis, ML				Rinn, K; Schiffman, K; Otero, HO; Disis, ML			Antigen-specific recall urticaria to a peptide-based vaccine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							COLONY-STIMULATING FACTOR; GRANULOCYTE		Univ Washington, Clin Res Ctr Facil, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Disis, ML (corresponding author), Univ Washington, Clin Res Ctr Facil, Box 356527, Seattle, WA 98195 USA.				NATIONAL CANCER INSTITUTE [R01CA075163, T32CA009515, K08CA061834] Funding Source: NIH RePORTER; NCI NIH HHS [K08 CA61834, R01 CA75163, P32 CA09515] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DISIS M, 1999, IN PRESS CLIN CANC R; Disis ML, 1996, CURR OPIN IMMUNOL, V8, P637, DOI 10.1016/S0952-7915(96)80079-3; Disis ML, 1996, BLOOD, V88, P202; KAPLAN G, 1992, J EXP MED, V175, P1717, DOI 10.1084/jem.175.6.1717; Karaayvaz M, 1996, J ALLERGY CLIN IMMUN, V97, P1419, DOI 10.1016/S0091-6749(96)70215-4	5	11	13	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					240	242		10.1016/S0091-6749(99)70143-0	http://dx.doi.org/10.1016/S0091-6749(99)70143-0			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400869				2022-12-18	WOS:000081738900039
J	Rosa, F				Rosa, F			Databases in the assessment of the effects of drugs during pregnancy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							GASTROSCHISIS	There is limited information on the effects of marketed drugs in pregnant women, largely because premarketing studies are not conducted in this population unless the agent is intended for specific use during pregnancy. Current information on the use of available medications during pregnancy includes 3 types of data: (1) case reports, (2) case-control studies, and (3) cohort studies. Assessments of pregnancy risk related to medication use most commonly involve ease reports, and each year the Food and Drug Administration catalogs approximately 1000 suspected adverse drug experiences during pregnancy. The Food and Drug Administration, working with Michigan Medicaid, has developed a database of several hundred thousand pregnancy outcomes. Results of this study for asthma medications used between 1980 and 1992 are presented. However, interpretation of the results is complicated, and substantially more data are required, particularly as new medications become available.	US FDA, Div Drug Epidemiol & Surveillance, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Rosa, F (corresponding author), US FDA, Div Drug Epidemiol & Surveillance, Rockville, MD 20857 USA.							BASSINGER RE, 1990, OBSTET GYNECOL SURV, V45, P415; Briggs GG., 2008, DRUGS PREGNANCY LACT, P431; *COLL PER STUD NAT, 1992, NIH PUBL, P233; Heinonen OP, 1977, BIRTH DEFECTS DRUGS; PARK JM, 1990, SOUTHERN MED J, V83, P1487, DOI 10.1097/00007611-199012000-00031; Rodriguez-Pinilla E, 1998, TERATOLOGY, V58, P2, DOI 10.1002/(SICI)1096-9926(199807)58:1<2::AID-TERA2>3.0.CO;2-4; ROSA F, 1989, TERATOLOGY, V40, P298; ROSA F, 1992, PEDIAT PHARM, P97; ROSA F, 1993, REPROD TOXICOL, V7, P166; SCHARDAIN JL, 1993, CHEM INDUCED BIRTH D; Torfs CP, 1996, TERATOLOGY, V54, P84, DOI 10.1002/(SICI)1096-9926(199606)54:2<84::AID-TERA4>3.0.CO;2-4; WERLER MM, 1992, TERATOLOGY, V45, P361, DOI 10.1002/tera.1420450407	13	11	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1999	103	2	2	S			S360	S361		10.1016/S0091-6749(99)70264-2	http://dx.doi.org/10.1016/S0091-6749(99)70264-2			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	171KA	9949339				2022-12-18	WOS:000078861500008
J	Scialli, AR				Scialli, AR			The Organization of Teratology Information Services (OTIS) Registry Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							1ST TRIMESTER; PREGNANCY; EXPOSURE; FETAL; MULTICENTER	Some population-based studies of the risks of gestational medication use are limited by differential recall or enrollment of mothers of children with abnormalities. Prospective acquisition of exposure information, before knowledge of pregnancy outcome, is the most unbiased manner in which to obtain denominator-based outcome information. The Organization of Teratology Information Services (OTIS) Registry Study will prospectively evaluate pregnancy outcomes in relation to exposures to asthma medications. Patients will be enrolled by participating Teratology Information Services. Information regarding medication exposure, asthma severity, and other important medical events will be assessed during pregnancy by means of standardized interviews, supplemented by medical records, Outcome information will be obtained from copies of the pediatric records. Data analysis will evaluate relative risks of adverse outcomes in exposed compared with unexposed asthmatic and nonasthmatic subjects.			Scialli, AR (corresponding author), Georgetown Univ, Med Ctr, Dept Obstet & Gynecol, Washington, DC 20007 USA.							BARR M, 1991, TERATOLOGY, V44, P485, DOI 10.1002/tera.1420440503; Chambers CD, 1996, NEW ENGL J MED, V335, P1010, DOI 10.1056/NEJM199610033351402; HANSSENS M, 1991, OBSTET GYNECOL, V78, P128; JACOBSON SJ, 1992, LANCET, V339, P530, DOI 10.1016/0140-6736(92)90346-5; JONES KL, 1989, NEW ENGL J MED, V320, P1661, DOI 10.1056/NEJM198906223202505; JONES KL, 1994, REPROD TOXICOL, V8, P439; KOREN G, 1991, REPROD TOXICOL, V5, P397, DOI 10.1016/0890-6238(91)90002-W; LEVY M, 1991, AM J PERINAT, V8, P174, DOI 10.1055/s-2007-999371; MOORE JA, 1995, REPROD TOXICOL, V9, P61, DOI 10.1016/0890-6238(94)00057-4; PASTUSZAK A, 1993, JAMA-J AM MED ASSOC, V269, P2246, DOI 10.1001/jama.269.17.2246; ROTHBERG AD, 1984, PEDIATR PHARMACOL, V4, P189; Schick B, 1996, REPROD TOXICOL, V10, P162; Schick-Boschetto B, 1992, TERATOLOGY, V45, P460	13	11	12	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1999	103	2	2	S			S373	S376		10.1016/S0091-6749(99)70267-8	http://dx.doi.org/10.1016/S0091-6749(99)70267-8			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	171KA	9949342				2022-12-18	WOS:000078861500011
J	Shimbara, A; Soussi-Gounni, A; Cameron, L; Olivenstein, R; Wallaert, B; Fahy, O; LaFitte, JJ; Tsicopoulos, A; Tonnel, AB; Hazcku, A; Holroyd, K; Nicolaides, N; Levitt, R; Hamid, QA				Shimbara, A; Soussi-Gounni, A; Cameron, L; Olivenstein, R; Wallaert, B; Fahy, O; LaFitte, JJ; Tsicopoulos, A; Tonnel, AB; Hazcku, A; Holroyd, K; Nicolaides, N; Levitt, R; Hamid, QA			Differential expression of IL-9 and its receptor (IL-9R) in allergic and non-allergic lung disease: Increased expression in asthma.	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada; Magainin Pharmaceut, Plymouth Meeting, PA USA	McGill University			Tsicopoulos, Anne/C-2260-2019; Gounni, Abdelilah Soussi/AAH-3456-2020	Tsicopoulos, Anne/0000-0002-1579-2763; 					0	11	11	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1999	103	1	2	S		408	S107	S107						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	165FC					2022-12-18	WOS:000078509000413
J	Kraft, M; Striz, I; Georges, G; Umino, T; Takigawa, K; Rennard, S; Martin, RJ				Kraft, M; Striz, I; Georges, G; Umino, T; Takigawa, K; Rennard, S; Martin, RJ			Expression of epithelial markers in nocturnal asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nocturnal asthma; airway epithelium; circadian rhythm	COLONY-STIMULATING FACTOR; GROWTH-FACTOR-BETA; EOSINOPHIL SURVIVAL; CELLS; FIBRONECTIN; COLLAGEN; MATRIX; INFLAMMATION; MODULATION; RECEPTORS	Background: Although the airway epithelium participates in inflammation and repair, the circadian expression of epithelial cell markers involved in these processes has not been investigated. Objective: We sought to determine whether expression of CD51 (vitronectin and fibronectin receptor), CD54 (intercellular adhesion molecule-1), HLA-DR (activation marker), CD29 (beta 1 integrin), CD49b (collagen receptor), and CD11b (complement receptor) exhibit a circadian rhythm in asthma. Methods: Eleven patients with nocturnal asthma (NA), 9 subjects with nonnocturnal asthma (NNA), and 10 control subjects underwent bronchoscopy at 4 PM and 4 AM in a random order 1 week apart, with brushing of the proximal and distal airways. The percentage of cells staining for a particular marker was determined. Results: At 4 PM, HLA-DR in the proximal airways and CD54 in the distal airways was significantly greater in control subjects as compared with asthmatic subjects (HLA-DR, control subjects: 10.0% [range, 5.0% to 21.0%]; NNA: 8.0% [range, 4.0% to 14.5%] NA: 3.5% [range, 2.0% to 6.0%], P =.01; CD54, control subjects: 17.0% [range, 8.0% to 25.0%], NNA: 8.0% [range, 5.3% to 11.5%], NA: 7.0% [range, 4.0% to 15.0%], P =.03), At 4 AM, CD51 in the distal airways was significantly greater in patients with NA as compared with patients with NNA and control subjects (control subjects, 23.0% [range, 13.8% to 30.5%]; NNA, 32.0% [range, 13.0% to 35.0%]; NA, 40.0% [range, 23.0% to 50.0%], P =.05). Expression of CD51 in the distal airways correlated with the degree of airway obstruction (r = -0.57, P =.001), Control subjects exhibited significant circadian variation in the expression of HLA-DR in the proximal airways and CD54 in the distal airways. Conclusion: The increased CD51 at night in patients with NA may be related to increased airway inflammation and repair processes in response to injury. The circadian changes in CD54 and HLA-DR in control subjects require further study to determine their significance.	Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Inst Clin & Expt Med, Dept Immunol, Prague, Czech Republic; Univ Nebraska, Div Pulm & Crit Care Med, Omaha, NE 68182 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Institute for Clinical & Experimental Medicine (IKEM); University of Nebraska System	Kraft, M (corresponding author), Natl Jewish Med & Res Ctr, 1400 jackson St,J107, Denver, CO 80206 USA.		Striz, Ilja/J-6340-2017	Striz, Ilja/0000-0001-9269-5652	FOGARTY INTERNATIONAL CENTER [F05TW004895] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577, K08HL003343] Funding Source: NIH RePORTER	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Cohen J., 1988, STAT POWER ANAL BEHA; COSTABEL U, 1985, B EUR PHYSIOPATH RES, V21, P381; COX G, 1991, AM J RESP CELL MOL, V4, P525, DOI 10.1165/ajrcmb/4.6.525; DAVIES RJ, 1995, INT ARCH ALLERGY IMM, V107, P428, DOI 10.1159/000237068; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; KURKINEN M, 1980, LAB INVEST, V43, P47; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; MARINI M, 1991, AM J RESP CELL MOL, V4, P519, DOI 10.1165/ajrcmb/4.6.519; MARTIN RJ, 1991, AM REV RESPIR DIS, V143, P351, DOI 10.1164/ajrccm/143.2.351; MASUDA T, 1992, RESPIRATION, V59, P238; MCKINNON KP, 1993, TOXICOL APPL PHARM, V118, P215, DOI 10.1006/taap.1993.1027; METTE SA, 1993, AM J RESP CELL MOL, V8, P562, DOI 10.1165/ajrcmb/8.5.562; MONTEFORT S, 1992, EUR RESPIR J, V5, P815; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cb.07.110191.001423; ROMBERGER DJ, 1992, AM J RESP CELL MOL, V7, P149, DOI 10.1165/ajrcmb/7.2.149; SNEDECOR GW, 1989, STAT METHODS, P242; SOLOPERTO M, 1991, AM J PHYSIOL, V260, pL530, DOI 10.1152/ajplung.1991.260.6.L530; TOOTHAKER LE, 1991, MULTIPLE COMP RES, P41; VIGNOLA AM, 1993, ALLERGY, V48, P32, DOI 10.1111/j.1398-9995.1993.tb04696.x; WELCH MP, 1990, J CELL BIOL, V110, P133, DOI 10.1083/jcb.110.1.133; WOODS A, 1988, COLLAGEN REL RES, V8, P155	27	11	17	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1998	102	3					376	381		10.1016/S0091-6749(98)70123-X	http://dx.doi.org/10.1016/S0091-6749(98)70123-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	124ZN	9768576				2022-12-18	WOS:000076212800007
J	Barry, PW; O'Callaghan, C				Barry, PW; O'Callaghan, C			The output of budesonide from nebulizers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									Univ Leicester, Leicester Royal Infirm, Dept Child Hlth, Leicester LE2 7LX, Leics, England	University of Leicester	Barry, PW (corresponding author), Univ Leicester, Leicester Royal Infirm, Dept Child Hlth, Robert Kilpatrick Clin Sci Bldg,POB 65, Leicester LE2 7LX, Leics, England.							BELL J H, 1973, Journal of Pharmacy and Pharmacology, V25, P32; Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102; NEWNHAM DM, 1994, THORAX, V49, P762, DOI 10.1136/thx.49.8.762	3	11	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1998	102	2					321	322		10.1016/S0091-6749(98)70103-4	http://dx.doi.org/10.1016/S0091-6749(98)70103-4			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	113EH	9723679				2022-12-18	WOS:000075537100028
J	Avunduk, AM; Avunduk, MC; Dayanir, V; Tekelioglu, Y; Dayioglu, YS				Avunduk, AM; Avunduk, MC; Dayanir, V; Tekelioglu, Y; Dayioglu, YS			A flow cytometric study about the immunopathology of vernal keratoconjuctivitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						vernal keratoconjunctivitis; CD4+ lymphocyte; CD4/29+ lymphocyte; CD4/45RA+ lymphocyte; immunopathology	T-CELL SUBSETS; KERATOCONJUNCTIVITIS; CONJUNCTIVITIS; ANTIBODIES; DISEASE; TEARS; SERUM; IGE	Background: Vernal keratoconjunctivitis (VKC) is a bilateral seasonal conjunctival inflammation. Exact pathogenesis of the disease is unknown, but some evidences suggest T-H lymphocyte-mediated immune reactions. Objective: The aim of this study was to investigate the role of the T lymphocyte and its subsets in the pathogenesis of VKC. Methods: We obtained tear samples from patients with VKC and normal volunteers during active (spring) and quiescent (winter) periods, The patients' records were also obtained for assessment of symptom scores, The percentages of CD4/29+, CD4/45RA+, CD4+, and CD8+ in tear samples were established by using Bow cytometry, and the results of all three groups were compared with each other by using the Wilcoxon matched-pair signed-rank test and the Mann-Whitney U test. Results: The percentages of CD4/29+ and CD-If cells in tears of patients with VKC increased significantly in the active period and decreased to normal levels in the quiescent stage. In contrast, the percentages of CD4/45RA+ and CD8+ cells in tears of patients with VKC did not show any significant change between spring and winter, The patients' symptoms were significantly lower in the quiescent period (winter) compared with the active stage (spring). Conclusion: We propose that increased numbers of CD-IC and CD4/29+ cells in tears may be exacerbating the disease during the spring season.	Karadeniz Tech Univ, Sch Med, Dept Ophthalmol, TR-61080 Trabzon, Turkey; Karadeniz Tech Univ, Sch Med, Dept Histol, TR-61080 Trabzon, Turkey; Selcuk Univ, Sch Med, Dept Pathol, Konya, Turkey; Eskisehir AF Hosp, Ophthalmol Clin, Eskisehir, Turkey	Karadeniz Technical University; Karadeniz Technical University; Selcuk University; Eskisehir Military Hospital	Avunduk, AM (corresponding author), Karadeniz Tech Univ, Sch Med, Dept Ophthalmol, Lojmanlari 31-17, TR-61080 Trabzon, Turkey.		Avunduk, Mustafa Cihat/ABI-4613-2020; Tekelioğlu, Yavuz/AAL-6922-2021	Avunduk, Mustafa Cihat/0000-0002-8709-8949; 				ABBAS AK, 1995, CELLULAR MOL IMMUNOL, P283; ABELSON MB, 1994, PRINCIPLES PRACTICE, V1, P77; AbuElAsrar AM, 1996, AM J OPHTHALMOL, V121, P156, DOI 10.1016/S0002-9394(14)70579-3; ALLANSMITH MR, 1976, AM J OPHTHALMOL, V81, P506, DOI 10.1016/0002-9394(76)90310-X; ALLANSMITH MR, 1991, DUANES CLIN OPHTHALM, V4; Avunduk AM, 1997, JPN J OPHTHALMOL, V41, P67, DOI 10.1016/S0021-5155(97)00012-9; Avunduk AM, 1997, EXP EYE RES, V65, P803, DOI 10.1006/exer.1997.0398; BALLOW M, 1980, J ALLERGY CLIN IMMUN, V66, P112, DOI 10.1016/0091-6749(80)90057-3; BLEIK JH, 1991, OPHTHALMOLOGY, V98, P1679; BONINI S, 1993, ANN ALLERGY, V71, P296; BONINI S, 1995, INT ARCH ALLERGY IMM, V107, P95, DOI 10.1159/000236942; BUCKLEY RJ, 1988, INT OPHTHALMOL CLIN, V28, P303, DOI 10.1097/00004397-198802840-00009; COON JS, 1991, DIAGNOSTIC FLOW CYTO; FOSTER CS, 1995, ALLERGY, V50, P6, DOI 10.1111/j.1398-9995.1995.tb04250.x; FUJISHIMA H, 1995, CLIN EXP IMMUNOL, V102, P395; HINGORANI M, 1995, DRUGS, V50, P208, DOI 10.2165/00003495-199550020-00002; JOHNSON RL, 1993, CLIN LAB MED, V13, P831, DOI 10.1016/S0272-2712(18)30411-6; LEUNG DYM, 1981, J ALLERGY CLIN IMMUN, V67, P450, DOI 10.1016/0091-6749(81)90098-1; MAGGI E, 1991, J IMMUNOL, V146, P1169; Mendicute J, 1997, EYE, V11, P75, DOI 10.1038/eye.1997.14; MONTAN PG, 1995, OPHTHALMOLOGY, V102, P725, DOI 10.1016/S0161-6420(95)30962-1; Monteseirin J, 1994, Allergol Immunopathol (Madr), V22, P9; NORN MS, 1966, ACTA OPHTHALMOL, V44, P212; PELTZ G, 1991, IMMUNOL REV, V123, P23, DOI 10.1111/j.1600-065X.1991.tb00604.x; RICE NSC, 1973, CLIN ALLERGY, V3, P629, DOI 10.1111/j.1365-2222.1973.tb03066.x; SAMRA Z, 1984, INT ARCH ALLER A IMM, V74, P158, DOI 10.1159/000233537	26	11	11	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1998	101	6	1				821	824		10.1016/S0091-6749(98)70310-0	http://dx.doi.org/10.1016/S0091-6749(98)70310-0			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZW470	9648710				2022-12-18	WOS:000074414200017
J	Roncarolo, D; Minale, P; Mistrello, G; Voltolini, S; Falagiani, P				Roncarolo, D; Minale, P; Mistrello, G; Voltolini, S; Falagiani, P			Food allergy to Boletus edulis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									Lab Farmaceut Lofarma, I-20143 Milan, Italy; Osped San Martino Genova, Dept Allergol, Genoa, Italy	University of Genoa; IRCCS AOU San Martino IST	Mistrello, G (corresponding author), Lab Farmaceut Lofarma, Viale Cassala 40, I-20143 Milan, Italy.							BRANDER KA, 1997, J ALLERGY CLIN IMMUN, V99, pS348; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OLIVIERI V, 1993, J IMMUNOL METHODS, V157, P65, DOI 10.1016/0022-1759(93)90071-E; Seeger Ruth, 1995, Czech Mycology, V48, P97; TORRICELLI R, 1995, 6 INT S IMM CLIN PRO	5	11	11	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1998	101	6	1				850	851		10.1016/S0091-6749(98)70315-X	http://dx.doi.org/10.1016/S0091-6749(98)70315-X			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZW470	9648715				2022-12-18	WOS:000074414200022
J	Hargreave, FE; Pizzichini, E; Pizzichini, M				Hargreave, FE; Pizzichini, E; Pizzichini, M			Induced sputum examination	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									McMaster Univ, St Joseph Hosp, Firestone Reg Chest & Allergy Unit, Hamilton, ON L8N 4A6, Canada	McMaster University	Hargreave, FE (corresponding author), McMaster Univ, St Joseph Hosp, Firestone Reg Chest & Allergy Unit, 50 Charleton Ave E, Hamilton, ON L8N 4A6, Canada.		Pizzichini, Emilio/L-2252-2014; Pizzichini, Marcia/K-5168-2013	Pizzichini, Emilio/0000-0001-7046-9996; Pizzichini, Marcia/0000-0001-7409-7536; Barnes, Peter/0000-0002-5122-4018; Pizzichini, Marcia/0000-0001-6336-7203				FAHY JV, 1993, AM REV RESPIR DIS, V147, P1126, DOI 10.1164/ajrccm/147.5.1126; GERSHMAN NH, 1997, AM J RESP CRIT CARE, V155, P819; Keatings VM, 1997, J ALLERGY CLIN IMMUN, V99, P693, DOI 10.1016/S0091-6749(97)70032-0; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Veen JCCMI, 1996, EUR RESPIR J, V9, P2441, DOI 10.1183/09031936.96.09122441	5	11	12	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1998	101	4	1				569	569						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZH469	9564818				2022-12-18	WOS:000073113500028
J	Tovey, ER; Sluyter, R; Duffy, DL; Britton, WJ				Tovey, ER; Sluyter, R; Duffy, DL; Britton, WJ			Immunoblotting analysis of twin sera provides evidence for limited genetic control of specific IgE to house dust mite allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE repertoire; atopy; twins; house dust mites; immunoblotting; genetic; gene; allergy	ASTHMA; ATOPY	Background: Although some studies have shown genetic control of specific IgE responses to purified grass allergens, studies with other allergens have not supported this. The extent of such control for house dust mite (HDM) (Dermatophagoides pteronyssinus) allergens is unclear. Objective: We sought to determine the extent to which genetic factors control the specificity of IgE responses to individual HDM allergens by comparing the immunoblot patterns of IgE binding of serum from monozygotic and dizygotic members of a large cohort of Australian twins. Methods: HDM proteins separated by sodium dodecylsulfate-polyacrylamide gel electrophoresis were immunoblotted with sera from 317 twin pairs in which at least one twin had at least a weak HDM skin test response. Concordance levels for IgE binding to the individual HDM components were compared in the subset of 142 pairs of twins in which both twins were allergic to HDMs (skin prick test wheal diameter, > 3 mm). Results: Over all 36 blotted bands, the mean case-wise concordance was 41% for monozygotic twins and 17% for dizygotic twins. Of the components detected, only those of molecular weights 23 kd and 16 lid mere significantly different between the groups (p < 0.01). Differences observed between the monozygotic and dizygotic twins could be partly explained by overall IgE hyperresponsiveness. Conclusion: Evidence for genetic control of IgE responses to 36 IgE-binding HDM components from a large sample of twins showed significant differences in concordance for two components and nonsignificant differences for several others. In the monozygotic twins, concordance never exceeded 67% for any band, and most monozygotic individuals recognized components their co-twin did not. Genetic control of overall atopy in monozygotic twins is far stronger than that controlling specific sensitization to HDM allergens.	Univ Sydney, Dept Med, Sydney, NSW 2006, Australia; Queensland Inst Med Res, Genet Epidemiol Lab, Herston, Qld 4006, Australia; Med Res Inst, Sydney, NSW, Australia	University of Sydney; QIMR Berghofer Medical Research Institute	Tovey, ER (corresponding author), Univ Sydney, Dept Med, Blackburn Bldg,DO6, Sydney, NSW 2006, Australia.		Duffy, David L/B-7392-2013; Tovey, Euan R/G-8604-2017; Sluyter, Ronald/B-5798-2009	Duffy, David L/0000-0001-7227-632X; Tovey, Euan R/0000-0002-1802-7266; Sluyter, Ronald/0000-0003-4909-686X				BLUMENTHAL MN, 1990, GENETIC ENV FACTORS, P132; Cooke RA, 1916, J IMMUNOL, V1, P201; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; DUFFY DL, 1990, AM REV RESPIR DIS, V142, P1351, DOI 10.1164/ajrccm/142.6_Pt_1.1351; DUFFY DL, 1994, AM J HUM GENET S, V55, P332; LEVINE BB, 1972, SCIENCE, V178, P1201, DOI 10.1126/science.178.4066.1201; MARSH DG, 1981, NEW ENGL J MED, V305, P1551, DOI 10.1056/NEJM198112243052603; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; Moffatt MF, 1997, IMMUNOGENETICS, V46, P226, DOI 10.1007/s002510050266; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; SLUYTER R, 1998, IN PRESS CLIN EXP AL; TOVEY ER, 1987, J ALLERGY CLIN IMMUN, V79, P93, DOI 10.1016/S0091-6749(87)80022-2; TOVEY ER, 1995, J ALLERGY CLIN IMMUN, V739, P325	15	11	12	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1998	101	4	1				491	497		10.1016/S0091-6749(98)70356-2	http://dx.doi.org/10.1016/S0091-6749(98)70356-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZH469	9564802	Bronze			2022-12-18	WOS:000073113500011
J	Schatz, M				Schatz, M			Special considerations for the pregnant woman and senior citizen with airway disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	21st Century Management of Upper Respiratory Allergic Diseases - a Focus on Allergy and Asthma	JAN 13-14, 1997	CHICAGO, IL				ASTHMATIC WOMEN; SAFETY; IMMUNOTHERAPY; GASTROSCHISIS; RHINITIS; GROWTH		Kaiser Permanente Med Ctr, Dept Allergy, San Diego, CA 92111 USA; Univ Calif San Diego, Sch Med, Dept Med, San Diego, CA 92103 USA	Kaiser Permanente; University of California System; University of California San Diego	Schatz, M (corresponding author), Kaiser Permanente Med Ctr, Dept Allergy, 7060 Clairemont Mesa Blvd, San Diego, CA 92111 USA.							BERTRAND JM, 1985, NEW ENGL J MED, V312, P742, DOI 10.1056/NEJM198503213121202; BRAMAN SS, 1991, AM REV RESPIR DIS, V143, P336, DOI 10.1164/ajrccm/143.2.336; BURROWS B, 1991, CHEST, V100, P935, DOI 10.1378/chest.100.4.935; COATES ML, 1995, J FAM PRACTICE, V40, P22; GLUCK JC, 1976, ANN ALLERGY, V37, P164; GREENBERGER PA, 1988, NEW ENGL REG ALLERGY, V9, P539, DOI 10.2500/108854188778965555; JUNIPER EF, 1988, ASTMA IMMUNOLOGICAL, P401; LUND VJ, 1994, ALLERGY S, V49, P21; MABRY RL, 1986, SOUTHERN MED J, V79, P965, DOI 10.1097/00007611-198608000-00012; McCue JD, 1996, ARCH FAM MED, V5, P464, DOI 10.1001/archfami.5.8.464; METZGER WJ, 1978, J ALLERGY CLIN IMMUN, V61, P268, DOI 10.1016/0091-6749(78)90202-6; Mygind N, 1990, AM J RHINOL, V4, P1; *NAT ASTHM ED PROG, 1996, 963662 NIH NAT ASTHM; *NAT ASTHM ED PROG, 1993, 933279A NIH NAT ASTH; PERLOW JH, 1992, AM J OBSTET GYNECOL, V167, P963, DOI 10.1016/S0002-9378(12)80020-2; REINISCH JM, 1978, SCIENCE, V202, P436, DOI 10.1126/science.705336; SCHATZ M, 1990, CHEST, V98, P389, DOI 10.1378/chest.98.2.389; Schatz M, 1997, ANN ALLERG ASTHMA IM, V78, P157, DOI 10.1016/S1081-1206(10)63382-0; SCHATZ M, 1988, Journal of Allergy and Clinical Immunology, V81, P509, DOI 10.1016/0091-6749(88)90187-X; SCHATZ M, 1995, AM J RESP CRIT CARE, V151, P1170; Schatz M, 1996, IMMUNOL ALLERGY CLIN, V16, P893, DOI 10.1016/S0889-8561(05)70277-0; SCHATZ M, 1988, NEW ENGL REG ALLERGY, V9, P545, DOI 10.2500/108854188778965627; SCHATZ M, ALLERGY PRINCIPLES P; SCHATZ M, 1996, ALLERGY CLIN IMMUNOL, P729; SCHATZ M, 1992, PRINCIPLES PRACTICE, P435; SHAIKH WA, 1993, CLIN EXP ALLERGY, V23, P857, DOI 10.1111/j.1365-2222.1993.tb00264.x; SNASHALL PD, 1991, AM REV RESPIR DIS, V144, P945, DOI 10.1164/ajrccm/144.4.945; SORRI M, 1980, Rhinology (Utrecht), V18, P83; STENIUSAARNIALA B, 1988, THORAX, V43, P12, DOI 10.1136/thx.43.1.12; STENIUSAARNIALA B, 1995, CHEST, V107, P642, DOI 10.1378/chest.107.3.642; SteniusAarniala BSM, 1996, THORAX, V51, P411, DOI 10.1136/thx.51.4.411; Torfs CP, 1996, TERATOLOGY, V54, P84, DOI 10.1002/(SICI)1096-9926(199606)54:2<84::AID-TERA4>3.0.CO;2-4; Wendel PJ, 1996, AM J OBSTET GYNECOL, V175, P150, DOI 10.1016/S0002-9378(96)70265-X; WERLER MM, 1992, TERATOLOGY, V45, P361, DOI 10.1002/tera.1420450407	34	11	11	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1998	101	2	2	S			S373	S378		10.1016/S0091-6749(98)70224-6	http://dx.doi.org/10.1016/S0091-6749(98)70224-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	ZA245	9500732				2022-12-18	WOS:000072343900008
J	Cheng, KC; Lee, KM; Krug, MS; Watanabe, T; Suzuki, M; Choe, IS; Yoo, TJ				Cheng, KC; Lee, KM; Krug, MS; Watanabe, T; Suzuki, M; Choe, IS; Yoo, TJ			House dust mite-induced sensitivity in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HDM-induced sensitivity; T-cell receptor use; Der p I; T-cell epitopes; eosinophilic cells; mononuclear-cell infiltration	DER-P-I; T-CELL RESPONSES; DERMATOPHAGOIDES-PTERONYSSINUS; SEQUENCE-ANALYSIS; HUMAN IGE; ALLERGEN; ANTIBODY; RECOGNITION; EPITOPES; BINDING	Sensitivity induced by house dust mite (HDM) extract in mice was investigated in this study. Sensitized B10.RIII mice (H-2(r) background) had T-cell proliferative responses to HDM extract in vitro and an HDM-specific IgE response. When mice were immunized by injection and intranasal inhalation with HDM extract, a histologic study showed eosinophils and mononuclear cell infiltration in the lung tissue and bronchial wall. Tcr alpha beta-positive cells were also found in the cell infiltration area of the lung lesions. In the control mice that were immunized by injection or intranasal inhalation (but not both), we did not observe cell accumulation in the lung tissue or in the bronchial wall. Epitope studies suggest that T cells recognize multiple epitopes. Molecular analysis of these HDM-specific T-cell hybridoma clones suggest that T-cell receptor use is restricted to members of the V alpha 8 and V beta 6 subfamilies.	Univ Tennessee, Sch Med, Dept Med, Div Allergy & Immunol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Yoo, TJ (corresponding author), Univ Tennessee, Sch Med, Dept Med, Div Allergy & Immunol, 956 Court Ave,Room H300, Memphis, TN 38163 USA.							CHAPMAN MD, 1984, J IMMUNOL, V133, P2488; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P124, DOI 10.1159/000235102; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P118, DOI 10.1159/000235101; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; DILWORTH RJ, 1991, CLIN EXP ALLERGY, V21, P25, DOI 10.1111/j.1365-2222.1991.tb00800.x; HOYNE GF, 1993, J EXP MED, V178, P1783, DOI 10.1084/jem.178.5.1783; INAGAKI N, 1985, J PHARMACOBIO-DYNAM, V8, P958; ISHIZAKA K, 1984, ANNU REV IMMUNOL, V2, P159, DOI 10.1146/annurev.immunol.2.1.159; LANZAVECCHIA A, 1983, CLIN EXP IMMUNOL, V52, P21; Lett-Brown M A, 1989, Year Immunol, V5, P195; LIND P, 1988, J IMMUNOL, V140, P4256; LIND P, 1983, SCAND J IMMUNOL, V17, P263, DOI 10.1111/j.1365-3083.1983.tb00789.x; OBRIEN RM, 1992, J ALLERGY CLIN IMMUN, V89, P1021, DOI 10.1016/0091-6749(92)90225-Q; OHEHIR RE, 1993, EUR J CLIN INVEST, V23, P763, DOI 10.1111/j.1365-2362.1993.tb00729.x; OHEHIR RE, 1987, IMMUNOLOGY, V62, P635; RAWLE FC, 1984, J IMMUNOL, V133, P195; STEWART GA, 1987, INT ARCH ALLER A IMM, V83, P44, DOI 10.1159/000234329; TADA T, 1971, J IMMUNOL, V106, P1002; TRUDINGER M, 1991, CLIN EXP ALLERGY, V21, P33, DOI 10.1111/j.1365-2222.1991.tb00801.x; WEDDERBURN LR, 1993, P NATL ACAD SCI USA, V90, P8214, DOI 10.1073/pnas.90.17.8214; YSSEL H, 1992, J IMMUNOL, V148, P738	21	11	15	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	1				51	59		10.1016/S0091-6749(98)70193-9	http://dx.doi.org/10.1016/S0091-6749(98)70193-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YR872	9449501				2022-12-18	WOS:000071539800009
J	Ferrer, M; Kinet, JP; Kaplan, AP				Ferrer, M; Kinet, JP; Kaplan, AP			Activation of cutaneous mast cells by chronic urticaria sera	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									Harvard Univ, Sch Med, Boston, MA USA; Med Univ S Carolina, Charleston, SC 29425 USA	Harvard University; Harvard Medical School; Medical University of South Carolina			Ferrer, Marta/C-4319-2016	Ferrer, Marta/0000-0001-8495-1302					0	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	2			636	S154	S154						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YW339					2022-12-18	WOS:000071924800636
J	Graham, SM; Ballas, ZK				Graham, SM; Ballas, ZK			Preoperative steroids confuse the diagnosis of allergic fungal sinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									Univ Iowa, Dept Otolaryngol Head & Neck Surg, Div Head & Neck Surg, Iowa City, IA 52242 USA; Univ Iowa, Dept Internal Med, Div Allergy & Immunol, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Graham, SM (corresponding author), Univ Iowa Hosp & Clin, Dept Otolaryngol Head & Neck Surg, 200 Hawkins Dr,E230 GH, Iowa City, IA 52242 USA.			Ballas, Zuhair/0000-0001-5569-1230; Knaack, Aaron/0000-0001-7712-1415; Graham, Scott/0000-0003-2969-2998				BENT JP, 1994, OTOLARYNG HEAD NECK, V111, P580, DOI 10.1016/S0194-5998(94)70525-9; ENGLISH GM, 1991, OTOLARYNGOLOGY, P1; MANNING SC, 1991, ARCH OTOLARYNGOL, V117, P174; Roth M, 1994, Ear Nose Throat J, V73, P928; WAXMAN JE, 1987, LARYNGOSCOPE, V97, P261	5	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	1				139	140		10.1016/S0091-6749(98)70211-8	http://dx.doi.org/10.1016/S0091-6749(98)70211-8			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YR872	9449519	Bronze			2022-12-18	WOS:000071539800027
J	Kalberg, CJ; Nelson, H; Yancey, S; Petrocella, V; Emmett, AH; Richard, KA				Kalberg, CJ; Nelson, H; Yancey, S; Petrocella, V; Emmett, AH; Richard, KA		FP Clinical Study Grp	A comparison of added Salmeterol versus increased-dose fluticasone in patients symptomatic on low-dose fluticasone.	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									Glaxo Wellcome, Res Triangle Pk, NC USA; Natl Jewish Med & Res Ctr, Denver, CO USA	GlaxoSmithKline; National Jewish Health									0	11	11	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	2			23	S6	S6						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YW339					2022-12-18	WOS:000071924800024
J	Villavicencio, AT; Hey, LA; Patel, D; Bressler, P				Villavicencio, AT; Hey, LA; Patel, D; Bressler, P			Acute cardiac and pulmonary arrest after infusion of vancomycin with subsequent desensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									Duke Univ, Med Ctr, Div Neurosurg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Div Orthoped Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Div Rheumatol Allergy & Immunol, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Villavicencio, AT (corresponding author), Duke Univ, Med Ctr, Div Neurosurg, Box 3468, Durham, NC 27710 USA.							KUNAKOLN CW, 1982, ANN INTERN MED, V97, P376; MYERS JP, 1982, J INFECT DIS, V145, P532, DOI 10.1093/infdis/145.4.532; POLK RE, 1988, J INFECT DIS, V157, P502, DOI 10.1093/infdis/157.3.502; ROSCOW CE, 1982, ANESTHESIOLOGY, V56, P93; WONG JT, 1994, J ALLERGY CLIN IMMUN, V94, P189, DOI 10.1016/0091-6749(94)90039-6	5	11	11	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1997	100	6	1				853	854		10.1016/S0091-6749(97)70287-2	http://dx.doi.org/10.1016/S0091-6749(97)70287-2			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YQ151	9438500				2022-12-18	WOS:000071353600024
J	Perzanowski, MS; Wheatley, LM; Avner, DB; Woodfolk, JA; PlattsMills, TAE				Perzanowski, MS; Wheatley, LM; Avner, DB; Woodfolk, JA; PlattsMills, TAE			The effectiveness of Allerpet/c in reducing the cat allergen Fel d 1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							D-I		UNIV VIRGINIA,HLTH SCI CTR,ASTHMA & ALLERG DIS CTR,CHARLOTTESVILLE,VA 22908	University of Virginia				Platts-Mills, Thomas/0000-0002-1263-329X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020565, U01AI034607, R37AI020565] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20565, 1U01-AI-34607] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334, DOI 10.1164/ajrccm/143.6.1334; FINDLAY SR, 1983, AM REV RESPIR DIS, V128, P1008; KLUCKA CV, 1995, J ALLERGY CLIN IMMUN, V95, P1164, DOI 10.1016/S0091-6749(95)70072-2; KOREN LGH, 1995, J ALLERGY CLIN IMMUN, V95, P322; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361	5	11	12	1	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1997	100	3					428	430		10.1016/S0091-6749(97)70261-6	http://dx.doi.org/10.1016/S0091-6749(97)70261-6			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XX479	9314360				2022-12-18	WOS:A1997XX47900025
J	Plaut, M				Plaut, M			New directions in food allergy research	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HISTAMINE-RELEASING FACTOR; ATOPIC-DERMATITIS; HYPERSENSITIVITY; BASOPHILS				Plaut, M (corresponding author), NIAID, ASTHMA ALLERGY & INFLAMMAT BRANCH, DIV ALLERGY IMMUNOL & TRANSPLANTAT, NIH, ROOM 4A25, BETHESDA, MD 20892 USA.							Arruda LK, 1995, J BIOL CHEM, V270, P31196, DOI 10.1074/jbc.270.52.31196; BURKS AW, 1995, J CLIN INVEST, V96, P1715, DOI 10.1172/JCI118216; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; James JM, 1996, AM J RESP CRIT CARE, V153, P597, DOI 10.1164/ajrccm.153.2.8564104; JAMES JM, 1993, J ALLERGY CLIN IMMUN, V91, P1155, DOI 10.1016/0091-6749(93)90318-A; MACDONALD SM, 1995, SCIENCE, V269, P688, DOI 10.1126/science.7542803; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P432, DOI 10.1016/0091-6749(76)90124-X; Metcalfe DD, 1996, CRIT REV FOOD SCI, V36, pS165, DOI 10.1080/10408399609527763; METCALFE DD, 1995, CLIN IMMUNOLOGY PRIN, P966; NELSON HS, 1994, J ALLERGY CLIN IMMUN, V93, P211; Nicklas RA, 1996, J ALLERGY CLIN IMMUN, V98, P1001, DOI 10.1016/S0091-6749(96)80183-7; Nordlee JA, 1996, NEW ENGL J MED, V334, P688, DOI 10.1056/NEJM199603143341103; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; Rumsaeng V, 1996, Semin Gastrointest Dis, V7, P134; Sampson HA, 1996, ANNU REV NUTR, V16, P161, DOI [10.1146/annurev.nu.16.070196.001113, 10.1146/annurev.nutr.16.1.161]; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SAMPSON HA, 1989, NEW ENGL J MED, V321, P228, DOI 10.1056/NEJM198907273210405; SAMPSON HA, 1993, ALLERGY PRINCIPLES P, P1661; Tada Y, 1996, FEBS LETT, V391, P341, DOI 10.1016/0014-5793(96)00773-9; *USDA, 1983, FED REGISTER, V48, P32749; Whitacre CC, 1996, ANN NY ACAD SCI, V778, P217, DOI 10.1111/j.1749-6632.1996.tb21130.x; YOCUM MW, 1994, MAYO CLIN PROC, V69, P16, DOI 10.1016/S0025-6196(12)61606-1	26	11	11	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1997	100	1					7	10		10.1016/S0091-6749(97)70187-8	http://dx.doi.org/10.1016/S0091-6749(97)70187-8			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XP428	9257780				2022-12-18	WOS:A1997XP42800002
J	Sporik, R; Kemp, AS				Sporik, R; Kemp, AS			Topical triclosan treatment of atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									ROYAL CHILDRENS HOSP,DEPT ALLERGY,MELBOURNE,VIC 3052,AUSTRALIA	Royal Children's Hospital Melbourne	Sporik, R (corresponding author), ROYAL CHILDRENS HOSP,DEPT CLIN IMMUNOL,MELBOURNE,VIC 3052,AUSTRALIA.							KJAERHEIM V, 1995, J CLIN PERIODONTOL, V22, P423, DOI 10.1111/j.1600-051X.1995.tb00172.x; KOLMER, 1996, J ALLERGY CLIN IMMUN, V98, P702; REGOS J, 1979, DERMATOLOGICA, V158, P72, DOI 10.1159/000250746; WEBSTER J, 1994, J PAEDIATR CHILD H, V30, P59, DOI 10.1111/j.1440-1754.1994.tb00568.x	4	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1997	99	6	1				861	861		10.1016/S0091-6749(97)80029-2	http://dx.doi.org/10.1016/S0091-6749(97)80029-2			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XH193	9215263				2022-12-18	WOS:A1997XH19300028
J	Leipzig, JR; Martin, DS; Eisenbeis, JF; Slavin, RG				Leipzig, JR; Martin, DS; Eisenbeis, JF; Slavin, RG			Computed tomographic study of the paranasal sinuses in allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST LOUIS UNIV,SCH MED,DEPT INTERNAL MED,ST LOUIS,MO; ST LOUIS UNIV,SCH MED,DEPT RADIOL,ST LOUIS,MO; ST LOUIS UNIV,SCH MED,DEPT OTOLARYNGOL HEAD & NECK SURG,ST LOUIS,MO	Saint Louis University; Saint Louis University; Saint Louis University								CALHOUN KH, 1991, OTOLARYNG HEAD NECK, V104, P480, DOI 10.1177/019459989110400409; GWALTNEY JM, 1994, NEW ENGL J MED, V330, P25, DOI 10.1056/NEJM199401063300105; SLAVIN RG, 1988, J ALLERGY CLIN IMMUN, V81, P284, DOI 10.1016/0091-6749(88)90700-2	3	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	1				1130	1131		10.1016/S0091-6749(96)80206-5	http://dx.doi.org/10.1016/S0091-6749(96)80206-5			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WB378	8977520	Bronze			2022-12-18	WOS:A1996WB37800024
J	Djukanovic, R				Djukanovic, R			Section 2: Drug modulation of inflammation - Bronchoscopy as a research tool for the study of asthma pathogenesis and effects of antiasthma drugs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway inflammation; bronchial biopsy; bronchoalveolar lavage; drug effects	BRONCHOALVEOLAR LAVAGE; ATOPIC ASTHMA; MAST-CELLS; BRONCHIAL RESPONSIVENESS; LYMPHOCYTE-ACTIVATION; AIRWAY EPITHELIUM; GENE-EXPRESSION; EOSINOPHILS; INTERLEUKIN-4; SYMPTOMS	Fiberoptic bronchoscopic methods have greatly improved our understanding of asthma pathogenesis and of the mode of action of established and experimental antiasthma drugs It is probably most appropriate to study bronchoalveolar lavage (BAL) and bronchial biopsy simultaneously because there are major differences between the airway lumen and tissue compartments: for example, T cells al-e the most abundant cells in endobronchial biopsy samples but form only 10% to 20% of total BAL cells and eosinophils and mast cells are mole numerous in the airway tissue than in the lumina. Immunostaining is currently the most reliable method for enumerating cells and assessing their activation state with a panel of cell surface and intracellular activation markers. In situ hybridization can be used to study a cell's capacity for cytokine production. Newer techniques allow immunohistochemistry of adjacent cell sections to co-localize staining with different antibodies, showing for example that mast cells contain preformed cytokines IL-4, IL-5, and IL-6 and tumor necrosis factor-alpha. A combination of immunohistochemistry and in situ hybridization can colocalize messenger RNA transcription to individual cell types; this approach is useful for T cells, which do not have storage capacity and cannot be shown by immunohistochemistry to contain cytokines. An additional tool to assess cellular activity is reverse transcriptase polymerase chain reaction, which has recently been rued to confirm a predominant T-H2-type cytokine profile in allergic disease.			Djukanovic, R (corresponding author), SOUTHAMPTON GEN HOSP,LEVEL D,CTR BLOCK,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.			Djukanovic, Ratko/0000-0001-6039-5612				AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BARNES PJ, 1994, EUR RESPIR J, V7, P579, DOI 10.1183/09031936.94.07030579; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500, DOI 10.1164/ajrccm/146.2.500; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; BROIDE DH, 1991, J ALLERGY CLIN IMMUN, V88, P637, DOI 10.1016/0091-6749(91)90158-K; CALHOUN WJ, 1995, ASTHMA RHINITIS, P467; CORRIGAN CJ, 1988, LANCET, V1, P1129; DIAZ P, 1984, J ALLERGY CLIN IMMUN, V74, P41, DOI 10.1016/0091-6749(84)90085-X; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P863, DOI 10.1164/ajrccm/142.4.863; DJUKANOVIC R, 1992, EUR RESPIR J, V5, P538; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; DJUKANOVIC R, 1991, AM REV RESPIR DIS, V143, P772, DOI 10.1164/ajrccm/143.4_Pt_1.772; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V143, pA627; KIDNEY J, 1995, AM J RESP CRIT CARE, V151, P1907, DOI 10.1164/ajrccm.151.6.7767539; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LEUNG DYM, 1995, J EXP MED, V181, P33, DOI 10.1084/jem.181.1.33; MCWILLIAM AS, 1995, ASTHMA RHINITIS, P474; MONTEFORT S, 1992, AM J RESP CELL MOL, V7, P393, DOI 10.1165/ajrcmb/7.4.393; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; ROBINSON DS, 1993, THORAX, V48, P26, DOI 10.1136/thx.48.1.26; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SPRINGALL DR, 1991, LANCET, V337, P697, DOI 10.1016/0140-6736(91)90279-X; SULLIVAN P, 1994, LANCET, V343, P1006, DOI 10.1016/S0140-6736(94)90127-9; VANVYVE T, 1992, AM REV RESPIR DIS, V146, P116, DOI 10.1164/ajrccm/146.1.116; WAITERS EH, 1989, RESPIR MED, V83, P457; WILSON JW, 1994, AM J RESP CRIT CARE, V149, P86, DOI 10.1164/ajrccm.149.1.8111605; WILSON JW, 1992, AM REV RESPIR DIS, V145, P958, DOI 10.1164/ajrccm/145.4_Pt_1.958; ZANGRILLI JG, 1995, ASTHMA RHINITIS, P426; 1991, J ALLERGY CLIN IMMUN, V88, P808	35	11	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1996	98	5	2	S			S41	S45		10.1016/S0091-6749(96)80127-8	http://dx.doi.org/10.1016/S0091-6749(96)80127-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VW140	8939175				2022-12-18	WOS:A1996VW14000008
J	Nakagawa, T; Nakagomi, T; Hisamatsu, S; Itaya, H; Nakagomi, O; Mizushima, Y				Nakagawa, T; Nakagomi, T; Hisamatsu, S; Itaya, H; Nakagomi, O; Mizushima, Y			Increased prevalence of elevated serum IgE and IgG(4) antibodies in students over a decade	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									AKITA UNIV,SCH MED,DEPT MICROBIOL,AKITA 010,JAPAN; AKITA UNIV,SCH MED,DEPT PUBL HLTH,AKITA 010,JAPAN; HITACHI CHEM CO LTD,PHARMACEUT RES LAB,IBARAKI,OSAKA,JAPAN	Akita University; Akita University; Hitachi Limited	Nakagawa, T (corresponding author), ST MARIANNA UNIV,SCH MED,INST MED SCI,MIYAMAE KU,2-16-1 SUGAO,KAWASAKI,KANAGAWA 216,JAPAN.			Hisamatsu, Shun'ichi/0000-0001-6410-5387				AALBERSE RC, 1993, ALLERGY, V48, P559, DOI 10.1111/j.1398-9995.1993.tb00749.x; NAKAGAWA T, 1987, INT ARCH ALLER A IMM, V82, P95, DOI 10.1159/000234297; NAKAGAWA T, 1991, ACI NEWS, V3, P103; NAKAGOMI T, 1994, LANCET, V343, P121, DOI 10.1016/S0140-6736(94)90854-0; YANAGAWA T, 1985, ENVIRON HEALTH PERSP, V63, P217, DOI 10.2307/3430049; 1995, J ALLERGY CLIN IMMUN, V95, P652	6	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1996	97	5					1165	1166		10.1016/S0091-6749(96)70272-5	http://dx.doi.org/10.1016/S0091-6749(96)70272-5			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UL261	8626995				2022-12-18	WOS:A1996UL26100018
J	BelchiHernandez, J; MoraGonzalez, A; IniestaPerez, J				BelchiHernandez, J; MoraGonzalez, A; IniestaPerez, J			Baker's asthma caused by Saccharomyces cerevisiae in dry powder form	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ALLERGENS		J MA MORALES MESEGUER UNIV HOSP,DEPT ALLERGY,MURCIA,SPAIN; HIGH SCH CARRUS,DEPT BIOL,ELCHE,SPAIN									ARMENTIA A, 1990, ANN ALLERGY, V65, P265; BALDO BA, 1988, INT ARCH ALLER A IMM, V86, P201, DOI 10.1159/000234572; BAUR X, 1988, RESPIRATION, V54, P70, DOI 10.1159/000195503; BAUR X, 1994, SCHWEIZ MED WSCHR, V124, P846; BLOCK G, 1984, CLIN ALLERGY, V14, P177, DOI 10.1111/j.1365-2222.1984.tb02650.x; BUSH RK, 1988, J ALLERGY CLIN IMMUN, V82, P251, DOI 10.1016/0091-6749(88)91007-X; CARMONA JG, 1991, ALLERGY, V46, P244; HOCKING AD, 1980, APPL ENVIRON MICROB, V39, P488, DOI 10.1128/AEM.39.3.488-492.1980; LAVAUD F, 1994, ALLERGY, V49, P159, DOI 10.1111/j.1398-9995.1994.tb00819.x; LOSADA E, 1986, J ALLERGY CLIN IMMUN, V77, P635, DOI 10.1016/0091-6749(86)90358-1; SANDIFORD CP, 1994, CLIN EXP ALLERGY, V24, P549, DOI 10.1111/j.1365-2222.1994.tb00952.x; SOHMEN R, 1993, ALLERGOLOGIE, V16, P248; SUTTON R, 1984, CLIN ALLERGY, V14, P93, DOI 10.1111/j.1365-2222.1984.tb02196.x; WUTHRICH B, 1990, SCHWEIZ MED WSCHR, V120, P446; WUTHRICH B, 1990, SCHWEIZ MED WOCHENSC, V120, P448	15	11	11	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1996	97	1	1				131	134		10.1016/S0091-6749(96)70293-2	http://dx.doi.org/10.1016/S0091-6749(96)70293-2			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TR947	8568127				2022-12-18	WOS:A1996TR94700018
J	Torricelli, R; Wuthrich, B				Torricelli, R; Wuthrich, B			Inhalative and ingestive occupational allergy to Boletus edulis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1996	97	1	3				76	76						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TV536					2022-12-18	WOS:A1996TV53600076
J	Fukuda, T; Mochida, S; Fukushima, Y; Makino, S				Fukuda, T; Mochida, S; Fukushima, Y; Makino, S			Detection of allergen-induced genes in peripheral blood mononuclear cells of patients with allergic asthma using subtractive hybridization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	New Trends in Immunopharmacology 1994 Conference	JUL   23, 1994	TOKYO, JAPAN	Sandoz Pharm Ltd		asthma; eosinophil chemotactic activity; subtractive hybridization; IL-5; lone-linker PCR; peripheral blood mononuclear cells; mite antigen; ferritin	RECOMBINANT HUMAN INTERLEUKIN-5; BRONCHIAL BIOPSIES; EOSINOPHILS; DNA; LYMPHOCYTES; CLONING; RNA	When stimulated with mite antigens, peripheral blood mononuclear cells obtained from patients with mite allergy release eosinophil chemotactic factor, a type of protein. Complementary DNA libraries were formulated from both peripheral blood mononuclear cells stimulated with mite antigens and those nor stimulated with mite antigens and underwent subtraction and differential screening. The authors obtained 13 genes for which expression had increased because of mite antigens. Of these, nine were mitochondrial genes; two, h-satellite DNA III; one, factor XIII and one, ferritin heavy subunit. As a result of polymerase chain reaction on both cDNA libraries, IL-5 genes were amplified only from the cDNA library that had been stimulated with mite antigens.	TSUMURA & CO,RES INST MOLEC GENET,AMI,IBARAKI,JAPAN	Tsumura & Company	Fukuda, T (corresponding author), DOKKYO UNIV,SCH MED,DEPT INTERNAL MED & CLIN IMMUNOL,MIBU,TOCHIGI 32102,JAPAN.							AULBERT E, 1991, MED KLIN, V86, P297; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BASCOM R, 1988, AM REV RESPIR DIS, V138, P496; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DIAZ P, 1989, AM REV RESPIR DIS, V139, P1383, DOI 10.1164/ajrccm/139.6.1383; DUGID JR, 1990, NUCLEIC ACIDS RES, V18, P2789; FORSTER AC, 1985, NUCLEIC ACIDS RES, V13, P745, DOI 10.1093/nar/13.3.745; FREW AJ, 1988, J IMMUNOL, V141, P4158; FUJISAWA T, 1990, J IMMUNOL, V144, P642; FUKUDA T, 1994, J ALLERGY CLIN IMMUN, V94, P584, DOI 10.1016/0091-6749(94)90134-1; FUKUSHIMA Y, 1991, Japanese Journal of Allergology, V40, P108; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; KINASHI T, 1986, NATURE, V324, P70, DOI 10.1038/324070a0; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KO MSH, 1990, NUCLEIC ACIDS RES, V18, P4293, DOI 10.1093/nar/18.14.4293; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; Maniatis T., 1982, MOL CLONING; NOMA Y, 1986, NATURE, V319, P640, DOI 10.1038/319640a0; RESNICK MB, 1993, AM J RESP CELL MOL, V8, P349, DOI 10.1165/ajrcmb/8.4.349; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I; WANG JM, 1989, EUR J IMMUNOL, V19, P701, DOI 10.1002/eji.1830190420; WARDLAW AJ, 1994, ALLERGY, V49, P797, DOI 10.1111/j.1398-9995.1994.tb00778.x; Wu A H, 1990, Immunol Ser, V53, P403	25	11	14	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1995	96	6	2	S			1076	1082		10.1016/S0091-6749(95)70193-1	http://dx.doi.org/10.1016/S0091-6749(95)70193-1			7	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ509	8543765				2022-12-18	WOS:A1995TQ50900004
J	Souques, F; Crampette, L; Mondain, M; Vignola, AM; Chanez, P; Bousquet, J; Campbell, AM				Souques, F; Crampette, L; Mondain, M; Vignola, AM; Chanez, P; Bousquet, J; Campbell, AM			Stimulation of dispersed nasal polyp cells by hyperosmolar solutions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						osmolarity; exercise-induced rhinitis; nasal polyp; mast cell	EXERCISE-INDUCED ASTHMA; HUMAN ALVEOLAR MACROPHAGES; HISTAMINE-RELEASE; ARACHIDONIC-ACID; INFLAMMATORY MEDIATORS; EPITHELIAL-CELLS; INVIVO RELEASE; MAST-CELLS; LUNG-CELLS; BASOPHILS	It has been suggested that hyperosmolarity may be one of the stimuli that provoke exercise-induced asthma and rhinitis. We investigated whether changes in osmolarity could result in increased levels of mediator release from nasal cells. Cells were dispersed from nasal cells. Cells were dispersed from nasal polyps by enzymatic digestion and were incubated for 15 minutes with solutions of varying osmolarity obtained by the addition of mannitol to Hanks' balanced salt solution. After incubation was performed, cell supernatants were removed, and the release of 15-hydroxyeicosatetraenoic acid, prostaglandin(2) leukotriene B-4, and fibronectin was measured. Lactate dehydrogenase was measured to assess cell viability. Epithelial cells made up 40% to 60% of cells and mononuclear cells 40% to 65%. At 900 mOsm/kg H2O, which has been suggested as the osmolarity of the fluid lining the airways during exercise, we observed a significant increase (Wilcoxon W test) in the release of 15-hydroxyeicosatetraenoic acid (p<0.008), leukotriene B-4 (p<0.008), and prostaglandin(2) (p<0.008), but not significant increase in the release of fibronectin was seen. No significant increase was seen between hydroxyeicosatetraenoic acid release, suggesting that the increase in mediator levels was not caused by cell death.	CHU MONTPELLIER,HOP ARNAUD DE VILLENEUVE,INSERM,CJF 9210,F-34295 MONTPELLIER 5,FRANCE; CHU MONTPELLIER,HOP ARNAUD DE VILLENEUVE,MALAD RESP CLIN,F-34295 MONTPELLIER 5,FRANCE; CNR,IST FISIOPATOL RESP,PALERMO,ITALY; CHU MONTPELLIER,SERV OTORHINOLARYNGOL,MONTPELLIER,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier; Consiglio Nazionale delle Ricerche (CNR); Universite de Montpellier; CHU de Montpellier			Bousquet, Jean/O-4221-2019	chanez, pascal/0000-0003-4059-0917				ANDERSON SD, 1992, THORAX, V47, P748, DOI 10.1136/thx.47.9.748; ANDERSON SD, 1984, J ALLERGY CLIN IMMUN, V73, P660, DOI 10.1016/0091-6749(84)90301-4; CAMPBELL AM, 1993, AM REV RESPIR DIS, V147, P529, DOI 10.1164/ajrccm/147.3.529; CAMPBELL AM, 1993, ALLERGY, V48, P125, DOI 10.1111/j.1398-9995.1993.tb00697.x; CHURCH MK, 1983, BRIT J PHARMACOL, V78, P671, DOI 10.1111/j.1476-5381.1983.tb09419.x; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DEVALIA JL, 1993, EUR RESPIR J, V6, P1308; EGGLESTON PA, 1987, AM REV RESPIR DIS, V135, P1043; EGGLESTON PA, 1984, AM REV RESPIR DIS, V130, P86; FINDLAY SR, 1981, J CLIN INVEST, V67, P1604, DOI 10.1172/JCI110195; FINNEY MJB, 1990, AM REV RESPIR DIS, V141, P1151, DOI 10.1164/ajrccm/141.5_Pt_1.1151; FORSYTH RD, 1983, J APPL PHYSIOL, V55, P860, DOI 10.1152/jappl.1983.55.3.860; GOETZL EJ, 1983, FED PROC, V42, P3128; HASEGAWA M, 1985, OTOLARYNG HEAD NECK, V93, P772, DOI 10.1177/019459988509300614; HERSHKOVIZ R, 1992, CELL IMMUNOL, V141, P352, DOI 10.1016/0008-8749(92)90154-H; HOLGATE ST, 1984, J IMMUNOL, V133, P2138; HUNTER JA, 1985, P NATL ACAD SCI USA, V82, P4633, DOI 10.1073/pnas.82.14.4633; JACKSON RT, 1981, PROSTAGLANDINS, V21, P1015, DOI 10.1016/0090-6980(81)90169-6; KUMLIN M, 1990, ARCH BIOCHEM BIOPHYS, V282, P254, DOI 10.1016/0003-9861(90)90114-E; LAI CKW, 1990, AM REV RESPIR DIS, V141, P1423; MAKHDUM A, 1993, AGENTS ACTIONS, V38, pC192; MAROM Z, 1981, J CLIN INVEST, V67, P1695, DOI 10.1172/JCI110207; MCFADDEN ER, 1990, LANCET, V335, P880, DOI 10.1016/0140-6736(90)90478-N; MCKINNON KP, 1993, TOXICOL APPL PHARM, V118, P215, DOI 10.1006/taap.1993.1027; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MUSSER JH, 1992, J MED CHEM, V35, P2501, DOI 10.1021/jm00092a001; NAGY L, 1982, CLIN EXP IMMUNOL, V47, P541; PUERINGER RJ, 1992, AM J PHYSIOL, V262, pL78, DOI 10.1152/ajplung.1992.262.1.L78; RADEAU T, 1993, PULM PHARMACOL, V6, P27, DOI 10.1006/pulp.1993.1005; RAMIS I, 1991, PROSTAG OTH LIPID M, V42, P411, DOI 10.1016/0090-6980(91)90032-B; SILBER G, 1988, AM REV RESPIR DIS, V137, P606, DOI 10.1164/ajrccm/137.3.606; SILVERS WS, 1992, ANN ALLERGY, V68, P58; SMITH CM, 1989, EUR RESPIR J, V2, P36; STANFORD CF, 1988, BRIT MED J, V297, P660, DOI 10.1136/bmj.297.6649.660; SYABBALO NC, 1985, B EUR PHYSIOPATH RES, V21, P507; TOGIAS AG, 1985, J CLIN INVEST, V76, P1375, DOI 10.1172/JCI112113; VIGNOLA AM, 1993, AM REV RESPIR DIS, V148, P689, DOI 10.1164/ajrccm/148.3.689	37	11	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1995	96	6	1				980	985		10.1016/S0091-6749(95)70236-9	http://dx.doi.org/10.1016/S0091-6749(95)70236-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TN124	8543757				2022-12-18	WOS:A1995TN12400016
J	Twarog, F; Weiler, JM; Wolf, SI; Barron, RJ; Lang, DM; Wells, JH; Zitt, M; Virant, FS; Katz, RM; Banyash, LW; Wolk, MH; Orfan, N; Guill, MF				Twarog, F; Weiler, JM; Wolf, SI; Barron, RJ; Lang, DM; Wells, JH; Zitt, M; Virant, FS; Katz, RM; Banyash, LW; Wolk, MH; Orfan, N; Guill, MF			Discussion of risk of scuba diving in individuals with allergic and respiratory diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							DIVERS											CORSON K, 1991, ALERT DIVER      SEP; Corson KS, 1991, UNDERSEA BIOMED RES, V18, P16; CORSON KS, 1992, UNDERSEA BIOMED RES, V18, P18; DICK APK, 1985, NEUROLOGY, V35, P667, DOI 10.1212/WNL.35.5.667; DOVENBARGER J, 1992, ALERT DIVER      NOV, P4; FARMER JC, 1987, 34TH P UND HYP MED S, V70, P70; FARRELL PJS, 1990, BRIT MED J, V300, P166, DOI 10.1136/bmj.300.6718.166; MELAMED Y, 1992, NEW ENGL J MED, V326, P30; NEBLETT LM, 1985, ANN OTOL RHINOL S115, V94, P1; NEUMAN TS, 1987, 34TH P UND HYP MED S, V70, P49; NEUMAN TS, 1990, DIVING MED, P233; TURKELTAUB PC, 1991, ANN ALLERGY, V67, P147; WACHHOLZ C, 1988, ALERT DIVER, V4, P1; WALKER D, 1984, J S PACIFIC UNDERWAT, V14, P12	14	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1995	96	6	1				871	873		10.1016/S0091-6749(95)70221-0	http://dx.doi.org/10.1016/S0091-6749(95)70221-0			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TN124	8543742				2022-12-18	WOS:A1995TN12400001
J	GAGNON, R; BOUTIN, Y; HEBERT, J				GAGNON, R; BOUTIN, Y; HEBERT, J			LOL-P-I-SPECIFIC IGE AND IGG SYNTHESIS BY PERIPHERAL-BLOOD MONONUCLEAR-CELLS FROM ATOPIC SUBJECTS IN SCID MICE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LOL P I; IGE; IGG; SEVERE COMBINED IMMUNODEFICIENCY; ATOPIC	SEVERE COMBINED IMMUNODEFICIENCY; MONOCLONAL-ANTIBODIES; NONATOPIC SUBJECTS; IMMUNE-RESPONSE; IFN-GAMMA; IL-4; INVITRO; LYMPHOCYTES; CLONES; INTERLEUKIN-4	Background: The development of an animal model representative of the in vivo situation of human atopic diseases is always of interest for a better understanding of IgE production and regulation. Along these lines, mice with severe combined immunodeficiency (SCID mice) engrafted with lymphocytes from atopic subjects might be a suitable model for such studies. Objective: This study aims to analyze the production of Lol p I-specific IgE and IgG antibodies in SCID mice after transplantation of human peripheral blood mononuclear cells from atopic patients sensitive to grass pollens and from nonatopic donors. Methods: Peripheral blood mononuclear cells were transplanted into SCID mice, which were then challenged with Lol p I, and antibody responses (IgG and IgE) were analyzed over a 6-week period. Results: Total IgG antibody was measured in each mouse serum after transplantation. Also, most mice (regardless of whether donors were atopic) that were challenged with Lol p I produced specific IgG antibody. Total IgE antibody production was observed only in mice grafted with cells from atopic patients. Lol p I-specific IgE antibodies were also produced after immunization with Lol p I. Although IgG antibody response tended to plateau, the IgE antibody response increased until it peaked and declined thereafter. Interferon-gamma was detected in sera from mice producing IgE antibody, which supports a possible role of interferon-gamma in the decrease of IgE response. Conclusion: This study suggests that the SCID mouse model could represent an interesting approach to studying specific, total IgG and IgE antibody production, and ultimately their regulation.	CTR RECH IMMUNOL & ALLERGIE, Ste Foy, PQ, CANADA									BOSE R, 1986, CLIN EXP IMMUNOL, V66, P231; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; CARLSSON R, 1992, J IMMUNOL, V148, P1065; CLAASSEN JL, 1990, J IMMUNOL, V144, P2123; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DUCHOSAL MA, 1992, CELL IMMUNOL, V139, P468, DOI 10.1016/0008-8749(92)90086-5; GAGNON, 1993, J ALLERGY CLIN IMMUN, V91, P1238; GAGNON R, 1993, J ALLERGY CLIN IMMUN, V91, P950, DOI 10.1016/0091-6749(93)90353-H; GAGNON R, 1993, CLIN EXP ALLERGY, V23, P498, DOI 10.1111/j.1365-2222.1993.tb03237.x; HEBERT J, 1990, CLIN EXP IMMUNOL, V80, P413; HEBERT J, 1981, CELL IMMUNOL, V58, P366, DOI 10.1016/0008-8749(81)90230-6; ITO M, 1992, INT ARCH ALLERGY IMM, V99, P373, DOI 10.1159/000236288; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KILCHHERR E, 1993, CELL IMMUNOL, V151, P241, DOI 10.1006/cimm.1993.1235; MARKHAM RB, 1992, INFECT IMMUN, V60, P2305, DOI 10.1128/IAI.60.6.2305-2308.1992; MAZINGUE C, 1991, EUR J IMMUNOL, V21, P1763, DOI 10.1002/eji.1830210728; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; MOURAD W, 1989, MOL IMMUNOL, V26, P1051, DOI 10.1016/0161-5890(89)90069-2; MOURAD W, 1987, CLIN EXP IMMUNOL, V67, P391; NONOYAMA S, 1993, J IMMUNOL, V151, P3894; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PENE J, 1988, J IMMUNOL, V141, P1218; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PENE J, 1989, INT ARCH ALLER A IMM, V90, P32, DOI 10.1159/000235073; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROMAGNANI S, 1982, CLIN EXP IMMUNOL, V49, P185; SAXON A, 1991, J CLIN INVEST, V87, P658, DOI 10.1172/JCI115043; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; TURNER KJ, 1983, CLIN EXP IMMUNOL, V51, P387; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; WIERENGA EA, 1991, J IMMUNOL, V147, P2942; YANG XD, 1988, EUR J IMMUNOL, V18, P1699, DOI 10.1002/eji.1830181107	32	11	11	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1995	95	6					1268	1275		10.1016/S0091-6749(95)70085-4	http://dx.doi.org/10.1016/S0091-6749(95)70085-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RD309	7797796				2022-12-18	WOS:A1995RD30900016
J	CABALLERO, T; FERRER, A; DIAZPENA, JM; GARCIAARA, C; PASCUAL, C; MARTINESTEBAN, M				CABALLERO, T; FERRER, A; DIAZPENA, JM; GARCIAARA, C; PASCUAL, C; MARTINESTEBAN, M			CHILDHOOD ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							DIAGNOSIS				CABALLERO, T (corresponding author), HOSP LA PAZ,SERV ALERGIA INFANTIL,PASEO CASTELLANA 261,E-28046 MADRID,SPAIN.		Caballero, Teresa/AAU-3982-2020; Caballero, Teresa/H-6454-2014	Caballero, Teresa/0000-0003-3005-9858; Caballero, Teresa/0000-0003-3005-9858; Ferrer, Angel/0000-0001-6567-053X				GREENBERGER PA, 1986, ANN ALLERGY, V56, P444; IMBEAU SA, 1977, AM J DIS CHILD, V131, P1127, DOI 10.1001/archpedi.1977.02120230073013; KIEFER TA, 1986, ANN ALLERGY, V56, P233; LESER C, 1992, J ALLERGY CLIN IMMUN, V90, P589, DOI 10.1016/0091-6749(92)90131-K; PATTERSON R, 1983, ANN INTERN MED, V99, P18, DOI 10.7326/0003-4819-99-1-18; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; ROSENBERG M, 1978, AM J MED, V64, P599, DOI 10.1016/0002-9343(78)90579-X; SLAVIN R G, 1970, Journal of Pediatrics, V76, P416, DOI 10.1016/S0022-3476(70)80482-6; TURNER ES, 1989, ALLERGY PROC, V10, P63, DOI 10.2500/108854189778968506	9	11	11	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1995	95	5	1				1044	1047		10.1016/S0091-6749(95)70106-0	http://dx.doi.org/10.1016/S0091-6749(95)70106-0			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QY917	7751501				2022-12-18	WOS:A1995QY91700017
J	MELTZER, EO; TYRELL, RJ; RICH, D; WOOD, CC				MELTZER, EO; TYRELL, RJ; RICH, D; WOOD, CC			A PHARMACOLOGICAL CONTINUUM IN THE TREATMENT OF RHINORRHEA - THE CLINICIAN AS ECONOMIST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ECONOMICS; PRESCRIPTION; RHINITIS; COMMON COLD	HEALTH-CARE COSTS; ALLERGIC RHINITIS; NASAL SPRAY	The economics of medications are now of great concern to health-care providers. Pharmacoeconomic issues ave by no means simple, and yet, ironically, they assume greater importance in prescribing for modest disorders like rhinorrhea than for life-threatening conditions. The therapeutic continuum of quality and cost becomes foreshortened, and safety is an additional concern. Choosing the appropriate medication for rhinorrhea, then, can pose a challenge to the clinician, just as choosing a vital medication. This paper reviews the usage, qualify, and cost of major therapies for the rhinorrhea that occurs secondary to various conditions, including nasal steroids, antihistamines and anticholinergics, and discusses the role of the clinician in factoring costs into therapy.	BOEHRINGER INGELHEIM PHARMACEUT INC,RIDGEFIELD,CT 06877	Boehringer Ingelheim	MELTZER, EO (corresponding author), ALLERGY & ASTHMA MED GRP & RES CTR,9610 GRANITE RIDGE DR,SUITE B,SAN DIEGO,CA 92123, USA.							BARANIUK JN, 1992, J ALLERGY CLIN IMMUN, V90, P1045, DOI 10.1016/0091-6749(92)90121-H; BERGER WE, 1994, HLTH CARE REFORM MAN, P1; BORUM P, 1981, AM REV RESPIR DIS, V123, P418; BORUM P, 1979, J ALLERGY CLIN IMMUN, V63, P253, DOI 10.1016/0091-6749(79)90109-X; BRATTMAN G, 1989, J ALLERGY CLIN IMMUN, V83, P411; ECKHOLM E, 1994, NY TIMES        1218, P1; EGGLESTON PA, 1984, ACTA OTOLARYNGOL S, V413, P23; ENTHOVEN AC, 1991, JAMA-J AM MED ASSOC, V266, P2751; FRIES JF, 1993, NEW ENGL J MED, V329, P321, DOI 10.1056/NEJM199307293290506; GEORGITIS JW, 1994, CLIN EXP ALLERGY, V24, P1049, DOI 10.1111/j.1365-2222.1994.tb02742.x; GROSSMAN J, 1995, J ALLERGY CLIN IMMUN, V95, P1123, DOI 10.1016/S0091-6749(95)70216-4; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; KAISER HB, 1995, J ALLERGY CLIN IMMUN, V95, P1128, DOI 10.1016/S0091-6749(95)70217-2; MELTZER EO, 1992, J ALLERGY CLIN IMMUN, V90, P242, DOI 10.1016/0091-6749(92)90078-G; OLSEN A, 1994, MED MARKET MEDIA, V29, P55; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; REINBERG A, 1988, J ALLERGY CLIN IMMUN, V81, P51, DOI 10.1016/0091-6749(88)90220-5; SMITH A, 1988, CHRONOBIOL INT, V5, P441; WELLIVER RC, 1990, J ALLERGY CLIN IMMUN, V86, P633, DOI 10.1016/S0091-6749(05)80228-3; WINTHER B, 1984, ACTA OTOLARYNGOL S S, V413, P19; ZWILLICH CW, 1981, AM REV RESPIR DIS, V124, P158	21	11	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1995	95	5	2				1147	1152		10.1016/S0091-6749(95)70220-2	http://dx.doi.org/10.1016/S0091-6749(95)70220-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QY918	7538521				2022-12-18	WOS:A1995QY91800012
J	TURJANMAA, K; CACIOLI, P; THOMPSON, RL; SIMLOTE, P; LOPEZ, M				TURJANMAA, K; CACIOLI, P; THOMPSON, RL; SIMLOTE, P; LOPEZ, M			FREQUENCY OF NATURAL-RUBBER LATEX ALLERGY AMONG US OPERATING-ROOM NURSES USING SKIN PRICK TESTING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	11	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1995	95	1	2				214	214						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QE854					2022-12-18	WOS:A1995QE85400293
J	THOMAS, LH; FRAENKEL, DJ; BARDIN, PG; JOHNSTON, SL; HOLGATE, ST; WARNER, JA				THOMAS, LH; FRAENKEL, DJ; BARDIN, PG; JOHNSTON, SL; HOLGATE, ST; WARNER, JA			LEUKOCYTE RESPONSES TO EXPERIMENTAL-INFECTION WITH HUMAN RHINOVIRUS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							RESPIRATORY-TRACT INFECTION; INFLUENZA-A VIRUS; HISTAMINE-RELEASE; INVITRO INCUBATION; HUMAN BASOPHILS; ASTHMA; ENHANCEMENT; INTERFERON; HYPERREACTIVITY; EXACERBATIONS		UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,SOUTHAMPTON,HANTS,ENGLAND	University of Southampton	THOMAS, LH (corresponding author), UNIV SOUTHAMPTON,DEPT PHYSIOL & PHARMACOL,BASSETT CRESCENT E,SOUTHAMPTON SO9 3TU,HANTS,ENGLAND.		Johnston, Sebastian Lennox/I-2423-2012	Johnston, Sebastian Lennox/0000-0003-3009-9200	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARDIN PG, 1992, CLIN EXP ALLERGY, V22, P809, DOI 10.1111/j.1365-2222.1992.tb02825.x; BARDIN PG, IN PRESS CLIN EXP AL; BEASLEY R, 1988, THORAX, V43, P679, DOI 10.1136/thx.43.9.679; BECKER S, 1993, AM J RESPIR CELL MOL, V3, P20; BJORNSDOTTIR US, 1992, MED CLIN N AM, V76, P895; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; BUSSE WW, 1991, AM J RESP CELL MOL, V4, P347, DOI 10.1165/ajrcmb/4.4.347; BUSSE WW, 1983, J ALLERGY CLIN IMMUN, V71, P382, DOI 10.1016/0091-6749(83)90066-0; BUSSE WW, 1990, J ALLERGY CLIN IMMUN, V85, P671, DOI 10.1016/0091-6749(90)90181-3; CHONMAITREE T, 1988, J INFECT DIS, V157, P127, DOI 10.1093/infdis/157.1.127; COUCH RB, 1990, VIROLOGY, P607; CYPCAR D, 1992, PEDIATR CLIN N AM, V39, P1259; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FADEN H, 1983, J INFECT DIS, V148, P110, DOI 10.1093/infdis/148.1.110; FLINT KC, 1985, BRIT MED J, V291, P923, DOI 10.1136/bmj.291.6500.923; FOX CC, 1990, GASTROENTEROLOGY, V99, P119, DOI 10.1016/0016-5085(90)91238-2; FRAENKEL DJ, IN PRESS AM REV RESP; GAROFALO R, 1992, J PEDIATR-US, V120, P28, DOI 10.1016/S0022-3476(05)80592-X; HALPERIN SA, 1983, AM REV RESPIR DIS, V128, P806; HUFTEL MA, 1992, AM J RESP CELL MOL, V7, P434, DOI 10.1165/ajrcmb/7.4.434; IDA S, 1977, J EXP MED, V145, P892, DOI 10.1084/jem.145.4.892; JACKSON GG, 1958, ARCH INTERN MED, V101, P267, DOI 10.1001/archinte.1958.00260140099015; KIMIRA I, 1975, CLIN ALLERGY, V1, P95; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; LEONARD EJ, 1990, AM J RESP CELL MOL, V2, P479, DOI 10.1165/ajrcmb/2.6.479; LETTBROWN MA, 1981, J CLIN INVEST, V67, P547, DOI 10.1172/JCI110065; LEVANDOWSKI RA, 1986, J INFECT DIS, V153, P743, DOI 10.1093/infdis/153.4.743; MCFADDEN ER, 1982, J CLIN INVEST, V69, P700, DOI 10.1172/JCI110498; NACLERIO RM, 1987, J INFECT DIS, V157, P133; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; SANCHEZLEGRAND F, 1989, J ALLERGY CLIN IMMUN, V84, P538, DOI 10.1016/0091-6749(89)90368-0; SIRAGANIAN R, 1974, ANAL BIOCHEM, V57, P283; VRTIS R, 1990, Journal of Allergy and Clinical Immunology, V85, P165; VRTIS R, 1993, J ALLERGY CLIN IMMUN, V91, pA262; WELLIVER RC, 1986, J PEDIATR-US, V109, P776, DOI 10.1016/S0022-3476(86)80692-8; WINTHER B, 1984, ACTA OTOLARYNGOL S S, V413, P19	36	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	2	S			1255	1262		10.1016/0091-6749(94)90340-9	http://dx.doi.org/10.1016/0091-6749(94)90340-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA020	7528234	Bronze			2022-12-18	WOS:A1994QA02000020
J	WALKER, C; BRAUN, RK; BOER, C; KROEGEL, C; VIRCHOW, JC; HANSEL, TT				WALKER, C; BRAUN, RK; BOER, C; KROEGEL, C; VIRCHOW, JC; HANSEL, TT			CYTOKINE CONTROL OF EOSINOPHILS IN PULMONARY-DISEASES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							COLONY-STIMULATING FACTOR; PERIPHERAL-BLOOD EOSINOPHILS; LYMPHOCYTES-T; HYPERSENSITIVITY PNEUMONITIS; BRONCHOALVEOLAR LAVAGE; ALVEOLAR MACROPHAGES; ADHESION MOLECULES; BRONCHIAL-MUCOSA; MESSENGER-RNA; GM-CSF		UNIV CALIF DAVIS, DAVIS, CA 95616 USA; UNIV FREIBURG, MED CLIN, DEPT PNEUMOL, FREIBURG, GERMANY	University of California System; University of California Davis; University of Freiburg	WALKER, C (corresponding author), SANDOZ PHARMA AG, PRECLIN RES ASTHMA, CH-4002 BASEL, SWITZERLAND.			Braun, Rudolf/0000-0002-1778-9613; Boer, Christa/0000-0002-7781-6951				ALBELDA SM, 1991, AM J RESP CELL MOL, V4, P195, DOI 10.1165/ajrcmb/4.3.195; ALLEN JN, 1990, AM REV RESPIR DIS, V142, P642, DOI 10.1164/ajrccm/142.3.642; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500, DOI 10.1164/ajrccm/146.2.500; BOCHNER BS, 1994, J IMMUNOL, V152, P774; BRAUM RK, UNPUB EOSINOPHIL SUR; BRAUN RK, 1993, EUR J IMMUNOL, V23, P956, DOI 10.1002/eji.1830230429; BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; BUTTERFIELD JH, 1993, HDB IMMUNOPHARMACOLO, P151; BUTTERWORTH AE, 1993, HDB IMMUNOPHARMACOLO, P119; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; DAHINDEN CA, 1994, J EXP MED, V179, P751, DOI 10.1084/jem.179.2.751; DUBUCQUOI S, 1994, J EXP MED, V179, P703, DOI 10.1084/jem.179.2.703; GEORAS SN, 1992, AM J RESP CELL MOL, V7, P261, DOI 10.1165/ajrcmb/7.3.261; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; GREENBERGER PA, 1984, J ALLERGY CLIN IMMUN, V74, P645, DOI 10.1016/0091-6749(84)90223-9; HALLGREN R, 1989, AM REV RESPIR DIS, V139, P373; HAMID Q, 1992, BLOOD, V80, P1496; HANSEL TT, 1992, J IMMUNOL, V149, P2130; HANSEL TT, 1991, CLIN EXP IMMUNOL, V86, P271; HANSEL TT, 1993, AGENT ACTION SUPPL, V43, P197; HANSEL TT, 1992, CLIN EXP ALLERGY, V22, P345, DOI 10.1111/j.1365-2222.1992.tb03096.x; HARTNELL A, 1992, J IMMUNOL, V148, P1471; HASLAM PL, 1992, EUR RESPIR REV, V2, P58; KITA H, 1991, J EXP MED, V174, P745, DOI 10.1084/jem.174.3.745; LOPEZ AF, 1992, IMMUNOL TODAY, V13, P495, DOI 10.1016/0167-5699(92)90025-3; LYNCH JP, 1992, AM REV RESPIR DIS, V145, P1433, DOI 10.1164/ajrccm/145.6.1433; MAESTRELLI P, 1993, J ALLERGY CLIN IMMUN, V91, P220; MULLERQUERNHEIM J, 1991, AM REV RESPIR DIS, V144, P1322; OHNO I, 1991, AM J RESP CELL MOL, V5, P505, DOI 10.1165/ajrcmb/5.6.505; OWEN WF, 1991, ALLERGY CLIN IMMUNOL, V3, P85; PFORTE A, 1990, J EXP MED, V171, P1163, DOI 10.1084/jem.171.4.1163; PISANI CV, 1991, BLOOD, V78, P1538, DOI 10.1182/blood.V78.6.1538.1538; POULTER LW, 1992, EUR RESPIR REV, V2, P75; PRIN L, 1986, CLIN EXP IMMUNOL, V63, P249; RESNICK MB, 1993, AM J RESP CELL MOL, V8, P349, DOI 10.1165/ajrcmb/8.4.349; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROMAGNANI S, 1993, ACI NEWS, V5, P19; SAETTA M, 1993, AM REV RESPIR DIS, V147, P301, DOI 10.1164/ajrccm/147.2.301; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SEDGWICK JB, 1992, J IMMUNOL, V149, P3710; SEMENZATO G, 1991, EUR RESPIR J, V4, P94; SEMENZATO G, 1992, EUR RESPIR REV, V2, P69; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STEFFEN M, 1993, J ALLERGY CLIN IMMUN, V91, P939, DOI 10.1016/0091-6749(93)90352-G; STREET NE, 1991, FASEB J, V5, P171, DOI 10.1096/fasebj.5.2.1825981; TRENTIN L, 1990, J IMMUNOL, V145, P2147; WALKER C, 1993, J IMMUNOL, V150, P4061; WALKER C, 1991, J IMMUNOL, V146, P1829; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; WALKER C, IN PRESS ACTIVATED T; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; WILLIAMS TJ, 1992, AM REV RESPIR DIS, V146, pS45, DOI 10.1164/ajrccm/146.5_Pt_2.S45; YAMAGUCHI Y, 1990, J IMMUNOL, V145, P873	58	11	11	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	2	S			1262	1271		10.1016/0091-6749(94)90341-7	http://dx.doi.org/10.1016/0091-6749(94)90341-7			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA020	7798567				2022-12-18	WOS:A1994QA02000021
J	FINK, JN; FORMAN, S; SILVERS, WS; SOIFER, MM; TASHKIN, DP; WILSON, AF				FINK, JN; FORMAN, S; SILVERS, WS; SOIFER, MM; TASHKIN, DP; WILSON, AF			A DOUBLE-BLIND-STUDY OF THE EFFICACY OF NEDOCROMIL SODIUM IN THE MANAGEMENT OF ASTHMA IN PATIENTS USING HIGH-DOSES OF BRONCHODILATORS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; NEDOCROMIL SODIUM; ALBUTEROL; ANTIINFLAMMATORY; BRONCHODILATOR	INHALED BECLOMETHASONE DIPROPIONATE; BRONCHIAL-ASTHMA; THERAPY; RESPONSIVENESS; THEOPHYLLINE; CHILDREN; PLACEBO	The effects of nedocromil sodium were assessed in 110 patients with asthma who experienced asthma symptoms despite the use of high doses of inhaled bronchodilators. During the baseline period antiinflammatory agents were not permitted, and patients were treated with inhaled beta-agonists on an as-needed basis. Patients who required 12 or more puffs of albuterol and experienced continuing asthma symptoms for 7 of the 14 baseline days were randomized to treatment groups. Subjects received either nedocromil sodium (4 mg) or placebo four times a day for to weeks. Statistically significant (p < 0.05) between-treatment differences (weeks 3 to 10), favoring nedocromil sodium, were determined for the asthma summary score, daytime asthma severity asthmatic cough, morning peak flow rates, reduction of as-needed bronchodilator use, physician's assessment of asthma severity and patient and physician opinions of treatment effectiveness. By trial end (week 10), sleep difficulty caused by asthma decreased 29% in the nedocromil sodium group and 4% in the placebo group (p = 0.006). Nedocromil sodium was well tolerated and improved asthma control while reducing the inhaled bronchodilator load of these patients with moderately severe asthma.	ASTHMA ALLERGY & IMMUNOL CLIN COLORADO,ENGLEWOOD,CO; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF IRVINE,IRVINE MED CTR,DEPT MED,ORANGE,CA 92668	University of California System; University of California Los Angeles; University of California System; University of California Irvine	FINK, JN (corresponding author), MED COLL WISCONSIN,DEPT MED,DIV ALLERGY IMMUNOL,8700 W WISCONSIN AVE,MILWAUKEE,WI 53226, USA.							ALI N, 1991, BRIT MED J, V302, P1080, DOI 10.1136/bmj.302.6784.1080; AUTY RM, 1989, ALLERGY ASTHMA NEW T, P171; BEL EH, 1990, AM REV RESPIR DIS, V141, P21, DOI 10.1164/ajrccm/141.1.21; BERGMANN KC, 1989, CURR MED RES OPIN, V11, P533, DOI 10.1185/03007998909110465; BROGDEN RN, 1993, DRUGS, V45, P693, DOI 10.2165/00003495-199345050-00007; CAIRNS H, 1985, J MED CHEM, V28, P1832, DOI 10.1021/jm00150a014; CALLAGHAN B, 1992, CHEST, V101, P787, DOI 10.1378/chest.101.3.787; CHERNIACK R M, 1990, Chest, V97, P1299; COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; DYSON C, 1991, Journal of Allergy and Clinical Immunology, V87, P258, DOI 10.1016/0091-6749(91)91758-L; ERNST P, 1993, AM REV RESPIR DIS, V148, P75, DOI 10.1164/ajrccm/148.1.75; FAIRFAX AJ, 1988, J INT MED RES, V16, P216, DOI 10.1177/030006058801600309; GRANT JA, 1986, J ALLERGY CLIN IMMUN, V78, P669, DOI 10.1016/0091-6749(86)90043-6; HARPER GD, 1990, RESP MED, V84, P463, DOI 10.1016/S0954-6111(08)80110-2; KARIM AKA, 1989, BRIT MED J, V299, P918, DOI 10.1136/bmj.299.6704.918; KONIG P, 1988, J ALLERGY CLIN IMMUN, V82, P297, DOI 10.1016/0091-6749(88)91015-9; NICKLAS RA, 1986, J ALLERGY CLIN IMMUN, V78, P806, DOI 10.1016/0091-6749(86)90065-5; PRAHL P, 1991, CLIN EXP ALLERGY, V21, P145, DOI 10.1111/j.1365-2222.1991.tb00817.x; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; TABACHNIK E, 1991, J PEDIATR-US, V118, P294, DOI 10.1016/S0022-3476(05)80506-2; TEELUCKSINGH S, 1991, American Review of Respiratory Disease, V143, pA626; WAHEDNA I, 1993, AM REV RESPIR DIS, V148, P707, DOI 10.1164/ajrccm/148.3.707; WOLTHERS OD, 1992, PEDIATRICS, V89, P839; 1991, NIH923091 US DEP HLT; 1992, NIH923091 US DEP HLT	26	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1994	94	3	1				473	481		10.1016/0091-6749(94)90203-8	http://dx.doi.org/10.1016/0091-6749(94)90203-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG907	8083452	Bronze			2022-12-18	WOS:A1994PG90700006
J	SAEKI, H; KUWATA, S; NAKAGAWA, H; ETOH, T; YANAGISAWA, M; MIYAMOTO, M; TOKUNAGA, K; JUJI, T; SHIBATA, Y				SAEKI, H; KUWATA, S; NAKAGAWA, H; ETOH, T; YANAGISAWA, M; MIYAMOTO, M; TOKUNAGA, K; JUJI, T; SHIBATA, Y			HLA AND ATOPIC-DERMATITIS WITH HIGH SERUM IGE LEVELS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HLA; POLYMERASE CHAIN REACTION; ATOPIC DERMATITIS; IGE	DEPENDENT DIABETES-MELLITUS; SUSCEPTIBILITY; NONRESPONSIVENESS; AMPLIFICATION; POLYMERASE; BETA	Patients with atopic dermatitis usually exibit allergen-specific IgE antibodies against several environmental antigens. HLA restriction is presumed to be involved in the recognition of such antigens, but several previous reports have so far failed to find a significant association between atopic dermatitis and HLA antigens. In this study we examined 38 unrelated Japanese patients with severe atopic dermatitis and high serum IgE levels (greater than 8000 U/ml). We investigated the serological HLA types and HLA class II alleles in this group of patients with atopic dermatitis. Frequencies of HLA-A24, A33, Cwblank, B44, DR13 and HLA-DRB1*1302, DQB1*0604, DPB1*0301 alleles were increased in the patients. In contrast, frequencies of HLA-Cw1, Bw6, DR4, DR53, and HLA-DQB1*0302 allele were decreased. However, none of these remained significant after p values were corrected. Further study on HLA association with atopic dermatitis through characterization of specific antigens or antigen epitopes is needed.	UNIV TOKYO, FAC MED, DEPT TRANSFUS MED & IMMUNOHEMATOL, TOKYO 113, JAPAN; JAPANESE RED CROSS, CENT BLOOD CTR, TOKYO, JAPAN	University of Tokyo; Japanese Red Cross Medical Center	SAEKI, H (corresponding author), UNIV TOKYO, FAC MED, DEPT DERMATOL, BUNKYO KU, HONGO 7-3-1, TOKYO 113, JAPAN.							BERDOZ J, 1989, IMMUNOGENETICS, V29, P241, DOI 10.1007/BF00717908; BODMER JG, 1992, HUM IMMUNOL, V34, P4, DOI 10.1016/0198-8859(92)90079-3; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; IKEGAMI H, 1992, J CLIN ENDOCR METAB, V75, P1381, DOI 10.1210/jc.75.5.1381; Kitao Y, 1987, Acta Paediatr Jpn, V29, P654; KUMAI M, 1990, AM J RHINOL, V4, P273; KUWATA S, 1991, NEW ENGL J MED, V324, P271; LARSEN FS, 1987, TISSUE ANTIGENS, V29, P1; LIN L, 1992, HLA 1991, V2, P333; MANIATIS T, 1982, MOL CLONING LABORATO, P280; MATSUSHITA S, 1987, J IMMUNOL, V138, P109; MITSUNAGA S, 1992, HUM IMMUNOL, V34, P203, DOI 10.1016/0198-8859(92)90113-2; OKADA K, 1985, P NATL ACAD SCI USA, V82, P3410, DOI 10.1073/pnas.82.10.3410; OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x; OZAWA A, 1981, J AM ACAD DERMATOL, V4, P205, DOI 10.1016/S0190-9622(81)70024-0; RAJKA G, 1989, ACTA DERM-VENEREOL, P13; REID MJ, 1992, J ALLERGY CLIN IMMUN, V89, P593, DOI 10.1016/0091-6749(92)90327-X; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SASAZUKI T, 1983, IMMUNOL REV, V70, P51, DOI 10.1111/j.1600-065X.1983.tb00709.x; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; SVEJGAARD A, 1983, IMMUNOL REV, V70, P193, DOI 10.1111/j.1600-065X.1983.tb00715.x; SVEJGAARD E, 1985, ACTA DERM-VENEREOL, P72; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; UCHIGATA Y, 1992, LANCET, V339, P393, DOI 10.1016/0140-6736(92)90080-M	24	11	15	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1994	94	3	2	S			575	583		10.1016/0091-6749(94)90133-3	http://dx.doi.org/10.1016/0091-6749(94)90133-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PH235	7916023				2022-12-18	WOS:A1994PH23500002
J	MULLER, BA; LEICK, CA; SUELZER, M; PIYAMAHUNT, A; RICHERSON, HB				MULLER, BA; LEICK, CA; SUELZER, M; PIYAMAHUNT, A; RICHERSON, HB			PROGNOSTIC VALUE OF METHACHOLINE CHALLENGE IN PATIENTS WITH RESPIRATORY SYMPTOMS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; METHACHOLINE; BRONCHOPROVOCATION; HYPERRESPONSIVENESS; TIGHTNESS; WHEEZING; DYSPNEA; COUGH; PROGNOSIS	AIRWAY REACTIVITY; BRONCHIAL-ASTHMA; COUGH; HYPERRESPONSIVENESS; STANDARDIZATION; QUESTIONNAIRE; PREDICTION; HISTAMINE; DIAGNOSIS	Background: The objective was to study the current clinical status of 78 adults with respiratory symptoms, who were referred 3 to 10 years ago for diagnostic methacholine challenge. We tested the hypothesis that methacholine hyperresponsiveness would be associated on follow-up with increased symptoms of chest tightness, dyspnea, wheezing, cough, and more frequent use of selected treatment modalities. Methods: Current symptoms were evaluated by means of interview questionnaire, and methacholine challenge was repeated during follow-up examination. Comparisons were made between patients who were and those who were not hyperresponsive to methacholine at initial and follow-up challenges by using specific symptoms and calculated symptom and treatment scores. Results: We found that subjects who had positive methacholine challenge results on initial challenge (n = 37) were significantly more likely than those with negative results (n = 41) to have nonexertional chest tightness, wheezing, and dyspnea, but not cough. A high proportion of both groups had current symptoms. Two thirds of the patients continued to have positive (n = 25) or negative (n = 27) methacholine challenge results, and one third had a change in status (n = 26). Significant correlations were also found between follow-up methacholine responsiveness and concurrent symptoms, again with the exception of cough. Conclusions: Methacholine challenge warrants cautious interpretation in the individual patient as an aid to diagnosis and prognosis in the evaluation of respiratory symptoms, especially cough.	UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA HOSP & CLIN,IOWA CITY,IA 52242	University of Iowa; University of Iowa					NCRR NIH HHS [RR59] Funding Source: Medline; NIAID NIH HHS [AI19093] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI019093] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADELROTH E, 1986, AM REV RESPIR DIS, V134, P704; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BRITTON J, 1986, EUR J RESPIR DIS, V68, P233; BROWN PJ, 1984, THORAX, V39, P131, DOI 10.1136/thx.39.2.131; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1992, J ALLERGY CLIN IMMUN, V89, P23, DOI 10.1016/S0091-6749(05)80037-5; COCKCROFT DW, 1990, AM REV RESPIR DIS, V142, P497, DOI 10.1164/ajrccm/142.3.497; Corrao W M, 1982, Compr Ther, V8, P22; CORRAO WM, 1979, NEW ENGL J MED, V300, P633, DOI 10.1056/NEJM197903223001201; DALES RE, 1987, AM REV RESPIR DIS, V135, P817, DOI 10.1164/arrd.1987.135.4.817; DALES RE, 1988, CHEST, V93, P984, DOI 10.1378/chest.93.5.984; DESJARDINS A, 1988, AM REV RESPIR DIS, V137, P1020, DOI 10.1164/ajrccm/137.5.1020; DEVRIES K, 1987, BRONCHIAL HYPERESPON, P359; EISER NM, 1987, BRONCHIAL HYPERRESPO, P173; FERRIS BG, 1978, AM REV RESPIR DIS S, V118, P10; GARDNER MJ, 1989, STATISTICS CONFIDENC; GILBERT R, 1990, CHEST, V97, P562, DOI 10.1378/chest.97.3.562; GOLDSTEIN RA, 1992, CHEST, V101, pS355, DOI 10.1016/S0012-3692(16)32931-2; GROSS NJ, 1980, AM REV RESPIR DIS, V121, P203; HARGREAVE FE, 1985, AIRWAY RESPONSIVENES, P80; HOPP RJ, 1990, AM REV RESPIR DIS, V141, P2, DOI 10.1164/ajrccm/141.1.2; LEICK C, 1991, Journal of Allergy and Clinical Immunology, V87, P166, DOI 10.1016/0091-6749(91)91394-9; MCFADDEN ER, 1975, NEW ENGL J MED, V292, P555, DOI 10.1056/NEJM197503132921103; METZGER WJ, 1981, J ALLERGY CLIN IMMUN, V68, P442, DOI 10.1016/0091-6749(81)90198-6; OCONNELL EJ, 1991, ANN ALLERGY, V66, P278; PATTEMORE PK, 1990, AM REV RESPIR DIS, V142, P549, DOI 10.1164/ajrccm/142.3.549; RYAN G, 1981, AM REV RESPIR DIS, V123, P195; SPELMAN R, 1991, BRIT J GEN PRACT, V41, P406; 1982, STATISTICS; [No title captured]; 1991, 913042 US DEP HLTH H; 1988, LANCET, V1, P447; 1987, AM REV RESPIR DIS, V136, P224	35	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1994	94	1					77	87		10.1016/0091-6749(94)90074-4	http://dx.doi.org/10.1016/0091-6749(94)90074-4			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NX393	8027501				2022-12-18	WOS:A1994NX39300011
J	KELSO, JM; HUGH, MY; LIN, FL				KELSO, JM; HUGH, MY; LIN, FL			RECALL URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									USN,MED CTR,DEPT INTERNAL MED,DIV ALLERGY,SAN DIEGO,CA; USN,MED CTR,DEPT CLIN INVEST,SAN DIEGO,CA	United States Department of Defense; United States Navy; United States Department of Defense; United States Navy								BRUYNZEEL DP, 1986, ARCH DERMATOL, V122, P323, DOI 10.1001/archderm.122.3.323; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; NELSON BL, 1986, ANN ALLERGY, V56, P331; TIPTON WR, 1980, ANN ALLERGY, V44, P204; VOORHORST R, 1973, ANN ALLERGY, V31, P137	5	11	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1994	93	5					949	950		10.1016/0091-6749(94)90392-1	http://dx.doi.org/10.1016/0091-6749(94)90392-1			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NL919	8182240				2022-12-18	WOS:A1994NL91900023
J	APPLEYARD, JK; MCCULLOUGH, JA; OWNBY, DR				APPLEYARD, JK; MCCULLOUGH, JA; OWNBY, DR			CROSS-REACTIVITY BETWEEN LATEX, RAGWEED, AND BLUE GRASS ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1994	93	1	2				182	182						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MV317					2022-12-18	WOS:A1994MV31700118
J	NELSON, HS; ARESON, J; REISMAN, R				NELSON, HS; ARESON, J; REISMAN, R			A PROSPECTIVE ASSESSMENT OF THE REMOTE PRACTICE OF ALLERGY - COMPARISON OF THE DIAGNOSIS OF ALLERGIC DISEASE AND THE RECOMMENDATIONS FOR ALLERGEN IMMUNOTHERAPY BY BOARD-CERTIFIED ALLERGISTS AND A LABORATORY PERFORMING IN-VITRO ASSAYS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											NELSON, HS (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED, 1400 JACKSON ST, DENVER, CO 80206 USA.							ANDERSON JA, 1986, J ALLERGY CLIN IMMUN, V77, P651, DOI 10.1016/0091-6749(86)90403-3; BROWN WG, 1979, J ALLERGY CLIN IMMUN, V63, P328, DOI 10.1016/0091-6749(79)90127-1; MANSFIELD LE, 1982, ANN ALLERGY, V48, P205; Solomon W. R., 1988, ALLERGY PRINCIPLES P, P312; SOLOMON WR, 1992, J RESPIR DIS, V13, P753; 1983, J ALLERGY CLIN IMMUN, V72, P515	6	11	12	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1993	92	3					380	386		10.1016/0091-6749(93)90116-W	http://dx.doi.org/10.1016/0091-6749(93)90116-W			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LX309	8360388	Bronze			2022-12-18	WOS:A1993LX30900003
J	COLUMBO, M; HOROWITZ, EM; PATELLA, V; KAGEYSOBOTKA, A; CHILTON, FH; LICHTENSTEIN, LM				COLUMBO, M; HOROWITZ, EM; PATELLA, V; KAGEYSOBOTKA, A; CHILTON, FH; LICHTENSTEIN, LM			A COMPARATIVE-STUDY OF THE EFFECTS OF 1-ACYL-2-ACETYL-SN-GLYCERO-3-PHOSPHOCHOLINE AND PLATELET-ACTIVATING-FACTOR ON HISTAMINE AND LEUKOTRIENE-C(4) RELEASE FROM HUMAN-LEUKOCYTES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HISTAMINE; LTC(4); BASOPHILS; PHOSPHOLIPIDS; PAF	METHIONYL-LEUCYL-PHENYLALANINE; HUMAN BASOPHILS; HUMAN EOSINOPHILS; HUMAN NEUTROPHIL; FACTOR PAF; DE-GRANULATION; CYTOCHALASIN-B; STIMULATION; CELLS; BIOSYNTHESIS	Background: IgE-mediated stimulation of human basophils and lung mast cells causes the synthesis of larger amounts of 1-acyl-2-acetyl-sn-glycero-3-phosphocholine (1-acyl-2-acetyl-GPC) than 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet activating factor [PAF]). Methods: To study the biologic activity of 1-acyl-2-acetyl-GPC, we compared its effects and those of PAF on histamine and leukoinene C4 (LTC4) release from human mixed leukocytes that contained basophils. Results: 1-Acyl-2-acetyl-GPC (0.1 to 10 mumol/L) failed to release significant amounts of histamine (greater-than-or-equal-to 10%) in most donors tested (20 of 24), whereas PAF (0. 01 to 1 mumol/L) was active in 58%. I-Acyl-2-acetyl-GPC (0.1 to 10 mumol/L) was a stimulus for LTC4 release (132 +/- 30 ng/mug of histamine) with a potency of about 1000 times less than PAF. The kinetics of 1-acyl-2-acetyl-GPC-activated LTC4 release were similar to those of PAF (half-life congruent-to 2 minutes). The specific PAF receptor antagonist, WEB 2086 (10 nmol/L to 10 mumol/L), inhibited both 1-acyl-2-acetyl-GPC- and PAF-mediated LTC4 release with the same potency (inhibitory concentration of 50% congruent-to 1.5 mumol/L). Brief (2-minute) cell preincubation with 1-acyl-2-acetyl-GPC in the absence of extracellular Ca2+ induced a decrease in the subsequent Ca2+ dependent activation of PAF. Similarly 1-acyl-2-acetyl-GPC (0.1 to 10 mumol/L) caused a concentration-dependent inhibition of PAF-activated histamine secretion (inhibitory concentration of 50% congruent-to 0.2 mumol/L). Conclusions: Our data suggest that 1-acyl-2-acetyl-GPC may represent, under certain circumstances, a modulator of human basophil mediator release via mechanisms shared with PAF.	JOHNS HOPKINS UNIV,SCH MED,JOHNS HOPKINS ASTHMA & ALLERGY CTR,DEPT MED,BALTIMORE,MD 21224	Johns Hopkins University; Johns Hopkins Medicine				Patella, Vincenzo/0000-0001-5640-6446	NIAID NIH HHS [AI7290] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADKINSON NF, 1980, MANUAL CLIN IMMUNOLO, P800; BETZ SJ, 1980, J IMMUNOL, V125, P2756; BRAQUET P, 1985, PROSTAGLANDINS, V30, P687, DOI 10.1016/0090-6980(85)90031-0; CAMUSSI G, 1981, IMMUNOLOGY, V42, P191; CASALSSTENZEL J, 1986, 2ND P INT C PLAT ACT, P107; CHILTON FH, 1982, J BIOL CHEM, V257, P5402; CHILTON FH, 1989, HDB INFLAMMATION, V6, P77; COLUMBO M, 1990, J IMMUNOL, V145, P3855; DEMOPOULOS CA, 1979, J BIOL CHEM, V254, P9355; GILLESPIE E, 1972, J CLIN INVEST, V51, P2941, DOI 10.1172/JCI107118; GOCKE DJ, 1965, J IMMUNOL, V94, P236; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HAYES EC, 1983, J IMMUNOL, V131, P429; KNAUER KA, 1984, INT ARCH ALLER A IMM, V74, P29, DOI 10.1159/000233511; KROEGEL C, 1989, J IMMUNOL, V142, P3518; LEE TC, 1984, J BIOL CHEM, V259, P5526; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; MACGLASHAN DW, 1991, LUNG, V1, P591; MACLOUF J, 1990, BLOOD, V76, P1838; MARONE G, 1984, J IMMUNOL, V133, P1542; OKUDA Y, 1988, INT ARCH ALLER A IMM, V85, P341, DOI 10.1159/000234529; RAO GHR, 1982, BIOCHIM BIOPHYS ACTA, V715, P205, DOI 10.1016/0304-4165(82)90360-9; SATOUCHI K, 1985, BIOCHEM BIOPH RES CO, V128, P1409, DOI 10.1016/0006-291X(85)91097-6; SCHLEIMER RP, 1986, DRUG RECEPTORS DYNAM, P202; SHAW JO, 1981, J IMMUNOL, V127, P1250; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; SOBOTKA AK, 1979, J IMMUNOL, V122, P511; TAMURA N, 1988, J IMMUNOL, V141, P4291; TRIGGIANI M, 1991, BIOCHIM BIOPHYS ACTA, V1084, P41, DOI 10.1016/0005-2760(91)90053-K; TRIGGIANI M, 1991, J IMMUNOL, V147, P660; TRIGGIANI M, 1990, J IMMUNOL, V144, P4773; WARNER JA, 1989, J LEUKOCYTE BIOL, V45, P558, DOI 10.1002/jlb.45.6.558; WHATLEY RE, 1992, PROSTAGLANDINS, V43, P21, DOI 10.1016/0090-6980(92)90061-W; WILLIAMS JD, 1986, J IMMUNOL, V136, P642; YASAKA T, 1982, J IMMUNOL, V128, P1939	35	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1993	92	2					325	333		10.1016/0091-6749(93)90176-G	http://dx.doi.org/10.1016/0091-6749(93)90176-G			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LT469	7688778	Bronze			2022-12-18	WOS:A1993LT46900013
J	CHURCH, MK; HUTSON, PA; HOLGATE, ST				CHURCH, MK; HUTSON, PA; HOLGATE, ST			NEDOCROMIL SODIUM BLOCKS THE EARLY AND LATE PHASES OF ALLERGEN CHALLENGE IN A GUINEA-PIG MODEL OF ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							NEUTROPHIL CHEMOTACTIC ACTIVITY; BRONCHOALVEOLAR LAVAGE; MAST-CELLS; BRONCHIAL PROVOCATION; OVALBUMIN INHALATION; AIRWAY; ANTIGEN; LUNG; BRONCHOCONSTRICTION; CROMOGLYCATE	We developed a model of asthma in conscious guinea pigs in which both early- and late-phase reductions in specific airways conductance are demonstrable after inhalation challenge. Neutrophilia that peaks 17 hours after challenge was discovered by bronchoalveolar lavage in this model, as was eosinophilia that develops more slowly, peaking at 72 hours. Nedocromil sodium blocked both the early- and late-phase reductions in airflow, but salbutamol blocked only the early phase. Both drugs blocked the neutrophilia when given before challenge, but not when given 6 hours afterward. This suggests that the neutrophilia is secondary to an intact early phase response. Nedocromil sodium, given 6 hours after challenge, reduced the eosinophilia at 72 hours but not at 17 hours. Salbutamol had no effect on the eosinophilia at either time. These results suggest that nedocromil sodium has antiinflammatory properties in the lung that are not shared by the beta2-adrenergic stimulant drug, salbutamol.			CHURCH, MK (corresponding author), SOUTHAMPTON GEN HOSP,IMMUNOPHARMACOL GRP,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.							ABRAHAM WM, 1983, AM REV RESPIR DIS, V128, P839; ATKINS PC, 1978, J ALLERGY CLIN IMMUN, V62, P149, DOI 10.1016/0091-6749(78)90099-4; AUTY RM, 1986, EUR J RESPIR DIS, V69, P120; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; CHURCH MK, 1987, BRIT J PHARMACOL, V90, P42; CHURCH MK, 1985, PULMONARY ANTIALLERG, P43; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; FREW AJ, 1990, AM REV RESPIR DIS, V141, P407, DOI 10.1164/ajrccm/141.2.407; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; HAMEL R, 1986, J APPL PHYSIOL, V61, P2081, DOI 10.1152/jappl.1986.61.6.2081; HEGARDT B, 1981, ALLERGY, V36, P115, DOI 10.1111/j.1398-9995.1981.tb04105.x; HOLGATE ST, 1985, INT ARCH ALLER A IMM, V77, P47, DOI 10.1159/000233752; HOLGATE ST, 1986, EUR J RESPIR DIS, V69, P149; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; HUTSON PA, 1990, AM REV RESPIR DIS, V141, P535, DOI 10.1164/ajrccm/141.3.535; HUTSON PA, 1988, AM REV RESPIR DIS, V137, P548, DOI 10.1164/ajrccm/137.3.548; HUTSON PA, 1988, BRIT J PHARMACOL, V94, P6, DOI 10.1111/j.1476-5381.1988.tb11493.x; HUTSON PA, 1988, AM REV RESPIR DIS, V138, P839; IIJIMA H, 1987, AM REV RESPIR DIS, V136, P922, DOI 10.1164/ajrccm/136.4.922; LEUNG KBP, 1986, EUR J RESPIR DIS, V69, P223; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; NOORD HB, 1971, J ALLERGY CLIN IMMUN, V48, P344; ODRISCOLL BRC, 1983, J ALLERGY CLIN IMMUN, V72, P695, DOI 10.1016/0091-6749(83)90632-2; SANJAR S, 1990, BRIT J PHARMACOL, V99, P267, DOI 10.1111/j.1476-5381.1990.tb14692.x; SCHENKEL E, 1982, J ALLERGY CLIN IMMUN, V70, P321, DOI 10.1016/0091-6749(82)90020-3; SHAMPAIN MP, 1982, AM REV RESPIR DIS, V126, P493; SLIFMAN NR, 1988, ALLERGY PRINCIPLES P, P179; WIESLANDER E, 1985, AGENTS ACTIONS, V16, P37, DOI 10.1007/BF01999639; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0	32	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1993	92	1	2				177	182		10.1016/0091-6749(93)90102-L	http://dx.doi.org/10.1016/0091-6749(93)90102-L			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LQ354	8393024				2022-12-18	WOS:A1993LQ35400008
J	PEARCE, FL				PEARCE, FL			EFFECT OF NEDOCROMIL SODIUM ON MEDIATOR RELEASE FROM MAST-CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							BRONCHOALVEOLAR LAVAGE; HISTAMINE-SECRETION; CROMOGLYCATE; ASTHMA	Bronchial asthma is a complex inflammatory disorder that involves activation of, and mediator release by, a variety of cells including mast cells. Nedocromil sodium can inhibit the activity of a range of inflammatory cells including mast cells, as has been demonstrated in several studies. In human beings nedocromil sodium inhibited histamine secretion from mast cells obtained by bronchoalveolar lavage and from dispersed lung mast cells. Tachyphylaxis was noted with the latter cells only. Because the bronchoalveolar lavage mast cells would come into direct contact with inhaled drugs, these cells may be a major target for the action of nedocromil sodium. The inhibitory effects of nedocromil sodium on mast cell activation and secretion are one way the drug may be effective in controlling airway obstruction.			PEARCE, FL (corresponding author), UNIV LONDON UNIV COLL,DEPT CHEM,20 GORDON ST,LONDON WC1H 0AJ,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARNES PJ, 1988, ASTHMA BASIC MECHANI; CHURCH MK, 1978, MED ACT DRUGS TODAY, V14, P281; FLINT KC, 1985, BRIT MED J, V291, P923, DOI 10.1136/bmj.291.6500.923; FLINT KC, 1985, CLIN SCI, V68, P427, DOI 10.1042/cs0680427; KAY AB, 1987, AM REV RESPIR DIS, V135, pS63; LEUNG KBP, 1988, THORAX, V43, P756, DOI 10.1136/thx.43.10.756; LIU WL, 1990, AGENTS ACTIONS, V30, P70, DOI 10.1007/BF01969001; MOQBEL R, 1988, ALLERGY, V43, P268, DOI 10.1111/j.1398-9995.1988.tb00899.x; PEARCE FL, 1987, INT ARCH ALLER A IMM, V82, P507, DOI 10.1159/000234266; PEARCE FL, 1989, DRUGS, V37, P37, DOI 10.2165/00003495-198900371-00009; TAINSH KR, 1991, AGENTS ACTIONS, V33, P16, DOI 10.1007/BF01993115	11	11	11	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1993	92	1	2				155	158		10.1016/0091-6749(93)90098-Z	http://dx.doi.org/10.1016/0091-6749(93)90098-Z			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LQ354	7687609				2022-12-18	WOS:A1993LQ35400004
J	JUJO, K; RENZ, H; ABE, J; TRUMBLE, A; GELFAND, EW; LEUNG, DYM				JUJO, K; RENZ, H; ABE, J; TRUMBLE, A; GELFAND, EW; LEUNG, DYM			POKEWEED MITOGEN INDUCES IGE SYNTHESIS IN THE PRESENCE OF A BLOCKING ANTIBODY TO THE INTERFERON-GAMMA RECEPTOR	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IMMUNOGLOBULIN E (IGE); PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS); POKEWEED MITOGEN (PWM)	HUMAN B-CELLS; BLOOD MONONUCLEAR-CELLS; MONOCLONAL-ANTIBODIES; IFN-GAMMA; T-CELLS; INVITRO; INTERLEUKIN-4; IL-4; INDUCTION; SUPERNATANTS	Background: Although pokeweed mitogen (PWEM) can induce peripheral blood mononuclear cells (PBMCs) to synthesize IgG, IgA, and IgM, such cultures fail to induce IgE synthesis. The present study examined the possibility that the stimulation of interferon-gamma (IFN-gamma) production plays a role in the failure of PWM to induce IgE synthesis. Methods: We examined PBMCs from eight normal control subjects for IFN-gamma and IL-4 production. Since IFN-gamma synthesis is known to inhibit IgE synthesis, we also examined the effect of a neutralizing anti-IFN-gamma antibody and of two anti-IFN-gamma receptor antibodies, monoclonal antibody (mAb) GIR208, which blocks cellular binding of IFN-gamma, and mAB GIR94.5, which binds to the IFN-gamma receptor but does wt block the binding of IFN-gamma to its receptor on PWM-stimulated PBMCs. Results: After stimulation with PWM, culture supernatants contained significantly more IFN-gamma (p = 0. 001) and IL-4 (P = 0. 001) compared with supernatants from nonstimulated cultures. PWM-stimulated PBMCs also expressed higher levels of IFN-gamma and IL-4 gene transcripts than unstimulated cells. When cultured in the presence of anti-IFN-gamma, superantants from PWM-stimulated cultures also induced CD23 on Ramos B cells in an IL-4-dependent manner. In the presence of mAB GIR208 and a neutralizing anti-IFN-gamma antibody, but not mAb GIR94.5, PWM stimulated PBMCs from eight normal control subjects and six patients with atopic dermatitis to produce IgE. Monoclonal antibody GIR208, however, did not enhance IgG synthesis. Furthermore, the exogenous addition of IFN-gamma inhibited the IgE-stimulatory effect of mAb GIR208. Monoclonal antibody GIR208 was unable to induce purified B cells to synthesize IgE in the presence of IL-4. Conclusions: Thus unlike anti-CD40, mAb GIR208 does not act as a second signal for the induction of IgE synthesis. These results demonstrate that the induction of IFN-gamma production contributes to the failure of PWM to stimulate synthesis of IgE in PBMCs from atopic and nonatopic donors.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,ROOM K926,1400 JACKSON ST,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT PEDIAT,DENVER,CO 80262	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36577] Funding Source: Medline; NIAID NIH HHS [AI-26490] Funding Source: Medline; NIAMS NIH HHS [AR-41256] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSSON J, 1992, IMMUNOL REV, V127, P1; CHRETIEN I, 1989, J IMMUNOL METHODS, V117, P67, DOI 10.1016/0022-1759(89)90120-8; CLAASSEN JL, 1990, J IMMUNOL, V144, P2123; CLAASSEN JL, 1992, CELL IMMUNOL, V140, P357, DOI 10.1016/0008-8749(92)90202-Z; COFFMAN RL, 1986, J IMMUNOL, V136, P949; CUSTER MC, 1990, J IMMUNOL METHODS, V128, P109, DOI 10.1016/0022-1759(90)90469-C; DELPRETE G, 1988, J IMMUNOL, V140, P4193; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; FINKELMAN FD, 1988, J IMMUNOL, V140, P1022; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; GASCAN H, 1991, J IMMUNOL, V147, P8; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; ISHIZAKA T, 1984, PROG ALLERGY, V34, P188; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; LEUNG DYM, 1986, J CLIN IMMUNOL, V6, P273, DOI 10.1007/BF00917327; PENE J, 1989, J CELL BIOCHEM, V39, P253, DOI 10.1002/jcb.240390305; ROMAGNANI S, 1980, CLIN EXP IMMUNOL, V42, P167; ROUSSET F, 1991, J ALLERGY CLIN IMMUN, V87, P58, DOI 10.1016/0091-6749(91)90213-8; SAMPSON HA, 1981, J IMMUNOL, V127, P829; SARYAN JA, 1983, J IMMUNOL, V130, P242; SHEEHAN KCF, 1988, J IMMUNOL, V140, P4231; SPIEGELBERG HL, 1983, J IMMUNOL, V131, P3001; TIJO AH, 1979, J IMMUNOL, V122, P2131; TURNER KJ, 1983, CLIN EXP IMMUNOL, V51, P387; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717	26	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1993	91	6					1206	1216		10.1016/0091-6749(93)90324-9	http://dx.doi.org/10.1016/0091-6749(93)90324-9			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LG740	8509581	Bronze			2022-12-18	WOS:A1993LG74000013
J	HAN, SH; CHANG, ZN; CHANG, HH; CHI, CW; WANG, JY; LIN, CY				HAN, SH; CHANG, ZN; CHANG, HH; CHI, CW; WANG, JY; LIN, CY			IDENTIFICATION AND CHARACTERIZATION OF EPITOPES ON CYN-D-I, THE MAJOR ALLERGEN OF BERMUDA GRASS-POLLEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EPITOPE; ALLERGENIC EPITOPE; CYN-D-I; ALLERGEN; BERMUDA GRASS POLLEN; MONOCLONAL ANTIBODY	CYNODON-DACTYLON POLLEN; LOL P-I; MONOCLONAL-ANTIBODIES; SITES; BINDING	Background: We identified three epitopes on Cyn d I by using four anti-Cyn d I monoclonal antibodies (MoAbs). Methods: In a cross-inhibition binding assay, the binding of MoAbs 1-61 and 10-7 to Cyn d I was completely blocked by each other but not by MoAbs 4-37 and 11-7; the binding of MoAb 4-37 and MoAb 11-7 to Cyn d I was inhibited by themselves but not by other MoAbs. The epitope recognized by MoAbs 1-61 and 10-7 is designated as E1, and those recognized by MoAbs 4-37 and 11-7 are designated as E2 and E3, respectively. Results: In a radioallergosorbent inhibition assay, we found that MoAbs 1-61 and 4-37 (1:50 diluted) can inhibit the binding of human Immunoglobulin Es to Cyn d I by more than 30%, whereas MoAb 11-7 was less efficient (reduced by only 6%). These results suggest that both E1 and E2 are major allergenic epitopes but that E3 is only a minor one. Further characterization of E1 and E2 reveals that they are labile in alkaline but resistant to acid and sodium periodate treatments. Moreover, E1 is heat-labile, but quanidine- and urea-sensitive, whereas E2 is not. Both E1 and E2 lost their antigenicity after reduction and alkylation. Conclusions: Results of the present study provide important information on the physicochemical properties of major allergenic epitopes on Cyn d I, which may be useful for future development of therapeutic peptides for patients allergic to Bermuda grass pollen.	NATL CHENG KUNG UNIV, COLL MED, DEPT PEDIAT, TAINAN, TAIWAN; NATL YANG MING MED COLL, SCH MED TECHNOL, TAIPEI, TAIWAN; NATL YANG MING MED COLL, INST MOLEC BIOL, TAIPEI, TAIWAN; TAIWAN ALLERGY CTR, TAIPEI, TAIWAN; VET GEN HOSP, DEPT MED RES, TAIPEI, TAIWAN	National Cheng Kung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University								ATASSI H, 1986, EUR J IMMUNOL, V16, P229, DOI 10.1002/eji.1830160304; BOSE R, 1986, IMMUNOLOGY, V59, P309; CHANG LH, 1990, ELECTROPHORESIS, V265, P16210; CHANG Z-N, 1988, Proceedings of the National Science Council Republic of China Part B Life Sciences, V12, P140; CHANG ZN, 1991, CLIN EXP ALLERGY, V21, P503, DOI 10.1111/j.1365-2222.1991.tb01692.x; CHANG ZN, 1991, ALLERGY, V46, P520, DOI 10.1111/j.1398-9995.1991.tb00615.x; FORD SA, 1987, J ALLERGY CLIN IMMUN, V79, P711, DOI 10.1016/0091-6749(87)90201-6; JAGGI KS, 1989, J ALLERGY CLIN IMMUN, V83, P845, DOI 10.1016/0091-6749(89)90024-9; LIN ZW, 1990, INT ARCH ALLER A IMM, V91, P217, DOI 10.1159/000235120; LOMBARDERO M, 1990, J IMMUNOL, V144, P1353; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATTHIESEN F, 1989, J ALLERGY CLIN IMMUN, V83, P1124, DOI 10.1016/0091-6749(89)90456-9; MATTHIESEN F, 1991, J ALLERGY CLIN IMMUN, V88, P763, DOI 10.1016/0091-6749(91)90184-P; MATTHIESEN F, 1991, CLIN EXP ALLERGY, V21, P297, DOI 10.1111/j.1365-2222.1991.tb01661.x; MOURAD W, 1988, J IMMUNOL, V141, P3486; OLSON JR, 1986, J IMMUNOL, V136, P2109; SCHUMACHER MJ, 1985, ANN ALLERGY, V55, P584; SHEN HD, 1988, CLIN ALLERGY, V18, P401, DOI 10.1111/j.1365-2222.1988.tb02888.x; TSAI LC, 1987, ASIA PAC COMMUN BIOC, V1, P133; WOODWARD MP, 1985, J IMMUNOL METHODS, V78, P143, DOI 10.1016/0022-1759(85)90337-0; WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532	21	11	13	1	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1993	91	5					1035	1041		10.1016/0091-6749(93)90217-4	http://dx.doi.org/10.1016/0091-6749(93)90217-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LC978	7684053				2022-12-18	WOS:A1993LC97800011
J	MAKINENKILJUNEN, S; ALENIUS, H; AHLROTH, M; TURJANMAA, K; PALOSUO, T; REUNALA, T				MAKINENKILJUNEN, S; ALENIUS, H; AHLROTH, M; TURJANMAA, K; PALOSUO, T; REUNALA, T			IMMUNOBLOT INHIBITION DETECTS SEVERAL COMMON ALLERGENS IN RUBBER LATEX AND BANANA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1993	91	1	2				242	242						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK431					2022-12-18	WOS:A1993KK43100405
J	MELTZER, EO; JALOWAYSKI, AA; FIELD, EA; ROGENES, PR; KRAL, KM				MELTZER, EO; JALOWAYSKI, AA; FIELD, EA; ROGENES, PR; KRAL, KM			INTRANASAL FLUTICASONE PROPIONATE REDUCES HISTAMINE AND TRYPTASE IN THE MUCOSA OF ALLERGIC RHINITIS PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1993	91	1	2				298	298						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK431					2022-12-18	WOS:A1993KK43100629
J	NORDLEE, JA; ATKINS, FM; BUSH, RK; TAYLOR, SL				NORDLEE, JA; ATKINS, FM; BUSH, RK; TAYLOR, SL			ANAPHYLAXIS FROM UNDECLARED WALNUT IN COMMERCIALLY PROCESSED COOKIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract													Taylor, Steve L./V-1341-2019						0	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1993	91	1	2				154	154						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK431					2022-12-18	WOS:A1993KK43100056
J	HUANG, SW				HUANG, SW			A CLINICAL APPROACH TO A PATIENT WITH PRAZIQUANTEL HYPERSENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note											HUANG, SW (corresponding author), UNIV FLORIDA,COLL MED,DEPT PEDIAT,POB 100296,GAINESVILLE,FL 32610, USA.							MITCHELL AA, 1988, PEDIATRICS, V82, P24; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P275, DOI 10.1016/S0091-6749(82)80004-3	2	11	11	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1992	90	5					867	867		10.1016/0091-6749(92)90114-H	http://dx.doi.org/10.1016/0091-6749(92)90114-H			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JZ319	1430712				2022-12-18	WOS:A1992JZ31900020
J	NACLERIO, RM				NACLERIO, RM			INHIBITION OF MEDIATOR RELEASE DURING THE EARLY REACTION TO ANTIGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGIC RHINITIS; ANTIGEN; HISTAMINE; MAST CELL; CETIRIZINE; LORATADINE; TERFENADINE		A nasal lavage model and a new filter paper disk model have been used to measure biologic and physiologic responses to antigen challenge in patients with allergic rhinitis. Pretreatment Of subjects with cetirizine reduced the number of sneezes induced by antigen challenge but did not significantly reduce levels of histamine or prostaglandin D2 in a double-blind, placebo-controlled trial with the lavage model. Pretreatment with 60 or 300 mg of terfenadine did significantly reduce levels of histamine, kinin, albumin, and TAME-esterase activity in a double-blind, placebo-controlled study with this model. Again with the nasal lavage model, a double-blind, placebo-controlled comparison of pretreatment with 60 mg of terfenadine or 10 mg of loratadine showed that both agents significantly reduced sneezing. Both drugs also lowered levels of antigen-induced histamine and TAME-esterase, but only terfenadine did so significantly. In a double-blind, placebo-controlled study, the new disk method showed that terfenadine reduced sneezing but not nasal congestion in eight patients with allergic rhinitis. Terfenadine significantly reduced the weight of nasal secretions on both sides of the nose and significantly reduced histamine on the ipsilateral side.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21205	Johns Hopkins University								NACLERIO RM, 1990, AM REV RESPIR DIS, V142, P167, DOI 10.1164/ajrccm/142.1.167; NACLERIO RM, 1989, LARYNGOSCOPE, V99, P596	2	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1992	90	4	2	S			715	719		10.1016/0091-6749(92)90157-W	http://dx.doi.org/10.1016/0091-6749(92)90157-W			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JV009	1401653				2022-12-18	WOS:A1992JV00900003
J	APTER, AJ; KAPLAN, AA				APTER, AJ; KAPLAN, AA			AN APPROACH TO IMMUNOLOGICAL REACTIONS ASSOCIATED WITH PLASMA-EXCHANGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ETHYLENE-OXIDE GAS; ANAPHYLACTOID REACTIONS; COMPLEMENT ACTIVATION; MEDIA REACTIONS; COMPLICATIONS; HEMODIALYSIS; IGE; PLASMAPHERESIS; HEMOFILTRATION; SPECIFICITY				APTER, AJ (corresponding author), UNIV CONNECTICUT, CTR HLTH, DEPT MED, LG-006, FARMINGTON, CT 06030 USA.							APTER AJ, 1989, ARCH INTERN MED, V149, P2571, DOI 10.1001/archinte.149.11.2571; APTER AJ, 1988, AM J ASTHMA ALLERGY, V2, P19; AUFEUVRE JP, 1980, PLASMA EXCHANGE, P149; BELL WR, 1991, NEW ENGL J MED, V325, P398, DOI 10.1056/NEJM199108083250605; BURKS AW, 1986, NEW ENGL J MED, V314, P560, DOI 10.1056/NEJM198602273140907; CRADDOCK PR, 1977, NEW ENGL J MED, V296, P769, DOI 10.1056/NEJM197704072961401; DAUGIRDAS JT, 1985, ARCH INTERN MED, V145, P489, DOI 10.1001/archinte.145.3.489; DOLOVICH J, 1978, J ALLERGY CLIN IMMUN, V62, P30, DOI 10.1016/0091-6749(78)90069-6; DOLOVICH J, 1987, TRANSFUSION, V27, P90, DOI 10.1046/j.1537-2995.1987.27187121484.x; DUMLER F, 1987, ARTIF ORGANS, V11, P128, DOI 10.1111/j.1525-1594.1987.tb02643.x; FABRE M, 1980, PLASMA EXCHANGE, P143; FUNDENBERG HH, 1964, COLD SPRING HARB SYM, V29, P463; GOLD M, 1991, J ALLERGY CLIN IMMUN, V87, P662, DOI 10.1016/0091-6749(91)90385-2; GRAMMER LC, 1985, J ALLERGY CLIN IMMUN, V76, P511, DOI 10.1016/0091-6749(85)90736-5; GREENBERGER PA, 1985, NEW ENGL J MED, V312, P897, DOI 10.1056/NEJM198504043121406; GREENBERGER PA, 1985, ARCH INTERN MED, V145, P2197, DOI 10.1001/archinte.145.12.2197; GREENBERGER PA, 1988, NEW ENGL REG ALLERGY, V9, P539, DOI 10.2500/108854188778965555; GREENBERGER PA, 1984, J ALLERGY CLIN IMMUN, V74, P600, DOI 10.1016/0091-6749(84)90113-1; Greenberger PA, 1991, PRINCIPLES TRANSFUSI, P635; HAKIM RM, 1984, NEW ENGL J MED, V311, P878, DOI 10.1056/NEJM198410043111403; ISBISTER J P, 1976, Anaesthesia and Intensive Care, V4, P105; ISBISTER JP, 1990, THERAPEUTIC HEMAPHER, V57, P10; JACOB AI, 1980, KIDNEY INT, V18, P505, DOI 10.1038/ki.1980.164; KAPLAN AA, 1988, BLOOD PURIFICAT, V6, P27, DOI 10.1159/000169481; KAPLAN AA, 1990, KIDNEY INT, V38, P160, DOI 10.1038/ki.1990.181; KWAAN HC, 1987, SEMIN HEMATOL, V24, P71; LAMBIN P, 1984, VOX SANG, V47, P242, DOI 10.1111/j.1423-0410.1984.tb01592.x; MATSSON P, 1991, AGENTS ACTIONS, V33, P218, DOI 10.1007/BF01993172; MOLLISON PL, 1987, SOME UNFAVOURABLE EF, P723; MOSCICKI RA, 1990, J ALLERGY CLIN IMMUN, V86, P325, DOI 10.1016/S0091-6749(05)80095-8; NICHOLLS AJ, 1982, BRIT MED J, V285, P1607, DOI 10.1136/bmj.285.6355.1607; PATTEN E, 1986, CRC CR REV CL LAB SC, V23, P147, DOI 10.3109/10408368609165798; ROCK G, 1990, PROG CLIN BIOL RES, P523; ROCK G, 1990, APHERESIS; ROCK GA, 1991, NEW ENGL J MED, V325, P393, DOI 10.1056/NEJM199108083250604; ROCK GA, 1990, CAN MED ASSOC J, V142, P557; ROUTLEDGE RC, 1976, BRIT MED J, V1, P434, DOI 10.1136/bmj.1.6007.434; RUBENSTEIN MD, 1983, AM J MED, V75, P171, DOI 10.1016/0002-9343(83)91184-1; SAMTLEBEN W, 1980, PLASMA EXCHANGE, P175; SCHATZ M, 1988, ALLERGY PRINCIPLES P, P1093; SCHMITT E, 1990, PROG CLIN BIOL RES, P513; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; SILBERSTEIN L, 1991, PRINCIPLES TRANSFUSI, P63; SPRENGER KBG, 1984, ARTIF ORGANS, V8, P360; SUTTON DMC, 1989, TRANSFUSION, V29, P124, DOI 10.1046/j.1537-2995.1989.29289146829.x; WASSERMAN SI, 1988, ALLERGY PRINCIPLES P, P1365; 1988, LANCET, V2, P1464	47	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1992	90	1					119	124		10.1016/S0091-6749(06)80018-7	http://dx.doi.org/10.1016/S0091-6749(06)80018-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JE255	1629498	Bronze			2022-12-18	WOS:A1992JE25500014
J	BARANIUK, JN; SILVER, PB; KALINER, MA; BARNES, PJ				BARANIUK, JN; SILVER, PB; KALINER, MA; BARNES, PJ			IBUPROFEN AUGMENTS BRADYKININ-INDUCED GLYCOCONJUGATE SECRETION BY HUMAN NASAL-MUCOSA INVIVO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BRADYKININ; IBUPROFEN; ALBUMIN; GLYCOCONJUGATE; MUCUS; LYSOZYME; MUCOSAL SECRETION; RHINITIS	PLATELET-ACTIVATING-FACTOR; HUMAN AIRWAYS INVITRO; PATHO-PHYSIOLOGY; MONOHYDROXYEICOSATETRAENOIC ACID; RESPIRATORY GLYCOCONJUGATE; MUCUS HYPERSECRETION; TRACHEA INVIVO; GUINEA-PIG; RHINITIS; RELEASE	Bradykinin (BK) stimulates vascular permeability and glycoconjugate secretion in human nasal mucosa. Since some of the effects of BK may be mediated by autocrine generation of arachidonic acid metabolites, the influence of ibuprofen, a cyclooxygenase inhibitor, on BK-induced nasal secretion was studied. Six normal male subjects had nasal provocations with 0, 10, 100, and 1000 nmol of BK before and after treatment with 400 mg of ibuprofen. Secretions were collected by nasal lavage. Total protein (marker of protein secretion), glycoconjugate (mucous cell marker), lysozyme (serous cell marker), and albumin (marker of vascular permeability) were measured. Basal glycoconjugate secretion was higher after ibuprofen (219 +/- 32-mu-g/ml) than before (81 +/- 56 -mu-g/ml; p < 0.05 by analysis of variance). BK stimulated significant, dose-dependent albumin, total protein, and glycoconjugate secretion. Lysozyme secretion was not stimulated. BK (1000 nmol) significantly increased total protein secretion, tenfold to twentyfold, and albumin secretion by 40-fold to 60-fold. Ibuprofen did not alter BK-induced total protein or albumin secretion. Glycoconjugate secretion after ibuprofen treatment was significantly higher than normal at 10 nmol (p < 0.05), 100 nmol (p < 0.02), and 1000 nmol of BK (519-mu-g/ml +/- 74 versus 213 +/- 15-mu-g/ml; p < 0.05). Therefore, BK induces vascular permeability and exocytosis from glycoconjugate-containing cells but does not stimulate serous cells. Ibuprofen increases baseline secretion of glycoconjugate and enhances BK-induced glycoconjugate secretion. Ibuprofen does not alter BK-induced vascular permeability.	NHLBI, DEPT THORAC MED, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	BARANIUK, JN (corresponding author), NIAID, CLIN INVEST LAB, ALLERG DIS SECT, BLDG 10, ROOM 11-C-205, BETHESDA, MD 20892 USA.			Barnes, Peter/0000-0002-5122-4018; Baraniuk, James Nicholas/0000-0002-1866-4177				AIZAWA H, 1989, Fukuoka Acta Medica, V80, P95; BARANIUK JN, 1990, AM REV RESPIR DIS, V141, P706, DOI 10.1164/ajrccm/141.3.706; BARANIUK JN, 1991, AM REV RESPIR DIS, V143, P617; BIRNBAUMER L, 1990, AM REV RESPIR DIS, V141, pS106, DOI 10.1164/ajrccm/141.3_Pt_2.S106; BISGAARD H, 1986, CLIN ALLERGY, V16, P289, DOI 10.1111/j.1365-2222.1986.tb01960.x; BROOKS PM, 1991, NEW ENGL J MED, V324, P1716; COLES SJ, 1983, PROSTAGLANDINS, V25, P155, DOI 10.1016/0090-6980(83)90101-6; ERJAFALT I, 1991, CLIN EXP ALLERGY, V21, P217; GOSWAMI SK, 1989, J ALLERGY CLIN IMMUN, V84, P726, DOI 10.1016/0091-6749(89)90301-1; HOLMBERG K, 1990, EUR J PHARMACOL, V175, P35, DOI 10.1016/0014-2999(90)90149-Z; HOWARTH P, 1990, Journal of Allergy and Clinical Immunology, V85, P223; JOHNSON HG, 1985, AM REV RESPIR DIS, V131, P917; JOHNSON HG, 1983, INT J IMMUNOPHARMACO, V5, P391, DOI 10.1016/0192-0561(83)90013-9; JUERGENS U R, 1991, Journal of Allergy and Clinical Immunology, V87, P221, DOI 10.1016/0091-6749(91)91609-W; KOWALSKI M, 1991, Journal of Allergy and Clinical Immunology, V87, P216, DOI 10.1016/0091-6749(91)91589-L; LAU WAK, 1989, CLIN EXP PHARMACOL P, V16, P849, DOI 10.1111/j.1440-1681.1989.tb01524.x; LEIKAUF GD, 1986, AM J PHYSIOL, V250, pF47, DOI 10.1152/ajprenal.1986.250.1.F47; LEIKAUF GD, 1985, AM J PHYSIOL, V248, pF48, DOI 10.1152/ajprenal.1985.248.1.F48; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDGREN JD, 1990, J ALLERGY CLIN IMMUN, V85, P399, DOI 10.1016/0091-6749(90)90147-V; LUNDGREN JD, 1985, ANN ALLERGY, V55, P5; LUNDGREN JD, 1990, AGENTS ACTIONS, V30, P329, DOI 10.1007/BF01966296; LYON R A, 1990, Pulmonary Pharmacology, V3, P209, DOI 10.1016/0952-0600(90)90019-F; MAK JCW, 1991, EUR J PHARMACOL, V194, P37, DOI 10.1016/0014-2999(91)90121-6; MAROM Z, 1983, J CLIN INVEST, V72, P122, DOI 10.1172/JCI110949; MAROM Z, 1981, J CLIN INVEST, V67, P1695, DOI 10.1172/JCI110207; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; MEREDITH SD, 1989, J ALLERGY CLIN IMMUN, V84, P920, DOI 10.1016/0091-6749(89)90390-4; MIADONNA A, 1987, AM REV RESPIR DIS, V136, P357, DOI 10.1164/ajrccm/136.2.357; MIADONNA A, 1990, Journal of Allergy and Clinical Immunology, V85, P223; NACLERIO RM, 1988, J INFECT DIS, V157, P133, DOI 10.1093/infdis/157.1.133; PATOW CA, 1984, AM J OTOLARYNG, V5, P334, DOI 10.1016/S0196-0709(84)80003-4; PATOW CA, 1984, OTOLARYNG HEAD NECK, V92, P424, DOI 10.1177/019459988409200410; PEATFIELD AC, 1982, BRIT J PHARMACOL, V77, P391, DOI 10.1111/j.1476-5381.1982.tb09310.x; PONGRACIC JA, 1991, BRIT J CLIN PHARMACO, V31, P287, DOI 10.1111/j.1365-2125.1991.tb05532.x; PROUD D, 1990, J INFECT DIS, V161, P120, DOI 10.1093/infdis/161.1.120; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; PROUD D, 1988, AM REV RESPIR DIS, V137, P613, DOI 10.1164/ajrccm/137.3.613; RAJAKULASINGAM K, 1991, J PHYSIOL-LONDON, V437, P557; RAJAKULASINGAM K, 1991, Journal of Allergy and Clinical Immunology, V87, P215, DOI 10.1016/0091-6749(91)91587-J; RAPHAEL G, 1989, J ALLERGY CLIN IMMUN, V83, P110, DOI 10.1016/0091-6749(89)90484-3; RAPHAEL GD, 1988, AM REV RESPIR DIS, V138, P413, DOI 10.1164/ajrccm/138.2.413; RAPHAEL GD, 1989, J CLIN INVEST, V84, P1528, DOI 10.1172/JCI114329; RAPHAEL GD, 1991, J ALLERGY CLIN IMMUN, V87, P457, DOI 10.1016/0091-6749(91)90001-5; RAPHAEL GD, 1989, AM REV RESPIR DIS, V139, P791, DOI 10.1164/ajrccm/139.3.791; ROGERS DF, 1990, BRIT J PHARMACOL, V101, P739, DOI 10.1111/j.1476-5381.1990.tb14150.x; ROGERS DF, 1989, LANCET, V1, P930; SALARI H, 1989, AM J RESP CELL MOL, V1, P245, DOI 10.1165/ajrcmb/1.3.245; SMITH JJ, 1990, AM J PHYSIOL, V258, pL369, DOI 10.1152/ajplung.1990.258.6.L369; WINZLER R J, 1955, Methods Biochem Anal, V2, P279, DOI 10.1002/9780470110188.ch10	51	11	11	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1992	89	5					1032	1039		10.1016/0091-6749(92)90226-R	http://dx.doi.org/10.1016/0091-6749(92)90226-R			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HU542	1583245				2022-12-18	WOS:A1992HU54200014
J	RANKIN, JA; HARRIS, P; ACKERMAN, SJ				RANKIN, JA; HARRIS, P; ACKERMAN, SJ			THE EFFECTS OF EOSINOPHIL-GRANULE MAJOR BASIC-PROTEIN ON LUNG-MACROPHAGE SUPEROXIDE ANION GENERATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALVEOLAR MACROPHAGES; MAJOR BASIC PROTEIN; SUPEROXIDE ANION; VIABILITY	LEYDEN CRYSTAL PROTEIN; CELL HISTAMINE-RELEASE; CATIONIC PROTEINS; TRACHEAL EPITHELIUM; BRONCHIAL-ASTHMA; BRONCHOALVEOLAR LAVAGE; ALVEOLAR MACROPHAGES; SCHISTOSOMA-MANSONI; ACTIVATION; INVITRO	The effects of major basic protein (MBP) on superoxide anion release in vitro from normal guinea pig (GP) alveolar macrophages (AM) was determined. Native MBP at 55-mu-g/ml had an immediate effect (reduction) on phorbol myristate acetate (PMA)-induced (p < 0.01) and spontaneous (p = 0.055) superoxide (O2-) release by GP AMs. A similar effect was not observed from AMs incubated for 24 hours with MBP before assessment of O2- release. However, after AMs were incubated with MBP for 48 hours, again there was a significant reduction observed in both PMA-induced (p = 0.01) and spontaneous (p = 0.002) O2- release compared to that of control cultures. The immediate effect of MBP on AM O2- release was not due to cytotoxicity of MBP for AM. In contrast, the effect observed after 48 hours of culture was due, in part, to a direct toxic effect of the MBP on the AM because the viability of AM cultured for 48 hours with MBP (55-mu-g/ml) was 63.6% +/- 13% compared to the viability of control cultures of AM that was 83.9% +/- 7%; p = 0.03. The effect of MBP on AM O2- release at 48 hours was progressive over concentrations ranging from 2 to 55-mu-g/ml. These data suggest that native MBP can affect adversely PMA-induced and spontaneous release of O2- by GP AMs and that this effect depends only in part on the cytotoxic properties of MBP.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; YALE UNIV,SCH MED,PULM & CRIT CARE SECT,NEW HAVEN,CT 06510; BETH ISRAEL HOSP,DIV INFECT DIS,BOSTON,MA 02215	Harvard University; Harvard Medical School; Yale University; Harvard University; Beth Israel Deaconess Medical Center	RANKIN, JA (corresponding author), VET ADM MED CTR,PULM SECT 111A,RES SERV,W HAVEN,CT 06516, USA.				NIAID NIH HHS [R01 AI22660, R01 AI25230] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025230, R01AI022660] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKERMAN SJ, 1983, J IMMUNOL, V131, P2977; ACKERMAN SJ, 1985, AM J TROP MED HYG, V34, P735, DOI 10.4269/ajtmh.1985.34.735; BUTTERWORTH AE, 1979, J IMMUNOL, V122, P221; COOPER JAD, 1988, J APPL PHYSIOL, V64, P1615, DOI 10.1152/jappl.1988.64.4.1615; DOR PJ, 1984, AM REV RESPIR DIS, V130, P1072; FILLEY WV, 1982, LANCET, V2, P11; FRIGAS E, 1980, LAB INVEST, V42, P35; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; GLEICH GJ, 1976, J CLIN INVEST, V57, P633, DOI 10.1172/JCI108319; GODARD P, 1982, J ALLERGY CLIN IMMUN, V70, P88, DOI 10.1016/0091-6749(82)90234-2; HISAMATSU K, 1990, J ALLERGY CLIN IMMUN, V86, P52, DOI 10.1016/S0091-6749(05)80123-X; HOWELL CJ, 1989, AM REV RESPIR DIS, V140, P1340, DOI 10.1164/ajrccm/140.5.1340; JACOBY DB, 1988, AM REV RESPIR DIS, V137, P13, DOI 10.1164/ajrccm/137.1.13; JOHNSTON RB, 1978, J EXP MED, V148, P115; KELLY C, 1988, THORAX, V43, P684, DOI 10.1136/thx.43.9.684; MOTOJIMA S, 1989, AM REV RESPIR DIS, V139, P801, DOI 10.1164/ajrccm/139.3.801; MOY JN, 1990, J IMMUNOL, V145, P2626; ODONNELL MC, 1983, J EXP MED, V157, P1981, DOI 10.1084/jem.157.6.1981; RANKIN JA, 1989, J ALLERGY CLIN IMMUN, V83, P722, DOI 10.1016/0091-6749(89)90005-5; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WASMOEN TL, 1988, J BIOL CHEM, V263, P12559; WASSOM DL, 1979, AM J TROP MED HYG, V28, P860, DOI 10.4269/ajtmh.1979.28.860; YUKAWA T, 1990, AM J RESP CELL MOL, V2, P341, DOI 10.1165/ajrcmb/2.4.341; ZHEUTLIN LM, 1984, J IMMUNOL, V133, P2180	24	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1992	89	3					746	752		10.1016/0091-6749(92)90383-D	http://dx.doi.org/10.1016/0091-6749(92)90383-D			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HJ340	1312101				2022-12-18	WOS:A1992HJ34000015
J	ATKINS, PC; KAPLAN, AP; VONALLMEN, C; MOSKOVITZ, A; ZWEIMAN, B				ATKINS, PC; KAPLAN, AP; VONALLMEN, C; MOSKOVITZ, A; ZWEIMAN, B			ACTIVATION OF THE COAGULATION PATHWAY DURING ONGOING ALLERGIC CUTANEOUS REACTIONS IN HUMANS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						FIBRIN; CUTANEOUS ALLERGIC REACTIONS; LATE-PHASE RESPONSES	HUMAN FIBRINOPEPTIDE-A; HAGEMAN-FACTOR; HUMAN-LUNG; ANAPHYLACTIC RELEASE; ANTIGEN CHALLENGE; MEDIATOR RELEASE; SKIN REACTION; LATE PHASE; HISTAMINE; PLASMA	The levels of histamine, fibrinopeptide A (FPA), and IgG were determined in chamber fluids overlying sites of antigen versus buffer incubation for up to 7 hours in seven atopic and four antigen-nonreactive subjects. Significant increases in histamine were observed at antigen versus buffer sites in the atopic subjects throughout the 7-hour period. FPA and IgG levels were higher in antigen than in buffer sites from 0 to 5 hours in the atopic subjects. Furthermore, FPA levels correlated with the magnitude of induration at 6 hours after antigen injection in atopic subjects. There were no differences in the levels of histamine, FPA, or IgG at antigen versus buffer sites in the skin test-negative subjects. We suggest that the combination of vascular leakage of proteins, induced by vasoactive mediator release, and activation of these proteins during ongoing cutaneous reactions is responsible for fibrin formation that contributes to the pathophysiology of late-phase allergic responses in the skin.	SUNY STONY BROOK, DEPT MED, ALLERGY IMMUNOL & RHEUMATOL SECT, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	ATKINS, PC (corresponding author), UNIV PENN, SCH MED, DEPT MED, ALLERGY IMMUNOL SECT, PHILADELPHIA, PA 19104 USA.				NIAID NIH HHS [AI 14332, AI 16337-12] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014332, P50AI016337] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATKINS PC, 1982, J ALLERGY CLIN IMMUN, V69, P39, DOI 10.1016/0091-6749(82)90085-9; ATKINS PC, 1987, J IMMUNOL, V139, P2744; ATKINS PC, 1990, J ALLERGY CLIN IMMUN, V86, P360, DOI 10.1016/S0091-6749(05)80099-5; BERNSTEIN IL, 1988, J ALLERGY CLIN IMMUN, V82, P487, DOI 10.1016/0091-6749(88)90958-X; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; GAFFNEY PJ, 1980, THROMB RES, V19, P815, DOI 10.1016/0049-3848(80)90009-2; HOJIMA Y, 1984, BLOOD, V63, P1453; KOCKUM C, 1980, THROMB RES, V19, P589, DOI 10.1016/0049-3848(80)90031-6; LISAK RP, 1986, J IMMUNOL, V137, P1221; MEIER HL, 1983, J CLIN INVEST, V72, P574, DOI 10.1172/JCI111005; NEWBALL HH, 1979, J CLIN INVEST, V64, P457, DOI 10.1172/JCI109483; NEWBALL HH, 1981, T ASSOC AM PHYSICIAN, V94, P126; NOSSEL HL, 1971, P NATL ACAD SCI USA, V68, P2350, DOI 10.1073/pnas.68.10.2350; PROUD D, 1985, AM REV RESPIR DIS, V132, P405; SHALIT M, 1989, J ALLERGY CLIN IMMUN, V83, P691, DOI 10.1016/0091-6749(89)90084-5; SILVERBERG M, 1987, ANN NY ACAD SCI, V516, P268, DOI 10.1111/j.1749-6632.1987.tb33047.x; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; TALBOT SF, 1985, J CLIN INVEST, V76, P650, DOI 10.1172/JCI112018; TALBOT SF, 1984, J ALLERGY CLIN IMMUN, V74, P819, DOI 10.1016/0091-6749(84)90185-4	20	11	11	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1992	89	2					552	559		10.1016/0091-6749(92)90322-S	http://dx.doi.org/10.1016/0091-6749(92)90322-S			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD753	1740585	Bronze			2022-12-18	WOS:A1992HD75300007
J	BIAGINI, RE; BERNSTEIN, DM; KLINCEWICZ, SL; MITTMAN, R; BERNSTEIN, IL; HENNINGSEN, GM				BIAGINI, RE; BERNSTEIN, DM; KLINCEWICZ, SL; MITTMAN, R; BERNSTEIN, IL; HENNINGSEN, GM			EVALUATION OF CUTANEOUS RESPONSES AND LUNG-FUNCTION FROM EXPOSURE TO OPIATE COMPOUNDS AMONG ETHICAL NARCOTICS-MANUFACTURING WORKERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HYPERSENSITIVITY; ASTHMA; MORPHINE; CODEINE; DIHYDROCODEINE; OXYCODONE; HYDROCODONE; ANTIBODIES; LUNG FUNCTION	CELL SURFACE-RECEPTORS; MECHANISTIC IMPLICATIONS; ANTIGENIC MARKERS; MORPHINE; BRONCHOSPASM; HISTAMINE; ANAPHYLAXIS; ANTIBODIES; CODEINE; HEROIN	We recently demonstrated morphine-6-hemisuccinate-human serum albumin conjugate (M-6-HS-HSA)-specific IgG in serum from ethic narcotics-manufacturing workers. In this article, we present results of epicutaneous tests to opiate compounds and lung-function studies in these same workers. Thirty-nine workers, exposed to opiates, were evaluated for possible work-related changes in lung function and were administered a questionnaire concerning opiate exposure and health history in February 1988. In December 1988, 33 employees with occupational exposure to opiates, six other workers (New Jersey referent) employed at the same factory with minimal exposure to opiate compounds, and 17 nonexposed individuals from Cincinnati, Ohio, were subjected to epicutaneous threshold testing with a panel of six opiate compounds and nine common aeroallergens. In opiate-exposed workers, significantly lower epicutaneous threshold concentrations were detected (compared to New Jersey referent and Cincinnati control subjects) for dihydrocodeine (p < 0.01), hydrocodone (p < 0.05), codeine (p < 0.01), and morphine (p < 0.05). Significant associates existed among epicutaneous threshold concentrations between the agents tested; that is, individuals with a positive morphine skin test would generally have a positive codeine skin test, etc. Atopic status (positive cutaneous test results to two or more of nine common aeroallergens) was not significantly associated (p > 0.05) with positive opiate skin sensitivity. Although the mean cross-shift decrements in FEV1 for all workers were nonsignificant, five opiate-exposed individuals demonstated cross-shift decrements in FEV1 of > 10%. Daily maximum-minus-minimum changes in workweek PEFR (PEFR(max-min)) were significantly reduced for Monday through Thursday (p < 0.05) compared to PEFR(max-min) changes during a nonwork, nonexposure 3-day weekend. Ten exposed workers demonstrated daily PEFR(max-min) changes of > 20%, suggesting acute airway obstruction. Increased cutaneous reactivity to opiate compounds among opiate-exposed workers may reflect development of pharmacologic hyperresponsiveness to opiate compounds.	HAZARDS EVALUAT & TECH ASSISTANCE BRANCH,DIV SURVEILLANCE HAZARDS EVALUAT & FIELD STUDIES,CINCINNATI,OH; UNIV CINCINNATI,MED CTR,DEPT INTERNAL MED,DIV IMMUNOL,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati	BIAGINI, RE (corresponding author), NIOSH,CTR DIS CONTROL,DIV BIOMED & BEHAV SCI,APPL BIOL BRANCH,IMMUNOCHEM RES SECT,CINCINNATI,OH 45226, USA.							ALENINA A N, 1970, Klinicheskaya Meditsina (Moscow), V48, P99; ANDERSON K, 1986, LANCET, V1, P1208; BIAGINI RE, 1990, LIFE SCI, V44, P897; CASALE TB, 1984, J ALLERGY CLIN IMMUN, V73, P775, DOI 10.1016/0091-6749(84)90447-0; CHRISTOPHER MA, 1988, J ALLERGY CLIN IMMUN, V82, P1037, DOI 10.1016/0091-6749(88)90141-8; DONAHOE RM, 1987, ANN NY ACAD SCI, V496, P711, DOI 10.1111/j.1749-6632.1987.tb35834.x; FJELLNER B, 1982, ARCH DERMATOL RES, V274, P29, DOI 10.1007/BF00510355; HARLE DG, 1989, ANESTHESIOLOGY, V71, P489, DOI 10.1097/00000542-198910000-00003; HARRINGTON JM, 1988, RECENT ADV OCCUPATIO, P1; HENNINGSEN GM, 1990, TOXICOLOGIST, V10, P135; KEFFER JM, 1989, J ALLERGY CLIN IMMUN, V83, P595, DOI 10.1016/0091-6749(89)90071-7; KLINCEWICZ SL, 1990, HHE HETA87311 NAT I, P6; MCDONOUGH RJ, 1980, J IMMUNOL, V125, P2539; OLIVER RM, 1986, LANCET, V1, P915; PRIVETTE PR, 1988, AM SOC HOSPITAL PHAR, V23, P164; ROMAGUERA C, 1983, CONTACT DERMATITIS, V9, P170, DOI 10.1111/j.1600-0536.1983.tb04349.x; ROY BF, 1988, ANN NEUROL, V24, P57, DOI 10.1002/ana.410240111; SAUCEDO R, 1985, CLIN PHARMACOL THER, V38, P365, DOI 10.1038/clpt.1985.189; SAWADA J, 1988, MOL IMMUNOL, V25, P937; SHOOK JE, 1990, AM REV RESPIR DIS, V142, P895, DOI 10.1164/ajrccm/142.4.895; TURNER CR, 1989, J ALLERGY CLIN IMMUN, V83, P643, DOI 10.1016/0091-6749(89)90077-8; WAINER BH, 1972, SCIENCE, V176, P1143, DOI 10.1126/science.176.4039.1143; WAINER BH, 1973, J IMMUNOL, V110, P667; WAINER BH, 1972, SCIENCE, V178, P647, DOI 10.1126/science.178.4061.647; YAHYA MD, 1987, LIFE SCI, V41, P2503; 1987, AM REV RESPIR DIS, V138, P1285	26	11	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1992	89	1	1				108	118		10.1016/S0091-6749(05)80047-8	http://dx.doi.org/10.1016/S0091-6749(05)80047-8			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ908	1370509				2022-12-18	WOS:A1992GZ90800013
J	FURUKAWA, CT; SHARPE, M; BIERMAN, CW; PIERSON, WE; SHAPIRO, GG; ALTMAN, LC; VIRANT, FS; WILLIAMS, PV; MINOTTI, DA				FURUKAWA, CT; SHARPE, M; BIERMAN, CW; PIERSON, WE; SHAPIRO, GG; ALTMAN, LC; VIRANT, FS; WILLIAMS, PV; MINOTTI, DA			ALLERGIC PATIENTS HAVE MORE FREQUENT SINUS INFECTIONS THAN NONALLERGIC PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1992	89	1	2				332	332						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HB760					2022-12-18	WOS:A1992HB76000703
J	MELTZER, EO; BUSSE, WW; DRUCE, HM; METZGER, WJ; MITCHELL, DQ; SELNER, JC; SHAPIRO, GG; VANBAVEL, JH				MELTZER, EO; BUSSE, WW; DRUCE, HM; METZGER, WJ; MITCHELL, DQ; SELNER, JC; SHAPIRO, GG; VANBAVEL, JH			ASSESSMENT OF FLUNISOLIDE NASAL SPRAY VS PLACEBO AS AN ADJUNCT TO ANTIBIOTIC-TREATMENT OF SINUSITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1992	89	1	2				301	301						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HB760					2022-12-18	WOS:A1992HB76000577
J	CABALLER, BD; FERNANDEZRIVAS, M; LAZARO, JF; GANCEDO, SQ; RUIZ, ID; RUIZ, JP; HERRANZ, JC; CUESTA, EA; CUEVAS, M; ELIAS, MJP				CABALLER, BD; FERNANDEZRIVAS, M; LAZARO, JF; GANCEDO, SQ; RUIZ, ID; RUIZ, JP; HERRANZ, JC; CUESTA, EA; CUEVAS, M; ELIAS, MJP			MANAGEMENT OF SULFADIAZINE ALLERGY IN PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							TRIMETHOPRIM-SULFAMETHOXAZOLE; DESENSITIZATION		HOSP RAMON & CAJAL,DEPT IMMUNOL,E-28034 MADRID,SPAIN; HOSP RAMON & CAJAL,DEPT INFECT DIS,E-28034 MADRID,SPAIN	Hospital Universitario Ramon y Cajal; Hospital Universitario Ramon y Cajal	CABALLER, BD (corresponding author), HOSP RAMON & CAJAL,SERV ALERGIA,CARRETERA COLMENAR VIEJO KM 9 100,E-28034 MADRID,SPAIN.			Perez Elias/0000-0001-5700-5257				BELL ET, 1985, LANCET, V1, P163; CARRINGTON DM, 1987, J ALLERGY CLIN IMMUN, V79, P442, DOI 10.1016/0091-6749(87)90361-7; DESWARTE RD, 1988, ENFERMEDADES ALERGIC, P504; GORDIN FM, 1984, ANN INTERN MED, V100, P495, DOI 10.7326/0003-4819-100-4-495; GREENBERGER PA, 1987, J ALLERGY CLIN IMMUN, V79, P484, DOI 10.1016/0091-6749(87)90366-6; WHITE MV, 1989, ANN ALLERGY, V62, P177	6	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1991	88	1					137	138		10.1016/0091-6749(91)90311-B	http://dx.doi.org/10.1016/0091-6749(91)90311-B			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY204	2071778				2022-12-18	WOS:A1991FY20400017
J	RAZIUDDIN, S; ELAWAD, ME; MIR, NA				RAZIUDDIN, S; ELAWAD, ME; MIR, NA			BACTERIAL-MENINGITIS - T-CELL ACTIVATION AND IMMUNOREGULATORY CD4+ T-CELL SUBSET ALTERATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							MONOCLONAL-ANTIBODY; MULTIPLE-SCLEROSIS; HELPER-INDUCER; SELECTIVE LOSS; CEREBROSPINAL-FLUID; ABNORMALITIES; DISEASE; UCHL1; BLOOD	Meningitis is the most important cause of acquired postnatal deafness and neurologic disorders in children. To determine if cell-mediated immunity is casually related to the pathogenesis of bacterial meningitis, T cell subsets were quantiated from blood of the 29 children with clinical and bacteriologic diagnosis of Haemophilus influenzae, Streptococcus pneumoniae, and Neisseria meningitidis bacterial meningitis. The CD4+ T cells increased and CD8+ T cells decreased in patients with meningitis as compared to patient control subjects (bacterial infections without meningitis) and normal healthy control subjects. An elevated percentage of CD25+ (interleukin-2 receptors) and HLA-DR+ (immune-response gene-associated antigen) T cells were detected from all patients with meningitis. All 29 patients with meningitis had highly elevated CD4+ CD45R+ (suppressor-inducer) cells and reciprocally depressed CD4+ CDw29+ (helper-inducer) cells compared with healthy age-matched normal and patient control subjects. These findings indicate characteristic immunologic T cell abnormalities from meningitis. The abnormal increase in the CD4+ CD45R+ suppressor-inducer or "virgin" cells and expression of activation antigens on T cells may be of help in future understanding of abnormal immune reactions from bacterial meningitis. However, deficiency of the CD4+ CDw29+ helper-inducer or "memory" cells may contribute to the impaired helper function for B cell-induced protective antibody synthesis to bacterial capsular polysaccharides found in this disease.	KING SAUD UNIV,COLL MED,DEPT PEDIAT,ABHA,SAUDI ARABIA; ASIR CENT HOSP,ABHA,SAUDI ARABIA	King Saud University; Assir Central Hospital	RAZIUDDIN, S (corresponding author), KING SAUD UNIV,COLL MED,DEPT CLIN IMMUNOL,POB 641,ABHA,SAUDI ARABIA.							AKBAR AN, 1988, J IMMUNOL, V140, P2171; AZUBUIKE JC, 1990, ANN SAUDI MED, V10, P145, DOI 10.5144/0256-4947.1990.145; BARNES PF, 1989, J IMMUNOL, V142, P1114; CORRIGAN CJ, 1988, LANCET, V1, P1129; HAFLER DA, 1985, NEW ENGL J MED, V312, P1405, DOI 10.1056/NEJM198505303122201; JANOSSY G, 1981, LANCET, V2, P839; LASCOLEA LJ, 1984, J CLIN MICROBIOL, V19, P187, DOI 10.1128/JCM.19.2.187-190.1984; LUDGATE ME, 1984, BRIT MED J, V288, P526, DOI 10.1136/bmj.288.6416.526; MODLIN RL, 1988, P NATL ACAD SCI USA, V85, P1213, DOI 10.1073/pnas.85.4.1213; MORIMOTO C, 1988, AM J MED, V84, P817, DOI 10.1016/0002-9343(88)90058-7; MORIMOTO C, 1987, NEW ENGL J MED, V316, P67, DOI 10.1056/NEJM198701083160202; MORIMOTO C, 1985, J IMMUNOL, V134, P3762; PITZALIS C, 1987, CLIN IMMUNOL IMMUNOP, V45, P252, DOI 10.1016/0090-1229(87)90040-7; RABINOWE SL, 1986, AM J MED, V81, P779, DOI 10.1016/0002-9343(86)90344-X; RAZIUDDIN S, 1988, BRIT J HAEMATOL, V70, P283, DOI 10.1111/j.1365-2141.1988.tb02483.x; RAZIUDDIN S, 1989, J RHEUMATOL, V16, P1315; RAZIUDDIN S, 1990, CLIN EXP IMMUNOL, V79, P67; REINHERZ EL, 1979, P NATL ACAD SCI USA, V76, P4061, DOI 10.1073/pnas.76.8.4061; ROSE LM, 1985, P NATL ACAD SCI USA, V82, P7389, DOI 10.1073/pnas.82.21.7389; SANDERS ME, 1988, IMMUNOL TODAY, V9, P195, DOI 10.1016/0167-5699(88)91212-1; TERRY LA, 1988, IMMUNOLOGY, V64, P331; WAAGE A, 1987, LANCET, V1, P355; Winchester R J, 1979, Adv Immunol, V28, P221; 1989, LANCET, V2, P1307; [No title captured]	25	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1991	87	6					1115	1120		10.1016/0091-6749(91)92157-V	http://dx.doi.org/10.1016/0091-6749(91)92157-V			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR066	1710632				2022-12-18	WOS:A1991FR06600011
J	MONROE, EW				MONROE, EW			THE ROLE OF ANTIHISTAMINES IN THE TREATMENT OF CHRONIC URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MILWAUKEE MED CLIN, MILWAUKEE, WI USA; MED COLL WISCONSIN, MILWAUKEE, WI 53226 USA	Medical College of Wisconsin								BERNSTEIN IL, 1986, J ALLERGY CLIN IMMUN, V77, P37, DOI 10.1016/0091-6749(86)90319-2; CAINELLI T, 1986, PHARMATHERAPEUTICA, V4, P679; CERIO R, 1984, CLIN ALLERGY, V14, P139, DOI 10.1111/j.1365-2222.1984.tb02644.x; COMMENS CA, 1978, BRIT J DERMATOL, V99, P675, DOI 10.1111/j.1365-2133.1978.tb07062.x; DAMSEAUX M, 1981, CLIN RES REP, V43, P1; FERGUSON J, 1985, BRIT J CLIN PHARMACO, V20, P639, DOI 10.1111/j.1365-2125.1985.tb05122.x; FOX RW, 1986, J ALLERGY CLIN IMMUN, V78, P1159, DOI 10.1016/0091-6749(86)90266-6; FREDRIKSSON T, 1986, CUTIS, V38, P128; GOLDSOBEL AB, 1986, J ALLERGY CLIN IMMUN, V78, P867, DOI 10.1016/0091-6749(86)90232-0; GRANT JA, 1988, J ALLERGY CLIN IMMUN, V81, P563, DOI 10.1016/0091-6749(88)90197-2; GREENE SL, 1985, J AM ACAD DERMATOL, V12, P669, DOI 10.1016/S0190-9622(85)70092-8; HARADA S, 1985, ANN ALLERGY, V55, P284; HARVEY RP, 1981, J ALLERGY CLIN IMMUN, V68, P262, DOI 10.1016/0091-6749(81)90149-4; HONSINGER R, 1986, J ALLERGY CLIN IMMUN, V77, P187; JUHLIN L, 1988, BRIT J DERMATOL, V119, P67, DOI 10.1111/j.1365-2133.1988.tb07103.x; KAILASAM V, 1987, J AM ACAD DERMATOL, V16, P797, DOI 10.1016/S0190-9622(87)70104-2; KNIGHT A, 1984, ASTEMIZOLE NEW NONSE, P95; KRAUSE LB, 1984, BRIT J DERMATOL, V110, P73, DOI 10.1111/j.1365-2133.1984.tb07315.x; KRAUSE LB, 1985, ANN ALLERGY, V55, P284; KRAUSE LB, 1985, BRIT J DERMATOL, V112, P447, DOI 10.1111/j.1365-2133.1985.tb02319.x; MOBACKEN H, 1985, ANN ALLERGY, V55, P254; MONROE EW, 1988, J AM ACAD DERMATOL, V19, P138, DOI 10.1016/S0190-9622(88)80230-5; MONROE EW, 1981, ARCH DERMATOL, V117, P404, DOI 10.1001/archderm.117.7.404; MONROE EW, 1988, J AM ACAD DERMATOL, V19, P842, DOI 10.1016/S0190-9622(88)70243-1; PAUL E, 1989, ANN ALLERGY, V62, P318; RICHARDS DM, 1984, DRUGS, V28, P38, DOI 10.2165/00003495-198428010-00003; SPECTOR SL, 1987, AM J RHINOL, V1, P147; VANDENBUSSCHE G, 1987, ANN ALLERGY, V58, P184	28	11	11	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1990	86	4	2	S			662	665		10.1016/S0091-6749(05)80236-2	http://dx.doi.org/10.1016/S0091-6749(05)80236-2			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EH093	2229832	Bronze			2022-12-18	WOS:A1990EH09300017
J	TAL, A; AVIRAM, M; GORODISCHER, R				TAL, A; AVIRAM, M; GORODISCHER, R			VARIATIONS IN THEOPHYLLINE CONCENTRATIONS DETECTED BY 24-HOUR SALIVA CONCENTRATION PROFILES IN AMBULATORY CHILDREN WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SOROKA MED CTR,DIV PEDIAT,IL-84101 BEER SHEVA,ISRAEL; SOROKA MED CTR,CLIN PHARMACOL UNIT,IL-84101 BEER SHEVA,ISRAEL; BEN GURION UNIV NEGEV,FAC HLTH SCI,IL-84105 BEER SHEVA,ISRAEL	Ben Gurion University; Soroka Medical Center; Ben Gurion University; Soroka Medical Center; Ben Gurion University	TAL, A (corresponding author), SOROKA MED CTR,PEDIAT PULM UNIT,POB 151,IL-84101 BEER SHEVA,ISRAEL.		Tal, Asher/B-4286-2012; Gorodischer, Rafael/AAQ-8132-2020	Tal, Asher/0000-0002-5670-8804; Gorodischer, Rafael/0000-0002-7649-3353				AHRENS RC, 1980, PEDIATRIC PHARM, P233; AVIRAM M, 1987, PEDIATRICS, V80, P894; BAKER MD, 1986, J PEDIATR-US, V109, P538, DOI 10.1016/S0022-3476(86)80140-8; CHUNG KC, 1978, LANCET, V1, P1132; ELLIS EF, 1976, PEDIATRICS, V58, P542; ENEY RD, 1976, PEDIATRICS, V57, P513; GALANT SP, 1977, AM J DIS CHILD, V131, P970, DOI 10.1001/archpedi.1977.02120220036004; GOLDSWORTHY SJ, 1981, J ROY SOC MED, V74, P415, DOI 10.1177/014107688107400604; HENDELES L, 1982, PHARMACOL THERAPEUT, V18, P91, DOI 10.1016/0163-7258(82)90027-4; ISLES AF, 1984, SUSTAINED RELEASE TH, P91; JONKMAN JHG, 1986, J ALLERGY CLIN IMMUN, V78, P736, DOI 10.1016/0091-6749(86)90054-0; KARIM A, 1985, CLIN PHARMACOL THER, V38, P642, DOI 10.1038/clpt.1985.238; KNOTT C, 1984, BRIT J CLIN PHARMACO, V17, P9, DOI 10.1111/j.1365-2125.1984.tb04991.x; LEVY G, 1974, PEDIATRICS, V53, P873; MCKENZIE S, 1986, ARCH DIS CHILD, V61, P1046, DOI 10.1136/adc.61.11.1046; MILAVETZ G, 1986, J PEDIATR-US, V109, P351, DOI 10.1016/S0022-3476(86)80403-6; MUNZENBERGER PJ, 1986, CLIN PEDIATR, V25, P448, DOI 10.1177/000992288602500907; PEDERSEN S, 1986, J ALLERGY CLIN IMMUN, V78, P704, DOI 10.1016/0091-6749(86)90049-7; RACHELEFSKY G, 1986, AM J DIS CHILD, V140, P336, DOI 10.1001/archpedi.1986.02140180070028; REINHARDT D, 1987, CHRONOBIOL INT, V4, P369, DOI 10.3109/07420528709083526; ROGERS RJ, 1987, AM REV RESPIR DIS, V136, P1168, DOI 10.1164/ajrccm/136.5.1168; ROGERS RJ, 1985, J PEDIATR-US, V106, P496, DOI 10.1016/S0022-3476(85)80690-9; ROSEN JP, 1979, PEDIATRICS, V64, P248; RUPCHOCK P, 1985, CLIN CHEM, V31, P737; SCOTT PH, 1981, J PEDIATR-US, V99, P476, DOI 10.1016/S0022-3476(81)80354-X; SMOLENSKY MH, 1986, J ALLERGY CLIN IMMUN, V78, P716, DOI 10.1016/0091-6749(86)90051-5; SZEFLER SJ, 1983, PEDIATR CLIN N AM, V30, P943; SZEFLER SJ, 1986, J ALLERGY CLIN IMMUN, V78, P710, DOI 10.1016/0091-6749(86)90050-3; UDEN DL, 1987, CLIN PEDIATR, V26, P285, DOI 10.1177/000992288702600601; WALSON PD, 1977, J PEDIATR-US, V91, P321, DOI 10.1016/S0022-3476(77)80844-5	30	11	11	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1990	86	2					238	243						6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DV316	2384651				2022-12-18	WOS:A1990DV31600014
J	BOULET, LP; TURCOTTE, H; LAMPRON, N; LAVIOLETTE, M				BOULET, LP; TURCOTTE, H; LAMPRON, N; LAVIOLETTE, M			INFLUENCE OF NATURAL ANTIGENIC EXPOSURE ON BRONCHOALVEOLAR LAVAGE IN SUBJECTS WITH POLLEN-INDUCED RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV LAVAL,DEPT MED,ST FOY,QUEBEC,CANADA	Laval University	BOULET, LP (corresponding author), HOP LAVAL,CTR PNEUMOL,UNITE RECH PNEUMOL,2725 CHEMIN STE FOY,ST FOY G1V 4G5,QUEBEC,CANADA.							BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; BOULET LP, 1989, ANN ALLERGY, V63, P114; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BOUSQUET J, 1987, HIGHLIGHTS ASTHMOLOG, P306; BRAMAN SS, 1987, CHEST, V91, P671, DOI 10.1378/chest.91.5.671; BRODER I, 1974, J ALLERGY CLIN IMMUN, V54, P100, DOI 10.1016/0091-6749(74)90038-4; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHUNG KF, 1985, J APPL PHYSIOL, V58, P1347, DOI 10.1152/jappl.1985.58.4.1347; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CUSS FM, 1986, LANCET, V2, P189; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DIAZ P, 1987, IMMUNOL ALLERGY PRAC, V9, P17; EGGLESTON PA, 1988, J ALLERGY CLIN IMMUN, V81, P1036, DOI 10.1016/0091-6749(88)90176-5; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; Gniazdowski R, 1984, Otolaryngol Pol, V38, P143; HARGREAVE FE, 1986, EUR J RESPIR DIS, V69, P16; HOLGATE ST, 1988, ALLERGY PRINCIPLES P, P147; HOLTZMAN MJ, 1983, AM REV RESPIR DIS, V127, P686; KIRBY JG, 1987, AM REV RESPIR DIS, V136, P379, DOI 10.1164/ajrccm/136.2.379; LAVIOLETTE M, 1985, THORAX, V40, P651, DOI 10.1136/thx.40.9.651; MADONINI E, 1987, J ALLERGY CLIN IMMUN, V79, P358, DOI 10.1016/0091-6749(87)90156-4; MARSH WR, 1985, AM REV RESPIR DIS, V131, P875; Metzger W J, 1987, Agents Actions Suppl, V21, P151; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; METZGER WJ, 1985, CLIN REV ALLERG, V3, P145, DOI 10.1007/BF02992980; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; METZGER WJ, 1985, CHEST, V87, pS15; OBYRNE PM, 1986, CHEST, V90, P575, DOI 10.1378/chest.90.4.575; PLATTSMILLS TAE, 1982, LANCET, V2, P675; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; YAN K, 1983, EUR J RESPIR DIS, V64, P105	32	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1990	86	1					19	25		10.1016/S0091-6749(05)80118-6	http://dx.doi.org/10.1016/S0091-6749(05)80118-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DQ688	2370387				2022-12-18	WOS:A1990DQ68800004
J	CRIMI, E; GIANIORIO, P; ORENGO, G; VOLTOLINI, S; CRIMI, P; BRUSASCO, V				CRIMI, E; GIANIORIO, P; ORENGO, G; VOLTOLINI, S; CRIMI, P; BRUSASCO, V			LATE ASTHMATIC REACTION TO PERENNIAL AND SEASONAL ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									OSPED SAN MARTINO GENOVA,SERV ALLERGOL,GENOA,ITALY; UNIV GENOA,IST IGIENE & MED PREVENT,CATTEDRA MED COMUNITA,I-16132 GENOA,ITALY	University of Genoa; IRCCS AOU San Martino IST; University of Genoa	CRIMI, E (corresponding author), UNIV GENOA,IST MED SPORT,CATTEDRA ALLERGOL RESP,VIALE BENEDETTO XV-10,I-16132 GENOA,ITALY.							ALTOUNYAN REC, 1969, DISODIUM CROMOGLYCAT, P47; BOOIJ-NOORD H, 1972, Clinical Allergy, V2, P43, DOI 10.1111/j.1365-2222.1972.tb01267.x; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; CRIMI E, 1983, ALLERGY, V38, P553, DOI 10.1111/j.1398-9995.1983.tb04139.x; CRIMI E, 1989, American Review of Respiratory Disease, V139, pA461; CRIMI E, 1986, J ALLERGY CLIN IMMUN, V78, P908, DOI 10.1016/0091-6749(86)90239-3; CRIMI E, 1986, ANN ALLERGY, V56, P183; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; FABBRI LM, 1984, AM REV RESPIR DIS, V129, P288; GERBLICH AA, 1984, NEW ENGL J MED, V310, P1349, DOI 10.1056/NEJM198405243102103; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; GRAMMER L, 1981, INT ARCH ALLER A IMM, V66, P179, DOI 10.1159/000232817; HUGGINS KG, 1975, LANCET, V2, P148; LOWELL FC, 1967, J AMER MED ASSOC, V202, P875, DOI 10.1001/jama.202.9.875; MACLERIO RM, 1985, NEW ENGL J MED, V313, P65; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; MUTO K, 1986, ANN ALLERGY, V57, P249; PLATTMILLS TAE, 1985, LANCET, V2, P675; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; PRICE JF, 1982, CLIN EXP IMMUNOL, V47, P587; QUANJER PLH, 1983, B EUROP PHYSIOPAT S5, V19, P7; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; WARNER JO, 1976, ARCH DIS CHILD, V51, P905, DOI 10.1136/adc.51.12.905	25	11	12	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1990	85	5					885	890		10.1016/0091-6749(90)90073-D	http://dx.doi.org/10.1016/0091-6749(90)90073-D			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DD959	1692048				2022-12-18	WOS:A1990DD95900011
J	TING, S				TING, S			KETOTIFEN AND SYSTEMIC MASTOCYTOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter																		CZARNETZKI BM, 1983, DERMATOLOGICA, V166, P44, DOI 10.1159/000249832; KETTELHUT BV, 1989, J ALLERGY CLIN IMMUN, V83, P866, DOI 10.1016/0091-6749(89)90097-3; LEWIS RA, 1984, J ALLERGY CLIN IMMUN, V74, P755, DOI 10.1016/0091-6749(84)90172-6; LICHTENSTEIN LM, 1985, CURRENT THERAPY ALLE, P51	4	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1990	85	4					818	818		10.1016/0091-6749(90)90205-I	http://dx.doi.org/10.1016/0091-6749(90)90205-I			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA437	2324420				2022-12-18	WOS:A1990DA43700022
J	SOLER, M; MANSOUR, E; FERNANDEZ, A; DBROT, J; AHMED, T; ABRAHAM, WM				SOLER, M; MANSOUR, E; FERNANDEZ, A; DBROT, J; AHMED, T; ABRAHAM, WM			PAF-INDUCED AIRWAY RESPONSES IN SHEEP - EFFECTS OF A PAF ANTAGONIST AND NEDOCROMIL SODIUM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MT SINAI MED CTR,DEPT RES,4300 ALTON RD,MIAMI BEACH,FL 33140; UNIV BASEL,MED KLIN,CH-4051 BASEL,SWITZERLAND	Mount Sinai Medical Center; University of Basel					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033897] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 33897] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM WM, 1987, CHEST, V92, P913, DOI 10.1378/chest.92.5.913; ABRAHAM WM, 1988, J APPL PHYSIOL, V65, P1062, DOI 10.1152/jappl.1988.65.3.1062; ABRAHAM WM, 1989, J APPL PHYSIOL, V66, P2351, DOI 10.1152/jappl.1989.66.5.2351; ALLEGRA L, 1983, J APPL PHYSIOL, V55, P726, DOI 10.1152/jappl.1983.55.3.726; ANDERSON GP, 1988, AGENTS ACTIONS, V24, P1, DOI 10.1007/BF01968073; ARNOUX B, 1988, AM REV RESPIR DIS, V137, P855, DOI 10.1164/ajrccm/137.4.855; BARNES PJ, 1988, J ALLERGY CLIN IMMUN, V81, P919, DOI 10.1016/0091-6749(88)90952-9; BRAQUET P, 1987, PHARMACOL REV, V39, P98; BRUIJNZEEL PLB, 1989, BRIT J PHARMACOL, V96, P631, DOI 10.1111/j.1476-5381.1989.tb11862.x; CHRISTMAN BW, 1987, AM REV RESPIR DIS, V135, P1267; CHUNG KF, 1986, J PHARMACOL EXP THER, V236, P580; CHUNG KF, 1989, THORAX, V44, P102, DOI 10.1136/thx.44.2.102; COYLE AJ, 1988, EUR J PHARMACOL, V148, P51, DOI 10.1016/0014-2999(88)90453-0; CUSS FM, 1986, LANCET, V2, P189; DENJEAN A, 1988, AM REV RESPIR DIS, V137, pA283; FERNANDEZ A, 1989, American Review of Respiratory Disease, V139, pA370; FITZGERALD MF, 1986, BRIT J PHARMACOL, V88, P149, DOI 10.1111/j.1476-5381.1986.tb09481.x; GUINOT P, 1987, PROSTAGLANDINS, V34, P723, DOI 10.1016/0090-6980(87)90295-4; LEFER AM, 1984, N-S ARCH PHARMACOL, V326, P186, DOI 10.1007/BF00517318; LELLOUCHTUBIANA A, 1988, AM REV RESPIR DIS, V137, P948, DOI 10.1164/ajrccm/137.4.948; LEUNG KBP, 1988, THORAX, V43, P756, DOI 10.1136/thx.43.10.756; MAZZONI L, 1985, BRIT J PHARMACOL, V86, P571; METZGER WJ, 1988, NEW TRENDS LIPID RES, P40; Morley J, 1988, Agents Actions Suppl, V23, P187; PATTERSON R, 1983, J LAB CLIN MED, V102, P933; PATTERSON R, 1984, J LAB CLIN MED, V104, P340; PINCKARD RN, 1988, INFLAMMATION BASIC P, P139; PRETOLANI M, 1989, J PHARMACOL EXP THER, V248, P353; ROBERTSON DN, 1988, AM REV RESPIR DIS, V137, P1317, DOI 10.1164/ajrccm/137.6.1317; SMITH HR, 1987, AM REV RESPIR DIS, V137, P283; SMITH LJ, 1988, AM REV RESPIR DIS, V137, P1015, DOI 10.1164/ajrccm/137.5.1015; SOLER M, 1989, J APPL PHYSIOL, V67, P406, DOI 10.1152/jappl.1989.67.1.406; THOREL T, 1988, INT ARCH ALLER A IMM, V85, P232, DOI 10.1159/000234508; VOELKEL NF, 1982, SCIENCE, V218, P286, DOI 10.1126/science.7123233; WELLS E, 1986, J IMMUNOL, V137, P3941	35	11	11	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1990	85	3					661	668		10.1016/0091-6749(90)90108-G	http://dx.doi.org/10.1016/0091-6749(90)90108-G			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CU668	2155959	Bronze			2022-12-18	WOS:A1990CU66800019
J	BONER, AL; GUARISE, A; VALLONE, G; FORNARI, A; PIACENTINI, F; SETTE, L				BONER, AL; GUARISE, A; VALLONE, G; FORNARI, A; PIACENTINI, F; SETTE, L			METABISULFITE ORAL CHALLENGE - INCIDENCE OF ADVERSE RESPONSES IN CHRONIC CHILDHOOD ASTHMA AND ITS RELATIONSHIP WITH BRONCHIAL HYPERREACTIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV VERONA,DEPT PEDIAT,I-37100 VERONA,ITALY; IST PIO 12,MISURINA,ITALY	University of Verona								ALTMAN LC, 1985, J ALLERGY CLIN IMMUN, V75, P144, DOI 10.1016/0091-6749(85)90293-3; BUSH RK, 1986, J ALLERGY CLIN IMMUN, V78, P191, DOI 10.1016/0091-6749(86)90012-6; CALABRESE E, 1981, MED HYPOTHESES, V7, P133, DOI 10.1016/0306-9877(81)90110-9; Friedman ME, 1987, PEDIATR ASTHMA ALLER, V1, P53; GOLDFARB F, 1984, J ALLERGY CLIN IMMUN, V73, P135; JACOBSEN D W, 1984, Journal of Allergy and Clinical Immunology, V73, P135; MATHISON DA, 1985, CHEST S, V871, P505; MEGGS WJ, 1985, J ALLERGY CLIN IMMUN, V75, P144, DOI 10.1016/0091-6749(85)90295-7; Polgar G, 1971, PULMONARY FUNCTION T; ROSENTHAL RR, 1979, J ALLERGY CLIN IMMUN, V64, P564, DOI 10.1016/0091-6749(79)90013-7; SETTIPANE GA, 1984, J AM ACAD DERMATOL, V10, P1077, DOI 10.1016/S0190-9622(84)80355-2; STEVENSON DD, 1981, J ALLERGY CLIN IMMUN, V68, P26, DOI 10.1016/0091-6749(81)90119-6; TOWNS SJ, 1984, PEDIATRICS, V73, P631; 1970, AM REV RESPIR DIS, V85, P762	14	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1990	85	2					479	483		10.1016/0091-6749(90)90158-Z	http://dx.doi.org/10.1016/0091-6749(90)90158-Z			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CP511	2406325				2022-12-18	WOS:A1990CP51100009
J	NORMAN, PS; CRETICOS, PS; MARSH, DG				NORMAN, PS; CRETICOS, PS; MARSH, DG			FREQUENCY OF BOOSTER INJECTIONS OF ALLERGOIDS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									GOOD SAMARITAN HOSP,BALTIMORE,MD 21239		NORMAN, PS (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MED,CTR ASTHMA & ALLERGY,DIV CLIN IMMUNOL,301 BAYVIEW BLVD,BALTIMORE,MD 21224, USA.							ANFOSSO F, 1982, ALLERGY, V37, P613, DOI 10.1111/j.1398-9995.1982.tb02349.x; BAUMGARTEN C, 1984, RESPIRATION, V46, P97, DOI 10.1159/000194676; BOUSQUET J, 1987, INT ARCH ALLER A IMM, V82, P550, DOI 10.1159/000234277; BOUSQUET J, 1986, ANN ALLERGY, V56, P456; GOLDEN DBK, 1989, J ALLERGY CLIN IMMUN, V84, P161; KALVERAM CM, 1986, Z HAUTKRANKHEITEN, V61, P118; KUHN W, 1983, KLIN PADIATR, V195, P411, DOI 10.1055/s-2008-1034409; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; MAASCH HJ, 1987, CLIN REV ALLERG, V5, P89; MAASCH HJ, 1983, ARB PAUL EHRLICH I G, V78, P91; MARSH DG, 1981, J ALLERGY CLIN IMMUN, V68, P449, DOI 10.1016/0091-6749(81)90199-8; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; MARSH DG, 1971, INT ARCH ALLER A IMM, V41, P199, DOI 10.1159/000230518; MERINEY DK, 1986, ANN ALLERGY, V56, P34; NORMAN PS, 1974, MED CLIN N AM, V58, P111, DOI 10.1016/S0025-7125(16)32181-2; NORMAN PS, 1971, J ALLERGY, V47, P273, DOI 10.1016/S0091-6749(71)80005-2; NORMAN PS, 1981, J ALLERGY CLIN IMMUN, V68, P460, DOI 10.1016/0091-6749(81)90200-1; NORMAN PS, 1982, J ALLERGY CLIN IMMUN, V70, P248, DOI 10.1016/0091-6749(82)90061-6; VARGIU G, 1986, Bollettino dell'Istituto Sieroterapico Milanese, V65, P230; WIHL JA, 1985, INT ARCH ALLER A IMM, V76, P162, DOI 10.1159/000233684	20	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1990	85	1	1				88	94		10.1016/0091-6749(90)90227-U	http://dx.doi.org/10.1016/0091-6749(90)90227-U			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM378	2405042				2022-12-18	WOS:A1990CM37800015
J	SULLIVAN, KM				SULLIVAN, KM			INTRAVENOUS IMMUNE GLOBULIN PROPHYLAXIS IN RECIPIENTS OF A MARROW TRANSPLANT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WASHINGTON,SCH MED,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	SULLIVAN, KM (corresponding author), FRED HUTCHINSON CANC RES CTR,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.				NATIONAL CANCER INSTITUTE [P01CA018029, P01CA018221, P30CA015704] Funding Source: NIH RePORTER; NCI NIH HHS [CA18029, CA15704, CA18221] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGNOSTI JM, 1988, NEW ENGL J MED, V319, P1623; ATKINSON K, 1982, BLOOD, V60, P714; AUCOUTURIER P, 1987, BLOOD, V70, P779; BESCHORNER WE, 1981, J INFECT DIS, V144, P38, DOI 10.1093/infdis/144.1.38; BORTIN MM, 1988, BLOOD S, V72, pA380; BOWDEN RA, 1986, NEW ENGL J MED, V314, P1006, DOI 10.1056/NEJM198604173141602; CLARK JG, 1987, ANN INTERN MED, V107, P648, DOI 10.7326/0003-4819-107-5-648; CONDIE RM, 1984, AM J MED, V76, P134, DOI 10.1016/0002-9343(84)90332-2; GRAHAMPOLE J, 1988, BONE MARROW TRANSPL, V3, P559; HAGENBEEK A, 1987, J INFECT DIS, V155, P897, DOI 10.1093/infdis/155.5.897; HEYD J, 1988, BLOOD, V72, P442; HOLLAND HK, 1988, BLOOD, V72, P621; IZUTSU KT, 1983, TRANSPLANTATION, V35, P411; KALHS P, 1988, ANN INTERN MED, V109, P461, DOI 10.7326/0003-4819-109-6-461; LUM LG, 1985, BLOOD, V65, P1422, DOI 10.1182/blood.V65.6.1422.bloodjournal6561422; LUM LG, 1987, BLOOD, V69, P369; MARTIN PJ, 1988, BONE MARROW TRANSPL, V3, P45; MEYERS JD, 1983, ANN INTERN MED, V98, P442, DOI 10.7326/0003-4819-98-4-442; MEYERS JD, 1986, AM J MED, V81, P27, DOI 10.1016/0002-9343(86)90511-5; MEYERS JD, 1986, J INFECT DIS, V153, P478, DOI 10.1093/infdis/153.3.478; MEYERS JD, 1987, ANN INTERN MED, V107, P809, DOI 10.7326/0003-4819-107-6-809; PERREAULT C, 1985, BLUT, V51, P137, DOI 10.1007/BF00320027; PETERSEN F, 1988, INFECTION, V16, P199, DOI 10.1007/BF01650752; PETERSEN FB, 1987, BONE MARROW TRANSPL, V2, P141; REED EC, 1988, ANN INTERN MED, V109, P783, DOI 10.7326/0003-4819-109-10-783; STORB R, 1983, NEW ENGL J MED, V308, P302, DOI 10.1056/NEJM198302103080602; STORB R, 1986, NEW ENGL J MED, V314, P729, DOI 10.1056/NEJM198603203141201; SULLIVAN KM, 1989, TRANSPL P, V21, P2926; SULLIVAN KM, 1986, INT J CELL CLONING, V4, P107, DOI 10.1002/stem.5530040712; SULLIVAN KM, 1988, BLOOD, V72, P546; SULLIVAN KM, 1986, INT J CELL CLONING, V4, P42, DOI 10.1002/stem.5530040710; SULLIVAN KM, 1987, AM J MED, V83, P34, DOI 10.1016/0002-9343(87)90549-3; SULLIVAN KM, 1988, BLOOD, V72, P555; SULLIVAN KM, 1988, BLOOD S, V72, pA410; SULLIVAN KM, 1989, BLOOD, V73, P720; SULLIVAN KM, 1989, UCLA S MOL CELLULAR, V91, P511; THOMAS ED, 1975, NEW ENGL J MED, V292, P832, DOI 10.1056/NEJM197504172921605; THOMAS ED, 1975, NEW ENGL J MED, V292, P895, DOI 10.1056/NEJM197504242921706; THOMAS ED, 1989, BLOOD, V73, P861; VUVAN H, 1985, EXP HEMATOL, V13, P105; WEIDEN PL, 1981, NEW ENGL J MED, V304, P1529, DOI 10.1056/NEJM198106183042507; WINSTON DJ, 1987, ANN INTERN MED, V106, P12, DOI 10.7326/0003-4819-106-1-12; WINSTON DJ, 1982, ANN INTERN MED, V97, P11, DOI 10.7326/0003-4819-97-1-11; WITHERSPOON RP, 1981, BLOOD, V58, P360; WITHERSPOON RP, 1988, BONE MARROW TRANSPL, V3, P425; WITHERSPOON RP, 1982, BLOOD, V59, P844	46	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1989	84	4	2	S			632	639		10.1016/0091-6749(89)90202-9	http://dx.doi.org/10.1016/0091-6749(89)90202-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZ398	2551949				2022-12-18	WOS:A1989AZ39800011
J	STAFFORD, CT; RHOADES, RB; BUNKERSOLER, AL; THOMPSON, WO; IMPSON, LK				STAFFORD, CT; RHOADES, RB; BUNKERSOLER, AL; THOMPSON, WO; IMPSON, LK			SURVEY OF WHOLE-BODY EXTRACT IMMUNOTHERAPY FOR IMPORTED FIRE ANT-STING AND OTHER HYMENOPTERA-STING ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		ADAMS CT, 1981, J MED ENTOMOL, V18, P378, DOI 10.1093/jmedent/18.5.378; BARNARD JH, 1973, J ALLERGY CLIN IMMUN, V52, P259, DOI 10.1016/0091-6749(73)90044-4; Bloom F L, 1984, J Fla Med Assoc, V71, P87; BUREN W F, 1972, Journal of the Georgia Entomological Society, V7, P1; CLEMMER DI, 1975, SOUTHERN MED J, V68, P1133, DOI 10.1097/00007611-197509000-00017; DESHAZO RD, 1984, J ALLERGY CLIN IMMUN, V74, P841, DOI 10.1016/0091-6749(84)90188-X; FAVORITE FG, 1958, PUBLIC HEALTH REP, V73, P445, DOI 10.2307/4590149; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; JAMES FK, 1976, J ALLERGY CLIN IMMUN, V58, P110, DOI 10.1016/0091-6749(76)90112-3; LOCKEY RF, 1974, J ALLERGY CLIN IMMUN, V53, P132; PAULL BR, 1983, J ALLERGY CLIN IMMUN, V71, P448, DOI 10.1016/0091-6749(83)90460-8; REISMAN RE, 1983, ALLERGY PRINCIPLES P, V2, P1361; Rhoades R.B., 1977, MED ASPECTS IMPORTED; RHOADES RB, 1988, J ALLERGY CLIN IMMUN, V81, P202, DOI 10.1016/0091-6749(88)90373-9; RHOADES RB, 1977, J FLA MED ASSOC, V64, P247; Rhoades RB, 1987, IMMUNOL ALLERGY PRAC, V9, P23; STAFFORD CT, 1985, IMMUNOL ALLERGY PRAC, V7, P33; STROM GB, 1983, J ALLERGY CLIN IMMUN, V72, P46, DOI 10.1016/0091-6749(83)90051-9; TORSNEY PJ, 1973, J ALLERGY CLIN IMMUN, V52, P303, DOI 10.1016/0091-6749(73)90049-3; TRIPLETT RF, 1976, SOUTHERN MED J, V69, P258, DOI 10.1097/00007611-197603000-00002; TRIPLETT RF, 1973, SOUTHERN MED J, V66, P477, DOI 10.1097/00007611-197304000-00019; [No title captured]	22	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1989	83	6					1107	1111		10.1016/0091-6749(89)90453-3	http://dx.doi.org/10.1016/0091-6749(89)90453-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC235	2732410	Bronze			2022-12-18	WOS:A1989AC23500015
J	GRAMMER, LC; SHAUGHNESSY, MA; SHAUGHNESSY, JJ; PATTERSON, R				GRAMMER, LC; SHAUGHNESSY, MA; SHAUGHNESSY, JJ; PATTERSON, R			SAFETY AND IMMUNOGENICITY OF IMMUNOTHERAPY WITH ACCELERATED DOSAGE SCHEDULES OF POLYMERIZED GRASS AND RAGWEED IN PATIENTS WITH DUAL INHALANT SENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOPE COLL,HOLLAND,MI 49423	Hope College	GRAMMER, LC (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,303 E CHICAGO AVE,CHICAGO,IL 60611, USA.			Grammer, Leslie/0000-0001-6860-2014	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOUSQUET J, 1988, ALLERGY PRINCIPLES P, V1, P419; FITZSIMONS R, 1986, ANN ALLERGY, V57, P291; GRAMMER LC, 1987, J ALLERGY CLIN IMMUN, V80, P177, DOI 10.1016/0091-6749(87)90127-8; GRAMMER LC, 1984, J ALLERGY CLIN IMMUN, V73, P484, DOI 10.1016/0091-6749(84)90359-2; GRAMMER LC, 1983, J ALLERGY CLIN IMMUN, V72, P448, DOI 10.1016/0091-6749(83)90580-8; GRAMMER LC, 1986, J ALLERGY CLIN IMMUN, V78, P1180, DOI 10.1016/0091-6749(86)90269-1; GRAMMER LC, 1982, J ALLERGY CLIN IMMUN, V69, P494, DOI 10.1016/0091-6749(82)90173-7; GRAMMER LC, 1986, J ALLERGY CLIN IMMUN, V77, P53, DOI 10.1016/0091-6749(86)90322-2; HENDRIX S, 1980, J ALLERGY CLIN IMMUN, V65, P57, DOI 10.1016/0091-6749(80)90177-3; HENDRIX SG, 1980, J ALLERGY CLIN IMMUN, V66, P486, DOI 10.1016/0091-6749(80)90010-X; HENDRIX SG, 1981, J ALLERGY CLIN IMMUN, V67, P124, DOI 10.1016/0091-6749(81)90007-5; LEVY DA, 1980, REGULATORY CONTROL S, P178; LIDD D, 1962, J ALLERGY, V33, P45, DOI 10.1016/0021-8707(62)90062-X; PATTERSON R, 1983, J ALLERGY CLIN IMMUN, V72, P129, DOI 10.1016/0091-6749(83)90519-5; PATTERSON R, 1979, J ALLERGY CLIN IMMUN, V63, P47, DOI 10.1016/0091-6749(79)90161-1; SEPULVEDA R, 1979, CLIN ALLERGY, V9, P359, DOI 10.1111/j.1365-2222.1979.tb02494.x; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55; ZEISS CR, 1981, J ALLERGY CLIN IMMUN, V67, P105, DOI 10.1016/0091-6749(81)90004-X; ZEISS CR, 1977, CLIN EXP IMMUNOL, V28, P250; ZEISS CR, 1973, J IMMUNOL, V110, P414	20	11	11	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1989	83	4					750	756		10.1016/0091-6749(89)90010-9	http://dx.doi.org/10.1016/0091-6749(89)90010-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U3420	2708735				2022-12-18	WOS:A1989U342000007
J	HORNER, WE; IBANEZ, MD; LEHRER, SB				HORNER, WE; IBANEZ, MD; LEHRER, SB			IMMUNOPRINT ANALYSIS OF CALVATIA-CYATHIFORMIS ALLERGENS .1. REACTIVITY WITH INDIVIDUAL SERA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV,SCH MED,NEW ORLEANS,LA 70112	Tulane University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007376] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020331] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 07376] Funding Source: Medline; NIAID NIH HHS [AI 20331] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DEMEULEMESTER C, 1987, ELECTROPHORESIS, V8, P71, DOI 10.1002/elps.1150080113; GIANNINI EH, 1975, ANN ALLERGY, V35, P372; GREGORY P, 1957, J GEN MICROBIOL, V7, P135; HASNAIN SM, 1985, NEW ZEAL MED J, V98, P342; HASNAIN SM, 1985, NEW ZEAL MED J, V98, P393; HERXHEIMER H, 1969, LANCET, V2, P131; IBANEZ MD, 1988, J ALLERGY CLIN IMMUN, V82, P787, DOI 10.1016/0091-6749(88)90080-2; LEHRER SB, 1986, J ALLERGY CLIN IMMUN, V78, P478, DOI 10.1016/0091-6749(86)90036-9; LOPEZ M, 1976, J ALLERGY CLIN IMMUN, V57, P480, DOI 10.1016/0091-6749(76)90064-6; MARSH DG, 1986, B WORLD HEALTH ORGAN, V64, P767; MCDONALD MS, 1980, CLIN ALLERGY, V10, P211, DOI 10.1111/j.1365-2222.1980.tb02099.x; PADY SM, 1967, J ALLERGY, V39, P302, DOI 10.1016/0021-8707(67)90094-9; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P82, DOI 10.1016/0091-6749(71)90090-X; SANTILLI J, 1985, ANN ALLERGY, V55, P469; TARLO SM, 1979, J ALLERGY CLIN IMMUN, V64, P43, DOI 10.1016/0091-6749(79)90082-4	15	11	11	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1989	83	4					784	792		10.1016/0091-6749(89)90015-8	http://dx.doi.org/10.1016/0091-6749(89)90015-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U3420	2708738				2022-12-18	WOS:A1989U342000012
